<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1, viewport-fit=cover" />
  <meta name="color-scheme" content="light" />
  <meta http-equiv="Cache-Control" content="no-cache, no-store, must-revalidate" />
  <meta http-equiv="Pragma" content="no-cache" />
  <meta http-equiv="Expires" content="0" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="default" />
  <meta name="apple-mobile-web-app-title" content="PCP Learning" />
  <link rel="manifest" href="manifest.json" />
  <title>Primary Care Provider Learning Program</title>
  <meta name="description" content="Primary care learning program: clinical microlearning, quizzes, and rapid review." />
  <style>
    html, body {
      height: 100%;
      margin: 0;
      padding: 0;
      background: #f8fafc;
      font-family: system-ui, -apple-system, Segoe UI, Roboto, Helvetica, Arial, "Apple Color Emoji", "Segoe UI Emoji";
    }
    #root {
      min-height: 100%;
    }
    button, a, [role="button"] {
      -webkit-tap-highlight-color: transparent;
      touch-action: manipulation;
    }
      details:not([open]) >:not(summary) { display: none !important; }
</style>
</head>
<body>
  <noscript>This app requires JavaScript to run.</noscript>
  <div id="root"></div>

  <!-- React 18/19 (bundled inline â€” no external requests needed) -->
  <script>
(()=>{var Ft=(l,t)=>()=>(t||l((t={exports:{}}).exports,t),t.exports);var We=Ft(O=>{"use strict";var Le=Symbol.for("react.transitional.element"),om=Symbol.for("react.portal"),sm=Symbol.for("react.fragment"),bm=Symbol.for("react.strict_mode"),zm=Symbol.for("react.profiler"),Tm=Symbol.for("react.consumer"),Em=Symbol.for("react.context"),Am=Symbol.for("react.forward_ref"),Mm=Symbol.for("react.suspense"),Om=Symbol.for("react.memo"),Ri=Symbol.for("react.lazy"),_m=Symbol.for("react.activity"),Ni=Symbol.iterator;function Dm(l){return l===null||typeof l!="object"?null:(l=Ni&&l[Ni]||l["@@iterator"],typeof l=="function"?l:null)}var pi={isMounted:function(){return!1},enqueueForceUpdate:function(){},enqueueReplaceState:function(){},enqueueSetState:function(){}},Ci=Object.assign,Gi={};function bu(l,t,u){this.props=l,this.context=t,this.refs=Gi,this.updater=u||pi}bu.prototype.isReactComponent={};bu.prototype.setState=function(l,t){if(typeof l!="object"&&typeof l!="function"&&l!=null)throw Error("takes an object of state variables to update or a function which returns an object of state variables.");this.updater.enqueueSetState(this,l,t,"setState")};bu.prototype.forceUpdate=function(l){this.updater.enqueueForceUpdate(this,l,"forceUpdate")};function Xi(){}Xi.prototype=bu.prototype;function Ke(l,t,u){this.props=l,this.context=t,this.refs=Gi,this.updater=u||pi}var Je=Ke.prototype=new Xi;Je.constructor=Ke;Ci(Je,bu.prototype);Je.isPureReactComponent=!0;var qi=Array.isArray;function xe(){}var L={H:null,A:null,T:null,S:null},Qi=Object.prototype.hasOwnProperty;function re(l,t,u){var a=u.ref;return{$$typeof:Le,type:l,key:t,ref:a!==void 0?a:null,props:u}}function Um(l,t){return re(l.type,t,l.props)}function we(l){return typeof l=="object"&&l!==null&&l.$$typeof===Le}function Hm(l){var t={"=":"=0",":":"=2"};return"$"+l.replace(/[=:]/g,function(u){return t[u]})}var Yi=/\/+/g;function Ve(l,t){return typeof l=="object"&&l!==null&&l.key!=null?Hm(""+l.key):t.toString(36)}function Nm(l){switch(l.status){case"fulfilled":return l.value;case"rejected":throw l.reason;default:switch(typeof l.status=="string"?l.then(xe,xe):(l.status="pending",l.then(function(t){l.status==="pending"&&(l.status="fulfilled",l.value=t)},function(t){l.status==="pending"&&(l.status="rejected",l.reason=t)})),l.status){case"fulfilled":return l.value;case"rejected":throw l.reason}}throw l}function su(l,t,u,a,n){var e=typeof l;(e==="undefined"||e==="boolean")&&(l=null);var f=!1;if(l===null)f=!0;else switch(e){case"bigint":case"string":case"number":f=!0;break;case"object":switch(l.$$typeof){case Le:case om:f=!0;break;case Ri:return f=l._init,su(f(l._payload),t,u,a,n)}}if(f)return n=n(l),f=a===""?"."+Ve(l,0):a,qi(n)?(u="",f!=null&&(u=f.replace(Yi,"$&/")+"/"),su(n,t,u,"",function(m){return m})):n!=null&&(we(n)&&(n=Um(n,u+(n.key==null||l&&l.key===n.key?"":(""+n.key).replace(Yi,"$&/")+"/")+f)),t.push(n)),1;f=0;var c=a===""?".":a+":";if(qi(l))for(var i=0;i<l.length;i++)a=l[i],e=c+Ve(a,i),f+=su(a,t,u,e,n);else if(i=Dm(l),typeof i=="function")for(l=i.call(l),i=0;!(a=l.next()).done;)a=a.value,e=c+Ve(a,i++),f+=su(a,t,u,e,n);else if(e==="object"){if(typeof l.then=="function")return su(Nm(l),t,u,a,n);throw t=String(l),Error("Objects are not valid as a React child (found: "+(t==="[object Object]"?"object with keys {"+Object.keys(l).join(", ")+"}":t)+"). If you meant to render a collection of children, use an array instead.")}return f}function mn(l,t,u){if(l==null)return l;var a=[],n=0;return su(l,a,"","",function(e){return t.call(u,e,n++)}),a}function qm(l){if(l._status===-1){var t=l._result;t=t(),t.then(function(u){(l._status===0||l._status===-1)&&(l._status=1,l._result=u)},function(u){(l._status===0||l._status===-1)&&(l._status=2,l._result=u)}),l._status===-1&&(l._status=0,l._result=t)}if(l._status===1)return l._result.default;throw l._result}var Bi=typeof reportError=="function"?reportError:function(l){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof l=="object"&&l!==null&&typeof l.message=="string"?String(l.message):String(l),error:l});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",l);return}console.error(l)},Ym={map:mn,forEach:function(l,t,u){mn(l,function(){t.apply(this,arguments)},u)},count:function(l){var t=0;return mn(l,function(){t++}),t},toArray:function(l){return mn(l,function(t){return t})||[]},only:function(l){if(!we(l))throw Error("React.Children.only expected to receive a single React element child.");return l}};O.Activity=_m;O.Children=Ym;O.Component=bu;O.Fragment=sm;O.Profiler=zm;O.PureComponent=Ke;O.StrictMode=bm;O.Suspense=Mm;O.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=L;O.__COMPILER_RUNTIME={__proto__:null,c:function(l){return L.H.useMemoCache(l)}};O.cache=function(l){return function(){return l.apply(null,arguments)}};O.cacheSignal=function(){return null};O.cloneElement=function(l,t,u){if(l==null)throw Error("The argument must be a React element, but you passed "+l+".");var a=Ci({},l.props),n=l.key;if(t!=null)for(e in t.key!==void 0&&(n=""+t.key),t)!Qi.call(t,e)||e==="key"||e==="__self"||e==="__source"||e==="ref"&&t.ref===void 0||(a[e]=t[e]);var e=arguments.length-2;if(e===1)a.children=u;else if(1<e){for(var f=Array(e),c=0;c<e;c++)f[c]=arguments[c+2];a.children=f}return re(l.type,n,a)};O.createContext=function(l){return l={$$typeof:Em,_currentValue:l,_currentValue2:l,_threadCount:0,Provider:null,Consumer:null},l.Provider=l,l.Consumer={$$typeof:Tm,_context:l},l};O.createElement=function(l,t,u){var a,n={},e=null;if(t!=null)for(a in t.key!==void 0&&(e=""+t.key),t)Qi.call(t,a)&&a!=="key"&&a!=="__self"&&a!=="__source"&&(n[a]=t[a]);var f=arguments.length-2;if(f===1)n.children=u;else if(1<f){for(var c=Array(f),i=0;i<f;i++)c[i]=arguments[i+2];n.children=c}if(l&&l.defaultProps)for(a in f=l.defaultProps,f)n[a]===void 0&&(n[a]=f[a]);return re(l,e,n)};O.createRef=function(){return{current:null}};O.forwardRef=function(l){return{$$typeof:Am,render:l}};O.isValidElement=we;O.lazy=function(l){return{$$typeof:Ri,_payload:{_status:-1,_result:l},_init:qm}};O.memo=function(l,t){return{$$typeof:Om,type:l,compare:t===void 0?null:t}};O.startTransition=function(l){var t=L.T,u={};L.T=u;try{var a=l(),n=L.S;n!==null&&n(u,a),typeof a=="object"&&a!==null&&typeof a.then=="function"&&a.then(xe,Bi)}catch(e){Bi(e)}finally{t!==null&&u.types!==null&&(t.types=u.types),L.T=t}};O.unstable_useCacheRefresh=function(){return L.H.useCacheRefresh()};O.use=function(l){return L.H.use(l)};O.useActionState=function(l,t,u){return L.H.useActionState(l,t,u)};O.useCallback=function(l,t){return L.H.useCallback(l,t)};O.useContext=function(l){return L.H.useContext(l)};O.useDebugValue=function(){};O.useDeferredValue=function(l,t){return L.H.useDeferredValue(l,t)};O.useEffect=function(l,t){return L.H.useEffect(l,t)};O.useEffectEvent=function(l){return L.H.useEffectEvent(l)};O.useId=function(){return L.H.useId()};O.useImperativeHandle=function(l,t,u){return L.H.useImperativeHandle(l,t,u)};O.useInsertionEffect=function(l,t){return L.H.useInsertionEffect(l,t)};O.useLayoutEffect=function(l,t){return L.H.useLayoutEffect(l,t)};O.useMemo=function(l,t){return L.H.useMemo(l,t)};O.useOptimistic=function(l,t){return L.H.useOptimistic(l,t)};O.useReducer=function(l,t,u){return L.H.useReducer(l,t,u)};O.useRef=function(l){return L.H.useRef(l)};O.useState=function(l){return L.H.useState(l)};O.useSyncExternalStore=function(l,t,u){return L.H.useSyncExternalStore(l,t,u)};O.useTransition=function(){return L.H.useTransition()};O.version="19.2.0"});var Wi=Ft(w=>{"use strict";function Ie(l,t){var u=l.length;l.push(t);l:for(;0<u;){var a=u-1>>>1,n=l[a];if(0<dn(n,t))l[a]=t,l[u]=n,u=a;else break l}}function Wl(l){return l.length===0?null:l[0]}function Sn(l){if(l.length===0)return null;var t=l[0],u=l.pop();if(u!==t){l[0]=u;l:for(var a=0,n=l.length,e=n>>>1;a<e;){var f=2*(a+1)-1,c=l[f],i=f+1,m=l[i];if(0>dn(c,u))i<n&&0>dn(m,c)?(l[a]=m,l[i]=u,a=i):(l[a]=c,l[f]=u,a=f);else if(i<n&&0>dn(m,u))l[a]=m,l[i]=u,a=i;else break l}}return t}function dn(l,t){var u=l.sortIndex-t.sortIndex;return u!==0?u:l.id-t.id}w.unstable_now=void 0;typeof performance=="object"&&typeof performance.now=="function"?(Zi=performance,w.unstable_now=function(){return Zi.now()}):($e=Date,ji=$e.now(),w.unstable_now=function(){return $e.now()-ji});var Zi,$e,ji,tt=[],At=[],Bm=1,pl=null,hl=3,Pe=!1,ya=!1,va=!1,lf=!1,Li=typeof setTimeout=="function"?setTimeout:null,Ki=typeof clearTimeout=="function"?clearTimeout:null,Vi=typeof setImmediate<"u"?setImmediate:null;function hn(l){for(var t=Wl(At);t!==null;){if(t.callback===null)Sn(At);else if(t.startTime<=l)Sn(At),t.sortIndex=t.expirationTime,Ie(tt,t);else break;t=Wl(At)}}function tf(l){if(va=!1,hn(l),!ya)if(Wl(tt)!==null)ya=!0,Tu||(Tu=!0,zu());else{var t=Wl(At);t!==null&&uf(tf,t.startTime-l)}}var Tu=!1,ma=-1,Ji=5,ri=-1;function wi(){return lf?!0:!(w.unstable_now()-ri<Ji)}function Fe(){if(lf=!1,Tu){var l=w.unstable_now();ri=l;var t=!0;try{l:{ya=!1,va&&(va=!1,Ki(ma),ma=-1),Pe=!0;var u=hl;try{t:{for(hn(l),pl=Wl(tt);pl!==null&&!(pl.expirationTime>l&&wi());){var a=pl.callback;if(typeof a=="function"){pl.callback=null,hl=pl.priorityLevel;var n=a(pl.expirationTime<=l);if(l=w.unstable_now(),typeof n=="function"){pl.callback=n,hn(l),t=!0;break t}pl===Wl(tt)&&Sn(tt),hn(l)}else Sn(tt);pl=Wl(tt)}if(pl!==null)t=!0;else{var e=Wl(At);e!==null&&uf(tf,e.startTime-l),t=!1}}break l}finally{pl=null,hl=u,Pe=!1}t=void 0}}finally{t?zu():Tu=!1}}}var zu;typeof Vi=="function"?zu=function(){Vi(Fe)}:typeof MessageChannel<"u"?(ke=new MessageChannel,xi=ke.port2,ke.port1.onmessage=Fe,zu=function(){xi.postMessage(null)}):zu=function(){Li(Fe,0)};var ke,xi;function uf(l,t){ma=Li(function(){l(w.unstable_now())},t)}w.unstable_IdlePriority=5;w.unstable_ImmediatePriority=1;w.unstable_LowPriority=4;w.unstable_NormalPriority=3;w.unstable_Profiling=null;w.unstable_UserBlockingPriority=2;w.unstable_cancelCallback=function(l){l.callback=null};w.unstable_forceFrameRate=function(l){0>l||125<l?console.error("forceFrameRate takes a positive int between 0 and 125, forcing frame rates higher than 125 fps is not supported"):Ji=0<l?Math.floor(1e3/l):5};w.unstable_getCurrentPriorityLevel=function(){return hl};w.unstable_next=function(l){switch(hl){case 1:case 2:case 3:var t=3;break;default:t=hl}var u=hl;hl=t;try{return l()}finally{hl=u}};w.unstable_requestPaint=function(){lf=!0};w.unstable_runWithPriority=function(l,t){switch(l){case 1:case 2:case 3:case 4:case 5:break;default:l=3}var u=hl;hl=l;try{return t()}finally{hl=u}};w.unstable_scheduleCallback=function(l,t,u){var a=w.unstable_now();switch(typeof u=="object"&&u!==null?(u=u.delay,u=typeof u=="number"&&0<u?a+u:a):u=a,l){case 1:var n=-1;break;case 2:n=250;break;case 5:n=1073741823;break;case 4:n=1e4;break;default:n=5e3}return n=u+n,l={id:Bm++,callback:t,priorityLevel:l,startTime:u,expirationTime:n,sortIndex:-1},u>a?(l.sortIndex=u,Ie(At,l),Wl(tt)===null&&l===Wl(At)&&(va?(Ki(ma),ma=-1):va=!0,uf(tf,u-a))):(l.sortIndex=n,Ie(tt,l),ya||Pe||(ya=!0,Tu||(Tu=!0,zu()))),l};w.unstable_shouldYield=wi;w.unstable_wrapCallback=function(l){var t=hl;return function(){var u=hl;hl=t;try{return l.apply(this,arguments)}finally{hl=u}}}});var Fi=Ft((d2,$i)=>{"use strict";$i.exports=Wi()});var af=Ft((h2,ki)=>{"use strict";ki.exports=We()});var Pi=Ft(gl=>{"use strict";var Rm=af();function Ii(l){var t="https://react.dev/errors/"+l;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var u=2;u<arguments.length;u++)t+="&args[]="+encodeURIComponent(arguments[u])}return"Minified React error #"+l+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function Mt(){}var Sl={d:{f:Mt,r:function(){throw Error(Ii(522))},D:Mt,C:Mt,L:Mt,m:Mt,X:Mt,S:Mt,M:Mt},p:0,findDOMNode:null},pm=Symbol.for("react.portal");function Cm(l,t,u){var a=3<arguments.length&&arguments[3]!==void 0?arguments[3]:null;return{$$typeof:pm,key:a==null?null:""+a,children:l,containerInfo:t,implementation:u}}var da=Rm.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE;function gn(l,t){if(l==="font")return"";if(typeof t=="string")return t==="use-credentials"?t:""}gl.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE=Sl;gl.createPortal=function(l,t){var u=2<arguments.length&&arguments[2]!==void 0?arguments[2]:null;if(!t||t.nodeType!==1&&t.nodeType!==9&&t.nodeType!==11)throw Error(Ii(299));return Cm(l,t,null,u)};gl.flushSync=function(l){var t=da.T,u=Sl.p;try{if(da.T=null,Sl.p=2,l)return l()}finally{da.T=t,Sl.p=u,Sl.d.f()}};gl.preconnect=function(l,t){typeof l=="string"&&(t?(t=t.crossOrigin,t=typeof t=="string"?t==="use-credentials"?t:"":void 0):t=null,Sl.d.C(l,t))};gl.prefetchDNS=function(l){typeof l=="string"&&Sl.d.D(l)};gl.preinit=function(l,t){if(typeof l=="string"&&t&&typeof t.as=="string"){var u=t.as,a=gn(u,t.crossOrigin),n=typeof t.integrity=="string"?t.integrity:void 0,e=typeof t.fetchPriority=="string"?t.fetchPriority:void 0;u==="style"?Sl.d.S(l,typeof t.precedence=="string"?t.precedence:void 0,{crossOrigin:a,integrity:n,fetchPriority:e}):u==="script"&&Sl.d.X(l,{crossOrigin:a,integrity:n,fetchPriority:e,nonce:typeof t.nonce=="string"?t.nonce:void 0})}};gl.preinitModule=function(l,t){if(typeof l=="string")if(typeof t=="object"&&t!==null){if(t.as==null||t.as==="script"){var u=gn(t.as,t.crossOrigin);Sl.d.M(l,{crossOrigin:u,integrity:typeof t.integrity=="string"?t.integrity:void 0,nonce:typeof t.nonce=="string"?t.nonce:void 0})}}else t==null&&Sl.d.M(l)};gl.preload=function(l,t){if(typeof l=="string"&&typeof t=="object"&&t!==null&&typeof t.as=="string"){var u=t.as,a=gn(u,t.crossOrigin);Sl.d.L(l,u,{crossOrigin:a,integrity:typeof t.integrity=="string"?t.integrity:void 0,nonce:typeof t.nonce=="string"?t.nonce:void 0,type:typeof t.type=="string"?t.type:void 0,fetchPriority:typeof t.fetchPriority=="string"?t.fetchPriority:void 0,referrerPolicy:typeof t.referrerPolicy=="string"?t.referrerPolicy:void 0,imageSrcSet:typeof t.imageSrcSet=="string"?t.imageSrcSet:void 0,imageSizes:typeof t.imageSizes=="string"?t.imageSizes:void 0,media:typeof t.media=="string"?t.media:void 0})}};gl.preloadModule=function(l,t){if(typeof l=="string")if(t){var u=gn(t.as,t.crossOrigin);Sl.d.m(l,{as:typeof t.as=="string"&&t.as!=="script"?t.as:void 0,crossOrigin:u,integrity:typeof t.integrity=="string"?t.integrity:void 0})}else Sl.d.m(l)};gl.requestFormReset=function(l){Sl.d.r(l)};gl.unstable_batchedUpdates=function(l,t){return l(t)};gl.useFormState=function(l,t,u){return da.H.useFormState(l,t,u)};gl.useFormStatus=function(){return da.H.useHostTransitionStatus()};gl.version="19.2.0"});var u0=Ft((g2,t0)=>{"use strict";function l0(){if(!(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__>"u"||typeof __REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE!="function"))try{__REACT_DEVTOOLS_GLOBAL_HOOK__.checkDCE(l0)}catch(l){console.error(l)}}l0(),t0.exports=Pi()});var Sm=Ft(je=>{"use strict";var nl=Fi(),H1=af(),Gm=u0();function b(l){var t="https://react.dev/errors/"+l;if(1<arguments.length){t+="?args[]="+encodeURIComponent(arguments[1]);for(var u=2;u<arguments.length;u++)t+="&args[]="+encodeURIComponent(arguments[u])}return"Minified React error #"+l+"; visit "+t+" for the full message or use the non-minified dev environment for full errors and additional helpful warnings."}function N1(l){return!(!l||l.nodeType!==1&&l.nodeType!==9&&l.nodeType!==11)}function Ia(l){var t=l,u=l;if(l.alternate)for(;t.return;)t=t.return;else{l=t;do t=l,(t.flags&4098)!==0&&(u=t.return),l=t.return;while(l)}return t.tag===3?u:null}function q1(l){if(l.tag===13){var t=l.memoizedState;if(t===null&&(l=l.alternate,l!==null&&(t=l.memoizedState)),t!==null)return t.dehydrated}return null}function Y1(l){if(l.tag===31){var t=l.memoizedState;if(t===null&&(l=l.alternate,l!==null&&(t=l.memoizedState)),t!==null)return t.dehydrated}return null}function a0(l){if(Ia(l)!==l)throw Error(b(188))}function Xm(l){var t=l.alternate;if(!t){if(t=Ia(l),t===null)throw Error(b(188));return t!==l?null:l}for(var u=l,a=t;;){var n=u.return;if(n===null)break;var e=n.alternate;if(e===null){if(a=n.return,a!==null){u=a;continue}break}if(n.child===e.child){for(e=n.child;e;){if(e===u)return a0(n),l;if(e===a)return a0(n),t;e=e.sibling}throw Error(b(188))}if(u.return!==a.return)u=n,a=e;else{for(var f=!1,c=n.child;c;){if(c===u){f=!0,u=n,a=e;break}if(c===a){f=!0,a=n,u=e;break}c=c.sibling}if(!f){for(c=e.child;c;){if(c===u){f=!0,u=e,a=n;break}if(c===a){f=!0,a=e,u=n;break}c=c.sibling}if(!f)throw Error(b(189))}}if(u.alternate!==a)throw Error(b(190))}if(u.tag!==3)throw Error(b(188));return u.stateNode.current===u?l:t}function B1(l){var t=l.tag;if(t===5||t===26||t===27||t===6)return l;for(l=l.child;l!==null;){if(t=B1(l),t!==null)return t;l=l.sibling}return null}var r=Object.assign,Qm=Symbol.for("react.element"),on=Symbol.for("react.transitional.element"),Ta=Symbol.for("react.portal"),Du=Symbol.for("react.fragment"),R1=Symbol.for("react.strict_mode"),Qf=Symbol.for("react.profiler"),p1=Symbol.for("react.consumer"),yt=Symbol.for("react.context"),Rc=Symbol.for("react.forward_ref"),Zf=Symbol.for("react.suspense"),jf=Symbol.for("react.suspense_list"),pc=Symbol.for("react.memo"),Ot=Symbol.for("react.lazy");Symbol.for("react.scope");var Vf=Symbol.for("react.activity");Symbol.for("react.legacy_hidden");Symbol.for("react.tracing_marker");var Zm=Symbol.for("react.memo_cache_sentinel");Symbol.for("react.view_transition");var n0=Symbol.iterator;function ha(l){return l===null||typeof l!="object"?null:(l=n0&&l[n0]||l["@@iterator"],typeof l=="function"?l:null)}var jm=Symbol.for("react.client.reference");function xf(l){if(l==null)return null;if(typeof l=="function")return l.$$typeof===jm?null:l.displayName||l.name||null;if(typeof l=="string")return l;switch(l){case Du:return"Fragment";case Qf:return"Profiler";case R1:return"StrictMode";case Zf:return"Suspense";case jf:return"SuspenseList";case Vf:return"Activity"}if(typeof l=="object")switch(l.$$typeof){case Ta:return"Portal";case yt:return l.displayName||"Context";case p1:return(l._context.displayName||"Context")+".Consumer";case Rc:var t=l.render;return l=l.displayName,l||(l=t.displayName||t.name||"",l=l!==""?"ForwardRef("+l+")":"ForwardRef"),l;case pc:return t=l.displayName||null,t!==null?t:xf(l.type)||"Memo";case Ot:t=l._payload,l=l._init;try{return xf(l(t))}catch{}}return null}var Ea=Array.isArray,M=H1.__CLIENT_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,C=Gm.__DOM_INTERNALS_DO_NOT_USE_OR_WARN_USERS_THEY_CANNOT_UPGRADE,uu={pending:!1,data:null,method:null,action:null},Lf=[],Uu=-1;function Pl(l){return{current:l}}function cl(l){0>Uu||(l.current=Lf[Uu],Lf[Uu]=null,Uu--)}function x(l,t){Uu++,Lf[Uu]=l.current,l.current=t}var Il=Pl(null),Qa=Pl(null),Ct=Pl(null),$n=Pl(null);function Fn(l,t){switch(x(Ct,t),x(Qa,l),x(Il,null),t.nodeType){case 9:case 11:l=(l=t.documentElement)&&(l=l.namespaceURI)?m1(l):0;break;default:if(l=t.tagName,t=t.namespaceURI)t=m1(t),l=lm(t,l);else switch(l){case"svg":l=1;break;case"math":l=2;break;default:l=0}}cl(Il),x(Il,l)}function Ju(){cl(Il),cl(Qa),cl(Ct)}function Kf(l){l.memoizedState!==null&&x($n,l);var t=Il.current,u=lm(t,l.type);t!==u&&(x(Qa,l),x(Il,u))}function kn(l){Qa.current===l&&(cl(Il),cl(Qa)),$n.current===l&&(cl($n),$a._currentValue=uu)}var nf,e0;function It(l){if(nf===void 0)try{throw Error()}catch(u){var t=u.stack.trim().match(/\n( *(at )?)/);nf=t&&t[1]||"",e0=-1<u.stack.indexOf(`
    at`)?" (<anonymous>)":-1<u.stack.indexOf("@")?"@unknown:0:0":""}return`
`+nf+l+e0}var ef=!1;function ff(l,t){if(!l||ef)return"";ef=!0;var u=Error.prepareStackTrace;Error.prepareStackTrace=void 0;try{var a={DetermineComponentFrameRoot:function(){try{if(t){var s=function(){throw Error()};if(Object.defineProperty(s.prototype,"props",{set:function(){throw Error()}}),typeof Reflect=="object"&&Reflect.construct){try{Reflect.construct(s,[])}catch(S){var h=S}Reflect.construct(l,[],s)}else{try{s.call()}catch(S){h=S}l.call(s.prototype)}}else{try{throw Error()}catch(S){h=S}(s=l())&&typeof s.catch=="function"&&s.catch(function(){})}}catch(S){if(S&&h&&typeof S.stack=="string")return[S.stack,h.stack]}return[null,null]}};a.DetermineComponentFrameRoot.displayName="DetermineComponentFrameRoot";var n=Object.getOwnPropertyDescriptor(a.DetermineComponentFrameRoot,"name");n&&n.configurable&&Object.defineProperty(a.DetermineComponentFrameRoot,"name",{value:"DetermineComponentFrameRoot"});var e=a.DetermineComponentFrameRoot(),f=e[0],c=e[1];if(f&&c){var i=f.split(`
`),m=c.split(`
`);for(n=a=0;a<i.length&&!i[a].includes("DetermineComponentFrameRoot");)a++;for(;n<m.length&&!m[n].includes("DetermineComponentFrameRoot");)n++;if(a===i.length||n===m.length)for(a=i.length-1,n=m.length-1;1<=a&&0<=n&&i[a]!==m[n];)n--;for(;1<=a&&0<=n;a--,n--)if(i[a]!==m[n]){if(a!==1||n!==1)do if(a--,n--,0>n||i[a]!==m[n]){var g=`
`+i[a].replace(" at new "," at ");return l.displayName&&g.includes("<anonymous>")&&(g=g.replace("<anonymous>",l.displayName)),g}while(1<=a&&0<=n);break}}}finally{ef=!1,Error.prepareStackTrace=u}return(u=l?l.displayName||l.name:"")?It(u):""}function Vm(l,t){switch(l.tag){case 26:case 27:case 5:return It(l.type);case 16:return It("Lazy");case 13:return l.child!==t&&t!==null?It("Suspense Fallback"):It("Suspense");case 19:return It("SuspenseList");case 0:case 15:return ff(l.type,!1);case 11:return ff(l.type.render,!1);case 1:return ff(l.type,!0);case 31:return It("Activity");default:return""}}function f0(l){try{var t="",u=null;do t+=Vm(l,u),u=l,l=l.return;while(l);return t}catch(a){return`
Error generating stack: `+a.message+`
`+a.stack}}var Jf=Object.prototype.hasOwnProperty,Cc=nl.unstable_scheduleCallback,cf=nl.unstable_cancelCallback,xm=nl.unstable_shouldYield,Lm=nl.unstable_requestPaint,Hl=nl.unstable_now,Km=nl.unstable_getCurrentPriorityLevel,C1=nl.unstable_ImmediatePriority,G1=nl.unstable_UserBlockingPriority,In=nl.unstable_NormalPriority,Jm=nl.unstable_LowPriority,X1=nl.unstable_IdlePriority,rm=nl.log,wm=nl.unstable_setDisableYieldValue,Pa=null,Nl=null;function qt(l){if(typeof rm=="function"&&wm(l),Nl&&typeof Nl.setStrictMode=="function")try{Nl.setStrictMode(Pa,l)}catch{}}var ql=Math.clz32?Math.clz32:Fm,Wm=Math.log,$m=Math.LN2;function Fm(l){return l>>>=0,l===0?32:31-(Wm(l)/$m|0)|0}var sn=256,bn=262144,zn=4194304;function Pt(l){var t=l&42;if(t!==0)return t;switch(l&-l){case 1:return 1;case 2:return 2;case 4:return 4;case 8:return 8;case 16:return 16;case 32:return 32;case 64:return 64;case 128:return 128;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:return l&261888;case 262144:case 524288:case 1048576:case 2097152:return l&3932160;case 4194304:case 8388608:case 16777216:case 33554432:return l&62914560;case 67108864:return 67108864;case 134217728:return 134217728;case 268435456:return 268435456;case 536870912:return 536870912;case 1073741824:return 0;default:return l}}function Oe(l,t,u){var a=l.pendingLanes;if(a===0)return 0;var n=0,e=l.suspendedLanes,f=l.pingedLanes;l=l.warmLanes;var c=a&134217727;return c!==0?(a=c&~e,a!==0?n=Pt(a):(f&=c,f!==0?n=Pt(f):u||(u=c&~l,u!==0&&(n=Pt(u))))):(c=a&~e,c!==0?n=Pt(c):f!==0?n=Pt(f):u||(u=a&~l,u!==0&&(n=Pt(u)))),n===0?0:t!==0&&t!==n&&(t&e)===0&&(e=n&-n,u=t&-t,e>=u||e===32&&(u&4194048)!==0)?t:n}function ln(l,t){return(l.pendingLanes&~(l.suspendedLanes&~l.pingedLanes)&t)===0}function km(l,t){switch(l){case 1:case 2:case 4:case 8:case 64:return t+250;case 16:case 32:case 128:case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:return t+5e3;case 4194304:case 8388608:case 16777216:case 33554432:return-1;case 67108864:case 134217728:case 268435456:case 536870912:case 1073741824:return-1;default:return-1}}function Q1(){var l=zn;return zn<<=1,(zn&62914560)===0&&(zn=4194304),l}function yf(l){for(var t=[],u=0;31>u;u++)t.push(l);return t}function tn(l,t){l.pendingLanes|=t,t!==268435456&&(l.suspendedLanes=0,l.pingedLanes=0,l.warmLanes=0)}function Im(l,t,u,a,n,e){var f=l.pendingLanes;l.pendingLanes=u,l.suspendedLanes=0,l.pingedLanes=0,l.warmLanes=0,l.expiredLanes&=u,l.entangledLanes&=u,l.errorRecoveryDisabledLanes&=u,l.shellSuspendCounter=0;var c=l.entanglements,i=l.expirationTimes,m=l.hiddenUpdates;for(u=f&~u;0<u;){var g=31-ql(u),s=1<<g;c[g]=0,i[g]=-1;var h=m[g];if(h!==null)for(m[g]=null,g=0;g<h.length;g++){var S=h[g];S!==null&&(S.lane&=-536870913)}u&=~s}a!==0&&Z1(l,a,0),e!==0&&n===0&&l.tag!==0&&(l.suspendedLanes|=e&~(f&~t))}function Z1(l,t,u){l.pendingLanes|=t,l.suspendedLanes&=~t;var a=31-ql(t);l.entangledLanes|=t,l.entanglements[a]=l.entanglements[a]|1073741824|u&261930}function j1(l,t){var u=l.entangledLanes|=t;for(l=l.entanglements;u;){var a=31-ql(u),n=1<<a;n&t|l[a]&t&&(l[a]|=t),u&=~n}}function V1(l,t){var u=t&-t;return u=(u&42)!==0?1:Gc(u),(u&(l.suspendedLanes|t))!==0?0:u}function Gc(l){switch(l){case 2:l=1;break;case 8:l=4;break;case 32:l=16;break;case 256:case 512:case 1024:case 2048:case 4096:case 8192:case 16384:case 32768:case 65536:case 131072:case 262144:case 524288:case 1048576:case 2097152:case 4194304:case 8388608:case 16777216:case 33554432:l=128;break;case 268435456:l=134217728;break;default:l=0}return l}function Xc(l){return l&=-l,2<l?8<l?(l&134217727)!==0?32:268435456:8:2}function x1(){var l=C.p;return l!==0?l:(l=window.event,l===void 0?32:mm(l.type))}function c0(l,t){var u=C.p;try{return C.p=l,t()}finally{C.p=u}}var Wt=Math.random().toString(36).slice(2),yl="__reactFiber$"+Wt,Al="__reactProps$"+Wt,ua="__reactContainer$"+Wt,rf="__reactEvents$"+Wt,Pm="__reactListeners$"+Wt,ld="__reactHandles$"+Wt,i0="__reactResources$"+Wt,un="__reactMarker$"+Wt;function Qc(l){delete l[yl],delete l[Al],delete l[rf],delete l[Pm],delete l[ld]}function Hu(l){var t=l[yl];if(t)return t;for(var u=l.parentNode;u;){if(t=u[ua]||u[yl]){if(u=t.alternate,t.child!==null||u!==null&&u.child!==null)for(l=o1(l);l!==null;){if(u=l[yl])return u;l=o1(l)}return t}l=u,u=l.parentNode}return null}function aa(l){if(l=l[yl]||l[ua]){var t=l.tag;if(t===5||t===6||t===13||t===31||t===26||t===27||t===3)return l}return null}function Aa(l){var t=l.tag;if(t===5||t===26||t===27||t===6)return l.stateNode;throw Error(b(33))}function Qu(l){var t=l[i0];return t||(t=l[i0]={hoistableStyles:new Map,hoistableScripts:new Map}),t}function fl(l){l[un]=!0}var L1=new Set,K1={};function du(l,t){ru(l,t),ru(l+"Capture",t)}function ru(l,t){for(K1[l]=t,l=0;l<t.length;l++)L1.add(t[l])}var td=RegExp("^[:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD][:A-Z_a-z\\u00C0-\\u00D6\\u00D8-\\u00F6\\u00F8-\\u02FF\\u0370-\\u037D\\u037F-\\u1FFF\\u200C-\\u200D\\u2070-\\u218F\\u2C00-\\u2FEF\\u3001-\\uD7FF\\uF900-\\uFDCF\\uFDF0-\\uFFFD\\-.0-9\\u00B7\\u0300-\\u036F\\u203F-\\u2040]*$"),y0={},v0={};function ud(l){return Jf.call(v0,l)?!0:Jf.call(y0,l)?!1:td.test(l)?v0[l]=!0:(y0[l]=!0,!1)}function pn(l,t,u){if(ud(t))if(u===null)l.removeAttribute(t);else{switch(typeof u){case"undefined":case"function":case"symbol":l.removeAttribute(t);return;case"boolean":var a=t.toLowerCase().slice(0,5);if(a!=="data-"&&a!=="aria-"){l.removeAttribute(t);return}}l.setAttribute(t,""+u)}}function Tn(l,t,u){if(u===null)l.removeAttribute(t);else{switch(typeof u){case"undefined":case"function":case"symbol":case"boolean":l.removeAttribute(t);return}l.setAttribute(t,""+u)}}function ut(l,t,u,a){if(a===null)l.removeAttribute(u);else{switch(typeof a){case"undefined":case"function":case"symbol":case"boolean":l.removeAttribute(u);return}l.setAttributeNS(t,u,""+a)}}function Gl(l){switch(typeof l){case"bigint":case"boolean":case"number":case"string":case"undefined":return l;case"object":return l;default:return""}}function J1(l){var t=l.type;return(l=l.nodeName)&&l.toLowerCase()==="input"&&(t==="checkbox"||t==="radio")}function ad(l,t,u){var a=Object.getOwnPropertyDescriptor(l.constructor.prototype,t);if(!l.hasOwnProperty(t)&&typeof a<"u"&&typeof a.get=="function"&&typeof a.set=="function"){var n=a.get,e=a.set;return Object.defineProperty(l,t,{configurable:!0,get:function(){return n.call(this)},set:function(f){u=""+f,e.call(this,f)}}),Object.defineProperty(l,t,{enumerable:a.enumerable}),{getValue:function(){return u},setValue:function(f){u=""+f},stopTracking:function(){l._valueTracker=null,delete l[t]}}}}function wf(l){if(!l._valueTracker){var t=J1(l)?"checked":"value";l._valueTracker=ad(l,t,""+l[t])}}function r1(l){if(!l)return!1;var t=l._valueTracker;if(!t)return!0;var u=t.getValue(),a="";return l&&(a=J1(l)?l.checked?"true":"false":l.value),l=a,l!==u?(t.setValue(l),!0):!1}function Pn(l){if(l=l||(typeof document<"u"?document:void 0),typeof l>"u")return null;try{return l.activeElement||l.body}catch{return l.body}}var nd=/[\n"\\]/g;function Zl(l){return l.replace(nd,function(t){return"\\"+t.charCodeAt(0).toString(16)+" "})}function Wf(l,t,u,a,n,e,f,c){l.name="",f!=null&&typeof f!="function"&&typeof f!="symbol"&&typeof f!="boolean"?l.type=f:l.removeAttribute("type"),t!=null?f==="number"?(t===0&&l.value===""||l.value!=t)&&(l.value=""+Gl(t)):l.value!==""+Gl(t)&&(l.value=""+Gl(t)):f!=="submit"&&f!=="reset"||l.removeAttribute("value"),t!=null?$f(l,f,Gl(t)):u!=null?$f(l,f,Gl(u)):a!=null&&l.removeAttribute("value"),n==null&&e!=null&&(l.defaultChecked=!!e),n!=null&&(l.checked=n&&typeof n!="function"&&typeof n!="symbol"),c!=null&&typeof c!="function"&&typeof c!="symbol"&&typeof c!="boolean"?l.name=""+Gl(c):l.removeAttribute("name")}function w1(l,t,u,a,n,e,f,c){if(e!=null&&typeof e!="function"&&typeof e!="symbol"&&typeof e!="boolean"&&(l.type=e),t!=null||u!=null){if(!(e!=="submit"&&e!=="reset"||t!=null)){wf(l);return}u=u!=null?""+Gl(u):"",t=t!=null?""+Gl(t):u,c||t===l.value||(l.value=t),l.defaultValue=t}a=a??n,a=typeof a!="function"&&typeof a!="symbol"&&!!a,l.checked=c?l.checked:!!a,l.defaultChecked=!!a,f!=null&&typeof f!="function"&&typeof f!="symbol"&&typeof f!="boolean"&&(l.name=f),wf(l)}function $f(l,t,u){t==="number"&&Pn(l.ownerDocument)===l||l.defaultValue===""+u||(l.defaultValue=""+u)}function Zu(l,t,u,a){if(l=l.options,t){t={};for(var n=0;n<u.length;n++)t["$"+u[n]]=!0;for(u=0;u<l.length;u++)n=t.hasOwnProperty("$"+l[u].value),l[u].selected!==n&&(l[u].selected=n),n&&a&&(l[u].defaultSelected=!0)}else{for(u=""+Gl(u),t=null,n=0;n<l.length;n++){if(l[n].value===u){l[n].selected=!0,a&&(l[n].defaultSelected=!0);return}t!==null||l[n].disabled||(t=l[n])}t!==null&&(t.selected=!0)}}function W1(l,t,u){if(t!=null&&(t=""+Gl(t),t!==l.value&&(l.value=t),u==null)){l.defaultValue!==t&&(l.defaultValue=t);return}l.defaultValue=u!=null?""+Gl(u):""}function $1(l,t,u,a){if(t==null){if(a!=null){if(u!=null)throw Error(b(92));if(Ea(a)){if(1<a.length)throw Error(b(93));a=a[0]}u=a}u==null&&(u=""),t=u}u=Gl(t),l.defaultValue=u,a=l.textContent,a===u&&a!==""&&a!==null&&(l.value=a),wf(l)}function wu(l,t){if(t){var u=l.firstChild;if(u&&u===l.lastChild&&u.nodeType===3){u.nodeValue=t;return}}l.textContent=t}var ed=new Set("animationIterationCount aspectRatio borderImageOutset borderImageSlice borderImageWidth boxFlex boxFlexGroup boxOrdinalGroup columnCount columns flex flexGrow flexPositive flexShrink flexNegative flexOrder gridArea gridRow gridRowEnd gridRowSpan gridRowStart gridColumn gridColumnEnd gridColumnSpan gridColumnStart fontWeight lineClamp lineHeight opacity order orphans scale tabSize widows zIndex zoom fillOpacity floodOpacity stopOpacity strokeDasharray strokeDashoffset strokeMiterlimit strokeOpacity strokeWidth MozAnimationIterationCount MozBoxFlex MozBoxFlexGroup MozLineClamp msAnimationIterationCount msFlex msZoom msFlexGrow msFlexNegative msFlexOrder msFlexPositive msFlexShrink msGridColumn msGridColumnSpan msGridRow msGridRowSpan WebkitAnimationIterationCount WebkitBoxFlex WebKitBoxFlexGroup WebkitBoxOrdinalGroup WebkitColumnCount WebkitColumns WebkitFlex WebkitFlexGrow WebkitFlexPositive WebkitFlexShrink WebkitLineClamp".split(" "));function m0(l,t,u){var a=t.indexOf("--")===0;u==null||typeof u=="boolean"||u===""?a?l.setProperty(t,""):t==="float"?l.cssFloat="":l[t]="":a?l.setProperty(t,u):typeof u!="number"||u===0||ed.has(t)?t==="float"?l.cssFloat=u:l[t]=(""+u).trim():l[t]=u+"px"}function F1(l,t,u){if(t!=null&&typeof t!="object")throw Error(b(62));if(l=l.style,u!=null){for(var a in u)!u.hasOwnProperty(a)||t!=null&&t.hasOwnProperty(a)||(a.indexOf("--")===0?l.setProperty(a,""):a==="float"?l.cssFloat="":l[a]="");for(var n in t)a=t[n],t.hasOwnProperty(n)&&u[n]!==a&&m0(l,n,a)}else for(var e in t)t.hasOwnProperty(e)&&m0(l,e,t[e])}function Zc(l){if(l.indexOf("-")===-1)return!1;switch(l){case"annotation-xml":case"color-profile":case"font-face":case"font-face-src":case"font-face-uri":case"font-face-format":case"font-face-name":case"missing-glyph":return!1;default:return!0}}var fd=new Map([["acceptCharset","accept-charset"],["htmlFor","for"],["httpEquiv","http-equiv"],["crossOrigin","crossorigin"],["accentHeight","accent-height"],["alignmentBaseline","alignment-baseline"],["arabicForm","arabic-form"],["baselineShift","baseline-shift"],["capHeight","cap-height"],["clipPath","clip-path"],["clipRule","clip-rule"],["colorInterpolation","color-interpolation"],["colorInterpolationFilters","color-interpolation-filters"],["colorProfile","color-profile"],["colorRendering","color-rendering"],["dominantBaseline","dominant-baseline"],["enableBackground","enable-background"],["fillOpacity","fill-opacity"],["fillRule","fill-rule"],["floodColor","flood-color"],["floodOpacity","flood-opacity"],["fontFamily","font-family"],["fontSize","font-size"],["fontSizeAdjust","font-size-adjust"],["fontStretch","font-stretch"],["fontStyle","font-style"],["fontVariant","font-variant"],["fontWeight","font-weight"],["glyphName","glyph-name"],["glyphOrientationHorizontal","glyph-orientation-horizontal"],["glyphOrientationVertical","glyph-orientation-vertical"],["horizAdvX","horiz-adv-x"],["horizOriginX","horiz-origin-x"],["imageRendering","image-rendering"],["letterSpacing","letter-spacing"],["lightingColor","lighting-color"],["markerEnd","marker-end"],["markerMid","marker-mid"],["markerStart","marker-start"],["overlinePosition","overline-position"],["overlineThickness","overline-thickness"],["paintOrder","paint-order"],["panose-1","panose-1"],["pointerEvents","pointer-events"],["renderingIntent","rendering-intent"],["shapeRendering","shape-rendering"],["stopColor","stop-color"],["stopOpacity","stop-opacity"],["strikethroughPosition","strikethrough-position"],["strikethroughThickness","strikethrough-thickness"],["strokeDasharray","stroke-dasharray"],["strokeDashoffset","stroke-dashoffset"],["strokeLinecap","stroke-linecap"],["strokeLinejoin","stroke-linejoin"],["strokeMiterlimit","stroke-miterlimit"],["strokeOpacity","stroke-opacity"],["strokeWidth","stroke-width"],["textAnchor","text-anchor"],["textDecoration","text-decoration"],["textRendering","text-rendering"],["transformOrigin","transform-origin"],["underlinePosition","underline-position"],["underlineThickness","underline-thickness"],["unicodeBidi","unicode-bidi"],["unicodeRange","unicode-range"],["unitsPerEm","units-per-em"],["vAlphabetic","v-alphabetic"],["vHanging","v-hanging"],["vIdeographic","v-ideographic"],["vMathematical","v-mathematical"],["vectorEffect","vector-effect"],["vertAdvY","vert-adv-y"],["vertOriginX","vert-origin-x"],["vertOriginY","vert-origin-y"],["wordSpacing","word-spacing"],["writingMode","writing-mode"],["xmlnsXlink","xmlns:xlink"],["xHeight","x-height"]]),cd=/^[\u0000-\u001F ]*j[\r\n\t]*a[\r\n\t]*v[\r\n\t]*a[\r\n\t]*s[\r\n\t]*c[\r\n\t]*r[\r\n\t]*i[\r\n\t]*p[\r\n\t]*t[\r\n\t]*:/i;function Cn(l){return cd.test(""+l)?"javascript:throw new Error('React has blocked a javascript: URL as a security precaution.')":l}function vt(){}var Ff=null;function jc(l){return l=l.target||l.srcElement||window,l.correspondingUseElement&&(l=l.correspondingUseElement),l.nodeType===3?l.parentNode:l}var Nu=null,ju=null;function d0(l){var t=aa(l);if(t&&(l=t.stateNode)){var u=l[Al]||null;l:switch(l=t.stateNode,t.type){case"input":if(Wf(l,u.value,u.defaultValue,u.defaultValue,u.checked,u.defaultChecked,u.type,u.name),t=u.name,u.type==="radio"&&t!=null){for(u=l;u.parentNode;)u=u.parentNode;for(u=u.querySelectorAll('input[name="'+Zl(""+t)+'"][type="radio"]'),t=0;t<u.length;t++){var a=u[t];if(a!==l&&a.form===l.form){var n=a[Al]||null;if(!n)throw Error(b(90));Wf(a,n.value,n.defaultValue,n.defaultValue,n.checked,n.defaultChecked,n.type,n.name)}}for(t=0;t<u.length;t++)a=u[t],a.form===l.form&&r1(a)}break l;case"textarea":W1(l,u.value,u.defaultValue);break l;case"select":t=u.value,t!=null&&Zu(l,!!u.multiple,t,!1)}}}var vf=!1;function k1(l,t,u){if(vf)return l(t,u);vf=!0;try{var a=l(t);return a}finally{if(vf=!1,(Nu!==null||ju!==null)&&(Ge(),Nu&&(t=Nu,l=ju,ju=Nu=null,d0(t),l)))for(t=0;t<l.length;t++)d0(l[t])}}function Za(l,t){var u=l.stateNode;if(u===null)return null;var a=u[Al]||null;if(a===null)return null;u=a[t];l:switch(t){case"onClick":case"onClickCapture":case"onDoubleClick":case"onDoubleClickCapture":case"onMouseDown":case"onMouseDownCapture":case"onMouseMove":case"onMouseMoveCapture":case"onMouseUp":case"onMouseUpCapture":case"onMouseEnter":(a=!a.disabled)||(l=l.type,a=!(l==="button"||l==="input"||l==="select"||l==="textarea")),l=!a;break l;default:l=!1}if(l)return null;if(u&&typeof u!="function")throw Error(b(231,t,typeof u));return u}var gt=!(typeof window>"u"||typeof window.document>"u"||typeof window.document.createElement>"u"),kf=!1;if(gt)try{Eu={},Object.defineProperty(Eu,"passive",{get:function(){kf=!0}}),window.addEventListener("test",Eu,Eu),window.removeEventListener("test",Eu,Eu)}catch{kf=!1}var Eu,Yt=null,Vc=null,Gn=null;function I1(){if(Gn)return Gn;var l,t=Vc,u=t.length,a,n="value"in Yt?Yt.value:Yt.textContent,e=n.length;for(l=0;l<u&&t[l]===n[l];l++);var f=u-l;for(a=1;a<=f&&t[u-a]===n[e-a];a++);return Gn=n.slice(l,1<a?1-a:void 0)}function Xn(l){var t=l.keyCode;return"charCode"in l?(l=l.charCode,l===0&&t===13&&(l=13)):l=t,l===10&&(l=13),32<=l||l===13?l:0}function En(){return!0}function h0(){return!1}function Ml(l){function t(u,a,n,e,f){this._reactName=u,this._targetInst=n,this.type=a,this.nativeEvent=e,this.target=f,this.currentTarget=null;for(var c in l)l.hasOwnProperty(c)&&(u=l[c],this[c]=u?u(e):e[c]);return this.isDefaultPrevented=(e.defaultPrevented!=null?e.defaultPrevented:e.returnValue===!1)?En:h0,this.isPropagationStopped=h0,this}return r(t.prototype,{preventDefault:function(){this.defaultPrevented=!0;var u=this.nativeEvent;u&&(u.preventDefault?u.preventDefault():typeof u.returnValue!="unknown"&&(u.returnValue=!1),this.isDefaultPrevented=En)},stopPropagation:function(){var u=this.nativeEvent;u&&(u.stopPropagation?u.stopPropagation():typeof u.cancelBubble!="unknown"&&(u.cancelBubble=!0),this.isPropagationStopped=En)},persist:function(){},isPersistent:En}),t}var hu={eventPhase:0,bubbles:0,cancelable:0,timeStamp:function(l){return l.timeStamp||Date.now()},defaultPrevented:0,isTrusted:0},_e=Ml(hu),an=r({},hu,{view:0,detail:0}),id=Ml(an),mf,df,Sa,De=r({},an,{screenX:0,screenY:0,clientX:0,clientY:0,pageX:0,pageY:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,getModifierState:xc,button:0,buttons:0,relatedTarget:function(l){return l.relatedTarget===void 0?l.fromElement===l.srcElement?l.toElement:l.fromElement:l.relatedTarget},movementX:function(l){return"movementX"in l?l.movementX:(l!==Sa&&(Sa&&l.type==="mousemove"?(mf=l.screenX-Sa.screenX,df=l.screenY-Sa.screenY):df=mf=0,Sa=l),mf)},movementY:function(l){return"movementY"in l?l.movementY:df}}),S0=Ml(De),yd=r({},De,{dataTransfer:0}),vd=Ml(yd),md=r({},an,{relatedTarget:0}),hf=Ml(md),dd=r({},hu,{animationName:0,elapsedTime:0,pseudoElement:0}),hd=Ml(dd),Sd=r({},hu,{clipboardData:function(l){return"clipboardData"in l?l.clipboardData:window.clipboardData}}),gd=Ml(Sd),od=r({},hu,{data:0}),g0=Ml(od),sd={Esc:"Escape",Spacebar:" ",Left:"ArrowLeft",Up:"ArrowUp",Right:"ArrowRight",Down:"ArrowDown",Del:"Delete",Win:"OS",Menu:"ContextMenu",Apps:"ContextMenu",Scroll:"ScrollLock",MozPrintableKey:"Unidentified"},bd={8:"Backspace",9:"Tab",12:"Clear",13:"Enter",16:"Shift",17:"Control",18:"Alt",19:"Pause",20:"CapsLock",27:"Escape",32:" ",33:"PageUp",34:"PageDown",35:"End",36:"Home",37:"ArrowLeft",38:"ArrowUp",39:"ArrowRight",40:"ArrowDown",45:"Insert",46:"Delete",112:"F1",113:"F2",114:"F3",115:"F4",116:"F5",117:"F6",118:"F7",119:"F8",120:"F9",121:"F10",122:"F11",123:"F12",144:"NumLock",145:"ScrollLock",224:"Meta"},zd={Alt:"altKey",Control:"ctrlKey",Meta:"metaKey",Shift:"shiftKey"};function Td(l){var t=this.nativeEvent;return t.getModifierState?t.getModifierState(l):(l=zd[l])?!!t[l]:!1}function xc(){return Td}var Ed=r({},an,{key:function(l){if(l.key){var t=sd[l.key]||l.key;if(t!=="Unidentified")return t}return l.type==="keypress"?(l=Xn(l),l===13?"Enter":String.fromCharCode(l)):l.type==="keydown"||l.type==="keyup"?bd[l.keyCode]||"Unidentified":""},code:0,location:0,ctrlKey:0,shiftKey:0,altKey:0,metaKey:0,repeat:0,locale:0,getModifierState:xc,charCode:function(l){return l.type==="keypress"?Xn(l):0},keyCode:function(l){return l.type==="keydown"||l.type==="keyup"?l.keyCode:0},which:function(l){return l.type==="keypress"?Xn(l):l.type==="keydown"||l.type==="keyup"?l.keyCode:0}}),Ad=Ml(Ed),Md=r({},De,{pointerId:0,width:0,height:0,pressure:0,tangentialPressure:0,tiltX:0,tiltY:0,twist:0,pointerType:0,isPrimary:0}),o0=Ml(Md),Od=r({},an,{touches:0,targetTouches:0,changedTouches:0,altKey:0,metaKey:0,ctrlKey:0,shiftKey:0,getModifierState:xc}),_d=Ml(Od),Dd=r({},hu,{propertyName:0,elapsedTime:0,pseudoElement:0}),Ud=Ml(Dd),Hd=r({},De,{deltaX:function(l){return"deltaX"in l?l.deltaX:"wheelDeltaX"in l?-l.wheelDeltaX:0},deltaY:function(l){return"deltaY"in l?l.deltaY:"wheelDeltaY"in l?-l.wheelDeltaY:"wheelDelta"in l?-l.wheelDelta:0},deltaZ:0,deltaMode:0}),Nd=Ml(Hd),qd=r({},hu,{newState:0,oldState:0}),Yd=Ml(qd),Bd=[9,13,27,32],Lc=gt&&"CompositionEvent"in window,_a=null;gt&&"documentMode"in document&&(_a=document.documentMode);var Rd=gt&&"TextEvent"in window&&!_a,P1=gt&&(!Lc||_a&&8<_a&&11>=_a),s0=" ",b0=!1;function ly(l,t){switch(l){case"keyup":return Bd.indexOf(t.keyCode)!==-1;case"keydown":return t.keyCode!==229;case"keypress":case"mousedown":case"focusout":return!0;default:return!1}}function ty(l){return l=l.detail,typeof l=="object"&&"data"in l?l.data:null}var qu=!1;function pd(l,t){switch(l){case"compositionend":return ty(t);case"keypress":return t.which!==32?null:(b0=!0,s0);case"textInput":return l=t.data,l===s0&&b0?null:l;default:return null}}function Cd(l,t){if(qu)return l==="compositionend"||!Lc&&ly(l,t)?(l=I1(),Gn=Vc=Yt=null,qu=!1,l):null;switch(l){case"paste":return null;case"keypress":if(!(t.ctrlKey||t.altKey||t.metaKey)||t.ctrlKey&&t.altKey){if(t.char&&1<t.char.length)return t.char;if(t.which)return String.fromCharCode(t.which)}return null;case"compositionend":return P1&&t.locale!=="ko"?null:t.data;default:return null}}var Gd={color:!0,date:!0,datetime:!0,"datetime-local":!0,email:!0,month:!0,number:!0,password:!0,range:!0,search:!0,tel:!0,text:!0,time:!0,url:!0,week:!0};function z0(l){var t=l&&l.nodeName&&l.nodeName.toLowerCase();return t==="input"?!!Gd[l.type]:t==="textarea"}function uy(l,t,u,a){Nu?ju?ju.push(a):ju=[a]:Nu=a,t=se(t,"onChange"),0<t.length&&(u=new _e("onChange","change",null,u,a),l.push({event:u,listeners:t}))}var Da=null,ja=null;function Xd(l){kv(l,0)}function Ue(l){var t=Aa(l);if(r1(t))return l}function T0(l,t){if(l==="change")return t}var ay=!1;gt&&(gt?(Mn="oninput"in document,Mn||(Sf=document.createElement("div"),Sf.setAttribute("oninput","return;"),Mn=typeof Sf.oninput=="function"),An=Mn):An=!1,ay=An&&(!document.documentMode||9<document.documentMode));var An,Mn,Sf;function E0(){Da&&(Da.detachEvent("onpropertychange",ny),ja=Da=null)}function ny(l){if(l.propertyName==="value"&&Ue(ja)){var t=[];uy(t,ja,l,jc(l)),k1(Xd,t)}}function Qd(l,t,u){l==="focusin"?(E0(),Da=t,ja=u,Da.attachEvent("onpropertychange",ny)):l==="focusout"&&E0()}function Zd(l){if(l==="selectionchange"||l==="keyup"||l==="keydown")return Ue(ja)}function jd(l,t){if(l==="click")return Ue(t)}function Vd(l,t){if(l==="input"||l==="change")return Ue(t)}function xd(l,t){return l===t&&(l!==0||1/l===1/t)||l!==l&&t!==t}var Bl=typeof Object.is=="function"?Object.is:xd;function Va(l,t){if(Bl(l,t))return!0;if(typeof l!="object"||l===null||typeof t!="object"||t===null)return!1;var u=Object.keys(l),a=Object.keys(t);if(u.length!==a.length)return!1;for(a=0;a<u.length;a++){var n=u[a];if(!Jf.call(t,n)||!Bl(l[n],t[n]))return!1}return!0}function A0(l){for(;l&&l.firstChild;)l=l.firstChild;return l}function M0(l,t){var u=A0(l);l=0;for(var a;u;){if(u.nodeType===3){if(a=l+u.textContent.length,l<=t&&a>=t)return{node:u,offset:t-l};l=a}l:{for(;u;){if(u.nextSibling){u=u.nextSibling;break l}u=u.parentNode}u=void 0}u=A0(u)}}function ey(l,t){return l&&t?l===t?!0:l&&l.nodeType===3?!1:t&&t.nodeType===3?ey(l,t.parentNode):"contains"in l?l.contains(t):l.compareDocumentPosition?!!(l.compareDocumentPosition(t)&16):!1:!1}function fy(l){l=l!=null&&l.ownerDocument!=null&&l.ownerDocument.defaultView!=null?l.ownerDocument.defaultView:window;for(var t=Pn(l.document);t instanceof l.HTMLIFrameElement;){try{var u=typeof t.contentWindow.location.href=="string"}catch{u=!1}if(u)l=t.contentWindow;else break;t=Pn(l.document)}return t}function Kc(l){var t=l&&l.nodeName&&l.nodeName.toLowerCase();return t&&(t==="input"&&(l.type==="text"||l.type==="search"||l.type==="tel"||l.type==="url"||l.type==="password")||t==="textarea"||l.contentEditable==="true")}var Ld=gt&&"documentMode"in document&&11>=document.documentMode,Yu=null,If=null,Ua=null,Pf=!1;function O0(l,t,u){var a=u.window===u?u.document:u.nodeType===9?u:u.ownerDocument;Pf||Yu==null||Yu!==Pn(a)||(a=Yu,"selectionStart"in a&&Kc(a)?a={start:a.selectionStart,end:a.selectionEnd}:(a=(a.ownerDocument&&a.ownerDocument.defaultView||window).getSelection(),a={anchorNode:a.anchorNode,anchorOffset:a.anchorOffset,focusNode:a.focusNode,focusOffset:a.focusOffset}),Ua&&Va(Ua,a)||(Ua=a,a=se(If,"onSelect"),0<a.length&&(t=new _e("onSelect","select",null,t,u),l.push({event:t,listeners:a}),t.target=Yu)))}function kt(l,t){var u={};return u[l.toLowerCase()]=t.toLowerCase(),u["Webkit"+l]="webkit"+t,u["Moz"+l]="moz"+t,u}var Bu={animationend:kt("Animation","AnimationEnd"),animationiteration:kt("Animation","AnimationIteration"),animationstart:kt("Animation","AnimationStart"),transitionrun:kt("Transition","TransitionRun"),transitionstart:kt("Transition","TransitionStart"),transitioncancel:kt("Transition","TransitionCancel"),transitionend:kt("Transition","TransitionEnd")},gf={},cy={};gt&&(cy=document.createElement("div").style,"AnimationEvent"in window||(delete Bu.animationend.animation,delete Bu.animationiteration.animation,delete Bu.animationstart.animation),"TransitionEvent"in window||delete Bu.transitionend.transition);function Su(l){if(gf[l])return gf[l];if(!Bu[l])return l;var t=Bu[l],u;for(u in t)if(t.hasOwnProperty(u)&&u in cy)return gf[l]=t[u];return l}var iy=Su("animationend"),yy=Su("animationiteration"),vy=Su("animationstart"),Kd=Su("transitionrun"),Jd=Su("transitionstart"),rd=Su("transitioncancel"),my=Su("transitionend"),dy=new Map,lc="abort auxClick beforeToggle cancel canPlay canPlayThrough click close contextMenu copy cut drag dragEnd dragEnter dragExit dragLeave dragOver dragStart drop durationChange emptied encrypted ended error gotPointerCapture input invalid keyDown keyPress keyUp load loadedData loadedMetadata loadStart lostPointerCapture mouseDown mouseMove mouseOut mouseOver mouseUp paste pause play playing pointerCancel pointerDown pointerMove pointerOut pointerOver pointerUp progress rateChange reset resize seeked seeking stalled submit suspend timeUpdate touchCancel touchEnd touchStart volumeChange scroll toggle touchMove waiting wheel".split(" ");lc.push("scrollEnd");function wl(l,t){dy.set(l,t),du(t,[l])}var le=typeof reportError=="function"?reportError:function(l){if(typeof window=="object"&&typeof window.ErrorEvent=="function"){var t=new window.ErrorEvent("error",{bubbles:!0,cancelable:!0,message:typeof l=="object"&&l!==null&&typeof l.message=="string"?String(l.message):String(l),error:l});if(!window.dispatchEvent(t))return}else if(typeof process=="object"&&typeof process.emit=="function"){process.emit("uncaughtException",l);return}console.error(l)},Cl=[],Ru=0,Jc=0;function He(){for(var l=Ru,t=Jc=Ru=0;t<l;){var u=Cl[t];Cl[t++]=null;var a=Cl[t];Cl[t++]=null;var n=Cl[t];Cl[t++]=null;var e=Cl[t];if(Cl[t++]=null,a!==null&&n!==null){var f=a.pending;f===null?n.next=n:(n.next=f.next,f.next=n),a.pending=n}e!==0&&hy(u,n,e)}}function Ne(l,t,u,a){Cl[Ru++]=l,Cl[Ru++]=t,Cl[Ru++]=u,Cl[Ru++]=a,Jc|=a,l.lanes|=a,l=l.alternate,l!==null&&(l.lanes|=a)}function rc(l,t,u,a){return Ne(l,t,u,a),te(l)}function gu(l,t){return Ne(l,null,null,t),te(l)}function hy(l,t,u){l.lanes|=u;var a=l.alternate;a!==null&&(a.lanes|=u);for(var n=!1,e=l.return;e!==null;)e.childLanes|=u,a=e.alternate,a!==null&&(a.childLanes|=u),e.tag===22&&(l=e.stateNode,l===null||l._visibility&1||(n=!0)),l=e,e=e.return;return l.tag===3?(e=l.stateNode,n&&t!==null&&(n=31-ql(u),l=e.hiddenUpdates,a=l[n],a===null?l[n]=[t]:a.push(t),t.lane=u|536870912),e):null}function te(l){if(50<Ga)throw Ga=0,Ec=null,Error(b(185));for(var t=l.return;t!==null;)l=t,t=l.return;return l.tag===3?l.stateNode:null}var pu={};function wd(l,t,u,a){this.tag=l,this.key=u,this.sibling=this.child=this.return=this.stateNode=this.type=this.elementType=null,this.index=0,this.refCleanup=this.ref=null,this.pendingProps=t,this.dependencies=this.memoizedState=this.updateQueue=this.memoizedProps=null,this.mode=a,this.subtreeFlags=this.flags=0,this.deletions=null,this.childLanes=this.lanes=0,this.alternate=null}function Dl(l,t,u,a){return new wd(l,t,u,a)}function wc(l){return l=l.prototype,!(!l||!l.isReactComponent)}function dt(l,t){var u=l.alternate;return u===null?(u=Dl(l.tag,t,l.key,l.mode),u.elementType=l.elementType,u.type=l.type,u.stateNode=l.stateNode,u.alternate=l,l.alternate=u):(u.pendingProps=t,u.type=l.type,u.flags=0,u.subtreeFlags=0,u.deletions=null),u.flags=l.flags&65011712,u.childLanes=l.childLanes,u.lanes=l.lanes,u.child=l.child,u.memoizedProps=l.memoizedProps,u.memoizedState=l.memoizedState,u.updateQueue=l.updateQueue,t=l.dependencies,u.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext},u.sibling=l.sibling,u.index=l.index,u.ref=l.ref,u.refCleanup=l.refCleanup,u}function Sy(l,t){l.flags&=65011714;var u=l.alternate;return u===null?(l.childLanes=0,l.lanes=t,l.child=null,l.subtreeFlags=0,l.memoizedProps=null,l.memoizedState=null,l.updateQueue=null,l.dependencies=null,l.stateNode=null):(l.childLanes=u.childLanes,l.lanes=u.lanes,l.child=u.child,l.subtreeFlags=0,l.deletions=null,l.memoizedProps=u.memoizedProps,l.memoizedState=u.memoizedState,l.updateQueue=u.updateQueue,l.type=u.type,t=u.dependencies,l.dependencies=t===null?null:{lanes:t.lanes,firstContext:t.firstContext}),l}function Qn(l,t,u,a,n,e){var f=0;if(a=l,typeof l=="function")wc(l)&&(f=1);else if(typeof l=="string")f=Fh(l,u,Il.current)?26:l==="html"||l==="head"||l==="body"?27:5;else l:switch(l){case Vf:return l=Dl(31,u,t,n),l.elementType=Vf,l.lanes=e,l;case Du:return au(u.children,n,e,t);case R1:f=8,n|=24;break;case Qf:return l=Dl(12,u,t,n|2),l.elementType=Qf,l.lanes=e,l;case Zf:return l=Dl(13,u,t,n),l.elementType=Zf,l.lanes=e,l;case jf:return l=Dl(19,u,t,n),l.elementType=jf,l.lanes=e,l;default:if(typeof l=="object"&&l!==null)switch(l.$$typeof){case yt:f=10;break l;case p1:f=9;break l;case Rc:f=11;break l;case pc:f=14;break l;case Ot:f=16,a=null;break l}f=29,u=Error(b(130,l===null?"null":typeof l,"")),a=null}return t=Dl(f,u,t,n),t.elementType=l,t.type=a,t.lanes=e,t}function au(l,t,u,a){return l=Dl(7,l,a,t),l.lanes=u,l}function of(l,t,u){return l=Dl(6,l,null,t),l.lanes=u,l}function gy(l){var t=Dl(18,null,null,0);return t.stateNode=l,t}function sf(l,t,u){return t=Dl(4,l.children!==null?l.children:[],l.key,t),t.lanes=u,t.stateNode={containerInfo:l.containerInfo,pendingChildren:null,implementation:l.implementation},t}var _0=new WeakMap;function jl(l,t){if(typeof l=="object"&&l!==null){var u=_0.get(l);return u!==void 0?u:(t={value:l,source:t,stack:f0(t)},_0.set(l,t),t)}return{value:l,source:t,stack:f0(t)}}var Cu=[],Gu=0,ue=null,xa=0,Xl=[],Ql=0,Kt=null,$l=1,Fl="";function ct(l,t){Cu[Gu++]=xa,Cu[Gu++]=ue,ue=l,xa=t}function oy(l,t,u){Xl[Ql++]=$l,Xl[Ql++]=Fl,Xl[Ql++]=Kt,Kt=l;var a=$l;l=Fl;var n=32-ql(a)-1;a&=~(1<<n),u+=1;var e=32-ql(t)+n;if(30<e){var f=n-n%5;e=(a&(1<<f)-1).toString(32),a>>=f,n-=f,$l=1<<32-ql(t)+n|u<<n|a,Fl=e+l}else $l=1<<e|u<<n|a,Fl=l}function Wc(l){l.return!==null&&(ct(l,1),oy(l,1,0))}function $c(l){for(;l===ue;)ue=Cu[--Gu],Cu[Gu]=null,xa=Cu[--Gu],Cu[Gu]=null;for(;l===Kt;)Kt=Xl[--Ql],Xl[Ql]=null,Fl=Xl[--Ql],Xl[Ql]=null,$l=Xl[--Ql],Xl[Ql]=null}function sy(l,t){Xl[Ql++]=$l,Xl[Ql++]=Fl,Xl[Ql++]=Kt,$l=t.id,Fl=t.overflow,Kt=l}var vl=null,J=null,Y=!1,Gt=null,Vl=!1,tc=Error(b(519));function Jt(l){var t=Error(b(418,1<arguments.length&&arguments[1]!==void 0&&arguments[1]?"text":"HTML",""));throw La(jl(t,l)),tc}function D0(l){var t=l.stateNode,u=l.type,a=l.memoizedProps;switch(t[yl]=l,t[Al]=a,u){case"dialog":U("cancel",t),U("close",t);break;case"iframe":case"object":case"embed":U("load",t);break;case"video":case"audio":for(u=0;u<wa.length;u++)U(wa[u],t);break;case"source":U("error",t);break;case"img":case"image":case"link":U("error",t),U("load",t);break;case"details":U("toggle",t);break;case"input":U("invalid",t),w1(t,a.value,a.defaultValue,a.checked,a.defaultChecked,a.type,a.name,!0);break;case"select":U("invalid",t);break;case"textarea":U("invalid",t),$1(t,a.value,a.defaultValue,a.children)}u=a.children,typeof u!="string"&&typeof u!="number"&&typeof u!="bigint"||t.textContent===""+u||a.suppressHydrationWarning===!0||Pv(t.textContent,u)?(a.popover!=null&&(U("beforetoggle",t),U("toggle",t)),a.onScroll!=null&&U("scroll",t),a.onScrollEnd!=null&&U("scrollend",t),a.onClick!=null&&(t.onclick=vt),t=!0):t=!1,t||Jt(l,!0)}function U0(l){for(vl=l.return;vl;)switch(vl.tag){case 5:case 31:case 13:Vl=!1;return;case 27:case 3:Vl=!0;return;default:vl=vl.return}}function Au(l){if(l!==vl)return!1;if(!Y)return U0(l),Y=!0,!1;var t=l.tag,u;if((u=t!==3&&t!==27)&&((u=t===5)&&(u=l.type,u=!(u!=="form"&&u!=="button")||Dc(l.type,l.memoizedProps)),u=!u),u&&J&&Jt(l),U0(l),t===13){if(l=l.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(317));J=g1(l)}else if(t===31){if(l=l.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(317));J=g1(l)}else t===27?(t=J,$t(l.type)?(l=qc,qc=null,J=l):J=t):J=vl?Ll(l.stateNode.nextSibling):null;return!0}function cu(){J=vl=null,Y=!1}function bf(){var l=Gt;return l!==null&&(Tl===null?Tl=l:Tl.push.apply(Tl,l),Gt=null),l}function La(l){Gt===null?Gt=[l]:Gt.push(l)}var uc=Pl(null),ou=null,mt=null;function Dt(l,t,u){x(uc,t._currentValue),t._currentValue=u}function ht(l){l._currentValue=uc.current,cl(uc)}function ac(l,t,u){for(;l!==null;){var a=l.alternate;if((l.childLanes&t)!==t?(l.childLanes|=t,a!==null&&(a.childLanes|=t)):a!==null&&(a.childLanes&t)!==t&&(a.childLanes|=t),l===u)break;l=l.return}}function nc(l,t,u,a){var n=l.child;for(n!==null&&(n.return=l);n!==null;){var e=n.dependencies;if(e!==null){var f=n.child;e=e.firstContext;l:for(;e!==null;){var c=e;e=n;for(var i=0;i<t.length;i++)if(c.context===t[i]){e.lanes|=u,c=e.alternate,c!==null&&(c.lanes|=u),ac(e.return,u,l),a||(f=null);break l}e=c.next}}else if(n.tag===18){if(f=n.return,f===null)throw Error(b(341));f.lanes|=u,e=f.alternate,e!==null&&(e.lanes|=u),ac(f,u,l),f=null}else f=n.child;if(f!==null)f.return=n;else for(f=n;f!==null;){if(f===l){f=null;break}if(n=f.sibling,n!==null){n.return=f.return,f=n;break}f=f.return}n=f}}function na(l,t,u,a){l=null;for(var n=t,e=!1;n!==null;){if(!e){if((n.flags&524288)!==0)e=!0;else if((n.flags&262144)!==0)break}if(n.tag===10){var f=n.alternate;if(f===null)throw Error(b(387));if(f=f.memoizedProps,f!==null){var c=n.type;Bl(n.pendingProps.value,f.value)||(l!==null?l.push(c):l=[c])}}else if(n===$n.current){if(f=n.alternate,f===null)throw Error(b(387));f.memoizedState.memoizedState!==n.memoizedState.memoizedState&&(l!==null?l.push($a):l=[$a])}n=n.return}l!==null&&nc(t,l,u,a),t.flags|=262144}function ae(l){for(l=l.firstContext;l!==null;){if(!Bl(l.context._currentValue,l.memoizedValue))return!0;l=l.next}return!1}function iu(l){ou=l,mt=null,l=l.dependencies,l!==null&&(l.firstContext=null)}function ml(l){return by(ou,l)}function On(l,t){return ou===null&&iu(l),by(l,t)}function by(l,t){var u=t._currentValue;if(t={context:t,memoizedValue:u,next:null},mt===null){if(l===null)throw Error(b(308));mt=t,l.dependencies={lanes:0,firstContext:t},l.flags|=524288}else mt=mt.next=t;return u}var Wd=typeof AbortController<"u"?AbortController:function(){var l=[],t=this.signal={aborted:!1,addEventListener:function(u,a){l.push(a)}};this.abort=function(){t.aborted=!0,l.forEach(function(u){return u()})}},$d=nl.unstable_scheduleCallback,Fd=nl.unstable_NormalPriority,tl={$$typeof:yt,Consumer:null,Provider:null,_currentValue:null,_currentValue2:null,_threadCount:0};function Fc(){return{controller:new Wd,data:new Map,refCount:0}}function nn(l){l.refCount--,l.refCount===0&&$d(Fd,function(){l.controller.abort()})}var Ha=null,ec=0,Wu=0,Vu=null;function kd(l,t){if(Ha===null){var u=Ha=[];ec=0,Wu=Ei(),Vu={status:"pending",value:void 0,then:function(a){u.push(a)}}}return ec++,t.then(H0,H0),t}function H0(){if(--ec===0&&Ha!==null){Vu!==null&&(Vu.status="fulfilled");var l=Ha;Ha=null,Wu=0,Vu=null;for(var t=0;t<l.length;t++)(0,l[t])()}}function Id(l,t){var u=[],a={status:"pending",value:null,reason:null,then:function(n){u.push(n)}};return l.then(function(){a.status="fulfilled",a.value=t;for(var n=0;n<u.length;n++)(0,u[n])(t)},function(n){for(a.status="rejected",a.reason=n,n=0;n<u.length;n++)(0,u[n])(void 0)}),a}var N0=M.S;M.S=function(l,t){Bv=Hl(),typeof t=="object"&&t!==null&&typeof t.then=="function"&&kd(l,t),N0!==null&&N0(l,t)};var nu=Pl(null);function kc(){var l=nu.current;return l!==null?l:V.pooledCache}function Zn(l,t){t===null?x(nu,nu.current):x(nu,t.pool)}function zy(){var l=kc();return l===null?null:{parent:tl._currentValue,pool:l}}var ea=Error(b(460)),Ic=Error(b(474)),qe=Error(b(542)),ne={then:function(){}};function q0(l){return l=l.status,l==="fulfilled"||l==="rejected"}function Ty(l,t,u){switch(u=l[u],u===void 0?l.push(t):u!==t&&(t.then(vt,vt),t=u),t.status){case"fulfilled":return t.value;case"rejected":throw l=t.reason,B0(l),l;default:if(typeof t.status=="string")t.then(vt,vt);else{if(l=V,l!==null&&100<l.shellSuspendCounter)throw Error(b(482));l=t,l.status="pending",l.then(function(a){if(t.status==="pending"){var n=t;n.status="fulfilled",n.value=a}},function(a){if(t.status==="pending"){var n=t;n.status="rejected",n.reason=a}})}switch(t.status){case"fulfilled":return t.value;case"rejected":throw l=t.reason,B0(l),l}throw eu=t,ea}}function lu(l){try{var t=l._init;return t(l._payload)}catch(u){throw u!==null&&typeof u=="object"&&typeof u.then=="function"?(eu=u,ea):u}}var eu=null;function Y0(){if(eu===null)throw Error(b(459));var l=eu;return eu=null,l}function B0(l){if(l===ea||l===qe)throw Error(b(483))}var xu=null,Ka=0;function _n(l){var t=Ka;return Ka+=1,xu===null&&(xu=[]),Ty(xu,l,t)}function ga(l,t){t=t.props.ref,l.ref=t!==void 0?t:null}function Dn(l,t){throw t.$$typeof===Qm?Error(b(525)):(l=Object.prototype.toString.call(t),Error(b(31,l==="[object Object]"?"object with keys {"+Object.keys(t).join(", ")+"}":l)))}function Ey(l){function t(v,y){if(l){var d=v.deletions;d===null?(v.deletions=[y],v.flags|=16):d.push(y)}}function u(v,y){if(!l)return null;for(;y!==null;)t(v,y),y=y.sibling;return null}function a(v){for(var y=new Map;v!==null;)v.key!==null?y.set(v.key,v):y.set(v.index,v),v=v.sibling;return y}function n(v,y){return v=dt(v,y),v.index=0,v.sibling=null,v}function e(v,y,d){return v.index=d,l?(d=v.alternate,d!==null?(d=d.index,d<y?(v.flags|=67108866,y):d):(v.flags|=67108866,y)):(v.flags|=1048576,y)}function f(v){return l&&v.alternate===null&&(v.flags|=67108866),v}function c(v,y,d,o){return y===null||y.tag!==6?(y=of(d,v.mode,o),y.return=v,y):(y=n(y,d),y.return=v,y)}function i(v,y,d,o){var E=d.type;return E===Du?g(v,y,d.props.children,o,d.key):y!==null&&(y.elementType===E||typeof E=="object"&&E!==null&&E.$$typeof===Ot&&lu(E)===y.type)?(y=n(y,d.props),ga(y,d),y.return=v,y):(y=Qn(d.type,d.key,d.props,null,v.mode,o),ga(y,d),y.return=v,y)}function m(v,y,d,o){return y===null||y.tag!==4||y.stateNode.containerInfo!==d.containerInfo||y.stateNode.implementation!==d.implementation?(y=sf(d,v.mode,o),y.return=v,y):(y=n(y,d.children||[]),y.return=v,y)}function g(v,y,d,o,E){return y===null||y.tag!==7?(y=au(d,v.mode,o,E),y.return=v,y):(y=n(y,d),y.return=v,y)}function s(v,y,d){if(typeof y=="string"&&y!==""||typeof y=="number"||typeof y=="bigint")return y=of(""+y,v.mode,d),y.return=v,y;if(typeof y=="object"&&y!==null){switch(y.$$typeof){case on:return d=Qn(y.type,y.key,y.props,null,v.mode,d),ga(d,y),d.return=v,d;case Ta:return y=sf(y,v.mode,d),y.return=v,y;case Ot:return y=lu(y),s(v,y,d)}if(Ea(y)||ha(y))return y=au(y,v.mode,d,null),y.return=v,y;if(typeof y.then=="function")return s(v,_n(y),d);if(y.$$typeof===yt)return s(v,On(v,y),d);Dn(v,y)}return null}function h(v,y,d,o){var E=y!==null?y.key:null;if(typeof d=="string"&&d!==""||typeof d=="number"||typeof d=="bigint")return E!==null?null:c(v,y,""+d,o);if(typeof d=="object"&&d!==null){switch(d.$$typeof){case on:return d.key===E?i(v,y,d,o):null;case Ta:return d.key===E?m(v,y,d,o):null;case Ot:return d=lu(d),h(v,y,d,o)}if(Ea(d)||ha(d))return E!==null?null:g(v,y,d,o,null);if(typeof d.then=="function")return h(v,y,_n(d),o);if(d.$$typeof===yt)return h(v,y,On(v,d),o);Dn(v,d)}return null}function S(v,y,d,o,E){if(typeof o=="string"&&o!==""||typeof o=="number"||typeof o=="bigint")return v=v.get(d)||null,c(y,v,""+o,E);if(typeof o=="object"&&o!==null){switch(o.$$typeof){case on:return v=v.get(o.key===null?d:o.key)||null,i(y,v,o,E);case Ta:return v=v.get(o.key===null?d:o.key)||null,m(y,v,o,E);case Ot:return o=lu(o),S(v,y,d,o,E)}if(Ea(o)||ha(o))return v=v.get(d)||null,g(y,v,o,E,null);if(typeof o.then=="function")return S(v,y,d,_n(o),E);if(o.$$typeof===yt)return S(v,y,d,On(y,o),E);Dn(y,o)}return null}function z(v,y,d,o){for(var E=null,B=null,T=y,D=y=0,N=null;T!==null&&D<d.length;D++){T.index>D?(N=T,T=null):N=T.sibling;var R=h(v,T,d[D],o);if(R===null){T===null&&(T=N);break}l&&T&&R.alternate===null&&t(v,T),y=e(R,y,D),B===null?E=R:B.sibling=R,B=R,T=N}if(D===d.length)return u(v,T),Y&&ct(v,D),E;if(T===null){for(;D<d.length;D++)T=s(v,d[D],o),T!==null&&(y=e(T,y,D),B===null?E=T:B.sibling=T,B=T);return Y&&ct(v,D),E}for(T=a(T);D<d.length;D++)N=S(T,v,D,d[D],o),N!==null&&(l&&N.alternate!==null&&T.delete(N.key===null?D:N.key),y=e(N,y,D),B===null?E=N:B.sibling=N,B=N);return l&&T.forEach(function(Et){return t(v,Et)}),Y&&ct(v,D),E}function A(v,y,d,o){if(d==null)throw Error(b(151));for(var E=null,B=null,T=y,D=y=0,N=null,R=d.next();T!==null&&!R.done;D++,R=d.next()){T.index>D?(N=T,T=null):N=T.sibling;var Et=h(v,T,R.value,o);if(Et===null){T===null&&(T=N);break}l&&T&&Et.alternate===null&&t(v,T),y=e(Et,y,D),B===null?E=Et:B.sibling=Et,B=Et,T=N}if(R.done)return u(v,T),Y&&ct(v,D),E;if(T===null){for(;!R.done;D++,R=d.next())R=s(v,R.value,o),R!==null&&(y=e(R,y,D),B===null?E=R:B.sibling=R,B=R);return Y&&ct(v,D),E}for(T=a(T);!R.done;D++,R=d.next())R=S(T,v,D,R.value,o),R!==null&&(l&&R.alternate!==null&&T.delete(R.key===null?D:R.key),y=e(R,y,D),B===null?E=R:B.sibling=R,B=R);return l&&T.forEach(function(gm){return t(v,gm)}),Y&&ct(v,D),E}function Q(v,y,d,o){if(typeof d=="object"&&d!==null&&d.type===Du&&d.key===null&&(d=d.props.children),typeof d=="object"&&d!==null){switch(d.$$typeof){case on:l:{for(var E=d.key;y!==null;){if(y.key===E){if(E=d.type,E===Du){if(y.tag===7){u(v,y.sibling),o=n(y,d.props.children),o.return=v,v=o;break l}}else if(y.elementType===E||typeof E=="object"&&E!==null&&E.$$typeof===Ot&&lu(E)===y.type){u(v,y.sibling),o=n(y,d.props),ga(o,d),o.return=v,v=o;break l}u(v,y);break}else t(v,y);y=y.sibling}d.type===Du?(o=au(d.props.children,v.mode,o,d.key),o.return=v,v=o):(o=Qn(d.type,d.key,d.props,null,v.mode,o),ga(o,d),o.return=v,v=o)}return f(v);case Ta:l:{for(E=d.key;y!==null;){if(y.key===E)if(y.tag===4&&y.stateNode.containerInfo===d.containerInfo&&y.stateNode.implementation===d.implementation){u(v,y.sibling),o=n(y,d.children||[]),o.return=v,v=o;break l}else{u(v,y);break}else t(v,y);y=y.sibling}o=sf(d,v.mode,o),o.return=v,v=o}return f(v);case Ot:return d=lu(d),Q(v,y,d,o)}if(Ea(d))return z(v,y,d,o);if(ha(d)){if(E=ha(d),typeof E!="function")throw Error(b(150));return d=E.call(d),A(v,y,d,o)}if(typeof d.then=="function")return Q(v,y,_n(d),o);if(d.$$typeof===yt)return Q(v,y,On(v,d),o);Dn(v,d)}return typeof d=="string"&&d!==""||typeof d=="number"||typeof d=="bigint"?(d=""+d,y!==null&&y.tag===6?(u(v,y.sibling),o=n(y,d),o.return=v,v=o):(u(v,y),o=of(d,v.mode,o),o.return=v,v=o),f(v)):u(v,y)}return function(v,y,d,o){try{Ka=0;var E=Q(v,y,d,o);return xu=null,E}catch(T){if(T===ea||T===qe)throw T;var B=Dl(29,T,null,v.mode);return B.lanes=o,B.return=v,B}finally{}}}var yu=Ey(!0),Ay=Ey(!1),_t=!1;function Pc(l){l.updateQueue={baseState:l.memoizedState,firstBaseUpdate:null,lastBaseUpdate:null,shared:{pending:null,lanes:0,hiddenCallbacks:null},callbacks:null}}function fc(l,t){l=l.updateQueue,t.updateQueue===l&&(t.updateQueue={baseState:l.baseState,firstBaseUpdate:l.firstBaseUpdate,lastBaseUpdate:l.lastBaseUpdate,shared:l.shared,callbacks:null})}function Xt(l){return{lane:l,tag:0,payload:null,callback:null,next:null}}function Qt(l,t,u){var a=l.updateQueue;if(a===null)return null;if(a=a.shared,(p&2)!==0){var n=a.pending;return n===null?t.next=t:(t.next=n.next,n.next=t),a.pending=t,t=te(l),hy(l,null,u),t}return Ne(l,a,t,u),te(l)}function Na(l,t,u){if(t=t.updateQueue,t!==null&&(t=t.shared,(u&4194048)!==0)){var a=t.lanes;a&=l.pendingLanes,u|=a,t.lanes=u,j1(l,u)}}function zf(l,t){var u=l.updateQueue,a=l.alternate;if(a!==null&&(a=a.updateQueue,u===a)){var n=null,e=null;if(u=u.firstBaseUpdate,u!==null){do{var f={lane:u.lane,tag:u.tag,payload:u.payload,callback:null,next:null};e===null?n=e=f:e=e.next=f,u=u.next}while(u!==null);e===null?n=e=t:e=e.next=t}else n=e=t;u={baseState:a.baseState,firstBaseUpdate:n,lastBaseUpdate:e,shared:a.shared,callbacks:a.callbacks},l.updateQueue=u;return}l=u.lastBaseUpdate,l===null?u.firstBaseUpdate=t:l.next=t,u.lastBaseUpdate=t}var cc=!1;function qa(){if(cc){var l=Vu;if(l!==null)throw l}}function Ya(l,t,u,a){cc=!1;var n=l.updateQueue;_t=!1;var e=n.firstBaseUpdate,f=n.lastBaseUpdate,c=n.shared.pending;if(c!==null){n.shared.pending=null;var i=c,m=i.next;i.next=null,f===null?e=m:f.next=m,f=i;var g=l.alternate;g!==null&&(g=g.updateQueue,c=g.lastBaseUpdate,c!==f&&(c===null?g.firstBaseUpdate=m:c.next=m,g.lastBaseUpdate=i))}if(e!==null){var s=n.baseState;f=0,g=m=i=null,c=e;do{var h=c.lane&-536870913,S=h!==c.lane;if(S?(q&h)===h:(a&h)===h){h!==0&&h===Wu&&(cc=!0),g!==null&&(g=g.next={lane:0,tag:c.tag,payload:c.payload,callback:null,next:null});l:{var z=l,A=c;h=t;var Q=u;switch(A.tag){case 1:if(z=A.payload,typeof z=="function"){s=z.call(Q,s,h);break l}s=z;break l;case 3:z.flags=z.flags&-65537|128;case 0:if(z=A.payload,h=typeof z=="function"?z.call(Q,s,h):z,h==null)break l;s=r({},s,h);break l;case 2:_t=!0}}h=c.callback,h!==null&&(l.flags|=64,S&&(l.flags|=8192),S=n.callbacks,S===null?n.callbacks=[h]:S.push(h))}else S={lane:h,tag:c.tag,payload:c.payload,callback:c.callback,next:null},g===null?(m=g=S,i=s):g=g.next=S,f|=h;if(c=c.next,c===null){if(c=n.shared.pending,c===null)break;S=c,c=S.next,S.next=null,n.lastBaseUpdate=S,n.shared.pending=null}}while(!0);g===null&&(i=s),n.baseState=i,n.firstBaseUpdate=m,n.lastBaseUpdate=g,e===null&&(n.shared.lanes=0),wt|=f,l.lanes=f,l.memoizedState=s}}function My(l,t){if(typeof l!="function")throw Error(b(191,l));l.call(t)}function Oy(l,t){var u=l.callbacks;if(u!==null)for(l.callbacks=null,l=0;l<u.length;l++)My(u[l],t)}var $u=Pl(null),ee=Pl(0);function R0(l,t){l=zt,x(ee,l),x($u,t),zt=l|t.baseLanes}function ic(){x(ee,zt),x($u,$u.current)}function li(){zt=ee.current,cl($u),cl(ee)}var Rl=Pl(null),xl=null;function Ut(l){var t=l.alternate;x(k,k.current&1),x(Rl,l),xl===null&&(t===null||$u.current!==null||t.memoizedState!==null)&&(xl=l)}function yc(l){x(k,k.current),x(Rl,l),xl===null&&(xl=l)}function _y(l){l.tag===22?(x(k,k.current),x(Rl,l),xl===null&&(xl=l)):Ht(l)}function Ht(){x(k,k.current),x(Rl,Rl.current)}function _l(l){cl(Rl),xl===l&&(xl=null),cl(k)}var k=Pl(0);function fe(l){for(var t=l;t!==null;){if(t.tag===13){var u=t.memoizedState;if(u!==null&&(u=u.dehydrated,u===null||Hc(u)||Nc(u)))return t}else if(t.tag===19&&(t.memoizedProps.revealOrder==="forwards"||t.memoizedProps.revealOrder==="backwards"||t.memoizedProps.revealOrder==="unstable_legacy-backwards"||t.memoizedProps.revealOrder==="together")){if((t.flags&128)!==0)return t}else if(t.child!==null){t.child.return=t,t=t.child;continue}if(t===l)break;for(;t.sibling===null;){if(t.return===null||t.return===l)return null;t=t.return}t.sibling.return=t.return,t=t.sibling}return null}var ot=0,_=null,j=null,P=null,ce=!1,Lu=!1,vu=!1,ie=0,Ja=0,Ku=null,Pd=0;function $(){throw Error(b(321))}function ti(l,t){if(t===null)return!1;for(var u=0;u<t.length&&u<l.length;u++)if(!Bl(l[u],t[u]))return!1;return!0}function ui(l,t,u,a,n,e){return ot=e,_=t,t.memoizedState=null,t.updateQueue=null,t.lanes=0,M.H=l===null||l.memoizedState===null?uv:hi,vu=!1,e=u(a,n),vu=!1,Lu&&(e=Uy(t,u,a,n)),Dy(l),e}function Dy(l){M.H=ra;var t=j!==null&&j.next!==null;if(ot=0,P=j=_=null,ce=!1,Ja=0,Ku=null,t)throw Error(b(300));l===null||ul||(l=l.dependencies,l!==null&&ae(l)&&(ul=!0))}function Uy(l,t,u,a){_=l;var n=0;do{if(Lu&&(Ku=null),Ja=0,Lu=!1,25<=n)throw Error(b(301));if(n+=1,P=j=null,l.updateQueue!=null){var e=l.updateQueue;e.lastEffect=null,e.events=null,e.stores=null,e.memoCache!=null&&(e.memoCache.index=0)}M.H=av,e=t(u,a)}while(Lu);return e}function lh(){var l=M.H,t=l.useState()[0];return t=typeof t.then=="function"?en(t):t,l=l.useState()[0],(j!==null?j.memoizedState:null)!==l&&(_.flags|=1024),t}function ai(){var l=ie!==0;return ie=0,l}function ni(l,t,u){t.updateQueue=l.updateQueue,t.flags&=-2053,l.lanes&=~u}function ei(l){if(ce){for(l=l.memoizedState;l!==null;){var t=l.queue;t!==null&&(t.pending=null),l=l.next}ce=!1}ot=0,P=j=_=null,Lu=!1,Ja=ie=0,Ku=null}function ol(){var l={memoizedState:null,baseState:null,baseQueue:null,queue:null,next:null};return P===null?_.memoizedState=P=l:P=P.next=l,P}function I(){if(j===null){var l=_.alternate;l=l!==null?l.memoizedState:null}else l=j.next;var t=P===null?_.memoizedState:P.next;if(t!==null)P=t,j=l;else{if(l===null)throw _.alternate===null?Error(b(467)):Error(b(310));j=l,l={memoizedState:j.memoizedState,baseState:j.baseState,baseQueue:j.baseQueue,queue:j.queue,next:null},P===null?_.memoizedState=P=l:P=P.next=l}return P}function Ye(){return{lastEffect:null,events:null,stores:null,memoCache:null}}function en(l){var t=Ja;return Ja+=1,Ku===null&&(Ku=[]),l=Ty(Ku,l,t),t=_,(P===null?t.memoizedState:P.next)===null&&(t=t.alternate,M.H=t===null||t.memoizedState===null?uv:hi),l}function Be(l){if(l!==null&&typeof l=="object"){if(typeof l.then=="function")return en(l);if(l.$$typeof===yt)return ml(l)}throw Error(b(438,String(l)))}function fi(l){var t=null,u=_.updateQueue;if(u!==null&&(t=u.memoCache),t==null){var a=_.alternate;a!==null&&(a=a.updateQueue,a!==null&&(a=a.memoCache,a!=null&&(t={data:a.data.map(function(n){return n.slice()}),index:0})))}if(t==null&&(t={data:[],index:0}),u===null&&(u=Ye(),_.updateQueue=u),u.memoCache=t,u=t.data[t.index],u===void 0)for(u=t.data[t.index]=Array(l),a=0;a<l;a++)u[a]=Zm;return t.index++,u}function st(l,t){return typeof t=="function"?t(l):t}function jn(l){var t=I();return ci(t,j,l)}function ci(l,t,u){var a=l.queue;if(a===null)throw Error(b(311));a.lastRenderedReducer=u;var n=l.baseQueue,e=a.pending;if(e!==null){if(n!==null){var f=n.next;n.next=e.next,e.next=f}t.baseQueue=n=e,a.pending=null}if(e=l.baseState,n===null)l.memoizedState=e;else{t=n.next;var c=f=null,i=null,m=t,g=!1;do{var s=m.lane&-536870913;if(s!==m.lane?(q&s)===s:(ot&s)===s){var h=m.revertLane;if(h===0)i!==null&&(i=i.next={lane:0,revertLane:0,gesture:null,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null}),s===Wu&&(g=!0);else if((ot&h)===h){m=m.next,h===Wu&&(g=!0);continue}else s={lane:0,revertLane:m.revertLane,gesture:null,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null},i===null?(c=i=s,f=e):i=i.next=s,_.lanes|=h,wt|=h;s=m.action,vu&&u(e,s),e=m.hasEagerState?m.eagerState:u(e,s)}else h={lane:s,revertLane:m.revertLane,gesture:m.gesture,action:m.action,hasEagerState:m.hasEagerState,eagerState:m.eagerState,next:null},i===null?(c=i=h,f=e):i=i.next=h,_.lanes|=s,wt|=s;m=m.next}while(m!==null&&m!==t);if(i===null?f=e:i.next=c,!Bl(e,l.memoizedState)&&(ul=!0,g&&(u=Vu,u!==null)))throw u;l.memoizedState=e,l.baseState=f,l.baseQueue=i,a.lastRenderedState=e}return n===null&&(a.lanes=0),[l.memoizedState,a.dispatch]}function Tf(l){var t=I(),u=t.queue;if(u===null)throw Error(b(311));u.lastRenderedReducer=l;var a=u.dispatch,n=u.pending,e=t.memoizedState;if(n!==null){u.pending=null;var f=n=n.next;do e=l(e,f.action),f=f.next;while(f!==n);Bl(e,t.memoizedState)||(ul=!0),t.memoizedState=e,t.baseQueue===null&&(t.baseState=e),u.lastRenderedState=e}return[e,a]}function Hy(l,t,u){var a=_,n=I(),e=Y;if(e){if(u===void 0)throw Error(b(407));u=u()}else u=t();var f=!Bl((j||n).memoizedState,u);if(f&&(n.memoizedState=u,ul=!0),n=n.queue,ii(Yy.bind(null,a,n,l),[l]),n.getSnapshot!==t||f||P!==null&&P.memoizedState.tag&1){if(a.flags|=2048,Fu(9,{destroy:void 0},qy.bind(null,a,n,u,t),null),V===null)throw Error(b(349));e||(ot&127)!==0||Ny(a,t,u)}return u}function Ny(l,t,u){l.flags|=16384,l={getSnapshot:t,value:u},t=_.updateQueue,t===null?(t=Ye(),_.updateQueue=t,t.stores=[l]):(u=t.stores,u===null?t.stores=[l]:u.push(l))}function qy(l,t,u,a){t.value=u,t.getSnapshot=a,By(t)&&Ry(l)}function Yy(l,t,u){return u(function(){By(t)&&Ry(l)})}function By(l){var t=l.getSnapshot;l=l.value;try{var u=t();return!Bl(l,u)}catch{return!0}}function Ry(l){var t=gu(l,2);t!==null&&El(t,l,2)}function vc(l){var t=ol();if(typeof l=="function"){var u=l;if(l=u(),vu){qt(!0);try{u()}finally{qt(!1)}}}return t.memoizedState=t.baseState=l,t.queue={pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:l},t}function py(l,t,u,a){return l.baseState=u,ci(l,j,typeof a=="function"?a:st)}function th(l,t,u,a,n){if(pe(l))throw Error(b(485));if(l=t.action,l!==null){var e={payload:n,action:l,next:null,isTransition:!0,status:"pending",value:null,reason:null,listeners:[],then:function(f){e.listeners.push(f)}};M.T!==null?u(!0):e.isTransition=!1,a(e),u=t.pending,u===null?(e.next=t.pending=e,Cy(t,e)):(e.next=u.next,t.pending=u.next=e)}}function Cy(l,t){var u=t.action,a=t.payload,n=l.state;if(t.isTransition){var e=M.T,f={};M.T=f;try{var c=u(n,a),i=M.S;i!==null&&i(f,c),p0(l,t,c)}catch(m){mc(l,t,m)}finally{e!==null&&f.types!==null&&(e.types=f.types),M.T=e}}else try{e=u(n,a),p0(l,t,e)}catch(m){mc(l,t,m)}}function p0(l,t,u){u!==null&&typeof u=="object"&&typeof u.then=="function"?u.then(function(a){C0(l,t,a)},function(a){return mc(l,t,a)}):C0(l,t,u)}function C0(l,t,u){t.status="fulfilled",t.value=u,Gy(t),l.state=u,t=l.pending,t!==null&&(u=t.next,u===t?l.pending=null:(u=u.next,t.next=u,Cy(l,u)))}function mc(l,t,u){var a=l.pending;if(l.pending=null,a!==null){a=a.next;do t.status="rejected",t.reason=u,Gy(t),t=t.next;while(t!==a)}l.action=null}function Gy(l){l=l.listeners;for(var t=0;t<l.length;t++)(0,l[t])()}function Xy(l,t){return t}function G0(l,t){if(Y){var u=V.formState;if(u!==null){l:{var a=_;if(Y){if(J){t:{for(var n=J,e=Vl;n.nodeType!==8;){if(!e){n=null;break t}if(n=Ll(n.nextSibling),n===null){n=null;break t}}e=n.data,n=e==="F!"||e==="F"?n:null}if(n){J=Ll(n.nextSibling),a=n.data==="F!";break l}}Jt(a)}a=!1}a&&(t=u[0])}}return u=ol(),u.memoizedState=u.baseState=t,a={pending:null,lanes:0,dispatch:null,lastRenderedReducer:Xy,lastRenderedState:t},u.queue=a,u=Py.bind(null,_,a),a.dispatch=u,a=vc(!1),e=di.bind(null,_,!1,a.queue),a=ol(),n={state:t,dispatch:null,action:l,pending:null},a.queue=n,u=th.bind(null,_,n,e,u),n.dispatch=u,a.memoizedState=l,[t,u,!1]}function X0(l){var t=I();return Qy(t,j,l)}function Qy(l,t,u){if(t=ci(l,t,Xy)[0],l=jn(st)[0],typeof t=="object"&&t!==null&&typeof t.then=="function")try{var a=en(t)}catch(f){throw f===ea?qe:f}else a=t;t=I();var n=t.queue,e=n.dispatch;return u!==t.memoizedState&&(_.flags|=2048,Fu(9,{destroy:void 0},uh.bind(null,n,u),null)),[a,e,l]}function uh(l,t){l.action=t}function Q0(l){var t=I(),u=j;if(u!==null)return Qy(t,u,l);I(),t=t.memoizedState,u=I();var a=u.queue.dispatch;return u.memoizedState=l,[t,a,!1]}function Fu(l,t,u,a){return l={tag:l,create:u,deps:a,inst:t,next:null},t=_.updateQueue,t===null&&(t=Ye(),_.updateQueue=t),u=t.lastEffect,u===null?t.lastEffect=l.next=l:(a=u.next,u.next=l,l.next=a,t.lastEffect=l),l}function Zy(){return I().memoizedState}function Vn(l,t,u,a){var n=ol();_.flags|=l,n.memoizedState=Fu(1|t,{destroy:void 0},u,a===void 0?null:a)}function Re(l,t,u,a){var n=I();a=a===void 0?null:a;var e=n.memoizedState.inst;j!==null&&a!==null&&ti(a,j.memoizedState.deps)?n.memoizedState=Fu(t,e,u,a):(_.flags|=l,n.memoizedState=Fu(1|t,e,u,a))}function Z0(l,t){Vn(8390656,8,l,t)}function ii(l,t){Re(2048,8,l,t)}function ah(l){_.flags|=4;var t=_.updateQueue;if(t===null)t=Ye(),_.updateQueue=t,t.events=[l];else{var u=t.events;u===null?t.events=[l]:u.push(l)}}function jy(l){var t=I().memoizedState;return ah({ref:t,nextImpl:l}),function(){if((p&2)!==0)throw Error(b(440));return t.impl.apply(void 0,arguments)}}function Vy(l,t){return Re(4,2,l,t)}function xy(l,t){return Re(4,4,l,t)}function Ly(l,t){if(typeof t=="function"){l=l();var u=t(l);return function(){typeof u=="function"?u():t(null)}}if(t!=null)return l=l(),t.current=l,function(){t.current=null}}function Ky(l,t,u){u=u!=null?u.concat([l]):null,Re(4,4,Ly.bind(null,t,l),u)}function yi(){}function Jy(l,t){var u=I();t=t===void 0?null:t;var a=u.memoizedState;return t!==null&&ti(t,a[1])?a[0]:(u.memoizedState=[l,t],l)}function ry(l,t){var u=I();t=t===void 0?null:t;var a=u.memoizedState;if(t!==null&&ti(t,a[1]))return a[0];if(a=l(),vu){qt(!0);try{l()}finally{qt(!1)}}return u.memoizedState=[a,t],a}function vi(l,t,u){return u===void 0||(ot&1073741824)!==0&&(q&261930)===0?l.memoizedState=t:(l.memoizedState=u,l=pv(),_.lanes|=l,wt|=l,u)}function wy(l,t,u,a){return Bl(u,t)?u:$u.current!==null?(l=vi(l,u,a),Bl(l,t)||(ul=!0),l):(ot&42)===0||(ot&1073741824)!==0&&(q&261930)===0?(ul=!0,l.memoizedState=u):(l=pv(),_.lanes|=l,wt|=l,t)}function Wy(l,t,u,a,n){var e=C.p;C.p=e!==0&&8>e?e:8;var f=M.T,c={};M.T=c,di(l,!1,t,u);try{var i=n(),m=M.S;if(m!==null&&m(c,i),i!==null&&typeof i=="object"&&typeof i.then=="function"){var g=Id(i,a);Ba(l,t,g,Yl(l))}else Ba(l,t,a,Yl(l))}catch(s){Ba(l,t,{then:function(){},status:"rejected",reason:s},Yl())}finally{C.p=e,f!==null&&c.types!==null&&(f.types=c.types),M.T=f}}function nh(){}function dc(l,t,u,a){if(l.tag!==5)throw Error(b(476));var n=$y(l).queue;Wy(l,n,t,uu,u===null?nh:function(){return Fy(l),u(a)})}function $y(l){var t=l.memoizedState;if(t!==null)return t;t={memoizedState:uu,baseState:uu,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:uu},next:null};var u={};return t.next={memoizedState:u,baseState:u,baseQueue:null,queue:{pending:null,lanes:0,dispatch:null,lastRenderedReducer:st,lastRenderedState:u},next:null},l.memoizedState=t,l=l.alternate,l!==null&&(l.memoizedState=t),t}function Fy(l){var t=$y(l);t.next===null&&(t=l.alternate.memoizedState),Ba(l,t.next.queue,{},Yl())}function mi(){return ml($a)}function ky(){return I().memoizedState}function Iy(){return I().memoizedState}function eh(l){for(var t=l.return;t!==null;){switch(t.tag){case 24:case 3:var u=Yl();l=Xt(u);var a=Qt(t,l,u);a!==null&&(El(a,t,u),Na(a,t,u)),t={cache:Fc()},l.payload=t;return}t=t.return}}function fh(l,t,u){var a=Yl();u={lane:a,revertLane:0,gesture:null,action:u,hasEagerState:!1,eagerState:null,next:null},pe(l)?lv(t,u):(u=rc(l,t,u,a),u!==null&&(El(u,l,a),tv(u,t,a)))}function Py(l,t,u){var a=Yl();Ba(l,t,u,a)}function Ba(l,t,u,a){var n={lane:a,revertLane:0,gesture:null,action:u,hasEagerState:!1,eagerState:null,next:null};if(pe(l))lv(t,n);else{var e=l.alternate;if(l.lanes===0&&(e===null||e.lanes===0)&&(e=t.lastRenderedReducer,e!==null))try{var f=t.lastRenderedState,c=e(f,u);if(n.hasEagerState=!0,n.eagerState=c,Bl(c,f))return Ne(l,t,n,0),V===null&&He(),!1}catch{}finally{}if(u=rc(l,t,n,a),u!==null)return El(u,l,a),tv(u,t,a),!0}return!1}function di(l,t,u,a){if(a={lane:2,revertLane:Ei(),gesture:null,action:a,hasEagerState:!1,eagerState:null,next:null},pe(l)){if(t)throw Error(b(479))}else t=rc(l,u,a,2),t!==null&&El(t,l,2)}function pe(l){var t=l.alternate;return l===_||t!==null&&t===_}function lv(l,t){Lu=ce=!0;var u=l.pending;u===null?t.next=t:(t.next=u.next,u.next=t),l.pending=t}function tv(l,t,u){if((u&4194048)!==0){var a=t.lanes;a&=l.pendingLanes,u|=a,t.lanes=u,j1(l,u)}}var ra={readContext:ml,use:Be,useCallback:$,useContext:$,useEffect:$,useImperativeHandle:$,useLayoutEffect:$,useInsertionEffect:$,useMemo:$,useReducer:$,useRef:$,useState:$,useDebugValue:$,useDeferredValue:$,useTransition:$,useSyncExternalStore:$,useId:$,useHostTransitionStatus:$,useFormState:$,useActionState:$,useOptimistic:$,useMemoCache:$,useCacheRefresh:$};ra.useEffectEvent=$;var uv={readContext:ml,use:Be,useCallback:function(l,t){return ol().memoizedState=[l,t===void 0?null:t],l},useContext:ml,useEffect:Z0,useImperativeHandle:function(l,t,u){u=u!=null?u.concat([l]):null,Vn(4194308,4,Ly.bind(null,t,l),u)},useLayoutEffect:function(l,t){return Vn(4194308,4,l,t)},useInsertionEffect:function(l,t){Vn(4,2,l,t)},useMemo:function(l,t){var u=ol();t=t===void 0?null:t;var a=l();if(vu){qt(!0);try{l()}finally{qt(!1)}}return u.memoizedState=[a,t],a},useReducer:function(l,t,u){var a=ol();if(u!==void 0){var n=u(t);if(vu){qt(!0);try{u(t)}finally{qt(!1)}}}else n=t;return a.memoizedState=a.baseState=n,l={pending:null,lanes:0,dispatch:null,lastRenderedReducer:l,lastRenderedState:n},a.queue=l,l=l.dispatch=fh.bind(null,_,l),[a.memoizedState,l]},useRef:function(l){var t=ol();return l={current:l},t.memoizedState=l},useState:function(l){l=vc(l);var t=l.queue,u=Py.bind(null,_,t);return t.dispatch=u,[l.memoizedState,u]},useDebugValue:yi,useDeferredValue:function(l,t){var u=ol();return vi(u,l,t)},useTransition:function(){var l=vc(!1);return l=Wy.bind(null,_,l.queue,!0,!1),ol().memoizedState=l,[!1,l]},useSyncExternalStore:function(l,t,u){var a=_,n=ol();if(Y){if(u===void 0)throw Error(b(407));u=u()}else{if(u=t(),V===null)throw Error(b(349));(q&127)!==0||Ny(a,t,u)}n.memoizedState=u;var e={value:u,getSnapshot:t};return n.queue=e,Z0(Yy.bind(null,a,e,l),[l]),a.flags|=2048,Fu(9,{destroy:void 0},qy.bind(null,a,e,u,t),null),u},useId:function(){var l=ol(),t=V.identifierPrefix;if(Y){var u=Fl,a=$l;u=(a&~(1<<32-ql(a)-1)).toString(32)+u,t="_"+t+"R_"+u,u=ie++,0<u&&(t+="H"+u.toString(32)),t+="_"}else u=Pd++,t="_"+t+"r_"+u.toString(32)+"_";return l.memoizedState=t},useHostTransitionStatus:mi,useFormState:G0,useActionState:G0,useOptimistic:function(l){var t=ol();t.memoizedState=t.baseState=l;var u={pending:null,lanes:0,dispatch:null,lastRenderedReducer:null,lastRenderedState:null};return t.queue=u,t=di.bind(null,_,!0,u),u.dispatch=t,[l,t]},useMemoCache:fi,useCacheRefresh:function(){return ol().memoizedState=eh.bind(null,_)},useEffectEvent:function(l){var t=ol(),u={impl:l};return t.memoizedState=u,function(){if((p&2)!==0)throw Error(b(440));return u.impl.apply(void 0,arguments)}}},hi={readContext:ml,use:Be,useCallback:Jy,useContext:ml,useEffect:ii,useImperativeHandle:Ky,useInsertionEffect:Vy,useLayoutEffect:xy,useMemo:ry,useReducer:jn,useRef:Zy,useState:function(){return jn(st)},useDebugValue:yi,useDeferredValue:function(l,t){var u=I();return wy(u,j.memoizedState,l,t)},useTransition:function(){var l=jn(st)[0],t=I().memoizedState;return[typeof l=="boolean"?l:en(l),t]},useSyncExternalStore:Hy,useId:ky,useHostTransitionStatus:mi,useFormState:X0,useActionState:X0,useOptimistic:function(l,t){var u=I();return py(u,j,l,t)},useMemoCache:fi,useCacheRefresh:Iy};hi.useEffectEvent=jy;var av={readContext:ml,use:Be,useCallback:Jy,useContext:ml,useEffect:ii,useImperativeHandle:Ky,useInsertionEffect:Vy,useLayoutEffect:xy,useMemo:ry,useReducer:Tf,useRef:Zy,useState:function(){return Tf(st)},useDebugValue:yi,useDeferredValue:function(l,t){var u=I();return j===null?vi(u,l,t):wy(u,j.memoizedState,l,t)},useTransition:function(){var l=Tf(st)[0],t=I().memoizedState;return[typeof l=="boolean"?l:en(l),t]},useSyncExternalStore:Hy,useId:ky,useHostTransitionStatus:mi,useFormState:Q0,useActionState:Q0,useOptimistic:function(l,t){var u=I();return j!==null?py(u,j,l,t):(u.baseState=l,[l,u.queue.dispatch])},useMemoCache:fi,useCacheRefresh:Iy};av.useEffectEvent=jy;function Ef(l,t,u,a){t=l.memoizedState,u=u(a,t),u=u==null?t:r({},t,u),l.memoizedState=u,l.lanes===0&&(l.updateQueue.baseState=u)}var hc={enqueueSetState:function(l,t,u){l=l._reactInternals;var a=Yl(),n=Xt(a);n.payload=t,u!=null&&(n.callback=u),t=Qt(l,n,a),t!==null&&(El(t,l,a),Na(t,l,a))},enqueueReplaceState:function(l,t,u){l=l._reactInternals;var a=Yl(),n=Xt(a);n.tag=1,n.payload=t,u!=null&&(n.callback=u),t=Qt(l,n,a),t!==null&&(El(t,l,a),Na(t,l,a))},enqueueForceUpdate:function(l,t){l=l._reactInternals;var u=Yl(),a=Xt(u);a.tag=2,t!=null&&(a.callback=t),t=Qt(l,a,u),t!==null&&(El(t,l,u),Na(t,l,u))}};function j0(l,t,u,a,n,e,f){return l=l.stateNode,typeof l.shouldComponentUpdate=="function"?l.shouldComponentUpdate(a,e,f):t.prototype&&t.prototype.isPureReactComponent?!Va(u,a)||!Va(n,e):!0}function V0(l,t,u,a){l=t.state,typeof t.componentWillReceiveProps=="function"&&t.componentWillReceiveProps(u,a),typeof t.UNSAFE_componentWillReceiveProps=="function"&&t.UNSAFE_componentWillReceiveProps(u,a),t.state!==l&&hc.enqueueReplaceState(t,t.state,null)}function mu(l,t){var u=t;if("ref"in t){u={};for(var a in t)a!=="ref"&&(u[a]=t[a])}if(l=l.defaultProps){u===t&&(u=r({},u));for(var n in l)u[n]===void 0&&(u[n]=l[n])}return u}function nv(l){le(l)}function ev(l){console.error(l)}function fv(l){le(l)}function ye(l,t){try{var u=l.onUncaughtError;u(t.value,{componentStack:t.stack})}catch(a){setTimeout(function(){throw a})}}function x0(l,t,u){try{var a=l.onCaughtError;a(u.value,{componentStack:u.stack,errorBoundary:t.tag===1?t.stateNode:null})}catch(n){setTimeout(function(){throw n})}}function Sc(l,t,u){return u=Xt(u),u.tag=3,u.payload={element:null},u.callback=function(){ye(l,t)},u}function cv(l){return l=Xt(l),l.tag=3,l}function iv(l,t,u,a){var n=u.type.getDerivedStateFromError;if(typeof n=="function"){var e=a.value;l.payload=function(){return n(e)},l.callback=function(){x0(t,u,a)}}var f=u.stateNode;f!==null&&typeof f.componentDidCatch=="function"&&(l.callback=function(){x0(t,u,a),typeof n!="function"&&(Zt===null?Zt=new Set([this]):Zt.add(this));var c=a.stack;this.componentDidCatch(a.value,{componentStack:c!==null?c:""})})}function ch(l,t,u,a,n){if(u.flags|=32768,a!==null&&typeof a=="object"&&typeof a.then=="function"){if(t=u.alternate,t!==null&&na(t,u,n,!0),u=Rl.current,u!==null){switch(u.tag){case 31:case 13:return xl===null?Se():u.alternate===null&&F===0&&(F=3),u.flags&=-257,u.flags|=65536,u.lanes=n,a===ne?u.flags|=16384:(t=u.updateQueue,t===null?u.updateQueue=new Set([a]):t.add(a),Bf(l,a,n)),!1;case 22:return u.flags|=65536,a===ne?u.flags|=16384:(t=u.updateQueue,t===null?(t={transitions:null,markerInstances:null,retryQueue:new Set([a])},u.updateQueue=t):(u=t.retryQueue,u===null?t.retryQueue=new Set([a]):u.add(a)),Bf(l,a,n)),!1}throw Error(b(435,u.tag))}return Bf(l,a,n),Se(),!1}if(Y)return t=Rl.current,t!==null?((t.flags&65536)===0&&(t.flags|=256),t.flags|=65536,t.lanes=n,a!==tc&&(l=Error(b(422),{cause:a}),La(jl(l,u)))):(a!==tc&&(t=Error(b(423),{cause:a}),La(jl(t,u))),l=l.current.alternate,l.flags|=65536,n&=-n,l.lanes|=n,a=jl(a,u),n=Sc(l.stateNode,a,n),zf(l,n),F!==4&&(F=2)),!1;var e=Error(b(520),{cause:a});if(e=jl(e,u),Ca===null?Ca=[e]:Ca.push(e),F!==4&&(F=2),t===null)return!0;a=jl(a,u),u=t;do{switch(u.tag){case 3:return u.flags|=65536,l=n&-n,u.lanes|=l,l=Sc(u.stateNode,a,l),zf(u,l),!1;case 1:if(t=u.type,e=u.stateNode,(u.flags&128)===0&&(typeof t.getDerivedStateFromError=="function"||e!==null&&typeof e.componentDidCatch=="function"&&(Zt===null||!Zt.has(e))))return u.flags|=65536,n&=-n,u.lanes|=n,n=cv(n),iv(n,l,u,a),zf(u,n),!1}u=u.return}while(u!==null);return!1}var Si=Error(b(461)),ul=!1;function il(l,t,u,a){t.child=l===null?Ay(t,null,u,a):yu(t,l.child,u,a)}function L0(l,t,u,a,n){u=u.render;var e=t.ref;if("ref"in a){var f={};for(var c in a)c!=="ref"&&(f[c]=a[c])}else f=a;return iu(t),a=ui(l,t,u,f,e,n),c=ai(),l!==null&&!ul?(ni(l,t,n),bt(l,t,n)):(Y&&c&&Wc(t),t.flags|=1,il(l,t,a,n),t.child)}function K0(l,t,u,a,n){if(l===null){var e=u.type;return typeof e=="function"&&!wc(e)&&e.defaultProps===void 0&&u.compare===null?(t.tag=15,t.type=e,yv(l,t,e,a,n)):(l=Qn(u.type,null,a,t,t.mode,n),l.ref=t.ref,l.return=t,t.child=l)}if(e=l.child,!gi(l,n)){var f=e.memoizedProps;if(u=u.compare,u=u!==null?u:Va,u(f,a)&&l.ref===t.ref)return bt(l,t,n)}return t.flags|=1,l=dt(e,a),l.ref=t.ref,l.return=t,t.child=l}function yv(l,t,u,a,n){if(l!==null){var e=l.memoizedProps;if(Va(e,a)&&l.ref===t.ref)if(ul=!1,t.pendingProps=a=e,gi(l,n))(l.flags&131072)!==0&&(ul=!0);else return t.lanes=l.lanes,bt(l,t,n)}return gc(l,t,u,a,n)}function vv(l,t,u,a){var n=a.children,e=l!==null?l.memoizedState:null;if(l===null&&t.stateNode===null&&(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),a.mode==="hidden"){if((t.flags&128)!==0){if(e=e!==null?e.baseLanes|u:u,l!==null){for(a=t.child=l.child,n=0;a!==null;)n=n|a.lanes|a.childLanes,a=a.sibling;a=n&~e}else a=0,t.child=null;return J0(l,t,e,u,a)}if((u&536870912)!==0)t.memoizedState={baseLanes:0,cachePool:null},l!==null&&Zn(t,e!==null?e.cachePool:null),e!==null?R0(t,e):ic(),_y(t);else return a=t.lanes=536870912,J0(l,t,e!==null?e.baseLanes|u:u,u,a)}else e!==null?(Zn(t,e.cachePool),R0(t,e),Ht(t),t.memoizedState=null):(l!==null&&Zn(t,null),ic(),Ht(t));return il(l,t,n,u),t.child}function Ma(l,t){return l!==null&&l.tag===22||t.stateNode!==null||(t.stateNode={_visibility:1,_pendingMarkers:null,_retryCache:null,_transitions:null}),t.sibling}function J0(l,t,u,a,n){var e=kc();return e=e===null?null:{parent:tl._currentValue,pool:e},t.memoizedState={baseLanes:u,cachePool:e},l!==null&&Zn(t,null),ic(),_y(t),l!==null&&na(l,t,a,!0),t.childLanes=n,null}function xn(l,t){return t=ve({mode:t.mode,children:t.children},l.mode),t.ref=l.ref,l.child=t,t.return=l,t}function r0(l,t,u){return yu(t,l.child,null,u),l=xn(t,t.pendingProps),l.flags|=2,_l(t),t.memoizedState=null,l}function ih(l,t,u){var a=t.pendingProps,n=(t.flags&128)!==0;if(t.flags&=-129,l===null){if(Y){if(a.mode==="hidden")return l=xn(t,a),t.lanes=536870912,Ma(null,l);if(yc(t),(l=J)?(l=um(l,Vl),l=l!==null&&l.data==="&"?l:null,l!==null&&(t.memoizedState={dehydrated:l,treeContext:Kt!==null?{id:$l,overflow:Fl}:null,retryLane:536870912,hydrationErrors:null},u=gy(l),u.return=t,t.child=u,vl=t,J=null)):l=null,l===null)throw Jt(t);return t.lanes=536870912,null}return xn(t,a)}var e=l.memoizedState;if(e!==null){var f=e.dehydrated;if(yc(t),n)if(t.flags&256)t.flags&=-257,t=r0(l,t,u);else if(t.memoizedState!==null)t.child=l.child,t.flags|=128,t=null;else throw Error(b(558));else if(ul||na(l,t,u,!1),n=(u&l.childLanes)!==0,ul||n){if(a=V,a!==null&&(f=V1(a,u),f!==0&&f!==e.retryLane))throw e.retryLane=f,gu(l,f),El(a,l,f),Si;Se(),t=r0(l,t,u)}else l=e.treeContext,J=Ll(f.nextSibling),vl=t,Y=!0,Gt=null,Vl=!1,l!==null&&sy(t,l),t=xn(t,a),t.flags|=4096;return t}return l=dt(l.child,{mode:a.mode,children:a.children}),l.ref=t.ref,t.child=l,l.return=t,l}function Ln(l,t){var u=t.ref;if(u===null)l!==null&&l.ref!==null&&(t.flags|=4194816);else{if(typeof u!="function"&&typeof u!="object")throw Error(b(284));(l===null||l.ref!==u)&&(t.flags|=4194816)}}function gc(l,t,u,a,n){return iu(t),u=ui(l,t,u,a,void 0,n),a=ai(),l!==null&&!ul?(ni(l,t,n),bt(l,t,n)):(Y&&a&&Wc(t),t.flags|=1,il(l,t,u,n),t.child)}function w0(l,t,u,a,n,e){return iu(t),t.updateQueue=null,u=Uy(t,a,u,n),Dy(l),a=ai(),l!==null&&!ul?(ni(l,t,e),bt(l,t,e)):(Y&&a&&Wc(t),t.flags|=1,il(l,t,u,e),t.child)}function W0(l,t,u,a,n){if(iu(t),t.stateNode===null){var e=pu,f=u.contextType;typeof f=="object"&&f!==null&&(e=ml(f)),e=new u(a,e),t.memoizedState=e.state!==null&&e.state!==void 0?e.state:null,e.updater=hc,t.stateNode=e,e._reactInternals=t,e=t.stateNode,e.props=a,e.state=t.memoizedState,e.refs={},Pc(t),f=u.contextType,e.context=typeof f=="object"&&f!==null?ml(f):pu,e.state=t.memoizedState,f=u.getDerivedStateFromProps,typeof f=="function"&&(Ef(t,u,f,a),e.state=t.memoizedState),typeof u.getDerivedStateFromProps=="function"||typeof e.getSnapshotBeforeUpdate=="function"||typeof e.UNSAFE_componentWillMount!="function"&&typeof e.componentWillMount!="function"||(f=e.state,typeof e.componentWillMount=="function"&&e.componentWillMount(),typeof e.UNSAFE_componentWillMount=="function"&&e.UNSAFE_componentWillMount(),f!==e.state&&hc.enqueueReplaceState(e,e.state,null),Ya(t,a,e,n),qa(),e.state=t.memoizedState),typeof e.componentDidMount=="function"&&(t.flags|=4194308),a=!0}else if(l===null){e=t.stateNode;var c=t.memoizedProps,i=mu(u,c);e.props=i;var m=e.context,g=u.contextType;f=pu,typeof g=="object"&&g!==null&&(f=ml(g));var s=u.getDerivedStateFromProps;g=typeof s=="function"||typeof e.getSnapshotBeforeUpdate=="function",c=t.pendingProps!==c,g||typeof e.UNSAFE_componentWillReceiveProps!="function"&&typeof e.componentWillReceiveProps!="function"||(c||m!==f)&&V0(t,e,a,f),_t=!1;var h=t.memoizedState;e.state=h,Ya(t,a,e,n),qa(),m=t.memoizedState,c||h!==m||_t?(typeof s=="function"&&(Ef(t,u,s,a),m=t.memoizedState),(i=_t||j0(t,u,i,a,h,m,f))?(g||typeof e.UNSAFE_componentWillMount!="function"&&typeof e.componentWillMount!="function"||(typeof e.componentWillMount=="function"&&e.componentWillMount(),typeof e.UNSAFE_componentWillMount=="function"&&e.UNSAFE_componentWillMount()),typeof e.componentDidMount=="function"&&(t.flags|=4194308)):(typeof e.componentDidMount=="function"&&(t.flags|=4194308),t.memoizedProps=a,t.memoizedState=m),e.props=a,e.state=m,e.context=f,a=i):(typeof e.componentDidMount=="function"&&(t.flags|=4194308),a=!1)}else{e=t.stateNode,fc(l,t),f=t.memoizedProps,g=mu(u,f),e.props=g,s=t.pendingProps,h=e.context,m=u.contextType,i=pu,typeof m=="object"&&m!==null&&(i=ml(m)),c=u.getDerivedStateFromProps,(m=typeof c=="function"||typeof e.getSnapshotBeforeUpdate=="function")||typeof e.UNSAFE_componentWillReceiveProps!="function"&&typeof e.componentWillReceiveProps!="function"||(f!==s||h!==i)&&V0(t,e,a,i),_t=!1,h=t.memoizedState,e.state=h,Ya(t,a,e,n),qa();var S=t.memoizedState;f!==s||h!==S||_t||l!==null&&l.dependencies!==null&&ae(l.dependencies)?(typeof c=="function"&&(Ef(t,u,c,a),S=t.memoizedState),(g=_t||j0(t,u,g,a,h,S,i)||l!==null&&l.dependencies!==null&&ae(l.dependencies))?(m||typeof e.UNSAFE_componentWillUpdate!="function"&&typeof e.componentWillUpdate!="function"||(typeof e.componentWillUpdate=="function"&&e.componentWillUpdate(a,S,i),typeof e.UNSAFE_componentWillUpdate=="function"&&e.UNSAFE_componentWillUpdate(a,S,i)),typeof e.componentDidUpdate=="function"&&(t.flags|=4),typeof e.getSnapshotBeforeUpdate=="function"&&(t.flags|=1024)):(typeof e.componentDidUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=4),typeof e.getSnapshotBeforeUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=1024),t.memoizedProps=a,t.memoizedState=S),e.props=a,e.state=S,e.context=i,a=g):(typeof e.componentDidUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=4),typeof e.getSnapshotBeforeUpdate!="function"||f===l.memoizedProps&&h===l.memoizedState||(t.flags|=1024),a=!1)}return e=a,Ln(l,t),a=(t.flags&128)!==0,e||a?(e=t.stateNode,u=a&&typeof u.getDerivedStateFromError!="function"?null:e.render(),t.flags|=1,l!==null&&a?(t.child=yu(t,l.child,null,n),t.child=yu(t,null,u,n)):il(l,t,u,n),t.memoizedState=e.state,l=t.child):l=bt(l,t,n),l}function $0(l,t,u,a){return cu(),t.flags|=256,il(l,t,u,a),t.child}var Af={dehydrated:null,treeContext:null,retryLane:0,hydrationErrors:null};function Mf(l){return{baseLanes:l,cachePool:zy()}}function Of(l,t,u){return l=l!==null?l.childLanes&~u:0,t&&(l|=Ul),l}function mv(l,t,u){var a=t.pendingProps,n=!1,e=(t.flags&128)!==0,f;if((f=e)||(f=l!==null&&l.memoizedState===null?!1:(k.current&2)!==0),f&&(n=!0,t.flags&=-129),f=(t.flags&32)!==0,t.flags&=-33,l===null){if(Y){if(n?Ut(t):Ht(t),(l=J)?(l=um(l,Vl),l=l!==null&&l.data!=="&"?l:null,l!==null&&(t.memoizedState={dehydrated:l,treeContext:Kt!==null?{id:$l,overflow:Fl}:null,retryLane:536870912,hydrationErrors:null},u=gy(l),u.return=t,t.child=u,vl=t,J=null)):l=null,l===null)throw Jt(t);return Nc(l)?t.lanes=32:t.lanes=536870912,null}var c=a.children;return a=a.fallback,n?(Ht(t),n=t.mode,c=ve({mode:"hidden",children:c},n),a=au(a,n,u,null),c.return=t,a.return=t,c.sibling=a,t.child=c,a=t.child,a.memoizedState=Mf(u),a.childLanes=Of(l,f,u),t.memoizedState=Af,Ma(null,a)):(Ut(t),oc(t,c))}var i=l.memoizedState;if(i!==null&&(c=i.dehydrated,c!==null)){if(e)t.flags&256?(Ut(t),t.flags&=-257,t=_f(l,t,u)):t.memoizedState!==null?(Ht(t),t.child=l.child,t.flags|=128,t=null):(Ht(t),c=a.fallback,n=t.mode,a=ve({mode:"visible",children:a.children},n),c=au(c,n,u,null),c.flags|=2,a.return=t,c.return=t,a.sibling=c,t.child=a,yu(t,l.child,null,u),a=t.child,a.memoizedState=Mf(u),a.childLanes=Of(l,f,u),t.memoizedState=Af,t=Ma(null,a));else if(Ut(t),Nc(c)){if(f=c.nextSibling&&c.nextSibling.dataset,f)var m=f.dgst;f=m,a=Error(b(419)),a.stack="",a.digest=f,La({value:a,source:null,stack:null}),t=_f(l,t,u)}else if(ul||na(l,t,u,!1),f=(u&l.childLanes)!==0,ul||f){if(f=V,f!==null&&(a=V1(f,u),a!==0&&a!==i.retryLane))throw i.retryLane=a,gu(l,a),El(f,l,a),Si;Hc(c)||Se(),t=_f(l,t,u)}else Hc(c)?(t.flags|=192,t.child=l.child,t=null):(l=i.treeContext,J=Ll(c.nextSibling),vl=t,Y=!0,Gt=null,Vl=!1,l!==null&&sy(t,l),t=oc(t,a.children),t.flags|=4096);return t}return n?(Ht(t),c=a.fallback,n=t.mode,i=l.child,m=i.sibling,a=dt(i,{mode:"hidden",children:a.children}),a.subtreeFlags=i.subtreeFlags&65011712,m!==null?c=dt(m,c):(c=au(c,n,u,null),c.flags|=2),c.return=t,a.return=t,a.sibling=c,t.child=a,Ma(null,a),a=t.child,c=l.child.memoizedState,c===null?c=Mf(u):(n=c.cachePool,n!==null?(i=tl._currentValue,n=n.parent!==i?{parent:i,pool:i}:n):n=zy(),c={baseLanes:c.baseLanes|u,cachePool:n}),a.memoizedState=c,a.childLanes=Of(l,f,u),t.memoizedState=Af,Ma(l.child,a)):(Ut(t),u=l.child,l=u.sibling,u=dt(u,{mode:"visible",children:a.children}),u.return=t,u.sibling=null,l!==null&&(f=t.deletions,f===null?(t.deletions=[l],t.flags|=16):f.push(l)),t.child=u,t.memoizedState=null,u)}function oc(l,t){return t=ve({mode:"visible",children:t},l.mode),t.return=l,l.child=t}function ve(l,t){return l=Dl(22,l,null,t),l.lanes=0,l}function _f(l,t,u){return yu(t,l.child,null,u),l=oc(t,t.pendingProps.children),l.flags|=2,t.memoizedState=null,l}function F0(l,t,u){l.lanes|=t;var a=l.alternate;a!==null&&(a.lanes|=t),ac(l.return,t,u)}function Df(l,t,u,a,n,e){var f=l.memoizedState;f===null?l.memoizedState={isBackwards:t,rendering:null,renderingStartTime:0,last:a,tail:u,tailMode:n,treeForkCount:e}:(f.isBackwards=t,f.rendering=null,f.renderingStartTime=0,f.last=a,f.tail=u,f.tailMode=n,f.treeForkCount=e)}function dv(l,t,u){var a=t.pendingProps,n=a.revealOrder,e=a.tail;a=a.children;var f=k.current,c=(f&2)!==0;if(c?(f=f&1|2,t.flags|=128):f&=1,x(k,f),il(l,t,a,u),a=Y?xa:0,!c&&l!==null&&(l.flags&128)!==0)l:for(l=t.child;l!==null;){if(l.tag===13)l.memoizedState!==null&&F0(l,u,t);else if(l.tag===19)F0(l,u,t);else if(l.child!==null){l.child.return=l,l=l.child;continue}if(l===t)break l;for(;l.sibling===null;){if(l.return===null||l.return===t)break l;l=l.return}l.sibling.return=l.return,l=l.sibling}switch(n){case"forwards":for(u=t.child,n=null;u!==null;)l=u.alternate,l!==null&&fe(l)===null&&(n=u),u=u.sibling;u=n,u===null?(n=t.child,t.child=null):(n=u.sibling,u.sibling=null),Df(t,!1,n,u,e,a);break;case"backwards":case"unstable_legacy-backwards":for(u=null,n=t.child,t.child=null;n!==null;){if(l=n.alternate,l!==null&&fe(l)===null){t.child=n;break}l=n.sibling,n.sibling=u,u=n,n=l}Df(t,!0,u,null,e,a);break;case"together":Df(t,!1,null,null,void 0,a);break;default:t.memoizedState=null}return t.child}function bt(l,t,u){if(l!==null&&(t.dependencies=l.dependencies),wt|=t.lanes,(u&t.childLanes)===0)if(l!==null){if(na(l,t,u,!1),(u&t.childLanes)===0)return null}else return null;if(l!==null&&t.child!==l.child)throw Error(b(153));if(t.child!==null){for(l=t.child,u=dt(l,l.pendingProps),t.child=u,u.return=t;l.sibling!==null;)l=l.sibling,u=u.sibling=dt(l,l.pendingProps),u.return=t;u.sibling=null}return t.child}function gi(l,t){return(l.lanes&t)!==0?!0:(l=l.dependencies,!!(l!==null&&ae(l)))}function yh(l,t,u){switch(t.tag){case 3:Fn(t,t.stateNode.containerInfo),Dt(t,tl,l.memoizedState.cache),cu();break;case 27:case 5:Kf(t);break;case 4:Fn(t,t.stateNode.containerInfo);break;case 10:Dt(t,t.type,t.memoizedProps.value);break;case 31:if(t.memoizedState!==null)return t.flags|=128,yc(t),null;break;case 13:var a=t.memoizedState;if(a!==null)return a.dehydrated!==null?(Ut(t),t.flags|=128,null):(u&t.child.childLanes)!==0?mv(l,t,u):(Ut(t),l=bt(l,t,u),l!==null?l.sibling:null);Ut(t);break;case 19:var n=(l.flags&128)!==0;if(a=(u&t.childLanes)!==0,a||(na(l,t,u,!1),a=(u&t.childLanes)!==0),n){if(a)return dv(l,t,u);t.flags|=128}if(n=t.memoizedState,n!==null&&(n.rendering=null,n.tail=null,n.lastEffect=null),x(k,k.current),a)break;return null;case 22:return t.lanes=0,vv(l,t,u,t.pendingProps);case 24:Dt(t,tl,l.memoizedState.cache)}return bt(l,t,u)}function hv(l,t,u){if(l!==null)if(l.memoizedProps!==t.pendingProps)ul=!0;else{if(!gi(l,u)&&(t.flags&128)===0)return ul=!1,yh(l,t,u);ul=(l.flags&131072)!==0}else ul=!1,Y&&(t.flags&1048576)!==0&&oy(t,xa,t.index);switch(t.lanes=0,t.tag){case 16:l:{var a=t.pendingProps;if(l=lu(t.elementType),t.type=l,typeof l=="function")wc(l)?(a=mu(l,a),t.tag=1,t=W0(null,t,l,a,u)):(t.tag=0,t=gc(null,t,l,a,u));else{if(l!=null){var n=l.$$typeof;if(n===Rc){t.tag=11,t=L0(null,t,l,a,u);break l}else if(n===pc){t.tag=14,t=K0(null,t,l,a,u);break l}}throw t=xf(l)||l,Error(b(306,t,""))}}return t;case 0:return gc(l,t,t.type,t.pendingProps,u);case 1:return a=t.type,n=mu(a,t.pendingProps),W0(l,t,a,n,u);case 3:l:{if(Fn(t,t.stateNode.containerInfo),l===null)throw Error(b(387));a=t.pendingProps;var e=t.memoizedState;n=e.element,fc(l,t),Ya(t,a,null,u);var f=t.memoizedState;if(a=f.cache,Dt(t,tl,a),a!==e.cache&&nc(t,[tl],u,!0),qa(),a=f.element,e.isDehydrated)if(e={element:a,isDehydrated:!1,cache:f.cache},t.updateQueue.baseState=e,t.memoizedState=e,t.flags&256){t=$0(l,t,a,u);break l}else if(a!==n){n=jl(Error(b(424)),t),La(n),t=$0(l,t,a,u);break l}else{switch(l=t.stateNode.containerInfo,l.nodeType){case 9:l=l.body;break;default:l=l.nodeName==="HTML"?l.ownerDocument.body:l}for(J=Ll(l.firstChild),vl=t,Y=!0,Gt=null,Vl=!0,u=Ay(t,null,a,u),t.child=u;u;)u.flags=u.flags&-3|4096,u=u.sibling}else{if(cu(),a===n){t=bt(l,t,u);break l}il(l,t,a,u)}t=t.child}return t;case 26:return Ln(l,t),l===null?(u=b1(t.type,null,t.pendingProps,null))?t.memoizedState=u:Y||(u=t.type,l=t.pendingProps,a=be(Ct.current).createElement(u),a[yl]=t,a[Al]=l,dl(a,u,l),fl(a),t.stateNode=a):t.memoizedState=b1(t.type,l.memoizedProps,t.pendingProps,l.memoizedState),null;case 27:return Kf(t),l===null&&Y&&(a=t.stateNode=am(t.type,t.pendingProps,Ct.current),vl=t,Vl=!0,n=J,$t(t.type)?(qc=n,J=Ll(a.firstChild)):J=n),il(l,t,t.pendingProps.children,u),Ln(l,t),l===null&&(t.flags|=4194304),t.child;case 5:return l===null&&Y&&((n=a=J)&&(a=Xh(a,t.type,t.pendingProps,Vl),a!==null?(t.stateNode=a,vl=t,J=Ll(a.firstChild),Vl=!1,n=!0):n=!1),n||Jt(t)),Kf(t),n=t.type,e=t.pendingProps,f=l!==null?l.memoizedProps:null,a=e.children,Dc(n,e)?a=null:f!==null&&Dc(n,f)&&(t.flags|=32),t.memoizedState!==null&&(n=ui(l,t,lh,null,null,u),$a._currentValue=n),Ln(l,t),il(l,t,a,u),t.child;case 6:return l===null&&Y&&((l=u=J)&&(u=Qh(u,t.pendingProps,Vl),u!==null?(t.stateNode=u,vl=t,J=null,l=!0):l=!1),l||Jt(t)),null;case 13:return mv(l,t,u);case 4:return Fn(t,t.stateNode.containerInfo),a=t.pendingProps,l===null?t.child=yu(t,null,a,u):il(l,t,a,u),t.child;case 11:return L0(l,t,t.type,t.pendingProps,u);case 7:return il(l,t,t.pendingProps,u),t.child;case 8:return il(l,t,t.pendingProps.children,u),t.child;case 12:return il(l,t,t.pendingProps.children,u),t.child;case 10:return a=t.pendingProps,Dt(t,t.type,a.value),il(l,t,a.children,u),t.child;case 9:return n=t.type._context,a=t.pendingProps.children,iu(t),n=ml(n),a=a(n),t.flags|=1,il(l,t,a,u),t.child;case 14:return K0(l,t,t.type,t.pendingProps,u);case 15:return yv(l,t,t.type,t.pendingProps,u);case 19:return dv(l,t,u);case 31:return ih(l,t,u);case 22:return vv(l,t,u,t.pendingProps);case 24:return iu(t),a=ml(tl),l===null?(n=kc(),n===null&&(n=V,e=Fc(),n.pooledCache=e,e.refCount++,e!==null&&(n.pooledCacheLanes|=u),n=e),t.memoizedState={parent:a,cache:n},Pc(t),Dt(t,tl,n)):((l.lanes&u)!==0&&(fc(l,t),Ya(t,null,null,u),qa()),n=l.memoizedState,e=t.memoizedState,n.parent!==a?(n={parent:a,cache:a},t.memoizedState=n,t.lanes===0&&(t.memoizedState=t.updateQueue.baseState=n),Dt(t,tl,a)):(a=e.cache,Dt(t,tl,a),a!==n.cache&&nc(t,[tl],u,!0))),il(l,t,t.pendingProps.children,u),t.child;case 29:throw t.pendingProps}throw Error(b(156,t.tag))}function at(l){l.flags|=4}function Uf(l,t,u,a,n){if((t=(l.mode&32)!==0)&&(t=!1),t){if(l.flags|=16777216,(n&335544128)===n)if(l.stateNode.complete)l.flags|=8192;else if(Xv())l.flags|=8192;else throw eu=ne,Ic}else l.flags&=-16777217}function k0(l,t){if(t.type!=="stylesheet"||(t.state.loading&4)!==0)l.flags&=-16777217;else if(l.flags|=16777216,!fm(t))if(Xv())l.flags|=8192;else throw eu=ne,Ic}function Un(l,t){t!==null&&(l.flags|=4),l.flags&16384&&(t=l.tag!==22?Q1():536870912,l.lanes|=t,ku|=t)}function oa(l,t){if(!Y)switch(l.tailMode){case"hidden":t=l.tail;for(var u=null;t!==null;)t.alternate!==null&&(u=t),t=t.sibling;u===null?l.tail=null:u.sibling=null;break;case"collapsed":u=l.tail;for(var a=null;u!==null;)u.alternate!==null&&(a=u),u=u.sibling;a===null?t||l.tail===null?l.tail=null:l.tail.sibling=null:a.sibling=null}}function K(l){var t=l.alternate!==null&&l.alternate.child===l.child,u=0,a=0;if(t)for(var n=l.child;n!==null;)u|=n.lanes|n.childLanes,a|=n.subtreeFlags&65011712,a|=n.flags&65011712,n.return=l,n=n.sibling;else for(n=l.child;n!==null;)u|=n.lanes|n.childLanes,a|=n.subtreeFlags,a|=n.flags,n.return=l,n=n.sibling;return l.subtreeFlags|=a,l.childLanes=u,t}function vh(l,t,u){var a=t.pendingProps;switch($c(t),t.tag){case 16:case 15:case 0:case 11:case 7:case 8:case 12:case 9:case 14:return K(t),null;case 1:return K(t),null;case 3:return u=t.stateNode,a=null,l!==null&&(a=l.memoizedState.cache),t.memoizedState.cache!==a&&(t.flags|=2048),ht(tl),Ju(),u.pendingContext&&(u.context=u.pendingContext,u.pendingContext=null),(l===null||l.child===null)&&(Au(t)?at(t):l===null||l.memoizedState.isDehydrated&&(t.flags&256)===0||(t.flags|=1024,bf())),K(t),null;case 26:var n=t.type,e=t.memoizedState;return l===null?(at(t),e!==null?(K(t),k0(t,e)):(K(t),Uf(t,n,null,a,u))):e?e!==l.memoizedState?(at(t),K(t),k0(t,e)):(K(t),t.flags&=-16777217):(l=l.memoizedProps,l!==a&&at(t),K(t),Uf(t,n,l,a,u)),null;case 27:if(kn(t),u=Ct.current,n=t.type,l!==null&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(!a){if(t.stateNode===null)throw Error(b(166));return K(t),null}l=Il.current,Au(t)?D0(t,l):(l=am(n,a,u),t.stateNode=l,at(t))}return K(t),null;case 5:if(kn(t),n=t.type,l!==null&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(!a){if(t.stateNode===null)throw Error(b(166));return K(t),null}if(e=Il.current,Au(t))D0(t,e);else{var f=be(Ct.current);switch(e){case 1:e=f.createElementNS("http://www.w3.org/2000/svg",n);break;case 2:e=f.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;default:switch(n){case"svg":e=f.createElementNS("http://www.w3.org/2000/svg",n);break;case"math":e=f.createElementNS("http://www.w3.org/1998/Math/MathML",n);break;case"script":e=f.createElement("div"),e.innerHTML="<script><\/script>",e=e.removeChild(e.firstChild);break;case"select":e=typeof a.is=="string"?f.createElement("select",{is:a.is}):f.createElement("select"),a.multiple?e.multiple=!0:a.size&&(e.size=a.size);break;default:e=typeof a.is=="string"?f.createElement(n,{is:a.is}):f.createElement(n)}}e[yl]=t,e[Al]=a;l:for(f=t.child;f!==null;){if(f.tag===5||f.tag===6)e.appendChild(f.stateNode);else if(f.tag!==4&&f.tag!==27&&f.child!==null){f.child.return=f,f=f.child;continue}if(f===t)break l;for(;f.sibling===null;){if(f.return===null||f.return===t)break l;f=f.return}f.sibling.return=f.return,f=f.sibling}t.stateNode=e;l:switch(dl(e,n,a),n){case"button":case"input":case"select":case"textarea":a=!!a.autoFocus;break l;case"img":a=!0;break l;default:a=!1}a&&at(t)}}return K(t),Uf(t,t.type,l===null?null:l.memoizedProps,t.pendingProps,u),null;case 6:if(l&&t.stateNode!=null)l.memoizedProps!==a&&at(t);else{if(typeof a!="string"&&t.stateNode===null)throw Error(b(166));if(l=Ct.current,Au(t)){if(l=t.stateNode,u=t.memoizedProps,a=null,n=vl,n!==null)switch(n.tag){case 27:case 5:a=n.memoizedProps}l[yl]=t,l=!!(l.nodeValue===u||a!==null&&a.suppressHydrationWarning===!0||Pv(l.nodeValue,u)),l||Jt(t,!0)}else l=be(l).createTextNode(a),l[yl]=t,t.stateNode=l}return K(t),null;case 31:if(u=t.memoizedState,l===null||l.memoizedState!==null){if(a=Au(t),u!==null){if(l===null){if(!a)throw Error(b(318));if(l=t.memoizedState,l=l!==null?l.dehydrated:null,!l)throw Error(b(557));l[yl]=t}else cu(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;K(t),l=!1}else u=bf(),l!==null&&l.memoizedState!==null&&(l.memoizedState.hydrationErrors=u),l=!0;if(!l)return t.flags&256?(_l(t),t):(_l(t),null);if((t.flags&128)!==0)throw Error(b(558))}return K(t),null;case 13:if(a=t.memoizedState,l===null||l.memoizedState!==null&&l.memoizedState.dehydrated!==null){if(n=Au(t),a!==null&&a.dehydrated!==null){if(l===null){if(!n)throw Error(b(318));if(n=t.memoizedState,n=n!==null?n.dehydrated:null,!n)throw Error(b(317));n[yl]=t}else cu(),(t.flags&128)===0&&(t.memoizedState=null),t.flags|=4;K(t),n=!1}else n=bf(),l!==null&&l.memoizedState!==null&&(l.memoizedState.hydrationErrors=n),n=!0;if(!n)return t.flags&256?(_l(t),t):(_l(t),null)}return _l(t),(t.flags&128)!==0?(t.lanes=u,t):(u=a!==null,l=l!==null&&l.memoizedState!==null,u&&(a=t.child,n=null,a.alternate!==null&&a.alternate.memoizedState!==null&&a.alternate.memoizedState.cachePool!==null&&(n=a.alternate.memoizedState.cachePool.pool),e=null,a.memoizedState!==null&&a.memoizedState.cachePool!==null&&(e=a.memoizedState.cachePool.pool),e!==n&&(a.flags|=2048)),u!==l&&u&&(t.child.flags|=8192),Un(t,t.updateQueue),K(t),null);case 4:return Ju(),l===null&&Ai(t.stateNode.containerInfo),K(t),null;case 10:return ht(t.type),K(t),null;case 19:if(cl(k),a=t.memoizedState,a===null)return K(t),null;if(n=(t.flags&128)!==0,e=a.rendering,e===null)if(n)oa(a,!1);else{if(F!==0||l!==null&&(l.flags&128)!==0)for(l=t.child;l!==null;){if(e=fe(l),e!==null){for(t.flags|=128,oa(a,!1),l=e.updateQueue,t.updateQueue=l,Un(t,l),t.subtreeFlags=0,l=u,u=t.child;u!==null;)Sy(u,l),u=u.sibling;return x(k,k.current&1|2),Y&&ct(t,a.treeForkCount),t.child}l=l.sibling}a.tail!==null&&Hl()>de&&(t.flags|=128,n=!0,oa(a,!1),t.lanes=4194304)}else{if(!n)if(l=fe(e),l!==null){if(t.flags|=128,n=!0,l=l.updateQueue,t.updateQueue=l,Un(t,l),oa(a,!0),a.tail===null&&a.tailMode==="hidden"&&!e.alternate&&!Y)return K(t),null}else 2*Hl()-a.renderingStartTime>de&&u!==536870912&&(t.flags|=128,n=!0,oa(a,!1),t.lanes=4194304);a.isBackwards?(e.sibling=t.child,t.child=e):(l=a.last,l!==null?l.sibling=e:t.child=e,a.last=e)}return a.tail!==null?(l=a.tail,a.rendering=l,a.tail=l.sibling,a.renderingStartTime=Hl(),l.sibling=null,u=k.current,x(k,n?u&1|2:u&1),Y&&ct(t,a.treeForkCount),l):(K(t),null);case 22:case 23:return _l(t),li(),a=t.memoizedState!==null,l!==null?l.memoizedState!==null!==a&&(t.flags|=8192):a&&(t.flags|=8192),a?(u&536870912)!==0&&(t.flags&128)===0&&(K(t),t.subtreeFlags&6&&(t.flags|=8192)):K(t),u=t.updateQueue,u!==null&&Un(t,u.retryQueue),u=null,l!==null&&l.memoizedState!==null&&l.memoizedState.cachePool!==null&&(u=l.memoizedState.cachePool.pool),a=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(a=t.memoizedState.cachePool.pool),a!==u&&(t.flags|=2048),l!==null&&cl(nu),null;case 24:return u=null,l!==null&&(u=l.memoizedState.cache),t.memoizedState.cache!==u&&(t.flags|=2048),ht(tl),K(t),null;case 25:return null;case 30:return null}throw Error(b(156,t.tag))}function mh(l,t){switch($c(t),t.tag){case 1:return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 3:return ht(tl),Ju(),l=t.flags,(l&65536)!==0&&(l&128)===0?(t.flags=l&-65537|128,t):null;case 26:case 27:case 5:return kn(t),null;case 31:if(t.memoizedState!==null){if(_l(t),t.alternate===null)throw Error(b(340));cu()}return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 13:if(_l(t),l=t.memoizedState,l!==null&&l.dehydrated!==null){if(t.alternate===null)throw Error(b(340));cu()}return l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 19:return cl(k),null;case 4:return Ju(),null;case 10:return ht(t.type),null;case 22:case 23:return _l(t),li(),l!==null&&cl(nu),l=t.flags,l&65536?(t.flags=l&-65537|128,t):null;case 24:return ht(tl),null;case 25:return null;default:return null}}function Sv(l,t){switch($c(t),t.tag){case 3:ht(tl),Ju();break;case 26:case 27:case 5:kn(t);break;case 4:Ju();break;case 31:t.memoizedState!==null&&_l(t);break;case 13:_l(t);break;case 19:cl(k);break;case 10:ht(t.type);break;case 22:case 23:_l(t),li(),l!==null&&cl(nu);break;case 24:ht(tl)}}function fn(l,t){try{var u=t.updateQueue,a=u!==null?u.lastEffect:null;if(a!==null){var n=a.next;u=n;do{if((u.tag&l)===l){a=void 0;var e=u.create,f=u.inst;a=e(),f.destroy=a}u=u.next}while(u!==n)}}catch(c){X(t,t.return,c)}}function rt(l,t,u){try{var a=t.updateQueue,n=a!==null?a.lastEffect:null;if(n!==null){var e=n.next;a=e;do{if((a.tag&l)===l){var f=a.inst,c=f.destroy;if(c!==void 0){f.destroy=void 0,n=t;var i=u,m=c;try{m()}catch(g){X(n,i,g)}}}a=a.next}while(a!==e)}}catch(g){X(t,t.return,g)}}function gv(l){var t=l.updateQueue;if(t!==null){var u=l.stateNode;try{Oy(t,u)}catch(a){X(l,l.return,a)}}}function ov(l,t,u){u.props=mu(l.type,l.memoizedProps),u.state=l.memoizedState;try{u.componentWillUnmount()}catch(a){X(l,t,a)}}function Ra(l,t){try{var u=l.ref;if(u!==null){switch(l.tag){case 26:case 27:case 5:var a=l.stateNode;break;case 30:a=l.stateNode;break;default:a=l.stateNode}typeof u=="function"?l.refCleanup=u(a):u.current=a}}catch(n){X(l,t,n)}}function kl(l,t){var u=l.ref,a=l.refCleanup;if(u!==null)if(typeof a=="function")try{a()}catch(n){X(l,t,n)}finally{l.refCleanup=null,l=l.alternate,l!=null&&(l.refCleanup=null)}else if(typeof u=="function")try{u(null)}catch(n){X(l,t,n)}else u.current=null}function sv(l){var t=l.type,u=l.memoizedProps,a=l.stateNode;try{l:switch(t){case"button":case"input":case"select":case"textarea":u.autoFocus&&a.focus();break l;case"img":u.src?a.src=u.src:u.srcSet&&(a.srcset=u.srcSet)}}catch(n){X(l,l.return,n)}}function Hf(l,t,u){try{var a=l.stateNode;Yh(a,l.type,u,t),a[Al]=t}catch(n){X(l,l.return,n)}}function bv(l){return l.tag===5||l.tag===3||l.tag===26||l.tag===27&&$t(l.type)||l.tag===4}function Nf(l){l:for(;;){for(;l.sibling===null;){if(l.return===null||bv(l.return))return null;l=l.return}for(l.sibling.return=l.return,l=l.sibling;l.tag!==5&&l.tag!==6&&l.tag!==18;){if(l.tag===27&&$t(l.type)||l.flags&2||l.child===null||l.tag===4)continue l;l.child.return=l,l=l.child}if(!(l.flags&2))return l.stateNode}}function sc(l,t,u){var a=l.tag;if(a===5||a===6)l=l.stateNode,t?(u.nodeType===9?u.body:u.nodeName==="HTML"?u.ownerDocument.body:u).insertBefore(l,t):(t=u.nodeType===9?u.body:u.nodeName==="HTML"?u.ownerDocument.body:u,t.appendChild(l),u=u._reactRootContainer,u!=null||t.onclick!==null||(t.onclick=vt));else if(a!==4&&(a===27&&$t(l.type)&&(u=l.stateNode,t=null),l=l.child,l!==null))for(sc(l,t,u),l=l.sibling;l!==null;)sc(l,t,u),l=l.sibling}function me(l,t,u){var a=l.tag;if(a===5||a===6)l=l.stateNode,t?u.insertBefore(l,t):u.appendChild(l);else if(a!==4&&(a===27&&$t(l.type)&&(u=l.stateNode),l=l.child,l!==null))for(me(l,t,u),l=l.sibling;l!==null;)me(l,t,u),l=l.sibling}function zv(l){var t=l.stateNode,u=l.memoizedProps;try{for(var a=l.type,n=t.attributes;n.length;)t.removeAttributeNode(n[0]);dl(t,a,u),t[yl]=l,t[Al]=u}catch(e){X(l,l.return,e)}}var it=!1,ll=!1,qf=!1,I0=typeof WeakSet=="function"?WeakSet:Set,el=null;function dh(l,t){if(l=l.containerInfo,Oc=Ae,l=fy(l),Kc(l)){if("selectionStart"in l)var u={start:l.selectionStart,end:l.selectionEnd};else l:{u=(u=l.ownerDocument)&&u.defaultView||window;var a=u.getSelection&&u.getSelection();if(a&&a.rangeCount!==0){u=a.anchorNode;var n=a.anchorOffset,e=a.focusNode;a=a.focusOffset;try{u.nodeType,e.nodeType}catch{u=null;break l}var f=0,c=-1,i=-1,m=0,g=0,s=l,h=null;t:for(;;){for(var S;s!==u||n!==0&&s.nodeType!==3||(c=f+n),s!==e||a!==0&&s.nodeType!==3||(i=f+a),s.nodeType===3&&(f+=s.nodeValue.length),(S=s.firstChild)!==null;)h=s,s=S;for(;;){if(s===l)break t;if(h===u&&++m===n&&(c=f),h===e&&++g===a&&(i=f),(S=s.nextSibling)!==null)break;s=h,h=s.parentNode}s=S}u=c===-1||i===-1?null:{start:c,end:i}}else u=null}u=u||{start:0,end:0}}else u=null;for(_c={focusedElem:l,selectionRange:u},Ae=!1,el=t;el!==null;)if(t=el,l=t.child,(t.subtreeFlags&1028)!==0&&l!==null)l.return=t,el=l;else for(;el!==null;){switch(t=el,e=t.alternate,l=t.flags,t.tag){case 0:if((l&4)!==0&&(l=t.updateQueue,l=l!==null?l.events:null,l!==null))for(u=0;u<l.length;u++)n=l[u],n.ref.impl=n.nextImpl;break;case 11:case 15:break;case 1:if((l&1024)!==0&&e!==null){l=void 0,u=t,n=e.memoizedProps,e=e.memoizedState,a=u.stateNode;try{var z=mu(u.type,n);l=a.getSnapshotBeforeUpdate(z,e),a.__reactInternalSnapshotBeforeUpdate=l}catch(A){X(u,u.return,A)}}break;case 3:if((l&1024)!==0){if(l=t.stateNode.containerInfo,u=l.nodeType,u===9)Uc(l);else if(u===1)switch(l.nodeName){case"HEAD":case"HTML":case"BODY":Uc(l);break;default:l.textContent=""}}break;case 5:case 26:case 27:case 6:case 4:case 17:break;default:if((l&1024)!==0)throw Error(b(163))}if(l=t.sibling,l!==null){l.return=t.return,el=l;break}el=t.return}}function Tv(l,t,u){var a=u.flags;switch(u.tag){case 0:case 11:case 15:et(l,u),a&4&&fn(5,u);break;case 1:if(et(l,u),a&4)if(l=u.stateNode,t===null)try{l.componentDidMount()}catch(f){X(u,u.return,f)}else{var n=mu(u.type,t.memoizedProps);t=t.memoizedState;try{l.componentDidUpdate(n,t,l.__reactInternalSnapshotBeforeUpdate)}catch(f){X(u,u.return,f)}}a&64&&gv(u),a&512&&Ra(u,u.return);break;case 3:if(et(l,u),a&64&&(l=u.updateQueue,l!==null)){if(t=null,u.child!==null)switch(u.child.tag){case 27:case 5:t=u.child.stateNode;break;case 1:t=u.child.stateNode}try{Oy(l,t)}catch(f){X(u,u.return,f)}}break;case 27:t===null&&a&4&&zv(u);case 26:case 5:et(l,u),t===null&&a&4&&sv(u),a&512&&Ra(u,u.return);break;case 12:et(l,u);break;case 31:et(l,u),a&4&&Mv(l,u);break;case 13:et(l,u),a&4&&Ov(l,u),a&64&&(l=u.memoizedState,l!==null&&(l=l.dehydrated,l!==null&&(u=Eh.bind(null,u),Zh(l,u))));break;case 22:if(a=u.memoizedState!==null||it,!a){t=t!==null&&t.memoizedState!==null||ll,n=it;var e=ll;it=a,(ll=t)&&!e?ft(l,u,(u.subtreeFlags&8772)!==0):et(l,u),it=n,ll=e}break;case 30:break;default:et(l,u)}}function Ev(l){var t=l.alternate;t!==null&&(l.alternate=null,Ev(t)),l.child=null,l.deletions=null,l.sibling=null,l.tag===5&&(t=l.stateNode,t!==null&&Qc(t)),l.stateNode=null,l.return=null,l.dependencies=null,l.memoizedProps=null,l.memoizedState=null,l.pendingProps=null,l.stateNode=null,l.updateQueue=null}var W=null,zl=!1;function nt(l,t,u){for(u=u.child;u!==null;)Av(l,t,u),u=u.sibling}function Av(l,t,u){if(Nl&&typeof Nl.onCommitFiberUnmount=="function")try{Nl.onCommitFiberUnmount(Pa,u)}catch{}switch(u.tag){case 26:ll||kl(u,t),nt(l,t,u),u.memoizedState?u.memoizedState.count--:u.stateNode&&(u=u.stateNode,u.parentNode.removeChild(u));break;case 27:ll||kl(u,t);var a=W,n=zl;$t(u.type)&&(W=u.stateNode,zl=!1),nt(l,t,u),Xa(u.stateNode),W=a,zl=n;break;case 5:ll||kl(u,t);case 6:if(a=W,n=zl,W=null,nt(l,t,u),W=a,zl=n,W!==null)if(zl)try{(W.nodeType===9?W.body:W.nodeName==="HTML"?W.ownerDocument.body:W).removeChild(u.stateNode)}catch(e){X(u,t,e)}else try{W.removeChild(u.stateNode)}catch(e){X(u,t,e)}break;case 18:W!==null&&(zl?(l=W,h1(l.nodeType===9?l.body:l.nodeName==="HTML"?l.ownerDocument.body:l,u.stateNode),ta(l)):h1(W,u.stateNode));break;case 4:a=W,n=zl,W=u.stateNode.containerInfo,zl=!0,nt(l,t,u),W=a,zl=n;break;case 0:case 11:case 14:case 15:rt(2,u,t),ll||rt(4,u,t),nt(l,t,u);break;case 1:ll||(kl(u,t),a=u.stateNode,typeof a.componentWillUnmount=="function"&&ov(u,t,a)),nt(l,t,u);break;case 21:nt(l,t,u);break;case 22:ll=(a=ll)||u.memoizedState!==null,nt(l,t,u),ll=a;break;default:nt(l,t,u)}}function Mv(l,t){if(t.memoizedState===null&&(l=t.alternate,l!==null&&(l=l.memoizedState,l!==null))){l=l.dehydrated;try{ta(l)}catch(u){X(t,t.return,u)}}}function Ov(l,t){if(t.memoizedState===null&&(l=t.alternate,l!==null&&(l=l.memoizedState,l!==null&&(l=l.dehydrated,l!==null))))try{ta(l)}catch(u){X(t,t.return,u)}}function hh(l){switch(l.tag){case 31:case 13:case 19:var t=l.stateNode;return t===null&&(t=l.stateNode=new I0),t;case 22:return l=l.stateNode,t=l._retryCache,t===null&&(t=l._retryCache=new I0),t;default:throw Error(b(435,l.tag))}}function Hn(l,t){var u=hh(l);t.forEach(function(a){if(!u.has(a)){u.add(a);var n=Ah.bind(null,l,a);a.then(n,n)}})}function sl(l,t){var u=t.deletions;if(u!==null)for(var a=0;a<u.length;a++){var n=u[a],e=l,f=t,c=f;l:for(;c!==null;){switch(c.tag){case 27:if($t(c.type)){W=c.stateNode,zl=!1;break l}break;case 5:W=c.stateNode,zl=!1;break l;case 3:case 4:W=c.stateNode.containerInfo,zl=!0;break l}c=c.return}if(W===null)throw Error(b(160));Av(e,f,n),W=null,zl=!1,e=n.alternate,e!==null&&(e.return=null),n.return=null}if(t.subtreeFlags&13886)for(t=t.child;t!==null;)_v(t,l),t=t.sibling}var rl=null;function _v(l,t){var u=l.alternate,a=l.flags;switch(l.tag){case 0:case 11:case 14:case 15:sl(t,l),bl(l),a&4&&(rt(3,l,l.return),fn(3,l),rt(5,l,l.return));break;case 1:sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),a&64&&it&&(l=l.updateQueue,l!==null&&(a=l.callbacks,a!==null&&(u=l.shared.hiddenCallbacks,l.shared.hiddenCallbacks=u===null?a:u.concat(a))));break;case 26:var n=rl;if(sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),a&4){var e=u!==null?u.memoizedState:null;if(a=l.memoizedState,u===null)if(a===null)if(l.stateNode===null){l:{a=l.type,u=l.memoizedProps,n=n.ownerDocument||n;t:switch(a){case"title":e=n.getElementsByTagName("title")[0],(!e||e[un]||e[yl]||e.namespaceURI==="http://www.w3.org/2000/svg"||e.hasAttribute("itemprop"))&&(e=n.createElement(a),n.head.insertBefore(e,n.querySelector("head > title"))),dl(e,a,u),e[yl]=l,fl(e),a=e;break l;case"link":var f=T1("link","href",n).get(a+(u.href||""));if(f){for(var c=0;c<f.length;c++)if(e=f[c],e.getAttribute("href")===(u.href==null||u.href===""?null:u.href)&&e.getAttribute("rel")===(u.rel==null?null:u.rel)&&e.getAttribute("title")===(u.title==null?null:u.title)&&e.getAttribute("crossorigin")===(u.crossOrigin==null?null:u.crossOrigin)){f.splice(c,1);break t}}e=n.createElement(a),dl(e,a,u),n.head.appendChild(e);break;case"meta":if(f=T1("meta","content",n).get(a+(u.content||""))){for(c=0;c<f.length;c++)if(e=f[c],e.getAttribute("content")===(u.content==null?null:""+u.content)&&e.getAttribute("name")===(u.name==null?null:u.name)&&e.getAttribute("property")===(u.property==null?null:u.property)&&e.getAttribute("http-equiv")===(u.httpEquiv==null?null:u.httpEquiv)&&e.getAttribute("charset")===(u.charSet==null?null:u.charSet)){f.splice(c,1);break t}}e=n.createElement(a),dl(e,a,u),n.head.appendChild(e);break;default:throw Error(b(468,a))}e[yl]=l,fl(e),a=e}l.stateNode=a}else E1(n,l.type,l.stateNode);else l.stateNode=z1(n,a,l.memoizedProps);else e!==a?(e===null?u.stateNode!==null&&(u=u.stateNode,u.parentNode.removeChild(u)):e.count--,a===null?E1(n,l.type,l.stateNode):z1(n,a,l.memoizedProps)):a===null&&l.stateNode!==null&&Hf(l,l.memoizedProps,u.memoizedProps)}break;case 27:sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),u!==null&&a&4&&Hf(l,l.memoizedProps,u.memoizedProps);break;case 5:if(sl(t,l),bl(l),a&512&&(ll||u===null||kl(u,u.return)),l.flags&32){n=l.stateNode;try{wu(n,"")}catch(z){X(l,l.return,z)}}a&4&&l.stateNode!=null&&(n=l.memoizedProps,Hf(l,n,u!==null?u.memoizedProps:n)),a&1024&&(qf=!0);break;case 6:if(sl(t,l),bl(l),a&4){if(l.stateNode===null)throw Error(b(162));a=l.memoizedProps,u=l.stateNode;try{u.nodeValue=a}catch(z){X(l,l.return,z)}}break;case 3:if(rn=null,n=rl,rl=ze(t.containerInfo),sl(t,l),rl=n,bl(l),a&4&&u!==null&&u.memoizedState.isDehydrated)try{ta(t.containerInfo)}catch(z){X(l,l.return,z)}qf&&(qf=!1,Dv(l));break;case 4:a=rl,rl=ze(l.stateNode.containerInfo),sl(t,l),bl(l),rl=a;break;case 12:sl(t,l),bl(l);break;case 31:sl(t,l),bl(l),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 13:sl(t,l),bl(l),l.child.flags&8192&&l.memoizedState!==null!=(u!==null&&u.memoizedState!==null)&&(Ce=Hl()),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 22:n=l.memoizedState!==null;var i=u!==null&&u.memoizedState!==null,m=it,g=ll;if(it=m||n,ll=g||i,sl(t,l),ll=g,it=m,bl(l),a&8192)l:for(t=l.stateNode,t._visibility=n?t._visibility&-2:t._visibility|1,n&&(u===null||i||it||ll||tu(l)),u=null,t=l;;){if(t.tag===5||t.tag===26){if(u===null){i=u=t;try{if(e=i.stateNode,n)f=e.style,typeof f.setProperty=="function"?f.setProperty("display","none","important"):f.display="none";else{c=i.stateNode;var s=i.memoizedProps.style,h=s!=null&&s.hasOwnProperty("display")?s.display:null;c.style.display=h==null||typeof h=="boolean"?"":(""+h).trim()}}catch(z){X(i,i.return,z)}}}else if(t.tag===6){if(u===null){i=t;try{i.stateNode.nodeValue=n?"":i.memoizedProps}catch(z){X(i,i.return,z)}}}else if(t.tag===18){if(u===null){i=t;try{var S=i.stateNode;n?S1(S,!0):S1(i.stateNode,!1)}catch(z){X(i,i.return,z)}}}else if((t.tag!==22&&t.tag!==23||t.memoizedState===null||t===l)&&t.child!==null){t.child.return=t,t=t.child;continue}if(t===l)break l;for(;t.sibling===null;){if(t.return===null||t.return===l)break l;u===t&&(u=null),t=t.return}u===t&&(u=null),t.sibling.return=t.return,t=t.sibling}a&4&&(a=l.updateQueue,a!==null&&(u=a.retryQueue,u!==null&&(a.retryQueue=null,Hn(l,u))));break;case 19:sl(t,l),bl(l),a&4&&(a=l.updateQueue,a!==null&&(l.updateQueue=null,Hn(l,a)));break;case 30:break;case 21:break;default:sl(t,l),bl(l)}}function bl(l){var t=l.flags;if(t&2){try{for(var u,a=l.return;a!==null;){if(bv(a)){u=a;break}a=a.return}if(u==null)throw Error(b(160));switch(u.tag){case 27:var n=u.stateNode,e=Nf(l);me(l,e,n);break;case 5:var f=u.stateNode;u.flags&32&&(wu(f,""),u.flags&=-33);var c=Nf(l);me(l,c,f);break;case 3:case 4:var i=u.stateNode.containerInfo,m=Nf(l);sc(l,m,i);break;default:throw Error(b(161))}}catch(g){X(l,l.return,g)}l.flags&=-3}t&4096&&(l.flags&=-4097)}function Dv(l){if(l.subtreeFlags&1024)for(l=l.child;l!==null;){var t=l;Dv(t),t.tag===5&&t.flags&1024&&t.stateNode.reset(),l=l.sibling}}function et(l,t){if(t.subtreeFlags&8772)for(t=t.child;t!==null;)Tv(l,t.alternate,t),t=t.sibling}function tu(l){for(l=l.child;l!==null;){var t=l;switch(t.tag){case 0:case 11:case 14:case 15:rt(4,t,t.return),tu(t);break;case 1:kl(t,t.return);var u=t.stateNode;typeof u.componentWillUnmount=="function"&&ov(t,t.return,u),tu(t);break;case 27:Xa(t.stateNode);case 26:case 5:kl(t,t.return),tu(t);break;case 22:t.memoizedState===null&&tu(t);break;case 30:tu(t);break;default:tu(t)}l=l.sibling}}function ft(l,t,u){for(u=u&&(t.subtreeFlags&8772)!==0,t=t.child;t!==null;){var a=t.alternate,n=l,e=t,f=e.flags;switch(e.tag){case 0:case 11:case 15:ft(n,e,u),fn(4,e);break;case 1:if(ft(n,e,u),a=e,n=a.stateNode,typeof n.componentDidMount=="function")try{n.componentDidMount()}catch(m){X(a,a.return,m)}if(a=e,n=a.updateQueue,n!==null){var c=a.stateNode;try{var i=n.shared.hiddenCallbacks;if(i!==null)for(n.shared.hiddenCallbacks=null,n=0;n<i.length;n++)My(i[n],c)}catch(m){X(a,a.return,m)}}u&&f&64&&gv(e),Ra(e,e.return);break;case 27:zv(e);case 26:case 5:ft(n,e,u),u&&a===null&&f&4&&sv(e),Ra(e,e.return);break;case 12:ft(n,e,u);break;case 31:ft(n,e,u),u&&f&4&&Mv(n,e);break;case 13:ft(n,e,u),u&&f&4&&Ov(n,e);break;case 22:e.memoizedState===null&&ft(n,e,u),Ra(e,e.return);break;case 30:break;default:ft(n,e,u)}t=t.sibling}}function oi(l,t){var u=null;l!==null&&l.memoizedState!==null&&l.memoizedState.cachePool!==null&&(u=l.memoizedState.cachePool.pool),l=null,t.memoizedState!==null&&t.memoizedState.cachePool!==null&&(l=t.memoizedState.cachePool.pool),l!==u&&(l!=null&&l.refCount++,u!=null&&nn(u))}function si(l,t){l=null,t.alternate!==null&&(l=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==l&&(t.refCount++,l!=null&&nn(l))}function Jl(l,t,u,a){if(t.subtreeFlags&10256)for(t=t.child;t!==null;)Uv(l,t,u,a),t=t.sibling}function Uv(l,t,u,a){var n=t.flags;switch(t.tag){case 0:case 11:case 15:Jl(l,t,u,a),n&2048&&fn(9,t);break;case 1:Jl(l,t,u,a);break;case 3:Jl(l,t,u,a),n&2048&&(l=null,t.alternate!==null&&(l=t.alternate.memoizedState.cache),t=t.memoizedState.cache,t!==l&&(t.refCount++,l!=null&&nn(l)));break;case 12:if(n&2048){Jl(l,t,u,a),l=t.stateNode;try{var e=t.memoizedProps,f=e.id,c=e.onPostCommit;typeof c=="function"&&c(f,t.alternate===null?"mount":"update",l.passiveEffectDuration,-0)}catch(i){X(t,t.return,i)}}else Jl(l,t,u,a);break;case 31:Jl(l,t,u,a);break;case 13:Jl(l,t,u,a);break;case 23:break;case 22:e=t.stateNode,f=t.alternate,t.memoizedState!==null?e._visibility&2?Jl(l,t,u,a):pa(l,t):e._visibility&2?Jl(l,t,u,a):(e._visibility|=2,Ou(l,t,u,a,(t.subtreeFlags&10256)!==0||!1)),n&2048&&oi(f,t);break;case 24:Jl(l,t,u,a),n&2048&&si(t.alternate,t);break;default:Jl(l,t,u,a)}}function Ou(l,t,u,a,n){for(n=n&&((t.subtreeFlags&10256)!==0||!1),t=t.child;t!==null;){var e=l,f=t,c=u,i=a,m=f.flags;switch(f.tag){case 0:case 11:case 15:Ou(e,f,c,i,n),fn(8,f);break;case 23:break;case 22:var g=f.stateNode;f.memoizedState!==null?g._visibility&2?Ou(e,f,c,i,n):pa(e,f):(g._visibility|=2,Ou(e,f,c,i,n)),n&&m&2048&&oi(f.alternate,f);break;case 24:Ou(e,f,c,i,n),n&&m&2048&&si(f.alternate,f);break;default:Ou(e,f,c,i,n)}t=t.sibling}}function pa(l,t){if(t.subtreeFlags&10256)for(t=t.child;t!==null;){var u=l,a=t,n=a.flags;switch(a.tag){case 22:pa(u,a),n&2048&&oi(a.alternate,a);break;case 24:pa(u,a),n&2048&&si(a.alternate,a);break;default:pa(u,a)}t=t.sibling}}var Oa=8192;function Mu(l,t,u){if(l.subtreeFlags&Oa)for(l=l.child;l!==null;)Hv(l,t,u),l=l.sibling}function Hv(l,t,u){switch(l.tag){case 26:Mu(l,t,u),l.flags&Oa&&l.memoizedState!==null&&kh(u,rl,l.memoizedState,l.memoizedProps);break;case 5:Mu(l,t,u);break;case 3:case 4:var a=rl;rl=ze(l.stateNode.containerInfo),Mu(l,t,u),rl=a;break;case 22:l.memoizedState===null&&(a=l.alternate,a!==null&&a.memoizedState!==null?(a=Oa,Oa=16777216,Mu(l,t,u),Oa=a):Mu(l,t,u));break;default:Mu(l,t,u)}}function Nv(l){var t=l.alternate;if(t!==null&&(l=t.child,l!==null)){t.child=null;do t=l.sibling,l.sibling=null,l=t;while(l!==null)}}function sa(l){var t=l.deletions;if((l.flags&16)!==0){if(t!==null)for(var u=0;u<t.length;u++){var a=t[u];el=a,Yv(a,l)}Nv(l)}if(l.subtreeFlags&10256)for(l=l.child;l!==null;)qv(l),l=l.sibling}function qv(l){switch(l.tag){case 0:case 11:case 15:sa(l),l.flags&2048&&rt(9,l,l.return);break;case 3:sa(l);break;case 12:sa(l);break;case 22:var t=l.stateNode;l.memoizedState!==null&&t._visibility&2&&(l.return===null||l.return.tag!==13)?(t._visibility&=-3,Kn(l)):sa(l);break;default:sa(l)}}function Kn(l){var t=l.deletions;if((l.flags&16)!==0){if(t!==null)for(var u=0;u<t.length;u++){var a=t[u];el=a,Yv(a,l)}Nv(l)}for(l=l.child;l!==null;){switch(t=l,t.tag){case 0:case 11:case 15:rt(8,t,t.return),Kn(t);break;case 22:u=t.stateNode,u._visibility&2&&(u._visibility&=-3,Kn(t));break;default:Kn(t)}l=l.sibling}}function Yv(l,t){for(;el!==null;){var u=el;switch(u.tag){case 0:case 11:case 15:rt(8,u,t);break;case 23:case 22:if(u.memoizedState!==null&&u.memoizedState.cachePool!==null){var a=u.memoizedState.cachePool.pool;a!=null&&a.refCount++}break;case 24:nn(u.memoizedState.cache)}if(a=u.child,a!==null)a.return=u,el=a;else l:for(u=l;el!==null;){a=el;var n=a.sibling,e=a.return;if(Ev(a),a===u){el=null;break l}if(n!==null){n.return=e,el=n;break l}el=e}}}var Sh={getCacheForType:function(l){var t=ml(tl),u=t.data.get(l);return u===void 0&&(u=l(),t.data.set(l,u)),u},cacheSignal:function(){return ml(tl).controller.signal}},gh=typeof WeakMap=="function"?WeakMap:Map,p=0,V=null,H=null,q=0,G=0,Ol=null,Bt=!1,fa=!1,bi=!1,zt=0,F=0,wt=0,fu=0,zi=0,Ul=0,ku=0,Ca=null,Tl=null,bc=!1,Ce=0,Bv=0,de=1/0,he=null,Zt=null,al=0,jt=null,Iu=null,St=0,zc=0,Tc=null,Rv=null,Ga=0,Ec=null;function Yl(){return(p&2)!==0&&q!==0?q&-q:M.T!==null?Ei():x1()}function pv(){if(Ul===0)if((q&536870912)===0||Y){var l=bn;bn<<=1,(bn&3932160)===0&&(bn=262144),Ul=l}else Ul=536870912;return l=Rl.current,l!==null&&(l.flags|=32),Ul}function El(l,t,u){(l===V&&(G===2||G===9)||l.cancelPendingCommit!==null)&&(Pu(l,0),Rt(l,q,Ul,!1)),tn(l,u),((p&2)===0||l!==V)&&(l===V&&((p&2)===0&&(fu|=u),F===4&&Rt(l,q,Ul,!1)),lt(l))}function Cv(l,t,u){if((p&6)!==0)throw Error(b(327));var a=!u&&(t&127)===0&&(t&l.expiredLanes)===0||ln(l,t),n=a?bh(l,t):Yf(l,t,!0),e=a;do{if(n===0){fa&&!a&&Rt(l,t,0,!1);break}else{if(u=l.current.alternate,e&&!oh(u)){n=Yf(l,t,!1),e=!1;continue}if(n===2){if(e=t,l.errorRecoveryDisabledLanes&e)var f=0;else f=l.pendingLanes&-536870913,f=f!==0?f:f&536870912?536870912:0;if(f!==0){t=f;l:{var c=l;n=Ca;var i=c.current.memoizedState.isDehydrated;if(i&&(Pu(c,f).flags|=256),f=Yf(c,f,!1),f!==2){if(bi&&!i){c.errorRecoveryDisabledLanes|=e,fu|=e,n=4;break l}e=Tl,Tl=n,e!==null&&(Tl===null?Tl=e:Tl.push.apply(Tl,e))}n=f}if(e=!1,n!==2)continue}}if(n===1){Pu(l,0),Rt(l,t,0,!0);break}l:{switch(a=l,e=n,e){case 0:case 1:throw Error(b(345));case 4:if((t&4194048)!==t)break;case 6:Rt(a,t,Ul,!Bt);break l;case 2:Tl=null;break;case 3:case 5:break;default:throw Error(b(329))}if((t&62914560)===t&&(n=Ce+300-Hl(),10<n)){if(Rt(a,t,Ul,!Bt),Oe(a,0,!0)!==0)break l;St=t,a.timeoutHandle=tm(P0.bind(null,a,u,Tl,he,bc,t,Ul,fu,ku,Bt,e,"Throttled",-0,0),n);break l}P0(a,u,Tl,he,bc,t,Ul,fu,ku,Bt,e,null,-0,0)}}break}while(!0);lt(l)}function P0(l,t,u,a,n,e,f,c,i,m,g,s,h,S){if(l.timeoutHandle=-1,s=t.subtreeFlags,s&8192||(s&16785408)===16785408){s={stylesheets:null,count:0,imgCount:0,imgBytes:0,suspenseyImages:[],waitingForImages:!0,waitingForViewTransition:!1,unsuspend:vt},Hv(t,e,s);var z=(e&62914560)===e?Ce-Hl():(e&4194048)===e?Bv-Hl():0;if(z=Ih(s,z),z!==null){St=e,l.cancelPendingCommit=z(t1.bind(null,l,t,e,u,a,n,f,c,i,g,s,null,h,S)),Rt(l,e,f,!m);return}}t1(l,t,e,u,a,n,f,c,i)}function oh(l){for(var t=l;;){var u=t.tag;if((u===0||u===11||u===15)&&t.flags&16384&&(u=t.updateQueue,u!==null&&(u=u.stores,u!==null)))for(var a=0;a<u.length;a++){var n=u[a],e=n.getSnapshot;n=n.value;try{if(!Bl(e(),n))return!1}catch{return!1}}if(u=t.child,t.subtreeFlags&16384&&u!==null)u.return=t,t=u;else{if(t===l)break;for(;t.sibling===null;){if(t.return===null||t.return===l)return!0;t=t.return}t.sibling.return=t.return,t=t.sibling}}return!0}function Rt(l,t,u,a){t&=~zi,t&=~fu,l.suspendedLanes|=t,l.pingedLanes&=~t,a&&(l.warmLanes|=t),a=l.expirationTimes;for(var n=t;0<n;){var e=31-ql(n),f=1<<e;a[e]=-1,n&=~f}u!==0&&Z1(l,u,t)}function Ge(){return(p&6)===0?(cn(0,!1),!1):!0}function Ti(){if(H!==null){if(G===0)var l=H.return;else l=H,mt=ou=null,ei(l),xu=null,Ka=0,l=H;for(;l!==null;)Sv(l.alternate,l),l=l.return;H=null}}function Pu(l,t){var u=l.timeoutHandle;u!==-1&&(l.timeoutHandle=-1,ph(u)),u=l.cancelPendingCommit,u!==null&&(l.cancelPendingCommit=null,u()),St=0,Ti(),V=l,H=u=dt(l.current,null),q=t,G=0,Ol=null,Bt=!1,fa=ln(l,t),bi=!1,ku=Ul=zi=fu=wt=F=0,Tl=Ca=null,bc=!1,(t&8)!==0&&(t|=t&32);var a=l.entangledLanes;if(a!==0)for(l=l.entanglements,a&=t;0<a;){var n=31-ql(a),e=1<<n;t|=l[n],a&=~e}return zt=t,He(),u}function Gv(l,t){_=null,M.H=ra,t===ea||t===qe?(t=Y0(),G=3):t===Ic?(t=Y0(),G=4):G=t===Si?8:t!==null&&typeof t=="object"&&typeof t.then=="function"?6:1,Ol=t,H===null&&(F=1,ye(l,jl(t,l.current)))}function Xv(){var l=Rl.current;return l===null?!0:(q&4194048)===q?xl===null:(q&62914560)===q||(q&536870912)!==0?l===xl:!1}function Qv(){var l=M.H;return M.H=ra,l===null?ra:l}function Zv(){var l=M.A;return M.A=Sh,l}function Se(){F=4,Bt||(q&4194048)!==q&&Rl.current!==null||(fa=!0),(wt&134217727)===0&&(fu&134217727)===0||V===null||Rt(V,q,Ul,!1)}function Yf(l,t,u){var a=p;p|=2;var n=Qv(),e=Zv();(V!==l||q!==t)&&(he=null,Pu(l,t)),t=!1;var f=F;l:do try{if(G!==0&&H!==null){var c=H,i=Ol;switch(G){case 8:Ti(),f=6;break l;case 3:case 2:case 9:case 6:Rl.current===null&&(t=!0);var m=G;if(G=0,Ol=null,Xu(l,c,i,m),u&&fa){f=0;break l}break;default:m=G,G=0,Ol=null,Xu(l,c,i,m)}}sh(),f=F;break}catch(g){Gv(l,g)}while(!0);return t&&l.shellSuspendCounter++,mt=ou=null,p=a,M.H=n,M.A=e,H===null&&(V=null,q=0,He()),f}function sh(){for(;H!==null;)jv(H)}function bh(l,t){var u=p;p|=2;var a=Qv(),n=Zv();V!==l||q!==t?(he=null,de=Hl()+500,Pu(l,t)):fa=ln(l,t);l:do try{if(G!==0&&H!==null){t=H;var e=Ol;t:switch(G){case 1:G=0,Ol=null,Xu(l,t,e,1);break;case 2:case 9:if(q0(e)){G=0,Ol=null,l1(t);break}t=function(){G!==2&&G!==9||V!==l||(G=7),lt(l)},e.then(t,t);break l;case 3:G=7;break l;case 4:G=5;break l;case 7:q0(e)?(G=0,Ol=null,l1(t)):(G=0,Ol=null,Xu(l,t,e,7));break;case 5:var f=null;switch(H.tag){case 26:f=H.memoizedState;case 5:case 27:var c=H;if(f?fm(f):c.stateNode.complete){G=0,Ol=null;var i=c.sibling;if(i!==null)H=i;else{var m=c.return;m!==null?(H=m,Xe(m)):H=null}break t}}G=0,Ol=null,Xu(l,t,e,5);break;case 6:G=0,Ol=null,Xu(l,t,e,6);break;case 8:Ti(),F=6;break l;default:throw Error(b(462))}}zh();break}catch(g){Gv(l,g)}while(!0);return mt=ou=null,M.H=a,M.A=n,p=u,H!==null?0:(V=null,q=0,He(),F)}function zh(){for(;H!==null&&!xm();)jv(H)}function jv(l){var t=hv(l.alternate,l,zt);l.memoizedProps=l.pendingProps,t===null?Xe(l):H=t}function l1(l){var t=l,u=t.alternate;switch(t.tag){case 15:case 0:t=w0(u,t,t.pendingProps,t.type,void 0,q);break;case 11:t=w0(u,t,t.pendingProps,t.type.render,t.ref,q);break;case 5:ei(t);default:Sv(u,t),t=H=Sy(t,zt),t=hv(u,t,zt)}l.memoizedProps=l.pendingProps,t===null?Xe(l):H=t}function Xu(l,t,u,a){mt=ou=null,ei(t),xu=null,Ka=0;var n=t.return;try{if(ch(l,n,t,u,q)){F=1,ye(l,jl(u,l.current)),H=null;return}}catch(e){if(n!==null)throw H=n,e;F=1,ye(l,jl(u,l.current)),H=null;return}t.flags&32768?(Y||a===1?l=!0:fa||(q&536870912)!==0?l=!1:(Bt=l=!0,(a===2||a===9||a===3||a===6)&&(a=Rl.current,a!==null&&a.tag===13&&(a.flags|=16384))),Vv(t,l)):Xe(t)}function Xe(l){var t=l;do{if((t.flags&32768)!==0){Vv(t,Bt);return}l=t.return;var u=vh(t.alternate,t,zt);if(u!==null){H=u;return}if(t=t.sibling,t!==null){H=t;return}H=t=l}while(t!==null);F===0&&(F=5)}function Vv(l,t){do{var u=mh(l.alternate,l);if(u!==null){u.flags&=32767,H=u;return}if(u=l.return,u!==null&&(u.flags|=32768,u.subtreeFlags=0,u.deletions=null),!t&&(l=l.sibling,l!==null)){H=l;return}H=l=u}while(l!==null);F=6,H=null}function t1(l,t,u,a,n,e,f,c,i){l.cancelPendingCommit=null;do Qe();while(al!==0);if((p&6)!==0)throw Error(b(327));if(t!==null){if(t===l.current)throw Error(b(177));if(e=t.lanes|t.childLanes,e|=Jc,Im(l,u,e,f,c,i),l===V&&(H=V=null,q=0),Iu=t,jt=l,St=u,zc=e,Tc=n,Rv=a,(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?(l.callbackNode=null,l.callbackPriority=0,Mh(In,function(){return rv(),null})):(l.callbackNode=null,l.callbackPriority=0),a=(t.flags&13878)!==0,(t.subtreeFlags&13878)!==0||a){a=M.T,M.T=null,n=C.p,C.p=2,f=p,p|=4;try{dh(l,t,u)}finally{p=f,C.p=n,M.T=a}}al=1,xv(),Lv(),Kv()}}function xv(){if(al===1){al=0;var l=jt,t=Iu,u=(t.flags&13878)!==0;if((t.subtreeFlags&13878)!==0||u){u=M.T,M.T=null;var a=C.p;C.p=2;var n=p;p|=4;try{_v(t,l);var e=_c,f=fy(l.containerInfo),c=e.focusedElem,i=e.selectionRange;if(f!==c&&c&&c.ownerDocument&&ey(c.ownerDocument.documentElement,c)){if(i!==null&&Kc(c)){var m=i.start,g=i.end;if(g===void 0&&(g=m),"selectionStart"in c)c.selectionStart=m,c.selectionEnd=Math.min(g,c.value.length);else{var s=c.ownerDocument||document,h=s&&s.defaultView||window;if(h.getSelection){var S=h.getSelection(),z=c.textContent.length,A=Math.min(i.start,z),Q=i.end===void 0?A:Math.min(i.end,z);!S.extend&&A>Q&&(f=Q,Q=A,A=f);var v=M0(c,A),y=M0(c,Q);if(v&&y&&(S.rangeCount!==1||S.anchorNode!==v.node||S.anchorOffset!==v.offset||S.focusNode!==y.node||S.focusOffset!==y.offset)){var d=s.createRange();d.setStart(v.node,v.offset),S.removeAllRanges(),A>Q?(S.addRange(d),S.extend(y.node,y.offset)):(d.setEnd(y.node,y.offset),S.addRange(d))}}}}for(s=[],S=c;S=S.parentNode;)S.nodeType===1&&s.push({element:S,left:S.scrollLeft,top:S.scrollTop});for(typeof c.focus=="function"&&c.focus(),c=0;c<s.length;c++){var o=s[c];o.element.scrollLeft=o.left,o.element.scrollTop=o.top}}Ae=!!Oc,_c=Oc=null}finally{p=n,C.p=a,M.T=u}}l.current=t,al=2}}function Lv(){if(al===2){al=0;var l=jt,t=Iu,u=(t.flags&8772)!==0;if((t.subtreeFlags&8772)!==0||u){u=M.T,M.T=null;var a=C.p;C.p=2;var n=p;p|=4;try{Tv(l,t.alternate,t)}finally{p=n,C.p=a,M.T=u}}al=3}}function Kv(){if(al===4||al===3){al=0,Lm();var l=jt,t=Iu,u=St,a=Rv;(t.subtreeFlags&10256)!==0||(t.flags&10256)!==0?al=5:(al=0,Iu=jt=null,Jv(l,l.pendingLanes));var n=l.pendingLanes;if(n===0&&(Zt=null),Xc(u),t=t.stateNode,Nl&&typeof Nl.onCommitFiberRoot=="function")try{Nl.onCommitFiberRoot(Pa,t,void 0,(t.current.flags&128)===128)}catch{}if(a!==null){t=M.T,n=C.p,C.p=2,M.T=null;try{for(var e=l.onRecoverableError,f=0;f<a.length;f++){var c=a[f];e(c.value,{componentStack:c.stack})}}finally{M.T=t,C.p=n}}(St&3)!==0&&Qe(),lt(l),n=l.pendingLanes,(u&261930)!==0&&(n&42)!==0?l===Ec?Ga++:(Ga=0,Ec=l):Ga=0,cn(0,!1)}}function Jv(l,t){(l.pooledCacheLanes&=t)===0&&(t=l.pooledCache,t!=null&&(l.pooledCache=null,nn(t)))}function Qe(){return xv(),Lv(),Kv(),rv()}function rv(){if(al!==5)return!1;var l=jt,t=zc;zc=0;var u=Xc(St),a=M.T,n=C.p;try{C.p=32>u?32:u,M.T=null,u=Tc,Tc=null;var e=jt,f=St;if(al=0,Iu=jt=null,St=0,(p&6)!==0)throw Error(b(331));var c=p;if(p|=4,qv(e.current),Uv(e,e.current,f,u),p=c,cn(0,!1),Nl&&typeof Nl.onPostCommitFiberRoot=="function")try{Nl.onPostCommitFiberRoot(Pa,e)}catch{}return!0}finally{C.p=n,M.T=a,Jv(l,t)}}function u1(l,t,u){t=jl(u,t),t=Sc(l.stateNode,t,2),l=Qt(l,t,2),l!==null&&(tn(l,2),lt(l))}function X(l,t,u){if(l.tag===3)u1(l,l,u);else for(;t!==null;){if(t.tag===3){u1(t,l,u);break}else if(t.tag===1){var a=t.stateNode;if(typeof t.type.getDerivedStateFromError=="function"||typeof a.componentDidCatch=="function"&&(Zt===null||!Zt.has(a))){l=jl(u,l),u=cv(2),a=Qt(t,u,2),a!==null&&(iv(u,a,t,l),tn(a,2),lt(a));break}}t=t.return}}function Bf(l,t,u){var a=l.pingCache;if(a===null){a=l.pingCache=new gh;var n=new Set;a.set(t,n)}else n=a.get(t),n===void 0&&(n=new Set,a.set(t,n));n.has(u)||(bi=!0,n.add(u),l=Th.bind(null,l,t,u),t.then(l,l))}function Th(l,t,u){var a=l.pingCache;a!==null&&a.delete(t),l.pingedLanes|=l.suspendedLanes&u,l.warmLanes&=~u,V===l&&(q&u)===u&&(F===4||F===3&&(q&62914560)===q&&300>Hl()-Ce?(p&2)===0&&Pu(l,0):zi|=u,ku===q&&(ku=0)),lt(l)}function wv(l,t){t===0&&(t=Q1()),l=gu(l,t),l!==null&&(tn(l,t),lt(l))}function Eh(l){var t=l.memoizedState,u=0;t!==null&&(u=t.retryLane),wv(l,u)}function Ah(l,t){var u=0;switch(l.tag){case 31:case 13:var a=l.stateNode,n=l.memoizedState;n!==null&&(u=n.retryLane);break;case 19:a=l.stateNode;break;case 22:a=l.stateNode._retryCache;break;default:throw Error(b(314))}a!==null&&a.delete(t),wv(l,u)}function Mh(l,t){return Cc(l,t)}var ge=null,_u=null,Ac=!1,oe=!1,Rf=!1,pt=0;function lt(l){l!==_u&&l.next===null&&(_u===null?ge=_u=l:_u=_u.next=l),oe=!0,Ac||(Ac=!0,_h())}function cn(l,t){if(!Rf&&oe){Rf=!0;do for(var u=!1,a=ge;a!==null;){if(!t)if(l!==0){var n=a.pendingLanes;if(n===0)var e=0;else{var f=a.suspendedLanes,c=a.pingedLanes;e=(1<<31-ql(42|l)+1)-1,e&=n&~(f&~c),e=e&201326741?e&201326741|1:e?e|2:0}e!==0&&(u=!0,a1(a,e))}else e=q,e=Oe(a,a===V?e:0,a.cancelPendingCommit!==null||a.timeoutHandle!==-1),(e&3)===0||ln(a,e)||(u=!0,a1(a,e));a=a.next}while(u);Rf=!1}}function Oh(){Wv()}function Wv(){oe=Ac=!1;var l=0;pt!==0&&Rh()&&(l=pt);for(var t=Hl(),u=null,a=ge;a!==null;){var n=a.next,e=$v(a,t);e===0?(a.next=null,u===null?ge=n:u.next=n,n===null&&(_u=u)):(u=a,(l!==0||(e&3)!==0)&&(oe=!0)),a=n}al!==0&&al!==5||cn(l,!1),pt!==0&&(pt=0)}function $v(l,t){for(var u=l.suspendedLanes,a=l.pingedLanes,n=l.expirationTimes,e=l.pendingLanes&-62914561;0<e;){var f=31-ql(e),c=1<<f,i=n[f];i===-1?((c&u)===0||(c&a)!==0)&&(n[f]=km(c,t)):i<=t&&(l.expiredLanes|=c),e&=~c}if(t=V,u=q,u=Oe(l,l===t?u:0,l.cancelPendingCommit!==null||l.timeoutHandle!==-1),a=l.callbackNode,u===0||l===t&&(G===2||G===9)||l.cancelPendingCommit!==null)return a!==null&&a!==null&&cf(a),l.callbackNode=null,l.callbackPriority=0;if((u&3)===0||ln(l,u)){if(t=u&-u,t===l.callbackPriority)return t;switch(a!==null&&cf(a),Xc(u)){case 2:case 8:u=G1;break;case 32:u=In;break;case 268435456:u=X1;break;default:u=In}return a=Fv.bind(null,l),u=Cc(u,a),l.callbackPriority=t,l.callbackNode=u,t}return a!==null&&a!==null&&cf(a),l.callbackPriority=2,l.callbackNode=null,2}function Fv(l,t){if(al!==0&&al!==5)return l.callbackNode=null,l.callbackPriority=0,null;var u=l.callbackNode;if(Qe()&&l.callbackNode!==u)return null;var a=q;return a=Oe(l,l===V?a:0,l.cancelPendingCommit!==null||l.timeoutHandle!==-1),a===0?null:(Cv(l,a,t),$v(l,Hl()),l.callbackNode!=null&&l.callbackNode===u?Fv.bind(null,l):null)}function a1(l,t){if(Qe())return null;Cv(l,t,!0)}function _h(){Ch(function(){(p&6)!==0?Cc(C1,Oh):Wv()})}function Ei(){if(pt===0){var l=Wu;l===0&&(l=sn,sn<<=1,(sn&261888)===0&&(sn=256)),pt=l}return pt}function n1(l){return l==null||typeof l=="symbol"||typeof l=="boolean"?null:typeof l=="function"?l:Cn(""+l)}function e1(l,t){var u=t.ownerDocument.createElement("input");return u.name=t.name,u.value=t.value,l.id&&u.setAttribute("form",l.id),t.parentNode.insertBefore(u,t),l=new FormData(l),u.parentNode.removeChild(u),l}function Dh(l,t,u,a,n){if(t==="submit"&&u&&u.stateNode===n){var e=n1((n[Al]||null).action),f=a.submitter;f&&(t=(t=f[Al]||null)?n1(t.formAction):f.getAttribute("formAction"),t!==null&&(e=t,f=null));var c=new _e("action","action",null,a,n);l.push({event:c,listeners:[{instance:null,listener:function(){if(a.defaultPrevented){if(pt!==0){var i=f?e1(n,f):new FormData(n);dc(u,{pending:!0,data:i,method:n.method,action:e},null,i)}}else typeof e=="function"&&(c.preventDefault(),i=f?e1(n,f):new FormData(n),dc(u,{pending:!0,data:i,method:n.method,action:e},e,i))},currentTarget:n}]})}}for(Nn=0;Nn<lc.length;Nn++)qn=lc[Nn],f1=qn.toLowerCase(),c1=qn[0].toUpperCase()+qn.slice(1),wl(f1,"on"+c1);var qn,f1,c1,Nn;wl(iy,"onAnimationEnd");wl(yy,"onAnimationIteration");wl(vy,"onAnimationStart");wl("dblclick","onDoubleClick");wl("focusin","onFocus");wl("focusout","onBlur");wl(Kd,"onTransitionRun");wl(Jd,"onTransitionStart");wl(rd,"onTransitionCancel");wl(my,"onTransitionEnd");ru("onMouseEnter",["mouseout","mouseover"]);ru("onMouseLeave",["mouseout","mouseover"]);ru("onPointerEnter",["pointerout","pointerover"]);ru("onPointerLeave",["pointerout","pointerover"]);du("onChange","change click focusin focusout input keydown keyup selectionchange".split(" "));du("onSelect","focusout contextmenu dragend focusin keydown keyup mousedown mouseup selectionchange".split(" "));du("onBeforeInput",["compositionend","keypress","textInput","paste"]);du("onCompositionEnd","compositionend focusout keydown keypress keyup mousedown".split(" "));du("onCompositionStart","compositionstart focusout keydown keypress keyup mousedown".split(" "));du("onCompositionUpdate","compositionupdate focusout keydown keypress keyup mousedown".split(" "));var wa="abort canplay canplaythrough durationchange emptied encrypted ended error loadeddata loadedmetadata loadstart pause play playing progress ratechange resize seeked seeking stalled suspend timeupdate volumechange waiting".split(" "),Uh=new Set("beforetoggle cancel close invalid load scroll scrollend toggle".split(" ").concat(wa));function kv(l,t){t=(t&4)!==0;for(var u=0;u<l.length;u++){var a=l[u],n=a.event;a=a.listeners;l:{var e=void 0;if(t)for(var f=a.length-1;0<=f;f--){var c=a[f],i=c.instance,m=c.currentTarget;if(c=c.listener,i!==e&&n.isPropagationStopped())break l;e=c,n.currentTarget=m;try{e(n)}catch(g){le(g)}n.currentTarget=null,e=i}else for(f=0;f<a.length;f++){if(c=a[f],i=c.instance,m=c.currentTarget,c=c.listener,i!==e&&n.isPropagationStopped())break l;e=c,n.currentTarget=m;try{e(n)}catch(g){le(g)}n.currentTarget=null,e=i}}}}function U(l,t){var u=t[rf];u===void 0&&(u=t[rf]=new Set);var a=l+"__bubble";u.has(a)||(Iv(t,l,2,!1),u.add(a))}function pf(l,t,u){var a=0;t&&(a|=4),Iv(u,l,a,t)}var Yn="_reactListening"+Math.random().toString(36).slice(2);function Ai(l){if(!l[Yn]){l[Yn]=!0,L1.forEach(function(u){u!=="selectionchange"&&(Uh.has(u)||pf(u,!1,l),pf(u,!0,l))});var t=l.nodeType===9?l:l.ownerDocument;t===null||t[Yn]||(t[Yn]=!0,pf("selectionchange",!1,t))}}function Iv(l,t,u,a){switch(mm(t)){case 2:var n=t2;break;case 8:n=u2;break;default:n=Di}u=n.bind(null,t,u,l),n=void 0,!kf||t!=="touchstart"&&t!=="touchmove"&&t!=="wheel"||(n=!0),a?n!==void 0?l.addEventListener(t,u,{capture:!0,passive:n}):l.addEventListener(t,u,!0):n!==void 0?l.addEventListener(t,u,{passive:n}):l.addEventListener(t,u,!1)}function Cf(l,t,u,a,n){var e=a;if((t&1)===0&&(t&2)===0&&a!==null)l:for(;;){if(a===null)return;var f=a.tag;if(f===3||f===4){var c=a.stateNode.containerInfo;if(c===n)break;if(f===4)for(f=a.return;f!==null;){var i=f.tag;if((i===3||i===4)&&f.stateNode.containerInfo===n)return;f=f.return}for(;c!==null;){if(f=Hu(c),f===null)return;if(i=f.tag,i===5||i===6||i===26||i===27){a=e=f;continue l}c=c.parentNode}}a=a.return}k1(function(){var m=e,g=jc(u),s=[];l:{var h=dy.get(l);if(h!==void 0){var S=_e,z=l;switch(l){case"keypress":if(Xn(u)===0)break l;case"keydown":case"keyup":S=Ad;break;case"focusin":z="focus",S=hf;break;case"focusout":z="blur",S=hf;break;case"beforeblur":case"afterblur":S=hf;break;case"click":if(u.button===2)break l;case"auxclick":case"dblclick":case"mousedown":case"mousemove":case"mouseup":case"mouseout":case"mouseover":case"contextmenu":S=S0;break;case"drag":case"dragend":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"dragstart":case"drop":S=vd;break;case"touchcancel":case"touchend":case"touchmove":case"touchstart":S=_d;break;case iy:case yy:case vy:S=hd;break;case my:S=Ud;break;case"scroll":case"scrollend":S=id;break;case"wheel":S=Nd;break;case"copy":case"cut":case"paste":S=gd;break;case"gotpointercapture":case"lostpointercapture":case"pointercancel":case"pointerdown":case"pointermove":case"pointerout":case"pointerover":case"pointerup":S=o0;break;case"toggle":case"beforetoggle":S=Yd}var A=(t&4)!==0,Q=!A&&(l==="scroll"||l==="scrollend"),v=A?h!==null?h+"Capture":null:h;A=[];for(var y=m,d;y!==null;){var o=y;if(d=o.stateNode,o=o.tag,o!==5&&o!==26&&o!==27||d===null||v===null||(o=Za(y,v),o!=null&&A.push(Wa(y,o,d))),Q)break;y=y.return}0<A.length&&(h=new S(h,z,null,u,g),s.push({event:h,listeners:A}))}}if((t&7)===0){l:{if(h=l==="mouseover"||l==="pointerover",S=l==="mouseout"||l==="pointerout",h&&u!==Ff&&(z=u.relatedTarget||u.fromElement)&&(Hu(z)||z[ua]))break l;if((S||h)&&(h=g.window===g?g:(h=g.ownerDocument)?h.defaultView||h.parentWindow:window,S?(z=u.relatedTarget||u.toElement,S=m,z=z?Hu(z):null,z!==null&&(Q=Ia(z),A=z.tag,z!==Q||A!==5&&A!==27&&A!==6)&&(z=null)):(S=null,z=m),S!==z)){if(A=S0,o="onMouseLeave",v="onMouseEnter",y="mouse",(l==="pointerout"||l==="pointerover")&&(A=o0,o="onPointerLeave",v="onPointerEnter",y="pointer"),Q=S==null?h:Aa(S),d=z==null?h:Aa(z),h=new A(o,y+"leave",S,u,g),h.target=Q,h.relatedTarget=d,o=null,Hu(g)===m&&(A=new A(v,y+"enter",z,u,g),A.target=d,A.relatedTarget=Q,o=A),Q=o,S&&z)t:{for(A=Hh,v=S,y=z,d=0,o=v;o;o=A(o))d++;o=0;for(var E=y;E;E=A(E))o++;for(;0<d-o;)v=A(v),d--;for(;0<o-d;)y=A(y),o--;for(;d--;){if(v===y||y!==null&&v===y.alternate){A=v;break t}v=A(v),y=A(y)}A=null}else A=null;S!==null&&i1(s,h,S,A,!1),z!==null&&Q!==null&&i1(s,Q,z,A,!0)}}l:{if(h=m?Aa(m):window,S=h.nodeName&&h.nodeName.toLowerCase(),S==="select"||S==="input"&&h.type==="file")var B=T0;else if(z0(h))if(ay)B=Vd;else{B=Zd;var T=Qd}else S=h.nodeName,!S||S.toLowerCase()!=="input"||h.type!=="checkbox"&&h.type!=="radio"?m&&Zc(m.elementType)&&(B=T0):B=jd;if(B&&(B=B(l,m))){uy(s,B,u,g);break l}T&&T(l,h,m),l==="focusout"&&m&&h.type==="number"&&m.memoizedProps.value!=null&&$f(h,"number",h.value)}switch(T=m?Aa(m):window,l){case"focusin":(z0(T)||T.contentEditable==="true")&&(Yu=T,If=m,Ua=null);break;case"focusout":Ua=If=Yu=null;break;case"mousedown":Pf=!0;break;case"contextmenu":case"mouseup":case"dragend":Pf=!1,O0(s,u,g);break;case"selectionchange":if(Ld)break;case"keydown":case"keyup":O0(s,u,g)}var D;if(Lc)l:{switch(l){case"compositionstart":var N="onCompositionStart";break l;case"compositionend":N="onCompositionEnd";break l;case"compositionupdate":N="onCompositionUpdate";break l}N=void 0}else qu?ly(l,u)&&(N="onCompositionEnd"):l==="keydown"&&u.keyCode===229&&(N="onCompositionStart");N&&(P1&&u.locale!=="ko"&&(qu||N!=="onCompositionStart"?N==="onCompositionEnd"&&qu&&(D=I1()):(Yt=g,Vc="value"in Yt?Yt.value:Yt.textContent,qu=!0)),T=se(m,N),0<T.length&&(N=new g0(N,l,null,u,g),s.push({event:N,listeners:T}),D?N.data=D:(D=ty(u),D!==null&&(N.data=D)))),(D=Rd?pd(l,u):Cd(l,u))&&(N=se(m,"onBeforeInput"),0<N.length&&(T=new g0("onBeforeInput","beforeinput",null,u,g),s.push({event:T,listeners:N}),T.data=D)),Dh(s,l,m,u,g)}kv(s,t)})}function Wa(l,t,u){return{instance:l,listener:t,currentTarget:u}}function se(l,t){for(var u=t+"Capture",a=[];l!==null;){var n=l,e=n.stateNode;if(n=n.tag,n!==5&&n!==26&&n!==27||e===null||(n=Za(l,u),n!=null&&a.unshift(Wa(l,n,e)),n=Za(l,t),n!=null&&a.push(Wa(l,n,e))),l.tag===3)return a;l=l.return}return[]}function Hh(l){if(l===null)return null;do l=l.return;while(l&&l.tag!==5&&l.tag!==27);return l||null}function i1(l,t,u,a,n){for(var e=t._reactName,f=[];u!==null&&u!==a;){var c=u,i=c.alternate,m=c.stateNode;if(c=c.tag,i!==null&&i===a)break;c!==5&&c!==26&&c!==27||m===null||(i=m,n?(m=Za(u,e),m!=null&&f.unshift(Wa(u,m,i))):n||(m=Za(u,e),m!=null&&f.push(Wa(u,m,i)))),u=u.return}f.length!==0&&l.push({event:t,listeners:f})}var Nh=/\r\n?/g,qh=/\u0000|\uFFFD/g;function y1(l){return(typeof l=="string"?l:""+l).replace(Nh,`
`).replace(qh,"")}function Pv(l,t){return t=y1(t),y1(l)===t}function Z(l,t,u,a,n,e){switch(u){case"children":typeof a=="string"?t==="body"||t==="textarea"&&a===""||wu(l,a):(typeof a=="number"||typeof a=="bigint")&&t!=="body"&&wu(l,""+a);break;case"className":Tn(l,"class",a);break;case"tabIndex":Tn(l,"tabindex",a);break;case"dir":case"role":case"viewBox":case"width":case"height":Tn(l,u,a);break;case"style":F1(l,a,e);break;case"data":if(t!=="object"){Tn(l,"data",a);break}case"src":case"href":if(a===""&&(t!=="a"||u!=="href")){l.removeAttribute(u);break}if(a==null||typeof a=="function"||typeof a=="symbol"||typeof a=="boolean"){l.removeAttribute(u);break}a=Cn(""+a),l.setAttribute(u,a);break;case"action":case"formAction":if(typeof a=="function"){l.setAttribute(u,"javascript:throw new Error('A React form was unexpectedly submitted. If you called form.submit() manually, consider using form.requestSubmit() instead. If you\\'re trying to use event.stopPropagation() in a submit event handler, consider also calling event.preventDefault().')");break}else typeof e=="function"&&(u==="formAction"?(t!=="input"&&Z(l,t,"name",n.name,n,null),Z(l,t,"formEncType",n.formEncType,n,null),Z(l,t,"formMethod",n.formMethod,n,null),Z(l,t,"formTarget",n.formTarget,n,null)):(Z(l,t,"encType",n.encType,n,null),Z(l,t,"method",n.method,n,null),Z(l,t,"target",n.target,n,null)));if(a==null||typeof a=="symbol"||typeof a=="boolean"){l.removeAttribute(u);break}a=Cn(""+a),l.setAttribute(u,a);break;case"onClick":a!=null&&(l.onclick=vt);break;case"onScroll":a!=null&&U("scroll",l);break;case"onScrollEnd":a!=null&&U("scrollend",l);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(b(61));if(u=a.__html,u!=null){if(n.children!=null)throw Error(b(60));l.innerHTML=u}}break;case"multiple":l.multiple=a&&typeof a!="function"&&typeof a!="symbol";break;case"muted":l.muted=a&&typeof a!="function"&&typeof a!="symbol";break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"defaultValue":case"defaultChecked":case"innerHTML":case"ref":break;case"autoFocus":break;case"xlinkHref":if(a==null||typeof a=="function"||typeof a=="boolean"||typeof a=="symbol"){l.removeAttribute("xlink:href");break}u=Cn(""+a),l.setAttributeNS("http://www.w3.org/1999/xlink","xlink:href",u);break;case"contentEditable":case"spellCheck":case"draggable":case"value":case"autoReverse":case"externalResourcesRequired":case"focusable":case"preserveAlpha":a!=null&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,""+a):l.removeAttribute(u);break;case"inert":case"allowFullScreen":case"async":case"autoPlay":case"controls":case"default":case"defer":case"disabled":case"disablePictureInPicture":case"disableRemotePlayback":case"formNoValidate":case"hidden":case"loop":case"noModule":case"noValidate":case"open":case"playsInline":case"readOnly":case"required":case"reversed":case"scoped":case"seamless":case"itemScope":a&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,""):l.removeAttribute(u);break;case"capture":case"download":a===!0?l.setAttribute(u,""):a!==!1&&a!=null&&typeof a!="function"&&typeof a!="symbol"?l.setAttribute(u,a):l.removeAttribute(u);break;case"cols":case"rows":case"size":case"span":a!=null&&typeof a!="function"&&typeof a!="symbol"&&!isNaN(a)&&1<=a?l.setAttribute(u,a):l.removeAttribute(u);break;case"rowSpan":case"start":a==null||typeof a=="function"||typeof a=="symbol"||isNaN(a)?l.removeAttribute(u):l.setAttribute(u,a);break;case"popover":U("beforetoggle",l),U("toggle",l),pn(l,"popover",a);break;case"xlinkActuate":ut(l,"http://www.w3.org/1999/xlink","xlink:actuate",a);break;case"xlinkArcrole":ut(l,"http://www.w3.org/1999/xlink","xlink:arcrole",a);break;case"xlinkRole":ut(l,"http://www.w3.org/1999/xlink","xlink:role",a);break;case"xlinkShow":ut(l,"http://www.w3.org/1999/xlink","xlink:show",a);break;case"xlinkTitle":ut(l,"http://www.w3.org/1999/xlink","xlink:title",a);break;case"xlinkType":ut(l,"http://www.w3.org/1999/xlink","xlink:type",a);break;case"xmlBase":ut(l,"http://www.w3.org/XML/1998/namespace","xml:base",a);break;case"xmlLang":ut(l,"http://www.w3.org/XML/1998/namespace","xml:lang",a);break;case"xmlSpace":ut(l,"http://www.w3.org/XML/1998/namespace","xml:space",a);break;case"is":pn(l,"is",a);break;case"innerText":case"textContent":break;default:(!(2<u.length)||u[0]!=="o"&&u[0]!=="O"||u[1]!=="n"&&u[1]!=="N")&&(u=fd.get(u)||u,pn(l,u,a))}}function Mc(l,t,u,a,n,e){switch(u){case"style":F1(l,a,e);break;case"dangerouslySetInnerHTML":if(a!=null){if(typeof a!="object"||!("__html"in a))throw Error(b(61));if(u=a.__html,u!=null){if(n.children!=null)throw Error(b(60));l.innerHTML=u}}break;case"children":typeof a=="string"?wu(l,a):(typeof a=="number"||typeof a=="bigint")&&wu(l,""+a);break;case"onScroll":a!=null&&U("scroll",l);break;case"onScrollEnd":a!=null&&U("scrollend",l);break;case"onClick":a!=null&&(l.onclick=vt);break;case"suppressContentEditableWarning":case"suppressHydrationWarning":case"innerHTML":case"ref":break;case"innerText":case"textContent":break;default:if(!K1.hasOwnProperty(u))l:{if(u[0]==="o"&&u[1]==="n"&&(n=u.endsWith("Capture"),t=u.slice(2,n?u.length-7:void 0),e=l[Al]||null,e=e!=null?e[u]:null,typeof e=="function"&&l.removeEventListener(t,e,n),typeof a=="function")){typeof e!="function"&&e!==null&&(u in l?l[u]=null:l.hasAttribute(u)&&l.removeAttribute(u)),l.addEventListener(t,a,n);break l}u in l?l[u]=a:a===!0?l.setAttribute(u,""):pn(l,u,a)}}}function dl(l,t,u){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"img":U("error",l),U("load",l);var a=!1,n=!1,e;for(e in u)if(u.hasOwnProperty(e)){var f=u[e];if(f!=null)switch(e){case"src":a=!0;break;case"srcSet":n=!0;break;case"children":case"dangerouslySetInnerHTML":throw Error(b(137,t));default:Z(l,t,e,f,u,null)}}n&&Z(l,t,"srcSet",u.srcSet,u,null),a&&Z(l,t,"src",u.src,u,null);return;case"input":U("invalid",l);var c=e=f=n=null,i=null,m=null;for(a in u)if(u.hasOwnProperty(a)){var g=u[a];if(g!=null)switch(a){case"name":n=g;break;case"type":f=g;break;case"checked":i=g;break;case"defaultChecked":m=g;break;case"value":e=g;break;case"defaultValue":c=g;break;case"children":case"dangerouslySetInnerHTML":if(g!=null)throw Error(b(137,t));break;default:Z(l,t,a,g,u,null)}}w1(l,e,c,i,m,f,n,!1);return;case"select":U("invalid",l),a=f=e=null;for(n in u)if(u.hasOwnProperty(n)&&(c=u[n],c!=null))switch(n){case"value":e=c;break;case"defaultValue":f=c;break;case"multiple":a=c;default:Z(l,t,n,c,u,null)}t=e,u=f,l.multiple=!!a,t!=null?Zu(l,!!a,t,!1):u!=null&&Zu(l,!!a,u,!0);return;case"textarea":U("invalid",l),e=n=a=null;for(f in u)if(u.hasOwnProperty(f)&&(c=u[f],c!=null))switch(f){case"value":a=c;break;case"defaultValue":n=c;break;case"children":e=c;break;case"dangerouslySetInnerHTML":if(c!=null)throw Error(b(91));break;default:Z(l,t,f,c,u,null)}$1(l,a,n,e);return;case"option":for(i in u)if(u.hasOwnProperty(i)&&(a=u[i],a!=null))switch(i){case"selected":l.selected=a&&typeof a!="function"&&typeof a!="symbol";break;default:Z(l,t,i,a,u,null)}return;case"dialog":U("beforetoggle",l),U("toggle",l),U("cancel",l),U("close",l);break;case"iframe":case"object":U("load",l);break;case"video":case"audio":for(a=0;a<wa.length;a++)U(wa[a],l);break;case"image":U("error",l),U("load",l);break;case"details":U("toggle",l);break;case"embed":case"source":case"link":U("error",l),U("load",l);case"area":case"base":case"br":case"col":case"hr":case"keygen":case"meta":case"param":case"track":case"wbr":case"menuitem":for(m in u)if(u.hasOwnProperty(m)&&(a=u[m],a!=null))switch(m){case"children":case"dangerouslySetInnerHTML":throw Error(b(137,t));default:Z(l,t,m,a,u,null)}return;default:if(Zc(t)){for(g in u)u.hasOwnProperty(g)&&(a=u[g],a!==void 0&&Mc(l,t,g,a,u,void 0));return}}for(c in u)u.hasOwnProperty(c)&&(a=u[c],a!=null&&Z(l,t,c,a,u,null))}function Yh(l,t,u,a){switch(t){case"div":case"span":case"svg":case"path":case"a":case"g":case"p":case"li":break;case"input":var n=null,e=null,f=null,c=null,i=null,m=null,g=null;for(S in u){var s=u[S];if(u.hasOwnProperty(S)&&s!=null)switch(S){case"checked":break;case"value":break;case"defaultValue":i=s;default:a.hasOwnProperty(S)||Z(l,t,S,null,a,s)}}for(var h in a){var S=a[h];if(s=u[h],a.hasOwnProperty(h)&&(S!=null||s!=null))switch(h){case"type":e=S;break;case"name":n=S;break;case"checked":m=S;break;case"defaultChecked":g=S;break;case"value":f=S;break;case"defaultValue":c=S;break;case"children":case"dangerouslySetInnerHTML":if(S!=null)throw Error(b(137,t));break;default:S!==s&&Z(l,t,h,S,a,s)}}Wf(l,f,c,i,m,g,e,n);return;case"select":S=f=c=h=null;for(e in u)if(i=u[e],u.hasOwnProperty(e)&&i!=null)switch(e){case"value":break;case"multiple":S=i;default:a.hasOwnProperty(e)||Z(l,t,e,null,a,i)}for(n in a)if(e=a[n],i=u[n],a.hasOwnProperty(n)&&(e!=null||i!=null))switch(n){case"value":h=e;break;case"defaultValue":c=e;break;case"multiple":f=e;default:e!==i&&Z(l,t,n,e,a,i)}t=c,u=f,a=S,h!=null?Zu(l,!!u,h,!1):!!a!=!!u&&(t!=null?Zu(l,!!u,t,!0):Zu(l,!!u,u?[]:"",!1));return;case"textarea":S=h=null;for(c in u)if(n=u[c],u.hasOwnProperty(c)&&n!=null&&!a.hasOwnProperty(c))switch(c){case"value":break;case"children":break;default:Z(l,t,c,null,a,n)}for(f in a)if(n=a[f],e=u[f],a.hasOwnProperty(f)&&(n!=null||e!=null))switch(f){case"value":h=n;break;case"defaultValue":S=n;break;case"children":break;case"dangerouslySetInnerHTML":if(n!=null)throw Error(b(91));break;default:n!==e&&Z(l,t,f,n,a,e)}W1(l,h,S);return;case"option":for(var z in u)if(h=u[z],u.hasOwnProperty(z)&&h!=null&&!a.hasOwnProperty(z))switch(z){case"selected":l.selected=!1;break;default:Z(l,t,z,null,a,h)}for(i in a)if(h=a[i],S=u[i],a.hasOwnProperty(i)&&h!==S&&(h!=null||S!=null))switch(i){case"selected":l.selected=h&&typeof h!="function"&&typeof h!="symbol";break;default:Z(l,t,i,h,a,S)}return;case"img":case"link":case"area":case"base":case"br":case"col":case"embed":case"hr":case"keygen":case"meta":case"param":case"source":case"track":case"wbr":case"menuitem":for(var A in u)h=u[A],u.hasOwnProperty(A)&&h!=null&&!a.hasOwnProperty(A)&&Z(l,t,A,null,a,h);for(m in a)if(h=a[m],S=u[m],a.hasOwnProperty(m)&&h!==S&&(h!=null||S!=null))switch(m){case"children":case"dangerouslySetInnerHTML":if(h!=null)throw Error(b(137,t));break;default:Z(l,t,m,h,a,S)}return;default:if(Zc(t)){for(var Q in u)h=u[Q],u.hasOwnProperty(Q)&&h!==void 0&&!a.hasOwnProperty(Q)&&Mc(l,t,Q,void 0,a,h);for(g in a)h=a[g],S=u[g],!a.hasOwnProperty(g)||h===S||h===void 0&&S===void 0||Mc(l,t,g,h,a,S);return}}for(var v in u)h=u[v],u.hasOwnProperty(v)&&h!=null&&!a.hasOwnProperty(v)&&Z(l,t,v,null,a,h);for(s in a)h=a[s],S=u[s],!a.hasOwnProperty(s)||h===S||h==null&&S==null||Z(l,t,s,h,a,S)}function v1(l){switch(l){case"css":case"script":case"font":case"img":case"image":case"input":case"link":return!0;default:return!1}}function Bh(){if(typeof performance.getEntriesByType=="function"){for(var l=0,t=0,u=performance.getEntriesByType("resource"),a=0;a<u.length;a++){var n=u[a],e=n.transferSize,f=n.initiatorType,c=n.duration;if(e&&c&&v1(f)){for(f=0,c=n.responseEnd,a+=1;a<u.length;a++){var i=u[a],m=i.startTime;if(m>c)break;var g=i.transferSize,s=i.initiatorType;g&&v1(s)&&(i=i.responseEnd,f+=g*(i<c?1:(c-m)/(i-m)))}if(--a,t+=8*(e+f)/(n.duration/1e3),l++,10<l)break}}if(0<l)return t/l/1e6}return navigator.connection&&(l=navigator.connection.downlink,typeof l=="number")?l:5}var Oc=null,_c=null;function be(l){return l.nodeType===9?l:l.ownerDocument}function m1(l){switch(l){case"http://www.w3.org/2000/svg":return 1;case"http://www.w3.org/1998/Math/MathML":return 2;default:return 0}}function lm(l,t){if(l===0)switch(t){case"svg":return 1;case"math":return 2;default:return 0}return l===1&&t==="foreignObject"?0:l}function Dc(l,t){return l==="textarea"||l==="noscript"||typeof t.children=="string"||typeof t.children=="number"||typeof t.children=="bigint"||typeof t.dangerouslySetInnerHTML=="object"&&t.dangerouslySetInnerHTML!==null&&t.dangerouslySetInnerHTML.__html!=null}var Gf=null;function Rh(){var l=window.event;return l&&l.type==="popstate"?l===Gf?!1:(Gf=l,!0):(Gf=null,!1)}var tm=typeof setTimeout=="function"?setTimeout:void 0,ph=typeof clearTimeout=="function"?clearTimeout:void 0,d1=typeof Promise=="function"?Promise:void 0,Ch=typeof queueMicrotask=="function"?queueMicrotask:typeof d1<"u"?function(l){return d1.resolve(null).then(l).catch(Gh)}:tm;function Gh(l){setTimeout(function(){throw l})}function $t(l){return l==="head"}function h1(l,t){var u=t,a=0;do{var n=u.nextSibling;if(l.removeChild(u),n&&n.nodeType===8)if(u=n.data,u==="/$"||u==="/&"){if(a===0){l.removeChild(n),ta(t);return}a--}else if(u==="$"||u==="$?"||u==="$~"||u==="$!"||u==="&")a++;else if(u==="html")Xa(l.ownerDocument.documentElement);else if(u==="head"){u=l.ownerDocument.head,Xa(u);for(var e=u.firstChild;e;){var f=e.nextSibling,c=e.nodeName;e[un]||c==="SCRIPT"||c==="STYLE"||c==="LINK"&&e.rel.toLowerCase()==="stylesheet"||u.removeChild(e),e=f}}else u==="body"&&Xa(l.ownerDocument.body);u=n}while(u);ta(t)}function S1(l,t){var u=l;l=0;do{var a=u.nextSibling;if(u.nodeType===1?t?(u._stashedDisplay=u.style.display,u.style.display="none"):(u.style.display=u._stashedDisplay||"",u.getAttribute("style")===""&&u.removeAttribute("style")):u.nodeType===3&&(t?(u._stashedText=u.nodeValue,u.nodeValue=""):u.nodeValue=u._stashedText||""),a&&a.nodeType===8)if(u=a.data,u==="/$"){if(l===0)break;l--}else u!=="$"&&u!=="$?"&&u!=="$~"&&u!=="$!"||l++;u=a}while(u)}function Uc(l){var t=l.firstChild;for(t&&t.nodeType===10&&(t=t.nextSibling);t;){var u=t;switch(t=t.nextSibling,u.nodeName){case"HTML":case"HEAD":case"BODY":Uc(u),Qc(u);continue;case"SCRIPT":case"STYLE":continue;case"LINK":if(u.rel.toLowerCase()==="stylesheet")continue}l.removeChild(u)}}function Xh(l,t,u,a){for(;l.nodeType===1;){var n=u;if(l.nodeName.toLowerCase()!==t.toLowerCase()){if(!a&&(l.nodeName!=="INPUT"||l.type!=="hidden"))break}else if(a){if(!l[un])switch(t){case"meta":if(!l.hasAttribute("itemprop"))break;return l;case"link":if(e=l.getAttribute("rel"),e==="stylesheet"&&l.hasAttribute("data-precedence"))break;if(e!==n.rel||l.getAttribute("href")!==(n.href==null||n.href===""?null:n.href)||l.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin)||l.getAttribute("title")!==(n.title==null?null:n.title))break;return l;case"style":if(l.hasAttribute("data-precedence"))break;return l;case"script":if(e=l.getAttribute("src"),(e!==(n.src==null?null:n.src)||l.getAttribute("type")!==(n.type==null?null:n.type)||l.getAttribute("crossorigin")!==(n.crossOrigin==null?null:n.crossOrigin))&&e&&l.hasAttribute("async")&&!l.hasAttribute("itemprop"))break;return l;default:return l}}else if(t==="input"&&l.type==="hidden"){var e=n.name==null?null:""+n.name;if(n.type==="hidden"&&l.getAttribute("name")===e)return l}else return l;if(l=Ll(l.nextSibling),l===null)break}return null}function Qh(l,t,u){if(t==="")return null;for(;l.nodeType!==3;)if((l.nodeType!==1||l.nodeName!=="INPUT"||l.type!=="hidden")&&!u||(l=Ll(l.nextSibling),l===null))return null;return l}function um(l,t){for(;l.nodeType!==8;)if((l.nodeType!==1||l.nodeName!=="INPUT"||l.type!=="hidden")&&!t||(l=Ll(l.nextSibling),l===null))return null;return l}function Hc(l){return l.data==="$?"||l.data==="$~"}function Nc(l){return l.data==="$!"||l.data==="$?"&&l.ownerDocument.readyState!=="loading"}function Zh(l,t){var u=l.ownerDocument;if(l.data==="$~")l._reactRetry=t;else if(l.data!=="$?"||u.readyState!=="loading")t();else{var a=function(){t(),u.removeEventListener("DOMContentLoaded",a)};u.addEventListener("DOMContentLoaded",a),l._reactRetry=a}}function Ll(l){for(;l!=null;l=l.nextSibling){var t=l.nodeType;if(t===1||t===3)break;if(t===8){if(t=l.data,t==="$"||t==="$!"||t==="$?"||t==="$~"||t==="&"||t==="F!"||t==="F")break;if(t==="/$"||t==="/&")return null}}return l}var qc=null;function g1(l){l=l.nextSibling;for(var t=0;l;){if(l.nodeType===8){var u=l.data;if(u==="/$"||u==="/&"){if(t===0)return Ll(l.nextSibling);t--}else u!=="$"&&u!=="$!"&&u!=="$?"&&u!=="$~"&&u!=="&"||t++}l=l.nextSibling}return null}function o1(l){l=l.previousSibling;for(var t=0;l;){if(l.nodeType===8){var u=l.data;if(u==="$"||u==="$!"||u==="$?"||u==="$~"||u==="&"){if(t===0)return l;t--}else u!=="/$"&&u!=="/&"||t++}l=l.previousSibling}return null}function am(l,t,u){switch(t=be(u),l){case"html":if(l=t.documentElement,!l)throw Error(b(452));return l;case"head":if(l=t.head,!l)throw Error(b(453));return l;case"body":if(l=t.body,!l)throw Error(b(454));return l;default:throw Error(b(451))}}function Xa(l){for(var t=l.attributes;t.length;)l.removeAttributeNode(t[0]);Qc(l)}var Kl=new Map,s1=new Set;function ze(l){return typeof l.getRootNode=="function"?l.getRootNode():l.nodeType===9?l:l.ownerDocument}var Tt=C.d;C.d={f:jh,r:Vh,D:xh,C:Lh,L:Kh,m:Jh,X:wh,S:rh,M:Wh};function jh(){var l=Tt.f(),t=Ge();return l||t}function Vh(l){var t=aa(l);t!==null&&t.tag===5&&t.type==="form"?Fy(t):Tt.r(l)}var ca=typeof document>"u"?null:document;function nm(l,t,u){var a=ca;if(a&&typeof t=="string"&&t){var n=Zl(t);n='link[rel="'+l+'"][href="'+n+'"]',typeof u=="string"&&(n+='[crossorigin="'+u+'"]'),s1.has(n)||(s1.add(n),l={rel:l,crossOrigin:u,href:t},a.querySelector(n)===null&&(t=a.createElement("link"),dl(t,"link",l),fl(t),a.head.appendChild(t)))}}function xh(l){Tt.D(l),nm("dns-prefetch",l,null)}function Lh(l,t){Tt.C(l,t),nm("preconnect",l,t)}function Kh(l,t,u){Tt.L(l,t,u);var a=ca;if(a&&l&&t){var n='link[rel="preload"][as="'+Zl(t)+'"]';t==="image"&&u&&u.imageSrcSet?(n+='[imagesrcset="'+Zl(u.imageSrcSet)+'"]',typeof u.imageSizes=="string"&&(n+='[imagesizes="'+Zl(u.imageSizes)+'"]')):n+='[href="'+Zl(l)+'"]';var e=n;switch(t){case"style":e=la(l);break;case"script":e=ia(l)}Kl.has(e)||(l=r({rel:"preload",href:t==="image"&&u&&u.imageSrcSet?void 0:l,as:t},u),Kl.set(e,l),a.querySelector(n)!==null||t==="style"&&a.querySelector(yn(e))||t==="script"&&a.querySelector(vn(e))||(t=a.createElement("link"),dl(t,"link",l),fl(t),a.head.appendChild(t)))}}function Jh(l,t){Tt.m(l,t);var u=ca;if(u&&l){var a=t&&typeof t.as=="string"?t.as:"script",n='link[rel="modulepreload"][as="'+Zl(a)+'"][href="'+Zl(l)+'"]',e=n;switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":e=ia(l)}if(!Kl.has(e)&&(l=r({rel:"modulepreload",href:l},t),Kl.set(e,l),u.querySelector(n)===null)){switch(a){case"audioworklet":case"paintworklet":case"serviceworker":case"sharedworker":case"worker":case"script":if(u.querySelector(vn(e)))return}a=u.createElement("link"),dl(a,"link",l),fl(a),u.head.appendChild(a)}}}function rh(l,t,u){Tt.S(l,t,u);var a=ca;if(a&&l){var n=Qu(a).hoistableStyles,e=la(l);t=t||"default";var f=n.get(e);if(!f){var c={loading:0,preload:null};if(f=a.querySelector(yn(e)))c.loading=5;else{l=r({rel:"stylesheet",href:l,"data-precedence":t},u),(u=Kl.get(e))&&Mi(l,u);var i=f=a.createElement("link");fl(i),dl(i,"link",l),i._p=new Promise(function(m,g){i.onload=m,i.onerror=g}),i.addEventListener("load",function(){c.loading|=1}),i.addEventListener("error",function(){c.loading|=2}),c.loading|=4,Jn(f,t,a)}f={type:"stylesheet",instance:f,count:1,state:c},n.set(e,f)}}}function wh(l,t){Tt.X(l,t);var u=ca;if(u&&l){var a=Qu(u).hoistableScripts,n=ia(l),e=a.get(n);e||(e=u.querySelector(vn(n)),e||(l=r({src:l,async:!0},t),(t=Kl.get(n))&&Oi(l,t),e=u.createElement("script"),fl(e),dl(e,"link",l),u.head.appendChild(e)),e={type:"script",instance:e,count:1,state:null},a.set(n,e))}}function Wh(l,t){Tt.M(l,t);var u=ca;if(u&&l){var a=Qu(u).hoistableScripts,n=ia(l),e=a.get(n);e||(e=u.querySelector(vn(n)),e||(l=r({src:l,async:!0,type:"module"},t),(t=Kl.get(n))&&Oi(l,t),e=u.createElement("script"),fl(e),dl(e,"link",l),u.head.appendChild(e)),e={type:"script",instance:e,count:1,state:null},a.set(n,e))}}function b1(l,t,u,a){var n=(n=Ct.current)?ze(n):null;if(!n)throw Error(b(446));switch(l){case"meta":case"title":return null;case"style":return typeof u.precedence=="string"&&typeof u.href=="string"?(t=la(u.href),u=Qu(n).hoistableStyles,a=u.get(t),a||(a={type:"style",instance:null,count:0,state:null},u.set(t,a)),a):{type:"void",instance:null,count:0,state:null};case"link":if(u.rel==="stylesheet"&&typeof u.href=="string"&&typeof u.precedence=="string"){l=la(u.href);var e=Qu(n).hoistableStyles,f=e.get(l);if(f||(n=n.ownerDocument||n,f={type:"stylesheet",instance:null,count:0,state:{loading:0,preload:null}},e.set(l,f),(e=n.querySelector(yn(l)))&&!e._p&&(f.instance=e,f.state.loading=5),Kl.has(l)||(u={rel:"preload",as:"style",href:u.href,crossOrigin:u.crossOrigin,integrity:u.integrity,media:u.media,hrefLang:u.hrefLang,referrerPolicy:u.referrerPolicy},Kl.set(l,u),e||$h(n,l,u,f.state))),t&&a===null)throw Error(b(528,""));return f}if(t&&a!==null)throw Error(b(529,""));return null;case"script":return t=u.async,u=u.src,typeof u=="string"&&t&&typeof t!="function"&&typeof t!="symbol"?(t=ia(u),u=Qu(n).hoistableScripts,a=u.get(t),a||(a={type:"script",instance:null,count:0,state:null},u.set(t,a)),a):{type:"void",instance:null,count:0,state:null};default:throw Error(b(444,l))}}function la(l){return'href="'+Zl(l)+'"'}function yn(l){return'link[rel="stylesheet"]['+l+"]"}function em(l){return r({},l,{"data-precedence":l.precedence,precedence:null})}function $h(l,t,u,a){l.querySelector('link[rel="preload"][as="style"]['+t+"]")?a.loading=1:(t=l.createElement("link"),a.preload=t,t.addEventListener("load",function(){return a.loading|=1}),t.addEventListener("error",function(){return a.loading|=2}),dl(t,"link",u),fl(t),l.head.appendChild(t))}function ia(l){return'[src="'+Zl(l)+'"]'}function vn(l){return"script[async]"+l}function z1(l,t,u){if(t.count++,t.instance===null)switch(t.type){case"style":var a=l.querySelector('style[data-href~="'+Zl(u.href)+'"]');if(a)return t.instance=a,fl(a),a;var n=r({},u,{"data-href":u.href,"data-precedence":u.precedence,href:null,precedence:null});return a=(l.ownerDocument||l).createElement("style"),fl(a),dl(a,"style",n),Jn(a,u.precedence,l),t.instance=a;case"stylesheet":n=la(u.href);var e=l.querySelector(yn(n));if(e)return t.state.loading|=4,t.instance=e,fl(e),e;a=em(u),(n=Kl.get(n))&&Mi(a,n),e=(l.ownerDocument||l).createElement("link"),fl(e);var f=e;return f._p=new Promise(function(c,i){f.onload=c,f.onerror=i}),dl(e,"link",a),t.state.loading|=4,Jn(e,u.precedence,l),t.instance=e;case"script":return e=ia(u.src),(n=l.querySelector(vn(e)))?(t.instance=n,fl(n),n):(a=u,(n=Kl.get(e))&&(a=r({},u),Oi(a,n)),l=l.ownerDocument||l,n=l.createElement("script"),fl(n),dl(n,"link",a),l.head.appendChild(n),t.instance=n);case"void":return null;default:throw Error(b(443,t.type))}else t.type==="stylesheet"&&(t.state.loading&4)===0&&(a=t.instance,t.state.loading|=4,Jn(a,u.precedence,l));return t.instance}function Jn(l,t,u){for(var a=u.querySelectorAll('link[rel="stylesheet"][data-precedence],style[data-precedence]'),n=a.length?a[a.length-1]:null,e=n,f=0;f<a.length;f++){var c=a[f];if(c.dataset.precedence===t)e=c;else if(e!==n)break}e?e.parentNode.insertBefore(l,e.nextSibling):(t=u.nodeType===9?u.head:u,t.insertBefore(l,t.firstChild))}function Mi(l,t){l.crossOrigin==null&&(l.crossOrigin=t.crossOrigin),l.referrerPolicy==null&&(l.referrerPolicy=t.referrerPolicy),l.title==null&&(l.title=t.title)}function Oi(l,t){l.crossOrigin==null&&(l.crossOrigin=t.crossOrigin),l.referrerPolicy==null&&(l.referrerPolicy=t.referrerPolicy),l.integrity==null&&(l.integrity=t.integrity)}var rn=null;function T1(l,t,u){if(rn===null){var a=new Map,n=rn=new Map;n.set(u,a)}else n=rn,a=n.get(u),a||(a=new Map,n.set(u,a));if(a.has(l))return a;for(a.set(l,null),u=u.getElementsByTagName(l),n=0;n<u.length;n++){var e=u[n];if(!(e[un]||e[yl]||l==="link"&&e.getAttribute("rel")==="stylesheet")&&e.namespaceURI!=="http://www.w3.org/2000/svg"){var f=e.getAttribute(t)||"";f=l+f;var c=a.get(f);c?c.push(e):a.set(f,[e])}}return a}function E1(l,t,u){l=l.ownerDocument||l,l.head.insertBefore(u,t==="title"?l.querySelector("head > title"):null)}function Fh(l,t,u){if(u===1||t.itemProp!=null)return!1;switch(l){case"meta":case"title":return!0;case"style":if(typeof t.precedence!="string"||typeof t.href!="string"||t.href==="")break;return!0;case"link":if(typeof t.rel!="string"||typeof t.href!="string"||t.href===""||t.onLoad||t.onError)break;switch(t.rel){case"stylesheet":return l=t.disabled,typeof t.precedence=="string"&&l==null;default:return!0}case"script":if(t.async&&typeof t.async!="function"&&typeof t.async!="symbol"&&!t.onLoad&&!t.onError&&t.src&&typeof t.src=="string")return!0}return!1}function fm(l){return!(l.type==="stylesheet"&&(l.state.loading&3)===0)}function kh(l,t,u,a){if(u.type==="stylesheet"&&(typeof a.media!="string"||matchMedia(a.media).matches!==!1)&&(u.state.loading&4)===0){if(u.instance===null){var n=la(a.href),e=t.querySelector(yn(n));if(e){t=e._p,t!==null&&typeof t=="object"&&typeof t.then=="function"&&(l.count++,l=Te.bind(l),t.then(l,l)),u.state.loading|=4,u.instance=e,fl(e);return}e=t.ownerDocument||t,a=em(a),(n=Kl.get(n))&&Mi(a,n),e=e.createElement("link"),fl(e);var f=e;f._p=new Promise(function(c,i){f.onload=c,f.onerror=i}),dl(e,"link",a),u.instance=e}l.stylesheets===null&&(l.stylesheets=new Map),l.stylesheets.set(u,t),(t=u.state.preload)&&(u.state.loading&3)===0&&(l.count++,u=Te.bind(l),t.addEventListener("load",u),t.addEventListener("error",u))}}var Xf=0;function Ih(l,t){return l.stylesheets&&l.count===0&&wn(l,l.stylesheets),0<l.count||0<l.imgCount?function(u){var a=setTimeout(function(){if(l.stylesheets&&wn(l,l.stylesheets),l.unsuspend){var e=l.unsuspend;l.unsuspend=null,e()}},6e4+t);0<l.imgBytes&&Xf===0&&(Xf=62500*Bh());var n=setTimeout(function(){if(l.waitingForImages=!1,l.count===0&&(l.stylesheets&&wn(l,l.stylesheets),l.unsuspend)){var e=l.unsuspend;l.unsuspend=null,e()}},(l.imgBytes>Xf?50:800)+t);return l.unsuspend=u,function(){l.unsuspend=null,clearTimeout(a),clearTimeout(n)}}:null}function Te(){if(this.count--,this.count===0&&(this.imgCount===0||!this.waitingForImages)){if(this.stylesheets)wn(this,this.stylesheets);else if(this.unsuspend){var l=this.unsuspend;this.unsuspend=null,l()}}}var Ee=null;function wn(l,t){l.stylesheets=null,l.unsuspend!==null&&(l.count++,Ee=new Map,t.forEach(Ph,l),Ee=null,Te.call(l))}function Ph(l,t){if(!(t.state.loading&4)){var u=Ee.get(l);if(u)var a=u.get(null);else{u=new Map,Ee.set(l,u);for(var n=l.querySelectorAll("link[data-precedence],style[data-precedence]"),e=0;e<n.length;e++){var f=n[e];(f.nodeName==="LINK"||f.getAttribute("media")!=="not all")&&(u.set(f.dataset.precedence,f),a=f)}a&&u.set(null,a)}n=t.instance,f=n.getAttribute("data-precedence"),e=u.get(f)||a,e===a&&u.set(null,n),u.set(f,n),this.count++,a=Te.bind(this),n.addEventListener("load",a),n.addEventListener("error",a),e?e.parentNode.insertBefore(n,e.nextSibling):(l=l.nodeType===9?l.head:l,l.insertBefore(n,l.firstChild)),t.state.loading|=4}}var $a={$$typeof:yt,Provider:null,Consumer:null,_currentValue:uu,_currentValue2:uu,_threadCount:0};function l2(l,t,u,a,n,e,f,c,i){this.tag=1,this.containerInfo=l,this.pingCache=this.current=this.pendingChildren=null,this.timeoutHandle=-1,this.callbackNode=this.next=this.pendingContext=this.context=this.cancelPendingCommit=null,this.callbackPriority=0,this.expirationTimes=yf(-1),this.entangledLanes=this.shellSuspendCounter=this.errorRecoveryDisabledLanes=this.expiredLanes=this.warmLanes=this.pingedLanes=this.suspendedLanes=this.pendingLanes=0,this.entanglements=yf(0),this.hiddenUpdates=yf(null),this.identifierPrefix=a,this.onUncaughtError=n,this.onCaughtError=e,this.onRecoverableError=f,this.pooledCache=null,this.pooledCacheLanes=0,this.formState=i,this.incompleteTransitions=new Map}function cm(l,t,u,a,n,e,f,c,i,m,g,s){return l=new l2(l,t,u,f,i,m,g,s,c),t=1,e===!0&&(t|=24),e=Dl(3,null,null,t),l.current=e,e.stateNode=l,t=Fc(),t.refCount++,l.pooledCache=t,t.refCount++,e.memoizedState={element:a,isDehydrated:u,cache:t},Pc(e),l}function im(l){return l?(l=pu,l):pu}function ym(l,t,u,a,n,e){n=im(n),a.context===null?a.context=n:a.pendingContext=n,a=Xt(t),a.payload={element:u},e=e===void 0?null:e,e!==null&&(a.callback=e),u=Qt(l,a,t),u!==null&&(El(u,l,t),Na(u,l,t))}function A1(l,t){if(l=l.memoizedState,l!==null&&l.dehydrated!==null){var u=l.retryLane;l.retryLane=u!==0&&u<t?u:t}}function _i(l,t){A1(l,t),(l=l.alternate)&&A1(l,t)}function vm(l){if(l.tag===13||l.tag===31){var t=gu(l,67108864);t!==null&&El(t,l,67108864),_i(l,67108864)}}function M1(l){if(l.tag===13||l.tag===31){var t=Yl();t=Gc(t);var u=gu(l,t);u!==null&&El(u,l,t),_i(l,t)}}var Ae=!0;function t2(l,t,u,a){var n=M.T;M.T=null;var e=C.p;try{C.p=2,Di(l,t,u,a)}finally{C.p=e,M.T=n}}function u2(l,t,u,a){var n=M.T;M.T=null;var e=C.p;try{C.p=8,Di(l,t,u,a)}finally{C.p=e,M.T=n}}function Di(l,t,u,a){if(Ae){var n=Yc(a);if(n===null)Cf(l,t,a,Me,u),O1(l,a);else if(n2(n,l,t,u,a))a.stopPropagation();else if(O1(l,a),t&4&&-1<a2.indexOf(l)){for(;n!==null;){var e=aa(n);if(e!==null)switch(e.tag){case 3:if(e=e.stateNode,e.current.memoizedState.isDehydrated){var f=Pt(e.pendingLanes);if(f!==0){var c=e;for(c.pendingLanes|=2,c.entangledLanes|=2;f;){var i=1<<31-ql(f);c.entanglements[1]|=i,f&=~i}lt(e),(p&6)===0&&(de=Hl()+500,cn(0,!1))}}break;case 31:case 13:c=gu(e,2),c!==null&&El(c,e,2),Ge(),_i(e,2)}if(e=Yc(a),e===null&&Cf(l,t,a,Me,u),e===n)break;n=e}n!==null&&a.stopPropagation()}else Cf(l,t,a,null,u)}}function Yc(l){return l=jc(l),Ui(l)}var Me=null;function Ui(l){if(Me=null,l=Hu(l),l!==null){var t=Ia(l);if(t===null)l=null;else{var u=t.tag;if(u===13){if(l=q1(t),l!==null)return l;l=null}else if(u===31){if(l=Y1(t),l!==null)return l;l=null}else if(u===3){if(t.stateNode.current.memoizedState.isDehydrated)return t.tag===3?t.stateNode.containerInfo:null;l=null}else t!==l&&(l=null)}}return Me=l,null}function mm(l){switch(l){case"beforetoggle":case"cancel":case"click":case"close":case"contextmenu":case"copy":case"cut":case"auxclick":case"dblclick":case"dragend":case"dragstart":case"drop":case"focusin":case"focusout":case"input":case"invalid":case"keydown":case"keypress":case"keyup":case"mousedown":case"mouseup":case"paste":case"pause":case"play":case"pointercancel":case"pointerdown":case"pointerup":case"ratechange":case"reset":case"resize":case"seeked":case"submit":case"toggle":case"touchcancel":case"touchend":case"touchstart":case"volumechange":case"change":case"selectionchange":case"textInput":case"compositionstart":case"compositionend":case"compositionupdate":case"beforeblur":case"afterblur":case"beforeinput":case"blur":case"fullscreenchange":case"focus":case"hashchange":case"popstate":case"select":case"selectstart":return 2;case"drag":case"dragenter":case"dragexit":case"dragleave":case"dragover":case"mousemove":case"mouseout":case"mouseover":case"pointermove":case"pointerout":case"pointerover":case"scroll":case"touchmove":case"wheel":case"mouseenter":case"mouseleave":case"pointerenter":case"pointerleave":return 8;case"message":switch(Km()){case C1:return 2;case G1:return 8;case In:case Jm:return 32;case X1:return 268435456;default:return 32}default:return 32}}var Bc=!1,Vt=null,xt=null,Lt=null,Fa=new Map,ka=new Map,Nt=[],a2="mousedown mouseup touchcancel touchend touchstart auxclick dblclick pointercancel pointerdown pointerup dragend dragstart drop compositionend compositionstart keydown keypress keyup input textInput copy cut paste click change contextmenu reset".split(" ");function O1(l,t){switch(l){case"focusin":case"focusout":Vt=null;break;case"dragenter":case"dragleave":xt=null;break;case"mouseover":case"mouseout":Lt=null;break;case"pointerover":case"pointerout":Fa.delete(t.pointerId);break;case"gotpointercapture":case"lostpointercapture":ka.delete(t.pointerId)}}function ba(l,t,u,a,n,e){return l===null||l.nativeEvent!==e?(l={blockedOn:t,domEventName:u,eventSystemFlags:a,nativeEvent:e,targetContainers:[n]},t!==null&&(t=aa(t),t!==null&&vm(t)),l):(l.eventSystemFlags|=a,t=l.targetContainers,n!==null&&t.indexOf(n)===-1&&t.push(n),l)}function n2(l,t,u,a,n){switch(t){case"focusin":return Vt=ba(Vt,l,t,u,a,n),!0;case"dragenter":return xt=ba(xt,l,t,u,a,n),!0;case"mouseover":return Lt=ba(Lt,l,t,u,a,n),!0;case"pointerover":var e=n.pointerId;return Fa.set(e,ba(Fa.get(e)||null,l,t,u,a,n)),!0;case"gotpointercapture":return e=n.pointerId,ka.set(e,ba(ka.get(e)||null,l,t,u,a,n)),!0}return!1}function dm(l){var t=Hu(l.target);if(t!==null){var u=Ia(t);if(u!==null){if(t=u.tag,t===13){if(t=q1(u),t!==null){l.blockedOn=t,c0(l.priority,function(){M1(u)});return}}else if(t===31){if(t=Y1(u),t!==null){l.blockedOn=t,c0(l.priority,function(){M1(u)});return}}else if(t===3&&u.stateNode.current.memoizedState.isDehydrated){l.blockedOn=u.tag===3?u.stateNode.containerInfo:null;return}}}l.blockedOn=null}function Wn(l){if(l.blockedOn!==null)return!1;for(var t=l.targetContainers;0<t.length;){var u=Yc(l.nativeEvent);if(u===null){u=l.nativeEvent;var a=new u.constructor(u.type,u);Ff=a,u.target.dispatchEvent(a),Ff=null}else return t=aa(u),t!==null&&vm(t),l.blockedOn=u,!1;t.shift()}return!0}function _1(l,t,u){Wn(l)&&u.delete(t)}function e2(){Bc=!1,Vt!==null&&Wn(Vt)&&(Vt=null),xt!==null&&Wn(xt)&&(xt=null),Lt!==null&&Wn(Lt)&&(Lt=null),Fa.forEach(_1),ka.forEach(_1)}function Bn(l,t){l.blockedOn===t&&(l.blockedOn=null,Bc||(Bc=!0,nl.unstable_scheduleCallback(nl.unstable_NormalPriority,e2)))}var Rn=null;function D1(l){Rn!==l&&(Rn=l,nl.unstable_scheduleCallback(nl.unstable_NormalPriority,function(){Rn===l&&(Rn=null);for(var t=0;t<l.length;t+=3){var u=l[t],a=l[t+1],n=l[t+2];if(typeof a!="function"){if(Ui(a||u)===null)continue;break}var e=aa(u);e!==null&&(l.splice(t,3),t-=3,dc(e,{pending:!0,data:n,method:u.method,action:a},a,n))}}))}function ta(l){function t(i){return Bn(i,l)}Vt!==null&&Bn(Vt,l),xt!==null&&Bn(xt,l),Lt!==null&&Bn(Lt,l),Fa.forEach(t),ka.forEach(t);for(var u=0;u<Nt.length;u++){var a=Nt[u];a.blockedOn===l&&(a.blockedOn=null)}for(;0<Nt.length&&(u=Nt[0],u.blockedOn===null);)dm(u),u.blockedOn===null&&Nt.shift();if(u=(l.ownerDocument||l).$$reactFormReplay,u!=null)for(a=0;a<u.length;a+=3){var n=u[a],e=u[a+1],f=n[Al]||null;if(typeof e=="function")f||D1(u);else if(f){var c=null;if(e&&e.hasAttribute("formAction")){if(n=e,f=e[Al]||null)c=f.formAction;else if(Ui(n)!==null)continue}else c=f.action;typeof c=="function"?u[a+1]=c:(u.splice(a,3),a-=3),D1(u)}}}function hm(){function l(e){e.canIntercept&&e.info==="react-transition"&&e.intercept({handler:function(){return new Promise(function(f){return n=f})},focusReset:"manual",scroll:"manual"})}function t(){n!==null&&(n(),n=null),a||setTimeout(u,20)}function u(){if(!a&&!navigation.transition){var e=navigation.currentEntry;e&&e.url!=null&&navigation.navigate(e.url,{state:e.getState(),info:"react-transition",history:"replace"})}}if(typeof navigation=="object"){var a=!1,n=null;return navigation.addEventListener("navigate",l),navigation.addEventListener("navigatesuccess",t),navigation.addEventListener("navigateerror",t),setTimeout(u,100),function(){a=!0,navigation.removeEventListener("navigate",l),navigation.removeEventListener("navigatesuccess",t),navigation.removeEventListener("navigateerror",t),n!==null&&(n(),n=null)}}}function Hi(l){this._internalRoot=l}Ze.prototype.render=Hi.prototype.render=function(l){var t=this._internalRoot;if(t===null)throw Error(b(409));var u=t.current,a=Yl();ym(u,a,l,t,null,null)};Ze.prototype.unmount=Hi.prototype.unmount=function(){var l=this._internalRoot;if(l!==null){this._internalRoot=null;var t=l.containerInfo;ym(l.current,2,null,l,null,null),Ge(),t[ua]=null}};function Ze(l){this._internalRoot=l}Ze.prototype.unstable_scheduleHydration=function(l){if(l){var t=x1();l={blockedOn:null,target:l,priority:t};for(var u=0;u<Nt.length&&t!==0&&t<Nt[u].priority;u++);Nt.splice(u,0,l),u===0&&dm(l)}};var U1=H1.version;if(U1!=="19.2.0")throw Error(b(527,U1,"19.2.0"));C.findDOMNode=function(l){var t=l._reactInternals;if(t===void 0)throw typeof l.render=="function"?Error(b(188)):(l=Object.keys(l).join(","),Error(b(268,l)));return l=Xm(t),l=l!==null?B1(l):null,l=l===null?null:l.stateNode,l};var f2={bundleType:0,version:"19.2.0",rendererPackageName:"react-dom",currentDispatcherRef:M,reconcilerVersion:"19.2.0"};if(typeof __REACT_DEVTOOLS_GLOBAL_HOOK__<"u"&&(za=__REACT_DEVTOOLS_GLOBAL_HOOK__,!za.isDisabled&&za.supportsFiber))try{Pa=za.inject(f2),Nl=za}catch{}var za;je.createRoot=function(l,t){if(!N1(l))throw Error(b(299));var u=!1,a="",n=nv,e=ev,f=fv;return t!=null&&(t.unstable_strictMode===!0&&(u=!0),t.identifierPrefix!==void 0&&(a=t.identifierPrefix),t.onUncaughtError!==void 0&&(n=t.onUncaughtError),t.onCaughtError!==void 0&&(e=t.onCaughtError),t.onRecoverableError!==void 0&&(f=t.onRecoverableError)),t=cm(l,1,!1,null,null,u,a,null,n,e,f,hm),l[ua]=t.current,Ai(l),new Hi(t)};je.hydrateRoot=function(l,t,u){if(!N1(l))throw Error(b(299));var a=!1,n="",e=nv,f=ev,c=fv,i=null;return u!=null&&(u.unstable_strictMode===!0&&(a=!0),u.identifierPrefix!==void 0&&(n=u.identifierPrefix),u.onUncaughtError!==void 0&&(e=u.onUncaughtError),u.onCaughtError!==void 0&&(f=u.onCaughtError),u.onRecoverableError!==void 0&&(c=u.onRecoverableError),u.formState!==void 0&&(i=u.formState)),t=cm(l,1,!0,t,u??null,a,n,i,e,f,c,hm),t.context=im(null),u=t.current,a=Yl(),a=Gc(a),n=Xt(a),n.callback=null,Qt(u,n,a),u=a,t.current.lanes=u,tn(t,u),lt(t),l[ua]=t.current,Ai(l),new Ze(t)};je.version="19.2.0"});var c2=We();window.React=c2;var i2=Sm();window.ReactDOM=i2;})();
/*! Bundled license information:

react/cjs/react.production.js:
  (**
   * @license React
   * react.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

scheduler/cjs/scheduler.production.js:
  (**
   * @license React
   * scheduler.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

react-dom/cjs/react-dom.production.js:
  (**
   * @license React
   * react-dom.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)

react-dom/cjs/react-dom-client.production.js:
  (**
   * @license React
   * react-dom-client.production.js
   *
   * Copyright (c) Meta Platforms, Inc. and affiliates.
   *
   * This source code is licensed under the MIT license found in the
   * LICENSE file in the root directory of this source tree.
   *)
*/
  </script>

  <!-- App (pre-compiled, no Babel needed) -->
  <script>
const { useState, useEffect, useCallback, useRef, useMemo } = React;
if (!window.storage) {
  const mem = {};
  const localOk = (() => {
    try {
      const testKey = "__pcp_storage_test__";
      window.localStorage.setItem(testKey, "1");
      window.localStorage.removeItem(testKey);
      return true;
    } catch (e) {
      return false;
    }
  })();
  window.storage = {
    get: async (key) => {
      if (localOk) {
        return { value: window.localStorage.getItem(key) };
      }
      return { value: mem[key] ?? null };
    },
    set: async (key, value) => {
      if (localOk) {
        window.localStorage.setItem(key, value);
        return;
      }
      mem[key] = value;
    },
    remove: async (key) => {
      if (localOk) {
        window.localStorage.removeItem(key);
        return;
      }
      delete mem[key];
    }
  };
}
const FemaleIcon = ({ size = 24 }) => {
  const s = size > 20 ? size * 1.1: size;
  return /* @__PURE__ */ React.createElement("svg", { width: s, height: s, viewBox: "0 0 64 64", fill: "none", xmlns: "http://www.w3.org/2000/svg" },
    /* @__PURE__ */ React.createElement("circle", { cx: "32", cy: "24", r: "14", stroke: "#1a1a2e", strokeWidth: "2.5", fill: "none" }),
    /* @__PURE__ */ React.createElement("line", { x1: "32", y1: "38", x2: "32", y2: "58", stroke: "#1a1a2e", strokeWidth: "2.5", strokeLinecap: "round" }),
    /* @__PURE__ */ React.createElement("line", { x1: "24", y1: "49", x2: "40", y2: "49", stroke: "#1a1a2e", strokeWidth: "2.5", strokeLinecap: "round" })
  );
};
const GeriatricsWizardIcon = ({ size = 24 }) => {
  const useCategoryBackdrop = size >= 42 || size <= 18;
  if (!useCategoryBackdrop) {
    return /* @__PURE__ */ React.createElement("img", { src: "IMG_0058.png", alt: "", style: { width: size, height: size, objectFit: "contain", display: "block" } });
  }
  return /* @__PURE__ */ React.createElement(
    "span",
    {
      style: {
        width: size,
        height: size,
        display: "inline-flex",
        alignItems: "center",
        justifyContent: "center",
        borderRadius: size <= 18 ? "4px": "10px",
        background: "#E5E7EB",
        overflow: "hidden"
      }
    },
    /* @__PURE__ */ React.createElement("img", { src: "IMG_0058.png", alt: "", style: { width: "100%", height: "100%", objectFit: "contain", display: "block", mixBlendMode: "multiply" } })
  );
};
const PancreasIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement(
  "img",
  {
    src: "data:image/png;base64,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",
    alt: "",
    style: {
      width: size,
      height: size,
      objectFit: "contain",
      borderRadius: "6px",
      mixBlendMode: "multiply"
    }
  }
);
const KidneyBeansIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M8 12C4 14 2 20 2 28C2 36 4 42 8 44C12 46 16 44 18 40C20 36 20 32 18 28C16 24 18 20 20 18C22 16 22 12 18 10C14 8 12 10 8 12Z",
    fill: "#CD5C5C",
    stroke: "#8B0000",
    strokeWidth: "1.5"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M18 24C16 26 16 30 18 34", stroke: "#8B0000", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M10 20C8 24 8 32 10 38", stroke: "#B22222", strokeWidth: "1", opacity: "0.5" }), /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M56 16C60 18 62 24 62 32C62 40 60 46 56 48C52 50 48 48 46 44C44 40 44 36 46 32C48 28 46 24 44 22C42 20 42 16 46 14C50 12 54 14 56 16Z",
    fill: "#CD5C5C",
    stroke: "#8B0000",
    strokeWidth: "1.5"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M46 28C48 30 48 34 46 38", stroke: "#8B0000", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M54 24C56 28 56 36 54 42", stroke: "#B22222", strokeWidth: "1", opacity: "0.5" }), /* @__PURE__ */ React.createElement("path", { d: "M14 44C14 50 18 56 24 58", stroke: "#DEB887", strokeWidth: "1.5", fill: "none" }), /* @__PURE__ */ React.createElement("path", { d: "M50 48C50 54 46 58 40 60", stroke: "#DEB887", strokeWidth: "1.5", fill: "none" }));
const TelophaseIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement(
  "path",
  {
    d: "M8 32C8 18 16 8 24 8C28 8 30 12 32 12C34 12 36 8 40 8C48 8 56 18 56 32C56 46 48 56 40 56C36 56 34 52 32 52C30 52 28 56 24 56C16 56 8 46 8 32Z",
    fill: "#E8F5E9",
    stroke: "#4CAF50",
    strokeWidth: "2"
  }
), /* @__PURE__ */ React.createElement("path", { d: "M32 12C32 12 28 22 28 32C28 42 32 52 32 52", stroke: "#81C784", strokeWidth: "2", strokeDasharray: "3 2" }), /* @__PURE__ */ React.createElement("path", { d: "M32 12C32 12 36 22 36 32C36 42 32 52 32 52", stroke: "#81C784", strokeWidth: "2", strokeDasharray: "3 2" }), /* @__PURE__ */ React.createElement("ellipse", { cx: "20", cy: "32", rx: "6", ry: "8", fill: "#7B1FA2", opacity: "0.8" }), /* @__PURE__ */ React.createElement("path", { d: "M17 28L23 28M17 32L23 32M17 36L23 36", stroke: "#9C27B0", strokeWidth: "1.5" }), /* @__PURE__ */ React.createElement("ellipse", { cx: "44", cy: "32", rx: "6", ry: "8", fill: "#7B1FA2", opacity: "0.8" }), /* @__PURE__ */ React.createElement("path", { d: "M41 28L47 28M41 32L47 32M41 36L47 36", stroke: "#9C27B0", strokeWidth: "1.5" }), /* @__PURE__ */ React.createElement("path", { d: "M26 32L38 32", stroke: "#BDBDBD", strokeWidth: "1", strokeDasharray: "2 2" }));
const LotionBottleIcon = ({ size = 24 }) => /* @__PURE__ */ React.createElement("svg", { width: size, height: size, viewBox: "0 0 64 64", fill: "none" }, /* @__PURE__ */ React.createElement("rect", { x: "16", y: "24", width: "32", height: "36", rx: "4", fill: "#FFECD2", stroke: "#DEB887", strokeWidth: "2" }), /* @__PURE__ */ React.createElement("rect", { x: "26", y: "12", width: "12", height: "12", rx: "2", fill: "#E0E0E0", stroke: "#BDBDBD", strokeWidth: "2" }), /* @__PURE__ */ React.createElement("rect", { x: "30", y: "6", width: "4", height: "8", fill: "#BDBDBD" }), /* @__PURE__ */ React.createElement("rect", { x: "34", y: "8", width: "10", height: "4", rx: "2", fill: "#9E9E9E" }), /* @__PURE__ */ React.createElement("rect", { x: "20", y: "32", width: "24", height: "16", rx: "2", fill: "#87CEEB" }), /* @__PURE__ */ React.createElement("circle", { cx: "28", cy: "38", r: "2", fill: "#FFF" }), /* @__PURE__ */ React.createElement("circle", { cx: "36", cy: "40", r: "2", fill: "#FFF" }), /* @__PURE__ */ React.createElement("circle", { cx: "32", cy: "44", r: "1.5", fill: "#FFF" }));
const CATEGORIES = [
  { id: 1, name: "Cardiovascular", icon: "cardio", color: "#E63946" },
  { id: 2, name: "Pulmonology", icon: "\u{1FAC1}", color: "#457B9D" },
  { id: 3, name: "Gastroenterology", icon: "\u{1F4A9}", color: "#2A9D8F" },
  { id: 4, name: "Endocrine", icon: "pancreas", color: "#E9C46A" },
  { id: 5, name: "Urology", icon: "kidneys", color: "#F4A261" },
  { id: 6, name: "Neurology", icon: "neuro", color: "#9B5DE5" },
  { id: 7, name: "Musculoskeletal", icon: "\u{1F9B4}", color: "#00BBF9" },
  { id: 8, name: "Infectious Disease", icon: "virus", color: "#0F766E" },
  { id: 9, name: "Hematology", icon: "hema", color: "#F15BB5" },
  { id: 10, name: "Dermatology", icon: "lotion", color: "#B45309" },
  { id: 11, name: "Mental Health", icon: "\u{1F60A}", color: "#8AC926" },
  { id: 12, name: "Pediatric", icon: "\u{1F476}", color: "#FF99C8" },
  { id: 13, name: "Rheumatology", icon: "\u{1F9B5}", color: "#A8DADC" },
  { id: 14, name: "Oncology", icon: "telophase", color: "#E056FD" },
  { id: 15, name: "Emergency", icon: "\u{1F691}", color: "#FF6B6B" },
  { id: 16, name: "Preventive", icon: "shield", color: "#4ECDC4" },
  { id: 17, name: "HEENT", icon: "heent", color: "#7B8794" },
  { id: 18, name: "Women's Health", icon: "womens", color: "#E88BC4" },
  { id: 19, name: "Geriatrics", icon: "wizard", color: "#6B7280" }
];
const QUESTIONS = [
  {
    "id": 1,
    "categoryId": 17,
    "question": "A 3-year-old female presents with left ear pain. Exam shows a bulging, erythematous TM with absent mobility. She was treated with Amoxicillin for an ear infection 3 weeks ago. What is the appropriate treatment now?",
    "options": [
      "A) Amoxicillin (90mg/kg)",
      "B) Amoxicillin-Clavulanate (Augmentin)",
      "C) Azithromycin",
      "D) Cephalexin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Augmentin).\n\nPATHOPHYSIOLOGY:\nAcute otitis media (AOM) is a bacterial infection of the middle ear, most commonly caused by Streptococcus pneumoniae, non-typeable Haemophilus influenzae, and Moraxella catarrhalis. In children, the Eustachian tube is shorter, more horizontal, and more compliant than in adults, predisposing to reflux of nasopharyngeal secretions into the middle ear space, especially during or after upper respiratory infections.\n\nCLINICAL REASONING:\nThe AAP 2013 Clinical Practice Guidelines recommend high-dose amoxicillin (80-90 mg/kg/day) as first-line therapy for AOM. However, if the child has received amoxicillin within the preceding 30 days, has concurrent purulent conjunctivitis (suggesting H. influenzae), or has recurrent AOM unresponsive to amoxicillin, the clinician must assume beta-lactamase-producing organisms. Amoxicillin-clavulanate (Augmentin) adds a beta-lactamase inhibitor that restores activity against resistant H. influenzae and M. catarrhalis while maintaining high-dose amoxicillin coverage for S. pneumoniae.\n\nTREATMENT:\n1. First-line (no recent antibiotics): High-dose amoxicillin (80-90 mg/kg/day divided BID)\n2. Treatment failure or recent amoxicillin use (<30 days): High-dose amoxicillin-clavulanate (90 mg/kg/day of amoxicillin component)\n3. Severe PCN allergy (Type I/anaphylaxis): Ceftriaxone IM x3 days or clindamycin\n- Azithromycin has poor middle ear penetration and high S. pneumoniae resistance rates and is no longer routinely recommended\n\nCLINICAL PEARL:\nObservation without antibiotics for 48-72 hours (with safety-net prescription) is appropriate for children over 2 years with unilateral, non-severe AOM. Pain management with ibuprofen or acetaminophen should accompany all treatment decisions.\n\nKEY POINTS:\nRecent amoxicillin use within 30 days necessitates escalation to amoxicillin-clavulanate to cover beta-lactamase-producing organisms. High-dose formulations (90 mg/kg/day) are essential to overcome intermediate S. pneumoniae resistance. Azithromycin is a poor choice for AOM due to inadequate middle ear concentration and resistance.\n---",
    "bulletExplanation": "- CORRECT: B (Augmentin).\n- Recent amoxicillin use (<30 days) increases likelihood of beta-lactamase-producing H. influenzae/M. catarrhalis, so escalate to high-dose amoxicillin-clavulanate.\n- Azithromycin is generally a poor AOM choice due to resistance and limited middle-ear efficacy. Provide analgesia and reassess if severe symptoms persist."
  },
  {
    "id": 2,
    "categoryId": 4,
    "question": "A 28-year-old female who is 10 weeks pregnant presents with a TSH of 4.5 mIU/L (High). Free T4 is normal. She is asymptomatic. What is the best step?",
    "options": [
      "A) Recheck TSH in 4 weeks",
      "B) Initiate Levothyroxine",
      "C) Reassure, this is normal in pregnancy",
      "D) Order Thyroid Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Initiate Levothyroxine).\n\nPATHOPHYSIOLOGY:\nPregnancy increases thyroid hormone demands by 25-50% for maternal metabolism and fetal neurodevelopment, as the fetus depends entirely on maternal thyroxine until the fetal thyroid becomes functional at ~12 weeks gestation. hCG stimulates the TSH receptor, normally causing physiologic TSH decrease in the first trimester. Women with limited thyroid reserve (subclinical hypothyroidism, Hashimoto thyroiditis, iodine deficiency) cannot compensate, and TSH rises above trimester-specific ranges.\n\nCLINICAL REASONING:\nThe ATA 2017 Guidelines recommend trimester-specific TSH references, with a first-trimester upper limit of ~4.0 mIU/L (many institutions use 2.5 mIU/L per earlier ATA guidance). This patient's TSH of 4.5 mIU/L at 10 weeks exceeds both thresholds. Untreated maternal hypothyroidism causes miscarriage, preeclampsia, preterm delivery, and impaired fetal neurodevelopment. Haddow et al. (NEJM 1999) demonstrated children of untreated hypothyroid mothers had IQ scores averaging 7 points lower.\n\nTREATMENT:\nLevothyroxine is safe throughout pregnancy. Starting dose is 1-2 mcg/kg/day; women already on levothyroxine require a 25-50% dose increase upon pregnancy confirmation, ideally within 4-6 weeks. The ATA recommends TSH monitoring every 4 weeks during the first half of pregnancy and at least once in the second half. Take on an empty stomach, separated from prenatal vitamins containing iron and calcium by at least 4 hours. Postpartum, reduce to pre-pregnancy dose and recheck TSH at 6 weeks.\n\nKEY POINTS:\nElevated first-trimester TSH requires prompt levothyroxine to prevent adverse maternal and fetal outcomes. Untreated hypothyroidism impairs fetal neurodevelopment with measurable IQ deficits. Women on levothyroxine need a 25-50% dose increase upon pregnancy confirmation with TSH monitoring every 4 weeks.",
    "bulletExplanation": "- CORRECT: B (Initiate Levothyroxine).\n- First-trimester TSH 4.5 mIU/L is above accepted pregnancy thresholds and should not be observed without treatment.\n- Start levothyroxine now to reduce miscarriage, hypertensive, preterm, and fetal neurodevelopment risks; recheck TSH about every 4 weeks in early pregnancy."
  },
  {
    "id": 3,
    "categoryId": 7,
    "question": "A 45-year-old runner presents with lateral knee pain. It is sharp and occurs after running 2 miles. Exam reveals tenderness 2cm above the lateral joint line. Ober's test is positive. What is the diagnosis?",
    "options": [
      "A) Lateral Meniscus Tear",
      "B) LCL Sprain",
      "C) Iliotibial (IT) Band Syndrome",
      "D) Patellofemoral Pain Syndrome"
    ],
    "correctAnswer": 2,
    "explanationImages": [
      { "src": "assets/21967-Iliotibial-band-syndrome.jpg", "alt": "Iliotibial band syndrome", "caption": "IT band syndrome image." }
    ],
    "explanation": "CORRECT: C (Iliotibial Band Syndrome).\n\nPATHOPHYSIOLOGY:\nThe iliotibial band originates from the iliac crest (via tensor fasciae latae and gluteus maximus) and inserts on Gerdy's tubercle of the lateral tibia. During running, the IT band repeatedly slides over the lateral femoral epicondyle, generating friction-induced inflammation at ~30 degrees of knee flexion. It accounts for up to 12% of running-related overuse injuries. Contributing factors include excessive hip adduction, tibial internal rotation, rapid mileage increases, and cambered surfaces.\n\nCLINICAL PRESENTATION:\nThe hallmark is sharp or burning pain at the lateral femoral epicondyle, 2-3 cm above the lateral joint line, distinguishing it from lateral meniscal pathology (joint line tenderness) and lateral collateral ligament sprains (traumatic, with tenderness over the ligament). Pain begins predictably during runs and worsens with continued activity. Downhill running and stair descent exacerbate symptoms as the knee spends more time near the 30-degree impingement zone. Ober's test assesses IT band tightness: patient lies on the unaffected side while the examiner abducts and extends the affected hip, then allows adduction; failure to adduct past midline indicates tightness.\n\nTREATMENT:\nInitial management includes activity modification, relative rest, and ice. Physical therapy targeting hip abductor strengthening (particularly gluteus medius) and IT band stretching is the rehabilitation cornerstone, as gluteus medius weakness is a consistently identified risk factor. Foam rolling may reduce fascial tension. NSAIDs provide short-term relief. Corticosteroid injection into the bursa beneath the IT band may be considered for refractory cases. Gradual return to running with correction of training errors prevents recurrence.\n\nKEY POINTS:\nIT band syndrome causes lateral knee pain at the lateral femoral epicondyle, 2-3 cm above the joint line, distinguishing it from meniscal and ligamentous pathology. Ober's test evaluates IT band tightness. Hip abductor strengthening is the rehabilitation cornerstone because gluteus medius weakness is a primary contributing factor.",
    "bulletExplanation": "- CORRECT: C (Iliotibial Band Syndrome).\n- Lateral knee pain 2-3 cm above the joint line with a positive Ober test supports IT band syndrome over meniscal tear or LCL injury.\n- First-line care is load modification plus PT focused on hip abductor strengthening and IT band flexibility, then graded return to running."
  },
  {
    "id": 4,
    "categoryId": 3,
    "question": "You are treating a patient for H. pylori. They have a documented Penicillin allergy (rash). Which regimen is the best choice?",
    "options": [
      "A) Clarithromycin Triple Therapy",
      "B) Bismuth Quadruple Therapy",
      "C) Levofloxacin Triple Therapy",
      "D) Sequential Therapy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bismuth Quadruple Therapy).\n\nPATHOPHYSIOLOGY:\nHelicobacter pylori is a gram-negative spiral bacterium that colonizes the gastric mucosa, causing chronic active gastritis, peptic ulcer disease, gastric adenocarcinoma, and MALT lymphoma. Eradication requires combination therapy because monotherapy rapidly induces resistance. Standard first-line clarithromycin triple therapy (PPI, clarithromycin, amoxicillin) relies on amoxicillin as its penicillin-class backbone.\n\nCLINICAL REASONING:\nIn patients with a documented penicillin allergy, amoxicillin-containing regimens are contraindicated. Bismuth quadruple therapy (PPI, bismuth subsalicylate, metronidazole, tetracycline) avoids all penicillin-class antibiotics entirely and is recommended by ACG guidelines as the preferred alternative. This regimen achieves eradication rates of 85-90% even in areas with high metronidazole resistance, because the combination of bismuth and tetracycline compensates for potential resistance. The standard duration is 14 days.\n\nDIFFERENTIAL TREATMENT CONSIDERATIONS:\nClarithromycin triple therapy (Option A) requires amoxicillin and is therefore contraindicated. Levofloxacin triple therapy (Option C) also contains amoxicillin in its standard formulation. Sequential therapy (Option D) uses amoxicillin in its initial phase. Additionally, fluoroquinolone resistance rates now exceed 30% in many regions, making levofloxacin-based regimens less reliable as empiric choices.\n\nKEY POINTS:\nBismuth quadruple therapy is the preferred regimen for H. pylori eradication in penicillin-allergic patients because it contains no beta-lactam antibiotics. Standard duration is 14 days with eradication rates of 85-90%. All three alternative options (clarithromycin triple, levofloxacin triple, sequential therapy) contain amoxicillin and are contraindicated with penicillin allergy.",
    "bulletExplanation": "- CORRECT: B (Bismuth quadruple therapy).\n- In penicillin allergy, avoid amoxicillin-containing regimens; bismuth + PPI + tetracycline + metronidazole is guideline-preferred.\n- Use a 14-day course for best eradication performance. Clarithromycin triple, levofloxacin triple, and sequential regimens are poor choices here because they typically include amoxicillin."
  },
  {
    "id": 5,
    "categoryId": 6,
    "question": "A 30-year-old obese female presents with daily pulsatile headaches and transient visual obscurations. Fundoscopy reveals papilledema. MRI Brain is normal. What is the next diagnostic step?",
    "options": [
      "A) CT Angiogram",
      "B) Lumbar Puncture",
      "C) Trial of Topiramate",
      "D) referral to Ophthalmology"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar Puncture).\n\nIDIOPATHIC INTRACRANIAL HYPERTENSION:\nThis presentation is classic for idiopathic intracranial hypertension (IIH), formerly called pseudotumor cerebri. IIH predominantly affects obese women of childbearing age and presents with daily headaches (often pulsatile and positional), transient visual obscurations (brief episodes of vision loss), pulsatile tinnitus, and papilledema on fundoscopy. The condition results from impaired CSF absorption or increased CSF production, leading to elevated intracranial pressure without a structural lesion.\n\nPATHOPHYSIOLOGY:\nThe exact mechanism remains debated, but elevated intracranial pressure is thought to result from impaired CSF outflow at the arachnoid granulations, potentially linked to elevated venous sinus pressures. Obesity and female sex hormones play a role, though the precise pathways are not fully understood. The elevated pressure is transmitted to the optic nerve sheaths, causing papilledema and threatening vision.\n\nDIAGNOSIS:\nThe Modified Dandy Criteria require signs and symptoms of elevated ICP, normal neurological examination (except CN VI palsy), normal brain imaging (MRI preferred), elevated opening pressure on lumbar puncture (greater than 25 cm H2O in adults), and normal CSF composition. MRI should be performed first to exclude mass lesions, venous sinus thrombosis, and hydrocephalus. Once imaging is normal, lumbar puncture is the definitive diagnostic step.\n\nTREATMENT:\nWeight loss is the most effective long-term treatment, with even modest reductions (5-10%) improving symptoms. Acetazolamide is first-line pharmacotherapy, reducing CSF production by inhibiting carbonic anhydrase. Topiramate is an alternative that also promotes weight loss. Serial visual field testing monitors for progression. Optic nerve sheath fenestration or CSF shunting may be required for refractory cases threatening vision.\n\nKEY POINTS:\nIIH presents in obese young women with headaches, visual obscurations, and papilledema. Lumbar puncture showing elevated opening pressure (greater than 25 cm H2O) with normal CSF is diagnostic after normal imaging. Weight loss is curative and acetazolamide is first-line medical therapy; untreated IIH can cause permanent blindness.",
    "bulletExplanation": "- CORRECT: B (Lumbar puncture).\n- With papilledema and normal MRI, the next step is LP to confirm elevated opening pressure and normal CSF composition for IIH diagnosis.\n- Prompt diagnosis matters because untreated IIH can cause permanent visual loss; start vision-protective management (weight reduction, acetazolamide, ophthalmic follow-up)."
  },
  {
    "id": 6,
    "categoryId": 2,
    "question": "A COPD patient (GOLD Group E) with frequent exacerbations is on LAMA + LABA. Their eosinophil count is 350 cells/uL. What is the next pharmacologic step?",
    "options": [
      "A) Add Inhaled Corticosteroid (ICS)",
      "B) Start Roflumilast",
      "C) Start Azithromycin prophylaxis",
      "D) Add Theophylline"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Add Inhaled Corticosteroid).\n\nPATHOPHYSIOLOGY:\nCOPD involves persistent airflow limitation confirmed by a post-bronchodilator FEV1/FVC ratio less than 0.70 on spirometry. The disease results from chronic inflammatory responses to inhaled noxious particles (predominantly cigarette smoke), causing small airway fibrosis and parenchymal destruction (emphysema) that progressively trap air and impair gas exchange. Exacerbations, defined as acute worsening of respiratory symptoms requiring additional therapy, accelerate lung function decline, worsen quality of life, and increase mortality.\n\nCLINICAL REASONING:\nThe patient is classified as GOLD Group E (2 or more moderate exacerbations or 1 or more severe exacerbation requiring hospitalization in the past year) and is already on dual bronchodilator therapy with LAMA plus LABA. The blood eosinophil count of 350 cells/uL is the critical decision point. The GOLD 2024 guidelines use blood eosinophils to guide ICS therapy: eosinophils 300 or greater strongly support adding ICS, eosinophils 100 to 300 provide moderate support, and eosinophils less than 100 predict minimal ICS benefit with increased pneumonia risk. This patient's eosinophil count of 350 exceeds the 300 threshold, making escalation to LAMA/LABA/ICS triple therapy the recommended next step. The landmark IMPACT trial (published in the New England Journal of Medicine) and the ETHOS trial demonstrated that triple therapy significantly reduces moderate and severe exacerbations and all-cause mortality compared to dual bronchodilator therapy in patients with elevated eosinophils.\n\nALTERNATIVE ESCALATION OPTIONS:\nRoflumilast, a phosphodiesterase-4 inhibitor, is reserved for patients who continue to exacerbate despite triple therapy, specifically those with chronic bronchitis phenotype and FEV1 less than 50% predicted. Chronic azithromycin prophylaxis is also a post-triple-therapy option for former smokers with persistent exacerbations, though it requires baseline ECG (QTc monitoring) and audiometry. Theophylline has a narrow therapeutic index, significant drug interactions, and limited evidence for exacerbation reduction.\n\nKEY POINTS:\nBlood eosinophils 300 or greater in a COPD patient with frequent exacerbations on LAMA/LABA strongly supports adding ICS to form triple therapy. Roflumilast and azithromycin are reserved for patients who continue to exacerbate despite triple therapy. Only smoking cessation and long-term oxygen therapy (in hypoxemic patients) have been proven to improve survival in COPD.",
    "bulletExplanation": "- CORRECT: A (Add inhaled corticosteroid).\n- In GOLD Group E COPD already on LAMA/LABA, eosinophils 350 cells/uL strongly favor ICS escalation to triple therapy.\n- Roflumilast or chronic azithromycin are later-line options after persistent exacerbations despite triple therapy; weigh pneumonia risk and phenotype when selecting chronic regimens."
  },
  {
    "id": 7,
    "categoryId": 1,
    "question": "A 62-year-old female with no history of ASCVD has an LDL of 160 mg/dL. Her calculated 10-year ASCVD risk is 8.5% (Intermediate Risk). She is hesitant to start medication. According to the 2018 AHA/ACC Guidelines, what is the most appropriate next step to aid decision making?",
    "options": [
      "A) Reassurance and lifestyle changes alone",
      "B) Coronary Artery Calcium (CAC) Score",
      "C) Immediate start of Rosuvastatin 20mg",
      "D) Carotid Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Coronary Artery Calcium Score).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines define intermediate risk as a 10-year ASCVD risk between 7.5% and 19.9%, which places patients in a clinical decision zone where statin benefit is present but not overwhelming. For patients in this borderline or intermediate-risk range who are uncertain about starting statin therapy, the guidelines specifically recommend coronary artery calcium (CAC) scoring as a shared decision-making tool to further refine risk stratification. CAC scoring uses non-contrast cardiac CT to quantify calcified atherosclerotic plaque in the coronary arteries, expressed as an Agatston score.\n\nINTERPRETATION AND IMPACT:\nA CAC score of zero indicates the absence of calcified coronary plaque and is linked to a very low 10-year event rate (approximately 1 to 2%), which can reasonably support deferring statin therapy and focusing on lifestyle modification. A CAC score of 1 to 99 suggests mild atherosclerosis and favors initiating moderate-intensity statin therapy. A CAC score of 100 or greater (or at or above the 75th percentile for age, sex, and ethnicity) indicates significant subclinical atherosclerosis and strongly favors statin initiation. In this patient with an intermediate 10-year ASCVD risk of 8.5% and hesitancy about medication, the CAC score provides objective evidence of subclinical disease burden that can either justify treatment initiation or support deferral.\n\nSTATIN INTENSITY TIERS:\nHigh-intensity statins (atorvastatin 40 to 80 mg, rosuvastatin 20 to 40 mg) lower LDL by 50% or more and are indicated for clinical ASCVD, LDL 190 mg/dL or greater, and diabetes with multiple risk factors. Moderate-intensity statins (atorvastatin 10 to 20 mg, rosuvastatin 5 to 10 mg, simvastatin 20 to 40 mg) lower LDL by 30 to 49% and are appropriate for intermediate-risk primary prevention and diabetes aged 40 to 75.\n\nKEY POINTS:\nCAC scoring is the guideline-recommended risk-refinement tool for intermediate-risk patients (7.5 to 19.9% 10-year ASCVD risk) who are uncertain about starting statin therapy. A CAC score of zero supports deferring statin therapy, while a score of 100 or greater strongly favors initiation. CAC scoring should not be used in patients who already qualify for statin therapy by other criteria (clinical ASCVD, LDL 190 or greater, diabetes).",
    "bulletExplanation": "- CORRECT: B (Coronary artery calcium score).\n- In intermediate ASCVD risk (7.5-19.9%) with statin hesitation, CAC refines treatment decisions.\n- CAC 0 may support deferring statin; CAC 1-99 favors treatment (especially older adults); CAC >=100 or >=75th percentile strongly supports statin initiation."
  },
  {
    "id": 8,
    "categoryId": 4,
    "question": "A 58-year-old male with T2DM and established Heart Failure with Reduced Ejection Fraction (HFrEF) is on Metformin and lisinopril. A1c is 7.8%. Which second-line agent is MANDATED by the ADA 2024 Standards of Care?",
    "options": [
      "A) Glipizide (Sulfonylurea)",
      "B) Empagliflozin (SGLT2 Inhibitor)",
      "C) Sitagliptin (DPP-4 Inhibitor)",
      "D) Insulin Glargine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Empagliflozin / SGLT2 Inhibitor).\n\nPATHOPHYSIOLOGY:\nSGLT2 inhibitors block glucose reabsorption in the proximal tubule, producing glycosuria, osmotic diuresis, and natriuresis. Beyond glucose lowering, they exert cardiovascular and renal benefits largely independent of glycemic control. Osmotic diuresis reduces preload; natriuresis lowers afterload. SGLT2 inhibitors shift myocardial fuel metabolism toward ketone body utilization, a more oxygen-efficient substrate for the failing heart, and reduce interstitial fluid preferentially over intravascular volume, preserving organ perfusion while relieving congestion.\n\nCLINICAL EVIDENCE:\nEMPA-REG OUTCOME (NEJM 2015) showed empagliflozin reduced cardiovascular death by 38% and HF hospitalization by 35% in T2DM with established CVD. DAPA-HF (NEJM 2019) demonstrated dapagliflozin reduced worsening HF and CV death by 26% in HFrEF regardless of diabetes status. EMPEROR-Reduced (NEJM 2020) confirmed empagliflozin reduced HF hospitalization and CV death by 25% in HFrEF.\n\nCLINICAL REASONING:\nThe ADA 2024 Standards of Care use a comorbidity-centric approach: heart failure (HFrEF or HFpEF) or CKD mandates SGLT2 inhibitor use independent of A1c. For this patient with HFrEF, empagliflozin or dapagliflozin is guideline-mandated. Sulfonylureas lack CV benefit and cause hypoglycemia and weight gain. DPP-4 inhibitors are CV-neutral without HF benefit; saxagliptin increased HF hospitalization in SAVOR-TIMI 53. Insulin lacks CV benefit and promotes weight gain.\n\nKEY POINTS:\nSGLT2 inhibitors are mandated by ADA 2024 for T2DM with heart failure or CKD, independent of A1c, based on landmark trials showing reduced CV death and HF hospitalization. Benefits involve preload and afterload reduction, favorable myocardial metabolic shifts, and preferential interstitial fluid clearance. DPP-4 inhibitors lack HF benefit and saxagliptin may increase HF risk.",
    "bulletExplanation": "- CORRECT: B (Empagliflozin/SGLT2 inhibitor).\n- In T2DM with established HFrEF, ADA standards prioritize an SGLT2 inhibitor regardless of A1c because it reduces HF hospitalization and cardiovascular mortality.\n- Sulfonylureas, DPP-4 inhibitors, and basal insulin do not provide comparable heart-failure outcome benefit in this scenario."
  },
  {
    "id": 9,
    "categoryId": 12,
    "question": "A 4-year-old presents with 5 days of high fever (>102 F). Exam shows bilateral non-exudative conjunctivitis, fissured 'strawberry' tongue, and desquamation of the periungual region of the fingers. What is the most critical complication to screen for?",
    "options": [
      "A) Rheumatic Heart Disease",
      "B) Coronary Artery Aneurysms",
      "C) Glomerulonephritis",
      "D) Encephalitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Coronary Artery Aneurysms).\n\nPATHOPHYSIOLOGY:\nKawasaki disease is an acute, self-limited febrile vasculitis of unknown etiology that predominantly affects children under 5 years of age and has particular tropism for medium-sized muscular arteries, especially the coronary arteries. The disease is the leading cause of acquired heart disease in children in developed countries. The inflammatory process involves all three layers of the arterial wall (panarteritis), and in the coronary arteries this inflammation weakens the vessel wall and leads to aneurysmal dilation in 15 to 25% of untreated children. Coronary artery aneurysms can thrombose, causing myocardial infarction in young children, or progress to stenotic lesions that produce chronic ischemic heart disease decades later.\n\nDIAGNOSTIC CRITERIA:\nKawasaki disease is diagnosed clinically when fever persists for 5 or more days plus at least 4 of the following 5 features: bilateral non-exudative conjunctival injection (characteristically limbic-sparing), oral mucosal changes (strawberry tongue, erythematous cracked lips, diffuse oropharyngeal erythema), extremity changes (erythema and edema of hands and feet acutely, followed by periungual desquamation in the subacute phase), polymorphous rash (often accentuated in the perineal region with early desquamation), and unilateral cervical lymphadenopathy (at least 1.5 cm diameter). Incomplete Kawasaki disease (fever plus fewer than 4 criteria) should be considered in any child with prolonged unexplained fever, particularly infants who are at highest risk for coronary complications.\n\nTREATMENT:\nHigh-dose IVIG (2 g/kg as a single infusion) plus aspirin administered within the first 10 days of illness reduces the incidence of coronary artery aneurysms from approximately 25% to <5%. High-dose aspirin (80 to 100 mg/kg/day in 4 divided doses) is given during the acute febrile phase for its anti-inflammatory effect, then reduced to low-dose aspirin (3 to 5 mg/kg/day) for 6 to 8 weeks or longer if coronary abnormalities are detected. Echocardiography is mandatory at diagnosis, at 2 weeks, and at 6 to 8 weeks to screen for coronary artery involvement, with more frequent monitoring if abnormalities are found.\n\nKEY POINTS:\nKawasaki disease requires fever for 5 or more days plus 4 of 5 clinical criteria, and coronary artery aneurysms developing in up to 25% of untreated children are the most feared complication. IVIG plus aspirin within 10 days of illness reduces aneurysm risk to <5%. Incomplete Kawasaki should be suspected in any child with prolonged unexplained fever, especially infants who carry the highest risk.",
    "bulletExplanation": "- CORRECT: B (Coronary artery aneurysms).\n- In Kawasaki disease, the highest-risk complication is coronary artery involvement, especially if treatment is delayed.\n- Give IVIG plus aspirin within 10 days and schedule serial echocardiography; this markedly lowers aneurysm risk and guides ongoing management."
  },
  {
    "id": 10,
    "categoryId": 7,
    "question": "A 50-year-old diabetic female presents with insidious onset of shoulder stiffness. She has lost both active AND passive range of motion in all planes, especially external rotation. X-rays are normal. What is the diagnosis?",
    "options": [
      "A) Rotator Cuff Tear",
      "B) Adhesive Capsulitis (Frozen Shoulder)",
      "C) Subacromial Impingement",
      "D) Glenohumeral Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/frozen-shoulder.jpg", "alt": "Adhesive capsulitis", "caption": "Frozen shoulder image." }
    ],
    "explanation": "CORRECT: B (Adhesive Capsulitis).\n\nPATHOPHYSIOLOGY:\nAdhesive capsulitis (frozen shoulder) is a fibroproliferative disorder with progressive fibrosis and contracture of the glenohumeral joint capsule. Chronic synovial inflammation leads to capsular thickening, particularly of the coracohumeral ligament and rotator interval. Histologically, dense type I and III collagen deposition with fibroblast proliferation resembles Dupuytren's contracture. Diabetes mellitus is the strongest risk factor, affecting 10-20% of diabetic patients versus 2-5% of the general population, likely due to advanced glycation end-products promoting collagen cross-linking. Other associations include thyroid disease, autoimmune conditions, prolonged immobilization, and cardiac or breast surgery.\n\nCLINICAL PRESENTATION:\nThe hallmark is loss of both active and passive range of motion in all planes, with external rotation most restricted and earliest affected. This distinguishes it from rotator cuff pathology and subacromial impingement, where passive ROM is preserved because the capsule is normal. The disease progresses through three stages: freezing (2-9 months, progressive pain and stiffness), frozen (4-12 months, minimal pain but significant restriction), and thawing (5-24 months, gradual return of motion). Total duration averages 1-3 years, though some develop permanent mild restriction. Normal radiographs help exclude glenohumeral osteoarthritis.\n\nTREATMENT:\nPhysical therapy with gentle stretching and ROM exercises is the foundation across all stages. NSAIDs and acetaminophen provide symptomatic relief. Intra-articular corticosteroid injection offers significant short-term improvement, particularly during the freezing phase. For refractory cases, manipulation under anesthesia or arthroscopic capsular release may be considered. Hydrodilatation is an emerging option with growing evidence.\n\nKEY POINTS:\nLoss of both active and passive ROM defines adhesive capsulitis, distinguishing it from rotator cuff tears and impingement where passive ROM is preserved. Diabetes is the strongest risk factor (10-20% of diabetics). Natural history involves freezing, frozen, and thawing phases over 1-3 years.",
    "bulletExplanation": "- CORRECT: B (Adhesive capsulitis).\n- Diagnostic clue: loss of both active and passive ROM, especially external rotation, with normal X-rays.\n- Diabetes is a major risk factor. Treat with structured ROM-focused therapy, analgesia, and consider intra-articular steroid in painful early phase; recovery is often prolonged over months to years."
  },
  {
    "id": 11,
    "categoryId": 3,
    "question": "A 24-year-old male complains of chronic bloody diarrhea, weight loss, and RLQ pain. Colonoscopy shows 'skip lesions' and a 'cobblestone appearance' in the terminal ileum. Biopsy shows transmural inflammation. Diagnosis?",
    "options": [
      "A) Ulcerative Colitis",
      "B) Crohn's Disease",
      "C) Celiac Disease",
      "D) Irritable Bowel Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Crohn's Disease).\n\nPATHOPHYSIOLOGY:\nCrohn's disease is a chronic inflammatory bowel disease characterized by transmural inflammation that can affect any segment of the gastrointestinal tract from mouth to anus, though it has a strong predilection for the terminal ileum and proximal colon. The transmural nature of inflammation distinguishes it from ulcerative colitis, which is limited to the mucosa and submucosa. Genetic susceptibility (NOD2/CARD15 mutations), environmental triggers, and dysregulated immune responses to gut microbiota drive a Th1/Th17-mediated inflammatory cascade.\n\nCLINICAL PRESENTATION:\nThe classic triad includes chronic diarrhea (often bloody), abdominal pain (typically right lower quadrant), and weight loss. Endoscopic hallmarks include skip lesions (areas of diseased bowel separated by normal segments), cobblestone mucosa (created by intersecting longitudinal and transverse ulcers with intervening edematous mucosa), and aphthous ulcers. Biopsy reveals transmural inflammation with non-caseating granulomas in approximately 30% of cases, which is pathognomonic when present.\n\nCOMPLICATIONS AND MANAGEMENT:\nTransmural inflammation predisposes to strictures, fistulae (perianal, enteroenteric, enterovesical), and abscess formation. Treatment follows a step-up approach: 5-ASA for mild disease, corticosteroids for flares, immunomodulators (azathioprine, methotrexate) for maintenance, and biologic agents (anti-TNF, anti-integrin, anti-IL-12/23) for moderate-to-severe disease. Approximately 70-80% of patients eventually require surgery.\n\nKEY POINTS:\nCrohn's disease is distinguished by transmural inflammation, skip lesions, cobblestone mucosa, and non-caseating granulomas. It can affect any part of the GI tract but favors the terminal ileum. Complications include strictures, fistulae, and abscesses. Approximately 70-80% of patients require surgery during their lifetime.",
    "bulletExplanation": "- CORRECT: B (Crohn's disease).\n- Terminal ileal disease with skip lesions, cobblestoning, and transmural inflammation is classic for Crohn's (not ulcerative colitis).\n- Transmural inflammation drives complications (strictures, fistulas, abscesses); treatment escalates from induction control to immunomodulator/biologic maintenance based on severity."
  },
  {
    "id": 12,
    "categoryId": 11,
    "question": "A patient started on Haloperidol and Lithium develops high fever (104 F), 'lead-pipe' muscle rigidity, and autonomic instability (BP 180/100). CK is elevated to 50,000. Diagnosis?",
    "options": [
      "A) Serotonin Syndrome",
      "B) Neuroleptic Malignant Syndrome (NMS)",
      "C) Malignant Hyperthermia",
      "D) Lithium Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neuroleptic Malignant Syndrome).\n\nPATHOPHYSIOLOGY:\nNeuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine receptor-blocking agents, most classically high-potency first-generation antipsychotics such as haloperidol. The syndrome results from acute central dopamine D2 receptor blockade in the hypothalamus (causing temperature dysregulation and autonomic instability), the nigrostriatal pathway (causing muscle rigidity), and the mesocortical pathway (causing altered mental status). NMS occurs in approximately 0.01 to 0.02% of patients exposed to antipsychotics and carries a mortality rate of 5 to 10% if untreated.\n\nCLINICAL PRESENTATION:\nThe classic tetrad of NMS is hyperthermia (often exceeding 104Â°F/40Â°C), severe \"lead-pipe\" muscle rigidity (continuous resistance throughout passive range of motion, distinct from the cogwheel rigidity of parkinsonism), autonomic instability (labile blood pressure, tachycardia, diaphoresis), and altered mental status ranging from confusion to obtundation. The mnemonic FARM captures these features: Fever, Autonomic instability, Rigidity, Mental status change. Laboratory findings include markedly elevated creatine phosphokinase (CPK) from rhabdomyolysis (often exceeding 1,000 IU/L and frequently above 10,000), leukocytosis, elevated liver transaminases, and metabolic acidosis.\n\nDIFFERENTIAL DIAGNOSIS:\nNMS must be distinguished from serotonin syndrome, which features clonus, hyperreflexia, and mydriasis (absent in NMS) and develops rapidly (within hours) with serotonergic drugs. Malignant hyperthermia occurs with volatile anesthetics and succinylcholine, not antipsychotics. Lithium toxicity causes tremor and ataxia but not lead-pipe rigidity.\n\nMANAGEMENT:\nImmediate discontinuation of the offending antipsychotic is essential. Supportive care includes aggressive IV hydration to prevent renal failure from myoglobinuria, active cooling measures, and ICU monitoring. Dantrolene (a direct-acting skeletal muscle relaxant that blocks ryanodine receptor calcium release) and bromocriptine (a dopamine agonist that restores dopaminergic transmission) are the specific pharmacologic treatments.\n\nKEY POINTS:\nNMS presents with the FARM tetrad (Fever, Autonomic instability, Rigidity, Mental status change) and markedly elevated CPK from rhabdomyolysis. It results from central dopamine D2 blockade, most commonly from high-potency antipsychotics like haloperidol. Treatment requires immediate drug discontinuation, aggressive hydration, and specific therapy with dantrolene or bromocriptine.",
    "bulletExplanation": "- CORRECT: B (Neuroleptic malignant syndrome).\n- Hyperthermia, lead-pipe rigidity, autonomic instability, and marked CK elevation after dopamine-blocking drugs strongly indicate NMS.\n- Differentiate from serotonin syndrome (clonus/hyperreflexia). Stop offending agents immediately, start aggressive supportive care, and consider dantrolene or bromocriptine."
  },
  {
    "id": 13,
    "categoryId": 4,
    "question": "A 52-year-old post-menopausal female presents with vaginal spotting. She has a history of PCOS and obesity (BMI 35). Ultrasound shows an endometrial stripe of 12mm. What is the REQUIRED next step?",
    "options": [
      "A) Reassure and monitor",
      "B) Oral Progesterone taper",
      "C) Endometrial Biopsy",
      "D) Total Hysterectomy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Endometrial Biopsy).\n\nPATHOPHYSIOLOGY:\nEndometrial cancer develops through chronic unopposed estrogen exposure. Estrogen stimulates endometrial proliferation; without progesterone-mediated shedding, the endometrium undergoes progressive hyperplasia from simple hyperplasia without atypia through complex atypical hyperplasia (~25-30% progression risk to carcinoma). This patient has three sources of unopposed estrogen: obesity (adipose aromatase converts androgens to estrone), PCOS (chronic anovulation eliminates cyclic progesterone), and postmenopausal status (loss of ovarian progesterone). Type I endometrial cancers (~80% of cases) are estrogen-driven, typically endometrioid histology, and carry favorable prognosis when detected early.\n\nCLINICAL REASONING:\nPostmenopausal bleeding should be considered malignant until proven otherwise; endometrial cancer is present in ~10% of cases. Transvaginal ultrasound is appropriate initial evaluation. An endometrial stripe \u22644 mm carries >99% negative predictive value for cancer, and biopsy may be deferred. A stripe >4 mm requires tissue sampling. This patient's 12 mm stripe combined with multiple risk factors mandates prompt biopsy.\n\nDIAGNOSIS:\nOffice Pipelle endometrial biopsy is first-line, with 90-98% sensitivity for endometrial cancer, performed without anesthesia in the outpatient setting. When office biopsy yields insufficient tissue, is technically unsuccessful (e.g., cervical stenosis), or returns inconclusive results, dilation and curettage with or without hysteroscopy is indicated. Hysteroscopy with directed biopsy is useful for focal lesions such as polyps that may harbor focal malignancy.\n\nKEY POINTS:\nPostmenopausal bleeding is endometrial cancer until proven otherwise (~10% of cases). Endometrial stripe >4 mm with bleeding requires tissue sampling; Pipelle biopsy is first-line with 90-98% sensitivity. Risk factors including obesity, PCOS, nulliparity, tamoxifen, and estrogen-only HRT share a common mechanism of unopposed estrogen.",
    "bulletExplanation": "- CORRECT: C (Endometrial biopsy).\n- Postmenopausal bleeding is malignant until proven otherwise; endometrial thickness >4 mm requires tissue diagnosis.\n- With 12 mm stripe plus obesity/PCOS risk, immediate biopsy is required rather than reassurance or empiric hormonal therapy."
  },
  {
    "id": 14,
    "categoryId": 8,
    "question": "A 22-year-old male presents with purulent penile discharge. NAAT is positive for Gonorrhea. He has no known allergies. What is the CDC 2021 Update treatment?",
    "options": [
      "A) Ceftriaxone 250mg IM x1",
      "B) Ceftriaxone 500mg IM x1",
      "C) Azithromycin 1g PO x1",
      "D) Cefixime 400mg PO x1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ceftriaxone 500mg IM).\n\nPATHOPHYSIOLOGY:\nNeisseria gonorrhoeae is a gram-negative diplococcus that infects columnar and transitional epithelium of the urethra, cervix, rectum, pharynx, and conjunctiva. The organism attaches via pili and Opa proteins, invades mucosal cells, and triggers an intense neutrophilic inflammatory response that produces the characteristic purulent discharge. N. gonorrhoeae has demonstrated a remarkable ability to develop antimicrobial resistance through chromosomal mutations and plasmid-mediated mechanisms, driving repeated changes in treatment guidelines.\n\nCLINICAL MANIFESTATIONS:\nIn men, urethritis with purulent discharge and dysuria is the most common presentation, typically appearing 2-5 days after exposure. Women may present with mucopurulent cervicitis, but up to 50% of female genital infections are asymptomatic. Untreated infection can ascend to cause epididymitis in men and pelvic inflammatory disease (PID) in women, potentially leading to infertility. Disseminated gonococcal infection presents with the classic triad of tenosynovitis, dermatitis (pustular skin lesions), and migratory polyarthralgia.\n\nTREATMENT:\nThe CDC 2021 STI Treatment Guidelines recommend ceftriaxone 500mg IM as a single dose for uncomplicated gonorrhea in patients weighing less than 150 kg (1g IM for those â‰¥150 kg). This represents a dose increase from the prior 250mg recommendation due to rising minimum inhibitory concentrations. Dual therapy with azithromycin is no longer routinely recommended; however, if chlamydial co-infection has not been excluded, doxycycline 100mg BID for 7 days should be added. Oral cefixime is an alternative only when IM ceftriaxone is unavailable, and requires a test-of-cure at 7 days. All patients should be retested for reinfection at 3 months.\n\nKEY POINTS:\nCeftriaxone 500mg IM is the current standard for uncomplicated gonorrhea. Add doxycycline if chlamydia has not been excluded. Oral cefixime requires test-of-cure and is only used when ceftriaxone is unavailable. Retest for reinfection at 3 months.\n---",
    "bulletExplanation": "- CORRECT: B (Ceftriaxone 500 mg IM once).\n- This is CDC first-line therapy for uncomplicated gonorrhea in most adults (<150 kg; use 1 g if >=150 kg).\n- If chlamydia status is unknown, add doxycycline; retest for reinfection at about 3 months."
  },
  {
    "id": 15,
    "categoryId": 6,
    "question": "A 65-year-old male presents with acute continuous vertigo, nausea, and gait instability. He cannot walk without falling to the left. Head Impulse Test is NORMAL. No hearing loss. What is the most likely diagnosis?",
    "options": [
      "A) Vestibular Neuritis",
      "B) BPPV",
      "C) Cerebellar Stroke",
      "D) Meniere's Disease"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Cerebellar Stroke).\n\nCLINICAL REASONING:\nThe distinction between central and peripheral vertigo is critical in the emergency setting. This patient's presentation suggests a central cause (cerebellar stroke) based on three key findings: inability to walk (severe gait ataxia with falling to one side), normal Head Impulse Test (HIT), and the acute, continuous nature of symptoms.\n\nHEAD IMPULSE TEST INTERPRETATION:\nThe HIT assesses the vestibulo-ocular reflex. In peripheral vertigo (vestibular neuritis), the affected labyrinth cannot generate a compensatory eye movement, so the patient makes a \"catch-up\" saccade when the head is turned toward the affected side (abnormal/positive HIT). In central vertigo, the peripheral vestibular apparatus is intact, so the HIT is normal. A NORMAL HIT in a patient with acute vertigo should raise concern for stroke.\n\nHINTS EXAM:\nThe HINTS exam (Head Impulse, Nystagmus type, Test of Skew) is more sensitive than early MRI for posterior circulation stroke. Central signs include: normal head impulse test, direction-changing nystagmus, and skew deviation (vertical misalignment of eyes).\n\nCEREBELLAR STROKE RED FLAGS:\nSevere gait instability with inability to walk, vertical nystagmus or direction-changing nystagmus, new headache, and any focal neurological deficits.\n\nKEY POINTS:\nA normal Head Impulse Test in acute vertigo suggests central pathology (stroke). Inability to walk with acute vertigo is a red flag for cerebellar stroke. The HINTS exam outperforms MRI in the first 24-48 hours for posterior circulation stroke.",
    "bulletExplanation": "- CORRECT: C (Cerebellar stroke).\n- Acute continuous vertigo with inability to walk and a normal head impulse test is high-risk for central vertigo.\n- Manage as posterior circulation stroke until excluded: urgent stroke evaluation and neuroimaging are required."
  },
  {
    "id": 16,
    "categoryId": 2,
    "question": "An 18-year-old with asthma uses his Albuterol inhaler 4 times a week and wakes up coughing 3 times a month. FEV1 is 85%. According to NHLBI 'Rules of Two', how is this classified?",
    "options": [
      "A) Intermittent",
      "B) Mild Persistent",
      "C) Moderate Persistent",
      "D) Severe Persistent"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mild Persistent).\n\nPATHOPHYSIOLOGY:\nAsthma involves chronic airway inflammation with bronchial hyperresponsiveness and reversible airflow obstruction. Severity classification guides initial controller therapy selection.\n\nCLASSIFICATION (NHLBI EPR-3):\nThe NHLBI \"Rules of Two\" provide a quick severity screen:\n- SABA use >2 days/week\n- Nighttime symptoms >2 times/month\n- Refills >2 per year\nMeeting any of these indicates at least Mild Persistent asthma.\n\nSeverity tiers for patients not yet on controller therapy:\n- Intermittent: Symptoms â‰¤2 days/week, nighttime awakenings two or fewer times per month, SABA use â‰¤2 days/week, FEV1 >80%, no activity limitation\n- Mild Persistent: Symptoms >2 days/week (but not daily), nighttime awakenings 3-4 times per month, FEV1 â‰¥80%\n- Moderate Persistent: Daily symptoms, nighttime awakenings more than once per week, FEV1 60-80%\n- Severe Persistent: Symptoms throughout the day, nightly awakenings, FEV1 <60%\n\nCLINICAL REASONING:\nThis patient uses albuterol 4 times/week (>2) and has nighttime coughing 3 times/month (>2). Both exceed the \"Rules of Two\" thresholds. FEV1 of 85% (â‰¥80%) is consistent with Mild Persistent, not Moderate (which requires FEV1 60-80%). Severity is assigned based on the most severe feature across all domains.\n\nTREATMENT:\nMild Persistent asthma warrants initiation of a low-dose inhaled corticosteroid (ICS) as preferred controller therapy. Alternatives include leukotriene receptor antagonists (montelukast) or as-needed ICS-formoterol (GINA 2023).\n\nKEY POINTS:\nThe \"Rules of Two\" is a validated, rapid screening tool. Any breach of these thresholds moves classification from Intermittent to at least Mild Persistent, requiring daily controller medication.\n---",
    "bulletExplanation": "- CORRECT: B (Mild persistent asthma).\n- He exceeds NHLBI \"Rules of Two\" (SABA >2 days/week and nighttime symptoms >2/month), so this is not intermittent asthma.\n- FEV1 85% fits mild persistent severity; start controller therapy (typically low-dose ICS) rather than SABA-only management."
  },
  {
    "id": 17,
    "categoryId": 14,
    "question": "You are performing a biopsy on a suspicious pigmented lesion on the back. What is the correct biopsy technique?",
    "options": [
      "A) Shave Biopsy",
      "B) Punch Biopsy",
      "C) Excisional Biopsy with 1-3mm margins",
      "D) Wide Local Excision with 1cm margins"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Excisional Biopsy with 1-3mm margins).\n\nPATHOPHYSIOLOGY:\nWhen melanoma is suspected based on clinical features such as asymmetry, border irregularity, color variation, diameter greater than 6mm, or evolution (the ABCDE criteria), the biopsy technique must preserve the full depth of the lesion to allow accurate histopathologic assessment. The single most important prognostic factor in melanoma is Breslow depth, which measures the vertical thickness of the tumor in millimeters from the granular layer of the epidermis to the deepest identifiable melanoma cell. Breslow depth directly determines the recommended surgical margins for definitive wide local excision, sentinel lymph node biopsy candidacy, AJCC staging, and overall prognosis.\n\nBIOPSY TECHNIQUE:\nAn excisional biopsy removes the entire visible lesion with narrow 1 to 3mm clinical margins down to the subcutaneous fat, providing the pathologist with the complete specimen for assessment of Breslow depth, ulceration status, mitotic rate, microsatellite status, and peripheral margins. This information is essential for accurate staging and planning definitive surgical management. For lesions where complete excision is impractical due to size or anatomic location (face, digits, acral sites), an incisional biopsy or deep punch biopsy through the thickest or most clinically suspicious area is an acceptable alternative and AAD guidelines, as studies have not shown that incisional biopsy worsens prognosis.\n\nWHY SHAVE AND PUNCH BIOPSIES ARE INADEQUATE:\nShave biopsies transect the lesion horizontally and frequently fail to capture the deepest point of invasion, resulting in an artificially thin Breslow measurement that understages the tumor and may lead to inadequate surgical margins and failure to offer sentinel lymph node biopsy when indicated. Punch biopsies sample only a small portion of the lesion and may miss the thickest area, similarly compromising staging accuracy. Wide local excision with 1cm or greater margins should not be performed as the initial biopsy because definitive margins depend on Breslow depth, which is unknown prior to pathologic evaluation.\n\nKEY POINTS:\nSuspected melanoma requires excisional biopsy with 1 to 3mm margins to accurately measure Breslow depth, the most important prognostic factor that determines definitive surgical margins and sentinel lymph node biopsy candidacy. Shave biopsies are contraindicated for suspected melanoma because transecting the base may lead to inaccurate staging. When excision is impractical, a deep incisional biopsy through the thickest area is acceptable.",
    "bulletExplanation": "- CORRECT: C (Excisional biopsy with 1-3 mm margins).\n- Suspected melanoma requires full-depth sampling to measure Breslow depth accurately, which drives staging and definitive surgical planning.\n- Avoid shave biopsy for primary diagnosis when melanoma is suspected because transection can understage disease; use deep targeted incisional sampling only when full excision is impractical."
  },
  {
    "id": 18,
    "categoryId": 5,
    "question": "A 78-year-old female presents with Urge Incontinence (overactive bladder). She has a history of dementia. Which medication should be AVOIDED?",
    "options": [
      "A) Mirabegron (Beta-3 agonist)",
      "B) Oxybutynin (Anticholinergic)",
      "C) Kegel Exercises",
      "D) Timed Voiding"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oxybutynin should be AVOIDED).\n\nPHARMACOLOGY:\nOxybutynin is an anticholinergic (antimuscarinic) medication used for urge incontinence and overactive bladder (OAB) that acts by blocking muscarinic M3 receptors on the detrusor muscle, reducing involuntary bladder contractions. However, oxybutynin is the most centrally-penetrating anticholinergic in its class because it readily crosses the blood-brain barrier due to its high lipophilicity, and it has significant M1 receptor antagonism in the central nervous system.\n\nCOGNITIVE RISK IN ELDERLY:\nThe American Geriatrics Society Beers Criteria strongly recommend avoiding all anticholinergic medications in patients with dementia or cognitive impairment. Anticholinergic medications worsen cognitive function by blocking central muscarinic M1 receptors in the hippocampus and cortex, which are critical for memory consolidation and attention. A landmark study published in JAMA Internal Medicine demonstrated that cumulative anticholinergic exposure over 3 or more years was associated with a 54% increased risk of developing dementia. In patients with existing dementia, anticholinergics directly oppose the mechanism of cholinesterase inhibitors (donepezil, rivastigmine) that are prescribed to improve cognitive function.\n\nSAFER ALTERNATIVES:\nMirabegron (Myrbetriq), a beta-3 adrenergic agonist that relaxes the detrusor muscle through a non-anticholinergic mechanism, is the preferred pharmacologic option for OAB in elderly patients with cognitive impairment. Vibegron is another beta-3 agonist alternative. If an anticholinergic must be used, darifenacin, trospium, or fesoterodine have lower CNS penetration than oxybutynin. Non-pharmacologic interventions (bladder training, timed voiding, pelvic floor exercises, fluid management) should be first-line in all elderly patients.\n\nKEY POINTS:\nOxybutynin should be avoided in patients with dementia because it crosses the blood-brain barrier and blocks M1 receptors critical for memory, opposing the effect of cholinesterase inhibitors. Cumulative anticholinergic exposure increases dementia risk by 54%. Mirabegron (beta-3 agonist) is the preferred alternative as it has no anticholinergic CNS effects.",
    "bulletExplanation": "- CORRECT: B (Avoid oxybutynin).\n- In dementia, high anticholinergic CNS burden can worsen cognition and counter therapeutic goals.\n- Prefer non-pharmacologic OAB strategies first; if medication is needed, beta-3 agonists (e.g., mirabegron) are generally safer for cognition than oxybutynin."
  },
  {
    "id": 19,
    "categoryId": 9,
    "question": "A 30-year-old female has Microcytic Anemia (MCV 72). Ferritin is Normal. TIBC is Normal. Electrophoresis shows elevated Hemoglobin A2 (>3.5%). Diagnosis?",
    "options": [
      "A) Iron Deficiency Anemia",
      "B) Alpha Thalassemia Trait",
      "C) Beta Thalassemia Trait",
      "D) Sideroblastic Anemia"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Beta Thalassemia Trait).\n\nDIAGNOSTIC REASONING:\nThis patient presents with microcytic anemia (MCV 72) but normal ferritin and normal total iron-binding capacity (TIBC), which effectively rules out iron deficiency anemia (where ferritin is low and TIBC is elevated as the body attempts to maximize iron absorption). The hemoglobin electrophoresis showing elevated HbA2 (greater than 3.5%) is the diagnostic hallmark of beta-thalassemia trait.\n\nPATHOPHYSIOLOGY:\nBeta-thalassemia results from mutations (over 300 identified) in the beta-globin gene on chromosome 11, causing reduced (beta-plus) or absent (beta-zero) production of beta-globin chains. In beta-thalassemia trait (heterozygous, one normal and one affected beta-globin gene), the mild reduction in beta-chain synthesis produces a characteristic pattern: mild microcytic hypochromic anemia (hemoglobin typically 9 to 12 g/dL with MCV 60 to 75 fL), elevated red blood cell count (a key distinguishing feature from iron deficiency, which has low RBC count), and compensatory increase in delta-chain production leading to elevated HbA2 (alpha-2-delta-2 tetramer).\n\nDIFFERENTIAL DIAGNOSIS OF MICROCYTIC ANEMIA:\nThe mnemonic TAILS covers the major causes: Thalassemia, Anemia of chronic disease, Iron deficiency, Lead poisoning, and Sideroblastic anemia. The Mentzer Index (MCV divided by RBC count) helps distinguish thalassemia trait (less than 13, reflecting high RBC count with low MCV) from iron deficiency anemia (greater than 13, reflecting low RBC count). Iron studies (ferritin, TIBC, serum iron, transferrin saturation) further differentiate the causes.\n\nCLINICAL SIGNIFICANCE:\nBeta-thalassemia trait is clinically benign and typically requires no treatment, but genetic counseling is essential because two carrier parents have a 25% chance of producing a child with beta-thalassemia major (Cooley's anemia), a severe transfusion-dependent hemolytic anemia. Patients with thalassemia trait should not be treated with iron supplementation unless concomitant iron deficiency is documented, as unnecessary iron can lead to iron overload.\n\nKEY POINTS:\nBeta-thalassemia trait presents with microcytic anemia, normal iron studies, and elevated HbA2 on electrophoresis. The Mentzer Index (MCV/RBC) less than 13 favors thalassemia over iron deficiency. Thalassemia trait is benign but requires genetic counseling, and unnecessary iron supplementation should be avoided.",
    "bulletExplanation": "- CORRECT: C (Beta-thalassemia trait).\n- Microcytosis with normal iron studies plus elevated HbA2 (>3.5%) is diagnostic for beta-thal trait.\n- Do not give routine iron unless deficiency is proven; counsel on carrier status and reproductive risk because two carriers can have a child with beta-thalassemia major."
  },
  {
    "id": 20,
    "categoryId": 7,
    "question": "A 65-year-old male complains of leg pain that worsens with walking and is relieved by leaning forward (shopping cart sign) or sitting. Pulses are normal. What is the diagnosis?",
    "options": [
      "A) Vascular Claudication",
      "B) Lumbar Spinal Stenosis (Neurogenic Claudication)",
      "C) Herniated Disc",
      "D) Hip Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar Spinal Stenosis / Neurogenic Claudication).\n\nPATHOPHYSIOLOGY:\nLumbar spinal stenosis is degenerative narrowing of the central spinal canal, lateral recesses, or neural foramina compressing cauda equina nerve roots. Narrowing results from ligamentum flavum hypertrophy (thickening from normal 2-4 mm to >7 mm), facet joint arthropathy with osteophytes, disc bulging, and spondylolisthesis. These changes are nearly universal over age 60, though only a subset become symptomatic. Spinal extension further narrows the canal by telescoping laminae and buckling the ligamentum flavum; flexion opens the canal by separating posterior elements.\n\nCLINICAL PRESENTATION:\nNeurogenic claudication presents as bilateral or unilateral leg pain, heaviness, numbness, or weakness provoked by walking and standing, relieved by sitting or forward flexion. The \"shopping cart sign\" describes patients leaning forward because flexion opens the spinal canal. Patients report greater comfort walking uphill (flexion) than downhill (extension). This positional dependence distinguishes neurogenic from vascular claudication: vascular claudication produces pain with walking only (not standing), resolves with rest without a positional component, and features diminished pulses with ABI <0.9. In neurogenic claudication, pulses are normal with ABI \u22650.9.\n\nDIAGNOSIS AND MANAGEMENT:\nLumbar MRI is the gold standard. Conservative management is first-line: physical therapy with flexion-based exercises (Williams flexion exercises), NSAIDs, and gabapentin or pregabalin for neuropathic symptoms. Epidural steroid injections may provide intermediate-term relief. Decompressive laminectomy is reserved for refractory cases and demonstrated sustained improvement in the SPORT trial.\n\nKEY POINTS:\nNeurogenic claudication causes leg pain with walking and standing relieved by sitting or forward flexion; vascular claudication causes pain with walking only relieved by rest alone. The shopping cart sign reflects instinctive flexion to open the narrowed canal. Normal pulses and ABI distinguish neurogenic from vascular claudication.",
    "bulletExplanation": "- CORRECT: B (Lumbar spinal stenosis with neurogenic claudication).\n- Leg pain worsened by walking/standing but relieved by flexion or sitting (shopping-cart sign) plus normal pulses favors neurogenic over vascular claudication.\n- Start conservative treatment (flexion-based PT, symptom control); obtain lumbar MRI to confirm anatomy and guide escalation if refractory."
  },
  {
    "id": 21,
    "categoryId": 7,
    "question": "A 66-year-old female has a T-score of -2.6 in the lumbar spine. You start Alendronate. What is the most important patient education instruction?",
    "options": [
      "A) Take with food to prevent nausea",
      "B) Take with a full glass of water and stay upright for 30 mins",
      "C) Take at bedtime",
      "D) Take with milk to increase absorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Take with a full glass of water and stay upright for 30 minutes).\n\nPATHOPHYSIOLOGY:\nOral bisphosphonates such as alendronate are nitrogen-containing pyrophosphate analogs that bind hydroxyapatite on bone surfaces and are internalized by osteoclasts during bone resorption. They inhibit farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast cytoskeletal organization and inducing apoptosis. The same physicochemical properties enabling bone binding make these agents highly caustic to esophageal mucosa. Oral bioavailability is less than 1% under optimal conditions and drops to near zero with food, non-water beverages, or concurrent medications due to chelation with divalent cations (calcium, magnesium, iron).\n\nCLINICAL REASONING:\nProper administration is essential for both efficacy and safety. Patients must take alendronate first thing in the morning on an empty stomach with 6-8 ounces of plain water. Coffee, juice, and mineral water significantly reduce absorption. The patient must remain upright (sitting or standing) for at least 30 minutes without eating, drinking, or taking other medications. These measures prevent esophageal lodging, which can cause erosive esophagitis, ulceration, and stricture formation. For patients unable to comply due to GERD, esophageal motility disorders, or inability to sit upright, annual IV zoledronic acid is an effective alternative per the HORIZON trial and NOF guidelines. DXA should be repeated after 2-3 years to assess treatment response. Rare serious adverse effects include osteonecrosis of the jaw and atypical subtrochanteric femur fractures with prolonged use beyond 5 years.\n\nKEY POINTS:\nOral bisphosphonates require fasting administration with plain water and at least 30 minutes of upright positioning to prevent esophageal injury and ensure absorption. Bioavailability is less than 1% and is virtually eliminated by food or non-water beverages. Per AACE guidelines, a bisphosphonate drug holiday should be considered after 5 years of oral therapy. IV zoledronic acid is the preferred alternative for patients unable to comply with oral administration requirements."
  },
  {
    "id": 22,
    "categoryId": 5,
    "question": "A patient has Na+ of 128. They are clinically euvolemic (no edema, moist membranes). Urine Osmolality is High (>100). Urine Sodium is High (>20). TSH and Cortisol are normal. Diagnosis?",
    "options": [
      "A) Psychogenic Polydipsia",
      "B) SIADH",
      "C) Dehydration",
      "D) Heart Failure"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SIADH).\n\nDIAGNOSTIC REASONING:\nThis patient presents with hyponatremia (Na+ 128), clinical euvolemia, concentrated urine (osmolality greater than 100 mOsm/kg), and elevated urine sodium (greater than 40 mEq/L), which is the classic laboratory profile of the syndrome of inappropriate antidiuretic hormone secretion (SIADH). SIADH is a common cause of euvolemic hyponatremia.\n\nPATHOPHYSIOLOGY:\nIn SIADH, antidiuretic hormone (ADH, vasopressin) is released from the posterior pituitary without appropriate physiologic stimuli (hyperosmolality or hypovolemia). Excess ADH causes insertion of aquaporin-2 channels into the collecting duct principal cells, producing inappropriate free water reabsorption that dilutes serum sodium. The patient remains euvolemic (rather than becoming edematous) because the expanded volume triggers compensatory natriuresis via suppression of the renin-angiotensin-aldosterone system and release of atrial natriuretic peptide (ANP), which maintains near-normal volume status at the cost of continued sodium wasting.\n\nDIAGNOSTIC CRITERIA:\nSIADH is a diagnosis of exclusion requiring: serum osmolality less than 275 mOsm/kg, urine osmolality greater than 100 mOsm/kg (inappropriately concentrated), urine sodium greater than 20 mEq/L (typically >40 in classic SIADH), clinical euvolemia, normal thyroid and adrenal function, and no diuretic use. Hypothyroidism and adrenal insufficiency must be excluded because both can mimic SIADH.\n\nCOMMON CAUSES:\nSIADH results from CNS disorders (stroke, meningitis, SAH, trauma), pulmonary disease (pneumonia, lung cancer, positive-pressure ventilation), medications (SSRIs, carbamazepine, cyclophosphamide, vincristine, oxytocin, ecstasy/MDMA), malignancy (small cell lung cancer is the classic association, producing ectopic ADH), pain, nausea, and the postoperative state.\n\nMANAGEMENT:\nFluid restriction (typically 800 to 1,000 mL/day) is first-line treatment. For severe symptomatic hyponatremia (seizures, obtundation), hypertonic saline (3% NaCl) is administered with careful rate correction not exceeding 8 to 10 mEq/L per 24 hours to prevent osmotic demyelination syndrome (central pontine myelinolysis).\n\nKEY POINTS:\nSIADH presents with euvolemic hyponatremia, concentrated urine (osmolality greater than 100), and elevated urine sodium (greater than 40) from inappropriate ADH-mediated free water reabsorption. It is a diagnosis of exclusion requiring normal thyroid and adrenal function. Correction must not exceed 8 to 10 mEq/L per 24 hours to prevent osmotic demyelination syndrome."
  },
  {
    "id": 23,
    "categoryId": 11,
    "question": "A patient wants to quit smoking. He has a history of Seizure Disorder. Which medication is CONTRAINDICATED?",
    "options": [
      "A) Nicotine Patches",
      "B) Varenicline (Chantix)",
      "C) Bupropion (Wellbutrin/Zyban)",
      "D) Nicotine Gum"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Bupropion is contraindicated).\n\nPHARMACOLOGY:\nBupropion (marketed as Wellbutrin for depression and Zyban for smoking cessation) is contraindicated in patients with a seizure disorder or conditions that lower the seizure threshold. Bupropion inhibits the reuptake of norepinephrine and dopamine (an NDRI) and has a dose-dependent risk of seizures that increases significantly above 450 mg/day, with an incidence of approximately 0.4% at standard doses.\n\nSEIZURE RISK MECHANISM:\nBupropion lowers the seizure threshold through its effects on catecholamine neurotransmission. Additional contraindications include current or prior diagnosis of bulimia or anorexia nervosa (electrolyte disturbances, particularly hyponatremia and hypokalemia from purging, further lower the seizure threshold), abrupt discontinuation of alcohol or benzodiazepines (withdrawal states independently lower seizure threshold), and concurrent use of MAO inhibitors.\n\nSAFE ALTERNATIVES FOR SMOKING CESSATION:\nNicotine replacement therapy (patches, gum, lozenges, inhaler, nasal spray) is safe in patients with seizure disorders and works by providing controlled nicotine delivery that reduces withdrawal symptoms and cravings. Varenicline (Chantix), a partial agonist at the alpha-4-beta-2 nicotinic acetylcholine receptor, has the highest single-agent quit rates (approximately 25 to 30% sustained abstinence at one year) and does not lower the seizure threshold. Initial FDA concerns about neuropsychiatric adverse effects with varenicline were addressed by the EAGLES trial, which found no significant increase in neuropsychiatric events compared to placebo.\n\nKEY POINTS:\nBupropion is contraindicated in seizure disorders due to dose-dependent seizure risk from catecholamine-mediated lowering of the seizure threshold. Additional bupropion contraindications include bulimia/anorexia, alcohol/benzodiazepine withdrawal, and concurrent MAO inhibitor use. Varenicline (highest quit rates) and nicotine replacement therapy are safe alternatives for smoking cessation in seizure patients."
  },
  {
    "id": 24,
    "categoryId": 5,
    "question": "A 30-year-old female has a UTI. She is otherwise healthy. Local E. coli resistance to Bactrim is >20%. What is the first-line choice?",
    "options": [
      "A) Ciprofloxacin",
      "B) Nitrofurantoin (Macrobid)",
      "C) Amoxicillin",
      "D) Cephalexin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrofurantoin).\n\nGUIDELINE BASIS:\nThe Infectious Diseases Society of America (IDSA) guidelines recommend nitrofurantoin (Macrobid, 100 mg twice daily for 5 days) as first-line treatment for uncomplicated cystitis when local TMP-SMX resistance exceeds 20%. This case specifies local E. coli resistance to Bactrim (TMP-SMX) above 20%, making TMP-SMX an inappropriate empiric choice.\n\nPHARMACOLOGY:\nNitrofurantoin is a nitrofuran antibiotic that is reduced by bacterial flavoproteins to reactive intermediates that damage DNA, RNA, proteins, and cell wall synthesis. It achieves high concentrations in urine (its site of action) but negligible serum levels, making it effective for lower UTIs (cystitis) but inappropriate for pyelonephritis or systemic infections. Resistance rates remain remarkably low (<5% for most E. coli isolates) despite decades of use, attributed to its multiple concurrent mechanisms of bacterial damage.\n\nCONTRAINDICATIONS:\nNitrofurantoin is contraindicated in patients with CrCl less than 30 mL/min (previously 60 mL/min, updated to 30 mL/min) because inadequate urinary drug concentrations reduce efficacy and systemic accumulation increases toxicity risk. Rare but serious adverse effects include pulmonary fibrosis (with chronic use), hepatotoxicity, and peripheral neuropathy. It should be avoided in the third trimester of pregnancy (risk of neonatal hemolytic anemia in G6PD-deficient infants).\n\nOTHER FIRST-LINE OPTIONS:\nTMP-SMX (160/800 mg twice daily for 3 days) remains first-line when local resistance is below 20%. Fosfomycin (3 g single dose) is an alternative, though it may be slightly less effective. Fluoroquinolones should be reserved for complicated UTIs and pyelonephritis due to resistance concerns and serious adverse effects (tendon rupture, aortic dissection, QT prolongation, peripheral neuropathy, CNS effects).\n\nKEY POINTS:\nNitrofurantoin is first-line for uncomplicated cystitis when local TMP-SMX resistance exceeds 20%, with <5% E. coli resistance rates despite decades of use. It achieves therapeutic concentrations only in urine and is inappropriate for pyelonephritis. Contraindicated when CrCl is less than 30 mL/min and in late pregnancy."
  },
  {
    "id": 25,
    "categoryId": 1,
    "question": "Which of the following contributes points to the CHA2DS2-VASc score?",
    "options": [
      "A) Obesity",
      "B) Female Sex",
      "C) Smoking",
      "D) Hyperlipidemia"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/atrial-fibrillation-stroke.png", "alt": "Atrial fibrillation leading to blood clots that travel to brain and cause ischemic stroke", "caption": "Atrial fibrillation leading to blood clots; clot travel to brain causes ischemic stroke (Mayo Clinic)." }
    ],
    "explanation": "CORRECT: B (Female Sex).\n\nCLINICAL REASONING:\nThe CHA2DS2-VASc score is the standard tool for estimating annual stroke risk in patients with non-valvular atrial fibrillation and guiding anticoagulation decisions. Female sex contributes 1 point to the score, making it the correct answer, though it is considered a stroke risk modifier rather than a standalone indication for anticoagulation. Obesity, smoking, and hyperlipidemia are not components of CHA2DS2-VASc despite being general cardiovascular risk factors.\n\nSCORE COMPONENTS:\nThe mnemonic CHA2DS2-VASc represents: Congestive heart failure (1 point), Hypertension (1 point), Age 75 years or older (2 points), Diabetes mellitus (1 point), prior Stroke, TIA, or thromboembolism (2 points), Vascular disease including prior MI, peripheral artery disease, or aortic plaque (1 point), Age 65 to 74 (1 point), and Sex category female (1 point), for a maximum of 9.\n\nANTICOAGULATION THRESHOLDS:\nFor men, oral anticoagulation is recommended with a CHA2DS2-VASc score of 2 or greater. For women, because female sex alone does not warrant anticoagulation, the effective threshold is 3 or greater (meaning at least one additional risk factor beyond female sex). Direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) are generally preferred over warfarin for non-valvular AF based on their favorable risk-benefit profile.\n\nKEY POINTS:\nFemale sex adds 1 point to CHA2DS2-VASc but is a modifier rather than a standalone indication for anticoagulation. Obesity, smoking, and hyperlipidemia are not score components. Men with score 2 or greater and women with score 3 or greater should receive oral anticoagulation, with DOACs preferred over warfarin for non-valvular AF."
  },
  {
    "id": 26,
    "categoryId": 12,
    "question": "Red flag for Autism Spectrum Disorder requiring immediate evaluation?",
    "options": [
      "A) No babbling by 12 months",
      "B) No single words by 16 months",
      "C) No two-word phrases by 24 months",
      "D) Walking on toes at 15 months"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (No babbling by 12 months).\n\nPATHOPHYSIOLOGY:\nAutism spectrum disorder is a neurodevelopmental condition characterized by persistent deficits in social communication and social interaction, along with restricted, repetitive patterns of behavior, interests, or activities. The neurobiological basis involves atypical neural connectivity and synaptic development, with evidence of both genetic susceptibility (heritability estimated at 80 to 90%) and environmental modifiers. Early signs emerge because the social communication circuits that underlie joint attention, prelinguistic communication, and reciprocal social interaction develop during the first 12 to 18 months of life, and disruptions in these circuits produce detectable behavioral differences before formal language develops.\n\nCLINICAL REASONING:\nThe absence of babbling by 12 months is the earliest of the listed red flags and represents failure of prelinguistic communication, a foundational milestone that should emerge by 6 to 9 months and be well-established by 12 months. Babbling (repetitive consonant-vowel sequences such as \"ba-ba\" and \"da-da\") reflects the infant's engagement with the social environment and is a precursor to intentional speech. Its absence by 12 months suggests fundamental differences in social communication development that warrant immediate referral rather than watchful waiting. Other red flags include no gesturing (pointing, waving) by 12 months, no single words by 16 months, no two-word spontaneous phrases by 24 months, and any loss of previously acquired language or social skills at any age, which is an absolute red flag.\n\nSCREENING AND INTERVENTION:\nThe AAP recommends universal autism-specific screening using the M-CHAT-R/F (Modified Checklist for Autism in Toddlers, Revised with Follow-Up) at the 18-month and 24-month well-child visits. However, developmental surveillance should occur at every well-child visit, and any parental concern should prompt formal evaluation regardless of screening results. Early identification is critical because intensive behavioral intervention initiated before age 3 produces significantly better outcomes in language acquisition, cognitive function, and adaptive behavior, capitalizing on the heightened neuroplasticity of the developing brain.\n\nKEY POINTS:\nAbsence of babbling by 12 months is the earliest red flag for autism spectrum disorder and warrants immediate developmental evaluation rather than watchful waiting. Any loss of previously acquired language or social skills at any age is an absolute red flag. Early intervention before age 3 leverages peak neuroplasticity and produces the best developmental outcomes."
  },
  {
    "id": 27,
    "categoryId": 13,
    "question": "A 72-year-old female presents with a new onset severe headache, jaw claudication (pain when chewing), and scalp tenderness when brushing her hair. ESR is 85. What is the immediate next step?",
    "options": [
      "A) MRI Brain",
      "B) Temporal Artery Biopsy",
      "C) Start High-Dose Prednisone immediately",
      "D) Prescribe Sumatriptan"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Start High-Dose Prednisone immediately).\n\nCLINICAL URGENCY:\nThis presentation is classic for Giant Cell Arteritis (GCA), also known as temporal arteritis, a large-vessel vasculitis that predominantly affects the branches of the external carotid artery in patients over 50 years of age. The most feared complication is irreversible vision loss from anterior ischemic optic neuropathy caused by occlusion of the posterior ciliary arteries (branches of the ophthalmic artery). Vision loss occurs in 15 to 20 percent of untreated patients and is almost always permanent once established. For this reason, high-dose glucocorticoids (prednisone 40 to 60 mg daily) must be initiated immediately upon clinical suspicion, before biopsy confirmation.\n\nDIAGNOSTIC WORKUP:\nTemporal artery biopsy remains the gold standard for confirming GCA, revealing transmural granulomatous inflammation with multinucleated giant cells and intimal hyperplasia. biopsy can be performed up to two weeks after starting steroids without significantly affecting sensitivity, because the histologic changes resolve slowly. Skip lesions (patchy involvement) mean that a negative unilateral biopsy does not exclude the diagnosis, and contralateral biopsy should be considered. Temporal artery ultrasound showing a hypoechoic \"halo sign\" is an emerging noninvasive alternative endorsed by EULAR for early diagnosis.\n\nCLINICAL FEATURES AND LABORATORY FINDINGS:\nThe classic triad includes new-onset temporal headache, jaw claudication (pain with sustained chewing from ischemia of the masseter muscles), and scalp tenderness. Visual symptoms such as amaurosis fugax, diplopia, or sudden vision loss demand emergent treatment. Approximately 40 to 60 percent of GCA patients have concurrent polymyalgia rheumatica with proximal shoulder and hip girdle stiffness. ESR is typically markedly elevated (often greater than 50 mm/hr, sometimes exceeding 100), and CRP is almost universally elevated. A normal ESR does not exclude the diagnosis.\n\nKEY POINTS:\nGCA is a medical emergency because of the risk of permanent blindness. High-dose prednisone must be started immediately upon clinical suspicion without waiting for biopsy results. Temporal artery biopsy remains diagnostic and can be performed up to two weeks after initiating steroids. Jaw claudication is the most specific clinical symptom for GCA."
  },
  {
    "id": 28,
    "categoryId": 7,
    "question": "A 45-year-old male with chronic back pain presents with new urinary retention (cannot void) and numbness in his inner thighs/perineum. What is the diagnosis?",
    "options": [
      "A) Sciatica",
      "B) Cauda Equina Syndrome",
      "C) Lumbar Strain",
      "D) Renal Colic"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/22132-cauda-equina-syndrome.jpg", "alt": "Cauda equina syndrome", "caption": "Cauda equina syndrome image." }
    ],
    "explanation": "CORRECT: B (Cauda Equina Syndrome).\n\nPATHOPHYSIOLOGY:\nCauda equina syndrome results from compression of cauda equina nerve roots below the conus medullaris (~L1-L2 level). Below this point, the spinal canal contains only free-floating nerve roots innervating the lower extremities, bladder, bowel, and perineum. The most common cause is large central lumbar disc herniation at L4-L5 or L5-S1; other etiologies include spinal tumors, epidural abscess, epidural hematoma, and severe stenosis. These peripheral nerve roots lack spinal cord regenerative capacity, so delayed decompression causes permanent deficits.\n\nCLINICAL PRESENTATION:\nUrinary retention is the most sensitive finding (~90% sensitivity), resulting from disrupted sacral parasympathetic innervation to the detrusor muscle. Saddle anesthesia involves decreased sensation in the perineum, perianal region, and inner thighs (S2-S5 dermatomes). Additional findings include fecal incontinence from lost anal sphincter tone, bilateral lower extremity weakness or sciatica, and progressive neurological deterioration. Post-void residual >100-200 mL in a patient with back pain and urinary symptoms should prompt emergent evaluation.\n\nDIAGNOSIS AND MANAGEMENT:\nEmergent lumbar MRI is the diagnostic study of choice and should not be delayed. Cauda equina syndrome is a surgical emergency requiring urgent decompressive laminectomy. Surgery within 24-48 hours of symptom onset yields significantly better recovery of bladder, bowel, and motor function. Delay beyond 48 hours markedly increases permanent dysfunction. Every clinician evaluating back pain must recognize these red flags.\n\nKEY POINTS:\nCauda equina syndrome requires decompressive laminectomy within 24-48 hours to prevent permanent bladder, bowel, and motor dysfunction. Urinary retention is the most sensitive finding (~90%). Saddle anesthesia, bilateral leg weakness, and bowel incontinence complete the classic presentation. Post-void residual should be measured in any patient with back pain and urinary symptoms."
  },
  {
    "id": 29,
    "categoryId": 12,
    "question": "A 6-month-old male has intermittent episodes of severe crying where he pulls his legs up to his chest. Between episodes, he is lethargic. He just passed a stool that looks like 'currant jelly'. What is the diagnosis?",
    "options": [
      "A) Constipation",
      "B) Gastroenteritis",
      "C) Intussusception",
      "D) Pyloric Stenosis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Intussusception).\n\nPATHOPHYSIOLOGY:\nIntussusception is a common cause of intestinal obstruction in children 6 months to 3 years, peaking at 5-10 months. A proximal bowel segment (intussusceptum) telescopes into the adjacent distal segment (intussuscipiens), most commonly at the ileocecal junction (~90% of cases). The telescoped segment carries its mesentery, causing venous congestion, edema, and eventually arterial compromise with ischemia. A pathologic lead point (Meckel diverticulum, polyp, lymphoma, HSP) is found in ~25% of children over 2; most cases in younger infants are idiopathic, often following viral infection with Peyer patch hypertrophy.\n\nCLINICAL PRESENTATION:\nThe classic triad: episodic colicky pain (child draws knees to chest, screaming during paroxysms, with intervals of well-being or lethargy), palpable sausage-shaped mass in the right upper quadrant, and currant jelly stool. Currant jelly stool (blood and mucus) is a late, ominous sign indicating mucosal ischemia. Between episodes, lethargy and pallor are red flags. The complete triad is present in <50% of cases; lethargy alone may be the only sign in young infants.\n\nDIAGNOSIS AND TREATMENT:\nAbdominal ultrasound is the study of choice, showing the pathognomonic target sign (cross-section) or pseudokidney sign (longitudinal) with sensitivity and specificity >95%. Air enema (pneumatic) or contrast enema (hydrostatic) reduction is both diagnostic and therapeutic, succeeding in 80-90% of cases. Contraindications include peritonitis, perforation, or hemodynamic instability, which require emergent surgery. Recurrence occurs in 5-10% after successful reduction.\n\nKEY POINTS:\nIntussusception presents with episodic colicky pain, lethargy, and currant jelly stool (late ischemia sign) in children 6 months to 3 years. Ultrasound target sign is diagnostic; air or contrast enema is diagnostic and therapeutic with 80-90% success. Peritonitis or hemodynamic instability requires emergent surgery."
  },
  {
    "id": 30,
    "categoryId": 1,
    "question": "A 65-year-old diabetic female presents with vague fatigue, shortness of breath, and nausea for 2 days. She denies chest pain. EKG shows new T-wave inversions in V1-V4. What is the likely diagnosis?",
    "options": [
      "A) Viral Gastroenteritis",
      "B) Anxiety Attack",
      "C) Acute Coronary Syndrome (ACS)",
      "D) GERD"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Acute Coronary Syndrome).\n\nCLINICAL REASONING:\nThis presentation illustrates a critically important concept: diabetic patients and women frequently present with atypical symptoms of acute coronary syndrome, including fatigue, dyspnea, nausea, diaphoresis, and epigastric discomfort rather than classic crushing substernal chest pain. Diabetic patients have a higher rate of silent myocardial infarction (with no chest pain at all) due to autonomic neuropathy affecting the cardiac afferent sensory fibers that mediate anginal pain. The new T-wave inversions in V1 through V4 (anterior leads) in this clinical context are diagnostic of myocardial ischemia until proven otherwise.\n\nPATHOPHYSIOLOGY:\nAcute coronary syndrome encompasses a spectrum from unstable angina (ischemia without myocardial necrosis, normal troponins) to non-ST-elevation myocardial infarction (NSTEMI, with elevated troponins but no persistent ST elevation) to ST-elevation myocardial infarction (STEMI, with ST elevation and elevated troponins). T-wave inversions with troponin elevation represent NSTEMI, where partial coronary occlusion or distal embolization from a disrupted plaque causes subendocardial rather than transmural ischemia. The anterior distribution (V1 through V4) localizes the ischemia to the left anterior descending coronary artery territory.\n\nDIAGNOSTIC APPROACH:\nAny elderly or diabetic patient presenting with unexplained dyspnea, fatigue, nausea, or diaphoresis should receive a 12-lead EKG and serial troponin measurements, even without chest pain. High-sensitivity troponin assays can detect myocardial injury within 1 to 3 hours of symptom onset and have a negative predictive value approaching 99% when serial measurements are obtained. Initial management of NSTEMI includes dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor), anticoagulation (heparin), beta-blocker, and high-intensity statin, with early invasive strategy (cardiac catheterization within 24 hours) for high-risk features.\n\nKEY POINTS:\nDiabetic patients and women often present with atypical ACS symptoms (dyspnea, fatigue, nausea, diaphoresis) rather than classic chest pain due to autonomic neuropathy affecting cardiac pain fibers. Always obtain an EKG and troponins in elderly diabetic patients with unexplained fatigue or dyspnea. T-wave inversions in V1 through V4 localize ischemia to the LAD territory."
  },
  {
    "id": 31,
    "categoryId": 15,
    "question": "A 24-year-old female presents with sudden onset severe LLQ pain and shoulder pain. Her LMP was 6 weeks ago. BP is 90/60, HR 110. Urine HCG is positive. What is the likely diagnosis?",
    "options": [
      "A) Ruptured Ovarian Cyst",
      "B) Ruptured Ectopic Pregnancy",
      "C) Appendicitis",
      "D) PID"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ruptured Ectopic Pregnancy).\n\nPATHOPHYSIOLOGY:\nAn ectopic pregnancy occurs when a fertilized ovum implants outside the uterine cavity, most commonly in the ampulla of the fallopian tube (approximately 70% of cases). As the embryo grows, it distends and eventually ruptures the thin-walled tube, causing hemorrhage into the peritoneal cavity. Ectopic pregnancy is the leading cause of pregnancy-related mortality in the first trimester, accounting for approximately 3 to 4% of pregnancy-related deaths in the United States. Risk factors include prior ectopic pregnancy (the strongest risk factor, with 10 to 25% recurrence), prior pelvic inflammatory disease or tubal surgery, current IUD use, infertility treatments, and smoking.\n\nCLINICAL REASONING:\nThe patient demonstrates the classic presentation of ruptured ectopic pregnancy: a reproductive-age woman with lower abdominal pain, a positive pregnancy test, hemodynamic instability (BP 90/60, HR 110 indicating hemorrhagic shock), and shoulder pain. The shoulder pain is Kehr sign, a critically important finding that results from diaphragmatic irritation by free intraperitoneal blood (hemoperitoneum). The phrenic nerve (C3-C5) innervates the diaphragm, and irritation of its peritoneal surface produces referred pain to the ipsilateral shoulder. Any reproductive-age woman presenting with abdominal pain, vaginal bleeding, and a positive pregnancy test must be evaluated for ectopic pregnancy.\n\nDIAGNOSIS AND MANAGEMENT:\nTransvaginal ultrasound combined with serial serum beta-hCG measurement is the standard diagnostic approach. The discriminatory zone (beta-hCG level of 1,500 to 2,000 mIU/mL) is the threshold above which an intrauterine pregnancy should be visible on transvaginal ultrasound; absence of an intrauterine pregnancy above this level strongly suggests ectopic pregnancy. In hemodynamically unstable patients with suspected ruptured ectopic pregnancy, as in this case, emergent surgical intervention (laparoscopy or laparotomy with salpingectomy or salpingostomy) is required promptly for imaging. In hemodynamically stable patients with unruptured ectopic pregnancies smaller than 3.5cm and beta-hCG less than 5,000, medical management with methotrexate (a folate antagonist that inhibits trophoblast proliferation) is an effective alternative.\n\nKEY POINTS:\nShoulder pain (Kehr sign) in a pregnant woman with abdominal pain indicates hemoperitoneum from ruptured ectopic pregnancy until proven otherwise, caused by diaphragmatic irritation via the phrenic nerve. Hemodynamically unstable patients require emergent surgical intervention promptly for imaging. The beta-hCG discriminatory zone (1,500 to 2,000 mIU/mL) guides ultrasound interpretation, and absence of intrauterine pregnancy above this level suggests ectopic pregnancy."
  },
  {
    "id": 32,
    "categoryId": 10,
    "question": "A 40-year-old presents with recurrent painful clusters of vesicles on erythematous bases on the lips, preceded by tingling. Episodes occur 6-8 times per year, especially during times of stress. What is the most appropriate management?",
    "questionImages": [
      {
        "src": "assets/derm-q1-herpes.png",
        "alt": "Grouped vesicular herpes lesion on the lip border",
        "caption": "Question image: recurrent herpes labialis lesion at the vermilion border."
      }
    ],
    "options": [
      "A) Topical acyclovir cream only",
      "B) Oral valacyclovir 500mg daily for chronic suppression",
      "C) Oral antibiotics for secondary infection",
      "D) Topical corticosteroids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral valacyclovir for chronic suppression).\n\nPATHOPHYSIOLOGY:\nHerpes simplex virus type 1 (HSV-1) establishes lifelong latency in the trigeminal ganglion after primary infection. Periodic reactivation occurs when the virus travels down sensory nerves to the lips, triggered by stress, sun exposure, fever, or immunosuppression. The prodromal tingling sensation reflects viral replication in nerve endings before visible lesions appear. Recurrent episodes are typically shorter and less severe than primary infection because pre-existing immunity limits viral replication.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes a prodrome of tingling, burning, or itching at the lip border, followed within 24-48 hours by grouped vesicles on an erythematous base. Vesicles ulcerate, crust, and heal over 7-10 days. Frequency varies widely; patients with 6 or more recurrences annually are candidates for suppressive therapy.\n\nMANAGEMENT OPTIONS:\nFor frequent recurrences (6 or more episodes per year), chronic suppressive therapy reduces outbreak frequency by 70-80%. Valacyclovir 500mg-1g daily or acyclovir 400mg twice daily are effective regimens. For less frequent recurrences, episodic treatment initiated during prodrome shortens duration: valacyclovir 2g twice daily for one day is convenient and effective. Topical antivirals have minimal efficacy compared to oral therapy, reducing duration by less than one day. Topical steroids are contraindicated as they can worsen and spread viral infection.\n\nKEY POINTS:\nChronic suppressive antiviral therapy is indicated for 6 or more recurrences annually. Treatment initiated during prodrome is most effective. Oral antivirals far outperform topical preparations. Topical steroids are contraindicated in herpetic lesions."
  },
  {
    "id": 33,
    "categoryId": 4,
    "question": "A patient with Graves' disease stops taking her meds. She presents with fever (104F), agitation, HR 140, and vomiting. What is the diagnosis?",
    "options": [
      "A) Sepsis",
      "B) Thyroid Storm",
      "C) Pheochromocytoma",
      "D) Malignant Hyperthermia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thyroid Storm).\n\nPATHOPHYSIOLOGY:\nThyroid storm is a life-threatening endocrine emergency with 10-30% mortality even with treatment. It reflects a qualitative shift where compensatory mechanisms fail, producing systemic hypermetabolic and hyperadrenergic crisis. Excess thyroid hormone upregulates beta-adrenergic receptors, amplifying catecholamine sensitivity and causing severe tachycardia, hypertension, and arrhythmias. Thermogenesis exceeds heat dissipation, causing extreme hyperthermia. Multiorgan dysfunction ensues. Precipitants include antithyroid medication discontinuation, infection, surgery, trauma, iodine contrast load, DKA, and parturition.\n\nCLINICAL PRESENTATION:\nThe triad includes hyperthermia (often >104\u00b0F/40\u00b0C), severe cardiovascular dysfunction (tachycardia, high-output heart failure, atrial fibrillation), and altered mental status (agitation to coma). GI symptoms including nausea, vomiting, diarrhea, and jaundice are common. The Burch-Wartofsky Point Scale assesses likelihood based on thermoregulatory, cardiovascular, CNS, and GI dysfunction; score \u226545 is highly suggestive. Thyroid function tests do not distinguish storm from uncomplicated thyrotoxicosis\u2014the diagnosis is clinical.\n\nTREATMENT:\nMulti-agent therapy in correct sequence is essential. Propranolol first for adrenergic crisis (also inhibits peripheral T4-to-T3 conversion). PTU (preferred over methimazole as it blocks both synthesis and peripheral conversion) to halt new hormone production. Iodine (potassium iodide or Lugol's) given \u22651 hour after thionamide to block hormone release via the Wolff-Chaikoff effect; giving iodine first provides synthesis substrate and worsens crisis. Hydrocortisone 100 mg IV q8h reduces T4-to-T3 conversion and treats possible adrenal insufficiency. Supportive care includes aggressive cooling (avoid aspirin, which displaces thyroid hormone from binding proteins), IV fluids, and ICU monitoring.\n\nKEY POINTS:\nThyroid storm is a clinical diagnosis: hyperthermia, cardiovascular dysfunction, and altered mental status with an identifiable precipitant. Treatment sequence: beta-blocker, then PTU, then iodine (\u22651 hour after PTU), then glucocorticoids. Mortality is 10-30%, making early recognition and aggressive therapy essential."
  },
  {
    "id": 34,
    "categoryId": 11,
    "question": "A patient on Sertraline and Tramadol presents with agitation, dilated pupils (mydriasis), hyperreflexia, and ocular clonus. Diagnosis?",
    "options": [
      "A) Neuroleptic Malignant Syndrome",
      "B) Serotonin Syndrome",
      "C) Opioid Overdose",
      "D) Anticholinergic Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin Syndrome).\n\nPATHOPHYSIOLOGY:\nSerotonin syndrome is a potentially life-threatening drug-induced toxidrome caused by excessive serotonergic activity at central and peripheral serotonin receptors, primarily 5-HT1A and 5-HT2A. It most commonly occurs when two or more serotonergic medications are combined, as in this case: sertraline (an SSRI that blocks serotonin reuptake) plus tramadol (an opioid with significant serotonin reuptake inhibition activity). Other high-risk combinations include SSRIs with MAO inhibitors, triptans, linezolid, meperidine, dextromethorphan, fentanyl, or St. John's Wort.\n\nCLINICAL PRESENTATION:\nThe Hunter Serotonin Toxicity Criteria, the most validated diagnostic tool, require the presence of a serotonergic agent plus one of: spontaneous clonus, inducible clonus with agitation or diaphoresis, ocular clonus with agitation or diaphoresis, tremor with hyperreflexia, or hypertonia with hyperthermia. The classic triad is neuromuscular excitation (clonus, hyperreflexia, myoclonus, rigidity), autonomic dysfunction (hyperthermia, tachycardia, diaphoresis, diarrhea), and altered mental status (agitation, confusion). Onset is typically rapid, within 6 to 24 hours of drug initiation or dose change, distinguishing it from NMS which develops over days.\n\nDIFFERENTIAL DIAGNOSIS:\nSerotonin syndrome is distinguished from NMS by the presence of clonus and hyperreflexia (NMS features rigidity with normal or decreased reflexes), rapid onset (NMS develops over days), and the causative drug class (serotonergic agents versus dopamine antagonists). Mydriasis (dilated pupils) and hyperactive bowel sounds favor serotonin syndrome, while lead-pipe rigidity and markedly elevated CPK favor NMS.\n\nMANAGEMENT:\nImmediate discontinuation of all serotonergic agents is the main treatment. Mild cases resolve within 24 to 72 hours with supportive care. Moderate to severe cases require benzodiazepines (for agitation and myoclonus), active cooling, and cyproheptadine (a 5-HT2A receptor antagonist, 12 mg initial dose followed by 2 mg every 2 hours).\n\nKEY POINTS:\nSerotonin syndrome presents with the triad of neuromuscular excitation (clonus, hyperreflexia), autonomic dysfunction (hyperthermia, diaphoresis), and altered mental status, with rapid onset within hours. Clonus and hyperreflexia distinguish it from NMS. Tramadol is a commonly overlooked serotonergic agent that precipitates the syndrome when combined with SSRIs."
  },
  {
    "id": 35,
    "categoryId": 14,
    "question": "A 60-year-old male presents with back pain and fatigue. Labs show Calcium 11.5 (High), Creatinine 2.1 (High), and Hemoglobin 9.0 (Low). Total Protein is elevated with an 'M-Spike' on electrophoresis. Diagnosis?",
    "options": [
      "A) Metastatic Prostate Cancer",
      "B) Multiple Myeloma",
      "C) Hyperparathyroidism",
      "D) Vitamin D Toxicity"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multiple Myeloma).\n\nPATHOPHYSIOLOGY:\nMultiple myeloma is a clonal plasma cell neoplasm arising in the bone marrow, characterized by uncontrolled proliferation of a single plasma cell clone that produces a monoclonal immunoglobulin (M-protein) detectable as an M-spike on serum protein electrophoresis. Malignant plasma cells secrete osteoclast-activating factors including RANKL, macrophage inflammatory protein-1 alpha, and interleukin-6, which drive excessive bone resorption while simultaneously inhibiting osteoblast function through secretion of dickkopf-1. This uncoupled bone remodeling produces the characteristic purely lytic bone lesions and releases calcium into the circulation, causing hypercalcemia. Renal insufficiency results from light chain cast nephropathy (the most common mechanism), hypercalcemia-induced nephrocalcinosis, and dehydration. Anemia develops from direct bone marrow infiltration crowding out normal hematopoietic precursors.\n\nCLINICAL REASONING:\nThe patient demonstrates the classic CRAB criteria for myeloma end-organ damage: Calcium elevation (11.5 mg/dL), Renal insufficiency (creatinine 2.1), Anemia (hemoglobin 9.0), and Bone involvement (back pain). The M-spike on serum protein electrophoresis confirms the monoclonal protein, which is the diagnostic hallmark. The revised International Myeloma Working Group diagnostic criteria require clonal bone marrow plasma cells of 10% or greater or a biopsy-proven plasmacytoma, plus one or more CRAB features or myeloma-defining events.\n\nDIAGNOSTIC WORKUP:\nThe evaluation includes serum protein electrophoresis with immunofixation, serum free light chains with ratio, 24-hour urine protein electrophoresis, bone marrow biopsy with flow cytometry and FISH for high-risk abnormalities (deletion 17p, translocation t(4;14), translocation t(14;16)), beta-2 microglobulin and LDH for prognosis, and imaging with low-dose whole-body CT or PET-CT. An essential diagnostic pearl is that myeloma causes purely lytic lesions without reactive osteoblastic activity, meaning conventional bone scans are frequently falsely negative and should not be used.\n\nTREATMENT:\nInduction therapy typically consists of a three-drug regimen combining a proteasome inhibitor (bortezomib), an immunomodulatory drug (lenalidomide), and dexamethasone (VRd), followed by autologous stem cell transplant in eligible patients. Bisphosphonates (zoledronic acid) or denosumab are administered to reduce skeletal events.\n\nKEY POINTS:\nMultiple myeloma presents with the CRAB criteria (hypercalcemia, renal insufficiency, anemia, lytic bone lesions) and an M-spike on protein electrophoresis. Bone scan is often falsely negative because myeloma produces purely lytic lesions without osteoblastic activity, making low-dose whole-body CT or PET-CT the preferred imaging. Beta-2 microglobulin is the most important prognostic marker."
  },
  {
    "id": 36,
    "categoryId": 17,
    "question": "A 60-year-old female presents with severe eye pain, headache, and halos around lights. The pupil is mid-dilated and non-reactive. The eye feels 'rock hard' to palpation. Diagnosis?",
    "options": [
      "A) Uveitis",
      "B) Acute Angle-Closure Glaucoma",
      "C) Corneal Abrasion",
      "D) Conjunctivitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Angle-Closure Glaucoma).\n\nPATHOPHYSIOLOGY:\nAcute angle-closure glaucoma (AACG) occurs when the peripheral iris apposes the trabecular meshwork, obstructing aqueous humor outflow and causing a rapid, severe rise in intraocular pressure (IOP), often exceeding 40-60 mmHg (normal less than 21 mmHg). The resultant ischemia to the optic nerve and corneal edema produce the characteristic symptoms. The most common mechanism is pupillary block, where the iris bows forward against the lens, trapping aqueous humor in the posterior chamber.\n\nCLINICAL PRESENTATION:\n- Sudden onset severe eye pain, often with ipsilateral headache\n- Nausea and vomiting (vagal response to elevated IOP)\n- Halos around lights (corneal edema diffracts light)\n- Decreased visual acuity, blurred vision\n- Red eye with fixed, mid-dilated, non-reactive pupil\n- Eye firm or rock hard to palpation\n\nRISK FACTORS:\nHyperopia (farsightedness, shallow anterior chamber), older age, female sex, Asian or Inuit descent, family history, and medications that dilate the pupil (anticholinergics, sympathomimetics, sulfonamides).\n\nTREATMENT:\nThis is an ophthalmologic emergency requiring immediate IOP reduction:\n1. Topical timolol 0.5% (decreases aqueous production)\n2. Topical pilocarpine 1-2% (constricts pupil, opens drainage angle)\n3. Topical apraclonidine 1% (decreases aqueous production)\n4. IV acetazolamide 500 mg (systemic carbonic anhydrase inhibitor)\n5. IV mannitol if IOP remains refractory\n6. Definitive treatment: Laser peripheral iridotomy (creates bypass channel for aqueous humor)\n- Do NOT dilate this pupil - mydriatics worsen angle closure\n\nKEY POINTS:\nA mid-dilated, non-reactive pupil with a rock-hard eye is acute angle-closure glaucoma until proven otherwise. Immediate IOP reduction prevents irreversible optic nerve damage and blindness. Definitive treatment is laser peripheral iridotomy. Prophylactic iridotomy is recommended for the contralateral eye.\n---"
  },
  {
    "id": 37,
    "categoryId": 7,
    "question": "A 13-year-old obese male presents with knee pain. He walks with the foot externally rotated. Knee X-ray is normal. What is the mandatory next step?",
    "options": [
      "A) MRI Knee",
      "B) X-ray of both Hips (Frog-leg view)",
      "C) Reassurance",
      "D) Physical Therapy"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/slipped-capital-femoral-epiphysis-scfe.jpg", "alt": "Slipped capital femoral epiphysis", "caption": "SCFE image." }
    ],
    "explanation": "CORRECT: B (X-ray of both Hips, Frog-leg view).\n\nPATHOPHYSIOLOGY:\nSlipped Capital Femoral Epiphysis is a Salter-Harris type I fracture through the proximal femoral physis in which the epiphysis displaces posteriorly and inferiorly relative to the femoral neck. It occurs during rapid adolescent growth when the physis is weakened by orientation changes and growth hormone-mediated hypertrophic zone expansion. Obesity is the strongest risk factor due to increased shear forces. Endocrine conditions (hypothyroidism, growth hormone deficiency, hypogonadism) also predispose to SCFE.\n\nCLINICAL PRESENTATION:\nThe classic patient is an obese adolescent (more commonly male, age 10-16) with hip, groin, thigh, or knee pain and an antalgic gait with the leg held in external rotation. Critically, knee pain in an adolescent is hip pathology until proven otherwise\u2014the obturator nerve innervates both the hip and medial knee, creating referred pain that frequently misleads clinicians. A normal knee radiograph does not exclude the diagnosis. Examination reveals limited internal rotation and abduction, with obligate external rotation during passive hip flexion.\n\nDIAGNOSIS AND MANAGEMENT:\nAP and frog-leg lateral radiographs of both hips are mandatory. On AP view, Klein's line along the superior femoral neck should intersect the lateral epiphysis; in SCFE, the epiphysis falls below this line. Frog-leg lateral is more sensitive for early slips. Both hips must be imaged because contralateral SCFE develops in 25-40%. Management requires immediate non-weight-bearing and urgent in-situ pinning with a single cannulated screw. Closed reduction is contraindicated as it dramatically increases avascular necrosis risk.\n\nKEY POINTS:\nKnee pain in an adolescent must prompt hip evaluation because SCFE commonly presents as referred pain via the obturator nerve. SCFE requires immediate non-weight-bearing and urgent in-situ pinning without attempted reduction. Both hips must be imaged as contralateral involvement occurs in 25-40%."
  },
  {
    "id": 38,
    "categoryId": 2,
    "question": "A 30-year-old female on oral contraceptives presents with sudden dyspnea and pleuritic chest pain. HR is 110. O2 sat 92%. Wells Score is Moderate. D-Dimer is elevated. Next best test?",
    "options": [
      "A) V/Q Scan",
      "B) CT Pulmonary Angiography (CTPA)",
      "C) Leg Ultrasound",
      "D) Echocardiogram"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/pulmonary-embolism.png", "alt": "Pulmonary embolism: blood clot from leg vein traveling to lung, embolus in pulmonary artery, damaged lung tissue", "caption": "Pulmonary embolism: clot from vein to pulmonary artery with damaged lung tissue (Cleveland Clinic ©2022)." }
    ],
    "explanation": "CORRECT: B (CT Pulmonary Angiography).\n\nPATHOPHYSIOLOGY:\nPulmonary embolism results from venous thromboembolism, most commonly originating from deep veins of the lower extremities, that lodges in the pulmonary arterial vasculature. The thrombus obstructs blood flow to the affected lung segments, creating dead space ventilation (ventilated but not perfused), causing hypoxemia through V/Q mismatch and increased alveolar-arterial gradient. Massive PE can cause acute right ventricular failure from sudden pressure overload. Estrogen-containing oral contraceptives increase VTE risk approximately 3 to 4-fold by increasing hepatic synthesis of procoagulant factors (factors II, VII, VIII, X, fibrinogen) while decreasing natural anticoagulants (antithrombin III, protein S).\n\nCLINICAL REASONING:\nThe patient presents with classic PE features: sudden dyspnea, pleuritic chest pain, tachycardia, and hypoxia in a young woman on oral contraceptives. The diagnostic algorithm for suspected PE follows the Wells score risk stratification. With a moderate Wells score and elevated D-dimer, CTPA is required for definitive diagnosis. D-dimer is a sensitive but nonspecific test useful primarily for its negative predictive value: a negative D-dimer in a low-probability patient effectively excludes PE, but an elevated D-dimer does not confirm PE and requires imaging. CTPA is the standard imaging study, offering high sensitivity (>95%) and specificity (greater than 97%) for PE. V/Q scan is an alternative when CTPA is contraindicated (contrast allergy, severe renal insufficiency) but has a high rate of indeterminate results.\n\nMANAGEMENT:\nAnticoagulation with direct oral anticoagulants (apixaban or rivaroxaban, preferred over warfarin for most patients), with a minimum treatment duration of 3 months for a provoked PE. Estrogen-containing contraceptives must be stopped immediately, and future use is absolutely contraindicated after VTE. Safe alternatives include progestin-only methods (progestin-only pill, etonogestrel implant, levonorgestrel IUD), copper IUD, and barrier methods.\n\nKEY POINTS:\nCTPA is the standard test for PE diagnosis, indicated when Wells score is moderate or high, or when D-dimer is positive in a low-probability patient. Estrogen-containing contraceptives increase VTE risk 3 to 4-fold and are absolutely contraindicated after a VTE event. DOACs (apixaban, rivaroxaban) are preferred over warfarin for most PE treatment per current CHEST guidelines."
  },
  {
    "id": 39,
    "categoryId": 3,
    "question": "A 70-year-old with A-Fib presents with severe abdominal pain out of proportion to physical exam (soft abdomen, but patient is screaming in pain). Lactate is 4.0. Diagnosis?",
    "options": [
      "A) Diverticulitis",
      "B) Acute Mesenteric Ischemia",
      "C) Pancreatitis",
      "D) Cholecystitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Mesenteric Ischemia).\n\nPATHOPHYSIOLOGY:\nAcute mesenteric ischemia (AMI) results from sudden reduction in blood flow to the small intestine, most commonly due to embolism to the superior mesenteric artery (SMA), which accounts for approximately 50% of cases. Atrial fibrillation is the leading source of emboli. Other etiologies include SMA thrombosis (25%), non-occlusive mesenteric ischemia from low-flow states (20%), and mesenteric venous thrombosis (5%). The intestinal mucosa is highly metabolically active and exquisitely sensitive to ischemia, leading to rapid mucosal breakdown, bacterial translocation, and if untreated, transmural necrosis within 6-12 hours.\n\nCLINICAL PRESENTATION:\nThe hallmark is severe, poorly localized abdominal pain out of proportion to physical examination findings. Early in the disease, the abdomen remains soft and nontender despite excruciating pain because the ischemia has not yet progressed to peritonitis. Elevated serum lactate reflects tissue hypoperfusion and anaerobic metabolism. As ischemia progresses to infarction, peritoneal signs develop, signaling bowel necrosis and a rapidly worsening prognosis. Mortality exceeds 60-80% once bowel infarction occurs.\n\nDIAGNOSIS AND MANAGEMENT:\nCT angiography is the diagnostic study of choice, demonstrating arterial occlusion and bowel wall changes. Early surgical consultation is essential. Treatment depends on etiology: embolectomy or thrombectomy for occlusive disease, anticoagulation for venous thrombosis, and vasodilator infusion for non-occlusive ischemia. Necrotic bowel requires resection. Time to intervention is the strongest predictor of survival.\n\nKEY POINTS:\nPain out of proportion to exam with a soft abdomen in a patient with atrial fibrillation is the classic presentation of acute mesenteric ischemia. Elevated lactate supports the diagnosis. CT angiography is the study of choice. Mortality exceeds 60-80% once bowel infarction occurs, making early recognition critical."
  },
  {
    "id": 40,
    "categoryId": 8,
    "question": "A college student presents with fever, headache, and a petechial rash on the trunk/legs. Neck stiffness is present. Which organism is most likely?",
    "options": [
      "A) Strep pneumo",
      "B) Neisseria meningitidis",
      "C) Listeria monocytogenes",
      "D) Haemophilus influenzae"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neisseria).\n\nPATHOPHYSIOLOGY:\nNeisseria meningitidis is a gram-negative diplococcus that colonizes the nasopharynx and is transmitted via respiratory droplets. In susceptible individuals, the organism invades the bloodstream and crosses the blood-brain barrier. Its polysaccharide capsule resists complement-mediated killing, and endotoxin (lipooligosaccharide) release triggers a massive inflammatory cascade that can cause disseminated intravascular coagulation (DIC), leading to the characteristic petechial and purpuric skin lesions. Fulminant meningococcemia can progress from initial symptoms to death within hours.\n\nCLINICAL PRESENTATION:\nThe classic presentation is a previously healthy adolescent or young adult with rapid-onset fever, headache, neck stiffness, and a petechial or purpuric rash that begins on the trunk and extremities and may coalesce into large ecchymotic areas (purpura fulminans). Hypotension, altered mental status, and multiorgan failure develop rapidly in meningococcal septicemia. The rash is a critical distinguishing feature, as other causes of bacterial meningitis rarely produce petechiae.\n\nDIAGNOSIS AND TREATMENT:\nImmediate empiric IV antibiotics with ceftriaxone 2g (or penicillin G) must not be delayed for lumbar puncture if the patient is hemodynamically unstable. Blood cultures should be obtained before antibiotics when possible, but treatment takes absolute priority. CSF analysis typically reveals a neutrophilic pleocytosis, elevated protein, low glucose, and gram-negative diplococci on Gram stain. Place the patient on droplet precautions immediately upon suspicion.\n\nPREVENTION:\nChemoprophylaxis for close contacts (household members, roommates, those exposed to oral secretions) should be initiated within 24 hours of diagnosis using rifampin, ciprofloxacin, or ceftriaxone. The MenACWY vaccine is recommended for adolescents (routine at age 11-12 with booster at 16) and is required for college dormitory residents. MenB vaccine is available for those aged 16-23.\n\nKEY POINTS:\nMeningococcal meningitis presents with rapid-onset fever, headache, and petechial/purpuric rash in young adults. Do not delay IV antibiotics for LP if the patient is unstable. Mortality is 10-15% even with treatment. Chemoprophylaxis for close contacts within 24 hours is essential.\n---"
  },
  {
    "id": 41,
    "categoryId": 6,
    "question": "A patient presents with acute left-sided face weakness and left arm drift. It started 2 hours ago. CT Head is negative for bleed. BP is 160/90. Glucose is 100. What is the next step?",
    "options": [
      "A) Administer Aspirin",
      "B) Administer tPA (Alteplase/Tenecteplase)",
      "C) Lower BP to <140/90",
      "D) MRI Brain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thrombolytics - IV tPA/Alteplase or Tenecteplase).\n\nACUTE ISCHEMIC STROKE MANAGEMENT:\nThis patient presents with acute-onset focal neurological deficits (facial weakness and arm drift) within the treatment window. The non-contrast CT has excluded hemorrhage, which is the critical prerequisite for thrombolytic therapy. Acute stroke management follows the principle of \"time is brain,\" as approximately 1.9 million neurons die per minute during an untreated ischemic stroke.\n\nPATHOPHYSIOLOGY:\nAcute ischemic stroke results from thrombotic or embolic occlusion of a cerebral artery, causing ischemia in the downstream territory. The ischemic core undergoes rapid irreversible injury, while the surrounding ischemic penumbra remains viable but at risk. Reperfusion therapy aims to salvage the penumbra before it progresses to infarction.\n\nTHROMBOLYTIC THERAPY:\nIV alteplase (0.9 mg/kg, maximum 90 mg) is indicated within 4.5 hours of symptom onset (or last known well) after CT exclusion of hemorrhage. Blood pressure must be below 185/110 before administration. Tenecteplase is emerging as an alternative with simpler dosing (single bolus). Key exclusions include active bleeding, recent major surgery, prior intracranial hemorrhage, and platelet count below 100,000. The door-to-needle goal is under 60 minutes.\n\nCRITICAL MANAGEMENT PEARLS:\nAspirin must NOT be given until 24 hours after tPA due to increased hemorrhagic risk. Blood pressure is maintained below 180/105 for 24 hours post-thrombolysis. For non-tPA candidates, permissive hypertension is allowed unless BP exceeds 220/120. Mechanical thrombectomy can extend the window to 24 hours for large vessel occlusions with favorable perfusion imaging.\n\nKEY POINTS:\nIV thrombolysis is indicated within 4.5 hours of symptom onset after CT excludes hemorrhage. Aspirin is withheld for 24 hours after tPA administration due to bleeding risk. Blood pressure must be below 185/110 before and below 180/105 after thrombolytic therapy."
  },
  {
    "id": 42,
    "categoryId": 10,
    "question": "A patient started Allopurinol 2 weeks ago. Now presents with fever, flu-like symptoms, and a rash with skin sloughing (positive Nikolsky sign) involving 15% of BSA. Mucous membranes are involved. Diagnosis?",
    "questionImages": [
      {
        "src": "assets/derm-q2-question-image.png",
        "alt": "Severe mucocutaneous eruption with widespread lesions and lip involvement",
        "caption": "Question image: severe drug-related mucocutaneous eruption with skin and mucosal involvement."
      }
    ],
    "options": [
      "A) Staph Scalded Skin Syndrome",
      "B) Stevens-Johnson Syndrome (SJS)",
      "C) Toxic Epidermal Necrolysis (TEN)",
      "D) Drug Reaction with Eosinophilia (DRESS)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stevens-Johnson Syndrome).\n\nPATHOPHYSIOLOGY:\nSJS is a severe immune-mediated mucocutaneous reaction most commonly triggered by medications. Cytotoxic T lymphocytes and NK cells target drug-modified keratinocytes, releasing granulysin, perforin, and granzyme B, causing widespread keratinocyte apoptosis and full-thickness epidermal necrosis with dermal detachment. BSA detachment defines severity: SJS <10%, SJS-TEN overlap 10-30%, TEN >30%. This patient with 15% BSA detachment falls within SJS-TEN overlap, though SJS is the best available answer among the choices.\n\nCLINICAL PRESENTATION:\nSJS begins 1-3 weeks after drug initiation with a prodrome of fever, malaise, and flu-like symptoms. A painful macular rash with dusky centers progresses to flaccid blisters and epidermal sloughing. The Nikolsky sign (lateral pressure on uninvolved skin causes epidermal shearing) reflects loss of epidermal cohesion. Mucous membrane involvement occurs in >90%, affecting oral mucosa, conjunctivae, and genitourinary tract\u2014a hallmark distinguishing SJS from other severe drug reactions. Ocular involvement risks corneal scarring and permanent vision loss.\n\nCOMMON CULPRIT MEDICATIONS:\nAllopurinol is among the most frequently implicated drugs. Other high-risk medications include lamotrigine, carbamazepine, phenytoin, trimethoprim-sulfamethoxazole, and nevirapine. HLA-B*5801 testing before allopurinol initiation is recommended by the American College of Rheumatology, particularly in Southeast Asian and African American patients where allele prevalence exceeds 6-8%.\n\nMANAGEMENT:\nImmediate drug discontinuation is the most critical intervention\u2014each day of delay increases mortality. Patients require burn unit or ICU transfer for wound care, fluid resuscitation, temperature regulation, and infection surveillance. SCORTEN predicts mortality based on age, heart rate, BUN, glucose, bicarbonate, BSA, and malignancy; scores \u22655 carry >90% mortality. Cyclosporine may reduce progression when initiated early. Ophthalmologic consultation is mandatory.\n\nKEY POINTS:\nSJS involves <10% BSA detachment with mucous membrane involvement; TEN involves >30%. Allopurinol is a common cause; HLA-B*5801 screening is recommended in high-risk populations. Immediate drug discontinuation is the most critical intervention. Nikolsky sign reflects keratinocyte apoptosis. Burn unit care and SCORTEN guide management."
  },
  {
    "id": 43,
    "categoryId": 5,
    "question": "A 16-year-old male wakes up with severe unilateral testicular pain. The testicle is high-riding and transverse. The Cremasteric reflex is absent. Diagnosis?",
    "options": [
      "A) Epididymitis",
      "B) Testicular Torsion",
      "C) Hydrocele",
      "D) Varicocele"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Testicular Torsion).\n\nPATHOPHYSIOLOGY:\nTesticular torsion is a urologic emergency caused by rotation of the spermatic cord, which occludes the testicular artery and pampiniform venous plexus, causing ischemia and infarction of the testis. The underlying predisposing anatomic variant in most cases is the \"bell-clapper deformity,\" in which the tunica vaginalis has an abnormally high attachment on the spermatic cord, allowing the testis to rotate freely within the tunica like a bell clapper, present bilaterally in most affected patients.\n\nCLINICAL PRESENTATION:\nThe classic presentation is sudden onset of severe unilateral scrotal pain (often waking the patient from sleep), with a high-riding testis (retracted superiorly due to cord shortening from twisting), transverse (horizontal) lie (the normal vertical orientation is lost), and absent cremasteric reflex (the most sensitive physical exam finding, absent in 99% of torsion cases). Nausea and vomiting are common due to the severity of pain.\n\nTIME-CRITICAL MANAGEMENT:\nTesticular salvage rates are directly related to the duration of ischemia: >90% salvage within 6 hours, approximately 50% at 12 hours, and <10% after 24 hours. Surgical exploration and detorsion must not be delayed for imaging when the clinical presentation is classic. If imaging is obtained (typically in equivocal cases), color Doppler ultrasound showing absent or decreased blood flow to the affected testis is diagnostic. Bilateral orchiopexy (surgical fixation of both testes to the scrotal wall) is performed because the bell-clapper deformity is bilateral in most cases.\n\nDIFFERENTIAL DIAGNOSIS:\nEpididymitis (gradual onset, positive cremasteric reflex, pain relieved by scrotal elevation/Prehn sign, often with pyuria and urethral discharge in sexually active young men) and testicular appendage torsion (\"blue dot sign\" visible through scrotal skin, less severe pain, intact cremasteric reflex) are the main differentials.\n\nKEY POINTS:\nTesticular torsion presents with sudden severe pain, a high-riding transverse testis, and absent cremasteric reflex, caused by spermatic cord rotation (bell-clapper deformity). Salvage exceeds 90% within 6 hours but drops below 10% after 24 hours. Surgery must not be delayed for imaging when clinical presentation is classic, and bilateral orchiopexy is required."
  },
  {
    "id": 44,
    "categoryId": 2,
    "question": "A tall, thin 20-year-old male develops sudden chest pain and shortness of breath. Breath sounds are decreased on the right. Trachea is deviated to the LEFT. BP is 80/50. Immediate action?",
    "options": [
      "A) Stat Chest X-ray",
      "B) Needle Decompression",
      "C) Intubation",
      "D) IV Fluids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Needle Decompression).\n\nPATHOPHYSIOLOGY:\nTension pneumothorax occurs when air enters the pleural space through a one-way valve mechanism (either from a lung parenchymal injury or a chest wall wound) and becomes trapped, with intrapleural pressure progressively increasing with each breath. The rising intrapleural pressure compresses the ipsilateral lung (causing complete collapse), shifts the mediastinum toward the contralateral side (compressing the opposite lung and deviating the trachea), and kinks the great veins (superior and inferior vena cava), severely reducing venous return to the heart. The resulting obstructive shock produces rapidly fatal cardiovascular collapse if not immediately decompressed.\n\nCLINICAL REASONING:\nThe patient presents with the classic features of tension pneumothorax in a classic patient: a tall, thin young male (the demographic at highest risk for primary spontaneous pneumothorax from rupture of apical subpleural blebs) with sudden chest pain, decreased breath sounds on the right, tracheal deviation to the left (away from the affected side), and hypotension. Tension pneumothorax is a clinical diagnosis that requires immediate intervention without waiting for radiographic confirmation. Needle decompression is performed by inserting a large-bore (14 to 16-gauge) needle into the second intercostal space at the midclavicular line or the fourth to fifth intercostal space at the anterior axillary line on the affected side, converting the tension pneumothorax to a simple pneumothorax by releasing the trapped pressurized air. This is followed by definitive tube thoracostomy (chest tube placement).\n\nPRIMARY SPONTANEOUS PNEUMOTHORAX:\nWhen a primary spontaneous pneumothorax does not produce tension physiology, management depends on size and symptoms. Small pneumothoraces (less than 2 cm at the hilum on upright chest radiograph) in stable patients can be observed with supplemental oxygen, which accelerates reabsorption by creating a nitrogen gradient. Large or symptomatic pneumothoraces require needle aspiration or chest tube placement. Recurrence occurs in approximately 30% within 1 to 2 years, and surgical intervention (video-assisted thoracoscopic surgery with mechanical pleurodesis or bullectomy) is recommended after a second ipsilateral episode.\n\nKEY POINTS:\nTension pneumothorax is a clinical diagnosis (hypotension, tracheal deviation, absent breath sounds) requiring immediate needle decompression without waiting for imaging. Decompression is performed at the second intercostal space midclavicular line or fourth to fifth intercostal space anterior axillary line, followed by chest tube. Primary spontaneous pneumothorax classically occurs in tall, thin young males from rupture of apical blebs."
  },
  {
    "id": 45,
    "categoryId": 17,
    "question": "A 5-year-old unimmunized child presents with high fever, drooling, and 'tripod' positioning. He appears toxic. What should you NOT do?",
    "options": [
      "A) Keep the child calm",
      "B) Call Anesthesia/ENT",
      "C) Examine the throat with a tongue depressor",
      "D) Administer blow-by oxygen"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Do NOT examine the throat with a tongue depressor).\n\nDIAGNOSIS:\nAcute epiglottitis is a life-threatening infection of the epiglottis and surrounding supraglottic structures that can cause complete airway obstruction within hours. In unimmunized children, Haemophilus influenzae type b (Hib) is the most common cause. In adults and immunized children, Streptococcus species, Staphylococcus aureus, and other organisms predominate.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes the 4 Ds: Dysphagia, Dysphonia (muffled hot potato voice), Drooling, and Distress. The child assumes the tripod position (sitting upright, leaning forward, neck hyperextended, chin thrust out) to maximize airway patency. High fever and toxic appearance are typical. Onset is rapid, typically over hours.\n\nCRITICAL MANAGEMENT POINTS:\n- Do NOT examine the oropharynx with a tongue depressor or attempt to visualize the epiglottis at bedside. This can trigger laryngospasm and complete airway obstruction.\n- Do NOT agitate the child (avoid blood draws, IV starts, or separation from parents)\n- Do NOT lay the child supine\n- Allow the child to remain in the position of comfort\n- Call anesthesia and ENT/otolaryngology immediately for controlled airway management in the operating room\n\nTREATMENT:\n1. Secure the airway in the OR via direct laryngoscopy and intubation (or surgical airway if needed)\n2. IV antibiotics: Third-generation cephalosporin (ceftriaxone or cefotaxime) plus vancomycin if MRSA is suspected\n3. IV corticosteroids (dexamethasone) to reduce airway edema\n4. The classic lateral neck X-ray thumbprint sign (swollen epiglottis) supports diagnosis but should NOT delay airway management\n\nKEY POINTS:\nNever examine the throat of a child with suspected epiglottitis at bedside - this can precipitate fatal airway obstruction. The triad of drooling, tripod positioning, and toxic appearance should prompt immediate airway management by anesthesia and ENT. Hib vaccination has dramatically reduced pediatric epiglottitis incidence.\n---"
  },
  {
    "id": 46,
    "categoryId": 15,
    "question": "A patient ingested a bottle of Tylenol 4 hours ago. What determines if N-Acetylcysteine (NAC) is needed?",
    "options": [
      "A) Presence of liver tenderness",
      "B) The Rumack-Matthew Nomogram",
      "C) The dose reported by the patient",
      "D) Coagulation studies (INR)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The Rumack-Matthew Nomogram).\n\nPATHOPHYSIOLOGY:\nAcetaminophen is a common cause of acute liver failure in the US. At therapeutic doses, it is primarily metabolized via glucuronidation and sulfation. A small fraction is oxidized by CYP2E1 to the toxic metabolite NAPQI, normally detoxified by glutathione conjugation. In overdose, glucuronidation and sulfation saturate, shunting metabolism through CYP2E1. When NAPQI production exceeds glutathione stores, unbound NAPQI binds hepatocyte proteins, causing centrilobular hepatic necrosis.\n\nCLINICAL REASONING:\nThe Rumack-Matthew nomogram determines NAC treatment need following acute single-ingestion overdose. A serum acetaminophen level drawn at 4 hours post-ingestion (earliest validated time) is plotted against time; levels above the treatment line indicate NAC. Toxicity progresses through four phases: Phase 1 (0-24h) with nonspecific nausea and malaise or no symptoms, Phase 2 (24-72h) with RUQ pain and rising transaminases, Phase 3 (72-96h) with peak hepatotoxicity and potential liver failure, and Phase 4 (4 days to 2 weeks) with recovery or death.\n\nTREATMENT:\nNAC replenishes hepatic glutathione, providing greatest benefit within 8 hours but remaining beneficial at 24+ hours with hepatotoxicity evidence. NAC is given IV (preferred for reliability and shorter duration) or via 72-hour oral protocol. Continue until transaminases trend down, INR improves, and acetaminophen is undetectable. For unknown ingestion time or staggered overdose, the nomogram cannot be applied\u2014initiate empiric NAC if acetaminophen is detectable with elevated transaminases. Chronic alcohol use and malnutrition deplete glutathione, lowering the toxicity threshold.\n\nKEY POINTS:\nThe Rumack-Matthew nomogram using a 4-hour post-ingestion level determines NAC need in acute single-ingestion overdose. NAC replenishes glutathione to detoxify NAPQI, most effective within 8 hours but beneficial beyond 24 hours. For staggered or unknown-time ingestions, give empiric NAC if APAP is detectable with elevated transaminases."
  },
  {
    "id": 47,
    "categoryId": 4,
    "question": "A pregnant patient at 34 weeks has BP 160/110 and new onset severe headache. Urine protein is 3+. What is the seizure prophylaxis of choice?",
    "options": [
      "A) Lorazepam",
      "B) Magnesium Sulfate",
      "C) Phenytoin",
      "D) Labetalol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium Sulfate).\n\nPATHOPHYSIOLOGY:\nPreeclampsia originates from abnormal placentation with defective trophoblast invasion of spiral arteries, leading to inadequate remodeling and high-resistance uteroplacental flow. Resulting placental ischemia triggers release of antiangiogenic factors (sFlt-1, soluble endoglin) that sequester proangiogenic factors (VEGF, PlGF), causing widespread maternal endothelial dysfunction manifesting as hypertension, proteinuria, and end-organ damage. Eclampsia results from cerebral vasospasm, endothelial dysfunction, and blood-brain barrier disruption causing cerebral edema and cortical irritability.\n\nCLINICAL REASONING:\nThis patient meets ACOG criteria for severe preeclampsia: BP \u2265160/110 and severe headache (cerebral symptom indicating high eclampsia risk). Other severe features include thrombocytopenia (<100,000), transaminase elevation to twice normal, creatinine >1.1, pulmonary edema, or new cerebral or visual disturbances.\n\nTREATMENT:\nMagnesium sulfate is first-line for seizure prophylaxis and eclamptic seizure treatment. The Magpie Trial (Lancet 2002) demonstrated 58% eclampsia risk reduction versus placebo. Loading dose: 4-6 g IV over 15-20 minutes; maintenance: 1-2 g/hour. Magnesium acts via NMDA receptor antagonism, cerebral vasodilation, and reduced calcium-mediated neuronal excitability. Therapeutic range: 4-7 mEq/L. Toxicity follows predictable sequence: lost reflexes (7-10 mEq/L), respiratory depression (10-13 mEq/L), cardiac arrest (>15 mEq/L); treat with IV calcium gluconate. Monitor patellar reflexes, respiratory rate, and urine output (renal clearance). Concurrent acute BP management with IV labetalol or hydralazine targets <160/110 to prevent hemorrhagic stroke. Definitive treatment is delivery; at \u226534 weeks with severe features, deliver after maternal stabilization.\n\nKEY POINTS:\nMagnesium sulfate is standard of care for seizure prophylaxis in severe preeclampsia, reducing eclampsia risk by 58% (Magpie Trial). Monitor toxicity via reflexes, respirations, and urine output; calcium gluconate is the antidote. Definitive treatment is delivery; at \u226534 weeks with severe features, deliver after stabilization."
  },
  {
    "id": 48,
    "categoryId": 8,
    "question": "A patient wakes up to find a bat in his bedroom. He is unsure if he was bitten. There is no visible wound. Recommendation?",
    "options": [
      "A) No treatment unless bite marks found",
      "B) Observe the patient for symptoms",
      "C) Rabies Immunoglobulin (RIG) + Vaccine Series",
      "D) Test the patient for rabies antibodies"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Rabies Immunoglobulin + Vaccine Series).\n\nPATHOPHYSIOLOGY:\nRabies virus is a neurotropic RNA virus (family Rhabdoviridae) transmitted through the saliva of infected animals. After inoculation, the virus replicates locally in muscle tissue before entering peripheral nerves at neuromuscular junctions. It travels via retrograde axonal transport to the central nervous system, where it causes progressive, fatal encephalomyelitis. The incubation period ranges from weeks to months, depending on the distance from the bite site to the CNS. Once clinical symptoms appear, rabies is nearly 100% fatal.\n\nCLINICAL REASONING:\nBats present a unique exposure risk because their bites can be virtually undetectable. Bat teeth are small enough that a sleeping, intoxicated, or cognitively impaired person may be bitten without awareness. The CDC considers finding a bat in a room with a sleeping person, an unattended child, or a cognitively impaired individual to constitute a potential rabies exposure requiring post-exposure prophylaxis (PEP), even if no bite wound is visible.\n\nTREATMENT:\nPEP for previously unvaccinated individuals consists of rabies immunoglobulin (RIG) 20 IU/kg infiltrated around the wound site (or IM at a distant site if no wound is identifiable) plus a 4-dose rabies vaccine series administered on days 0, 3, 7, and 14. RIG provides immediate passive immunity while the vaccine induces active humoral immunity over 7-10 days. For previously vaccinated individuals, RIG is omitted, and only 2 vaccine doses (days 0 and 3) are needed. PEP is extremely effective when initiated before symptom onset but is futile once clinical disease develops.\n\nKEY POINTS:\nFinding a bat in a room with a sleeping or impaired person constitutes rabies exposure requiring PEP, even without visible bite marks. PEP consists of both RIG and a vaccine series for unvaccinated individuals. Rabies is nearly 100% fatal once symptoms appear, making timely prevention critical.\n---"
  },
  {
    "id": 49,
    "categoryId": 7,
    "question": "A 60-year-old male presents with a hot, swollen, painful knee. He cannot bear weight. He has a fever. Arthrocentesis shows WBC 80,000 with >90% neutrophils. Diagnosis?",
    "options": [
      "A) Gout",
      "B) Septic Arthritis",
      "C) Rheumatoid Arthritis Flare",
      "D) Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Septic Arthritis).\n\nPATHOPHYSIOLOGY:\nSeptic arthritis is a bacterial joint infection constituting an orthopedic emergency\u2014proteolytic enzymes from bacteria and the inflammatory response destroy articular cartilage within hours. Bacteria typically reach the joint hematogenously, as the synovial membrane is highly vascular and lacks a basement membrane. The intense neutrophilic response generates cytokines and matrix metalloproteinases that irreversibly degrade cartilage. Staphylococcus aureus (including MRSA) is the most common pathogen in adults. In sexually active young adults, consider Neisseria gonorrhoeae, presenting with migratory polyarthralgia, tenosynovitis, and dermatitis before localizing to a single joint.\n\nCLINICAL PRESENTATION AND DIAGNOSIS:\nAn acutely hot, swollen, erythematous joint with fever demands immediate arthrocentesis before antibiotics. Synovial fluid WBC thresholds: normal <200/microliter, non-inflammatory (OA) 200-2,000, inflammatory (gout, RA) 2,000-50,000. WBC >50,000 with >90% PMNs is highly suggestive of septic arthritis, though lower counts do not exclude it. Gram stain is positive in ~50-75% of non-gonococcal infections. Crystals on polarized microscopy do not exclude concurrent infection\u2014gout and septic arthritis can coexist.\n\nMANAGEMENT:\nEmpiric IV antibiotics covering S. aureus and gram-negatives (vancomycin plus ceftriaxone) are initiated emergently. Joint drainage via serial aspiration or surgical irrigation and debridement removes destructive purulent material. Antibiotics are tailored to culture results, typically continuing 2-4 weeks. Delayed treatment causes permanent joint destruction, sepsis, and significant mortality.\n\nKEY POINTS:\nSeptic arthritis is an orthopedic emergency with joint destruction beginning within hours, requiring immediate arthrocentesis, empiric IV antibiotics, and drainage. Synovial WBC >50,000 with >90% neutrophils is highly suggestive. Crystals do not exclude infection\u2014treat both when clinical suspicion is high. S. aureus is the most common adult pathogen."
  },
  {
    "id": 50,
    "categoryId": 4,
    "question": "First step in management of Diabetic Ketoacidosis (DKA) after ABCs?",
    "options": [
      "A) IV Insulin Bolus",
      "B) IV Fluids (Normal Saline)",
      "C) Bicarbonate",
      "D) Potassium replacement"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Fluids / Normal Saline).\n\nPATHOPHYSIOLOGY:\nDKA results from absolute or relative insulin deficiency with excess counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone). Absent insulin permits unrestrained lipolysis; hepatic beta-oxidation of free fatty acids generates ketone bodies (beta-hydroxybutyrate, acetoacetate, acetone) faster than peripheral utilization, producing high anion gap metabolic acidosis. Unrestrained gluconeogenesis and glycogenolysis cause severe hyperglycemia. Resulting osmotic diuresis drives profound volume depletion (typically 5-7 liters) with losses of sodium, potassium, phosphate, and magnesium. Diagnostic criteria: pH <7.3 or bicarbonate <18, ketonemia or ketonuria, and elevated anion gap.\n\nCLINICAL REASONING:\nIV normal saline is the critical first intervention. Volume depletion is the most immediately life-threatening aspect\u2014hypovolemia impairs renal glucose and ketone clearance, reduces tissue perfusion, and compounds acidosis via lactic acid production. Starting insulin before adequate volume resuscitation risks cardiovascular collapse. Potassium must be assessed before insulin, as insulin drives potassium intracellularly and can cause fatal hypokalemia.\n\nTREATMENT:\nPer ADA protocol: NS 1-1.5 L in the first hour, then 250-500 mL/hour adjusted to hemodynamics. Switch to half-NS when sodium is normal or elevated. Add D5 half-NS when glucose reaches 200-250 mg/dL to prevent hypoglycemia while continuing insulin to close the anion gap. Regular insulin at 0.1 units/kg/hour targets glucose decline of 50-75 mg/dL/hour. Critically, insulin continues until the anion gap closes regardless of glucose normalization. Potassium management: if K+ <3.3 mEq/L, withhold insulin and replace aggressively; initiate replacement when K+ <5.2 with confirmed urine output. Bicarbonate reserved for pH <6.9.\n\nKEY POINTS:\nIV NS is the first DKA intervention because 5-7 L volume depletion is immediately life-threatening. The anion gap\u2014not glucose\u2014determines DKA resolution; insulin continues until the gap closes. If K+ <3.3, withhold insulin until repleted to prevent fatal hypokalemia."
  },
  {
    "id": 51,
    "categoryId": 17,
    "question": "Patient describes a 'curtain coming down' over their vision, accompanied by flashes of light (photopsia) and new floaters. No pain. Diagnosis?",
    "options": [
      "A) Retinal Detachment",
      "B) Central Retinal Artery Occlusion",
      "C) Vitreous Hemorrhage",
      "D) Optic Neuritis"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Retinal Detachment).\n\nPATHOPHYSIOLOGY:\nRetinal detachment occurs when the neurosensory retina separates from the underlying retinal pigment epithelium (RPE), disrupting the metabolic support necessary for photoreceptor function. The most common type is rhegmatogenous retinal detachment, in which vitreous fluid passes through a retinal tear or hole and accumulates in the subretinal space, progressively lifting the retina. Posterior vitreous detachment (age-related vitreous liquefaction and separation from the retina) is the most frequent inciting event.\n\nCLINICAL PRESENTATION:\n- Photopsia (flashes of light): Caused by vitreous traction on the retina stimulating photoreceptors mechanically\n- New floaters: Represent vitreous hemorrhage, pigment cells (tobacco dust or Shafer sign), or vitreous condensations\n- Progressive visual field loss described as a curtain or shadow moving across the visual field\n- Painless - distinguishes from acute angle-closure glaucoma and uveitis\n\nRISK FACTORS:\nMyopia (elongated globe with thinner retina), prior cataract surgery (most common risk factor for pseudophakic detachment), trauma, lattice degeneration, family history, and prior retinal detachment in the contralateral eye.\n\nDIAGNOSIS AND URGENCY:\nDilated fundoscopic examination or bedside ultrasound if media is opaque. Macula-on detachment (central vision intact) is a true surgical emergency requiring repair within 24 hours to preserve central vision. Macula-off detachment has a worse visual prognosis but still warrants urgent repair.\n\nTREATMENT:\n1. Pneumatic retinopexy (office-based, for selected superior detachments)\n2. Scleral buckle (external silicone band compresses the eye wall against the retina)\n3. Pars plana vitrectomy with gas or silicone oil tamponade\n\nKEY POINTS:\nThe triad of flashes, floaters, and visual field loss is retinal detachment until proven otherwise and requires emergent ophthalmology referral. Macula-on detachments must be repaired within 24 hours. Myopia and prior cataract surgery are the most important risk factors.\n---"
  },
  {
    "id": 52,
    "categoryId": 12,
    "question": "A 4-month-old infant presents with constipation, poor feeding, and 'floppy' muscle tone (hypotonia). The parents feed the child honey. Mechanism?",
    "options": [
      "A) Autoimmune attack on Acetylcholine receptors",
      "B) Toxin prevents release of Acetylcholine",
      "C) Viral destruction of anterior horn cells",
      "D) Genetic mutation (SMA)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Toxin prevents release of Acetylcholine).\n\nPATHOPHYSIOLOGY:\nInfant botulism is the most common form of botulism in the United States, caused by ingestion of Clostridium botulinum spores that germinate and produce toxin within the infant's intestinal tract. Unlike foodborne botulism in adults (caused by ingestion of preformed toxin), infant botulism occurs because the immature infant gut flora lacks the competitive bacteria that prevent C. botulinum colonization in older children and adults. The botulinum toxin (a zinc endopeptidase) irreversibly cleaves SNARE proteins (synaptobrevin, SNAP-25, syntaxin) at the presynaptic terminal of the neuromuscular junction, preventing fusion of acetylcholine-containing vesicles with the presynaptic membrane and blocking acetylcholine release. The result is flaccid, descending paralysis because motor nerve terminals cannot signal muscle contraction.\n\nCLINICAL PRESENTATION:\nInfant botulism typically presents in infants aged 2 weeks to 6 months. Constipation is often the first symptom (due to autonomic dysfunction), followed by poor feeding, weak cry, progressive descending weakness producing the classic \"floppy baby\" presentation, ptosis, sluggish pupillary reflexes, diminished gag reflex, and potentially respiratory failure from diaphragmatic paralysis. the infant remains afebrile and alert despite the progressive paralysis. The descending pattern (cranial nerves affected first, then trunk and extremities) distinguishes botulism from Guillain-Barre syndrome, which produces ascending paralysis.\n\nSOURCE AND PREVENTION:\nHoney is the only dietary source definitively linked to infant botulism (C. botulinum spores survive in honey), which is why honey must never be given to infants under 12 months. However, most cases have no identifiable source and are attributed to environmental spore exposure from soil or dust.\n\nTREATMENT:\nHuman botulism immune globulin (BabyBIG) is the specific treatment for infant botulism, providing passive immunization with human-derived botulinum antitoxin that neutralizes circulating toxin. BabyBIG significantly reduces hospitalization duration (from approximately 6 weeks to 2 weeks) and the need for mechanical ventilation. Aminoglycoside antibiotics are avoided because they can potentiate neuromuscular blockade, and antibiotic-induced bacterial lysis can release additional intraluminal toxin. With modern supportive care, mortality is less than 2%.\n\nKEY POINTS:\nInfant botulism results from intestinal colonization with C. botulinum spores (not preformed toxin) in infants whose immature gut flora cannot prevent colonization. The toxin irreversibly blocks presynaptic acetylcholine release, producing flaccid descending paralysis. Honey is contraindicated under 12 months, BabyBIG is the specific treatment, and aminoglycosides are avoided."
  },
  {
    "id": 53,
    "categoryId": 1,
    "question": "A 55-year-old hypertensive male presents with sudden 'tearing' chest pain radiating to the back between the scapulae. BP in right arm is 180/100, left arm 110/60. Next step?",
    "options": [
      "A) EKG",
      "B) CT Angiogram of Aorta",
      "C) Cardiac Enzymes",
      "D) Chest X-ray"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/aortic-dissection.png", "alt": "Aortic dissection: tear in wall, true and false lumen, blood flow", "caption": "Aortic dissection: tear in wall with blood entering false lumen (Cleveland Clinic ©2024)." }
    ],
    "explanation": "CORRECT: B (CT Angiogram of the Aorta).\n\nCLINICAL REASONING:\nThis presentation is classic for acute aortic dissection: sudden-onset severe tearing or ripping chest pain radiating to the back between the scapulae, with a greater than 20 mmHg blood pressure differential between the arms. The inter-arm BP discrepancy (180/100 right versus 110/60 left) indicates that the dissection flap is compromising flow to the left subclavian artery. CTA of the aorta is the diagnostic study of choice due to its rapid acquisition, near-100% sensitivity and specificity, and ability to define the extent of dissection, involvement of branch vessels, and presence of complications.\n\nPATHOPHYSIOLOGY:\nAortic dissection begins with a tear in the tunica intima that allows blood to enter the tunica media, where it propagates along the vessel wall creating a false lumen that separates the intimal-medial layers. The Stanford classification divides dissections into Type A (involving the ascending aorta regardless of where the tear originates, requiring emergent surgical repair) and Type B (involving only the descending aorta distal to the left subclavian artery, managed medically unless complicated). Hypertension is the most important risk factor, present in approximately 70% of cases. Other predisposing conditions include Marfan syndrome, Ehlers-Danlos type IV, bicuspid aortic valve, cocaine use, and Turner syndrome.\n\nMANAGEMENT:\nImmediate management centers on anti-impulse therapy: rapidly reducing both blood pressure and the rate of rise of aortic pressure (dP/dt). IV esmolol or labetalol are first-line to reduce heart rate to below 60 bpm, followed by nitroprusside if additional BP reduction is needed, with a target systolic BP of 100 to 120 mmHg. Beta-blockers must be administered before vasodilators because vasodilators alone cause reflex tachycardia that increases aortic shear stress and worsens dissection propagation. Type A dissections require emergent open surgical repair, while uncomplicated Type B dissections are managed medically with close surveillance.\n\nKEY POINTS:\nAcute aortic dissection presents with sudden tearing chest or back pain and inter-arm blood pressure differential, and CTA of the aorta is the diagnostic study of choice. Stanford Type A (ascending aorta) requires emergent surgery, while uncomplicated Type B (descending only) is managed medically. Anti-impulse therapy with IV beta-blockers first (to reduce heart rate and dP/dt) is the critical initial management step."
  },
  {
    "id": 54,
    "categoryId": 10,
    "question": "A patient presents with Bell's Palsy (CN VII). He also mentions knee pain. He went camping in Connecticut 1 month ago. Diagnosis?",
    "options": [
      "A) Stroke",
      "B) Lyme Disease",
      "C) HSV-1 reactivation",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/derm-q3-image-2.png",
        "alt": "Anatomy and clinical findings in Bell's palsy",
        "caption": "Facial nerve distribution and classic Bell's palsy clinical findings."
      },
      {
        "src": "assets/derm-q3-image-1.png",
        "alt": "Erythema migrans target lesions suggestive of Lyme disease",
        "caption": "Typical erythema migrans (bull's-eye) lesions seen in Lyme disease."
      }
    ],
    "explanation": "CORRECT: B (Lyme Disease).\n\nPATHOPHYSIOLOGY:\nLyme disease, caused by the spirochete Borrelia burgdorferi, is transmitted through Ixodes tick bites in endemic areas (Northeast, Upper Midwest). The infection progresses through stages: early localized disease at the bite site, early disseminated disease with hematogenous spread, and late disseminated disease affecting joints and nervous system. Facial nerve palsy occurs during early disseminated disease when spirochetes invade cranial nerve sheaths, causing inflammation and demyelination.\n\nCLINICAL STAGES:\nEarly localized disease (days to weeks) presents with erythema migrans, the expanding \"bull's-eye\" rash at the bite site, accompanied by flu-like symptoms. Early disseminated disease (weeks to months) manifests with neurologic involvement (facial palsy, meningitis, radiculopathy), cardiac involvement (AV block, myocarditis), and multiple erythema migrans lesions. Late disseminated disease (months to years) causes Lyme arthritis affecting large joints, particularly the knee, and chronic neurologic symptoms.\n\nDIAGNOSIS AND TREATMENT:\nErythema migrans is diagnosed clinically without waiting for serology, which may be negative early. Disseminated disease requires two-tier serologic testing (ELISA screening followed by Western blot confirmation). Treatment for early disease is doxycycline 100mg twice daily for 10-21 days. Lyme carditis with heart block or neurologic involvement beyond isolated facial palsy requires IV ceftriaxone.\n\nKEY POINTS:\nBell's palsy in a patient from an endemic area with systemic symptoms suggests Lyme disease. Facial palsy in Lyme may be bilateral, which is unusual for idiopathic Bell's palsy. Treat erythema migrans clinically without waiting for serology. Doxycycline is first-line for early Lyme disease."
  },
  {
    "id": 55,
    "categoryId": 11,
    "question": "A patient on Lithium presents with tremor, ataxia, vomiting, and confusion. He started a new BP medication last week. Which drug likely precipitated this?",
    "options": [
      "A) Amlodipine",
      "B) Hydrochlorothiazide (HCTZ)",
      "C) Metoprolol",
      "D) Clonidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hydrochlorothiazide).\n\nPHARMACOLOGY:\nLithium is a monovalent cation with an extremely narrow therapeutic index (therapeutic level 0.6 to 1.2 mEq/L, toxicity above 1.5 mEq/L) that is almost entirely eliminated by renal excretion. Lithium is freely filtered at the glomerulus and approximately 80% is reabsorbed in the proximal tubule via the same sodium channels used for sodium reabsorption. Any condition or medication that reduces sodium delivery to the proximal tubule increases lithium reabsorption and raises serum lithium levels.\n\nMECHANISM OF INTERACTION:\nThiazide diuretics (hydrochlorothiazide, chlorthalidone) block sodium reabsorption in the distal convoluted tubule, causing natriuresis and volume contraction. The resulting volume depletion triggers compensatory increased sodium (and lithium) reabsorption in the proximal tubule, raising lithium levels by approximately 25 to 40%. This interaction can precipitate lithium toxicity within days to weeks of thiazide initiation.\n\nCLINICAL PRESENTATION OF LITHIUM TOXICITY:\nMild toxicity (1.5 to 2.0 mEq/L) presents with coarse tremor (distinct from the fine tremor seen at therapeutic levels), nausea, vomiting, and diarrhea. Moderate toxicity (2.0 to 2.5 mEq/L) produces ataxia, confusion, dysarthria, and hyperreflexia. Severe toxicity (above 2.5 mEq/L) can cause seizures, coma, cardiac arrhythmias, and death. Management includes IV normal saline for volume repletion and enhanced renal lithium clearance, with hemodialysis indicated for levels above 4.0 mEq/L or severe neurologic symptoms.\n\nOTHER DRUGS THAT RAISE LITHIUM LEVELS:\nACE inhibitors and ARBs (by reducing GFR and increasing proximal reabsorption), NSAIDs (by reducing renal prostaglandin-mediated GFR), and volume depletion from any cause all increase lithium levels. Amlodipine (a calcium channel blocker), metoprolol (a beta-blocker), and clonidine (a central alpha-2 agonist) do not significantly affect lithium levels.\n\nKEY POINTS:\nThiazide diuretics raise lithium levels by 25 to 40% through volume depletion-induced compensatory proximal tubular lithium reabsorption, potentially precipitating toxicity within days of initiation. Lithium has an extremely narrow therapeutic index (0.6 to 1.2 mEq/L) with toxicity presenting as coarse tremor, ataxia, and confusion. ACE inhibitors, ARBs, and NSAIDs also raise lithium levels and require monitoring."
  },
  {
    "id": 56,
    "categoryId": 12,
    "question": "In a 2-week-old neonate with meningitis, what are the most common pathogens?",
    "options": [
      "A) Strep pneumo, Neisseria",
      "B) Group B Strep, E. coli, Listeria",
      "C) H. flu, Moraxella",
      "D) Staphylococcus, Pseudomonas"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group B Strep, E. coli, Listeria).\n\nPATHOPHYSIOLOGY:\nNeonatal meningitis (first 28 days of life) has a unique pathogen spectrum reflecting exposure to maternal genital flora and neonatal immune immaturity. Three organisms cause >70% of cases: Group B Streptococcus (S. agalactiae), the most common cause, acquired from the maternal genital tract; Escherichia coli (K1 capsular strain with antiphagocytic properties), the second most common and leading cause in preterm infants; and Listeria monocytogenes, acquired transplacentally or during delivery from maternal colonization associated with unpasteurized dairy, deli meats, or soft cheeses.\n\nCLINICAL PRESENTATION:\nNeonates lack the classic meningitis triad of fever, neck stiffness, and headache. Instead they present with nonspecific signs: temperature instability, irritability or lethargy, poor feeding, vomiting, bulging fontanelle (late sign), seizures, apnea, respiratory distress, and jaundice. Any neonate under 28 days with fever (\u226538\u00b0C) requires full sepsis evaluation including lumbar puncture, blood cultures, urine culture, and empiric antibiotics, even if appearing well.\n\nTREATMENT:\nEmpiric therapy: ampicillin (covers GBS and Listeria) plus gentamicin (synergistic gram-negative coverage) or cefotaxime (enhanced CSF penetration). Ceftriaxone is avoided in neonates under 28 days because it displaces bilirubin from albumin, increasing kernicterus risk. Mortality is ~10-15% with significant risk of long-term sequelae including hearing loss, developmental delay, seizures, and hydrocephalus.\n\nKEY POINTS:\nGBS, E. coli (K1), and Listeria cause >70% of neonatal meningitis, reflecting maternal flora exposure. Neonates present with nonspecific findings, so any febrile neonate under 28 days requires full sepsis workup including LP. Empiric therapy is ampicillin plus gentamicin or cefotaxime; ceftriaxone is avoided due to kernicterus risk."
  },
  {
    "id": 57,
    "categoryId": 9,
    "question": "A 65-year-old male on Warfarin (INR stable at 2.5) is prescribed Bactrim (TMP-SMX) for a UTI. What will happen to his INR, and what is the management?",
    "options": [
      "A) INR will decrease; Increase Warfarin dose",
      "B) INR will increase; Decrease Warfarin dose by 50%",
      "C) No change expected",
      "D) INR will decrease; Add Aspirin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (INR will increase; decrease Warfarin dose by 50%).\n\nPHARMACOLOGY:\nTrimethoprim-sulfamethoxazole (TMP-SMX, Bactrim) is one of the most clinically significant drug interactions with warfarin, consistently causing marked INR elevation through two synergistic mechanisms. First, sulfamethoxazole is a potent inhibitor of CYP2C9, the primary cytochrome P450 enzyme responsible for metabolizing the more potent S-enantiomer of warfarin, resulting in decreased warfarin clearance and elevated drug levels. Second, trimethoprim has an independent anticoagulant effect by inhibiting the renal tubular secretion of creatinine and directly suppressing vitamin K-producing gut flora.\n\nCLINICAL SIGNIFICANCE:\nThe INR increase with TMP-SMX is substantial and predictable, typically occurring within 3 to 5 days of concurrent use. Studies demonstrate an average INR increase of 50 to 100%, with some patients experiencing supratherapeutic INR levels exceeding 4.0, placing them at significant risk for major hemorrhage. This interaction is a leading cause of warfarin-related emergency department visits and hospitalizations.\n\nMANAGEMENT:\nWhen TMP-SMX must be prescribed to a patient on warfarin, the warfarin dose should be empirically reduced by approximately 25 to 50% at the time of TMP-SMX initiation, with INR checked within 3 to 5 days. Alternative antibiotics that do not significantly interact with warfarin (nitrofurantoin for uncomplicated UTI, or fluoroquinolones with caution as they have a weaker CYP interaction) should be considered when possible.\n\nOTHER HIGH-RISK WARFARIN INTERACTIONS:\nClinicians should be aware of other potent CYP2C9 inhibitors that increase INR: fluconazole, metronidazole, amiodarone, and fluvastatin. CYP2C9 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) decrease INR and increase thrombotic risk.\n\nKEY POINTS:\nTMP-SMX (Bactrim) increases INR substantially through CYP2C9 inhibition of warfarin metabolism and suppression of vitamin K-producing gut flora. Warfarin dose should be empirically reduced by 25 to 50% when TMP-SMX is initiated, with INR rechecked within 3 to 5 days. This interaction is a leading cause of warfarin-related bleeding emergencies."
  },
  {
    "id": 58,
    "categoryId": 8,
    "question": "Which antibiotic is associated with an increased risk of tendon rupture and aortic dissection, especially in the elderly?",
    "options": [
      "A) Doxycycline",
      "B) Ciprofloxacin (Fluoroquinolones)",
      "C) Amoxicillin",
      "D) Azithromycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fluoroquinolones â€” Ciprofloxacin, Levofloxacin, Moxifloxacin).\n\nPATHOPHYSIOLOGY:\nFluoroquinolones inhibit bacterial DNA gyrase and topoisomerase IV, which are essential for DNA replication. However, these drugs also impair collagen synthesis and cross-linking in mammalian connective tissues, including tendons and the aortic wall. This mechanism underlies the increased risk of tendon rupture (particularly Achilles tendon) and aortic aneurysm or dissection. The effect is cumulative with factors that already compromise connective tissue integrity, such as aging, corticosteroid use, and genetic connective tissue disorders.\n\nCLINICAL MANIFESTATIONS:\nTendinitis and tendon rupture can occur within hours of the first dose or months after completing therapy. The Achilles tendon is most frequently affected. Risk is significantly increased in patients over age 60, those on concurrent corticosteroids, and organ transplant recipients. Aortic dissection and aneurysm risk is approximately doubled with fluoroquinolone use, with the highest risk in elderly patients, those with hypertension, and those with known connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome. Additional serious adverse effects include peripheral neuropathy (potentially irreversible), CNS effects (seizures, confusion, hallucinations), QT prolongation (especially moxifloxacin), hypoglycemia, and Clostridioides difficile colitis.\n\nCLINICAL REASONING:\nThe FDA has issued multiple black box warnings advising that fluoroquinolones should be reserved for conditions without safer alternative treatments. For uncomplicated cystitis, nitrofurantoin or TMP-SMX should be used instead. Appropriate indications include complicated UTI or pyelonephritis, hospital-acquired pneumonia, Pseudomonas infections, and situations where no safer alternative exists. Patients prescribed fluoroquinolones should be counseled to discontinue the medication immediately and seek evaluation if they develop tendon pain, swelling, or inflammation.\n\nKEY POINTS:\nFluoroquinolones carry FDA black box warnings for tendon rupture (especially Achilles), aortic dissection, peripheral neuropathy, and CNS effects. Risk factors include age over 60, corticosteroid use, and connective tissue disorders. Reserve fluoroquinolones for conditions without safer alternatives.\n---"
  },
  {
    "id": 59,
    "categoryId": 4,
    "question": "A patient with T2DM has a GFR of 25. Which medication is CONTRAINDICATED?",
    "options": [
      "A) Insulin Glargine",
      "B) Metformin",
      "C) Glipizide",
      "D) Linagliptin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metformin).\n\nPATHOPHYSIOLOGY:\nMetformin reduces hepatic gluconeogenesis and improves insulin sensitivity via AMPK activation. It is renally cleared without hepatic metabolism, so renal impairment causes drug accumulation, increasing lactic acidosis risk (mortality ~50%). Metformin inhibits mitochondrial complex I, shifting metabolism toward anaerobic glycolysis and increasing lactate production. With normal renal function, this effect is clinically insignificant; with impaired clearance, accumulation drives lactate production beyond hepatic clearance capacity, especially when concurrent insults (dehydration, sepsis, hypoxia) further compromise lactate metabolism.\n\nCLINICAL REASONING:\nThe FDA's 2016 revised guidance uses eGFR-based thresholds. Metformin is safe at eGFR \u226545 without dose adjustment. At eGFR 30-45, it may continue with dose reduction (max 1000 mg daily) and closer monitoring but should not be newly initiated. At eGFR <30, metformin is contraindicated. This patient's GFR of 25 falls well below this threshold. Metformin should also be held before iodinated contrast in patients with eGFR 30-60 and withheld 48 hours afterward.\n\nALTERNATIVE AGENTS IN ADVANCED CKD:\nInsulin is safe at all renal levels but requires dose reduction in advanced CKD. Among sulfonylureas, glipizide is preferred (hepatically metabolized to inactive metabolites) over glyburide (active metabolites accumulate, increasing hypoglycemia). Linagliptin is the only DPP-4 inhibitor requiring no renal dose adjustment (hepatobiliary elimination). SGLT2 inhibitors have reduced glycemic efficacy at low eGFR but retain cardiorenal benefits; DAPA-CKD (NEJM 2020) and EMPA-KIDNEY (NEJM 2023) support use at eGFR as low as 20. GLP-1 receptor agonists require no renal dose adjustment.\n\nKEY POINTS:\nMetformin is contraindicated at eGFR <30 due to lactic acidosis risk from impaired clearance. Glipizide is preferred over glyburide in CKD (no active metabolites). Linagliptin requires no renal dose adjustment. SGLT2 inhibitors retain cardiorenal benefits at eGFR as low as 20 despite reduced glycemic efficacy."
  },
  {
    "id": 60,
    "categoryId": 11,
    "question": "You are starting Citalopram (Celexa). What is the maximum dose for a patient > 60 years old due to QT prolongation risk?",
    "options": [
      "A) 10 mg",
      "B) 20 mg",
      "C) 40 mg",
      "D) 60 mg"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (20 mg).\n\nPHARMACOLOGY:\nCitalopram (Celexa), a selective serotonin reuptake inhibitor, carries a dose-dependent risk of QT interval prolongation that prompted the FDA to issue a safety communication in 2011 limiting the maximum dose to 40 mg per day in the general population and 20 mg per day in patients older than 60 years. The QT prolongation results from citalopram's blockade of the hERG (human ether-à-go-go-related gene) potassium channel, which conducts the rapid delayed rectifier potassium current (IKr) essential for ventricular repolarization.\n\nAGE-RELATED RISK:\nOlder adults are at increased risk of citalopram-induced QT prolongation for several reasons. Age-related decline in hepatic metabolism (reduced CYP2C19 and CYP3A4 activity) increases citalopram plasma concentrations at any given dose. Older patients have higher baseline QT intervals, reduced cardiac repolarization reserve, and are more likely to be taking concurrent QT-prolonging medications (macrolide antibiotics, fluoroquinolones, antiarrhythmics, antifungals). They also more frequently have electrolyte abnormalities (hypokalemia, hypomagnesemia from diuretic use) that independently predispose to torsades de pointes.\n\nCLINICAL APPLICATION:\nBefore initiating citalopram, clinicians should obtain a baseline ECG in patients with cardiac risk factors or those over 60, check electrolytes (potassium, magnesium), and review the medication list for other QT-prolonging drugs. If doses above 20 mg are needed in an elderly patient, escitalopram (Lexapro, the S-enantiomer of citalopram) is preferred because it has lower QT prolongation risk at therapeutic doses, with a maximum of 20 mg in the elderly. Other SSRIs (sertraline, fluoxetine) have minimal QT effects and are alternatives.\n\nKEY POINTS:\nCitalopram's maximum dose is 20 mg per day in adults over 60 due to dose-dependent QT prolongation from hERG potassium channel blockade. Older adults have increased risk from reduced hepatic metabolism, lower cardiac repolarization reserve, and polypharmacy. Escitalopram and sertraline are safer SSRI alternatives in elderly patients requiring higher antidepressant doses."
  },
  {
    "id": 61,
    "categoryId": 1,
    "question": "A patient on Digoxin presents with nausea, vomiting, and yellow-green visual halos. Which electrolyte abnormality precipitates Digoxin toxicity?",
    "options": [
      "A) Hyperkalemia",
      "B) Hypokalemia",
      "C) Hypermagnesemia",
      "D) Hyponatremia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypokalemia).\n\nPATHOPHYSIOLOGY:\nDigoxin exerts its therapeutic effect by inhibiting the Na+/K+-ATPase pump on cardiac myocytes, which increases intracellular sodium, via the Na+/Ca2+ exchanger, secondarily increases intracellular calcium, enhancing cardiac contractility (positive inotrope). digoxin and potassium compete for the same binding site on the Na+/K+-ATPase pump. When serum potassium is low, there is less competition for this binding site, allowing more digoxin to bind and producing excessive Na+/K+-ATPase inhibition even at therapeutic serum digoxin levels. This is why hypokalemia is the most important electrolyte abnormality precipitating digoxin toxicity.\n\nCLINICAL PRESENTATION:\nDigoxin toxicity presents with gastrointestinal symptoms (nausea, vomiting, anorexia), neurologic symptoms (confusion, fatigue), and the characteristic visual disturbances including yellow-green halos around lights (xanthopsia). Cardiac manifestations range from bradyarrhythmias (sinus bradycardia, AV block) to tachyarrhythmias (atrial tachycardia with block, bidirectional ventricular tachycardia, ventricular fibrillation), with bidirectional VT being nearly pathognomonic for digoxin toxicity.\n\nRISK FACTORS AND MANAGEMENT:\nBeyond hypokalemia, other conditions that increase digoxin toxicity risk include hypomagnesemia (magnesium is required for Na+/K+-ATPase function), hypercalcemia (which potentiates digoxin's calcium-loading effect), renal insufficiency (digoxin is renally cleared), and concurrent use of amiodarone, verapamil, or quinidine (which raise digoxin levels by inhibiting P-glycoprotein efflux). The antidote for life-threatening digoxin toxicity is digoxin-specific antibody fragments (DigiFab), which bind free digoxin and prevent it from reaching the Na+/K+-ATPase. Loop and thiazide diuretics commonly precipitate hypokalemia-induced digoxin toxicity in heart failure patients.\n\nKEY POINTS:\nHypokalemia precipitates digoxin toxicity because potassium and digoxin compete for the same Na+/K+-ATPase binding site, and low potassium allows excessive digoxin binding. Classic toxicity presents with GI symptoms, xanthopsia (yellow-green halos), and characteristic arrhythmias (bidirectional VT is nearly pathognomonic). DigiFab is the antidote for life-threatening toxicity."
  },
  {
    "id": 62,
    "categoryId": 6,
    "question": "Which opioid lowers the seizure threshold and causes neurotoxicity (tremors/seizures) in renal failure?",
    "options": [
      "A) Morphine",
      "B) Hydromorphone",
      "C) Meperidine (Demerol)",
      "D) Fentanyl"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Meperidine/Demerol).\n\nMEPERIDINE NEUROTOXICITY:\nMeperidine is unique among opioids in producing a neurotoxic metabolite, normeperidine, which is a CNS stimulant with a prolonged half-life of 15 to 30 hours. Normeperidine is renally excreted, and its accumulation in patients with renal impairment creates a dangerous scenario where therapeutic doses of meperidine can produce seizures, tremors, and delirium.\n\nPATHOPHYSIOLOGY:\nMeperidine undergoes hepatic N-demethylation to normeperidine, which lowers the seizure threshold through direct CNS excitatory effects. Unlike the parent compound, normeperidine has minimal analgesic activity but potent proconvulsant properties. In renal failure, the elimination half-life of normeperidine can extend to over 35 hours, leading to progressive accumulation even with standard dosing. Meperidine also inhibits serotonin reuptake, creating a risk of serotonin syndrome when combined with SSRIs, SNRIs, or MAOIs.\n\nCLINICAL MANIFESTATIONS:\nEarly signs of normeperidine toxicity include tremors, myoclonus, and irritability. As accumulation progresses, patients may develop generalized seizures, delirium, and hallucinations. Seizures can occur even at therapeutic doses in patients with renal impairment, elderly patients, or those receiving prolonged therapy exceeding 48 hours. seizures may persist even after meperidine discontinuation due to normeperidine's long half-life.\n\nSAFER ALTERNATIVES IN RENAL FAILURE:\nFentanyl is the preferred opioid in renal failure because it has no active metabolites and is metabolized hepatically. Hydromorphone is another reasonable option with minimal active metabolite accumulation. Morphine should be used cautiously because its active metabolite (morphine-6-glucuronide) accumulates in renal failure, causing prolonged sedation.\n\nKEY POINTS:\nMeperidine produces the neurotoxic metabolite normeperidine, which causes seizures and accumulates in renal failure. Fentanyl is the safest opioid in renal impairment due to the absence of active metabolites. Meperidine also carries serotonin syndrome risk and is now rarely indicated outside of treating rigors and shivering."
  },
  {
    "id": 63,
    "categoryId": 11,
    "question": "A 24-year-old female with bipolar disorder is trying to conceive. Which mood stabilizer causes Ebstein Anomaly (atrialization of the right ventricle)?",
    "options": [
      "A) Lithium",
      "B) Lamotrigine",
      "C) Valproic Acid",
      "D) Quetiapine"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Lithium).\n\nTERATOGENICITY:\nLithium use during the first trimester of pregnancy is linked to an increased risk of Ebstein anomaly, a congenital cardiac malformation in which the tricuspid valve is displaced apically into the right ventricle (atrialization of the right ventricle), causing tricuspid regurgitation, right atrial enlargement, and right-to-left shunting through a patent foramen ovale. While early registry data suggested a relative risk as high as 400-fold, subsequent studies have demonstrated that the absolute risk is lower than initially feared (approximately 1 in 1,000 lithium-exposed pregnancies versus 1 in 20,000 in the general population), though this still represents a clinically significant 20-fold increase.\n\nSAFER ALTERNATIVES:\nLamotrigine is generally considered the safest mood stabilizer during pregnancy, with no significant increase in major congenital malformations at standard doses. Valproic acid is the most teratogenic mood stabilizer and is absolutely contraindicated in pregnancy: it causes neural tube defects (spina bifida in 1 to 2% of exposed pregnancies), craniofacial anomalies, cardiac defects, and neurodevelopmental impairment (reduced IQ by 8 to 11 points). Carbamazepine also carries neural tube defect risk (approximately 0.5 to 1%) and is considered intermediate risk.\n\nCLINICAL MANAGEMENT:\nFor women of childbearing age with bipolar disorder, preconception counseling is essential. If lithium is continued during pregnancy (which may be appropriate for severe bipolar I disorder where relapse risk is high), a fetal echocardiogram should be performed at 16 to 20 weeks' gestation to screen for Ebstein anomaly and other cardiac defects. Lithium levels should be monitored more frequently during pregnancy because the 50% increase in GFR and blood volume during pregnancy reduces lithium levels, often requiring dose adjustments.\n\nKEY POINTS:\nLithium exposure in the first trimester increases the risk of Ebstein anomaly (apical displacement of the tricuspid valve) approximately 20-fold, though the absolute risk remains approximately 1 in 1,000. Lamotrigine is the safest mood stabilizer in pregnancy, while valproic acid is absolutely contraindicated (neural tube defects, neurodevelopmental harm). Fetal echocardiography at 16 to 20 weeks is recommended for lithium-exposed pregnancies."
  },
  {
    "id": 64,
    "categoryId": 8,
    "question": "Which antibiotic provides coverage against anaerobes (Bacteroides) 'below the diaphragm' (intra-abdominal)?",
    "options": [
      "A) Clindamycin",
      "B) Metronidazole (Flagyl)",
      "C) Cephalexin",
      "D) Vancomycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metronidazole).\n\nPATHOPHYSIOLOGY:\nAnaerobic bacteria are normal flora of the gastrointestinal tract, female genital tract, and oral cavity. When mucosal barriers are breached (e.g., perforated appendicitis, diverticular abscess, post-surgical contamination), these organisms cause serious infections. The dominant pathogenic anaerobe below the diaphragm is Bacteroides fragilis, which possesses a polysaccharide capsule that promotes abscess formation and resists phagocytosis. Metronidazole is a prodrug that is reduced intracellularly within anaerobic organisms, generating cytotoxic free radicals that damage bacterial DNA.\n\nCLINICAL REASONING:\nThe anatomic distinction between infections above and below the diaphragm guides antibiotic selection for anaerobic coverage. Below the diaphragm, Bacteroides fragilis predominates in intra-abdominal and pelvic infections, and metronidazole provides excellent coverage with superior abscess penetration. Above the diaphragm, oral anaerobes (Peptostreptococcus, Fusobacterium, Prevotella) predominate in lung abscesses and dental infections, and clindamycin is preferred. Metronidazole has additional clinical utility as a first-line agent for Clostridioides difficile infection (oral formulation), trichomoniasis, giardiasis, and as a component of H. pylori eradication regimens.\n\nTREATMENT CONSIDERATIONS:\nPatients on metronidazole must avoid alcohol during treatment and for at least 48 hours afterward due to a disulfiram-like reaction (nausea, vomiting, flushing, tachycardia). Antibiotics that lack anaerobic coverage and should not be relied upon for these infections include fluoroquinolones (except moxifloxacin), aminoglycosides, aztreonam, and most cephalosporins.\n\nKEY POINTS:\nMetronidazole is the drug of choice for Bacteroides fragilis and intra-abdominal anaerobic infections (below the diaphragm). Clindamycin is preferred for anaerobic infections above the diaphragm. Patients must avoid alcohol with metronidazole due to disulfiram-like reaction.\n---"
  },
  {
    "id": 65,
    "categoryId": 2,
    "question": "Which inhaler class is associated with urinary retention and exacerbation of Glaucoma?",
    "options": [
      "A) SABA (Albuterol)",
      "B) LAMA (Tiotropium/Spiriva)",
      "C) ICS (Fluticasone)",
      "D) LABA (Salmeterol)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (LAMA - Long-Acting Muscarinic Antagonist).\n\nPATHOPHYSIOLOGY:\nLong-acting muscarinic antagonists (tiotropium, umeclidinium, glycopyrrolate, aclidinium) are inhaled anticholinergic bronchodilators that block muscarinic M3 receptors on airway smooth muscle, reducing acetylcholine-mediated bronchoconstriction and mucus secretion. Because muscarinic receptors are distributed throughout the body, systemic anticholinergic effects can occur even with inhaled administration. Blockade of muscarinic receptors on the detrusor muscle of the bladder inhibits contraction, impairing bladder emptying and causing urinary retention, particularly in patients with pre-existing bladder outlet obstruction from benign prostatic hyperplasia. Blockade of muscarinic receptors on the iris sphincter causes mydriasis (pupil dilation), which in patients with anatomically narrow anterior chamber angles can precipitate acute angle-closure glaucoma by pushing the peripheral iris against the trabecular meshwork and obstructing aqueous humor drainage.\n\nCLINICAL APPLICATION:\nBefore prescribing LAMA inhalers, clinicians should screen for a history of narrow-angle glaucoma, benign prostatic hyperplasia, or bladder outlet obstruction. Patients should be counseled to avoid directing the inhaler mist toward the eyes, particularly with nebulized formulations, as direct ocular exposure concentrates the anticholinergic effect on the iris. Additional anticholinergic side effects include dry mouth (the most common), constipation from decreased gastrointestinal motility, and tachycardia from blockade of vagal tone at the sinoatrial node.\n\nCOMPARISON OF INHALER SIDE EFFECT PROFILES:\nSABA and LABA (albuterol, salmeterol, formoterol) are beta-2 agonists whose side effects include tremor, tachycardia, and hypokalemia from beta-2-mediated intracellular potassium shift. Inhaled corticosteroids (fluticasone, budesonide) cause oropharyngeal candidiasis (thrush) and dysphonia from local immunosuppression in the oropharynx, mitigated by mouth rinsing after use, and carry an increased pneumonia risk specifically in COPD patients.\n\nKEY POINTS:\nLAMA inhalers cause urinary retention and can precipitate acute angle-closure glaucoma through systemic anticholinergic effects on the bladder detrusor and iris sphincter muscles. Always screen for narrow-angle glaucoma and BPH before prescribing. The key side effect distinction is that LAMAs cause anticholinergic effects (dry, retention), beta-agonists cause sympathomimetic effects (tremor, tachycardia), and ICS cause local immunosuppression (thrush, dysphonia)."
  },
  {
    "id": 66,
    "categoryId": 1,
    "question": "A patient develops a dry, hacking cough after starting a BP med. Which class is responsible and what is the alternative?",
    "options": [
      "A) Beta Blocker; switch to CCB",
      "B) ACE Inhibitor; switch to ARB",
      "C) CCB; switch to Thiazide",
      "D) ARB; switch to ACE Inhibitor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitor; switch to ARB).\n\nPATHOPHYSIOLOGY:\nACE inhibitors (lisinopril, enalapril, ramipril) block angiotensin-converting enzyme, which normally converts angiotensin I to angiotensin II and simultaneously degrades bradykinin. When ACE is inhibited, bradykinin accumulates in the pulmonary and upper airway epithelium, stimulating C-fiber sensory neurons and triggering the cough reflex via substance P and prostaglandins. This ACE inhibitor-induced cough occurs in approximately 5 to 20% of patients (with higher incidence in women and individuals of East Asian or African descent), is characteristically dry, persistent, and nonproductive, and typically develops within 1 to 6 months of starting therapy. The cough is a class effect affecting all ACE inhibitors and does not improve with dose reduction.\n\nCLINICAL APPLICATION:\nAngiotensin II receptor blockers (ARBs such as losartan, valsartan, irbesartan) block the angiotensin II type 1 receptor directly without affecting bradykinin metabolism, which is why they do not cause the bradykinin-mediated cough. ARBs are therefore the appropriate substitution. while ACE inhibitor cough is common and benign, ACE inhibitor-induced angioedema (swelling of the lips, tongue, and upper airway) is a rare but potentially life-threatening complication also mediated by bradykinin accumulation. Patients with ACE inhibitor angioedema can generally be switched to ARBs with caution (approximately 1 to 2% cross-reactivity), though both ACE inhibitors and ARBs are contraindicated in hereditary angioedema.\n\nKEY POINTS:\nACE inhibitor cough results from bradykinin accumulation in the airways (ACE normally degrades bradykinin), affects 5 to 20% of patients, and is a class effect not improved by dose reduction. ARBs block angiotensin II receptors without affecting bradykinin and are the appropriate switch. ACE inhibitor angioedema is a separate, more dangerous bradykinin-mediated reaction requiring vigilance."
  },
  {
    "id": 67,
    "categoryId": 6,
    "question": "Triptans (Sumatriptan) are contraindicated in which patient population?",
    "options": [
      "A) Renal Failure",
      "B) History of Coronary Artery Disease / Stroke",
      "C) Liver Failure",
      "D) Depression"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (History of CAD/Stroke).\n\nTRIPTAN CONTRAINDICATIONS:\nTriptans are serotonin 5-HT1B/1D receptor agonists that abort migraine attacks by causing cranial vasoconstriction and inhibiting trigeminal nerve activation. However, the same vasoconstrictive mechanism affects coronary and cerebral arteries, which can precipitate myocardial ischemia or stroke in patients with pre-existing cardiovascular or cerebrovascular disease.\n\nPATHOPHYSIOLOGY:\nActivation of 5-HT1B receptors on vascular smooth muscle causes arterial constriction. In healthy coronary and cerebral vessels, this effect is clinically insignificant. In patients with atherosclerotic disease, vasoconstriction of already-narrowed vessels can reduce blood flow below critical thresholds, triggering angina, myocardial infarction, or cerebral ischemia. Rare cases of coronary vasospasm have been reported even in patients without known CAD.\n\nCONTRAINDICATED POPULATIONS:\nTriptans are contraindicated in patients with coronary artery disease (prior MI, angina, known CAD), cerebrovascular disease (prior stroke or TIA), peripheral vascular disease, uncontrolled hypertension, and hemiplegic or basilar migraine. Concurrent use with ergotamines or other triptans within 24 hours is also contraindicated, as is use within 2 weeks of MAO inhibitor therapy.\n\nACUTE MIGRAINE TREATMENT APPROACH:\nFor patients who cannot use triptans, alternatives include NSAIDs (ibuprofen, naproxen), antiemetics with analgesic properties (metoclopramide, prochlorperazine), gepants (CGRP receptor antagonists such as ubrogepant and rimegepant), and ditans (lasmiditan, a 5-HT1F agonist without vasoconstrictive effects). Opioids and barbiturates should be avoided due to medication overuse headache risk. Prophylaxis with beta-blockers, topiramate, valproate, amitriptyline, or CGRP monoclonal antibodies is indicated for patients with four or more headache days per month.\n\nKEY POINTS:\nTriptans cause vasoconstriction and are contraindicated in patients with cardiovascular or cerebrovascular disease. Gepants and ditans are newer migraine abortives without vasoconstrictive effects, making them safe alternatives. Migraine prophylaxis is indicated when patients have four or more headache days per month or significant disability."
  },
  {
    "id": 68,
    "categoryId": 10,
    "question": "A female patient is starting Isotretinoin (Accutane). What is the mandatory monitoring requirement (iPLEDGE)?",
    "options": [
      "A) Liver enzymes every week",
      "B) Two forms of birth control and monthly pregnancy tests",
      "C) Renal function monthly",
      "D) Eye exam monthly"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Two forms of birth control and monthly pregnancy tests).\n\nPATHOPHYSIOLOGY:\nIsotretinoin (13-cis-retinoic acid) targets all four acne pathogenesis pillars: reduces sebaceous gland size and sebum production by up to 90%, normalizes follicular keratinization, reduces C. acnes colonization, and exerts anti-inflammatory effects. It is the only acne medication producing long-term remission after a single course. However, isotretinoin is an FDA Category X teratogen causing retinoic acid embryopathy: craniofacial defects (microtia, anotia, micrognathia, cleft palate), cardiovascular malformations (conotruncal defects), CNS abnormalities (hydrocephalus, microcephaly), and thymic aplasia. Fetal loss rates reach ~40% with major malformation rates >25% among live births.\n\nTHE iPLEDGE PROGRAM:\niPLEDGE is an FDA-mandated REMS to prevent fetal exposure. Requirements for females of childbearing potential: two negative pregnancy tests before starting therapy (one at prescriber's office, one at CLIA-certified lab), with the second during the first 5 days of menstruation or within 11 days of last intercourse. Monthly pregnancy tests throughout treatment and one month after discontinuation. Two simultaneous contraception forms (or documented abstinence) from one month before through one month after treatment. Prescriptions are limited to 30-day supplies with a 7-day fill window after testing. All patients, prescribers, and pharmacies must register.\n\nMONITORING:\nIsotretinoin causes hypertriglyceridemia in up to 45% and transaminase elevations in 10-20%. Baseline and periodic (every 1-2 months) fasting lipids and LFTs are standard. Counsel patients about mucocutaneous dryness (cheilitis in ~100%), photosensitivity, myalgias, and avoiding waxing and elective procedures during and 6 months after treatment due to impaired wound healing.\n\nKEY POINTS:\nIsotretinoin is the most effective acne therapy and only one inducing long-term remission, but requires iPLEDGE REMS. Two contraception forms, monthly pregnancy tests, and 7-day prescription fill windows are mandatory. Fasting lipids and LFTs need baseline and periodic monitoring. Contraception must continue one month after discontinuation."
  },
  {
    "id": 69,
    "categoryId": 3,
    "question": "Long-term use of Proton Pump Inhibitors (Omeprazole) is associated with deficiencies in which nutrients?",
    "options": [
      "A) Vitamin C and Zinc",
      "B) Vitamin B12, Magnesium, and Calcium",
      "C) Vitamin A and E",
      "D) Potassium and Sodium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B12, Magnesium, and Calcium).\n\nPATHOPHYSIOLOGY:\nProton pump inhibitors suppress gastric acid secretion by irreversibly inhibiting the hydrogen-potassium ATPase pump in parietal cells, raising intragastric pH. Gastric acid is required for the cleavage of vitamin B12 from dietary proteins and for the ionization of insoluble calcium and magnesium salts into absorbable forms. Chronic acid suppression therefore impairs the absorption of all three nutrients through distinct but related mechanisms.\n\nCLINICAL MANIFESTATIONS:\nVitamin B12 deficiency (reported in 12-33% of chronic PPI users) can produce macrocytic anemia, peripheral neuropathy, cognitive impairment, and glossitis. Hypomagnesemia (typically after more than one year of use) may present with muscle cramps, cardiac arrhythmias, or seizures and is refractory to magnesium supplementation while the PPI is continued. Impaired calcium absorption increases fracture risk, particularly hip, wrist, and spine fractures in postmenopausal women and elderly patients, with studies showing a 25-35% increased risk after more than one year of use.\n\nMONITORING AND MANAGEMENT:\nThe FDA issued safety communications regarding hypomagnesemia (2011) and fracture risk with PPIs. Current recommendations include checking magnesium levels prior to initiation and periodically during long-term use, monitoring B12 in patients on PPIs for more than 2-3 years, ensuring adequate dietary calcium and vitamin D, and using the lowest effective PPI dose for the shortest necessary duration.\n\nKEY POINTS:\nChronic PPI use impairs absorption of vitamin B12, magnesium, and calcium by suppressing gastric acid needed for nutrient liberation and ionization. B12 deficiency causes neurologic and hematologic complications. Hypomagnesemia can be refractory to supplementation until the PPI is discontinued. Fracture risk increases 25-35% with prolonged use."
  },
  {
    "id": 70,
    "categoryId": 4,
    "question": "How should Levothyroxine be taken for maximal absorption?",
    "options": [
      "A) With breakfast",
      "B) On an empty stomach, 30-60 mins before food, separated from Calcium/Iron by 4 hours",
      "C) With dinner",
      "D) With milk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (On an empty stomach, 30-60 minutes before food, separated from Calcium/Iron by 4 hours).\n\nPATHOPHYSIOLOGY:\nLevothyroxine is a narrow therapeutic index medication with oral bioavailability of 40-80%. Absorption occurs in the jejunum and upper ileum and depends on acidic gastric pH for tablet dissolution and absence of chelating substances. Calcium, iron, and aluminum form insoluble complexes with levothyroxine that pass unabsorbed. Food (particularly fiber and soy) impairs absorption. Improper administration is one of the most common causes of persistently elevated TSH in adherent patients, leading to unnecessary dose escalation.\n\nCLINICAL REASONING:\nPer ATA guidelines, take levothyroxine on an empty stomach with water, 30-60 minutes before the first meal. Key interactions: calcium carbonate reduces absorption by up to 25% (JAMA Internal Medicine), iron supplements reduce it similarly, and PPIs impair absorption by raising gastric pH. Coffee reduces absorption ~30% when taken simultaneously. Aluminum antacids, sucralfate, bile acid sequestrants, and soy also impair absorption\u2014all should be separated by \u22654 hours. Bedtime dosing (\u22653-4 hours after last meal) is a validated alternative with equivalent or slightly superior TSH control.\n\nTREATMENT OPTIMIZATION:\nBefore increasing dose for persistently elevated TSH, assess administration technique: timing relative to meals, concurrent calcium or iron, coffee habits, and PPI use. Liquid or gel capsule formulations improve absorption in patients with GI conditions, as they are less pH-dependent. Monitor TSH 6-8 weeks after dose changes, targeting 0.5-4.0 mIU/L for non-pregnant adults, with individualized targets for elderly patients (4-6 mIU/L may be acceptable).\n\nKEY POINTS:\nLevothyroxine must be taken on an empty stomach 30-60 minutes before food, separated from calcium, iron, and antacids by \u22654 hours. Before escalating dose for elevated TSH, verify proper administration\u2014improper timing is among the most common causes of apparent treatment failure. Coffee, PPIs, fiber, and soy also reduce absorption."
  },
  {
    "id": 71,
    "categoryId": 5,
    "question": "Sildenafil (Viagra) is strictly contraindicated with which medication class?",
    "options": [
      "A) Alpha Blockers (Tamsulosin)",
      "B) Nitrates (Nitroglycerin/Isosorbide)",
      "C) Beta Blockers",
      "D) Statins"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrates).\n\nPHARMACOLOGY:\nSildenafil (Viagra) is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction and pulmonary arterial hypertension that is absolutely contraindicated with nitrate medications. The combination produces severe, refractory, and potentially fatal hypotension through synergistic vasodilation via the nitric oxide-cGMP pathway.\n\nMECHANISM OF INTERACTION:\nNitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate) are metabolized to nitric oxide (NO), which activates soluble guanylyl cyclase in vascular smooth muscle cells, increasing cyclic guanosine monophosphate (cGMP) production. cGMP activates protein kinase G, which reduces intracellular calcium and produces vascular smooth muscle relaxation (vasodilation). PDE5 is the enzyme that normally degrades cGMP, terminating the vasodilatory signal. Sildenafil blocks PDE5, preventing cGMP breakdown, which massively potentiates and prolongs the vasodilatory effect of nitrates. The result is a precipitous drop in blood pressure that may be refractory to vasopressors.\n\nTIME RESTRICTIONS:\nNitrates must not be administered within 24 hours of sildenafil or vardenafil use, or within 48 hours of tadalafil (Cialis) use (which has a longer 17.5-hour half-life). This restriction applies to all nitrate formulations including sublingual nitroglycerin, oral isosorbide, nitroglycerin patches, and recreational amyl nitrite (\"poppers\"). In the emergency department, if a patient presenting with chest pain has recently taken a PDE5 inhibitor, alternative anti-anginal agents (beta-blockers, calcium channel blockers, morphine) must be used instead of nitroglycerin.\n\nOTHER PDE5 INHIBITOR CONSIDERATIONS:\nPDE5 inhibitors can also cause hypotension when combined with alpha-blockers (use lowest doses with caution). They are contraindicated in patients taking riociguat (a soluble guanylyl cyclase stimulator).\n\nKEY POINTS:\nPDE5 inhibitors (sildenafil, tadalafil, vardenafil) are absolutely contraindicated with all nitrate formulations because PDE5 inhibition prevents cGMP degradation, synergistically potentiating nitrate-induced vasodilation to produce severe refractory hypotension. The restriction is 24 hours for sildenafil/vardenafil and 48 hours for tadalafil. In the ED, use beta-blockers or calcium channel blockers instead of nitroglycerin."
  },
  {
    "id": 72,
    "categoryId": 11,
    "question": "Which Benzodiazepine is preferred in patients with Liver Failure?",
    "options": [
      "A) Diazepam (Valium)",
      "B) Lorazepam (Ativan)",
      "C) Clonazepam (Klonopin)",
      "D) Alprazolam (Xanax)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lorazepam).\n\nPHARMACOLOGY:\nLorazepam (Ativan) is the preferred benzodiazepine in hepatic failure because it undergoes phase II conjugation (direct glucuronidation by UGT enzymes) without prior phase I oxidative metabolism by cytochrome P450 enzymes. This distinction is critical because phase I oxidation (the CYP-dependent reactions of hydroxylation, demethylation, and dealkylation) is significantly impaired in liver disease, while phase II glucuronidation is relatively preserved until very advanced cirrhosis.\n\nHEPATIC METABOLISM COMPARISON:\nMost benzodiazepines (diazepam, alprazolam, chlordiazepoxide, midazolam) require phase I CYP3A4 or CYP2C19 oxidation before glucuronidation, and their metabolism is markedly prolonged in liver failure, leading to drug accumulation and excessive sedation. Diazepam is particularly dangerous because it has active metabolites (desmethyldiazepam, with a half-life of 40 to 200 hours) that also require hepatic oxidation, creating extreme drug accumulation and prolonged sedation in cirrhotic patients. The mnemonic LOT (Lorazepam, Oxazepam, Temazepam) identifies the three benzodiazepines that undergo only phase II glucuronidation and are therefore safe in liver disease.\n\nCLINICAL SIGNIFICANCE:\nIn patients with cirrhosis, benzodiazepine accumulation can precipitate or worsen hepatic encephalopathy by enhancing GABAergic inhibition in an already sensitized central nervous system. Clinicians should use the lowest effective dose of lorazepam for the shortest duration, as even glucuronidation may be impaired in decompensated cirrhosis (Child-Pugh C). For alcohol withdrawal in cirrhotic patients, lorazepam is the preferred agent using symptom-triggered dosing guided by the CIWA-Ar protocol.\n\nKEY POINTS:\nLorazepam is preferred in liver failure because it undergoes only phase II glucuronidation (preserved in liver disease) without phase I CYP oxidation (impaired in liver disease). The LOT mnemonic (Lorazepam, Oxazepam, Temazepam) identifies the three safe benzodiazepines in hepatic impairment. Diazepam is particularly dangerous in cirrhosis due to active metabolites with half-lives up to 200 hours."
  },
  {
    "id": 73,
    "categoryId": 8,
    "question": "A patient on Isoniazid (INH) for latent TB develops numbness and tingling in the hands. What supplement prevents this?",
    "options": [
      "A) Vitamin B12",
      "B) Vitamin B6 (Pyridoxine)",
      "C) Folate",
      "D) Thiamine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B6 / pyridoxine).\n\nPATHOPHYSIOLOGY:\nIsoniazid (INH) causes peripheral neuropathy through functional pyridoxine (vitamin B6) depletion. INH and its metabolites form hydrazones with pyridoxal 5'-phosphate (PLP), the active coenzyme form of B6, and increase its renal excretion. PLP is essential for over 140 enzymatic reactions including neurotransmitter synthesis (GABA, serotonin, dopamine), amino acid metabolism, and sphingolipid production critical for myelin integrity. The resulting deficiency produces a dose-dependent, symmetric, length-dependent sensorimotor neuropathy beginning with paresthesias and numbness in the distal extremities.\n\nCLINICAL REASONING:\nThe classic presentation is numbness and tingling in the hands and feet developing weeks to months after INH initiation. Risk factors for INH-induced neuropathy include diabetes, HIV infection, alcoholism, malnutrition, chronic kidney disease, and pregnancy, all conditions associated with baseline pyridoxine depletion or increased metabolic demand. The CDC and ATS/IDSA guidelines recommend routine pyridoxine supplementation at 25-50 mg daily for all patients on INH, particularly those with risk factors. If neuropathy develops despite supplementation, the dose may be increased to 100 mg daily. Severe or refractory cases may require INH dose reduction or regimen modification in consultation with infectious disease specialists. The TB treatment regimen should not be discontinued solely for mild neuropathy if pyridoxine supplementation resolves symptoms.\n\nIt is important to distinguish INH neuropathy from other vitamin deficiency neuropathies. Vitamin B12 deficiency produces a similar presentation but involves posterior column dysfunction with proprioceptive loss and a positive Romberg sign. Thiamine deficiency causes beriberi neuropathy, typically in the context of alcoholism. Folate deficiency primarily causes megaloblastic anemia rather than neuropathy.\n\nKEY POINTS:\nINH depletes pyridoxal 5'-phosphate, causing peripheral neuropathy preventable with B6 supplementation at 25-50 mg daily per CDC and ATS/IDSA guidelines. High-risk groups include diabetics, HIV-positive patients, pregnant women, and those with alcoholism or renal disease. Always co-prescribe pyridoxine when initiating INH therapy for latent tuberculosis."
  },
  {
    "id": 74,
    "categoryId": 1,
    "question": "Entresto (Sacubitril/Valsartan) requires a washout period of 36 hours before starting if the patient was previously taking:",
    "options": [
      "A) Amlodipine",
      "B) Metoprolol",
      "C) Lisinopril (ACE Inhibitor)",
      "D) Furosemide"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Lisinopril, an ACE Inhibitor).\n\nPATHOPHYSIOLOGY:\nEntresto (sacubitril/valsartan) is a combination angiotensin receptor-neprilysin inhibitor (ARNI) that simultaneously blocks the angiotensin II receptor (via the valsartan component) and inhibits neprilysin (via the sacubitril component). Neprilysin is the enzyme that degrades natriuretic peptides (ANP, BNP, CNP), bradykinin, adrenomedullin, and substance P. By inhibiting neprilysin, sacubitril increases levels of these beneficial vasoactive peptides, promoting vasodilation, natriuresis, and favorable cardiac remodeling.\n\nSAFETY CONCERN:\nThe mandatory 36-hour washout period between discontinuing an ACE inhibitor and starting sacubitril/valsartan exists to prevent life-threatening angioedema. ACE inhibitors block bradykinin degradation via one pathway, and neprilysin is another major pathway for bradykinin clearance. If both pathways are simultaneously blocked (residual ACE inhibition plus neprilysin inhibition from sacubitril), bradykinin levels can rise dramatically, precipitating severe angioedema involving the lips, tongue, pharynx, and larynx with risk of fatal airway obstruction. This 36-hour window allows complete clearance of the ACE inhibitor before neprilysin inhibition begins.\n\nCLINICAL EVIDENCE:\nThe PARADIGM-HF trial demonstrated that sacubitril/valsartan reduced cardiovascular death and heart failure hospitalization by 20% compared to enalapril in patients with HFrEF (EF 40% or less), establishing it as a cornerstone of guideline-directed medical therapy. No washout is needed when switching from an ARB because ARBs do not affect bradykinin metabolism.\n\nKEY POINTS:\nSacubitril/valsartan requires a mandatory 36-hour washout from ACE inhibitors (but not ARBs) to prevent catastrophic angioedema from dual bradykinin pathway inhibition. The PARADIGM-HF trial demonstrated 20% reduction in cardiovascular death and HF hospitalization versus enalapril in HFrEF. No washout is required when switching from ARBs because they do not affect bradykinin."
  },
  {
    "id": 75,
    "categoryId": 6,
    "question": "Which antiepileptic drug causes gingival hyperplasia and hirsutism?",
    "options": [
      "A) Levetiracetam (Keppra)",
      "B) Phenytoin (Dilantin)",
      "C) Valproic Acid",
      "D) Lamotrigine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Phenytoin/Dilantin).\n\nPHENYTOIN SIDE EFFECTS:\nPhenytoin (Dilantin) is a first-generation antiepileptic drug known for several distinctive cosmetic and systemic adverse effects not commonly seen with newer agents. Gingival hyperplasia and hirsutism are the most recognizable phenytoin-specific side effects and often limit its long-term use, particularly in young patients and women.\n\nPATHOPHYSIOLOGY OF GINGIVAL HYPERPLASIA:\nGingival hyperplasia occurs in approximately 50% of patients on chronic phenytoin therapy. Phenytoin stimulates fibroblast proliferation and collagen synthesis in gingival tissue, causing progressive overgrowth. Meticulous oral hygiene and regular dental care can reduce severity but may not prevent it entirely. Severe cases may require gingivectomy or switching to an alternative antiepileptic drug. Hirsutism results from phenytoin's effects on androgen metabolism, causing excessive hair growth on the face and trunk.\n\nADDITIONAL PHENYTOIN TOXICITIES:\nChronic use can cause cerebellar atrophy (manifesting as ataxia, nystagmus, and dysarthria), peripheral neuropathy, osteomalacia (through induction of vitamin D metabolism), and megaloblastic anemia (due to impaired folate absorption). Phenytoin is a potent CYP450 inducer, leading to numerous drug interactions. Fetal hydantoin syndrome (craniofacial abnormalities, nail and digit hypoplasia, developmental delay) makes it particularly dangerous in pregnancy.\n\nPHARMACOKINETICS:\nPhenytoin exhibits zero-order (saturable) kinetics, meaning small dose adjustments can cause disproportionately large changes in serum levels. This necessitates careful therapeutic drug monitoring with a target range of 10 to 20 mcg/mL. The narrow therapeutic window and nonlinear kinetics make dosing challenging compared to newer agents.\n\nTREATMENT CONSIDERATIONS:\nGiven the cosmetic side effects and complex pharmacokinetics, newer antiepileptic drugs such as levetiracetam, lamotrigine, and lacosamide are often preferred, especially for young patients and women of childbearing age. Phenytoin remains useful in acute settings (fosphenytoin for status epilepticus) and in resource-limited environments.\n\nKEY POINTS:\nPhenytoin causes gingival hyperplasia (in approximately 50% of patients) and hirsutism through fibroblast stimulation and altered androgen metabolism. Zero-order kinetics require careful drug monitoring because small dose changes cause large serum level shifts. Newer antiepileptic drugs are generally preferred for chronic therapy due to better side effect profiles."
  },
  {
    "id": 76,
    "categoryId": 9,
    "question": "Clopidogrel (Plavix) is a prodrug requiring activation by CYP2C19. Which PPI inhibits this enzyme and reduces Clopidogrel efficacy?",
    "options": [
      "A) Pantoprazole",
      "B) Omeprazole",
      "C) Rabeprazole",
      "D) Famotidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Omeprazole).\n\nPHARMACOLOGY:\nClopidogrel (Plavix) is an inactive prodrug that requires hepatic biotransformation by CYP2C19 to generate its active thiol metabolite, which irreversibly binds the P2Y12 ADP receptor on platelets to inhibit platelet aggregation. Omeprazole (Prilosec) is a potent inhibitor of CYP2C19 and reduces the conversion of clopidogrel to its active metabolite by approximately 40 to 50%, significantly diminishing its antiplatelet effect.\n\nCLINICAL EVIDENCE:\nThe FDA issued a safety communication in 2009 advising against concomitant use of clopidogrel and omeprazole based on pharmacokinetic studies showing reduced platelet inhibition. The COGENT trial provided reassurance that the combination did not significantly increase cardiovascular events in the study population, but this trial was underpowered and terminated early. Given the available pharmacokinetic data, guidelines recommend avoiding the combination when alternatives exist.\n\nSAFE ALTERNATIVES:\nPantoprazole (Protonix) has the weakest CYP2C19 inhibitory effect among PPIs and is the preferred PPI when gastroprotection is needed in patients on clopidogrel. Lansoprazole and esomeprazole have intermediate CYP2C19 inhibition and are less preferred. H2-receptor antagonists (famotidine) are an alternative class with no CYP2C19 interaction, though they provide less acid suppression than PPIs.\n\nGENETIC CONSIDERATIONS:\nApproximately 2 to 15% of the population (higher in Asian and Pacific Islander populations) are CYP2C19 poor metabolizers who have genetically reduced clopidogrel activation regardless of PPI use. Pharmacogenomic testing for CYP2C19 variants can guide antiplatelet selection, with alternative agents (prasugrel, ticagrelor) recommended for poor metabolizers.\n\nKEY POINTS:\nOmeprazole inhibits CYP2C19, reducing clopidogrel activation by 40 to 50% and diminishing its antiplatelet effect. Pantoprazole is the preferred PPI with clopidogrel due to minimal CYP2C19 inhibition. CYP2C19 poor metabolizers (2 to 15% of the population) have genetically reduced clopidogrel activation and may need prasugrel or ticagrelor instead."
  },
  {
    "id": 77,
    "categoryId": 4,
    "question": "SGLT2 inhibitors (Empagliflozin) carry a risk of which genital infection?",
    "options": [
      "A) Bacterial Vaginosis",
      "B) Fournier's Gangrene",
      "C) Syphilis",
      "D) HPV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fournier's Gangrene).\n\nPATHOPHYSIOLOGY:\nSGLT2 inhibitors block glucose reabsorption in the proximal tubule, causing excretion of 40-80 g glucose daily. This persistent glycosuria creates a glucose-rich perineal environment promoting bacterial and fungal growth. Genital mycotic infections occur in 10-15% of patients (vulvovaginal candidiasis in women, candidal balanitis in men). UTIs increase modestly. Fournier's gangrene, necrotizing fasciitis of the perineal and genital regions, is a rare but devastating complication. The FDA issued a 2018 safety communication identifying 55 cases over 5 years\u2014significantly exceeding background rates with other diabetes agents. The mechanism involves glucose-laden urine promoting polymicrobial perineal infection that spreads through fascial planes, facilitated by diabetic immunocompromise and SGLT2-associated volume depletion.\n\nCLINICAL PRESENTATION:\nFournier's gangrene presents with rapidly progressive perineal pain, erythema, and swelling. The hallmark is pain out of proportion to examination. Within hours, infection spreads along fascial planes producing crepitus (gas-producing organisms), tissue necrosis, and systemic sepsis. The infection is polymicrobial: aerobes (E. coli, Klebsiella, Staphylococcus, Streptococcus) and anaerobes (Bacteroides, Clostridium). Mortality ranges from 20-40%. Patients on SGLT2 inhibitors with perineal symptoms require urgent evaluation.\n\nTREATMENT:\nImmediate surgical debridement of all necrotic tissue is the definitive intervention. Broad-spectrum IV antibiotics covering gram-positive, gram-negative, and anaerobic organisms are adjunctive. The SGLT2 inhibitor must be permanently discontinued. Multiple debridements are often necessary. For prevention, counsel patients on perineal hygiene and prompt attention to genital or perineal symptoms. Common mycotic infections can be managed with antifungals without drug discontinuation.\n\nKEY POINTS:\nSGLT2 inhibitors cause glycosuria increasing genital mycotic infection risk (10-15%) and rarely Fournier's gangrene (20-40% mortality). The FDA issued a 2018 warning identifying significantly increased rates. Perineal pain out of proportion to examination on an SGLT2 inhibitor warrants urgent surgical evaluation; the drug must be permanently discontinued."
  },
  {
    "id": 78,
    "categoryId": 13,
    "question": "Allopurinol can be started during an acute gout flare (per 2020 ACR guidelines) because:",
    "options": [
      "A) It causes renal failure",
      "B) It can precipitate/worsen the flare due to rapid uric acid shifts",
      "C) It is ineffective",
      "D) It causes bleeding"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It can precipitate or worsen the flare due to rapid uric acid shifts).\n\nMECHANISM OF FLARE EXACERBATION:\nInitiating allopurinol (a xanthine oxidase inhibitor) during an acute gout flare is contraindicated because any rapid change in serum uric acid levels, whether an increase or decrease, destabilizes existing monosodium urate crystal deposits in and around joints. When uric acid drops suddenly, crystals that were previously in equilibrium with surrounding tissue begin to partially dissolve or shed from tophi and cartilage surfaces. These newly mobilized microcrystals are recognized by resident macrophages, which activate the NLRP3 inflammasome and release interleukin-1 beta, amplifying the inflammatory cascade and prolonging or worsening the acute attack.\n\nACR GUIDELINES ON TIMING:\nThe 2020 American College of Rheumatology guidelines recommend initiating urate-lowering therapy (ULT) even during an acute flare, rather than waiting (a change from prior practice). However, if a patient is already taking ULT at the time of a flare, it should be continued at the current dose rather than discontinued, because stopping and restarting would cause additional uric acid fluctuations that further destabilize crystals. When ULT is eventually started, it should be initiated at a low dose (allopurinol 100 mg daily, or 50 mg in patients with chronic kidney disease stage 3 or higher) and titrated gradually every two to four weeks to minimize the risk of mobilization flares.\n\nFLARE PROPHYLAXIS DURING ULT INITIATION:\nBecause mobilization flares are expected during the first three to six months of ULT, concurrent anti-inflammatory prophylaxis is essential. Low-dose colchicine (0.6 mg once or twice daily) is the preferred prophylactic agent. Low-dose NSAIDs are an alternative when colchicine is contraindicated. Prophylaxis should continue for at least three to six months or until the serum urate target has been maintained and the patient has been flare-free.\n\nKEY POINTS:\nAllopurinol should not be started during an acute gout flare because rapid uric acid shifts mobilize crystals and worsen inflammation. Wait two to four weeks after flare resolution to initiate ULT. Start at low doses and titrate gradually to target uric acid below 6.0 mg/dL. Provide anti-inflammatory prophylaxis (low-dose colchicine) for the first three to six months of ULT."
  },
  {
    "id": 79,
    "categoryId": 2,
    "question": "Why is Monotherapy with a Long-Acting Beta Agonist (LABA) contraindicated in Asthma?",
    "options": [
      "A) It causes tachycardia",
      "B) Increased risk of asthma-related death",
      "C) It is ineffective",
      "D) It causes thrush"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased risk of asthma-related death).\n\nPATHOPHYSIOLOGY:\nLong-acting beta-agonists provide sustained bronchodilation by activating beta-2 adrenergic receptors on airway smooth muscle, causing relaxation for 12 or more hours. However, LABAs address only the symptom of bronchoconstriction without treating the underlying eosinophilic airway inflammation that drives asthma pathophysiology. When used as monotherapy, LABAs mask worsening airway inflammation by relieving symptoms, creating a dangerous discordance between the patient's perception of control and the actual severity of underlying disease.\n\nCLINICAL EVIDENCE:\nThe landmark Salmeterol Multicenter Asthma Research Trial (SMART), a large randomized controlled trial published in Chest and reported by the FDA, demonstrated a statistically significant increase in asthma-related deaths and life-threatening asthma exacerbations in patients using salmeterol monotherapy compared to placebo. The risk was particularly pronounced in African American patients. This finding led the FDA to issue a Black Box Warning on all LABA products when used without concomitant ICS, and eventually to mandate that all LABA products for asthma be available only in fixed-dose ICS-LABA combination inhalers (such as fluticasone-salmeterol and budesonide-formoterol).\n\nCLINICAL APPLICATION:\nThe fundamental principle is that in asthma, a LABA must always be combined with an inhaled corticosteroid. ICS-LABA combinations are a mainstay of Step 3 and above asthma therapy. In contrast, LABA monotherapy is acceptable in COPD because the underlying pathophysiology differs: COPD is driven by neutrophilic inflammation and structural changes rather than the eosinophilic, steroid-responsive inflammation of asthma, and LABA monotherapy has not been associated with increased mortality in COPD.\n\nKEY POINTS:\nLABA monotherapy in asthma is contraindicated because the SMART trial demonstrated increased asthma-related deaths from masking worsening inflammation while relieving symptoms. LABAs must always be combined with ICS in asthma, which is why they are available only in fixed-dose combination inhalers for asthma. LABA monotherapy is acceptable in COPD, where the inflammatory pathophysiology differs."
  },
  {
    "id": 80,
    "categoryId": 12,
    "question": "Doxycycline is generally avoided in children < 8 years old unless for life-threatening disease (RMSF) because:",
    "options": [
      "A) Cartilage damage",
      "B) Teeth staining and enamel hypoplasia",
      "C) Growth plate closure",
      "D) Seizures"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Teeth staining and enamel hypoplasia).\n\nPATHOPHYSIOLOGY:\nTetracycline-class antibiotics (including doxycycline, minocycline, and tetracycline) chelate calcium ions and are incorporated into calcifying tissues, including developing tooth enamel and dentin, where they form stable tetracycline-calcium orthophosphate complexes. When these complexes are exposed to ultraviolet light, they undergo photochemical oxidation, producing a characteristic yellow-brown discoloration that is permanent. The teeth most susceptible are those undergoing active mineralization, which occurs from the second trimester of pregnancy (for primary teeth) through approximately age 8 years (for permanent teeth, particularly the premolars and second molars that complete crown calcification last).\n\nCLINICAL APPLICATION:\nThe traditional teaching and classic board answer is that tetracyclines are contraindicated in children under 8 years and in pregnant or breastfeeding women. However, an important nuance is that the AAP have updated guidance recognizing that doxycycline specifically causes significantly less dental staining than older tetracyclines because it binds calcium less avidly. Short courses of doxycycline (21 days or fewer) in children of any age have not been shown to cause clinically significant tooth staining in multiple studies. This is clinically important because doxycycline is the treatment of choice for Rocky Mountain spotted fever, ehrlichiosis, and anaplasmosis, all of which can be rapidly fatal if treatment is delayed while awaiting confirmatory testing. The CDC explicitly states that doxycycline should never be withheld from a child with suspected tickborne rickettsial disease regardless of age.\n\nADDITIONAL TETRACYCLINE EFFECTS:\nBeyond dental staining, tetracyclines can cause enamel hypoplasia (defective enamel formation), and high-dose or prolonged tetracycline use can deposit in bone, temporarily slowing bone growth (though this is reversible upon discontinuation and distinct from fluoroquinolone-associated cartilage damage).\n\nKEY POINTS:\nTetracyclines are classically avoided in children under 8 due to permanent tooth discoloration from calcium chelation in developing enamel. However, doxycycline causes significantly less staining than older tetracyclines, and short courses should never be withheld for life-threatening tickborne diseases (RMSF, ehrlichiosis) regardless of age. This remains a high-yield board topic where the classic answer (avoid under 8) and the clinical update (doxycycline is safer) are both tested."
  },
  {
    "id": 81,
    "categoryId": 11,
    "question": "Bupropion (Wellbutrin) has a favorable side effect profile compared to SSRIs because it lacks:",
    "options": [
      "A) Weight gain and Sexual dysfunction",
      "B) Seizure risk",
      "C) Insomnia",
      "D) Dry mouth"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Weight gain and sexual dysfunction).\n\nPHARMACOLOGY:\nBupropion (Wellbutrin) is a norepinephrine-dopamine reuptake inhibitor (NDRI) with a distinct mechanism of action and side effect profile compared to SSRIs. Because bupropion does not affect serotonin reuptake, it avoids the two most common and treatment-limiting adverse effects of SSRIs: weight gain and sexual dysfunction.\n\nMECHANISM OF SSRI SIDE EFFECTS:\nSSRI-induced sexual dysfunction (decreased libido, anorgasmia, erectile dysfunction) occurs in 30 to 70% of patients and is mediated by serotonin's inhibitory effects on dopaminergic and noradrenergic pathways in the mesolimbic reward circuit and spinal cord ejaculatory centers. SSRI-induced weight gain (averaging 2 to 5 kg over 6 to 12 months, more pronounced with paroxetine and mirtazapine) results from serotonergic effects on hypothalamic appetite centers, antihistaminic properties (in some agents), and metabolic changes.\n\nBUPROPION ADVANTAGES AND RISKS:\nBupropion is weight-neutral or mildly weight-reducing (average 1 to 2 kg loss), making it advantageous for patients with obesity or metabolic syndrome. Its dopaminergic and noradrenergic activity avoids sexual dysfunction and may actually improve libido, which is why it is sometimes added to SSRIs specifically to counteract sexual side effects. However, bupropion carries a dose-dependent seizure risk (approximately 0.4% at 300 to 450 mg/day), is contraindicated in seizure disorders, bulimia, anorexia, and acute alcohol or benzodiazepine withdrawal. Common side effects include insomnia (due to noradrenergic activation), dry mouth, headache, and agitation.\n\nKEY POINTS:\nBupropion avoids SSRI-induced weight gain and sexual dysfunction because it acts on norepinephrine and dopamine rather than serotonin. SSRI sexual dysfunction affects 30 to 70% of patients via serotonergic inhibition of dopaminergic reward pathways. Bupropion's key risks are dose-dependent seizures and contraindication in seizure disorders, bulimia, anorexia, and withdrawal states."
  },
  {
    "id": 82,
    "categoryId": 1,
    "question": "Spironolactone causes Hyperkalemia. This risk is highest when combined with:",
    "options": [
      "A) Furosemide",
      "B) ACE Inhibitors / ARBs",
      "C) Amlodipine",
      "D) Atenolol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitors / ARBs).\n\nPATHOPHYSIOLOGY:\nSpironolactone is a mineralocorticoid receptor antagonist that blocks aldosterone in the distal nephron (principal cells of the collecting duct), reducing sodium reabsorption and critically reducing potassium secretion. Normally, aldosterone stimulates the epithelial sodium channel (ENaC) and the Na+/K+-ATPase, creating an electrochemical gradient that drives potassium secretion into the tubular lumen via ROMK channels. By blocking this aldosterone effect, spironolactone directly reduces potassium excretion.\n\nDRUG INTERACTION:\nACE inhibitors and ARBs independently raise serum potassium by reducing aldosterone production (ACE inhibitors decrease angiotensin II, the primary stimulus for aldosterone secretion; ARBs block angiotensin II's effect on the adrenal cortex). When spironolactone is combined with an ACE inhibitor or ARB, there is dual suppression of the aldosterone axis at two levels: reduced aldosterone synthesis plus receptor blockade of residual aldosterone, creating a potent setup for life-threatening hyperkalemia. The risk is further amplified in patients with renal insufficiency, diabetes (hyporeninemic hypoaldosteronism), advanced age, or concurrent use of potassium supplements or NSAIDs.\n\nCLINICAL SIGNIFICANCE:\nDespite the hyperkalemia risk, the combination of spironolactone with ACE inhibitors/ARBs is guideline-directed therapy in HFrEF. The RALES trial demonstrated that adding spironolactone to standard HFrEF therapy reduced mortality by 30%. However, the survival benefit requires careful monitoring of serum potassium and creatinine within 1 week of initiation and regularly thereafter.\n\nKEY POINTS:\nSpironolactone combined with ACE inhibitors or ARBs carries the highest hyperkalemia risk due to dual aldosterone axis suppression at two mechanistic levels. Despite this risk, the combination is guideline-directed in HFrEF (RALES trial: 30% mortality reduction). Serum potassium and renal function must be monitored closely, especially with concurrent CKD, diabetes, or NSAID use."
  },
  {
    "id": 83,
    "categoryId": 1,
    "question": "Which antihypertensive class is strictly contraindicated in pregnancy due to fetal renal dysgenesis and other developmental abnormalities?",
    "options": [
      "A) Labetalol",
      "B) ACE Inhibitors (Lisinopril) / ARBs",
      "C) Nifedipine",
      "D) Methyldopa"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (ACE Inhibitors / ARBs).\n\nPATHOPHYSIOLOGY:\nACE inhibitors and ARBs are absolutely contraindicated throughout all trimesters of pregnancy. The mechanism of fetal harm relates to the critical role of the fetal renin-angiotensin system in renal development. Angiotensin II is essential for maintaining fetal renal perfusion pressure, stimulating nephron differentiation, and promoting normal ureteral bud branching. Blocking this system produces fetal renal dysgenesis (malformed or absent kidneys), leading to oligohydramnios (decreased amniotic fluid from reduced fetal urine output), which in turn causes pulmonary hypoplasia and limb contractures.\n\nTRIMESTER-SPECIFIC EFFECTS:\nFirst-trimester exposure has been associated with increased risk of cardiovascular malformations and central nervous system anomalies in some studies. Second and third-trimester exposure produces the classic fetal toxicity syndrome: renal tubular dysgenesis, anuria, oligohydramnios, pulmonary hypoplasia, intrauterine growth restriction, and neonatal skull ossification defects (calvaria hypoplasia). Neonatal complications include hypotension, renal failure, and hyperkalemia.\n\nSAFE ALTERNATIVES:\nAntihypertensive medications considered safe in pregnancy include labetalol (the most commonly used first-line agent), nifedipine (a dihydropyridine CCB), and methyldopa (a centrally acting alpha-2 agonist with the longest safety track record in pregnancy). Women of childbearing potential taking ACE inhibitors or ARBs should be counseled about the teratogenic risk and advised to use reliable contraception or switch to a pregnancy-safe agent before conception.\n\nKEY POINTS:\nACE inhibitors and ARBs are absolutely contraindicated in pregnancy because angiotensin II blockade disrupts fetal renal development, causing renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and skull ossification defects. Safe alternatives are labetalol, nifedipine, and methyldopa. Women of childbearing potential on ACEi/ARBs must be counseled about teratogenicity."
  },
  {
    "id": 84,
    "categoryId": 7,
    "question": "Which class of diabetes medication causes hypoglycemia and is a major fall risk in the elderly?",
    "options": [
      "A) Metformin",
      "B) Sulfonylureas (Glipizide/Glyburide)",
      "C) GLP-1 Agonists",
      "D) SGLT2 Inhibitors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sulfonylureas).\n\nPATHOPHYSIOLOGY:\nSulfonylureas such as glipizide and glyburide are insulin secretagogues that bind to the sulfonylurea receptor (SUR1) on pancreatic beta cell membranes, closing ATP-sensitive potassium channels regardless of the ambient blood glucose level. This closure depolarizes the cell membrane, opens voltage-gated calcium channels, and triggers insulin exocytosis. Because this mechanism operates independently of glucose concentration, sulfonylureas stimulate insulin release even when blood glucose is already normal or low, creating a significant risk of hypoglycemia. This glucose-independent insulin secretion distinguishes sulfonylureas from newer incretin-based therapies such as GLP-1 receptor agonists and DPP-4 inhibitors, which enhance insulin secretion only with elevated glucose.\n\nCLINICAL SIGNIFICANCE IN ELDERLY PATIENTS:\nHypoglycemia from sulfonylureas is a leading cause of medication-related emergency department visits in older adults and a major contributor to falls, fractures, and fall-related mortality. Elderly patients are particularly vulnerable due to decreased renal clearance (prolonging drug half-life), irregular meal patterns, polypharmacy, and reduced counter-regulatory hormonal responses to hypoglycemia. Glyburide is especially dangerous in this population because it has active metabolites that accumulate in renal impairment and a prolonged duration of action exceeding 24 hours, increasing the risk of severe and recurrent hypoglycemia. When a sulfonylurea must be used, glipizide is preferred because it has no active metabolites and a shorter duration of action. The American Geriatrics Society Beers Criteria specifically recommend avoiding glyburide in older adults due to its heightened hypoglycemia risk.\n\nSAFER ALTERNATIVES:\nCurrent ADA Standards of Care and geriatric guidelines recommend prioritizing glucose-lowering agents with low hypoglycemia risk for older adults. Metformin remains first-line if renal function permits. GLP-1 receptor agonists and SGLT2 inhibitors offer cardiovascular and renal benefits without intrinsic hypoglycemia risk. DPP-4 inhibitors provide modest glucose lowering with an excellent safety profile and are well tolerated in the elderly. When selecting diabetes therapy for older adults, the risk of hypoglycemia-related falls and fractures must be weighed heavily alongside glycemic efficacy.\n\nKEY POINTS:\nSulfonylureas stimulate insulin release independently of blood glucose levels, creating significant hypoglycemia risk that is amplified in elderly patients with renal impairment and irregular eating patterns. Glyburide is particularly dangerous due to active metabolites and prolonged duration, and should be avoided in older adults. Medication-related hypoglycemia is a leading cause of falls in the elderly, making agent selection a critical safety consideration in geriatric diabetes management."
  },
  {
    "id": 85,
    "categoryId": 15,
    "question": "Symptoms: 'Mad as a hatter, Blind as a bat, Red as a beet, Hot as a hare, Dry as a bone'. Diagnosis?",
    "options": [
      "A) Cholinergic Toxicity",
      "B) Anticholinergic Toxicity",
      "C) Opioid Withdrawal",
      "D) Sympathomimetic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anticholinergic Toxicity).\n\nPATHOPHYSIOLOGY:\nAnticholinergic toxicity results from competitive antagonism of muscarinic acetylcholine receptors throughout the central and peripheral nervous system. Blockade of peripheral muscarinic receptors produces the classic constellation of signs captured by the mnemonic: \"Mad as a hatter\" (altered mental status, agitation, delirium, hallucinations from central muscarinic blockade), \"Blind as a bat\" (mydriasis and cycloplegia from blockade of the pupillary sphincter and ciliary muscle), \"Red as a beet\" (cutaneous vasodilation and flushing), \"Hot as a hare\" (hyperthermia from inability to dissipate heat via sweating), and \"Dry as a bone\" (anhidrosis, dry mucous membranes, and urinary retention from blockade of exocrine gland secretion and detrusor muscle function). Additional findings include tachycardia (from vagal blockade at the sinoatrial node), decreased bowel sounds or ileus, and in severe cases seizures.\n\nCOMMON CAUSES:\nThe most frequent cause of anticholinergic toxicity is diphenhydramine (Benadryl) overdose. Other common offenders include tricyclic antidepressants (amitriptyline, nortriptyline), first-generation antipsychotics, atropine, scopolamine, skeletal muscle relaxants (cyclobenzaprine), and the plant Datura stramonium (jimson weed). The elderly are particularly susceptible due to polypharmacy and the cumulative anticholinergic burden of multiple medications.\n\nTREATMENT:\nManagement is primarily supportive: external cooling for hyperthermia, intravenous fluids for dehydration, benzodiazepines for agitation and seizure control, and bladder catheterization for urinary retention. Physostigmine, a carbamate acetylcholinesterase inhibitor that crosses the blood-brain barrier, is the specific antidote reserved for severe anticholinergic toxicity with life-threatening features (refractory seizures, severe agitation with hyperthermia, hemodynamically significant tachydysrhythmias). Physostigmine is contraindicated when tricyclic antidepressant ingestion is suspected because it can precipitate asystole and intractable seizures with sodium channel blockade. The critical clinical distinction between anticholinergic and sympathomimetic toxicity is skin moisture: anticholinergic toxicity produces dry skin and mucous membranes, while sympathomimetic toxicity produces diaphoresis (wet skin), though both cause tachycardia, agitation, and mydriasis.\n\nKEY POINTS:\nThe anticholinergic toxidrome is identified by the classic mnemonic of mad, blind, red, hot, and dry, reflecting central delirium, mydriasis, flushing, hyperthermia, and anhidrosis from muscarinic receptor blockade. Dry skin distinguishes anticholinergic from sympathomimetic toxicity, which produces diaphoresis. Physostigmine is the specific antidote for severe cases but is contraindicated when tricyclic antidepressant ingestion is suspected."
  },
  {
    "id": 86,
    "categoryId": 4,
    "question": "According to the landmark Diabetes Prevention Program (DPP) study published in NEJM, which intervention was most effective at reducing the incidence of Type 2 Diabetes over 3 years?",
    "options": [
      "A) Metformin 850mg BID",
      "B) Intensive Lifestyle Intervention (7% weight loss + 150min/wk activity)",
      "C) Troglitazone",
      "D) Placebo"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Intensive Lifestyle Intervention).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes develops through progressive insulin resistance, compensatory hyperinsulinemia, beta-cell exhaustion, and overt hyperglycemia. Prediabetes (ADA: fasting glucose 100-125 mg/dL, 2-hour glucose 140-199 on OGTT, or A1c 5.7-6.4%) represents the window where sufficient beta-cell reserve remains for lifestyle modification to reverse the trajectory. Per CDC data, ~70% with prediabetes will develop T2DM without intervention. Visceral adiposity drives insulin resistance through chronic inflammation, free fatty acid release, and impaired insulin signaling. Even modest weight reduction significantly improves insulin sensitivity.\n\nCLINICAL EVIDENCE:\nThe Diabetes Prevention Program (NEJM 2002) enrolled 3,234 adults with prediabetes (mean BMI 34, 68% female) with deliberate oversampling of minority populations. Three arms: intensive lifestyle (targeting 7% weight loss via diet and \u2265150 min/week moderate activity), metformin 850 mg BID, or placebo. Over 2.8 years, lifestyle reduced T2DM incidence by 58% versus placebo; metformin reduced it by 31%. NNT over 3 years: 7 for lifestyle versus 14 for metformin. Lifestyle was effective across all subgroups; metformin benefited most those under 60 and BMI \u226535. The DPP Outcomes Study confirmed sustained 27% risk reduction at 15-year follow-up.\n\nCLINICAL APPLICATION:\nADA Standards of Care recommend DPP-modeled intensive lifestyle intervention as first-line for prediabetes. The CDC's National DPP provides recognized programs nationwide. Metformin may be adjunctive for patients under 60, BMI \u226535, women with prior gestational diabetes, or those progressing despite lifestyle changes alone. Metformin complements but does not substitute for lifestyle modification.\n\nKEY POINTS:\nThe DPP demonstrated intensive lifestyle intervention (7% weight loss, 150 min/week activity) reduces T2DM incidence by 58%, nearly double metformin's 31%. Lifestyle modification is first-line for prediabetes; metformin is adjunctive for patients under 60, BMI \u226535, or prior GDM. The 15-year follow-up confirmed durable benefit."
  },
  {
    "id": 87,
    "categoryId": 16,
    "question": "A 55-year-old male with high cardiovascular risk asks about diet. The PREDIMED trial (NEJM) showed that a Mediterranean Diet supplemented with ______ significantly reduced major cardiovascular events compared to a low-fat diet.",
    "options": [
      "A) Fish Oil supplements",
      "B) Extra Virgin Olive Oil (EVOO) or Mixed Nuts",
      "C) Red Wine",
      "D) Lean Poultry"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (EVOO or Nuts).\n\nEVIDENCE:\nThe PREDIMED trial (Prevención con Dieta Mediterránea), published in the New England Journal of Medicine, was a landmark randomized controlled trial of over 7,400 participants at high cardiovascular risk that demonstrated a Mediterranean diet supplemented with extra virgin olive oil (EVOO) or mixed nuts reduced major adverse cardiovascular events (myocardial infarction, stroke, and cardiovascular death) by approximately 30% compared to a low-fat control diet. The trial was stopped early by its data safety monitoring board because the benefit was so significant that it would have been unethical to continue withholding the intervention. The number needed to treat (NNT) was approximately 67 patients over 5 years to prevent one major cardiovascular event.\n\nMECHANISMS OF BENEFIT:\nEVOO is rich in oleic acid (a monounsaturated fatty acid) and polyphenols (oleocanthal, hydroxytyrosol) that reduce LDL oxidation, lower systemic inflammation (reducing hs-CRP and IL-6), improve endothelial function by increasing nitric oxide bioavailability, and have antiplatelet effects. Mixed nuts (walnuts, almonds, hazelnuts) provide alpha-linolenic acid (an omega-3 precursor), L-arginine (a nitric oxide substrate), fiber, phytosterols, and tocopherols that synergistically reduce cardiovascular risk. The Mediterranean dietary pattern as a whole emphasizes fruits, vegetables, legumes, whole grains, fish, and moderate red wine while limiting red meat, processed foods, and refined sugars.\n\nCLINICAL APPLICATION:\nThe 2019 ACC/AHA Primary Prevention Guidelines cite the Mediterranean diet as having the strongest evidence base for cardiovascular risk reduction among dietary patterns. Clinicians should counsel high-risk patients that supplementing their diet with approximately 4 tablespoons of EVOO daily or 30 grams of mixed nuts daily (the PREDIMED intervention doses) provides measurable cardiovascular protection.\n\nKEY POINTS:\nThe PREDIMED trial demonstrated a 30% reduction in major cardiovascular events with a Mediterranean diet supplemented with EVOO or mixed nuts versus a low-fat diet, with an NNT of 67 over 5 years. Benefits are mediated by polyphenol-driven anti-inflammatory, antioxidant, and endothelial-protective mechanisms. The Mediterranean diet has the strongest evidence base for cardiovascular dietary prevention."
  },
  {
    "id": 88,
    "categoryId": 4,
    "question": "Exercise lowers blood glucose acutely in Type 2 Diabetics via which non-insulin dependent mechanism?",
    "options": [
      "A) Increased pancreatic beta-cell secretion",
      "B) Translocation of GLUT4 transporters to the muscle cell surface",
      "C) Inhibition of hepatic gluconeogenesis",
      "D) Increased renal excretion of glucose"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Translocation of GLUT4 transporters to the muscle cell surface).\n\nPATHOPHYSIOLOGY:\nGlucose uptake into skeletal muscle requires GLUT4 translocation from intracellular vesicles to the cell surface. Normally, insulin drives this via the PI3K-Akt pathway, which is impaired in type 2 diabetes due to defective insulin receptor substrate signaling. However, muscle contraction activates an entirely independent, insulin-independent pathway for GLUT4 translocation mediated by AMP-activated protein kinase (AMPK). During exercise, ATP consumption increases AMP, activating AMPK, which triggers GLUT4 vesicle trafficking through TBC1D1 and AS160 phosphorylation \u2014 completely bypassing defective insulin signaling. This explains why exercise lowers blood glucose effectively even in severe insulin resistance, as the contraction-mediated pathway remains fully intact in type 2 diabetes (Diabetes Care).\n\nCLINICAL EVIDENCE:\nResearch in Diabetes Care and the Journal of Clinical Investigation shows a single bout of moderate-intensity exercise increases muscle glucose uptake 7 to 20-fold via AMPK-mediated GLUT4 translocation, with enhanced insulin sensitivity persisting 24 to 72 hours post-exercise due to ongoing GLUT4 expression and glycogen repletion demands. This provides the mechanistic rationale for the ADA recommendation of avoiding more than two consecutive sedentary days.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care recommend at least 150 minutes per week of moderate-intensity aerobic activity spread over at least 3 days per week, plus resistance training 2 to 3 days per week to increase muscle mass and expand the total GLUT4 reservoir. Combined aerobic and resistance exercise produces greater glycemic improvement than either alone. For patients on insulin or sulfonylureas, coordinate exercise timing and carbohydrate intake to minimize hypoglycemia risk from additive exercise-mediated and insulin-mediated glucose uptake.\n\nKEY POINTS:\nExercise lowers blood glucose through AMPK-mediated GLUT4 translocation, independent of insulin signaling and fully functional in insulin-resistant patients. The glucose-lowering effect persists 24 to 72 hours post-exercise. The ADA recommends 150 minutes per week of aerobic activity plus 2 to 3 resistance training sessions, with no more than 2 consecutive sedentary days."
  },
  {
    "id": 89,
    "categoryId": 16,
    "question": "A patient sleeps 5 hours a night. What is the expected metabolic consequence supported by experimental sleep restriction studies?",
    "options": [
      "A) Increased Leptin and Decreased Ghrelin",
      "B) Decreased Insulin Sensitivity and Increased Ghrelin",
      "C) Increased Thyroid Hormone production",
      "D) Decreased Cortisol levels"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Decreased Insulin Sensitivity and Increased Ghrelin).\n\nEVIDENCE:\nExperimental sleep restriction studies (limiting sleep to 4 to 5 hours per night for as few as 4 to 6 nights) consistently demonstrate two key metabolic derangements: decreased insulin sensitivity (by 20 to 30%) and increased ghrelin with decreased leptin, producing a hormonal milieu that promotes hunger and weight gain. The landmark study by Spiegel and colleagues showed that restricting healthy young men to 4 hours of sleep for 6 nights reduced glucose tolerance to a pre-diabetic range.\n\nHORMONAL DISRUPTION:\nGhrelin (the hunger hormone, produced by gastric fundus cells) increases with sleep deprivation, signaling the hypothalamus to stimulate appetite, particularly cravings for high-carbohydrate and calorie-dense foods. Simultaneously, leptin (the satiety hormone, produced by adipocytes) decreases, removing the brake on appetite. This dual hormonal shift creates a net positive energy balance that promotes weight gain independent of volitional food choices. Sleep deprivation also elevates evening cortisol levels, further impairing insulin sensitivity and promoting visceral fat deposition.\n\nINSULIN RESISTANCE MECHANISM:\nSleep restriction impairs insulin signaling through increased sympathetic nervous system activation, elevated inflammatory cytokines (TNF-alpha, IL-6), and disrupted growth hormone secretion patterns. Growth hormone, which is predominantly secreted during slow-wave (deep) sleep, helps glucose homeostasis and lipid metabolism, and its suppression contributes to the metabolic dysfunction observed with chronic sleep loss.\n\nKEY POINTS:\nSleep restriction to 4 to 5 hours per night decreases insulin sensitivity by 20 to 30% and shifts appetite hormones (increased ghrelin, decreased leptin) to promote hunger and weight gain. These metabolic effects occur within days and are independent of dietary changes. Adequate sleep (7 to 9 hours per night)."
  },
  {
    "id": 90,
    "categoryId": 4,
    "question": "According to NCEP ATP III criteria, a diagnosis of Metabolic Syndrome requires 3 of 5 components. Which of the following is NOT a criterion?",
    "options": [
      "A) Waist Circumference >40 in (men) or >35 in (women)",
      "B) Triglycerides > 150 mg/dL",
      "C) LDL Cholesterol > 130 mg/dL",
      "D) HDL Cholesterol < 40 mg/dL (men) or < 50 mg/dL (women)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (LDL Cholesterol is NOT a criterion for Metabolic Syndrome).\n\nPATHOPHYSIOLOGY:\nMetabolic syndrome is driven by insulin resistance and visceral adiposity. Visceral adipose tissue secretes proinflammatory cytokines (TNF-alpha, IL-6), reduces adiponectin, and delivers free fatty acids via portal circulation to the liver, driving hepatic insulin resistance, increased VLDL production, and enhanced gluconeogenesis. Peripheral insulin resistance promotes compensatory hyperinsulinemia, stimulating renal sodium retention and sympathetic activation contributing to hypertension. The resulting dyslipidemia features elevated triglycerides (from hepatic VLDL secretion) and reduced HDL (from accelerated catabolism), with formation of small, dense LDL particles despite potentially normal total LDL levels.\n\nDIAGNOSTIC CRITERIA:\nThe NCEP ATP III criteria, endorsed by AHA and NHLBI, require three or more of five components: waist circumference greater than 40 inches (men) or 35 inches (women), triglycerides 150 mg/dL or greater, HDL less than 40 mg/dL (men) or 50 mg/dL (women), blood pressure 130/85 mmHg or greater, and fasting glucose 100 mg/dL or greater (or drug treatment for any). LDL cholesterol is not included because it does not correlate with the insulin resistance phenotype. A patient may have elevated LDL from familial hypercholesterolemia without metabolic syndrome, while a patient with full metabolic syndrome may have normal LDL but harbor atherogenic small dense LDL particles. The IDF recommends ethnicity-specific waist circumference thresholds, with lower cut-points for Asian populations (90 cm men, 80 cm women).\n\nCLINICAL SIGNIFICANCE:\nMetabolic syndrome confers 5-fold increased risk of type 2 diabetes and 2-fold increased cardiovascular disease risk over 5 to 10 years. It is associated with MASLD, PCOS, obstructive sleep apnea, and hyperuricemia. Management centers on lifestyle modification targeting 7 to 10% weight loss and at least 150 minutes per week of moderate physical activity, with pharmacotherapy for individual components when insufficient.\n\nKEY POINTS:\nMetabolic syndrome requires three of five criteria: elevated waist circumference, elevated triglycerides, reduced HDL, elevated blood pressure, and elevated fasting glucose. LDL is excluded because the characteristic dyslipidemia of insulin resistance involves high triglycerides and low HDL rather than elevated LDL. Metabolic syndrome confers 5-fold increased diabetes risk and 2-fold increased cardiovascular risk."
  },
  {
    "id": 91,
    "categoryId": 11,
    "question": "For mild-to-moderate Generalized Anxiety Disorder (GAD), which non-pharmacologic intervention has efficacy comparable to pharmacotherapy in meta-analyses?",
    "options": [
      "A) Lavender aromatherapy",
      "B) Cognitive Behavioral Therapy (CBT)",
      "C) Psychoanalysis",
      "D) Vitamin D supplementation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cognitive Behavioral Therapy).\n\nEVIDENCE:\nCognitive Behavioral Therapy (CBT) has the strongest evidence base among psychotherapies for generalized anxiety disorder (GAD) and is recommended as a first-line treatment (equivalent to pharmacotherapy) by the APA, NICE, and multiple international guidelines. Multiple meta-analyses demonstrate that CBT produces clinically significant reductions in anxiety symptoms with effect sizes comparable to SSRIs and SNRIs, with the added advantage of more durable effects after treatment discontinuation.\n\nMECHANISM:\nCBT for GAD targets the cognitive distortions and maladaptive behavioral patterns that perpetuate chronic worry. The cognitive component teaches patients to identify, challenge, and restructure automatic negative thoughts and catastrophic predictions (such as probability overestimation and catastrophizing) through techniques including cognitive restructuring, Socratic questioning, and thought records. The behavioral component employs graded exposure to feared situations, behavioral activation, relaxation training (progressive muscle relaxation, diaphragmatic breathing), and worry scheduling (confining worry to a designated time period) to reduce avoidance behaviors that maintain anxiety.\n\nCLINICAL APPLICATION:\nA typical CBT course for GAD consists of 8 to 16 weekly sessions. For mild to moderate GAD, CBT monotherapy is appropriate and avoids medication side effects. For moderate to severe GAD, combination therapy (CBT plus an SSRI or SNRI) produces superior outcomes to either alone. SSRIs (sertraline, escitalopram) and SNRIs (venlafaxine, duloxetine) are first-line pharmacologic options, while benzodiazepines should be reserved for short-term use due to dependence risk.\n\nKEY POINTS:\nCBT is first-line treatment for mild to moderate GAD with efficacy comparable to pharmacotherapy and more durable effects after treatment ends. It targets cognitive distortions (catastrophizing, probability overestimation) and maladaptive avoidance through cognitive restructuring and graded exposure. For moderate to severe GAD, combining CBT with an SSRI or SNRI produces the best outcomes."
  },
  {
    "id": 92,
    "categoryId": 4,
    "question": "The first-line treatment for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD/NAFLD) is?",
    "options": [
      "A) Vitamin E",
      "B) Pioglitazone",
      "C) Weight loss of 7-10%",
      "D) Metformin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Weight loss of 7-10%).\n\nPATHOPHYSIOLOGY:\nMASLD (formerly NAFLD) spans simple steatosis through MASH (formerly NASH) with inflammation and ballooning, to fibrosis and cirrhosis. Insulin resistance drives the disease: impaired adipose lipolysis suppression delivers excess free fatty acids to the liver, while hyperinsulinemia upregulates hepatic de novo lipogenesis via SREBP-1c. Lipid overload generates reactive oxygen species and ER stress, activating inflammatory pathways (NF-kB, JNK) and stellate cell fibrogenesis. MASLD affects approximately 30% of adults globally (Journal of Hepatology) and is the fastest-growing indication for liver transplantation in the US.\n\nCLINICAL REASONING:\nWeight loss addresses root pathophysiology by reducing visceral adiposity, improving hepatic insulin sensitivity, and decreasing de novo lipogenesis. A dose-response relationship exists: 5% or greater weight loss improves steatosis, 7 to 10% resolves steatohepatitis in most patients, and exceeding 10% can induce fibrosis regression (Vilar-Gomez et al., Gastroenterology 2015). The AASLD 2023 Practice Guidance recommends 7 to 10% weight loss through lifestyle modification as first-line treatment.\n\nTREATMENT:\nWeight loss is achieved via caloric restriction (500 to 1000 kcal/day deficit) and 150 to 200 minutes per week of moderate aerobic exercise. The Mediterranean diet has the strongest evidence, reducing steatosis partly independent of weight loss. Reducing refined carbohydrates and sugar-sweetened beverages is important given fructose's role in hepatic lipogenesis. For biopsy-confirmed MASH with fibrosis unresponsive to lifestyle changes, resmetirom (Rezdiffra) is the first FDA-approved MASH medication for moderate-to-advanced fibrosis (March 2024). GLP-1 receptor agonists, particularly semaglutide, show significant MASH resolution (NEJM 2021). Pioglitazone improves histology regardless of diabetes status but causes weight gain and fluid retention. Vitamin E 800 IU daily benefits non-diabetic MASH patients (PIVENS trial, NEJM 2010) but is not recommended for diabetic patients.\n\nKEY POINTS:\nWeight loss of 7 to 10% is first-line for MASLD/MASH, with dose-response histologic improvement including fibrosis regression above 10%. Resmetirom is the first FDA-approved MASH-specific medication. GLP-1 agonists show significant promise. Vitamin E is effective only in non-diabetic biopsy-confirmed MASH."
  },
        {
      "id": 93,
      "categoryId": 16,
      "question": "In most adults, the most evidence-supported way time-restricted eating (TRE) improves cardiometabolic markers is by:",
      "options": [
        "A) Activating liver \u201cdetox\u201d pathways that lower LDL independent of diet quality",
        "B) Helping reduce total calorie intake, promoting weight loss and downstream improvements in insulin sensitivity and metabolic risk factors",
        "C) Permanently increasing basal metabolic rate even when calories are unchanged",
        "D) Producing large improvements in HbA1c and lipids even when weight and calories are unchanged, in most people"
      ],
      "correctAnswer": 1,
      "explanation": "CORRECT: B (Reduced energy intake leading to weight loss).\n\nPATHOPHYSIOLOGY:\nMost cardiometabolic improvement from dietary interventions is mediated by changes in total energy intake and body weight. Weight loss reduces visceral adiposity, improves hepatic and peripheral insulin sensitivity, lowers blood pressure, and often improves triglycerides.\n\nCLINICAL REASONING:\nTime-restricted eating (TRE), a form of intermittent fasting, often works in practice because a shorter eating window can reduce late-evening eating and snacking, making it easier to consume fewer calories. Major clinical summaries (e.g., ) emphasize that intermittent fasting can aid weight loss and related metabolic improvements, but that benefits vary and are not unique if calories and weight change are the same.\n\nEVIDENCE:\nRandomized trials comparing TRE with conventional daily calorie restriction commonly show similar outcomes when weight loss is similar, suggesting the primary driver for most patients is reduced caloric intake/weight loss rather than a large fasting-specific effect independent of energy balance.\n\nCLINICAL APPLICATION:\nTRE can be reasonable if it is sustainable and fits the patient\u2019s preferences. Use caution in patients at risk of hypoglycemia (e.g., insulin or sulfonylureas) and avoid in pregnancy, underweight patients, or those with an eating disorder history. Individualize to the patient\u2019s comorbidities, medications, and goals.\n\nKEY POINTS:\nFor most adults, TRE improves metabolic health primarily by helping reduce total calorie intake and facilitating weight loss, with downstream improvements in insulin sensitivity and cardiometabolic risk factors.\n---"
    },
  {
    "id": 94,
    "categoryId": 11,
    "question": "The 'SMILE' trial (and others) demonstrated that aerobic exercise in Major Depressive Disorder (MDD) is:",
    "options": [
      "A) Ineffective compared to Zoloft",
      "B) Effective only as an adjunct",
      "C) As effective as Sertraline after 4 months",
      "D) Dangerous due to fatigue"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (As effective as Sertraline after 4 months).\n\nEVIDENCE:\nThe SMILE trial (Standard Medical Intervention and Long-term Exercise) randomized adults with major depressive disorder (MDD) to supervised aerobic exercise, sertraline (an SSRI), or combined exercise plus sertraline. At 4 months, all three groups achieved equivalent reductions in depression severity, demonstrating that structured aerobic exercise was as effective as pharmacotherapy for MDD. At 10-month follow-up, the exercise group had significantly lower relapse rates than the sertraline-only group, suggesting more durable antidepressant effects.\n\nNEUROBIOLOGICAL MECHANISMS:\nExercise produces antidepressant effects through multiple converging mechanisms. Aerobic exercise potently increases brain-derived neurotrophic factor (BDNF), which promotes hippocampal neurogenesis and synaptic plasticity, directly countering the hippocampal volume loss observed in depression. Exercise increases serotonin, norepinephrine, and dopamine neurotransmission (the same monoamine targets of antidepressant medications). It reduces hypothalamic-pituitary-adrenal (HPA) axis hyperactivity and cortisol levels, addressing the stress-hormone dysregulation central to depression. Exercise also reduces systemic inflammation (IL-6, TNF-alpha, CRP), which is increasingly recognized as a pathogenic factor in depression.\n\nCLINICAL APPLICATION:\nThe 2024 ACP guidelines and multiple international guidelines recommend exercise as both a standalone and adjunctive treatment for MDD. The effective dose in trials is typically 150 minutes per week of moderate-intensity aerobic activity (brisk walking, cycling, swimming). Exercise prescriptions should be specific (type, intensity, frequency, duration) to maximize adherence and should be incorporated into collaborative treatment planning.\n\nKEY POINTS:\nThe SMILE trial demonstrated that structured aerobic exercise is as effective as sertraline for MDD at 4 months, with lower relapse rates at 10-month follow-up. Mechanisms include increased BDNF and hippocampal neurogenesis, enhanced monoamine neurotransmission, reduced HPA axis hyperactivity, and decreased systemic inflammation. Exercise at 150 minutes per week of moderate intensity is an evidence-based treatment for depression."
  },
  {
    "id": 95,
    "categoryId": 16,
    "question": "Which dietary fat is most strongly associated with improved insulin sensitivity and reduced inflammation?",
    "options": [
      "A) Saturated Fat (Palmitic acid)",
      "B) Trans Fat",
      "C) Omega-3 Polyunsaturated Fats (EPA/DHA)",
      "D) Omega-6 Polyunsaturated Fats"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Omega-3 Polyunsaturated Fats, EPA/DHA).\n\nPATHOPHYSIOLOGY:\nOmega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are the dietary fats most strongly associated with improved insulin sensitivity and reduced systemic inflammation. EPA and DHA are found predominantly in fatty fish (salmon, mackerel, sardines, herring) and in smaller amounts in walnuts and flaxseed (as alpha-linolenic acid, which is inefficiently converted to EPA/DHA).\n\nANTI-INFLAMMATORY MECHANISMS:\nEPA and DHA serve as precursors to specialized pro-resolving mediators (SPMs) including resolvins, protectins, and maresins, which are bioactive lipids that actively resolve inflammation rather than merely suppressing it. Unlike NSAIDs that block prostaglandin synthesis, SPMs promote macrophage clearance of cellular debris, reduce neutrophil infiltration, and restore tissue homeostasis. EPA and DHA also competitively inhibit arachidonic acid metabolism, reducing production of pro-inflammatory eicosanoids (prostaglandin E2, thromboxane A2, leukotriene B4) and shifting the eicosanoid profile toward anti-inflammatory mediators.\n\nINSULIN SENSITIVITY:\nOmega-3 fatty acids improve insulin sensitivity by incorporating into cell membrane phospholipids, increasing membrane fluidity, and enhancing insulin receptor signaling. They also reduce hepatic lipogenesis, lower triglycerides (by 20 to 30% at pharmacologic doses), and decrease visceral adipose tissue inflammation. In contrast, saturated fats promote insulin resistance through ceramide accumulation and toll-like receptor 4 (TLR4) activation, while trans fats impair membrane fluidity and worsen inflammatory signaling.\n\nKEY POINTS:\nOmega-3 fatty acids (EPA/DHA) improve insulin sensitivity and reduce inflammation by generating specialized pro-resolving mediators (resolvins, protectins) that actively resolve inflammation. They competitively displace arachidonic acid, shifting eicosanoid production away from pro-inflammatory prostaglandins. Fatty fish is the best dietary source, as conversion from plant-based alpha-linolenic acid is inefficient."
  },
  {
    "id": 96,
    "categoryId": 4,
    "question": "Why is Waist Circumference a better predictor of metabolic risk than BMI?",
    "options": [
      "A) It is easier to measure",
      "B) It serves as a proxy for Visceral Adipose Tissue (VAT)",
      "C) It corrects for height",
      "D) It is not better than BMI"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It serves as a proxy for Visceral Adipose Tissue).\n\nPATHOPHYSIOLOGY:\nAdipose tissue distribution, not total fat mass, determines cardiometabolic risk. Visceral adipose tissue (VAT) differs fundamentally from subcutaneous fat: visceral adipocytes are more metabolically active, more lipolysis-sensitive, and more insulin-resistant. They release free fatty acids directly into portal circulation, driving hepatic insulin resistance, increased VLDL production, steatosis, and gluconeogenesis. Visceral fat secretes elevated IL-6, TNF-alpha, PAI-1, and angiotensinogen while reducing adiponectin, creating a proinflammatory, insulin-resistant milieu linking central obesity to type 2 diabetes, cardiovascular disease, metabolic syndrome, and MASLD (Framingham Heart Study).\n\nCLINICAL REASONING:\nBMI cannot distinguish lean from fat mass or visceral from subcutaneous distribution. Individuals with normal BMI but elevated visceral adiposity \u2014 metabolically obese normal weight (MONW) \u2014 carry substantially increased cardiometabolic risk missed by BMI screening alone. Studies in JAMA and Annals of Internal Medicine demonstrate waist circumference predicts cardiovascular events, type 2 diabetes, and mortality independently of and more accurately than BMI, particularly at BMI 25 to 35 where metabolic heterogeneity is greatest. Waist circumference is measured at the iliac crest at end-expiration and serves as a validated proxy for VAT volume as quantified by CT or MRI.\n\nRISK THRESHOLDS:\nNCEP ATP III/NHLBI thresholds: greater than 40 inches (102 cm) in men, greater than 35 inches (88 cm) in women for European-descent populations. The IDF recognizes ethnicity-specific thresholds with lower cut-points for South Asian, Chinese, and Japanese populations (90 cm men, 80 cm women) reflecting higher visceral fat at lower waist circumferences. The waist-to-height ratio target of less than 0.5 has strong predictive accuracy across diverse populations.\n\nKEY POINTS:\nWaist circumference is superior to BMI for predicting cardiometabolic risk because it serves as a proxy for visceral adipose tissue, which drives insulin resistance and inflammation through portal free fatty acid delivery and proinflammatory cytokines. Thresholds are greater than 40 inches (men) and 35 inches (women), with lower cut-points for Asian populations. Normal-BMI individuals with elevated waist circumference carry significant risk that BMI alone would miss."
  },
  {
    "id": 97,
    "categoryId": 16,
    "question": "Resistance training is essential in aging populations primarily to prevent:",
    "options": [
      "A) Cellulite",
      "B) Sarcopenia",
      "C) Hypotension",
      "D) Varicose veins"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sarcopenia).\n\nPATHOPHYSIOLOGY:\nSarcopenia is the progressive, age-related loss of skeletal muscle mass, strength, and function that begins around age 30 and accelerates significantly after age 60, with muscle mass declining approximately 3 to 8% per decade. The pathophysiology involves multiple converging mechanisms: declining anabolic hormones (testosterone, growth hormone, IGF-1), increased inflammatory cytokines (TNF-alpha, IL-6) that promote muscle catabolism, mitochondrial dysfunction in myocytes, motor neuron loss with denervation of muscle fibers, and reduced satellite cell (muscle stem cell) regenerative capacity.\n\nCLINICAL SIGNIFICANCE:\nSarcopenia is a major driver of frailty, falls, fractures, functional dependence, and mortality in older adults. Loss of muscle mass reduces basal metabolic rate (muscle is the body's largest metabolic organ), contributing to age-related weight gain and insulin resistance. Sarcopenia also impairs glucose disposal since skeletal muscle is responsible for approximately 80% of insulin-stimulated glucose uptake, creating a vicious cycle of metabolic deterioration.\n\nRESISTANCE TRAINING EVIDENCE:\nResistance (strength) training is the most effective intervention for preventing and reversing sarcopenia. Progressive resistance exercise stimulates muscle protein synthesis through the mTOR (mechanistic target of rapamycin) pathway, increases satellite cell activation, improves neuromuscular recruitment, and enhances mitochondrial biogenesis. The CDC and ACSM recommend adults perform resistance training targeting all major muscle groups at least 2 days per week, with evidence showing benefits even in adults over age 90. Adequate protein intake (1.0 to 1.2 g/kg/day for older adults, higher than the standard RDA of 0.8 g/kg/day) supports the anabolic response to resistance exercise.\n\nKEY POINTS:\nSarcopenia (age-related muscle loss of 3 to 8% per decade) is a major driver of frailty, falls, metabolic dysfunction, and mortality in older adults. Resistance training is the most effective intervention, stimulating muscle protein synthesis via the mTOR pathway and providing benefits even in the very elderly. Older adults should perform resistance training at least twice weekly with adequate protein intake of 1.0 to 1.2 g/kg/day."
  },
  {
    "id": 98,
    "categoryId": 11,
    "question": "Which of the following is a core component of the 'Maslach Burnout Inventory'?",
    "options": [
      "A) Depression",
      "B) Depersonalization / Cynicism",
      "C) Insomnia",
      "D) Anxiety"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Depersonalization/Cynicism).\n\nDEFINITION:\nThe Maslach Burnout Inventory (MBI), developed by Christina Maslach and Susan Jackson, is the most widely used and validated research instrument for measuring occupational burnout. The MBI defines burnout as a three-dimensional syndrome consisting of emotional exhaustion (feeling emotionally drained and depleted by work), depersonalization/cynicism (a detached, negative, or cynical attitude toward patients or clients), and reduced personal accomplishment (feeling ineffective and questioning the value of one's work).\n\nCLINICAL SIGNIFICANCE:\nDepersonalization, characterized by treating patients as objects rather than individuals and developing a callous or dismissive attitude, is considered the interpersonal dimension of burnout and is particularly concerning in healthcare because it directly impairs the therapeutic relationship and patient care quality. Studies demonstrate that physician burnout (affecting approximately 40 to 50% of US physicians) is linked to increased medical errors, reduced patient satisfaction, higher malpractice claims, and increased physician substance abuse and suicidality.\n\nDISTINCTION FROM DEPRESSION:\nBurnout is occupationally specific (symptoms are tied to the work context and improve with vacation or job change), whereas major depressive disorder is pervasive across all life domains. However, the two conditions frequently co-occur, and prolonged burnout is a risk factor for developing clinical depression. The WHO International Classification of Diseases (ICD-11) classifies burnout as an occupational phenomenon rather than a medical condition.\n\nKEY POINTS:\nThe Maslach Burnout Inventory measures three dimensions: emotional exhaustion, depersonalization/cynicism, and reduced personal accomplishment. Depersonalization (treating patients as objects) is the interpersonal component that directly impairs patient care. Burnout affects approximately 40 to 50% of US physicians and is linked to medical errors, malpractice, and physician suicidality."
  },
  {
    "id": 99,
    "categoryId": 16,
    "question": "What is the recommended daily intake of fiber, and what is the average American intake?",
    "options": [
      "A) Rec: 10g; Avg: 10g",
      "B) Rec: 25-30g; Avg: 15g",
      "C) Rec: 50g; Avg: 30g",
      "D) Rec: 15g; Avg: 25g"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Recommended 25 to 30g; Average American intake approximately 15g).\n\nEVIDENCE:\nThe Academy of Nutrition and Dietetics and the USDA Dietary Guidelines recommend 25 to 30 grams of dietary fiber per day (25g for women, 38g for men), yet the average American consumes only approximately 15 grams daily, a deficit termed the fiber gap. Only about 5% of Americans meet the recommended fiber intake, making fiber one of the most significant nutrient shortfalls in the Western diet.\n\nPATHOPHYSIOLOGY OF FIBER BENEFITS:\nDietary fiber provides health benefits through multiple mechanisms. Soluble fiber (found in oats, beans, barley, psyllium) forms a viscous gel in the intestinal lumen that slows glucose absorption (improving glycemic control), binds bile acids (lowering LDL cholesterol by forcing hepatic bile acid resynthesis from cholesterol), and increases satiety. Insoluble fiber (found in whole wheat, vegetables, nuts) adds bulk to stool, accelerates colonic transit, and reduces constipation. gut bacteria ferment fiber into short-chain fatty acids (SCFAs), predominantly butyrate, propionate, and acetate, which serve as the primary energy source for colonocytes, strengthen the intestinal epithelial barrier, reduce systemic inflammation, and may protect against colorectal cancer.\n\nCLINICAL IMPACT:\nMeta-analyses demonstrate that each 10-gram increase in daily fiber intake is linked to approximately 10% reduction in colorectal cancer risk and 14% reduction in coronary events. High-fiber diets also reduce the risk of type 2 diabetes, obesity, and diverticular disease.\n\nKEY POINTS:\nThe recommended daily fiber intake is 25 to 30 grams, but the average American consumes only about 15 grams (only 5% meet guidelines). Fiber benefits include LDL reduction via bile acid binding, improved glycemic control, and production of short-chain fatty acids (especially butyrate) that nourish colonocytes and reduce systemic inflammation. Each 10g/day increase in fiber reduces colorectal cancer risk by approximately 10%."
  },
  {
    "id": 100,
    "categoryId": 1,
    "question": "A 55-year-old Black male with no history of DM or CKD presents for BP management. BP is 152/92. Which initial monotherapy provides the best stroke reduction benefit for this specific demographic?",
    "options": [
      "A) Lisinopril (ACEi)",
      "B) Losartan (ARB)",
      "C) Amlodipine (CCB)",
      "D) Metoprolol Succinate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Amlodipine, a CCB).\n\nCLINICAL REASONING:\nThe 2017 ACC/AHA Hypertension Guidelines and multiple landmark trials (ALLHAT being the most influential) demonstrate that in Black patients without diabetes or chronic kidney disease, thiazide-type diuretics and calcium channel blockers provide superior blood pressure reduction and greater stroke risk reduction compared to ACE inhibitors. The ALLHAT trial (over 33,000 patients) found that Black patients randomized to the ACE inhibitor lisinopril had a 40% higher rate of stroke compared to those randomized to the CCB amlodipine or the thiazide chlorthalidone. This difference is attributed to lower circulating renin levels in Black patients, which reduces the efficacy of RAAS-targeting agents (ACE inhibitors and ARBs) as monotherapy.\n\nPATHOPHYSIOLOGY:\nBlack patients as a population tend to have lower plasma renin activity and a more volume-dependent (salt-sensitive) form of hypertension, with greater reliance on sodium retention and increased peripheral vascular resistance as the drivers of elevated blood pressure. CCBs (amlodipine, nifedipine) directly relax vascular smooth muscle regardless of renin status by blocking L-type calcium channels, making them effective first-line agents in this population. Thiazide diuretics (chlorthalidone, hydrochlorothiazide) address the volume-sensitive component. when combination therapy is used (which is common given that most hypertensive patients require 2 or more agents), ACE inhibitors and ARBs are effective and appropriate as add-on therapy.\n\nKEY POINTS:\nIn Black patients without diabetes or CKD, CCBs or thiazide diuretics are preferred first-line monotherapy due to the typically low-renin, volume-sensitive hypertension physiology. The ALLHAT trial demonstrated 40% higher stroke rates with ACE inhibitor monotherapy versus CCB or thiazide in Black patients. ACE inhibitors and ARBs are effective as add-on agents in combination regimens."
  },
  {
    "id": 101,
    "categoryId": 4,
    "question": "The root cause driver of Polycystic Ovarian Syndrome (PCOS) in the majority of patients is:",
    "options": [
      "A) Estrogen deficiency",
      "B) Insulin Resistance / Hyperinsulinemia",
      "C) Prolactin excess",
      "D) Thyroid dysfunction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Insulin Resistance / Hyperinsulinemia).\n\nPATHOPHYSIOLOGY:\nInsulin resistance affects 50-70% of PCOS patients regardless of BMI. When insulin levels are chronically elevated, three key disruptions occur in reproductive physiology. First, hyperinsulinemia directly stimulates ovarian theca cells to overproduce androgens, particularly testosterone. Second, high insulin suppresses hepatic production of sex hormone-binding globulin (SHBG), which increases the fraction of free, biologically active testosterone. Third, the hyperandrogenic environment impairs normal follicular development, leading to anovulation and the characteristic \"string of pearls\" appearance of arrested follicles on ultrasound.\n\nCLINICAL MANIFESTATIONS:\nThe downstream effects of this hormonal disruption include oligomenorrhea or amenorrhea from anovulation, hirsutism and acne from androgen excess, infertility from failed ovulation, acanthosis nigricans as a visible marker of insulin resistance, and central/abdominal obesity.\n\nMETABOLIC CONSEQUENCES:\nPCOS carries significant long-term metabolic risks including a 4-fold increased risk of developing type 2 diabetes, elevated cardiovascular disease risk, and high prevalence of non-alcoholic fatty liver disease (NAFLD).\n\nTREATMENT APPROACH:\nLifestyle modification is first-line therapy, as even 5-10% weight loss can restore ovulatory cycles. Combined oral contraceptives address menstrual irregularity and suppress androgen production. Metformin improves insulin sensitivity and may restore ovulation in some patients. Inositol supplements have emerging evidence for improving insulin sensitivity. For patients seeking pregnancy, letrozole is now the preferred first-line ovulation induction agent over clomiphene citrate."
  },
  {
    "id": 102,
    "categoryId": 16,
    "question": "Studies of 'Blue Zones' (areas with highest longevity) share which common dietary characteristic?",
    "options": [
      "A) Strict Veganism",
      "B) High protein / Keto",
      "C) Plant-slant (95% plant-based) with legumes as a staple",
      "D) Heavy reliance on dairy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Plant-slant diet with legumes as a staple).\n\nEVIDENCE:\nThe Blue Zones research, led by Dan Buettner in collaboration with National Geographic and the National Institute on Aging, identified five regions with the highest concentrations of centenarians: Okinawa (Japan), Sardinia (Italy), Nicoya Peninsula (Costa Rica), Ikaria (Greece), and Loma Linda (California, specifically Seventh-day Adventists). Despite geographic and cultural diversity, these populations share common dietary and lifestyle patterns that correlate with exceptional longevity.\n\nDIETARY COMMONALITIES:\nAll five Blue Zones follow a predominantly plant-based dietary pattern (approximately 95% of calories from plant sources) with legumes (beans, lentils, chickpeas) as a daily staple, consuming roughly half a cup to one cup per day. Legumes provide a unique combination of plant protein, soluble and insoluble fiber, resistant starch, folate, iron, and polyphenols with very low caloric density. Meat is consumed sparingly (approximately 5 times per month in small portions), diets are rich in whole grains and vegetables, and caloric intake is moderate, often following the Okinawan practice of hara hachi bu (eating until 80% full).\n\nLIFESTYLE FACTORS:\nBeyond diet, Blue Zones populations share natural daily movement (gardening, walking) rather than structured exercise, strong social connections and sense of community, a sense of purpose (ikigai in Okinawa, plan de vida in Nicoya), moderate alcohol consumption (particularly red wine in Sardinia and Ikaria), stress-reduction rituals, and faith-based community participation.\n\nKEY POINTS:\nBlue Zones populations share a plant-predominant dietary pattern (approximately 95% plant-based) with legumes as the cornerstone protein source, consumed daily. Despite cultural diversity, all five zones emphasize whole foods, moderate caloric intake, daily natural movement, strong social bonds, and sense of purpose. Legumes provide a unique combination of protein, fiber, and resistant starch at very low caloric density."
  },
  {
    "id": 103,
    "categoryId": 11,
    "question": "Mindfulness-Based Stress Reduction (MBSR) has been shown to reduce cortical thinning in which brain area associated with aging?",
    "options": [
      "A) Amygdala",
      "B) Prefrontal Cortex",
      "C) Brainstem",
      "D) Cerebellum"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Prefrontal Cortex).\n\nNEUROSCIENCE:\nMindfulness-Based Stress Reduction (MBSR), an 8-week structured program developed by Jon Kabat-Zinn at the University of Massachusetts Medical Center, has been shown through neuroimaging studies to preserve cortical thickness in the prefrontal cortex, a brain region that normally thins with aging. The prefrontal cortex is responsible for executive functions including decision-making, attention regulation, working memory, impulse control, and top-down emotional regulation of the amygdala.\n\nNEUROPLASTICITY EVIDENCE:\nA landmark study from Harvard Medical School (Lazar et al.) using MRI demonstrated that experienced meditators had significantly greater cortical thickness in the prefrontal cortex and right anterior insula compared to age-matched controls, and that this difference was most pronounced in older participants, suggesting that meditation may offset age-related cortical thinning. A subsequent randomized controlled trial showed that 8 weeks of MBSR produced measurable increases in gray matter density in the hippocampus (memory consolidation), temporoparietal junction (empathy and perspective-taking), and posterior cingulate cortex (self-referential processing), while decreasing gray matter density in the amygdala (threat detection and fear response).\n\nCLINICAL APPLICATIONS:\nMBSR has demonstrated efficacy in randomized trials for chronic pain, anxiety disorders, depression relapse prevention (Mindfulness-Based Cognitive Therapy, MBCT), insomnia, and stress-related conditions. The APA recognizes MBCT as an evidence-based treatment for preventing depressive relapse in patients with three or more prior episodes, with efficacy comparable to maintenance antidepressant therapy.\n\nKEY POINTS:\nMBSR preserves prefrontal cortical thickness (executive function, emotional regulation) against age-related thinning. Harvard neuroimaging studies demonstrate that 8 weeks of MBSR increases gray matter density in the hippocampus and reduces amygdala gray matter density. MBCT is evidence-based for preventing depressive relapse with efficacy comparable to maintenance antidepressants."
  },
  {
    "id": 104,
    "categoryId": 4,
    "question": "Why is Liquid Fructose (soda/juice) more metabolically damaging than Glucose?",
    "options": [
      "A) It spikes insulin higher",
      "B) It bypasses PFK-1 regulation in the liver",
      "C) It is not absorbed",
      "D) It is excreted by the kidneys"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It bypasses PFK-1 regulation in the liver).\n\nPATHOPHYSIOLOGY:\nHepatic glucose metabolism is regulated by phosphofructokinase-1 (PFK-1), the rate-limiting glycolytic enzyme allosterically inhibited by ATP and citrate when energy stores are replete, directing excess glucose toward glycogen rather than lipogenesis. Fructose bypasses this checkpoint entirely: fructokinase rapidly phosphorylates fructose to fructose-1-phosphate, cleaved by aldolase B into glyceraldehyde and DHAP, entering glycolysis at the triose phosphate level. Fructokinase has no negative feedback and operates at near-maximal velocity regardless of energy status, flooding hepatocytes with triose phosphates shunted into de novo lipogenesis.\n\nMETABOLIC CONSEQUENCES:\nThis unregulated metabolism produces cascading harms (Journal of Hepatology, JAMA, Nature Reviews Endocrinology). Rapid fructose phosphorylation depletes ATP, generating AMP degraded to uric acid via the purine pathway \u2014 contributing to gout, endothelial dysfunction, and hypertension through eNOS inhibition. Excess triose phosphates drive de novo lipogenesis far exceeding glucose-equivalent loads, promoting hepatic steatosis and MASLD. Chronic fructose-driven lipogenesis induces hepatic insulin resistance via diacylglycerol-mediated PKC-epsilon activation. Unlike glucose, fructose does not stimulate insulin secretion, suppress ghrelin, or stimulate leptin, so the brain receives no satiety signals despite caloric intake, promoting overconsumption.\n\nCLINICAL CONTEXT:\nWhole fruit is metabolically distinct from liquid fructose: fiber slows intestinal absorption, promotes satiety, limits consumption, and accompanying vitamins and polyphenols provide metabolic benefits. Large cohort studies (BMJ, JAMA) consistently show sugar-sweetened beverages increase risk of type 2 diabetes, CVD, MASLD, and obesity, while whole fruit reduces these risks. The AHA recommends limiting added sugar to no more than 25 grams per day for women and 36 grams per day for men, emphasizing elimination of sugar-sweetened beverages.\n\nKEY POINTS:\nLiquid fructose bypasses PFK-1 regulation, enabling uncontrolled hepatic metabolism that drives de novo lipogenesis, hepatic steatosis, ATP depletion with uric acid generation, and absent satiety signaling. Whole fruit is metabolically distinct because fiber slows absorption. The AHA recommends limiting added sugar to 25 grams per day for women and 36 grams per day for men."
  },
  {
    "id": 105,
    "categoryId": 1,
    "question": "The DASH Diet emphasizes high intake of which electrolyte to lower blood pressure?",
    "options": [
      "A) Sodium",
      "B) Potassium",
      "C) Chloride",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/dash-diet-servings.png", "alt": "DASH diet suggested servings: grains, vegetables, fruits, dairy, lean meats, nuts and legumes, fats and oils", "caption": "DASH Diet suggested servings by food group (Cleveland Clinic)." }
    ],
    "explanation": "CORRECT: B (Potassium).\n\nCLINICAL REASONING:\nThe DASH (Dietary Approaches to Stop Hypertension) diet emphasizes high intake of potassium through fruits, vegetables, whole grains, and low-fat dairy products as a core mechanism for blood pressure reduction. The original DASH trial and the subsequent DASH-Sodium trial demonstrated that the DASH dietary pattern reduces systolic blood pressure by approximately 5 to 6 mmHg in hypertensive individuals and 3 mmHg in normotensive individuals, with additional reductions when combined with sodium restriction.\n\nPATHOPHYSIOLOGY:\nPotassium lowers blood pressure through several physiologic mechanisms. It promotes natriuresis (sodium excretion) by inhibiting sodium reabsorption in the proximal tubule and suppressing renin secretion. Potassium causes direct vasodilation by hyperpolarizing vascular smooth muscle cells through activation of the Na+/K+-ATPase and inward-rectifier potassium channels, and it reduces sympathetic nervous system activity. The recommended potassium intake for blood pressure reduction is approximately 3,500 to 5,000 mg per day. Rich dietary sources include bananas, potatoes, spinach, avocados, beans, and citrus fruits.\n\nTHE DASH DIET COMPONENTS:\nBeyond potassium, the DASH diet is rich in calcium, magnesium, and fiber while being low in sodium (ideally less than 1,500 mg/day for the maximum BP-lowering effect), saturated fat, and added sugars. The combination of these nutrients produces greater blood pressure reduction than any single nutrient supplement alone. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle intervention for most patients with elevated blood pressure or stage 1 hypertension.\n\nKEY POINTS:\nThe DASH diet emphasizes high potassium intake (3,500 to 5,000 mg/day) through fruits, vegetables, and low-fat dairy, which lowers blood pressure via natriuresis, direct vasodilation, and reduced sympathetic activity. The DASH trial showed approximately 5 to 6 mmHg systolic BP reduction in hypertensive patients, with greater benefit when combined with sodium restriction to less than 1,500 mg/day."
  },
  {
    "id": 106,
    "categoryId": 4,
    "question": "Which lab marker is the most sensitive early indicator of insulin resistance, often elevating years before A1c?",
    "options": [
      "A) Fasting Glucose",
      "B) Fasting Insulin (or HOMA-IR)",
      "C) LDL Cholesterol",
      "D) TSH"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fasting Insulin or HOMA-IR).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes follows a prolonged preclinical trajectory where insulin resistance is present but glucose homeostasis is maintained through compensatory beta-cell hyperfunction. During this phase, fasting glucose and A1c remain normal because beta cells increase insulin output to overcome tissue resistance. Fasting glucose rises only after beta-cell capacity has declined approximately 50 to 80% from peak compensatory output (UKPDS). Thus, glucose-based tests (fasting glucose, OGTT, A1c) are inherently late markers detecting disease only after significant, potentially irreversible beta-cell loss, missing the optimal prevention window.\n\nCLINICAL REASONING:\nFasting insulin captures compensatory hyperinsulinemia years before glucose derangement. Elevated fasting insulin (generally above 10 to 12 microIU/mL) indicates the pancreas is working above baseline to suppress hepatic glucose output, signaling underlying insulin resistance. HOMA-IR refines this measurement: (fasting insulin in microIU/mL multiplied by fasting glucose in mg/dL) divided by 405. Values below 1.0 indicate optimal sensitivity; 1.0 to 2.0 are normal; above 2.0 suggests insulin resistance; above 2.5 to 3.0 indicates significant resistance warranting attention. HOMA-IR has been validated against the hyperinsulinemic-euglycemic clamp with strong correlation (Diabetes Care, Journal of Clinical Endocrinology and Metabolism).\n\nCLINICAL APPLICATION:\nEarly identification of insulin resistance enables timely lifestyle interventions during the period of greatest effectiveness, as demonstrated by the Diabetes Prevention Program. Elevated fasting insulin also correlates with visceral adiposity, atherogenic dyslipidemia, hypertension, MASLD, and PCOS (where hyperinsulinemia directly stimulates ovarian androgen production). A practical alternative is the triglyceride-to-HDL ratio, where values exceeding 3.0 correlate with insulin resistance. HOMA-IR is not validated for patients on exogenous insulin or secretagogues.\n\nKEY POINTS:\nFasting insulin and HOMA-IR detect compensatory hyperinsulinemia years before glucose or A1c become abnormal, as glucose-based tests rise only after 50 to 80% beta-cell loss. HOMA-IR is calculated as (fasting insulin multiplied by fasting glucose) divided by 405, with values above 2.5 indicating significant resistance. Early detection enables timely lifestyle intervention for diabetes prevention."
  },
  {
    "id": 107,
    "categoryId": 11,
    "question": "Which factor is the most potent stimulator of BDNF (Brain-Derived Neurotrophic Factor)?",
    "options": [
      "A) Sudoku puzzles",
      "B) Aerobic Exercise",
      "C) Vitamin C",
      "D) Classical music"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Aerobic Exercise).\n\nNEUROBIOLOGY:\nBrain-derived neurotrophic factor (BDNF) is the most abundant neurotrophin in the central nervous system and helps neuronal survival, synaptic plasticity, long-term potentiation (the cellular basis of learning and memory), and hippocampal neurogenesis. Aerobic exercise is the most potent known stimulator of BDNF expression, producing increases of 2 to 3-fold in peripheral BDNF levels acutely and sustained elevations with chronic training.\n\nMECHANISM:\nDuring aerobic exercise, skeletal muscle contraction produces signaling molecules (myokines, including irisin and cathepsin B) that cross the blood-brain barrier and stimulate BDNF transcription in hippocampal neurons via activation of the PGC-1-alpha/FNDC5/irisin pathway. Lactate produced during exercise also crosses the blood-brain barrier and activates the SIRT1/PGC-1-alpha signaling cascade, further upregulating BDNF expression. The hippocampus is particularly responsive to exercise-induced BDNF because of its high density of TrkB receptors (the cognate receptor for BDNF) and its unique capacity for adult neurogenesis in the dentate gyrus.\n\nCLINICAL SIGNIFICANCE:\nReduced BDNF levels are a consistent finding in major depressive disorder, Alzheimer's disease, and age-related cognitive decline. Exercise-induced BDNF elevation is a key mechanism underlying the antidepressant, anxiolytic, and neuroprotective effects of physical activity. Randomized trials demonstrate that aerobic exercise increases hippocampal volume by approximately 2% (equivalent to reversing 1 to 2 years of age-related volume loss) in older adults, an effect mediated by BDNF-driven neurogenesis. Cognitive activities (puzzles, reading) have modest effects on synaptic strengthening but do not significantly increase BDNF production or drive neurogenesis.\n\nKEY POINTS:\nAerobic exercise is the most potent stimulator of BDNF, producing 2 to 3-fold increases via the irisin/PGC-1-alpha pathway from exercising muscle. BDNF drives hippocampal neurogenesis, and exercise increases hippocampal volume by approximately 2% in older adults. Low BDNF levels are implicated in depression, Alzheimer's disease, and cognitive decline, making exercise a neuroprotective intervention."
  },
  {
    "id": 108,
    "categoryId": 16,
    "question": "What is the timeline for cardiovascular risk reduction after smoking cessation?",
    "options": [
      "A) 10 years to see any benefit",
      "B) HR and BP drop in 20 mins; MI risk drops 50% in 1 year",
      "C) Damage is permanent",
      "D) 5 years for BP to normalize"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HR and BP drop in 20 minutes; MI risk drops 50% in 1 year).\n\nPATHOPHYSIOLOGY OF SMOKING-INDUCED DAMAGE:\nCigarette smoke causes cardiovascular harm through multiple simultaneous mechanisms. Nicotine activates the sympathetic nervous system, increasing heart rate, blood pressure, and myocardial oxygen demand. Carbon monoxide binds hemoglobin (forming carboxyhemoglobin) with 200 times the affinity of oxygen, reducing oxygen-carrying capacity and promoting tissue hypoxia. Smoke constituents damage vascular endothelium, reduce nitric oxide bioavailability, promote LDL oxidation, increase platelet aggregation, and elevate fibrinogen levels, creating a prothrombotic, pro-atherogenic milieu.\n\nCESSATION TIMELINE:\nWithin 20 minutes of the last cigarette, heart rate and blood pressure begin to normalize as the acute sympathomimetic effects of nicotine dissipate. Within 12 hours, carbon monoxide levels drop to normal, restoring oxygen-carrying capacity. Within 2 to 12 weeks, circulation improves and lung function begins to recover. At 1 year, the excess risk of coronary heart disease is reduced by approximately 50% compared to a continuing smoker. At 5 years, stroke risk approaches that of a never-smoker. At 10 years, lung cancer mortality is approximately half that of a continuing smoker. At 15 years, coronary heart disease risk approaches that of a never-smoker.\n\nCLINICAL APPLICATION:\nSmoking cessation is the single most impactful preventive intervention a clinician can facilitate, with a number needed to treat (NNT) for mortality benefit that exceeds virtually any pharmacologic intervention. FDA-approved cessation aids include nicotine replacement therapy (patch, gum, lozenge, inhaler, nasal spray), varenicline (Chantix, a partial nicotinic receptor agonist with the highest quit rates), and bupropion (Wellbutrin/Zyban). Combining behavioral counseling with pharmacotherapy produces the highest sustained quit rates.\n\nKEY POINTS:\nHemodynamic benefits of smoking cessation begin within 20 minutes (HR and BP normalization), MI risk drops 50% at 1 year, and coronary risk approaches never-smoker levels at 15 years. Smoking cessation is the single most impactful preventive intervention in medicine. Varenicline has the highest quit rates among FDA-approved cessation pharmacotherapies, and combining medication with behavioral counseling optimizes outcomes."
  },
  {
    "id": 109,
    "categoryId": 13,
    "question": "Hyperuricemia (High Uric Acid) is not just a cause of gout, but an independent risk factor for:",
    "options": [
      "A) Hypertension and Metabolic Syndrome",
      "B) Hypothyroidism",
      "C) Osteoporosis",
      "D) Asthma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypertension and Metabolic Syndrome).\n\nPATHOPHYSIOLOGY OF URIC ACID-MEDIATED VASCULAR DAMAGE:\nElevated serum uric acid exerts harmful effects on the cardiovascular system through several mechanisms that are independent of crystal deposition and gout. Uric acid activates the renin-angiotensin system, stimulates vascular smooth muscle proliferation, and induces endothelial dysfunction by reducing nitric oxide bioavailability. In the kidney, hyperuricemia causes afferent arteriolar vasoconstriction and tubulointerstitial inflammation, leading to sodium retention and impaired pressure natriuresis. These effects explain why hyperuricemia precedes and predicts the development of hypertension, particularly in adolescents and young adults. Additionally, uric acid promotes oxidative stress and inflammation in adipose tissue, contributing to insulin resistance.\n\nEPIDEMIOLOGICAL ASSOCIATIONS:\nLarge prospective studies consistently demonstrate that hyperuricemia independently predicts hypertension, metabolic syndrome, type 2 diabetes, chronic kidney disease progression, and cardiovascular events. The Framingham Heart Study showed that each 1 mg/dL increase in serum uric acid is linked to a 13% increased risk of cardiovascular mortality in men. In the metabolic syndrome cluster, hyperuricemia correlates strongly with central obesity, insulin resistance, dyslipidemia, and elevated blood pressure, likely because fructose metabolism simultaneously generates uric acid and drives hepatic de novo lipogenesis.\n\nCLINICAL IMPLICATIONS FOR PRIMARY CARE:\nWhen evaluating a patient with elevated uric acid, consider it a marker of broader cardiometabolic risk rather than simply a gout predictor. Screen for hypertension, metabolic syndrome, and chronic kidney disease. Lifestyle interventions that lower uric acid, such as reducing fructose and alcohol intake, weight loss, and limiting purine-rich foods, simultaneously address multiple metabolic risk factors.\n\nKEY POINTS:\nHyperuricemia is an independent risk factor for hypertension, metabolic syndrome, CKD progression, and cardiovascular mortality. The mechanisms include RAAS activation, endothelial dysfunction, and promotion of insulin resistance. An elevated uric acid should prompt evaluation for cardiometabolic comorbidities beyond gout risk assessment."
  },
  {
    "id": 110,
    "categoryId": 11,
    "question": "According to the Harvard Study of Adult Development (longest longitudinal study on humans), the #1 predictor of happiness and longevity is:",
    "options": [
      "A) Cholesterol levels",
      "B) Quality of Relationships",
      "C) Financial success",
      "D) Genetic profile"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Quality of Relationships).\n\nEVIDENCE:\nThe Harvard Study of Adult Development, initiated in 1938 and now spanning over 85 years across multiple generations, is the longest longitudinal study of human health and well-being ever conducted. The study has followed two original cohorts (268 Harvard College sophomores and 456 inner-city Boston men) and subsequently their spouses and offspring, with comprehensive assessments including questionnaires, medical examinations, brain imaging, and blood biomarkers.\n\nCORE FINDING:\nThe single strongest predictor of both life satisfaction and physical health at age 80 was not cholesterol levels, socioeconomic status, fame, or IQ, but the quality of close personal relationships at age 50. Individuals with warm, secure, and supportive relationships experienced less cognitive decline, maintained better physical function, lived longer, and reported greater happiness than those who were socially isolated or in conflicted relationships. Robert Waldinger, the study's current director, summarized: close relationships are the factor that most consistently predicted healthy aging across all measures studied.\n\nBIOLOGICAL MECHANISMS:\nSecure social bonds buffer the physiologic stress response by reducing HPA axis activation and cortisol production, lowering sympathetic nervous system tone, and dampening systemic inflammation (reduced CRP, IL-6, fibrinogen). Social connection activates oxytocin and endogenous opioid pathways that promote parasympathetic tone, emotional regulation, and immune function. Conversely, loneliness and social isolation activate the conserved transcriptional response to adversity (CTRA), upregulating inflammatory gene expression and downregulating antiviral immune responses.\n\nKEY POINTS:\nThe Harvard Study of Adult Development (85+ years, the longest human longitudinal study) found that quality of relationships at age 50 is the strongest predictor of health and happiness at age 80. Close relationships buffer physiologic stress responses by reducing cortisol, sympathetic tone, and systemic inflammation. Social isolation activates inflammatory gene expression and is an independent mortality risk factor."
  },
  {
    "id": 111,
    "categoryId": 16,
    "question": "Why are Ultra-Processed Foods harmful to human health?",
    "options": [
      "A) They contain too much protein",
      "B) They are high in fiber",
      "C) They bypass satiety mechanisms, promote overconsumption, disrupt the gut microbiome, and drive metabolic dysfunction",
      "D) They are difficult to digest"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (They bypass satiety mechanisms, promote overconsumption, disrupt the gut microbiome, and drive metabolic dysfunction).\n\nDEFINITION AND PREVALENCE:\nUltra-processed foods (UPFs), as defined by the NOVA classification system, are industrial formulations made mostly or entirely from substances derived from foods and additives, with little or no intact whole food. UPFs include soft drinks, packaged snacks, reconstituted meat products, instant noodles, and most fast food. They constitute approximately 58% of total caloric intake in the American diet and nearly 90% of added sugar consumption.\n\nMECHANISMS OF HARM:\nUPFs promote overconsumption through several pathways. They are engineered for hyper-palatability by optimizing combinations of sugar, salt, fat, and flavor enhancers that activate dopaminergic reward circuits in a manner analogous to addictive substances. They have high caloric density with low fiber and water content, which bypasses normal satiety signaling from gastric stretch receptors and gut hormones (GLP-1, PYY, CCK). A landmark NIH randomized controlled trial by Hall and colleagues (2019) demonstrated that participants consuming an ultra-processed diet for 2 weeks ate approximately 500 more calories per day and gained 2 pounds compared to an unprocessed diet matched for macronutrients, sodium, sugar, and fiber, establishing that food processing itself drives overconsumption.\n\nMETABOLIC AND MICROBIOME EFFECTS:\nUPFs disrupt the gut microbiome by providing rapidly absorbed simple sugars and lacking the dietary fiber that sustains beneficial commensal bacteria. Additives such as emulsifiers (polysorbate 80, carboxymethylcellulose) have been shown in animal models to erode the protective mucus layer of the intestinal epithelium, promoting intestinal permeability and systemic inflammation. Large prospective cohort studies (NutriNet-Santé, UK Biobank) have associated high UPF consumption with increased risk of obesity, type 2 diabetes, cardiovascular disease, depression, and all-cause mortality.\n\nKEY POINTS:\nUltra-processed foods constitute approximately 58% of American caloric intake and drive overconsumption through hyper-palatability engineering that activates dopaminergic reward circuits and bypasses satiety mechanisms. The NIH Hall study showed UPFs cause approximately 500 extra calories per day of intake independent of macronutrient composition. UPFs also disrupt the gut microbiome and are associated with increased cardiovascular, metabolic, and all-cause mortality risk."
  },
  {
    "id": 112,
    "categoryId": 14,
    "question": "Insulin resistance and Hyperinsulinemia are strongly linked to an increased risk of which cancers?",
    "options": [
      "A) Lung and Brain",
      "B) Breast, Colon, and Endometrial",
      "C) Leukemia",
      "D) Skin cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Breast, Colon, and Endometrial).\n\nPATHOPHYSIOLOGY:\nInsulin is an anabolic hormone that promotes cell proliferation through activation of the insulin receptor and cross-activation of the insulin-like growth factor-1 (IGF-1) receptor, both of which signal through the PI3K-Akt-mTOR pathway to stimulate cell growth and inhibit apoptosis. In states of chronic insulin resistance and compensatory hyperinsulinemia, such as obesity, metabolic syndrome, and type 2 diabetes, these mitogenic pathways are persistently activated in susceptible tissues. Adipose tissue also produces excess estrogen through peripheral aromatization of androgens, directly stimulating proliferation of estrogen receptor-positive tissues in the breast and endometrium. Chronic low-grade inflammation associated with visceral adiposity produces elevated levels of tumor necrosis factor-alpha and interleukin-6 that promote a microenvironment conducive to tumor development.\n\nCLINICAL EVIDENCE:\nThe International Agency for Research on Cancer has identified sufficient evidence linking excess body fat to at least 13 cancer types, with the strongest associations for endometrial cancer (relative risk approximately 7-fold for BMI greater than 40), esophageal adenocarcinoma, and colorectal cancer. Breast cancer risk in postmenopausal women increases approximately 12% for every 5 kg/m2 increase in BMI, mediated primarily through elevated circulating estrogen. Colorectal cancer risk increases approximately 30% with obesity, driven by hyperinsulinemia-mediated proliferation of colonic epithelial cells.\n\nCLINICAL APPLICATION:\nWeight management and physical activity are among the most impactful modifiable cancer risk reduction strategies. The American Cancer Society recommends 150 to 300 minutes of moderate-intensity physical activity per week. Metformin, which reduces circulating insulin levels, is under active investigation in cancer prevention trials, with observational data suggesting reduced cancer incidence among diabetic patients taking metformin per review in the Journal of Clinical Oncology.\n\nKEY POINTS:\nHyperinsulinemia promotes cancer through activation of the IGF-1 and PI3K-Akt-mTOR mitogenic pathways, with breast, colorectal, and endometrial cancers showing the strongest associations. Obesity drives cancer risk through hyperinsulinemia, excess peripheral estrogen production, and chronic inflammation. Weight management and physical activity are among the most effective modifiable strategies for cancer risk reduction."
  },
  {
    "id": 113,
    "categoryId": 16,
    "question": "In Motivational Interviewing (MI), the 'OARS' acronym stands for:",
    "options": [
      "A) Open-ended questions, Affirmations, Reflections, Summaries",
      "B) Order, Advise, Repeat, Schedule",
      "C) Observe, Assess, React, Support",
      "D) Object, Argue, Reframe, Stop"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Open-ended questions, Affirmations, Reflections, Summaries).\n\nCLINICAL FRAMEWORK:\nMotivational Interviewing (MI) is an evidence-based, patient-centered counseling method developed by William Miller and Stephen Rollnick that enhances intrinsic motivation for behavior change by exploring and resolving ambivalence. MI moves away from the traditional expert-driven (prescriptive) model of patient education toward a collaborative, guiding approach that elicits the patient's own reasons and motivation for change. Multiple systematic reviews and meta-analyses have demonstrated MI's effectiveness for smoking cessation, alcohol reduction, weight management, medication adherence, and chronic disease self-management.\n\nOARS COMPONENTS:\nOpen-ended questions (such as 'What concerns you most about your drinking?') invite the patient to elaborate and explore their own thinking, rather than providing yes/no answers that close down conversation. Affirmations acknowledge the patient's strengths, efforts, and past successes (such as 'It took courage to bring this up today'), building self-efficacy and therapeutic alliance. Reflective listening is the cornerstone skill, where the clinician mirrors back the patient's statements to deepen understanding and demonstrate empathy (such as 'It sounds like you want to quit but are worried about the stress'). Summaries collect and synthesize what the patient has said, reinforcing change talk while organizing the conversation.\n\nSPIRIT OF MI:\nThe underlying spirit of MI rests on four principles: partnership (collaborative rather than authoritarian), acceptance (respecting autonomy and affirming worth), compassion (prioritizing the patient's welfare), and evocation (drawing out the patient's own ideas rather than imposing the clinician's). MI specifically avoids the righting reflex, the clinician's natural tendency to correct, advise, or fix, which paradoxically increases patient resistance.\n\nKEY POINTS:\nOARS stands for Open-ended questions, Affirmations, Reflective listening, and Summaries, forming the core communication skills of Motivational Interviewing. MI is an evidence-based approach that enhances intrinsic motivation by resolving ambivalence through collaboration rather than prescription. The clinician avoids the righting reflex and instead draws out the patient's own reasons for change."
  },
  {
    "id": 114,
    "categoryId": 4,
    "question": "A patient on Semaglutide (Wegovy) for weight loss presents with severe, persistent mid-epigastric pain radiating to the back and vomiting. What is the diagnosis and next step?",
    "options": [
      "A) Gastroparesis; Stop med and hydration",
      "B) Acute Pancreatitis; Stop med and send to ER",
      "C) GERD; Start Omeprazole",
      "D) Cholecystitis; Order Ultrasound"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Pancreatitis; Stop med and send to ER).\n\nPATHOPHYSIOLOGY:\nGLP-1 receptor agonists (GLP-1 RAs) such as semaglutide carry a recognized risk of acute pancreatitis, reflected in FDA labeling warnings and post-marketing surveillance data. Proposed mechanisms include direct stimulation of pancreatic acinar cells via GLP-1 receptors, increased pancreatic ductal pressure, and gallbladder dysmotility promoting biliary sludge and cholelithiasis that can trigger biliary pancreatitis. The estimated incidence is approximately 1-3 per 1,000 patient-years based on pooled clinical trial data.\n\nCLINICAL REASONING:\nSevere, persistent mid-epigastric pain radiating to the back with vomiting is the classic presentation of acute pancreatitis and should raise immediate concern in any patient taking a GLP-1 RA. This pattern differs markedly from the transient, dose-related nausea and GI upset common during GLP-1 RA initiation or dose escalation. Diagnosis is confirmed when two of three revised Atlanta classification criteria are met: characteristic abdominal pain, serum lipase or amylase greater than three times the upper limit of normal, and confirmatory imaging findings on CT or MRI. Management requires immediate discontinuation of the GLP-1 RA and emergency department referral for IV fluid resuscitation, pain management, and monitoring for complications such as pancreatic necrosis, pseudocyst formation, or organ failure. Per FDA guidance, rechallenge with any GLP-1 RA is contraindicated after drug-induced pancreatitis.\n\nProviders should also recognize that GLP-1 RAs increase the risk of cholelithiasis, particularly during rapid weight loss. Patients presenting with right upper quadrant pain should be evaluated with ultrasonography for cholecystitis, which may coexist with or precipitate pancreatitis.\n\nKEY POINTS:\nAcute pancreatitis is a rare but serious adverse effect of GLP-1 RAs including semaglutide. Epigastric pain radiating to the back warrants immediate drug discontinuation and ER referral. Rechallenge with any GLP-1 RA is contraindicated after drug-induced pancreatitis. Always distinguish this presentation from benign GI side effects common during dose titration."
  },
  {
    "id": 115,
    "categoryId": 4,
    "question": "Potential benefits of assessing 'Time in Range' with a Continuous Glucose Monitor (CGM) over solely relying on A1c levels to determine control of Type 2 DM include:",
    "options": [
      "A) Time in Range is less accurate than A1c",
      "B) Detection of glycemic variability and hypoglycemia that A1c alone cannot reveal",
      "C) Time in Range eliminates the need for any fingerstick glucose testing",
      "D) A1c provides more actionable data for medication adjustment"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Detection of glycemic variability and hypoglycemia that A1c alone cannot reveal).\n\nPATHOPHYSIOLOGY:\nA1c estimates average blood glucose over 2 to 3 months but cannot capture glucose distribution, variability, or temporal patterns. Two patients with identical A1c of 7.0% may have vastly different profiles: one stable between 130 and 180 mg/dL, another oscillating between 50 and 300 mg/dL. Glycemic variability independently contributes to complications through oxidative stress and endothelial dysfunction (Diabetes Care, The Lancet Diabetes and Endocrinology). A1c is also unreliable in conditions altering RBC turnover (hemolytic anemias, transfusion, EPO therapy), hemoglobinopathies, advanced CKD, and pregnancy.\n\nCLINICAL REASONING:\nCGM provides measurements every 1 to 5 minutes, generating hundreds of daily data points. The primary metric is Time in Range (TIR): percentage of time glucose remains within 70 to 180 mg/dL. The 2019 International Consensus (Diabetes Care), endorsed by the ADA, established targets: TIR greater than 70% for most adults, less than 4% below 70 mg/dL, and less than 1% below 54 mg/dL. For older or high-risk patients: TIR greater than 50% with less than 1% below 70 mg/dL. Each 10% TIR increase correlates with meaningful reductions in retinopathy and microalbuminuria (DCCT data). CGM also reveals nocturnal hypoglycemia, postprandial excursions, dawn phenomenon, and glycemic impact of specific foods and activities.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards recommend CGM for most type 1 diabetes patients and type 2 patients on intensive insulin regimens or not meeting targets. The Ambulatory Glucose Profile (AGP) presents 14 days of data for rapid pattern recognition. The glucose management indicator (GMI) can substitute for A1c when laboratory values are unreliable. A1c and TIR are complementary: A1c provides long-term average while CGM provides granular detail for precision adjustments.\n\nKEY POINTS:\nA1c cannot reveal glycemic variability or hypoglycemia, both independent contributors to complications. TIR target is greater than 70% with less than 4% below 70 mg/dL; each 10% TIR increase reduces microvascular complications. CGM reveals actionable patterns enabling precision therapy beyond A1c-guided management."
  },
  {
    "id": 116,
    "categoryId": 1,
    "question": "A 50-year-old patient is on Amlodipine, Lisinopril, and HCTZ at max doses. BP remains 150/95. Potassium is 3.3 (Low). What is the most likely secondary cause?",
    "options": [
      "A) Pheochromocytoma",
      "B) Primary Hyperaldosteronism (Conn's)",
      "C) Renal Artery Stenosis",
      "D) Cushing's Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Primary Hyperaldosteronism / Conn Syndrome).\n\nCLINICAL REASONING:\nThe patient has resistant hypertension (uncontrolled BP despite adherence to 3 antihypertensive agents at maximum doses including a diuretic) combined with unexplained hypokalemia (potassium 3.3 mEq/L). The combination of treatment-resistant hypertension and spontaneous or diuretic-exacerbated hypokalemia is the classic presentation of primary hyperaldosteronism, which is now recognized as the most common cause of secondary hypertension, affecting 5 to 15% of all hypertensive patients and up to 20% of those with resistant hypertension.\n\nPATHOPHYSIOLOGY:\nPrimary hyperaldosteronism involves autonomous aldosterone secretion from the adrenal glands (either from a unilateral aldosterone-producing adenoma, known as Conn syndrome, or bilateral adrenal hyperplasia) that is independent of the renin-angiotensin system. Excess aldosterone stimulates sodium reabsorption via ENaC channels in the collecting duct (causing volume expansion and hypertension) and simultaneously drives potassium secretion into the tubular lumen (causing hypokalemia). However, it is important to note that up to 50% of patients with primary hyperaldosteronism are normokalemic, so the absence of hypokalemia does not exclude the diagnosis.\n\nDIAGNOSTIC APPROACH:\nThe screening test is the plasma aldosterone-to-renin ratio (ARR), which shows elevated aldosterone with suppressed renin (high ratio, typically greater than 30 with aldosterone greater than 15 ng/dL). Confirmatory testing (oral sodium loading test, saline infusion test, or fludrocortisone suppression test) follows a positive screen. Adrenal CT and adrenal vein sampling distinguish unilateral adenoma (treated surgically with adrenalectomy) from bilateral hyperplasia (treated medically with mineralocorticoid receptor antagonists such as spironolactone or eplerenone).\n\nKEY POINTS:\nResistant hypertension with hypokalemia is the classic clue for primary hyperaldosteronism (Conn syndrome), the most common cause of secondary hypertension. The aldosterone-to-renin ratio is the screening test (high aldosterone, suppressed renin). Up to 50% of patients are normokalemic, so screening should be considered in all patients with resistant hypertension regardless of potassium level."
  },
  {
    "id": 117,
    "categoryId": 7,
    "question": "A patient complains of shoulder pain. You perform a 'Spurling's Test' (Neck extension + rotation to affected side + axial load), which reproduces pain radiating down the arm. The problem is:",
    "options": [
      "A) Rotator Cuff Tear",
      "B) Cervical Radiculopathy (Disc herniation)",
      "C) AC Joint Separation",
      "D) Thoracic Outlet Syndrome"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/22639-cervical-radiculopathy.jpg", "alt": "Cervical radiculopathy", "caption": "Cervical radiculopathy image." }
    ],
    "explanation": "CORRECT: B (Cervical Radiculopathy).\n\nCERVICAL RADICULOPATHY AND REFERRED SHOULDER PAIN:\nA positive Spurling's test is highly specific (approximately 93%) for cervical radiculopathy and redirects evaluation from shoulder to cervical spine. C5 and C6 dermatomes overlap the shoulder region, creating referred pain mimicking primary shoulder pathology. Full painless shoulder ROM with radiating arm pain on Spurling's test indicates the cervical spine is the culprit.\n\nPATHOPHYSIOLOGY:\nCervical radiculopathy results from nerve root compression at the neural foramen, most commonly C5-C6 or C6-C7. In younger patients, posterolateral disc herniation predominates; in older patients, foraminal stenosis from spondylosis and uncovertebral joint hypertrophy. C6 radiculopathy produces pain from neck through shoulder and lateral arm to thumb and index finger, explaining why patients localize complaints to the shoulder.\n\nSPURLING'S TEST MECHANISM:\nThe maneuver combines cervical extension, ipsilateral rotation, and axial compression, collectively narrowing the neural foramen by 20 to 30%. Extension closes the posterior disc space, rotation narrows the ipsilateral foramen, and compression further reduces foraminal volume. A positive test reproduces radicular symptoms (pain, paresthesias radiating into the arm), not merely neck pain.\n\nCLINICAL EVALUATION:\nAdditional findings include dermatomal sensory changes, myotomal weakness (biceps weakness and diminished reflex for C6; triceps weakness and diminished reflex for C7), and symptom exacerbation with neck movement. MRI of the cervical spine is preferred when red flags are present or symptoms persist beyond 4 to 6 weeks.\n\nTREATMENT:\nConservative management resolves 80 to 90% of cases: NSAIDs, short-course oral corticosteroids for severe radicular pain, cervical physical therapy with postural correction and nerve gliding exercises, and activity modification. Epidural steroid injections are considered for persistent pain. Surgical decompression is reserved for progressive neurological deficits, myelopathy, or refractory symptoms.\n\nKEY POINTS:\nA positive Spurling's test is highly specific for cervical radiculopathy, indicating the neck as the pain source. Full painless shoulder ROM with radicular arm symptoms rules out primary shoulder pathology. Conservative management resolves approximately 80 to 90% of cases."
  },
  {
    "id": 118,
    "categoryId": 11,
    "question": "A 24-year-old presents with depression. Before starting an SSRI, which screening question is CRITICAL to prevent a manic episode?",
    "options": [
      "A) 'Do you hear voices?'",
      "B) 'Have you ever had periods where you felt no need for sleep and had racing thoughts?'",
      "C) 'Do you have anxiety?'",
      "D) 'Do you drink alcohol?'"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B ('Have you ever had periods where you felt no need for sleep and had racing thoughts?').\n\nCLINICAL REASONING:\nBefore initiating an SSRI for depression, screening for a history of manic or hypomanic episodes is essential because antidepressant monotherapy in undiagnosed bipolar disorder can precipitate a manic episode, rapid cycling, or mixed states. Approximately 40% of patients with bipolar disorder initially present with a depressive episode (bipolar depression is clinically indistinguishable from unipolar MDD on cross-sectional assessment), and the average delay from symptom onset to correct bipolar diagnosis is 5 to 10 years.\n\nSCREENING APPROACH:\nAsking about prior periods of markedly decreased need for sleep (not insomnia, but feeling rested after 3 to 4 hours), racing thoughts, pressured speech, grandiosity, increased goal-directed activity, and impulsive risk-taking behavior (spending sprees, sexual indiscretions, reckless driving) screens for DSM-5 criteria for manic or hypomanic episodes. The Mood Disorder Questionnaire (MDQ) is a validated self-report screening instrument with 13 yes/no items covering manic symptoms that can be administered in primary care.\n\nCONSEQUENCES OF MISSED DIAGNOSIS:\nSSRI monotherapy in bipolar disorder activates the serotonergic system without the mood-stabilizing protection of lithium, valproate, or a second-generation antipsychotic, creating a risk of switching from depression into mania (estimated at 10 to 25% with SSRI monotherapy). Antidepressant-induced mania can be severe, with psychotic features, dangerous impulsivity, and hospitalization. The correct approach to bipolar depression is mood stabilizer-based therapy (lithium, lamotrigine, quetiapine, or lurasidone).\n\nKEY POINTS:\nScreening for prior manic or hypomanic episodes is essential before starting any antidepressant because SSRI monotherapy can precipitate mania in undiagnosed bipolar disorder (10 to 25% switch rate). Approximately 40% of bipolar patients first present with depression, and the average diagnostic delay is 5 to 10 years. Decreased need for sleep with racing thoughts is the most sensitive screening question for prior mania."
  },
  {
    "id": 119,
    "categoryId": 1,
    "question": "According to the 2018 AHA Guidelines, in a patient with Diabetes aged 40-75, regardless of their 10-year risk score, what is the recommendation?",
    "options": [
      "A) Start Moderate-Intensity Statin",
      "B) Start High-Intensity Statin",
      "C) No statin unless LDL > 190",
      "D) Calculate risk score first"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Start Moderate-Intensity Statin).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines identify diabetes mellitus (type 1 or type 2) in patients aged 40 to 75 as a statin benefit group that warrants at least moderate-intensity statin therapy regardless of the calculated 10-year ASCVD risk score. This recommendation reflects the strong and consistent evidence that diabetes is an independent and powerful risk factor for ASCVD, and that statin therapy reduces cardiovascular events in diabetic patients across a wide range of baseline LDL levels.\n\nGUIDELINE FRAMEWORK:\nFor diabetic patients aged 40 to 75 without additional risk enhancers or established ASCVD, moderate-intensity statin therapy (targeting a 30 to 49% LDL reduction) is the baseline recommendation. High-intensity statin therapy (targeting 50% or greater LDL reduction) is recommended when diabetes is accompanied by multiple ASCVD risk enhancers such as long duration of diabetes (10 or more years for type 2, 20 or more years for type 1), albuminuria (30 mg/g or greater), eGFR less than 60, retinopathy, neuropathy, or ABI less than 0.9. The Cholesterol Treatment Trialists meta-analysis of over 18,000 diabetic patients across 14 randomized trials demonstrated a 21% relative risk reduction in major vascular events per 1 mmol/L (39 mg/dL) LDL reduction with statin therapy.\n\nKEY POINTS:\nDiabetes aged 40 to 75 is an automatic indication for at least moderate-intensity statin therapy regardless of the 10-year ASCVD risk score. Escalation to high-intensity statin is indicated when additional risk enhancers are present (long diabetes duration, albuminuria, retinopathy, low eGFR). The recommendation is based on the consistent 21% relative risk reduction in major vascular events per 39 mg/dL LDL lowering demonstrated in diabetic patients."
  },
  {
    "id": 120,
    "categoryId": 4,
    "question": "When counseling a patient on obesity, the 'Set Point Theory' explains why:",
    "options": [
      "A) Patients lack willpower",
      "B) Metabolic rate slows down (adaptive thermogenesis) as weight is lost to defend the higher weight",
      "C) Exercise is useless",
      "D) Genetics are the only factor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Metabolic rate slows down via adaptive thermogenesis as weight is lost, defending the higher weight).\n\nPATHOPHYSIOLOGY:\nThe set point theory posits that the hypothalamus defends a biologically determined weight range through coordinated adjustments in energy expenditure, appetite, and neuroendocrine signaling. When weight falls below this set point, falling leptin signals the hypothalamus to activate orexigenic pathways (NPY/AgRP) while suppressing anorexigenic pathways (POMC). Ghrelin also increases, amplifying hunger. The metabolic component \u2014 adaptive thermogenesis \u2014 reduces resting energy expenditure beyond what decreased body mass predicts. The Biggest Loser study (Obesity, Fothergill et al., 2016) showed resting metabolic rate decreased approximately 500 kcal/day beyond predictions, persisting at least 6 years post-weight loss.\n\nCLINICAL EVIDENCE:\nLeibl and Rosenbaum studies (NEJM 1995, Journal of Clinical Investigation) demonstrated that 10% weight loss produces a 20 to 25% decrease in total energy expenditure through increased skeletal muscle efficiency, reduced sympathetic activity, and decreased thyroid-mediated thermogenesis. This creates a 200 to 400 kcal/day energy gap requiring perpetual conscious restriction. This explains why most individuals regain weight within 3 to 5 years \u2014 not from inadequate willpower, but from sustained neurohormonal opposition evolved to prevent starvation.\n\nCLINICAL APPLICATION:\nFraming weight regain as biological rather than personal failure reduces stigma. The Obesity Medicine Association emphasizes obesity is a chronic, relapsing neurohormonal disease requiring sustained treatment. GLP-1 receptor agonists (semaglutide, tirzepatide) counteract compensatory hormonal responses by reducing appetite through central satiety signaling; weight regain occurs upon discontinuation. Bariatric surgery achieves sustained loss partly by altering gut hormone profiles (increasing GLP-1 and PYY, reducing ghrelin), effectively resetting the defended set point. Exercise helps attenuate metabolic adaptation by preserving lean mass.\n\nKEY POINTS:\nThe set point theory explains weight regain through falling leptin, rising ghrelin, and adaptive thermogenesis reducing metabolic rate up to 500 kcal/day beyond body composition predictions, persisting for years. Counseling that regain is neurobiologically driven reduces stigma and supports long-term management including pharmacotherapy and bariatric surgery when indicated."
  },
  {
    "id": 121,
    "categoryId": 7,
    "question": "A 52-year-old construction worker presents with right low back pain radiating down the right buttock, posterior thigh, and into the calf. What is the most likely diagnosis?",
    "explanationImages": [
      { "src": "assets/lumbarradiculopathy.webp", "alt": "Lumbar radiculopathy", "caption": "Lumbar radiculopathy image." },
      { "src": "assets/sciatica.webp", "alt": "Sciatica", "caption": "Sciatica image." }
    ],
    "options": [
      "A) Lumbar muscle strain",
      "B) Lumbar radiculopathy (sciatica) from disc herniation",
      "C) Hip osteoarthritis",
      "D) Peripheral arterial disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar radiculopathy/sciatica from disc herniation).\n\nPATHOPHYSIOLOGY:\nLumbar disc herniation occurs when the nucleus pulposus protrudes through a weakened annulus fibrosus, typically in a posterolateral direction where the annulus is thinnest. The L4-L5 and L5-S1 levels account for over 90% of lumbar herniations. When herniated disc material compresses or inflames an adjacent nerve root, radiculopathy results. The sciatic nerve, formed from L4-S3 roots, is the largest nerve in the body and travels through the buttock and down the posterior thigh, explaining the characteristic pain distribution. Construction work involving repetitive bending, lifting, and twisting accelerates disc degeneration and increases herniation risk.\n\nCLINICAL PRESENTATION:\nThe hallmark of lumbar radiculopathy is pain radiating below the knee in a dermatomal pattern, distinguishing it from referred pain of musculoskeletal origin which rarely extends past the knee. L5 radiculopathy causes pain radiating to the lateral leg and dorsum of the foot with weakness of ankle dorsiflexion and great toe extension. S1 radiculopathy produces pain down the posterior calf to the lateral foot with weakness of ankle plantarflexion and diminished Achilles reflex. The straight leg raise test, positive when leg elevation between 30-70 degrees reproduces radicular leg pain, has 91% sensitivity for disc herniation.\n\nMANAGEMENT:\nMost lumbar radiculopathy resolves with conservative management over 6-12 weeks. First-line treatment includes NSAIDs, activity modification (avoiding bed rest), and physical therapy emphasizing core stabilization. Red flags requiring urgent imaging and referral include cauda equina syndrome (saddle anesthesia, urinary retention, bilateral weakness), progressive motor deficit, or intractable pain despite conservative care.\n\nKEY POINTS:\nRadicular pain radiates below the knee in a dermatomal distribution, while musculoskeletal back pain rarely extends past the knee. The straight leg raise test (30-70 degrees reproducing leg pain) has 91% sensitivity for disc herniation. Most cases resolve conservatively; urgent referral is needed for cauda equina syndrome or progressive neurologic deficit."
  },
  {
    "id": 122,
    "categoryId": 11,
    "question": "An adult patient requests stimulants for ADHD. He reports symptoms started 2 years ago after a job change. Can you diagnose ADHD?",
    "options": [
      "A) Yes, adult onset is common",
      "B) No, symptoms MUST be present prior to age 12",
      "C) Yes, if the job is demanding",
      "D) No, stimulants are illegal for adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No, symptoms must be present prior to age 12).\n\nDIAGNOSTIC CRITERIA:\nThe DSM-5 requires that several inattentive or hyperactive-impulsive symptoms be present prior to age 12 for a diagnosis of attention-deficit/hyperactivity disorder (ADHD). This criterion reflects the neurodevelopmental nature of ADHD: it originates from differences in brain maturation (particularly prefrontal cortex development, catecholamine signaling, and fronto-striatal-cerebellar circuitry) that are present from early childhood, even if the functional impairment becomes more apparent later in life.\n\nCLINICAL SIGNIFICANCE:\nThe age-of-onset criterion is critical for distinguishing genuine ADHD from other conditions that mimic ADHD symptoms in adulthood. New-onset attention difficulties, distractibility, and restlessness beginning in adulthood (as in this case, where symptoms started 2 years ago with a job change) are more likely attributable to anxiety disorders, depression, sleep disorders (obstructive sleep apnea), substance use, thyroid dysfunction, or adjustment to increased cognitive demands. These conditions require different treatment approaches and do not warrant stimulant medication.\n\nADULT ADHD EVALUATION:\nAdults presenting for ADHD evaluation should undergo a comprehensive assessment including detailed developmental history (ideally corroborated by parents, school records, or childhood report cards), screening for psychiatric comorbidities (anxiety, depression, substance use), sleep assessment, thyroid function testing, and validated rating scales (Adult ADHD Self-Report Scale, ASRS). Approximately 60% of children with ADHD continue to have impairing symptoms into adulthood. First-line pharmacotherapy for confirmed adult ADHD is stimulant medication (methylphenidate or amphetamine) with non-stimulant alternatives (atomoxetine, bupropion, guanfacine) for patients with contraindications.\n\nKEY POINTS:\nADHD diagnosis requires symptom onset prior to age 12, reflecting its neurodevelopmental origin. Adult-onset attention difficulties are more likely anxiety, depression, sleep disorders, or thyroid dysfunction and require different treatment. Approximately 60% of childhood ADHD persists into adulthood, and comprehensive evaluation including developmental history is essential before prescribing stimulants."
  },
  {
    "id": 123,
    "categoryId": 4,
    "question": "A 52-year-old female with severe hot flashes (Vasomotor Symptoms) wants HRT. She has no uterus (Hysterectomy). What is the preferred regimen?",
    "options": [
      "A) Estrogen + Progesterone",
      "B) Estrogen Only",
      "C) Progesterone Only",
      "D) Testosterone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Estrogen Only).\n\nPATHOPHYSIOLOGY:\nMenopausal vasomotor symptoms result from estrogen withdrawal narrowing the hypothalamic thermoneutral zone from approximately 0.4 degrees Celsius to nearly zero, causing minor core temperature fluctuations to trigger inappropriate vasodilation and diaphoresis. These episodes affect up to 80% of peri- and postmenopausal women and persist a median of 7 to 10 years (SWAN, JAMA Internal Medicine). Estrogen replacement restores the thermoneutral zone, reducing hot flash frequency by 75 to 95%.\n\nCLINICAL REASONING:\nThe critical principle is whether the patient has an intact uterus. Unopposed estrogen stimulates endometrial proliferation, increasing hyperplasia and adenocarcinoma risk, so progesterone must be co-administered for endometrial protection. After hysterectomy, this protection is unnecessary. Furthermore, progesterone adds risk: the WHI estrogen-plus-progestin arm (JAMA 2002) showed increased invasive breast cancer (HR 1.26), while the estrogen-only arm (JAMA 2004) in post-hysterectomy women showed no increase, with extended follow-up (The Lancet) suggesting possible reduction. This differential is attributed to synthetic progestins' proliferative effects on breast tissue.\n\nTREATMENT:\nFor this post-hysterectomy patient, estrogen-only therapy is preferred. Options include oral conjugated equine estrogen (0.625 mg), oral estradiol (0.5 to 2 mg), or transdermal estradiol (0.025 to 0.1 mg patch). Transdermal is preferred in women with elevated cardiovascular risk, hypertriglyceridemia, obesity, or VTE history because it avoids first-pass hepatic metabolism without increasing clotting factors or triglycerides. The lowest effective dose for the shortest necessary duration remains the guiding principle, though NAMS 2022 emphasizes individualized duration based on symptom burden. Contraindications include unexplained vaginal bleeding, breast cancer, active liver disease, VTE or stroke history, and known thrombophilia.\n\nKEY POINTS:\nProgesterone is added solely for endometrial protection; after hysterectomy it is unnecessary and adds breast cancer risk. The WHI estrogen-only arm showed no breast cancer increase, while estrogen-plus-progestin increased risk. Transdermal estrogen is preferred over oral in patients with elevated cardiovascular or thrombotic risk."
  },
  {
    "id": 124,
    "categoryId": 14,
    "question": "The 'Ugly Duckling Sign' refers to:",
    "options": [
      "A) A mole that is slightly lighter-colored than others",
      "B) A mole that looks different/stands out compared to the patient's other nevi",
      "C) A mole on the foot",
      "D) A mole that is slightly smaller than others"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A mole that looks different from the patient's other nevi).\n\nCLINICAL SIGNIFICANCE:\nThe Ugly Duckling sign is a clinical screening strategy for melanoma detection based on the principle that an individual's benign nevi tend to share a common morphologic pattern in terms of size, shape, and color. Most patients produce one or two predominant nevus types reflecting their genetic background and sun exposure history. A lesion that deviates significantly from this personal baseline, the mole that does not resemble its neighbors, should raise suspicion for melanoma even if it does not meet all formal ABCDE criteria and AAD guidelines.\n\nDIAGNOSTIC VALUE:\nThe Ugly Duckling sign was formally described by Grob and Bonerandi and has been validated as a complementary screening tool alongside the ABCDE criteria. Its particular value lies in detecting melanomas with atypical morphology, including small-diameter melanomas (less than 6mm), amelanotic melanomas that lack typical dark pigmentation, and nodular melanomas that may appear symmetric and well-bordered per review in the Journal of the American Academy of Dermatology. In patients with numerous nevi or dysplastic nevus syndrome, where many individual lesions may meet some ABCDE criteria, the Ugly Duckling approach helps identify the single outlier that warrants biopsy.\n\nCLINICAL APPLICATION:\nDuring a full skin examination, the clinician should first observe the overall pattern of the patient's nevi before evaluating individual lesions. The lesion that breaks the pattern, whether by being darker, larger, more irregular, or simply morphologically distinct, merits the closest scrutiny and lowest threshold for biopsy. Patient education on self-monitoring using the Ugly Duckling concept improves early detection, particularly for melanomas arising in patients with many moles.\n\nKEY POINTS:\nThe Ugly Duckling sign identifies melanoma by detecting the nevus that deviates from the patient's own overall mole pattern, complementing the ABCDE criteria. It is especially useful for detecting small-diameter, amelanotic, and nodular melanomas that may not meet traditional screening thresholds. During skin examinations, observing the overall nevus pattern before evaluating individual lesions improves melanoma detection sensitivity."
  },
  {
    "id": 125,
    "categoryId": 4,
    "question": "Which two classes of Diabetes medications are FDA approved to reduce the progression of Diabetic Nephropathy (CKD)?",
    "options": [
      "A) Metformin and Sulfonylureas",
      "B) SGLT2 Inhibitors and GLP-1 Agonists",
      "C) Insulin and Pioglitazone",
      "D) DPP-4 Inhibitors and Meglitinides"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SGLT2 Inhibitors and GLP-1 Agonists).\n\nPATHOPHYSIOLOGY:\nDiabetic kidney disease affects 30 to 40% of diabetic patients and is the leading cause of ESRD worldwide. Hyperglycemia increases proximal tubular sodium-glucose reabsorption, reducing sodium delivery to the macula densa. This activates tubuloglomerular feedback, dilating the afferent arteriole. Combined with RAAS-mediated efferent constriction, intraglomerular pressure rises, producing podocyte shear stress. AGEs, PKC activation, and ROS drive mesangial expansion, basement membrane thickening, and fibrosis. Progression follows: hyperfiltration, microalbuminuria, macroalbuminuria, declining GFR, and ESRD.\n\nSGLT2 INHIBITORS:\nSGLT2 inhibitors block proximal tubular sodium-glucose reabsorption, restoring sodium delivery to the macula densa and triggering afferent arteriolar constriction via tubuloglomerular feedback, reducing intraglomerular pressure. An initial eGFR dip of approximately 3 to 5 mL/min reflects beneficial hemodynamic correction, not nephrotoxicity. CREDENCE (NEJM 2019): canagliflozin reduced composite kidney endpoint by 34%. DAPA-CKD (NEJM 2020): dapagliflozin reduced kidney endpoint by 44%, including in non-diabetic CKD. EMPA-KIDNEY (NEJM 2023): empagliflozin reduced progression by 28%.\n\nGLP-1 RECEPTOR AGONISTS:\nGLP-1 RAs provide complementary renal protection through anti-inflammatory effects, natriuretic actions, weight loss, BP reduction, and improved glycemic control. The FLOW trial (NEJM 2024), the first dedicated GLP-1 RA renal outcomes trial, demonstrated semaglutide reduced the composite kidney endpoint by 24% in type 2 diabetes with CKD. LEADER, SUSTAIN-6, and REWIND previously showed renal benefits for liraglutide, semaglutide, and dulaglutide.\n\nCLINICAL APPLICATION:\nADA 2024 and KDIGO 2024 guidelines recommend SGLT2 inhibitors and GLP-1 RAs as foundational kidney-protective therapy for type 2 diabetes with CKD, independent of glycemic needs, alongside maximally tolerated RAAS blockade and finerenone (FIDELIO-DKD, FIGARO-DKD). The initial SGLT2i eGFR dip should not prompt discontinuation.\n\nKEY POINTS:\nSGLT2 inhibitors protect kidneys by restoring tubuloglomerular feedback and reducing intraglomerular pressure (28 to 44% reductions in progression). The FLOW trial established semaglutide as the first GLP-1 RA with dedicated renal benefit (24% reduction). Both classes are recommended for type 2 diabetes with CKD regardless of A1c."
  },
  {
    "id": 126,
    "categoryId": 1,
    "question": "A patient in clinic has a BP of 190/110. He is asymptomatic (no chest pain, vision changes, or headache). How should you manage this?",
    "options": [
      "A) Send to ER immediately",
      "B) Give Nifedipine immediate release",
      "C) Adjust oral meds and recheck in 48-72 hours",
      "D) Administer IV Labetalol"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Adjust oral medications and recheck in 48 to 72 hours).\n\nCLINICAL REASONING:\nThe patient has a markedly elevated blood pressure of 190/110 but is completely asymptomatic with no evidence of end-organ damage (no chest pain, no headache, no visual changes, no neurologic deficits, no dyspnea). This is classified as a hypertensive urgency (severely elevated BP without acute end-organ damage), which is fundamentally different from a hypertensive emergency (severely elevated BP with evidence of acute target organ damage such as hypertensive encephalopathy, acute MI, aortic dissection, acute heart failure, eclampsia, or acute renal failure).\n\nMANAGEMENT DISTINCTION:\nHypertensive urgencies are managed with adjustment or intensification of oral antihypertensive medications and close outpatient follow-up within 48 to 72 hours, not with acute IV therapy or emergency department referral. Rapid reduction of blood pressure without end-organ damage can actually cause harm by inducing cerebral, coronary, or renal hypoperfusion, particularly in patients with chronic hypertension whose autoregulatory curves have shifted rightward. The goal is gradual BP reduction over 24 to 48 hours.\n\nCRITICAL DISTINCTION:\nSublingual or immediate-release nifedipine is specifically contraindicated in hypertensive urgencies because it causes precipitous, unpredictable blood pressure drops that have been associated with stroke and myocardial infarction. IV labetalol and other parenteral agents are reserved for hypertensive emergencies where acute end-organ damage demands rapid (but controlled) blood pressure reduction in an ICU setting.\n\nKEY POINTS:\nAsymptomatic severe hypertension without end-organ damage (hypertensive urgency) is managed by adjusting oral medications and rechecking BP within 48 to 72 hours, not with IV therapy or ER referral. Rapid BP reduction without end-organ damage risks cerebral, coronary, and renal hypoperfusion. Immediate-release nifedipine is contraindicated due to unpredictable precipitous drops."
  },
  {
    "id": 127,
    "categoryId": 7,
    "question": "Which physical exam test is most sensitive for an ACL tear?",
    "options": [
      "A) Anterior Drawer",
      "B) Lachman Test",
      "C) McMurray Test",
      "D) Valgus Stress"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/knee-ligaments.jpg", "alt": "Knee ligaments", "caption": "Knee ligament anatomy image." }
    ],
    "explanation": "CORRECT: B (Lachman Test).\n\nPATHOPHYSIOLOGY:\nThe ACL is the primary restraint against anterior tibial translation. Rupture typically occurs through noncontact pivoting during deceleration, cutting, or landing, producing immediate hemarthrosis within 2 hours from middle genicular artery disruption. The ACL cannot heal spontaneously because its intra-articular, synovial fluid-bathed environment prevents organized clot formation and repair.\n\nCLINICAL EXAMINATION:\nThe Lachman test is the most sensitive maneuver for ACL rupture (85 to 95% sensitivity vs. 40 to 60% for the anterior drawer). Performed at 20 to 30 degrees of knee flexion, the examiner stabilizes the distal femur and applies anteriorly directed force to the proximal tibia. A positive test demonstrates increased anterior translation with a soft or absent endpoint. The anterior drawer test at 90 degrees is significantly less sensitive acutely because hamstring tension at this flexion angle splints the tibia posteriorly, masking anterior laxity. Additionally, the posterior horn of the medial meniscus acts as a secondary restraint at 90 degrees. The pivot shift test is the most specific but is difficult to perform acutely due to guarding.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI confirms ACL rupture and evaluates associated injuries including meniscal tears (present in over 50% of acute ACL injuries), bone bruises, and collateral ligament sprains. Initial management includes rest, ice, compression, elevation, and early ROM exercises to prevent arthrofibrosis. ACL reconstruction is recommended for patients with functional instability, high activity demands, or repairable meniscal tears, as the unstable knee accelerates meniscal and chondral degeneration.\n\nKEY POINTS:\nThe Lachman test is the most sensitive bedside ACL test at 85 to 95% sensitivity, performed at 20 to 30 degrees to eliminate hamstring guarding. The anterior drawer is significantly less sensitive acutely because hamstring tension at 90 degrees masks anterior translation. MRI confirms the diagnosis and evaluates associated injuries present in over 50% of cases."
  },
  {
    "id": 128,
    "categoryId": 3,
    "question": "A 45-year-old obese male has elevated ALT/AST. Hepatitis panel is negative. Ultrasound shows fatty liver. What is the next calculation you should perform?",
    "options": [
      "A) BMI",
      "B) FIB-4 Index",
      "C) GFR",
      "D) ASCVD Risk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (FIB-4 Index).\n\nPATHOPHYSIOLOGY:\nMetabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) affects approximately 30% of the global population and represents a spectrum from simple steatosis to steatohepatitis (MASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The critical prognostic determinant is not steatosis or inflammation but rather the degree of hepatic fibrosis, as fibrosis stage is the strongest predictor of liver-related morbidity and mortality.\n\nCLINICAL REASONING:\nThe FIB-4 index is a validated, non-invasive fibrosis assessment tool calculated using age, AST, ALT, and platelet count. It is recommended as the initial screening test by the AASLD and AGA because it is inexpensive, widely available, and effectively stratifies patients into low-risk (score less than 1.3), indeterminate (1.3-2.67), and high-risk (greater than 2.67) categories. Patients in the low-risk category have a >90% negative predictive value for advanced fibrosis and can be managed in primary care. Indeterminate and high-risk patients require secondary assessment with elastography (FibroScan or MR elastography) or referral to hepatology.\n\nMANAGEMENT IMPLICATIONS:\nIdentifying fibrosis stage guides management intensity. Patients with advanced fibrosis require hepatocellular carcinoma surveillance every 6 months with ultrasound and alpha-fetoprotein. Weight loss of 7-10% of body weight improves steatohepatitis and can reverse fibrosis. Resmetirom (a thyroid hormone receptor beta agonist) is the first FDA-approved medication specifically for MASH with moderate-to-advanced fibrosis.\n\nKEY POINTS:\nFIB-4 is the recommended first-line non-invasive test for fibrosis staging in MASLD, using age, AST, ALT, and platelets. A FIB-4 below 1.3 has >90% negative predictive value for advanced fibrosis. Fibrosis stage, not steatosis, is the strongest predictor of liver-related outcomes. Weight loss of 7-10% can reverse steatohepatitis and fibrosis."
  },
  {
    "id": 129,
    "categoryId": 1,
    "question": "Phentermine is FDA approved for short-term use. It is chemically similar to amphetamines and should be avoided in patients with:",
    "options": [
      "A) Hypothyroidism",
      "B) Uncontrolled Hypertension or history of Arrhythmia",
      "C) Depression",
      "D) Osteoarthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Uncontrolled Hypertension or history of Arrhythmia).\n\nPATHOPHYSIOLOGY:\nPhentermine is a sympathomimetic amine structurally related to amphetamine that works primarily by stimulating norepinephrine release in the hypothalamus, activating the sympathetic nervous system and suppressing appetite. This same catecholaminergic mechanism that produces weight loss also raises heart rate, increases blood pressure, and elevates myocardial oxygen demand, which can precipitate arrhythmias in susceptible individuals.\n\nCARDIOVASCULAR CONTRAINDICATIONS:\nBecause of its sympathomimetic properties, phentermine is contraindicated in patients with cardiovascular disease including coronary artery disease, heart failure, arrhythmias, and uncontrolled hypertension. Additional contraindications include hyperthyroidism (which already produces a hyperadrenergic state), glaucoma, history of substance abuse, MAO inhibitor use within 14 days, and pregnancy.\n\nCLINICAL USE:\nPhentermine is FDA-approved only for short-term use (up to 12 weeks) as an adjunct to lifestyle modification in patients with BMI 30 or greater, or BMI 27 or greater with weight-related comorbidities. It is classified as a DEA Schedule IV controlled substance due to its abuse potential. The combination product phentermine-topiramate (Qsymia) is approved for longer-term use and may provide additional weight loss through topiramate's effects on satiety.\n\nKEY POINTS:\nPhentermine is a sympathomimetic contraindicated in uncontrolled hypertension, arrhythmias, and cardiovascular disease due to its norepinephrine-releasing mechanism that raises heart rate, blood pressure, and arrhythmia risk. It is FDA-approved for short-term use only (12 weeks) and is a Schedule IV controlled substance. Cardiovascular screening before prescribing is essential."
  },
  {
    "id": 130,
    "categoryId": 11,
    "question": "First-line treatment for Chronic Insomnia according to ACP guidelines?",
    "options": [
      "A) Zolpidem (Ambien)",
      "B) Melatonin",
      "C) Trazodone",
      "D) CBT-I (Cognitive Behavioral Therapy for Insomnia)"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (CBT-I, Cognitive Behavioral Therapy for Insomnia).\n\nGUIDELINE BASIS:\nCognitive Behavioral Therapy for Insomnia (CBT-I) is recommended as first-line treatment for chronic insomnia disorder by the American College of Physicians (ACP 2016), the American Academy of Sleep Medicine (AASM), and the European Sleep Research Society. These guidelines uniformly prioritize CBT-I over pharmacotherapy because it has equivalent short-term efficacy with superior long-term durability and no risk of medication dependence, tolerance, or adverse effects.\n\nCOMPONENTS:\nCBT-I is a structured 6 to 8-session program that addresses the cognitive and behavioral perpetuating factors of chronic insomnia. Sleep restriction therapy limits time in bed to match actual sleep time, consolidating fragmented sleep and building homeostatic sleep drive. Stimulus control re-establishes the bed as a cue for sleep (bed used only for sleep and sex; leave bed after 20 minutes of wakefulness). Cognitive restructuring addresses maladaptive beliefs about sleep (catastrophizing about consequences of poor sleep). Sleep hygiene education addresses environmental and behavioral factors (consistent wake times, avoiding screens before bed, limiting caffeine).\n\nPHARMACOLOGIC ALTERNATIVES:\nWhen CBT-I is unavailable or insufficient, pharmacologic options include low-dose doxepin (the only FDA-approved medication for sleep maintenance insomnia), suvorexant or lemborexant (dual orexin receptor antagonists), ramelteon (melatonin receptor agonist for sleep onset), and short-term use of Z-drugs (zolpidem, zaleplon, eszopiclone). Benzodiazepines are not recommended for chronic insomnia due to tolerance, dependence, rebound insomnia, falls in elderly patients, and cognitive impairment.\n\nKEY POINTS:\nCBT-I is the ACP and AASM recommended first-line treatment for chronic insomnia, with equivalent short-term efficacy and superior long-term outcomes compared to medications. Its core components are sleep restriction, stimulus control, and cognitive restructuring. Benzodiazepines and Z-drugs are not recommended for chronic insomnia due to dependence, tolerance, and fall risk."
  },
  {
    "id": 131,
    "categoryId": 7,
    "question": "Classic presentation of Plantar Fasciitis includes:",
    "options": [
      "A) Pain at night while sleeping",
      "B) Pain with the first few steps in the morning (Post-static dyskinesia)",
      "C) Numbness in the toes",
      "D) Swelling of the ankle"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/plantar_1280.jpg", "alt": "Plantar fascia", "caption": "Plantar fascia image." }
    ],
    "explanation": "CORRECT: B (Pain with the first few steps in the morning).\n\nPATHOPHYSIOLOGY:\nPlantar fasciitis is a degenerative enthesopathy at the plantar fascia origin on the medial calcaneal tubercle. Histopathology reveals collagen disorganization and angiofibroblastic hyperplasia (fasciosis) rather than true inflammation. The plantar fascia supports the longitudinal arch and functions as a windlass mechanism during gait. Risk factors include obesity, prolonged standing, pes planus or cavus, Achilles tightness, and sudden increases in weight-bearing activity.\n\nCLINICAL PRESENTATION:\nThe hallmark is sharp medial plantar heel pain with the first steps after rest \u2014 post-static dyskinesia. During sleep or prolonged sitting, the plantar fascia contracts as the ankle plantarflexes. Upon standing, sudden weight-bearing stretches the contracted, degenerative fascia across the enthesis, producing acute pain that improves after several minutes of walking as the fascia elongates, then worsens again with prolonged standing. This start-up pain pattern distinguishes plantar fasciitis from calcaneal stress fracture (progressive worsening with all weight bearing, no improvement with warming up), fat pad atrophy (central rather than medial heel pain), and tarsal tunnel syndrome (burning or tingling with positive Tinel sign posterior to the medial malleolus).\n\nTREATMENT:\nFirst-line management includes plantar fascia-specific stretching (toe dorsiflexion engaging the windlass mechanism), Achilles stretching, supportive footwear with arch support, avoiding barefoot walking on hard surfaces, and ice massage. Night splints maintain ankle dorsiflexion during sleep, preventing fascial contracture and reducing morning pain. NSAIDs provide short-term relief. Physical therapy with eccentric loading and intrinsic foot muscle strengthening accelerates recovery. Corticosteroid injection is considered for refractory cases but risks plantar fascia rupture and fat pad atrophy. The condition is self-limiting in 80 to 90% of patients within 10 to 12 months with conservative management.\n\nKEY POINTS:\nPlantar fasciitis presents with medial heel pain worst with first steps after rest (post-static dyskinesia) that improves with gentle activity. The condition is degenerative, not inflammatory, at the plantar fascia enthesis. Conservative management including stretching, supportive footwear, and night splints resolves 80 to 90% of cases."
  },
  {
    "id": 132,
    "categoryId": 4,
    "question": "A patient on a Sulfonylurea (Glipizide) keeps having lows. You switch them to a DPP-4 Inhibitor (Sitagliptin). Why does Sitagliptin NOT cause hypoglycemia?",
    "options": [
      "A) It is weaker",
      "B) It is glucose-dependent",
      "C) It increases glucagon",
      "D) It works on the kidney"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It is glucose-dependent).\n\nPATHOPHYSIOLOGY:\nSulfonylureas bind the SUR1 receptor on beta-cell KATP channels, forcing closure regardless of ambient glucose concentration. This depolarizes the membrane, opens calcium channels, and triggers insulin secretion independent of blood glucose \u2014 rendering the beta cell blind to its metabolic environment. This glucose-independent mechanism directly causes hypoglycemia, which can be severe and prolonged, particularly with glyburide in renal impairment and in elderly patients (ACCORD trial, The Lancet Diabetes and Endocrinology).\n\nGLUCOSE-DEPENDENT MECHANISM OF DPP-4 INHIBITORS:\nDPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin) prolong endogenous incretins (GLP-1, GIP) by blocking their degradation by dipeptidyl peptidase-4. The critical safety feature: incretin-mediated insulin secretion is inherently glucose-dependent. GLP-1 and GIP amplify the beta-cell signaling cascade initiated by glucose metabolism itself. When glucose is elevated, glucose metabolism increases the ATP-to-ADP ratio, partially closing KATP channels; incretins amplify this existing signal via cAMP and PKA pathways. As glucose falls, reduced metabolism lowers the ATP-to-ADP ratio, KATP channels open, and incretins have no signal to amplify. Insulin secretion self-limits, making clinically significant hypoglycemia virtually impossible with DPP-4 inhibitor monotherapy.\n\nCLINICAL APPLICATION:\nDPP-4 inhibitors are well-suited for elderly patients, those with renal impairment (linagliptin requires no dose adjustment), and those with erratic meals or hypoglycemia unawareness. They are weight-neutral with modest A1c reduction (0.5 to 0.8%) compared to sulfonylureas (1.0 to 1.5%) or GLP-1 RAs (1.0 to 2.0%). They should not be combined with GLP-1 RAs due to overlapping incretin pathways. Cardiovascular safety is neutral (TECOS, EXAMINE, CARMELINA), though SAVOR-TIMI 53 raised concern about heart failure hospitalization with saxagliptin.\n\nKEY POINTS:\nSulfonylureas cause hypoglycemia by forcing glucose-independent insulin secretion through direct KATP channel closure. DPP-4 inhibitors enhance glucose-dependent incretin-mediated signaling that self-limits as glucose normalizes. DPP-4 inhibitors are weight-neutral with modest potency and should not be combined with GLP-1 RAs."
  },
  {
    "id": 133,
    "categoryId": 1,
    "question": "Thiazide diuretics (HCTZ/Chlorthalidone) can worsen which three metabolic conditions?",
    "options": [
      "A) Gout, Diabetes, Hypercalcemia",
      "B) Hypothyroidism, Anemia, Lupus",
      "C) Asthma, COPD, GERD",
      "D) Depression, Anxiety, Insomnia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Gout, Diabetes, Hypercalcemia).\n\nPATHOPHYSIOLOGY:\nThiazide diuretics (hydrochlorothiazide, chlorthalidone) inhibit the sodium-chloride cotransporter (NCC) in the distal convoluted tubule, promoting natriuresis and reducing intravascular volume. While effective first-line antihypertensives, their metabolic side effect profile affects three important systems. First, thiazides cause hyperuricemia by competing with uric acid for secretion in the proximal tubule (both use the organic anion transporter OAT1/OAT3) and by increasing proximal tubular uric acid reabsorption secondary to volume contraction, raising serum urate levels and potentially precipitating gout flares in susceptible individuals. Second, thiazides impair glucose tolerance and can worsen or unmask diabetes mellitus through several mechanisms: hypokalemia impairs pancreatic beta-cell insulin secretion, and direct effects on insulin sensitivity and hepatic gluconeogenesis contribute. Third, thiazides cause hypercalcemia by enhancing passive calcium reabsorption in the proximal tubule (secondary to volume contraction) and by directly stimulating calcium reabsorption in the distal tubule through upregulation of the TRPV5 calcium channel.\n\nCLINICAL APPLICATIONS:\nThe hypercalcemic effect of thiazides is therapeutically exploited in patients with calcium-containing kidney stones (idiopathic hypercalciuria), where thiazides reduce urinary calcium excretion and stone recurrence. Conversely, thiazides should be avoided in patients with primary hyperparathyroidism where they can mask or worsen hypercalcemia. The metabolic effects are dose-dependent, and current guidelines favor lower doses (chlorthalidone 12.5 to 25 mg, HCTZ 25 mg) that provide antihypertensive benefit with fewer metabolic consequences.\n\nKEY POINTS:\nThiazide diuretics worsen gout (competitive uric acid secretion blockade), diabetes (hypokalemia-impaired insulin secretion), and hypercalcemia (enhanced distal tubular calcium reabsorption). The hypercalcemic effect is therapeutically useful for calcium kidney stone prevention. These metabolic effects are dose-dependent and minimized with lower doses."
  },
  {
    "id": 134,
    "categoryId": 4,
    "question": "A 27-year-old female with BMI 39 is only having periods every 3-4 months and exhibits some darker chin hair. What is the most likely diagnosis?",
    "options": [
      "A) Hypothyroidism",
      "B) Polycystic Ovary Syndrome (PCOS)",
      "C) Premature ovarian insufficiency",
      "D) Hyperprolactinemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polycystic Ovary Syndrome).\n\nPATHOPHYSIOLOGY:\nPCOS is the most common endocrine disorder in reproductive-age women (6 to 12%). A self-reinforcing cycle of insulin resistance and hyperandrogenism drives the disease. Insulin resistance (present in 50 to 70% regardless of BMI) produces hyperinsulinemia that stimulates ovarian theca cell androgen production and suppresses hepatic SHBG synthesis, increasing bioavailable testosterone. The hyperandrogenic intraovarian environment disrupts folliculogenesis: dominant follicle selection fails, multiple follicles arrest at the antral stage producing the characteristic polycystic morphology. Without ovulation, no corpus luteum forms, progesterone is absent, and unopposed estrogen causes oligo-amenorrhea and increased endometrial hyperplasia risk.\n\nCLINICAL REASONING:\nThis patient presents with the classic triad: obesity (BMI 39), oligomenorrhea (periods every 3 to 4 months), and clinical hyperandrogenism (hirsutism). The Rotterdam Criteria (2003), endorsed by the Endocrine Society 2013 guidelines, require two of three features after excluding other etiologies: oligo-anovulation, clinical or biochemical hyperandrogenism, and polycystic ovarian morphology. This patient satisfies two criteria without requiring ultrasound. The workup must exclude thyroid dysfunction (TSH), hyperprolactinemia, non-classic CAH (17-hydroxyprogesterone), and Cushing syndrome. Obesity is not a diagnostic criterion; 20 to 30% of PCOS patients have normal BMI.\n\nTREATMENT:\nLifestyle modification is first-line \u2014 even 5 to 10% weight loss can restore ovulation and reduce androgens. Combined OCPs suppress ovarian androgens, increase SHBG, and provide endometrial protection. Spironolactone (50 to 200 mg) treats hirsutism and acne but requires contraception due to teratogenicity. Metformin improves insulin sensitivity. For fertility, letrozole has replaced clomiphene as preferred first-line ovulation induction (NICHD trial, NEJM 2014 \u2014 higher live birth rates). Metabolic screening (fasting glucose or A1c, lipids, BP) is recommended at diagnosis given the 4-fold increased type 2 diabetes risk.\n\nKEY POINTS:\nPCOS requires two of three Rotterdam criteria (oligo-anovulation, hyperandrogenism, polycystic ovaries) after excluding thyroid disease, hyperprolactinemia, CAH, and Cushing. Obesity worsens PCOS but is not diagnostic; lean PCOS accounts for 20 to 30%. Letrozole is preferred over clomiphene for ovulation induction per the NICHD trial."
  },
  {
    "id": 135,
    "categoryId": 12,
    "question": "M-CHAT screening for Autism is routinely performed at which well-child checks?",
    "options": [
      "A) 6 and 12 months",
      "B) 18 and 24 months",
      "C) 3 and 4 years",
      "D) Only if symptomatic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (18 and 24 months).\n\nCLINICAL REASONING:\nThe American Academy of Pediatrics recommends universal autism spectrum disorder screening at the 18-month and 24-month well-child visits using a validated screening tool, specifically the Modified Checklist for Autism in Toddlers, Revised with Follow-Up (M-CHAT-R/F). This timing is strategic because core features of ASD, including deficits in joint attention, social reciprocity, pretend play, and the emergence of restricted or repetitive behaviors, become reliably detectable between 12 and 24 months of age. Screening at both time points captures children whose symptoms emerge at different rates across this developmental window and reduces the false-negative rate inherent in single-timepoint screening.\n\nTHE M-CHAT-R/F:\nThe M-CHAT-R/F is a two-stage parent-completed screening instrument. The initial screener consists of 20 yes/no questions targeting behaviors associated with ASD (response to name, pointing, interest in other children, imitation, eye contact). Children who screen positive on the initial questionnaire undergo the structured follow-up interview to reduce false positives. The overall positive predictive value of the two-stage M-CHAT-R/F is approximately 50%, meaning that roughly half of children who screen positive will ultimately receive an ASD diagnosis, while others may have other developmental delays that still benefit from early intervention.\n\nEARLY IDENTIFICATION AND INTERVENTION:\nThe rationale for early screening is that autism-specific interventions initiated before age 3 produce the most significant improvements in language, cognitive abilities, and adaptive functioning, leveraging the heightened neuroplasticity of the developing brain. The median age of ASD diagnosis in the United States remains approximately 4 to 5 years, which represents a missed window of optimal intervention for many children. Universal screening at 18 and 24 months aims to close this gap. Developmental surveillance (informal monitoring of milestones and parental concerns) should occur at every well-child visit, and any concern raised by parents, caregivers, or clinicians at any visit should prompt formal evaluation regardless of screening results.\n\nKEY POINTS:\nUniversal ASD screening with the M-CHAT-R/F occurs at 18 and 24 months, timed to when core autism features become reliably detectable. Developmental surveillance should occur at every well-child visit, and parental concerns warrant evaluation regardless of screening results. Early diagnosis enables intervention before age 3, when neuroplasticity offers the greatest potential for developmental gains."
  },
  {
    "id": 136,
    "categoryId": 7,
    "question": "A 70-year-old female has a Vertebral Compression Fracture. Her DEXA T-score is -1.8 (Osteopenia). Does she meet criteria for Osteoporosis treatment?",
    "options": [
      "A) No, she is only osteopenic",
      "B) Yes, this is Clinical Osteoporosis",
      "C) Only if she smokes",
      "D) Wait and repeat DEXA in 2 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, this is Clinical Osteoporosis).\n\nPATHOPHYSIOLOGY:\nOsteoporosis is characterized by low bone mass and microarchitectural deterioration resulting in fracture susceptibility. While typically diagnosed by DXA T-score of -2.5 or lower, a fragility fracture (from fall at standing height or less) establishes clinical osteoporosis regardless of bone density. Vertebral compression fractures are the most common osteoporotic fractures, indicating structural integrity has already failed. A prior vertebral fracture is the single strongest predictor of future fracture, increasing subsequent vertebral fracture risk 4 to 5-fold and hip fracture risk 2 to 3-fold within the following year.\n\nCLINICAL REASONING:\nThis patient's T-score of -1.8 falls in the osteopenia range by densitometry alone. However, the vertebral compression fracture overrides the T-score and establishes osteoporosis, mandating pharmacologic treatment. Relying solely on T-score thresholds would inappropriately delay treatment in a patient who has demonstrated skeletal fragility through fracture. AACE and NOGG guidelines recognize fragility fracture as an independent diagnostic criterion requiring treatment.\n\nTREATMENT:\nA secondary osteoporosis workup should include vitamin D, BMP, CBC, TSH, and consideration of PTH, celiac serologies, and SPEP/UPEP to exclude secondary causes. For high fracture risk patients (prior vertebral or hip fracture), AACE recommends initial anabolic therapy (teriparatide or romosozumab) for 1 to 2 years, followed by antiresorptive consolidation (bisphosphonate or denosumab), as this anabolic-first sequence builds bone more effectively than starting with antiresorptives alone. For moderate-risk patients, bisphosphonate therapy is appropriate first-line. Calcium, vitamin D supplementation, fall prevention, and weight-bearing exercise are essential adjuncts.\n\nKEY POINTS:\nA fragility fracture establishes clinical osteoporosis and mandates treatment regardless of T-score. Prior vertebral fracture is the strongest future fracture predictor, increasing subsequent vertebral fracture risk 4 to 5-fold. For high-risk patients, anabolic-first therapy followed by antiresorptive consolidation is the preferred treatment sequence."
  },
  {
    "id": 137,
    "categoryId": 11,
    "question": "A patient stops Paroxetine (Paxil) abruptly. 2 days later they feel dizzy, have 'brain zaps', and nausea. Diagnosis?",
    "options": [
      "A) Relapse of Depression",
      "B) Serotonin Discontinuation Syndrome",
      "C) Viral labyrinthitis",
      "D) Stroke"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin Discontinuation Syndrome).\n\nPATHOPHYSIOLOGY:\nSerotonin discontinuation syndrome (also called SSRI/SNRI discontinuation syndrome) occurs when serotonergic antidepressants are abruptly stopped or rapidly tapered, triggering a constellation of neurologic, gastrointestinal, and psychological symptoms within 1 to 4 days of cessation. The syndrome results from sudden loss of serotonergic tone at postsynaptic receptors that have been downregulated during chronic SSRI exposure; these receptors require time to upregulate back to baseline sensitivity.\n\nHIGH-RISK MEDICATIONS:\nParoxetine (Paxil) has the highest incidence of discontinuation syndrome among SSRIs due to its short half-life (approximately 21 hours), potent serotonin reuptake inhibition, and anticholinergic rebound properties. Venlafaxine (Effexor), an SNRI with a half-life of only 5 hours, also has very high discontinuation risk. Fluoxetine (Prozac) has the lowest risk because its active metabolite norfluoxetine has a half-life of 4 to 16 days, providing a built-in self-taper.\n\nCLINICAL PRESENTATION:\nThe mnemonic FINISH captures the key symptoms: Flu-like symptoms (fatigue, myalgias, chills), Insomnia, Nausea, Imbalance (dizziness, vertigo), Sensory disturbances (\"brain zaps\" described as electric shock-like sensations in the head, the most characteristic symptom), and Hyperarousal (anxiety, agitation, irritability). Symptoms are self-limited, typically resolving within 1 to 2 weeks, but can be highly distressing.\n\nPREVENTION AND MANAGEMENT:\nAll SSRIs and SNRIs (except fluoxetine) should be tapered gradually over a minimum of 2 to 4 weeks, with longer tapers for higher doses and longer duration of use. If discontinuation syndrome is severe, restarting the medication at the previous dose and then tapering more slowly is the most effective treatment. Switching to fluoxetine (taking advantage of its long half-life) before discontinuation is a useful bridge strategy for difficult tapers.\n\nKEY POINTS:\nSerotonin discontinuation syndrome (FINISH: Flu-like, Insomnia, Nausea, Imbalance, Sensory disturbances, Hyperarousal) occurs 1 to 4 days after abrupt SSRI cessation, with \"brain zaps\" as the hallmark. Paroxetine and venlafaxine have the highest risk due to short half-lives. SSRIs should be tapered over 2 to 4 weeks minimum, and fluoxetine can serve as a bridge for difficult tapers."
  },
  {
    "id": 138,
    "categoryId": 6,
    "question": "A family brings in an 80-year-old male for 'memory loss'. It started SUDDENLY 1 week ago and fluctuates during the day. He sees animals in the room. This is:",
    "options": [
      "A) Alzheimer's Disease",
      "B) Delirium",
      "C) Lewy Body Dementia",
      "D) Normal Aging"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Delirium).\n\nDISTINGUISHING DELIRIUM FROM DEMENTIA:\nThe key clinical features in this case point to delirium rather than dementia: sudden onset (over 1 week vs. months/years), fluctuating course throughout the day, and visual hallucinations (seeing animals). These features distinguish delirium from the insidious, progressive course of dementia.\n\nDELIRIUM CHARACTERISTICS:\nDelirium is an acute confusional state characterized by disturbance in attention and awareness that develops over hours to days, fluctuates in severity, and represents a change from baseline. Visual hallucinations are common. It always has an underlying medical cause that must be identified and treated.\n\nDEMENTIA CHARACTERISTICS:\nDementia develops insidiously over months to years with progressive decline and stable day-to-day symptoms (not fluctuating). Memory loss is prominent early, but attention is relatively preserved until advanced stages. Hallucinations are uncommon except in Lewy body dementia.\n\nDELIRIUM WORKUP:\nSearch for underlying causes: infection (UTI, pneumonia), metabolic derangements (electrolytes, glucose, renal/hepatic function), medications (anticholinergics, opioids, benzodiazepines), substance withdrawal, urinary retention, fecal impaction, pain, and hypoxia.\n\nKEY POINTS:\nSudden onset, fluctuating course, and visual hallucinations indicate delirium, not dementia. Delirium always has an underlying cause that must be identified. Dementia is insidious and progressive without significant day-to-day fluctuation."
  },
  {
    "id": 139,
    "categoryId": 16,
    "question": "USPSTF Lung Cancer screening now begins at age:",
    "options": [
      "A) 55",
      "B) 50",
      "C) 60",
      "D) 45"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Age 50).\n\nGUIDELINE UPDATE:\nThe USPSTF 2021 recommendation for lung cancer screening with low-dose computed tomography (LDCT) expanded eligibility by lowering the starting age from 55 to 50 and reducing the smoking history requirement from 30 to 20 pack-years. Current criteria are: age 50 to 80 years, 20 pack-year or greater smoking history, and currently smoking or quit within the past 15 years. Screening should be discontinued once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or the ability to have curative lung surgery.\n\nEVIDENCE BASIS:\nThe National Lung Screening Trial (NLST) demonstrated that annual LDCT screening reduced lung cancer mortality by 20% compared to chest radiography in high-risk adults. The NELSON trial (Nederlands-Leuvens Longkanker Screenings Onderzoek) confirmed these findings in a European population, showing 24% lung cancer mortality reduction in men and up to 33% in women. The expanded criteria were designed to improve equity and capture a broader at-risk population, particularly women and African Americans who develop lung cancer at lower pack-year exposures.\n\nCLINICAL CONSIDERATIONS:\nLDCT screening has a high false-positive rate (approximately 25% of screened patients have positive findings, most of which are benign), requiring careful shared decision-making about the risks of follow-up procedures (biopsy, surgery) and the anxiety associated with indeterminate nodules. The USPSTF recommends shared decision-making conversations that include the benefits, limitations, and potential harms of screening.\n\nKEY POINTS:\nUSPSTF lung cancer screening criteria are age 50 to 80, 20 or more pack-year smoking history, and current smoker or quit within 15 years, using annual LDCT. The NLST and NELSON trials demonstrated 20 to 33% lung cancer mortality reduction with screening. The high false-positive rate (approximately 25%) necessitates shared decision-making about benefits and harms."
  },
  {
    "id": 140,
    "categoryId": 4,
    "question": "A patient wants Wegovy but has a personal history of Medullary Thyroid Cancer. Is this safe?",
    "options": [
      "A) Yes, risk is only in rodents",
      "B) No, it is Contraindicated",
      "C) Yes, if TSH is monitored",
      "D) Only at low doses"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No, it is Contraindicated).\n\nPATHOPHYSIOLOGY:\nAll GLP-1 receptor agonists carry an FDA Black Box Warning for thyroid C-cell tumor risk based on preclinical data. Rodent studies showed dose-dependent C-cell hyperplasia, adenomas, and medullary thyroid carcinoma (MTC) through direct GLP-1 receptor-mediated C-cell proliferation via cAMP signaling. However, human thyroid C-cells express GLP-1 receptors at substantially lower density than rodent C-cells. Clinical data from cardiovascular outcomes trials (LEADER, SUSTAIN-6, REWIND, SELECT) and a meta-analysis (The Lancet Diabetes and Endocrinology) have not demonstrated increased MTC incidence in humans. Nevertheless, the preclinical signal maintains the FDA contraindication as a precautionary measure.\n\nCLINICAL REASONING:\nGLP-1 RAs are contraindicated in patients with personal or family history of MTC and in patients with MEN2 syndrome. MEN2 is an autosomal dominant syndrome caused by activating RET proto-oncogene mutations, predisposing to MTC (virtually 100% penetrance), pheochromocytoma, and hyperparathyroidism (MEN2A). The theoretical risk of GLP-1 receptor-mediated C-cell stimulation is considered unacceptable in these patients. Crucially, papillary thyroid carcinoma (approximately 80% of thyroid cancers) and follicular thyroid carcinoma arise from follicular cells, not C-cells, and do not express relevant GLP-1 receptors. A history of papillary or follicular thyroid cancer is NOT a contraindication.\n\nMONITORING:\nRoutine calcitonin monitoring or thyroid ultrasound is not recommended by the FDA, ATA, or Endocrine Society for patients without MTC risk factors. Patients should report new thyroid masses, dysphagia, dysphonia, or persistent neck swelling. Clinicians should screen for personal and family history of MTC and MEN2 before initiating therapy.\n\nKEY POINTS:\nAll GLP-1 RAs carry a Black Box Warning and are contraindicated in personal or family history of MTC or MEN2, based on rodent C-cell tumor data. This does not apply to papillary or follicular thyroid cancers, which arise from follicular cells without relevant GLP-1 receptors. Human data have not confirmed increased MTC risk, but the precautionary contraindication remains."
  },
  {
    "id": 141,
    "categoryId": 1,
    "question": "Best way to confirm White Coat Hypertension?",
    "options": [
      "A) Have the nurse check it",
      "B) Ambulatory Blood Pressure Monitoring (ABPM) or Home logs",
      "C) Treat empirically",
      "D) Check it lying down"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ambulatory Blood Pressure Monitoring or Home BP Logs).\n\nCLINICAL REASONING:\nWhite coat hypertension means persistently elevated office blood pressure readings (140/90 mmHg or greater) with normal out-of-office blood pressure readings (daytime ambulatory average less than 135/85 mmHg or home average less than 135/85 mmHg). It occurs in approximately 15 to 30% of patients diagnosed with hypertension based on office readings alone. White coat hypertension results from a sympathetic nervous system-mediated stress response to the clinical environment, producing transient blood pressure elevation that does not reflect the patient's usual hemodynamic state.\n\nDIAGNOSTIC GOLD STANDARD:\n24-hour ambulatory blood pressure monitoring (ABPM) is the gold standard for confirming white coat hypertension. The device measures blood pressure at regular intervals (typically every 15 to 30 minutes during the day and every 30 to 60 minutes at night) over a full 24-hour cycle, providing daytime, nighttime, and overall mean blood pressure values. ABPM also assesses nocturnal dipping (the normal 10 to 20% decrease in blood pressure during sleep), the absence of which (non-dipping pattern) is an independent cardiovascular risk factor. Home blood pressure monitoring (HBPM) with a validated device is an acceptable alternative when ABPM is unavailable, with duplicate readings taken morning and evening for at least 3 to 7 days.\n\nCLINICAL SIGNIFICANCE:\nWhite coat hypertension carries a lower cardiovascular risk than sustained hypertension but may not be entirely benign, as some studies suggest a modestly increased risk of progression to sustained hypertension and cardiovascular events compared to true normotension. Patients with confirmed white coat hypertension should receive lifestyle counseling and annual monitoring with out-of-office BP assessment rather than pharmacotherapy.\n\nKEY POINTS:\nABPM is the gold standard for diagnosing white coat hypertension (elevated office BP with normal out-of-office BP), occurring in 15 to 30% of patients diagnosed by office readings alone. Home BP monitoring is an acceptable alternative (duplicate readings, morning and evening, for 3 to 7 days). White coat hypertension warrants lifestyle modification and monitoring rather than pharmacotherapy."
  },
  {
    "id": 142,
    "categoryId": 7,
    "question": "Classic X-ray finding in chronic, untreated Gout?",
    "options": [
      "A) Joint space narrowing",
      "B) Rat-bite erosions (punched out lesions)",
      "C) Osteophytes",
      "D) Bamboo spine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rat-bite erosions / punched-out lesions).\n\nPATHOPHYSIOLOGY:\nGout results from monosodium urate crystal deposition when serum uric acid chronically exceeds the saturation threshold of approximately 6.8 mg/dL. In chronic untreated gout, tophi form \u2014 organized urate crystal deposits surrounded by granulomatous inflammation of macrophages, giant cells, and fibrous tissue. Tophi adjacent to bone activate osteoclasts and erode cortex through pressure necrosis and cytokine-mediated bone resorption.\n\nRADIOGRAPHIC FINDINGS:\nThe hallmark finding is well-defined punched-out periarticular erosions with sclerotic borders and characteristic overhanging edges of cortical bone (Martel sign). The overhanging edges result from the tophus eroding into bone while overlying cortex remains partially intact. Erosions are typically asymmetric, juxta-articular, and may be accompanied by soft tissue nodular densities representing tophi. Joint space width is preserved until late in the disease because articular cartilage is not the primary destructive target. This distinguishes gout from rheumatoid arthritis (periarticular osteopenia and early uniform joint space narrowing from pannus), osteoarthritis (asymmetric narrowing with osteophytes, no erosions), and ankylosing spondylitis (bamboo spine from vertebral fusion).\n\nDIAGNOSIS AND MANAGEMENT:\nRadiographic changes require years of inadequately treated hyperuricemia and represent advanced disease; plain films are often normal in early or acute gout. Dual-energy CT detects urate deposits with high specificity before erosions appear, useful for atypical presentations. The cornerstone of chronic management is urate-lowering therapy titrated to serum urate below 6.0 mg/dL, gradually dissolving crystals, shrinking tophi, and preventing further erosive damage.\n\nKEY POINTS:\nChronic tophaceous gout produces punched-out periarticular erosions with overhanging edges (Martel sign) and preserved joint space, distinguishing it from RA and OA. Erosions represent advanced disease from years of inadequately treated hyperuricemia. Urate-lowering therapy targeting uric acid below 6.0 mg/dL dissolves deposits and prevents further joint destruction."
  },
  {
    "id": 143,
    "categoryId": 17,
    "question": "A patient has a vesicular rash on the tip of the nose (Hutchinson's Sign). This warrants urgent referral to:",
    "options": [
      "A) Dermatology",
      "B) Ophthalmology",
      "C) Neurology",
      "D) ENT"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ophthalmology).\n\nPATHOPHYSIOLOGY:\nHerpes zoster ophthalmicus (HZO) results from reactivation of varicella-zoster virus (VZV) latent in the trigeminal (gasserian) ganglion, specifically within the ophthalmic division (V1). The nasociliary branch of V1 innervates both the tip of the nose (via the external nasal nerve) and the cornea. A vesicular rash on the nasal tip (Hutchinson sign) indicates nasociliary nerve involvement and confers a significantly increased risk (approximately 76%) of ocular complications, including keratitis, anterior uveitis, and secondary glaucoma.\n\nCLINICAL PRESENTATION:\n- Prodromal pain, tingling, or hyperesthesia in the V1 distribution (forehead, upper eyelid, nose)\n- Unilateral dermatomal vesicular rash that does not cross midline\n- Hutchinson sign: Vesicles on the tip, side, or root of the nose\n- Ocular involvement may include conjunctivitis, episcleritis, keratitis (dendritic or stromal), anterior uveitis, and elevated IOP\n\nDIAGNOSIS:\nClinical diagnosis based on characteristic dermatomal distribution. Hutchinson sign warrants urgent ophthalmology referral even without current eye symptoms, as ocular complications can develop days to weeks after rash onset.\n\nTREATMENT:\n1. Antiviral therapy: Valacyclovir 1g TID or acyclovir 800mg five times daily for 7 days, ideally started within 72 hours of rash onset\n2. Ophthalmology referral: Slit-lamp examination to evaluate for keratitis, uveitis, and IOP elevation\n3. Topical steroids and cycloplegics (prescribed by ophthalmology) for anterior uveitis\n4. Pain management: Often requires combination therapy; postherpetic neuralgia is common in V1 distribution\n\nKEY POINTS:\nHutchinson sign (vesicles on the nasal tip) indicates nasociliary nerve involvement and a high probability of ocular complications requiring urgent ophthalmology referral. HZO can cause vision-threatening keratitis and uveitis even after the rash resolves. Shingrix vaccination (recombinant, adjuvanted) is recommended for adults 50 and older to prevent herpes zoster and its complications.\n---"
  },
  {
    "id": 144,
    "categoryId": 3,
    "question": "A 35-year-old female complains of severe bloating and distension that worsens throughout the day. She has constipation-predominant IBS. A 'Low FODMAP' diet has provided minimal relief. What is a common, often missed differential diagnosis?",
    "options": [
      "A) Gastroparesis",
      "B) Small Intestinal Bacterial Overgrowth (SIBO)",
      "C) Zollinger-Ellison Syndrome",
      "D) Wilson's Disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small Intestinal Bacterial Overgrowth - SIBO).\n\nCLINICAL PRESENTATION:\nSIBO classically presents with bloating that worsens throughout the day (as bacteria ferment ingested carbohydrates), distension, flatulence, and often diarrhea. The pattern of worsening as the day progresses and improving overnight is characteristic.\n\nPATHOPHYSIOLOGY:\nNormally, the small intestine has relatively few bacteria compared to the colon. In SIBO, colonic-type bacteria overgrow in the small intestine, fermenting carbohydrates before they can be absorbed. This produces hydrogen and methane gas (bloating), damages the intestinal mucosa (malabsorption), and deconjugates bile acids (fat malabsorption, steatorrhea).\n\nRISK FACTORS:\nImpaired motility (diabetes, scleroderma, opioids), anatomic abnormalities (strictures, blind loops, post-surgical), reduced gastric acid (PPIs), immune deficiency, and IBS with constipation predispose to SIBO.\n\nDIAGNOSIS AND TREATMENT:\nGlucose or lactulose breath testing detects hydrogen/methane production. Treatment is antibiotics, most commonly rifaximin (non-absorbed, gut-selective). Addressing underlying cause is essential to prevent recurrence. A low-FODMAP diet may help symptoms.\n\nKEY POINTS:\nSIBO causes bloating that worsens throughout the day due to bacterial fermentation of carbohydrates. Risk factors include PPI use, diabetes, and prior abdominal surgery. Breath testing diagnoses; rifaximin is first-line treatment."
  },
  {
    "id": 145,
    "categoryId": 3,
    "question": "A 50-year-old male with chronic GERD has been on Omeprazole 40mg daily for 10 years. He is asymptomatic. According to ACG guidelines, he should be screened for Barrett's Esophagus if he has:",
    "options": [
      "A) No risk factors needed; all GERD patients get screened",
      "B) Chronic symptoms (>5 yrs) AND 2+ risk factors (Male, White, Age >50, Obesity, Family Hx)",
      "C) Only if he develops dysphagia",
      "D) Only if he smokes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic symptoms greater than 5 years AND 2 or more risk factors).\n\nPATHOPHYSIOLOGY:\nBarrett's esophagus develops when chronic gastroesophageal reflux causes the normal stratified squamous epithelium of the distal esophagus to undergo intestinal metaplasia, replacing it with specialized columnar epithelium containing goblet cells. This metaplastic change represents an adaptive response to chronic acid and bile exposure but carries a significantly increased risk of progression to esophageal adenocarcinoma, estimated at 0.5% per year.\n\nSCREENING CRITERIA:\nThe ACG guidelines recommend screening with upper endoscopy in patients with chronic GERD symptoms lasting more than 5 years who also have two or more additional risk factors: male sex, Caucasian race, age over 50, central obesity (waist circumference greater than 102 cm in men or greater than 88 cm in women), current or past smoking history, and first-degree family history of Barrett's esophagus or esophageal adenocarcinoma. Routine endoscopy for all GERD patients is not recommended because the vast majority will never develop Barrett's esophagus.\n\nDIAGNOSIS AND SURVEILLANCE:\nDiagnosis requires both endoscopic visualization of salmon-colored mucosa extending above the gastroesophageal junction and histologic confirmation of intestinal metaplasia with goblet cells. Once diagnosed, surveillance intervals depend on the presence and degree of dysplasia: no dysplasia warrants repeat endoscopy every 3-5 years, low-grade dysplasia every 6-12 months, and high-grade dysplasia prompts endoscopic eradication therapy with radiofrequency ablation.\n\nKEY POINTS:\nBarrett's esophagus screening requires chronic GERD greater than 5 years plus two or more risk factors (male, white, age over 50, central obesity, smoking, family history). Routine EGD is not indicated for all GERD patients. Barrett's carries a 0.5% annual risk of esophageal adenocarcinoma. High-grade dysplasia is treated with endoscopic radiofrequency ablation."
  },
  {
    "id": 146,
    "categoryId": 3,
    "question": "A 60-year-old female presents with mild LLQ pain and low-grade fever. CT confirms acute uncomplicated diverticulitis (no abscess/perforation). She is immunocompetent and tolerating liquids. What is the AGA guideline-recommended treatment?",
    "options": [
      "A) Ciprofloxacin + Metronidazole",
      "B) Amoxicillin-Clavulanate",
      "C) Clear liquid diet and observation (No Antibiotics)",
      "D) Surgical resection"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Selective Antibiotics â€” observation without antibiotics is appropriate).\n\nPATHOPHYSIOLOGY:\nDiverticulitis occurs when a diverticulum becomes inflamed or micro-perforated, traditionally attributed to fecalith obstruction. However, current understanding recognizes that mucosal inflammation, altered microbiome composition, and visceral hypersensitivity play important roles. Uncomplicated diverticulitis, defined as inflammation without abscess, perforation, obstruction, or fistula, accounts for approximately 75% of cases and has an excellent prognosis.\n\nPARADIGM SHIFT IN MANAGEMENT:\nThe AGA guideline and multiple randomized controlled trials (including the DIABOLO and AVOD trials) have demonstrated that immunocompetent patients with CT-confirmed uncomplicated diverticulitis have equivalent outcomes whether treated with or without antibiotics. Recovery time, complication rates, recurrence rates, and need for surgery showed no significant differences between antibiotic and no-antibiotic groups. This reflects the evolving understanding that uncomplicated diverticulitis is primarily an inflammatory rather than infectious process.\n\nCLINICAL APPLICATION:\nAppropriate candidates for observation without antibiotics include immunocompetent patients with CT-confirmed uncomplicated disease who are tolerating oral intake, have no significant comorbidities, and have reliable follow-up. Antibiotics remain indicated for complicated diverticulitis (abscess, perforation, fistula), immunosuppressed patients, patients with significant comorbidities, and those with systemic signs of sepsis. When antibiotics are prescribed, the standard regimen is ciprofloxacin plus metronidazole or amoxicillin-clavulanate for 7-10 days.\n\nKEY POINTS:\nAGA guidelines now recommend selective rather than routine antibiotic use for uncomplicated diverticulitis in immunocompetent patients. Randomized trials show equivalent outcomes with and without antibiotics. This reflects the understanding that uncomplicated diverticulitis is primarily inflammatory, not infectious. Antibiotics remain essential for complicated disease and immunosuppressed patients."
  },
  {
    "id": 147,
    "categoryId": 3,
    "question": "A 65-year-old female presents with chronic, watery, non-bloody diarrhea. Colonoscopy reveals visually normal mucosa. What MUST be done to rule out Microscopic Colitis?",
    "options": [
      "A) Stool O&P",
      "B) Random biopsies of the colon",
      "C) CT Abdomen",
      "D) Prometheus IBS blood panel"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Random biopsies of the colon).\n\nPATHOPHYSIOLOGY:\nMicroscopic colitis encompasses two subtypes, lymphocytic colitis and collagenous colitis, both characterized by chronic inflammation visible only on histology. In lymphocytic colitis, there is an increase in intraepithelial lymphocytes (greater than 20 per 100 epithelial cells). In collagenous colitis, a thickened subepithelial collagen band (greater than 10 micrometers) is the hallmark finding. The condition predominantly affects women over age 60 and is strongly associated with autoimmune disorders, celiac disease, and certain medications including PPIs, NSAIDs, SSRIs, and statins.\n\nCLINICAL PRESENTATION:\nPatients present with chronic, watery, non-bloody diarrhea that may produce 4-9 stools per day and can persist for months to years. Fecal urgency and nocturnal diarrhea are common, leading to significant impact on quality of life. Abdominal pain is typically mild or absent. inflammatory markers and stool studies are usually normal.\n\nDIAGNOSIS:\nThe defining feature of microscopic colitis is that the colonic mucosa appears completely normal on endoscopic inspection, making it a diagnosis that is invisible to the naked eye. Random biopsies from both the right and left colon during colonoscopy are absolutely required because the histologic changes may be patchy. Without biopsies, the diagnosis will be missed entirely.\n\nMANAGEMENT:\nOral budesonide is the first-line treatment, with clinical remission rates of 80% or higher within 2-4 weeks. Offending medications should be discontinued. Cholestyramine and bismuth subsalicylate are alternative options. Relapse is common upon budesonide discontinuation, and some patients require low-dose maintenance therapy.\n\nKEY POINTS:\nMicroscopic colitis causes chronic watery diarrhea with a visually normal colonoscopy, making random biopsies from both sides of the colon essential for diagnosis. It predominantly affects women over 60 and is linked to PPIs, NSAIDs, and SSRIs. Oral budesonide achieves remission in over 80% of cases."
  },
  {
    "id": 148,
    "categoryId": 3,
    "question": "Which medication is an antispasmodic specifically useful for post-prandial abdominal pain/cramping in IBS?",
    "options": [
      "A) Loperamide",
      "B) Dicyclomine (Bentyl)",
      "C) Ondansetron",
      "D) Famotidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dicyclomine/Bentyl).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome involves visceral hypersensitivity and disordered gastrointestinal motility, with the gastrocolic reflex (increased colonic contractility triggered by gastric distension after eating) often amplified. This exaggerated reflex produces post-prandial abdominal cramping and urgency that significantly impairs quality of life. Smooth muscle spasm in the colon is a major driver of pain in IBS.\n\nMECHANISM OF ACTION:\nDicyclomine is an anticholinergic antispasmodic that blocks muscarinic receptors on gastrointestinal smooth muscle, reducing the amplitude and frequency of colonic contractions. It also has a direct smooth muscle relaxant effect independent of its anticholinergic activity. A Cochrane meta-analysis demonstrated that antispasmodics are significantly more effective than placebo for global IBS symptom improvement, with a number needed to treat of approximately 5.\n\nCLINICAL APPLICATION:\nDicyclomine is most effective when taken 30-60 minutes before meals to preemptively blunt the gastrocolic reflex, rather than after symptoms have already developed. The typical starting dose is 20 mg four times daily before meals. Hyoscyamine is an alternative anticholinergic antispasmodic with similar efficacy. Common side effects include dry mouth, blurred vision, urinary retention, and constipation, and these agents should be used with caution in elderly patients due to anticholinergic burden.\n\nKEY POINTS:\nDicyclomine is an anticholinergic antispasmodic that reduces post-prandial IBS cramping by blocking the amplified gastrocolic reflex. It should be taken 30-60 minutes before meals for maximal benefit. Antispasmodics have a number needed to treat of approximately 5 for IBS symptom improvement. Anticholinergic side effects require caution in elderly patients."
  },
  {
    "id": 149,
    "categoryId": 3,
    "question": "A patient goes 'Gluten Free' on their own for 6 months and now wants to be tested for Celiac Disease. What is the correct approach?",
    "options": [
      "A) Order tTG-IgA immediately",
      "B) Order HLA-DQ2/DQ8 genetic testing",
      "C) Gluten Challenge (eat gluten daily for 2-6 weeks) then test",
      "D) Colonoscopy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Gluten challenge â€” the patient must be eating gluten for accurate testing).\n\nPATHOPHYSIOLOGY:\nCeliac disease is an autoimmune enteropathy triggered by gluten exposure in genetically susceptible individuals (HLA-DQ2 or HLA-DQ8 positive). Gluten-derived gliadin peptides activate an adaptive immune response that produces tissue transglutaminase IgA (tTG-IgA) antibodies and causes villous atrophy in the small intestine. both the serologic markers and the histologic changes are dependent on ongoing gluten exposure and will normalize on a gluten-free diet.\n\nCLINICAL REASONING:\nA patient who has been gluten-free for 6 months will likely have negative tTG-IgA and normal duodenal biopsies even if they truly have celiac disease, producing a false-negative result. The ACG guideline recommends a gluten challenge, in which the patient consumes the equivalent of at least 3 grams of gluten daily (approximately 1-2 slices of wheat bread) for a minimum of 2 weeks, ideally 6-8 weeks, before serologic testing. Some patients may not tolerate a full challenge duration, and testing can be performed earlier if symptoms recur, as antibodies may rise within 2 weeks of gluten reintroduction.\n\nALTERNATIVE APPROACH:\nHLA-DQ2/DQ8 genetic testing (Option B) can be performed regardless of diet because it tests for inherited genes, not immune response. However, HLA testing can only exclude celiac disease (negative predictive value >99%) but cannot confirm it, as approximately 30-40% of the general population carries these alleles without having celiac disease.\n\nKEY POINTS:\nCeliac serologies and biopsies require active gluten ingestion to be accurate and will be falsely negative on a gluten-free diet. A gluten challenge of 3 grams daily for 2-6 weeks is required before testing. HLA-DQ2/DQ8 testing is diet-independent but can only exclude, not confirm, celiac disease. Approximately 30-40% of the population carries HLA-DQ2 or DQ8 without having celiac disease."
  },
  {
    "id": 150,
    "categoryId": 3,
    "question": "In a patient with dyspepsia (heartburn/indigestion), which symptom is an absolute indication for immediate Upper Endoscopy (EGD)?",
    "options": [
      "A) Bloating",
      "B) Dysphagia (Difficulty swallowing)",
      "C) Nausea",
      "D) Belching"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dysphagia â€” difficulty swallowing).\n\nPATHOPHYSIOLOGY:\nDysphagia indicates mechanical obstruction or motility disorder of the esophagus and raises concern for serious underlying pathology including esophageal stricture (peptic or radiation-induced), esophageal adenocarcinoma, squamous cell carcinoma, eosinophilic esophagitis, esophageal rings or webs, and achalasia. In the context of chronic dyspepsia or GERD, new-onset dysphagia may signal the development of a peptic stricture from chronic inflammation or, more ominously, malignant transformation of Barrett's esophagus.\n\nCLINICAL SIGNIFICANCE:\nDysphagia is classified as an alarm feature (also called a red flag) in dyspepsia guidelines from the ACG and AGA. Other alarm features include unintentional weight loss greater than 5% of body weight, evidence of gastrointestinal bleeding (melena, hematemesis, iron deficiency anemia), persistent vomiting, palpable abdominal mass, and progressive dysphagia. The presence of any alarm feature mandates prompt upper endoscopy regardless of age or duration of symptoms, because empiric acid suppression without endoscopic evaluation risks delaying the diagnosis of malignancy.\n\nDIAGNOSTIC APPROACH:\nUpper endoscopy (EGD) allows direct visualization, tissue sampling, and potential therapeutic intervention (dilation of strictures). For patients under 60 without alarm features, the ACG recommends a non-invasive test-and-treat strategy for H. pylori before proceeding to endoscopy. Patients over 60 with new-onset dyspepsia should undergo endoscopy to rule out gastric malignancy, as gastric cancer incidence increases significantly with age.\n\nKEY POINTS:\nDysphagia is an alarm feature requiring immediate upper endoscopy regardless of age or symptom duration. Other alarm features include weight loss, GI bleeding, and persistent vomiting. Alarm features bypass the test-and-treat H. pylori strategy. In patients over 60 with new-onset dyspepsia, EGD is indicated to rule out gastric malignancy."
  },
  {
    "id": 151,
    "categoryId": 3,
    "question": "You treated a patient for H. pylori. You need to confirm eradication (Test of Cure). Which test is INAPPROPRIATE?",
    "options": [
      "A) Urea Breath Test",
      "B) Stool Antigen Test",
      "C) Serum Antibody (IgG)",
      "D) Repeat Biopsy (if EGD indicated)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Serum Antibody IgG).\n\nPATHOPHYSIOLOGY:\nHelicobacter pylori infection triggers a systemic immune response with production of IgG antibodies against bacterial antigens. These antibodies persist in the circulation for months to years after successful eradication, reflecting immunologic memory rather than active infection. Consequently, IgG serology cannot distinguish between active infection and prior exposure, making it fundamentally unsuitable for confirming eradication.\n\nAPPROPRIATE TESTS OF CURE:\nThe urea breath test (Option A) detects active H. pylori urease activity by measuring labeled carbon dioxide in exhaled breath after ingestion of carbon-13 or carbon-14 labeled urea. The stool antigen test (Option B) uses monoclonal antibodies to detect H. pylori antigens in feces and reflects current infection status. Both tests have sensitivity and specificity exceeding 95% for confirming eradication. Repeat biopsy during endoscopy (Option D) is appropriate when EGD is indicated for other reasons such as complicated ulcer disease or gastric ulcer follow-up.\n\nTESTING REQUIREMENTS:\nTest of cure should be performed at least 4 weeks after completing antibiotic therapy and at least 1-2 weeks after discontinuing PPI therapy. PPIs suppress H. pylori metabolic activity without eradicating it, which can produce false-negative results on breath testing and stool antigen testing. Bismuth compounds and antibiotics must also be withheld for a minimum of 4 weeks prior to testing.\n\nKEY POINTS:\nSerum IgG antibodies persist for months to years after eradication and cannot confirm cure. Urea breath test and stool antigen test are the preferred non-invasive tests of cure with >95% accuracy. PPIs must be discontinued 1-2 weeks before testing to avoid false negatives. Test of cure is performed at least 4 weeks after completing antibiotic therapy."
  },
  {
    "id": 152,
    "categoryId": 3,
    "question": "A patient has chronic epigastric pain and early satiety. EGD is normal. H. pylori is negative. This is Functional Dyspepsia. Which class of antidepressants can be helpful for the visceral pain component?",
    "options": [
      "A) Tricyclic Antidepressants (Amitriptyline)",
      "B) MAOIs",
      "C) Benzodiazepines",
      "D) Stimulants"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Tricyclic Antidepressants â€” Amitriptyline).\n\nPATHOPHYSIOLOGY:\nFunctional dyspepsia is a disorder of gut-brain interaction characterized by epigastric pain, postprandial fullness, early satiation, and epigastric burning without structural pathology on endoscopy. The pathophysiology involves visceral hypersensitivity (augmented perception of normal gastric stimuli), impaired gastric accommodation (failure of the fundus to relax after eating), delayed gastric emptying, and central nervous system dysregulation of pain processing. The gut-brain axis, mediated through vagal afferents and central pain modulation pathways, plays a central role.\n\nMECHANISM OF ACTION:\nTricyclic antidepressants modulate visceral pain through multiple mechanisms: they inhibit norepinephrine and serotonin reuptake in descending pain inhibitory pathways, block sodium channels in peripheral visceral afferent neurons, and have anticholinergic effects that slow gastric motility. The analgesic effect occurs at doses far below those required for antidepressant activity, typically 10-50 mg nightly. The landmark FD-TCA trial published in Gastroenterology demonstrated that amitriptyline provided significant symptomatic relief compared to placebo, particularly for the epigastric pain syndrome subtype.\n\nCLINICAL APPLICATION:\nAmitriptyline is typically started at 10 mg at bedtime and titrated upward by 10 mg every 2-4 weeks to a maximum of 50 mg, allowing time for therapeutic effect. Common side effects include dry mouth, constipation, drowsiness, and weight gain. SSRIs have not shown consistent benefit for functional dyspepsia. Mirtazapine may be considered when early satiation and weight loss are prominent due to its appetite-stimulating effects.\n\nKEY POINTS:\nFunctional dyspepsia is a disorder of gut-brain interaction involving visceral hypersensitivity and central pain dysregulation. Low-dose tricyclic antidepressants (amitriptyline 10-50 mg nightly) modulate visceral pain through descending inhibitory pathways. TCAs are particularly effective for the epigastric pain syndrome subtype. SSRIs have not shown consistent benefit for functional dyspepsia."
  },
  {
    "id": 153,
    "categoryId": 3,
    "question": "Current ACG first-line treatment for an initial episode of non-severe Clostridioides difficile (C. diff) infection?",
    "options": [
      "A) Oral Metronidazole",
      "B) Oral Fidaxomicin or Oral Vancomycin",
      "C) IV Vancomycin",
      "D) Fecal Transplant"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fidaxomicin or Oral Vancomycin).\n\nPATHOPHYSIOLOGY:\nClostridioides difficile is a spore-forming, toxin-producing anaerobic bacterium that causes infection when the normal gut microbiome is disrupted, most commonly by antibiotic exposure. C. difficile produces toxin A (enterotoxin) and toxin B (cytotoxin), which cause intestinal epithelial cell death, neutrophilic inflammation, and pseudomembrane formation. The disease spectrum ranges from mild diarrhea to fulminant colitis with toxic megacolon, perforation, and death.\n\nCURRENT GUIDELINE RECOMMENDATIONS:\nThe ACG guidelines recommend oral fidaxomicin (200 mg twice daily for 10 days) as the preferred first-line agent for initial non-severe C. difficile infection, with oral vancomycin (125 mg four times daily for 10 days) as an acceptable alternative. Fidaxomicin is preferred because it produces significantly lower recurrence rates compared to vancomycin (approximately 13% versus 27%) due to its narrow-spectrum activity that preserves the anaerobic gut microbiome. Oral metronidazole is no longer recommended as first-line therapy due to inferior cure rates compared to vancomycin.\n\nSEVERITY STRATIFICATION:\nNon-severe disease is defined by white blood cell count below 15,000 and serum creatinine below 1.5 mg/dL. Severe disease (WBC greater than 15,000 or creatinine greater than 1.5) warrants oral vancomycin or fidaxomicin. Fulminant disease (hypotension, shock, ileus, toxic megacolon) requires oral vancomycin 500 mg four times daily plus intravenous metronidazole 500 mg every 8 hours, with rectal vancomycin instillation if ileus is present. Fecal microbiota transplantation is recommended after two or more recurrences.\n\nKEY POINTS:\nFidaxomicin or oral vancomycin are first-line for initial non-severe C. difficile infection, replacing metronidazole. Fidaxomicin is preferred due to lower recurrence rates (13% versus 27%). Severity is stratified by WBC and creatinine. Fecal microbiota transplantation is recommended after two or more recurrences."
  },
  {
    "id": 154,
    "categoryId": 3,
    "question": "A patient on a PPI for GERD asks about stopping. You advise tapering slowly to avoid:",
    "options": [
      "A) Withdrawal seizures",
      "B) Rebound Acid Hypersecretion",
      "C) Hypotension",
      "D) Constipation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rebound Acid Hypersecretion).\n\nPATHOPHYSIOLOGY:\nDuring chronic PPI use, the body compensates for reduced acid by increasing gastrin secretion and parietal cell mass (hyperplasia). When the PPI is stopped abruptly, these upregulated mechanisms produce acid output that exceeds pre-treatment levels, causing rebound symptoms worse than the original complaint.\n\nCLINICAL PRESENTATION:\nPatients who abruptly discontinue PPIs often experience severe heartburn, dyspepsia, and acid regurgitation within days, even if they had minimal symptoms before starting the medication. This can create a cycle of dependence where patients believe they \"need\" the PPI.\n\nDURATION AND MANAGEMENT:\nRebound hypersecretion can last 2-4 weeks or longer. Gradual tapering over 2-4 weeks reduces rebound severity. Strategies include dose reduction (from twice daily to once daily, then every other day), switching to H2 blockers as a bridge, and using antacids for breakthrough symptoms during the taper.\n\nCLINICAL IMPLICATIONS:\nThis phenomenon contributes to long-term PPI overuse. Patients should be counseled before starting PPIs that discontinuation may temporarily worsen symptoms, and a tapering plan should be established.\n\nKEY POINTS:\nAbrupt PPI discontinuation causes rebound acid hypersecretion due to compensatory gastrin elevation and parietal cell hyperplasia. Symptoms can exceed baseline and last 2-4 weeks. Gradual tapering over 2-4 weeks minimizes rebound effects."
  },
  {
    "id": 155,
    "categoryId": 3,
    "question": "A patient with chronic constipation has failed fiber, water, and laxatives. They report 'straining' even with soft stool and a feeling of incomplete evacuation. The next best diagnostic test is:",
    "options": [
      "A) Colonoscopy",
      "B) Anorectal Manometry",
      "C) CT Abdomen",
      "D) Sitz Marker Study"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anorectal Manometry).\n\nPATHOPHYSIOLOGY:\nDyssynergic defecation (also called pelvic floor dyssynergia) is a functional defecation disorder in which the pelvic floor muscles and external anal sphincter paradoxically contract rather than relax during attempted evacuation. Under normal conditions, the act of defecation involves coordinated relaxation of the puborectalis muscle and external anal sphincter combined with increased intra-abdominal pressure. In dyssynergia, this coordination fails, producing a functional outlet obstruction that prevents effective evacuation even when stool is soft.\n\nCLINICAL PRESENTATION:\nPatients typically describe excessive straining with defecation, a sensation of incomplete evacuation, the need for digital facilitation, and symptoms that persist despite adequate fiber intake, hydration, and osmotic laxatives. The diagnosis should be suspected in any patient with chronic constipation refractory to standard medical therapy, particularly when straining occurs even with soft stool formation. Dyssynergic defecation accounts for approximately 40% of patients referred for refractory constipation.\n\nDIAGNOSIS AND TREATMENT:\nAnorectal manometry is the key diagnostic test, measuring sphincter pressures and coordination during simulated defecation. It identifies the paradoxical contraction pattern by demonstrating increased rather than decreased anal sphincter pressure during bearing down. Balloon expulsion testing is a complementary test in which the patient attempts to expel a water-filled balloon, with failure to expel within 60 seconds supporting the diagnosis. The standard treatment is pelvic floor biofeedback therapy, which retrains patients to properly coordinate relaxation during defecation and achieves success rates of 70-80% in randomized trials.\n\nKEY POINTS:\nDyssynergic defecation causes refractory constipation due to paradoxical pelvic floor contraction during evacuation. Anorectal manometry is the diagnostic test of choice, demonstrating paradoxical sphincter contraction. Biofeedback therapy is the standard treatment with 70-80% success rates. Suspect this diagnosis when constipation persists despite adequate softening of stool."
  },
  {
    "id": 156,
    "categoryId": 3,
    "question": "The Low FODMAP diet reduces bloating by restricting:",
    "options": [
      "A) Fat and Protein",
      "B) Fermentable Oligo-, Di-, Mono-saccharides And Polyols",
      "C) Gluten and Casein",
      "D) Histamine rich foods"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fermentable Oligo-, Di-, Mono-saccharides And Polyols).\n\nPATHOPHYSIOLOGY:\nFODMAPs are short-chain carbohydrates that share two key properties: they are poorly absorbed in the small intestine and are rapidly fermented by colonic bacteria. This combination produces both an osmotic effect (drawing water into the intestinal lumen, causing diarrhea) and a gas-producing effect (bacterial fermentation generates hydrogen, methane, and carbon dioxide, causing bloating and distension). Common high-FODMAP foods include garlic, onions, wheat, apples, pears, milk (lactose), honey (excess fructose), beans (galacto-oligosaccharides), and sugar-free sweeteners containing sorbitol or mannitol.\n\nCLINICAL APPLICATION:\nThe low FODMAP diet is an evidence-based dietary intervention for IBS, with randomized trials demonstrating symptom improvement in 50-80% of patients. The diet is implemented in three phases: elimination (strict FODMAP restriction for 2-6 weeks), reintroduction (systematic testing of individual FODMAP groups to identify personal triggers), and personalization (long-term modified diet avoiding only identified triggers). The reintroduction phase is critical because the goal is not lifelong restriction but rather identification of individual sensitivities.\n\nCLINICAL CONSIDERATIONS:\nThe diet should be supervised by a dietitian experienced in FODMAPs to ensure nutritional adequacy and proper reintroduction methodology. Long-term strict FODMAP restriction is not recommended because it reduces beneficial bifidobacteria and overall microbial diversity. The diet may also reduce caloric intake, particularly in patients who are already underweight. It is not appropriate for diagnosing or managing celiac disease, food allergies, or inflammatory bowel disease.\n\nKEY POINTS:\nFODMAPs are poorly absorbed, rapidly fermented carbohydrates that cause osmotic diarrhea and gas production in the colon. The low FODMAP diet improves IBS symptoms in 50-80% of patients through a three-phase approach: elimination, reintroduction, and personalization. Long-term strict restriction is discouraged due to adverse effects on the gut microbiome. Dietitian supervision ensures proper implementation."
  },
  {
    "id": 157,
    "categoryId": 3,
    "question": "Gilbert's Syndrome typically presents as:",
    "options": [
      "A) Elevated Direct Bilirubin and itching",
      "B) Isolated Mild Indirect (Unconjugated) Hyperbilirubinemia, often triggered by stress/fasting",
      "C) Elevated ALT/AST > 1000",
      "D) Elevated Alkaline Phosphatase"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Isolated mild indirect/unconjugated hyperbilirubinemia, often triggered by stress or fasting).\n\nPATHOPHYSIOLOGY:\nGilbert's syndrome is the most common inherited disorder of bilirubin metabolism, affecting approximately 5-10% of the population. It results from a genetic polymorphism in the UGT1A1 gene promoter region (typically a TA repeat insertion) that reduces the activity of uridine diphosphate-glucuronosyltransferase to approximately 30% of normal. This enzyme is responsible for conjugating indirect (unconjugated) bilirubin in hepatocytes, making it water-soluble for biliary excretion. The reduced enzyme activity causes mild accumulation of unconjugated bilirubin, typically between 1-3 mg/dL.\n\nCLINICAL PRESENTATION:\nGilbert's syndrome is characteristically asymptomatic and discovered incidentally on routine laboratory testing. Episodes of visible jaundice or scleral icterus may be precipitated by fasting (reduced hepatic UDP-glucuronic acid availability), physical stress, illness, sleep deprivation, dehydration, or menstruation. all liver enzymes (AST, ALT, alkaline phosphatase, GGT) are completely normal, direct bilirubin is normal, and there is no evidence of hemolysis (normal reticulocyte count, haptoglobin, and LDH). The condition is entirely benign and requires no treatment.\n\nDIFFERENTIAL DIAGNOSIS:\nOther causes of unconjugated hyperbilirubinemia include hemolytic anemias (elevated LDH, low haptoglobin, reticulocytosis), ineffective erythropoiesis (megaloblastic anemia, thalassemia), and Crigler-Najjar syndrome (types I and II, which present with more severe hyperbilirubinemia, often in neonates). Elevated direct bilirubin suggests hepatocellular disease or biliary obstruction and is not.\n\nKEY POINTS:\nGilbert's syndrome affects 5-10% of the population and results from reduced UGT1A1 enzyme activity causing mild unconjugated hyperbilirubinemia. Jaundice is triggered by fasting, stress, or illness. All liver enzymes and direct bilirubin are normal. It is entirely benign and requires no treatment, but awareness prevents unnecessary workup."
  },
  {
    "id": 158,
    "categoryId": 3,
    "question": "Most common cause of Lower GI Bleed (hematochezia) in adults > 60?",
    "options": [
      "A) Colon Cancer",
      "B) Diverticulosis",
      "C) Hemorrhoids",
      "D) IBD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Diverticulosis).\n\nPATHOPHYSIOLOGY:\nDiverticulosis affects over 50% of adults over age 60 in Western countries. Diverticula form when mucosa herniates through weak points in the colonic wall where vasa recta penetrate the muscular layer. These arterial vessels become draped over the dome of the diverticulum, separated from the lumen only by thin mucosa. Erosion of these exposed vessels causes painless, often massive hemorrhage. Despite the dramatic presentation, approximately 80% of diverticular bleeds stop spontaneously.\n\nCLINICAL PRESENTATION:\nDiverticular bleeding typically presents with sudden, painless, large-volume hematochezia (bright red or maroon blood per rectum). Unlike diverticulitis, there is no abdominal pain, fever, or leukocytosis. Hemodynamic instability may occur with significant blood loss. The bleeding source is usually in the right colon (ascending or cecum), even though diverticula are more common in the left colon, because right-sided diverticula have wider necks and thinner walls.\n\nDIFFERENTIAL DIAGNOSIS:\nOther common causes of lower GI bleeding include hemorrhoids (most common overall cause of rectal bleeding, typically small volume with defecation), angiodysplasia (arteriovenous malformations, more common in elderly and those with renal disease or aortic stenosis), colorectal cancer and polyps, ischemic colitis (typically causes bloody diarrhea with abdominal pain), and inflammatory bowel disease.\n\nMANAGEMENT:\nInitial management includes hemodynamic resuscitation and correction of coagulopathy. Colonoscopy after bowel preparation is both diagnostic and potentially therapeutic (epinephrine injection, clipping, or cautery). CT angiography or tagged red blood cell scan can localize active bleeding when colonoscopy is not feasible.\n\nKEY POINTS:\nDiverticulosis is a common cause of major lower GI bleeding in adults. Bleeding is typically painless and massive but stops spontaneously in 80% of cases. Right-sided diverticula bleed more often despite left-sided predominance. Colonoscopy is diagnostic and therapeutic after stabilization."
  },
  {
    "id": 159,
    "categoryId": 3,
    "question": "Which vitamin deficiency is commonly seen in SIBO because bacteria consume it?",
    "options": [
      "A) Vitamin K",
      "B) Vitamin B12",
      "C) Folate",
      "D) Vitamin C"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin B12).\n\nPATHOPHYSIOLOGY:\nIn small intestinal bacterial overgrowth (SIBO), colonic-type bacteria proliferate abnormally in the small bowel, where they compete with the host for nutrients. These bacteria avidly consume vitamin B12 (cobalamin) and utilize it for their own metabolic processes, significantly reducing the amount available for absorption in the terminal ileum. In a clinically important contrast, bacterial metabolism actually produces folate as a byproduct, which explains why patients with SIBO characteristically have low B12 but normal or elevated folate levels. This dissociation between B12 and folate is an important diagnostic clue that helps distinguish SIBO from other causes of macrocytic anemia.\n\nCLINICAL MANIFESTATIONS:\nB12 deficiency in SIBO can produce macrocytic anemia (MCV greater than 100 fL), glossitis, and angular cheilitis. Neurologic complications develop with prolonged deficiency and include peripheral neuropathy (paresthesias in a stocking-glove distribution), subacute combined degeneration of the spinal cord (posterior column and lateral corticospinal tract demyelination), gait ataxia, and cognitive impairment. Neurologic damage may be irreversible if not corrected promptly.\n\nDIAGNOSIS AND TREATMENT:\nSerum B12 levels should be checked in all symptomatic SIBO patients, particularly those with anemia or neurologic symptoms. Methylmalonic acid and homocysteine levels are more sensitive markers of functional B12 deficiency when serum B12 is borderline (200-400 pg/mL). Treatment requires both eradication of SIBO (typically with rifaximin) and B12 repletion. Parenteral B12 (intramuscular injections) may be preferred initially in patients with significant malabsorption or neurologic involvement, as oral supplementation depends on intact absorption.\n\nKEY POINTS:\nSIBO causes B12 deficiency because overgrown bacteria consume B12, while simultaneously producing folate, creating a characteristic low B12 with normal or elevated folate pattern. Neurologic complications of B12 deficiency can be irreversible. Methylmalonic acid is a sensitive marker when B12 is borderline. Treatment addresses both SIBO eradication and B12 repletion."
  },
  {
    "id": 160,
    "categoryId": 3,
    "question": "Chronic Pancreatitis (often alcohol-induced) leads to Exocrine Insufficiency. The classic symptom is:",
    "options": [
      "A) Constipation",
      "B) Steatorrhea (Greasy, floating, foul-smelling stool)",
      "C) Melena",
      "D) Hematemesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Steatorrhea).\n\nPATHOPHYSIOLOGY:\nChronic pancreatitis is a progressive inflammatory condition that destroys pancreatic parenchyma over years, replacing functional acinar and islet tissue with fibrosis and calcification. Alcohol accounts for approximately 50-70% of cases, with the remainder caused by genetic mutations (PRSS1, SPINK1, CFTR), autoimmune disease, recurrent acute pancreatitis, and idiopathic causes. The exocrine pancreas has enormous functional reserve, and steatorrhea does not develop until approximately 90% of lipase-secreting capacity has been lost, meaning that fat malabsorption represents advanced, irreversible disease.\n\nCLINICAL PRESENTATION:\nSteatorrhea is the key sign of exocrine pancreatic insufficiency. Stools are characteristically pale, greasy, bulky, foul-smelling, and float due to their high fat content. Patients may notice an oily residue in the toilet bowl or stools that are difficult to flush. Fat malabsorption leads to deficiency of fat-soluble vitamins (A, D, E, K), causing night blindness, osteoporosis, coagulopathy, and neuropathy. Weight loss occurs despite adequate caloric intake. Chronic epigastric pain radiating to the back is common and often requires escalating analgesia.\n\nDIAGNOSIS AND MANAGEMENT:\nFecal elastase-1 is the preferred non-invasive test for exocrine insufficiency, with levels below 200 mcg/g indicating insufficiency and below 100 mcg/g indicating severe insufficiency. CT imaging may reveal pancreatic calcifications, ductal dilation, and parenchymal atrophy, which are pathognomonic for chronic pancreatitis. Pancreatic enzyme replacement therapy (PERT) with meals is the main treatment. Lipase doses of 40,000-50,000 units per meal and 25,000 units per snack are typical starting points, titrated to symptom response. A PPI may be added to prevent acid degradation of enzyme supplements. Alcohol cessation is essential to slow disease progression.\n\nKEY POINTS:\nSteatorrhea indicates that over 90% of exocrine function has been lost and represents advanced chronic pancreatitis. Fecal elastase-1 is the preferred non-invasive diagnostic test. Pancreatic enzyme replacement therapy with meals is the mainstay of treatment. Fat-soluble vitamin deficiencies (A, D, E, K) should be monitored in all patients with exocrine insufficiency."
  },
  {
    "id": 161,
    "categoryId": 16,
    "question": "A patient has a first-degree relative with Colon Cancer diagnosed at age 50. When should the patient begin screening?",
    "options": [
      "A) Age 45",
      "B) Age 40 (or 10 years before diagnosis)",
      "C) Age 50",
      "D) Age 35"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Age 40 or 10 years before the relative's diagnosis, whichever comes first).\n\nGUIDELINE BASIS:\nFor individuals with a first-degree relative (parent, sibling, or child) diagnosed with colorectal cancer before age 60, both the ACS and ACG recommend initiating screening at age 40 or 10 years before the age of the relative's diagnosis, whichever is earlier. In this case, the relative was diagnosed at age 50, so screening should begin at age 40 (10 years prior). Colonoscopy is the preferred screening modality for high-risk individuals and should be repeated every 5 years (rather than the standard 10-year interval for average-risk patients).\n\nRISK STRATIFICATION:\nHaving a first-degree relative with CRC diagnosed before age 60 approximately doubles the lifetime risk of colorectal cancer compared to the general population. If the first-degree relative was diagnosed at age 60 or older, the risk increase is more modest, and screening can begin at age 40 with a standard 10-year colonoscopy interval. Multiple first-degree relatives with CRC or a relative with an advanced adenoma before age 60 further increases risk and warrants earlier and more frequent surveillance.\n\nHEREDITARY SYNDROMES:\nClinicians should evaluate family history for patterns suggestive of hereditary syndromes such as Lynch syndrome (hereditary nonpolyposis colorectal cancer, HNPCC) or familial adenomatous polyposis (FAP), which require genetic counseling, earlier screening (as young as age 20 to 25 for Lynch, age 10 to 12 for FAP), and more frequent surveillance. Red flags include multiple generations affected, early-onset cancers, and associated extracolonic malignancies (endometrial, ovarian, urinary tract in Lynch syndrome).\n\nKEY POINTS:\nFirst-degree relative with CRC diagnosed before age 60 triggers screening at age 40 or 10 years before the relative's diagnosis (whichever is earlier) with colonoscopy every 5 years. This is earlier and more frequent than the average-risk recommendation of age 45 with 10-year intervals. Family history patterns suggestive of Lynch syndrome or FAP require genetic evaluation and even earlier screening."
  },
  {
    "id": 162,
    "categoryId": 3,
    "question": "Eosinophilic Esophagitis (EoE) is strongly associated with which comorbidity?",
    "options": [
      "A) Diabetes",
      "B) Atopic Disease (Asthma, Eczema, Allergies)",
      "C) Alcohol use",
      "D) Smoking"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Atopic Disease â€” Asthma, Eczema, Allergies).\n\nPATHOPHYSIOLOGY:\nEosinophilic esophagitis (EoE) is a chronic, immune-mediated inflammatory disease of the esophagus driven by a Th2-type allergic response to food and possibly environmental antigens. Exposure to allergens triggers release of interleukin-5 (IL-5) and IL-13, which recruit eosinophils to the esophageal mucosa and stimulate esophageal epithelial remodeling. Over time, chronic eosinophilic infiltration leads to subepithelial fibrosis, muscular hypertrophy, and esophageal stricture formation. The disease shares its immunologic foundation with other atopic conditions, which is why it has been called the \"asthma of the esophagus.\"\n\nCLINICAL PRESENTATION:\nEoE predominantly affects young males (male-to-female ratio of 3:1) with a strong personal or family history of atopic disease. Approximately 50-80% of EoE patients have concurrent asthma, allergic rhinitis, eczema, or food allergies. Adults typically present with dysphagia to solids and food impaction episodes, while children may present with feeding difficulties, vomiting, and failure to thrive. Endoscopic findings include esophageal rings (trachealization), linear furrows, white exudates (representing eosinophilic microabscesses), and strictures.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires esophageal biopsies showing 15 or more eosinophils per high-power field after excluding other causes of esophageal eosinophilia, particularly GERD. Current first-line treatment options include proton pump inhibitors (which have direct anti-inflammatory effects in EoE), swallowed topical corticosteroids (fluticasone or budesonide), and dietary elimination therapy. Dupilumab, an anti-IL-4 receptor alpha monoclonal antibody, is FDA-approved for EoE and represents the first biologic therapy for this condition.\n\nKEY POINTS:\nEoE is strongly associated with atopic disease, with 50-80% of patients having concurrent asthma, eczema, or food allergies. Diagnosis requires 15 or more eosinophils per high-power field on esophageal biopsy. First-line treatments include PPIs, swallowed topical corticosteroids, and dietary elimination. Dupilumab is the first FDA-approved biologic for EoE."
  },
  {
    "id": 163,
    "categoryId": 3,
    "question": "Chronic cannabis use is paradoxically associated with:",
    "options": [
      "A) Increased appetite only",
      "B) Hyperemesis Syndrome (cyclic vomiting relieved by hot showers)",
      "C) Constipation",
      "D) Peptic Ulcers"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cannabinoid Hyperemesis Syndrome â€” cyclic vomiting relieved by hot showers).\n\nPATHOPHYSIOLOGY:\nCannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which chronic cannabis use (typically daily use for more than one year) causes recurrent episodes of severe nausea, vomiting, and abdominal pain despite the well-known antiemetic properties of cannabinoids. The pathophysiology is not fully understood, but chronic overstimulation of CB1 receptors in the enteric nervous system and hypothalamus is believed to dysregulate the emetic threshold and gastric motility. Cannabis accumulates in fat tissue, so chronic users maintain persistently elevated levels that may desensitize central antiemetic CB1 pathways while overstimulating peripheral CB1 receptors that slow gastric emptying.\n\nCLINICAL PRESENTATION:\nCHS presents in three phases: a prodromal phase with early morning nausea and vague abdominal discomfort, a hyperemetic phase with intractable vomiting and compulsive hot bathing or showering (which temporarily relieves symptoms by activating TRPV1 thermoreceptors in the skin that counteract visceral CB1-mediated nausea), and a recovery phase after cannabis cessation. Patients often present repeatedly to emergency departments before the diagnosis is made, frequently undergoing extensive and costly negative workups.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis is clinical, based on chronic cannabis use (greater than one year), recurrent severe vomiting, and the characteristic relief with hot water bathing. The Rome IV criteria include these features. Capsaicin cream applied topically to the abdomen (also a TRPV1 agonist) has shown benefit in acute episodes. Haloperidol is effective for acute symptom relief in the emergency setting. The only definitive treatment is complete cannabis cessation, after which symptoms typically resolve within 1-2 weeks and do not recur unless use resumes.\n\nKEY POINTS:\nCHS should be suspected in any chronic daily cannabis user presenting with cyclic vomiting and compulsive hot shower use. The condition results from chronic CB1 receptor overstimulation in the gut. Topical capsaicin and haloperidol provide acute symptomatic relief. Complete cannabis cessation is the only definitive treatment."
  },
  {
    "id": 164,
    "categoryId": 3,
    "question": "Which lifestyle modification has the strongest evidence for improving nocturnal GERD?",
    "options": [
      "A) Avoiding spicy food",
      "B) Elevating the head of the bed (or sleeping on left side)",
      "C) Eating more fiber",
      "D) Drinking milk before bed"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Elevating the head of the bed or sleeping on the left side).\n\nPATHOPHYSIOLOGY:\nNocturnal GERD occurs because the supine position eliminates gravity-assisted esophageal acid clearance, prolongs acid contact time with the esophageal mucosa, and reduces the frequency of swallowing (which normally triggers primary peristalsis to clear refluxate). Studies using 24-hour pH monitoring have demonstrated that supine acid exposure is a stronger predictor of esophageal mucosal injury than upright reflux. Additionally, the recumbent position places the gastroesophageal junction at the same level as the gastric acid pool, facilitating retrograde flow.\n\nEVIDENCE BASE:\nElevating the head of the bed by 6-8 inches (using bed blocks or a wedge pillow, not simply stacking pillows, which only flexes the neck) harnesses gravity to keep the gastroesophageal junction above the gastric acid pool. Randomized controlled trials demonstrate significant reductions in acid exposure time, reflux episodes, and symptom severity with bed elevation. Sleeping in the left lateral decubitus position further reduces reflux because the gastric cardia and esophagogastric junction are positioned above the gastric acid pool due to the anatomic J-shape of the stomach, whereas right-side sleeping places the junction below the acid pool, increasing reflux.\n\nCLINICAL APPLICATION:\nThe combination of head-of-bed elevation with left lateral positioning provides additive benefit and represents the strongest evidence-based lifestyle modification for nocturnal GERD. Other important behavioral measures include avoiding meals within 2-3 hours of bedtime and avoiding alcohol and high-fat foods in the evening, which delay gastric emptying and reduce lower esophageal sphincter pressure.\n\nKEY POINTS:\nElevating the head of the bed by 6-8 inches and left lateral sleeping position have the strongest evidence among lifestyle modifications for nocturnal GERD. Bed elevation should use blocks or a wedge pillow, not stacked pillows. Right-side sleeping worsens reflux due to gastric anatomy. Avoiding meals 2-3 hours before bedtime provides additional benefit."
  },
  {
    "id": 165,
    "categoryId": 3,
    "question": "For IBS-C (Constipation), which secretagogue is approved and works by increasing cGMP to secrete fluid into the gut?",
    "options": [
      "A) Polyethylene Glycol (Miralax)",
      "B) Linaclotide (Linzess)",
      "C) Senna",
      "D) Docusate"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Linaclotide/Linzess).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome with constipation (IBS-C) involves disordered intestinal motility and visceral hypersensitivity, with reduced intestinal fluid secretion contributing to hard stools and incomplete evacuation. The guanylate cyclase-C (GC-C) receptor system, located on the luminal surface of intestinal epithelial cells, helps regulating fluid and electrolyte secretion into the intestinal lumen.\n\nMECHANISM OF ACTION:\nLinaclotide is a GC-C receptor agonist that binds to GC-C on enterocytes, increasing intracellular cyclic guanosine monophosphate (cGMP). Elevated intracellular cGMP activates the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel, driving chloride and bicarbonate secretion into the intestinal lumen, followed by sodium and water through a paracellular pathway. This accelerates intestinal transit and softens stool. extracellular cGMP also acts on submucosal pain-sensing afferent neurons to reduce visceral hypersensitivity, providing an analgesic effect that distinguishes linaclotide from simple laxatives.\n\nCLINICAL APPLICATION:\nLinaclotide is FDA-approved for IBS-C (290 mcg daily) and chronic idiopathic constipation (145 mcg daily). It should be taken on an empty stomach at least 30 minutes before the first meal of the day to maximize efficacy. The most common adverse effect is diarrhea, occurring in approximately 16-20% of patients. Linaclotide is contraindicated in children under 2 years old due to risk of severe dehydration. Plecanatide is another GC-C agonist with a similar mechanism but lower diarrhea rates.\n\nKEY POINTS:\nLinaclotide is a GC-C agonist that increases intestinal cGMP, activating CFTR chloride channels to secrete fluid into the gut lumen. It uniquely reduces visceral pain through extracellular cGMP effects on submucosal afferents. It is taken 30 minutes before the first meal. Diarrhea is the most common side effect, occurring in 16-20% of patients."
  },
  {
    "id": 166,
    "categoryId": 3,
    "question": "Typical presentation of Biliary Colic?",
    "options": [
      "A) Constant LLQ pain",
      "B) RUQ/Epigastric pain occurring 30-60 mins after a fatty meal, lasting 1-4 hours",
      "C) Burning chest pain relieved by antacids",
      "D) Periumbilical pain migrating to RLQ"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (RUQ/Epigastric pain occurring 30-60 minutes after a fatty meal, lasting 1-4 hours).\n\nPATHOPHYSIOLOGY:\nBiliary colic occurs when a gallstone temporarily obstructs the cystic duct during gallbladder contraction. Cholecystokinin (CCK), released from duodenal I-cells in response to fatty food entering the duodenum, stimulates gallbladder contraction. When a stone impacts the cystic duct, the gallbladder contracts against a fixed obstruction, producing visceral pain. Despite the name \"colic,\" the pain is typically steady rather than wavelike, as the gallbladder maintains sustained contraction. When the stone dislodges or falls back into the gallbladder, the obstruction resolves and pain subsides.\n\nCLINICAL PRESENTATION:\nPain characteristically begins 30-60 minutes after a fatty meal, localizes to the right upper quadrant or epigastrium, may radiate to the right scapula or shoulder (referred pain via the phrenic nerve and C3-C5 dermatomes), and lasts 1-4 hours before resolving completely. Episodes are typically intermittent, with symptom-free intervals of days to months. Nausea and vomiting are common accompaniments. the physical examination between episodes is entirely normal, and laboratory values (liver enzymes, bilirubin, lipase) are normal.\n\nDIFFERENTIAL DIAGNOSIS AND MANAGEMENT:\nIf pain persists beyond 4-6 hours or is accompanied by fever and leukocytosis, acute cholecystitis (sustained cystic duct obstruction with gallbladder wall inflammation) should be suspected. Ultrasound is the imaging study of choice, with sensitivity exceeding 95% for gallstones. Elective laparoscopic cholecystectomy is recommended for symptomatic gallstones, as recurrent episodes occur in approximately 70% of patients within 2 years. A HIDA scan is used when cholecystitis is suspected but ultrasound is equivocal.\n\nKEY POINTS:\nBiliary colic presents as steady RUQ or epigastric pain 30-60 minutes after fatty meals, lasting 1-4 hours before complete resolution. Pain persisting beyond 4-6 hours with fever suggests progression to acute cholecystitis. Ultrasound is the first-line imaging study with >95% sensitivity for gallstones. Elective cholecystectomy is recommended because recurrence approaches 70% within 2 years."
  },
  {
    "id": 167,
    "categoryId": 3,
    "question": "A Hiatal Hernia contributes to GERD primarily by:",
    "options": [
      "A) Increasing acid production",
      "B) Displacing the Lower Esophageal Sphincter (LES) into the chest, reducing the diaphragm's pinchcock effect",
      "C) Causing H. pylori infection",
      "D) Slowing gastric emptying"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Displacing the LES into the chest, reducing the diaphragm's pinchcock effect).\n\nPATHOPHYSIOLOGY:\nThe lower esophageal sphincter (LES) normally functions as an anti-reflux barrier through two complementary mechanisms: intrinsic smooth muscle tone of the LES itself and extrinsic compression by the crural diaphragm, which wraps around the distal esophagus at the hiatus and provides a \"pinchcock\" effect during inspiration. In a sliding hiatal hernia (type I, accounting for 95% of hiatal hernias), the gastroesophageal junction migrates cephalad through the diaphragmatic hiatus into the thorax, physically separating the LES from the crural diaphragm.\n\nCLINICAL SIGNIFICANCE:\nThis anatomic displacement eliminates the extrinsic diaphragmatic compression, reducing total anti-reflux barrier pressure by approximately 50%. The herniated gastric pouch above the diaphragm also creates an acid reservoir that can re-reflux into the esophagus during swallow-induced LES relaxation. Additionally, hiatal hernias impair esophageal acid clearance by trapping acid in the hernial sac. The combination of reduced LES pressure, an acid reservoir, and impaired clearance makes hiatal hernia one of the most important anatomic contributors to GERD severity.\n\nDIAGNOSIS AND MANAGEMENT:\nHiatal hernias are commonly identified on upper endoscopy, barium swallow, or CT imaging. Most small, asymptomatic sliding hernias require no treatment. Medical management of associated GERD follows standard guidelines (lifestyle modifications, PPIs). Surgical repair (fundoplication with hiatal hernia reduction) is considered for patients with refractory symptoms, large hernias (greater than 5 cm), or paraesophageal hernias (type II-IV) due to risk of volvulus and strangulation.\n\nKEY POINTS:\nHiatal hernias cause GERD primarily by separating the LES from the crural diaphragm, eliminating extrinsic compression and reducing anti-reflux barrier pressure by approximately 50%. The herniated gastric pouch creates an acid reservoir above the diaphragm. Sliding (type I) hernias account for 95% of cases. Surgical repair is considered for refractory symptoms, large hernias, or paraesophageal hernias."
  },
  {
    "id": 168,
    "categoryId": 3,
    "question": "A 70-year-old on Clopidogrel (Plavix) needs a colonoscopy for screening. Management?",
    "options": [
      "A) Continue Clopidogrel",
      "B) Stop Clopidogrel 5-7 days prior (if cardio risk permits)",
      "C) Switch to Warfarin",
      "D) Stop Aspirin only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stop Clopidogrel 5-7 days prior if cardiology risk permits).\n\nPATHOPHYSIOLOGY:\nClopidogrel (Plavix) is an irreversible P2Y12 ADP receptor antagonist that inhibits platelet aggregation for the entire 7-10 day lifespan of the platelet. Because the inhibition is irreversible, platelet function only recovers as new, uninhibited platelets are produced by the bone marrow. Polypectomy during colonoscopy carries a risk of delayed post-polypectomy bleeding of 1-2%, and this risk increases significantly when antiplatelet agents are continued.\n\nGUIDELINE RECOMMENDATIONS:\nThe ASGE/AHA guidelines recommend discontinuing clopidogrel 5-7 days prior to colonoscopy when polypectomy is anticipated, allowing sufficient new platelet production to restore adequate hemostasis. This decision must be made in collaboration with the prescribing cardiologist, particularly in patients with recent coronary stent placement, because premature discontinuation of dual antiplatelet therapy within 6 months of a drug-eluting stent carries a significant risk of in-stent thrombosis, which has a mortality rate of approximately 20-40%.\n\nCLINICAL NUANCES:\nAspirin is generally continued through colonoscopy and polypectomy because the bleeding risk associated with aspirin alone is minimal and the cardiovascular risk of stopping it outweighs the procedural bleeding risk. For patients in whom clopidogrel cannot be safely stopped (recent stent, high thrombotic risk), the procedure should be deferred until the minimum antiplatelet duration is completed, or the colonoscopy can proceed with biopsy only and cold snare polypectomy of small polyps, which carry lower bleeding risk than hot polypectomy.\n\nKEY POINTS:\nClopidogrel must be held 5-7 days before colonoscopy with anticipated polypectomy due to irreversible platelet inhibition. Aspirin is usually continued through the procedure. Cardiology clearance is essential, especially in patients with recent coronary stents. In high-thrombotic-risk patients, cold snare polypectomy is a safer alternative to hot polypectomy."
  },
  {
    "id": 169,
    "categoryId": 3,
    "question": "Secondary Lactose Intolerance is commonly seen after:",
    "options": [
      "A) Viral Gastroenteritis",
      "B) Constipation",
      "C) Appendectomy",
      "D) PPI use"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Viral Gastroenteritis).\n\nPATHOPHYSIOLOGY:\nLactase is a brush border enzyme located exclusively at the tips of the small intestinal villi, making it the most vulnerable of all disaccharidases to mucosal injury. Viral gastroenteritis (caused by rotavirus, norovirus, and other enteric viruses) damages the intestinal epithelium and shears off villous tips, causing a transient loss of lactase activity. This secondary (acquired) lactose intolerance is distinct from primary lactase non-persistence (the genetically programmed downregulation of lactase that occurs in approximately 65-70% of the world's population after weaning).\n\nCLINICAL PRESENTATION:\nFollowing a bout of viral gastroenteritis, patients may develop bloating, flatulence, abdominal cramps, and watery diarrhea specifically after consuming lactose-containing dairy products. Parents commonly notice that infants and toddlers develop worsened diarrhea when milk or formula is reintroduced after a gastroenteritis episode. The condition is self-limiting and typically resolves within 2-4 weeks as the intestinal epithelium regenerates and mature lactase-expressing enterocytes return to the villous tips.\n\nOTHER CAUSES OF SECONDARY LACTOSE INTOLERANCE:\nAny condition that damages the small intestinal mucosa can cause secondary lactose intolerance, including celiac disease, Crohn's disease involving the small bowel, tropical sprue, radiation enteritis, chemotherapy-induced mucositis, and giardiasis. In these conditions, lactose intolerance persists until the underlying disease is treated and mucosal healing occurs.\n\nKEY POINTS:\nLactase resides at the villous tips and is the first brush border enzyme lost with mucosal injury. Viral gastroenteritis is a common cause of secondary (transient) lactose intolerance. Symptoms typically resolve within 2-4 weeks as the epithelium regenerates. Any condition damaging small intestinal mucosa (celiac disease, Crohn's, giardiasis) can also cause secondary lactose intolerance."
  },
  {
    "id": 170,
    "categoryId": 3,
    "question": "Extra-intestinal manifestations of IBD (Crohn's/UC) include all EXCEPT:",
    "options": [
      "A) Uveitis",
      "B) Erythema Nodosum",
      "C) Ankylosing Spondylitis",
      "D) COPD"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (COPD is not an extra-intestinal manifestation of IBD).\n\nPATHOPHYSIOLOGY:\nInflammatory bowel disease is a systemic immune-mediated condition, and approximately 25-40% of patients develop extra-intestinal manifestations (EIMs) involving the joints, skin, eyes, hepatobiliary system, and other organs. These manifestations are driven by circulating immune complexes, cross-reactive antibodies, and shared mucosal homing receptors that allow activated intestinal lymphocytes to migrate to extra-intestinal sites. Some EIMs parallel disease activity and improve with treatment of the underlying bowel disease, while others follow an independent course.\n\nMAJOR EXTRA-INTESTINAL MANIFESTATIONS:\nOcular involvement includes uveitis and episcleritis, presenting as eye pain, redness, and photophobia, affecting approximately 2-5% of IBD patients. Dermatologic manifestations include erythema nodosum (tender, raised, red nodules on the anterior shins, most common skin EIM) and pyoderma gangrenosum (deep ulcerative lesions, often on the legs). Musculoskeletal involvement includes peripheral arthritis (parallels disease activity), axial spondyloarthropathy and ankylosing spondylitis (independent of disease activity, associated with HLA-B27). Primary sclerosing cholangitis (PSC) is strongly associated with ulcerative colitis, occurring in approximately 5% of UC patients, and increases the risk of cholangiocarcinoma.\n\nCLINICAL SIGNIFICANCE:\nCOPD is not an extra-intestinal manifestation of IBD. While rare pulmonary involvement (bronchiolitis, interstitial lung disease) has been reported in case series, COPD itself is a separate disease entity caused by chronic tobacco smoke or environmental exposures. Recognizing EIMs is critical because they may precede bowel symptoms, occur during remission, and occasionally cause greater morbidity than the intestinal disease itself.\n\nKEY POINTS:\nApproximately 25-40% of IBD patients develop extra-intestinal manifestations. Common EIMs include uveitis, erythema nodosum, pyoderma gangrenosum, peripheral arthritis, ankylosing spondylitis, and primary sclerosing cholangitis. COPD is not an IBD-associated extra-intestinal manifestation. Some EIMs parallel disease activity while others (spondylitis, PSC) follow an independent course."
  },
  {
    "id": 171,
    "categoryId": 3,
    "question": "A 40-year-old with dyspepsia tests positive for H. pylori. You treat them. Symptoms persist. EGD is normal. What is the diagnosis?",
    "options": [
      "A) Resistant H. pylori",
      "B) Functional Dyspepsia",
      "C) Gastric Cancer",
      "D) Gallstones"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Functional Dyspepsia).\n\nPATHOPHYSIOLOGY:\nFunctional dyspepsia is a common cause of chronic dyspepsia, accounting for approximately 70-80% of cases after organic causes have been excluded. When a patient with dyspepsia tests positive for H. pylori, current guidelines recommend eradication therapy because H. pylori causes chronic gastritis and peptic ulcer disease. However, only approximately 10% of H. pylori-positive patients with dyspepsia will have their symptoms resolve after successful eradication, reflecting the high prevalence of coexisting functional dyspepsia in which H. pylori is an incidental finding rather than the symptom driver.\n\nCLINICAL REASONING:\nIn this clinical scenario, the patient has persistent symptoms despite appropriate H. pylori treatment and a normal endoscopy, which excludes peptic ulcer disease, gastric malignancy, and esophagitis. Persistent symptoms after H. pylori eradication with normal EGD is the classic presentation of functional dyspepsia, a disorder of gut-brain interaction involving visceral hypersensitivity, impaired gastric accommodation, delayed gastric emptying, and central pain amplification. The ACG and Rome IV criteria define functional dyspepsia as bothersome postprandial fullness, early satiation, epigastric pain, or epigastric burning occurring for at least 3 months with onset at least 6 months prior.\n\nMANAGEMENT:\nTreatment of functional dyspepsia after H. pylori eradication includes low-dose tricyclic antidepressants (amitriptyline 10-50 mg nightly) for the epigastric pain subtype, prokinetics (buspirone for impaired accommodation) for the postprandial distress subtype, and cognitive behavioral therapy for refractory cases. PPI therapy can be trialed but has modest efficacy in functional dyspepsia.\n\nKEY POINTS:\nFunctional dyspepsia is the diagnosis when symptoms persist after H. pylori eradication and EGD is normal. Only about 10% of dyspeptic patients improve with H. pylori eradication alone. H. pylori eradication is still indicated to reduce gastric cancer risk regardless of symptom response. Low-dose TCAs are first-line for the epigastric pain subtype of functional dyspepsia."
  },
  {
    "id": 172,
    "categoryId": 3,
    "question": "Abdominal distension that resolves completely overnight suggests:",
    "options": [
      "A) Ascites",
      "B) Large Ovarian Cyst",
      "C) Functional Bloating / Gas",
      "D) Organomegaly"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Functional Bloating/Gas).\n\nPATHOPHYSIOLOGY:\nFunctional bloating is a disorder of gut-brain interaction in which abdominal distension results from a combination of visceral hypersensitivity, impaired gas transit, altered gut microbiome fermentation, and abnormal abdomino-phrenic reflexes. In healthy individuals, intestinal gas is produced and cleared in a steady state. In functional bloating, gas transit is delayed and the diaphragm paradoxically relaxes (descends) while abdominal wall muscles relax, creating visible distension that is often measurable by abdominal girth increase of 3-5 cm over the course of a day.\n\nCLINICAL SIGNIFICANCE:\nThe key diagnostic clue in this question is that the distension resolves completely overnight. During sleep, colonic motility shifts to propagating contractions that clear retained gas, and the conscious visceral hypersensitivity that amplifies the sensation of distension is absent. Structural causes of abdominal distension, including ascites, large ovarian cysts, organomegaly, and abdominal masses, produce fixed distension that does not resolve with sleep or positional changes.\n\nDIFFERENTIAL DIAGNOSIS:\nAscites causes progressive distension with shifting dullness, fluid wave, and associated signs of liver disease or malignancy. Ovarian masses cause persistent, gradually increasing distension unrelated to meals or time of day. Organomegaly (hepatomegaly, splenomegaly) is palpable on examination and constant. The fluctuating nature of bloating that worsens throughout the day and resolves overnight essentially excludes all structural etiologies and points definitively to a functional or fermentation-related process such as SIBO, carbohydrate malabsorption, or functional bloating.\n\nKEY POINTS:\nAbdominal distension that resolves completely overnight is characteristic of functional bloating or gas-related distension. Structural causes (ascites, masses, organomegaly) produce fixed distension that does not fluctuate with sleep. Functional bloating often worsens progressively throughout the day due to accumulated gas from fermentation. This clinical pattern helps avoid unnecessary imaging for structural pathology."
  },
  {
    "id": 173,
    "categoryId": 3,
    "question": "Which lab pattern suggests Alcoholic Liver Disease?",
    "options": [
      "A) AST > ALT (2:1 ratio)",
      "B) ALT > AST",
      "C) Elevated Alk Phos only",
      "D) Low GGT"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (AST greater than ALT, typically in a 2:1 ratio).\n\nPATHOPHYSIOLOGY:\nThe characteristic AST-to-ALT ratio of 2:1 or greater in alcoholic liver disease results from two complementary mechanisms. First, chronic alcohol consumption depletes pyridoxal-5-phosphate (the active form of vitamin B6), which is a required cofactor for ALT synthesis but not for AST synthesis. This selectively suppresses ALT production, lowering its serum level relative to AST. Second, alcohol causes direct mitochondrial injury in hepatocytes, and AST exists in both cytoplasmic and mitochondrial isoforms (mAST), whereas ALT is predominantly cytoplasmic. Mitochondrial damage releases the mitochondrial AST isoform, preferentially elevating AST.\n\nCLINICAL PRESENTATION:\nIn alcoholic hepatitis, transaminases are characteristically only mildly to moderately elevated, typically below 300-500 IU/L, even in severe disease. This distinguishes it from viral hepatitis and drug-induced liver injury, where transaminases may exceed 1000 IU/L. The AST:ALT ratio greater than 2:1 combined with an elevated GGT (gamma-glutamyl transferase, induced by alcohol) is highly suggestive of alcohol-related liver disease. Mean corpuscular volume (MCV) is often elevated due to direct toxic effects of alcohol on erythropoiesis.\n\nDIFFERENTIAL DIAGNOSIS:\nIn most other forms of hepatocellular injury (viral hepatitis, MASLD, drug-induced liver injury), ALT exceeds AST because the predominantly cytoplasmic injury releases more ALT. The notable exception is advanced cirrhosis from any etiology, where the AST:ALT ratio may reverse above 1 as the liver loses its capacity to clear AST and hepatic stellate cell activation alters aminotransferase release patterns.\n\nKEY POINTS:\nAST greater than ALT in a 2:1 ratio is characteristic of alcoholic liver disease due to B6 depletion suppressing ALT and mitochondrial injury releasing AST. Transaminases in alcoholic hepatitis rarely exceed 300-500 IU/L. Elevated GGT supports alcohol-related etiology. Advanced cirrhosis from any cause can also produce an AST-predominant pattern."
  },
  {
    "id": 174,
    "categoryId": 1,
    "question": "A 45-year-old male with a strong family history of premature MI (father died at 45) has an LDL of 110 mg/dL. You suspect genetic risk. Which specialized lipid marker does the National Lipid Association (NLA) and ACC/AHA recommend checking ONCE in a lifetime to risk-stratify him?",
    "options": [
      "A) Apolipoprotein B (ApoB)",
      "B) Lipoprotein(a) [Lp(a)]",
      "C) VLDL",
      "D) Homocysteine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lipoprotein(a) [Lp(a)]).\n\nCLINICAL REASONING:\nThe 2018 ACC/AHA Cholesterol Guidelines and the National Lipid Association recommend measuring lipoprotein(a) once in a patient's lifetime as a risk-enhancing factor that can inform statin therapy decisions in borderline or intermediate-risk patients. Lp(a) is particularly important to check in patients with a strong family history of premature atherosclerotic cardiovascular disease (ASCVD in first-degree male relative before age 55 or female relative before age 65, as in this patient whose father died of MI at 45).\n\nPATHOPHYSIOLOGY:\nLipoprotein(a) is an LDL-like particle with an additional apolipoprotein(a) molecule covalently bound to apolipoprotein B-100 via a disulfide bond. Lp(a) promotes atherosclerosis through the same mechanisms as LDL (cholesterol deposition in the arterial intima) but has additional prothrombotic properties because apolipoprotein(a) is structurally homologous to plasminogen, competing with plasminogen for binding to fibrin and thereby inhibiting fibrinolysis. Lp(a) levels are more than 90% genetically determined (primarily by the LPA gene) and are minimally affected by diet, exercise, or standard lipid-lowering therapies. Levels above 50 mg/dL (or 125 nmol/L) are considered elevated and represent a risk-enhancing factor.\n\nCLINICAL SIGNIFICANCE:\nElevated Lp(a) is present in approximately 20% of the population and independently increases ASCVD risk by 2 to 3-fold. Standard statins do not lower Lp(a) (and may modestly increase it), while PCSK9 inhibitors reduce Lp(a) by approximately 20 to 30%. Novel antisense oligonucleotides (pelacarsen) and small interfering RNA therapies targeting hepatic Lp(a) production are in advanced clinical trials.\n\nKEY POINTS:\nLp(a) should be measured once in a lifetime, especially in patients with family history of premature ASCVD, as it is more than 90% genetically determined and not affected by lifestyle. Levels above 50 mg/dL are a risk-enhancing factor that can inform statin therapy decisions. Lp(a) promotes both atherosclerosis and thrombosis due to its structural homology with plasminogen."
  },
  {
    "id": 175,
    "categoryId": 4,
    "question": "A 75-year-old female has a TSH of 7.5 mIU/L (High) and a normal Free T4. She is asymptomatic. She has no history of heart failure or goiter. According to American Thyroid Association (ATA) guidelines, what is the best management?",
    "options": [
      "A) Start full dose Levothyroxine (1.6 mcg/kg)",
      "B) Start low dose Levothyroxine (25 mcg)",
      "C) Monitor and repeat TSH in 3-6 months",
      "D) Order Thyroid Ultrasound"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Monitor and repeat TSH in 3-6 months).\n\nPATHOPHYSIOLOGY:\nSubclinical hypothyroidism (elevated TSH, normal free T4) affects 4 to 10% of adults, increasing to 15 to 20% over age 70. The TSH reference range shifts upward with age: NHANES III data show the 97.5th percentile is approximately 5.9 mIU/L at ages 70 to 79 and 7.5 mIU/L over 80, compared to 4.1 mIU/L at ages 20 to 29. This likely reflects physiologic changes in hypothalamic-pituitary set point and reduced hormone clearance rather than occult disease. Applying young-adult TSH ranges to elderly patients risks overdiagnosis and overtreatment.\n\nCLINICAL REASONING:\nFor TSH consistently above 10 mIU/L, the ATA and Endocrine Society recommend levothyroxine regardless of age (progression rate approximately 5% per year). For TSH between upper normal and 10, evidence for treatment in the elderly is weak. The TRUST trial (NEJM 2017), studying 737 adults aged 65 and older (mean TSH 6.4), demonstrated no improvement in symptoms, tiredness, quality of life, or cognition with levothyroxine over 12 months. An individual participant data meta-analysis (The Lancet) confirmed no benefit for TSH below 10. Overtreatment risks include atrial fibrillation, accelerated bone loss, osteoporotic fracture, and angina.\n\nMANAGEMENT:\nFor this asymptomatic 75-year-old with TSH 7.5, repeat TSH in 3 to 6 months to confirm persistence (up to 50% normalize on repeat). If persistently elevated, monitor every 6 to 12 months while asymptomatic and TSH remains below 10. Factors favoring treatment: TSH rising above 10, symptom development, positive anti-TPO antibodies (increasing progression to approximately 5% per year), heart failure, or planned pregnancy. If initiated in elderly patients, start at 25 mcg (12.5 mcg with CAD), targeting TSH 4 to 6 mIU/L rather than the 0.5 to 2.5 mIU/L target for younger adults.\n\nKEY POINTS:\nSubclinical hypothyroidism with TSH below 10 in asymptomatic elderly should be monitored, not treated \u2014 the TRUST trial showed no benefit in adults over 65. Age-adjusted TSH reference ranges prevent overtreatment with its consequences. If treated in the elderly, start low and target TSH 4 to 6 mIU/L."
  },
  {
    "id": 176,
    "categoryId": 13,
    "question": "You are managing a patient with chronic Gout. He is on Allopurinol 100mg daily. His Uric Acid is 6.8 mg/dL. He has had one flare in the last year. According to the ACR 'Treat-to-Target' guidelines, what is the next step?",
    "options": [
      "A) Continue current dose; 6.8 is acceptable",
      "B) Increase Allopurinol to target Uric Acid < 6.0 mg/dL",
      "C) Stop Allopurinol",
      "D) Add Probenecid"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increase Allopurinol to target Uric Acid below 6.0 mg/dL).\n\nTREAT-TO-TARGET STRATEGY:\nThe 2020 American College of Rheumatology conditional recommendation for gout management emphasizes a treat-to-target approach for urate-lowering therapy (ULT). The goal is to achieve and maintain a serum uric acid level below 6.0 mg/dL, which is well below the monosodium urate saturation point of approximately 6.8 mg/dL at physiologic temperature and pH. At levels below 6.0 mg/dL, existing crystal deposits gradually dissolve over months to years, reducing flare frequency, shrinking tophi, and preventing further joint damage. For patients with severe tophaceous gout, some guidelines recommend targeting below 5.0 mg/dL to accelerate tophus resolution.\n\nALLOPURINOL DOSE TITRATION:\nAllopurinol should be initiated at 100 mg daily (50 mg in chronic kidney disease stage 3 or higher) and increased by 100 mg every two to four weeks until the serum urate target is achieved. The maximum FDA-approved dose is 800 mg daily, though most patients achieve target at 300 to 400 mg. A common clinical error is leaving patients on 100 mg without titrating, which is rarely a therapeutic final dose. Serum urate should be checked two to four weeks after each dose adjustment. HLA-B*5801 testing is recommended before starting allopurinol in patients of Southeast Asian, African American, or Native Hawaiian/Pacific Islander descent due to increased risk of severe hypersensitivity reaction (DRESS or Stevens-Johnson syndrome).\n\nMONITORING AND LONG-TERM MANAGEMENT:\nOnce the target urate level is achieved, monitoring should continue every six to twelve months. ULT is generally a lifelong therapy. Febuxostat is an alternative xanthine oxidase inhibitor for patients who cannot tolerate allopurinol, though the CARES trial raised concerns about cardiovascular mortality, and it is now reserved as a second-line agent. Probenecid (a uricosuric) can be added or used as monotherapy in patients with adequate renal function and documented uric acid underexcretion.\n\nKEY POINTS:\nThe ACR treat-to-target goal for gout is serum uric acid below 6.0 mg/dL. Allopurinol 100 mg is a starting dose, not a therapeutic dose, and must be titrated upward every two to four weeks. Maintaining uric acid below the saturation point gradually dissolves crystal deposits and prevents future flares. HLA-B*5801 testing is indicated in high-risk populations before starting allopurinol."
  },
  {
    "id": 177,
    "categoryId": 7,
    "question": "A 68-year-old female has been on Alendronate (Fosamax) for 5 years. Her bone density is stable (T-score -2.0) and she has had no fractures. What does the American Association of Clinical Endocrinologists (AACE) suggest?",
    "options": [
      "A) Continue Alendronate indefinitely",
      "B) Consider a 'Drug Holiday' (stop for 2-3 years)",
      "C) Switch to Denosumab (Prolia)",
      "D) Switch to Teriparatide (Forteo)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Consider a Drug Holiday).\n\nPATHOPHYSIOLOGY:\nBisphosphonates bind hydroxyapatite on bone surfaces and persist in the skeletal matrix for years due to high binding affinity and resistance to degradation. When osteoclasts resorb bisphosphonate-containing bone, the released drug inhibits farnesyl pyrophosphate synthase in the mevalonate pathway, disrupting osteoclast function and inducing apoptosis. This skeletal reservoir effect means therapeutically relevant concentrations continue to be released for 2 to 5 years after discontinuation. Alendronate has a skeletal half-life of approximately 10 years.\n\nCLINICAL REASONING:\nProlonged continuous use beyond 5 years (oral) or 3 years (IV zoledronic acid) is linked to two rare but serious complications. Atypical subtrochanteric femur fractures occur from over-suppression of remodeling, preventing normal microdamage repair and producing stress fractures through brittle bone \u2014 often preceded by prodromal thigh or groin pain. Osteonecrosis of the jaw presents as exposed necrotic bone, typically following dental procedures. For patients at low to moderate fracture risk after 5 years of oral therapy (stable density, no interval fractures, no major ongoing risk factors), a drug holiday of 2 to 3 years allows the residual skeletal reservoir to continue providing benefit while reducing cumulative complication risk. Bone density should be reassessed periodically during the holiday.\n\nCONTRAST WITH DENOSUMAB:\nDenosumab (anti-RANKL antibody) does not incorporate into bone and has no residual effect after discontinuation. Stopping denosumab causes rapid rebound osteoclast activation with accelerated bone loss and elevated risk of multiple vertebral fractures within 6 to 18 months. Denosumab cannot be given a drug holiday and must be continued indefinitely or transitioned to a bisphosphonate to consolidate gains.\n\nKEY POINTS:\nBisphosphonates accumulate in bone matrix, enabling a drug holiday after 5 years of oral therapy in low-to-moderate risk patients. Prolonged use beyond 5 years increases risk of atypical femur fractures and osteonecrosis of the jaw from over-suppression of remodeling. Denosumab cannot be given a drug holiday due to rapid rebound bone loss upon discontinuation."
  },
  {
    "id": 178,
    "categoryId": 5,
    "question": "A patient with CKD Stage 3b (GFR 40) and Hypertension has a Potassium of 5.2. You want to start an ACE Inhibitor for proteinuria reduction. What is the management strategy?",
    "options": [
      "A) ACE Inhibitors are contraindicated if K > 5.0",
      "B) Start ACE Inhibitor and add a Potassium Binder (Patiromer)",
      "C) Start ACE Inhibitor and recommend a low-potassium diet; recheck labs in 1 week",
      "D) Use a Calcium Channel Blocker instead"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Start ACE inhibitor and recommend low-potassium diet; recheck labs in 1 week).\n\nCLINICAL REASONING:\nACE inhibitors and ARBs are the cornerstone of renoprotective therapy in CKD with proteinuria, reducing intraglomerular pressure by dilating the efferent arteriole, which decreases proteinuria and slows progression to end-stage renal disease. The REIN and RENAAL trials demonstrated that ACE inhibitors and ARBs reduce the risk of CKD progression by 30 to 40% in proteinuric patients. The presence of mild hyperkalemia (5.2 mEq/L) is not an absolute contraindication to initiating RAAS blockade, as the renoprotective benefits outweigh the manageable risk of potassium elevation.\n\nHYPERKALEMIA MANAGEMENT STRATEGY:\nACE inhibitors predictably raise serum potassium by 0.5 to 1.0 mEq/L by reducing aldosterone-mediated potassium excretion. With a baseline potassium of 5.2, the expected rise could push levels to 5.7 to 6.2, which is manageable with dietary counseling (avoiding high-potassium foods: bananas, oranges, potatoes, tomatoes, salt substitutes containing KCl) and close monitoring. Rechecking serum potassium and creatinine within 1 to 2 weeks of initiation is essential to detect clinically significant hyperkalemia (greater than 5.5 requiring intervention, greater than 6.0 requiring dose reduction or discontinuation).\n\nADDITIONAL STRATEGIES IF POTASSIUM RISES:\nSodium polystyrene sulfonate (Kayexalate) or the newer potassium binders patiromer (Veltassa) and sodium zirconium cyclosilicate (Lokelma) can be used to maintain potassium in a safe range while preserving the renoprotective benefits of RAAS blockade. Loop diuretics also promote potassium excretion. An initial rise in creatinine of up to 30% is expected and acceptable after starting ACE inhibitors (reflecting reduced intraglomerular pressure) and should not prompt discontinuation.\n\nKEY POINTS:\nACE inhibitors should be initiated despite mild hyperkalemia (5.2) in CKD with proteinuria because the renoprotective benefit (30 to 40% reduced progression) outweighs the manageable potassium risk. Dietary potassium restriction and lab rechecks within 1 to 2 weeks are essential. Newer potassium binders (patiromer, sodium zirconium cyclosilicate) allow continued RAAS blockade when hyperkalemia develops."
  },
  {
    "id": 179,
    "categoryId": 16,
    "question": "The USPSTF 2022 update on Aspirin for primary prevention of CVD changed the recommendation for adults aged 60+ to:",
    "options": [
      "A) Grade B: Recommended for all",
      "B) Grade C: Individualized decision",
      "C) Grade D: Recommend AGAINST starting",
      "D) Grade I: Insufficient Evidence"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Grade D: Recommend AGAINST starting aspirin).\n\nGUIDELINE CHANGE:\nThe USPSTF 2022 updated recommendation on aspirin for primary prevention of cardiovascular disease represents a significant shift from prior guidance. For adults aged 60 and older without established cardiovascular disease, the USPSTF now gives a Grade D recommendation (recommend against initiating aspirin) because the risk of major bleeding (gastrointestinal hemorrhage, hemorrhagic stroke, and intracranial bleeding) outweighs the modest reduction in atherosclerotic cardiovascular events.\n\nEVIDENCE BASIS:\nThree major randomized trials published in 2018 collectively shifted the risk-benefit calculus. ASPREE (Aspirin in Reducing Events in the Elderly) showed no cardiovascular benefit but increased major hemorrhage and unexpectedly higher all-cause mortality in healthy adults over 70. ASCEND (A Study of Cardiovascular Events in Diabetes) showed that aspirin reduced vascular events in diabetic patients but was offset by a nearly equivalent increase in major bleeding. ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events) found no significant cardiovascular benefit in moderate-risk adults. These trials reflected improvements in modern baseline cardiovascular risk management (widespread statin use, better blood pressure control) that reduced the incremental benefit of aspirin.\n\nAGE-STRATIFIED RECOMMENDATIONS:\nFor adults aged 40 to 59 with a 10-year ASCVD risk of 10% or greater, the USPSTF gives a Grade C recommendation (individualized decision based on patient preference, limited net benefit), and the decision should involve shared decision-making weighing cardiovascular benefit against bleeding risk. Aspirin for secondary prevention (patients with established ASCVD) remains strongly indicated.\n\nKEY POINTS:\nThe USPSTF recommends against initiating aspirin for primary CVD prevention in adults 60 and older (Grade D) because bleeding risk outweighs cardiovascular benefit in the modern era of statins and BP control. For ages 40 to 59 with 10-year ASCVD risk of 10% or greater, aspirin is an individualized shared decision (Grade C). Aspirin for secondary prevention in established ASCVD remains strongly indicated."
  },
  {
    "id": 180,
    "categoryId": 4,
    "question": "The FIGO classification system (PALM-COEIN) divides Abnormal Uterine Bleeding into Structural and Non-Structural causes. Which of the following is a 'COEIN' (Non-Structural) cause?",
    "options": [
      "A) Leiomyoma (Fibroid)",
      "B) Adenomyosis",
      "C) Coagulopathy (e.g., Von Willebrand)",
      "D) Polyp"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Coagulopathy).\n\nPATHOPHYSIOLOGY:\nThe FIGO PALM-COEIN classification (2011, revised 2018) categorizes abnormal uterine bleeding (AUB) in non-pregnant reproductive-age women. Structural causes (PALM): Polyps, Adenomyosis, Leiomyomas (submucosal most likely to cause bleeding), and Malignancy/hyperplasia. Non-structural causes (COEIN): Coagulopathy, Ovulatory dysfunction (PCOS, hypothalamic amenorrhea, thyroid disorders), Endometrial (disordered hemostasis), Iatrogenic (hormonal contraceptives, anticoagulants), and Not otherwise classified (AVMs, chronic endometritis).\n\nCLINICAL REASONING:\nCoagulopathy carries particular clinical importance. Von Willebrand disease (VWD), the most common inherited bleeding disorder (approximately 1% prevalence), is present in 13 to 20% of women with heavy menstrual bleeding yet often remains undiagnosed for years. ACOG recommends screening for bleeding disorders in any adolescent presenting with heavy menstrual bleeding at menarche, as this is frequently VWD's first manifestation. Screening should also be considered in adults with heavy bleeding plus easy bruising, bleeding with dental procedures, postpartum hemorrhage, or family bleeding history. Initial evaluation includes CBC with platelets, PT, aPTT, and if VWD is suspected: VWF antigen, VWF activity (ristocetin cofactor), and factor VIII level.\n\nTREATMENT:\nManagement depends on PALM-COEIN etiology. For coagulopathy-related AUB: tranexamic acid (reduces menstrual blood loss 40 to 50%), combined hormonal contraceptives or progestin IUD for endometrial stabilization, and desmopressin for type 1 VWD. For ovulatory dysfunction: hormonal regulation with OCPs or cyclic progestins. Structural causes may require hysteroscopic polypectomy, myomectomy or uterine artery embolization for fibroids, and endometrial biopsy for hyperplasia or malignancy evaluation.\n\nKEY POINTS:\nPALM-COEIN classifies AUB into structural (Polyps, Adenomyosis, Leiomyomas, Malignancy) and non-structural causes (Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic, Not classified). Von Willebrand disease is present in 13 to 20% of women with heavy menstrual bleeding and should be screened for, particularly in adolescents at menarche. Systematic PALM-COEIN classification ensures targeted evaluation rather than empiric treatment."
  },
  {
    "id": 181,
    "categoryId": 2,
    "question": "According to the Fleischner Society Guidelines (2017), an incidental solid pulmonary nodule < 6 mm in a low-risk patient requires:",
    "options": [
      "A) CT at 3 months",
      "B) CT at 12 months",
      "C) No routine follow-up",
      "D) PET Scan"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (No routine follow-up).\n\nCLINICAL REASONING:\nThe Fleischner Society 2017 guidelines provide evidence-based recommendations for management of incidentally detected pulmonary nodules on CT imaging. For a solitary solid nodule less than 6 mm in a low-risk patient (defined as minimal or no smoking history, no other known cancer risk factors), no routine follow-up imaging is recommended. The rationale is that the probability of malignancy for nodules in this size range is <1%, and the cumulative radiation exposure and psychological burden of serial CT surveillance outweigh the potential benefit of detecting malignancy.\n\nNODULE SIZE AND RISK STRATIFICATION:\nRisk increases substantially with nodule size. Solid nodules 6 to 8 mm in low-risk patients warrant a follow-up CT at 6 to 12 months, while the same size in high-risk patients warrants CT at 6 to 12 months with consideration of an additional scan at 18 to 24 months. Solid nodules greater than 8 mm warrant consideration of CT at 3 months, PET-CT, or tissue sampling depending on clinical context and probability of malignancy. High-risk features include significant smoking history (30 or more pack-years), upper lobe location, spiculated margins, family history of lung cancer, and exposure to asbestos or radon.\n\nSUBSOLID NODULES:\nGround-glass and part-solid nodules follow a different algorithm because they carry a higher malignancy risk per millimeter of size compared to solid nodules. Ground-glass nodules less than 6 mm require no routine follow-up, but those 6 mm or greater warrant CT at 6 to 12 months and then every 2 years for a total of 5 years. Part-solid nodules (containing both ground-glass and solid components) with a solid component of 6 mm or greater are concerning for invasive adenocarcinoma and require more aggressive evaluation.\n\nKEY POINTS:\nIncidental solid pulmonary nodules less than 6 mm in low-risk patients have <1% malignancy risk and require no routine follow-up. Risk of malignancy increases with nodule size, upper lobe location, spiculated margins, and smoking history. Subsolid nodules (ground-glass and part-solid) carry higher per-millimeter malignancy risk than solid nodules and follow a separate management algorithm."
  },
  {
    "id": 182,
    "categoryId": 10,
    "question": "You are prescribing a topical steroid for a rash on the face and groin (intertriginous areas). Which potency class is appropriate?",
    "options": [
      "A) Class 1 (Clobetasol)",
      "B) Class 3 (Triamcinolone)",
      "C) Class 7 (Hydrocortisone 1-2.5%)",
      "D) Class 5 (Betamethasone valerate)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Low Potency - Hydrocortisone 1-2.5%).\n\nPATHOPHYSIOLOGY:\nTopical corticosteroids bind intracellular glucocorticoid receptors, suppressing inflammatory cytokines (IL-1, IL-6, TNF-alpha), inhibiting phospholipase A2, decreasing capillary permeability, and suppressing T-cell activation. Potency ranges from Class 1 (superpotent, clobetasol 0.05%) to Class 7 (least potent, hydrocortisone 1%), determined by the molecule, vehicle, concentration, and formulation. Ointments are generally more potent than creams due to occlusive properties enhancing penetration.\n\nCLINICAL APPLICATION - SITE-SPECIFIC PRESCRIBING:\nThe face, eyelids, groin, axillae, and intertriginous areas have thin skin with high receptor density and minimal stratum corneum, dramatically increasing drug absorption. Mid- to high-potency steroids on these areas accelerate atrophy, striae, telangiectasias, perioral dermatitis, steroid rosacea, and acneiform eruptions. On eyelids, potent steroids risk glaucoma and cataracts. Prescribing principle: low potency (Class 6-7, hydrocortisone 1-2.5%) for face, eyelids, groin, axillae, and folds; medium potency (Class 3-5, triamcinolone 0.1%) for trunk and extremities; high to superpotent (Class 1-2, clobetasol, betamethasone dipropionate) for palms, soles, scalp, or recalcitrant dermatoses.\n\nMANAGEMENT PRINCIPLES:\nEven low-potency agents should not be used continuously on thin-skinned areas beyond 2 to 4 weeks without reassessment. For chronic conditions, topical calcineurin inhibitors (tacrolimus, pimecrolimus) are preferred for maintenance on face and intertriginous areas as they do not cause atrophy. Pulse therapy (weekends only) can minimize adverse effects when higher potency is transiently needed.\n\nKEY POINTS:\nFace, groin, and intertriginous areas require low-potency steroids (hydrocortisone 1-2.5%) due to thin skin and high receptor density. Medium potency for trunk and extremities; superpotent for palms, soles, and recalcitrant plaques. Calcineurin inhibitors provide steroid-sparing alternatives for chronic use on sensitive sites."
  },
  {
    "id": 183,
    "categoryId": 2,
    "question": "A 65-year-old with COPD develops Community Acquired Pneumonia. He received a Z-pack (Azithromycin) 2 months ago for bronchitis. What is the appropriate antibiotic choice now?",
    "options": [
      "A) Azithromycin alone",
      "B) Doxycycline alone",
      "C) Levofloxacin (Respiratory Fluoroquinolone) OR Augmentin + Macrolide",
      "D) Cephalexin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Respiratory Fluoroquinolone alone OR Beta-lactam plus Macrolide).\n\nPATHOPHYSIOLOGY:\nCommunity-acquired pneumonia is most commonly caused by Streptococcus pneumoniae, followed by atypical organisms (Mycoplasma pneumoniae, Chlamydophila pneumoniae, Legionella pneumophila) and respiratory viruses. Haemophilus influenzae is an important pathogen in patients with COPD due to impaired mucociliary clearance and chronic airway colonization. Empiric therapy must cover both typical and atypical pathogens because clinical presentation alone cannot reliably distinguish between them.\n\nCLINICAL REASONING:\nThe patient has two features that require broader empiric coverage: comorbid COPD and recent antibiotic exposure (azithromycin 2 months ago). Recent macrolide use within the past 3 months is a risk factor for macrolide-resistant organisms and mandates an alternative regimen. The ATS/IDSA guidelines recommend two equivalent options for outpatients with comorbidities or recent antibiotic use: a respiratory fluoroquinolone alone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily), or a beta-lactam (amoxicillin-clavulanate 2 grams/125 mg twice daily or ceftriaxone) plus a macrolide (azithromycin or doxycycline as a macrolide alternative). Given this patient's recent azithromycin use, either a respiratory fluoroquinolone alone or a beta-lactam plus doxycycline as a macrolide substitute would be appropriate.\n\nSEVERITY ASSESSMENT:\nThe CURB-65 score (Confusion, Uremia with BUN greater than 20, Respiratory rate 30 or greater, Blood pressure less than 90 systolic or 60 diastolic, age 65 or greater) guides site-of-care decisions. A score of 0 to 1 supports outpatient treatment, 2 supports short hospitalization or closely supervised outpatient care, and 3 to 5 warrants hospitalization with consideration of ICU for scores of 4 to 5. Inpatient non-ICU treatment uses the same two regimen options. ICU-level CAP requires a beta-lactam (ceftriaxone or ampicillin-sulbactam) plus either a macrolide or respiratory fluoroquinolone, with MRSA and pseudomonal coverage added when risk factors are present.\n\nKEY POINTS:\nOutpatient CAP with comorbidities or recent antibiotic use requires a respiratory fluoroquinolone alone or a beta-lactam plus macrolide. Recent macrolide use within 3 months is a risk factor for resistance and should prompt an alternative class. Treatment duration of 5 days is adequate for most patients who achieve clinical stability within 48 to 72 hours."
  },
  {
    "id": 184,
    "categoryId": 11,
    "question": "A 75-year-old female has been on Zolpidem (Ambien) 10mg for 10 years. You want to deprescribe due to fall risk. What is the safest approach?",
    "options": [
      "A) Stop immediately to prevent falls",
      "B) Reduce dose by 25% every 1-2 weeks",
      "C) Switch to Diazepam then taper",
      "D) Add Melatonin and stop Zolpidem"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reduce dose by 25% every 1 to 2 weeks).\n\nDEPRESCRIBING APPROACH:\nGradual dose reduction is the safest method for discontinuing long-term benzodiazepine receptor agonists (BzRAs) such as zolpidem in older adults. The recommended approach is to reduce the dose by approximately 25% every 1 to 2 weeks, though even slower tapers (10 to 12.5% reductions) may be necessary for patients who have been on these medications for years, as in this case.\n\nRATIONALE FOR GRADUAL TAPER:\nZolpidem acts on the same GABA-A receptor benzodiazepine binding site as traditional benzodiazepines, and chronic use produces neuroadaptive changes (receptor downregulation, reduced GABAergic sensitivity, and compensatory upregulation of excitatory glutamatergic signaling). Abrupt discontinuation can precipitate a withdrawal syndrome including rebound insomnia (often worse than the original insomnia), anxiety, tremor, diaphoresis, tachycardia, and in severe cases seizures. The Beers Criteria (American Geriatrics Society) strongly recommend avoiding BzRAs in older adults due to increased risk of falls, fractures, cognitive impairment, motor vehicle accidents, and delirium.\n\nADJUNCTIVE STRATEGIES:\nInitiating CBT-I (Cognitive Behavioral Therapy for Insomnia) concurrently with the taper significantly improves discontinuation success rates and provides a sustainable non-pharmacologic strategy for ongoing insomnia management. Melatonin (0.5 to 3 mg at bedtime) may provide modest sleep onset benefit during the taper. Trazodone (25 to 50 mg) or low-dose doxepin (3 to 6 mg) can serve as bridging agents if sleep disruption during the taper is severe.\n\nKEY POINTS:\nLong-term zolpidem should be tapered by 25% every 1 to 2 weeks (slower for prolonged use) to prevent withdrawal seizures, rebound insomnia, and anxiety. Abrupt discontinuation is dangerous due to GABA-A receptor neuroadaptation and compensatory glutamatergic excitation. Concurrent CBT-I initiation during the taper significantly improves discontinuation success rates."
  },
  {
    "id": 185,
    "categoryId": 1,
    "question": "Which class of medication is the FIRST to show unequivocal benefit in reducing the composite of cardiovascular death and heart failure hospitalization in Heart Failure with PRESERVED Ejection Fraction (HFpEF)?",
    "options": [
      "A) Beta Blockers",
      "B) ACE Inhibitors",
      "C) SGLT2 Inhibitors (Empagliflozin/Dapagliflozin)",
      "D) Digoxin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (SGLT2 Inhibitors).\n\nCLINICAL REASONING:\nSGLT2 inhibitors (empagliflozin and dapagliflozin) are the first medication class to demonstrate unequivocal mortality and hospitalization benefit in heart failure with preserved ejection fraction (HFpEF, EF 50% or greater). The EMPEROR-Preserved trial (empagliflozin) and DELIVER trial (dapagliflozin) both demonstrated significant reductions in the composite endpoint of cardiovascular death and heart failure hospitalization in HFpEF patients, regardless of diabetes status. Prior to these landmark trials, no pharmacologic therapy had shown consistent benefit in HFpEF, which accounts for approximately 50% of all heart failure cases.\n\nPATHOPHYSIOLOGY:\nThe mechanisms of SGLT2 inhibitor benefit in heart failure extend well beyond their glucose-lowering effect and include osmotic diuresis and natriuresis (reducing preload and congestion), improved cardiac energetics (shifting myocardial substrate utilization from fatty acids toward more oxygen-efficient ketone bodies), reduced interstitial fibrosis, decreased oxidative stress and inflammation, and improved endothelial function. These pleiotropic effects explain why the benefit is independent of diabetes status.\n\nGDMT FRAMEWORK:\nThe 2022 AHA/ACC/HFSA Heart Failure Guidelines now recommend SGLT2 inhibitors for the entire spectrum of heart failure, from HFrEF (EF 40% or less) through HFmrEF (EF 41 to 49%) to HFpEF (EF 50% or greater). For HFrEF specifically, the four pillars of guideline-directed medical therapy are an ARNI (or ACEi/ARB), a beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin).\n\nKEY POINTS:\nSGLT2 inhibitors (empagliflozin, dapagliflozin) are the first class to show mortality and hospitalization benefit in HFpEF (EMPEROR-Preserved, DELIVER trials), regardless of diabetes status. Their benefit derives from pleiotropic effects (natriuresis, improved cardiac energetics, reduced fibrosis) beyond glucose lowering. They are now recommended across the entire heart failure spectrum (HFrEF, HFmrEF, HFpEF)."
  },
  {
    "id": 186,
    "categoryId": 9,
    "question": "A patient has borderline low B12 (250 pg/mL) but complains of neuropathy. Which metabolite confirms tissue-level B12 deficiency?",
    "options": [
      "A) Ferritin",
      "B) Methylmalonic Acid (MMA)",
      "C) Folate",
      "D) Reticulocyte count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Methylmalonic Acid).\n\nPATHOPHYSIOLOGY:\nVitamin B12 (cobalamin) serves as a cofactor for two critical enzymatic reactions in human metabolism. First, B12 is a cofactor for methionine synthase, which converts homocysteine to methionine (deficiency causes elevated homocysteine). Second, B12 is the exclusive cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA to succinyl-CoA in the mitochondrial pathway of odd-chain fatty acid and branched-chain amino acid metabolism. When B12 is deficient at the tissue level, methylmalonyl-CoA accumulates and is converted to methylmalonic acid (MMA), which rises in the serum and urine.\n\nDIAGNOSTIC SIGNIFICANCE:\nSerum B12 levels have a significant \"gray zone\" (approximately 200 to 400 pg/mL) where levels may appear borderline normal despite true tissue-level deficiency. MMA is elevated specifically in B12 deficiency (not folate deficiency) because folate is not involved in the methylmalonyl-CoA mutase reaction. This makes MMA the most specific confirmatory test for tissue-level B12 deficiency, with a sensitivity exceeding 95%. Homocysteine, by contrast, is elevated in both B12 and folate deficiency (as both are required for the methionine synthase reaction) and is therefore less specific.\n\nNEUROLOGIC MANIFESTATIONS:\nB12 deficiency causes subacute combined degeneration of the spinal cord, affecting the dorsal columns (loss of proprioception and vibratory sense, sensory ataxia) and lateral corticospinal tracts (spasticity, weakness, hyperreflexia, Babinski sign). Peripheral neuropathy (paresthesias in a stocking-glove distribution) often precedes myelopathy. Neurologic damage can become irreversible if B12 replacement is delayed, even if hematologic parameters normalize.\n\nKEY POINTS:\nMethylmalonic acid (MMA) is the most specific confirmatory test for tissue-level B12 deficiency, elevated because B12 is the exclusive cofactor for methylmalonyl-CoA mutase. Serum B12 has a wide gray zone (200 to 400 pg/mL) where tissue deficiency may exist despite borderline-normal levels. Neurologic damage from B12 deficiency (subacute combined degeneration) can become irreversible if treatment is delayed."
  },
  {
    "id": 187,
    "categoryId": 7,
    "question": "Differentiating Olecranon Bursitis from Septic Arthritis of the elbow primarily relies on:",
    "questionImages": [
      { "src": "assets/22553-elbow-olecranon-bursitis.jpg", "alt": "Olecranon bursitis", "caption": "Olecranon bursitis image." }
    ],
    "options": [
      "A) Fever presence",
      "B) Range of Motion (ROM)",
      "C) X-ray findings",
      "D) Duration of pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Range of Motion).\n\nPATHOPHYSIOLOGY:\nOlecranon bursitis and septic arthritis both cause posterior elbow swelling, warmth, and pain but involve different compartments. Olecranon bursitis inflames the subcutaneous bursa, a superficial extra-articular sac; joint mechanics remain intact. Septic arthritis is bacterial infection within the synovial space, where neutrophilic inflammation increases intra-articular pressure, restricting motion in all planes and causing the patient to hold the elbow flexed.\n\nCLINICAL PRESENTATION:\nThe critical differentiator is range of motion. In bursitis, the patient flexes and extends the elbow through a full arc with minimal pain because the joint is uninvolved; swelling localizes to the fluctuant bursal sac. In septic arthritis, motion is severely limited with pain on even gentle passive movement due to capsular distension. Erythema, warmth, and fever occur in both conditions, making them unreliable differentiators.\n\nDIAGNOSIS AND MANAGEMENT:\nWhen septic arthritis is suspected, arthrocentesis is mandatory before antibiotics. Synovial WBC >50,000/\u00b5L with >90% neutrophils is highly suggestive; Gram stain and culture guide therapy. Empiric IV vancomycin plus a third-generation cephalosporin and joint drainage must begin emergently, as cartilage destruction starts within hours. For bursitis, bursal aspiration with fluid analysis (cell count, Gram stain, culture, crystals) distinguishes septic from other etiologies. Non-septic bursitis is managed conservatively with compression, ice, and pressure avoidance.\n\nKEY POINTS:\nPreserved range of motion distinguishes olecranon bursitis from septic arthritis because the bursa is extra-articular. Septic arthritis causes severe pain with any passive motion. Fever and erythema are unreliable differentiators."
  },
  {
    "id": 188,
    "categoryId": 16,
    "question": "A 55-year-old patient asks about the Shingles vaccine. He had Shingles 2 years ago. Does he need the vaccine?",
    "options": [
      "A) No, natural immunity is lifelong",
      "B) Yes, Shingrix is recommended even with prior history",
      "C) Wait until age 60",
      "D) Only if he is immunocompromised"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, Shingrix is recommended even with prior history of shingles).\n\nVACCINE RECOMMENDATION:\nShingrix (recombinant zoster vaccine, RZV) is recommended for all immunocompetent adults aged 50 and older, regardless of whether they have had a prior episode of herpes zoster (shingles), prior receipt of the older live zoster vaccine (Zostavax), or uncertain history of varicella. Patients who have had shingles should wait until the acute rash has resolved and ideally until the acute episode has fully subsided before receiving vaccination.\n\nRATIONALE FOR VACCINATION AFTER SHINGLES:\nShingles recurrence occurs in approximately 5 to 6% of patients within 8 years of the initial episode. A prior episode does not confer reliable long-term immunity because varicella-zoster virus (VZV) remains latent in dorsal root ganglia and can reactivate whenever cell-mediated immunity declines (aging, immunosuppression, stress). Shingrix boosts the VZV-specific T-cell response, providing robust and durable protection against future reactivation.\n\nVACCINE EFFICACY:\nShingrix is a two-dose series (administered at 0 and 2 to 6 months intramuscularly) with >90% efficacy in preventing shingles across all age groups studied, including adults over 70. Efficacy remains above 85% at 4 years post-vaccination. Shingrix is a recombinant (non-live) vaccine containing the VZV glycoprotein E with an AS01B adjuvant, meaning it is safe for immunocompromised patients (unlike the discontinued live Zostavax). Common side effects include injection site pain (approximately 80%), myalgia, and fatigue, which typically resolve within 2 to 3 days.\n\nKEY POINTS:\nShingrix is recommended for all adults 50 and older regardless of prior shingles episodes, prior Zostavax, or varicella history. It provides >90% efficacy through a two-dose recombinant (non-live) series safe for immunocompromised patients. Prior shingles does not confer reliable immunity, as VZV remains latent and recurrence rates are approximately 5 to 6% within 8 years."
  },
  {
    "id": 189,
    "categoryId": 5,
    "question": "A 60-year-old male has a PSA of 5.5 ng/mL. DRE is normal. He has benign prostatic hyperplasia (BPH). What calculation improves the specificity of PSA testing?",
    "options": [
      "A) PSA Velocity",
      "B) Free PSA %",
      "C) Total PSA",
      "D) PSA Density (PSA / Prostate Volume)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Free PSA percentage).\n\nCLINICAL REASONING:\nProstate-specific antigen (PSA) is produced by both benign and malignant prostate epithelial cells, making an elevated total PSA (reference range less than 4.0 ng/mL, though age-adjusted ranges are used) nonspecific for prostate cancer. In this patient with a PSA of 5.5 and known BPH, the elevation could reflect benign prostatic hypertrophy (which increases PSA by approximately 0.3 ng/mL per gram of prostate tissue) or occult prostate cancer.\n\nFREE PSA RATIO:\nPSA circulates in two forms: bound to serum proteins (alpha-1-antichymotrypsin, alpha-2-macroglobulin) and unbound (free PSA). Prostate cancer cells produce a higher proportion of complexed (bound) PSA, resulting in a lower free-to-total PSA ratio. BPH produces a higher proportion of free PSA. A free PSA percentage greater than 25% suggests BPH (low cancer risk, biopsy may be deferred), while free PSA <10% suggests a high probability of cancer (biopsy recommended). The free PSA ratio is most useful in the diagnostic \"gray zone\" of total PSA 4 to 10 ng/mL, where it improves specificity and reduces unnecessary biopsies by approximately 20%.\n\nOTHER PSA REFINEMENTS:\nPSA density (total PSA divided by prostate volume on ultrasound; greater than 0.15 suggests cancer), PSA velocity (rate of change over time; increase greater than 0.75 ng/mL/year is concerning), and age-specific reference ranges all improve PSA interpretation. The Prostate Health Index (PHI), which combines total PSA, free PSA, and p2PSA (a PSA isoform), and the 4Kscore (combining total PSA, free PSA, intact PSA, and human kallikrein 2) provide further risk stratification.\n\nSCREENING CONTEXT:\nThe USPSTF recommends shared decision-making for PSA screening in men aged 55 to 69 (Grade C) and recommends against screening in men 70 and older (Grade D).\n\nKEY POINTS:\nFree PSA percentage helps distinguish BPH (higher free PSA, greater than 25%) from prostate cancer (lower free PSA, <10%) in the PSA gray zone of 4 to 10 ng/mL. This reduces unnecessary biopsies by approximately 20%. PSA density, velocity, and newer indices (PHI, 4Kscore) further refine cancer risk stratification."
  },
  {
    "id": 190,
    "categoryId": 6,
    "question": "First-line pharmacologic treatment for Essential Tremor (Action tremor of hands)?",
    "options": [
      "A) Levodopa/Carbidopa",
      "B) Propranolol or Primidone",
      "C) Gabapentin",
      "D) Clonazepam"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Propranolol or Primidone).\n\nESSENTIAL TREMOR:\nEssential tremor is the most common movement disorder, presenting as an action/postural tremor affecting the hands, head, or voice. It differs from Parkinson's (resting tremor) in that it worsens with intention and improves at rest. Classic features include bilateral hand tremor that improves with alcohol.\n\nFIRST-LINE TREATMENT:\nPropranolol (non-selective beta-blocker) reduces tremor amplitude by 50-60% in most patients. Mechanism involves peripheral beta-2 receptor blockade in skeletal muscle. Primidone (anticonvulsant) is equally effective through unclear mechanisms. Either can be used first-line; choice depends on comorbidities.\n\nDOSING:\nPropranolol: Start 20-40mg BID, titrate to 120-320mg/day. Long-acting formulations improve compliance. Avoid in asthma, bradycardia, heart block. Primidone: Start 25mg at bedtime (initial sedation is common), titrate slowly to 250-750mg/day.\n\nREFRACTORY CASES:\nGabapentin, topiramate, and benzodiazepines are second-line options. Deep brain stimulation of the ventral intermediate nucleus of the thalamus is highly effective for medication-refractory cases.\n\nKEY POINTS:\nPropranolol and primidone are first-line for essential tremor with 50-60% improvement. Essential tremor is an action/postural tremor that improves with alcohol and at rest. Deep brain stimulation is available for refractory cases."
  },
  {
    "id": 191,
    "categoryId": 10,
    "question": "A 30-year-old female presents with diffuse hair thinning. The 'Pull Test' yields 4-5 hairs with white bulbs (telogen phase). She had a baby 4 months ago. Diagnosis?",
    "options": [
      "A) Alopecia Areata",
      "B) Telogen Effluvium",
      "C) Androgenetic Alopecia",
      "D) Trichotillomania"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Telogen Effluvium).\n\nPATHOPHYSIOLOGY:\nNormal hair cycles through anagen (active growth, 2-6 years, 85-90% of hairs), catagen (regression, 2-3 weeks), and telogen (resting, 2-3 months, then shedding). In telogen effluvium, a physiologic stressor synchronizes many anagen follicles into premature telogen simultaneously. Because telogen lasts approximately 3 months, shedding appears 2-4 months after the trigger. White bulbs on shed hairs confirm telogen (club) hairs, distinguishing this from anagen effluvium.\n\nCLINICAL PRESENTATION:\nPatients present with diffuse, non-scarring thinning. Hair pull test yields more than 3-5 telogen hairs per pull from multiple regions. The scalp appears normal without erythema or scaling. Common triggers include childbirth (affects up to 50% of women), major surgery, severe illness, crash dieting, emotional stress, and medication changes. Postpartum telogen effluvium results from abrupt estrogen withdrawal after delivery, releasing hairs maintained in prolonged anagen during pregnancy into simultaneous telogen.\n\nDIAGNOSIS AND DIFFERENTIAL:\nDiagnosis is clinical: diffuse thinning with an identifiable trigger 2-4 months prior. Labs should include TSH, ferritin, CBC, and vitamin D. Differential includes androgenetic alopecia (gradual vertex/frontal thinning without discrete trigger), alopecia areata (circular patches with exclamation point hairs), and diffuse alopecia areata.\n\nMANAGEMENT:\nTelogen effluvium is self-limiting, with regrowth in 3-6 months and full recovery by 6-12 months. Treatment targets reversible causes: iron deficiency (target ferritin above 40-70 ng/mL) and thyroid dysfunction. Supplement iron, vitamin D, and zinc when deficient. Reassure patients that shedding is temporary. If shedding persists beyond 6 months, consider chronic telogen effluvium and investigate ongoing triggers.\n\nKEY POINTS:\nTelogen effluvium causes diffuse shedding 2-4 months after a stressor, with telogen (white bulb) hairs on pull test. Postpartum hair loss is the most common trigger from estrogen withdrawal. The condition is self-limiting with recovery in 6-12 months. Iron deficiency and thyroid dysfunction are the key reversible causes."
  },
  {
    "id": 192,
    "categoryId": 17,
    "question": "Meniere's Disease is characterized by the classic triad of:",
    "options": [
      "A) Vertigo, Headache, Photophobia",
      "B) Vertigo, Tinnitus (roaring), Sensorineural Hearing Loss",
      "C) Vertigo, Ataxia, Dysarthria",
      "D) Vertigo, Syncope, Palpitations"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vertigo, Tinnitus, Sensorineural Hearing Loss).\n\nPATHOPHYSIOLOGY:\nMeniere disease results from endolymphatic hydrops, an abnormal accumulation of endolymph within the membranous labyrinth of the inner ear. The distension of the endolymphatic space disrupts the normal ionic gradients required for mechanoelectrical transduction, affecting both auditory (cochlear) and vestibular (semicircular canal and otolith) function. The exact etiology remains unclear, though impaired endolymph resorption by the endolymphatic sac is the leading hypothesis.\n\nCLINICAL PRESENTATION:\nThe classic triad consists of:\n- Episodic vertigo: Spontaneous rotational vertigo lasting 20 minutes to several hours (distinguishes from BPPV, which lasts seconds to minutes)\n- Tinnitus: Typically low-frequency roaring or buzzing, often fluctuating\n- Sensorineural hearing loss: Initially low-frequency and fluctuating; becomes progressive and permanent over years\n- Aural fullness (a sense of pressure in the affected ear) is considered the fourth hallmark symptom\n\nDIAGNOSIS:\nDiagnosis is clinical: two or more spontaneous episodes of vertigo lasting 20 minutes to 12 hours, audiometrically documented low- to mid-frequency sensorineural hearing loss in the affected ear, and fluctuating aural symptoms (hearing, tinnitus, fullness). MRI with gadolinium may be obtained to exclude vestibular schwannoma.\n\nTREATMENT:\n1. Lifestyle: Sodium restriction (less than 1500-2000 mg/day), caffeine and alcohol avoidance\n2. Acute episodes: Vestibular suppressants (meclizine, diazepam), antiemetics\n3. Prophylaxis: Thiazide diuretics (hydrochlorothiazide), betahistine (used outside the US)\n4. Refractory cases: Intratympanic dexamethasone or gentamicin injections, endolymphatic sac surgery\n\nKEY POINTS:\nMeniere disease produces episodes of vertigo lasting 20 minutes to hours, distinguishing it from BPPV (seconds) and vestibular neuritis (days). Low-frequency sensorineural hearing loss is the audiometric hallmark and becomes permanent over time. Sodium restriction and diuretics are first-line management.\n---"
  },
  {
    "id": 193,
    "categoryId": 6,
    "question": "In Diabetic Retinopathy, the presence of 'Cotton Wool Spots' signifies:",
    "options": [
      "A) Lipid exudates",
      "B) Retinal nerve fiber layer micro-infarctions (Ischemia)",
      "C) Proliferative new vessels",
      "D) Hemorrhage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Retinal nerve fiber layer micro-infarctions/Ischemia).\n\nCOTTON WOOL SPOTS IN DIABETIC RETINOPATHY:\nCotton wool spots are fluffy, white-bordered lesions on the retinal surface that represent micro-infarctions of the retinal nerve fiber layer. Their presence signifies retinal ischemia caused by occlusion of precapillary arterioles, and they indicate that diabetic retinopathy is progressing toward the proliferative stage.\n\nPATHOPHYSIOLOGY:\nChronic hyperglycemia damages retinal capillary pericytes and endothelial cells, leading to microaneurysms, capillary closure, and impaired blood flow. When precapillary arterioles become occluded, the downstream retinal nerve fiber layer undergoes ischemic infarction. The axoplasmic flow within retinal ganglion cell axons is interrupted, causing accumulation of organelles and cellular debris that appears as the characteristic white, fluffy lesion on fundoscopy. This ischemia triggers the release of vascular endothelial growth factor (VEGF), which drives the neovascularization seen in proliferative disease.\n\nCLASSIFICATION OF DIABETIC RETINOPATHY:\nNon-proliferative diabetic retinopathy (NPDR) progresses through mild (microaneurysms only), moderate (microaneurysms plus dot/blot hemorrhages and hard exudates), and severe stages (cotton wool spots, venous beading, intraretinal microvascular abnormalities). Proliferative diabetic retinopathy (PDR) is defined by the growth of new, fragile vessels (neovascularization) on the disc or retina, which can cause vitreous hemorrhage and tractional retinal detachment.\n\nDIAGNOSIS AND MANAGEMENT:\nScreening with dilated fundoscopic examination is recommended annually for patients with diabetes. Cotton wool spots on exam warrant closer follow-up intervals and urgent optimization of blood glucose (HbA1c below 7%) and blood pressure (below 130/80). Anti-VEGF intravitreal injections (ranibizumab, aflibercept, bevacizumab) and panretinal photocoagulation are standard treatments for proliferative disease and diabetic macular edema.\n\nKEY POINTS:\nCotton wool spots represent retinal nerve fiber layer ischemia from arteriolar occlusion and indicate pre-proliferative retinopathy. Their presence signals impending neovascularization driven by VEGF release from ischemic retina. Urgent glycemic and blood pressure optimization, with ophthalmology referral, is essential to prevent progression to vision-threatening proliferative disease."
  },
  {
    "id": 194,
    "categoryId": 1,
    "question": "A patient with high CV risk cannot tolerate any statin due to severe myalgia. What is the next best non-statin therapy to lower LDL and reduce CV events?",
    "options": [
      "A) Ezetimibe",
      "B) Niacin",
      "C) Fibrates",
      "D) Fish Oil"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Ezetimibe).\n\nCLINICAL REASONING:\nFor patients who cannot tolerate any statin due to statin-associated muscle symptoms (SAMS), ezetimibe is the recommended first-line non-statin LDL-lowering therapy. Ezetimibe inhibits the Niemann-Pick C1-Like 1 (NPC1L1) protein on the brush border of intestinal enterocytes, which is the primary transporter responsible for cholesterol absorption from the intestinal lumen. By blocking intestinal cholesterol absorption, ezetimibe reduces hepatic cholesterol delivery, which triggers compensatory upregulation of hepatic LDL receptors and increases LDL clearance from the blood.\n\nCLINICAL EVIDENCE:\nEzetimibe monotherapy lowers LDL by approximately 18 to 20%. The IMPROVE-IT trial demonstrated that adding ezetimibe to simvastatin in post-ACS patients produced an additional 6.4% relative risk reduction in major cardiovascular events compared to simvastatin alone, establishing ezetimibe as the first non-statin therapy with proven cardiovascular outcomes benefit. For statin-intolerant patients with very high cardiovascular risk requiring greater LDL reduction, PCSK9 inhibitors (evolocumab, alirocumab) can be added to ezetimibe and provide an additional 50 to 60% LDL reduction.\n\nALTERNATIVE NON-STATIN THERAPIES:\nBempedoic acid (an ATP citrate lyase inhibitor) is another option for statin-intolerant patients, with the CLEAR Outcomes trial demonstrating cardiovascular event reduction in statin-intolerant patients. Niacin and fibrates, while they affect lipid levels, have not demonstrated consistent cardiovascular outcomes benefit in the modern statin era and are not recommended as primary LDL-lowering alternatives.\n\nKEY POINTS:\nEzetimibe is the first-line non-statin therapy for statin-intolerant patients, lowering LDL approximately 18 to 20% by blocking intestinal cholesterol absorption via NPC1L1. The IMPROVE-IT trial proved cardiovascular benefit when combined with statin therapy. For patients needing greater LDL reduction, PCSK9 inhibitors or bempedoic acid can be added."
  },
  {
    "id": 195,
    "categoryId": 4,
    "question": "A patient has elevated Calcium (11.2). PTH is also elevated (85). Urine Calcium is very low. Family history is positive for mild hypercalcemia. Diagnosis?",
    "options": [
      "A) Primary Hyperparathyroidism",
      "B) Familial Hypocalciuric Hypercalcemia (FHH)",
      "C) Malignancy",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Familial Hypocalciuric Hypercalcemia).\n\nPATHOPHYSIOLOGY:\nFHH is an autosomal dominant disorder caused by an inactivating mutation in the calcium-sensing receptor (CaSR) gene. The CaSR on parathyroid and renal tubular cells functions as the body's calcium thermostat. In FHH, reduced CaSR sensitivity means higher-than-normal calcium is required to suppress PTH and activate renal calcium excretion. The parathyroid glands interpret normal or elevated calcium as low and continue secreting PTH, while kidneys reabsorb calcium avidly. This produces mild hypercalcemia (typically 10.5-12.0 mg/dL), inappropriately normal or mildly elevated PTH, and markedly low urinary calcium. The condition is lifelong, benign, and does not cause nephrolithiasis or osteoporosis.\n\nCLINICAL REASONING:\nThe key challenge is distinguishing FHH from primary hyperparathyroidism (PHPT), as both show hypercalcemia with elevated or inappropriately normal PTH. The differentiator is urinary calcium. In PHPT (85% from adenoma), filtered calcium overwhelms reabsorption, producing hypercalciuria (typically >200 mg/24h). In FHH, the renal CaSR defect causes hypocalciuria (<100 mg/24h). The calcium-to-creatinine clearance ratio (CCCR) is most reliable: CCCR below 0.01 strongly suggests FHH, above 0.02 supports PHPT, and 0.01-0.02 is indeterminate warranting CaSR genetic testing. This distinction is essential because parathyroidectomy, curative for PHPT, does not correct hypercalcemia in FHH and is contraindicated.\n\nDIFFERENTIAL DIAGNOSIS OF HYPERCALCEMIA:\nPHPT (outpatient) and malignancy (inpatient) account for approximately 90% of cases. PTH is the first step: elevated or normal PTH indicates PTH-dependent causes (PHPT, FHH, lithium-induced); suppressed PTH indicates PTH-independent causes (malignancy via PTHrP, granulomatous disease, vitamin D intoxication, milk-alkali syndrome) per Endocrine Society guidelines.\n\nKEY POINTS:\nFHH is distinguished from PHPT by low urinary calcium, with CCCR below 0.01 favoring FHH and above 0.02 supporting PHPT. FHH results from CaSR mutation and is benign; parathyroidectomy is contraindicated. A 24-hour urine calcium should be obtained in all PTH-dependent hypercalcemia before surgical planning."
  },
  {
    "id": 196,
    "categoryId": 12,
    "question": "The 'Frog-Leg' lateral view of the hips is essential to diagnose which pediatric condition?",
    "options": [
      "A) Developmental Dysplasia of the Hip",
      "B) Slipped Capital Femoral Epiphysis (SCFE)",
      "C) Septic Arthritis",
      "D) Osgood-Schlatter"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Slipped Capital Femoral Epiphysis).\n\nPATHOPHYSIOLOGY:\nSCFE is the most common hip disorder in adolescents, occurring when the femoral head displaces posteriorly and inferiorly relative to the femoral neck through the hypertrophic zone of the physis. The adolescent growth plate is weakened during rapid growth by widened hypertrophic chondrocytes, and mechanical shear stress from excess body weight exceeds the physis's structural capacity. SCFE predominantly affects obese adolescents aged 10-16 during the pubertal growth spurt, with males affected approximately 1.5 times more frequently. Endocrine disorders (hypothyroidism, growth hormone deficiency, renal osteodystrophy) should be considered in atypical presentations.\n\nCLINICAL PRESENTATION:\nPatients present with a limp and pain in the hip, groin, thigh, or knee. Knee pain as the presenting complaint (referred via the obturator nerve) is a classic pitfall leading to missed SCFE if the hip is not examined. The hallmark finding is obligate external rotation during passive hip flexion, reflecting posterior epiphyseal displacement. Internal rotation is limited and painful. Bilateral involvement occurs in 20-40% of cases.\n\nDIAGNOSIS:\nThe frog-leg lateral radiograph is essential because SCFE can be missed on the AP view alone, especially in early slips. On AP view, Klein's line (along the superior femoral neck) should intersect the lateral epiphysis; in SCFE, the epiphysis falls inferior. The frog-leg lateral directly visualizes the posterior displacement.\n\nMANAGEMENT:\nSCFE is a surgical emergency. The patient must be non-weight-bearing immediately, with urgent in situ percutaneous screw fixation to prevent further slippage. The most feared complications are avascular necrosis (risk increases with reduction attempts or delays) and chondrolysis.\n\nKEY POINTS:\nThe frog-leg lateral radiograph is essential for diagnosing SCFE because posterior slip can be missed on AP views. SCFE typically affects obese adolescents with hip, groin, or knee pain and obligate external rotation on flexion. It requires immediate non-weight-bearing and urgent screw fixation."
  },
  {
    "id": 197,
    "categoryId": 3,
    "question": "The ROME IV criteria for IBS requires abdominal pain at least 1 day/week associated with 2 of 3 features. Which is NOT a feature?",
    "options": [
      "A) Related to defecation",
      "B) Change in stool frequency",
      "C) Change in stool form",
      "D) Associated with nausea"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Nausea is not one of the three Rome IV features).\n\nPATHOPHYSIOLOGY:\nIrritable bowel syndrome is a disorder of gut-brain interaction defined by the Rome IV criteria as recurrent abdominal pain occurring at least one day per week in the last 3 months (with onset at least 6 months before diagnosis) associated with two or more of three specific features: pain related to defecation (either improvement or worsening), change in stool frequency, and change in stool form (appearance). These criteria deliberately focus on the relationship between pain and bowel habit because this association distinguishes IBS from other functional GI disorders.\n\nCLINICAL REASONING:\nNausea, while commonly reported by IBS patients (occurring in up to 40% of cases), is not one of the three defining Rome IV features because it lacks specificity and does not reliably distinguish IBS from functional dyspepsia, gastroparesis, or other upper GI functional disorders. The Rome IV criteria were designed to be specific enough to provide a positive diagnosis of IBS without requiring extensive exclusionary testing. The three features (relation to defecation, stool frequency change, stool form change) capture the core pathophysiologic disturbance of disordered bowel function with visceral hypersensitivity.\n\nSUBTYPE CLASSIFICATION:\nIBS is subtyped based on the predominant stool pattern using the Bristol Stool Form Scale: IBS with constipation (IBS-C, types 1-2), IBS with diarrhea (IBS-D, types 6-7), IBS with mixed bowel habits (IBS-M), and IBS unsubtyped. Subtyping guides treatment selection, as different pharmacologic agents target each subtype.\n\nKEY POINTS:\nThe Rome IV criteria for IBS require abdominal pain at least one day per week associated with two of three features: relation to defecation, change in stool frequency, and change in stool form. Nausea is common in IBS but is not a defining diagnostic feature. IBS subtypes (C, D, M) are classified using the Bristol Stool Form Scale and guide treatment selection."
  },
  {
    "id": 198,
    "categoryId": 8,
    "question": "Which physical exam finding is classic findings of Infective Endocarditis?",
    "options": [
      "A) Janeway Lesions (Painless palms/soles)",
      "B) Osler Nodes (Painful fingertips)",
      "C) Roth Spots (Retina)",
      "D) All of the above"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D.\n\nDIAGNOSIS:\nInfective endocarditis (IE), an infection of the endocardial surface of the heart, most commonly involving heart valves.\n\nCLINICAL REASONING:\nIE presents with persistent fever plus a new or changing heart murmur. Classic peripheral manifestations (present in minority of cases) include: Osler nodes (painful, raised lesions on fingers/toes - immune complex), Janeway lesions (painless, erythematous lesions on palms/soles - septic emboli), splinter hemorrhages, Roth spots (retinal hemorrhages), and embolic phenomena (stroke, pulmonary emboli, renal infarcts).\n\nDIAGNOSIS (Modified Duke Criteria):\nMajor criteria: Positive blood cultures (typical organisms, persistent bacteremia), evidence of endocardial involvement (vegetation, abscess, new regurgitation on echo)\nMinor criteria: Predisposing condition, fever, vascular phenomena, immunologic phenomena, suggestive blood cultures/echo\n\nMICROBIOLOGY:\n- Native valve: S. aureus (most common), Streptococci (viridans, bovis), Enterococci\n- Prosthetic valve (early <60 days): S. aureus, coagulase-negative staph, gram-negatives\n- Prosthetic valve (late): Similar to native valve\n- IVDU: S. aureus (often MRSA), right-sided (tricuspid) involvement common\n\nTREATMENT:\n- Blood cultures x3 from separate sites before antibiotics\n- Empiric therapy: Vancomycin + ceftriaxone (native) or + gentamicin (prosthetic)\n- Duration: 4-6 weeks IV antibiotics\n- Surgical indications: Heart failure, uncontrolled infection, large vegetations, embolic events\n\nCLINICAL PEARL:\nS. bovis (gallolyticus) bacteremia or endocarditis mandates colonoscopy due to strong association with colorectal malignancy. HACEK organisms (Haemophilus, Aggregatibacter, Cardiobacterium, Eikenella, Kingella) cause \"culture-negative\" endocarditis due to slow growth."
  },
  {
    "id": 199,
    "categoryId": 2,
    "question": "Which intervention reduces mortality in COPD patients with severe resting hypoxemia (O2 sat < 88%)?",
    "options": [
      "A) Long-Acting Inhalers (LAMA)",
      "B) Long-term Oxygen Therapy",
      "C) Oral Steroids",
      "D) Theophylline"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Long-term Oxygen Therapy).\n\nCLINICAL EVIDENCE:\nLong-term oxygen therapy is one of only two interventions proven to reduce mortality in COPD, along with smoking cessation. The landmark Nocturnal Oxygen Therapy Trial (NOTT, published in Annals of Internal Medicine) and the British Medical Research Council (MRC) trial demonstrated significant mortality reduction in COPD patients with severe chronic resting hypoxemia who received supplemental oxygen for 15 or more hours per day, with the NOTT trial showing that continuous oxygen (greater than 18 hours per day) was superior to nocturnal-only oxygen.\n\nINDICATIONS:\nThe standard indications for long-term oxygen therapy in COPD: resting PaO2 55 mmHg or less (or SpO2 88% or less), or PaO2 56 to 59 mmHg (SpO2 89%) with evidence of cor pulmonale (right heart failure from pulmonary hypertension), polycythemia (hematocrit greater than 55%), or peripheral edema. These measurements should be obtained during a period of clinical stability (not during an acute exacerbation) and confirmed on two occasions at least 3 weeks apart. The LOTT (Long-term Oxygen Treatment Trial) published in the New England Journal of Medicine demonstrated that supplemental oxygen does not benefit COPD patients with moderate resting or exercise-induced desaturation (SpO2 89 to 93%), confirming that the mortality benefit is limited to patients with severe hypoxemia.\n\nWHY NOT OTHER OPTIONS:\nBronchodilators (LAMA, LABA) improve symptoms, exercise tolerance, and reduce exacerbations but have not been proven to reduce all-cause mortality in COPD, with the exception of triple therapy (LAMA/LABA/ICS) which showed a modest mortality reduction in the IMPACT and ETHOS trials specifically in patients with elevated eosinophils. Chronic oral corticosteroids are not recommended due to substantial side effects (osteoporosis, diabetes, adrenal suppression) without proven mortality benefit. Theophylline has marginal bronchodilator efficacy with significant toxicity risk.\n\nKEY POINTS:\nLong-term oxygen therapy reduces mortality in COPD patients with severe resting hypoxemia (SpO2 88% or less, PaO2 55 or less) when used 15 or more hours per day. Only smoking cessation and long-term oxygen therapy have definitively been shown to improve survival in COPD. Supplemental oxygen does not benefit patients with only moderate desaturation (SpO2 89 to 93%)."
  },
  {
    "id": 200,
    "categoryId": 6,
    "question": "A high school athlete sustains a concussion. When can they return to play?",
    "options": [
      "A) When symptoms resolve (usually 2-3 days)",
      "B) After a stepwise 5-6 day return-to-play protocol, provided they remain symptom-free at each step",
      "C) Immediately if CT head is normal",
      "D) After 2 weeks mandatory rest"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (After a stepwise return-to-play protocol, provided they remain symptom-free at each step).\n\nSPORT-RELATED CONCUSSION MANAGEMENT:\nThe return-to-play (RTP) protocol is a graduated, stepwise approach endorsed by the Consensus Statement on Concussion in Sport and the American Academy of Neurology. Each step requires a minimum of 24 hours symptom-free before advancing, and if symptoms recur at any stage, the athlete must return to the previous asymptomatic step. The entire protocol takes a minimum of 5 to 6 days.\n\nPATHOPHYSIOLOGY:\nConcussion causes a neurometabolic cascade involving ionic flux, impaired glucose metabolism, altered cerebral blood flow, and mitochondrial dysfunction. The brain enters a vulnerable period during which cognitive and physical demands can exacerbate symptoms and prolong recovery. Second Impact Syndrome, though rare, occurs when a second concussion is sustained before the first has resolved, causing catastrophic cerebral edema that can be fatal.\n\nGRADUATED RETURN-TO-PLAY PROTOCOL:\nThe protocol begins with complete cognitive and physical rest until symptoms resolve (Step 1), followed by light aerobic activity such as walking or stationary cycling (Step 2), then sport-specific exercise without contact (Step 3), non-contact training drills with progressive resistance (Step 4), full-contact practice after medical clearance (Step 5), and finally return to competition (Step 6). A healthcare professional must provide written clearance before the athlete returns to full contact.\n\nDIAGNOSIS AND EVALUATION:\nConcussion is a clinical diagnosis based on symptoms, physical signs, cognitive impairment, and behavioral changes following a biomechanical force. The Sport Concussion Assessment Tool (SCAT6) is the standardized sideline evaluation. CT imaging is indicated only for suspected skull fracture or intracranial hemorrhage. Neuropsychological testing can help guide return-to-play decisions in complex cases.\n\nKEY POINTS:\nReturn to play requires a graduated 5-to-6-day stepwise protocol with 24 hours symptom-free at each step. Second Impact Syndrome can be fatal if a second concussion occurs before the first resolves. Symptom recurrence at any step requires returning to the previous asymptomatic level before progressing."
  },
  {
    "id": 201,
    "categoryId": 5,
    "question": "Microscopic Hematuria (>3 RBCs/hpf) in a smoker aged >35 requires:",
    "options": [
      "A) Repeat UA in 6 months",
      "B) Renal Ultrasound only",
      "C) CT Urogram and Cystoscopy",
      "D) Antibiotics for UTI"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (CT Urogram and Cystoscopy).\n\nCLINICAL REASONING:\nMicroscopic hematuria (greater than 3 RBCs per high-power field on two of three properly collected urine specimens) in a patient over 35 who smokes requires a complete urologic evaluation with both upper tract imaging (CT urogram) and lower tract visualization (cystoscopy) to exclude urinary tract malignancy. Smoking is the single strongest risk factor for urothelial (transitional cell) carcinoma of the bladder, with smokers having a 3 to 4-fold increased risk compared to nonsmokers.\n\nRATIONALE FOR DUAL EVALUATION:\nCT urogram (CT with contrast in nephrographic and excretory phases) evaluates the upper urinary tract (kidneys, renal pelvis, ureters) for renal cell carcinoma, urothelial carcinoma of the upper tract, nephrolithiasis, and other structural abnormalities. Cystoscopy provides direct visualization of the bladder mucosa and is the gold standard for detecting bladder cancer (which accounts for the majority of hematuria-associated malignancies). Neither test alone is sufficient: CT urogram misses flat (carcinoma in situ) bladder lesions, and cystoscopy does not evaluate the upper tracts.\n\nRISK STRATIFICATION:\nThe 2020 AUA guidelines stratify patients with microscopic hematuria by cancer risk. High-risk features (age greater than 50, greater than 25 RBCs/hpf, smoking history, gross hematuria, prior pelvic radiation, cyclophosphamide exposure, occupational chemical exposure) warrant full evaluation with CT urogram plus cystoscopy. Low-risk patients may be managed with repeat urinalysis in 6 months. Urine cytology has low sensitivity for low-grade tumors but is useful for detecting high-grade urothelial carcinoma and CIS.\n\nKEY POINTS:\nMicroscopic hematuria in a smoker over 35 requires both CT urogram (upper tract evaluation) and cystoscopy (bladder visualization) because neither alone is sufficient to exclude malignancy. Smoking confers a 3 to 4-fold increased bladder cancer risk. The AUA risk stratification guides which patients need full evaluation versus monitoring."
  },
  {
    "id": 202,
    "categoryId": 9,
    "question": "You are treating Iron Deficiency Anemia. How long should iron supplementation continue after the Hemoglobin normalizes?",
    "options": [
      "A) Stop immediately",
      "B) Continue for 1 month",
      "C) Continue for 3-6 months to replenish Ferritin stores",
      "D) Continue indefinitely"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Continue for 3 to 6 months to replenish ferritin stores).\n\nPATHOPHYSIOLOGY:\nIron deficiency anemia develops through three progressive stages. Stage 1 (iron depletion) involves exhaustion of storage iron (ferritin falls) while hemoglobin remains normal. Stage 2 (iron-deficient erythropoiesis) shows reduced transferrin saturation and early microcytosis. Stage 3 (frank iron deficiency anemia) produces overt microcytic hypochromic anemia with low hemoglobin. When oral iron therapy normalizes hemoglobin, the patient has corrected only stage 3; iron stores (reflected by ferritin) remain depleted and require an additional 3 to 6 months of supplementation to replenish.\n\nEVIDENCE:\nStudies demonstrate that premature discontinuation of iron therapy after hemoglobin normalization (but before ferritin replenishment) results in recurrent anemia in 30 to 50% of patients within 3 to 6 months. The target ferritin level before discontinuing iron therapy is generally above 50 to 100 ng/mL (indicating adequate stores) or above 30 ng/mL at minimum.\n\nIRON SUPPLEMENTATION BEST PRACTICES:\nFerrous sulfate 325 mg (containing 65 mg elemental iron) is the standard first-line oral iron preparation. Recent evidence supports alternate-day dosing (rather than daily or multiple daily doses) because oral iron triggers hepcidin release within 24 hours, which blocks subsequent iron absorption for approximately 48 hours. Vitamin C (200 to 500 mg) taken concurrently enhances non-heme iron absorption by reducing ferric iron (Fe3+) to ferrous iron (Fe2+) in the duodenum. Iron should be taken on an empty stomach and separated from calcium, antacids, PPIs, tea, and coffee by at least 2 hours.\n\nMONITORING:\nReticulocyte count should rise within 5 to 7 days of initiating iron therapy, confirming marrow response. Hemoglobin should increase by approximately 1 to 2 g/dL per month. Ferritin should be rechecked 3 months after hemoglobin normalization to confirm store replenishment.\n\nKEY POINTS:\nIron supplementation must continue 3 to 6 months after hemoglobin normalization to replenish ferritin stores and prevent recurrence in 30 to 50% of patients. Alternate-day dosing may improve absorption by avoiding hepcidin-mediated blockade. Target ferritin above 50 to 100 ng/mL before discontinuing therapy."
  },
  {
    "id": 203,
    "categoryId": 11,
    "question": "Which herbal supplement is notorious for causing Serotonin Syndrome if combined with SSRIs?",
    "options": [
      "A) Ginkgo Biloba",
      "B) St. John's Wort",
      "C) Valerian Root",
      "D) Saw Palmetto"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (St. John's Wort).\n\nPHARMACOLOGY:\nSt. John's Wort (Hypericum perforatum) is an herbal supplement widely used for mild to moderate depression that has significant serotonergic activity. Its active constituents, hypericin and hyperforin, inhibit the reuptake of serotonin, norepinephrine, and dopamine through mechanisms similar to conventional antidepressants. When combined with SSRIs, SNRIs, triptans, tramadol, MAO inhibitors, or other serotonergic agents, St. John's Wort can precipitate serotonin syndrome, a potentially life-threatening toxidrome characterized by clonus, hyperthermia, agitation, and autonomic instability.\n\nDRUG INTERACTIONS:\nBeyond serotonin syndrome risk, St. John's Wort is a potent inducer of CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (the most clinically significant enzyme induction of any herbal supplement), which reduces plasma concentrations of numerous critical medications. Affected drugs include oral contraceptives (risk of unintended pregnancy), warfarin (loss of anticoagulation), cyclosporine and tacrolimus (organ rejection risk), HIV protease inhibitors and NNRTIs (treatment failure), statins, digoxin, and direct oral anticoagulants.\n\nCLINICAL APPLICATION:\nClinicians should specifically ask about St. John's Wort during medication reconciliation, as many patients do not disclose herbal supplement use unless directly questioned. Patients should be counseled that \"natural\" does not mean safe, and that St. John's Wort has drug interaction potential exceeding many prescription medications.\n\nKEY POINTS:\nSt. John's Wort causes serotonin syndrome when combined with SSRIs due to its serotonin reuptake inhibition activity. It is also the most potent herbal CYP3A4 inducer, reducing levels of oral contraceptives (pregnancy risk), warfarin, immunosuppressants (rejection risk), and HIV medications. Always ask about herbal supplements during medication reconciliation."
  },
  {
    "id": 204,
    "categoryId": 5,
    "question": "NSAIDs (Ibuprofen) and ACE Inhibitors (Lisinopril) can cause Acute Kidney Injury (AKI) when combined. What is the physiological mechanism?",
    "options": [
      "A) NSAIDs dilate the Afferent arteriole; ACEi constrict the Efferent",
      "B) NSAIDs constrict the Afferent arteriole; ACEi dilate the Efferent arteriole",
      "C) Both drugs cause direct tubular necrosis",
      "D) Both drugs cause interstitial nephritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (NSAIDs constrict the afferent arteriole; ACE inhibitors dilate the efferent arteriole).\n\nRENAL PHYSIOLOGY:\nGlomerular filtration rate (GFR) depends on the net filtration pressure across the glomerular capillary, which is maintained by the balance of afferent arteriolar tone (controlling blood flow into the glomerulus) and efferent arteriolar tone (controlling blood flow out of the glomerulus). Prostaglandins (particularly PGE2 and PGI2) produced by cyclooxygenase enzymes in the kidney maintain afferent arteriolar vasodilation, especially under conditions of reduced renal perfusion (volume depletion, heart failure, CKD). Angiotensin II maintains GFR by constricting the efferent arteriole, which sustains filtration pressure when renal perfusion is compromised.\n\nMECHANISM OF DUAL INJURY:\nNSAIDs inhibit cyclooxygenase (COX-1 and COX-2), blocking prostaglandin-mediated afferent arteriolar vasodilation and causing afferent vasoconstriction (reduced blood flow into the glomerulus). Simultaneously, ACE inhibitors block angiotensin II production, removing efferent arteriolar constriction and causing efferent vasodilation (reduced resistance to blood flow out of the glomerulus). When both occur together, the glomerulus is \"squeezed\" from both sides: reduced inflow (afferent constriction) and reduced outflow resistance (efferent dilation), producing a catastrophic drop in glomerular filtration pressure and acute kidney injury.\n\nTRIPLE WHAMMY:\nThe combination of an NSAID plus an ACE inhibitor/ARB plus a diuretic (the \"triple whammy\") is the highest-risk drug combination for AKI, as the diuretic adds volume depletion that further reduces renal perfusion. Studies demonstrate a 30 to 40% increased risk of AKI within the first 30 days of triple therapy.\n\nCLINICAL APPLICATION:\nPatients on ACE inhibitors should be counseled to avoid NSAIDs (including OTC ibuprofen and naproxen) and use acetaminophen as an alternative analgesic. Creatinine should be monitored after any change involving these medications, especially in the elderly and those with baseline CKD.\n\nKEY POINTS:\nNSAIDs constrict the afferent arteriole (by blocking prostaglandins) while ACE inhibitors dilate the efferent arteriole (by blocking angiotensin II), together collapsing glomerular filtration pressure and causing AKI. The \"triple whammy\" (NSAID plus ACE/ARB plus diuretic) increases AKI risk by 30 to 40%. Patients on ACE inhibitors should avoid NSAIDs and use acetaminophen instead."
  },
  {
    "id": 205,
    "categoryId": 6,
    "question": "A patient presents with back pain radiating down the leg. He has weakness with Dorsiflexion (cannot walk on heels/Foot Drop). Which nerve root is affected?",
    "options": [
      "A) L4",
      "B) L5",
      "C) S1",
      "D) L3"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (L5 nerve root).\n\nL5 RADICULOPATHY:\nL5 radiculopathy is one of the most common lumbar nerve root compression syndromes, typically caused by a posterolateral disc herniation at L4-L5. The hallmark finding is weakness of ankle and great toe dorsiflexion (foot drop), which manifests clinically as the inability to walk on the heels. Pain typically radiates from the lower back through the buttock and lateral leg to the dorsum of the foot.\n\nPATHOPHYSIOLOGY:\nDisc herniation or degenerative foraminal stenosis compresses the L5 nerve root, disrupting both motor and sensory signals. The L5 root innervates the tibialis anterior (dorsiflexion), extensor hallucis longus (great toe extension), and gluteus medius (hip abduction). The sensory dermatome covers the lateral leg and dorsum of the foot, including the web space between the first and second toes. L5 does not have a dedicated deep tendon reflex, unlike L4 (patellar) and S1 (Achilles).\n\nCLINICAL DISTINCTION BY NERVE ROOT:\nDifferentiating lumbar radiculopathies is essential for localization. L4 radiculopathy causes quadriceps weakness (difficulty with squatting or climbing stairs), decreased patellar reflex, and numbness over the medial leg. L5 radiculopathy causes dorsiflexion weakness (foot drop and heel walking difficulty), with sensory changes between the first and second toes and no reflex change. S1 radiculopathy causes plantarflexion weakness (difficulty with toe walking), decreased Achilles reflex, and numbness along the lateral foot.\n\nDIAGNOSIS AND TREATMENT:\nMost lumbar radiculopathies are diagnosed clinically. MRI is reserved for red flags such as progressive neurological deficits, suspected cauda equina syndrome, cancer, infection, or symptoms persisting beyond 6 weeks. Conservative management with NSAIDs, physical therapy, and activity modification resolves most cases. Epidural steroid injections are considered for persistent pain, and surgical decompression (microdiscectomy) is indicated for progressive motor weakness or refractory symptoms.\n\nKEY POINTS:\nL5 radiculopathy causes foot drop (dorsiflexion weakness) and inability to walk on heels, with sensory changes on the dorsal foot. L5 has no associated deep tendon reflex, distinguishing it from L4 (patellar) and S1 (Achilles). Most cases resolve with conservative management; surgery is reserved for progressive weakness or cauda equina syndrome."
  },
  {
    "id": 206,
    "categoryId": 2,
    "question": "Why should high-flow oxygen be used with caution in severe COPD retainers (Chronic Hypercapnia)?",
    "options": [
      "A) It suppresses the hypoxic drive to breathe",
      "B) The Haldane Effect and V/Q mismatch worsening",
      "C) It causes pulmonary fibrosis",
      "D) It causes oxidative stress"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The Haldane Effect and V/Q mismatch worsening).\n\nPATHOPHYSIOLOGY:\nOxygen-induced hypercapnia in COPD is a clinically important phenomenon that has been incompletely understood for decades. The traditional teaching that high-flow oxygen simply suppresses the hypoxic ventilatory drive in chronic CO2 retainers is an oversimplification. Modern physiologic studies (including the landmark work by Aubier et al. and subsequent investigations) have demonstrated that the Haldane effect and worsening ventilation-perfusion mismatch are the predominant mechanisms, with decreased minute ventilation playing a contributory but lesser role.\n\nTHE HALDANE EFFECT:\nDeoxygenated hemoglobin has a significantly greater affinity for CO2 than oxygenated hemoglobin (both through direct carbamino binding and through enhanced bicarbonate formation via the chloride shift). When high-flow supplemental oxygen saturates hemoglobin, the oxygenated hemoglobin releases bound CO2 into the plasma and alveoli, directly raising PaCO2. This is the Haldane effect, and physiologic studies have demonstrated it to be the most significant single contributor to oxygen-induced hypercapnia.\n\nV/Q MISMATCH WORSENING:\nIn the diseased COPD lung, hypoxic pulmonary vasoconstriction is a critical compensatory mechanism that redirects pulmonary blood flow away from poorly ventilated alveolar units toward better-ventilated regions, optimizing gas exchange. High-flow oxygen abolishes this protective vasoconstriction in poorly ventilated zones, redistributing blood flow to these regions and effectively increasing dead space ventilation. The result is worsened V/Q mismatch and impaired CO2 elimination despite improved oxygenation.\n\nCLINICAL APPLICATION:\nFor COPD patients at risk for chronic hypercapnia, oxygen should be titrated to a target SpO2 of 88 to 92% rather than the standard 94 to 98%. Venturi masks allow precise FiO2 delivery and are preferred in the acute setting. The critical principle is that hypoxia kills faster than hypercapnia, so oxygen should never be completely withheld from a hypoxic COPD patient. Instead, it should be delivered at controlled, low-flow rates with close monitoring of arterial blood gases.\n\nKEY POINTS:\nThe Haldane effect (oxygenated hemoglobin releases CO2) and loss of hypoxic pulmonary vasoconstriction (worsening V/Q mismatch) are the primary mechanisms of oxygen-induced hypercapnia in COPD, while suppression of hypoxic ventilatory drive plays a smaller role than traditionally taught. Target SpO2 is 88 to 92% in chronic CO2 retainers using controlled oxygen delivery. Oxygen should never be withheld from a hypoxic COPD patient."
  },
  {
    "id": 207,
    "categoryId": 1,
    "question": "An S3 heart sound ('Kentucky') in an adult is a specific sign of:",
    "options": [
      "A) Left Ventricular Hypertrophy (Stiff ventricle)",
      "B) Volume Overload / Systolic Heart Failure",
      "C) Aortic Stenosis",
      "D) Mitral Prolapse"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Volume Overload / Systolic Heart Failure).\n\nPATHOPHYSIOLOGY:\nThe S3 heart sound (also called a ventricular gallop, with the cadence described by the mnemonic \"Ken-TUC-ky\" representing S1-S2-S3) is a low-pitched sound heard in early diastole, occurring immediately after S2 during the rapid ventricular filling phase. S3 is produced by the sudden deceleration of blood as it enters a volume-overloaded, dilated ventricle, causing vibration of the ventricular walls and chordae tendineae. In adults over 40 years of age, an S3 is highly specific for pathologically elevated ventricular filling pressures and is considered a hallmark physical examination finding of systolic (decompensated) heart failure with reduced ejection fraction.\n\nCLINICAL SIGNIFICANCE:\nThe S3 is a valuable bedside finding because it indicates elevated left ventricular end-diastolic pressure and volume overload. It has a specificity of approximately 90 to 97% for elevated filling pressures in adults, making it one of the most reliable physical examination findings for heart failure. The S3 is heard best with the bell of the stethoscope (designed for low-frequency sounds) at the cardiac apex with the patient in the left lateral decubitus position.\n\nDISTINCTION FROM S4:\nThe S4 heart sound (atrial gallop, with the cadence \"TEN-nes-see\" representing S4-S1-S2) occurs in late diastole just before S1 and is produced by forceful atrial contraction against a stiff, non-compliant ventricle. S4 is linked to diastolic dysfunction, left ventricular hypertrophy (from chronic hypertension, aortic stenosis, or hypertrophic cardiomyopathy), and acute ischemia. An S3 indicates volume overload and systolic failure, while an S4 indicates a stiff ventricle and diastolic dysfunction. A physiologic S3 can be normal in children, young adults, and during pregnancy (due to the hyperdynamic circulation).\n\nKEY POINTS:\nAn S3 gallop (Ken-TUC-ky cadence, early diastole) in an adult indicates volume overload and systolic heart failure with approximately 90 to 97% specificity for elevated filling pressures. It is heard best with the bell at the apex in the left lateral decubitus position. S4 (TEN-nes-see, late diastole) indicates a stiff ventricle and diastolic dysfunction from hypertrophy or ischemia."
  },
  {
    "id": 208,
    "categoryId": 7,
    "question": "Which Rotator Cuff muscle is responsible for the first 15 degrees of abduction?",
    "options": [
      "A) Deltoid",
      "B) Supraspinatus",
      "C) Infraspinatus",
      "D) Subscapularis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/RC.webp", "alt": "Rotator cuff", "caption": "Rotator cuff image." }
    ],
    "explanation": "CORRECT: B (Supraspinatus).\n\nPATHOPHYSIOLOGY:\nThe supraspinatus originates from the supraspinous fossa and inserts on the greater tuberosity of the humerus. It initiates shoulder abduction (0-15 degrees) by compressing the humeral head into the glenoid, creating a stable fulcrum for the deltoid. Without the supraspinatus, the deltoid drives the humeral head superiorly into the acromion rather than producing abduction, clinically seen as the \"shrug sign.\" Beyond 15 degrees, the deltoid is the primary abductor through approximately 90 degrees, after which scapular rotation by the trapezius and serratus anterior achieves full elevation.\n\nCLINICAL SIGNIFICANCE:\nThe supraspinatus is the most commonly injured rotator cuff muscle due to its passage through the subacromial space between the humeral head and coracoacromial arch. During abduction, the tendon is repeatedly compressed against the acromion, especially with type III (hooked) morphology. A hypovascular \"critical zone\" approximately 1 cm proximal to insertion creates a watershed area of relative ischemia. This combination of impingement and poor blood supply predisposes to degeneration, partial-thickness tears, and full-thickness rupture.\n\nCLINICAL EXAMINATION:\nThe Empty Can test (Jobe test) isolates supraspinatus function: arm at 90 degrees abduction in the scapular plane with thumb down (internal rotation), resisting downward force. Pain or weakness indicates supraspinatus pathology. The Full Can test (thumb up) may be equally sensitive with less discomfort. The other rotator cuff muscles (SITS mnemonic): infraspinatus and teres minor are external rotators tested with arm at side and elbow at 90 degrees; subscapularis is the internal rotator, tested with lift-off or belly press.\n\nKEY POINTS:\nThe supraspinatus initiates abduction (0-15 degrees) by stabilizing the humeral head as a fulcrum for the deltoid. It is the most commonly torn rotator cuff muscle due to subacromial impingement and its hypovascular critical zone. The Empty Can (Jobe) test isolates supraspinatus function."
  },
  {
    "id": 209,
    "categoryId": 4,
    "question": "In Type 2 Diabetes, which defect typically occurs first, often years before diagnosis?",
    "options": [
      "A) Destruction of Beta Cells",
      "B) Peripheral Insulin Resistance",
      "C) Loss of first-phase insulin secretion",
      "D) Ketoacidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peripheral Insulin Resistance).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes follows a well-characterized progression over 10-15 years before diagnosis. The initial defect is peripheral insulin resistance, where skeletal muscle, adipose tissue, and liver become progressively less responsive to insulin. In skeletal muscle (approximately 80% of insulin-stimulated glucose disposal), resistance impairs GLUT4 translocation and glycogen synthesis. In adipose tissue, inadequate suppression of hormone-sensitive lipase elevates free fatty acids, which impair insulin signaling through lipotoxic intermediates (diacylglycerols, ceramides) and cause ectopic lipid deposition. In the liver, resistance causes inappropriate fasting gluconeogenesis. Key drivers include visceral adiposity, inactivity, genetic susceptibility, and chronic inflammation from visceral fat (TNF-alpha, IL-6, reduced adiponectin).\n\nTHE COMPENSATORY PHASE:\nDuring early insulin resistance, beta cells increase insulin secretion 2-3 times baseline to maintain euglycemia. Fasting glucose, postprandial glucose, and A1c remain normal, but derangement is detectable through elevated fasting insulin, HOMA-IR, and metabolic syndrome features (visceral obesity, elevated triglycerides, low HDL, borderline glucose, mild hypertension). This phase is the optimal intervention window. The Diabetes Prevention Program demonstrated 58% reduction in diabetes incidence with lifestyle modification.\n\nTHE DECOMPENSATION PHASE:\nBeta-cell function declines from glucotoxicity, lipotoxicity, islet amyloid deposition, oxidative stress, and ER stress. The UKPDS showed that at diagnosis, approximately 50% of beta-cell function is already lost, declining approximately 4-5% per year regardless of therapy. Glucose rises first postprandially (lost incretin effect and first-phase insulin secretion), then fasting as hepatic glucose output becomes unrestrained.\n\nKEY POINTS:\nPeripheral insulin resistance is the earliest defect in type 2 diabetes, preceding diagnosis by 10-15 years while beta cells compensate with hyperinsulinemia. By the time glucose criteria are met, approximately 50% of beta-cell function is irreversibly lost. Early detection through fasting insulin, HOMA-IR, or metabolic syndrome enables intervention when lifestyle modification can prevent progression."
  },
  {
    "id": 210,
    "categoryId": 3,
    "question": "Intrinsic Factor, required for Vitamin B12 absorption, is secreted by which cells?",
    "options": [
      "A) Chief Cells",
      "B) Parietal Cells",
      "C) Goblet Cells",
      "D) G Cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parietal Cells).\n\nPATHOPHYSIOLOGY:\nParietal cells (oxyntic cells) are located in the gastric glands of the body and fundus of the stomach and serve two critical secretory functions: production of hydrochloric acid (HCl) via the hydrogen-potassium ATPase (proton pump) and secretion of intrinsic factor. Intrinsic factor is a glycoprotein essential for vitamin B12 absorption. It binds to dietary B12 in the duodenum, forming an intrinsic factor-B12 complex that is specifically recognized by cubilin receptors on the ileal mucosa, enabling receptor-mediated endocytosis of B12 in the terminal ileum.\n\nCLINICAL SIGNIFICANCE:\nPernicious anemia is an autoimmune condition in which autoantibodies target parietal cells and intrinsic factor, causing progressive destruction of parietal cell mass. This produces two consequences: achlorhydria (absent acid secretion) and loss of intrinsic factor, resulting in impaired B12 absorption and eventual megaloblastic anemia. Anti-intrinsic factor antibodies are highly specific for pernicious anemia (specificity >95%), while anti-parietal cell antibodies are more sensitive but less specific. Pernicious anemia is linked to other autoimmune conditions including autoimmune thyroiditis, type 1 diabetes, and vitiligo.\n\nRELATED CLINICAL CONSIDERATIONS:\nChronic PPI use suppresses acid secretion by blocking the proton pump in parietal cells, which impairs protein-bound B12 liberation from food but does not affect intrinsic factor secretion. This is why PPI-associated B12 deficiency is generally milder and more slowly progressive than pernicious anemia. Total gastrectomy eliminates all parietal cells, mandating lifelong parenteral B12 supplementation. Bariatric procedures that bypass the gastric body can similarly impair intrinsic factor availability.\n\nKEY POINTS:\nParietal cells in the gastric body and fundus secrete both hydrochloric acid and intrinsic factor. Intrinsic factor is essential for B12 absorption in the terminal ileum. Pernicious anemia results from autoimmune destruction of parietal cells, causing achlorhydria and B12 deficiency. Anti-intrinsic factor antibodies are highly specific (>95%) for pernicious anemia."
  },
  {
    "id": 211,
    "categoryId": 9,
    "question": "Microcytic Anemia is caused by a defect in Hemoglobin synthesis. In Iron Deficiency, the defect is in:",
    "options": [
      "A) Globin chain synthesis",
      "B) Heme synthesis (Protoporphyrin + Iron)",
      "C) DNA synthesis",
      "D) Stem cell production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heme synthesis, Protoporphyrin + Iron).\n\nPATHOPHYSIOLOGY:\nMicrocytic anemia results from impaired hemoglobin synthesis, which can occur at three levels: heme production (iron deficiency, sideroblastic anemia), globin chain production (thalassemias), or both. Normal hemoglobin is a tetramer of two alpha and two beta globin chains, each bound to a heme group (a protoporphyrin IX ring chelated with a central ferrous iron atom). In iron deficiency, the final step of heme synthesis (insertion of iron into protoporphyrin IX by the mitochondrial enzyme ferrochelatase) cannot be completed, resulting in reduced hemoglobin, which produces microcytosis and hypochromia.\n\nHEME SYNTHESIS PATHWAY:\nHeme synthesis begins in the mitochondria with condensation of glycine and succinyl-CoA by ALA synthase (the rate-limiting step, requiring pyridoxine/B6 as cofactor) to form delta-aminolevulinic acid (ALA). The pathway continues through porphobilinogen, uroporphyrinogen, coproporphyrinogen, and protoporphyrinogen before returning to the mitochondria where protoporphyrin IX is formed. The final step is iron chelation by ferrochelatase. In iron deficiency, excess protoporphyrin IX (free erythrocyte protoporphyrin, FEP) accumulates because there is insufficient iron to complete heme, and FEP elevation is a useful diagnostic marker.\n\nCOMPARISON WITH OTHER MICROCYTIC ANEMIAS:\nIn thalassemia, the defect is in globin chain synthesis (reduced or absent alpha or beta chains) while heme synthesis is intact. In sideroblastic anemia, the defect is also in heme synthesis but at earlier steps (typically ALA synthase dysfunction, often from pyridoxine deficiency, lead poisoning, or myelodysplasia), causing iron to accumulate in mitochondria forming pathognomonic ringed sideroblasts on Prussian blue staining. In anemia of chronic disease, the defect is iron sequestration (hepcidin-mediated trapping of iron in macrophages).\n\nKEY POINTS:\nIron deficiency causes microcytic anemia by impairing the final step of heme synthesis (iron insertion into protoporphyrin IX by ferrochelatase), producing elevated free erythrocyte protoporphyrin. This differs from thalassemia (globin chain defect) and sideroblastic anemia (early heme pathway defect with ringed sideroblasts). The rate-limiting step of heme synthesis is ALA synthase, which requires pyridoxine (B6) as a cofactor."
  },
  {
    "id": 212,
    "categoryId": 7,
    "question": "Numbness in the thumb, index, and middle finger (sparing the pinky) suggests compression of which nerve?",
    "questionImages": [
      { "src": "assets/carpal-tunnel-syndrome.jpg", "alt": "Carpal tunnel syndrome", "caption": "Carpal tunnel syndrome image." }
    ],
    "options": [
      "A) Ulnar Nerve",
      "B) Median Nerve",
      "C) Radial Nerve",
      "D) Axillary Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Median Nerve).\n\nPATHOPHYSIOLOGY:\nThe median nerve passes through the carpal tunnel, a rigid osseofibrous canal bounded by carpal bones dorsally and the transverse carpal ligament volarly. The tunnel also contains nine flexor tendons; any condition increasing content volume or decreasing tunnel capacity compresses the nerve. Carpal tunnel syndrome (CTS) is the most common peripheral entrapment neuropathy (3-6% of adults). Risk factors include pregnancy, hypothyroidism, diabetes, rheumatoid arthritis, obesity, and repetitive wrist motion. Compression initially damages myelin (intermittent sensory symptoms), progressing to axonal degeneration with motor weakness and thenar atrophy.\n\nCLINICAL PRESENTATION:\nThe median nerve provides sensation to the palmar first 3.5 digits (thumb, index, middle, radial half of ring finger) and motor innervation to thenar muscles (opponens pollicis, abductor pollicis brevis, superficial head of flexor pollicis brevis). Symptoms include numbness, tingling, and pain characteristically worse at night, as wrist flexion during sleep narrows the tunnel. The flick sign (shaking the hand) provides temporary relief. The ring finger splitting pattern\u2014numb radial half with normal ulnar half\u2014is pathognomonic for median nerve compression. The ulnar nerve travels through Guyon's canal, innervating the fifth and ulnar fourth digits.\n\nDIAGNOSIS AND MANAGEMENT:\nPhalen's test (sustained wrist flexion 60 seconds reproducing paresthesias) and Tinel's sign (tapping over the carpal tunnel) are standard provocative maneuvers with limited sensitivity. Nerve conduction studies and EMG are the gold standard for confirmation and severity grading. First-line treatment is nocturnal wrist splinting in neutral position. Corticosteroid injection provides intermediate-term relief. Surgical carpal tunnel release (dividing the transverse carpal ligament) is definitive for persistent symptoms, motor weakness, or thenar atrophy.\n\nKEY POINTS:\nThe median nerve innervates the first 3.5 digits; the ring finger splitting pattern is pathognomonic for CTS. Nocturnal wrist splinting is first-line treatment; surgical release is definitive for refractory or severe cases."
  },
  {
    "id": 213,
    "categoryId": 4,
    "question": "In Hashimoto's Thyroiditis, the primary mechanism of tissue destruction is:",
    "options": [
      "A) Bacterial infection",
      "B) Lymphocytic infiltration and fibrosis",
      "C) Excess Iodine uptake",
      "D) TSH receptor stimulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lymphocytic infiltration and fibrosis).\n\nPATHOPHYSIOLOGY:\nHashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions and the most common autoimmune disease (1-2% clinically evident, up to 10-15% subclinical). Loss of immune tolerance to thyroid antigens causes progressive follicular cell destruction through T-cell-mediated cytotoxicity. The pathologic hallmark is dense lymphocytic infiltration with germinal center formation and progressive replacement fibrosis. CD8+ T cells destroy follicular cells via perforin-granzyme and Fas-FasL pathways. B cells produce anti-TPO antibodies (>90% of patients) and anti-thyroglobulin antibodies (60-80%). While these serve as diagnostic markers, primary destruction is T-cell mediated\u2014distinguishing Hashimoto's from Graves' disease where TSI antibodies activate the TSH receptor. Genetic susceptibility involves HLA-DR3 and HLA-DR5.\n\nCLINICAL PRESENTATION:\nPatients present with fatigue, cold intolerance, weight gain, constipation, dry skin, hair thinning, menstrual irregularity, and cognitive slowing. The thyroid may be diffusely enlarged with firm, rubbery consistency, though atrophic Hashimoto's also occurs. Hashitoxicosis, a transient thyrotoxic phase in approximately 5% of patients, occurs when follicular destruction releases stored hormone. This lasts 2-8 weeks before transitioning to permanent hypothyroidism and is distinguished from Graves' by low radioactive iodine uptake. Associated conditions include type 1 diabetes, celiac disease, vitiligo, and Addison's disease.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires elevated TSH with low or normal free T4 and positive anti-TPO antibodies. Levothyroxine starts at 1.6 mcg/kg/day in healthy patients (25-50 mcg/day in elderly or cardiac patients). Target TSH is 0.5-2.5 mIU/L, monitored every 6-8 weeks during titration, then annually. Dose increases may be needed during pregnancy (25-50% increase) and with estrogen or absorption-impairing medications (calcium, iron, PPIs). Patients carry modestly increased risk of thyroid MALT lymphoma.\n\nKEY POINTS:\nHashimoto's destroys thyroid cells primarily through CD8+ T-cell cytotoxicity with lymphocytic infiltration and fibrosis, not through the diagnostic anti-TPO antibodies. Anti-TPO is positive in >90% and is the most sensitive serologic marker. Hashitoxicosis in approximately 5% is distinguished from Graves' by low radioactive iodine uptake."
  },
  {
    "id": 214,
    "categoryId": 2,
    "question": "Obstructive Lung Disease (COPD/Asthma) is defined by a reduction in:",
    "options": [
      "A) Total Lung Capacity (TLC)",
      "B) FEV1 / FVC Ratio",
      "C) Residual Volume",
      "D) Diffusion Capacity (DLCO)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (FEV1/FVC Ratio).\n\nPATHOPHYSIOLOGY:\nObstructive lung diseases (COPD, asthma, bronchiectasis, cystic fibrosis) are defined by airflow limitation during expiration, which is quantified by the ratio of forced expiratory volume in one second (FEV1) to forced vital capacity (FVC) on spirometry. In healthy lungs, at least 70 to 80% of the FVC can be exhaled in the first second (normal FEV1/FVC is approximately 0.70 to 0.85, declining slightly with age). In obstructive disease, narrowed airways (from bronchospasm, mucus plugging, airway wall thickening, or loss of elastic recoil with dynamic airway collapse) disproportionately reduce expiratory flow rates, causing FEV1 to decline more than FVC, and the FEV1/FVC ratio falls below 0.70. Air trapping from premature airway closure during expiration increases residual volume and total lung capacity, producing the characteristic hyperinflation seen on chest imaging.\n\nOBSTRUCTIVE VS RESTRICTIVE PATTERNS:\nRestrictive lung diseases (idiopathic pulmonary fibrosis, interstitial lung diseases, chest wall deformities, neuromuscular diseases, obesity hypoventilation) are defined by reduced total lung capacity (TLC) on full pulmonary function testing. In restriction, both FEV1 and FVC are proportionally reduced, so the FEV1/FVC ratio is preserved or even elevated (because the stiff lungs empty quickly). Reduced DLCO (diffusion capacity for carbon monoxide) suggests parenchymal disease affecting gas exchange across the alveolar-capillary membrane, as seen in emphysema and interstitial lung diseases.\n\nSPIROMETRIC INTERPRETATION:\nThe approach to spirometry begins with the FEV1/FVC ratio: if reduced (less than 0.70 or below the lower limit of normal), the pattern is obstructive. The severity of obstruction is then graded by the FEV1 percent predicted: mild (80% or greater), moderate (50 to 79%), severe (30 to 49%), and very severe (less than 30%). If the ratio is normal but FVC is reduced, restriction is suspected and requires confirmation with lung volumes (TLC) by plethysmography. A mixed obstructive-restrictive pattern shows both a reduced ratio and a reduced TLC.\n\nKEY POINTS:\nObstructive lung disease is defined by a reduced FEV1/FVC ratio (less than 0.70) reflecting disproportionate airflow limitation during expiration, while restrictive disease is defined by reduced total lung capacity with a preserved or increased ratio. Severity of obstruction is graded by FEV1 percent predicted. Reduced DLCO suggests parenchymal gas exchange impairment and is seen in both emphysema and interstitial lung disease."
  },
  {
    "id": 215,
    "categoryId": 1,
    "question": "According to the Frank-Starling Law, increasing Venous Return (Preload) results in:",
    "options": [
      "A) Decreased Heart Rate",
      "B) Increased Stroke Volume (via Frank-Starling mechanism)",
      "C) Increased Afterload",
      "D) Decreased Cardiac Output"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased Stroke Volume).\n\nPATHOPHYSIOLOGY:\nThe Frank-Starling law (also called the Frank-Starling mechanism or Starling's law of the heart) states that the force of ventricular contraction is directly proportional to the end-diastolic volume (preload) within physiologic limits. As venous return increases, the ventricle fills to a greater end-diastolic volume, stretching the cardiac sarcomeres toward their optimal length (approximately 2.2 micrometers), which increases the overlap between actin and myosin filaments and the sensitivity of troponin C to calcium, resulting in more forceful contraction and a larger stroke volume.\n\nMOLECULAR BASIS:\nAt the molecular level, increased sarcomere stretch produces a length-dependent increase in calcium sensitivity of the myofilaments (the Frank-Starling mechanism operates independently of sympathetic stimulation or changes in intracellular calcium concentration). This length-tension relationship allows the heart to match its output to changes in venous return on a beat-to-beat basis without neurohumoral input. The mechanism ensures that the right and left ventricles maintain matched outputs: if right ventricular output transiently increases (increasing pulmonary venous return to the left ventricle), the Frank-Starling mechanism automatically increases left ventricular stroke volume to match.\n\nCLINICAL APPLICATION:\nIn heart failure, the Frank-Starling curve is depressed and flattened: the failing ventricle operates on a lower curve where increasing preload produces diminishing returns in stroke volume and eventually leads to pulmonary congestion without meaningful improvement in cardiac output. Positive inotropes (digoxin, dobutamine, milrinone) shift the curve upward, restoring the ability to generate greater stroke volume at any given preload.\n\nKEY POINTS:\nThe Frank-Starling law states that increased preload (venous return) stretches sarcomeres toward optimal length, increasing myofilament calcium sensitivity and producing greater stroke volume. This mechanism operates on a beat-to-beat basis to match ventricular output to venous return. In heart failure, the Starling curve is depressed, and positive inotropes shift it upward."
  },
  {
    "id": 216,
    "categoryId": 3,
    "question": "Pain at McBurney's Point is associated with Appendicitis. Where is this point located?",
    "options": [
      "A) RUQ under the rib",
      "B) 1/3 distance from ASIS to Umbilicus",
      "C) Left Lower Quadrant",
      "D) Mid-epigastric"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (One-third of the distance from the anterior superior iliac spine to the umbilicus).\n\nPATHOPHYSIOLOGY:\nMcBurney's point corresponds to the surface anatomic landmark overlying the base of the appendix, located at the junction of the lateral one-third and medial two-thirds of the line drawn from the right anterior superior iliac spine (ASIS) to the umbilicus. Acute appendicitis begins with obstruction of the appendiceal lumen (by fecalith, lymphoid hyperplasia, or rarely tumor), leading to progressive distension, bacterial overgrowth, ischemia, and if untreated, perforation. As inflammation extends transmurally to the serosa, it irritates the overlying parietal peritoneum at McBurney's point, producing the characteristic localized right lower quadrant tenderness.\n\nCLINICAL PRESENTATION:\nThe classic sequence of appendicitis begins with vague periumbilical pain (visceral afferents from the midgut, referred to the T10 dermatome), followed by anorexia and nausea, then migration of pain to the right lower quadrant as parietal peritoneal inflammation develops (typically over 12-24 hours). Tenderness at McBurney's point has a sensitivity of approximately 50-70% and specificity of 75-85% for appendicitis. Additional examination findings include the Rovsing sign (RLQ pain with palpation of the LLQ), the psoas sign (RLQ pain with right hip extension, suggesting retrocecal appendicitis), and the obturator sign (RLQ pain with internal rotation of the flexed right hip, suggesting pelvic appendicitis).\n\nDIAGNOSIS:\nCT abdomen with contrast is the standard imaging study in adults, with sensitivity and specificity exceeding 95%. The Alvarado score integrates clinical findings and laboratory values to estimate the probability of appendicitis. Ultrasound is the preferred initial imaging modality in children and pregnant women to avoid radiation exposure.\n\nKEY POINTS:\nMcBurney's point is located one-third of the distance from the right ASIS to the umbilicus and overlies the appendiceal base. The classic pain sequence is periumbilical pain migrating to the RLQ over 12-24 hours. CT abdomen is the standard imaging in adults with >95% sensitivity. Ultrasound is preferred in children and pregnant women."
  },
  {
    "id": 217,
    "categoryId": 1,
    "question": "Isolated Systolic Hypertension in the elderly is primarily caused by:",
    "options": [
      "A) High Renin levels",
      "B) Increased Cardiac Output",
      "C) Arterial Stiffness (Loss of compliance)",
      "D) Renal Artery Stenosis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Arterial Stiffness / Loss of Compliance).\n\nPATHOPHYSIOLOGY:\nIsolated systolic hypertension (ISH, defined as systolic BP 130 mmHg or greater with diastolic BP less than 80 mmHg). With aging, the elastic fibers (elastin) in the tunica media of large conduit arteries (particularly the aorta) undergo fragmentation, cross-linking, and replacement by less distensible collagen, with additional medial calcification (arteriosclerosis). This loss of arterial compliance means the aorta can no longer adequately buffer the pulsatile output from the left ventricle during systole (the Windkessel function), resulting in higher peak systolic pressure.\n\nHEMODYNAMIC CONSEQUENCES:\nIn a compliant young aorta, the vessel wall expands during systole to store kinetic energy, then recoils during diastole to maintain diastolic blood flow (the Windkessel effect). When the aorta stiffens, systolic pressure rises because the rigid vessel cannot accommodate the stroke volume, while diastolic pressure actually falls because the stiff aorta does not recoil adequately to maintain diastolic flow. This widens the pulse pressure (systolic minus diastolic), which is itself an independent cardiovascular risk factor. Additionally, in stiff arteries, the reflected pulse wave returns to the heart during systole rather than diastole (increased pulse wave velocity), augmenting systolic pressure and reducing coronary perfusion (which occurs primarily during diastole).\n\nKEY POINTS:\nIsolated systolic hypertension in the elderly results from age-related loss of aortic elasticity (elastin fragmentation, collagen replacement, medial calcification) that impairs the Windkessel buffering function. Widened pulse pressure is an independent cardiovascular risk factor. The stiff aorta fails to recoil in diastole, reducing coronary perfusion while augmenting systolic pressure."
  },
  {
    "id": 218,
    "categoryId": 7,
    "question": "Parathyroid Hormone (PTH) increases serum Calcium by acting on which three organs?",
    "options": [
      "A) Bone, Kidney, Gut",
      "B) Liver, Pancreas, Bone",
      "C) Kidney, Spleen, Thyroid",
      "D) Muscle, Heart, Brain"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bone, Kidney, Gut).\n\nPATHOPHYSIOLOGY:\nPTH is an 84-amino acid polypeptide secreted by parathyroid chief cells in response to decreased ionized calcium detected by the calcium-sensing receptor. PTH raises serum calcium through coordinated actions on three target organs. In bone, PTH binds PTH1 receptors on osteoblasts, which upregulate RANK-ligand, stimulating osteoclast differentiation and bone resorption releasing calcium and phosphate. PTH acts on osteoclasts indirectly through osteoblasts, as osteoclasts lack PTH receptors. In the kidney, PTH increases calcium reabsorption in the distal convoluted tubule via TRPV5 channels while promoting phosphate excretion by downregulating sodium-phosphate cotransporters proximally. This phosphaturic effect prevents calcium-phosphate soft tissue precipitation. PTH also stimulates renal 1-alpha-hydroxylase, converting 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D (calcitriol).\n\nINDIRECT ACTION ON THE GUT:\nPTH does not act directly on intestinal mucosa. Calcitriol produced by PTH-stimulated renal 1-alpha-hydroxylase binds vitamin D receptors on enterocytes, upregulating calbindin, TRPV6 channels, and basolateral calcium ATPase to increase transcellular calcium absorption. This explains why vitamin D deficiency impairs the gut response to PTH.\n\nCLINICAL SIGNIFICANCE:\nPrimary hyperparathyroidism (most commonly a parathyroid adenoma) produces elevated PTH with hypercalcemia, hypophosphatemia, and elevated urinary calcium. Classic manifestations follow \"bones, stones, abdominal groans, and psychic moans.\" Secondary hyperparathyroidism occurs in CKD when impaired 1-alpha-hydroxylase reduces calcitriol, causing compensatory PTH elevation.\n\nKEY POINTS:\nPTH raises calcium through three organ-level actions: osteoclast-mediated bone resorption (indirectly via osteoblast RANK-ligand), renal calcium reabsorption with phosphate excretion, and intestinal calcium absorption indirectly through calcitriol production. PTH acts on osteoclasts indirectly through osteoblasts. The phosphaturic effect prevents calcium-phosphate precipitation when bone resorption releases both ions."
  },
  {
    "id": 219,
    "categoryId": 3,
    "question": "The primary pathophysiologic defect in Gastroesophageal Reflux Disease (GERD) is:",
    "options": [
      "A) Excess Acid Production",
      "B) H. pylori infection",
      "C) Transient Relaxation of the Lower Esophageal Sphincter (tLESR)",
      "D) Esophageal Motility Disorder"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Transient relaxation of the lower esophageal sphincter).\n\nPATHOPHYSIOLOGY:\nThe primary mechanism underlying gastroesophageal reflux disease is transient lower esophageal sphincter relaxation (tLESR), which accounts for approximately 70-80% of reflux episodes. tLESRs are vagally mediated, non-swallow-related relaxations of the LES that last 10-60 seconds and are triggered by gastric distension. During a tLESR, the LES pressure drops to zero, creating a wide-open conduit between the stomach and esophagus. most GERD patients produce normal amounts of gastric acid; the problem is inappropriate exposure of the esophageal mucosa to acid, not acid overproduction.\n\nCONTRIBUTING MECHANISMS:\nWhile tLESRs are the dominant mechanism, additional contributing factors include reduced basal LES tone (often exacerbated by dietary factors such as chocolate, caffeine, alcohol, and peppermint, or by medications such as calcium channel blockers and nitrates), hiatal hernia (which displaces the LES above the diaphragm, eliminating extrinsic compression), impaired esophageal acid clearance (prolonging mucosal contact time), and delayed gastric emptying (which increases gastric distension and tLESR frequency).\n\nTREATMENT IMPLICATIONS:\nUnderstanding that GERD is primarily a motility disorder rather than an acid-overproduction disorder explains why PPIs (which reduce acid volume and potency but do not prevent reflux events) are highly effective at healing esophagitis and relieving heartburn but do not eliminate reflux episodes entirely. Approximately 30-40% of GERD patients have persistent symptoms on PPI therapy. Surgical fundoplication mechanically reinforces the anti-reflux barrier and reduces tLESR frequency, making it the definitive treatment for the underlying pathophysiology.\n\nKEY POINTS:\nTransient LES relaxations account for 70-80% of reflux episodes and are the primary pathophysiologic mechanism of GERD. Most GERD patients produce normal amounts of acid; the problem is inappropriate acid exposure due to sphincter dysfunction. PPIs reduce acid potency but do not prevent reflux events. Fundoplication addresses the underlying mechanical defect by reducing tLESR frequency."
  },
  {
    "id": 220,
    "categoryId": 2,
    "question": "Anaphylaxis (Peanut allergy) is which type of Hypersensitivity reaction?",
    "options": [
      "A) Type I (Immediate)",
      "B) Type II (Cytotoxic)",
      "C) Type III (Immune Complex)",
      "D) Type IV (Delayed)"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Type I - IgE-mediated Immediate Hypersensitivity).\n\nPATHOPHYSIOLOGY:\nAnaphylaxis is the prototypical and most severe manifestation of Type I (immediate) hypersensitivity, mediated by immunoglobulin E (IgE). The reaction requires prior sensitization: upon initial exposure to an allergen (such as peanut protein Ara h1), antigen-presenting cells process and present the allergen to T-helper 2 (Th2) cells, which secrete IL-4 and IL-13 to drive B-cell class switching to IgE production. These allergen-specific IgE antibodies bind to high-affinity FcepsilonRI receptors on the surface of tissue mast cells and circulating basophils, priming them for rapid activation upon re-exposure. Upon subsequent allergen encounter, the antigen cross-links adjacent surface-bound IgE molecules, triggering immediate degranulation and release of preformed mediators (histamine, tryptase, heparin) and newly synthesized mediators (prostaglandins, leukotrienes, platelet-activating factor) within minutes.\n\nCLINICAL MANIFESTATIONS:\nHistamine binds H1 receptors to cause vasodilation (hypotension), increased vascular permeability (urticaria, angioedema), bronchospasm, and stimulation of sensory nerves (pruritus). Leukotrienes C4, D4, and E4 cause sustained bronchospasm and mucus secretion. The clinical triad of anaphylaxis involves cutaneous manifestations (urticaria, flushing, angioedema), respiratory compromise (bronchospasm, laryngeal edema, stridor), and cardiovascular collapse (hypotension, tachycardia). Gastrointestinal symptoms (nausea, cramping, diarrhea) may also occur.\n\nCOMPARISON OF HYPERSENSITIVITY TYPES:\nType II (cytotoxic) hypersensitivity involves IgG or IgM antibodies directed against cell-surface antigens, causing cell destruction (examples include autoimmune hemolytic anemia, Goodpasture syndrome, and Graves disease). Type III (immune complex) hypersensitivity involves antigen-antibody complexes that deposit in tissues and activate complement, causing inflammation (serum sickness, lupus nephritis, Arthus reaction). Type IV (delayed-type) hypersensitivity is T-cell mediated (no antibody involvement), takes 48 to 72 hours to develop, and includes contact dermatitis (poison ivy), tuberculin skin test reaction, and transplant rejection.\n\nKEY POINTS:\nAnaphylaxis is the prototypical Type I (IgE-mediated) immediate hypersensitivity reaction, requiring prior sensitization for IgE production and mast cell priming, with subsequent antigen cross-linking triggering rapid degranulation within minutes. The mnemonic ACID distinguishes the types: Allergy/Anaphylaxis (Type I, IgE), Cytotoxic (Type II, IgG/IgM), Immune complex (Type III), and Delayed (Type IV, T-cell). Epinephrine is the first-line treatment for anaphylaxis."
  },
  {
    "id": 221,
    "categoryId": 3,
    "question": "In Cirrhosis, portal hypertension leads to Ascites primarily via:",
    "options": [
      "A) Increased hydrostatic pressure and Low Albumin (Oncotic pressure)",
      "B) Blockage of bile ducts",
      "C) Renal failure",
      "D) Heart failure"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Increased hydrostatic pressure and low albumin/oncotic pressure).\n\nPATHOPHYSIOLOGY:\nAscites in cirrhosis results from the interplay of portal hypertension and hypoalbuminemia, understood through Starling forces. Cirrhotic scar tissue distorts hepatic architecture and increases resistance to portal venous flow, raising portal venous pressure above the threshold of 10-12 mmHg (sinusoidal portal hypertension). This increased hydrostatic pressure drives fluid from the hepatic sinusoids and splanchnic capillaries into the peritoneal cavity. Simultaneously, the cirrhotic liver has impaired synthetic function, producing insufficient albumin (the primary determinant of plasma oncotic pressure), which reduces the vascular compartment's ability to retain fluid.\n\nSYSTEMIC HEMODYNAMIC CHANGES:\nPortal hypertension triggers splanchnic vasodilation through increased nitric oxide production, which reduces effective arterial blood volume and activates compensatory neurohormonal systems: the renin-angiotensin-aldosterone system (RAAS), the sympathetic nervous system, and antidiuretic hormone (ADH/vasopressin). These systems promote avid sodium and water retention by the kidneys, perpetuating ascites formation and expansion of total body fluid even as the effective arterial volume remains depleted. This is known as the peripheral arterial vasodilation hypothesis.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnostic paracentesis with serum-ascites albumin gradient (SAAG) calculation is performed on all new-onset ascites. A SAAG of 1.1 g/dL or greater indicates portal hypertension with 97% accuracy. First-line management includes sodium restriction (less than 2 g/day) and diuretic therapy with spironolactone (100 mg) and furosemide (40 mg) in a 100:40 ratio. Refractory ascites may require serial large-volume paracentesis with albumin infusion or transjugular intrahepatic portosystemic shunt (TIPS) placement.\n\nKEY POINTS:\nAscites in cirrhosis results from increased portal hydrostatic pressure (greater than 10-12 mmHg) combined with decreased oncotic pressure from hypoalbuminemia. Splanchnic vasodilation activates RAAS and ADH, driving renal sodium and water retention. SAAG greater than 1.1 g/dL confirms portal hypertensive ascites. First-line treatment is sodium restriction plus spironolactone and furosemide in a 100:40 ratio."
  },
  {
    "id": 222,
    "categoryId": 6,
    "question": "Bell's Palsy involves lower motor neuron paralysis of which Cranial Nerve?",
    "options": [
      "A) CN V (Trigeminal)",
      "B) CN VII (Facial)",
      "C) CN III (Oculomotor)",
      "D) CN X (Vagus)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CN VII - Facial Nerve).\n\nBELL'S PALSY:\nBell's palsy is an acute, idiopathic, peripheral (lower motor neuron) paralysis of cranial nerve VII (the facial nerve), resulting in unilateral facial weakness affecting the entire hemiface including the forehead. It is a common cause of acute facial nerve paralysis, with an annual incidence of 15 to 30 per 100,000. The presumed etiology is viral reactivation (herpes simplex virus type 1) causing inflammation and edema of the facial nerve within the temporal bone's fallopian canal.\n\nPERIPHERAL VERSUS CENTRAL DISTINCTION:\nThe critical clinical distinction is between peripheral and central causes of facial weakness. In Bell's palsy (peripheral/LMN), the entire hemiface is affected because the nerve is damaged after both upper and lower face fibers have merged; the patient cannot wrinkle the forehead, close the eye, or raise the eyebrow on the affected side. In stroke (central/UMN), the forehead is spared because the upper face receives bilateral cortical innervation; only the lower face shows weakness. This distinction is essential for avoiding missed stroke diagnoses.\n\nDIAGNOSIS:\nBell's palsy is a clinical diagnosis of exclusion. The onset is acute (maximal weakness within 72 hours), and patients may report ipsilateral ear pain, hyperacusis, or altered taste. If symptoms progress beyond 3 weeks, if there is bilateral involvement, or if other cranial nerves are affected, alternative diagnoses such as Lyme disease, sarcoidosis, tumor, or Ramsay Hunt syndrome (varicella zoster with vesicular ear eruption) should be considered.\n\nTREATMENT:\nThe American Academy of Neurology recommends early corticosteroids (prednisone 60 to 80 mg daily for 7 days) initiated within 72 hours of onset to improve recovery rates. Adding antiviral therapy (valacyclovir) may provide modest additional benefit, particularly in severe cases. Eye protection is essential because incomplete lid closure leads to corneal exposure; management includes artificial tears, lubricating ointment at night, and taping the eye closed during sleep. Approximately 85% of patients recover completely, with poor prognostic factors including complete paralysis, age over 60, and diabetes.\n\nKEY POINTS:\nBell's palsy is peripheral CN VII paralysis affecting the entire hemiface including the forehead, unlike stroke which spares the forehead. Corticosteroids within 72 hours improve recovery, and eye protection is essential to prevent corneal damage. Complete recovery occurs in 85% of cases; consider alternative diagnoses if progression continues beyond 3 weeks."
  },
  {
    "id": 223,
    "categoryId": 13,
    "question": "Why does rapid weight loss or initiation of Thiazide diuretics trigger a Gout flare?",
    "options": [
      "A) Increased Calcium",
      "B) Competition for excretion in the Renal Tubule",
      "C) Liver toxicity",
      "D) Bone breakdown"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Competition for excretion in the Renal Tubule).\n\nRENAL URIC ACID HANDLING:\nApproximately 90 percent of serum uric acid is filtered by the glomerulus, with the vast majority reabsorbed in the proximal convoluted tubule via the urate transporter URAT1 and organic anion transporters (OAT1, OAT4). Only about 10 percent of filtered uric acid is ultimately excreted. This delicate balance of filtration, reabsorption, and secretion means that any substance competing for these same transporters can significantly alter uric acid clearance. Thiazide diuretics increase uric acid reabsorption in the proximal tubule by inducing volume contraction, which enhances sodium and urate reabsorption via URAT1. Additionally, the organic acids produced during thiazide metabolism compete with uric acid for secretion into the tubular lumen.\n\nRAPID WEIGHT LOSS AND KETOACIDOSIS:\nDuring rapid weight loss, starvation, or very-low-calorie diets, accelerated lipolysis generates ketone bodies (beta-hydroxybutyrate and acetoacetate). These organic acids compete with uric acid for secretion at the proximal tubular organic anion transporters, reducing uric acid clearance and causing acute hyperuricemia. Additionally, cellular catabolism from rapid weight loss increases purine turnover, generating more uric acid from nucleotide breakdown. The combination of increased production and decreased excretion creates a sudden spike in serum uric acid that destabilizes existing crystal deposits and triggers acute gout flares.\n\nOTHER MEDICATIONS THAT RAISE URIC ACID:\nBeyond thiazides, loop diuretics, low-dose aspirin (less than 1 gram daily), cyclosporine, pyrazinamide, and ethambutol all impair renal uric acid excretion through similar tubular competition mechanisms. In contrast, losartan and high-dose aspirin (greater than 3 grams daily) have mild uricosuric properties. When managing hypertension in a gout patient, losartan is preferred over thiazide diuretics when clinically appropriate.\n\nKEY POINTS:\nThiazide diuretics trigger gout by increasing proximal tubular uric acid reabsorption through volume contraction and transporter competition. Rapid weight loss causes hyperuricemia through both increased purine catabolism and competition of ketone bodies with uric acid for renal secretion. Any rapid shift in serum uric acid, whether up or down, can mobilize crystals and precipitate an acute gout flare."
  },
  {
    "id": 224,
    "categoryId": 4,
    "question": "The Renin-Angiotensin-Aldosterone System (RAAS) is triggered by:",
    "options": [
      "A) High Blood Pressure",
      "B) Low Renal Perfusion (Hypotension/Hypovolemia)",
      "C) High Sodium",
      "D) Hyperkalemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Low Renal Perfusion / Hypotension / Hypovolemia).\n\nPATHOPHYSIOLOGY:\nThe RAAS is the primary hormonal mechanism for maintaining blood pressure and fluid volume. It activates when the juxtaglomerular (JG) apparatus detects reduced renal perfusion through three mechanisms: (1) JG cells in the afferent arteriolar wall function as baroreceptors, sensing decreased stretch and secreting renin; (2) macula densa cells detect reduced distal sodium chloride delivery and signal JG cells via prostaglandin-mediated paracrine signaling; (3) sympathetic beta-1 adrenergic stimulation directly augments renin release. Renin cleaves hepatic angiotensinogen to angiotensin I, which ACE (concentrated on pulmonary endothelium) converts to angiotensin II.\n\nCLINICAL EFFECTS OF ANGIOTENSIN II:\nAngiotensin II is a potent vasoconstrictor raising BP via AT1 receptor activation. It preferentially constricts the efferent glomerular arteriole, maintaining GFR when perfusion is reduced (explaining ACE inhibitor-induced GFR decline, particularly with renal artery stenosis). It stimulates adrenal zona glomerulosa aldosterone secretion, promoting ENaC-mediated sodium reabsorption and potassium/hydrogen secretion in the collecting duct\u2014explaining hypokalemia and metabolic alkalosis in hyperaldosteronism. Angiotensin II also stimulates thirst and ADH release. Chronically, it drives pathologic cardiac hypertrophy and fibrosis.\n\nCLINICAL APPLICATION:\nACE inhibitors block angiotensin I to II conversion. ARBs block AT1 receptors directly. Both reduce afterload and provide renal and cardiac protection. Direct renin inhibitors (aliskiren) block the rate-limiting step. Mineralocorticoid receptor antagonists (spironolactone, eplerenone) treat resistant hypertension and heart failure. ACE inhibitors and ARBs are first-line for diabetic nephropathy by reducing efferent arteriolar tone and intraglomerular pressure. Both are contraindicated in pregnancy due to fetal renal agenesis and pulmonary hypoplasia.\n\nKEY POINTS:\nThe RAAS is triggered by low renal perfusion sensed via afferent arteriolar baroreceptors, macula densa sodium sensing, and sympathetic beta-1 JG cell stimulation. Angiotensin II raises BP through vasoconstriction, aldosterone-mediated sodium retention, and ADH-stimulated water retention. ACE inhibitors and ARBs provide renal protection in diabetic nephropathy."
  },
  {
    "id": 225,
    "categoryId": 2,
    "question": "The early phase of an asthma attack is bronchoconstriction. The late phase (4-6 hours later) is characterized by:",
    "options": [
      "A) Smooth muscle relaxation",
      "B) Inflammation and Mucus production",
      "C) Alveolar collapse",
      "D) Bacterial superinfection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inflammation and Mucus production).\n\nPATHOPHYSIOLOGY:\nThe asthmatic airway response to an allergen or trigger occurs in two distinct phases. The early phase (within minutes) is driven by mast cell degranulation releasing preformed histamine, tryptase, and newly synthesized leukotrienes and prostaglandins, which cause acute bronchoconstriction of airway smooth muscle. This early bronchospasm is what patients experience as sudden chest tightness and wheezing, and it is rapidly reversed by short-acting beta-2 agonists (albuterol). The late phase (4 to 8 hours after initial exposure) involves recruitment and activation of eosinophils, T-helper 2 lymphocytes, basophils, and neutrophils to the airway wall. These inflammatory cells release cytokines (IL-4, IL-5, IL-13), toxic granule proteins (major basic protein, eosinophil cationic protein), and additional leukotrienes that cause mucosal edema, mucus hypersecretion, epithelial damage, and sustained bronchoconstriction.\n\nCLINICAL SIGNIFICANCE:\nThe late-phase inflammatory response is the critical therapeutic target in asthma. Bronchodilators (albuterol, formoterol) reverse smooth muscle spasm but do not address the underlying eosinophilic inflammation that causes mucosal edema, goblet cell hyperplasia, subepithelial fibrosis, and airway remodeling. This is why inhaled corticosteroids (ICS) are the cornerstone of controller therapy for all persistent asthma. ICS suppress the late-phase inflammatory cascade by inhibiting cytokine transcription, reducing eosinophil recruitment and survival, and decreasing mucus production. Without adequate anti-inflammatory therapy, repeated cycles of inflammation and repair lead to permanent structural changes known as airway remodeling, including subepithelial fibrosis, smooth muscle hypertrophy, and fixed airflow limitation.\n\nCLINICAL APPLICATION:\nThe dual-phase response explains why GINA 2024 now recommends against SABA-only treatment even for the mildest asthma, favoring ICS-formoterol as the preferred reliever (Track 1), which delivers anti-inflammatory therapy with every rescue dose. It also explains why patients may experience a biphasic asthma attack: apparent improvement after initial bronchodilator use followed by worsening symptoms hours later as the late-phase response develops.\n\nKEY POINTS:\nThe late phase of asthma (4 to 8 hours after trigger) involves eosinophilic inflammation and mucus hypersecretion, which bronchodilators alone cannot address. Inhaled corticosteroids are essential because they target the late-phase inflammatory cascade and prevent airway remodeling. Untreated chronic airway inflammation leads to permanent structural changes and irreversible airflow limitation."
  },
  {
    "id": 226,
    "categoryId": 7,
    "question": "The Anterior Cruciate Ligament (ACL) prevents:",
    "options": [
      "A) Posterior translation of the tibia",
      "B) Anterior translation of the tibia relative to the femur",
      "C) Valgus stress",
      "D) Varus stress"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anterior translation of the tibia relative to the femur).\n\nPATHOPHYSIOLOGY:\nThe ACL originates from the posteromedial lateral femoral condyle and inserts on the anterior intercondylar tibial plateau. It is the principal restraint against anterior tibial translation (approximately 85% of total restraining force) and contributes to rotational stability during cutting and pivoting. Its two functional bundles\u2014anteromedial (taut in flexion, resists anterior translation) and posterolateral (taut in extension, provides rotational stability)\u2014maintain tension throughout full range of motion.\n\nCLINICAL PRESENTATION:\nACL rupture typically occurs through noncontact deceleration, cutting, pivoting, or landing from a jump with the knee near extension. Patients describe a \"pop\" followed by rapid hemarthrosis within 2-4 hours. The hallmark complaint is functional instability with the knee \"giving way\" during pivoting activities. This distinguishes ACL injury from collateral ligament injuries (valgus or varus instability) and PCL injury (posterior tibial translation from dashboard mechanism).\n\nDIAGNOSIS AND MANAGEMENT:\nThe Lachman test (performed at 20-30 degrees flexion) is the most sensitive examination. The pivot shift test is the most specific, reproducing the subluxation-reduction event. MRI confirms diagnosis and evaluates associated injuries\u2014meniscal tears accompany over 50% of acute ACL ruptures, along with bone bruises of the lateral femoral condyle and posterolateral tibial plateau. Surgical reconstruction with autograft (patellar tendon, hamstring, or quadriceps tendon) is recommended for patients with functional instability, high-demand activities, or concomitant meniscal tears, as chronic ACL deficiency accelerates meniscal degeneration and osteoarthritis.\n\nKEY POINTS:\nThe ACL provides approximately 85% of restraint against anterior tibial translation and is critical for rotational stability. Classic mechanism is noncontact pivoting with an audible pop and hemarthrosis within 2-4 hours. Surgical reconstruction is recommended for functional instability or associated meniscal tears to prevent degenerative disease."
  },
  {
    "id": 227,
    "categoryId": 3,
    "question": "Which pancreatic hormone is co-secreted with Insulin and forms amyloid deposits in the pancreas of Type 2 Diabetics?",
    "options": [
      "A) Glucagon",
      "B) Amylin",
      "C) Somatostatin",
      "D) Lipase"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amylin).\n\nPATHOPHYSIOLOGY:\nAmylin (islet amyloid polypeptide, IAPP) is a 37-amino acid peptide hormone co-secreted with insulin from pancreatic beta cells in a molar ratio of approximately 1:100 (amylin to insulin) in response to nutrient stimuli. Under normal physiologic conditions, amylin complements insulin action by slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety through central nervous system signaling. These actions collectively reduce the rate of glucose appearance in the circulation after meals.\n\nROLE IN TYPE 2 DIABETES:\nIn type 2 diabetes, chronic beta cell overstimulation leads to increased amylin production. The overproduced amylin misfolds into insoluble beta-sheet fibrils (amyloid) that deposit within and around pancreatic islets. These amyloid deposits are found in approximately 90% of patients with type 2 diabetes at autopsy and are believed to contribute to progressive beta cell dysfunction and apoptosis through membrane disruption and oxidative stress. The amyloid deposition creates a vicious cycle in which beta cell loss leads to further compensatory hypersecretion from remaining cells, promoting more amyloid formation.\n\nTHERAPEUTIC APPLICATION:\nPramlintide (Symlin) is a synthetic analog of amylin approved as an adjunctive therapy for type 1 and type 2 diabetes in patients using mealtime insulin. It is administered by subcutaneous injection before meals and reduces postprandial glucose excursions by slowing gastric emptying, suppressing inappropriate glucagon release, and enhancing satiety. Pramlintide modestly reduces HbA1c (0.3-0.5%) and promotes weight loss of 1-2 kg, distinguishing it from insulin, which typically causes weight gain.\n\nKEY POINTS:\nAmylin is co-secreted with insulin from beta cells and slows gastric emptying, suppresses glucagon, and promotes satiety. Amyloid deposits from misfolded amylin are found in approximately 90% of type 2 diabetic pancreata and contribute to beta cell loss. Pramlintide is a synthetic amylin analog used as adjunctive therapy to mealtime insulin. It lowers postprandial glucose and promotes modest weight loss."
  },
  {
    "id": 228,
    "categoryId": 1,
    "question": "Statins lower LDL primarily by inhibiting HMG-CoA Reductase, which leads to:",
    "options": [
      "A) Increased excretion of bile acids",
      "B) Upregulation of LDL Receptors on the liver",
      "C) Decreased absorption of dietary fat",
      "D) Oxidation of fatty acids"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Upregulation of LDL Receptors on the Liver).\n\nPATHOPHYSIOLOGY:\nStatins competitively inhibit HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway that converts HMG-CoA to mevalonate, a critical precursor for endogenous cholesterol synthesis in the liver. When hepatic cholesterol synthesis is reduced, the intracellular cholesterol content of hepatocytes decreases, which activates the sterol regulatory element-binding protein (SREBP) pathway. SREBP translocates to the nucleus and upregulates transcription of the LDL receptor gene, increasing the density of LDL receptors on the hepatocyte surface. These additional LDL receptors bind and internalize circulating LDL particles from the blood, which is the primary mechanism by which statins lower serum LDL cholesterol.\n\nPLEIOTROPIC EFFECTS:\nBeyond LDL lowering, statins have clinically important pleiotropic effects that contribute to their cardiovascular benefit. These include improvement of endothelial function (increased nitric oxide bioavailability), stabilization of atherosclerotic plaques (reduced metalloproteinase activity, increased collagen content of the fibrous cap), anti-inflammatory effects (reduced hs-CRP, decreased macrophage activation), and antithrombotic properties (reduced tissue factor expression, decreased platelet aggregation).\n\nCLINICAL CONTEXT:\nFamilial hypercholesterolemia (FH) illustrates why LDL receptor upregulation is the key mechanism: heterozygous FH patients (who have approximately 50% of normal LDL receptor activity) respond well to statins because the drug upregulates their remaining functional receptors, while homozygous FH patients (who have absent or severely deficient LDL receptors) show minimal response to statins and require alternative therapies such as PCSK9 inhibitors, lomitapide, or LDL apheresis.\n\nKEY POINTS:\nStatins lower LDL primarily by inhibiting hepatic cholesterol synthesis, which triggers SREBP-mediated upregulation of LDL receptors on hepatocytes that clear LDL from the blood. Pleiotropic effects (plaque stabilization, anti-inflammation, improved endothelial function) contribute additional cardiovascular benefit. Homozygous FH patients respond poorly because they lack functional LDL receptors to upregulate."
  },
  {
    "id": 229,
    "categoryId": 17,
    "question": "The Eustachian tube connects the Middle Ear to the:",
    "options": [
      "A) Inner Ear",
      "B) Nasopharynx",
      "C) Oropharynx",
      "D) Sinuses"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nasopharynx).\n\nANATOMY:\nThe Eustachian tube (pharyngotympanic tube or auditory tube) is a 36 mm channel connecting the middle ear cavity (tympanic cavity) to the nasopharynx. It serves three critical functions: ventilation (equalizing middle ear pressure with atmospheric pressure), protection (barrier against nasopharyngeal secretions and pathogens), and clearance (mucociliary drainage of middle ear secretions into the nasopharynx).\n\nPEDIATRIC SIGNIFICANCE:\nIn infants and young children, the Eustachian tube is shorter (approximately 18 mm vs 36 mm in adults), more horizontal (10 degrees vs 45 degrees from horizontal), and has less rigid cartilaginous support. These anatomic differences impair the tube's protective and drainage functions:\n- The horizontal orientation allows reflux of nasopharyngeal bacteria into the middle ear\n- The shorter length decreases the distance pathogens must travel\n- Floppy cartilage impairs active opening during swallowing\n- Adenoid hypertrophy can obstruct the nasopharyngeal orifice\n\nCLINICAL RELEVANCE:\nEustachian tube dysfunction is the primary pathophysiologic mechanism underlying otitis media in children. When the tube fails to open properly, negative pressure develops in the middle ear, drawing in fluid (effusion) that becomes a culture medium for bacteria ascending from the nasopharynx. The most common pathogens (S. pneumoniae, H. influenzae, M. catarrhalis) colonize the nasopharynx and migrate through the dysfunctional tube. As the child grows, the tube elongates and angles downward, which is why AOM incidence decreases significantly after age 3.\n\nKEY POINTS:\nThe Eustachian tube connects the middle ear to the nasopharynx and is critical for pressure equalization and drainage. Pediatric anatomy (short, horizontal tube) predisposes children to otitis media. Adenoid hypertrophy can obstruct the Eustachian tube orifice, contributing to recurrent middle ear disease.\n---"
  },
  {
    "id": 230,
    "categoryId": 16,
    "question": "Heart Failure with Preserved Ejection Fraction (Diastolic HF) is fundamentally a problem of:",
    "options": [
      "A) Pumping failure",
      "B) Filling failure (Stiffness/Relaxation)",
      "C) Valve regurgitation",
      "D) Arrhythmia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Filling failure due to ventricular stiffness and impaired relaxation).\n\nPATHOPHYSIOLOGY:\nHeart failure with preserved ejection fraction (HFpEF, formerly called diastolic heart failure) involves normal or near-normal left ventricular systolic function (EF 50% or greater) but impaired ventricular relaxation and increased myocardial stiffness that limit diastolic filling. The ventricle contracts (squeezes) adequately but cannot relax and fill properly, requiring elevated left atrial pressures to achieve adequate ventricular filling volume. These elevated filling pressures transmit retrograde to the pulmonary vasculature, producing pulmonary congestion and the classic symptoms of dyspnea, exercise intolerance, and peripheral edema.\n\nMECHANISMS OF DIASTOLIC DYSFUNCTION:\nConcentric left ventricular hypertrophy (from chronic hypertension, the most common cause of HFpEF) increases wall thickness and reduces chamber compliance. Myocardial fibrosis (both interstitial and replacement fibrosis) further stiffens the ventricle. Titin, the giant sarcomeric protein that functions as a molecular spring governing passive myocardial stiffness, is hypophosphorylated in HFpEF, reducing its compliance. Systemic microvascular inflammation (driven by comorbidities including obesity, diabetes, hypertension, and chronic kidney disease) causes coronary microvascular endothelial dysfunction, reducing nitric oxide signaling and impairing cardiomyocyte relaxation.\n\nCLINICAL SIGNIFICANCE:\nHFpEF now accounts for approximately 50% of all heart failure cases and is more common in older women with hypertension, obesity, and atrial fibrillation. SGLT2 inhibitors (empagliflozin, dapagliflozin) are the first drug class to demonstrate mortality and hospitalization benefit in HFpEF (EMPEROR-Preserved and DELIVER trials).\n\nKEY POINTS:\nHFpEF is fundamentally a filling failure caused by impaired ventricular relaxation and myocardial stiffness, not a pumping failure (EF is preserved). Concentric LVH from chronic hypertension, myocardial fibrosis, and titin hypophosphorylation all contribute to reduced compliance. SGLT2 inhibitors are the first class to show benefit in HFpEF."
  },
  {
    "id": 231,
    "categoryId": 4,
    "question": "Menopausal hot flashes are triggered by the withdrawal of Estrogen, which causes:",
    "options": [
      "A) Lower body temperature set-point",
      "B) Narrowing of the 'Thermoneutral Zone' in the hypothalamus",
      "C) Reduced Norepinephrine",
      "D) Increased Serotonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Narrowing of the Thermoneutral Zone in the hypothalamus).\n\nPATHOPHYSIOLOGY:\nMenopausal vasomotor symptoms result from estrogen withdrawal-induced dysfunction of the hypothalamic thermoregulatory center. Normally, the thermoneutral zone\u2014the core temperature range within which neither sweating nor shivering is triggered\u2014spans approximately 0.4 degrees Celsius. Estrogen modulates this zone through hypothalamic KNDy (kisspeptin, neurokinin B, dynorphin) neurons in the arcuate nucleus (NEJM). When estrogen declines, neurokinin B signaling becomes hyperactive and the thermoneutral zone narrows to near zero, meaning minor temperature fluctuations of 0.01-0.02 degrees Celsius trigger full heat dissipation: peripheral vasodilation (flushing), diaphoresis, and tachycardia. Per the SWAN study (JAMA Internal Medicine), vasomotor symptoms affect approximately 80% of peri- and postmenopausal women, persisting a median of 7.4 years.\n\nCLINICAL REASONING:\nKNDy neuron identification led to fezolinetant (Veozah), an NK3R antagonist approved by the FDA in 2023 that targets hyperactive neurokinin B signaling, restoring thermoneutral zone width without exogenous estrogen. Clinical trials (The Lancet) showed approximately 60% reduction in vasomotor symptom frequency.\n\nTREATMENT:\nHormone therapy is most effective, reducing hot flashes by 75-95%, and is first-line per the Endocrine Society and NAMS for symptomatic women within 10 years of menopause onset or under age 60. For women who cannot take estrogen, non-hormonal alternatives include fezolinetant, SSRIs/SNRIs (paroxetine 7.5 mg is the only FDA-approved non-hormonal agent), gabapentin (especially for nocturnal symptoms), and oxybutynin (OPAL trial). CBT reduces hot flash bothersomeness (The Lancet). Lifestyle modifications include cool ambient temperature, layered clothing, and avoiding triggers (alcohol, spicy foods, caffeine).\n\nKEY POINTS:\nEstrogen withdrawal narrows the hypothalamic thermoneutral zone to near zero through KNDy neurokinin B hyperactivation, causing minor temperature fluctuations to trigger hot flashes. Hormone therapy is most effective (75-95% reduction). Fezolinetant is the first mechanism-based non-hormonal therapy targeting the KNDy pathway."
  },
  {
    "id": 232,
    "categoryId": 10,
    "question": "The four pillars of Acne pathogenesis are: Hyperkeratinization, Sebum production, C. acnes bacteria, and:",
    "options": [
      "A) Viral infection",
      "B) Inflammation",
      "C) Poor hygiene",
      "D) Sun exposure"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/acne-types-chart.png",
        "alt": "Acne lesion types including papules, blackheads, whiteheads, nodules, pustules, and cysts",
        "caption": "Common acne lesion morphology (papules, comedones, pustules, nodules, and cysts)."
      }
    ],
    "explanation": "CORRECT: B (Inflammation).\n\nPATHOPHYSIOLOGY:\nAcne vulgaris is a chronic inflammatory disease of the pilosebaceous unit driven by four interrelated mechanisms. First, follicular hyperkeratinization: keratinocytes proliferate excessively and form a keratinous plug (microcomedo) obstructing the follicular ostium. Second, androgen-driven sebum overproduction, principally by DHT converted via 5-alpha reductase. Third, Cutibacterium acnes proliferates in the sebum-filled follicle, producing lipases and chemotactic factors. Fourth, inflammation: C. acnes activates TLR-2 on keratinocytes and monocytes, releasing IL-1, IL-8, TNF-alpha, and MMPs, transforming comedones into papules, pustules, and nodules. Evidence from the Journal of Investigative Dermatology shows subclinical inflammation is present even in early comedones, establishing it as a primary event.\n\nTREATMENT BY PATHOGENIC TARGET:\nPer the AAD, topical retinoids (tretinoin, adapalene) normalize keratinization and prevent microcomedones, forming the foundation of most regimens. Hormonal agents (combined OCPs with antiandrogenic progestins, spironolactone) reduce sebum. Benzoyl peroxide kills C. acnes without inducing resistance\u2014essential alongside antibiotics. Oral antibiotics (doxycycline, minocycline) target bacteria and inflammation but should be limited to 3-4 months. Isotretinoin uniquely addresses all four pillars and can induce long-term remission.\n\nMANAGEMENT LADDER:\nMild comedonal: topical retinoid. Mild inflammatory: add benzoyl peroxide with or without topical antibiotic. Moderate inflammatory: oral antibiotics plus topical retinoid and benzoyl peroxide. Severe nodulocystic or treatment-resistant: isotretinoin referral. Aggressive cleansing worsens inflammation by disrupting the epidermal barrier\u2014poor hygiene is not a cause.\n\nKEY POINTS:\nThe four pillars are hyperkeratinization, excess sebum, C. acnes, and inflammation, each with targeted therapies. Retinoids are foundational. Benzoyl peroxide must accompany antibiotics to prevent resistance. Isotretinoin targets all four pillars. Poor hygiene does not cause acne."
  },
  {
    "id": 233,
    "categoryId": 7,
    "question": "The Cauda Equina (Horse's Tail) begins at which vertebral level?",
    "options": [
      "A) C7",
      "B) T12",
      "C) L1-L2",
      "D) S1"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (L1-L2).\n\nPATHOPHYSIOLOGY:\nDuring embryonic development, the vertebral column elongates more than the spinal cord (ascensus medullae), so by adulthood the cord terminates as the conus medullaris at L1-L2. Below this, lumbar, sacral, and coccygeal nerve roots descend as the cauda equina\u2014free-floating roots in CSF within the thecal sac. The filum terminale, a pia mater strand, anchors the conus to the coccyx.\n\nCLINICAL SIGNIFICANCE:\nLumbar puncture is performed at L3-L4 or L4-L5 because the needle enters below the conus, passing through mobile cauda equina roots that are pushed aside rather than penetrated. Puncture above L2 risks direct spinal cord injury. The L4-L5 interspace is identified by palpating the iliac crests, corresponding to L4. Spinal and epidural anesthesia rely on the same landmark.\n\nCAUDA EQUINA SYNDROME:\nThis surgical emergency results from compression of cauda equina nerve roots, most commonly from large central lumbar disc herniation at L4-L5 or L5-S1, but also tumors, epidural abscess, or hematoma. Classic presentation includes severe bilateral radiating low back pain, progressive lower extremity weakness, saddle anesthesia (S2-S5 perineal and perianal dermatomes), and bladder/bowel dysfunction with urinary retention, overflow incontinence, and decreased rectal tone. Because the cauda equina carries sacral parasympathetic fibers, compression produces a lower motor neuron pattern with areflexic bladder and bowel. Emergent MRI is required, and surgical decompression via laminectomy must occur within 24-48 hours to maximize recovery; delay risks permanent bladder, bowel, and sexual dysfunction.\n\nKEY POINTS:\nThe spinal cord terminates at L1-L2; lumbar puncture at L3-L4 or L4-L5 avoids cord injury while accessing CSF among mobile cauda equina roots. Cauda equina syndrome presents with saddle anesthesia, urinary retention, and bilateral leg weakness, requiring emergent MRI and decompression within 24-48 hours."
  },
  {
    "id": 234,
    "categoryId": 1,
    "question": "A 55-year-old diabetic male presents with 'heartburn' and diaphoresis. An EKG shows ST elevation in leads II, III, and aVF. Which wall of the heart is affected, and which medication is CONTRAINDICATED?",
    "questionImages": [
      { "src": "assets/inferior-stemi-ekg.png", "alt": "12-lead EKG showing acute inferior wall STEMI with ST elevation in II, III, aVF and reciprocal ST depression in V1-V3", "caption": "Acute inferior wall ST segment elevation MI (STEMI); note ST segment elevation in leads II, III, aVF; ST segment depression in V1-3 represents true posterior injury." }
    ],
    "options": [
      "A) Anterior Wall; Avoid Beta Blockers",
      "B) Inferior Wall; Avoid Nitroglycerin",
      "C) Lateral Wall; Avoid Aspirin",
      "D) Posterior Wall; Avoid Morphine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inferior Wall MI; Avoid Nitroglycerin).\n\nCLINICAL REASONING:\nST elevation in leads II, III, and aVF localizes the infarction to the inferior wall of the heart, which is supplied by the right coronary artery (RCA) in approximately 85% of patients (right-dominant circulation) or the left circumflex artery in the remaining 15%. The presentation of \"heartburn\" with diaphoresis in a diabetic male is a classic atypical MI presentation, as diabetic patients frequently experience anginal equivalents rather than typical chest pain.\n\nPATHOPHYSIOLOGY:\nNitroglycerin is contraindicated in inferior wall MI because of the high frequency of associated right ventricular infarction (approximately 30 to 50% of inferior MIs have RV involvement). The right ventricle is a preload-dependent chamber that relies on adequate venous return to maintain cardiac output. Nitroglycerin is a potent venodilator that reduces preload by pooling blood in the venous capacitance vessels. In the setting of RV infarction, this preload reduction can cause catastrophic hemodynamic collapse with severe hypotension, bradycardia, and cardiogenic shock. Right-sided EKG leads (particularly V4R) should be obtained in all inferior MIs to assess for RV involvement.\n\nADDITIONAL CONTRAINDICATIONS:\nBeyond RV infarction, nitroglycerin is also contraindicated in patients who have taken a phosphodiesterase-5 inhibitor (sildenafil within 24 hours, tadalafil within 48 hours), as the combination can produce profound refractory hypotension. Morphine should also be used cautiously in inferior MI as it can cause vagal-mediated bradycardia and hypotension.\n\nKEY POINTS:\nST elevation in leads II, III, and aVF indicates inferior wall MI (RCA territory), and nitroglycerin is contraindicated because of frequent RV involvement (30 to 50% of inferior MIs) where preload reduction causes hemodynamic collapse. Right-sided EKG lead V4R should be obtained in all inferior MIs to assess for RV infarction. Diabetic patients commonly present with anginal equivalents rather than classic chest pain."
  },
  {
    "id": 235,
    "categoryId": 6,
    "question": "A 70-year-old patient had a TIA (slurred speech for 10 mins, now resolved). His ABCD2 score is 5 (Moderate/High Risk). What is the recommended management?",
    "options": [
      "A) Send home with Aspirin and outpatient neurology referral",
      "B) Schedule MRI next week",
      "C) Immediate ER referral for admission/workup",
      "D) Start Warfarin immediately"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Immediate ER referral for admission/workup).\n\nHIGH-RISK TIA:\nA TIA with ABCD2 score of 5 represents high short-term stroke riskâ€”approximately 4-5% within 48 hours. This patient requires urgent hospitalization for comprehensive workup and secondary prevention initiation. Outpatient management is inappropriate for high-risk TIA.\n\nABCD2 SCORE COMPONENTS:\nAge â‰¥60 (1 point), Blood pressure â‰¥140/90 (1 point), Clinical featuresâ€”unilateral weakness (2 points) or speech disturbance (1 point), Duration â‰¥60 min (2 points) or 10-59 min (1 point), Diabetes (1 point). Scores â‰¥4 indicate high risk requiring hospitalization.\n\nINPATIENT WORKUP:\nMRI with diffusion-weighted imaging (30-50% of TIAs show acute infarct), carotid imaging (duplex ultrasound or CTA), echocardiography, telemetry monitoring for atrial fibrillation, and lipid panel. Many \"TIAs\" prove to be minor strokes on DWI, changing management.\n\nTIME-SENSITIVE INTERVENTION:\nIf carotid stenosis >70% is found, endarterectomy within 2 weeks dramatically reduces stroke risk. Dual antiplatelet therapy (aspirin + clopidogrel for 21 days) reduces early recurrence. Statin initiation regardless of lipids provides neuroprotection.\n\nKEY POINTS:\nHigh ABCD2 score (â‰¥4) TIA requires hospitalization, not outpatient management. 30-50% of TIAs show infarct on MRI-DWI. Carotid intervention within 2 weeks and early dual antiplatelet therapy reduce stroke risk."
  },
  {
    "id": 236,
    "categoryId": 15,
    "question": "A patient develops lip swelling and wheezing after an injection. BP is 90/60. What is the correct dose and route of Epinephrine for an adult?",
    "options": [
      "A) 1mg (1:10,000) IV push",
      "B) 0.3mg to 0.5mg (1:1,000) Intramuscular (IM)",
      "C) 0.3mg Subcutaneous",
      "D) 50mg Oral Benadryl"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (0.3mg to 0.5mg of 1:1,000 concentration Intramuscular).\n\nPATHOPHYSIOLOGY:\nAnaphylaxis is a severe, life-threatening systemic hypersensitivity reaction mediated primarily by IgE-dependent mast cell and basophil degranulation, releasing histamine, tryptase, leukotrienes, and prostaglandins that cause widespread vasodilation, increased vascular permeability, bronchospasm, and upper airway edema. The resulting distributive shock with intravascular volume depletion can rapidly progress to cardiovascular collapse and death within minutes if untreated. Common triggers include medications (antibiotics, NSAIDs), foods (peanuts, tree nuts, shellfish), insect stings (Hymenoptera), and latex.\n\nCLINICAL REASONING:\nEpinephrine is the first-line treatment for anaphylaxis and the only medication that directly addresses all pathophysiologic mechanisms: alpha-1 adrenergic effects cause vasoconstriction (reversing hypotension and reducing mucosal edema), beta-1 effects increase cardiac output, and beta-2 effects cause bronchodilation and suppress further mediator release from mast cells. The correct dose for anaphylaxis is 0.3 to 0.5 mg of the 1:1,000 (1 mg/mL) concentration administered intramuscularly in the anterolateral thigh, which provides the most rapid and reliable absorption. This dose may be repeated every 5 to 15 minutes as needed. There are no absolute contraindications to epinephrine in anaphylaxis.\n\nCRITICAL SAFETY DISTINCTION:\nThe 1:10,000 concentration (0.1 mg/mL) of epinephrine is reserved exclusively for cardiac arrest (pulseless patient) and is given intravenously. Administering IV epinephrine to a patient with a perfusing rhythm can cause fatal ventricular tachycardia, hypertensive crisis, or myocardial ischemia. The intramuscular route in the anterolateral thigh is superior to subcutaneous injection because of faster and more reliable absorption due to the thigh's rich blood supply. Adjunctive treatments include aggressive IV crystalloid resuscitation (1 to 2 liters for hypotension), H1 antihistamines (diphenhydramine), H2 blockers (famotidine), and corticosteroids, though none of these replace epinephrine. Patients should be observed for a minimum of 4 to 6 hours due to the risk of biphasic reactions (recurrence of symptoms hours after initial resolution).\n\nKEY POINTS:\nAnaphylaxis requires immediate intramuscular epinephrine 0.3 to 0.5 mg of 1:1,000 concentration in the anterolateral thigh, with no contraindications. Intravenous epinephrine (1:10,000) is reserved exclusively for cardiac arrest and can cause fatal arrhythmias if given to a patient with a pulse. Patients must be observed 4 to 6 hours for biphasic reactions, and antihistamines and steroids are adjuncts that do not replace epinephrine."
  },
  {
    "id": 237,
    "categoryId": 17,
    "question": "A patient presents with a painful red eye. You see a 'ciliary flush' (redness around the iris) and the pupil is small and irregularly shaped. Shining light in the UNAFFECTED eye causes pain in the affected eye (Consensual Photophobia). Diagnosis?",
    "options": [
      "A) Conjunctivitis",
      "B) Anterior Uveitis (Iritis)",
      "C) Angle Closure Glaucoma",
      "D) Subconjunctival Hemorrhage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Uveitis).\n\nPATHOPHYSIOLOGY:\nAnterior uveitis (iritis) is inflammation of the iris and ciliary body. The inflamed iris develops spasm of the ciliary muscle and sphincter pupillae, causing the characteristic miotic (small) pupil and deep aching pain. When light enters either eye, the consensual pupillary response constricts the inflamed iris, producing pain in the affected eye even when light is shone in the contralateral eye (consensual photophobia). This finding is pathognomonic for anterior uveitis and reliably distinguishes it from conjunctivitis.\n\nCLINICAL PRESENTATION:\n- Unilateral eye pain (deep, aching)\n- Photophobia, including consensual photophobia (pathognomonic)\n- Ciliary flush: Ring of limbal (perilimbal) injection around the cornea\n- Miotic, irregularly shaped pupil (posterior synechiae from inflammatory adhesions)\n- Decreased visual acuity\n- Cells and flare in the anterior chamber on slit-lamp examination\n\nETIOLOGY:\nAnterior uveitis is strongly associated with HLA-B27-related systemic diseases:\n- Ankylosing spondylitis (most common systemic association)\n- Reactive arthritis (formerly Reiter syndrome)\n- Inflammatory bowel disease (Crohn disease, ulcerative colitis)\n- Psoriatic arthritis\n- Other causes include sarcoidosis, Behcet disease, infections (HSV, VZV, syphilis, tuberculosis), and idiopathic\n\nDIAGNOSIS:\nSlit-lamp examination is the gold standard, revealing anterior chamber cells, flare (protein leakage), and keratic precipitates. Workup for recurrent or bilateral disease includes HLA-B27, chest X-ray (sarcoidosis, TB), RPR/VDRL (syphilis), and ACE level (sarcoidosis).\n\nTREATMENT:\nUrgent ophthalmology referral is essential.\n1. Topical corticosteroids (prednisolone acetate 1%) to suppress inflammation\n2. Cycloplegics (cyclopentolate, atropine) to relieve ciliary spasm, reduce pain, and prevent posterior synechiae\n3. Treat underlying systemic disease when identified\n\nKEY POINTS:\nConsensual photophobia (pain in the affected eye when light is shone in the unaffected eye) is pathognomonic for anterior uveitis. Ciliary flush and a miotic pupil distinguish uveitis from conjunctivitis. Recurrent anterior uveitis warrants workup for HLA-B27-associated spondyloarthropathies.\n---"
  },
  {
    "id": 238,
    "categoryId": 1,
    "question": "A 65-year-old smoker presents with sudden onset severe leg pain. The leg is pale, cold, and pulseless. Capillary refill is absent. What is the diagnosis?",
    "options": [
      "A) Deep Vein Thrombosis (DVT)",
      "B) Acute Limb Ischemia",
      "C) Cellulitis",
      "D) Sciatica"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Limb Ischemia).\n\nCLINICAL REASONING:\nThe patient presents with the classic \"6 Ps\" of acute limb ischemia: Pain (sudden onset severe leg pain), Pallor (pale leg), Pulselessness (absent pulses), Poikilothermia (cold limb), Paresthesia (implied by the ischemic presentation), and Paralysis (in advanced cases). Acute limb ischemia is a vascular emergency defined as a sudden decrease in limb perfusion that threatens limb viability, typically caused by either arterial embolism (most commonly from a cardiac source such as atrial fibrillation, left ventricular thrombus post-MI, or valvular disease) or acute thrombosis of a pre-existing atherosclerotic stenosis.\n\nPATHOPHYSIOLOGY:\nThe distinction from DVT is critical: DVT causes limb swelling, warmth, and erythema (from venous outflow obstruction) with preserved arterial pulses, while acute arterial ischemia causes a pale, cold, pulseless limb. Skeletal muscle can tolerate approximately 6 hours of complete ischemia before irreversible necrosis begins, making rapid diagnosis and intervention essential.\n\nMANAGEMENT:\nImmediate systemic anticoagulation with IV unfractionated heparin is initiated upon diagnosis to prevent thrombus propagation. Definitive revascularization depends on the etiology and severity: catheter-directed thrombolysis (for acute thrombosis presenting within 14 days), surgical thromboembolectomy (Fogarty balloon catheter technique, particularly for embolic occlusion), or bypass grafting. Compartment pressures should be monitored after revascularization because reperfusion injury can cause compartment syndrome requiring fasciotomy.\n\nKEY POINTS:\nAcute limb ischemia presents with the 6 Ps (Pain, Pallor, Pulselessness, Poikilothermia, Paresthesia, Paralysis) and is a vascular emergency with approximately 6 hours before irreversible muscle necrosis. It is distinguished from DVT by the cold, pale, pulseless limb (DVT causes warm, swollen, erythematous limb with pulses). Immediate heparin anticoagulation is essential, followed by either thrombolysis or surgical embolectomy."
  },
  {
    "id": 239,
    "categoryId": 15,
    "question": "A 65-year-old male smoker presents with sudden onset severe back pain and syncope. BP is 80/50. He has a pulsatile abdominal mass. What is the next step?",
    "options": [
      "A) CT Abdomen with Contrast",
      "B) Abdominal Ultrasound",
      "C) Immediate Transfer to OR (Do not delay for imaging)",
      "D) IV Fluids and observe"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Immediate Transfer to OR).\n\nPATHOPHYSIOLOGY:\nAbdominal aortic aneurysm rupture is a surgical emergency with an overall mortality exceeding 80% and approaching 100% without operative intervention. An AAA means a focal dilation of the abdominal aorta to greater than 3.0 cm (normal diameter approximately 2.0 cm), and rupture occurs when wall stress exceeds tensile strength, most commonly in aneurysms exceeding 5.5 cm. Risk factors include male sex (6:1 male-to-female ratio), age over 65, smoking (the strongest modifiable risk factor), hypertension, family history, and connective tissue disorders. The USPSTF recommends one-time screening abdominal ultrasound for men aged 65 to 75 who have ever smoked.\n\nCLINICAL REASONING:\nThe patient presents with the classic diagnostic triad of ruptured AAA: sudden severe back or abdominal pain, hemodynamic instability (BP 80/50 indicating hemorrhagic shock), and a pulsatile abdominal mass. This triad is present in approximately 50% of ruptured AAA cases and is considered virtually diagnostic when all three components are identified. The critical management principle is that hemodynamically unstable patients with clinical signs of ruptured AAA must be taken directly to the operating room promptly for imaging. CT angiography is appropriate only for hemodynamically stable patients in whom the diagnosis is uncertain, as the time required for imaging in an unstable patient can be fatal. Permissive hypotension (target systolic BP 70 to 90 mmHg) is recommended during resuscitation to avoid disrupting any contained retroperitoneal hematoma.\n\nMANAGEMENT:\nSurgical repair is performed via open repair (laparotomy with graft placement) or endovascular aneurysm repair (EVAR) depending on anatomic suitability and institutional capability. Massive transfusion protocol should be activated, and type-specific or uncrossmatched blood should be available. For elective repair of unruptured AAA, current guidelines from the Society for Vascular Surgery recommend repair when the aneurysm reaches 5.5 cm in men or 5.0 cm in women, when the growth rate exceeds 0.5 cm over 6 months, or when the aneurysm becomes symptomatic.\n\nKEY POINTS:\nThe triad of sudden back pain, hypotension, and pulsatile abdominal mass is virtually diagnostic of ruptured AAA and requires immediate operative intervention promptly for imaging. Overall mortality of ruptured AAA exceeds 80%, approaching 100% without surgery. The USPSTF recommends one-time screening ultrasound for men aged 65 to 75 who have ever smoked."
  },
  {
    "id": 240,
    "categoryId": 10,
    "question": "A patient presents with a pimple on the upper lip that she 'popped'. It is now swollen, red, and she has a headache and fever. Why is this dangerous?",
    "options": [
      "A) Risk of scarring",
      "B) Risk of Cavernous Sinus Thrombosis",
      "C) Risk of Lyme disease",
      "D) It is not dangerous"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Risk of Cavernous Sinus Thrombosis).\n\nPATHOPHYSIOLOGY:\nThe central face\u2014bounded by the nasal bridge superiorly and mouth corners inferolaterally\u2014is the \"danger triangle\" due to its hazardous venous drainage. The facial vein communicates with the pterygoid venous plexus via the deep facial vein and with the cavernous sinus via the ophthalmic veins. These connections lack valves, allowing bidirectional flow. Manipulating a skin infection in this region can force bacteria retrograde through valveless veins into the cavernous sinus. Staphylococcus aureus, including MRSA, is the most common causative organism.\n\nCLINICAL PRESENTATION:\nCavernous sinus thrombosis presents with systemic sepsis (high fever, rigors) and cranial nerve dysfunction. CNs III, IV, V1, V2, and VI traverse the cavernous sinus, so thrombosis produces ophthalmoplegia, ptosis, periorbital edema, proptosis, chemosis, and V1/V2 sensory deficits. Because the two cavernous sinuses communicate via intercavernous sinuses, bilateral symptoms are a classic diagnostic clue. Mortality remains 20-30% with modern treatment, with morbidity including permanent cranial nerve palsies and pituitary insufficiency.\n\nDIAGNOSIS AND TREATMENT:\nMRI with MR venography is the imaging modality of choice, demonstrating filling defects and inflammatory changes. Treatment requires prolonged IV antibiotics with MRSA coverage (vancomycin plus ceftriaxone or meropenem) for 3-4 or more weeks. Most experts support systemic heparin anticoagulation to prevent clot propagation. Surgical drainage of the primary facial infection may be necessary.\n\nKEY POINTS:\nThe danger triangle has valveless venous connections to the cavernous sinus, enabling retrograde infection spread from manipulated facial lesions. Cavernous sinus thrombosis presents with fever, cranial nerve palsies (III, IV, V1, V2, VI), proptosis, and chemosis; bilateral involvement is hallmark. Patients should never squeeze central face lesions. Mortality remains 20-30%."
  },
  {
    "id": 241,
    "categoryId": 6,
    "question": "A 40-year-old female presents with the 'worst headache of my life' (Thunderclap) that reached max intensity in seconds. CT Head is negative. What is the mandatory next step?",
    "options": [
      "A) Discharge with NSAIDs",
      "B) MRI Brain",
      "C) Lumbar Puncture",
      "D) EEG"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Lumbar Puncture).\n\nSUBARACHNOID HEMORRHAGE EVALUATION:\nA thunderclap headache reaching maximal intensity within seconds is subarachnoid hemorrhage (SAH) until proven otherwise. SAH results from rupture of an intracranial aneurysm in approximately 85% of non-traumatic cases. Although CT head is the initial imaging study, a negative CT does not exclude SAH, particularly when imaging is performed more than 6 to 12 hours after symptom onset, making lumbar puncture mandatory in CT-negative cases with high clinical suspicion.\n\nPATHOPHYSIOLOGY:\nSaccular (berry) aneurysms develop at arterial branch points in the Circle of Willis, most commonly at the anterior communicating artery. Rupture releases arterial blood into the subarachnoid space, causing sudden severe headache, meningeal irritation, and potentially devastating complications including rebleeding, vasospasm, and hydrocephalus. Small sentinel leaks (warning leaks) may precede catastrophic rupture, making early detection lifesaving.\n\nDIAGNOSIS:\nNon-contrast CT detects SAH with approximately 98% sensitivity within 6 hours but sensitivity declines to 85-90% at 24 hours and continues to fall thereafter. When CT is negative, lumbar puncture is the definitive next step. CSF findings diagnostic of SAH include xanthochromia (yellow discoloration from bilirubin, a breakdown product of hemoglobin) and elevated red blood cell count that does not clear between tubes 1 and 4. CT angiography is then performed to identify the aneurysm.\n\nTREATMENT:\nConfirmed SAH requires immediate neurosurgical consultation for aneurysm securing via endovascular coiling (preferred) or surgical clipping. Nimodipine (a calcium channel blocker) is administered for 21 days to reduce the risk of delayed cerebral ischemia from vasospasm. Blood pressure control, seizure prophylaxis, and close neurological monitoring in an intensive care setting are essential components of management.\n\nKEY POINTS:\nA thunderclap headache is SAH until proven otherwise; a negative CT does not exclude the diagnosis. Lumbar puncture looking for xanthochromia is mandatory when CT is negative and clinical suspicion is high. Missing a sentinel bleed can result in fatal aneurysm re-rupture."
  },
  {
    "id": 242,
    "categoryId": 7,
    "question": "A patient falls on an outstretched hand (FOOSH). X-rays of the wrist are negative, but he has tenderness in the 'Anatomical Snuffbox'. Management?",
    "options": [
      "A) Ace wrap and NSAIDs",
      "B) Thumb Spica Splint and repeat X-ray in 2 weeks",
      "C) Physical Therapy",
      "D) Cortisone injection"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/scaphoidfx.png", "alt": "Scaphoid fracture", "caption": "Scaphoid fracture image." }
    ],
    "explanation": "CORRECT: B (Thumb spica splint and repeat X-ray in 2 weeks; treat as scaphoid fracture until proven otherwise).\n\nPATHOPHYSIOLOGY:\nThe scaphoid is the most commonly fractured carpal bone (60-70% of carpal fractures), typically from a fall on an outstretched hand (FOOSH) with wrist dorsiflexion. The scaphoid has a retrograde blood supply entering distally via radial artery branches, flowing from distal to proximal pole. Waist or proximal pole fractures can disrupt flow to the proximal fragment, creating significant avascular necrosis risk.\n\nCLINICAL PRESENTATION:\nPatients present with radial-sided wrist pain after FOOSH. The hallmark is anatomical snuffbox tenderness (bordered by extensor pollicis longus ulnarly and extensor pollicis brevis/abductor pollicis longus radially). Additional findings include pain with axial thumb compression and scaphoid tubercle tenderness. Initial radiographs have only approximately 70-80% sensitivity because nondisplaced hairline cracks become visible only after bone resorption widens the fracture line over 10-14 days.\n\nDIAGNOSIS AND MANAGEMENT:\nWith high clinical suspicion and negative initial X-rays, immobilize in a thumb spica splint and repeat radiographs in 10-14 days. MRI approaches 100% sensitivity within 24 hours and is increasingly used for early definitive diagnosis. CT provides good bony detail but is less sensitive than MRI for very early fractures. Nondisplaced waist fractures require 8-12 weeks of cast immobilization. Displaced fractures (greater than 1 mm step-off) and proximal pole fractures require surgical fixation with a headless compression screw. AVN develops in up to 30% of untreated proximal pole fractures, leading to scaphoid nonunion advanced collapse and progressive wrist arthritis.\n\nKEY POINTS:\nAnatomical snuffbox tenderness after FOOSH must be treated as scaphoid fracture until disproven, even with negative X-rays (sensitivity only 70-80%). The retrograde blood supply places the proximal pole at high AVN risk. Thumb spica immobilization with repeat imaging at 10-14 days or early MRI is standard of care."
  },
  {
    "id": 243,
    "categoryId": 2,
    "question": "A child presents with sudden onset respiratory distress and drooling. The parents report a 'choking episode' while eating peanuts 2 days ago. Chest X-ray is normal. What is suspected?",
    "options": [
      "A) Asthma",
      "B) Foreign Body Aspiration",
      "C) Pneumonia",
      "D) Croup"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Foreign Body Aspiration).\n\nPATHOPHYSIOLOGY:\nForeign body aspiration occurs most commonly in children between 1 and 3 years of age due to their tendency to explore objects orally, incomplete dentition limiting proper mastication, and immature airway protective reflexes. The most commonly aspirated items are organic materials (peanuts, seeds, grapes, hot dogs, popcorn) and small toys. Most aspirated objects lodge in the right mainstem bronchus in adults and older children (due to its wider diameter, shorter length, and more vertical orientation compared to the left), though in young children the angle of bifurcation is more symmetric and either side may be affected.\n\nCLINICAL REASONING:\nThis child presents with the classic scenario: a witnessed choking episode on peanuts followed by persistent respiratory distress and drooling. The critical teaching point is that organic materials (peanuts, food, seeds) and plastic objects are radiolucent and will not be visible on standard chest radiograph. A normal chest X-ray does not rule out foreign body aspiration. Indirect radiographic signs include unilateral hyperinflation from ball-valve air trapping (the object allows air entry during inspiration when airways dilate but obstructs outflow during expiration when airways narrow), atelectasis from complete obstruction, or mediastinal shift. Inspiratory and expiratory films or bilateral decubitus films may demonstrate differential air trapping. When clinical suspicion is high based on history, even with a completely normal chest X-ray, rigid bronchoscopy is indicated for both diagnostic and therapeutic purposes.\n\nMANAGEMENT:\nRigid bronchoscopy is the gold standard for both diagnosis and removal of aspirated foreign bodies in children. It provides superior visualization, ventilation capability during the procedure, and a large working channel for extraction instruments compared to flexible bronchoscopy. Delayed diagnosis (as in this case, 2 days after the event) increases the risk of complications including post-obstructive pneumonia, granulation tissue formation around the object, and bronchiectasis from chronic obstruction.\n\nKEY POINTS:\nA normal chest X-ray does not rule out foreign body aspiration because peanuts, food, and plastic are radiolucent. Unilateral wheezing or air trapping from ball-valve obstruction on expiratory films is a key radiographic clue. Rigid bronchoscopy is the gold standard for diagnosis and removal, and clinical suspicion from a witnessed choking episode should prompt bronchoscopy regardless of X-ray findings."
  },
  {
    "id": 244,
    "categoryId": 15,
    "question": "The 'qSOFA' score identifies patients at high risk for poor outcomes from sepsis outside the ICU. It includes Altered Mental Status and which two other criteria?",
    "options": [
      "A) Fever > 38 and WBC > 12k",
      "B) Systolic BP < 100 and Respiratory Rate > 22",
      "C) HR > 90 and Lactate > 2",
      "D) Age > 65 and Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Systolic BP less than or equal to 100 and Respiratory Rate greater than or equal to 22).\n\nPATHOPHYSIOLOGY:\nSepsis is defined by Sepsis-3 (JAMA 2016) as life-threatening organ dysfunction from a dysregulated host response to infection, operationalized as suspected infection with an acute SOFA score increase of 2 or more points. Septic shock is sepsis requiring vasopressors to maintain MAP of 65 mmHg or greater with lactate greater than 2 mmol/L despite adequate fluid resuscitation.\n\nCLINICAL REASONING:\nThe qSOFA score is a bedside screening tool for patients with suspected infection at high risk for poor outcomes outside the ICU. It uses three variables, each scored 1 point: altered mental status (GCS less than 15), systolic BP less than or equal to 100 mmHg, and respiratory rate greater than or equal to 22 breaths per minute. A score of 2 or more should prompt investigation for organ dysfunction, therapy escalation, and ICU consideration. qSOFA requires no laboratory testing, enabling rapid bedside assessment.\n\nMANAGEMENT:\nThe Surviving Sepsis Campaign Hour-1 Bundle mandates within one hour: measure lactate (repeat in 2-4 hours if above 2 mmol/L), obtain blood cultures before antibiotics (never delay antibiotics for cultures), administer broad-spectrum empiric antibiotics, begin IV crystalloid at 30 mL/kg for hypotension or lactate 4 mmol/L or greater, and start vasopressors (norepinephrine is first-line) if hypotension persists, targeting MAP of 65 mmHg or greater. Each hour of antibiotic delay increases mortality. Consider hydrocortisone 200 mg/day for refractory septic shock. Lactate clearance (greater than 10% decrease over 2-4 hours) monitors resuscitation response.\n\nKEY POINTS:\nqSOFA consists of altered mental status, systolic BP less than or equal to 100, and respiratory rate greater than or equal to 22; a score of 2 or more prompts urgent sepsis evaluation. The Hour-1 Bundle requires lactate, cultures, antibiotics, fluids, and vasopressors within one hour. Norepinephrine is first-line; each hour of antibiotic delay increases mortality."
  },
  {
    "id": 245,
    "categoryId": 15,
    "question": "A patient presents with confusion, cherry-red skin, and anion gap metabolic acidosis after a house fire. Diagnosis and Antidote?",
    "options": [
      "A) Carbon Monoxide; Oxygen",
      "B) Cyanide Poisoning; Hydroxocobalamin",
      "C) Arsenic; Chelation",
      "D) Methemoglobinemia; Methylene Blue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cyanide Poisoning; Hydroxocobalamin).\n\nPATHOPHYSIOLOGY:\nCyanide is a mitochondrial toxin that binds to cytochrome c oxidase (Complex IV) in the electron transport chain, halting aerobic metabolism and forcing cells into anaerobic glycolysis even with adequate oxygen delivery. This produces a state of cellular or histotoxic hypoxia in which tissues cannot utilize oxygen despite normal or elevated PaO2 and oxygen saturation. The resulting massive shift to anaerobic metabolism generates severe lactic acidosis. Cyanide is released during combustion of synthetic materials including plastics, wool, silk, nylon, and polyurethane commonly found in residential and industrial fires, making smoke inhalation the most common source of cyanide poisoning in clinical practice.\n\nCLINICAL REASONING:\nThe patient presents with confusion, cherry-red skin discoloration, and an anion gap metabolic acidosis following a house fire. The critical distinction from carbon monoxide poisoning, which also occurs in fire victims, is the presence of severe lactic acidosis (often greater than 8 mmol/L). Carbon monoxide poisoning produces cherry-red skin and altered mental status but typically does not cause a profound lactic acidosis because it impairs oxygen delivery rather than oxygen utilization. Cyanide poisoning causes a markedly elevated lactate because it blocks oxidative phosphorylation at the mitochondrial level. A serum lactate greater than 8 mmol/L in a fire victim should raise strong suspicion for concurrent cyanide toxicity. Many fire victims suffer combined carbon monoxide and cyanide poisoning simultaneously.\n\nTREATMENT:\nHydroxocobalamin (Cyanokit) is the preferred antidote. It is a vitamin B12 precursor that binds directly to cyanide, forming cyanocobalamin (vitamin B12), which is renally excreted. The standard adult dose is 5 grams intravenously over 15 minutes. Hydroxocobalamin is safe with concurrent smoke inhalation and does not compromise oxygen-carrying capacity, unlike the older cyanide antidote kit (amyl nitrite, sodium nitrite, sodium thiosulfate), which induces methemoglobinemia to sequester cyanide and can worsen tissue hypoxia in patients with concomitant carbon monoxide poisoning. High-flow 100% oxygen should be administered to all smoke inhalation victims to address any concurrent carbon monoxide poisoning.\n\nKEY POINTS:\nCyanide from burning synthetics blocks mitochondrial cytochrome c oxidase, causing histotoxic hypoxia with profound lactic acidosis (often greater than 8 mmol/L), which distinguishes it from pure carbon monoxide poisoning. Hydroxocobalamin is the preferred antidote because it does not induce methemoglobinemia and is safe in combined CO-cyanide exposure. All fire victims should receive high-flow oxygen, and concurrent CO and cyanide poisoning should be assumed until proven otherwise."
  },
  {
    "id": 246,
    "categoryId": 4,
    "question": "A patient with Addison's Disease (Adrenal Insufficiency) presents with vomiting and hypotension after a viral illness. BP is 80/50 and refractory to fluids. What medication is life-saving?",
    "options": [
      "A) Norepinephrine",
      "B) IV Hydrocortisone (Stress Dose)",
      "C) Oral Fludrocortisone",
      "D) Insulin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Hydrocortisone / Stress-dose Steroids).\n\nPATHOPHYSIOLOGY:\nAdrenal crisis is an endocrine emergency with approximately 6% mortality per episode (European Journal of Endocrinology). The adrenal cortex produces cortisol under HPA axis regulation (approximately 5-10 mg/day baseline), increasing 5-10 fold under stress. Cortisol maintains vascular reactivity to catecholamines, cardiac contractility, hepatic gluconeogenesis, and inflammatory modulation. In primary adrenal insufficiency (Addison's disease), autoimmune destruction eliminates cortisol and aldosterone production. Under stress, these patients cannot mount the cortisol surge, causing hemodynamic collapse refractory to fluids and vasopressors until exogenous cortisol is given. Common precipitants include GI infections causing vomiting (preventing oral steroid absorption), surgery, trauma, and abrupt discontinuation of chronic glucocorticoids (secondary crisis from HPA suppression).\n\nCLINICAL PRESENTATION:\nThe hallmark is hypotension refractory to fluids and vasopressors. Associated features include severe weakness, nausea, vomiting, abdominal pain mimicking acute abdomen, fever, altered mental status, and hypoglycemia. Labs show hyponatremia (impaired free water excretion plus aldosterone-mediated sodium wasting), hyperkalemia (aldosterone deficiency), and non-anion-gap metabolic acidosis. Hyperpigmentation of skin and mucous membranes (elevated ACTH/MSH from the POMC precursor) is a diagnostic clue in chronic primary insufficiency.\n\nTREATMENT:\nIV hydrocortisone 100 mg bolus immediately on clinical suspicion\u2014do not wait for lab confirmation. Follow with 50 mg IV every 6-8 hours until stable. At stress doses (greater than 50 mg/day), hydrocortisone provides sufficient mineralocorticoid activity without fludrocortisone. Concurrent management includes aggressive IV normal saline (patients may be 2-3 liters depleted), dextrose if hypoglycemic, and treating the precipitant. If diagnosis is unestablished, dexamethasone 4 mg IV can substitute as it does not cross-react with the cortisol assay, allowing diagnostic cortisol and ACTH measurement.\n\nPREVENTION:\nPer Endocrine Society guidelines: double or triple oral hydrocortisone during febrile illness. If vomiting, use emergency IM hydrocortisone 100 mg and seek emergency care. Patients must wear medical alert identification. Preoperative stress-dose steroids are required for surgical procedures.\n\nKEY POINTS:\nAdrenal crisis causes hypotension refractory to fluids and vasopressors because cortisol is required for vascular catecholamine reactivity. Give IV hydrocortisone 100 mg immediately on suspicion. Sick day rules and medical alert identification are essential prevention."
  },
  {
    "id": 247,
    "categoryId": 15,
    "question": "You suspect bacterial meningitis in a febrile, confused patient. You cannot get a CT head immediately. What is the priority?",
    "options": [
      "A) Wait for CT before doing anything",
      "B) Perform Lumbar Puncture immediately",
      "C) Administer IV Antibiotics + Steroids immediately (before CT/LP)",
      "D) Observe"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Administer IV Antibiotics and Dexamethasone immediately).\n\nPATHOPHYSIOLOGY:\nBacterial meningitis is a life-threatening infection of the leptomeninges that carries an overall mortality of 15 to 25% and causes permanent neurological sequelae in 20 to 30% of survivors. The most common causative organisms in adults are Streptococcus pneumoniae (the most common and most lethal) and Neisseria meningitidis, while Listeria monocytogenes must be covered in patients over age 50, immunocompromised individuals, and pregnant women. The inflammatory cascade triggered by bacterial replication in the subarachnoid space causes cerebral edema, increased intracranial pressure, cerebral ischemia, and cortical necrosis.\n\nCLINICAL REASONING:\nThe cardinal principle in suspected bacterial meningitis is that antibiotics must never be delayed for diagnostic testing. Each hour of delay in antibiotic administration significantly increases mortality and neurological morbidity. This patient is febrile and confused, strongly suggesting bacterial meningitis. Because CT is not immediately available, the correct sequence is to draw blood cultures, then immediately administer empiric intravenous antibiotics and adjunctive dexamethasone, and subsequently obtain CT and lumbar puncture when feasible. Dexamethasone (0.15 mg/kg every 6 hours for 4 days) should be given 15 to 20 minutes before or simultaneously with the first antibiotic dose, as it reduces mortality and hearing loss in pneumococcal meningitis by attenuating the inflammatory response to bacterial lysis.\n\nINDICATIONS FOR CT BEFORE LUMBAR PUNCTURE:\nCT head before LP is indicated only when specific risk factors for herniation are present: altered mental status or decreased level of consciousness, focal neurological deficits, new-onset seizures, papilledema, immunocompromised state, or history of CNS mass lesion. Patients without these features can proceed directly to LP without CT. A negative CT does not exclude elevated intracranial pressure, but the risk of herniation from LP in bacterial meningitis is low and the risk of delayed treatment is high.\n\nEMPIRIC ANTIBIOTIC REGIMENS:\nStandard empiric therapy for adults aged 18 to 50 is vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime). Ampicillin is added for Listeria coverage in patients over age 50 or immunocompromised individuals and NCCN guidelines.\n\nKEY POINTS:\nAntibiotics must never be delayed for CT or LP when bacterial meningitis is strongly suspected, as each hour of delay increases mortality. Dexamethasone given before or with the first antibiotic dose reduces mortality and hearing loss in pneumococcal meningitis. CT before LP is required only when specific herniation risk factors are present, and a negative CT does not exclude elevated intracranial pressure."
  },
  {
    "id": 248,
    "categoryId": 7,
    "question": "A patient with a tibial fracture develops severe pain out of proportion to injury, pain with passive stretch of the toes, and a 'woody' hard calf. Diagnosis?",
    "options": [
      "A) DVT",
      "B) Compartment Syndrome",
      "C) Nerve damage",
      "D) Hematoma"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Compartment Syndrome).\n\nPATHOPHYSIOLOGY:\nCompartment syndrome is an orthopedic emergency caused by elevated pressure within a closed osseofascial compartment exceeding capillary perfusion pressure, causing ischemia and necrosis. The lower leg has four compartments (anterior, lateral, superficial posterior, deep posterior), each bounded by noncompliant fascia and bone. Following tibial fracture, hemorrhage and edema raise intracompartmental pressure. When pressure approaches diastolic BP, capillary perfusion collapses, creating a vicious cycle: ischemia causes further edema, raising pressure further. Irreversible muscle necrosis begins within approximately 6 hours; nerve damage may occur sooner.\n\nCLINICAL PRESENTATION:\nThe earliest finding is pain out of proportion to injury. Pain with passive stretch of involved muscles is the most reliable early sign\u2014in the anterior compartment, passive toe plantarflexion reproduces severe pain. The compartment feels tense and woody. Paresthesias and motor weakness develop as nerve ischemia progresses. Critically, peripheral pulses are preserved until very late because compartment syndrome compromises microvascular perfusion before arterial inflow. Waiting for pulselessness is a catastrophic error.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis is primarily clinical. When findings are equivocal or the patient cannot participate in examination (obtunded, intubated, pediatric), direct intracompartmental pressure measurement is indicated. Absolute pressure exceeding 30 mmHg or delta pressure (diastolic minus compartment pressure) less than 30 mmHg warrants intervention. Emergent fasciotomy with complete release of all involved compartments is definitive treatment. Incisions are left open for delayed closure at 48-72 hours. Delay beyond 6-8 hours risks Volkmann ischemic contracture, rhabdomyolysis-induced renal failure, and limb loss.\n\nKEY POINTS:\nPain out of proportion and pain with passive stretch are the earliest, most sensitive findings. Pulses are preserved until late\u2014waiting for pulselessness is dangerous. Emergent fasciotomy must occur within 6 hours to prevent irreversible necrosis, contracture, and rhabdomyolysis."
  },
  {
    "id": 249,
    "categoryId": 15,
    "question": "ECG shows 'Peaked T Waves' and widened QRS. What is the electrolyte abnormality and the FIRST medication to give?",
    "options": [
      "A) Hyperkalemia; Calcium Gluconate",
      "B) Hyperkalemia; Insulin",
      "C) Hypokalemia; Magnesium",
      "D) Hypocalcemia; Calcium"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hyperkalemia; Calcium Gluconate).\n\nPATHOPHYSIOLOGY:\nHyperkalemia (serum potassium greater than 5.0 mEq/L) is a potentially lethal electrolyte emergency because potassium is the primary determinant of the resting membrane potential of cardiac myocytes. As extracellular potassium rises, the resting membrane potential becomes less negative (partially depolarized), which initially increases excitability but progressively impairs sodium channel recovery and slows conduction velocity. The characteristic ECG progression with rising potassium is: peaked T waves (earliest finding, potassium approximately 5.5 to 6.5), PR prolongation (6.5 to 7.0), loss of P waves (7.0 to 7.5), widened QRS complex (7.0 to 8.0), sine wave pattern (greater than 8.0), and ultimately ventricular fibrillation or asystole. Common causes include acute or chronic kidney disease (the most common cause), medications (ACE inhibitors, ARBs, potassium-sparing diuretics, NSAIDs), rhabdomyolysis, tumor lysis syndrome, and adrenal insufficiency.\n\nCLINICAL REASONING:\nPeaked T waves with widened QRS on ECG with hyperkalemia represent an immediate threat of cardiac arrest. The treatment follows a three-tiered approach. The first priority is cardiac membrane stabilization with intravenous calcium gluconate (10 mL of 10% solution over 2 to 3 minutes), which raises the threshold potential and restores the normal gradient between resting and threshold potentials, stabilizing the myocardium against arrhythmia within 1 to 3 minutes. Calcium does not lower serum potassium but buys critical time. The second tier is intracellular potassium shifting using regular insulin (10 units IV with 25 grams of dextrose to prevent hypoglycemia), which activates the Na-K-ATPase to drive potassium into cells, and inhaled albuterol (10 to 20 mg nebulized), which also promotes transcellular shift via beta-2 receptor stimulation. Sodium bicarbonate is less reliable for shifting and is reserved for concurrent metabolic acidosis. The third tier is total body potassium elimination via sodium polystyrene sulfonate (Kayexalate), patiromer, sodium zirconium cyclosilicate, loop diuretics, or hemodialysis (the most effective and definitive method for severe or refractory hyperkalemia).\n\nKEY POINTS:\nCalcium gluconate is always the first medication given in hyperkalemia with ECG changes because it stabilizes the cardiac membrane within minutes, though it does not lower potassium. The three-tiered treatment approach is stabilize (calcium), shift (insulin plus dextrose, albuterol), and eliminate (dialysis, binding resins, diuretics). Peaked T waves are the earliest ECG finding, and widened QRS indicates imminent risk of fatal arrhythmia."
  },
  {
    "id": 250,
    "categoryId": 17,
    "question": "A patient typically presents with 'Hot Potato Voice', trismus (lockjaw), and uvula deviation to the opposite side. Diagnosis?",
    "options": [
      "A) Strep Throat",
      "B) Peritonsillar Abscess",
      "C) Mononucleosis",
      "D) Epiglottitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peritonsillar abscess).\n\nPATHOPHYSIOLOGY:\nA peritonsillar abscess (PTA), also known as quinsy, is a collection of purulent material in the potential space between the tonsillar capsule and the superior pharyngeal constrictor muscle. It typically evolves from untreated or inadequately treated acute tonsillitis when infection penetrates the tonsillar capsule into the peritonsillar space. PTA is the most common deep neck space infection in adults and adolescents. The microbiology is usually polymicrobial, involving Group A Streptococcus (GAS), Fusobacterium necrophorum, Prevotella species, and other oropharyngeal anaerobes. Fusobacterium necrophorum warrants particular attention as it can cause Lemierre syndrome, a life-threatening septic thrombophlebitis of the internal jugular vein.\n\nCLINICAL REASONING:\nThe classic triad of muffled \"hot potato\" voice, trismus (limited jaw opening from inflammation of the medial pterygoid muscle), and uvular deviation away from the affected side is virtually pathognomonic for PTA. Additional findings include severe unilateral sore throat, odynophagia, drooling, ipsilateral referred ear pain via cranial nerve IX, and fever. The affected tonsil appears medially displaced with a bulging, erythematous soft palate. Diagnosis is primarily clinical. CT with IV contrast is indicated when the diagnosis is uncertain, deep space extension is suspected, or initial drainage fails. Intraoral point-of-care ultrasound is an emerging bedside diagnostic alternative.\n\nTreatment requires airway assessment as the first priority, followed by drainage via needle aspiration or incision and drainage per AAO-HNS recommendations. Antibiotics covering GAS and anaerobes are essential; first-line regimens include ampicillin-sulbactam IV or clindamycin. Corticosteroids may reduce pain and trismus. Recurrent PTA (two or more episodes) warrants referral for interval tonsillectomy.\n\nKEY POINTS:\nThe triad of hot potato voice, trismus, and contralateral uvular deviation is classic for PTA. Treatment requires drainage plus antibiotics covering streptococci and anaerobes. Always assess for airway compromise and consider Lemierre syndrome in patients with septic-appearing presentations."
  },
  {
    "id": 251,
    "categoryId": 15,
    "question": "Cord Prolapse (umbilical cord visible/palpable ahead of the baby) occurs in your clinic during an precipitous delivery. Management?",
    "options": [
      "A) Push the cord back in",
      "B) Elevate the presenting part (lift baby's head off the cord) and emergency C-Section",
      "C) Deliver immediately",
      "D) Place mother in trendelenburg and wait"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Elevate the presenting part off the cord and proceed to emergency Cesarean section).\n\nPATHOPHYSIOLOGY:\nUmbilical cord prolapse occurs when the umbilical cord descends through the cervix ahead of or alongside the fetal presenting part, and is an obstetric emergency because compression of the cord between the presenting part and the maternal pelvis occludes the umbilical vessels, cutting off fetal blood flow and oxygen supply. Without immediate intervention, sustained cord compression causes fetal hypoxia, bradycardia, acidosis, and death or permanent neurological injury within minutes. Risk factors include premature rupture of membranes, polyhydramnios, malpresentation (transverse lie, breech), multiparity, and unengaged presenting part at the time of membrane rupture.\n\nCLINICAL REASONING:\nWhen cord prolapse is identified (the cord is visible at the introitus or palpable on vaginal examination), the immediately life-saving maneuver is to insert a gloved hand into the vagina and manually elevate the fetal presenting part away from the prolapsed cord, relieving compression. The hand must remain in place continuously, maintaining upward pressure on the presenting part, while the patient is urgently transported for emergency Cesarean delivery. The cord must never be pushed back into the uterus, as manipulation can cause vasospasm and worsen ischemia. Positioning the mother in steep Trendelenburg or knee-chest position uses gravity to shift the presenting part away from the cord and may provide additional relief. If the cord is exposed and dry, it can be wrapped in warm saline-soaked gauze to minimize vasospasm, but manual elevation of the presenting part is the critical intervention.\n\nMANAGEMENT:\nEmergency Cesarean section is the definitive treatment and should be performed as rapidly as possible (decision-to-delivery interval ideally less than 30 minutes). Fetal heart rate monitoring should be continuous, and neonatal resuscitation should be prepared. Tocolysis with terbutaline may be considered to reduce uterine contractions and further decrease cord compression during transport.\n\nKEY POINTS:\nCord prolapse requires immediate manual elevation of the presenting part off the cord (hand in vagina lifting the fetal head) followed by emergency Cesarean section. The cord must never be pushed back in, as this causes vasospasm. Steep Trendelenburg or knee-chest positioning uses gravity to assist cord decompression while preparing for operative delivery."
  },
  {
    "id": 252,
    "categoryId": 11,
    "question": "A patient with Schizophrenia presents with fever, muscle rigidity, and confusion. CPK is 50,000. Diagnosis?",
    "options": [
      "A) Catatonia",
      "B) Neuroleptic Malignant Syndrome (NMS)",
      "C) Serotonin Syndrome",
      "D) Malignant Hyperthermia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neuroleptic Malignant Syndrome).\n\nPATHOPHYSIOLOGY:\nNeuroleptic Malignant Syndrome (NMS) is a life-threatening idiosyncratic reaction to dopamine D2 receptor-blocking agents, occurring most frequently with high-potency first-generation antipsychotics (haloperidol, fluphenazine) but also reported with second-generation antipsychotics and antiemetics (metoclopramide, prochlorperazine). The syndrome results from acute central dopaminergic blockade in the hypothalamus (producing hyperthermia and autonomic instability), nigrostriatal pathway (producing rigidity), and mesocortical pathway (producing altered mental status). The massively elevated CPK of 50,000 IU/L in this case reflects severe rhabdomyolysis from sustained skeletal muscle rigidity, which is a hallmark laboratory finding that distinguishes NMS from other hyperthermic emergencies.\n\nCLINICAL PRESENTATION:\nThe classic tetrad is captured by the mnemonic FARM: Fever (often exceeding 104Â°F/40Â°C), Autonomic instability (labile blood pressure, tachycardia, diaphoresis, tachypnea), Rigidity (\"lead-pipe\" quality with continuous resistance throughout passive range of motion), and Mental status change (confusion to coma). NMS typically develops over 1 to 3 days (slower onset than serotonin syndrome) and can occur at any point during antipsychotic therapy, though it is most common in the first 2 weeks of treatment or after dose escalation.\n\nDIFFERENTIAL DIAGNOSIS:\nNMS is distinguished from serotonin syndrome by the absence of clonus and hyperreflexia (NMS features rigidity with normal or decreased reflexes), slower onset (days versus hours), the causative drug class (dopamine antagonists versus serotonergic agents), and markedly higher CPK elevations. Malignant hyperthermia occurs exclusively after exposure to volatile anesthetics or succinylcholine, not antipsychotics. Lethal catatonia can appear identical and may require empiric treatment with lorazepam.\n\nMANAGEMENT:\nImmediate discontinuation of the antipsychotic is essential. Aggressive IV hydration prevents acute renal failure from myoglobinuria. Dantrolene (a ryanodine receptor antagonist that directly inhibits skeletal muscle calcium release) reduces rigidity and hyperthermia. Bromocriptine or amantadine (dopamine agonists) restore central dopaminergic transmission. ICU monitoring for cardiac arrhythmias, respiratory failure, and DIC is required.\n\nKEY POINTS:\nNMS presents with the FARM tetrad (Fever, Autonomic instability, Rigidity, Mental status change) with massively elevated CPK from rhabdomyolysis, developing over days after antipsychotic exposure. Lead-pipe rigidity with decreased reflexes distinguishes NMS from serotonin syndrome (which features clonus and hyperreflexia). Treatment requires immediate antipsychotic discontinuation, IV hydration, and dantrolene or bromocriptine."
  },
  {
    "id": 253,
    "categoryId": 15,
    "question": "Priapism (erection > 4 hours) is an emergency because:",
    "options": [
      "A) It is embarrassing",
      "B) It causes urinary retention",
      "C) It leads to cavernosal fibrosis and permanent impotence",
      "D) It causes infection"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (It leads to cavernosal fibrosis and permanent impotence).\n\nPATHOPHYSIOLOGY:\nIschemic (low-flow or veno-occlusive) priapism is a urologic emergency resulting from failure of venous outflow from the corpora cavernosa, causing blood to become trapped, deoxygenated, and acidotic within the erectile tissue. The stagnant, deoxygenated blood creates a compartment syndrome of the penis: progressive tissue hypoxia and acidosis cause endothelial damage, smooth muscle edema, and eventually irreversible smooth muscle necrosis and fibrosis of the corporal tissue. Smooth muscle necrosis begins after approximately 4 to 6 hours, and the risk of permanent erectile dysfunction increases dramatically with each hour of ischemia beyond this window. After 24 to 48 hours, fibrosis is nearly universal, resulting in permanent impotence.\n\nCLINICAL PRESENTATION:\nIschemic priapism presents as a painful, fully rigid erection lasting more than 4 hours, with the corpora cavernosa engorged and the glans penis and corpus spongiosum characteristically soft (flaccid). Common causes include sickle cell disease (the most common cause in children, due to sickling of erythrocytes within the corpora), medications (intracavernosal injection therapy for erectile dysfunction, trazodone, antipsychotics), illicit drug use (cocaine), and idiopathic cases. Corporal blood gas analysis showing dark blood with PaO2 less than 30 mmHg and pH less than 7.25 confirms the ischemic type.\n\nTREATMENT:\nFirst-line treatment, followed by irrigation with normal saline. If aspiration alone fails, intracavernosal injection of a sympathomimetic agent (phenylephrine, an alpha-1 agonist, is preferred because of its minimal beta-adrenergic cardiac effects) is administered in dilute aliquots (100 to 500 micrograms every 3 to 5 minutes) to cause smooth muscle contraction and restore venous outflow. Surgical shunt procedures (distal cavernosum-spongiosum shunts) are reserved for cases refractory to aspiration and phenylephrine.\n\nKEY POINTS:\nIschemic priapism is a urologic emergency because smooth muscle necrosis and irreversible fibrosis of the corpora cavernosa begin after 4 to 6 hours, leading to permanent erectile dysfunction. Treatment is corporal aspiration followed by intracavernosal phenylephrine injection. Sickle cell disease is the most common cause in children, while medications (trazodone, antipsychotics, intracavernosal injections) are common causes in adults."
  },
  {
    "id": 254,
    "categoryId": 12,
    "question": "A 2-year-old is swung by the arms and now refuses to use the left arm, holding it pronated and flexed. Diagnosis and Treatment?",
    "options": [
      "A) Clavicle fracture; Sling",
      "B) Nursemaid's Elbow; Reduction (Supination/Flexion)",
      "C) Supracondylar fracture; Surgery",
      "D) Shoulder dislocation; Reduction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nursemaid's Elbow; Reduction by Supination and Flexion).\n\nPATHOPHYSIOLOGY:\nNursemaid's elbow (radial head subluxation) is the most common elbow injury in children under 5 years, resulting from a sudden longitudinal traction force applied to the extended, pronated forearm. The mechanism typically involves a child being swung, lifted, or pulled by the hand or wrist (hence the historical name). The annular ligament, which encircles the radial head and holds it in articulation with the ulna, is relatively loose in young children and slips over the radial head when traction is applied, becoming interposed between the radial head and the capitellum of the humerus. After approximately age 5, the annular ligament strengthens and the radial head enlarges, making subluxation much less likely.\n\nCLINICAL PRESENTATION:\nThe child presents holding the affected arm in the classic position of slight flexion and pronation against the body, refusing to use the arm (pseudoparalysis). There is no swelling, deformity, or ecchymosis, and the child is not in severe distress but will resist any attempt to supinate the forearm or extend the elbow. The history of a pulling or swinging mechanism is usually clear. Radiographs are typically normal because the subluxation involves a soft tissue interposition rather than a bony displacement, and imaging is unnecessary when the history and presentation are classic.\n\nTREATMENT:\nReduction is performed at the bedside without sedation or imaging. The hyperpronation technique (firmly supinating the forearm with one hand while the other stabilizes the elbow, feeling for a palpable click at the radial head) or the supination-flexion technique (supinating the forearm and then fully flexing the elbow in one smooth motion) are both effective, with hyperpronation having slightly higher first-attempt success rates in some studies. A palpable click is felt as the annular ligament reduces, and the child typically resumes full use of the arm within 5 to 15 minutes. If the child does not improve after two reduction attempts, radiographs should be obtained to evaluate for occult fracture.\n\nKEY POINTS:\nNursemaid's elbow results from axial traction on an extended pronated arm causing the annular ligament to slip over the radial head, and it is the most common elbow injury in children under 5. The child holds the arm pronated and flexed, refusing to use it, with normal radiographs. Reduction by supination-flexion or hyperpronation produces a palpable click and rapid return to normal function."
  },
  {
    "id": 255,
    "categoryId": 15,
    "question": "In a trauma patient, Cushing's Triad indicates increased Intracranial Pressure (ICP). The triad is:",
    "options": [
      "A) Hypertension, Bradycardia, Irregular Respirations",
      "B) Hypotension, Tachycardia, Tachypnea",
      "C) Fever, Neck stiffness, Rash",
      "D) Muffled heart sounds, JVD, Hypotension"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypertension, Bradycardia, Irregular Respirations).\n\nPATHOPHYSIOLOGY:\nCushing's triad is a late and ominous clinical sign of critically elevated intracranial pressure indicating impending brainstem herniation. As intracranial pressure rises and approaches mean arterial pressure, cerebral perfusion pressure (CPP = MAP minus ICP) falls below the threshold needed to maintain adequate brainstem blood flow. The brainstem ischemia triggers a powerful sympathetic surge known as the Cushing reflex or vasomotor center response: systemic hypertension develops as the body attempts to force blood through the compressed cerebral vasculature to restore brainstem perfusion. The resulting hypertension is sensed by the aortic arch and carotid sinus baroreceptors, which trigger a reflex bradycardia via vagal stimulation of the sinoatrial node. Irregular respirations (Cheyne-Stokes, ataxic, or apneustic breathing patterns) reflect direct compression of the brainstem respiratory centers in the pons and medulla. The complete triad of hypertension, bradycardia, and irregular respirations constitutes Cushing's triad.\n\nCLINICAL SIGNIFICANCE:\nCushing's triad is a pre-terminal finding indicating that brainstem herniation is imminent or actively occurring, and it demands immediate intervention. It is most commonly seen with traumatic brain injury with expanding epidural or subdural hematomas, massive intracerebral hemorrhage, or obstructive hydrocephalus. The presence of Cushing's triad in a trauma patient should trigger emergent neurosurgical consultation and temporizing measures to reduce ICP.\n\nMANAGEMENT:\nImmediate temporizing measures to reduce ICP and the Brain Trauma Foundation guidelines include elevation of the head of bed to 30 degrees, administration of hyperosmolar therapy (mannitol 1 g/kg IV bolus or hypertonic saline 23.4% 30 mL via central line), brief hyperventilation to a target PaCO2 of 30 to 35 mmHg (which causes cerebral vasoconstriction and rapid but temporary ICP reduction), and ensuring adequate sedation and analgesia. Definitive treatment requires emergent neurosurgical intervention (craniotomy for hematoma evacuation or decompressive craniectomy) or external ventricular drain placement.\n\nKEY POINTS:\nCushing's triad (hypertension, bradycardia, irregular respirations) is a late, pre-terminal sign of critically elevated ICP indicating imminent brainstem herniation that demands emergent intervention. The Cushing reflex produces hypertension as the brainstem attempts to maintain perfusion against rising ICP, with reflex bradycardia from baroreceptor activation. Immediate temporizing measures include head elevation, hyperosmolar therapy, and brief hyperventilation while arranging emergent neurosurgery."
  },
  {
    "id": 256,
    "categoryId": 15,
    "question": "An avulsed permanent tooth (knocked out) has the best chance of survival if reimplanted within:",
    "options": [
      "A) 5 minutes",
      "B) 60 minutes",
      "C) 6 hours",
      "D) 24 hours"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Within 60 minutes).\n\nPATHOPHYSIOLOGY:\nWhen a permanent tooth is avulsed, periodontal ligament (PDL) cell viability on the root surface is the single most important determinant of successful reimplantation. PDL cells begin necrosis within 15-20 minutes of dry storage, and viability decreases rapidly. Reimplantation within 60 minutes provides the highest probability of functional healing with PDL regeneration; delays beyond 60 minutes cause progressive root resorption and tooth loss.\n\nCLINICAL MANAGEMENT:\nHandle the tooth only by the crown, never the root, to protect PDL cells. If contaminated, gently rinse with saline or milk for no more than 10 seconds without scrubbing. Ideally, reimplant immediately at the scene and have the patient bite on gauze. If not possible, store in a physiologic transport medium. Hank's Balanced Salt Solution (commercial tooth preservation kits) is optimal. Cold milk is the best readily available alternative due to its physiologic osmolality and pH. The patient's saliva (buccal vestibule) is acceptable in cooperative adults. Tap water should be avoided because hypotonicity causes osmotic lysis of PDL cells.\n\nFOLLOW-UP:\nOnce reimplanted, the tooth requires flexible splinting for 2 weeks and referral for root canal therapy (typically initiated 7-10 days post-reimplantation) as the pulp will be necrotic. Primary (baby) teeth should not be reimplanted due to risk of damage to the developing permanent tooth bud.\n\nKEY POINTS:\nAn avulsed permanent tooth has the best prognosis when reimplanted within 60 minutes. Handle by the crown only. Hank's solution is the optimal transport medium; cold milk is the best readily available alternative. Tap water causes osmotic PDL cell lysis and should be avoided."
  },
  {
    "id": 257,
    "categoryId": 13,
    "question": "Septic Arthritis vs Gout. A joint aspiration is performed. What WBC count confirms Septic Arthritis?",
    "options": [
      "A) > 2,000",
      "B) > 10,000",
      "C) > 50,000",
      "D) > 100,000"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Greater than 50,000 WBC/mm3).\n\nSYNOVIAL FLUID ANALYSIS:\nJoint aspiration with synovial fluid analysis is the single most important diagnostic test for differentiating septic arthritis from crystal arthropathy and other causes of acute monoarthritis. Synovial fluid WBC counts provide a useful diagnostic framework. Normal synovial fluid contains fewer than 200 WBC/mm3. Non-inflammatory conditions such as osteoarthritis typically show fewer than 2,000 WBC/mm3. Inflammatory arthritis (gout, pseudogout, rheumatoid arthritis) generally produces counts between 2,000 and 50,000 WBC/mm3, though gout can occasionally exceed 50,000. A WBC count greater than 50,000 WBC/mm3 with greater than 90 percent neutrophils is highly suggestive of septic arthritis and should be treated as infection until proven otherwise.\n\nSEPTIC ARTHRITIS AS A MEDICAL EMERGENCY:\nSeptic arthritis is an orthopedic emergency because bacterial enzymes and the inflammatory response can destroy articular cartilage within hours to days. Staphylococcus aureus is the most common causative organism in adults (responsible for approximately 40 to 50 percent of cases), followed by streptococcal species. Neisseria gonorrhoeae should be considered in sexually active young adults presenting with migratory polyarthralgia, tenosynovitis, and dermatitis preceding septic monoarthritis. Risk factors include pre-existing joint disease (especially rheumatoid arthritis), prosthetic joints, immunosuppression, diabetes, intravenous drug use, and skin infections.\n\nDIAGNOSTIC APPROACH:\nIn addition to cell count and differential, synovial fluid should be sent for Gram stain (positive in approximately 50 to 75 percent of non-gonococcal cases), culture (the most definitive test), and polarized light microscopy for crystals. the presence of crystals does not exclude concurrent infection, as gout and septic arthritis can coexist. Blood cultures should be obtained in all suspected cases. If septic arthritis is suspected based on clinical presentation and fluid analysis, empiric antibiotics and urgent orthopedic consultation for joint drainage (arthroscopic lavage or serial needle aspiration) should not be delayed.\n\nKEY POINTS:\nA synovial fluid WBC count greater than 50,000/mm3 with neutrophil predominance is highly suggestive of septic arthritis until proven otherwise. Gram stain and culture of synovial fluid are essential, but treatment should not await results. Crystal arthropathy and septic arthritis can coexist, so the presence of crystals does not rule out infection. Septic arthritis requires emergent antibiotics and joint drainage to prevent irreversible cartilage destruction."
  },
  {
    "id": 258,
    "categoryId": 15,
    "question": "Boerhaave's Syndrome is:",
    "options": [
      "A) Mucosal tear at the GE junction (Mallory-Weiss)",
      "B) Full-thickness Esophageal Rupture",
      "C) Gastric Volvulus",
      "D) Pyloric Stenosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Full-thickness Esophageal Rupture).\n\nPATHOPHYSIOLOGY:\nBoerhaave syndrome is a transmural (full-thickness) perforation of the esophagus caused by a sudden rise in intraesophageal pressure against a closed glottis, most commonly during forceful or protracted vomiting. The perforation typically occurs in the left posterolateral distal esophagus, approximately 2 to 3 cm above the gastroesophageal junction, which is the weakest point of the esophageal wall due to the absence of reinforcing serosal covering and the natural thinning at the junction of the longitudinal muscle fibers. This is distinct from Mallory-Weiss syndrome, which involves only a partial-thickness mucosal tear at the gastroesophageal junction and is typically self-limited. Boerhaave syndrome carries a mortality rate of 20 to 40% even with treatment, rising to nearly 100% if diagnosis and surgical repair are delayed beyond 24 hours.\n\nCLINICAL PRESENTATION:\nThe classic presentation, known as Mackler triad, is vomiting (or retching) followed by severe lower thoracic or epigastric pain and subcutaneous emphysema (crepitus). Hamman sign, a crunching or crackling sound heard on cardiac auscultation that is synchronous with the heartbeat (mediastinal crunch), results from air tracking into the mediastinum (pneumomediastinum) through the esophageal perforation. Patients frequently develop signs of sepsis rapidly as gastric contents and oral flora contaminate the mediastinum and pleural space, causing mediastinitis and empyema. A left-sided pleural effusion is common due to the location of the perforation. The diagnosis is confirmed by CT of the chest with oral water-soluble contrast (Gastrografin) demonstrating extraluminal contrast leakage.\n\nMANAGEMENT:\nBoerhaave syndrome is a surgical emergency requiring emergent operative repair (primary closure with tissue reinforcement) or esophageal diversion in cases of delayed diagnosis with extensive mediastinal contamination. Broad-spectrum antibiotics, aggressive fluid resuscitation, and chest tube drainage of any pleural collection are initiated immediately. Select patients with contained perforations, minimal contamination, and no sepsis may be candidates for conservative management with nil per os, IV antibiotics, and endoscopic stent placement.\n\nKEY POINTS:\nBoerhaave syndrome is full-thickness esophageal rupture from forceful vomiting (distinct from partial-thickness Mallory-Weiss tear), occurring at the left posterolateral distal esophagus. Mackler triad (vomiting, chest pain, subcutaneous emphysema) and Hamman sign (mediastinal crunch) are classic findings. Mortality approaches 100% without timely surgical repair, making early recognition critical."
  },
  {
    "id": 259,
    "categoryId": 9,
    "question": "A patient on Heparin develops a 50% drop in platelets and new blood clots (thrombosis). Diagnosis?",
    "options": [
      "A) DIC",
      "B) HIT (Heparin Induced Thrombocytopenia)",
      "C) ITP",
      "D) TTP"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heparin-Induced Thrombocytopenia).\n\nPATHOPHYSIOLOGY:\nHeparin-induced thrombocytopenia (HIT) type II is a life-threatening immune-mediated prothrombotic disorder caused by IgG antibodies directed against the heparin-platelet factor 4 (PF4) complex. When heparin binds to PF4 (a positively charged chemokine released from platelet alpha granules), it forms a neoantigen that stimulates IgG antibody production. These IgG-heparin-PF4 immune complexes bind to platelet Fc-gamma-RIIa receptors, causing massive platelet activation, aggregation, and consumption. The resulting paradox of HIT is that despite thrombocytopenia, the primary clinical risk is thrombosis (not bleeding), because the intensely activated platelets generate a massive prothrombotic state.\n\nCLINICAL PRESENTATION:\nHIT typically presents 5 to 10 days after heparin initiation (or within 24 hours in patients with prior heparin exposure within the past 100 days) with a platelet drop of greater than 50% from baseline. Thrombotic complications occur in 20 to 50% of untreated HIT patients and include deep venous thrombosis, pulmonary embolism, limb ischemia (potentially requiring amputation), stroke, and myocardial infarction.\n\nDIAGNOSIS AND MANAGEMENT:\nThe 4Ts scoring system (Thrombocytopenia, Timing, Thrombosis, oTher causes excluded) stratifies pretest probability. Laboratory confirmation requires a serotonin release assay (SRA, gold standard) or anti-PF4/heparin ELISA. All heparin products (including heparin flushes and heparin-coated catheters) must be immediately discontinued. Alternative anticoagulation with a direct thrombin inhibitor (argatroban, preferred in hepatic impairment; bivalirudin) or fondaparinux must be initiated immediately because the thrombotic risk persists for weeks after heparin cessation.\n\nKEY POINTS:\nHIT type II is an immune-mediated prothrombotic disorder caused by IgG antibodies against heparin-PF4 complexes, presenting with a greater than 50% platelet drop and paradoxical thrombosis (not bleeding). The 4Ts score stratifies pretest probability, and the serotonin release assay is the gold standard confirmatory test. All heparin must be discontinued immediately and replaced with a direct thrombin inhibitor."
  },
  {
    "id": 260,
    "categoryId": 11,
    "question": "Hypothermia on EKG is associated with which wave?",
    "options": [
      "A) Delta Wave",
      "B) Osborn (J) Wave",
      "C) U Wave",
      "D) Q Wave"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Osborn J Wave).\n\nPATHOPHYSIOLOGY:\nThe Osborn wave (also called the J wave or J-point elevation) is a distinctive positive deflection occurring at the junction of the QRS complex and ST segment that is pathognomonic of hypothermia. It appears as a dome-shaped or hump-shaped elevation at the J-point, most prominent in the lateral precordial leads (V4 through V6) and inferior leads (II, III, aVF). The wave was first described by John Osborn in 1953 during experimental hypothermia studies in dogs.\n\nMECHANISM:\nThe Osborn wave results from a temperature-dependent difference in action potential duration between the epicardial and endocardial layers of the ventricular myocardium. Hypothermia accentuates the transient outward potassium current (Ito) in epicardial cells more than endocardial cells, creating a transmural voltage gradient during early repolarization that manifests as the J-point deflection on surface ECG. The amplitude of the Osborn wave correlates with the degree of hypothermia, becoming more prominent as core temperature drops below 32Â°C (89.6Â°F).\n\nADDITIONAL ECG FINDINGS IN HYPOTHERMIA:\nBeyond the Osborn wave, hypothermia produces progressive ECG changes including sinus bradycardia (from decreased SA node automaticity), PR and QT prolongation (from slowed conduction), atrial fibrillation (common below 32Â°C), and ventricular fibrillation (the most dangerous arrhythmia, typically occurring below 28Â°C/82.4Â°F). Shivering artifact may obscure the baseline. The myocardium becomes increasingly irritable as temperature falls, and physical manipulation of a severely hypothermic patient can trigger ventricular fibrillation.\n\nCLINICAL SIGNIFICANCE:\nRecognizing the Osborn wave on ECG should prompt immediate core temperature measurement. Management of hypothermia follows the principle that patients are \"not dead until warm and dead,\" as cardiac resuscitation and defibrillation are often ineffective below 30Â°C and should be continued until core temperature is restored.\n\nKEY POINTS:\nThe Osborn (J) wave is a dome-shaped deflection at the QRS-ST junction that is pathognomonic of hypothermia, resulting from temperature-dependent differences in epicardial versus endocardial repolarization via the Ito potassium current. Its amplitude correlates with the degree of hypothermia. Ventricular fibrillation is the most dangerous arrhythmia in hypothermia, typically occurring below 28Â°C."
  },
  {
    "id": 261,
    "categoryId": 4,
    "question": "Myxedema Coma (Severe Hypothyroidism) presents with:",
    "options": [
      "A) Fever, Tachycardia, Agitation",
      "B) Hypothermia, Bradycardia, Altered Mental Status",
      "C) Hypertension, Tremor",
      "D) Hyperreflexia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypothermia, Bradycardia, Altered Mental Status).\n\nPATHOPHYSIOLOGY:\nMyxedema coma is the most severe hypothyroid manifestation with 25-60% mortality even with treatment. It occurs when compensatory mechanisms in chronic hypothyroidism are overwhelmed by a precipitant. Without thyroid hormone, the body enters a hypometabolic state: decreased thermogenesis (hypothermia), reduced cardiac output (bradycardia, hypotension), CNS depression (lethargy to coma), and decreased ventilatory drive (hypoventilation with respiratory acidosis). It typically affects elderly women with undiagnosed or undertreated hypothyroidism, precipitated by infection (most common), cold exposure, sedatives, surgery, or stroke. \"Myxedema\" refers to nonpitting edema from dermal glycosaminoglycan accumulation.\n\nCLINICAL PRESENTATION:\nThe classic triad is hypothermia, bradycardia, and altered mental status. Hypothermia (core temperature often below 95 degrees F or 35 degrees C) occurs in approximately 80% and may be missed without low-reading thermometers. Hypoventilation may require mechanical ventilation. Hyponatremia is present in approximately 50% from impaired free water excretion due to elevated ADH. Physical findings include periorbital and peripheral nonpitting edema, macroglossia, coarse dry skin, delayed DTR relaxation, and pericardial or pleural effusions.\n\nTREATMENT:\nIV levothyroxine loading dose of 200-400 mcg, then 50-100 mcg daily until oral intake is possible. Some experts add IV liothyronine (T3) 5-20 mcg initially, then 2.5-10 mcg every 8 hours, as T4-to-T3 conversion may be impaired in critical illness. IV stress-dose hydrocortisone (100 mg bolus, then 50 mg every 8 hours) must be given before or with thyroid hormone to prevent adrenal crisis\u2014hypothyroidism decreases cortisol clearance, and restoring thyroid function disrupts this equilibrium. Concurrent primary adrenal insufficiency must be excluded. Supportive care includes passive rewarming (active rewarming risks vasodilation and collapse), mechanical ventilation, cautious fluid management, and treating the precipitant.\n\nKEY POINTS:\nMyxedema coma presents with hypothermia, bradycardia, and altered mental status with 25-60% mortality. IV hydrocortisone must be given before or with levothyroxine to prevent adrenal crisis. Hyponatremia occurs in approximately 50%, and hypothermia may be missed without appropriate thermometers."
  },
  {
    "id": 262,
    "categoryId": 15,
    "question": "Massive Hemoptysis is defined as >100-600ml blood/24hr. If the patient is unstable, which lung should be placed DOWN?",
    "options": [
      "A) The Good Lung (Unaffected)",
      "B) The Bad Lung (Bleeding side)",
      "C) Supine only",
      "D) Prone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The bleeding lung placed down).\n\nPATHOPHYSIOLOGY:\nMassive hemoptysis, defined variably as expectoration of 100 to 600 mL of blood within 24 hours (with 300 mL being the most commonly cited threshold), is a life-threatening emergency in which the primary cause of death is asphyxiation from airway flooding rather than exsanguination. Even relatively modest volumes of blood can be fatal if they fill the tracheobronchial tree and prevent gas exchange. Blood in the airways acts as a liquid obstruction, and when a patient is supine, gravity causes blood from the bleeding lung to flow across the carina into the contralateral (non-bleeding) lung, drowning both lungs and eliminating any functional gas exchange capacity.\n\nCLINICAL REASONING:\nPositioning the patient with the bleeding lung in the dependent (down) position uses gravity to contain hemorrhage within the affected lung while keeping the unaffected lung in the non-dependent (up) position, protecting it from blood contamination and preserving ventilatory capacity. For example, if the right lung is bleeding, the patient is placed in the right lateral decubitus position. This is a critical and potentially life-saving temporizing maneuver that can be performed immediately at the bedside while preparing for definitive intervention.\n\nMANAGEMENT:\nDefinitive management depends on the clinical scenario. In hemodynamically unstable patients, securing the airway takes priority, and selective intubation of the non-bleeding mainstem bronchus (typically the left with a standard endotracheal tube advanced past the carina, or using a double-lumen endotracheal tube) can isolate the bleeding lung and protect ventilation. Bronchoscopy (rigid bronchoscopy preferred in massive hemoptysis for its superior suctioning capability and ability to maintain ventilation) identifies the bleeding source. Bronchial artery embolization by interventional radiology is the first-line definitive treatment, with success rates of 70 to 90%. Surgical resection is reserved for cases refractory to embolization or when a surgically resectable lesion (such as lung cancer or aspergilloma) is identified.\n\nKEY POINTS:\nIn massive hemoptysis, death occurs from asphyxiation (airway flooding) rather than exsanguination, and positioning the bleeding lung down protects the good lung from blood contamination. Bronchial artery embolization is the first-line definitive treatment with 70 to 90% success rates. Rigid bronchoscopy is preferred over flexible for massive hemoptysis due to superior suctioning and ventilation capability."
  },
  {
    "id": 263,
    "categoryId": 10,
    "question": "Necrotizing Fasciitis is suggested by:",
    "options": [
      "A) Pain out of proportion to exam and crepitus",
      "B) Red streak up the arm",
      "C) Itching and hives",
      "D) Honey-crusted lesions"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      {
        "src": "assets/derm-q9-necrosis.png",
        "alt": "Extensive necrotic skin changes of the lower foot and ankle",
        "caption": "Necrotizing soft tissue infection with rapidly progressive ischemic and necrotic skin changes."
      }
    ],
    "explanation": "CORRECT: A (Pain out of proportion to exam and crepitus).\n\nPATHOPHYSIOLOGY:\nNecrotizing fasciitis is a rapidly progressive infection of deep fascial planes spreading at 2-3 cm per hour. Type I (polymicrobial) involves synergistic aerobic and anaerobic organisms and typically occurs in diabetic or immunocompromised patients, often involving the perineum (Fournier gangrene). Type II (monomicrobial) is most commonly caused by Group A Streptococcus, whose exotoxins function as superantigens triggering massive cytokine release. The infection destroys fascia and subcutaneous fat, causing thrombosis of perforating vessels and secondary ischemic skin necrosis. This vascular occlusion explains pain out of proportion: deep destruction generates severe pain while overlying skin may appear deceptively normal.\n\nCLINICAL PRESENTATION:\nThe earliest and most important clue is pain far exceeding visible findings. The area is exquisitely tender with a wooden-hard quality from deep fascial edema. Systemic toxicity develops rapidly. Skin evolves from erythema to dusky discoloration, hemorrhagic bullae, and necrosis. Crepitus indicates gas-producing anaerobes and is a late but specific finding (approximately 18-30% of cases). Cutaneous anesthesia indicates nerve destruction. The LRINEC score (CRP, WBC, hemoglobin, sodium, creatinine, glucose; score of 6 or greater suggests necrotizing fasciitis) supports clinical suspicion but does not exclude the diagnosis when low.\n\nMANAGEMENT:\nImmediate aggressive surgical debridement is required, with return to OR every 24-48 hours until healthy tissue margins are achieved. Surgical findings include dishwater-gray fascia, lack of resistance to blunt dissection (the \"finger test\"), and foul-smelling fluid. Broad-spectrum IV antibiotics: vancomycin plus piperacillin-tazobactam or carbapenem plus clindamycin. Clindamycin is specifically included to suppress streptococcal and clostridial toxin production. Mortality is 20-40% even with optimal management and rises with each hour of surgical delay.\n\nKEY POINTS:\nPain out of proportion is the earliest critical diagnostic clue. Crepitus is specific but late. Do not delay surgery for imaging or labs\u2014surgical exploration is both diagnostic and therapeutic. Mortality increases with every hour of delay to debridement."
  },
  {
    "id": 264,
    "categoryId": 16,
    "question": "The concept of 'Caloric Density' explains why patients can eat MORE food but lose weight if they choose whole plant foods. Which food group has the lowest caloric density?",
    "options": [
      "A) Lean Meats",
      "B) Non-starchy Vegetables",
      "C) Whole Grains",
      "D) Nuts and Seeds"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Non-starchy Vegetables).\n\nCONCEPT:\nCaloric density (calories per unit weight of food) is the key principle explaining why patients can eat a greater volume of food while consuming fewer total calories, which is the foundation of volumetric eating strategies for weight management. Non-starchy vegetables have the lowest caloric density of any food group at approximately 100 to 200 calories per pound, compared to fruits (200 to 400 cal/lb), whole grains and legumes (400 to 700 cal/lb), meat and cheese (1,000 to 1,500 cal/lb), and oils (4,000 cal/lb).\n\nPHYSIOLOGIC MECHANISM:\nSatiety is primarily driven by gastric stretch receptors (vagal mechanoreceptors) that signal the nucleus tractus solitarius in the brainstem when the stomach is physically distended, triggering fullness independent of caloric content. Foods with low caloric density (high water and fiber content relative to calories) physically fill the stomach and activate these stretch receptors with far fewer calories than energy-dense foods. A pound of vegetables provides the same gastric volume and stretch receptor activation as a pound of cheese but at one-tenth the caloric cost.\n\nCLINICAL APPLICATION:\nThe volumetric approach to weight management, supported by research from Barbara Rolls at Penn State, demonstrates that reducing the caloric density of the diet (by increasing the proportion of vegetables, fruits, and water-rich foods) produces sustained weight loss without calorie counting or hunger. This explains why whole-food plant-based diets consistently produce weight loss in clinical trials despite ad libitum (unlimited) eating, as the high fiber and water content ensures satiety before caloric excess occurs.\n\nKEY POINTS:\nNon-starchy vegetables have the lowest caloric density (100 to 200 cal/lb versus 1,000 to 1,500 for meat/cheese and 4,000 for oils), allowing greater food volume with fewer calories. Satiety is driven by gastric stretch receptors that respond to volume, not calories. Volumetric eating strategies using low caloric density foods produce weight loss without calorie counting or hunger."
  },
  {
    "id": 265,
    "categoryId": 16,
    "question": "For a patient with Hypertension, what is the expected acute effect of a single bout of aerobic exercise (Post-Exercise Hypotension)?",
    "options": [
      "A) No change",
      "B) Increased BP for 24 hours",
      "C) Decreased SBP by 5-7 mmHg for up to 22 hours",
      "D) Increased Diastolic but decreased Systolic"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Decreased SBP by 5 to 7 mmHg for up to 22 hours).\n\nPATHOPHYSIOLOGY:\nPost-exercise hypotension (PEH) is a well-documented phenomenon in which blood pressure drops below pre-exercise resting levels following a single bout of aerobic exercise, with reductions of approximately 5 to 7 mmHg systolic and 2 to 4 mmHg diastolic persisting for up to 22 hours. The magnitude of PEH is greater in hypertensive individuals than normotensive individuals, making exercise a particularly effective intervention for those who need it most.\n\nMECHANISMS:\nPEH results from several converging physiologic mechanisms. Sustained post-exercise peripheral vasodilation occurs due to local release of nitric oxide, prostaglandins, and adenosine in exercised muscle beds, reducing total peripheral resistance. Reduced sympathetic nervous system activity and decreased cardiac output in the recovery period also contribute. Exercise-induced release of atrial natriuretic peptide (ANP) promotes natriuresis and vasodilation. Histamine receptor activation in exercised muscles maintains vasodilation for hours after exercise cessation.\n\nCLINICAL SIGNIFICANCE:\nThe 2017 ACC/AHA Hypertension Guidelines recommend 150 minutes per week of moderate-intensity aerobic activity (or 75 minutes of vigorous activity) as a first-line lifestyle intervention for blood pressure management. Regular aerobic exercise reduces resting systolic BP by approximately 5 to 8 mmHg in hypertensive adults, an effect comparable to single-drug antihypertensive therapy. Each individual exercise session contributes through the acute PEH effect, while chronic adaptations (improved endothelial function, reduced arterial stiffness, decreased sympathetic tone, and weight loss) produce the sustained long-term BP reduction.\n\nKEY POINTS:\nPost-exercise hypotension produces a 5 to 7 mmHg systolic BP reduction lasting up to 22 hours after a single aerobic exercise session, mediated by sustained vasodilation and reduced sympathetic tone. The effect is greater in hypertensive individuals. Regular aerobic exercise reduces resting BP by approximately 5 to 8 mmHg, comparable to single-drug antihypertensive therapy."
  },
  {
    "id": 266,
    "categoryId": 16,
    "question": "Alcohol is often used by patients as a sleep aid. While it reduces sleep latency (time to fall asleep), how does it negatively impact sleep architecture?",
    "options": [
      "A) It increases Deep Sleep (N3) too much",
      "B) It fragments REM sleep and causes rebound wakefulness in the second half of the night",
      "C) It causes Sleep Apnea to resolve",
      "D) It has no negative effect"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (It fragments REM sleep and causes rebound wakefulness in the second half of the night).\n\nPATHOPHYSIOLOGY:\nAlcohol is a central nervous system depressant that acts primarily by enhancing GABA-A receptor activity and inhibiting glutamate (NMDA) receptor signaling, which initially promotes sedation and reduces sleep onset latency. However, as alcohol is metabolized during the second half of the night (at approximately 0.015 g/dL per hour), a glutamate rebound occurs: the previously suppressed excitatory neurotransmitter system rebounds, producing sympathetic activation, sleep fragmentation, increased awakenings, vivid dreams, and diaphoresis.\n\nREM SLEEP DISRUPTION:\nAlcohol profoundly suppresses REM (rapid eye movement) sleep during the first half of the night. As blood alcohol levels fall, a compensatory REM rebound occurs with excessive and fragmented REM sleep in the latter portion of the night, often accompanied by vivid or disturbing dreams. Since REM sleep is critical for emotional memory consolidation, cognitive processing, and psychological restoration, this disruption impairs next-day cognitive function, emotional regulation, and learning. Even moderate alcohol consumption (1 to 2 drinks) within 4 hours of bedtime reduces sleep quality by 24% in healthy adults.\n\nCLINICAL SIGNIFICANCE:\nAlcohol also worsens obstructive sleep apnea by relaxing upper airway musculature, increasing airway collapsibility, and blunting the arousal response to apneic events. Chronic use of alcohol as a sleep aid promotes tolerance (requiring escalating doses for the same sedative effect) and can contribute to alcohol use disorder. Clinicians should counsel patients that while alcohol reduces the time to fall asleep, it fundamentally degrades sleep architecture and overall sleep quality.\n\nKEY POINTS:\nAlcohol reduces sleep latency but fragments REM sleep and causes second-half-of-night rebound wakefulness as it is metabolized, producing a glutamate/sympathetic surge. Even 1 to 2 drinks within 4 hours of bedtime reduce sleep quality by 24%. Alcohol worsens obstructive sleep apnea and promotes tolerance, making it counterproductive as a chronic sleep aid."
  },
  {
    "id": 267,
    "categoryId": 4,
    "question": "A Type 2 Diabetic asks about fruit. According to the ADA and large prospective cohorts, consumption of whole fruit is associated with:",
    "options": [
      "A) Worsening A1c",
      "B) Increased weight gain",
      "C) Reduced risk of complications and better glycemic control",
      "D) Spikes in Triglycerides"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Reduced risk of complications and better glycemic control).\n\nPATHOPHYSIOLOGY:\nThe paradox that whole fruit containing fructose reduces diabetes risk is explained by the food matrix and fiber. Intact fruit's cell wall matrix (cellulose, pectin) encapsulates sugars, dramatically slowing release and absorption. Soluble fiber forms a viscous gel that retards glucose absorption, attenuates postprandial glycemic spikes, and increases satiety through gastric distension. Slow fructose delivery to the liver prevents metabolic overload (ATP depletion, de novo lipogenesis, uric acid generation) that occurs with rapid fructose loading from sugar-sweetened beverages. Whole fruits also deliver polyphenols, carotenoids, and vitamins that independently improve insulin sensitivity and reduce oxidative stress.\n\nCLINICAL EVIDENCE:\nPooled analysis from the Nurses' Health Studies and Health Professionals Follow-up Study (BMJ; ~187,000 participants) demonstrated whole fruit consumption significantly reduced type 2 diabetes risk: blueberries (26% reduction per 3 servings/week), grapes/raisins (12%), apples/pears (7%). Fruit juice was associated with increased risk, confirming food matrix and fiber as critical protective elements. An RCT (Nutrition Journal) showed unrestricted fruit intake did not worsen HbA1c, weight, or waist circumference over 12 weeks in established diabetes. The PREDIMED trial (NEJM 2013) included regular fruit as a core Mediterranean diet component.\n\nCLINICAL APPLICATION:\nThe ADA 2024 Standards of Care recommend whole fruit as part of healthy eating for individuals with diabetes, stating fruit should not be restricted for blood glucose control. Practical counseling: encourage 2-4 servings daily with appropriate carbohydrate counting for insulin-treated patients, pair with protein or fat to blunt glycemic response, prioritize deeply pigmented fruits (berries, stone fruits) for higher polyphenol content, and distinguish whole fruit from juice, dried fruit with added sugar, and fruit-flavored products.\n\nKEY POINTS:\nWhole fruit consumption reduces type 2 diabetes risk and does not worsen glycemic control in established diabetes, unlike sugar-sweetened beverages and juice. Protection stems from fiber-mediated slowed absorption, polyphenol-driven insulin sensitization, and satiety promotion. The ADA recommends whole fruit and advises against restricting fruit intake for glycemic control."
  },
  {
    "id": 268,
    "categoryId": 16,
    "question": "In the 'Transtheoretical Model of Change', a patient who says 'I know I need to quit smoking, and I'm looking up cessation classes to start next month' is in which stage?",
    "options": [
      "A) Pre-contemplation",
      "B) Contemplation",
      "C) Preparation",
      "D) Action"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Preparation Stage).\n\nTRANSTHEORETICAL MODEL:\nThe Transtheoretical Model (TTM), developed by Prochaska and DiClemente, describes behavior change as a process through five sequential stages. Precontemplation is the stage where the individual is not considering change within the next 6 months and may not recognize the behavior as problematic. Contemplation involves acknowledging the problem and considering change within the next 6 months but remaining ambivalent. Preparation is the stage of active planning, where the individual intends to take action within 30 days and may have already taken preliminary steps (such as researching cessation programs, as in this patient).\n\nACTION AND MAINTENANCE:\nThe Action stage involves actively modifying the behavior (for example, the patient has quit smoking and is in the first 6 months of abstinence). Maintenance represents sustained behavior change for more than 6 months, during which the individual works to prevent relapse. Relapse is recognized as a normal part of the change process rather than a failure, and patients typically cycle through the stages multiple times before achieving long-term change.\n\nCLINICAL APPLICATION:\nIdentifying the patient's current stage guides the clinician's counseling approach. In Precontemplation, the clinician raises awareness and plants seeds of doubt. In Contemplation, motivational interviewing techniques help resolve ambivalence. In Preparation (this patient), the clinician should help develop a concrete action plan, set a quit date, identify triggers and coping strategies, and initiate pharmacotherapy (NRT, varenicline, or bupropion). The statement 'I know I need to quit smoking and I'm looking up cessation programs' reflects both intention to act within 30 days and preliminary action steps, placing this patient squarely in the Preparation stage.\n\nKEY POINTS:\nThe Preparation stage is defined by intention to take action within 30 days with preliminary steps already underway (such as researching programs). The five TTM stages are Precontemplation, Contemplation, Preparation, Action, and Maintenance. Identifying the patient's stage guides counseling: in Preparation, help set a quit date, develop an action plan, and initiate pharmacotherapy."
  },
  {
    "id": 269,
    "categoryId": 16,
    "question": "A common myth is that plant proteins are 'incomplete'. According to the Academy of Nutrition and Dietetics:",
    "options": [
      "A) Vegans must combine rice and beans at every meal",
      "B) Plant proteins lack essential amino acids",
      "C) Eating a variety of plant foods over the course of a day provides all essential amino acids",
      "D) Animal protein is required for muscle synthesis"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Eating a variety of plant foods over the course of a day provides all essential amino acids).\n\nEVIDENCE:\nThe Academy of Nutrition and Dietetics (the world's largest organization of nutrition professionals) states that appropriately planned vegetarian and vegan diets are healthful, nutritionally adequate, and provide all essential amino acids when a variety of plant foods are consumed throughout the day. The outdated concept of protein combining (eating complementary plant proteins at the same meal, such as rice and beans together) was popularized by Frances Moore Lappé in 1971 but has been refuted by subsequent research and retracted by Lappé herself.\n\nBIOCHEMISTRY:\nAll plant foods contain all 20 amino acids, including all 9 essential amino acids, albeit in varying proportions. The liver maintains a free amino acid pool that buffers dietary variation, drawing on amino acids absorbed from different meals throughout the day. As long as total caloric intake is adequate and dietary variety is present (grains, legumes, vegetables, nuts, and seeds), the amino acid pool will contain sufficient quantities of all essential amino acids for protein synthesis. Soy, quinoa, hemp, and buckwheat are notable for having amino acid profiles comparable to animal proteins.\n\nCLINICAL APPLICATION:\nThe recommended protein intake for adults is 0.8 g/kg/day (RDA), though older adults benefit from 1.0 to 1.2 g/kg/day. Plant-based protein sources include legumes (approximately 15g protein per cup cooked), tofu and tempeh (10 to 20g per serving), nuts and seeds (5 to 7g per ounce), and whole grains (5 to 8g per cup cooked). Large epidemiologic studies suggest that substituting plant protein for animal protein is linked to reduced all-cause and cardiovascular mortality.\n\nKEY POINTS:\nAll plant foods contain all essential amino acids in varying proportions, and the liver's amino acid pool buffers dietary variation, making protein combining at each meal unnecessary. The Academy of Nutrition and Dietetics confirms that varied plant-based diets are nutritionally adequate. Soy, quinoa, hemp, and buckwheat have particularly complete amino acid profiles."
  },
  {
    "id": 270,
    "categoryId": 16,
    "question": "Chronic stress activates the HPA axis, leading to elevated Cortisol. Long-term hypercortisolemia causes:",
    "options": [
      "A) Increased muscle mass",
      "B) Visceral fat deposition (Central Obesity) and Hippocampal atrophy",
      "C) Improved immune function",
      "D) Thickening of the skin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Visceral fat deposition and Hippocampal atrophy).\n\nPATHOPHYSIOLOGY:\nChronic activation of the hypothalamic-pituitary-adrenal (HPA) axis from persistent psychological stress produces sustained elevation of cortisol, which causes a characteristic pattern of metabolic and neurologic damage. Cortisol promotes visceral (central) adiposity preferentially because visceral adipocytes have a higher density of glucocorticoid receptors and greater expression of 11-beta-hydroxysteroid dehydrogenase type 1 (which converts inactive cortisone to active cortisol locally) compared to subcutaneous fat.\n\nMETABOLIC EFFECTS:\nHypercortisolemia induces insulin resistance through multiple mechanisms: it stimulates hepatic gluconeogenesis, impairs peripheral glucose uptake in skeletal muscle, and promotes lipolysis that releases free fatty acids into the portal circulation. The resulting visceral obesity further amplifies insulin resistance, creating a feed-forward cycle that increases risk of metabolic syndrome, type 2 diabetes, and cardiovascular disease. Cortisol also suppresses immune function (reducing lymphocyte proliferation and cytokine production), delays wound healing, promotes bone resorption (osteoporosis), and causes protein catabolism (muscle wasting and skin thinning).\n\nNEUROLOGIC EFFECTS:\nThe hippocampus, which is critical for memory consolidation and spatial navigation, has a particularly high density of glucocorticoid receptors. Chronic cortisol exposure causes hippocampal neuronal atrophy, dendritic retraction, impaired neurogenesis, and ultimately measurable volume loss on MRI. This hippocampal atrophy manifests clinically as impaired episodic memory and may contribute to the increased dementia risk observed with chronic stress and depression. Cortisol also impairs prefrontal cortex function (reducing executive function and decision-making) while enhancing amygdala reactivity (increasing anxiety and fear responses).\n\nKEY POINTS:\nChronic hypercortisolemia from HPA axis activation causes visceral fat deposition (via glucocorticoid receptor density in visceral adipocytes) and hippocampal atrophy (via glucocorticoid-mediated neuronal damage). The metabolic consequences include insulin resistance, metabolic syndrome, and cardiovascular risk. Hippocampal atrophy impairs memory consolidation and may contribute to dementia risk."
  },
  {
    "id": 271,
    "categoryId": 16,
    "question": "The primary fuel source for colonocytes (colon cells) is:",
    "options": [
      "A) Glucose",
      "B) Glutamine",
      "C) Butyrate (Short Chain Fatty Acid)",
      "D) Ketones"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Butyrate, a Short-Chain Fatty Acid).\n\nPATHOPHYSIOLOGY:\nButyrate is the primary energy source for colonocytes (epithelial cells lining the colon), providing approximately 60 to 70% of their energy needs. Unlike most cells in the body that rely on glucose as their primary fuel, colonocytes have evolved a preferential dependence on butyrate, reflecting the coevolutionary relationship between the human colon and its resident microbiota.\n\nPRODUCTION PATHWAY:\nHumans cannot synthesize butyrate endogenously. It is produced exclusively by bacterial fermentation of dietary fiber (particularly resistant starch and non-starch polysaccharides) in the colon. Key butyrate-producing bacterial genera include Faecalibacterium prausnitzii, Roseburia, and Eubacterium rectale, all of which are obligate anaerobes that thrive on dietary fiber substrates. When dietary fiber intake is insufficient, butyrate production falls, and colonocytes become energy-deprived, leading to increased intestinal permeability (leaky gut), mucosal inflammation, and impaired epithelial barrier function.\n\nCLINICAL SIGNIFICANCE:\nBeyond fueling colonocytes, butyrate exerts multiple protective effects. It strengthens tight junctions between epithelial cells, maintaining the intestinal barrier against bacterial translocation. It has anti-inflammatory properties by inhibiting NF-kB signaling in immune cells. It promotes regulatory T-cell differentiation, contributing to immune tolerance. And it has anti-proliferative and pro-apoptotic effects on dysplastic colonocytes, which may protect against colorectal cancer. These findings provide the mechanistic rationale for the observed association between high-fiber diets and reduced colorectal cancer risk.\n\nKEY POINTS:\nButyrate (produced by bacterial fermentation of dietary fiber) is the primary fuel for colonocytes, providing 60 to 70% of their energy needs. Humans cannot produce butyrate without dietary fiber as a substrate for colonic bacteria. Butyrate strengthens the epithelial barrier, reduces inflammation via NF-kB inhibition, and has anti-neoplastic properties that may protect against colorectal cancer."
  },
  {
    "id": 272,
    "categoryId": 16,
    "question": "What is the definition of 1 MET (Metabolic Equivalent of Task)?",
    "options": [
      "A) The energy used while running a 10-minute mile",
      "B) The energy used while sitting quietly at rest",
      "C) The energy used while walking 3 mph",
      "D) The energy used while sleeping"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The energy used while sitting quietly at rest).\n\nDEFINITION:\nOne MET (metabolic equivalent of task) means the rate of energy expenditure at rest, standardized to an oxygen consumption of approximately 3.5 mL O2/kg/min, which corresponds to the energy cost of sitting quietly. METs provide a standardized, body-weight-independent measure of exercise intensity that allows comparison across different activities and patients.\n\nINTENSITY CLASSIFICATION:\nActivities are classified by MET levels. Light-intensity activities (less than 3 METs) include casual walking, light housework, and standing. Moderate-intensity activities (3 to 6 METs) include brisk walking (3 to 4 mph), cycling (less than 10 mph), gardening, and doubles tennis. Vigorous-intensity activities (greater than 6 METs) include jogging, running, swimming laps, singles tennis, and high-intensity interval training. The 2018 Physical Activity Guidelines for Americans recommend 150 to 300 minutes per week of moderate-intensity (3 to 6 METs) or 75 to 150 minutes of vigorous-intensity (greater than 6 METs) aerobic activity.\n\nVO2 MAX AND PROGNOSTIC VALUE:\nMaximal oxygen consumption (VO2 max), expressed in METs, represents an individual's peak cardiorespiratory fitness and is one of the strongest independent predictors of all-cause mortality, surpassing traditional risk factors such as hypertension, diabetes, smoking, and obesity. Each 1-MET increase in exercise capacity is linked to approximately 12 to 15% reduction in cardiovascular and all-cause mortality. Patients unable to achieve 5 METs on exercise stress testing have significantly increased perioperative and long-term cardiac risk.\n\nKEY POINTS:\nOne MET equals resting energy expenditure (3.5 mL O2/kg/min), with moderate activity at 3 to 6 METs and vigorous at greater than 6 METs. VO2 max (expressed in METs) is one of the strongest independent predictors of all-cause mortality. Each 1-MET increase in fitness capacity reduces cardiovascular and all-cause mortality by approximately 12 to 15%."
  },
  {
    "id": 273,
    "categoryId": 16,
    "question": "Heme Iron (from meat) vs. Non-Heme Iron (from plants). Which statement is true regarding regulation?",
    "options": [
      "A) Non-Heme iron is absorbed more efficiently",
      "B) The body cannot regulate Heme iron absorption; it enters passively, increasing risk of Iron Overload/Oxidative stress",
      "C) Heme iron is safer",
      "D) Vitamin C helps Heme iron absorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The body cannot regulate heme iron absorption; it enters passively, increasing risk of iron overload and oxidative stress).\n\nPATHOPHYSIOLOGY:\nIron exists in two dietary forms with fundamentally different absorption mechanisms. Non-heme iron (found in plant foods, eggs, and dairy) is tightly regulated by hepcidin-ferroportin axis signaling: when iron stores are replete, hepcidin (produced by the liver) degrades ferroportin on enterocyte basolateral membranes, blocking iron export into the circulation and preventing iron overload. Heme iron (found exclusively in animal flesh from hemoglobin and myoglobin) bypasses this regulatory system entirely, entering duodenal enterocytes via the heme carrier protein 1 (HCP1) transporter in an unregulated fashion.\n\nCLINICAL SIGNIFICANCE:\nBecause heme iron absorption is not down-regulated when body iron stores are sufficient, chronic high intake of heme iron (from red meat) can contribute to iron overload and excess free iron in tissues. Free (unbound) iron participates in Fenton chemistry, generating hydroxyl radicals (the most reactive oxygen species) that damage lipids, proteins, and DNA. Epidemiologic studies have associated high heme iron intake with increased risk of type 2 diabetes (through pancreatic beta-cell oxidative damage), coronary heart disease (through LDL oxidation and endothelial dysfunction), and colorectal cancer (through DNA damage and promotion of N-nitroso compound formation).\n\nIRON ABSORPTION ENHANCERS AND INHIBITORS:\nNon-heme iron absorption is enhanced by vitamin C (ascorbic acid reduces ferric to ferrous iron), citric acid, and MFP factor (meat, fish, poultry). It is inhibited by phytates (whole grains, legumes), polyphenols (tea, coffee), calcium, and soy protein. These regulatory influences allow the body to modulate non-heme iron absorption based on need, a safety mechanism absent for heme iron.\n\nKEY POINTS:\nHeme iron (from animal flesh) bypasses the hepcidin-ferroportin regulatory system and is absorbed in an unregulated fashion, while non-heme iron (from plants) is tightly regulated based on body stores. Excess free iron generates hydroxyl radicals via Fenton chemistry, contributing to oxidative tissue damage. High heme iron intake is epidemiologically associated with increased risk of type 2 diabetes, coronary disease, and colorectal cancer."
  },
  {
    "id": 274,
    "categoryId": 16,
    "question": "For patients with CKD, a high dietary acid load (from animal proteins/cheese) worsens kidney function. The recommended intervention is:",
    "options": [
      "A) Sodium Bicarbonate supplementation or increasing Fruits/Vegetables",
      "B) Increasing protein intake",
      "C) Drinking cranberry juice",
      "D) Fasting"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Sodium bicarbonate supplementation or increasing fruits and vegetables).\n\nPATHOPHYSIOLOGY:\nAnimal protein metabolism generates a net acid load because sulfur-containing amino acids (methionine and cysteine, abundant in animal proteins and cheese) are metabolized to sulfuric acid. In patients with chronic kidney disease (CKD), the kidneys' ability to excrete this acid load through ammoniagenesis and titratable acid excretion is impaired, leading to metabolic acidosis that accelerates CKD progression. Chronic metabolic acidosis activates the complement system and endothelin-1 in the renal interstitium, promoting tubulointerstitial fibrosis, and it stimulates angiotensin II production, worsening glomerular hemodynamic injury.\n\nALKALINIZATION STRATEGIES:\nTwo evidence-based approaches to reduce dietary acid load in CKD patients are oral sodium bicarbonate supplementation and increased fruit and vegetable consumption. The landmark trial by de Brito-Ashurst and colleagues demonstrated that sodium bicarbonate supplementation (targeting a serum bicarbonate of 22 mEq/L or greater) slowed CKD progression by 60% compared to standard care. A separate trial by Goraya and colleagues showed that a fruit-and-vegetable-rich diet achieved equivalent acid reduction and nephroprotection compared to sodium bicarbonate, with the additional benefit of avoiding sodium loading.\n\nCLINICAL APPLICATION:\nKDIGO guidelines recommend maintaining serum bicarbonate at 22 mEq/L or greater in CKD patients, using oral sodium bicarbonate (500 to 1000 mg two to three times daily) when dietary modification is insufficient. Fruits and vegetables are natural base-generating foods (their organic anions, particularly citrate and malate, are metabolized to bicarbonate) and provide the additional benefits of potassium, fiber, and antioxidants.\n\nKEY POINTS:\nAnimal protein metabolism generates sulfuric acid that the CKD kidney cannot adequately excrete, accelerating kidney damage through tubulointerstitial fibrosis. Sodium bicarbonate supplementation and increased fruit/vegetable intake both effectively reduce acid load and slow CKD progression. KDIGO recommends maintaining serum bicarbonate at 22 mEq/L or greater in CKD patients."
  },
  {
    "id": 275,
    "categoryId": 16,
    "question": "The 'Glymphatic System' clears beta-amyloid toxins from the brain. When is this system most active?",
    "options": [
      "A) During intense exercise",
      "B) During Deep (Slow Wave) Sleep",
      "C) While solving puzzles",
      "D) After caffeine intake"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (During Deep Slow-Wave Sleep).\n\nDISCOVERY:\nThe glymphatic system (a portmanteau of glial and lymphatic) is a brain-wide paravascular clearance pathway discovered by Nedergaard and colleagues in 2012 that functions as the central nervous system's waste removal system. Unlike the rest of the body, which relies on the lymphatic system for interstitial waste clearance, the brain lacks conventional lymphatic vessels within its parenchyma. Instead, cerebrospinal fluid (CSF) flows along periarterial spaces (Virchow-Robin spaces), enters the brain parenchyma through aquaporin-4 (AQP4) water channels on astrocytic endfeet, mixes with interstitial fluid, and carries metabolic waste products along perivenous drainage pathways.\n\nSLEEP-DEPENDENT ACTIVATION:\nGlymphatic clearance is most active during deep slow-wave (non-REM stage 3) sleep, when it operates at approximately 60% greater efficiency than during wakefulness. This dramatic increase is mediated by the contraction of astrocytic cell bodies during sleep (expanding the interstitial space by approximately 60%), which reduces resistance to convective CSF flow through the parenchyma. Additionally, reduced noradrenergic tone from the locus coeruleus during sleep facilitates astrocytic volume changes that optimize interstitial clearance.\n\nCLINICAL SIGNIFICANCE:\nThe glymphatic system clears beta-amyloid, tau protein, and alpha-synuclein, the pathologic proteins implicated in Alzheimer's disease, frontotemporal dementia, and Parkinson's disease respectively. Chronic sleep deprivation impairs glymphatic clearance, leading to accumulation of these neurotoxic proteins. This provides a mechanistic link between chronic poor sleep quality and the increased risk of neurodegenerative diseases observed in epidemiologic studies.\n\nKEY POINTS:\nThe glymphatic system clears beta-amyloid and other neurotoxic waste from the brain via CSF flow through astrocytic AQP4 channels and is approximately 60% more active during deep slow-wave sleep than during wakefulness. Sleep-dependent activation occurs because astrocytes shrink during sleep, expanding the interstitial space for convective CSF flow. Chronic sleep deprivation impairs glymphatic clearance and is linked to increased neurodegenerative disease risk."
  },
  {
    "id": 276,
    "categoryId": 16,
    "question": "When setting goals with patients, 'SMART' stands for:",
    "options": [
      "A) Specific, Measurable, Achievable, Relevant, Time-bound",
      "B) Simple, Meaningful, Actionable, Real, True",
      "C) Scientific, Medical, Accurate, Required, Tested",
      "D) Strict, Mandatory, Absolute, Rigid, Tough"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Specific, Measurable, Achievable, Relevant, Time-bound).\n\nCLINICAL APPLICATION:\nSMART goal-setting is an evidence-based behavioral framework used across medical, psychological, and public health practice to convert vague patient intentions into concrete, actionable plans that can be objectively assessed at follow-up. Specific means the goal clearly defines what the patient will do (such as 'walk for 30 minutes' rather than 'exercise more'). Measurable means there is an objective metric to track progress (duration, frequency, or quantity). Achievable means the goal is realistic given the patient's current abilities and circumstances. Relevant means the goal aligns with the patient's values and health priorities. Time-bound means there is a defined deadline or timeframe.\n\nEVIDENCE:\nGoal-setting theory, established by Locke and Latham, demonstrates that specific and challenging (but achievable) goals consistently produce better performance outcomes than vague or overly easy goals. In healthcare, SMART goals improve outcomes in chronic disease management (diabetes self-management, cardiac rehabilitation, weight loss programs), smoking cessation, and mental health treatment. Combining SMART goals with self-monitoring (tracking behavior in a journal or app) and accountability (regular follow-up with a clinician or support person) further enhances adherence and outcomes.\n\nEXAMPLE:\nA vague goal like 'I want to eat healthier' becomes a SMART goal: 'I will eat at least 3 servings of vegetables with dinner, 5 days a week, for the next 4 weeks.' This transformation makes the behavior specific (vegetables at dinner), measurable (3 servings, 5 days), achievable (dinner is a modifiable meal), relevant (aligned with health goals), and time-bound (4-week trial).\n\nKEY POINTS:\nSMART stands for Specific, Measurable, Achievable, Relevant, and Time-bound, converting vague intentions into concrete behavioral plans. Goal-setting theory shows that specific and challenging goals produce better outcomes than vague goals. Combining SMART goals with self-monitoring and regular follow-up accountability maximizes adherence in chronic disease management."
  },
  {
    "id": 277,
    "categoryId": 4,
    "question": "Which hormone is secreted by adipose tissue and signals the brain to STOP eating (Satiety)?",
    "options": [
      "A) Ghrelin",
      "B) Leptin",
      "C) Insulin",
      "D) Cortisol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Leptin).\n\nPATHOPHYSIOLOGY:\nLeptin is a 16-kDa peptide hormone encoded by the ob gene, secreted by white adipose tissue in proportion to body fat mass. It functions as the primary afferent signal in a negative feedback loop between adipose tissue and the hypothalamus. Leptin crosses the blood-brain barrier via saturable receptor-mediated transport and binds to LepR-b receptors on arcuate nucleus neurons, stimulating anorexigenic POMC neurons (releasing alpha-MSH) and inhibiting orexigenic NPY/AgRP neurons. The net effect is suppressed food intake, increased energy expenditure through sympathetic activation and thermogenesis, and energy homeostasis. Discovered in 1994 by Friedman (Nature), ob/ob mice lacking functional leptin developed massive obesity reversible with recombinant leptin.\n\nLEPTIN RESISTANCE:\nObese individuals have markedly elevated leptin yet continue experiencing hunger, termed leptin resistance. Mechanisms include impaired blood-brain barrier transport (saturation at high levels), intracellular signaling defects (SOCS3 upregulation attenuating JAK-STAT signaling), endoplasmic reticulum stress in hypothalamic neurons, and chronic hypothalamic inflammation from saturated fatty acids and visceral adipose cytokines. The brain fails to perceive the energy surplus, defending an elevated body weight set point. Exogenous leptin is therefore ineffective for common obesity, unlike rare congenital leptin deficiency.\n\nCLINICAL APPLICATION:\nLeptin resistance provides a neurobiological framework for counseling: persistent hunger during weight loss reflects falling leptin levels triggering hypothalamic starvation signaling (disinhibited NPY/AgRP, suppressed POMC), increasing appetite and decreasing energy expenditure (adaptive thermogenesis). This is a physiologic response, not a character deficiency. GLP-1 receptor agonists (semaglutide, tirzepatide) achieve sustained weight loss partly by activating central satiety pathways that bypass leptin-resistant circuitry. Interventions that may improve leptin sensitivity include regular exercise, adequate sleep, reduced ultra-processed food intake, and Mediterranean diet patterns.\n\nKEY POINTS:\nLeptin signals the hypothalamus to suppress appetite and increase energy expenditure through POMC activation and NPY/AgRP inhibition. Obese individuals develop leptin resistance through impaired blood-brain barrier transport, SOCS3-mediated signaling attenuation, and hypothalamic inflammation. GLP-1 receptor agonists achieve weight loss partly by bypassing leptin-resistant circuitry."
  },
  {
    "id": 278,
    "categoryId": 7,
    "question": "The most effective exercise intervention for Osteoporosis is:",
    "options": [
      "A) Swimming",
      "B) Cycling",
      "C) High-Impact / Weight-Bearing Loading",
      "D) Yoga"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (High-Impact / Weight-Bearing Loading).\n\nPATHOPHYSIOLOGY:\nBone continuously remodels in response to mechanical loading (Wolff's Law). Mechanical stress generates fluid shear forces on osteocytes, the primary mechanosensory cells. Stimulated osteocytes downregulate sclerostin and release prostaglandin E2 and nitric oxide, shifting remodeling toward formation by activating osteoblasts and suppressing osteoclast-mediated resorption. The piezoelectric effect, in which mechanical deformation of hydroxyapatite crystals generates electrical potentials, provides additional osteoblast recruitment stimulus. The osteogenic response is driven by the magnitude and rate of strain, not duration, explaining why high-impact loading is far more effective than low-impact repetitive exercise.\n\nCLINICAL EVIDENCE:\nWeight-bearing impact exercise (jumping, running, heavy resistance training) produces ground reaction forces of 2-6 times body weight, generating the high-magnitude, rapidly applied strains necessary for significant bone mineral accrual. RCTs and meta-analyses endorsed by the National Osteoporosis Foundation and ACSM demonstrate that high-impact and progressive resistance training programs increase BMD at the hip and spine by 1-3% over 12-18 months and reduce fracture risk through improved muscle strength, balance, and fall prevention. Non-weight-bearing activities (swimming, cycling) do not generate axial skeletal loading and have consistently failed to show BMD benefit. Walking provides minimal osteogenic stimulus due to adaptation to habitual low-level loading.\n\nTREATMENT AND MANAGEMENT:\nOptimal exercise prescription combines high-impact weight-bearing exercise (jumping, stair climbing, jogging) with progressive resistance training at 70-85% of one-repetition maximum targeting hip and spine muscle groups. Balance and proprioceptive training should be incorporated to reduce fall risk. For patients with established osteoporosis or vertebral fractures, high-impact activities may need modification, with progressive resistance training as the primary intervention. Exercise is a lifelong strategy complementing pharmacotherapy, as bone density benefits are lost when activity is discontinued.\n\nKEY POINTS:\nHigh-impact weight-bearing exercise and progressive resistance training are the most effective exercise interventions for osteoporosis, generating high-magnitude mechanical strains that activate osteocyte mechanotransduction and osteoblast activity. Swimming and cycling do not improve BMD. Exercise must be maintained lifelong, and balance training should be incorporated to reduce fall-related fracture risk."
  },
  {
    "id": 279,
    "categoryId": 16,
    "question": "Sulforaphane, a potent inducer of the Nrf2 pathway (cellular antioxidant defense), is found most abundantly in:",
    "options": [
      "A) Blueberries",
      "B) Broccoli Sprouts / Cruciferous Vegetables",
      "C) Red Wine",
      "D) Turmeric"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Broccoli Sprouts and Cruciferous Vegetables).\n\nBIOCHEMISTRY:\nSulforaphane is an isothiocyanate compound formed when cruciferous vegetables (broccoli, Brussels sprouts, kale, cauliflower, cabbage) are chopped, chewed, or otherwise mechanically disrupted, releasing the enzyme myrosinase that converts the precursor glucoraphanin into active sulforaphane. Broccoli sprouts contain 20 to 100 times higher concentrations of glucoraphanin than mature broccoli, making them the most concentrated dietary source of sulforaphane.\n\nNRF2 PATHWAY:\nSulforaphane is the most potent naturally occurring inducer of the Nrf2 (nuclear factor erythroid 2-related factor 2) pathway, the master regulator of cellular antioxidant defense. Under normal conditions, Nrf2 is sequestered in the cytoplasm by Keap1 (Kelch-like ECH-associated protein 1) and targeted for proteasomal degradation. Sulforaphane modifies cysteine residues on Keap1, releasing Nrf2, which translocates to the nucleus and binds to antioxidant response elements (AREs) in the promoter regions of over 200 cytoprotective genes. These genes encode phase II detoxification enzymes (glutathione S-transferases, NAD(P)H quinone oxidoreductase 1), antioxidant proteins (heme oxygenase-1, thioredoxin reductase), and glutathione synthesis enzymes, collectively enhancing cellular resilience against oxidative and electrophilic stress.\n\nCLINICAL EVIDENCE:\nClinical trials have demonstrated that broccoli sprout extracts reduce markers of oxidative stress, improve insulin sensitivity in type 2 diabetes, and enhance detoxification of airborne pollutants (benzene, acrolein) in populations with high environmental exposure. Cooking methods affect sulforaphane availability: steaming preserves myrosinase activity, while boiling and microwaving at high temperatures can destroy it. Adding mustard seed powder (an exogenous myrosinase source) to cooked cruciferous vegetables can restore sulforaphane production.\n\nKEY POINTS:\nSulforaphane from cruciferous vegetables (most concentrated in broccoli sprouts) is the most potent natural Nrf2 pathway inducer, activating over 200 cytoprotective genes involved in antioxidant defense and detoxification. The compound is formed by myrosinase converting glucoraphanin when vegetables are chopped or chewed. Steaming preserves myrosinase activity, while boiling destroys it; adding mustard seed powder can restore sulforaphane production in cooked vegetables."
  },
  {
    "id": 280,
    "categoryId": 16,
    "question": "The 'STOP-BANG' questionnaire screens for:",
    "options": [
      "A) Alcohol Use Disorder",
      "B) Obstructive Sleep Apnea (OSA)",
      "C) Depression",
      "D) Fall Risk"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Obstructive Sleep Apnea).\n\nSCREENING TOOL:\nThe STOP-BANG questionnaire is a validated, widely used screening instrument for obstructive sleep apnea (OSA) that consists of eight yes/no questions corresponding to the mnemonic: Snoring (loud enough to be heard through closed doors), Tiredness (excessive daytime sleepiness), Observed apnea (witnessed breathing cessation during sleep), high blood Pressure (treated or untreated hypertension), BMI greater than 35, Age greater than 50, Neck circumference greater than 40 cm (approximately 16 inches), and Gender male. A score of 3 or greater indicates high risk for OSA and warrants referral for polysomnography (sleep study).\n\nCLINICAL SIGNIFICANCE OF OSA:\nOSA involves repetitive upper airway collapse during sleep, causing intermittent hypoxia, sleep fragmentation, and sympathetic nervous system activation. These pathophysiologic consequences drive a cascade of cardiovascular complications including resistant hypertension (OSA is the most common identifiable cause of resistant hypertension), atrial fibrillation, pulmonary hypertension, coronary artery disease, heart failure, and stroke. OSA also causes insulin resistance, impaired glucose tolerance, and nonalcoholic fatty liver disease through intermittent hypoxia-induced oxidative stress and systemic inflammation.\n\nDIAGNOSIS AND TREATMENT:\nPolysomnography remains the gold standard for diagnosis, with OSA severity classified by the apnea-hypopnea index (AHI): mild (5 to 14 events/hour), moderate (15 to 29), and severe (30 or greater). Continuous positive airway pressure (CPAP) is first-line therapy, reducing the AHI, improving daytime sleepiness, lowering blood pressure (by 2 to 3 mmHg), and reducing cardiovascular event risk.\n\nKEY POINTS:\nSTOP-BANG screens for obstructive sleep apnea with eight yes/no items (Snoring, Tiredness, Observed apnea, Pressure, BMI greater than 35, Age greater than 50, Neck greater than 40 cm, Gender male), with a score of 3 or greater indicating high risk. OSA is the most common identifiable cause of resistant hypertension. CPAP is first-line therapy, reducing AHI, daytime somnolence, and cardiovascular risk."
  },
  {
    "id": 281,
    "categoryId": 16,
    "question": "Autophagy ('Self-Eating') is a cellular cleanup process where cells recycle damaged organelles. It is upregulated by:",
    "options": [
      "A) High Insulin levels",
      "B) Continuous grazing",
      "C) Fasting / Caloric Restriction and Exercise",
      "D) High protein diet"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Fasting, Caloric Restriction, and Exercise).\n\nPATHOPHYSIOLOGY:\nAutophagy (from Greek auto meaning self and phagein meaning to eat) is a highly conserved cellular process in which damaged organelles, misfolded proteins, and dysfunctional mitochondria are sequestered within double-membrane vesicles called autophagosomes and delivered to lysosomes for degradation and recycling. Yoshinori Ohsumi received the 2016 Nobel Prize in Physiology or Medicine for elucidating the molecular mechanisms of autophagy.\n\nREGULATION:\nAutophagy is primarily regulated by the opposing actions of two nutrient-sensing pathways. mTOR (mechanistic target of rapamycin), activated by amino acids, insulin, and growth factors, is the master suppressor of autophagy when nutrients are abundant (growth mode). AMPK (AMP-activated protein kinase), activated by energy depletion, fasting, caloric restriction, and exercise, is the master activator of autophagy when nutrients are scarce (repair mode). During fasting or caloric restriction, declining insulin levels reduce mTOR activity, while rising AMP:ATP ratios activate AMPK, together shifting the cell from anabolic (growth) to catabolic (recycling) programs. Exercise independently activates autophagy through AMPK activation and increased oxidative stress signaling.\n\nCLINICAL SIGNIFICANCE:\nImpaired autophagy is implicated in aging, neurodegeneration (accumulation of misfolded proteins in Alzheimer's and Parkinson's disease), cancer (failure to clear damaged DNA and organelles), and cardiomyopathy. Enhancing autophagy through periodic fasting, caloric restriction, and regular exercise is hypothesized to promote cellular health and longevity, though optimal protocols for humans remain under investigation.\n\nKEY POINTS:\nAutophagy is a cellular recycling process that clears damaged organelles and misfolded proteins, regulated by the opposing mTOR (nutrient-sensing suppressor) and AMPK (energy-depletion activator) pathways. Fasting, caloric restriction, and exercise activate autophagy by reducing mTOR signaling and activating AMPK. Impaired autophagy is implicated in aging, neurodegeneration, and cancer."
  },
  {
    "id": 282,
    "categoryId": 16,
    "question": "A patient asks about Vaping (E-cigarettes) to quit smoking. The USPSTF and CDC stance is:",
    "options": [
      "A) It is FDA approved for cessation",
      "B) It is completely safe water vapor",
      "C) There is insufficient evidence to recommend it; FDA-approved aids (NRT/Chantix) are preferred",
      "D) It is more harmful than cigarettes"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Insufficient evidence to recommend e-cigarettes; FDA-approved aids are preferred).\n\nCURRENT GUIDANCE:\nThe USPSTF, CDC, and American Lung Association state that there is insufficient evidence to recommend electronic cigarettes (e-cigarettes, vaping devices) as a smoking cessation tool. While e-cigarettes likely expose users to fewer toxicants than combustible cigarettes, their long-term safety profile is unknown, and they are not FDA-approved for smoking cessation. FDA-approved cessation pharmacotherapies with established efficacy and safety include nicotine replacement therapy (patch, gum, lozenge, inhaler, nasal spray), varenicline (Chantix), and bupropion (Zyban).\n\nCONCERNS:\nE-cigarettes deliver nicotine via heated aerosol containing propylene glycol, vegetable glycerin, flavorings, and ultrafine particles that penetrate deep into the lungs. EVALI (e-cigarette or vaping product use-associated lung injury), identified in 2019, was linked primarily to vitamin E acetate in THC-containing cartridges but raised broader concerns about inhalation toxicity. E-cigarettes frequently perpetuate nicotine dependence rather than resolving it, with many dual users continuing both vaping and smoking. Youth uptake of e-cigarettes has created a new epidemic of nicotine addiction, with the Surgeon General declaring youth vaping an epidemic in 2018.\n\nCLINICAL APPLICATION:\nFor patients interested in smoking cessation, clinicians should offer FDA-approved pharmacotherapy combined with behavioral counseling as first-line treatment. Varenicline has the highest single-agent quit rates (approximately 25 to 30% sustained abstinence at 1 year). Combination NRT (patch plus short-acting form such as gum or lozenge) approaches varenicline efficacy. If a patient is already using e-cigarettes and has successfully quit combustible cigarettes, the clinician should encourage eventual cessation of e-cigarettes as well.\n\nKEY POINTS:\nThe USPSTF do not recommend e-cigarettes for smoking cessation due to insufficient evidence and unknown long-term safety. FDA-approved cessation aids (varenicline, NRT, bupropion) have established efficacy and are preferred. E-cigarettes often perpetuate nicotine dependence and have contributed to a youth nicotine addiction epidemic."
  },
  {
    "id": 283,
    "categoryId": 16,
    "question": "Social Isolation is an independent risk factor for mortality comparable to:",
    "options": [
      "A) Eating junk food",
      "B) Smoking 15 cigarettes a day",
      "C) Drinking 1 beer a day",
      "D) Living in a city"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Comparable to smoking approximately 15 cigarettes per day).\n\nEVIDENCE:\nThe U.S. Surgeon General's 2023 advisory on social isolation and loneliness identified social disconnection as a major public health crisis, with mortality risk comparable to smoking up to 15 cigarettes per day. A landmark meta-analysis by Holt-Lunstad and colleagues (encompassing 148 studies and over 300,000 participants) found that individuals with strong social relationships had a 50% increased likelihood of survival compared to those with weak social connections, an effect size exceeding that of many established risk factors including obesity and physical inactivity.\n\nBIOLOGIC MECHANISMS:\nSocial isolation activates the same neurobiological stress pathways as physical threats. Chronic loneliness increases sympathetic nervous system activity, elevates cortisol and inflammatory markers (CRP, IL-6, fibrinogen), disrupts sleep architecture, and impairs immune function (reduced natural killer cell activity and impaired vaccine responses). The conserved transcriptional response to adversity (CTRA), identified by Cole and colleagues, shows that social isolation upregulates pro-inflammatory gene expression and downregulates antiviral and antibody-related gene expression at the molecular level.\n\nCLINICAL SIGNIFICANCE:\nSocial isolation increases the risk of coronary heart disease by approximately 29%, stroke by 32%, and all-cause dementia by 50%. Depression and anxiety rates are significantly higher in socially isolated individuals. Clinicians should screen for social isolation (particularly in elderly patients, those with chronic illness, and post-bereavement) and consider social prescribing, referring patients to community groups, volunteer organizations, and structured social activities as a health intervention.\n\nKEY POINTS:\nSocial isolation carries mortality risk comparable to smoking 15 cigarettes per day and exceeds the risk conferred by obesity and physical inactivity. Biological mechanisms include chronic sympathetic activation, elevated cortisol and inflammatory markers, and impaired immune function. Clinicians should screen for social isolation and consider social prescribing as a health intervention."
  },
  {
    "id": 284,
    "categoryId": 16,
    "question": "Which dietary sugar is the primary driver of De Novo Lipogenesis (fat production) in the liver?",
    "options": [
      "A) Glucose",
      "B) Fructose",
      "C) Galactose",
      "D) Maltose"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fructose).\n\nPATHOPHYSIOLOGY:\nFructose is the primary dietary sugar driving de novo lipogenesis (DNL, the hepatic synthesis of new fat from non-fat substrates) because of its unique metabolic pathway. Unlike glucose, which can be metabolized by virtually every cell in the body via glycolysis and is regulated by insulin-mediated feedback mechanisms, fructose is metabolized almost exclusively by the liver through fructokinase (ketohexokinase), which has no negative feedback regulation. This means a large fructose load (such as from sugar-sweetened beverages) is rapidly and completely phosphorylated by the liver, depleting hepatic ATP and generating massive substrate flux into lipogenic pathways.\n\nMECHANISM:\nFructose metabolism bypasses the key regulatory enzyme of glycolysis (phosphofructokinase), flooding the liver with glyceraldehyde-3-phosphate and acetyl-CoA that are channeled directly into de novo lipogenesis. The resulting newly synthesized triglycerides are either exported as VLDL (raising serum triglycerides) or accumulate as intrahepatic fat (contributing to nonalcoholic fatty liver disease, NAFLD). Fructose also stimulates SREBP-1c (sterol regulatory element-binding protein), the master transcription factor for lipogenic genes, further amplifying fat synthesis.\n\nCLINICAL IMPACT:\nEpidemiologic and interventional studies associate high fructose intake (primarily from sugar-sweetened beverages and added sugars, not whole fruit) with NAFLD, hypertriglyceridemia, insulin resistance, visceral adiposity, and increased uric acid production (fructose metabolism generates uric acid as a byproduct of ATP depletion). Whole fruit, despite containing fructose, delivers it in a fiber matrix that slows absorption and limits hepatic fructose flux, and is linked to metabolic benefit rather than harm.\n\nKEY POINTS:\nFructose is the primary driver of hepatic de novo lipogenesis because it is metabolized exclusively by the liver through an unregulated pathway (fructokinase) that bypasses glycolytic feedback control. This produces hypertriglyceridemia, NAFLD, and hyperuricemia. Whole fruit is protective because fiber slows fructose absorption, but sugar-sweetened beverages deliver concentrated fructose loads that overwhelm hepatic capacity."
  },
  {
    "id": 285,
    "categoryId": 16,
    "question": "The DASH Diet (Dietary Approaches to Stop Hypertension) is rich in Calcium, Magnesium, and:",
    "options": [
      "A) Sodium",
      "B) Potassium",
      "C) Iron",
      "D) Zinc"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Potassium).\n\nMECHANISM:\nThe DASH diet (Dietary Approaches to Stop Hypertension) achieves blood pressure reduction through a high intake of three key minerals: potassium (approximately 4,700 mg/day), calcium (approximately 1,250 mg/day), and magnesium (approximately 500 mg/day), with potassium being the most emphasized electrolyte. Potassium lowers blood pressure by promoting renal sodium excretion (natriuresis) through inhibition of sodium reabsorption in the proximal tubule and suppression of the renin-angiotensin-aldosterone system. It also causes direct vasodilation by hyperpolarizing vascular smooth muscle cells through activation of the Na+/K+-ATPase and inward-rectifier potassium channels, and it reduces sympathetic nervous system activity.\n\nDASH DIET EVIDENCE:\nThe original DASH trial demonstrated that the DASH dietary pattern reduced systolic blood pressure by approximately 5.5 mmHg in hypertensive individuals and 3 mmHg in normotensive individuals compared to a typical American diet. The DASH-Sodium trial showed that combining the DASH diet with sodium restriction to 1,500 mg/day produced additional reductions of 6 to 11 mmHg systolic, approaching the efficacy of single-drug antihypertensive therapy.\n\nDIETARY SOURCES:\nRich potassium sources in the DASH diet include bananas, potatoes, sweet potatoes, spinach, avocados, beans, lentils, citrus fruits, and low-fat dairy products. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle modification for most patients with elevated blood pressure.\n\nKEY POINTS:\nThe DASH diet emphasizes potassium (4,700 mg/day), calcium, and magnesium from fruits, vegetables, whole grains, and low-fat dairy. Potassium lowers blood pressure via natriuresis, direct vasodilation, and reduced sympathetic tone. DASH plus sodium restriction to 1,500 mg/day achieves 6 to 11 mmHg systolic BP reduction, comparable to single-drug antihypertensive therapy."
  },
  {
    "id": 286,
    "categoryId": 16,
    "question": "Telomeres are protective caps on DNA. Which lifestyle factor is associated with SHORTER telomeres (accelerated aging)?",
    "options": [
      "A) Meditation",
      "B) Whole Food Plant Based Diet",
      "C) Sedentary behavior and Processed Meats",
      "D) Moderate Exercise"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Sedentary behavior and processed meat consumption).\n\nTELOMERE BIOLOGY:\nTelomeres are repetitive nucleotide sequences (TTAGGG in humans) capping the ends of chromosomes that protect genomic integrity during cell division. With each mitotic division, telomeres shorten by approximately 50 to 200 base pairs because DNA polymerase cannot fully replicate the 3-prime end of linear chromosomes (the end replication problem). When telomeres reach a critically short length, cells enter replicative senescence (permanent growth arrest) or apoptosis, contributing to tissue aging and organ dysfunction.\n\nLIFESTYLE AND TELOMERE LENGTH:\nTelomere length is influenced by both genetic inheritance and modifiable lifestyle factors. Oxidative stress and chronic inflammation accelerate telomere shortening by damaging the guanine-rich telomeric DNA (guanine is particularly susceptible to oxidative modification) and by increasing cell turnover rates. Sedentary behavior, processed meat consumption, smoking, obesity, chronic psychological stress, and sleep deprivation are all associated with shorter telomeres. Conversely, regular physical activity, plant-rich diets, stress management, and adequate sleep are associated with preserved telomere length and increased telomerase activity.\n\nCLINICAL EVIDENCE:\nThe landmark Ornish trial demonstrated that comprehensive lifestyle changes (plant-based diet, moderate exercise, stress management, social support) increased telomerase activity by approximately 30% at 3 months and were associated with telomere lengthening at 5-year follow-up. Processed meats are associated with shorter telomeres likely through their content of heme iron (pro-oxidant), advanced glycation end products (AGEs), nitrosamines, and sodium, all of which promote oxidative stress and inflammation.\n\nKEY POINTS:\nTelomeres shorten with each cell division and are accelerated by oxidative stress and inflammation from sedentary behavior, processed meat consumption, smoking, and chronic stress. The Ornish trial demonstrated that comprehensive lifestyle changes increase telomerase activity by 30% and can lengthen telomeres. Regular physical activity and plant-rich diets are associated with preserved telomere length."
  },
  {
    "id": 287,
    "categoryId": 11,
    "question": "In the treatment of Depression, which nutrient is often depleted and has shown benefit as an adjunct therapy?",
    "options": [
      "A) Vitamin C",
      "B) Omega-3 Fatty Acids (EPA)",
      "C) Calcium",
      "D) Vitamin K"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Omega-3 Fatty Acids, EPA).\n\nEVIDENCE:\nOmega-3 polyunsaturated fatty acids, specifically eicosapentaenoic acid (EPA), have demonstrated benefit as adjunctive therapy for major depressive disorder (MDD) in multiple randomized controlled trials and meta-analyses. A meta-analysis published in Translational Psychiatry pooling over 26 RCTs found that EPA-predominant formulations (EPA alone or with EPA:DHA ratio greater than 2:1) produced statistically significant improvements in depressive symptoms compared to placebo, while DHA-predominant formulations did not. The International Society for Nutritional Psychiatry Research recommends EPA at 1 to 2 grams per day as an adjunct to standard antidepressant therapy.\n\nPATHOPHYSIOLOGY:\nDepression is increasingly understood as a neuroimmune disorder with elevated pro-inflammatory cytokines (IL-6, TNF-alpha, CRP) that disrupt serotonin synthesis, promote tryptophan degradation via the kynurenine pathway, impair BDNF signaling, and contribute to hippocampal neuroinflammation. EPA exerts antidepressant effects by reducing neuroinflammation through multiple mechanisms: it competes with arachidonic acid for cyclooxygenase and lipoxygenase enzymes, shifting eicosanoid production away from pro-inflammatory prostaglandins and leukotrienes toward anti-inflammatory resolvins and protectins. EPA also modulates microglial activation, enhances serotonin release by improving cell membrane fluidity in presynaptic neurons, and supports BDNF expression.\n\nCLINICAL APPLICATION:\nOmega-3 supplementation is most effective as an augmentation strategy when added to standard antidepressant therapy rather than as monotherapy. Patients with elevated inflammatory markers (CRP greater than 3 mg/L) may show the greatest benefit, supporting the neuroinflammatory mechanism. The 2024 ACP guidelines for MDD do not include omega-3 as a primary recommendation but acknowledge accumulating evidence for its adjunctive role. Dietary sources include fatty fish (salmon, mackerel, sardines, anchovies), with supplemental EPA typically delivered as fish oil or purified EPA ethyl ester.\n\nKEY POINTS:\nEPA-predominant omega-3 supplementation (1 to 2 g/day) has evidence as adjunctive therapy for depression, particularly in patients with elevated inflammatory markers. EPA reduces neuroinflammation by competing with arachidonic acid and generating pro-resolving mediators (resolvins, protectins). DHA-predominant formulations have not shown antidepressant efficacy, making the EPA:DHA ratio critical in formulation selection."
  },
  {
    "id": 288,
    "categoryId": 17,
    "question": "Which two carotenoids accumulate in the macula of the eye and protect against Age-Related Macular Degeneration (AMD)?",
    "options": [
      "A) Beta-carotene and Alpha-carotene",
      "B) Lutein and Zeaxanthin",
      "C) Lycopene and Astaxanthin",
      "D) Retinol and Retinal"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lutein and zeaxanthin).\n\nPATHOPHYSIOLOGY:\nLutein and zeaxanthin are xanthophyll carotenoids that accumulate selectively in the macula lutea of the retina, forming the macular pigment. They serve two critical protective functions: filtering high-energy blue light (400-480 nm wavelength) before it reaches the photoreceptors, and scavenging reactive oxygen species generated by the constant photo-oxidative stress in retinal tissue. The macula is especially vulnerable to oxidative damage due to its high metabolic rate, dense concentration of polyunsaturated fatty acids, and intense light exposure.\n\nCLINICAL CONTEXT:\nAge-related macular degeneration (AMD) is the leading cause of irreversible blindness in adults over 50 in developed countries. The AREDS2 trial (Age-Related Eye Disease Study 2, NEI/NIH) established the current evidence-based supplementation formula for patients with intermediate or advanced AMD:\n- Vitamin C 500 mg\n- Vitamin E 400 IU\n- Lutein 10 mg + Zeaxanthin 2 mg (replaced beta-carotene from the original AREDS formula)\n- Zinc 80 mg + Copper 2 mg\n\nCRITICAL UPDATE:\nAREDS2 replaced beta-carotene with lutein/zeaxanthin because beta-carotene significantly increases lung cancer risk in current and former smokers (per the CARET and ATBC trials). Lutein and zeaxanthin demonstrated equivalent or superior efficacy without this risk.\n\nDIETARY SOURCES:\n- Lutein/zeaxanthin: Dark leafy greens (kale, spinach, collards), egg yolks, corn, orange peppers\n- Higher dietary intake is independently associated with reduced AMD risk in epidemiologic studies\n\nPRIMARY CARE PEARL:\nAREDS2 supplements are recommended only for intermediate or advanced AMD, not for primary prevention. Smoking cessation remains the single most impactful modifiable risk factor for AMD prevention.\n\nKEY POINTS:\nLutein and zeaxanthin are the macular carotenoids that filter blue light and provide antioxidant protection. The AREDS2 formula uses lutein/zeaxanthin instead of beta-carotene to avoid increased lung cancer risk in smokers. AREDS2 supplementation is indicated for intermediate and advanced AMD, not for primary prevention.\n---"
  },
  {
    "id": 289,
    "categoryId": 16,
    "question": "Erectile Dysfunction (ED) is often considered:",
    "options": [
      "A) A normal part of aging",
      "B) The 'Canary in the Coal Mine' for Cardiovascular Disease",
      "C) Only a hormonal issue (Low T)",
      "D) A psychological issue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The 'Canary in the Coal Mine' for Cardiovascular Disease).\n\nPATHOPHYSIOLOGY:\nErectile dysfunction (ED) is now recognized as an early clinical manifestation of systemic endothelial dysfunction and atherosclerosis that often precedes symptomatic coronary artery disease by 3 to 5 years. The mechanistic basis for this temporal relationship is vascular diameter: the penile arteries (1 to 2 mm diameter) are smaller than the coronary arteries (3 to 4 mm), carotid arteries (5 to 7 mm), and iliac/femoral arteries (6 to 8 mm). Because atherosclerotic plaque develops systemically, the smallest-diameter arteries become flow-limiting first, making ED the earliest clinical symptom of generalized vascular disease.\n\nENDOTHELIAL DYSFUNCTION:\nErection depends on nitric oxide (NO) release from endothelial cells and nitrergic nerves in the corpus cavernosum, which activates guanylate cyclase, increases cGMP, and produces smooth muscle relaxation and blood engorgement. The same endothelial dysfunction (reduced NO bioavailability from oxidative stress, inflammation, and dyslipidemia) that impairs erectile function also underlies coronary endothelial dysfunction and accelerates atherogenesis.\n\nCLINICAL SIGNIFICANCE:\nMultiple large prospective studies have demonstrated that ED is an independent risk factor for future myocardial infarction, stroke, and cardiovascular death, with a relative risk increase of approximately 1.5 to 2.0-fold. A man presenting with new-onset ED (particularly if under age 60 with no obvious psychological or medication-related cause) should be evaluated for cardiovascular risk factors including lipid panel, fasting glucose, blood pressure, smoking status, and family history. The Princeton III Consensus guidelines recommend cardiovascular risk stratification for all men with ED.\n\nKEY POINTS:\nED is an early marker of systemic atherosclerosis that precedes symptomatic coronary disease by 3 to 5 years because penile arteries (1 to 2 mm) occlude before larger coronary arteries (3 to 4 mm). ED results from endothelial dysfunction with reduced nitric oxide bioavailability, the same mechanism underlying coronary disease. Men with new-onset ED should undergo cardiovascular risk factor assessment."
  },
  {
    "id": 290,
    "categoryId": 16,
    "question": "Which vitamin prevents Neural Tube Defects and should be supplemented BEFORE conception?",
    "options": [
      "A) Vitamin D",
      "B) Folate (Vitamin B9)",
      "C) Vitamin B12",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Folate, Vitamin B9).\n\nPATHOPHYSIOLOGY:\nNeural tube closure occurs between days 21 and 28 after conception (approximately 6 weeks gestational age), before most women are aware of their pregnancy. Folate (vitamin B9) is essential for DNA synthesis, specifically providing one-carbon units for thymidylate synthase (converting deoxyuridylate to thymidylate) and for purine synthesis, both of which are required for the rapid cell division occurring during neural tube closure. Folate deficiency during this critical window impairs neural tube fusion, resulting in anencephaly (failure of cranial neural tube closure, uniformly fatal) or spina bifida (failure of caudal neural tube closure, causing paralysis and neurogenic bladder).\n\nPREVENTION:\nThe USPSTF recommends that all women of reproductive age who are planning or capable of pregnancy take a daily folic acid supplement of 400 to 800 micrograms beginning at least one month before conception and continuing through the first trimester. Women with a prior pregnancy affected by a neural tube defect require a higher dose of 4 mg daily. The United States mandated folic acid fortification of enriched grain products (flour, bread, cereals, pasta) in 1998, which has reduced the incidence of neural tube defects by approximately 25 to 30%.\n\nDIETARY SOURCES:\nFolate-rich foods include dark leafy greens (spinach, kale), legumes (lentils, chickpeas), asparagus, citrus fruits, and fortified grains. The synthetic form (folic acid) used in supplements and fortification has approximately 70% higher bioavailability than natural food folate because it does not require enzymatic conversion by dihydrofolate reductase before entering the folate cycle.\n\nKEY POINTS:\nFolic acid supplementation (400 to 800 mcg daily) must begin before conception because neural tube closure occurs by day 28 (before most women know they are pregnant). USPSTF recommends supplementation for all women of reproductive age capable of pregnancy. US grain fortification since 1998 has reduced neural tube defects by approximately 25 to 30%."
  },
  {
    "id": 291,
    "categoryId": 14,
    "question": "The World Health Organization (WHO) classifies Processed Meat (Bacon, Sausage, Deli meat) as:",
    "options": [
      "A) Group 2A: Probably Carcinogenic",
      "B) Group 1: Carcinogenic to Humans (Same category as Tobacco/Asbestos)",
      "C) Group 2B: Possibly Carcinogenic",
      "D) Safe in moderation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group 1: Carcinogenic to Humans).\n\nCLASSIFICATION:\nThe International Agency for Research on Cancer, a specialized agency of the World Health Organization, classified processed meat as a Group 1 carcinogen in 2015, placing it in the same evidence category as tobacco smoking and asbestos. This classification means there is sufficient epidemiologic and mechanistic evidence to conclude that processed meat causes cancer in humans, specifically colorectal cancer. Processed meat includes any meat transformed through salting, curing, fermentation, smoking, or other preservation processes, such as bacon, sausage, hot dogs, deli meats, and ham. Red meat (beef, pork, lamb) was classified as Group 2A (probably carcinogenic), one tier below.\n\nPATHOPHYSIOLOGY:\nSeveral mechanisms explain the carcinogenicity of processed meat. N-nitroso compounds are formed endogenously when nitrites and nitrates used as preservatives react with amino acids in the gastrointestinal tract, producing potent alkylating agents that directly damage colonocyte DNA. Heme iron catalyzes lipid peroxidation in the colonic lumen, generating cytotoxic and genotoxic aldehydes. Heterocyclic amines and polycyclic aromatic hydrocarbons produced during high-temperature cooking are established mutagens. The IARC meta-analysis estimated that each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18%.\n\nCLINICAL APPLICATION:\nThe American Institute for Cancer Research and World Cancer Research Fund recommend limiting red meat to no more than three servings per week (approximately 350 to 500 grams cooked weight) and avoiding processed meat entirely for cancer prevention. In primary care, replacing processed meats with poultry, fish, legumes, or plant-based protein is a meaningful and achievable risk reduction strategy, particularly for patients with additional colorectal cancer risk factors.\n\nKEY POINTS:\nProcessed meat is a WHO/IARC Group 1 carcinogen with sufficient evidence for causing colorectal cancer, while red meat is Group 2A (probable carcinogen). Each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18% through N-nitroso compound formation, heme iron-catalyzed lipid peroxidation, and heterocyclic amine generation. The AICR recommends avoiding processed meat and limiting red meat to three or fewer servings per week."
  },
  {
    "id": 292,
    "categoryId": 16,
    "question": "Soluble Fiber (Oats, Beans) lowers cholesterol by:",
    "options": [
      "A) Binding bile acids in the gut and excreting them",
      "B) Speeding up metabolism",
      "C) Blocking fat digestion",
      "D) Dilating blood vessels"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Binding bile acids in the gut and excreting them).\n\nMECHANISM:\nSoluble fiber (found in oats, beans, barley, psyllium, flaxseed, and apples) forms a viscous gel in the intestinal lumen that physically entraps bile acids and prevents their reabsorption in the terminal ileum. Normally, approximately 95% of bile acids are efficiently recycled through enterohepatic circulation, returning to the liver via the portal vein. When soluble fiber binds bile acids and carries them out in the feces, the liver must synthesize replacement bile acids from its primary substrate: cholesterol.\n\nHEPATIC RESPONSE:\nThe resulting hepatic cholesterol depletion triggers a compensatory upregulation of LDL receptor expression on hepatocyte surfaces (mediated by SREBP-2, the same transcription factor pathway activated by statins), increasing clearance of LDL-cholesterol from the bloodstream. This mechanism is additive with statin therapy, which is why adding soluble fiber to statin treatment produces additional LDL lowering beyond statin monotherapy.\n\nCLINICAL EVIDENCE:\nMeta-analyses demonstrate that 5 to 10 grams per day of soluble fiber reduces LDL cholesterol by approximately 5 to 10%. Psyllium husk (Metamucil) at 10 to 12 grams per day and beta-glucan from oats at 3 grams per day are the best-studied soluble fibers for cholesterol reduction. The 2018 ACC/AHA Cholesterol Guidelines include increased soluble fiber intake as a recommended lifestyle intervention to enhance LDL lowering. Beyond bile acid binding, soluble fiber also reduces cholesterol absorption, slows gastric emptying (improving postprandial glycemia), and produces short-chain fatty acids through colonic fermentation that may independently modulate hepatic cholesterol synthesis.\n\nKEY POINTS:\nSoluble fiber lowers LDL cholesterol by binding bile acids in the gut and forcing hepatic bile acid resynthesis from cholesterol, which upregulates LDL receptor expression via SREBP-2. This mechanism is additive with statins. Five to 10 grams per day of soluble fiber (oats, psyllium, beans) reduces LDL by approximately 5 to 10%."
  },
  {
    "id": 293,
    "categoryId": 16,
    "question": "Blue Light exposure at night suppresses which hormone?",
    "options": [
      "A) Cortisol",
      "B) Melatonin",
      "C) Insulin",
      "D) Testosterone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Melatonin).\n\nPATHOPHYSIOLOGY:\nBlue light (wavelength approximately 460 to 480 nm), emitted at high intensity by LED screens on smartphones, tablets, computers, and televisions, suppresses melatonin secretion by activating intrinsically photosensitive retinal ganglion cells (ipRGCs) that contain the photopigment melanopsin. These ipRGCs project via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), the master circadian clock in the anterior hypothalamus, which in turn inhibits the pineal gland from producing melatonin.\n\nMELATONIN PHYSIOLOGY:\nMelatonin is a chronobiotic hormone secreted by the pineal gland in response to darkness, with levels rising approximately 2 hours before habitual bedtime (dim light melatonin onset, DLMO) and peaking between 2 and 4 AM. Melatonin does not directly induce sleep but rather signals to the brain that it is nighttime, promoting sleep onset and circadian entrainment. Even relatively low levels of evening blue light exposure (100 to 200 lux from a tablet at reading distance) can suppress melatonin production by up to 50% and delay DLMO by 1 to 2 hours.\n\nCLINICAL APPLICATION:\nSleep hygiene recommendations include avoiding screen use for 1 to 2 hours before bedtime, using blue-light-filtering glasses or device settings (night mode) in the evening, and maximizing bright light exposure during the daytime to reinforce robust circadian rhythms. Exogenous melatonin (0.5 to 3 mg taken 1 to 2 hours before desired bedtime) is most effective for circadian rhythm disorders (jet lag, delayed sleep-wake phase disorder, shift work disorder) rather than primary insomnia.\n\nKEY POINTS:\nBlue light (460 to 480 nm) from screens suppresses melatonin by activating melanopsin-containing retinal ganglion cells that signal the SCN to inhibit pineal gland secretion. Even low-intensity evening screen exposure can suppress melatonin by 50% and delay sleep onset by 1 to 2 hours. Screen avoidance before bedtime and bright daytime light exposure support healthy circadian melatonin rhythms."
  },
  {
    "id": 294,
    "categoryId": 7,
    "question": "According to the American College of Physicians (ACP) guidelines for chronic low back pain, which non-pharmacologic treatment is recommended as a first-line intervention before NSAIDs?",
    "options": [
      "A) Bed rest",
      "B) Mindfulness-Based Stress Reduction (MBSR), Yoga, or Tai Chi",
      "C) Lumbar support brace",
      "D) TENS unit"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mindfulness-Based Stress Reduction, Yoga, or Tai Chi).\n\nPATHOPHYSIOLOGY:\nChronic low back pain (persisting >12 weeks) is the leading cause of disability worldwide. While acute low back pain often involves identifiable musculoligamentous strain or disc pathology, chronic low back pain involves central sensitization, where persistent nociceptive input reorganizes spinal cord and cortical pain circuits, amplifying pain perception after initial tissue injury has healed. Psychosocial factors (catastrophizing, fear-avoidance, depression, poor self-efficacy) are stronger predictors of chronicity than structural imaging findings, supporting the biopsychosocial model endorsed by the ACP, APS, and international guidelines.\n\nCLINICAL EVIDENCE:\nThe 2017 ACP clinical practice guideline (Annals of Internal Medicine) strongly recommends non-pharmacologic treatment before medications. Mindfulness-based stress reduction (8-week program of meditation, body scanning, yoga) demonstrated clinically meaningful improvements by modulating affective and cognitive pain dimensions through prefrontal cortical regulation of the amygdala and anterior cingulate cortex. Yoga (viniyoga, Iyengar styles) improved pain, function, and disability at 12 weeks versus usual care, with benefits sustained at 6-12 months. Tai chi showed similar benefits through improved core stability, proprioception, and pain self-efficacy. Additional supported options include exercise therapy, multidisciplinary rehabilitation, acupuncture, spinal manipulation, and CBT.\n\nTREATMENT AND MANAGEMENT:\nWhen non-pharmacologic therapies are insufficient, the ACP recommends NSAIDs as first-line pharmacotherapy, with tramadol or duloxetine as second-line. Opioids should be considered only as last resort after thorough risk discussion. Acetaminophen is not recommended based on evidence showing no benefit over placebo. Systemic corticosteroids, benzodiazepines, and gabapentinoids lack sufficient supporting evidence. Imaging should be reserved for red flag symptoms (progressive neurologic deficit, suspected cancer, infection, cauda equina syndrome).\n\nKEY POINTS:\nThe ACP strongly recommends non-pharmacologic therapies including mindfulness-based stress reduction, yoga, and tai chi as first-line for chronic low back pain before medications. These mind-body interventions address central sensitization and fear-avoidance behavior, which are stronger disability predictors than structural findings. When pharmacotherapy is needed, NSAIDs are first-line, acetaminophen is not recommended, and opioids are last resort."
  },
  {
    "id": 295,
    "categoryId": 3,
    "question": "Which herbal supplement has strong evidence (and ACG guideline support) for reducing abdominal pain and bloating in IBS via calcium channel blockade in smooth muscle?",
    "options": [
      "A) Ginger",
      "B) Peppermint Oil",
      "C) Aloe Vera",
      "D) Slippery Elm"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Peppermint Oil).\n\nPATHOPHYSIOLOGY:\nAbdominal pain and cramping in IBS result from exaggerated smooth muscle contractions in the colon combined with visceral hypersensitivity. The smooth muscle tone of the gastrointestinal tract is regulated in part by voltage-gated calcium channels; when calcium influx is reduced, smooth muscle relaxes and spasm-associated pain diminishes.\n\nMECHANISM OF ACTION:\nL-menthol, the primary active constituent of peppermint oil, acts as a natural calcium channel antagonist on intestinal smooth muscle cells. By blocking calcium influx through L-type voltage-gated calcium channels, it produces direct smooth muscle relaxation, reduces colonic motility, and decreases spasm-related pain. Additionally, peppermint oil activates TRPM8 (cold-sensing) receptors and kappa-opioid receptors in the gut, which contribute to its analgesic and anti-nociceptive effects. A meta-analysis of randomized controlled trials demonstrated that peppermint oil significantly improves global IBS symptoms and abdominal pain compared to placebo, with a number needed to treat of approximately 3-4.\n\nCLINICAL APPLICATION:\nThe ACG guidelines conditionally recommend enteric-coated peppermint oil capsules for IBS-related abdominal pain. Enteric coating is essential to prevent premature release in the stomach, which can cause heartburn by relaxing the lower esophageal sphincter. The typical dose is 180-200 mg taken 30-60 minutes before meals, two to three times daily. Peppermint oil should be used with caution in patients with severe GERD. Other antispasmodic options include dicyclomine and hyoscyamine (anticholinergic agents), though peppermint oil has a more favorable side-effect profile.\n\nKEY POINTS:\nPeppermint oil acts as a natural calcium channel blocker on intestinal smooth muscle and has ACG guideline support for IBS-related pain. Enteric-coated capsules are essential to prevent heartburn from LES relaxation. The number needed to treat is approximately 3-4 for global IBS symptom improvement. It should be taken 30-60 minutes before meals."
  },
  {
    "id": 296,
    "categoryId": 6,
    "question": "Which two supplements have Level A/B evidence from the American Academy of Neurology for migraine prophylaxis?",
    "options": [
      "A) Vitamin C and Zinc",
      "B) Magnesium and Riboflavin (Vitamin B2)",
      "C) Calcium and Vitamin D",
      "D) Fish Oil and Vitamin E"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium and Riboflavin/Vitamin B2).\n\nEVIDENCE-BASED SUPPLEMENTS FOR MIGRAINE PROPHYLAXIS:\nThe American Academy of Neurology (AAN) and the American Headache Society have reviewed evidence for complementary migraine prophylaxis. Magnesium (400 to 600 mg daily) and riboflavin (vitamin B2, 400 mg daily) carry Level B evidence (probably effective) for reducing migraine frequency. These supplements are particularly appealing for patients who prefer non-pharmacologic approaches or who have contraindications to standard prophylactic medications.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nMagnesium helps neuronal stability and neurotransmitter release. Magnesium deficiency has been demonstrated in the serum and brain tissue of migraine patients, and supplementation stabilizes neuronal membranes, blocks NMDA glutamate receptors, and reduces cortical spreading depression (the electrophysiological basis of migraine aura). Riboflavin is a precursor to flavin mononucleotide (FMN) and flavin adenine dinucleotide (FAD), essential cofactors in mitochondrial oxidative phosphorylation. Impaired mitochondrial energy metabolism has been implicated in migraine pathogenesis, and riboflavin supplementation enhances cerebral energy production.\n\nADDITIONAL SUPPLEMENTS WITH EVIDENCE:\nCoenzyme Q10 (100 mg three times daily) and feverfew also have supporting evidence, though less robust than magnesium and riboflavin. Butterbur (Petasites) previously had Level A evidence but was withdrawn from the market in some countries due to hepatotoxicity concerns from pyrrolizidine alkaloids.\n\nCOMPREHENSIVE MIGRAINE MANAGEMENT:\nFor acute treatment, NSAIDs and triptans are first-line (triptans for moderate to severe attacks). Prophylaxis is indicated when migraines occur four or more days per month or cause significant disability. First-line pharmacologic prophylaxis includes beta-blockers (propranolol), topiramate, valproate, and amitriptyline. CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab) represent a newer targeted approach. Medication overuse headache should be avoided by limiting acute analgesic use to fewer than 10 days per month.\n\nKEY POINTS:\nMagnesium and riboflavin carry AAN Level B evidence for migraine prophylaxis through neuronal membrane stabilization and mitochondrial energy enhancement respectively. Prophylaxis is indicated for four or more migraine days per month. Supplements can be combined with standard pharmacologic prophylaxis for additive benefit."
  },
  {
    "id": 297,
    "categoryId": 3,
    "question": "Ginger is clinically proven and safe for nausea in which condition, supported by ACOG (OBGYN) guidelines?",
    "options": [
      "A) Opioid-induced nausea",
      "B) Pregnancy-induced nausea (Morning Sickness)",
      "C) Vertigo",
      "D) Diabetic Gastroparesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pregnancy-induced nausea/Morning Sickness).\n\nPATHOPHYSIOLOGY:\nNausea and vomiting of pregnancy (NVP) affects approximately 70-80% of pregnant women, typically beginning between weeks 4-7 of gestation and resolving by weeks 12-16. The exact pathophysiology involves rising levels of human chorionic gonadotropin (hCG), estrogen, and progesterone, as well as alterations in gastric motility and enhanced olfactory sensitivity. The term \"morning sickness\" is a misnomer, as symptoms can occur at any time of day.\n\nMECHANISM OF ACTION:\nGinger (Zingiber officinale) contains bioactive compounds, primarily gingerols and shogaols, that exert antiemetic effects through multiple mechanisms: antagonism of serotonin 5-HT3 receptors in the gastrointestinal tract and chemoreceptor trigger zone (the same target as ondansetron), direct prokinetic effects that accelerate gastric emptying, and cholinergic antagonism in the vestibular system. Multiple randomized controlled trials have demonstrated that ginger at doses of 1 gram per day in divided doses (typically 250 mg four times daily) significantly reduces nausea and vomiting in pregnancy compared to placebo.\n\nGUIDELINE SUPPORT:\nThe American College of Obstetricians and Gynecologists (ACOG) recommends ginger as a first-line non-pharmacologic intervention for NVP. It is classified as safe in pregnancy with no evidence of teratogenicity, increased risk of preterm birth, or adverse neonatal outcomes at recommended doses. Ginger can be used alone for mild symptoms or in combination with pyridoxine (vitamin B6) and doxylamine, which is the ACOG-recommended first-line pharmacologic regimen.\n\nKEY POINTS:\nGinger at 1 gram per day in divided doses is an ACOG-recommended first-line non-pharmacologic treatment for pregnancy-induced nausea. It acts primarily through serotonin 5-HT3 receptor antagonism and prokinetic effects. No evidence of teratogenicity exists at recommended doses. It can be used alone for mild symptoms or in combination with vitamin B6 and doxylamine."
  },
  {
    "id": 298,
    "categoryId": 11,
    "question": "S-Adenosylmethionine (SAMe) is an over-the-counter supplement used for Depression. What is a critical risk to screen for before a patient takes it?",
    "options": [
      "A) Iron deficiency",
      "B) Bipolar Disorder",
      "C) Gout",
      "D) Hypertension"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bipolar Disorder).\n\nCLINICAL REASONING:\nS-Adenosylmethionine (SAMe) is a naturally occurring methyl donor involved in over 100 methylation reactions in the body, including the synthesis of monoamine neurotransmitters (serotonin, norepinephrine, dopamine). SAMe supplementation enhances monoaminergic neurotransmission, which accounts for its antidepressant properties but also creates the same risk as any monoamine-enhancing agent: the potential to precipitate a manic or hypomanic episode in patients with undiagnosed or known bipolar disorder.\n\nEVIDENCE FOR ANTIDEPRESSANT EFFICACY:\nSeveral randomized controlled trials have demonstrated that SAMe (800 to 1,600 mg/day) is superior to placebo and comparable to tricyclic antidepressants for mild to moderate unipolar depression. An AHRQ systematic review concluded that SAMe has evidence supporting its use for depression, though the overall quality of available trials is moderate. SAMe is available as an over-the-counter dietary supplement in the United States (it is a prescription medication in several European countries) and has a generally favorable side effect profile including mild GI upset, insomnia, and anxiety.\n\nMANIC SWITCH RISK:\nJust as SSRI monotherapy can trigger mania in bipolar patients, SAMe augmentation of monoamine neurotransmission can precipitate manic episodes in patients with bipolar disorder. Case reports document SAMe-induced mania, hypomania, and mixed states. Before recommending or approving SAMe for any patient with depressive symptoms, clinicians must screen for a history of manic or hypomanic episodes (decreased need for sleep, racing thoughts, grandiosity, impulsive behavior, pressured speech) using tools such as the Mood Disorder Questionnaire (MDQ).\n\nKEY POINTS:\nSAMe is an endogenous methyl donor that enhances monoamine neurotransmitter synthesis and has evidence for mild to moderate unipolar depression. The critical risk before use is undiagnosed bipolar disorder, as SAMe can precipitate manic episodes through the same monoaminergic mechanism that produces its antidepressant effect. Clinicians must screen for prior manic or hypomanic episodes before any patient takes SAMe."
  },
  {
    "id": 299,
    "categoryId": 1,
    "question": "Coenzyme Q10 (CoQ10) is often recommended for patients on Statins to address which side effect?",
    "options": [
      "A) Liver toxicity",
      "B) Statin-Associated Muscle Symptoms (SAMS)",
      "C) Cognitive decline",
      "D) Insomnia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Statin-Associated Muscle Symptoms).\n\nCLINICAL REASONING:\nCoenzyme Q10 (ubiquinone) is an essential cofactor in the mitochondrial electron transport chain (complexes I through III) and a potent lipid-soluble antioxidant. Statins inhibit HMG-CoA reductase in the mevalonate pathway, which is also the biosynthetic pathway for CoQ10 (the mevalonate pathway produces both cholesterol and CoQ10 via a shared farnesyl pyrophosphate intermediate). By reducing mevalonate production, statins decrease endogenous CoQ10 synthesis by approximately 20 to 40%, leading to reduced serum and potentially reduced skeletal muscle CoQ10 levels.\n\nPATHOPHYSIOLOGY:\nStatin-associated muscle symptoms (SAMS) encompass a spectrum from myalgia (muscle pain without CK elevation, the most common form affecting 5 to 10% of statin users) to myopathy (muscle pain with elevated CK) to the rare but serious rhabdomyolysis (massive CK elevation with myoglobinuria and risk of acute kidney injury). The CoQ10 depletion hypothesis proposes that reduced mitochondrial CoQ10 impairs oxidative phosphorylation in skeletal muscle, leading to energy deficit, increased oxidative stress, and muscle fiber damage.\n\nEVIDENCE AND RECOMMENDATIONS:\nThe evidence for CoQ10 supplementation alleviating SAMS remains mixed, with some randomized controlled trials showing modest benefit and others showing no significant difference from placebo. Despite this inconsistency, CoQ10 supplementation (100 to 200 mg daily) is commonly recommended as a low-risk intervention given its favorable safety profile and the plausible mechanistic rationale. The ACC/AHA guidelines note that CoQ10 may be considered for patients with SAMS but do not make a strong recommendation due to insufficient evidence.\n\nKEY POINTS:\nCoQ10 supplementation targets statin-associated muscle symptoms because statins reduce endogenous CoQ10 production through the shared mevalonate biosynthetic pathway. SAMS ranges from myalgia (5 to 10% of users) to rare rhabdomyolysis. Evidence for CoQ10 benefit is mixed, but supplementation (100 to 200 mg daily) is a reasonable low-risk intervention."
  },
  {
    "id": 300,
    "categoryId": 16,
    "question": "Melatonin is most effective for which type of sleep disturbance?",
    "options": [
      "A) Sleep Maintenance Insomnia (waking up at 2 AM)",
      "B) Circadian Rhythm Disorders (Jet Lag / Shift Work) and Sleep Onset",
      "C) Sleep Apnea",
      "D) Restless Leg Syndrome"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Circadian Rhythm Disorders such as Jet Lag and Shift Work, and Sleep Onset).\n\nPHARMACOLOGY:\nMelatonin is a chronobiotic (circadian rhythm-shifting) agent, not a conventional sedative-hypnotic. Unlike benzodiazepines or Z-drugs (zolpidem, zaleplon) that induce sleep through GABAergic sedation, melatonin works by binding to MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN), signaling darkness to the master circadian clock and shifting the timing of sleep propensity. This mechanism makes melatonin most effective for conditions involving circadian misalignment rather than primary insomnia.\n\nEVIDENCE BY INDICATION:\nFor jet lag, a Cochrane systematic review concluded that melatonin (0.5 to 5 mg taken at destination bedtime) is effective, particularly for eastward travel across 5 or more time zones. For delayed sleep-wake phase disorder (common in adolescents and young adults), low-dose melatonin (0.5 to 1 mg) administered 3 to 5 hours before habitual sleep onset can advance the circadian clock and improve sleep onset timing. For shift work disorder, melatonin taken before the desired daytime sleep period modestly improves sleep duration. For primary insomnia without circadian misalignment, melatonin's evidence is weaker and effect sizes are small (reducing sleep onset latency by approximately 7 minutes in meta-analyses).\n\nCLINICAL PEARLS:\nMelatonin has a favorable safety profile with no significant dependence, tolerance, or withdrawal. Timing of administration is more important than dose: for sleep onset, take 1 to 2 hours before desired bedtime; for circadian advance (jet lag, DSWPD), take 3 to 5 hours before habitual sleep onset. Ramelteon (Rozerem) is a prescription MT1/MT2 agonist FDA-approved for insomnia with sleep onset difficulty, with no abuse potential or DEA scheduling.\n\nKEY POINTS:\nMelatonin is a chronobiotic agent most effective for circadian rhythm disorders (jet lag, delayed sleep phase, shift work) rather than primary insomnia. It works by signaling darkness to the SCN via MT1/MT2 receptors, not through sedation. Timing of administration is more important than dose, and it has no significant dependence or tolerance potential."
  },
  {
    "id": 301,
    "categoryId": 13,
    "question": "Turmeric (Curcumin) has poor bioavailability on its own. It should be consumed with ______ to increase absorption by 2000%.",
    "options": [
      "A) Vitamin C",
      "B) Black Pepper (Piperine) and Fat",
      "C) Sugar",
      "D) Protein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Black Pepper containing Piperine, and Fat).\n\nPHARMACOKINETICS OF CURCUMIN:\nCurcumin, the principal bioactive polyphenol in turmeric (Curcuma longa), has potent anti-inflammatory and antioxidant properties in vitro but is limited by extremely poor oral bioavailability, estimated at less than 1 percent. The primary pharmacokinetic barriers are rapid Phase II hepatic metabolism (glucuronidation and sulfation), rapid intestinal metabolism, poor aqueous solubility, and limited gastrointestinal absorption. Without enhancement strategies, orally administered curcumin is largely metabolized before reaching systemic circulation, resulting in negligible plasma concentrations.\n\nPIPERINE ENHANCEMENT MECHANISM:\nPiperine, an alkaloid found in black pepper (Piper nigrum), dramatically enhances curcumin bioavailability by approximately 2,000 percent. published in Planta Medica. Piperine achieves this by inhibiting hepatic and intestinal glucuronidation, the primary pathway of curcumin elimination. Specifically, piperine inhibits UDP-glucuronosyltransferase enzymes, slowing the conjugation and clearance of curcumin and allowing it to remain in its unconjugated, bioactive form in plasma for longer. Additionally, piperine may enhance absorption by increasing intestinal permeability and inhibiting intestinal P-glycoprotein efflux pumps.\n\nROLE OF DIETARY FAT:\nCurcumin is highly lipophilic and poorly soluble in water. Co-administration with dietary fat enhances absorption by promoting incorporation into mixed micelles during digestion, facilitating transport across the intestinal epithelium via lymphatic uptake rather than portal circulation. This bypasses first-pass hepatic metabolism, further improving bioavailability. Novel formulations including liposomal curcumin, nanoparticle preparations, and curcumin-phospholipid complexes exploit this lipophilicity to achieve even greater absorption.\n\nKEY POINTS:\nCurcumin has less than 1 percent oral bioavailability due to rapid hepatic glucuronidation and poor water solubility. Piperine from black pepper inhibits glucuronidation, increasing curcumin bioavailability by approximately 2,000 percent. Co-administration with fat enhances absorption through micelle formation and lymphatic uptake. Patients interested in curcumin supplementation should be advised to take it with black pepper and a fat-containing meal."
  },
  {
    "id": 302,
    "categoryId": 11,
    "question": "Which herbal supplement has demonstrated efficacy comparable to Benzodiazepines for Generalized Anxiety Disorder (GAD) in some trials, but carries a risk of hepatotoxicity?",
    "options": [
      "A) Valerian Root",
      "B) Kava Kava",
      "C) Chamomile",
      "D) Lavender"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Kava Kava).\n\nEVIDENCE:\nKava (Piper methysticum), a plant native to the South Pacific, has demonstrated anxiolytic efficacy comparable to low-dose benzodiazepines in several randomized controlled trials for generalized anxiety disorder. A Cochrane systematic review of 11 RCTs found that kava extract significantly reduced anxiety symptoms compared to placebo, with effect sizes approaching those of standard anxiolytic medications. The active compounds, kavalactones (particularly kavain, dihydrokavain, and methysticin), modulate GABA-A receptor binding, inhibit voltage-gated sodium and calcium channels, reduce norepinephrine reuptake, and modulate MAO-B activity.\n\nHEPATOTOXICITY RISK:\nDespite its anxiolytic efficacy, kava carries a significant risk of hepatotoxicity ranging from transient liver enzyme elevation to fulminant hepatic failure requiring liver transplantation. This led to kava being banned or restricted in several European countries (Germany, France, United Kingdom, Switzerland) in the early 2000s, though some restrictions have since been relaxed. The mechanism of hepatotoxicity is not fully understood but may involve CYP2D6 poor metabolizer phenotype (concentrating hepatotoxic metabolites), glutathione depletion in the liver, inhibition of cyclooxygenase enzymes, or contamination with hepatotoxic stem peelings in low-quality preparations.\n\nCLINICAL APPLICATION:\nGiven the hepatotoxicity risk, kava is not recommended as a first-line treatment for anxiety by any major medical guideline. Patients who choose to use kava should be counseled about liver toxicity risk, should have baseline and periodic liver function monitoring, and should avoid concurrent use of alcohol, acetaminophen, or other hepatotoxic substances. Safer evidence-based alternatives for GAD include CBT, SSRIs (sertraline, escitalopram), SNRIs (venlafaxine, duloxetine), and buspirone.\n\nKEY POINTS:\nKava has demonstrated anxiolytic efficacy comparable to benzodiazepines through GABA-A modulation and sodium/calcium channel effects. However, it carries significant hepatotoxicity risk including fulminant liver failure, leading to bans in several European countries. Kava is not recommended as first-line therapy; CBT, SSRIs, and SNRIs are preferred for GAD."
  },
  {
    "id": 303,
    "categoryId": 3,
    "question": "The probiotic yeast *Saccharomyces boulardii* has the strongest evidence for preventing:",
    "options": [
      "A) Constipation",
      "B) Antibiotic-Associated Diarrhea and C. diff recurrence",
      "C) Acid Reflux",
      "D) Gastroparesis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Antibiotic-associated diarrhea and C. difficile recurrence).\n\nPATHOPHYSIOLOGY:\nAntibiotic-associated diarrhea (AAD) occurs in approximately 5-35% of patients receiving antibiotics, resulting from disruption of the normal colonic microbiome that allows overgrowth of pathogenic organisms (particularly C. difficile) and loss of the metabolic functions provided by commensal bacteria (including short-chain fatty acid production and bile acid metabolism). C. difficile recurrence affects approximately 20-25% of patients after initial treatment, driven by persistent spore colonization in a microbiome that lacks the competitive exclusion provided by normal flora.\n\nMECHANISM OF ACTION:\nSaccharomyces boulardii is a non-pathogenic yeast (taxonomically a strain of S. cerevisiae) with unique properties that make it an ideal probiotic for antibiotic-associated conditions. As a yeast, it is inherently resistant to all antibacterial antibiotics and can therefore maintain its population during antibiotic therapy. Its protective mechanisms include secretion of a 54-kDa serine protease that cleaves C. difficile toxin A and its receptor, stimulation of secretory IgA production, enhancement of enterocyte brush border enzyme activity, and trophic effects on intestinal mucosa through release of polyamines.\n\nCLINICAL EVIDENCE:\nMeta-analyses of randomized controlled trials demonstrate that S. boulardii reduces the risk of antibiotic-associated diarrhea by approximately 50% (number needed to treat of approximately 10) and reduces C. difficile recurrence by approximately 50-60% when used as adjunctive therapy with standard antibiotic treatment. The typical dose is 250-500 mg twice daily, started with the first antibiotic dose and continued for 2-4 weeks after antibiotic completion. S. boulardii should not be used in immunocompromised patients or those with central venous catheters due to rare reports of fungemia.\n\nKEY POINTS:\nS. boulardii has the strongest probiotic evidence base for preventing antibiotic-associated diarrhea and reducing C. difficile recurrence. As a yeast, it is resistant to antibacterial antibiotics and maintains its activity during antibiotic therapy. It reduces AAD risk by approximately 50% with a number needed to treat of 10. It is contraindicated in immunocompromised patients due to rare fungemia risk."
  },
  {
    "id": 304,
    "categoryId": 6,
    "question": "Biofeedback is an evidence-based therapy effective for:",
    "options": [
      "A) Tension Headaches and Migraines",
      "B) Alzheimer's prevention",
      "C) Parkinson's tremor",
      "D) Stroke recovery"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Tension Headaches and Migraines).\n\nBIOFEEDBACK FOR HEADACHE MANAGEMENT:\nBiofeedback is an evidence-based behavioral therapy recognized by the American Academy of Neurology and the Association for Applied Psychophysiology and Biofeedback as an effective non-pharmacologic treatment for both tension-type headaches and migraines. It carries Grade A evidence for migraine prevention and is recommended as a first-line option in patients who prefer non-pharmacologic therapy, are pregnant, have medication contraindications, or experience medication overuse headache.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nBiofeedback trains patients to gain voluntary control over physiological processes that are normally automatic, including muscle tension, skin temperature, and heart rate variability. Using electronic sensors, patients receive real-time visual or auditory feedback about their physiological state. For tension headaches, electromyographic (EMG) biofeedback monitors trapezius and frontalis muscle tension, teaching patients to recognize and reduce the sustained muscle contraction that perpetuates pain. For migraines, thermal biofeedback trains patients to increase peripheral skin temperature (reflecting vasodilation and sympathetic deactivation), which helps modulate the autonomic nervous system dysregulation implicated in migraine pathogenesis.\n\nCLINICAL EVIDENCE:\nStudies endorsed by the AAN demonstrate that biofeedback reduces headache frequency by 35 to 55% for migraines and 40 to 60% for tension-type headaches, comparable to some pharmacologic prophylactic agents. The effects are durable, with maintained improvement at long-term follow-up. Biofeedback can be combined with cognitive behavioral therapy and relaxation training for enhanced outcomes.\n\nTREATMENT CONTEXT:\nBiofeedback typically requires 8 to 12 sessions with a trained therapist. It is particularly valuable in populations where medication is less desirable, such as pregnant women, children, and patients with polypharmacy. While biofeedback has been investigated in other neurological conditions, the strongest evidence for clinical efficacy remains in headache management.\n\nKEY POINTS:\nBiofeedback carries Grade A evidence for migraine prophylaxis and is effective for both tension-type headaches and migraines. EMG biofeedback targets muscle tension in tension headaches, while thermal biofeedback modulates autonomic function in migraines. It is particularly valuable when pharmacologic therapy is contraindicated or when patients prefer non-drug approaches."
  },
  {
    "id": 305,
    "categoryId": 7,
    "question": "When supplementing Vitamin D for bone health, which other vitamin is often added to ensure Calcium is deposited in bone rather than soft tissue (arteries)?",
    "options": [
      "A) Vitamin A",
      "B) Vitamin K2",
      "C) Vitamin E",
      "D) Vitamin B6"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Vitamin K2).\n\nPATHOPHYSIOLOGY:\nVitamin D3 enhances intestinal calcium absorption by stimulating enterocyte expression of calbindin, TRPV6 calcium channels, and calcium ATPase through calcitriol signaling. However, increased serum calcium alone does not ensure skeletal deposition. Vitamin K2 (menaquinone) is the essential cofactor for gamma-glutamyl carboxylase, which performs post-translational gamma-carboxylation of vitamin K-dependent proteins. Osteocalcin, produced by osteoblasts, requires K2-dependent carboxylation to bind calcium and incorporate it into the hydroxyapatite crystal lattice. Undercarboxylated osteocalcin has markedly reduced calcium-binding capacity, impairing mineralization. Matrix Gla protein, expressed by vascular smooth muscle cells, similarly requires K2-dependent carboxylation to inhibit vascular calcification by chelating calcium from arterial walls.\n\nCLINICAL SIGNIFICANCE:\nThe calcium paradox describes simultaneous osteoporosis (insufficient bone calcium) and vascular calcification (excessive arterial calcium), partly explained by K2 insufficiency impairing both osteocalcin-mediated skeletal deposition and matrix Gla protein-mediated vascular protection. The Rotterdam Study demonstrated higher dietary K2 intake was associated with reduced aortic calcification, cardiovascular mortality, and all-cause mortality. The Prospect-EPIC cohort similarly found menaquinone intake inversely associated with coronary heart disease risk. Large-scale RCTs are still needed for definitive causation.\n\nTREATMENT AND MANAGEMENT:\nMK-7, derived from natto, has a longer half-life (~72 hours versus 1-2 hours for MK-4), providing sustained carboxylation with once-daily dosing. Dietary K2 sources include natto (richest source), hard and soft cheeses, egg yolks, and organ meats, though Western dietary intake is often low. Patients on warfarin or vitamin K antagonists must be counseled that K2 can antagonize anticoagulant effect, as warfarin works by inhibiting the vitamin K-dependent carboxylation cycle. Vitamin K1 (phylloquinone) in green leafy vegetables primarily supports hepatic coagulation factor synthesis with minimal extrahepatic carboxylation activity.\n\nKEY POINTS:\nVitamin K2 activates osteocalcin to deposit calcium into bone and matrix Gla protein to prevent arterial calcification, complementing vitamin D3's role in calcium absorption. The calcium paradox of simultaneous osteoporosis and vascular calcification is partly explained by inadequate K2-dependent carboxylation. Patients on warfarin must be cautioned about K2 supplementation."
  },
  {
    "id": 306,
    "categoryId": 4,
    "question": "Which mineral is often depleted in diabetics and aids in insulin sensitivity?",
    "options": [
      "A) Calcium",
      "B) Magnesium",
      "C) Sodium",
      "D) Iron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Magnesium).\n\nPATHOPHYSIOLOGY:\nMagnesium is a cofactor for over 300 enzymatic reactions, with critical roles in glucose metabolism and insulin signaling. It is required for autophosphorylation of the insulin receptor tyrosine kinase, the essential first step in transducing the insulin signal to intracellular glucose uptake via GLUT4 translocation. When intracellular magnesium is depleted, insulin receptor kinase activity is impaired and PI3K-Akt signaling is attenuated, producing insulin resistance independent of other factors. Magnesium depletion also increases intracellular calcium (magnesium normally antagonizes calcium entry through voltage-gated channels), impairing insulin-stimulated glucose transport and promoting beta-cell dysfunction. Type 2 diabetes patients face a self-reinforcing depletion cycle: insulin resistance reduces renal tubular magnesium reabsorption via TRPM6, and osmotic diuresis from glycosuria further increases urinary wasting. Hypomagnesemia prevalence is 14-48% in type 2 diabetes versus 2.5-15% in the general population (Diabetes Care).\n\nCLINICAL EVIDENCE:\nA meta-analysis (Journal of Internal Medicine; >500,000 participants, 25 prospective cohorts) demonstrated a significant inverse dose-response relationship, with each 100 mg/day magnesium increase associated with 8-13% diabetes risk reduction. The Framingham Offspring Study showed highest-quartile magnesium intake had significantly lower HOMA-IR and fasting insulin. RCTs of magnesium supplementation in type 2 diabetes with hypomagnesemia showed improvements in fasting glucose, HOMA-IR, and HbA1c, though effect sizes are modest (~0.3% HbA1c reduction per meta-analyses in Nutrients and Diabetes, Obesity and Metabolism).\n\nCLINICAL APPLICATION:\nCheck serum magnesium in type 2 diabetes patients, particularly with poor glycemic control, muscle cramps, arrhythmias, or magnesium-depleting medications (loop/thiazide diuretics, PPIs, calcineurin inhibitors). Normal serum magnesium (1.7-2.2 mg/dL) does not exclude intracellular depletion, as only 1% of total body magnesium is extracellular. Magnesium glycinate or taurate are preferred for superior bioavailability and fewer GI side effects versus magnesium oxide (4% bioavailability). Recommended dose: 250-400 mg elemental magnesium daily. Dietary sources include dark leafy greens, nuts, seeds, legumes, and whole grains. Assess renal function before supplementing, as magnesium accumulates with eGFR below 30 mL/min.\n\nKEY POINTS:\nMagnesium is required for insulin receptor tyrosine kinase autophosphorylation and its deficiency directly impairs insulin sensitivity. Hypomagnesemia affects 14-48% of type 2 diabetes patients due to renal wasting and osmotic diuresis. Magnesium glycinate 250-400 mg daily is preferred, and serum levels may not reflect intracellular depletion."
  },
  {
    "id": 307,
    "categoryId": 4,
    "question": "A pregnant patient asks about Acupuncture. The NIH Consensus Statement and clinical trials support its use for:",
    "options": [
      "A) Inducing labor (in late term) and Nausea and Vomiting of Pregnancy (NVP)",
      "B) Preventing Preeclampsia",
      "C) Correcting fetal chromosomal abnormalities",
      "D) Treating Gestational Diabetes"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Inducing labor in late term and Hyperemesis Gravidarum).\n\nPATHOPHYSIOLOGY:\nAcupuncture involves inserting thin needles at specific anatomical points to modulate physiologic processes. Relevant mechanisms in pregnancy include endorphin release, autonomic nervous system modulation, prostaglandin and oxytocin signaling alteration, and activation of descending inhibitory pain pathways. For pregnancy-related nausea, acupuncture and acupressure at Pericardium 6 (P6/Neiguan), located on the volar forearm approximately 2 inches proximal to the wrist crease between palmaris longus and flexor carpi radialis tendons, modulates vagal afferent signaling to the chemoreceptor trigger zone and nucleus tractus solitarius, reducing the emetic reflex. For labor induction, points including SP6, LI4, and BL67 may stimulate uterine contractility through enhanced oxytocin receptor sensitivity and prostaglandin release.\n\nCLINICAL EVIDENCE:\nThe 1997 NIH Consensus Statement identified pregnancy-related nausea as a condition with sufficient evidence for acupuncture recommendation. A Cochrane review found evidence supporting P6 acupressure for reducing nausea severity. Acupressure wristbands (Sea-Bands) targeting P6 offer a patient-directed option. For labor induction, a BJOG systematic review found acupuncture associated with improved cervical ripening (Bishop score) and reduced need for medical induction in post-term pregnancies, though evidence quality was moderate. Moxibustion at BL67 for breech presentation has some evidence of increased cephalic version rates per Cochrane review.\n\nCLINICAL APPLICATION:\nAcupuncture by trained, licensed practitioners using sterile disposable needles is generally safe during pregnancy when traditionally contraindicated points (SP6, LI4 in early pregnancy) are avoided. Side effects are minor: localized bruising, transient soreness, occasional lightheadedness. No documented teratogenic effects. Acupuncture is a reasonable adjunctive option for pregnancy-related nausea unresponsive to first-line interventions (dietary modifications, vitamin B6, doxylamine) or for patients preferring non-pharmacologic approaches. It may also be discussed for patients approaching their due date who wish to attempt natural labor induction. Acupuncture has no role in preventing preeclampsia, treating gestational diabetes, or addressing fetal chromosomal abnormalities.\n\nKEY POINTS:\nAcupuncture and acupressure at P6 have the strongest pregnancy evidence base for nausea and vomiting, with NIH Consensus Statement recognition. Evidence for acupuncture-assisted labor induction is moderate, showing improved cervical ripening in some studies. Acupuncture is safe during pregnancy when performed by trained practitioners with appropriate point selection."
  },
  {
    "id": 308,
    "categoryId": 1,
    "question": "Red Yeast Rice contains Monacolin K, which is chemically identical to:",
    "options": [
      "A) Metformin",
      "B) Lovastatin",
      "C) Aspirin",
      "D) Lisinopril"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lovastatin).\n\nCLINICAL REASONING:\nRed yeast rice is produced by fermenting rice with the mold Monascus purpureus, which generates monacolin K, a compound that is chemically identical to lovastatin (originally marketed as Mevacor, the first FDA-approved statin). Monacolin K inhibits HMG-CoA reductase through the exact same mechanism as prescription lovastatin, reducing hepatic cholesterol synthesis and triggering compensatory upregulation of LDL receptor expression on hepatocyte surfaces, thereby increasing clearance of circulating LDL particles.\n\nEFFICACY AND RISKS:\nStandardized red yeast rice products containing clinically meaningful amounts of monacolin K can lower LDL cholesterol by approximately 15 to 25%, comparable to low-dose prescription statin therapy. However, because monacolin K is functionally lovastatin, red yeast rice carries the same spectrum of adverse effects: myalgia and myopathy, hepatotoxicity (transaminase elevation), drug interactions (particularly with CYP3A4 inhibitors such as clarithromycin, itraconazole, and grapefruit juice that also affect lovastatin metabolism), and potential teratogenicity. Patients who experienced true statin intolerance (as opposed to nocebo effect) may also be intolerant to red yeast rice for the same pharmacologic reason.\n\nREGULATORY AND SAFETY CONCERNS:\nThe FDA considers supplements containing significant monacolin K to be unapproved drug products, which has led many manufacturers to reduce or remove monacolin K from their formulations to avoid regulatory action. This means commercial red yeast rice products vary enormously in potency, and many contain little to no active ingredient. Additionally, some products are contaminated with citrinin, a nephrotoxic and potentially hepatotoxic mycotoxin produced during the fermentation process, posing a safety concern not present with prescription statins.\n\nKEY POINTS:\nRed yeast rice contains monacolin K, which is chemically identical to the prescription statin lovastatin and lowers LDL through HMG-CoA reductase inhibition. It carries the same benefits and risks as prescription lovastatin, including myopathy, hepatotoxicity, and drug interactions. Product quality is highly variable, citrinin contamination is a concern, and patients with true statin intolerance may also react to red yeast rice."
  },
  {
    "id": 309,
    "categoryId": 4,
    "question": "Black Cohosh is a popular supplement for hot flashes. What is the current consensus on its safety regarding the liver?",
    "options": [
      "A) It is perfectly safe",
      "B) Rare cases of liver toxicity have been reported; monitor LFTs",
      "C) It causes kidney failure",
      "D) It causes heart arrhythmias"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Rare cases of liver toxicity have been reported; monitor LFTs).\n\nPATHOPHYSIOLOGY:\nBlack cohosh (Actaea racemosa) is widely used for menopausal vasomotor symptoms. Early phytoestrogen hypotheses have been largely refuted. Current evidence suggests effects are mediated through serotonergic activity (5-HT1A/5-HT7 receptor binding modulating central thermoregulation), dopaminergic activity (D2 receptor binding), opioid receptor modulation, and anti-inflammatory properties of triterpene glycoside constituents (actein, cimicifugoside). Hepatotoxic potential has prompted safety advisories from the Australian TGA, European Medicines Agency, and Health Canada.\n\nCLINICAL EVIDENCE:\nApproximately 80-90 cases of liver injury temporally associated with black cohosh have been reported worldwide (Menopause review; USP safety review). Hepatic injury patterns include hepatocellular damage, cholestatic injury, and autoimmune hepatitis-like injury with positive autoantibodies and interface hepatitis on biopsy. Several cases progressed to acute liver failure requiring transplantation, with some fatalities. However, absolute risk appears very low given millions of users, and definitive causation is difficult to establish due to confounding factors (concurrent medications, pre-existing liver disease, product contamination). Regarding efficacy, evidence is mixed: some RCTs show modest benefit, while a large NIH-funded trial (Annals of Internal Medicine) found no significant difference from placebo. A Cochrane review concluded insufficient evidence to support efficacy.\n\nCLINICAL APPLICATION:\nKey counseling points: efficacy data are mixed and do not clearly demonstrate benefit beyond placebo, and rare but serious hepatotoxicity has been reported. Patients choosing black cohosh should use standardized preparations from reputable manufacturers, limit use to 6 months or less, and report symptoms of liver injury (jaundice, dark urine, RUQ pain, unusual fatigue). Baseline and periodic LFT monitoring is reasonable. Avoid in patients with pre-existing liver disease or concurrent hepatotoxic medications. Evidence-based alternatives for vasomotor symptoms include hormone therapy, SSRIs/SNRIs (paroxetine, venlafaxine), fezolinetant, gabapentin, and CBT.\n\nKEY POINTS:\nBlack cohosh has been associated with rare hepatotoxicity including autoimmune hepatitis-like injury and acute liver failure, prompting regulatory safety advisories worldwide. Efficacy for hot flashes is not clearly demonstrated beyond placebo. Patients should have baseline and periodic LFT monitoring, limit duration of use, and be counseled on hepatotoxicity symptoms."
  },
  {
    "id": 310,
    "categoryId": 1,
    "question": "The 'Resperate' device is FDA-cleared for lowering blood pressure. How does it work?",
    "options": [
      "A) Electrical stimulation of the vagus nerve",
      "B) Guided Slow Paced Breathing (< 10 breaths/min)",
      "C) Acupuncture",
      "D) Transcranial magnetic stimulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Guided Slow Paced Breathing).\n\nCLINICAL REASONING:\nThe Resperate device is an FDA-cleared, non-pharmacologic device for adjunctive blood pressure reduction that works by guiding the user through device-paced slow breathing at a rate of fewer than 10 breaths per minute (typically 4 to 6 breaths per minute) for 15-minute sessions. The device uses a sensor to detect the user's respiratory pattern and provides musical tones that guide inhalation and exhalation, gradually slowing the breathing rate and prolonging exhalation over the session.\n\nPATHOPHYSIOLOGY:\nSlow paced breathing reduces blood pressure through several autonomic mechanisms. It increases vagal (parasympathetic) tone and reduces sympathetic nervous system activation, shifting the autonomic balance toward parasympathetic predominance. Prolonged exhalation enhances the respiratory sinus arrhythmia (the normal heart rate variability with breathing), which augments baroreflex sensitivity and reduces peripheral vascular resistance. Multiple meta-analyses suggest that device-guided breathing can produce modest systolic BP reductions of approximately 3 to 9 mmHg, though the evidence is heterogeneous in quality.\n\nCLINICAL CONTEXT:\nThe AHA has reviewed device-guided breathing and concluded that it may be considered as an adjunct to standard pharmacologic and lifestyle interventions for hypertension, though it is not a substitute for first-line therapies. It is particularly appealing for patients seeking non-pharmacologic approaches or as a complement to medication in patients with mildly elevated blood pressure.\n\nKEY POINTS:\nThe Resperate device is FDA-cleared for blood pressure reduction through guided slow paced breathing at fewer than 10 breaths per minute, which shifts autonomic balance toward parasympathetic dominance and reduces peripheral vascular resistance. Evidence suggests modest systolic BP reductions of 3 to 9 mmHg. It is an adjunct to, not a replacement for, standard antihypertensive therapy."
  },
  {
    "id": 311,
    "categoryId": 16,
    "question": "Tai Chi has been shown in randomized trials (NEJM) to produce results similar to or better than aerobic exercise for:",
    "options": [
      "A) Weight loss",
      "B) Fibromyalgia symptom management",
      "C) Building muscle mass",
      "D) Acute infection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fibromyalgia symptom management).\n\nPATHOPHYSIOLOGY:\nFibromyalgia is a chronic pain condition characterized by central sensitization, in which the central nervous system amplifies pain signaling and reduces descending pain inhibition, producing widespread musculoskeletal pain, fatigue, sleep disturbance, and cognitive dysfunction. The pathophysiology involves dysregulation of neurotransmitters including substance P (elevated in cerebrospinal fluid), serotonin and norepinephrine (reduced), and alterations in hypothalamic-pituitary-adrenal axis function. Exercise is a cornerstone of fibromyalgia management, but many patients struggle with conventional aerobic exercise due to post-exertional pain flares.\n\nCLINICAL EVIDENCE:\nA landmark randomized controlled trial published in the New England Journal of Medicine (Wang et al., 2018) demonstrated that tai chi produced equal or superior outcomes compared to aerobic exercise for fibromyalgia across multiple domains including pain, fatigue, sleep quality, depression, and overall quality of life. Patients randomized to tai chi (twice weekly for 24 weeks) showed significantly greater improvement in the Fibromyalgia Impact Questionnaire than those performing supervised aerobic exercise. The benefits persisted at 52-week follow-up.\n\nMECHANISM OF BENEFIT:\nTai chi is a mind-body practice that integrates slow, flowing movements with deep breathing, meditation, and body awareness. This combination addresses multiple pathophysiologic mechanisms simultaneously: the gentle movement improves physical conditioning without triggering post-exertional pain flares, the meditative component reduces sympathetic nervous system hyperactivity and cortisol dysregulation, and the body awareness training helps modulate central sensitization. Unlike conventional exercise, tai chi engages descending pain inhibition pathways through mindfulness and relaxation.\n\nKEY POINTS:\nTai chi is equal or superior to aerobic exercise for fibromyalgia management. It addresses central sensitization through combined gentle movement, meditation, and body awareness. Benefits span pain, fatigue, sleep, depression, and quality of life. It is particularly valuable for patients who cannot tolerate conventional aerobic exercise."
  },
  {
    "id": 312,
    "categoryId": 5,
    "question": "Saw Palmetto is widely used for BPH. The most recent large-scale Cochrane review concluded:",
    "options": [
      "A) It is superior to Tamsulosin",
      "B) It is no better than placebo for urinary flow or nighttime waking",
      "C) It shrinks the prostate by 50%",
      "D) It causes sexual dysfunction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (No better than placebo for urinary flow or nighttime waking).\n\nEVIDENCE:\nSaw palmetto (Serenoa repens) is one of the most widely used herbal supplements for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS), with an estimated 2 million men using it in the United States alone. However, the most rigorous evidence, including a large Cochrane systematic review of 32 randomized controlled trials, concluded that saw palmetto extract is no more effective than placebo for improving urinary flow rates (peak urinary flow, Qmax), reducing nocturia, decreasing International Prostate Symptom Score (IPSS), or reducing prostate size.\n\nLANDMARK TRIALS:\nThe STEP trial (Saw Palmetto for Treatment of Enlarged Prostates), a double-blind RCT funded by the NIH, found no significant difference between saw palmetto 320 mg daily and placebo for the American Urological Association Symptom Index (AUA-SI), peak urinary flow rate, or quality of life measures. A follow-up study using escalating doses up to 960 mg three times the standard dose also showed no benefit over placebo.\n\nPHARMACOLOGY:\nSaw palmetto extract contains fatty acids and phytosterols proposed to inhibit 5-alpha reductase (reducing dihydrotestosterone), provide anti-inflammatory effects, and have anti-androgenic properties. Despite plausible mechanisms, these have not translated into clinically meaningful outcomes in rigorous trials.\n\nEVIDENCE-BASED BPH TREATMENT:\nFor patients with moderate to severe LUTS from BPH, evidence-based options include alpha-1 adrenergic blockers (tamsulosin, alfuzosin) for rapid symptom relief, 5-alpha reductase inhibitors (finasteride, dutasteride) for prostate volume reduction in large prostates, and combination therapy for moderate to large prostates. Tadalafil (PDE5 inhibitor) is FDA-approved for BPH/LUTS with or without concurrent ED.\n\nKEY POINTS:\nThe Cochrane review and NIH-funded STEP trial demonstrate that saw palmetto is no more effective than placebo for BPH symptoms, urinary flow, or nocturia, even at triple the standard dose. Evidence-based BPH treatments include alpha-blockers (tamsulosin), 5-alpha reductase inhibitors (finasteride), and combination therapy. Patients should be counseled that \"natural\" does not mean effective."
  },
  {
    "id": 313,
    "categoryId": 13,
    "question": "Zinc lozenges can shorten the duration of the common cold if taken within 24 hours. What is the mechanism?",
    "options": [
      "A) Killing bacteria",
      "B) Inhibiting Rhinovirus replication in the nasal mucosa",
      "C) Increasing white blood cells",
      "D) Lowering fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inhibiting Rhinovirus replication in the nasal mucosa).\n\nMECHANISM OF ACTION:\nThe proposed mechanism by which zinc exerts antiviral activity centers on direct interference with rhinovirus, the causative agent of the majority of common colds. In vitro studies demonstrate that ionic zinc (Zn2+) inhibits rhinovirus replication by blocking viral RNA-dependent RNA polymerase activity and by interfering with viral capsid protein cleavage necessary for uncoating. Additionally, zinc ions may physically block the ICAM-1 receptor on nasal epithelial cells, preventing rhinovirus attachment and cell entry. Zinc also modulates local immune responses by enhancing interferon-gamma production and supporting natural killer cell cytotoxicity, contributing to more rapid viral clearance.\n\nCLINICAL EVIDENCE:\nA Cochrane systematic review and meta-analysis found that zinc lozenges or syrup administered within 24 hours of symptom onset reduced the duration of the common cold by approximately one to two days in adults. The benefit appears to depend on formulation (zinc acetate and zinc gluconate lozenges delivering greater than 75 mg of elemental zinc per day show the most consistent benefit), dose, and crucially, early initiation. Zinc lozenges taken after 24 hours of symptom onset show minimal benefit. The lozenge form is preferred because it allows prolonged contact of zinc ions with the nasopharyngeal mucosa, where rhinovirus replication occurs.\n\nADVERSE EFFECTS AND SAFETY:\nCommon side effects of zinc lozenges include dysgeusia (bad or metallic taste) and nausea. Prolonged supplementation at high doses (greater than 40 mg elemental zinc daily for extended periods) can cause copper deficiency, leading to sideroblastic anemia and neutropenia. Intranasal zinc gel formulations should be strictly avoided because they have been associated with irreversible anosmia (permanent loss of smell), prompting FDA safety warnings and voluntary market withdrawal.\n\nKEY POINTS:\nZinc inhibits rhinovirus replication and attachment in the nasal mucosa. Clinical benefit requires initiation within 24 hours of symptom onset, with lozenge formulations providing the most consistent evidence for shortening cold duration by one to two days. Intranasal zinc must be avoided due to risk of permanent anosmia. Prolonged high-dose zinc supplementation can cause copper deficiency."
  },
  {
    "id": 314,
    "categoryId": 9,
    "question": "A patient on Warfarin starts taking a 'Green Superfood' powder. What will likely happen to their INR?",
    "options": [
      "A) INR will increase (Bleeding risk)",
      "B) INR will decrease (Clotting risk)",
      "C) No change",
      "D) Powder causes Warfarin malabsorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (INR will decrease, creating clotting risk).\n\nPHARMACOLOGY:\nWarfarin exerts its anticoagulant effect by inhibiting vitamin K epoxide reductase (VKORC1), the enzyme that regenerates reduced vitamin K (the active form required as a cofactor for gamma-carboxylation of clotting factors II, VII, IX, and X, as well as the anticoagulant proteins C and S). \"Green superfood\" powders typically contain high concentrations of vitamin K1 (phylloquinone) from ingredients such as spinach, kale, spirulina, chlorella, wheatgrass, and broccoli.\n\nMECHANISM OF INTERACTION:\nExogenous vitamin K1 from dietary supplements directly replenishes the substrate that warfarin is designed to deplete, effectively overriding warfarin's anticoagulant mechanism and causing the INR to fall toward normal (subtherapeutic) levels. This creates a dangerous gap in anticoagulation for patients with indications such as atrial fibrillation (stroke prevention), mechanical heart valves (valve thrombosis risk), or venous thromboembolism.\n\nCLINICAL GUIDANCE:\nPatients on warfarin should maintain consistent daily vitamin K intake rather than avoiding vitamin K entirely. The key principle is consistency: fluctuations in vitamin K intake (either sudden increases from supplements/dietary changes or sudden decreases from illness or appetite loss) cause INR instability. Patients should be specifically counseled to notify their provider before starting any new supplement, particularly green superfood powders, multivitamins containing vitamin K, or significant dietary changes involving leafy green vegetables. INR should be rechecked within 3 to 7 days of any dietary change.\n\nKEY POINTS:\nGreen superfood powders contain high vitamin K1 concentrations that override warfarin's inhibition of VKORC1, causing INR to decrease and creating dangerous thrombotic risk. The key counseling point for warfarin patients is consistency in vitamin K intake rather than avoidance. Patients must notify providers before starting any new supplement."
  },
  {
    "id": 315,
    "categoryId": 4,
    "question": "Excessive supplementation with Biotin (Vitamin B7) for hair/nails causes what error in thyroid labs?",
    "options": [
      "A) True Hyperthyroidism",
      "B) Falsely Low TSH and Falsely High T4 (Mimics Graves')",
      "C) Falsely High TSH",
      "D) Liver damage"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Falsely Low TSH and Falsely High T4, mimicking Graves' disease).\n\nPATHOPHYSIOLOGY:\nBiotin (vitamin B7) is widely supplemented at 5,000-10,000 mcg daily for hair, skin, and nails (167-333 times the 30 mcg adequate intake). At supraphysiologic doses, biotin causes clinically significant interference with immunoassays using biotin-streptavidin chemistry. Streptavidin binds biotin with extraordinarily high affinity (Kd ~10^-15 M), and this interaction is exploited in assay design. Excess serum biotin competes with biotinylated assay reagents for streptavidin binding sites. In competitive immunoassays (free T4, free T3, cortisol, vitamin D), biotin produces falsely elevated results; in sandwich immunoassays (TSH, troponin, PTH, BNP), biotin produces falsely decreased results.\n\nCLINICAL REASONING:\nBiotin interference on thyroid testing produces falsely low TSH (sandwich assay) combined with falsely elevated free T4/T3 (competitive assays), a pattern biochemically indistinguishable from Graves' disease. This has led to documented misdiagnoses, unnecessary radioactive iodine scans, inappropriate methimazole therapy, and even thyroidectomy (NEJM, Thyroid). The FDA issued a 2017 safety communication after a patient death from missed MI when troponin was falsely lowered. Biotin can also mask hypothyroidism by producing falsely normal TSH.\n\nAFFECTED ASSAYS:\nBeyond thyroid tests, biotin interferes with troponin (falsely low, potentially missing MI), BNP/NT-proBNP (falsely low), PTH (falsely low), cortisol (falsely high), 25-hydroxyvitamin D (falsely high), PSA (falsely low), beta-hCG, testosterone, estradiol, and FSH/LH. Standard multivitamin doses (30 mcg) generally cause no significant interference. Patients on high-dose biotin (300 mg daily for MS) are at extremely high risk.\n\nCLINICAL APPLICATION:\nAsk all patients about biotin supplementation before ordering immunoassay-based labs. The FDA recommends discontinuing biotin for at least 48-72 hours before blood draw for standard doses, and up to 7 days for high-dose therapy. Maintain high suspicion when results are discordant with clinical presentation. Repeat testing after biotin washout or request a non-streptavidin-based platform.\n\nKEY POINTS:\nHigh-dose biotin supplements interfere with biotin-streptavidin immunoassays, producing falsely low TSH and falsely high free T4 mimicking Graves' disease, while also affecting troponin, BNP, and numerous other assays. The FDA issued a 2017 safety communication after adverse outcomes. Discontinue biotin 48-72 hours before testing and inquire about biotin use when results are clinically discordant."
  },
  {
    "id": 316,
    "categoryId": 3,
    "question": "The 'Elimination Diet' is the gold standard for diagnosing:",
    "options": [
      "A) IgE Food Allergies (Anaphylaxis)",
      "B) IgG Food Sensitivities / Intolerances",
      "C) Celiac Disease",
      "D) Gastric Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IgG Food Sensitivities/Intolerances).\n\nPATHOPHYSIOLOGY:\nFood sensitivities (also called food intolerances) are non-IgE-mediated adverse reactions to foods that produce delayed symptoms including bloating, abdominal pain, fatigue, headaches, and brain fog, typically occurring hours to days after ingestion. Unlike IgE-mediated food allergies (which produce immediate, potentially life-threatening reactions such as anaphylaxis, urticaria, and angioedema and are reliably diagnosed with skin prick testing or serum-specific IgE), food sensitivities involve poorly characterized immune or non-immune mechanisms that current serologic testing cannot reliably identify.\n\nCLINICAL REASONING:\nCommercial IgG food sensitivity panels (measuring IgG or IgG4 antibodies to various food antigens) are widely marketed but have been consistently shown to lack clinical validity. IgG antibodies to foods are part of the normal immune response to dietary exposure and reflect physiologic tolerance, not pathologic sensitivity. The AAAAI, EAACI, and CSACI have all issued position statements advising against IgG food sensitivity testing due to the absence of supporting evidence and the potential for unnecessary dietary restriction. The elimination diet remains the gold standard for identifying true food triggers.\n\nMETHODOLOGY:\nThe elimination diet involves removing suspected trigger foods (commonly gluten, dairy, soy, eggs, corn, and artificial additives) for 2-6 weeks, then systematically reintroducing them one at a time at 3-day intervals while monitoring for symptom recurrence. Each reintroduction should be consumed at normal portions for 2-3 days, followed by a washout period. Symptom recurrence upon reintroduction and resolution upon re-elimination confirms a causal relationship. Dietitian supervision is recommended to ensure nutritional adequacy.\n\nKEY POINTS:\nThe elimination diet is the gold standard for diagnosing food sensitivities because IgG food sensitivity panels lack clinical validity and are not recommended by allergy societies. Food sensitivities are distinct from IgE-mediated food allergies. The diet involves 2-6 weeks of elimination followed by systematic reintroduction at 3-day intervals. Dietitian supervision ensures proper implementation and nutritional adequacy."
  },
  {
    "id": 317,
    "categoryId": 6,
    "question": "A ketogenic diet (High Fat, Low Carb) is an an established evidence-based medical therapy for:",
    "options": [
      "A) Weight loss",
      "B) Drug-resistant Epilepsy in children",
      "C) Alzheimer's",
      "D) ADHD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Drug-resistant Epilepsy in children).\n\nKETOGENIC DIET FOR EPILEPSY:\nThe ketogenic diet is a high-fat, low-carbohydrate, adequate-protein dietary therapy that has been used since the 1920s for drug-resistant epilepsy. It carries strong evidence from randomized controlled trials and is endorsed by the International League Against Epilepsy as an effective treatment option when two or more appropriately chosen antiepileptic drugs fail to achieve seizure freedom. The classic ketogenic diet uses a 4:1 ratio of fat to combined protein and carbohydrate.\n\nPATHOPHYSIOLOGY AND MECHANISM:\nWhen carbohydrate intake is severely restricted, the liver converts fatty acids into ketone bodies (beta-hydroxybutyrate, acetoacetate, and acetone), which cross the blood-brain barrier and serve as an alternative fuel source for neurons. The anticonvulsant mechanism is multifactorial and includes enhanced GABAergic inhibition, reduced neuronal excitability through ketone body effects on ATP-sensitive potassium channels, decreased glutamate-mediated excitation, and anti-inflammatory and neuroprotective effects. The shift in cerebral energy metabolism fundamentally alters the neuronal environment in ways that dampen seizure activity.\n\nCLINICAL EFFECTIVENESS:\nApproximately 50% of children with drug-resistant epilepsy achieve a greater than 50% reduction in seizure frequency on the ketogenic diet, and about 10 to 15% become seizure-free. It is particularly effective in certain conditions including glucose transporter type 1 (GLUT1) deficiency syndrome and pyruvate dehydrogenase deficiency, where it is considered the treatment of choice.\n\nPRACTICAL CONSIDERATIONS:\nThe diet requires close supervision by a specialized nutritional team. Potential adverse effects include kidney stones, hyperlipidemia, growth retardation, constipation, and nutritional deficiencies. Modified versions including the modified Atkins diet and low glycemic index treatment offer less restrictive alternatives with similar efficacy for some patients.\n\nKEY POINTS:\nThe ketogenic diet is an established treatment for drug-resistant epilepsy, particularly in children, with approximately 50% of patients achieving significant seizure reduction. Ketone bodies provide an alternative cerebral fuel that dampens neuronal excitability through multiple mechanisms. It is the treatment of choice in GLUT1 deficiency syndrome and pyruvate dehydrogenase deficiency."
  },
  {
    "id": 318,
    "categoryId": 7,
    "question": "Glucosamine and Chondroitin Sulfate are popular for Knee Osteoarthritis. The GAIT trial showed efficacy primarily in:",
    "options": [
      "A) Mild pain",
      "B) Moderate-to-Severe pain (subset of patients)",
      "C) Preventing cartilage loss",
      "D) Rheumatoid Arthritis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Moderate-to-Severe pain subset).\n\nPATHOPHYSIOLOGY:\nOsteoarthritis involves progressive degradation of articular cartilage composed of type II collagen and proteoglycan-rich extracellular matrix. Glucosamine is an amino monosaccharide precursor for glycosaminoglycan chains of proteoglycans responsible for cartilage compressive resilience. Chondroitin sulfate is a major glycosaminoglycan component of cartilage matrix. The therapeutic hypothesis is that supplementation could support cartilage repair, reduce MMP-mediated degradation, and exert modest anti-inflammatory effects through NF-kB and IL-1 beta pathway inhibition.\n\nCLINICAL EVIDENCE:\nThe GAIT trial (NEJM 2006), an NIH-funded, multicenter, double-blind, placebo-controlled RCT of 1,583 patients, evaluated glucosamine HCl 1,500 mg daily, chondroitin sulfate 1,200 mg daily, their combination, celecoxib 200 mg daily, and placebo over 24 weeks. In the overall population, neither supplement alone nor combined achieved significant pain reduction versus placebo. However, a prespecified subgroup with moderate-to-severe pain (WOMAC pain subscale 301-400) showed statistically significant benefit with combination therapy: 79.2% response rate versus 54.3% for placebo. Celecoxib was effective across all pain subgroups. The GAIT structural study found no significant disease-modifying effect on radiographic joint space narrowing over 2 years.\n\nTREATMENT AND MANAGEMENT:\nThe ACR 2019 guidelines conditionally recommend against glucosamine and chondroitin for knee OA, citing inconsistent evidence. However, many clinicians offer a pragmatic 3-month trial for patients with moderate-to-severe pain who prefer complementary approaches or have NSAID contraindications, discontinuing if no improvement is observed. Glucosamine sulfate (the formulation in positive European trials, distinct from hydrochloride used in GAIT) at 1,500 mg daily combined with chondroitin sulfate 1,200 mg daily is preferred. Safety profile is excellent with placebo-comparable adverse effects, though glucosamine may theoretically affect glycemic control in diabetics, and chondroitin may potentiate warfarin.\n\nKEY POINTS:\nGAIT showed no benefit over placebo in the overall knee OA population, but a prespecified moderate-to-severe pain subgroup showed significant benefit with combination therapy. Glucosamine sulfate is preferred, and a 3-month trial is reasonable for moderate-to-severe symptoms. No disease-modifying structural benefit has been demonstrated, and the ACR conditionally recommends against routine use."
  },
  {
    "id": 319,
    "categoryId": 11,
    "question": "St. John's Wort is effective for mild depression, but it is dangerous because it is a potent:",
    "options": [
      "A) CYP 3A4 Inducer",
      "B) CYP 3A4 Inhibitor",
      "C) Renal toxin",
      "D) Sedative"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (CYP 3A4 Inducer).\n\nPHARMACOLOGY:\nSt. John's Wort (Hypericum perforatum) is the most potent known herbal inducer of the cytochrome P450 enzyme system, particularly CYP3A4 (the most clinically important drug-metabolizing enzyme, responsible for metabolizing approximately 50% of all prescription medications). The active constituent hyperforin activates the pregnane X receptor (PXR), a nuclear transcription factor that upregulates CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein (MDR1) gene expression in the liver and intestinal epithelium.\n\nCLINICAL CONSEQUENCES:\nEnzyme induction accelerates the metabolism of substrate drugs, reducing their plasma concentrations to subtherapeutic levels and causing treatment failures with potentially life-threatening consequences. Critical interactions include oral contraceptives (breakthrough bleeding and unintended pregnancy from reduced ethinyl estradiol levels), warfarin (loss of anticoagulation with thromboembolic risk), cyclosporine and tacrolimus (organ transplant rejection from subtherapeutic immunosuppression), HIV protease inhibitors and NNRTIs (viral resistance from subtherapeutic antiviral levels), direct oral anticoagulants, digoxin, statins, calcium channel blockers, and methadone.\n\nDISTINCTION FROM INHIBITION:\nEnzyme induction (which St. John's Wort causes) increases enzyme production over days to weeks, lowering drug levels. This is the opposite of enzyme inhibition (which drugs like ketoconazole, grapefruit juice, and erythromycin cause), which blocks enzyme activity and raises drug levels. The full induction effect of St. John's Wort develops over approximately 1 to 2 weeks of consistent use and may persist for a similar period after discontinuation.\n\nKEY POINTS:\nSt. John's Wort is the most potent herbal CYP3A4 inducer, activating PXR to upregulate CYP3A4, CYP2C9, CYP1A2, and P-glycoprotein. This reduces plasma levels of oral contraceptives (pregnancy risk), warfarin (thrombosis risk), immunosuppressants (rejection risk), and HIV medications (resistance risk). Clinicians must specifically screen for St. John's Wort during medication reconciliation."
  },
  {
    "id": 320,
    "categoryId": 16,
    "question": "Adaptogens (e.g., Ashwagandha, Rhodiola) are theorized to work by:",
    "options": [
      "A) Increasing Testosterone",
      "B) Modulating the HPA Axis and cortisol response to stress",
      "C) Sedating the brainstem",
      "D) Acting as a placebo"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Modulating the HPA Axis and cortisol response to stress).\n\nDEFINITION:\nAdaptogens are a category of herbal products theorized to improve the body's resistance to physical, chemical, and biological stressors by modulating the hypothalamic-pituitary-adrenal (HPA) axis and cortisol response. The term was coined by Soviet scientist Nikolai Lazarev in 1947, with the concept formalized by Israel Brekhman, who defined adaptogens as substances that increase nonspecific resistance to stress, have a normalizing (bidirectional) effect on physiology, and are relatively nontoxic.\n\nPROPOSED MECHANISMS:\nThe most studied adaptogens include ashwagandha (Withania somnifera), rhodiola (Rhodiola rosea), and eleuthero (Eleutherococcus senticosus). Proposed mechanisms include modulation of cortisol secretion (reducing peak cortisol in acute stress while supporting baseline cortisol function), regulation of heat shock protein 70 (Hsp70) expression (which stabilizes cellular proteins under stress), modulation of nitric oxide production, and effects on neuropeptide Y (NPY) signaling. A systematic review of ashwagandha showed modest reductions in serum cortisol (approximately 11 to 32%) and perceived stress scores in randomized trials, though study quality was variable and sample sizes were small.\n\nCLINICAL LIMITATIONS:\nThe evidence base for adaptogens remains limited by small, heterogeneous trials with variable preparations, doses, and endpoints. Standardization is a major concern because the active constituent concentrations vary widely between products and brands. Important drug interactions exist: ashwagandha may potentiate thyroid hormone, sedatives, and immunosuppressants. Clinicians should advise patients that while preliminary evidence is promising for stress and cortisol modulation, adaptogens should complement (not replace) evidence-based stress management strategies including exercise, sleep hygiene, cognitive behavioral therapy, and social connection.\n\nKEY POINTS:\nAdaptogens (ashwagandha, rhodiola) are theorized to improve stress resilience by modulating HPA axis cortisol responses, Hsp70 expression, and neuropeptide Y signaling. Evidence shows modest cortisol reductions (11 to 32%) with ashwagandha, but overall evidence quality is limited. Adaptogens should complement, not replace, evidence-based stress management strategies."
  },
  {
    "id": 321,
    "categoryId": 4,
    "question": "Omega-3 Fatty Acids (EPA/DHA) are often used in ADHD. A meta-analysis suggests the effect size is:",
    "options": [
      "A) Equal to Ritalin",
      "B) Small but statistically significant",
      "C) Zero",
      "D) Harmful"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small but statistically significant).\n\nPATHOPHYSIOLOGY:\nThe rationale for omega-3 supplementation in ADHD is grounded in the essential role of long-chain polyunsaturated fatty acids in brain structure and neurotransmitter function. The brain is approximately 60% lipid by dry weight. DHA is concentrated in synaptic membranes where it modulates membrane fluidity, receptor conformation, and signal transduction. EPA serves as an anti-inflammatory mediator through competitive inhibition of arachidonic acid-derived proinflammatory eicosanoids and production of resolvins and protectins. Both influence dopaminergic and serotonergic neurotransmission: omega-3 deficiency reduces frontal cortex dopamine receptor density and impairs dopamine release in animal models, while supplementation enhances prefrontal dopaminergic signaling critical for attention and executive function. Children with ADHD have significantly lower blood omega-3 levels correlating with symptom severity (JAACAP).\n\nCLINICAL EVIDENCE:\nA meta-analysis (Journal of Clinical Psychiatry, 2011; 10 trials, 699 children) found a statistically significant but small effect: pooled effect size 0.31 for inattention, 0.22 for hyperactivity. A larger meta-analysis (Neuropsychopharmacology, 2018; 16 RCTs) confirmed modest but significant benefit, with EPA-predominant formulations showing greater efficacy. For context, stimulant medications achieve effect sizes of 0.8-1.0, making omega-3 approximately one-quarter to one-third as effective. A Lancet Psychiatry review concluded omega-3 shows the most consistent evidence among nutritional approaches for ADHD.\n\nCLINICAL APPLICATION:\nOmega-3 supplementation should be adjunctive rather than a replacement for first-line ADHD treatments (behavioral therapy, stimulant/non-stimulant medications). Evidence best supports EPA-predominant formulations with at least 500 mg EPA daily. Supplementation may be most beneficial in patients with documented low omega-3 levels, mild symptoms, or partial response to pharmacotherapy. Side effects are minimal (mild GI complaints, fishy aftertaste) with excellent safety profile, making it reasonable for families exploring complementary approaches or patients unable to tolerate stimulants.\n\nKEY POINTS:\nOmega-3 supplementation produces a small but statistically significant improvement in ADHD symptoms (effect size ~0.2-0.3), roughly one-quarter to one-third the effect of stimulants. EPA-predominant formulations at 500 mg or more daily appear most effective. Omega-3s should be adjunctive to standard ADHD treatment and may be most beneficial in patients with documented omega-3 deficiency."
  },
  {
    "id": 322,
    "categoryId": 14,
    "question": "A cancer patient wants to take high-dose antioxidants (Vitamin C, E) during radiation therapy. You advise:",
    "options": [
      "A) Go ahead, it protects healthy cells",
      "B) Avoid, as it may protect the cancer cells from the oxidative damage of radiation",
      "C) It has no effect",
      "D) Only take Vitamin E"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Caution; antioxidants may reduce efficacy of radiation by protecting cancer cells).\n\nPATHOPHYSIOLOGY:\nRadiation therapy kills cancer cells primarily by generating reactive oxygen species (ROS) that cause lethal double-strand DNA breaks. Approximately 60 to 70% of radiation-induced cellular damage is mediated through ROS produced by radiolysis of intracellular water, with the remaining damage occurring through direct DNA ionization. Similarly, several chemotherapy agents including alkylating agents, platinum compounds, and anthracyclines exert their cytotoxic effects at least partially through oxidative mechanisms. High-dose exogenous antioxidant supplements could theoretically reduce treatment efficacy by neutralizing the very ROS intended to destroy tumor cells.\n\nCLINICAL EVIDENCE:\nThe Alpha-Tocopherol Beta-Carotene Cancer Prevention (ATBC) trial demonstrated that beta-carotene supplementation paradoxically increased lung cancer incidence and mortality in smokers by 18%, and the CARET trial confirmed this with a 28% increase in lung cancer incidence among high-risk participants taking beta-carotene plus retinol. Retrospective studies have shown trends toward worse disease-free survival in cancer patients taking high-dose antioxidants during treatment. A systematic review in the Journal of the National Cancer Institute concluded that potential harm from antioxidant supplementation during cancer treatment cannot be excluded.\n\nCLINICAL APPLICATION:\nASCO and the American Cancer Society recommend against high-dose antioxidant supplements (vitamin C, vitamin E, beta-carotene, selenium) during active radiation or oxidative chemotherapy per their respective clinical guidelines. This recommendation applies specifically to supplemental doses that far exceed physiologic levels, not to antioxidants consumed through whole foods at normal dietary levels, which are generally considered safe and potentially beneficial during treatment. After treatment completion, supplementation is a separate consideration with less concern for treatment interference. The treating oncologist should always be consulted.\n\nKEY POINTS:\nHigh-dose antioxidant supplements during radiation may protect cancer cells by neutralizing the reactive oxygen species that mediate the majority of radiation-induced damage. The ATBC and CARET trials demonstrated paradoxically increased cancer incidence with beta-carotene supplementation in at-risk populations. ASCO and the American Cancer Society recommend against high-dose antioxidant supplements during active cancer treatment, while dietary antioxidants from whole foods are generally acceptable."
  },
  {
    "id": 323,
    "categoryId": 16,
    "question": "In Integrative Medicine, the 'Placebo Effect' is viewed as:",
    "options": [
      "A) A nuisance to be eliminated",
      "B) A physiological response mediated by endorphins and expectation, to be harnessed ethically",
      "C) Evidence that the patient is faking",
      "D) Only relevant in psychology"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A physiological response mediated by endorphins and expectation, to be harnessed ethically).\n\nNEUROBIOLOGY:\nThe placebo effect is a genuine physiological phenomenon involving measurable changes in brain activity, neurotransmitter release, and peripheral physiology in response to inert treatments administered within a therapeutic context. Functional neuroimaging studies demonstrate that placebo analgesia activates endogenous opioid pathways (confirmed by naloxone reversal), the endocannabinoid system, and dopaminergic reward circuits in the nucleus accumbens, ventral tegmental area, and prefrontal cortex. Placebo treatments for Parkinson's disease produce measurable dopamine release in the striatum, and placebo bronchodilators produce subjective (though not spirometric) improvement in asthma.\n\nTHERAPEUTIC CONTEXT:\nThe magnitude of the placebo response is influenced by the therapeutic ritual: provider warmth and empathy, confident positive framing, sensory characteristics of the treatment (larger pills, injections versus pills, branded versus generic), and the patient's prior treatment experiences and expectations. The provider-patient relationship itself is a powerful active ingredient in healing, independent of specific pharmacologic or procedural interventions. Open-label placebos (where patients are told they are receiving a placebo) have shown benefit in irritable bowel syndrome, chronic low back pain, and cancer-related fatigue, suggesting that the therapeutic ritual and expectation framework contribute to benefit even without deception.\n\nINTEGRATIVE MEDICINE PERSPECTIVE:\nRather than viewing the placebo effect as a confound to be eliminated, integrative medicine conceptualizes it as an endogenous healing response to be ethically maximized through optimized therapeutic encounters, empathic communication, positive expectation framing, and treatment rituals. This approach does not endorse deception but rather leverages the neurobiology of healing through the clinician-patient interaction.\n\nKEY POINTS:\nThe placebo effect involves genuine neurobiological responses including endogenous opioid release, dopaminergic activation, and endocannabinoid signaling, measurable on functional neuroimaging. The therapeutic relationship, provider empathy, and treatment ritual are active ingredients that modulate these responses. Open-label placebos demonstrate that benefit occurs even without deception, supporting ethical harnessing of placebo mechanisms."
  },
  {
    "id": 324,
    "categoryId": 9,
    "question": "Which hormone is the master regulator of systemic iron homeostasis, blocking iron absorption in the gut when stores are high?",
    "options": [
      "A) Erythropoietin",
      "B) Hepcidin",
      "C) Ferritin",
      "D) Transferrin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hepcidin).\n\nPHYSIOLOGY:\nHepcidin is a 25-amino acid peptide hormone produced primarily by hepatocytes that serves as the master regulator of systemic iron homeostasis. Hepcidin controls iron availability by binding to and inducing internalization and degradation of ferroportin, the only known cellular iron export channel found on enterocytes (controlling dietary iron absorption), macrophages (controlling iron recycling from senescent red blood cells), and hepatocytes (controlling iron storage release).\n\nREGULATION:\nHepcidin expression is upregulated by high iron stores (sensed via transferrin saturation and the HFE/TfR2/HJV signaling complex on hepatocytes), inflammation (IL-6 directly induces hepcidin transcription via the JAK-STAT3 pathway, explaining iron sequestration in anemia of chronic disease), and infection (iron restriction as an innate immune defense against siderophilic pathogens). Hepcidin is downregulated by iron deficiency, erythropoietic drive (via erythroferrone produced by erythroblasts), hypoxia (via HIF pathway), and pregnancy.\n\nCLINICAL SIGNIFICANCE:\nHepcidin excess is the central mechanism of anemia of chronic disease (also called anemia of inflammation), where IL-6-driven hepcidin elevation blocks iron absorption and traps iron in macrophages despite adequate or increased total body iron stores. This produces the characteristic iron profile of low serum iron, low TIBC, normal to elevated ferritin, and low transferrin saturation. Conversely, inappropriately low hepcidin (as in hereditary hemochromatosis from HFE gene mutations) permits unregulated iron absorption leading to iron overload.\n\nKEY POINTS:\nHepcidin is the master regulator of iron homeostasis, controlling iron absorption and recycling by degrading ferroportin (the sole cellular iron export channel). Hepcidin excess (driven by IL-6 in inflammation) causes anemia of chronic disease by sequestering iron in macrophages. Hepcidin deficiency (as in hereditary hemochromatosis) causes unregulated iron absorption and iron overload."
  },
  {
    "id": 325,
    "categoryId": 9,
    "question": "You are evaluating a 2-year-old with Microcytic Anemia (MCV 65). The Mentzer Index (MCV / RBC count) is < 13. What is the most likely diagnosis?",
    "options": [
      "A) Iron Deficiency Anemia",
      "B) Thalassemia Trait",
      "C) Lead Poisoning",
      "D) B12 Deficiency"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thalassemia Trait).\n\nDIAGNOSTIC REASONING:\nThe Mentzer Index (MCV divided by RBC count) is a simple, rapid screening tool to distinguish thalassemia trait from iron deficiency anemia with microcytic anemia. A Mentzer Index less than 13 favors thalassemia trait, while greater than 13 favors iron deficiency. In this 2-year-old with MCV 65 and a Mentzer Index less than 13, thalassemia trait is the most likely diagnosis.\n\nPATHOPHYSIOLOGY:\nIn thalassemia trait, the mild reduction in globin chain production produces smaller red blood cells (low MCV) but the bone marrow compensates by increasing erythropoiesis, resulting in a characteristically elevated RBC count. This combination of low MCV with high RBC count produces a low Mentzer Index. In iron deficiency anemia, both hemoglobin content per cell (low MCV) and total red cell production (low RBC count) are reduced because iron is required for heme synthesis in all new erythrocytes, producing a high Mentzer Index.\n\nPEDIATRIC CONSIDERATIONS:\nThalassemia trait is particularly important to identify in the pediatric population to avoid unnecessary iron supplementation (which can cause iron overload in thalassemia) and to provide genetic counseling to families. In a 2-year-old, iron deficiency is extremely common (from dietary transition and rapid growth), so the Mentzer Index provides a valuable first step in differentiating the two most common causes of microcytic anemia. Confirmatory testing includes hemoglobin electrophoresis (elevated HbA2 in beta-thalassemia trait) and iron studies (ferritin, TIBC).\n\nADDITIONAL DIAGNOSTIC CLUES:\nThe peripheral smear in thalassemia trait shows target cells, microcytes, and a normal to mildly elevated red cell distribution width (RDW), while iron deficiency produces more marked anisocytosis with elevated RDW.\n\nKEY POINTS:\nThe Mentzer Index (MCV/RBC count) less than 13 favors thalassemia trait (low MCV with compensatory high RBC count), while greater than 13 favors iron deficiency (low MCV with low RBC count). Thalassemia trait in children should not be treated with iron, and confirmatory testing includes hemoglobin electrophoresis. RDW is typically normal in thalassemia trait but elevated in iron deficiency."
  },
  {
    "id": 326,
    "categoryId": 9,
    "question": "A patient with anemia has a Reticulocyte Count of 0.1% (Low). This indicates the anemia is due to:",
    "options": [
      "A) Hemolysis (Destruction)",
      "B) Acute Blood Loss",
      "C) Bone Marrow Production Failure",
      "D) Splenic Sequestration"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Bone Marrow Production Failure).\n\nPATHOPHYSIOLOGY:\nThe reticulocyte count measures the proportion of immature red blood cells (reticulocytes, which still contain residual ribosomal RNA) released from the bone marrow into the circulation, providing a direct assessment of erythropoietic activity. A low reticulocyte count (less than 0.5 to 1% or less than 25,000/microL absolute reticulocyte count) with anemia indicates that the bone marrow is failing to mount an appropriate compensatory erythropoietic response, pointing to a production failure (hypoproliferative) mechanism.\n\nCLASSIFICATION OF ANEMIA BY RETICULOCYTE COUNT:\nThis single test divides anemias into two fundamental categories. Hypoproliferative anemias (low reticulocyte count) include iron deficiency, B12/folate deficiency, anemia of chronic disease, aplastic anemia, myelodysplastic syndrome, pure red cell aplasia, renal failure (erythropoietin deficiency), and marrow infiltration (myelophthisis from metastatic disease, fibrosis, or granulomas). Hyperproliferative anemias (elevated reticulocyte count, typically greater than 2 to 3%) indicate that the marrow is responding appropriately to red cell destruction or loss, pointing to hemolysis (autoimmune, mechanical, sickle cell, G6PD deficiency, hereditary spherocytosis) or acute blood loss.\n\nRETICULOCYTE PRODUCTION INDEX:\nThe raw reticulocyte percentage can be misleadingly elevated in severe anemia because it is calculated relative to a reduced total RBC count. The reticulocyte production index (RPI) corrects for both the degree of anemia and the premature release of reticulocytes (shift reticulocytes with longer maturation time), providing a more accurate assessment of marrow response: RPI greater than 2 indicates appropriate marrow response, while less than 2 indicates inadequate production.\n\nKEY POINTS:\nA low reticulocyte count in anemia indicates bone marrow production failure (hypoproliferative anemia), encompassing iron deficiency, B12/folate deficiency, aplastic anemia, and marrow infiltration. A high reticulocyte count indicates appropriate marrow response to peripheral red cell destruction (hemolysis) or blood loss. The reticulocyte production index corrects the raw percentage for anemia severity."
  },
  {
    "id": 327,
    "categoryId": 9,
    "question": "Von Willebrand Disease (vWD) is the most common inherited bleeding disorder. What is the dual function of von Willebrand Factor (vWF)?",
    "options": [
      "A) Activates Factor X and lyses clots",
      "B) Binds platelets to injured endothelium AND carries Factor VIII",
      "C) Converts Fibrinogen to Fibrin",
      "D) Inhibits Vitamin K"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Binds platelets to injured endothelium AND carries Factor VIII).\n\nPHYSIOLOGY:\nVon Willebrand factor (vWF) is a large multimeric glycoprotein synthesized by endothelial cells and megakaryocytes that plays two essential and complementary roles in hemostasis. First, vWF mediates platelet adhesion to exposed subendothelial collagen at sites of vascular injury by serving as a bridge between platelet glycoprotein Ib (GPIb) receptors and collagen fibrils, a function critical in high-shear environments (arterioles and capillaries) where platelets cannot adhere to collagen directly. Second, vWF serves as the carrier protein for coagulation Factor VIII, protecting it from premature proteolytic degradation by activated protein C and extending its plasma half-life from approximately 2 hours (unbound) to 12 hours (vWF-bound).\n\nCLINICAL SIGNIFICANCE:\nVon Willebrand disease (vWD) is the most common inherited bleeding disorder, affecting approximately 1% of the population. The dual function of vWF explains the characteristic bleeding pattern: mucocutaneous bleeding (epistaxis, menorrhagia, gingival bleeding, easy bruising, GI bleeding) from defective platelet adhesion, and prolonged aPTT from secondary Factor VIII deficiency. Type 1 (partial quantitative deficiency, 75 to 80% of cases) is usually mild, Type 2 (qualitative dysfunction of vWF multimers) has multiple subtypes, and Type 3 (complete absence of vWF) is rare and severe.\n\nTREATMENT:\nDesmopressin (DDAVP) is first-line treatment for Type 1 vWD, stimulating release of stored vWF from endothelial Weibel-Palade bodies. For Type 2 (where released vWF is dysfunctional) and Type 3 (no vWF to release), vWF-containing Factor VIII concentrates (Humate-P) are required.\n\nKEY POINTS:\nVon Willebrand factor has dual hemostatic functions: bridging platelets to injured endothelium (GPIb-collagen adhesion) and carrying/stabilizing Factor VIII. Deficiency causes mucocutaneous bleeding (platelet adhesion defect) plus prolonged aPTT (secondary Factor VIII deficiency). Desmopressin is first-line for Type 1 vWD by releasing stored vWF from endothelial cells."
  },
  {
    "id": 328,
    "categoryId": 9,
    "question": "Immune Thrombocytopenia (ITP) in children is typically triggered by:",
    "options": [
      "A) A viral illness 1-3 weeks prior",
      "B) Bacterial Sepsis",
      "C) Trauma",
      "D) Iron deficiency"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (A viral illness 1 to 3 weeks prior).\n\nPATHOPHYSIOLOGY:\nImmune thrombocytopenia (ITP) in children is an autoimmune disorder in which IgG antibodies (most commonly directed against platelet GPIIb/IIIa or GPIb/IX surface glycoproteins) bind to platelets, causing their accelerated destruction by splenic macrophages via Fc receptor-mediated phagocytosis. In approximately 60 to 75% of pediatric ITP cases, the onset follows a viral illness (upper respiratory infection, varicella, measles, EBV, CMV, parvovirus B19) by 1 to 3 weeks, suggesting molecular mimicry or nonspecific immune activation as the triggering mechanism.\n\nCLINICAL PRESENTATION:\nPediatric ITP classically presents in a previously healthy child aged 2 to 6 years with sudden onset of petechiae, purpura, and mucocutaneous bleeding (epistaxis, gingival bleeding) following a viral prodrome. The hallmark is isolated thrombocytopenia (often below 20,000/microL) with an otherwise normal CBC (normal hemoglobin, normal WBC, normal peripheral smear morphology except for large platelets reflecting marrow compensation). The child typically appears well despite dramatic-appearing skin findings.\n\nPEDIATRIC VERSUS ADULT ITP:\nPediatric ITP is typically self-limited, with 80% of cases resolving spontaneously within 6 to 12 months without treatment. Adult ITP tends to be chronic (lasting more than 12 months in over 50% of cases), has no viral trigger, is more common in women, and usually requires treatment.\n\nMANAGEMENT:\nFor children with platelet counts above 20,000/microL and no active bleeding, observation alone is appropriate. For significant bleeding or very low counts, first-line treatments include corticosteroids (prednisone or dexamethasone), IVIG (which blocks splenic Fc receptors, temporarily reducing platelet destruction), and anti-D immunoglobulin (in Rh-positive, non-splenectomized patients).\n\nKEY POINTS:\nPediatric ITP is triggered by a viral illness in 60 to 75% of cases, presenting 1 to 3 weeks after infection with sudden isolated thrombocytopenia, petechiae, and mucocutaneous bleeding in an otherwise well child. Unlike adult ITP, 80% of pediatric cases resolve spontaneously within 6 to 12 months. Observation is appropriate for counts above 20,000 without active bleeding."
  },
  {
    "id": 329,
    "categoryId": 14,
    "question": "A 65-year-old male has an incidental finding of WBC 40,000 with 85% Lymphocytes. The blood smear shows 'Smudge Cells'. Diagnosis?",
    "options": [
      "A) Acute Myeloid Leukemia (AML)",
      "B) Chronic Lymphocytic Leukemia (CLL)",
      "C) CML",
      "D) Mononucleosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic Lymphocytic Leukemia).\n\nPATHOPHYSIOLOGY:\nChronic lymphocytic leukemia is the most common adult leukemia in Western countries, with a median age at diagnosis of approximately 70 years. CLL is a clonal malignancy of mature B lymphocytes that accumulate in the peripheral blood, bone marrow, lymph nodes, and spleen. The malignant B cells co-express CD5 (normally a T-cell marker) with B-cell markers CD19, CD20 (dim), and CD23, a combination that is virtually diagnostic on flow cytometry. These cells are inherently fragile due to cytoskeletal abnormalities, and when a blood smear is prepared, mechanical forces rupture the cells, producing the characteristic smudge cells (also called basket cells) that are a hallmark morphologic finding.\n\nCLINICAL PRESENTATION:\nCLL is frequently discovered incidentally on routine blood work with an unexpected lymphocytosis, as in this patient. Diagnosis requires an absolute lymphocyte count greater than 5,000 per microliter sustained for at least 3 months. Most patients are asymptomatic at diagnosis. When symptoms develop, they include painless lymphadenopathy, splenomegaly, fatigue, and recurrent infections from hypogammaglobulinemia. Autoimmune hemolytic anemia and immune thrombocytopenia are recognized complications. Richter transformation to aggressive diffuse large B-cell lymphoma occurs in approximately 2 to 10% of patients.\n\nMANAGEMENT:\nMany patients with early-stage, asymptomatic CLL are managed with active surveillance (watch and wait), as randomized trials have demonstrated no survival benefit from early treatment. Treatment is indicated for progressive cytopenias, massive or symptomatic lymphadenopathy or splenomegaly, constitutional symptoms, or rapidly rising lymphocyte counts. Modern therapy has been transformed by targeted agents including BTK inhibitors (ibrutinib, acalabrutinib) and BCL-2 inhibitors (venetoclax), which have largely replaced chemoimmunotherapy.\n\nKEY POINTS:\nCLL is the most common adult leukemia in Western countries and involves mature B-cell lymphocytosis with smudge cells on peripheral smear reflecting the fragility of the malignant lymphocytes. Flow cytometry showing CD5-positive, CD19-positive, CD20-dim, CD23-positive B cells is virtually diagnostic. Many patients are managed with active surveillance, with treatment initiated only for progressive symptoms or cytopenias."
  },
  {
    "id": 330,
    "categoryId": 9,
    "question": "Thrombotic Thrombocytopenic Purpura (TTP) is a medical emergency characterized by the 'Pentad' of symptoms. Which is NOT part of the pentad?",
    "options": [
      "A) Thrombocytopenia",
      "B) Microangiopathic Hemolytic Anemia (Schistocytes)",
      "C) Fever",
      "D) Joint Swelling"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Joint Swelling is NOT part of the TTP pentad).\n\nPATHOPHYSIOLOGY:\nThrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severe deficiency of ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, member 13), the enzyme responsible for cleaving ultra-large von Willebrand factor (UL-vWF) multimers released from endothelial cells. When ADAMTS13 activity falls below 10% (either from autoantibody inhibition in acquired TTP or from inherited mutations in congenital TTP), UL-vWF multimers accumulate and cause spontaneous platelet aggregation in the microvasculature, forming platelet-rich thrombi that occlude arterioles and capillaries throughout the body.\n\nTHE CLASSIC PENTAD:\nThe historical TTP pentad consists of thrombocytopenia (from platelet consumption in microthrombi), microangiopathic hemolytic anemia (MAHA, with schistocytes on peripheral smear from mechanical shearing of RBCs through occluded microvasculature), neurologic symptoms (confusion, headache, seizures, focal deficits from cerebral microthrombi), renal impairment (from renal microvascular occlusion), and fever. However, the complete pentad is present in fewer than 5% of patients at diagnosis, and waiting for all five features delays life-saving treatment. Joint swelling is not part of this pentad and is more characteristic of autoimmune conditions such as rheumatoid arthritis or systemic lupus erythematosus.\n\nDIAGNOSIS AND MANAGEMENT:\nTTP should be suspected in any patient with thrombocytopenia plus MAHA (schistocytes on smear), and treatment with plasma exchange (plasmapheresis) must begin emergently, as untreated TTP has a mortality exceeding 90%. Plasma exchange removes the autoantibody and UL-vWF multimers while replacing ADAMTS13. Adjunctive caplacizumab (an anti-vWF nanobody) and rituximab (anti-CD20) are increasingly used.\n\nKEY POINTS:\nThe TTP pentad is thrombocytopenia, microangiopathic hemolytic anemia (schistocytes), neurologic symptoms, renal impairment, and fever; joint swelling is not included. TTP results from severe ADAMTS13 deficiency causing ultra-large vWF multimer accumulation and microvascular platelet aggregation. Untreated mortality exceeds 90%, and emergent plasma exchange is life-saving."
  },
  {
    "id": 331,
    "categoryId": 9,
    "question": "Hydroxyurea is the standard of care for severe Sickle Cell Disease because it:",
    "options": [
      "A) Thins the blood",
      "B) Increases production of Fetal Hemoglobin (HbF)",
      "C) Suppresses the immune system",
      "D) Dilates blood vessels"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increases production of Fetal Hemoglobin).\n\nPHARMACOLOGY:\nHydroxyurea is the cornerstone disease-modifying therapy for sickle cell disease (SCD), with its primary therapeutic mechanism being induction of fetal hemoglobin (HbF, alpha-2-gamma-2) production in erythroid precursors. HbF does not contain the mutant beta-S globin chain (which contains the valine-for-glutamic acid substitution at position 6 that causes hemoglobin S polymerization under deoxygenated conditions), and therefore HbF does not participate in the sickling process.\n\nMECHANISM:\nHydroxyurea is a ribonucleotide reductase inhibitor that induces HbF through several proposed mechanisms: selective cytotoxicity to late erythroid progenitors (allowing earlier progenitors with higher gamma-globin expression to preferentially survive and differentiate), nitric oxide-mediated activation of soluble guanylyl cyclase, and epigenetic modifications of the gamma-globin gene promoter. Additional benefits include reduced neutrophil and monocyte counts (decreasing vaso-occlusive adhesion events), decreased WBC-endothelial adhesion, improved red cell hydration, and increased nitric oxide bioavailability.\n\nCLINICAL EVIDENCE:\nThe landmark MSH (Multicenter Study of Hydroxyurea) trial demonstrated that hydroxyurea reduced the frequency of painful vaso-occlusive crises by approximately 50%, reduced acute chest syndrome episodes, decreased transfusion requirements, and reduced hospitalizations. Long-term follow-up data show a significant mortality benefit with sustained use. The BABY HUG trial demonstrated safety and efficacy in children as young as 9 months.\n\nKEY POINTS:\nHydroxyurea reduces sickle cell crises by approximately 50% primarily by inducing fetal hemoglobin (HbF), which cannot participate in HbS polymerization and sickling. Additional benefits include reduced WBC adhesion and improved nitric oxide bioavailability. It is recommended for most patients with severe SCD, with evidence supporting use from infancy (BABY HUG trial)."
  },
  {
    "id": 332,
    "categoryId": 9,
    "question": "In Hereditary Hemochromatosis, the HFE gene mutation leads to:",
    "options": [
      "A) Excessive Iron excretion",
      "B) Unregulated Iron absorption from the gut",
      "C) Inability to bind Iron to Transferrin",
      "D) Destruction of Red Blood Cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Unregulated iron absorption from the gut).\n\nPATHOPHYSIOLOGY:\nHereditary hemochromatosis (HH) is the most common autosomal recessive genetic disorder in individuals of Northern European descent, with a prevalence of approximately 1 in 200 to 300 for the homozygous C282Y mutation in the HFE gene on chromosome 6. The HFE protein normally forms a complex with transferrin receptor 2 (TfR2) and hemojuvelin (HJV) on hepatocyte surfaces that senses iron-loaded transferrin and signals upregulation of hepcidin synthesis. When HFE is dysfunctional, this iron-sensing mechanism fails, hepcidin levels remain inappropriately low, and ferroportin (the sole cellular iron exporter on enterocytes and macrophages) remains active and uninhibited, resulting in unregulated intestinal iron absorption of 3 to 4 mg/day (versus the normal 1 to 2 mg/day).\n\nCLINICAL MANIFESTATIONS:\nProgressive iron accumulation over decades deposits iron in parenchymal cells of multiple organs. The classic presentation includes hepatic fibrosis and cirrhosis (with 200-fold increased hepatocellular carcinoma risk), diabetes mellitus (\"bronze diabetes\" from pancreatic beta-cell iron deposition), cardiomyopathy (both dilated and restrictive), hypogonadotropic hypogonadism (pituitary iron deposition), arthropathy (particularly second and third metacarpophalangeal joints), and skin hyperpigmentation.\n\nDIAGNOSIS AND MANAGEMENT:\nElevated transferrin saturation (greater than 45%) is the earliest and most sensitive screening marker, followed by elevated ferritin. HFE gene testing confirms the diagnosis. Treatment is therapeutic phlebotomy (removal of 500 mL blood weekly until ferritin falls below 50 ng/mL, then maintenance phlebotomy every 2 to 4 months). First-degree relatives should be screened with HFE genotyping and iron studies.\n\nKEY POINTS:\nHereditary hemochromatosis results from HFE gene mutations causing inappropriately low hepcidin, leading to unregulated iron absorption via uninhibited ferroportin. Iron deposits cause cirrhosis (200-fold HCC risk), diabetes, cardiomyopathy, and hypogonadism. Transferrin saturation greater than 45% is the earliest screening marker, and therapeutic phlebotomy is the treatment."
  },
  {
    "id": 333,
    "categoryId": 9,
    "question": "Factor V Leiden is the most common inherited thrombophilia. It increases clotting risk by:",
    "options": [
      "A) Causing Factor V to be resistant to degradation by Protein C",
      "B) Increasing Factor V production 10-fold",
      "C) Removing Factor V from the blood",
      "D) Activating platelets directly"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Causing Factor V to be resistant to degradation by Protein C).\n\nPATHOPHYSIOLOGY:\nFactor V Leiden is the most common inherited thrombophilia, present in approximately 5% of Caucasian populations (less common in African and Asian populations). The mutation is a single nucleotide substitution (G1691A) in the Factor V gene that replaces arginine with glutamine at position 506 (R506Q), which is the primary cleavage site where activated protein C (APC) normally inactivates Factor Va. The mutant Factor V Leiden is activated normally to Factor Va (functioning as a procoagulant cofactor in the prothrombinase complex) but resists proteolytic inactivation by APC, resulting in prolonged Factor Va activity and excessive thrombin generation.\n\nTHROMBOTIC RISK:\nHeterozygous Factor V Leiden carriers have a 3 to 8-fold increased risk of venous thromboembolism (VTE) over their lifetime, while homozygous carriers have a 50 to 80-fold increased risk. The thrombotic risk is primarily venous (deep vein thrombosis, pulmonary embolism) rather than arterial, and is significantly amplified by concurrent risk factors including oral contraceptive use (35-fold risk when combined with heterozygous FVL), pregnancy, surgery, immobilization, and obesity.\n\nCLINICAL APPLICATION:\nTesting for Factor V Leiden is performed using the APC resistance assay (functional screening) followed by confirmatory genetic testing. Routine population screening is not recommended; testing is indicated for patients with unprovoked VTE (especially before age 50), recurrent VTE, VTE at unusual sites (cerebral venous sinus, mesenteric, portal), and strong family history of VTE. Heterozygous carriers with a single provoked VTE do not require lifelong anticoagulation, while those with recurrent or unprovoked events may benefit from extended anticoagulation.\n\nKEY POINTS:\nFactor V Leiden (R506Q mutation) causes activated protein C resistance, the most common inherited thrombophilia (5% of Caucasians). Heterozygotes have 3 to 8-fold VTE risk, amplified to 35-fold by oral contraceptive use. The thrombotic risk is venous, not arterial, and testing is indicated for unprovoked VTE, recurrent VTE, or strong family history."
  },
  {
    "id": 334,
    "categoryId": 9,
    "question": "G6PD Deficiency causes hemolysis when patients are exposed to oxidative stressors. Which is a classic trigger?",
    "options": [
      "A) Fava Beans",
      "B) Penicillin",
      "C) Sunlight",
      "D) Gluten"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Fava Beans).\n\nPATHOPHYSIOLOGY:\nGlucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy, affecting over 400 million people worldwide with highest prevalence in malaria-endemic regions (Africa, Mediterranean, Middle East, Southeast Asia) due to heterozygote advantage against Plasmodium falciparum malaria. G6PD is the rate-limiting enzyme of the hexose monophosphate shunt (pentose phosphate pathway), which generates NADPH, the essential reducing agent that maintains glutathione in its reduced form (GSH). Reduced glutathione protects hemoglobin and red cell membranes from oxidative damage. Without adequate G6PD, red blood cells cannot regenerate NADPH and are exquisitely vulnerable to oxidative stress.\n\nOXIDATIVE TRIGGERS:\nFava beans (Vicia faba) contain the oxidant compounds vicine and convicine (and their aglycones divicine and isouramil), which generate reactive oxygen species that overwhelm the G6PD-deficient red cell's diminished antioxidant defense. The resulting oxidative damage denatures hemoglobin (forming Heinz bodies, precipitates of denatured hemoglobin visible with crystal violet staining) and damages the red cell membrane, leading to both intravascular and extravascular hemolysis. Other classic triggers include medications (primaquine, dapsone, sulfonamides, nitrofurantoin, rasburicase, methylene blue) and infections (which generate oxidative stress via the neutrophil respiratory burst).\n\nCLINICAL PRESENTATION:\nAcute hemolytic episodes present 1 to 3 days after oxidant exposure with dark urine (hemoglobinuria), jaundice, fatigue, tachycardia, and back/abdominal pain. Laboratory findings include anemia, elevated LDH, indirect hyperbilirubinemia, low haptoglobin, reticulocytosis, and Heinz bodies on special staining. The peripheral smear characteristically shows \"bite cells\" (where splenic macrophages have removed Heinz body inclusions).\n\nKEY POINTS:\nFava beans are a classic G6PD deficiency trigger, containing vicine and convicine that generate oxidative stress in NADPH-depleted red cells. G6PD deficiency is the most common enzymopathy worldwide, with selective advantage against malaria. The hemolytic episode produces Heinz bodies (denatured hemoglobin) and bite cells (post-splenic removal of inclusions)."
  },
  {
    "id": 335,
    "categoryId": 9,
    "question": "Folate Deficiency and B12 Deficiency both cause Megaloblastic Anemia. B12 deficiency is distinguished by:",
    "options": [
      "A) Jaundice",
      "B) Neurologic symptoms (Paresthesia, Ataxia)",
      "C) Glossitis",
      "D) Diarrhea"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Neurologic symptoms: paresthesia, ataxia).\n\nPATHOPHYSIOLOGY:\nBoth folate (B9) and vitamin B12 (cobalamin) are essential for DNA synthesis, specifically for the conversion of deoxyuridine monophosphate (dUMP) to deoxythymidine monophosphate (dTMP) by thymidylate synthase, which requires methylenetetrahydrofolate as the methyl donor. Deficiency of either vitamin impairs DNA synthesis while RNA and protein synthesis continue normally, producing megaloblastic changes (large cells with immature nuclei but mature cytoplasm) in rapidly dividing cells, particularly erythroid precursors (causing macrocytic anemia with hypersegmented neutrophils).\n\nWHY B12 UNIQUELY CAUSES NEUROLOGIC DISEASE:\nVitamin B12 serves as a cofactor for methylmalonyl-CoA mutase, an enzyme entirely independent of folate metabolism. When B12 is deficient, methylmalonyl-CoA accumulates and is shunted to abnormal odd-chain fatty acids that are incorporated into myelin sheaths, disrupting myelin structure and causing demyelination (subacute combined degeneration of the spinal cord). The dorsal columns are affected first (loss of proprioception and vibratory sense, positive Romberg sign, sensory ataxia), followed by the lateral corticospinal tracts (spasticity, weakness, hyperreflexia, Babinski sign). Peripheral neuropathy (symmetric paresthesias in stocking-glove distribution) often precedes myelopathy. Folate deficiency does not cause neurologic disease because folate is not involved in the methylmalonyl-CoA pathway.\n\nDIAGNOSTIC APPROACH:\nMethylmalonic acid (MMA) is elevated in B12 deficiency only (specific), while homocysteine is elevated in both B12 and folate deficiency (sensitive but not specific). This distinction makes MMA the key differentiating test.\n\nCRITICAL WARNING:\nAdministering folate alone to a patient with undiagnosed B12 deficiency will correct the anemia (by restoring DNA synthesis) but will not treat and may mask progressive irreversible neurologic damage.\n\nKEY POINTS:\nB12 deficiency uniquely causes neurologic disease (subacute combined degeneration: dorsal column and lateral corticospinal tract demyelination) because B12 is the exclusive cofactor for methylmalonyl-CoA mutase. Folate deficiency causes identical megaloblastic anemia but no neurologic symptoms. Folate supplementation alone can mask B12 deficiency while neurologic damage progresses irreversibly."
  },
  {
    "id": 336,
    "categoryId": 9,
    "question": "A patient develops fever, flank pain, and dark urine 15 minutes after starting a blood transfusion. Diagnosis?",
    "options": [
      "A) Febrile Non-Hemolytic Reaction",
      "B) Acute Hemolytic Transfusion Reaction (ABO incompatibility)",
      "C) TRALI",
      "D) Anaphylaxis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Hemolytic Transfusion Reaction from ABO incompatibility).\n\nPATHOPHYSIOLOGY:\nAcute hemolytic transfusion reaction (AHTR) is a medical emergency caused by transfusion of ABO-incompatible red blood cells, resulting in rapid intravascular hemolysis mediated by preformed recipient IgM antibodies (anti-A or anti-B) that activate the classical complement cascade (C1 through C9 membrane attack complex) on donor red cell surfaces. The most common cause is clerical error (misidentification of the patient or blood product) rather than serologic incompatibility.\n\nCLINICAL PRESENTATION:\nSymptoms begin within minutes of starting the transfusion (typically within the first 15 mL) and include fever, rigors, flank pain (from renal cortical ischemia), hemoglobinuria (dark or red-brown urine), hypotension, tachycardia, chest pain, and a sense of impending doom. Intravascular hemolysis releases free hemoglobin, which scavenges nitric oxide (causing vasoconstriction and renal ischemia), precipitates in renal tubules (causing acute tubular necrosis and renal failure), and triggers disseminated intravascular coagulation (DIC). Mortality ranges from 2 to 10% and correlates with the volume of incompatible blood transfused.\n\nIMMEDIATE MANAGEMENT:\nThe transfusion must be stopped immediately and the IV line kept open with normal saline. The blood product and patient identification must be rechecked at the bedside. IV fluids (normal saline) should be administered aggressively to maintain renal perfusion and urine output (goal greater than 1 mL/kg/hour). The blood bank should be notified immediately for repeat type and crossmatch, and a direct antiglobulin test (Coombs test) should be performed. Laboratory studies include CBC, haptoglobin, LDH, indirect bilirubin, plasma-free hemoglobin, and coagulation studies (PT, aPTT, fibrinogen, D-dimer) to assess for DIC.\n\nKEY POINTS:\nAcute hemolytic transfusion reaction presents within minutes with fever, flank pain, and dark urine from complement-mediated intravascular hemolysis of ABO-incompatible red cells. The most common cause is clerical error in patient/product identification. Immediate management requires stopping the transfusion, aggressive IV fluids to prevent renal failure, and blood bank notification."
  },
  {
    "id": 337,
    "categoryId": 14,
    "question": "In Multiple Myeloma, the 'CRAB' criteria for organ damage include Calcium elevation, Renal insufficiency, Anemia, and:",
    "options": [
      "A) Bone lesions (Lytic)",
      "B) Biliary obstruction",
      "C) Brain metastases",
      "D) Bleeding"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bone lesions - Lytic).\n\nPATHOPHYSIOLOGY:\nThe B in CRAB stands for Bone lesions, completing the mnemonic for myeloma end-organ damage: Calcium elevation, Renal insufficiency, Anemia, and Bone disease. Bone involvement is present in approximately 80% of patients at diagnosis and is a common cause of morbidity in multiple myeloma. Malignant plasma cells secrete osteoclast-activating factors including RANKL and interleukin-6 that drive excessive bone resorption, while simultaneously inhibiting osteoblast function through dickkopf-1 and sclerostin, resulting in uncoupled remodeling with resorption far exceeding formation.\n\nCLINICAL MANIFESTATIONS:\nThis pathologic bone resorption produces the characteristic punched-out lytic lesions visible on imaging, most commonly affecting the axial skeleton (spine, skull, pelvis, ribs). Released calcium causes hypercalcemia. Patients present with bone pain (particularly back pain), pathologic fractures, vertebral compression fractures, and in severe cases spinal cord compression. Skull radiographs classically show a raindrop or pepper-pot pattern of multiple small lytic lesions.\n\nMANAGEMENT:\nBone-protective therapy with intravenous zoledronic acid or denosumab (a RANKL inhibitor) is standard of care for all myeloma patients with bone disease, reducing skeletal events including pathologic fractures. Dental evaluation before initiating bisphosphonate therapy is essential due to the risk of osteonecrosis of the jaw. Vertebroplasty or kyphoplasty may be considered for symptomatic vertebral compression fractures refractory to analgesics.\n\nKEY POINTS:\nThe CRAB criteria for myeloma end-organ damage are Calcium elevation, Renal insufficiency, Anemia, and Bone lesions (lytic). Myeloma bone disease results from osteoclast activation with simultaneous osteoblast suppression, creating purely lytic lesions that appear as punched-out holes on imaging. Bone-protective therapy with bisphosphonates or denosumab is standard of care to reduce skeletal events."
  },
  {
    "id": 338,
    "categoryId": 12,
    "question": "A 4-year-old presents with petechiae and bruising. CBC shows platelets 20k, Hgb 11, WBC 4. The smear shows large platelets. What is the management?",
    "options": [
      "A) Bone Marrow Biopsy",
      "B) Observation (if no severe bleeding)",
      "C) Platelet Transfusion",
      "D) Splenectomy"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Observation if no severe bleeding).\n\nPATHOPHYSIOLOGY:\nImmune thrombocytopenia (ITP) in children is an acquired autoimmune condition in which IgG autoantibodies bind to platelet surface glycoproteins (most commonly GPIIb/IIIa and GPIb/IX), leading to accelerated platelet destruction primarily by splenic macrophages via Fc receptor-mediated phagocytosis. Unlike adult ITP, which tends to be chronic, childhood ITP is typically acute, self-limited, and often follows a viral infection or vaccination by 1 to 4 weeks. The peak incidence is between 2 and 5 years of age, affecting boys and girls equally.\n\nCLINICAL REASONING:\nThis child presents with the classic ITP picture: an otherwise well-appearing child with sudden onset of petechiae and bruising (mucocutaneous bleeding), isolated severe thrombocytopenia (platelets 20,000), but normal hemoglobin and normal white blood cell count. The peripheral smear showing large (megathrombocytes) platelets reflects increased bone marrow thrombopoiesis in response to peripheral destruction, confirming that the marrow is functioning normally. The isolated thrombocytopenia with an otherwise normal CBC distinguishes ITP from leukemia (which typically shows anemia, abnormal WBC, and blasts on smear) and aplastic anemia (which shows pancytopenia). Bone marrow biopsy is not routinely required when the presentation is classic.\n\nMANAGEMENT:\nThe majority of children with ITP (approximately 80%) recover spontaneously within 6 to 12 months regardless of treatment. The current evidence-based approach from the ASH guidelines is observation with activity modification (avoiding contact sports and activities with high bleeding risk) for children with no bleeding or only mild mucocutaneous bleeding (petechiae, bruising, minor epistaxis), regardless of platelet count. Platelet transfusion is generally avoided because autoantibodies destroy transfused platelets rapidly, making transfusion ineffective except with life-threatening hemorrhage. Pharmacologic treatment (IVIG, corticosteroids, or anti-D immunoglobulin in Rh-positive patients) is reserved for clinically significant mucosal bleeding (persistent epistaxis, oral mucosal hemorrhage, heavy menstrual bleeding, gastrointestinal bleeding) or if surgery is required.\n\nKEY POINTS:\nChildhood ITP presents with isolated thrombocytopenia (normal Hgb and WBC) with petechiae and bruising in an otherwise well child, typically after a viral illness. Observation is appropriate when bleeding is absent or mild, as 80% of children recover spontaneously. Platelet transfusion is ineffective due to autoantibody-mediated destruction, and pharmacologic treatment is reserved for clinically significant bleeding."
  },
  {
    "id": 339,
    "categoryId": 9,
    "question": "Patients who undergo Splenectomy are at lifelong risk for Overwhelming Post-Splenectomy Infection (OPSI) from which organisms?",
    "options": [
      "A) Viruses",
      "B) Encapsulated Bacteria (Strep pneumo, H. flu, Meningococcus)",
      "C) Fungi",
      "D) Parasites"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Encapsulated Bacteria: S. pneumoniae, H. influenzae, N. meningitidis).\n\nPATHOPHYSIOLOGY:\nThe spleen is the primary site for clearance of encapsulated (polysaccharide-coated) bacteria from the bloodstream. Encapsulated organisms resist phagocytosis by complement and neutrophils because their polysaccharide capsule prevents C3b opsonization; the spleen compensates through its unique structure of slow-flow sinusoidal circulation that maximizes contact time between macrophages and circulating pathogens, and through its production of opsonins (IgM, properdin, tuftsin) that are essential for clearing encapsulated bacteria. Following splenectomy, patients lose this critical immune defense and face a lifelong risk of overwhelming post-splenectomy infection (OPSI), a fulminant sepsis that can progress from mild symptoms to death within 12 to 24 hours with a mortality rate of 50 to 70%.\n\nHIGHEST-RISK ORGANISMS:\nStreptococcus pneumoniae is responsible for approximately 50 to 60% of OPSI cases and is the single most dangerous pathogen in asplenic patients. Haemophilus influenzae type b and Neisseria meningitidis are the second and third most common causes. Other encapsulated organisms (Capnocytophaga canimorsus from dog bites, Babesia from tick bites, Salmonella, E. coli) also pose increased risk.\n\nPREVENTION:\nVaccination is critical and should ideally be administered at least 2 weeks before elective splenectomy. Required vaccines include pneumococcal (both PCV20 conjugate and PPSV23 polysaccharide), meningococcal (MenACWY and MenB), and Haemophilus influenzae type b (Hib). Annual influenza vaccination reduces the risk of secondary bacterial infection. Some guidelines recommend prophylactic penicillin (particularly in children and for the first 1 to 2 years post-splenectomy) and standby emergency antibiotics for all asplenic patients.\n\nKEY POINTS:\nSplenectomized patients have lifelong risk of overwhelming post-splenectomy infection (OPSI) from encapsulated bacteria, primarily S. pneumoniae (50 to 60% of cases), with mortality of 50 to 70%. The spleen's slow-flow sinusoidal circulation and opsonin production are essential for encapsulated organism clearance. Vaccination (pneumococcal, meningococcal, Hib) ideally 2 weeks pre-splenectomy is critical prevention."
  },
  {
    "id": 340,
    "categoryId": 9,
    "question": "Polycythemia Vera (PV) is a myeloproliferative disorder characterized by high RBC mass. 95% of patients have a mutation in:",
    "options": [
      "A) BCR-ABL",
      "B) JAK2",
      "C) P53",
      "D) BRCA1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (JAK2).\n\nPATHOPHYSIOLOGY:\nPolycythemia vera (PV) is a clonal myeloproliferative neoplasm characterized by erythropoietin-independent erythrocytosis resulting from a gain-of-function mutation in the Janus kinase 2 (JAK2) gene. The JAK2 V617F point mutation (valine to phenylalanine substitution at position 617 in the pseudokinase domain) is present in approximately 95% of PV patients, while the remaining 5% carry JAK2 exon 12 mutations. This mutation causes constitutive activation of the JAK-STAT signaling pathway downstream of the erythropoietin receptor (as well as thrombopoietin and G-CSF receptors), driving unregulated proliferation of erythroid, megakaryocytic, and granulocytic lineages.\n\nCLINICAL PRESENTATION:\nPV presents with elevated hemoglobin and hematocrit (often discovered incidentally on CBC), erythromelalgia (burning pain and redness of hands and feet from microvascular thrombosis), pruritus (especially aquagenic pruritus after warm baths, mediated by basophil histamine release), splenomegaly, headache, and visual disturbances. The major complications are thrombosis (both arterial and venous, occurring in 40% of untreated patients, including Budd-Chiari syndrome, portal vein thrombosis, stroke, and MI) and transformation to myelofibrosis or acute myeloid leukemia.\n\nDIAGNOSIS AND MANAGEMENT:\nThe WHO diagnostic criteria require elevated hemoglobin (greater than 16.5 g/dL in men or 16.0 g/dL in women) or hematocrit (greater than 49% in men or 48% in women), bone marrow biopsy showing panmyelosis with pleomorphic megakaryocytes, and presence of JAK2 mutation. Serum erythropoietin is characteristically low (distinguishing PV from secondary polycythemia where EPO is elevated). First-line treatment is therapeutic phlebotomy (target hematocrit below 45%) plus low-dose aspirin. Cytoreductive therapy (hydroxyurea first-line) is added for high-risk patients (age over 60 or prior thrombosis).\n\nKEY POINTS:\nThe JAK2 V617F mutation is present in approximately 95% of polycythemia vera cases, causing constitutive activation of the JAK-STAT pathway and erythropoietin-independent erythrocytosis. Major complications are thrombosis (40% untreated) and transformation to myelofibrosis or AML. Treatment is phlebotomy (target hematocrit below 45%) plus low-dose aspirin, with hydroxyurea for high-risk patients."
  },
  {
    "id": 341,
    "categoryId": 14,
    "question": "The presence of the Philadelphia Chromosome t(9;22) is diagnostic for:",
    "options": [
      "A) CML (Chronic Myeloid Leukemia)",
      "B) CLL",
      "C) AML",
      "D) Hodgkin Lymphoma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (CML - Chronic Myeloid Leukemia).\n\nPATHOPHYSIOLOGY:\nThe Philadelphia chromosome is a reciprocal translocation between chromosomes 9 and 22, designated t(9;22)(q34;q11.2), that juxtaposes the ABL1 proto-oncogene from chromosome 9 with the BCR gene on chromosome 22, creating the BCR-ABL1 fusion gene. This fusion gene encodes a constitutively active tyrosine kinase that drives uncontrolled myeloid cell proliferation, decreased apoptosis, and genomic instability through activation of multiple downstream signaling pathways including RAS-MAPK, JAK-STAT, and PI3K-Akt. The Philadelphia chromosome is present in >95% of CML cases and is the defining molecular abnormality of the disease. It is also found in approximately 25% of adult acute lymphoblastic leukemia cases, where it confers a worse prognosis.\n\nCLINICAL PRESENTATION:\nCML typically presents in chronic phase (approximately 85% of diagnoses) with fatigue, weight loss, early satiety from splenomegaly, and a markedly elevated white blood cell count with a left-shifted differential showing the full spectrum of myeloid maturation along with basophilia. Without treatment, CML progresses through an accelerated phase to blast crisis, which resembles acute leukemia and carries a dismal prognosis.\n\nTREATMENT:\nThe development of imatinib (Gleevec), the first tyrosine kinase inhibitor specifically designed to block BCR-ABL1 kinase activity, transformed CML from a rapidly fatal disease into a chronic manageable condition. The landmark IRIS trial demonstrated complete cytogenetic responses in over 80% of patients, with 10-year overall survival exceeding 80% per data published in the New England Journal of Medicine. Second-generation TKIs (dasatinib, nilotinib, bosutinib) and the third-generation TKI ponatinib provide options for resistance or intolerance. Molecular monitoring of BCR-ABL1 transcript levels by quantitative RT-PCR guides treatment decisions.\n\nKEY POINTS:\nThe Philadelphia chromosome t(9;22) creates the BCR-ABL1 constitutively active tyrosine kinase that drives CML, present in >95% of cases. Imatinib and subsequent TKIs transformed CML into a chronic condition with greater than 80% ten-year survival. Quantitative BCR-ABL1 transcript monitoring by RT-PCR guides treatment response assessment."
  },
  {
    "id": 342,
    "categoryId": 9,
    "question": "Warfarin-induced Skin Necrosis is a rare complication seen in patients with undiagnosed:",
    "options": [
      "A) Protein C Deficiency",
      "B) Factor V Leiden",
      "C) Hemophilia",
      "D) Von Willebrand Disease"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Protein C Deficiency).\n\nPATHOPHYSIOLOGY:\nWarfarin-induced skin necrosis is a rare but devastating complication that occurs in patients with undiagnosed protein C (or less commonly protein S) deficiency during the first few days of warfarin initiation. The mechanism is a paradoxical transient hypercoagulable state that arises because warfarin inhibits not only the procoagulant factors (II, VII, IX, X) but also the endogenous anticoagulant proteins C and S, which are also vitamin K-dependent. Protein C has the shortest half-life (approximately 6 to 8 hours) among all vitamin K-dependent factors, so its levels fall first when warfarin is initiated.\n\nTIMECOURSE:\nIn patients with already low baseline protein C (heterozygous deficiency), warfarin causes protein C to reach critically low levels within 24 to 48 hours while the procoagulant factors (especially Factor II with its 60-hour half-life) are still functional. This creates a transient window of unopposed procoagulant activity, causing microvascular thrombosis in dermal and subcutaneous venules. The resulting thrombotic occlusion produces hemorrhagic skin infarction, typically in areas with abundant subcutaneous fat (breasts, buttocks, thighs, abdomen).\n\nPREVENTION AND MANAGEMENT:\nWarfarin-induced skin necrosis can be prevented by overlapping warfarin initiation with heparin (UFH or LMWH) for a minimum of 5 days and until the INR is therapeutic for at least 24 hours, ensuring adequate anticoagulation during the period of protein C depletion. Warfarin should never be started at high loading doses (which accelerate protein C depletion relative to procoagulant factors). If skin necrosis develops, warfarin must be discontinued immediately, full-dose heparin anticoagulation initiated, and protein C concentrate administered if available.\n\nKEY POINTS:\nWarfarin-induced skin necrosis occurs in protein C deficiency because protein C (half-life 6 to 8 hours) is depleted before procoagulant factors, creating a transient hypercoagulable state with microvascular thrombosis. It presents as hemorrhagic skin infarction in fat-rich areas within 3 to 5 days of warfarin initiation. Prevention requires heparin bridging for at least 5 days and avoidance of high warfarin loading doses."
  },
  {
    "id": 343,
    "categoryId": 14,
    "question": "Reed-Sternberg Cells ('Owl's Eye' appearance) are the hallmark of:",
    "options": [
      "A) Non-Hodgkin Lymphoma",
      "B) Hodgkin Lymphoma",
      "C) Burkitt Lymphoma",
      "D) Multiple Myeloma"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hodgkin Lymphoma).\n\nPATHOPHYSIOLOGY:\nReed-Sternberg cells are the pathognomonic malignant cells of Hodgkin lymphoma, recognized by their distinctive morphology: large binucleated or multinucleated cells with prominent eosinophilic nucleoli and abundant cytoplasm, creating the classic owl-eye appearance on microscopy. Despite their B-cell lineage origin (derived from germinal center B cells), Reed-Sternberg cells have lost expression of most B-cell markers due to crippling immunoglobulin gene mutations. They characteristically express CD15 and CD30 while lacking CD20 and CD45, an immunophenotypic profile that is diagnostically useful. Reed-Sternberg cells typically constitute less than 1 to 2% of the tumor mass, with the remainder composed of a reactive inflammatory infiltrate of lymphocytes, eosinophils, macrophages, and fibroblasts.\n\nCLINICAL PRESENTATION:\nHodgkin lymphoma has a characteristic bimodal age distribution with a first peak in young adults (ages 15 to 35) and a second peak in adults over age 55. The typical presentation is painless cervical or supraclavicular lymphadenopathy. A distinctive clinical feature is alcohol-induced lymph node pain, which is uncommon but highly specific for Hodgkin lymphoma when present. The disease spreads contiguously from one lymph node group to adjacent groups in a predictable anatomic pattern, distinguishing it from non-Hodgkin lymphomas that tend to spread hematogenously.\n\nTREATMENT:\nHodgkin lymphoma is one of the most curable malignancies. Early-stage disease is treated with abbreviated ABVD chemotherapy (Adriamycin, Bleomycin, Vinblastine, Dacarbazine) with or without involved-site radiation, achieving cure rates exceeding 90%. Advanced-stage disease is treated with extended chemotherapy with cure rates of approximately 70 to 80%. Long-term survivors require monitoring for secondary malignancies (particularly breast cancer after mediastinal radiation), cardiovascular disease from anthracyclines, and pulmonary toxicity from bleomycin.\n\nKEY POINTS:\nReed-Sternberg cells with owl-eye morphology are pathognomonic for Hodgkin lymphoma and express CD15 and CD30 while lacking typical B-cell markers. Hodgkin lymphoma spreads contiguously between adjacent lymph node groups, has a bimodal age distribution, and is one of the most curable malignancies with early-stage cure rates exceeding 90%. Long-term survivor surveillance for secondary malignancies and treatment-related toxicity is essential."
  },
  {
    "id": 344,
    "categoryId": 9,
    "question": "Which clotting pathway is measured by the PT/INR?",
    "options": [
      "A) Intrinsic Pathway",
      "B) Extrinsic Pathway",
      "C) Common Pathway only",
      "D) Fibrinolysis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Extrinsic Pathway).\n\nPHYSIOLOGY:\nThe prothrombin time (PT) and its standardized ratio (INR, International Normalized Ratio) measure the integrity of the extrinsic and common pathways of the coagulation cascade. The PT assay works by adding tissue factor (thromboplastin) and calcium to citrated plasma, which activates Factor VII (the sole component of the extrinsic pathway), initiating the extrinsic cascade through the Factor VII-tissue factor complex.\n\nCOAGULATION CASCADE:\nThe extrinsic pathway begins when tissue factor (TF) exposed at sites of vascular injury binds Factor VII, forming the TF-VIIa complex that activates Factor X. The common pathway then proceeds through Factor Xa (in complex with Factor Va on the prothrombinase complex) to convert prothrombin (Factor II) to thrombin, which cleaves fibrinogen to fibrin. The PT therefore reflects the function of Factor VII (extrinsic), and Factors X, V, II, and fibrinogen (common pathway).\n\nCOMPARISON WITH aPTT:\nThe activated partial thromboplastin time (aPTT) measures the intrinsic and common pathways by adding a contact activator (kaolin, celite, or ellagic acid), phospholipid, and calcium to plasma, activating the contact factors (XII, XI) and then Factors IX and VIII (intrinsic pathway) before converging on the common pathway. A prolonged PT with normal aPTT indicates isolated Factor VII deficiency or early warfarin effect (Factor VII has the shortest half-life). A prolonged aPTT with normal PT indicates intrinsic pathway factor deficiency (XII, XI, IX, VIII) as seen in hemophilia A (VIII) or B (IX). Both prolonged indicates common pathway or multiple factor involvement.\n\nCLINICAL APPLICATION:\nThe INR standardizes PT results across laboratories using the International Sensitivity Index (ISI) of the thromboplastin reagent, enabling consistent warfarin monitoring. Therapeutic INR ranges are 2.0 to 3.0 for most indications (atrial fibrillation, DVT/PE) and 2.5 to 3.5 for mechanical heart valves.\n\nKEY POINTS:\nThe PT/INR measures the extrinsic pathway (Factor VII) and common pathway (X, V, II, fibrinogen) and is used to monitor warfarin therapy. The aPTT measures the intrinsic pathway (XII, XI, IX, VIII) and common pathway, monitoring heparin therapy. Isolated PT prolongation suggests Factor VII deficiency or early warfarin effect."
  },
  {
    "id": 345,
    "categoryId": 9,
    "question": "Basophilic Stippling on a peripheral blood smear is classic for:",
    "options": [
      "A) Iron Deficiency",
      "B) Lead Poisoning",
      "C) B12 Deficiency",
      "D) Folate Deficiency"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lead Poisoning).\n\nPATHOPHYSIOLOGY:\nBasophilic stippling describes the presence of numerous fine blue granules (composed of aggregated ribosomal RNA and degraded mitochondrial remnants) distributed throughout the red blood cell cytoplasm on Wright-Giemsa staining. In lead poisoning, lead inhibits pyrimidine-5'-nucleotidase, the enzyme responsible for degrading residual ribosomal RNA during red cell maturation. Without this enzyme, ribosomal RNA aggregates persist in the mature erythrocyte and are visible as basophilic stippling.\n\nLEAD EFFECTS ON HEME SYNTHESIS:\nLead also inhibits two critical enzymes in the heme synthesis pathway: delta-aminolevulinic acid dehydratase (ALA dehydratase, also called porphobilinogen synthase), causing accumulation of ALA in blood and urine, and ferrochelatase, the final enzyme that inserts iron into protoporphyrin IX to form heme, causing elevated free erythrocyte protoporphyrin (FEP) and zinc protoporphyrin (ZPP). The combined result is a microcytic sideroblastic anemia with basophilic stippling, ringed sideroblasts on Prussian blue staining (from mitochondrial iron accumulation), and elevated ALA and FEP levels.\n\nCLINICAL PRESENTATION:\nLead poisoning in children (the most vulnerable population due to hand-to-mouth behavior and developing nervous system) presents with abdominal pain (\"lead colic\"), constipation, behavioral changes, developmental delay, and microcytic anemia with basophilic stippling. In adults, lead exposure (occupational: battery manufacturing, smelting, painting) causes peripheral neuropathy (wrist drop from radial nerve involvement), nephropathy, gout (saturniine gout from decreased uric acid excretion), and Burton lines (blue-black lines on the gingival margin).\n\nOTHER CAUSES OF BASOPHILIC STIPPLING:\nWhile lead poisoning is the classic association, basophilic stippling also occurs in thalassemia, myelodysplastic syndromes, and severe megaloblastic anemias. However, coarse basophilic stippling with microcytic anemia and clinical features of toxicity is highly suggestive of lead poisoning.\n\nKEY POINTS:\nBasophilic stippling is classic for lead poisoning, resulting from lead inhibition of pyrimidine-5'-nucleotidase (ribosomal RNA degradation failure). Lead also inhibits ALA dehydratase and ferrochelatase in heme synthesis, producing microcytic sideroblastic anemia with elevated FEP and ALA. In children, look for abdominal pain, developmental delay, and microcytic anemia; in adults, wrist drop, nephropathy, and Burton lines."
  },
  {
    "id": 346,
    "categoryId": 9,
    "question": "Aplastic Anemia presents with Pancytopenia (Low WBC, Low RBC, Low Platelets). The bone marrow biopsy will show:",
    "options": [
      "A) Hypercellularity with blasts",
      "B) Hypocellularity (mostly fat)",
      "C) Fibrosis",
      "D) Granulomas"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypocellularity, mostly fat).\n\nPATHOPHYSIOLOGY:\nAplastic anemia is a bone marrow failure syndrome characterized by pancytopenia (simultaneous reduction in all three blood cell lineages: red blood cells, white blood cells, and platelets) resulting from destruction or suppression of hematopoietic stem cells. The bone marrow biopsy in aplastic anemia reveals marked hypocellularity with replacement of normal hematopoietic tissue by fat (adipocytes), typically showing less than 25% cellularity (or less than 50% cellularity with less than 30% hematopoietic cells).\n\nETIOLOGY:\nIn approximately 70% of cases, aplastic anemia is idiopathic (presumed autoimmune, mediated by autoreactive cytotoxic T-lymphocytes that attack CD34-positive hematopoietic stem cells through interferon-gamma and TNF-alpha). Identifiable causes include medications (chloramphenicol, carbamazepine, phenytoin, sulfonamides, NSAIDs, gold), toxins (benzene), viral infections (hepatitis-associated aplastic anemia, particularly non-A through E hepatitis; EBV, CMV, parvovirus B19), radiation exposure, and inherited syndromes (Fanconi anemia, dyskeratosis congenita).\n\nCLINICAL PRESENTATION:\nPatients present with symptoms reflecting the pancytopenia: fatigue, pallor, and dyspnea (from anemia), recurrent or severe infections (from neutropenia), and petechiae, purpura, mucosal bleeding, and menorrhagia (from thrombocytopenia). The reticulocyte count is markedly low (reflecting bone marrow failure).\n\nTREATMENT:\nFor patients under 40 with a matched sibling donor, allogeneic hematopoietic stem cell transplantation is the treatment of choice with cure rates of 75 to 90%. For older patients or those without a matched donor, immunosuppressive therapy with anti-thymocyte globulin (ATG) plus cyclosporine produces response rates of 60 to 70% by eliminating the autoreactive T-cell clone. Eltrombopag (a thrombopoietin receptor agonist that stimulates hematopoietic stem cells) added to IST improves overall and complete response rates.\n\nKEY POINTS:\nAplastic anemia shows a hypocellular (fat-replaced) bone marrow with pancytopenia, caused by T-cell-mediated destruction of hematopoietic stem cells in 70% of cases. Allogeneic stem cell transplant is curative for young patients with matched donors. Immunosuppressive therapy (ATG plus cyclosporine plus eltrombopag) achieves 60 to 70% response in transplant-ineligible patients."
  },
  {
    "id": 347,
    "categoryId": 1,
    "question": "In a patient with low pre-test probability for DVT (Wells Score < 2), the appropriate initial test is:",
    "options": [
      "A) D-Dimer",
      "B) Ultrasound Doppler",
      "C) Venogram",
      "D) Start Anticoagulation"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (D-Dimer).\n\nCLINICAL REASONING:\nThe diagnostic approach to suspected deep vein thrombosis begins with clinical pre-test probability assessment using the Wells Score, which stratifies patients into DVT unlikely (less than 2 points) or DVT likely (2 or more points) using the modified two-tier model probability categories based on clinical features including active cancer, paralysis or immobilization, recent surgery, localized tenderness along the deep venous system, entire leg swelling, calf swelling greater than 3 cm compared to the asymptomatic leg, pitting edema, collateral superficial veins, and prior documented DVT.\n\nD-DIMER IN LOW PRE-TEST PROBABILITY:\nIn patients with a low Wells Score (less than 2), the D-dimer assay is the appropriate initial test because of its high sensitivity (95 to 97%) and excellent negative predictive value in this population. D-dimer is a fibrin degradation product generated when cross-linked fibrin within a thrombus undergoes plasmin-mediated lysis. A negative high-sensitivity D-dimer in a low-probability patient effectively rules out DVT without the need for imaging, sparing patients unnecessary ultrasound examinations and reducing healthcare costs. However, D-dimer is nonspecific and is elevated in many conditions including infection, inflammation, malignancy, pregnancy, recent surgery, trauma, and advanced age, which is why a positive result in a low-risk patient requires confirmatory compression ultrasonography before initiating treatment.\n\nWHEN TO SKIP D-DIMER:\nPatients with moderate or high Wells Scores should proceed directly to compression ultrasonography because D-dimer lacks sufficient negative predictive value in these higher-risk populations to safely exclude DVT. This risk-stratified algorithm reduces unnecessary imaging by approximately 30% while maintaining diagnostic safety.\n\nKEY POINTS:\nD-dimer is the appropriate initial test for suspected DVT when pre-test probability is low (Wells Score less than 2) because its high sensitivity and negative predictive value can safely rule out DVT without imaging. A positive D-dimer requires confirmatory ultrasound. Moderate or high pre-test probability patients should proceed directly to compression ultrasonography, bypassing D-dimer."
  },
  {
    "id": 348,
    "categoryId": 9,
    "question": "The '4 Ts' score is used to estimate the probability of Heparin-Induced Thrombocytopenia (HIT). Which is NOT a T?",
    "options": [
      "A) Thrombocytopenia (degree of drop)",
      "B) Timing (days 5-10)",
      "C) Thrombosis (new clot)",
      "D) Temperature (Fever)"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Temperature/Fever is NOT one of the 4 Ts).\n\nCLINICAL TOOL:\nThe 4Ts scoring system is a validated clinical prediction tool used to estimate the pretest probability of heparin-induced thrombocytopenia (HIT) type II, guiding the urgency of confirmatory testing and the decision to discontinue heparin. The four components (each scored 0, 1, or 2 points for a maximum of 8) are Thrombocytopenia (degree of platelet fall), Timing (of platelet drop relative to heparin exposure), Thrombosis (new thrombotic events or other clinical sequelae), and oTher causes of thrombocytopenia excluded.\n\nSCORING DETAILS:\nThrombocytopenia: platelet fall greater than 50% and nadir 20,000 or greater scores 2 points; fall of 30 to 50% or nadir 10,000 to 19,000 scores 1 point; fall less than 30% or nadir less than 10,000 scores 0. Timing: onset 5 to 10 days after heparin start (or within 1 day with prior exposure in past 30 days) scores 2 points. Thrombosis: confirmed new thrombosis, skin necrosis, or acute systemic reaction scores 2 points. Other causes: no other explanation for thrombocytopenia scores 2 points, while possible alternative causes (sepsis, DIC, other medications) reduce the score.\n\nINTERPRETATION:\nA 4Ts score of 0 to 3 indicates low probability (negative predictive value >99%, HIT essentially excluded), 4 to 5 indicates intermediate probability (requiring further testing with anti-PF4/heparin ELISA and possibly functional assay), and 6 to 8 indicates high probability (empiric treatment with non-heparin anticoagulant should begin immediately while awaiting confirmatory testing). Temperature (fever) is not included because while fever can occur as part of an acute systemic reaction to heparin in HIT, it is not a scored component of the 4Ts system.\n\nKEY POINTS:\nThe 4Ts for HIT probability are Thrombocytopenia (degree of platelet fall), Timing (5 to 10 days or within 1 day with prior exposure), Thrombosis (new events), and oTher causes excluded. Temperature/fever is not a scored component. A score of 0 to 3 has >99% negative predictive value, effectively ruling out HIT."
  },
  {
    "id": 349,
    "categoryId": 9,
    "question": "Tumor Lysis Syndrome causes which electrolyte abnormalities?",
    "options": [
      "A) Hyperkalemia, Hyperphosphatemia, Hyperuricemia, Hypocalcemia",
      "B) Hypokalemia, Hypophosphatemia, Hypercalcemia",
      "C) Hypernatremia, Hypercalcemia",
      "D) Normal electrolytes"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hyperkalemia, Hyperphosphatemia, Hyperuricemia, Hypocalcemia).\n\nPATHOPHYSIOLOGY:\nTumor lysis syndrome (TLS) is an oncologic emergency caused by the rapid massive destruction of malignant cells (either spontaneously or following initiation of cytotoxic therapy), releasing intracellular contents into the bloodstream in quantities that overwhelm the body's homeostatic and excretory mechanisms. The four characteristic electrolyte abnormalities each arise from a specific intracellular component.\n\nELECTROLYTE DERANGEMENTS:\nHyperkalemia results from release of intracellular potassium (the predominant intracellular cation, concentration approximately 140 mEq/L inside cells) and poses the most immediately life-threatening risk (cardiac arrhythmias, cardiac arrest). Hyperphosphatemia results from release of intracellular phosphate and phospholipids, and the excess phosphate binds serum calcium, causing secondary hypocalcemia (which can produce tetany, seizures, and QT prolongation). Hyperuricemia results from the massive catabolism of purine nucleic acids (adenine, guanine) through xanthine oxidase to uric acid, which can precipitate in renal tubules (particularly in acidic urine) causing acute uric acid nephropathy and oliguric renal failure.\n\nRISK FACTORS:\nTLS is most common in highly proliferative, bulky, and treatment-sensitive malignancies: Burkitt lymphoma (the highest risk), acute lymphoblastic leukemia (especially with high WBC count), diffuse large B-cell lymphoma, and acute myeloid leukemia with high WBC. High tumor burden (large mass, elevated LDH, elevated WBC), renal impairment, dehydration, and acidic urine increase risk.\n\nPREVENTION AND MANAGEMENT:\nAggressive IV hydration (maintain urine output above 2 mL/kg/hour) is the cornerstone of prevention. Allopurinol (xanthine oxidase inhibitor, prevents new uric acid formation) is used for moderate-risk patients. Rasburicase (recombinant urate oxidase that enzymatically converts existing uric acid to the highly soluble allantoin) is preferred for high-risk patients and established TLS. Rasburicase is contraindicated in G6PD deficiency (generates hydrogen peroxide that causes hemolysis in G6PD-deficient cells).\n\nKEY POINTS:\nTumor lysis syndrome produces hyperkalemia (cardiac arrest risk), hyperphosphatemia (from intracellular release), secondary hypocalcemia (phosphate-calcium binding), and hyperuricemia (purine catabolism causing renal failure). Highest risk in Burkitt lymphoma and ALL with high tumor burden. Rasburicase is preferred for high-risk prevention but is contraindicated in G6PD deficiency."
  },
  {
    "id": 350,
    "categoryId": 9,
    "question": "Hereditary Spherocytosis causes hemolytic anemia due to a defect in:",
    "options": [
      "A) Hemoglobin",
      "B) RBC Membrane Proteins (Spectrin/Ankyrin)",
      "C) Enzymes (G6PD)",
      "D) Mitochondria"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (RBC Membrane Proteins, Spectrin/Ankyrin).\n\nPATHOPHYSIOLOGY:\nHereditary spherocytosis (HS) is the most common inherited hemolytic anemia in individuals of Northern European descent (prevalence approximately 1 in 2,000) caused by mutations in genes encoding red blood cell membrane skeleton proteins, most commonly ankyrin (approximately 40% of cases), band 3 (approximately 25%), spectrin (alpha or beta, approximately 20%), and protein 4.2. These proteins form the vertical interactions that anchor the phospholipid bilayer to the underlying spectrin-actin cytoskeletal network.\n\nMEMBRANE DEFECT AND SPHEROCYTE FORMATION:\nWhen vertical linkage proteins are deficient, the lipid bilayer loses its structural support and undergoes progressive loss of membrane surface area through vesiculation (budding off of lipid microvesicles). As the cell loses surface area while maintaining its volume, it transitions from the normal biconcave disc shape to a sphere (the geometric shape with minimum surface-area-to-volume ratio). Spherocytes are rigid, less deformable, and cannot navigate the narrow fenestrations (2 to 3 micrometers) of the splenic red pulp sinusoidal slits, where they are trapped and destroyed by splenic macrophages (extravascular hemolysis).\n\nDIAGNOSIS:\nThe peripheral smear shows spherocytes (dense, round cells lacking central pallor) and the mean corpuscular hemoglobin concentration (MCHC) is elevated (greater than 36 g/dL, reflecting cellular dehydration). The osmotic fragility test (classic diagnostic test) demonstrates increased lysis of spherocytes in hypotonic saline because their reduced surface-area-to-volume ratio leaves less reserve for osmotic swelling. The eosin-5-maleimide (EMA) binding test (flow cytometry) is a newer, more specific diagnostic test that detects reduced band 3 protein on the red cell surface.\n\nMANAGEMENT:\nFolate supplementation (to support the compensatory erythropoietic drive) is recommended for most patients. Splenectomy is curative for severe cases (it eliminates the site of spherocyte destruction), but must be weighed against the lifelong risk of overwhelming post-splenectomy infection.\n\nKEY POINTS:\nHereditary spherocytosis results from mutations in RBC membrane skeleton proteins (ankyrin, band 3, spectrin), causing membrane loss, spherocyte formation, and extravascular hemolysis in the spleen. Elevated MCHC and increased osmotic fragility are characteristic. Splenectomy is curative but carries lifelong infection risk from encapsulated organisms."
  },
  {
    "id": 351,
    "categoryId": 9,
    "question": "Hemophilia A is a deficiency of Factor VIII. The inheritance pattern is:",
    "options": [
      "A) Autosomal Dominant",
      "B) Autosomal Recessive",
      "C) X-Linked Recessive",
      "D) Mitochondrial"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (X-Linked Recessive).\n\nGENETICS:\nHemophilia A results from mutations in the F8 gene located on the long arm of the X chromosome (Xq28), encoding coagulation Factor VIII. As an X-linked recessive disorder, hemophilia A predominantly affects males (who have only one X chromosome and therefore express the disease with a single mutant allele) while females are typically asymptomatic carriers (the normal F8 allele on the second X chromosome provides sufficient Factor VIII production). Approximately 30% of cases arise from de novo mutations with no prior family history.\n\nINHERITANCE PATTERN:\nA carrier mother (XHXh) has a 50% chance of passing the affected X chromosome to each son (who will have hemophilia) and a 50% chance of passing it to each daughter (who will be a carrier). An affected father (XhY) will pass his affected X to all daughters (making them obligate carriers) and his Y to all sons (who will be unaffected). In rare cases, females may manifest hemophilia through homozygous mutation, Turner syndrome (45,X with affected X), extreme lyonization (skewed X-inactivation), or compound heterozygosity.\n\nCLINICAL PRESENTATION:\nHemophilia A severity correlates with Factor VIII activity levels: severe (<1%, spontaneous hemarthroses and deep tissue bleeding), moderate (1 to 5%, bleeding after minor trauma), and mild (5 to 40%, bleeding only after significant trauma or surgery). Hemarthrosis (bleeding into joints, especially knees, elbows, and ankles) is the hallmark clinical manifestation, and recurrent hemarthroses lead to chronic hemophilic arthropathy. Laboratory findings include prolonged aPTT (intrinsic pathway, Factor VIII is in the intrinsic tenase complex) with normal PT (extrinsic pathway).\n\nTREATMENT:\nFactor VIII replacement (either plasma-derived or recombinant) is the standard treatment for bleeding episodes and prophylaxis. Emicizumab (a bispecific antibody that bridges Factor IXa and Factor X, mimicking Factor VIII cofactor function) has transformed prophylactic management.\n\nKEY POINTS:\nHemophilia A (Factor VIII deficiency) follows X-linked recessive inheritance: males are affected, females are carriers, and 30% of cases are de novo mutations. Severity correlates with Factor VIII level (<1% severe, with spontaneous hemarthroses). Laboratory hallmark is prolonged aPTT with normal PT. Emicizumab has transformed prophylaxis."
  },
  {
    "id": 352,
    "categoryId": 9,
    "question": "Alcoholics often have Macrocytic Anemia. The two primary drivers are:",
    "options": [
      "A) Iron deficiency and GI bleeding",
      "B) Folate deficiency and Direct Bone Marrow toxicity",
      "C) B12 deficiency and Hemolysis",
      "D) Renal failure and Low EPO"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Folate deficiency and direct bone marrow toxicity).\n\nPATHOPHYSIOLOGY:\nMacrocytic anemia (MCV greater than 100 fL) in patients with chronic alcohol use disorder results from two primary mechanisms that frequently coexist.\n\nFOLATE DEFICIENCY:\nFolate (vitamin B9) deficiency is the most common nutritional deficiency in alcoholic patients. Three mechanisms converge: poor dietary intake (alcoholic patients often substitute caloric intake from alcohol for nutrient-rich foods), impaired intestinal absorption (ethanol directly damages jejunal mucosal cells where folate is absorbed), and impaired hepatic storage and metabolism (ethanol disrupts folate enterohepatic circulation and inhibits methionine synthase). Folate deficiency impairs thymidylate synthesis (conversion of dUMP to dTMP), causing defective DNA synthesis with megaloblastic erythropoiesis (large erythroid precursors with immature nuclei).\n\nDIRECT BONE MARROW TOXICITY:\nEthanol is a direct myelotoxin that suppresses erythropoiesis independent of nutritional deficiency. Ethanol and its metabolite acetaldehyde directly inhibit hematopoietic progenitor cell proliferation, impair iron incorporation into heme, and cause vacuolization of erythroid and myeloid precursors visible on bone marrow biopsy. This direct toxic effect produces macrocytosis even in alcoholic patients with normal folate and B12 levels and can cause sideroblastic changes (ringed sideroblasts from mitochondrial iron accumulation).\n\nADDITIONAL CONTRIBUTING FACTORS:\nChronic liver disease (present in many alcoholic patients) contributes to macrocytosis through altered lipid metabolism, causing excess cholesterol deposition in RBC membranes that increases cell surface area. Reticulocytosis from chronic GI blood loss or hemolysis can also raise the MCV.\n\nKEY POINTS:\nAlcoholic macrocytic anemia results from folate deficiency (poor intake, impaired absorption, disrupted enterohepatic circulation) and direct ethanol myelotoxicity (suppression of erythroid progenitors and vacuolization of precursors). Direct marrow toxicity causes macrocytosis even with normal folate and B12 levels. Alcoholic patients should be assessed for multiple concurrent contributors including liver disease and GI blood loss."
  },
  {
    "id": 353,
    "categoryId": 9,
    "question": "Neutropenic Fever (ANC < 500 + Fever) in a chemotherapy patient is treated with:",
    "options": [
      "A) Oral Amoxicillin",
      "B) Immediate IV Broad-Spectrum Antibiotics (e.g., Cefepime/Zosyn)",
      "C) G-CSF only",
      "D) Antipyretics and observation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immediate IV broad-spectrum antibiotics, e.g., cefepime or piperacillin-tazobactam).\n\nCLINICAL EMERGENCY:\nNeutropenic fever means an absolute neutrophil count (ANC) less than 500 cells/microL (or expected to fall below 500 within 48 hours) with a single oral temperature of 38.3Â°C (101Â°F) or greater, or sustained temperature of 38.0Â°C (100.4Â°F) or greater for one hour. This represents an oncologic emergency because neutropenic patients lack the primary cellular immune defense against bacterial invasion and can progress from localized infection to septic shock and death within hours.\n\nIMPERATIVE FOR IMMEDIATE ANTIBIOTICS:\nEmpiric broad-spectrum IV antibiotics must be administered within 60 minutes of presentation (ideally within 30 minutes) without waiting for culture results, imaging, or identification of a source. Each hour of delay in antibiotic administration increases mortality. Blood cultures (at least 2 sets, including from any central line) should be obtained before antibiotics but must never delay antibiotic administration.\n\nANTIMICROBIAL SELECTION:\nFirst-line empiric monotherapy includes anti-pseudomonal beta-lactams: cefepime (fourth-generation cephalosporin), piperacillin-tazobactam (Zosyn), or meropenem (carbapenem, reserved for higher-risk patients or institutions with resistant organisms). Vancomycin (or linezolid/daptomycin) is added for specific indications: suspected catheter-related infection, skin/soft tissue infection, hemodynamic instability, or known MRSA colonization, but should not be used routinely as part of the initial empiric regimen.\n\nRISK STRATIFICATION:\nThe MASCC (Multinational Association for Supportive Care in Cancer) score stratifies patients into high-risk (requiring inpatient IV therapy) and low-risk (potentially eligible for outpatient oral antibiotics with ciprofloxacin plus amoxicillin-clavulanate).\n\nKEY POINTS:\nNeutropenic fever (ANC less than 500 plus temperature 38.3Â°C or greater) requires empiric IV anti-pseudomonal antibiotics (cefepime, piperacillin-tazobactam, or meropenem) within 60 minutes of presentation, before culture results. Vancomycin is added only for specific indications, not routinely. Each hour of antibiotic delay increases mortality in febrile neutropenia."
  },
  {
    "id": 354,
    "categoryId": 13,
    "question": "The Innate Immune System differs from the Adaptive Immune System because the Innate system:",
    "options": [
      "A) Produces antibodies",
      "B) Has memory of past infections",
      "C) Responds immediately but non-specifically",
      "D) Takes 7-10 days to activate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Responds immediately but non-specifically).\n\nINNATE IMMUNE SYSTEM:\nThe innate immune system is the body\"s first line of defense, activated within minutes to hours of pathogen exposure. It is evolutionarily ancient and present in all multicellular organisms. Its components include physical barriers (skin, mucosal epithelia, and their secretions), cellular defenses (neutrophils, macrophages, dendritic cells, natural killer cells, and mast cells), and soluble mediators (complement, cytokines, and acute phase proteins). Innate immune cells recognize conserved molecular patterns shared by broad categories of pathogens, known as pathogen-associated molecular patterns (PAMPs), through germline-encoded pattern recognition receptors (PRRs) such as Toll-like receptors (TLRs). This recognition is immediate but non-specific, meaning the innate system does not distinguish between individual strains of a given pathogen and does not improve its response with repeated exposures.\n\nADAPTIVE IMMUNE SYSTEM:\nThe adaptive immune system, found only in vertebrates, takes approximately four to seven days to mount a primary response but provides highly specific, targeted immunity. It relies on lymphocytes: B cells (which produce antibodies) and T cells (CD4+ helper and CD8+ cytotoxic). Through somatic recombination of immunoglobulin and T-cell receptor gene segments (V-D-J recombination), each lymphocyte generates a unique antigen receptor, creating a repertoire capable of recognizing virtually any molecular structure. After initial antigen encounter, a subset of activated lymphocytes differentiates into long-lived memory cells, enabling a faster and more robust secondary response upon re-exposure. This immunologic memory is the basis for vaccination.\n\nINTERPLAY BETWEEN SYSTEMS:\nThe innate and adaptive systems are deeply interconnected rather than independent. Dendritic cells serve as the critical bridge: they capture antigens at sites of infection using innate PRRs, then migrate to lymph nodes where they present processed antigen to naive T cells via MHC molecules, initiating the adaptive response. The quality of innate activation directly shapes adaptive immunity, determining whether a Th1, Th2, or Th17 response predominates.\n\nKEY POINTS:\nThe innate immune system responds within minutes to hours using germline-encoded pattern recognition receptors that detect broad pathogen-associated molecular patterns. The adaptive immune system takes days to activate but generates highly specific responses and immunologic memory through clonal expansion of antigen-specific lymphocytes. Dendritic cells bridge innate and adaptive immunity by presenting antigens to T cells."
  },
  {
    "id": 355,
    "categoryId": 13,
    "question": "Systemic Lupus Erythematosus (SLE) is a Type III Hypersensitivity reaction. The primary mechanism of tissue damage is:",
    "options": [
      "A) Direct T-cell attack on cells",
      "B) Deposition of Antigen-Antibody Immune Complexes",
      "C) IgE mediated histamine release",
      "D) Macrophage granuloma formation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immune complex deposition and complement activation).\n\nTYPE III HYPERSENSITIVITY:\nSystemic lupus erythematosus (SLE) is the prototypical Type III hypersensitivity disease. Autoantibodies (particularly anti-dsDNA) form immune complexes with their antigens. These complexes deposit in tissuesâ€”especially glomeruli, skin, and jointsâ€”where they activate the complement cascade, triggering inflammation and tissue damage.\n\nMECHANISM:\nImmune complex deposition activates complement (C3a, C5a), generating anaphylatoxins that recruit neutrophils and macrophages. These inflammatory cells release proteases and reactive oxygen species, causing local tissue injury. The size and properties of immune complexes determine where they deposit: small complexes penetrate basement membranes (glomerulonephritis), while larger complexes deposit in vessel walls (vasculitis).\n\nCONTRAST WITH OTHER TYPES:\nType I (IgE): Immediate, mast cell degranulation (anaphylaxis). Type II (IgG against cells): Antibodies target cell surfaces, causing cytotoxicity (autoimmune hemolytic anemia). Type III (Immune complexes): Antibody-antigen complexes deposit in tissues (SLE, serum sickness). Type IV (T-cell): Delayed, T-cell mediated (contact dermatitis).\n\nCLINICAL MANIFESTATIONS:\nIn SLE, immune complex deposition causes glomerulonephritis (renal failure), arthritis, vasculitis, and serositis. Complement levels (C3, C4) are often low during active disease due to consumption.\n\nKEY POINTS:\nSLE is a Type III hypersensitivity disease caused by immune complex deposition. Deposited complexes activate complement, recruiting inflammatory cells that damage tissue. Low complement levels indicate active immune complex-mediated disease."
  },
  {
    "id": 356,
    "categoryId": 8,
    "question": "Which antibody isotype is the first to be produced during an acute infection (Primary Response)?",
    "options": [
      "A) IgG",
      "B) IgM",
      "C) IgA",
      "D) IgE"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IgM).\n\nPRIMARY IMMUNE RESPONSE:\nDuring the first exposure to an antigen, the immune system produces IgM antibodies first, typically detectable within 5-7 days. IgM is produced by naive B cells before class switching occurs. Its pentameric structure makes it excellent at agglutination and complement activation, providing rapid but relatively short-lived protection.\n\nCLASS SWITCHING:\nOver the following weeks, with T-cell help, B cells undergo class switching to produce IgG (and other isotypes). This secondary response produces higher-affinity antibodies with longer half-lives. Memory B cells are established, enabling rapid IgG production upon re-exposure.\n\nDIAGNOSTIC UTILITY:\nThe presence of IgM antibodies indicates recent or acute infection, while IgG indicates past infection or immunity. This distinction is diagnostically valuable: for example, hepatitis B core antibody testing differentiates recent (IgM anti-HBc) from past (IgG anti-HBc) infection.\n\nIGM CHARACTERISTICS:\nIgM exists primarily as a pentamer in serum, giving it 10 antigen-binding sites. It cannot cross the placenta (too large), is an efficient complement activator, and is the predominant antibody in ABO blood group reactions.\n\nKEY POINTS:\nIgM is the first antibody produced during a primary immune response, appearing within days. Class switching to IgG occurs later with T-cell help. IgM indicates acute infection; IgG indicates past exposure or immunity."
  },
  {
    "id": 357,
    "categoryId": 13,
    "question": "Rheumatoid Arthritis (RA) is characterized by the presence of Anti-Citrullinated Protein Antibodies (ACPA). The pathologic hallmark in the joint is:",
    "options": [
      "A) Osteophyte formation",
      "B) Pannus formation",
      "C) Uric acid crystals",
      "D) Cartilage wear and tear"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pannus formation).\n\nPATHOPHYSIOLOGY OF PANNUS:\nRheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by inflammatory synovitis that progresses to joint destruction. The pathologic hallmark is pannus formation, a thickened, hyperplastic synovial membrane composed of activated fibroblast-like synoviocytes, macrophages, T cells, B cells, and neovascular tissue. This aggressive granulation tissue behaves almost like a locally invasive tumor, extending over and into articular cartilage and subchondral bone. Pannus produces matrix metalloproteinases (MMPs), cathepsins, and RANKL (receptor activator of nuclear factor kappa-B ligand), which drive cartilage degradation and osteoclast-mediated bone erosion.\n\nROLE OF ACPA AND AUTOANTIBODIES:\nAnti-citrullinated protein antibodies (ACPA, detected clinically as anti-CCP) are the most specific serologic marker for RA (specificity greater than 95 percent). Citrullination is a post-translational modification in which peptidylarginine deiminase enzymes convert arginine residues to citrulline in proteins within inflamed joints. The immune system generates antibodies against these citrullinated proteins, forming immune complexes that activate complement and perpetuate synovial inflammation. ACPA can be detected years before clinical disease onset, and their presence predicts a more aggressive, erosive disease course. Rheumatoid factor (IgM directed against the Fc portion of IgG) is present in approximately 70 percent of RA patients but is less specific.\n\nEARLY AGGRESSIVE TREATMENT:\nThe 2021 ACR guidelines emphasize early initiation of disease-modifying antirheumatic drug (DMARD) therapy to prevent irreversible joint damage. Methotrexate is the first-line DMARD, typically started at 7.5 to 15 mg weekly with folic acid supplementation. If disease activity remains moderate to high at three months, treatment is escalated by adding or switching to biologic DMARDs (TNF inhibitors such as adalimumab or etanercept, IL-6 inhibitors such as tocilizumab, or T-cell co-stimulation modulators such as abatacept) or targeted synthetic DMARDs (JAK inhibitors such as tofacitinib or baricitinib). The treat-to-target strategy aims for remission or low disease activity.\n\nKEY POINTS:\nPannus is the pathologic hallmark of RA, an aggressive synovial tissue that invades and destroys cartilage and bone through metalloproteinases and osteoclast activation. ACPA (anti-CCP) is highly specific for RA and predicts erosive disease. Early DMARD therapy with methotrexate is critical to prevent irreversible joint destruction. Pannus formation distinguishes RA from osteoarthritis (osteophytes) and gout (crystal deposition)."
  },
  {
    "id": 358,
    "categoryId": 4,
    "question": "Graves' Disease causes Hyperthyroidism via a Type II Hypersensitivity reaction. What is the specific target?",
    "options": [
      "A) Thyroid Peroxidase (TPO)",
      "B) Thyroglobulin",
      "C) TSH Receptor",
      "D) Iodine transporter"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (TSH Receptor - Stimulating Antibodies).\n\nPATHOPHYSIOLOGY:\nGraves' disease is the most common cause of hyperthyroidism (60-80% of cases), resulting from a Type II hypersensitivity reaction. IgG autoantibodies called thyroid-stimulating immunoglobulins (TSI) bind and activate the TSH receptor on thyroid follicular cells. Unlike most autoimmune antibodies, TSI function as receptor agonists, driving constitutive thyroid hormone synthesis independent of hypothalamic-pituitary feedback. TSI activates the Gs-coupled adenylyl cyclase cascade, increasing cAMP and stimulating every step of hormone production: iodide trapping, organification, thyroglobulin synthesis, and T3/T4 release. This produces elevated free T4/T3 with profoundly suppressed TSH. Genetic susceptibility includes HLA-DR3 and CTLA-4 polymorphisms, with environmental triggers including stress, smoking, postpartum immune rebound, and excess iodine.\n\nCLINICAL REASONING:\nType II hypersensitivity involves antibodies against cell surface receptors. Graves' is a stimulatory subtype (TSI activates TSH receptor), contrasting with myasthenia gravis (blocking anti-AChR) and autoimmune hemolytic anemia (cytotoxic anti-erythrocyte). Graves' ophthalmopathy (~25-50% of patients) results from TSH receptor expression on orbital fibroblasts, where TSI triggers proliferation, adipogenesis, and glycosaminoglycan accumulation causing proptosis and extraocular muscle dysfunction. Graves' dermopathy (pretibial myxedema, 1-2%) involves a similar dermal fibroblast mechanism. Thyroid acropachy (clubbing) is the rarest manifestation.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires suppressed TSH, elevated free T4/T3, and positive TRAb or TSI. Diffusely elevated RAIU distinguishes Graves' from thyroiditis (low uptake). Per ATA 2016 guidelines, treatment options include methimazole (preferred over PTU except first trimester), radioactive iodine ablation, and thyroidectomy, individualized by preference, severity, and reproductive plans. Methimazole may be trialed 12-18 months, with approximately 30-50% achieving lasting remission. Favorable predictors include mild disease, small goiter, low TRAb at discontinuation, and non-smoking status. Beta-blockers provide symptomatic relief while antithyroid drugs take effect.\n\nKEY POINTS:\nGraves' disease is a Type II hypersensitivity reaction in which TSI activates the TSH receptor, producing hyperthyroidism independent of normal feedback. TSI also affects orbital and dermal fibroblasts, causing ophthalmopathy and dermopathy. TRAb/TSI confirms autoimmune etiology, diffusely elevated RAIU distinguishes Graves' from thyroiditis, and methimazole is first-line medical therapy."
  },
  {
    "id": 359,
    "categoryId": 13,
    "question": "CD4+ Helper T-Cells coordinate the immune response. Th1 cells drive cellular immunity (Viruses/Bacteria), while Th2 cells drive:",
    "options": [
      "A) Autoimmunity",
      "B) Humoral immunity (Antibodies) and Allergy/Parasite response",
      "C) Tolerance",
      "D) Tumor surveillance"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Humoral immunity and Allergy/Parasite response).\n\nTH1 AND TH2 PARADIGM:\nCD4+ helper T cells are the central coordinators of adaptive immunity. Upon activation by antigen-presenting cells, naive CD4+ T cells differentiate into distinct effector subsets depending on the cytokine milieu. The two classical subsets are Th1 and Th2. Th1 cells differentiate under the influence of IL-12 and IFN-gamma, produce IFN-gamma and TNF-alpha, and drive cell-mediated (cellular) immunity. They activate macrophages to kill intracellular pathogens (mycobacteria, viruses, intracellular bacteria) and promote CD8+ cytotoxic T cell responses. Th2 cells differentiate under the influence of IL-4, and produce IL-4, IL-5, IL-10, and IL-13, driving humoral immunity and anti-parasitic defense.\n\nTH2 EFFECTOR FUNCTIONS:\nTh2 cytokines orchestrate several critical immune functions. IL-4 drives B cell activation, proliferation, and class switching to IgE. IL-5 is the principal activator and chemoattractant for eosinophils, which are the primary effector cells against multicellular parasites (helminths). IL-13 stimulates goblet cell hyperplasia and mucus production in the airways and gut, facilitating physical expulsion of parasites. In the context of allergic disease, this same Th2 machinery becomes pathologically activated against harmless environmental antigens (allergens), leading to IgE-mediated mast cell degranulation, eosinophilic tissue inflammation, and the clinical manifestations of asthma, allergic rhinitis, eczema, and food allergy.\n\nCLINICAL SIGNIFICANCE OF TH1/TH2 IMBALANCE:\nThe Th1/Th2 balance has profound clinical implications. Th2 dominance is linked to atopic diseases (asthma, eczema, allergic rhinitis) and is thought to contribute to the rising prevalence of allergic disease in developed nations, a concept central to the hygiene hypothesis. Conversely, excessive Th1 activity drives organ-specific autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, and multiple sclerosis. Additional T helper subsets discovered more recently, including Th17 (autoimmunity, mucosal defense) and T regulatory cells (immune suppression, tolerance), add further complexity to this paradigm.\n\nKEY POINTS:\nTh2 cells drive humoral immunity through B cell activation and IgE class switching, and anti-parasitic defense through eosinophil recruitment via IL-5. The same Th2 pathways are pathologically activated in allergic diseases (asthma, eczema, allergic rhinitis). Th1/Th2 imbalance contributes to the pathogenesis of both atopic and autoimmune diseases. Th17 and T regulatory cells add additional layers of immune regulation beyond the classical Th1/Th2 model."
  },
  {
    "id": 360,
    "categoryId": 6,
    "question": "Multiple Sclerosis (MS) involves the autoimmune destruction of:",
    "options": [
      "A) Axons in the Peripheral Nervous System",
      "B) Myelin sheaths in the Central Nervous System (Oligodendrocytes)",
      "C) Acetylcholine receptors",
      "D) Schwann cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Myelin sheaths in the Central Nervous System/Oligodendrocytes).\n\nMULTIPLE SCLEROSIS PATHOPHYSIOLOGY:\nMultiple sclerosis (MS) is a chronic, immune-mediated demyelinating disease of the central nervous system in which autoreactive T-cells cross the blood-brain barrier and attack oligodendrocytes, the cells responsible for producing and maintaining myelin sheaths around CNS axons. This demyelination disrupts saltatory nerve conduction, slowing or blocking signal transmission along affected pathways. MS is distinct from Guillain-Barré syndrome, which targets Schwann cells (the PNS myelinating cells) in the peripheral nervous system.\n\nCLINICAL MANIFESTATIONS:\nMS typically presents in young adults (ages 20 to 40) with a female predominance of approximately 3:1. The hallmark is neurological symptoms disseminated in time (occurring at different time points) and space (affecting different CNS regions). Common presentations include optic neuritis (unilateral vision loss with pain on eye movement), internuclear ophthalmoplegia, transverse myelitis (limb weakness and sensory levels), cerebellar ataxia, and neurogenic bladder. Uhthoff phenomenon, the transient worsening of symptoms with heat exposure, is characteristic and reflects the temperature sensitivity of demyelinated axons.\n\nDIAGNOSIS:\nThe McDonald Criteria require demonstration of dissemination in space and time, using MRI (periventricular, juxtacortical, infratentorial, and spinal cord white matter lesions), CSF analysis (oligoclonal bands), and clinical episodes. MRI showing both gadolinium-enhancing (active) and non-enhancing (chronic) lesions can satisfy both criteria simultaneously.\n\nTREATMENT:\nDisease-modifying therapies aim to reduce relapse frequency and slow disability progression. Options range from injectable therapies (interferon beta, glatiramer acetate) to high-efficacy agents (natalizumab, ocrelizumab, fingolimod, cladribine). Acute relapses are treated with high-dose IV methylprednisolone. Treatment selection depends on disease activity, risk tolerance, and patient preference.\n\nKEY POINTS:\nMS involves autoimmune destruction of CNS myelin (oligodendrocytes), not PNS myelin (Schwann cells, which are targeted in Guillain-Barré). Diagnosis requires dissemination in time and space via clinical episodes and MRI findings. Disease-modifying therapies reduce relapses and slow progression, with high-efficacy agents available for aggressive disease."
  },
  {
    "id": 361,
    "categoryId": 3,
    "question": "In Celiac Disease, tissue Transglutaminase (tTG) modifies Gliadin (gluten), causing T-cells to attack:",
    "options": [
      "A) The stomach lining",
      "B) The colonic mucosa",
      "C) The villi of the Small Intestine",
      "D) The pancreas"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (The villi of the small intestine).\n\nPATHOPHYSIOLOGY:\nCeliac disease is an autoimmune enteropathy in which the enzyme tissue transglutaminase (tTG) plays a central pathogenic role. When gliadin peptides from dietary gluten cross the intestinal epithelial barrier, tTG deamidates specific glutamine residues on gliadin, converting them to negatively charged glutamic acid residues. These modified (deamidated) gliadin peptides have dramatically increased binding affinity for HLA-DQ2 and HLA-DQ8 molecules on antigen-presenting cells in the lamina propria. This complex is presented to CD4+ T helper cells, triggering a robust Th1-mediated immune response that releases interferon-gamma and other pro-inflammatory cytokines.\n\nMUCOSAL DESTRUCTION:\nThe activated immune response targets the small intestinal mucosa, producing a characteristic spectrum of histologic changes classified by the Marsh-Oberhuber system: increased intraepithelial lymphocytes (Marsh 1), crypt hyperplasia (Marsh 2), and progressive villous atrophy ranging from partial to total (Marsh 3a-3c). Villous atrophy reduces the absorptive surface area of the small intestine, causing malabsorption of iron, calcium, folate, fat-soluble vitamins (A, D, E, K), and macronutrients. The proximal small intestine (duodenum and jejunum) is most severely affected because it is the site of highest gluten exposure.\n\nCLINICAL MANIFESTATIONS AND DIAGNOSIS:\nClassic celiac disease presents with diarrhea, steatorrhea, weight loss, and iron deficiency anemia. Atypical presentations (more common in adults) include isolated iron deficiency anemia, osteoporosis, elevated transaminases, dermatitis herpetiformis, infertility, or peripheral neuropathy. Serologic screening with tTG-IgA (sensitivity and specificity both >95%) is the first-line diagnostic test, followed by confirmatory duodenal biopsy. A strict lifelong gluten-free diet is the only effective treatment.\n\nKEY POINTS:\ntTG deamidates gliadin peptides, creating neo-epitopes with increased HLA-DQ2/DQ8 binding affinity that trigger T-cell-mediated destruction of small intestinal villi. Villous atrophy causes malabsorption of iron, calcium, folate, and fat-soluble vitamins. tTG-IgA has >95% sensitivity and specificity for celiac disease. Lifelong strict gluten-free diet is the only effective treatment."
  },
  {
    "id": 362,
    "categoryId": 13,
    "question": "Sjogren's Syndrome primarily targets exocrine glands. Which two symptoms are the hallmarks?",
    "options": [
      "A) Dry Eyes (Keratoconjunctivitis Sicca) and Dry Mouth (Xerostomia)",
      "B) Joint pain and Rash",
      "C) Hair loss and Weight gain",
      "D) Diarrhea and Vomiting"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Dry Eyes and Dry Mouth).\n\nPATHOPHYSIOLOGY:\nSjogren syndrome is a chronic systemic autoimmune disease characterized by lymphocytic infiltration and destruction of exocrine glands, predominantly the lacrimal and salivary glands. CD4+ T cells and B cells infiltrate the glandular tissue, forming periductal lymphocytic foci that progressively destroy acinar cells and reduce glandular secretion. The disease can occur as primary Sjogren syndrome (isolated) or secondary Sjogren syndrome (associated with another autoimmune disease, most commonly rheumatoid arthritis or systemic lupus erythematosus). It has a strong female predominance (approximately 9:1 female-to-male ratio) with peak onset between ages 40 and 60.\n\nCLINICAL MANIFESTATIONS:\nThe hallmark sicca symptoms are keratoconjunctivitis sicca (dry eyes causing a gritty, sandy sensation, photosensitivity, and risk of corneal abrasions and ulceration) and xerostomia (dry mouth leading to difficulty swallowing dry food, accelerated dental caries, oral candidiasis, and parotid gland enlargement). Beyond the glands, Sjogren syndrome can cause systemic manifestations including interstitial lung disease, renal tubular acidosis (type 1 distal RTA), peripheral neuropathy, arthralgia, fatigue, and cutaneous vasculitis. Approximately 5 percent of patients with primary Sjogren syndrome develop B-cell non-Hodgkin lymphoma (typically mucosa-associated lymphoid tissue or MALT lymphoma), making long-term monitoring essential.\n\nDIAGNOSIS:\nThe 2016 ACR/EULAR classification criteria incorporate objective measures: anti-SSA/Ro antibody positivity (the most important serologic marker), labial salivary gland biopsy showing focal lymphocytic sialadenitis with a focus score of 1 or greater, ocular staining score, Schirmer test (less than 5 mm in 5 minutes), and unstimulated salivary flow rate. Anti-SSB/La antibodies are less sensitive but more specific for Sjogren syndrome. ANA is positive in the majority of patients.\n\nKEY POINTS:\nSjogren syndrome causes dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia) through lymphocytic destruction of lacrimal and salivary glands. Anti-SSA/Ro is the most important serologic marker. Patients face increased risk of severe dental caries, corneal damage, and B-cell lymphoma (MALT type). Systemic manifestations can include interstitial lung disease, renal tubular acidosis, and peripheral neuropathy."
  },
  {
    "id": 363,
    "categoryId": 16,
    "question": "Live Attenuated Vaccines (e.g., MMR, Varicella) produce a stronger, longer-lasting immunity than Inactivated Vaccines because:",
    "options": [
      "A) They contain more antigen",
      "B) They replicate in the host, mimicking a real infection",
      "C) They have adjuvants",
      "D) They are given intravenously"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They replicate in the host, mimicking a real infection).\n\nIMMUNOLOGY:\nLive attenuated vaccines contain a weakened (attenuated) but still viable form of the pathogen that retains the ability to infect host cells and undergo limited replication. This replication mimics a natural infection, activating both the innate and adaptive immune systems comprehensively: antigen-presenting cells process and present viral antigens via MHC class I and class II pathways, stimulating robust CD8+ cytotoxic T-cell responses (cellular immunity), CD4+ T-helper cell responses, and B-cell-mediated antibody production (humoral immunity). The resulting immune memory is typically strong, broad, and long-lasting, often providing lifelong protection with one or two doses.\n\nCOMPARISON WITH INACTIVATED VACCINES:\nInactivated (killed) vaccines contain pathogen that cannot replicate, and are processed primarily through the exogenous (MHC class II) antigen presentation pathway, generating predominantly humoral (antibody) immunity with weaker cellular immune responses. Because inactivated vaccines cannot replicate and amplify antigen exposure internally, they typically require multiple doses and periodic boosters to maintain protective immunity. The influenza inactivated vaccine, for example, requires annual readministration.\n\nCLINICAL CONSIDERATIONS:\nLive attenuated vaccines (MMR, varicella, rotavirus, intranasal influenza, yellow fever, oral polio, BCG) are contraindicated in immunocompromised patients (HIV with CD4 less than 200, active chemotherapy, high-dose corticosteroids, biologic immunosuppressants) and during pregnancy because the attenuated organism could cause disease in an immunodeficient host. After administration, patients should avoid salicylates for 6 weeks (varicella and MMR, due to Reye syndrome risk in children) and allow at least 4 weeks between different live vaccines if not given simultaneously.\n\nKEY POINTS:\nLive attenuated vaccines replicate in the host, activating both cellular (CD8+ T-cell) and humoral (antibody) immunity and typically providing long-lasting protection with fewer doses. Inactivated vaccines primarily stimulate humoral immunity and require multiple doses and boosters. Live vaccines are contraindicated in immunocompromised patients and pregnancy because the attenuated organism could cause disease."
  },
  {
    "id": 364,
    "categoryId": 4,
    "question": "Type 1 Diabetes is caused by the autoimmune destruction of Pancreatic Beta Cells. Which autoantibody is commonly tested to confirm diagnosis?",
    "options": [
      "A) Anti-Nuclear Antibody (ANA)",
      "B) Anti-GAD65 (Glutamic Acid Decarboxylase)",
      "C) Anti-TPO",
      "D) Rheumatoid Factor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anti-GAD65 / Glutamic Acid Decarboxylase antibodies).\n\nPATHOPHYSIOLOGY:\nType 1 diabetes is an autoimmune disease in which autoreactive CD4+ and CD8+ T lymphocytes infiltrate pancreatic islets and selectively destroy insulin-producing beta cells (insulitis). The autoimmune response generates detectable autoantibodies as biomarkers of ongoing destruction. The ADA staging system defines: Stage 1 (two or more autoantibodies with normoglycemia), Stage 2 (autoantibodies with dysglycemia), Stage 3 (clinical diabetes with symptomatic hyperglycemia). By Stage 3, approximately 80-90% of beta-cell mass is destroyed. Genetic susceptibility is linked to HLA-DR3-DQ2 and HLA-DR4-DQ8 (present in ~90% of patients). Proposed environmental triggers include enterovirus (Coxsackievirus B), early cow's milk exposure, vitamin D deficiency, and gut microbiome alterations.\n\nCLINICAL REASONING:\nGAD65 catalyzes glutamate-to-GABA conversion in beta cells. Anti-GAD65 antibodies are the most commonly tested because they are present in 70-80% at diagnosis, persist for decades (unlike other autoantibodies that wane), and are most useful for diagnosing autoimmune diabetes in adults with ambiguous presentations. The complete panel includes anti-GAD65, IA-2/ICA512 (60-70% at diagnosis), insulin autoantibodies (IAA, often first in young children but invalidated by exogenous insulin), and ZnT8 (60-80% at diagnosis). Two or more positive autoantibodies confer >90% lifetime risk of clinical type 1 diabetes (TrialNet, TEDDY study).\n\nCLINICAL APPLICATION:\nAutoantibody testing is most valuable for: (1) distinguishing type 1 from type 2 when presentation is ambiguous (non-obese adult without metabolic syndrome or DKA); (2) identifying LADA, a slowly progressive form accounting for ~5-10% of adults initially diagnosed as type 2, typically anti-GAD65 positive and lean, progressing to insulin dependence within months to years, guiding insulin therapy rather than sulfonylureas which may accelerate beta-cell failure; (3) screening first-degree relatives for prevention trials or treatment with teplizumab (Tzield), the first FDA-approved therapy to delay Stage 3 onset by approximately 2 years in Stage 2 disease (NEJM 2019).\n\nKEY POINTS:\nAnti-GAD65 is the most commonly tested autoantibody for autoimmune diabetes, present in 70-80% at diagnosis and persisting decades. Two or more positive autoantibodies confer >90% lifetime type 1 diabetes risk. GAD65 testing is essential for identifying LADA in adults misclassified as type 2, and teplizumab is FDA-approved to delay Stage 3 onset in high-risk individuals."
  },
  {
    "id": 365,
    "categoryId": 13,
    "question": "Psoriasis is driven by which specific T-cell pathway, which is now the target of biologic drugs like Secukinumab?",
    "options": [
      "A) Th1 / Interferon-gamma",
      "B) Th17 / IL-17",
      "C) Th2 / IL-4",
      "D) Treg / IL-10"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Th17 / IL-17).\n\nPATHOPHYSIOLOGY:\nPsoriasis is a chronic immune-mediated inflammatory skin disease driven primarily by the Th17 pathway. In genetically susceptible individuals, environmental triggers (stress, infection, trauma, medications such as lithium or beta-blockers) activate dendritic cells in the skin, which produce IL-23. This cytokine drives the differentiation and expansion of Th17 cells, which in turn secrete IL-17A, IL-17F, and IL-22. These cytokines act on keratinocytes to induce massive proliferation and aberrant differentiation, shortening the epidermal turnover time from the normal 28 to 30 days to just 3 to 4 days. The result is the characteristic well-demarcated, erythematous plaques with silvery-white scale, most commonly on the extensor surfaces (elbows, knees), scalp, and lumbosacral area.\n\nBIOLOGIC THERAPY TARGETING THE TH17/IL-23 AXIS:\nThe elucidation of the IL-23/Th17/IL-17 axis revolutionized psoriasis treatment. IL-17A inhibitors (secukinumab, ixekizumab, and brodalumab) achieve PASI 90 (90 percent improvement in Psoriasis Area and Severity Index) in 60 to 70 percent of patients, representing dramatic efficacy. IL-23 inhibitors (guselkumab, risankizumab, tildrakizumab) target the upstream driver and offer the advantage of less frequent dosing with sustained efficacy. Older biologics targeting TNF-alpha (adalimumab, etanercept, infliximab) remain effective but generally achieve lower PASI 90 rates than IL-17 and IL-23 inhibitors.\n\nSTEPWISE TREATMENT APPROACH:\nMild psoriasis (less than 5 percent body surface area) is managed with topical corticosteroids (first-line), vitamin D analogs (calcipotriol), and calcineurin inhibitors for sensitive areas. Moderate-to-severe disease may require phototherapy (narrowband UVB), conventional systemic agents (methotrexate, cyclosporine, acitretin), or biologic therapy. All psoriasis patients should be screened for psoriatic arthritis (present in up to 30 percent), cardiovascular disease, metabolic syndrome, and depression, as these comorbidities significantly impact outcomes.\n\nKEY POINTS:\nPsoriasis is driven by the IL-23/Th17/IL-17 axis, which causes keratinocyte hyperproliferation and a shortened epidermal turnover from 28 days to 3 to 4 days. IL-17 inhibitors (secukinumab, ixekizumab) and IL-23 inhibitors (guselkumab, risankizumab) are the most effective biologic therapies. All psoriasis patients should be screened for psoriatic arthritis, metabolic syndrome, cardiovascular disease, and depression."
  },
  {
    "id": 366,
    "categoryId": 9,
    "question": "The Spleen's 'Red Pulp' function is to filter blood, while the 'White Pulp' function is:",
    "options": [
      "A) Fat storage",
      "B) Immune surveillance (B and T cell activation)",
      "C) Red blood cell production",
      "D) Bile production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Immune surveillance: B and T cell activation).\n\nANATOMY AND PHYSIOLOGY:\nThe spleen is the largest secondary lymphoid organ, weighing approximately 150 grams in adults, and is organized into two functionally distinct compartments: the red pulp and the white pulp, separated by the marginal zone.\n\nRED PULP FUNCTION:\nThe red pulp constitutes approximately 75% of splenic volume and serves as a blood filtration system. Its reticular meshwork of splenic cords (of Billroth) and sinusoidal capillaries with narrow interendothelial slits (2 to 3 micrometers) creates a mechanical filter that removes senescent or damaged red blood cells, RBC inclusions (Howell-Jolly bodies, Heinz bodies, siderotic granules, nuclear remnants), and opsonized pathogens. Splenic macrophages in the red pulp phagocytose cells that cannot deform through the sinusoidal slits (spherocytes, sickle cells, antibody-coated cells).\n\nWHITE PULP FUNCTION:\nThe white pulp constitutes approximately 25% of splenic volume and is the immunologic compartment. It is organized around the central arterioles in two zones: the periarteriolar lymphoid sheath (PALS), which contains T-lymphocytes (primarily CD4+ helper T cells that coordinate immune responses), and the lymphoid follicles (with germinal centers), which contain B-lymphocytes that undergo somatic hypermutation, affinity maturation, and class switching to produce high-affinity antibodies, particularly IgM against polysaccharide antigens of encapsulated bacteria.\n\nMARGINAL ZONE:\nThe marginal zone between red and white pulp contains specialized marginal zone B cells that are critical for the rapid T-independent IgM antibody response against blood-borne polysaccharide antigens (the primary defense against encapsulated bacteria such as S. pneumoniae, H. influenzae, and N. meningitidis). This explains why asplenic patients are uniquely vulnerable to these organisms.\n\nKEY POINTS:\nThe splenic white pulp provides immune surveillance through T-cell activation in the PALS and B-cell antibody production (especially IgM against polysaccharide antigens) in lymphoid follicles. The red pulp filters blood by removing senescent RBCs and inclusions through narrow sinusoidal slits. Marginal zone B cells provide the critical rapid IgM response against encapsulated bacteria, explaining post-splenectomy infection risk."
  },
  {
    "id": 367,
    "categoryId": 6,
    "question": "Myasthenia Gravis causes muscle weakness that worsens with use. The antibodies block/destroy:",
    "options": [
      "A) Calcium channels",
      "B) Acetylcholine Receptors (AChR) at the neuromuscular junction",
      "C) Myelin",
      "D) Dopamine receptors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acetylcholine Receptors at the neuromuscular junction).\n\nMYASTHENIA GRAVIS PATHOPHYSIOLOGY:\nMyasthenia gravis (MG) is an autoimmune disorder in which antibodies target acetylcholine receptors (AChR) at the postsynaptic membrane of the neuromuscular junction. Approximately 85% of patients have AChR antibodies, while a subset carry antibodies against muscle-specific kinase (MuSK) or lipoprotein-related protein 4 (LRP4). These antibodies reduce the number of functional receptors through complement-mediated destruction, accelerated endocytosis, and direct receptor blockade, resulting in impaired neuromuscular transmission.\n\nCLINICAL MANIFESTATIONS:\nThe cardinal feature is fatigable weakness that worsens with repetitive use and improves with rest. Ocular symptoms are the most common initial presentation, with ptosis (eyelid drooping) and diplopia (double vision) occurring in approximately 85% of patients at onset. Bulbar symptoms include dysarthria, dysphagia, and difficulty chewing that worsens throughout a meal. Limb weakness tends to affect proximal muscles. Myasthenic crisis, characterized by respiratory muscle weakness requiring mechanical ventilation, is a life-threatening emergency occurring in approximately 15 to 20% of patients.\n\nDIAGNOSIS:\nDiagnostic evaluation includes serum AChR antibody testing (positive in 85% of generalized MG), ice pack test (improvement of ptosis with cold application), edrophonium (Tensilon) test (rapid improvement after IV acetylcholinesterase inhibitor), and repetitive nerve stimulation showing decremental response. Single-fiber EMG is the most sensitive electrodiagnostic test. CT chest should be performed to evaluate for thymoma, present in 10 to 15% of MG patients.\n\nTREATMENT:\nPyridostigmine (acetylcholinesterase inhibitor) provides symptomatic relief by increasing ACh availability at the neuromuscular junction. Immunosuppressive therapy (corticosteroids, azathioprine, mycophenolate) addresses the underlying autoimmune process. Thymectomy is recommended for patients with thymoma and considered in generalized AChR-positive MG. Acute exacerbations and myasthenic crisis are treated with plasmapheresis or intravenous immunoglobulin (IVIG).\n\nKEY POINTS:\nMG results from antibodies against acetylcholine receptors at the neuromuscular junction, causing fatigable weakness that worsens with use. Ptosis and diplopia are the most common initial symptoms; myasthenic crisis with respiratory failure is the most dangerous complication. Treatment includes pyridostigmine for symptom relief, immunosuppression for disease control, and thymectomy when indicated."
  },
  {
    "id": 368,
    "categoryId": 13,
    "question": "Ankylosing Spondylitis (Fusion of the spine) is strongly associated with which genetic marker (MHC Class I allele)?",
    "options": [
      "A) HLA-DR4",
      "B) HLA-B27",
      "C) HLA-DQ2",
      "D) BRCA1"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HLA-B27).\n\nGENETIC ASSOCIATION:\nAnkylosing spondylitis (AS) has the strongest known association between an HLA allele and a disease. HLA-B27 is present in approximately 90 to 95 percent of patients with AS in White populations, compared to roughly 8 percent of the general population. However, only about 5 percent of HLA-B27-positive individuals develop AS, indicating that additional genetic and environmental factors are necessary. The exact mechanism by which HLA-B27 contributes to disease is debated, with leading theories including the arthritogenic peptide hypothesis (HLA-B27 presents specific self-peptides that trigger autoreactive CD8+ T cells), the misfolding hypothesis (HLA-B27 heavy chain misfolding in the endoplasmic reticulum activates inflammatory pathways), and the homodimer hypothesis.\n\nPATHOPHYSIOLOGY AND CLINICAL FEATURES:\nAS is the prototypical seronegative spondyloarthropathy, meaning rheumatoid factor and anti-CCP are characteristically negative. The primary pathologic target is the enthesis, the site where tendons, ligaments, and joint capsules insert into bone. Chronic enthesitis at the vertebral margins and sacroiliac joints leads to reactive new bone formation (syndesmophytes) that can progressively fuse the spine, producing the classic radiographic \"bamboo spine\" appearance. Patients typically present before age 40 with insidious-onset inflammatory low back pain (worse with rest, improves with exercise, morning stiffness greater than 30 minutes) and sacroiliitis. Extra-articular manifestations include anterior uveitis (the most common, occurring in 25 to 40 percent), inflammatory bowel disease, and psoriasis.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI of the sacroiliac joints is the most sensitive imaging modality for early disease, detecting bone marrow edema before radiographic changes appear. The modified New York criteria require radiographic sacroiliitis for definitive diagnosis. First-line pharmacotherapy is NSAIDs (used continuously rather than as-needed). For patients with inadequate NSAID response, TNF inhibitors (adalimumab, etanercept, infliximab) and IL-17A inhibitors (secukinumab, ixekizumab) are highly effective. Conventional DMARDs (methotrexate, sulfasalazine) are ineffective for axial disease. Physical therapy and regular exercise are essential components of management.\n\nKEY POINTS:\nHLA-B27 is present in 90 to 95 percent of ankylosing spondylitis patients and is the strongest HLA-disease association known. AS targets the entheses, causing progressive spinal fusion (bamboo spine). It is a seronegative spondyloarthropathy with negative RF and anti-CCP. First-line therapy is continuous NSAIDs, with TNF or IL-17 inhibitors for refractory disease."
  },
  {
    "id": 369,
    "categoryId": 2,
    "question": "The Complement System (C1-C9) ends in the formation of the Membrane Attack Complex (MAC). What does the MAC do?",
    "options": [
      "A) Tags bacteria for phagocytosis",
      "B) Punches a hole in the bacterial cell membrane, causing lysis",
      "C) Releases histamine",
      "D) Attracts neutrophils"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Punches a hole in the bacterial cell membrane, causing lysis).\n\nPATHOPHYSIOLOGY:\nThe complement system is a cascade of over 30 plasma proteins that serves as a critical arm of innate immunity. The cascade can be activated through three pathways: the classical pathway (initiated by antigen-antibody complexes binding C1q), the alternative pathway (spontaneous C3 hydrolysis amplified on microbial surfaces lacking regulatory proteins), and the lectin pathway (mannose-binding lectin recognizing mannose residues on microbial surfaces). All three pathways converge on C3, which is cleaved into C3a (an anaphylatoxin) and C3b (an opsonin that deposits on microbial surfaces and tags them for phagocytosis).\n\nMEMBRANE ATTACK COMPLEX:\nThe terminal complement pathway begins when C5 is cleaved into C5a (the most potent anaphylatoxin and chemotactic factor) and C5b. C5b sequentially recruits C6, C7, C8, and multiple molecules of C9 to assemble the membrane attack complex (C5b-9) on the target cell membrane. The C9 molecules polymerize to form a transmembrane pore approximately 10 nm in diameter that disrupts the osmotic integrity of the target cell, allowing uncontrolled influx of water and ions, resulting in cell swelling and lysis. The MAC is particularly effective against gram-negative bacteria (whose outer membrane is vulnerable to pore formation) and enveloped pathogens.\n\nCOMPLEMENT FUNCTIONS SUMMARY:\nThe complement system serves three major effector functions: opsonization (C3b coating of pathogens enhances phagocytosis), inflammation (C3a and C5a cause mast cell degranulation, vasodilation, and neutrophil chemotaxis), and direct killing (MAC-mediated lysis). Complement deficiencies predispose to specific infections: early classical pathway deficiencies (C1, C2, C4) are associated with autoimmune disease (particularly SLE), C3 deficiency causes severe recurrent pyogenic infections, and terminal complement deficiencies (C5 through C9) specifically predispose to recurrent Neisseria infections (meningococcus, gonococcus) because Neisseria species are uniquely dependent on MAC-mediated killing for clearance.\n\nKEY POINTS:\nThe membrane attack complex (C5b-9) assembles a pore in the bacterial cell membrane, causing osmotic lysis, particularly effective against gram-negative organisms. C3b opsonizes pathogens for phagocytosis, while C3a and C5a are anaphylatoxins driving inflammation. Terminal complement deficiency (C5 through C9) specifically predisposes to recurrent Neisseria infections."
  },
  {
    "id": 370,
    "categoryId": 13,
    "question": "Systemic Sclerosis (Scleroderma) involves vascular damage and excessive production of:",
    "options": [
      "A) Elastin",
      "B) Collagen",
      "C) Fibrin",
      "D) Keratin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Collagen).\n\nPATHOPHYSIOLOGY:\nSystemic sclerosis (SSc), commonly known as scleroderma, is a chronic autoimmune connective tissue disease characterized by three interrelated pathologic processes: vasculopathy (endothelial injury and intimal hyperplasia of small arteries and arterioles), immune activation (T cell and B cell-mediated inflammation), and fibrosis (excessive collagen deposition by activated myofibroblasts). The fibrotic process is driven by dysregulated fibroblasts that overproduce type I and type III collagen along with other extracellular matrix components. Transforming growth factor-beta (TGF-beta) is the central pro-fibrotic cytokine, stimulating collagen gene transcription and inhibiting matrix metalloproteinase-mediated collagen degradation. This excessive collagen deposition occurs in the skin and internal organs, producing the hallmark skin thickening and visceral fibrosis.\n\nCLINICAL SUBTYPES:\nSSc is classified into two major subtypes. Limited cutaneous SSc (formerly CREST syndrome: Calcinosis, Raynaud phenomenon, Esophageal dysmotility, Sclerodactyly, Telangiectasia) features skin thickening confined to the face and distal extremities, is linked to anti-centromere antibodies, and carries a risk of pulmonary arterial hypertension. Diffuse cutaneous SSc features rapid, widespread skin thickening extending proximally, is linked to anti-Scl-70 (anti-topoisomerase I) antibodies, and carries higher risk of interstitial lung disease, renal crisis (scleroderma renal crisis with malignant hypertension), and cardiac involvement.\n\nORGAN INVOLVEMENT AND MANAGEMENT:\nRaynaud phenomenon is nearly universal (present in greater than 95 percent of patients) and often the earliest manifestation. Esophageal dysmotility from smooth muscle fibrosis causes gastroesophageal reflux and dysphagia. Interstitial lung disease (most commonly nonspecific interstitial pneumonia pattern) is the leading cause of death and is screened for with pulmonary function tests and high-resolution CT. Scleroderma renal crisis, a life-threatening emergency with acute hypertension and rapidly progressive renal failure, is treated with ACE inhibitors. Immunosuppressive agents (mycophenolate mofetil, cyclophosphamide) are used for progressive interstitial lung disease, and nintedanib (an antifibrotic) has been approved for SSc-associated ILD.\n\nKEY POINTS:\nSystemic sclerosis is defined by excessive collagen deposition from dysregulated fibroblasts driven by TGF-beta, affecting skin and internal organs. Limited cutaneous SSc is linked to anti-centromere antibodies and pulmonary arterial hypertension risk. Diffuse cutaneous SSc is linked to anti-Scl-70 and carries higher risk of interstitial lung disease and scleroderma renal crisis. ACE inhibitors are the life-saving treatment for scleroderma renal crisis."
  },
  {
    "id": 371,
    "categoryId": 2,
    "question": "Which Hypersensitivity Reaction is 'Delayed' and T-Cell mediated (e.g., Poison Ivy or TB Skin Test)?",
    "options": [
      "A) Type I",
      "B) Type II",
      "C) Type III",
      "D) Type IV"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Type IV - Delayed T-Cell Mediated).\n\nPATHOPHYSIOLOGY:\nType IV hypersensitivity is the only type that is antibody-independent and entirely T-cell mediated, with a characteristic delayed onset of 48 to 72 hours after antigen exposure. Upon initial sensitization, antigen-presenting cells (Langerhans cells in the skin, dendritic cells) process the antigen and present it via MHC class II molecules to naive CD4+ T cells, generating antigen-specific memory T cells. Upon re-exposure, these memory T cells recognize the antigen and release pro-inflammatory cytokines (interferon-gamma, TNF-alpha, IL-2) that activate macrophages and recruit additional inflammatory cells, producing a localized inflammatory response over 48 to 72 hours.\n\nCLINICAL EXAMPLES:\nContact dermatitis (poison ivy, nickel allergy) is the prototypical Type IV reaction: urushiol from poison ivy penetrates the epidermis, is processed by Langerhans cells, and triggers a delayed T-cell response producing the characteristic pruritic, vesicular eruption at the site of contact 48 to 72 hours later. The tuberculin skin test (Mantoux/PPD test) is a diagnostic application of Type IV hypersensitivity: purified protein derivative injected intradermally triggers a delayed induration response in individuals previously sensitized to mycobacterial antigens, read at 48 to 72 hours. Other Type IV reactions include granulomatous inflammation (sarcoidosis, tuberculosis), transplant rejection, and graft-versus-host disease.\n\nCOMPARISON WITH OTHER TYPES:\nThe mnemonic ACID distinguishes the four types: Type I is Allergy/Anaphylaxis (IgE-mediated, minutes), Type II is Cytotoxic (IgG/IgM against cell surfaces, hours to days), Type III is Immune complex deposition (IgG complexes, days to weeks), and Type IV is Delayed (T-cell mediated, 48 to 72 hours). Types I through III are all antibody-mediated and can be transferred passively with serum, while Type IV requires intact T-cell immunity and cannot be transferred with serum.\n\nKEY POINTS:\nType IV hypersensitivity is the only antibody-independent, T-cell-mediated reaction, with a characteristic 48 to 72-hour delayed onset. Classic examples include contact dermatitis (poison ivy), the tuberculin skin test, granulomatous disease, and transplant rejection. The ACID mnemonic distinguishes the four types: Allergy (I), Cytotoxic (II), Immune complex (III), Delayed (IV)."
  },
  {
    "id": 372,
    "categoryId": 13,
    "question": "Pernicious Anemia is an autoimmune attack against:",
    "options": [
      "A) Red Blood Cells directly",
      "B) Parietal Cells and/or Intrinsic Factor",
      "C) The Terminal Ileum",
      "D) Bone Marrow stem cells"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parietal Cells/Intrinsic Factor).\n\nPATHOPHYSIOLOGY:\nPernicious anemia is an autoimmune disease in which antibodies target parietal cells and intrinsic factor. Parietal cells in the gastric fundus produce both hydrochloric acid and intrinsic factor. Intrinsic factor is essential for vitamin B12 absorption in the terminal ileum. Without it, B12 cannot be absorbed regardless of dietary intake.\n\nTWO TYPES OF ANTIBODIES:\nAnti-parietal cell antibodies destroy the cells that produce intrinsic factor. Anti-intrinsic factor antibodies directly block intrinsic factor from binding B12 (type I) or from binding the ileal receptor (type II). The result is B12 malabsorption and deficiency.\n\nCLINICAL CONSEQUENCES:\nB12 deficiency causes megaloblastic anemia (macrocytic RBCs with hypersegmented neutrophils) and neurological damage (subacute combined degeneration of the spinal cord: posterior columns and corticospinal tracts). Neurological damage can be irreversible if treatment is delayed.\n\nDIAGNOSIS AND TREATMENT:\nLow B12, elevated methylmalonic acid, and positive anti-intrinsic factor antibodies (more specific) or anti-parietal cell antibodies (more sensitive) confirm the diagnosis. Treatment is parenteral B12 (IM or high-dose oral), as the absorption defect makes normal oral supplementation ineffective.\n\nKEY POINTS:\nPernicious anemia results from autoimmune destruction of parietal cells and intrinsic factor. Without intrinsic factor, B12 cannot be absorbed in the terminal ileum. Parenteral B12 is required; oral absorption is impaired."
  },
  {
    "id": 373,
    "categoryId": 13,
    "question": "Molecular Mimicry is a leading theory for autoimmune triggers. Rheumatic Fever is the classic example, where antibodies against Strep bacteria cross-react with:",
    "options": [
      "A) Kidney tissue",
      "B) Heart Valves (Mitral)",
      "C) Brain tissue",
      "D) Liver tissue"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Group A Streptococcus and Heart Tissue).\n\nMOLECULAR MIMICRY:\nMolecular mimicry occurs when a pathogen's antigen structurally resembles a host tissue antigen. The immune response generated against the pathogen cross-reacts with self-tissue, causing autoimmune damage. Rheumatic fever is the classic example.\n\nRHEUMATIC FEVER MECHANISM:\nThe M protein on Group A Streptococcus (GAS) shares structural similarity with proteins in human cardiac myosin, tropomyosin, and heart valve tissue. Antibodies generated against streptococcal M protein cross-react with heart tissue, causing inflammatory damage to the valves, myocardium, and pericardium.\n\nJONES CRITERIA:\nRheumatic fever is diagnosed clinically using the Jones criteria: evidence of recent GAS infection plus major manifestations (carditis, polyarthritis, chorea, erythema marginatum, subcutaneous nodules) and minor manifestations (fever, arthralgia, elevated inflammatory markers, prolonged PR interval).\n\nPREVENTION:\nPrimary prevention (treating strep pharyngitis) prevents initial episodes. Secondary prevention (long-term penicillin prophylaxis) prevents recurrences in patients with prior rheumatic fever, as each strep infection risks additional cardiac damage.\n\nKEY POINTS:\nRheumatic fever results from molecular mimicry between streptococcal M protein and cardiac tissue. Antibodies against GAS cross-react with heart valves, causing chronic rheumatic heart disease. Penicillin prophylaxis prevents recurrent episodes and progressive valve damage."
  },
  {
    "id": 374,
    "categoryId": 13,
    "question": "Goodpasture's Syndrome involves anti-GBM antibodies attacking collagen in which two organs?",
    "options": [
      "A) Liver and Kidney",
      "B) Lungs and Kidney",
      "C) Heart and Lungs",
      "D) Skin and Joints"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lungs and Kidneys).\n\nPATHOPHYSIOLOGY:\nGoodpasture syndrome (anti-glomerular basement membrane disease) is a rare autoimmune condition in which circulating IgG autoantibodies target the non-collagenous (NC1) domain of the alpha-3 chain of type IV collagen. This specific collagen chain is highly concentrated in two locations: the glomerular basement membrane (GBM) of the kidneys and the alveolar basement membrane of the lungs. When anti-GBM antibodies bind to these basement membranes, they activate complement (via the classical pathway) and recruit neutrophils, causing a destructive Type II hypersensitivity reaction. The result is rapidly progressive (crescentic) glomerulonephritis and diffuse alveolar hemorrhage.\n\nCLINICAL PRESENTATION:\nPatients typically present with the pulmonary-renal syndrome: hemoptysis (from alveolar hemorrhage) and hematuria with rapidly declining renal function (from crescentic glomerulonephritis). Pulmonary hemorrhage tends to be more severe in smokers and patients with concurrent pulmonary infections or fluid overload, because alveolar capillary injury increases exposure of the alveolar basement membrane to circulating antibodies. Renal involvement manifests as nephritic syndrome (hematuria, RBC casts, proteinuria, oliguria, and rapidly rising creatinine). Without treatment, progression to end-stage renal disease occurs within weeks.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires detection of circulating anti-GBM antibodies by ELISA and confirmation by renal biopsy showing linear IgG deposits along the GBM on immunofluorescence (the pathognomonic finding). Treatment is aggressive and must be initiated emergently: plasmapheresis (to rapidly remove circulating anti-GBM antibodies), high-dose corticosteroids, and cyclophosphamide for immunosuppression. Early treatment is critical because renal recovery correlates with the percentage of crescents on biopsy and the serum creatinine at presentation. Patients presenting with dialysis-dependent renal failure rarely recover kidney function.\n\nKEY POINTS:\nGoodpasture syndrome targets type IV collagen in the glomerular and alveolar basement membranes, causing the pulmonary-renal syndrome of hemoptysis and rapidly progressive glomerulonephritis. Linear IgG staining on renal biopsy immunofluorescence is pathognomonic. Treatment requires emergent plasmapheresis combined with immunosuppression. Prognosis depends on the severity of renal involvement at presentation."
  },
  {
    "id": 375,
    "categoryId": 3,
    "question": "Which antibody is more commonly associated with Ulcerative Colitis (vs Crohn's)?",
    "options": [
      "A) ASCA (Anti-Saccharomyces cerevisiae)",
      "B) p-ANCA (Perinuclear Anti-Neutrophil Cytoplasmic Antibody)",
      "C) Anti-dsDNA",
      "D) Anti-Centromere"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (p-ANCA â€” perinuclear anti-neutrophil cytoplasmic antibody).\n\nPATHOPHYSIOLOGY:\nSerological markers in inflammatory bowel disease reflect distinct immune response patterns that help differentiate ulcerative colitis from Crohn's disease when clinical, endoscopic, and histologic features are ambiguous (indeterminate colitis, which occurs in approximately 10-15% of IBD cases). p-ANCA (perinuclear anti-neutrophil cytoplasmic antibody) targets nuclear envelope proteins including lactoferrin and nuclear histone, producing a perinuclear fluorescence pattern on indirect immunofluorescence. It is found in approximately 60-70% of ulcerative colitis patients and only 10-15% of Crohn's disease patients.\n\nANTIBODY PATTERNS IN IBD:\nASCA (anti-Saccharomyces cerevisiae antibodies) targets mannan in the cell wall of baker's yeast and is linked to Crohn's disease, found in approximately 50-70% of Crohn's patients and only 10-15% of ulcerative colitis patients. The combination of p-ANCA positive with ASCA negative is strongly suggestive of ulcerative colitis, while ASCA positive with p-ANCA negative favors Crohn's disease. When both markers are concordant, the positive predictive value for the respective diagnosis exceeds 90%. Additional antibodies associated with Crohn's disease include anti-OmpC, anti-CBir1, and anti-I2.\n\nCLINICAL APPLICATION:\nSerological testing is most useful as an adjunct to clinical evaluation when the distinction between ulcerative colitis and Crohn's disease remains uncertain after endoscopy and histology. It is not recommended as a screening test for IBD in the general population. The antibody profile may also carry prognostic significance, as ASCA-positive Crohn's patients tend to have more aggressive disease with stricturing and penetrating complications. These markers do not replace tissue diagnosis and should be interpreted within the full clinical context.\n\nKEY POINTS:\np-ANCA is found in 60-70% of ulcerative colitis patients and is the serological marker most associated with UC. ASCA is the corresponding marker for Crohn's disease (50-70% positive). The combination of p-ANCA positive and ASCA negative strongly suggests ulcerative colitis. Serological testing is an adjunct tool for indeterminate colitis, not a screening test."
  },
  {
    "id": 376,
    "categoryId": 13,
    "question": "Central Tolerance occurs in the Thymus. What happens to T-cells that react too strongly to 'Self' antigens?",
    "options": [
      "A) They are released to fight cancer",
      "B) They undergo Apoptosis (Negative Selection)",
      "C) They become B-cells",
      "D) They return to the bone marrow"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They undergo Apoptosis through Negative Selection).\n\nCENTRAL TOLERANCE IN THE THYMUS:\nCentral tolerance is the process by which the immune system eliminates self-reactive lymphocytes during their development, preventing autoimmunity. For T cells, this occurs in the thymus. Bone marrow-derived T cell precursors migrate to the thymus, where they undergo a rigorous two-stage selection process. In the thymic cortex, double-positive (CD4+CD8+) thymocytes undergo positive selection: those whose T cell receptors (TCRs) can bind self-MHC molecules with moderate affinity survive, while those that fail to bind undergo apoptosis (death by neglect). This ensures all mature T cells are MHC-restricted and can interact with antigen-presenting cells.\n\nNEGATIVE SELECTION:\nIn the thymic medulla, surviving thymocytes encounter medullary thymic epithelial cells (mTECs) that express a remarkable array of tissue-specific antigens under the control of the autoimmune regulator (AIRE) gene. AIRE drives ectopic expression of peripheral tissue proteins (such as insulin, thyroglobulin, and myelin basic protein) in the thymus. Thymocytes whose TCRs bind these self-antigens with high affinity receive apoptotic signals and are deleted (negative selection). This eliminates the most dangerous self-reactive T cells before they enter the peripheral circulation. Mutations in the AIRE gene cause autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), demonstrating the critical importance of this process.\n\nPERIPHERAL TOLERANCE AND AUTOIMMUNITY:\nCentral tolerance is highly effective but not perfect. Some self-reactive T cells escape to the periphery, where peripheral tolerance mechanisms (anergy, regulatory T cells, and activation-induced cell death) serve as backup. Autoimmune diseases arise when both central and peripheral tolerance mechanisms fail, allowing self-reactive T cells (and B cells) to mount immune responses against host tissues. Understanding these tolerance mechanisms has informed therapeutic strategies such as regulatory T cell expansion and tolerance-inducing protocols in transplantation.\n\nKEY POINTS:\nCentral tolerance in the thymus eliminates self-reactive T cells through negative selection (apoptosis of thymocytes that bind self-antigens with high affinity). The AIRE gene enables medullary thymic epithelial cells to express tissue-specific antigens for this screening process. AIRE mutations cause APECED, demonstrating the consequence of failed central tolerance. Peripheral tolerance mechanisms (Tregs, anergy) serve as backup when central tolerance is incomplete."
  },
  {
    "id": 377,
    "categoryId": 13,
    "question": "Granulomatosis with Polyangiitis (Wegener's) is a Small Vessel Vasculitis associated with which antibody?",
    "options": [
      "A) ANA",
      "B) c-ANCA (anti-PR3)",
      "C) p-ANCA (anti-MPO)",
      "D) Anti-Smith"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (c-ANCA / anti-PR3).\n\nDISEASE OVERVIEW:\nGranulomatosis with polyangiitis (GPA, formerly Wegener granulomatosis) is an ANCA-associated small-vessel vasculitinvolves necrotizing granulomatous inflammation of the respiratory tract, necrotizing vasculitis of small to medium vessels, and necrotizing glomerulonephritis. It is strongly associated with cytoplasmic ANCA (c-ANCA) directed against proteinase-3 (PR3), which is positive in approximately 80 to 95 percent of patients with active generalized disease. The pathogenic role of ANCA is supported by evidence that these antibodies activate neutrophils, causing them to adhere to vessel walls, degranulate, and release reactive oxygen species and proteolytic enzymes that damage the endothelium.\n\nCLINICAL MANIFESTATIONS:\nGPA classically affects three organ systems. Upper airway involvement (present in over 90 percent of cases) includes chronic sinusitis refractory to antibiotics, nasal crusting and epistaxis, saddle-nose deformity from nasal cartilage destruction, subglottic stenosis, and serous otitis media. Pulmonary involvement manifests as pulmonary nodules (often cavitating), alveolar hemorrhage with hemoptysis, and infiltrates that can mimic pneumonia or malignancy. Renal involvement presents as rapidly progressive (crescentic) glomerulonephritis with hematuria, proteinuria, RBC casts, and rapidly declining GFR. Other manifestations include scleritis or orbital pseudotumor, peripheral neuropathy (mononeuritis multiplex), and purpura.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is supported by positive c-ANCA/anti-PR3 serology but should be confirmed by tissue biopsy whenever possible, demonstrating necrotizing granulomatous vasculitis. Treatment follows a two-phase approach. Remission induction uses high-dose glucocorticoids combined with either rituximab (now preferred based on the RAVE trial) or cyclophosphamide. Remission maintenance uses rituximab, azathioprine, or methotrexate for at least two years. Plasma exchange may be considered in severe renal disease or pulmonary hemorrhage. Without treatment, generalized GPA has a mortality rate exceeding 80 percent within two years.\n\nKEY POINTS:\nGPA is strongly associated with c-ANCA (anti-PR3) and classically involves the upper airway, lungs, and kidneys. ANCA activates neutrophils to damage small vessel walls. Rituximab or cyclophosphamide with glucocorticoids is standard induction therapy. Untreated generalized GPA is rapidly fatal, making early diagnosis and aggressive immunosuppression essential."
  },
  {
    "id": 378,
    "categoryId": 13,
    "question": "Sarcoidosis involves the formation of Non-Caseating Granulomas. This is driven by an overactive:",
    "options": [
      "A) Th1 response",
      "B) Th2 response",
      "C) B-cell response",
      "D) Complement cascade"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Th1 response).\n\nPATHOPHYSIOLOGY OF GRANULOMA FORMATION:\nSarcoidosis is a systemic granulomatous disease of unknown etiology characterized by the formation of non-caseating (non-necrotizing) granulomas in affected organs. The pathogenesis centers on an exaggerated Th1-mediated immune response to an as-yet-unidentified antigen (proposed triggers include mycobacterial antigens, Propionibacterium acnes, and environmental inorganic particles). Antigen-presenting cells activate CD4+ Th1 cells, which release interferon-gamma (IFN-gamma) and IL-2. IFN-gamma is the critical cytokine that activates macrophages, causing them to aggregate and differentiate into epithelioid cells and multinucleated giant cells, forming the characteristic non-caseating granulomas. TNF-alpha, produced by activated macrophages, further amplifies granuloma formation and maintenance.\n\nHYPERCALCEMIA MECHANISM:\nA clinically important consequence of granulomatous inflammation in sarcoidosis is hypercalcemia, which occurs in approximately 10 to 13 percent of patients. Activated macrophages within granulomas express 1-alpha-hydroxylase, the enzyme that converts 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D (calcitriol). This extra-renal calcitriol production is not subject to normal PTH-mediated feedback regulation, leading to increased intestinal calcium absorption, in severe cases, hypercalciuria, nephrolithiasis, nephrocalcinosis, and renal insufficiency.\n\nCLINICAL FEATURES AND DIAGNOSIS:\nSarcoidosis most commonly presents in young adults (ages 20 to 40) with bilateral hilar lymphadenopathy (present in approximately 90 percent), pulmonary infiltrates, and skin lesions (erythema nodosum, lupus pernio). Other manifestations include anterior uveitis, hepatic granulomas, cardiac conduction abnormalities, cranial nerve palsies (especially facial nerve palsy), and parotid gland enlargement. Lofgren syndrome (bilateral hilar lymphadenopathy, erythema nodosum, fever, and polyarthralgia) carries an excellent prognosis with greater than 90 percent spontaneous resolution. Diagnosis requires compatible clinical and radiographic findings, histologic demonstration of non-caseating granulomas, and exclusion of other granulomatous diseases (tuberculosis, fungal infection). Elevated ACE levels support the diagnosis but are neither sensitive nor specific.\n\nKEY POINTS:\nSarcoidosis is driven by an overactive Th1 response producing IFN-gamma, which activates macrophages to form non-caseating granulomas. Granulomatous macrophages produce unregulated 1-alpha-hydroxylase, converting vitamin D to calcitriol and causing hypercalcemia. Bilateral hilar lymphadenopathy is the most common radiographic finding. Lofgren syndrome carries an excellent prognosis with high rates of spontaneous resolution."
  },
  {
    "id": 379,
    "categoryId": 6,
    "question": "Guillain-Barre Syndrome is an acute demyelinating polyneuropathy often triggered by Campylobacter infection. The paralysis is:",
    "options": [
      "A) Descending (Head to Toe)",
      "B) Ascending (Toe to Head)",
      "C) Unilateral",
      "D) Sensory only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ascending paralysis - Toe to Head).\n\nGUILLAIN-BARRÉ SYNDROME:\nGuillain-Barré syndrome (GBS) is an acute, immune-mediated demyelinating polyneuropathy that classically produces rapidly progressive, ascending, symmetric weakness beginning in the distal lower extremities and moving proximally. It is a common cause of acute flaccid paralysis worldwide and is frequently preceded (within 1 to 4 weeks) by a gastrointestinal or respiratory infection, with Campylobacter jejuni being the most commonly identified trigger.\n\nPATHOPHYSIOLOGY:\nGBS results from molecular mimicry in which antibodies generated against microbial surface antigens cross-react with gangliosides and glycolipids on peripheral nerve myelin and axons. In the most common subtype, acute inflammatory demyelinating polyradiculoneuropathy (AIDP), immune-mediated demyelination of peripheral nerves impairs saltatory conduction, producing weakness and sensory changes. Axonal variants (AMAN, AMSAN) involve direct antibody-mediated axonal injury and tend to have a more severe course.\n\nCLINICAL MANIFESTATIONS:\nWeakness begins in the feet and legs and ascends over hours to days, potentially reaching the trunk, arms, facial muscles, and most critically the respiratory muscles (diaphragm and intercostals). Areflexia (absent deep tendon reflexes) is an early and characteristic finding due to the peripheral nerve involvement. Autonomic dysfunction (blood pressure lability, cardiac arrhythmias, urinary retention) occurs in up to two-thirds of patients. Neuropathic pain, particularly back and limb pain, is common and often precedes weakness.\n\nDIAGNOSIS AND TREATMENT:\nCSF analysis classically shows albuminocytologic dissociation (elevated protein with normal white blood cell count), though this may be absent in the first week. Nerve conduction studies confirm demyelination. Treatment consists of intravenous immunoglobulin (IVIG) or plasmapheresis; corticosteroids are not effective. Respiratory monitoring is critical because diaphragmatic involvement can cause fatal respiratory failure.\n\nKEY POINTS:\nGBS causes ascending paralysis starting in the feet and progressing toward the head, with the greatest danger being respiratory failure from diaphragmatic involvement. Areflexia is an early hallmark finding, and CSF shows elevated protein with normal cell count. IVIG or plasmapheresis is the treatment; corticosteroids are ineffective in GBS."
  },
  {
    "id": 380,
    "categoryId": 13,
    "question": "Selective IgA Deficiency is the most common primary immunodeficiency. Patients are often asymptomatic but are at risk for:",
    "options": [
      "A) Fungal infections",
      "B) Anaphylaxis if given blood products containing IgA",
      "C) Cancer",
      "D) HIV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Anaphylaxis if given blood products containing IgA).\n\nPATHOPHYSIOLOGY:\nSelective IgA deficiency means a serum IgA level below 7 mg/dL (or undetectable) with normal IgG and IgM levels in a patient older than 4 years who has been evaluated and found to have no other cause of immunodeficiency. It is the most common primary immunodeficiency, with a prevalence of approximately 1 in 300 to 1 in 700 in populations of European descent. The exact etiology is unknown but involves impaired terminal differentiation of B cells into IgA-secreting plasma cells, with genetic susceptibility linked to the MHC region on chromosome 6. The majority of affected individuals (85 to 90 percent) are asymptomatic because compensatory secretory IgM partially substitutes for the mucosal protective role of IgA.\n\nTRANSFUSION ANAPHYLAXIS:\nThe most clinically dangerous complication is anaphylaxis following transfusion of blood products containing IgA. In a subset of IgA-deficient patients, the immune system produces anti-IgA antibodies (typically IgE class) because it has never been tolerized to IgA. When these patients receive blood products containing even trace amounts of donor IgA, the anti-IgA IgE antibodies trigger mast cell degranulation and systemic anaphylaxis. This reaction can be fatal. For this reason, IgA-deficient patients who require transfusion should receive washed red blood cells (to remove residual plasma IgA) or blood products from IgA-deficient donors.\n\nMUCOSAL INFECTIONS AND AUTOIMMUNE ASSOCIATIONS:\nSymptomatic patients may experience recurrent sinopulmonary infections (sinusitis, pneumonia, otitis media) and gastrointestinal infections, particularly Giardia lamblia, because secretory IgA normally provides first-line mucosal immunity. IgA deficiency is linked to increased prevalence of autoimmune diseases including celiac disease (10 to 15 times higher prevalence), type 1 diabetes, rheumatoid arthritis, and systemic lupus erythematosus. IgA deficiency causes false-negative IgA-based serologic tests (such as tTG-IgA for celiac disease), so IgG-based assays must be used instead.\n\nKEY POINTS:\nSelective IgA deficiency is the most common primary immunodeficiency, and most patients are asymptomatic. The major clinical risk is anaphylaxis from anti-IgA antibodies during blood transfusion; washed RBCs or IgA-deficient donor products should be used. Symptomatic patients may have recurrent sinopulmonary and Giardia infections. IgA deficiency is strongly associated with celiac disease and renders IgA-based serologic tests unreliable."
  },
  {
    "id": 381,
    "categoryId": 13,
    "question": "Vitiligo is the autoimmune destruction of:",
    "options": [
      "A) Keratinocytes",
      "B) Melanocytes",
      "C) Hair follicles",
      "D) Sweat glands"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Melanocytes).\n\nPATHOPHYSIOLOGY:\nVitiligo is an acquired autoimmune disorder in which CD8+ cytotoxic T cells selectively destroy melanocytes, the pigment-producing cells of the epidermis. The pathogenesis involves a combination of genetic susceptibility (polymorphisms in immune-regulatory genes including NLRP1, CTLA-4, and HLA alleles), environmental triggers (mechanical trauma, sunburn, chemical exposure), and intrinsic melanocyte stress (oxidative stress from reactive oxygen species accumulation). Stressed melanocytes release damage-associated molecular patterns (DAMPs) and heat shock proteins that activate innate immunity and dendritic cells, which in turn prime autoreactive CD8+ T cells to mount a targeted attack against melanocyte-specific antigens (tyrosinase, MART-1, gp100). This results in progressive, well-demarcated, depigmented (chalk-white) macules and patches.\n\nCLINICAL FEATURES:\nVitiligo affects approximately 0.5 to 2 percent of the world population, with onset most commonly before age 30. Lesions are typically symmetric and favor periorificial areas (around the eyes, mouth, nostrils), dorsal hands and feet, elbows, knees, and genitalia. The Koebner phenomenon (new lesions appearing at sites of mechanical trauma) is common. Wood lamp examination enhances the contrast of depigmented lesions, aiding diagnosis in fair-skinned patients. Vitiligo is strongly associated with other autoimmune conditions, including autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease), type 1 diabetes, pernicious anemia, Addison disease, and alopecia areata. Screening for thyroid dysfunction with TSH is recommended.\n\nTREATMENT:\nManagement is individualized based on extent and location. For limited disease (less than 20 percent body surface area), topical corticosteroids (for the body) and topical calcineurin inhibitors such as tacrolimus (preferred for the face and intertriginous areas) are first-line. For more extensive or refractory disease, narrowband UVB phototherapy is the most effective and well-studied treatment, achieving repigmentation in 40 to 70 percent of patients. The JAK inhibitor ruxolitinib cream (Opzelura) was approved by the FDA in 2022 for nonsegmental vitiligo, representing the first targeted therapy for this condition. Sun protection and psychosocial support are important components of comprehensive management.\n\nKEY POINTS:\nVitiligo results from autoimmune CD8+ T cell-mediated destruction of melanocytes, producing depigmented macules and patches. Koebner phenomenon and symmetric distribution are characteristic clinical features. Associated autoimmune conditions (especially thyroid disease) should be screened for. Treatment options include topical corticosteroids, calcineurin inhibitors, narrowband UVB phototherapy, and the JAK inhibitor ruxolitinib cream."
  },
  {
    "id": 382,
    "categoryId": 13,
    "question": "Antiphospholipid Syndrome (APS) causes a paradox in the lab: The patient is prone to clotting (Thrombosis), but which lab value is prolonged?",
    "options": [
      "A) PT",
      "B) PTT",
      "C) Bleeding Time",
      "D) Platelet Count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (PTT / Activated Partial Thromboplastin Time).\n\nTHE LUPUS ANTICOAGULANT PARADOX:\nAntiphospholipid syndrome (APS) presents one of medicine\"s most important paradoxes: patients have a prolonged PTT in the laboratory (suggesting a bleeding tendency) but clinically suffer from thrombosis. This occurs because antiphospholipid antibodies, specifically the lupus anticoagulant, interfere with the phospholipid-dependent coagulation reactions used in the PTT assay. In the test tube, the lupus anticoagulant binds to the phospholipid reagent, preventing assembly of the prothrombinase complex and prolonging clotting time. However, in vivo, these same antibodies are prothrombotic: they activate endothelial cells, platelets, and monocytes, upregulate tissue factor expression, inhibit natural anticoagulants (protein C, antithrombin), and interfere with the annexin A5 anticoagulant shield on trophoblast and endothelial surfaces.\n\nCLINICAL MANIFESTATIONS:\nAPS causes both arterial and venous thrombosis. Venous events include deep vein thrombosis and pulmonary embolism, while arterial events include stroke (especially in young patients) and myocardial infarction. Obstetric complications are a hallmark: recurrent early pregnancy loss (before 10 weeks), late pregnancy loss (after 10 weeks), preeclampsia, placental insufficiency, and intrauterine growth restriction. Catastrophic APS (CAPS) is a rare, life-threatening variant with simultaneous multi-organ thrombosis affecting three or more organs within one week, carrying mortality rates of approximately 50 percent.\n\nDIAGNOSIS AND TREATMENT:\nThe revised Sapporo (Sydney) criteria require at least one clinical criterion (vascular thrombosis or pregnancy morbidity) and one laboratory criterion (lupus anticoagulant, anticardiolipin antibodies at medium or high titer, or anti-beta-2 glycoprotein I antibodies) confirmed on two occasions at least 12 weeks apart. A mixing study that fails to correct the prolonged PTT confirms the presence of an inhibitor rather than a factor deficiency. Treatment of thrombotic APS requires long-term anticoagulation with warfarin (target INR 2.0 to 3.0); direct oral anticoagulants are not recommended based on the TRAPS trial showing inferior outcomes. Obstetric APS is managed with low-dose aspirin plus prophylactic heparin during pregnancy.\n\nKEY POINTS:\nThe lupus anticoagulant prolongs PTT in vitro by interfering with phospholipid-dependent coagulation assays, but causes thrombosis in vivo. APS causes both arterial and venous thrombosis and recurrent pregnancy loss. Diagnosis requires persistent positivity of antiphospholipid antibodies confirmed 12 weeks apart. Warfarin is the standard anticoagulant for thrombotic APS; direct oral anticoagulants are not recommended."
  },
  {
    "id": 383,
    "categoryId": 13,
    "question": "Eosinophils are specialized granulocytes designed to attack:",
    "options": [
      "A) Viruses",
      "B) Multicellular Parasites (Helminths)",
      "C) Bacteria",
      "D) Fungi"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multicellular Parasites / Helminths).\n\nEOSINOPHIL BIOLOGY:\nEosinophils are terminally differentiated granulocytes that develop in the bone marrow under the influence of IL-5 (the most critical cytokine for eosinophil differentiation, activation, and survival), IL-3, and GM-CSF. They constitute 1 to 3 percent of circulating leukocytes and are predominantly tissue-resident cells, concentrated in the gastrointestinal mucosa, skin, and respiratory tract. Eosinophils are distinguished by their bilobed nucleus and large cytoplasmic granules that stain intensely with eosin (acidic dye), which contain four major cationic proteins: major basic protein (MBP), eosinophil cationic protein (ECP), eosinophil peroxidase (EPO), and eosinophil-derived neurotoxin (EDN).\n\nANTI-PARASITIC FUNCTION:\nEosinophils evolved primarily as effector cells against multicellular parasites (helminths) that are too large to be phagocytosed by neutrophils or macrophages. The anti-helminth response is orchestrated by Th2 cytokines: IL-4 drives IgE class switching in B cells, and IgE coats the parasite surface (opsonization). Eosinophils bind to IgE-coated parasites via their low-affinity IgE receptor (FcepsilonRII/CD23) and high-affinity IgE receptor, then degranulate in a process called antibody-dependent cellular cytotoxicity (ADCC). The released cationic granule proteins, particularly MBP, are directly toxic to the parasite tegument, creating pores and disrupting membrane integrity. This extracellular killing mechanism is essential because the parasites cannot be internalized.\n\nROLE IN ALLERGIC DISEASE:\nThe same eosinophil-mediated effector mechanisms that evolved to combat parasites are pathologically activated in allergic diseases. In asthma, eosinophils infiltrate the bronchial mucosa and release granule proteins and leukotrienes that cause epithelial damage, mucus hypersecretion, bronchospasm, and airway remodeling. Peripheral eosinophilia (greater than 500 cells per microliter) is seen in parasitic infections, allergic conditions, drug reactions, adrenal insufficiency, and certain malignancies (the mnemonic NAACP: Neoplasm, Allergy, Addison disease, Collagen vascular disease, Parasites). Anti-IL-5 monoclonal antibodies (mepolizumab, reslizumab) and anti-IL-5 receptor antibodies (benralizumab) are now used for severe eosinophilic asthma.\n\nKEY POINTS:\nEosinophils are specialized effector cells that kill helminths via antibody-dependent cellular cytotoxicity, releasing toxic granule proteins (MBP, ECP) onto parasite surfaces. IL-5 is the key cytokine for eosinophil development, activation, and survival. The same Th2/IgE/eosinophil pathway that combats parasites drives pathologic inflammation in allergic diseases. Anti-IL-5 therapies (mepolizumab, benralizumab) are used for severe eosinophilic asthma."
  },
  {
    "id": 384,
    "categoryId": 6,
    "question": "A patient presents with a 'blown' (dilated and non-reactive) right pupil and left-sided hemiparesis. This indicates herniation of the temporal lobe compressing which Cranial Nerve?",
    "options": [
      "A) CN II (Optic)",
      "B) CN III (Oculomotor)",
      "C) CN VI (Abducens)",
      "D) CN VII (Facial)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CN III - Oculomotor Nerve).\n\nUNCAL HERNIATION SYNDROME:\nA dilated, non-reactive (\"blown\") pupil with contralateral hemiparesis is the classic presentation of uncal herniation, one of the most dangerous neurosurgical emergencies. The uncus, located on the medial aspect of the temporal lobe, herniates over the tentorium cerebelli due to rising supratentorial pressure, compressing the ipsilateral CN III and cerebral peduncle.\n\nPATHOPHYSIOLOGY:\nCN III carries parasympathetic fibers that constrict the pupil (via the ciliary ganglion and sphincter pupillae muscle). These parasympathetic fibers travel on the outer surface of the nerve, making them the first fibers compressed during uncal herniation. Loss of parasympathetic input results in unopposed sympathetic tone, causing ipsilateral pupillary dilation and loss of the light reflex. As herniation progresses, the ipsilateral cerebral peduncle is compressed against the tentorial edge, producing contralateral hemiparesis (motor fibers cross in the medullary pyramids). Continued herniation compresses the brainstem, causing progressive obtundation, posturing, and ultimately death.\n\nCLINICAL RECOGNITION:\nThe progression follows a predictable sequence: ipsilateral pupil dilation (earliest sign), then ptosis and oculomotor palsy (\"down and out\" eye), followed by contralateral hemiparesis, then bilateral posturing and loss of consciousness. Cushing's triad (hypertension, bradycardia, irregular respirations) is a late ominous sign of brainstem compression. Occasionally, the contralateral cerebral peduncle is compressed against the opposite tentorial edge (Kernohan notch phenomenon), causing ipsilateral hemiparesis (a false localizing sign).\n\nDIAGNOSIS AND TREATMENT:\nEmergent non-contrast CT identifies the mass lesion and herniation. Immediate temporizing measures include head-of-bed elevation to 30 degrees, hyperventilation to a target pCO2 of 30 to 35 mmHg, and hyperosmolar therapy (mannitol or hypertonic saline). Definitive treatment requires emergent neurosurgical intervention to address the underlying cause (evacuation of hematoma, tumor resection, decompressive craniectomy).\n\nKEY POINTS:\nUncal herniation compresses CN III (parasympathetic fibers on the outer surface), causing ipsilateral pupil dilation as the earliest sign. The cerebral peduncle is subsequently compressed, producing contralateral hemiparesis. This is a neurosurgical emergency requiring immediate intracranial pressure reduction and surgical intervention."
  },
  {
    "id": 385,
    "categoryId": 6,
    "question": "The Middle Cerebral Artery (MCA) supplies the lateral surface of the brain. An MCA stroke typically presents with:",
    "options": [
      "A) Leg weakness > Arm/Face weakness",
      "B) Arm/Face weakness > Leg weakness, and Aphasia (if dominant hemisphere)",
      "C) Visual hallucinations and Vertigo",
      "D) Pure sensory loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Arm/Face weakness greater than Leg weakness, and Aphasia if dominant hemisphere).\n\nMIDDLE CEREBRAL ARTERY STROKE:\nThe middle cerebral artery (MCA) is the largest branch of the internal carotid artery and supplies the lateral surface of the cerebral hemisphere, including the motor and sensory cortex for the face and upper extremity, Broca's area (speech production), Wernicke's area (speech comprehension), and the parietal association cortex. MCA stroke is the most common ischemic stroke syndrome, and its clinical presentation reflects the cortical territory it supplies.\n\nPATHOPHYSIOLOGY:\nThe motor and sensory homunculus maps body regions along the cortical surface, with the face and arm represented on the lateral convexity (MCA territory) and the leg represented on the medial surface (anterior cerebral artery territory). This somatotopic organization explains why MCA strokes produce arm and face weakness that is disproportionately greater than leg weakness. When the dominant hemisphere (typically left) is affected, aphasia results because the language centers reside in MCA territory.\n\nCLINICAL MANIFESTATIONS:\nMCA stroke presents with contralateral face and arm weakness (greater than leg), contralateral hemisensory loss, homonymous hemianopia (from optic radiation involvement), and gaze deviation toward the side of the lesion. Dominant hemisphere strokes produce Broca's aphasia (non-fluent, telegraphic speech with preserved comprehension), Wernicke's aphasia (fluent but nonsensical speech with impaired comprehension), or global aphasia. Non-dominant hemisphere strokes cause hemispatial neglect (unawareness of the contralateral side).\n\nACUTE MANAGEMENT:\nStroke management follows the \"time is brain\" paradigm. IV alteplase (0.9 mg/kg, maximum 90 mg) is indicated within 4.5 hours of symptom onset after CT excludes hemorrhage. Mechanical thrombectomy for large vessel occlusion (proximal MCA, internal carotid) can extend the treatment window to 24 hours based on perfusion imaging (per the DAWN and DEFUSE-3 trials). Aspirin is initiated after 24 hours if thrombolytics were given, or immediately if the patient is not a thrombolytic candidate.\n\nKEY POINTS:\nMCA stroke causes arm and face weakness greater than leg weakness because of the somatotopic organization of the motor cortex. Dominant hemisphere MCA strokes produce aphasia; non-dominant strokes cause hemispatial neglect. Mechanical thrombectomy can extend treatment to 24 hours for large vessel occlusion with favorable perfusion imaging."
  },
  {
    "id": 386,
    "categoryId": 6,
    "question": "Normal Pressure Hydrocephalus (NPH) presents with the classic triad of:",
    "options": [
      "A) Tremor, Rigidity, Bradykinesia",
      "B) Urinary Incontinence, Gait Disturbance ('Magnetic Gait'), Dementia",
      "C) Headache, Vomiting, Papilledema",
      "D) Visual loss, Eye pain, Weakness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gait disturbance, Urinary incontinence, Dementia - \"Wet, Wobbly, and Wacky\").\n\nNORMAL PRESSURE HYDROCEPHALUS:\nNPH involves the classic triad: gait apraxia (magnetic/shuffling gait), urinary incontinence, and dementia. The mnemonic \"wet (incontinence), wobbly (gait), and wacky (cognitive decline)\" captures the presentation. Gait disturbance is typically the earliest and most prominent feature.\n\nPATHOPHYSIOLOGY:\nNPH involves enlarged ventricles without elevated opening pressure on lumbar puncture (hence \"normal pressure\"). The mechanism likely involves impaired CSF absorption at the arachnoid granulations. Ventricular enlargement compresses periventricular white matter, particularly affecting frontal subcortical circuits controlling gait and bladder function.\n\nDIAGNOSIS:\nMRI shows ventriculomegaly out of proportion to cortical atrophy. The tap test (large-volume lumbar puncture removing 30-50cc CSF) temporarily improves symptoms in responsive patients. Gait improvement after tap test predicts response to shunting.\n\nTREATMENT:\nVentriculoperitoneal shunting can improve symptoms, particularly gait, in properly selected patients. Gait responds best, followed by incontinence; dementia responds least consistently. Early diagnosis and treatment produce better outcomes.\n\nKEY POINTS:\nNPH presents with the triad of gait disturbance, urinary incontinence, and dementia (\"wet, wobbly, wacky\"). Gait disturbance is earliest and most responsive to treatment. Large-volume lumbar puncture can predict shunt response."
  },
  {
    "id": 387,
    "categoryId": 6,
    "question": "An Epidural Hematoma is classically caused by rupture of the Middle Meningeal Artery. The CT scan appearance is:",
    "options": [
      "A) Crescent shape crossing suture lines",
      "B) Biconvex (Lens) shape NOT crossing suture lines",
      "C) Star shape in the center of the brain",
      "D) Diffuse white spots"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Biconvex/Lens shape NOT crossing suture lines).\n\nEPIDURAL HEMATOMA:\nAn epidural hematoma is a collection of blood between the inner table of the skull and the dura mater, classically caused by traumatic rupture of the middle meningeal artery following a temporal bone fracture. It produces a characteristic biconvex (lens-shaped) hyperdensity on CT scan that does not cross suture lines because the dura is tightly adherent to the periosteum at these junctures.\n\nPATHOPHYSIOLOGY:\nThe middle meningeal artery courses through a groove in the temporal bone and is vulnerable to laceration with temporal bone fractures. Because the bleeding source is arterial (high pressure), blood rapidly dissects the dura away from the calvarium, but expansion is limited by the firm dural attachments at suture lines, creating the characteristic biconvex shape. The classic clinical presentation is a \"lucid interval\" in which the patient initially appears well after head trauma, then deteriorates rapidly over hours as the hematoma expands and causes uncal herniation with ipsilateral pupil dilation and contralateral hemiparesis.\n\nDISTINCTION FROM SUBDURAL HEMATOMA:\nSubdural hematoma results from rupture of bridging veins between the cortical surface and the dural venous sinuses. Because the blood collects between the dura and arachnoid (not bound by suture lines), it forms a crescent-shaped collection that freely crosses suture lines. Subdural hematomas are common in elderly patients and those on anticoagulation due to cerebral atrophy placing greater stretch on bridging veins.\n\nDIAGNOSIS AND TREATMENT:\nNon-contrast CT is the imaging modality of choice. A biconvex hyperdensity in the temporal region is pathognomonic. Epidural hematomas are neurosurgical emergencies requiring emergent craniotomy for evacuation, particularly when there are signs of mass effect or neurological deterioration. Prognosis is generally excellent with timely surgical intervention because the underlying brain parenchyma is often uninjured.\n\nKEY POINTS:\nEpidural hematoma appears as a biconvex (lens-shaped) hyperdensity on CT that does not cross suture lines, caused by middle meningeal artery rupture. Subdural hematoma is crescent-shaped and crosses suture lines, caused by bridging vein rupture. The lucid interval followed by rapid deterioration is the classic clinical warning of an expanding epidural hematoma."
  },
  {
    "id": 388,
    "categoryId": 6,
    "question": "Carpal Tunnel Syndrome involves compression of the Median Nerve. Which physical exam finding indicates severe/advanced disease?",
    "options": [
      "A) Positive Tinel's sign",
      "B) Positive Phalen's sign",
      "C) Thenar Atrophy (Muscle wasting at base of thumb)",
      "D) Pain at night"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Thenar Atrophy - Muscle wasting at the base of the thumb).\n\nCARPAL TUNNEL SYNDROME SEVERITY:\nCarpal tunnel syndrome (CTS) is the most common entrapment neuropathy, caused by compression of the median nerve as it passes through the carpal tunnel at the wrist. While early disease presents with sensory symptoms (numbness, tingling, pain), thenar atrophy represents advanced motor involvement indicating significant and potentially irreversible nerve damage that typically warrants surgical intervention.\n\nPATHOPHYSIOLOGY:\nThe median nerve carries both sensory and motor fibers through the carpal tunnel. Sensory fibers have a lower threshold for compression injury, so they are affected first, producing numbness and paresthesias in the thumb, index, middle, and radial half of the ring finger. With prolonged or severe compression, motor fibers to the thenar muscles (abductor pollicis brevis, opponens pollicis, superficial head of flexor pollicis brevis) become compromised. Progressive denervation leads to thenar muscle atrophy, manifesting as visible wasting at the base of the thumb and weakness of thumb opposition and abduction.\n\nCLINICAL PROGRESSION AND DIAGNOSIS:\nEarly CTS presents with nocturnal paresthesias (patients shake their hands to relieve symptoms, known as the \"flick sign\"), positive Tinel sign (tapping the carpal tunnel reproduces symptoms), and positive Phalen sign (wrist flexion for 60 seconds reproduces symptoms). As disease progresses, constant numbness develops, followed by weakness and ultimately thenar atrophy. Nerve conduction studies and electromyography (EMG) are the gold standard for confirming diagnosis and grading severity, showing prolonged distal sensory and motor latencies across the wrist.\n\nTREATMENT:\nMild to moderate CTS is managed conservatively with nocturnal wrist splinting in neutral position, activity modification, and corticosteroid injection into the carpal tunnel. Surgical carpal tunnel release (open or endoscopic) is indicated for persistent symptoms despite conservative therapy, progressive motor weakness, or thenar atrophy. Once atrophy has developed, surgical outcomes are less predictable because axonal degeneration may be irreversible.\n\nKEY POINTS:\nThenar atrophy represents advanced carpal tunnel syndrome with motor fiber damage that may be irreversible. Sensory symptoms (numbness, tingling) precede motor involvement because sensory fibers have a lower threshold for compression injury. Surgical release is indicated for thenar atrophy, progressive weakness, or failure of conservative management."
  },
  {
    "id": 389,
    "categoryId": 6,
    "question": "The two pathologic hallmarks of Alzheimer's Disease found on autopsy are:",
    "options": [
      "A) Lewy Bodies and Alpha-synuclein",
      "B) Amyloid Plaques (Extracellular) and Neurofibrillary Tangles (Intracellular Tau)",
      "C) Prion proteins and Spongiform change",
      "D) Negri bodies and Gliosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amyloid Plaques and Neurofibrillary Tangles).\n\nALZHEIMER'S DISEASE NEUROPATHOLOGY:\nAlzheimer's disease (AD) is defined pathologically by two hallmark lesions: extracellular amyloid plaques composed of aggregated amyloid-beta (AÎ²) peptide, and intracellular neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. These pathological features, originally described by Alois Alzheimer in 1906, remain the definitive diagnostic criteria on neuropathological examination and form the basis of current therapeutic research.\n\nPATHOPHYSIOLOGY:\nThe amyloid cascade hypothesis proposes that abnormal processing of amyloid precursor protein (APP) by beta-secretase and gamma-secretase generates AÎ²42 peptides that aggregate into oligomers and eventually form insoluble extracellular plaques. These oligomeric species are neurotoxic, disrupting synaptic function, promoting inflammation, and triggering oxidative stress. Tau protein normally stabilizes microtubules in axons, maintaining the structural integrity of the neuronal cytoskeleton. In AD, tau becomes hyperphosphorylated, detaches from microtubules, and aggregates into paired helical filaments that form intracellular NFTs. The collapse of the microtubule transport system impairs axonal transport and ultimately causes neuronal death.\n\nCLINICAL CORRELATION:\nThe distribution of NFTs follows the Braak staging system, beginning in the entorhinal cortex and hippocampus (explaining early memory loss) and spreading to the neocortex (causing progressive language, visuospatial, and executive dysfunction). Amyloid plaques are more diffusely distributed and correlate less precisely with clinical symptoms than NFTs. Cholinergic neurons in the nucleus basalis of Meynert are particularly vulnerable, providing the rationale for cholinesterase inhibitor therapy.\n\nDIAGNOSIS AND TREATMENT:\nClinical diagnosis uses the NIA-AA criteria combining cognitive assessment, biomarkers (CSF AÎ²42/tau ratios, amyloid PET imaging), and exclusion of other causes. Current treatments include cholinesterase inhibitors (donepezil, rivastigmine, galantamine) for mild to moderate disease and memantine (NMDA receptor antagonist) for moderate to severe disease. Anti-amyloid monoclonal antibodies (lecanemab, donanemab) represent newer disease-modifying approaches targeting amyloid pathology.\n\nKEY POINTS:\nAlzheimer's is defined by extracellular amyloid plaques (AÎ² aggregates) and intracellular neurofibrillary tangles (hyperphosphorylated tau). Tau pathology follows the Braak staging pattern from the entorhinal cortex outward, correlating with clinical symptom progression. Anti-amyloid monoclonal antibodies represent the first disease-modifying therapies targeting the underlying pathology."
  },
  {
    "id": 390,
    "categoryId": 6,
    "question": "Trigeminal Neuralgia (Tic Douloureux) affects which nerve branches and causes what type of pain?",
    "options": [
      "A) CN VII; Dull aching pain",
      "B) CN V2/V3; Sudden, electric-shock, lancinating pain",
      "C) CN X; Burning throat pain",
      "D) CN V1; Throbbing forehead pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (V2 and V3 branches; Sharp, lancinating, electric shock-like pain).\n\nTRIGEMINAL NEURALGIA:\nTrigeminal neuralgia (tic douloureux) causes paroxysmal, severe, unilateral facial pain in the distribution of one or more branches of the trigeminal nerve (CN V). The pain is classically described as electric shock-like, stabbing, or lancinating, lasting seconds to minutes.\n\nANATOMICAL DISTRIBUTION:\nThe trigeminal nerve has three branches: V1 (ophthalmic), V2 (maxillary), and V3 (mandibular). V2 and V3 are most commonly affected, causing pain in the cheek, upper lip, lower lip, chin, and jaw. Pure V1 involvement is uncommon and should prompt evaluation for other etiologies.\n\nTRIGGER FACTORS:\nPain is typically triggered by innocuous stimuli to \"trigger zones\" on the face: light touch, chewing, talking, brushing teeth, cold air, or shaving. Patients may avoid eating or washing their face. Between attacks, they are pain-free.\n\nETIOLOGY AND TREATMENT:\nMost cases are caused by vascular compression of the trigeminal root entry zone, typically by the superior cerebellar artery. MRI should exclude secondary causes (MS, tumor). First-line treatment is carbamazepine or oxcarbazepine. Surgical options (microvascular decompression) are available for refractory cases.\n\nKEY POINTS:\nTrigeminal neuralgia causes brief, severe, electric shock-like pain in V2/V3 distribution. Pain is triggered by light touch, eating, or talking. First-line treatment is carbamazepine; MRI excludes secondary causes."
  },
  {
    "id": 391,
    "categoryId": 6,
    "question": "Which of the following is an Upper Motor Neuron (UMN) sign?",
    "options": [
      "A) Fasciculations (Muscle twitching)",
      "B) Hyporeflexia",
      "C) Spasticity and Hyperreflexia (+ Babinski)",
      "D) Muscle Atrophy"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Spasticity and Hyperreflexia with positive Babinski sign).\n\nUPPER MOTOR NEURON SIGNS:\nUpper motor neuron (UMN) lesions affect the descending motor pathways originating in the cerebral cortex and brainstem that normally exert inhibitory control over spinal reflex arcs. When this inhibitory input is lost, the result is a constellation of \"release\" phenomena in which spinal reflexes become exaggerated. The cardinal UMN signs are spasticity (velocity-dependent increase in muscle tone), hyperreflexia (exaggerated deep tendon reflexes), clonus (rhythmic involuntary contractions), and the Babinski sign (extensor plantar response with great toe dorsiflexion).\n\nPATHOPHYSIOLOGY:\nThe corticospinal tract provides tonic inhibition to spinal motor neuron pools and spinal interneurons. When this tract is damaged (by stroke, spinal cord injury, MS, or brain tumor), the loss of descending inhibition allows unchecked excitatory input from spinal reflex pathways. This explains why \"everything goes up\" in UMN lesions: increased tone (spasticity), increased reflexes (hyperreflexia), and upgoing toes (Babinski). The Babinski sign specifically reflects loss of corticospinal tract inhibition over the flexor withdrawal reflex in the lower extremity.\n\nLOWER MOTOR NEURON COMPARISON:\nLower motor neuron (LMN) lesions damage the final common pathway (anterior horn cell, peripheral nerve, or nerve root) that directly innervates muscle. Without innervation, \"everything goes down\": decreased tone (flaccidity), absent reflexes (areflexia), muscle atrophy from denervation, and fasciculations (spontaneous motor unit discharges visible as muscle twitching). The plantar response is absent or flexor (normal).\n\nCLINICAL APPLICATION:\nDistinguishing UMN from LMN patterns is fundamental to neurological localization. UMN signs localize the lesion to the brain or spinal cord, while LMN signs localize to the anterior horn cell, nerve root, plexus, or peripheral nerve. Some diseases, such as ALS, produce both UMN and LMN findings simultaneously, which is a critical diagnostic clue.\n\nKEY POINTS:\nUMN lesions cause spasticity, hyperreflexia, clonus, and Babinski sign due to loss of descending cortical inhibition over spinal reflexes. LMN lesions cause flaccidity, areflexia, atrophy, and fasciculations due to loss of the nerve signal to muscle. Distinguishing UMN from LMN patterns is essential for localizing neurological lesions to the brain/cord versus the peripheral nervous system."
  },
  {
    "id": 392,
    "categoryId": 6,
    "question": "Parkinson's Disease is caused by the loss of Dopaminergic neurons in the:",
    "options": [
      "A) Cerebellum",
      "B) Substantia Nigra (Pars Compacta)",
      "C) Hippocampus",
      "D) Caudate Nucleus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Substantia Nigra pars compacta).\n\nPARKINSON'S PATHOPHYSIOLOGY:\nParkinson's disease results from progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain. These neurons project to the striatum (caudate and putamen) via the nigrostriatal pathway, providing dopamine that is essential for smooth, coordinated movement.\n\nCLINICAL CONSEQUENCES:\nDopamine depletion in the striatum disrupts the balance between the direct (movement-facilitating) and indirect (movement-inhibiting) basal ganglia pathways, resulting in the cardinal features: bradykinesia (slowness), rigidity (lead-pipe or cogwheel), resting tremor (pill-rolling), and postural instability. Bradykinesia is required for diagnosis.\n\nLEWY BODIES:\nThe pathological hallmark of Parkinson's is Lewy bodiesâ€”intracytoplasmic inclusions containing aggregated alpha-synuclein protein. Lewy body pathology spreads through the brain in a predictable pattern, explaining the progression from motor to non-motor symptoms.\n\nTREATMENT IMPLICATIONS:\nLevodopa (dopamine precursor) and dopamine agonists replace lost dopaminergic signaling. Deep brain stimulation of the subthalamic nucleus or globus pallidus can modulate the dysregulated basal ganglia circuits.\n\nKEY POINTS:\nParkinson's results from dopaminergic neuron loss in the substantia nigra pars compacta. The cardinal features are bradykinesia, rigidity, resting tremor, and postural instability. Lewy bodies containing alpha-synuclein are the pathological hallmark."
  },
  {
    "id": 393,
    "categoryId": 6,
    "question": "A 'Focal Onset Impaired Awareness' seizure (formerly Complex Partial) differs from a 'Focal Aware' seizure because:",
    "options": [
      "A) It involves the whole body",
      "B) Consciousness is altered/lost",
      "C) It causes incontinence",
      "D) It lasts longer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Consciousness is altered/lost).\n\nCLASSIFICATION OF FOCAL SEIZURES:\nThe International League Against Epilepsy (ILAE) reclassified seizures in 2017, replacing older terminology with more descriptive categories. Focal seizures originate in networks limited to one hemisphere. The critical distinction between focal onset aware and focal onset impaired awareness seizures is whether the patient retains or loses awareness during the event.\n\nFOCAL ONSET AWARE SEIZURES (FORMERLY SIMPLE PARTIAL):\nThe patient remains fully conscious and aware throughout the seizure. They may experience motor symptoms (jerking of one limb), sensory phenomena (tingling, visual disturbances), or autonomic symptoms (flushing, nausea). the patient can describe what happened during the episode because consciousness is preserved. These seizures typically last seconds to under two minutes.\n\nFOCAL ONSET IMPAIRED AWARENESS SEIZURES (FORMERLY COMPLEX PARTIAL):\nConsciousness is altered or lost during the seizure. Patients may stare blankly, exhibit automatisms (lip smacking, picking at clothes, wandering), and have no memory of the event afterward. The temporal lobe is the most common origin. These seizures may evolve to bilateral tonic-clonic seizures if the abnormal electrical activity spreads to both hemispheres.\n\nCLINICAL SIGNIFICANCE:\nDistinguishing between these seizure types guides treatment and prognosis. Impaired awareness seizures may impair driving eligibility and require more aggressive management. Both types indicate focal brain pathology warranting MRI evaluation.\n\nKEY POINTS:\nFocal onset impaired awareness seizures alter consciousness; focal onset aware seizures preserve it. The temporal lobe is the most common source of focal impaired awareness seizures. Automatisms (repetitive purposeless movements) commonly accompany impaired awareness seizures."
  },
  {
    "id": 394,
    "categoryId": 6,
    "question": "The pathophysiology of Migraine pain involves the activation of the:",
    "options": [
      "A) Sciatic Nerve",
      "B) Trigeminovascular System",
      "C) Vagus Nerve",
      "D) Optic Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Trigeminovascular System).\n\nMIGRAINE PATHOPHYSIOLOGY:\nThe trigeminovascular system is the primary neuroanatomical substrate underlying migraine pain. This system consists of trigeminal sensory nerve fibers that densely innervate the intracranial meningeal blood vessels and the dural sinuses. Activation of this system releases vasoactive neuropeptides, most notably calcitonin gene-related peptide (CGRP), substance P, and neurokinin A, which trigger meningeal neurogenic inflammation and vasodilation, ultimately perceived as the characteristic throbbing headache.\n\nPATHOPHYSIOLOGY:\nCurrent understanding recognizes migraine as a complex neurovascular disorder. A migraine attack begins with cortical spreading depression (CSD), a wave of neuronal depolarization followed by suppression that propagates across the cortex (this underlies aura). CSD activates trigeminal afferents innervating the meninges, which then release CGRP and other neuropeptides from their peripheral terminals. This causes meningeal vasodilation, plasma protein extravasation, mast cell degranulation, and sensitization of perivascular nociceptors. The pain signals are transmitted via the trigeminal ganglion to the trigeminal nucleus caudalis in the brainstem, then to the thalamus and cortex, where they are perceived as headache.\n\nTREATMENT IMPLICATIONS:\nUnderstanding the trigeminovascular mechanism directly informs pharmacotherapy. Triptans (5-HT1B/1D agonists) abort migraines by constricting meningeal vessels and inhibiting CGRP release from trigeminal terminals. The newer CGRP-targeted therapies represent a paradigm shift: gepants (small molecule CGRP receptor antagonists such as ubrogepant and rimegepant) are used for acute treatment, while CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) provide targeted prophylaxis by blocking either the CGRP ligand or its receptor.\n\nCOMPREHENSIVE MANAGEMENT:\nAcute migraine treatment follows a stratified approach: NSAIDs for mild attacks, triptans or gepants for moderate to severe attacks, and antiemetics (metoclopramide, prochlorperazine) as adjuncts. Prophylaxis is indicated for four or more migraine days per month, with first-line options including beta-blockers, topiramate, valproate, and amitriptyline. Opioids and barbiturates should be avoided due to medication overuse headache risk.\n\nKEY POINTS:\nMigraine pain arises from activation of the trigeminovascular system, which releases CGRP and causes neurogenic meningeal inflammation. Triptans work by constricting meningeal vessels and inhibiting CGRP release; newer CGRP-targeted therapies offer alternatives without vasoconstrictive effects. Prophylaxis is indicated for four or more migraine days per month."
  },
  {
    "id": 395,
    "categoryId": 6,
    "question": "Brown-Sequard Syndrome (Hemisection of the cord) causes:",
    "options": [
      "A) Bilateral paralysis",
      "B) Ipsilateral motor loss/vibration loss; Contralateral pain/temp loss",
      "C) Contralateral motor loss; Ipsilateral pain loss",
      "D) Complete sensory loss only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ipsilateral motor and vibration loss; Contralateral pain and temperature loss).\n\nBROWN-SÉQUARD SYNDROME:\nBrown-Séquard syndrome results from hemisection (or asymmetric lesion) of the spinal cord, producing a characteristic pattern of ipsilateral motor paralysis and loss of proprioception/vibration with contralateral loss of pain and temperature sensation below the level of the lesion. This dissociated pattern is one of the most clinically important demonstrations of spinal cord neuroanatomy and tract organization.\n\nPATHOPHYSIOLOGY:\nThe dissociated findings are explained by where different ascending pathways decussate (cross the midline). The corticospinal tract (motor) descends from the cortex and crosses at the medullary pyramids, then travels ipsilaterally in the lateral cord. A hemisection therefore causes ipsilateral motor loss (UMN signs below the lesion). The dorsal column-medial lemniscus pathway (proprioception, vibration, fine touch) ascends ipsilaterally in the posterior columns and crosses in the medulla, so a hemisection causes ipsilateral loss of these modalities. In contrast, the spinothalamic tract (pain, temperature, crude touch) crosses within one to two segments of entering the spinal cord, then ascends contralaterally. Therefore, a hemisection disrupts already-crossed fibers, producing contralateral pain and temperature loss.\n\nCLINICAL PRESENTATION:\nAt the level of the lesion, there may be an ipsilateral LMN pattern (segmental weakness, areflexia) and a band of ipsilateral loss of all sensory modalities. Below the lesion, the classic pattern emerges: ipsilateral UMN weakness (spasticity, hyperreflexia, Babinski), ipsilateral loss of vibration and proprioception, and contralateral loss of pain and temperature beginning one to two dermatomes below the lesion level.\n\nCOMMON ETIOLOGIES:\nBrown-Séquard syndrome is most commonly caused by penetrating trauma (stab wounds, gunshot injuries). Other causes include spinal cord tumors, multiple sclerosis plaques, epidural hematoma, and disc herniation. Among spinal cord injury patterns, Brown-Séquard syndrome carries the best prognosis for functional recovery.\n\nKEY POINTS:\nBrown-Séquard syndrome causes ipsilateral motor and vibration/proprioception loss with contralateral pain and temperature loss due to different levels of tract decussation. The corticospinal and dorsal column pathways cross in the brainstem (ipsilateral signs), while the spinothalamic tract crosses at the spinal cord level (contralateral signs). It carries the best prognosis among incomplete spinal cord injury patterns."
  },
  {
    "id": 396,
    "categoryId": 17,
    "question": "Which maneuver distinguishes Central Vertigo (Stroke) from Peripheral Vertigo (Vestibular Neuritis)?",
    "options": [
      "A) Romberg Test",
      "B) HINTS Exam (Head Impulse, Nystagmus, Test of Skew)",
      "C) Dix-Hallpike",
      "D) Weber Test"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HINTS Exam - Head Impulse, Nystagmus, Test of Skew).\n\nPATHOPHYSIOLOGY:\nAcute vestibular syndrome presents with continuous vertigo, nausea/vomiting, nystagmus, and gait instability lasting days. The critical diagnostic challenge is distinguishing peripheral causes (vestibular neuritis, a benign condition) from central causes (posterior fossa stroke, a life-threatening emergency). The HINTS exam is a bedside three-component examination that has been shown to be more sensitive than early MRI (which can be falsely negative in the first 24-48 hours) for detecting posterior fossa stroke.\n\nHINTS EXAM COMPONENTS:\n1. Head Impulse test (HI):\n - NORMAL (no corrective saccade) = DANGEROUS - suggests central lesion (cerebellum compensates)\n - ABNORMAL (corrective saccade present) = Peripheral (vestibular neuritis - the VOR is impaired)\n2. Nystagmus type:\n - Unidirectional, horizontal = Peripheral (reassuring)\n - Direction-changing or vertical/torsional = DANGEROUS - suggests central lesion\n3. Test of Skew (alternate cover test):\n - No vertical correction = Peripheral (reassuring)\n - Vertical skew deviation present = DANGEROUS - suggests brainstem lesion\n\nCLINICAL REASONING:\nA dangerous HINTS pattern (any one of: normal head impulse, direction-changing nystagmus, or skew deviation) has greater than 96% sensitivity for posterior fossa stroke, outperforming MRI-DWI in the first 48 hours (Kattah et al., Stroke 2009). This patient has a normal head impulse test (dangerous sign), raising concern for cerebellar stroke.\n\nTREATMENT:\n- Peripheral (vestibular neuritis): Supportive care, short-course vestibular suppressants, early vestibular rehabilitation\n- Central (stroke): Emergent neurology/stroke team activation, MRI/MRA, antiplatelet or anticoagulation per etiology\n\nKEY POINTS:\nA normal head impulse test in acute vestibular syndrome is a red flag for stroke, not reassurance. The HINTS exam outperforms early MRI for posterior fossa stroke detection. Any single dangerous HINTS finding warrants urgent neuroimaging and stroke evaluation.\n---"
  },
  {
    "id": 397,
    "categoryId": 6,
    "question": "Myasthenia Gravis is an autoimmune disorder of the neuromuscular junction. Symptoms typically:",
    "options": [
      "A) Improve with use/exercise",
      "B) Worsen with use/exercise (Fatigability) and improve with rest",
      "C) Are constant throughout the day",
      "D) Start in the legs"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Symptoms worsen with use/exercise and improve with rest - Fatigability).\n\nMYASTHENIA GRAVIS FATIGABILITY:\nThe hallmark clinical feature of myasthenia gravis (MG) is fatigable weakness, meaning that muscle strength progressively decreases with sustained or repeated use and recovers after rest. This pattern directly reflects the underlying pathophysiology at the neuromuscular junction, where antibody-mediated destruction of acetylcholine receptors causes progressive neurotransmission failure during sustained activity.\n\nPATHOPHYSIOLOGY:\nUnder normal conditions, each nerve impulse releases acetylcholine (ACh) vesicles into the synaptic cleft, where ACh binds to postsynaptic nicotinic receptors and generates an endplate potential sufficient to trigger muscle contraction. In MG, autoantibodies reduce the number of functional AChR through complement-mediated lysis, accelerated internalization, and direct blockade. The remaining receptors can initially sustain neurotransmission, but with repeated nerve firing, the readily releasable ACh pool depletes (a normal phenomenon), and fewer ACh molecules encounter fewer receptors. Eventually, endplate potentials fall below the threshold for muscle fiber activation, producing clinical weakness. Rest allows ACh stores to replenish, temporarily restoring transmission.\n\nCLINICAL MANIFESTATIONS:\nPatients characteristically report feeling strongest in the morning and weakest by evening. Ptosis (eyelid drooping) and diplopia (double vision) are the most common initial symptoms because the extraocular muscles have a high firing frequency and low safety factor for neuromuscular transmission. Bulbar symptoms (difficulty chewing that worsens during a meal, nasal speech, dysphagia) and proximal limb weakness follow. In myasthenic crisis, respiratory muscle fatigue leads to ventilatory failure requiring intubation.\n\nDIAGNOSIS:\nThe pattern of fatigable weakness guides testing. The ice pack test (placing ice on the ptotic eyelid for 2 minutes improves ptosis by reducing acetylcholinesterase activity at the cooled neuromuscular junction) and serologic testing for AChR or MuSK antibodies confirm the diagnosis. Repetitive nerve stimulation shows a characteristic decremental response.\n\nKEY POINTS:\nMyasthenia gravis causes fatigable weakness that worsens with repetitive use and improves with rest, reflecting progressive ACh depletion at a receptor-depleted neuromuscular junction. Patients are strongest in the morning and weakest by evening, with ptosis and diplopia as the most common initial symptoms. The ice pack test and AChR antibody testing are key diagnostic tools."
  },
  {
    "id": 398,
    "categoryId": 6,
    "question": "Amyotrophic Lateral Sclerosis (ALS) is unique because it affects:",
    "options": [
      "A) Only Upper Motor Neurons",
      "B) Only Lower Motor Neurons",
      "C) Both Upper AND Lower Motor Neurons simultaneously",
      "D) Only Sensory Neurons"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Both Upper AND Lower Motor Neurons simultaneously).\n\nAMYOTROPHIC LATERAL SCLEROSIS:\nAmyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease uniquely characterized by the simultaneous degeneration of both upper motor neurons (corticospinal tract in the brain and spinal cord) and lower motor neurons (anterior horn cells of the spinal cord and brainstem motor nuclei). The coexistence of UMN and LMN signs in the same patient is the defining clinical feature that distinguishes ALS from other motor neuron diseases and neuropathies.\n\nPATHOPHYSIOLOGY:\nALS involves progressive loss of motor neurons through mechanisms including glutamate excitotoxicity, protein aggregation (TDP-43 inclusions are found in approximately 97% of ALS cases), oxidative stress, mitochondrial dysfunction, and impaired axonal transport. The disease affects motor neurons selectively while sparing sensory neurons, autonomic neurons, and the oculomotor nuclei. Approximately 5 to 10% of cases are familial, with mutations in SOD1, C9orf72, TARDBP, and FUS genes identified.\n\nCLINICAL MANIFESTATIONS:\nPatients present with the combination of LMN signs (muscle atrophy, fasciculations, flaccid weakness) and UMN signs (spasticity, hyperreflexia, Babinski sign), often in the same limb or in different body regions. Finding fasciculations and atrophy (LMN) together with hyperreflexia (UMN) in the same extremity is highly suggestive. Sensory function is strictly preserved. Symptoms typically begin asymmetrically in one limb and spread to contiguous regions. Bulbar-onset ALS (approximately 25% of cases) presents with dysarthria and dysphagia. Respiratory failure is the usual cause of death, with median survival of 3 to 5 years from symptom onset.\n\nDIAGNOSIS AND TREATMENT:\nThe revised El Escorial criteria require evidence of UMN and LMN degeneration in multiple body regions with progressive spread, absence of alternative explanations, and normal sensory examination. EMG confirms widespread active denervation. Riluzole modestly extends survival by reducing glutamate excitotoxicity (approximately 2 to 3 months). Edaravone may slow functional decline in selected patients. Multidisciplinary care including respiratory support, nutritional management, and physical therapy improves quality of life.\n\nKEY POINTS:\nALS uniquely affects both upper and lower motor neurons simultaneously, producing the combination of atrophy and fasciculations (LMN) with spasticity and hyperreflexia (UMN). Sensory function is strictly preserved, which is a critical diagnostic feature. Median survival is 3 to 5 years; riluzole provides modest survival benefit."
  },
  {
    "id": 399,
    "categoryId": 6,
    "question": "Wernicke's Encephalopathy is caused by Thiamine (B1) deficiency. The classic triad is:",
    "options": [
      "A) Fever, Headache, Rash",
      "B) Confusion, Ataxia, Ophthalmoplegia (Eye paralysis)",
      "C) Tremor, Rigidity, Shuffle",
      "D) Diarrhea, Dermatitis, Dementia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Confusion, Ataxia, Ophthalmoplegia).\n\nWERNICKE'S ENCEPHALOPATHY:\nWernicke's encephalopathy is an acute neurological emergency caused by thiamine (vitamin B1) deficiency, classically presenting with the triad of confusion (encephalopathy), ataxia (cerebellar dysfunction), and ophthalmoplegia (eye movement paralysis, typically CN VI palsy or conjugate gaze abnormalities). However, the complete triad is present in only about one-third of cases, making clinical suspicion essential for timely diagnosis and treatment.\n\nPATHOPHYSIOLOGY:\nThiamine is an essential cofactor for three critical enzymes in cerebral energy metabolism: pyruvate dehydrogenase, alpha-ketoglutarate dehydrogenase (both in the Krebs cycle), and transketolase (in the pentose phosphate pathway). Deficiency impairs oxidative metabolism in metabolically active brain regions, particularly the mammillary bodies, medial thalami, periaqueductal gray matter, and cerebellar vermis. These structures undergo hemorrhagic necrosis, producing the characteristic clinical triad. Thiamine stores are depleted within 2 to 3 weeks without intake.\n\nCLINICAL CONTEXT AND RISK FACTORS:\nWernicke's encephalopathy is most commonly associated with chronic alcohol use disorder (due to poor nutrition and impaired thiamine absorption and phosphorylation), but it also occurs with prolonged vomiting (hyperemesis gravidarum), malnutrition, bariatric surgery, refeeding syndrome, and prolonged IV glucose administration without thiamine supplementation. A critical clinical pearl is that glucose administration accelerates thiamine consumption, potentially precipitating or worsening Wernicke's encephalopathy. Therefore, thiamine must always be administered before or concurrent with glucose in patients at risk.\n\nTREATMENT AND PROGNOSIS:\nHigh-dose IV thiamine (500 mg three times daily for 2 to 3 days, then 250 mg daily) should be given empirically whenever Wernicke's encephalopathy is suspected, as the diagnosis is clinical and delay can be fatal. Ophthalmoplegia typically improves within hours of thiamine administration, ataxia improves over days, and confusion may take weeks. If untreated, Wernicke's encephalopathy progresses to Korsakoff syndrome, characterized by severe anterograde amnesia and confabulation (fabrication of memories to fill gaps), which is often irreversible.\n\nKEY POINTS:\nWernicke's encephalopathy presents with confusion, ataxia, and ophthalmoplegia due to thiamine deficiency affecting metabolically active brain regions. Thiamine must always be given before glucose to prevent worsening. Untreated Wernicke's progresses to Korsakoff syndrome with permanent amnesia and confabulation."
  },
  {
    "id": 400,
    "categoryId": 6,
    "question": "C6 Radiculopathy typically causes pain/numbness in the:",
    "options": [
      "A) Pinky finger",
      "B) Thumb and Index finger",
      "C) Middle finger",
      "D) Shoulder only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Thumb and index finger).\n\nC6 RADICULOPATHY:\nC6 radiculopathy results from compression of the C6 nerve root, most commonly by a herniated disc at C5-C6 or cervical spondylotic foraminal stenosis. The clinical presentation follows the C6 dermatome, producing pain and numbness radiating from the neck through the lateral forearm to the thumb and index finger. Motor involvement manifests as weakness of wrist extension and elbow flexion (biceps), with diminished biceps and brachioradialis reflexes.\n\nPATHOPHYSIOLOGY:\nThe cervical nerve roots exit above their corresponding vertebral body (C6 exits above C6, between C5 and C6). Degenerative disc disease, disc herniation, uncovertebral joint hypertrophy, or facet arthropathy can narrow the neural foramen and compress the exiting nerve root. Radicular pain is generated by mechanical compression combined with inflammatory mediators released from the degenerated disc, including phospholipase A2, TNF-alpha, and interleukin-6, which sensitize the dorsal root ganglion.\n\nCERVICAL RADICULOPATHY LOCALIZATION:\nDistinguishing cervical nerve root levels is essential for clinical localization. C5 radiculopathy causes shoulder pain with deltoid weakness and diminished biceps reflex. C6 radiculopathy causes lateral forearm pain and thumb/index numbness with biceps and wrist extensor weakness, and decreased biceps/brachioradialis reflexes. C7 radiculopathy (the most common) causes posterior forearm and middle finger numbness with triceps and wrist flexor weakness, and decreased triceps reflex. C8 radiculopathy causes medial forearm pain with ring and small finger numbness and hand grip weakness.\n\nDIAGNOSIS AND TREATMENT:\nHistory and physical examination are the cornerstones of diagnosis. Spurling test (axial loading with neck extension and ipsilateral rotation reproducing radicular symptoms) supports the diagnosis. MRI is indicated for progressive neurological deficits, suspected myelopathy, red flags (trauma, cancer, infection), or symptoms persisting beyond 6 weeks. Conservative management (NSAIDs, physical therapy, activity modification) resolves symptoms in 80 to 90% of patients. Epidural steroid injections or surgical decompression are considered for refractory or progressive cases.\n\nKEY POINTS:\nC6 radiculopathy causes pain and numbness in the thumb and index finger with biceps and wrist extensor weakness and diminished biceps/brachioradialis reflexes. Conservative management resolves the majority of cervical radiculopathies within 6 to 12 weeks. MRI is reserved for red flags, myelopathy signs, progressive weakness, or persistent symptoms beyond 6 weeks."
  },
  {
    "id": 401,
    "categoryId": 6,
    "question": "CSF analysis showing High Protein, Low Glucose, and High Neutrophils indicates:",
    "options": [
      "A) Viral Meningitis",
      "B) Bacterial Meningitis",
      "C) Fungal Meningitis",
      "D) Guillain-Barre"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bacterial Meningitis).\n\nCSF ANALYSIS IN MENINGITIS:\nThe combination of elevated protein, low glucose, and neutrophil (polymorphonuclear/PMN) predominance in cerebrospinal fluid is the classic pattern for bacterial meningitis. CSF analysis is the definitive diagnostic step when meningitis is suspected, and the pattern of cell count, differential, protein, and glucose allows differentiation between bacterial, viral, fungal, and tuberculous etiologies. Bacterial meningitis is a medical emergency requiring immediate empiric antibiotic therapy.\n\nPATHOPHYSIOLOGY:\nBacteria reach the meninges through hematogenous spread, direct extension from contiguous infections (sinusitis, otitis media), or following neurosurgical procedures or skull fractures. Once in the subarachnoid space, bacterial replication triggers an intense inflammatory response with neutrophil recruitment (explaining PMN predominance). Bacteria and neutrophils consume glucose through glycolysis (producing low CSF glucose, typically below 40 mg/dL or less than two-thirds of serum glucose). Inflammation increases blood-brain barrier permeability, allowing protein leakage into the CSF (elevated protein, often greater than 200 mg/dL). The opening pressure is characteristically elevated.\n\nCSF PATTERNS BY ETIOLOGY:\nViral meningitis shows mild WBC elevation (typically fewer than 500 cells/ÂµL) with lymphocyte predominance, normal glucose, and normal to mildly elevated protein. Fungal and tuberculous meningitis also show lymphocyte predominance but with low glucose and high protein, resembling bacterial meningitis except for the lymphocytic differential and subacute clinical presentation over days to weeks rather than hours. Guillain-Barré syndrome shows elevated protein with a normal cell count (albuminocytologic dissociation) and normal glucose.\n\nTREATMENT:\nEmpiric antibiotic therapy must be initiated immediately upon clinical suspicion, ideally within 60 minutes of presentation and before CSF results return. Empiric coverage for adults includes vancomycin plus a third-generation cephalosporin (ceftriaxone or cefotaxime). Dexamethasone should be given before or with the first antibiotic dose to reduce inflammation-mediated neuronal injury, particularly in pneumococcal meningitis. Gram stain, culture, and meningococcal/pneumococcal PCR panels guide definitive therapy.\n\nKEY POINTS:\nBacterial meningitis produces high protein, low glucose, and neutrophil-predominant CSF due to intense inflammation and bacterial glucose consumption. Viral meningitis shows lymphocyte predominance with normal glucose, while fungal/TB meningitis shows lymphocyte predominance with low glucose. Empiric antibiotics and dexamethasone must be given immediately upon clinical suspicion, before CSF results return."
  },
  {
    "id": 402,
    "categoryId": 6,
    "question": "Horner's Syndrome (Ptosis, Miosis, Anhidrosis) is caused by a lesion in the:",
    "options": [
      "A) Parasympathetic pathway",
      "B) Sympathetic chain",
      "C) Somatic motor pathway",
      "D) Cerebellum"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sympathetic chain).\n\nHORNER'S SYNDROME:\nHorner's syndrome is a clinical triad of ipsilateral ptosis (drooping eyelid), miosis (constricted pupil), and anhidrosis (decreased sweating of the face), resulting from disruption of the oculosympathetic pathway at any point along its three-neuron arc. The syndrome is clinically important not because it is dangerous itself, but because the underlying cause may be life-threatening, making localization and etiologic workup essential.\n\nPATHOPHYSIOLOGY:\nThe sympathetic pathway to the eye and face follows a three-neuron chain. First-order neurons travel from the hypothalamus to the ciliospinal center of Budge at C8-T2 in the spinal cord (lesions here include stroke, syringomyelia, and MS). Second-order (preganglionic) neurons ascend from C8-T2 over the lung apex and along the carotid artery to the superior cervical ganglion (lesions include Pancoast tumor of the lung apex, neck trauma, and thoracic surgery). Third-order (postganglionic) neurons travel from the superior cervical ganglion along the internal carotid artery to the orbit (lesions include carotid dissection, cavernous sinus pathology, and cluster headache). Sympathetic fibers normally dilate the pupil (via the iris dilator muscle) and elevate the upper eyelid (via Müller's muscle). When this pathway is interrupted, the unopposed parasympathetic tone produces miosis and ptosis.\n\nCLINICAL SIGNIFICANCE OF LOCALIZATION:\nCocaine eye drops can confirm Horner's syndrome (the affected pupil fails to dilate), while hydroxyamphetamine drops help distinguish preganglionic from postganglionic lesions. A new-onset Horner's syndrome demands urgent evaluation. Second-order neuron lesions raise concern for Pancoast tumor (apical lung mass invading the sympathetic chain) and require chest imaging. Third-order neuron lesions combined with ipsilateral head or neck pain suggest carotid artery dissection, requiring urgent CT or MR angiography.\n\nDIAGNOSIS AND WORKUP:\nPharmacologic pupil testing localizes the lesion. Imaging is guided by localization: MRI of the brain and cervical cord for first-order lesions, CT chest for second-order lesions (Pancoast tumor), and CT/MR angiography of the head and neck for third-order lesions (carotid dissection). A new-onset, painful Horner's syndrome should prompt emergent vascular imaging to exclude carotid dissection.\n\nKEY POINTS:\nHorner's syndrome (ptosis, miosis, anhidrosis) results from interruption of the three-neuron sympathetic chain to the eye. A Pancoast tumor (lung apex) is the classic cause of a second-order neuron lesion, and carotid dissection is the most important cause to exclude urgently. Pharmacologic pupil testing with cocaine and hydroxyamphetamine helps localize the lesion along the sympathetic pathway."
  },
  {
    "id": 403,
    "categoryId": 6,
    "question": "Unlike Alzheimer's, Vascular Dementia typically progresses:",
    "options": [
      "A) In a smooth, linear decline",
      "B) In a 'Stepwise' fashion",
      "C) With hallucinations first",
      "D) With personality changes first"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (In a 'Stepwise' fashion).\n\nPATHOPHYSIOLOGY OF VASCULAR DEMENTIA:\nVascular dementia results from cerebrovascular disease causing cumulative brain injury. Unlike the gradual neurodegeneration of Alzheimer's disease, vascular dementia occurs through discrete ischemic events: strokes, transient ischemic attacks, or chronic small vessel disease. Each vascular insult causes sudden neurological decline, followed by a plateau or partial recovery, then another decline with the next eventâ€”creating the characteristic stepwise pattern.\n\nCLINICAL PRESENTATION:\nThe stepwise progression is the hallmark distinguishing feature. Patients or families often report sudden worsening of cognition coinciding with vascular events. Executive dysfunction (planning, judgment, organization) tends to be more prominent than memory loss early in the disease, contrasting with Alzheimer's where memory impairment dominates initially. Focal neurological signs (gait disturbance, focal weakness, pseudobulbar affect) are common given the vascular etiology.\n\nDIAGNOSTIC CRITERIA:\nDiagnosis requires evidence of cerebrovascular disease on imaging (MRI showing multiple infarcts, strategic single infarcts, or extensive white matter disease) with temporal relationship between stroke and cognitive decline. Mixed dementia (vascular plus Alzheimer's pathology) is actually the most common presentation in elderly patients.\n\nRISK FACTOR MODIFICATION:\nUnlike Alzheimer's disease, vascular dementia progression can potentially be slowed through aggressive cardiovascular risk management: blood pressure control, statin therapy, antiplatelet agents, diabetes management, and smoking cessation.\n\nKEY POINTS:\nVascular dementia progresses stepwise with sudden declines, unlike Alzheimer's smooth decline. Executive dysfunction predominates early rather than memory loss. Vascular risk factor modification can slow progression, unlike neurodegenerative dementias."
  },
  {
    "id": 404,
    "categoryId": 6,
    "question": "A critical monitoring parameter for a patient with Guillain-Barre Syndrome is:",
    "options": [
      "A) Urea/Creatinine",
      "B) Negative Inspiratory Force (NIF) or Vital Capacity (FVC)",
      "C) Liver Enzymes",
      "D) Platelet Count"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Negative Inspiratory Force/NIF or Vital Capacity/FVC).\n\nRESPIRATORY MONITORING IN GUILLAIN-BARRÉ SYNDROME:\nGuillain-Barré syndrome (GBS) produces ascending paralysis that can progress to involve the respiratory muscles (diaphragm and intercostals), making respiratory failure the most life-threatening complication. Serial monitoring of forced vital capacity (FVC) and negative inspiratory force (NIF) is the standard of care for detecting impending ventilatory failure before clinical decompensation occurs, because relying on oxygen saturation or arterial blood gas alone detects respiratory failure too late.\n\nPATHOPHYSIOLOGY:\nAs GBS-related demyelination and axonal injury progress proximally from the lower extremities, the phrenic nerve (C3-C5) and intercostal nerves become involved, weakening the diaphragm and accessory muscles of respiration. Vital capacity (the maximum volume of air exhaled after maximal inhalation) and NIF (the maximum negative pressure generated during inspiration) are direct measures of respiratory muscle strength that decline before gas exchange deteriorates. Approximately 20 to 30% of GBS patients require mechanical ventilation.\n\nCLINICAL MONITORING PROTOCOL:\nFVC and NIF should be measured every 4 to 6 hours in hospitalized GBS patients. The \"20/30/40 rule\" guides intubation decisions: intubate electively if FVC falls below 20 mL/kg, NIF is weaker than -30 cmH2O, or there has been a greater than 30% decline in FVC from baseline. Additional warning signs include rapid symptom progression, bulbar dysfunction (difficulty swallowing or managing secretions), and autonomic instability. Elective intubation is far safer than emergent intubation after respiratory arrest.\n\nTREATMENT OF GBS:\nIn addition to respiratory support, definitive treatment includes intravenous immunoglobulin (IVIG) or plasmapheresis, both of which are equally effective when initiated within the first 2 weeks of symptom onset. Corticosteroids are not effective in GBS. Deep vein thrombosis prophylaxis, pain management (neuropathic pain is common), and physical rehabilitation are essential supportive measures. Recovery takes weeks to months, with approximately 80% of patients achieving independent ambulation within 6 months.\n\nKEY POINTS:\nSerial FVC and NIF monitoring is essential in GBS because respiratory muscle failure is the most dangerous complication. The \"20/30/40 rule\" guides elective intubation: FVC below 20 mL/kg, NIF weaker than -30 cmH2O, or greater than 30% decline from baseline. Approximately 20 to 30% of GBS patients require mechanical ventilation."
  },
  {
    "id": 405,
    "categoryId": 6,
    "question": "Cubital Tunnel Syndrome involves compression of the Ulnar nerve at the elbow. Symptoms include:",
    "options": [
      "A) Numbness in the thumb",
      "B) Numbness in the 4th and 5th digits (Pinky/Ring)",
      "C) Wrist drop",
      "D) Weakness of the biceps"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Numbness in the 4th and 5th digits/Pinky and Ring finger).\n\nCUBITAL TUNNEL SYNDROME:\nCubital tunnel syndrome is the second most common peripheral nerve entrapment (after carpal tunnel syndrome), caused by compression of the ulnar nerve at the elbow. The ulnar nerve passes through the cubital tunnel, a fibro-osseous channel between the medial epicondyle and the olecranon, where it is superficial and vulnerable to compression, traction, and friction. The resulting symptoms follow the ulnar nerve distribution in the hand.\n\nPATHOPHYSIOLOGY:\nThe ulnar nerve is susceptible to injury at the elbow because it lies in a relatively exposed position behind the medial epicondyle (the \"funny bone\"). Compression occurs within the cubital tunnel itself (between the two heads of the flexor carpi ulnaris) or at the retrocondylar groove. Repetitive elbow flexion stretches and flattens the nerve, increasing intraneural pressure. Prolonged elbow flexion (such as sleeping with bent elbows or leaning on the elbow) exacerbates symptoms. Over time, chronic compression leads to demyelination and ultimately axonal degeneration.\n\nCLINICAL MANIFESTATIONS:\nEarly symptoms include intermittent paresthesias and numbness in the ring and small (fifth) fingers and the ulnar border of the hand, particularly worsening with elbow flexion. As the condition progresses, patients develop weakness of the intrinsic hand muscles (interossei and lumbricals to digits 4 and 5), causing impaired fine motor function, weak grip, and difficulty with pinching. In advanced cases, visible atrophy of the hypothenar eminence and first dorsal interosseous muscle develops, and clawing of the ring and small fingers may appear (\"ulnar claw hand\").\n\nDIAGNOSIS AND TREATMENT:\nThe Tinel sign at the cubital tunnel (tapping behind the medial epicondyle reproduces tingling in digits 4 and 5) and the elbow flexion test (sustained flexion reproduces symptoms) are useful clinical provocative maneuvers. Electrodiagnostic studies (nerve conduction velocity showing slowing across the elbow, EMG showing denervation in ulnar-innervated muscles) confirm the diagnosis and grade severity. Conservative management includes activity modification, nighttime elbow extension splinting, and ergonomic changes. Surgical decompression or anterior transposition of the ulnar nerve is indicated for progressive weakness, muscle atrophy, or failure of conservative measures.\n\nKEY POINTS:\nCubital tunnel syndrome compresses the ulnar nerve at the elbow, causing numbness in the ring and small fingers and weakness of intrinsic hand muscles. Symptoms worsen with elbow flexion, making nocturnal splinting in extension an effective conservative measure. Surgery is indicated for progressive weakness, atrophy, or failure of conservative management."
  },
  {
    "id": 406,
    "categoryId": 6,
    "question": "The definition of Transient Ischemic Attack (TIA) has changed. It is now defined as:",
    "options": [
      "A) Symptoms lasting < 24 hours",
      "B) Transient episode of neurologic dysfunction without acute infarction on MRI",
      "C) Symptoms lasting < 1 hour",
      "D) Any stroke that improves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Tissue-based definition - Transient neurologic dysfunction without acute infarction on MRI).\n\nUPDATED TIA DEFINITION:\nThe definition of transient ischemic attack has evolved from a time-based criterion (symptoms <24 hours) to a tissue-based definition: a transient episode of neurologic dysfunction caused by focal brain, spinal cord, or retinal ischemia without acute infarction on imaging. This reflects recognition that many patients with transient symptoms <24 hours have brain infarction on diffusion-weighted MRI, making them stroke patients despite symptom resolution.\n\nPATHOPHYSIOLOGY:\nTIA occurs when transient blood flow reduction (from thromboembolism, large vessel atherosclerosis, or cardioembolism) causes temporary neuronal dysfunction without progressing to permanent tissue death, resolving through clot dissolution, collateral flow, or both. However, 30-50% of clinically diagnosed TIA patients show acute infarction on DWI, reclassifying them as minor ischemic stroke.\n\nRISK STRATIFICATION:\nTIA is a critical warning with 90-day stroke risk of 10-20%, highest in the first 48 hours to 7 days. The ABCD2 score stratifies risk: Age 60 or older (1 point), Blood pressure 140/90 or higher (1 point), Clinical features of unilateral weakness (2 points) or speech disturbance without weakness (1 point), Duration 60 minutes or longer (2 points) or 10-59 minutes (1 point), and Diabetes (1 point). Scores of 4 or higher warrant urgent hospitalization.\n\nSECONDARY PREVENTION:\nUrgent evaluation includes brain MRI with DWI, vascular imaging (CTA or carotid duplex), echocardiography, and cardiac monitoring for atrial fibrillation. Dual antiplatelet therapy (aspirin plus clopidogrel for 21 days) reduces early recurrence in high-risk TIA and minor stroke. High-intensity statin therapy is initiated regardless of lipid levels. Carotid endarterectomy within 2 weeks for symptomatic stenosis of 70-99% dramatically reduces subsequent stroke risk. Blood pressure target below 130/80 is recommended after the acute phase.\n\nKEY POINTS:\nTIA is now defined by absence of infarction on imaging, not symptom duration; many TIAs show infarction on MRI and are actually minor strokes. The 90-day stroke risk is 10-20%, highest in the first week. Dual antiplatelet therapy for 21 days, high-intensity statin, and urgent carotid imaging with possible endarterectomy are key secondary prevention strategies."
  },
  {
    "id": 407,
    "categoryId": 6,
    "question": "Frontotemporal Dementia (Pick's Disease) typically presents differently from Alzheimer's. The early signs are:",
    "options": [
      "A) Short term memory loss",
      "B) Behavioral/Personality changes and Aphasia",
      "C) Visual hallucinations",
      "D) Tremors"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Behavioral/Personality changes and Aphasia).\n\nPATHOPHYSIOLOGY:\nFrontotemporal dementia (FTD), including Pick's disease, involves selective degeneration of the frontal and temporal lobes. Unlike Alzheimer's disease where the hippocampus and parietal lobes are affected early, FTD targets the neural circuits governing personality, social behavior, and language. Abnormal accumulations of tau protein or TDP-43 cause neuronal death in these regions. The frontal lobes mediate executive function, impulse control, and social judgment, while the temporal lobes process language and emotional recognition.\n\nCLINICAL PRESENTATION:\nThe behavioral variant presents with striking personality changes: disinhibition (inappropriate comments, impulsive actions), apathy, loss of empathy, compulsive behaviors, and dietary changes (carbohydrate craving). Patients may make inappropriate sexual comments, shoplift without concern, or become emotionally cold to loved ones. Memory is relatively preserved early, distinguishing FTD from Alzheimer's. Language variants present with progressive aphasia: primary progressive aphasia (nonfluent type) causes effortful, halting speech; semantic dementia causes fluent but empty speech with loss of word meaning.\n\nAGE OF ONSET:\nFTD typically presents earlier than Alzheimer's (ages 45-65), making it a leading cause of early-onset dementia. Family history is present in 30-50% of cases, with autosomal dominant mutations identified in some families.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI shows frontal and/or temporal atrophy. No disease-modifying treatments exist. Management focuses on behavioral interventions, caregiver support, and symptomatic treatment of depression or compulsive behaviors.\n\nKEY POINTS:\nFTD presents with behavioral/personality changes and language dysfunction, NOT memory loss like Alzheimer's. Onset is typically younger (45-65 years). Disinhibition, apathy, and loss of empathy are hallmark features of the behavioral variant."
  },
  {
    "id": 408,
    "categoryId": 6,
    "question": "Diabetic Neuropathy is typically a 'Stocking-Glove' distribution. Which fiber type is lost first, causing burning/pain?",
    "options": [
      "A) Large myelinated fibers (Vibration/Proprioception)",
      "B) Small unmyelinated fibers (Pain/Temperature)",
      "C) Motor fibers",
      "D) Cranial nerves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Small fiber (C and A-delta) sensory neurons).\n\nDIABETIC PERIPHERAL NEUROPATHY:\nThe most common form of diabetic neuropathy is distal symmetric polyneuropathy (DSPN) with a \"stocking-glove\" distribution affecting the longest nerves first. Small unmyelinated (C) and thinly myelinated (A-delta) fibers are affected earliest.\n\nSMALL FIBER VS LARGE FIBER:\nSmall fibers carry pain, temperature, and autonomic function. Their damage causes burning pain, allodynia (pain from light touch), and loss of temperature/pinprick sensation. Large fibers (A-alpha, A-beta) carry proprioception, vibration, and light touch; their damage causes numbness, loss of vibration sense, and ataxia.\n\nCLINICAL PROGRESSION:\nSymptoms typically begin in the toes and ascend proximally as longer nerves become affected. When symptoms reach the mid-calf, hand involvement begins (also a \"length-dependent\" pattern). Patients may describe burning, tingling, or \"walking on cotton.\"\n\nPATHOPHYSIOLOGY:\nHyperglycemia damages nerves through multiple mechanisms: polyol pathway activation, advanced glycation end-products, oxidative stress, and impaired microvascular blood supply to nerve fibers. Tight glycemic control slows progression.\n\nKEY POINTS:\nDiabetic neuropathy affects small fibers (C and A-delta) first, causing burning pain and temperature loss. The stocking-glove distribution reflects length-dependent nerve damage. Early symptoms are painful; later stages may become painless but insensate."
  },
  {
    "id": 409,
    "categoryId": 6,
    "question": "A Deep Tendon Reflex (e.g., Knee Jerk) is a monosynaptic reflex. The sensory signal goes to the spinal cord and:",
    "options": [
      "A) Goes up to the brain for processing",
      "B) Synapses directly on the motor neuron to fire the muscle",
      "C) Crosses to the other side",
      "D) Is inhibited by GABA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Synapses directly on the motor neuron to fire the muscle).\n\nTHE MONOSYNAPTIC REFLEX ARC:\nThe deep tendon reflex (also called the myotatic or stretch reflex) is the simplest and fastest neural circuit in the human nervous system, involving only a single synapse between the sensory (afferent) neuron and the motor (efferent) neuron within the spinal cord. When a tendon is struck, the muscle spindle is stretched, generating an afferent signal via Ia sensory fibers that travels to the spinal cord and synapses directly on the alpha motor neuron, which fires the same muscle to contract. No cortical processing is required.\n\nPATHOPHYSIOLOGY:\nThe reflex arc is designed for protective speed. Muscle spindles detect rapid stretch and relay this information to the spinal cord at high velocity through large-diameter, heavily myelinated Ia afferent fibers. In the spinal cord, the afferent synapse is monosynaptic (no interneurons are involved), ensuring minimal transmission delay. Simultaneously, inhibitory interneurons suppress the antagonist muscle (reciprocal inhibition), allowing coordinated movement. The entire arc from stretch to contraction occurs in approximately 25 to 50 milliseconds.\n\nCORTICAL MODULATION:\nThe brain does not initiate the reflex but does modulate its gain through descending corticospinal and reticulospinal pathways, which provide tonic inhibition to spinal motor neurons. When these descending pathways are damaged (upper motor neuron lesion from stroke, spinal cord injury, or demyelinating disease), the loss of inhibition results in hyperreflexia (exaggerated reflexes) and clonus (repetitive rhythmic contractions). Conversely, damage to the afferent or efferent limb of the arc itself (lower motor neuron lesion from peripheral neuropathy, radiculopathy, or anterior horn cell disease) results in hyporeflexia or areflexia.\n\nCLINICAL APPLICATION:\nDeep tendon reflexes are graded 0 (absent) through 4+ (clonus) and are among the most valuable tools in the neurological examination. Hyperreflexia localizes pathology to the brain or spinal cord (UMN), while hyporeflexia localizes to the peripheral nerve or nerve root (LMN). Asymmetric reflexes suggest focal pathology and guide further evaluation.\n\nKEY POINTS:\nThe deep tendon reflex is a monosynaptic arc that bypasses the brain for speed, synapsing directly from sensory to motor neurons in the spinal cord. The brain provides tonic inhibition of this reflex, explaining why UMN lesions cause hyperreflexia and LMN lesions cause hyporeflexia. Reflex assessment is fundamental to distinguishing central from peripheral neurological pathology."
  },
  {
    "id": 410,
    "categoryId": 6,
    "question": "Glutamate is the primary _______ neurotransmitter, while GABA is the primary _______ neurotransmitter.",
    "options": [
      "A) Inhibitory; Excitatory",
      "B) Excitatory; Inhibitory",
      "C) Motor; Sensory",
      "D) Peripheral; Central"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Excitatory; Inhibitory).\n\nGLUTAMATE AND GABA NEUROTRANSMISSION:\nGlutamate is the principal excitatory neurotransmitter in the central nervous system, while gamma-aminobutyric acid (GABA) is the principal inhibitory neurotransmitter. Together, they form the fundamental excitatory-inhibitory balance that governs virtually all neural processing, from basic sensory perception to complex cognition. Disruption of this balance underlies many neurological and psychiatric disorders.\n\nPATHOPHYSIOLOGY:\nGlutamate mediates fast excitatory neurotransmission by activating ionotropic receptors (NMDA, AMPA, and kainate subtypes) that allow cation influx, depolarizing the postsynaptic neuron. NMDA receptors are particularly important for synaptic plasticity and learning (long-term potentiation). However, excessive glutamatergic activity causes excitotoxicity: sustained NMDA receptor activation allows massive calcium influx, activating destructive intracellular enzymes (calpains, endonucleases, phospholipases) that trigger neuronal death. Excitotoxicity is a major mechanism of neuronal injury in ischemic stroke, traumatic brain injury, and status epilepticus. GABA counterbalances excitation by activating GABA-A receptors (ligand-gated chloride channels that hyperpolarize neurons) and GABA-B receptors (G-protein-coupled receptors that reduce neuronal excitability).\n\nPHARMACOLOGICAL SIGNIFICANCE:\nThis excitatory-inhibitory framework explains the mechanisms of numerous medications used in primary care. Benzodiazepines and barbiturates enhance GABA-A receptor function, explaining their anxiolytic, sedative, anticonvulsant, and muscle relaxant properties as well as their additive CNS depression with alcohol (which also potentiates GABAergic transmission). Memantine blocks excessive NMDA receptor activation and is used in Alzheimer's disease. Many anesthetic agents (propofol, volatile anesthetics) act primarily through GABAergic enhancement.\n\nCLINICAL RELEVANCE FOR PRIMARY CARE:\nWhen evaluating elderly patients with falls, cognitive decline, or delirium, many centrally acting medications exert their effects through GABAergic enhancement (benzodiazepines, certain sleep aids, gabapentinoids). Reduced GABA tone or excessive glutamatergic excitation facilitates seizures, which is why GABA-enhancing drugs are first-line anticonvulsants and why conditions causing neuronal excitotoxicity (stroke, hypoglycemia) can provoke seizures.\n\nKEY POINTS:\nGlutamate is the main excitatory and GABA the main inhibitory CNS neurotransmitter; their balance governs all neural processing. Excessive glutamate causes excitotoxic neuronal death (a major mechanism in stroke and status epilepticus), while GABA enhancement is the basis of anxiolytics, sedatives, and many anticonvulsants. Awareness of GABAergic drug effects is essential when evaluating falls, sedation, and delirium in primary care patients."
  },
  {
    "id": 411,
    "categoryId": 6,
    "question": "Status Epilepticus is defined as a seizure lasting > 5 minutes or recurrent seizures without return to baseline. First line treatment is:",
    "options": [
      "A) Phenytoin",
      "B) Propofol",
      "C) Benzodiazepine (Lorazepam/Midazolam)",
      "D) Levetiracetam"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (IV Benzodiazepines - Lorazepam or Diazepam).\n\nSTATUS EPILEPTICUS DEFINITION:\nStatus epilepticus means a seizure lasting >5 minutes or recurrent seizures without return to baseline consciousness. This represents a neurological emergency with risk of permanent brain damage and death if not promptly terminated.\n\nFIRST-LINE TREATMENT:\nIV benzodiazepines are first-line: lorazepam 4mg IV (preferred due to longer duration of anticonvulsant effect) or diazepam 10mg IV. Can repeat once in 5-10 minutes if seizure continues. IM midazolam is an alternative if IV access is not immediately available.\n\nTREATMENT ALGORITHM:\n0-5 min: Stabilize (ABCs, O2, IV access, glucose check). 5-20 min: First-line benzodiazepines. 20-40 min: Second-line agents (fosphenytoin, levetiracetam, or valproate IV). >40 min: Refractory status - consider propofol, midazolam infusion, or pentobarbital with continuous EEG monitoring.\n\nCOMMON CAUSES:\nAnticonvulsant non-compliance, alcohol withdrawal, metabolic derangements (hypoglycemia, hyponatremia), CNS infection, stroke, and brain tumors. Identifying and treating the underlying cause is essential.\n\nKEY POINTS:\nStatus epilepticus is a seizure >5 minutes requiring emergent treatment. IV lorazepam or diazepam is first-line therapy. If benzodiazepines fail, second-line agents include fosphenytoin, levetiracetam, or valproate."
  },
  {
    "id": 412,
    "categoryId": 6,
    "question": "Essential Tremor is distinguished from Parkinson's because Essential Tremor is:",
    "options": [
      "A) A resting tremor",
      "B) An action/postural tremor that improves with alcohol",
      "C) Unilateral",
      "D) Associated with shuffling gait"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (An action/postural tremor that improves with alcohol).\n\nPATHOPHYSIOLOGY:\nEssential tremor and Parkinson's disease represent distinct movement disorders with different underlying mechanisms. Essential tremor involves dysfunction of the cerebello-thalamo-cortical circuit, producing tremor during voluntary movement. Parkinson's disease results from dopaminergic neuron loss in the substantia nigra, causing tremor at rest when the affected limb is not engaged in purposeful activity.\n\nDISTINGUISHING FEATURES - ESSENTIAL TREMOR:\nEssential tremor is an ACTION or POSTURAL tremor, meaning it appears when holding a posture (arms outstretched) or during movement (bringing a cup to the mouth). It characteristically improves with small amounts of alcohol (though this is not recommended as treatment). Essential tremor is bilateral and symmetric, commonly affecting the hands but also the head (causing a \"no-no\" or \"yes-yes\" movement) and voice. There is often a family history (autosomal dominant inheritance pattern). essential tremor does NOT cause bradykinesia, rigidity, or postural instability.\n\nDISTINGUISHING FEATURES - PARKINSON'S:\nParkinson's tremor is a RESTING tremor that diminishes or disappears with voluntary movement. It is classically described as \"pill-rolling.\" Parkinson's presents with the motor triad: tremor, bradykinesia (slowness), and rigidity (cogwheel or lead-pipe). The tremor is typically asymmetric at onset. Postural instability, masked facies, and shuffling gait develop as the disease progresses.\n\nCLINICAL SIGNIFICANCE:\nThis distinction matters for treatment: essential tremor responds to propranolol or primidone, while Parkinson's requires dopaminergic therapy (levodopa/carbidopa, dopamine agonists).\n\nKEY POINTS:\nEssential tremor is an action/postural tremor; Parkinson's is a resting tremor. Alcohol improves essential tremor (not Parkinson's). Essential tremor lacks bradykinesia and rigidity; Parkinson's has both."
  },
  {
    "id": 413,
    "categoryId": 6,
    "question": "The spinal cord ends at L1. Below this is the Cauda Equina (nerve roots). Compression here causes LMN signs because:",
    "options": [
      "A) It is part of the CNS",
      "B) These are peripheral nerves, not the spinal cord itself",
      "C) It affects the brainstem",
      "D) It is a demyelinating process"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The nerve roots below L1 are peripheral nerves, not spinal cord).\n\nANATOMY:\nThe spinal cord ends at the conus medullaris, typically at the L1-L2 vertebral level. Below this, the lumbar cistern contains only nerve roots (the cauda equina, Latin for \"horse's tail\"), which are peripheral nerves, not central nervous system structures.\n\nLMN VS UMN SIGNS:\nUpper motor neuron (UMN) lesions (spinal cord damage) cause spasticity, hyperreflexia, clonus, and Babinski sign due to loss of cortical inhibition. Lower motor neuron (LMN) lesions (peripheral nerve/root damage) cause flaccidity, hyporeflexia, fasciculations, and muscle atrophy. Because the cauda equina contains peripheral nerves, its compression produces LMN findings.\n\nCAUDA EQUINA SYNDROME:\nCompression of the cauda equina (often by large disc herniation) causes bilateral leg weakness (LMN pattern), saddle anesthesia, bowel/bladder dysfunction (urinary retention, fecal incontinence), and decreased lower extremity reflexes. This is a surgical emergency requiring urgent decompression.\n\nCLINICAL DISTINCTION:\nA lesion at L1 affecting the conus medullaris may show mixed UMN/LMN signs. Pure cauda equina lesions below L1-L2 show only LMN signs.\n\nKEY POINTS:\nThe spinal cord ends at L1; below this are peripheral nerve roots (cauda equina). Cauda equina compression causes LMN signs (flaccid, areflexic) because only peripheral nerves are affected. Cauda equina syndrome is a surgical emergency."
  },
  {
    "id": 414,
    "categoryId": 4,
    "question": "A patient presents with visual field deficits (Bitemporal Hemianopsia) and galactorrhea. MRI shows a pituitary macroadenoma. What is the anatomical explanation for the vision loss?",
    "options": [
      "A) Compression of the Optic Nerve",
      "B) Compression of the Optic Chiasm",
      "C) Compression of the Occipital Lobe",
      "D) Compression of the Cavernous Sinus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Compression of the Optic Chiasm).\n\nPATHOPHYSIOLOGY:\nThe pituitary gland sits within the sella turcica of the sphenoid bone. Immediately superior, separated by the diaphragma sellae, lies the optic chiasm where nasal retinal fibers (carrying temporal visual field information) decussate while temporal retinal fibers remain ipsilateral. A pituitary macroadenoma (>10 mm) growing superiorly compresses the chiasm from below, preferentially affecting the crossing nasal fibers in the central and inferior chiasm. This produces bitemporal hemianopsia, loss of temporal visual fields bilaterally, essentially pathognomonic for a chiasmal lesion with pituitary mass being the most common cause (Endocrine Society).\n\nCLINICAL REASONING:\nBitemporal hemianopsia with galactorrhea strongly suggests a prolactin-secreting macroadenoma (macroprolactinoma), the most common functioning pituitary adenoma (~40% of all pituitary adenomas). Galactorrhea results from excess prolactin on mammary tissue; amenorrhea results from prolactin-mediated GnRH suppression causing hypogonadotropic hypogonadism. Microadenomas (<10 mm) present with endocrine symptoms alone, while macroadenomas produce both endocrine and compressive symptoms (visual field deficits, headache, hypopituitarism). Formal Humphrey visual field testing is essential in all macroadenoma patients. Lateral extension into cavernous sinuses may compress cranial nerves III, IV, V1, V2, VI.\n\nDIAGNOSIS AND TREATMENT:\nMRI of the sella with gadolinium is the imaging modality of choice. Hormonal evaluation includes prolactin (typically >200 ng/mL for macroprolactinomas), IGF-1, cortisol testing, free T4/TSH, gonadotropins, and alpha-subunit. Prolactinoma treatment is unique: dopamine agonists (cabergoline first-line, superior to bromocriptine) are primary therapy even for macroadenomas with visual compromise, normalizing prolactin and producing significant tumor shrinkage (>50% volume reduction) in 80-90% of patients. Visual field improvement often begins within days to weeks. Transsphenoidal surgery is reserved for dopamine agonist intolerance/resistance or acute visual deterioration from pituitary apoplexy.\n\nKEY POINTS:\nBitemporal hemianopsia results from suprasellar compression of crossing nasal retinal fibers by a pituitary macroadenoma. Prolactinomas are treated with dopamine agonists (cabergoline first-line) rather than surgery, even when large, normalizing prolactin and shrinking tumors in 80-90% of cases. All macroadenomas require formal visual field testing and comprehensive hormonal evaluation."
  },
  {
    "id": 415,
    "categoryId": 4,
    "question": "Prolactin secretion is unique among pituitary hormones because it is primarily under tonic INHIBITION by:",
    "options": [
      "A) Serotonin",
      "B) Dopamine",
      "C) Acetylcholine",
      "D) GABA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Dopamine from the Hypothalamus).\n\nPATHOPHYSIOLOGY:\nProlactin regulation is unique among anterior pituitary hormones because its dominant regulatory input is tonic inhibition rather than stimulation. All other anterior pituitary hormones are primarily driven by hypothalamic releasing hormones (GnRH, CRH, GHRH, TRH). Prolactin is under continuous inhibitory control by dopamine, synthesized by tuberoinfundibular dopaminergic (TIDA) neurons in the arcuate nucleus and transported via the hypothalamic-hypophyseal portal system. Dopamine binds D2 receptors (Gi-coupled) on lactotrophs, inhibiting adenylyl cyclase, reducing cAMP, suppressing prolactin gene transcription and exocytosis. This inhibition is so dominant that severing the pituitary stalk causes prolactin to rise dramatically while all other anterior pituitary hormones fall, known as the stalk effect.\n\nCLINICAL REASONING:\nThe stalk effect has critical diagnostic implications: any mass compressing or transecting the pituitary stalk (craniopharyngioma, non-functioning adenoma, metastasis, granulomatous disease) causes moderate hyperprolactinemia (typically 25-150 ng/mL) by interrupting dopamine delivery, even without producing prolactin. This must be distinguished from true prolactinoma, where prolactin correlates with tumor size: microadenomas produce 50-200 ng/mL, macroprolactinomas 200 to over 10,000 ng/mL. A large mass with only modest prolactin elevation likely represents a non-functioning adenoma causing stalk effect, requiring surgery rather than dopamine agonist therapy. The hook effect is an important pitfall: extremely high prolactin (>10,000 ng/mL) from giant prolactinomas can saturate assay antibodies, producing falsely normal results. Request serial dilution when a large mass shows unexpectedly low prolactin.\n\nCLINICAL APPLICATION:\nMedications blocking D2 receptors are among the most common causes of hyperprolactinemia: antipsychotics (haloperidol, risperidone), metoclopramide, and prochlorperazine. Resulting hyperprolactinemia causes galactorrhea, amenorrhea, decreased libido, erectile dysfunction, and decreased BMD from hypogonadism. Prolactinoma treatment leverages this axis: cabergoline (preferred for twice-weekly dosing and better tolerability) stimulates D2 receptors, normalizing prolactin and inducing tumor shrinkage through D2-mediated apoptosis, with greater than 50% volume reduction in most macroadenomas.\n\nKEY POINTS:\nProlactin is uniquely under tonic dopaminergic inhibition from TIDA neurons; stalk transection raises prolactin while lowering all other pituitary hormones. The stalk effect must be distinguished from true prolactinoma based on prolactin level relative to tumor size. Cabergoline is the preferred dopamine agonist, normalizing prolactin and shrinking tumors in most cases."
  },
  {
    "id": 416,
    "categoryId": 4,
    "question": "Diabetes Insipidus (DI) results from a failure of ADH (Vasopressin). Neurogenic DI is caused by damage to the:",
    "options": [
      "A) Anterior Pituitary",
      "B) Posterior Pituitary / Hypothalamus",
      "C) Kidney Tubules",
      "D) Adrenal Cortex"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Posterior Pituitary / Hypothalamus).\n\nPATHOPHYSIOLOGY:\nDiabetes insipidus (DI) results from the inability to concentrate urine, causing polyuria (typically 3-20 L/day) with dilute urine (osmolality <300 mOsm/kg) and compensatory polydipsia. ADH (arginine vasopressin) is synthesized by magnocellular neurons in the supraoptic and paraventricular nuclei of the hypothalamus, transported via axons through the pituitary stalk, and stored in the posterior pituitary for release in response to increased plasma osmolality or decreased circulating volume. ADH binds V2 receptors on renal collecting duct principal cells, activating cAMP-PKA signaling that inserts aquaporin-2 water channels into the apical membrane, enabling water reabsorption.\n\nCLINICAL REASONING:\nCentral (neurogenic) DI results from insufficient ADH production or secretion due to damage anywhere along the hypothalamic-neurohypophyseal axis. Common causes include pituitary or hypothalamic surgery (most frequent; transient DI occurs in up to 30% of transsphenoidal procedures), traumatic brain injury, neoplasms (craniopharyngioma, germinoma, metastases), infiltrative diseases (Langerhans cell histiocytosis, sarcoidosis), autoimmune hypophysitis, and idiopathic cases (25-30%). The anterior pituitary does not synthesize or store ADH, making option A incorrect. Nephrogenic DI results from renal resistance to ADH despite normal or elevated levels; the most common acquired cause is chronic lithium use, affecting up to 40% of long-term users through AQP2 downregulation.\n\nThe water deprivation test with desmopressin challenge distinguishes central from nephrogenic DI: urine osmolality increases greater than 50% in central DI but remains dilute in nephrogenic DI. Copeptin measurement is emerging as a simpler diagnostic alternative per recent Endocrine Society guidance. Central DI is treated with desmopressin (DDAVP). Nephrogenic DI management includes addressing the underlying cause, thiazide diuretics, sodium restriction, and amiloride for lithium-induced cases.\n\nKEY POINTS:\nADH is produced in the hypothalamus and stored in the posterior pituitary; damage to either structure causes central DI. Central DI responds to desmopressin while nephrogenic DI does not. The water deprivation test with desmopressin challenge is the key diagnostic study differentiating the two forms."
  },
  {
    "id": 417,
    "categoryId": 4,
    "question": "Hypocalcemia causes neuronal hyperexcitability (Tetany/Seizures). A classic physical exam sign is Chvostek's Sign, which is:",
    "options": [
      "A) Carpal spasm upon inflation of BP cuff",
      "B) Twitching of the facial muscles when tapping the facial nerve",
      "C) Hyperreflexia of the knee",
      "D) Clonus of the ankle"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Twitching of the facial muscles when tapping the facial nerve).\n\nPATHOPHYSIOLOGY:\nHypocalcemia produces neuromuscular hyperexcitability because extracellular calcium normally stabilizes voltage-gated sodium channels in their closed conformation, raising the depolarization threshold. When calcium falls (total <8.5 mg/dL or ionized <4.5 mg/dL), sodium channels open more readily at lower membrane potentials, decreasing the action potential threshold. This produces paresthesias (perioral tingling, fingertip numbness), carpopedal spasm, laryngospasm, tetany, and seizures. Severity depends on both degree and rate of decline; rapid decreases produce symptoms at higher absolute levels than gradual changes.\n\nCLINICAL REASONING:\nChvostek's sign is elicited by tapping the facial nerve ~2 cm anterior to the earlobe below the zygomatic arch. In hypocalcemia, this triggers involuntary ipsilateral facial muscle twitching, from subtle upper lip twitching to entire facial contraction. Sensitivity is moderate (~10-25% of normocalcemic individuals may test positive). Trousseau's sign is elicited by inflating a BP cuff 20 mmHg above systolic for 3 minutes; hypocalcemia triggers carpal spasm (adducted thumb, flexed MCPs, extended IPs, flexed wrist). Trousseau's is more sensitive and specific (positive in ~94% of hypocalcemic patients, only 1-4% of normocalcemic individuals).\n\nCLINICAL APPLICATION:\nThe most common cause is iatrogenic hypoparathyroidism following thyroid/parathyroid surgery. Other causes include vitamin D deficiency, chronic kidney disease (impaired 1-alpha-hydroxylation), hypomagnesemia (magnesium is required for PTH secretion and receptor signaling; severe hypomagnesemia produces functional hypoparathyroidism refractory to calcium until magnesium is corrected), acute pancreatitis, tumor lysis syndrome, massive blood transfusion (citrate chelation), and medications (bisphosphonates, denosumab, loop diuretics). Acute symptomatic hypocalcemia is a medical emergency requiring IV calcium gluconate (1-2 g over 10-20 minutes with cardiac monitoring). Chronic management includes oral calcium (1-3 g elemental daily) and calcitriol (0.25-1 mcg daily).\n\nKEY POINTS:\nChvostek's sign (facial twitching on tapping CN VII) and Trousseau's sign (carpal spasm on BP cuff inflation) are bedside tests for hypocalcemia, with Trousseau's being more sensitive and specific. Hypocalcemia lowers the depolarization threshold by reducing calcium-mediated sodium channel stabilization. Hypomagnesemia must be corrected before hypocalcemia will respond to treatment."
  },
  {
    "id": 418,
    "categoryId": 4,
    "question": "The Adrenal Medulla acts as a modified sympathetic ganglion. Upon stimulation by the splanchnic nerves, it releases:",
    "options": [
      "A) Cortisol",
      "B) Aldosterone",
      "C) Epinephrine (80%) and Norepinephrine (20%)",
      "D) Acetylcholine"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Epinephrine 80% and Norepinephrine 20%).\n\nPATHOPHYSIOLOGY:\nThe adrenal gland has two distinct regions. The cortex (mesodermal origin) produces steroid hormones by zone: zona glomerulosa (aldosterone, RAAS-regulated), zona fasciculata (cortisol, ACTH-regulated), and zona reticularis (androgens: DHEA, DHEA-S, androstenedione). The medulla (neural crest ectodermal origin) is a modified sympathetic ganglion. Chromaffin cells are developmentally homologous to postganglionic sympathetic neurons but secrete catecholamines directly into the bloodstream. Preganglionic sympathetic fibers from the thoracic spinal cord travel via the greater splanchnic nerve and synapse on chromaffin cells using acetylcholine at nicotinic receptors. Upon stimulation, chromaffin cells release approximately 80% epinephrine and 20% norepinephrine. Epinephrine predominance reflects unique expression of PNMT (phenylethanolamine N-methyltransferase), which methylates norepinephrine to epinephrine. PNMT expression is induced by high local cortisol from the adjacent cortex via the intra-adrenal portal venous system.\n\nCLINICAL REASONING:\nSympathetic postganglionic neurons release norepinephrine directly at target organs for rapid, localized, short-duration responses. The adrenal medulla complements this by releasing epinephrine systemically, producing a slower-onset, generalized, and more sustained response. Epinephrine is a more potent beta-2 agonist than norepinephrine, producing bronchodilation, skeletal muscle vasodilation, hepatic glycogenolysis, and insulin suppression, while maintaining beta-1 (cardiac stimulation) and alpha-1 (vasoconstriction) activity. This beta-2 activity drives metabolic mobilization (hyperglycemia, lipolysis) during the fight-or-flight response.\n\nCLINICAL APPLICATION:\nThe adrenal medulla is the origin of pheochromocytoma, a catecholamine-secreting chromaffin cell tumor producing episodic or sustained hypertension with headache, diaphoresis, and palpitations. Extra-adrenal paragangliomas arise from sympathetic paravertebral chromaffin cells. Diagnosis uses plasma free metanephrines or 24-hour urine metanephrines. The cortex-medulla distinction is clinically relevant: Addison's disease destroys both regions, while secondary adrenal insufficiency (pituitary ACTH deficiency) affects only cortisol, sparing aldosterone and medullary function.\n\nKEY POINTS:\nThe adrenal medulla releases approximately 80% epinephrine and 20% norepinephrine upon preganglionic cholinergic stimulation via the splanchnic nerve. Epinephrine predominance results from PNMT expression induced by high local cortisol. Unlike direct sympathetic neurotransmission, medullary catecholamine release produces a systemic, sustained metabolic and cardiovascular stress response."
  },
  {
    "id": 419,
    "categoryId": 4,
    "question": "A patient with Pheochromocytoma (Tumor of the Adrenal Medulla) presents with the classic triad of:",
    "options": [
      "A) Hypotension, Bradycardia, Flushing",
      "B) Headache, Palpitations/Sweating, Tachycardia",
      "C) Weight gain, Striae, Moon face",
      "D) Polyuria, Polydipsia, Polyphagia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Headache, Palpitations/Sweating, Tachycardia).\n\nPATHOPHYSIOLOGY:\nPheochromocytoma is a catecholamine-secreting neuroendocrine tumor of adrenal medullary chromaffin cells (incidence 2-8 per million person-years). Extra-adrenal tumors from sympathetic paravertebral chromaffin tissue are termed paragangliomas (~15-20% of catecholamine-secreting tumors). These tumors episodically release excessive catecholamines (epinephrine, norepinephrine, sometimes dopamine), triggered by exertion, abdominal palpation, postural changes, anesthesia, or spontaneously. Approximately 30-40% have hereditary basis, associated with RET (MEN2A/2B), VHL, NF1, and succinate dehydrogenase subunit mutations (SDHB, SDHC, SDHD). SDHB carries highest malignancy risk (30-40% metastatic), while MEN2-associated tumors are almost always bilateral and benign.\n\nCLINICAL PRESENTATION:\nThe classic triad is episodic headache (acute hypertension), diaphoresis (catecholamine-mediated eccrine activation), and palpitations/tachycardia (beta-1 stimulation), with ~90% sensitivity and ~94% specificity when all three occur episodically in hypertensive patients. Hypertension may be paroxysmal (~50%), sustained with paroxysms (~40%), or sustained alone (~10%). Additional features include anxiety, pallor (alpha-mediated vasoconstriction, distinguishing from flushing), tremor, weight loss, and hyperglycemia. Suspect in patients with paroxysmal hypertension with the triad, refractory hypertension, hypertensive crisis during anesthesia, adrenal incidentaloma, or relevant family history.\n\nDIAGNOSIS AND TREATMENT:\nBiochemical testing precedes imaging. Plasma free metanephrines are the recommended screening test (96-99% sensitivity). After confirmation, abdominal CT or MRI localizes the tumor, and functional imaging (I-123 MIBG or Ga-68 DOTATATE PET/CT) identifies metastatic or extra-adrenal disease. Preoperative preparation follows a strict sequence: alpha-blockade first (phenoxybenzamine or doxazosin) for 10-14 or more days to normalize BP and allow volume re-expansion. Beta-blockade is added only after adequate alpha-blockade; beta-blockers before alpha-blockade risk lethal hypertensive crisis from unopposed alpha stimulation. Laparoscopic adrenalectomy is definitive treatment.\n\nKEY POINTS:\nPheochromocytoma presents with the classic triad of episodic headache, diaphoresis, and palpitations with hypertension. Plasma free metanephrines are the recommended screening test (96-99% sensitivity). Alpha-blockade must always precede beta-blockade to prevent hypertensive crisis, and genetic testing should be considered given the 30-40% hereditary rate."
  },
  {
    "id": 420,
    "categoryId": 4,
    "question": "Diabetic Autonomic Neuropathy (DAN) affects the Vagus nerve, leading to Gastroparesis. Symptoms include:",
    "options": [
      "A) Rapid gastric emptying and diarrhea",
      "B) Early satiety, bloating, and vomiting undigested food",
      "C) Increased hunger",
      "D) Peptic ulcers"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Early satiety, bloating, and vomiting undigested food).\n\nPATHOPHYSIOLOGY:\nDiabetic gastroparesis is delayed gastric emptying without mechanical obstruction, resulting from autonomic neuropathy affecting the vagus nerve and enteric nervous system. The vagus coordinates gastric accommodation, antral grinding, and pyloric relaxation. Chronic hyperglycemia damages vagal fibers through sorbitol accumulation (polyol pathway), advanced glycation end-products, oxidative stress, and vasa nervorum microangiopathy. Loss of interstitial cells of Cajal (ICC), the GI pacemaker cells generating the 3-cycles-per-minute gastric slow wave, is a key pathologic finding (Gastroenterology). ICC loss disrupts gastric rhythm, producing dysrhythmias and impaired antral contractility. Hyperglycemia also acutely inhibits motility independent of neuropathy, creating a vicious cycle: gastroparesis impairs glycemic control through erratic nutrient delivery, and poor control further inhibits motility.\n\nCLINICAL PRESENTATION:\nGastroparesis affects ~5% of type 1 and ~1% of type 2 diabetes patients, though subclinical delayed emptying may occur in up to 40-50% with longstanding disease. Symptoms include early satiety, postprandial bloating, nausea, vomiting of partially digested food eaten hours to days earlier (a distinguishing feature), epigastric discomfort, and weight loss. Symptoms fluctuate with glycemic control. Gastroparesis complicates insulin management through mismatch between insulin action and glucose absorption, causing both postprandial hyperglycemia and hypoglycemia.\n\nDIAGNOSIS AND TREATMENT:\nGastric emptying scintigraphy (gold standard) measures retention of a radiolabeled meal; >10% retention at 4 hours confirms delayed emptying. Upper endoscopy excludes mechanical obstruction and identifies bezoars. Treatment is multimodal: dietary modification is first-line, emphasizing small frequent meals (5-6/day), low fat, reduced fiber (prevents bezoars), pureed/liquid consistency for severe cases, plus glycemic optimization. Prokinetics include metoclopramide (D2 antagonist/5-HT4 agonist; FDA Black Box Warning limits use to 12 weeks due to tardive dyskinesia risk) and erythromycin (motilin receptor agonist at 50-100 mg before meals, limited by tachyphylaxis). Antiemetics provide symptomatic relief. Refractory cases may benefit from gastric electrical stimulation (Enterra device) or G-POEM per AGA and ACG guidelines.\n\nKEY POINTS:\nDiabetic gastroparesis results from vagal neuropathy and ICC loss, manifesting as early satiety, bloating, and vomiting of undigested food. Scintigraphy with >10% retention at 4 hours is diagnostic. Treatment centers on dietary modification, glycemic optimization, and prokinetics (metoclopramide with Black Box Warning, erythromycin limited by tachyphylaxis)."
  },
  {
    "id": 421,
    "categoryId": 4,
    "question": "Cushing's Disease (specifically) refers to hypercortisolism caused by:",
    "options": [
      "A) An Adrenal Tumor",
      "B) Exogenous Steroid use (Prednisone)",
      "C) An ACTH-secreting Pituitary Adenoma",
      "D) Small Cell Lung Cancer (Ectopic ACTH)"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (An ACTH-secreting Pituitary Adenoma).\n\nPATHOPHYSIOLOGY:\nCushing's syndrome is the clinical state from chronic glucocorticoid excess from any cause; Cushing's disease specifically denotes hypercortisolism from an ACTH-secreting pituitary adenoma (~70% of endogenous cases). These typically microadenomas (<10 mm) arise from corticotrophs and autonomously secrete ACTH, driving bilateral adrenal hyperplasia and excess cortisol. Neoplastic corticotrophs have a higher glucocorticoid feedback threshold, continuing ACTH secretion at cortisol levels that would suppress normal cells. The most common overall cause is iatrogenic glucocorticoid administration. Among endogenous causes, ACTH-dependent sources (pituitary adenoma, ectopic ACTH from small cell lung cancer, bronchial carcinoids) account for ~80%; ACTH-independent sources (adrenal adenoma, carcinoma) account for ~20%.\n\nCLINICAL PRESENTATION:\nChronic hypercortisolism produces central obesity, moon facies, buffalo hump, and supraclavicular fat pads from cortisol-stimulated visceral lipogenesis. Proximal muscle weakness results from protein catabolism. Wide (>1 cm) violaceous striae reflect collagen degradation. Additional features include easy bruising, facial plethora, hirsutism, osteoporosis, hypertension, glucose intolerance, immunosuppression, psychiatric disturbances, and menstrual irregularity.\n\nDIAGNOSIS:\nThree sequential steps: (1) Confirm hypercortisolism with two or more concordant tests: 24-hour urinary free cortisol, late-night salivary cortisol, or 1 mg overnight dexamethasone suppression test (failure to suppress below 1.8 mcg/dL). (2) Determine ACTH dependence: elevated ACTH indicates ACTH-dependent source; suppressed ACTH (<5 pg/mL) indicates adrenal source. (3) Localize ACTH source: pituitary MRI identifies the adenoma in ~60%; high-dose dexamethasone shows pituitary tumors retain partial suppression while ectopic sources do not; bilateral inferior petrosal sinus sampling (IPSS) with CRH stimulation is the gold standard, with central-to-peripheral gradient >3:1 confirming pituitary origin.\n\nTREATMENT:\nTranssphenoidal surgery is first-line, achieving 70-90% remission for microadenomas. Patients require perioperative stress-dose glucocorticoids and postoperative replacement (6-18 months) while the HPA axis recovers. Refractory options include repeat surgery, pituitary radiation, bilateral adrenalectomy (immediate cure but lifelong replacement and Nelson's syndrome risk), and medical therapy (ketoconazole, osilodrostat, pasireotide).\n\nKEY POINTS:\nCushing's disease specifically denotes hypercortisolism from an ACTH-secreting pituitary adenoma. Diagnosis proceeds sequentially: confirm hypercortisolism, determine ACTH dependence, then localize source. IPSS is the gold standard for distinguishing pituitary from ectopic ACTH, and transsphenoidal surgery achieves 70-90% remission."
  },
  {
    "id": 422,
    "categoryId": 4,
    "question": "Thyroid hormone is critical for the development of the fetal nervous system. Untreated Congenital Hypothyroidism (Cretinism) results in:",
    "options": [
      "A) Gigantism",
      "B) Profound Intellectual Disability and Stunted Growth",
      "C) Precocious Puberty",
      "D) Blindness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Profound Intellectual Disability and Stunted Growth).\n\nPATHOPHYSIOLOGY:\nThyroid hormone is essential for neurodevelopment\u2014neuronal migration, myelination, synaptogenesis, and dendritic arborization. The fetus depends on maternal thyroid hormone until fetal thyroid function begins at ~12 weeks gestation. Postnatally, endogenous thyroid hormone remains critical through the first 2-3 years. In congenital hypothyroidism, inadequate hormone causes irreversible damage: impaired cortical neuronal migration, deficient CNS myelination, and impaired cerebellar Purkinje cell development. This manifests as profound intellectual disability (IQ loss of 6-15 points per month untreated per NEJM/Pediatrics), growth retardation (thyroid hormone is required for GH secretion, IGF-1 generation, and growth plate proliferation), delayed skeletal maturation with epiphyseal dysgenesis, macroglossia, umbilical hernia, prolonged jaundice, and hypotonia.\n\nCLINICAL REASONING:\nIncidence is ~1:2,000-4,000 live births. In iodine-sufficient regions, thyroid dysgenesis (absent, ectopic, or hypoplastic gland) accounts for ~85% of cases; dyshormonogenesis ~10-15%. In iodine-deficient regions, iodine deficiency remains the leading preventable cause of intellectual disability globally. Critically, congenital hypothyroidism is clinically silent at birth because residual maternal thyroid hormone provides partial neonatal protection\u2014without newborn screening, diagnosis typically occurs after irreversible neurologic damage.\n\nDIAGNOSIS AND TREATMENT:\nUniversal newborn screening (AAP/WHO-recommended) uses heel-prick blood at 24-48 hours measuring TSH or T4 with reflex testing. Abnormal results trigger confirmatory serum TSH and free T4, then immediate levothyroxine. Treatment must begin within 2 weeks of life. The AAP recommends 10-15 mcg/kg/day, targeting free T4 normalization within 2 weeks and TSH within 1 month. Early detection and treatment achieve essentially normal cognitive outcomes.\n\nKEY POINTS:\nUntreated congenital hypothyroidism causes irreversible intellectual disability and growth retardation. Newborn screening at 24-48 hours is among the most successful preventive programs. Levothyroxine must begin within 2 weeks at 10-15 mcg/kg/day. Iodine deficiency remains the leading preventable cause of intellectual disability worldwide."
  },
  {
    "id": 423,
    "categoryId": 4,
    "question": "A female patient has severe hemorrhage during childbirth. Post-partum, she fails to lactate and develops amenorrhea. Diagnosis?",
    "options": [
      "A) Prolactinoma",
      "B) Sheehan's Syndrome (Postpartum Pituitary Necrosis)",
      "C) Post-partum Depression",
      "D) PCOS"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sheehan's Syndrome / Pituitary Apoplexy).\n\nPATHOPHYSIOLOGY:\nSheehan's syndrome is postpartum pituitary necrosis from severe hemorrhage and hypovolemic shock. During pregnancy, the anterior pituitary enlarges ~120-136% (primarily lactotroph hyperplasia from estrogen), compressing against the sella turcica. Its blood supply derives from the low-pressure hypothalamic-hypophyseal portal system rather than direct arterial supply. When postpartum hemorrhage causes shock, the combination of increased metabolic demand, reduced perfusion pressure, and vasospasm produces ischemic infarction of the anterior pituitary. The posterior pituitary is typically spared because it receives direct arterial supply from the inferior hypophyseal arteries (per JCEM).\n\nCLINICAL PRESENTATION:\nManifestations reflect sequential loss of anterior pituitary hormones. Failure of lactation (agalactia) is the earliest sign, from prolactin-secreting lactotroph loss. Amenorrhea results from gonadotropin (LH/FSH) deficiency. Secondary adrenal insufficiency (ACTH deficiency) may present acutely with hypotension and hyponatremia, or insidiously months to years later. Secondary hypothyroidism (TSH deficiency) produces fatigue, cold intolerance, and weight gain over weeks to months. GH deficiency contributes to fatigue and decreased lean body mass. Partial necrosis may produce selective deficiencies not apparent for years, requiring high suspicion in women with postpartum hemorrhage history.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is based on postpartum hemorrhage history with agalactia and amenorrhea, confirmed by low pituitary hormones (ACTH, TSH, LH, FSH, prolactin) with low target hormones (cortisol, free T4, estradiol). MRI characteristically shows a partially empty sella. Treatment requires lifelong replacement: glucocorticoids (hydrocortisone 15-25 mg daily with stress dosing) must begin before thyroid replacement to avoid precipitating adrenal crisis. Levothyroxine is titrated to free T4 (TSH unreliable in secondary hypothyroidism). Estrogen-progesterone replacement for premenopausal women. Patients need medical alert identification and sick-day steroid education.\n\nKEY POINTS:\nSheehan's syndrome results from ischemic anterior pituitary infarction during severe postpartum hemorrhage, with agalactia and amenorrhea as earliest signs. Glucocorticoid replacement must precede thyroid replacement. Diagnosis may be delayed years when partial necrosis produces insidious selective deficiencies."
  },
  {
    "id": 424,
    "categoryId": 4,
    "question": "In the Hypothalamic-Pituitary-Adrenal (HPA) axis, negative feedback is provided by:",
    "options": [
      "A) ACTH inhibiting the Adrenal",
      "B) Cortisol inhibiting both the Hypothalamus (CRH) and Pituitary (ACTH)",
      "C) Adrenaline inhibiting the Sympathetic nervous system",
      "D) Renin inhibiting Angiotensin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cortisol inhibiting both the Hypothalamus CRH and Pituitary ACTH).\n\nPATHOPHYSIOLOGY:\nThe HPA axis regulates cortisol through negative feedback. CRH from the hypothalamic paraventricular nucleus is secreted in response to circadian input (diurnal cortisol rhythm with AM peak, midnight nadir), physiologic stress, and psychological stress. CRH stimulates anterior pituitary corticotrophs to secrete ACTH (cleaved from the POMC precursor). ACTH binds MC2R on adrenal zona fasciculata cells, stimulating cortisol synthesis (cholesterol \u2192 pregnenolone \u2192 17-hydroxyprogesterone \u2192 11-deoxycortisol \u2192 cortisol). Cortisol provides negative feedback at two levels: binding glucocorticoid receptors on hypothalamic CRH neurons to suppress CRH transcription, and on pituitary corticotrophs to suppress POMC/ACTH secretion. This dual feedback prevents excessive glucocorticoid exposure.\n\nCLINICAL SIGNIFICANCE OF HPA AXIS SUPPRESSION:\nChronic pharmacologic glucocorticoids (>7.5 mg prednisone daily equivalent, or any dose >3 weeks) suppress CRH and ACTH, causing bilateral adrenal cortical atrophy from loss of trophic ACTH stimulation. Abrupt discontinuation can precipitate adrenal crisis (hypotension, cardiovascular collapse, death) because the suppressed axis cannot resume adequate cortisol production. HPA axis recovery may take 6-12 months and requires gradual tapering.\n\nCLINICAL APPLICATION:\nRisk factors for HPA suppression: higher total dose, longer duration, multiple daily dosing (vs. single morning dose mimicking physiologic cortisol peak), and higher potency agents (dexamethasone > prednisone > hydrocortisone). Tapering should reduce doses gradually over weeks to months, monitoring for adrenal insufficiency symptoms (fatigue, weakness, hypotension, nausea). Morning cortisol or ACTH stimulation testing assesses recovery. Stress-dose steroids are required during illness, surgery, or trauma until recovery is confirmed. Understanding the HPA axis also explains why secondary adrenal insufficiency preserves aldosterone (RAAS-regulated, not ACTH-dependent) and informs Cushing's syndrome diagnostic workup.\n\nKEY POINTS:\nCortisol provides negative feedback at both the hypothalamus (suppressing CRH) and pituitary (suppressing ACTH). Exogenous glucocorticoids >3 weeks suppress the HPA axis and cause adrenal atrophy, requiring gradual tapering. Recovery takes 6-12 months, and stress-dose steroids are needed during intercurrent illness until recovery is confirmed."
  },
  {
    "id": 425,
    "categoryId": 4,
    "question": "Syndrome of Inappropriate ADH (SIADH) is a common paraneoplastic syndrome associated with Small Cell Lung Cancer. It causes:",
    "options": [
      "A) Hypernatremia and Dehydration",
      "B) Euvolemic Hyponatremia and concentrated urine",
      "C) Hypokalemia",
      "D) Hypercalcemia"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Euvolemic Hyponatremia and concentrated urine).\n\nPATHOPHYSIOLOGY:\nSIADH results from persistent non-physiologic ADH secretion without normal osmotic or hemodynamic stimuli. Normally, ADH from the posterior pituitary acts on V2 receptors in the collecting duct to insert aquaporin-2 channels, promoting free water reabsorption. In SIADH, inappropriate ADH causes water retention despite low plasma osmolality, producing dilutional hyponatremia. Mild volume expansion triggers secondary natriuretic mechanisms (ANP release, pressure natriuresis, aldosterone suppression), worsening hyponatremia through sodium wasting. Patients remain clinically euvolemic because water retention is modest (~2-3 liters) and natriuresis prevents significant volume expansion.\n\nCLINICAL REASONING:\nDiagnostic criteria (Bartter and Schwartz, Endocrine Society) require: serum osmolality <275 mOsm/kg, urine osmolality >100 mOsm/kg (inappropriately concentrated), urine sodium >30 mEq/L, clinical euvolemia, and normal thyroid/adrenal/renal function. Small cell lung cancer is the classic ectopic ADH source (~10-15% of SCLC). More common overall causes include CNS disorders (stroke, TBI, meningitis, SAH), pulmonary diseases (pneumonia, TB), medications (SSRIs, carbamazepine, cyclophosphamide, desmopressin), and the postoperative state (pain and nausea are potent ADH secretagogues).\n\nTREATMENT:\nAcute symptomatic hyponatremia (seizures, altered mental status) requires hypertonic saline (3% NaCl) to raise sodium 4-6 mEq/L in the first 4-6 hours, maximum correction 8 mEq/L in 24 hours to prevent osmotic demyelination syndrome (ODS)\u2014a devastating complication causing quadriplegia and locked-in syndrome from central pontine demyelination. For chronic/mild SIADH, first-line is fluid restriction (<800 mL-1 L/day). Second-line options include oral sodium chloride with loop diuretics, urea, or vasopressin V2 receptor antagonists (tolvaptan, requiring monitoring for hepatotoxicity and overcorrection).\n\nKEY POINTS:\nSIADH produces euvolemic hyponatremia with urine osmolality >100 mOsm/kg and urine sodium >30 mEq/L. SCLC is the classic paraneoplastic cause, but medications (especially SSRIs) and CNS disorders are more common overall. Sodium correction must not exceed 8 mEq/L in 24 hours to prevent ODS."
  },
  {
    "id": 426,
    "categoryId": 4,
    "question": "Hypoglycemia Unawareness (loss of warning symptoms like shaking/sweating) in long-standing diabetics is caused by:",
    "options": [
      "A) Beta cell burnout",
      "B) Autonomic Neuropathy and blunted Glucagon/Epinephrine response",
      "C) Insulin resistance",
      "D) Metformin use"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Autonomic Neuropathy and blunted Glucagon/Epinephrine response).\n\nPATHOPHYSIOLOGY:\nHypoglycemia counterregulation is a hierarchical defense system. As glucose drops below ~80 mg/dL, endogenous insulin secretion is suppressed. At ~65-70 mg/dL, glucagon stimulates hepatic glycogenolysis and gluconeogenesis. Below ~65 mg/dL, epinephrine augments hepatic glucose output, suppresses peripheral glucose utilization, stimulates lipolysis, and produces autonomic warning symptoms (tremor, palpitations, diaphoresis, hunger). Cortisol and GH provide additional support during prolonged hypoglycemia. In long-standing diabetes, this system is progressively compromised.\n\nCLINICAL REASONING:\nTwo critical defects develop (per Diabetes Care, NEJM). First, the glucagon response is lost within 5-10 years of type 1 diabetes and impaired in advanced type 2. Normally, falling beta-cell insulin disinhibits alpha cells to trigger glucagon release; with beta-cell destruction, this paracrine signal is absent. Second, the epinephrine response becomes attenuated through hypoglycemia-associated autonomic failure (HAAF). Recurrent hypoglycemia shifts the glycemic threshold for epinephrine release downward (from ~65 to below 50 mg/dL) by altering ventromedial hypothalamic glucose-sensing neurons. Without epinephrine, autonomic warnings do not occur, and patients progress directly to neuroglycopenia (confusion, seizures, LOC). HAAF is partially reversible: strict hypoglycemia avoidance for 2-3 weeks can restore awareness.\n\nCLINICAL APPLICATION:\nHypoglycemia unawareness affects ~25-40% of type 1 patients, increasing severe hypoglycemia risk 6-fold (Diabetes Care). Management includes relaxed glycemic targets (ADA recommends higher A1c for patients with unawareness), CGM with predictive low-glucose alerts (strongly recommended per ADA 2024 Standards of Care), automated insulin delivery systems that suspend insulin during predicted lows, and structured awareness training (BGAT). Beta-blockers mask tremor and tachycardia, potentially worsening unawareness\u2014consider alternative antihypertensives. Islet cell or pancreas transplantation may be considered for refractory cases.\n\nKEY POINTS:\nHypoglycemia unawareness results from lost glucagon response (within 5-10 years of type 1 diabetes) and attenuated epinephrine response through HAAF. Strict hypoglycemia avoidance for 2-3 weeks can partially restore awareness. CGM with predictive alerts and relaxed glycemic targets are management cornerstones."
  },
  {
    "id": 427,
    "categoryId": 4,
    "question": "Carcinoid Syndrome (neuroendocrine tumor) presents with flushing, diarrhea, and wheezing. This is due to the secretion of:",
    "options": [
      "A) Dopamine",
      "B) Serotonin (5-HT)",
      "C) Insulin",
      "D) Cortisol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Serotonin / 5-HT).\n\nPATHOPHYSIOLOGY:\nCarcinoid syndrome results from systemic release of vasoactive substances, predominantly serotonin (5-HT), from neuroendocrine tumors (NETs) that have metastasized to the liver. NETs, most commonly from ileal enterochromaffin cells, synthesize serotonin from tryptophan via tryptophan hydroxylase and also produce histamine, bradykinin, and prostaglandins. Critically, carcinoid syndrome occurs almost exclusively with hepatic metastases because the liver normally inactivates serotonin via first-pass metabolism through monoamine oxidase. Only hepatic metastases allow direct systemic access via hepatic venous drainage. Exceptions: bronchial and ovarian carcinoids drain directly into systemic circulation and can cause syndrome without liver metastases.\n\nCLINICAL PRESENTATION:\nThe classic triad is episodic flushing (~85%), secretory diarrhea (~80%), and bronchospasm (~20%). Flushing (face, neck, upper trunk) is mediated primarily by histamine and bradykinin, triggered by stress, alcohol, or tyramine-containing foods. Diarrhea results from serotonin-stimulated intestinal motility via 5-HT3/5-HT4 receptors. Bronchospasm mimics asthma. Carcinoid heart disease (Hedinger syndrome) affects 20-50% (per NEJM): serotonin stimulates fibroblast proliferation via 5-HT2B receptors on right-sided valve endocardium, producing tricuspid regurgitation and pulmonic stenosis. Left-sided valves are spared because pulmonary monoamine oxidase inactivates serotonin.\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis is confirmed by elevated 24-hour urinary 5-HIAA (>25 mg/24h, sensitivity/specificity >90%). Imaging with Ga-68 DOTATATE PET/CT or Octreoscan localizes somatostatin receptor-expressing tumors. Treatment centers on somatostatin analogs (octreotide LAR, lanreotide), which inhibit serotonin secretion and demonstrate antiproliferative effects, with symptomatic relief in ~70%. Telotristat ethyl (tryptophan hydroxylase inhibitor) is FDA-approved as adjunct for inadequately controlled diarrhea. Additional options include hepatic debulking, embolization, and PRRT with lutetium-177 DOTATATE (Lutathera).\n\nKEY POINTS:\nCarcinoid syndrome occurs almost exclusively with hepatic metastases because liver first-pass metabolism inactivates serotonin. The classic triad is flushing, diarrhea, and bronchospasm, with right-sided carcinoid heart disease as a major late complication. Diagnosis relies on 24-hour urinary 5-HIAA, and somatostatin analogs are the treatment mainstay."
  },
  {
    "id": 428,
    "categoryId": 4,
    "question": "Thyroid Storm is a life-threatening crisis. Why are Beta Blockers (Propranolol) a critical first-line treatment?",
    "options": [
      "A) They block Thyroid Peroxidase",
      "B) They block the peripheral conversion of T4 to T3 and blunt the sympathetic overdrive",
      "C) They sedate the patient",
      "D) They lower fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (They block the peripheral conversion of T4 to T3 and blunt the sympathetic overdrive).\n\nPATHOPHYSIOLOGY:\nThyroid storm is a life-threatening thyrotoxicosis exacerbation with fever (often >104\u00b0F/40\u00b0C), severe tachycardia (often >140 bpm, AF in ~50%), altered mental status, GI dysfunction, and cardiovascular collapse, carrying 10-30% mortality. Clinical severity exceeds what thyroid hormone levels alone predict, suggesting increased adrenergic receptor sensitivity and the precipitating illness contribute. Precipitants include infection, surgery, radioactive iodine, iodinated contrast, and antithyroid medication cessation. The Burch-Wartofsky Point Scale score \u226545 suggests thyroid storm.\n\nCLINICAL REASONING:\nPropranolol provides a unique dual mechanism. First, as a nonselective beta-blocker, it blocks beta-1 (reducing heart rate, contractility) and beta-2 receptors (reducing tremor, anxiety, diaphoresis). Thyroid hormone excess increases beta-receptor density, producing catecholamine hypersensitivity that propranolol counteracts. Second, at high doses (>160 mg/day), propranolol inhibits peripheral T4-to-T3 conversion by blocking type 1 deiodinase. Since T3 is 3-5\u00d7 more potent than T4, this directly reduces hormonal excess. This dual mechanism makes propranolol preferred over cardioselective beta-blockers (atenolol, metoprolol), which lack T4-to-T3 conversion inhibition.\n\nTREATMENT CONTEXT:\nThyroid storm requires multimodal treatment in specific sequence. Propranolol (60-80 mg PO q4-6h, or 0.5-1 mg IV) is given first for immediate symptom control. If contraindicated (decompensated HF, severe bronchospasm), esmolol or diltiazem may substitute. PTU is preferred over methimazole because PTU also inhibits T4-to-T3 conversion. Inorganic iodide (Lugol's or SSKI) is given \u22651 hour after thionamide to block hormone release via the Wolff-Chaikoff effect\u2014giving iodide first would provide substrate for new synthesis. Glucocorticoids (hydrocortisone 100 mg IV q8h) further inhibit T4-to-T3 conversion and provide adrenal support. Aspirin must be avoided as it displaces thyroid hormone from binding proteins, increasing free hormone.\n\nKEY POINTS:\nPropranolol is preferred because it provides both beta-adrenergic blockade and inhibition of peripheral T4-to-T3 conversion. Treatment sequence: propranolol \u2192 thionamide (PTU preferred) \u2192 iodide (\u22651 hour after thionamide) \u2192 glucocorticoids. Avoid aspirin."
  },
  {
    "id": 429,
    "categoryId": 4,
    "question": "Acromegaly (Growth Hormone excess in adults) is often diagnosed late. Besides coarsening facial features, a key neurologic symptom is:",
    "options": [
      "A) Carpal Tunnel Syndrome",
      "B) Foot drop",
      "C) Sciatica",
      "D) Hearing loss"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Carpal Tunnel Syndrome).\n\nPATHOPHYSIOLOGY:\nAcromegaly results from GH excess in adults, most commonly from a pituitary somatotroph adenoma (>95%). Since GH excess occurs after epiphyseal closure, it drives acral and soft tissue overgrowth through IGF-1 (produced by the liver) rather than linear growth. Changes develop so gradually that average diagnostic delay is 7-10 years (Endocrine Society, JAMA). Carpal tunnel syndrome occurs in 20-65% of patients due to GH/IGF-1-mediated hypertrophy of the transverse carpal ligament, peritendinous connective tissue, and synovium within the rigid carpal tunnel, plus edema from increased extracellular fluid, all compressing the median nerve.\n\nCLINICAL PRESENTATION:\nFeatures reflect widespread overgrowth: progressive hand enlargement (increasing ring size) and foot enlargement (increasing shoe size), frontal bossing, prognathism, widened nose, thickened lips, macroglossia (contributing to OSA in ~70%), skin thickening with hyperhidrosis, and large-joint arthropathy. Metabolic consequences include insulin resistance and diabetes (up to 50%), hypertension, cardiomyopathy (biventricular hypertrophy progressing to failure), and increased risk of colorectal polyps and cancer from IGF-1's mitogenic effects. These cardiovascular and metabolic complications drive the 2-3-fold increased mortality (JCEM).\n\nDIAGNOSIS AND TREATMENT:\nScreen with serum IGF-1 (reflects integrated 24-hour GH secretion); random GH is unreliable due to pulsatile secretion. Confirm with OGTT: normally 75g glucose suppresses GH below 0.4 ng/mL; in acromegaly, GH fails to suppress or paradoxically rises. Pituitary MRI identifies the adenoma (~70% are macroadenomas at diagnosis). First-line treatment is transsphenoidal surgery (remission: 80-90% microadenomas, 40-60% macroadenomas). Persistent disease is managed with somatostatin analogs (octreotide LAR, lanreotide, pasireotide), GH receptor antagonist pegvisomant, or cabergoline. Colonoscopy screening is recommended at diagnosis and periodically given increased neoplasia risk.\n\nKEY POINTS:\nCarpal tunnel occurs in 20-65% of acromegaly patients from GH/IGF-1-mediated soft tissue hypertrophy compressing the median nerve. New-onset carpal tunnel with increasing ring or shoe size should prompt IGF-1 and OGTT screening. Average diagnostic delay is 7-10 years with 2-3-fold increased cardiovascular mortality."
  },
  {
    "id": 430,
    "categoryId": 4,
    "question": "In an elderly patient, 'Apathetic Hyperthyroidism' presents differently than classic Graves. Symptoms include:",
    "options": [
      "A) Hyperactivity and Tremor",
      "B) Lethargy, Depression, and Atrial Fibrillation",
      "C) Weight gain",
      "D) Constipation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lethargy, Depression, and Atrial Fibrillation).\n\nPATHOPHYSIOLOGY:\nApathetic hyperthyroidism is an atypical presentation in elderly patients where classic hyperadrenergic features are absent, replaced by symptoms mimicking hypothyroidism or depression. With aging, beta-adrenergic receptor density and responsiveness decline, along with reduced sympathetic tone and catecholamine sensitivity. The adrenergic amplification producing the hyperkinetic presentation in younger patients (anxiety, tremor, hyperreflexia, heat intolerance) is absent or attenuated. Instead, dominant features reflect direct thyroid hormone effects: atrial fibrillation (shortened atrial refractory periods), proximal myopathy, weight loss, and depression/apathy/cognitive decline (possibly from serotonin depletion and altered dopaminergic signaling).\n\nCLINICAL PRESENTATION:\nFirst described by Lahey (1931), the classic presentation includes lethargy rather than agitation, depression rather than anxiety, weight loss with anorexia rather than increased appetite, proximal weakness, and prominent cardiovascular manifestations. Atrial fibrillation occurs in 25-40% of elderly hyperthyroid patients versus 10-15% of younger patients and may be the sole presenting feature (per JAMA Internal Medicine). Heart failure may develop from increased cardiac workload or rate-related cardiomyopathy. Unexplained weight loss may trigger malignancy workup before thyroid is considered, and the absence of expected hyperadrenergic features frequently delays diagnosis.\n\nCLINICAL APPLICATION:\nTSH should be checked in every elderly patient with unexplained weight loss, new-onset atrial fibrillation (~3-5% of new AF in elderly is from hyperthyroidism), treatment-resistant depression, unexplained heart failure, or failure to thrive. Suppressed TSH with elevated free T4/T3 confirms diagnosis. Some patients show T3 thyrotoxicosis (elevated free T3, normal free T4), requiring free T3 measurement when TSH is suppressed but free T4 is normal. Treatment considerations include preference for definitive therapy (radioactive iodine or surgery), careful beta-blocker initiation (HF/COPD risk), and pre-treatment with antithyroid drugs before RAI. Approximately 50-60% of thyrotoxicosis-induced AF converts spontaneously once euthyroid.\n\nKEY POINTS:\nApathetic hyperthyroidism in elderly patients presents with lethargy, depression, weight loss, and AF due to age-related decline in beta-adrenergic receptor responsiveness. Check TSH in elderly with unexplained weight loss, new AF, depression, or failure to thrive. ~50-60% of thyrotoxicosis-induced AF converts spontaneously with euthyroidism."
  },
  {
    "id": 431,
    "categoryId": 4,
    "question": "Orthostatic Hypotension in diabetes is a sign of damage to the:",
    "options": [
      "A) Parasympathetic Nervous System",
      "B) Sympathetic Nervous System fibers innervating blood vessels",
      "C) Somatic Motor Nerves",
      "D) Vestibular Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sympathetic Nervous System fibers innervating blood vessels).\n\nPATHOPHYSIOLOGY:\nOrthostatic hypotension in diabetes is a manifestation of cardiovascular autonomic neuropathy (CAN). Upon standing, ~500-700 mL of blood redistributes to dependent venous capacitance vessels. Normally, carotid sinus and aortic arch baroreceptors (via CN IX and X) relay to the medullary nucleus tractus solitarius, triggering increased sympathetic outflow (arteriolar vasoconstriction, increased HR/contractility) and parasympathetic withdrawal, restoring BP within 1-2 heartbeats. In diabetic CAN, chronic hyperglycemia damages sympathetic nerve fibers through polyol pathway activation, advanced glycation end-product formation, oxidative stress, and vasa nervorum microangiopathy.\n\nCLINICAL PRESENTATION:\nOrthostatic hypotension is defined as sustained SBP drop \u226520 mmHg or DBP drop \u226510 mmHg within 3 minutes of standing, causing lightheadedness, presyncope, syncope, visual blurring, and coat-hanger neck/shoulder pain. CAN affects ~20% of type 2 and up to 40% of type 1 patients with >20 years duration (ADA), carrying ~3.4-fold increased mortality (Diabetes Care) from silent myocardial ischemia and arrhythmias. Other CAN features include resting tachycardia (90-100 bpm from vagal loss), exercise intolerance, silent MI, and QT prolongation.\n\nDIAGNOSIS AND TREATMENT:\nScreen all type 2 patients at diagnosis and type 1 after 5 years using cardiovascular autonomic reflex tests: heart rate variability with deep breathing (earliest abnormality), Valsalva ratio, and orthostatic BP test. Non-pharmacologic management: rise slowly, hydrate 2-3 L/day, increase dietary sodium if appropriate, waist-high compression (30-40 mmHg), elevate head of bed 10-20 degrees, avoid exacerbating factors (large meals, heat, alcohol). Pharmacologic options for refractory cases: midodrine (alpha-1 agonist, 2.5-10 mg TID, last dose by 6 PM to avoid supine hypertension), droxidopa (synthetic NE precursor, FDA-approved for neurogenic orthostatic hypotension), and fludrocortisone (limited by supine hypertension and hypokalemia).\n\nKEY POINTS:\nOrthostatic hypotension in diabetes results from sympathetic vasomotor nerve damage impairing the baroreceptor reflex. CAN affects 20-40% of long-standing diabetics with 3.4-fold increased mortality. Management includes slow positional changes, volume expansion, compression garments, and midodrine or droxidopa for refractory cases."
  },
  {
    "id": 432,
    "categoryId": 4,
    "question": "Multiple Endocrine Neoplasia (MEN 1) is characterized by the '3 Ps'. Which is NOT one of them?",
    "options": [
      "A) Parathyroid hyperplasia",
      "B) Pituitary adenoma",
      "C) Pancreatic neuroendocrine tumors",
      "D) Pheochromocytoma"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (Pheochromocytoma is NOT a feature of MEN 1).\n\nPATHOPHYSIOLOGY:\nThe MEN syndromes are autosomal dominant hereditary cancer predisposition syndromes. MEN 1 (three Ps: Parathyroid, Pituitary, Pancreas) results from inactivating mutations in the MEN1 gene (chromosome 11q13), encoding menin, a tumor suppressor involved in transcription regulation, histone modification, and DNA repair. Biallelic inactivation (germline mutation plus somatic LOH, per Knudson two-hit hypothesis) produces: primary hyperparathyroidism (>95% by age 50, typically multigland hyperplasia), pancreatic/duodenal NETs (30-80%, including gastrinomas causing Zollinger-Ellison syndrome, insulinomas, and non-functioning tumors), and anterior pituitary adenomas (15-50%, most commonly prolactinomas).\n\nCLINICAL REASONING:\nPheochromocytoma is characteristic of MEN 2, not MEN 1. MEN 2 results from activating mutations in the RET proto-oncogene (chromosome 10q11.2), a receptor tyrosine kinase in neural crest-derived tissues. MEN 2A (~95% of cases) features medullary thyroid carcinoma (MTC, virtually 100%), pheochromocytoma (~50%, bilateral in up to 65%), and hyperparathyroidism (20-30%). MEN 2B (~5%) features aggressive early-onset MTC, pheochromocytoma (~50%), mucosal neuromas, and marfanoid habitus\u2014without hyperparathyroidism. Genotype-phenotype correlations guide management: codon 634 mutations carry highest pheochromocytoma/HPT risk; codon 918 (M918T, MEN 2B) carries highest MTC risk, requiring thyroidectomy ideally within 6 months of life.\n\nCLINICAL APPLICATION:\nGenetic testing should be offered for patients with \u22652 MEN-spectrum endocrine tumors, any MTC (~25% hereditary), first-degree relatives of carriers, or bilateral pheochromocytoma. MEN 1 screening begins age 5-8 with annual calcium/PTH, prolactin/IGF-1, fasting glucose/insulin/gastrin, and periodic imaging. In MEN 2 families, prophylactic total thyroidectomy timing follows RET mutation risk: within 6 months for highest-risk (MEN 2B, codon 918), by age 5 for high-risk (codon 634), potentially deferred for moderate-risk. Annual plasma free metanephrines screen for pheochromocytoma lifelong.\n\nKEY POINTS:\nMEN 1 (Parathyroid, Pituitary, Pancreas) from MEN1 mutations does NOT include pheochromocytoma. MEN 2 (RET activating mutations) features MTC, pheochromocytoma, and HPT (2A) or mucosal neuromas (2B). Prophylactic thyroidectomy timing is guided by specific RET codon mutation risk category."
  },
  {
    "id": 433,
    "categoryId": 4,
    "question": "The Pineal Gland secretes Melatonin in response to darkness. It receives signals from the retina via the:",
    "options": [
      "A) Optic Nerve -> Occipital Lobe",
      "B) Suprachiasmatic Nucleus (SCN) of the Hypothalamus",
      "C) Vagus Nerve",
      "D) Thalamus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Suprachiasmatic Nucleus of the Hypothalamus).\n\nPATHOPHYSIOLOGY:\nMelatonin synthesis is regulated through a multisynaptic pathway originating in intrinsically photosensitive retinal ganglion cells (ipRGCs), which express melanopsin (maximally sensitive to blue light ~460-480 nm). These project via the retinohypothalamic tract to the suprachiasmatic nucleus (SCN), the master circadian pacemaker in the anterior hypothalamus. The SCN generates ~24-hour rhythms through a CLOCK/BMAL1/PER/CRY transcription-translation feedback loop, entrained to the light-dark cycle by ipRGC input. During darkness, the SCN disinhibits a sympathetic pathway: paraventricular nucleus \u2192 thoracic intermediolateral cell column \u2192 superior cervical ganglion \u2192 pineal gland. Norepinephrine activates beta-1/alpha-1 receptors on pinealocytes, stimulating AANAT (rate-limiting enzyme) to convert serotonin to N-acetylserotonin, then HIOMT produces melatonin. Light suppresses this pathway.\n\nCLINICAL REASONING:\nMelatonin follows a robust circadian pattern: rising ~2 hours before habitual bedtime (dim light melatonin onset, DLMO), peaking 2-4 AM, declining by morning. Evening blue light from screens suppresses melatonin via melanopsin activation even at 100-200 lux, delaying sleep onset. Melatonin production declines with aging (pineal calcification). Totally blind individuals lacking ipRGC-mediated light perception develop non-24-hour sleep-wake disorder (free-running circadian rhythm) with cyclical insomnia (per NEJM, JCEM).\n\nCLINICAL APPLICATION:\nFor jet lag, melatonin (0.5-5 mg at destination bedtime) is effective per Cochrane review. For delayed sleep-wake phase disorder, low-dose melatonin (0.5-1 mg) given 3-5 hours before desired bedtime advances circadian timing. For non-24-hour disorder in totally blind patients, tasimelteon (Hetlioz, MT1/MT2 agonist) is FDA-approved. Ramelteon (Rozerem, MT1/MT2 agonist) is FDA-approved for sleep-onset insomnia with no abuse potential or DEA scheduling. Melatonin is a chronobiotic signal that shifts circadian timing, not a conventional sedative\u2014efficacy depends on timing relative to circadian phase.\n\nKEY POINTS:\nMelatonin synthesis is regulated via ipRGCs \u2192 SCN (master clock) \u2192 pineal gland through sympathetic projections via the superior cervical ganglion. Blue light (460-480 nm) suppresses melatonin via melanopsin. Melatonin is a chronobiotic, and clinical efficacy depends on administration timing relative to circadian phase."
  },
  {
    "id": 434,
    "categoryId": 4,
    "question": "Primary Hyperaldosteronism (Conn's Syndrome) causes Hypertension and:",
    "options": [
      "A) Hyperkalemia",
      "B) Hypokalemia and Metabolic Alkalosis",
      "C) Hyponatremia",
      "D) Metabolic Acidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypokalemia and Metabolic Alkalosis).\n\nPATHOPHYSIOLOGY:\nPrimary hyperaldosteronism (PA) affects ~5-10% of hypertensives and ~20% with resistant hypertension (Endocrine Society, JAMA). Aldosterone is autonomously secreted from the adrenal zona glomerulosa, most commonly from bilateral hyperplasia (~60-70%) or unilateral adenoma (Conn's syndrome, ~30-40%). Aldosterone binds mineralocorticoid receptors on cortical collecting duct principal cells, inducing ENaC and Na-K ATPase, driving sodium reabsorption. This creates a lumen-negative potential driving potassium secretion via ROMK channels and H+ secretion via intercalated cell H+-ATPase. The net result: sodium retention (hypertension), potassium wasting (hypokalemia), and hydrogen ion loss (metabolic alkalosis). The aldosterone escape mechanism (ANP, pressure natriuresis) prevents edema but does not normalize blood pressure.\n\nCLINICAL PRESENTATION:\nSuspect PA in resistant hypertension, spontaneous or disproportionate diuretic-induced hypokalemia (though normokalemic PA is far more common at 63-91%), hypertension with adrenal incidentaloma, or early-onset hypertension. Aldosterone directly promotes myocardial fibrosis, LVH, and vascular inflammation independent of BP, causing excess cardiovascular morbidity versus matched essential hypertension (per Annals of Internal Medicine, JAMA).\n\nDIAGNOSIS AND TREATMENT:\nThree-step approach: (1) Screen with aldosterone-to-renin ratio (ARR)\u2014ratio >30 with aldosterone >15 ng/dL is positive. Discontinue spironolactone/eplerenone \u22654-6 weeks before; switch to non-interfering agents (verapamil, hydralazine). (2) Confirm with salt loading test demonstrating failure of aldosterone suppression. (3) Subtype differentiation: adrenal CT and adrenal venous sampling (AVS, gold standard for lateralization). Unilateral adenoma: laparoscopic adrenalectomy (cures HTN in ~30-60%). Bilateral hyperplasia: mineralocorticoid receptor antagonists\u2014spironolactone (25-100 mg/day, limited by anti-androgenic effects including gynecomastia) or eplerenone (50-200 mg/day, fewer side effects but lower potency).\n\nKEY POINTS:\nPA is common (5-10% of hypertensives) and produces hypokalemia and metabolic alkalosis via ENaC-mediated sodium reabsorption driving K+/H+ secretion. ARR is the screening test; adrenal venous sampling is gold standard for lateralization. Adenoma is treated surgically; bilateral hyperplasia with mineralocorticoid receptor antagonists."
  },
  {
    "id": 435,
    "categoryId": 4,
    "question": "Leptin is produced by adipocytes and acts on the Hypothalamus to:",
    "options": [
      "A) Increase hunger",
      "B) Signal satiety (Fullness) and increase energy expenditure",
      "C) Lower body temperature",
      "D) Store fat"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Signal satiety and increase energy expenditure).\n\nPATHOPHYSIOLOGY:\nLeptin is a 16-kDa adipokine secreted by white adipose tissue in proportion to fat mass, functioning as the primary long-term adiposity signal to the CNS. Leptin crosses the blood-brain barrier via saturable receptor-mediated transport and binds LepR-b on two opposing arcuate nucleus neuronal populations (per foundational Nature research). It activates anorexigenic POMC neurons, which release alpha-MSH binding MC4R on paraventricular nucleus neurons\u2014suppressing intake and increasing sympathetic-mediated thermogenesis in brown/beige adipose tissue. Simultaneously, leptin inhibits orexigenic NPY/AgRP neurons. The net effect: suppressed appetite and increased energy expenditure. This positions leptin as a lipostatic signal\u2014rising with fat mass to reduce intake, falling with fat loss to increase appetite and reduce expenditure.\n\nCLINICAL REASONING:\nLeptin is a metabolic gatekeeper for reproduction: adequate levels are required for normal GnRH pulsatility, explaining hypothalamic amenorrhea in anorexia nervosa and female athlete triad. Congenital leptin deficiency (rare autosomal recessive ob gene mutations) produces severe early-onset obesity, hyperphagia, and hypogonadotropic hypogonadism, responding dramatically to metreleptin replacement. Common obesity, however, features leptin resistance (elevated levels with central insensitivity) rather than deficiency. Resistance mechanisms include saturated BBB transport, SOCS3 upregulation attenuating JAK-STAT signaling, ER stress in hypothalamic neurons, and chronic hypothalamic inflammation from visceral adiposity.\n\nCLINICAL APPLICATION:\nMetreleptin (Myalept) is FDA-approved for generalized lipodystrophy, where absent adipose tissue causes leptin deficiency with hypertriglyceridemia, hepatic steatosis, and insulin-resistant diabetes. For common obesity, weight loss reduces leptin, which the hypothalamus interprets as starvation\u2014triggering compensatory appetite increases and reduced energy expenditure (adaptive thermogenesis) that promote regain. This neurobiological mechanism, not willpower, explains high weight-loss recidivism. GLP-1 receptor agonists (semaglutide, tirzepatide) achieve sustained weight loss partly by activating central satiety pathways that bypass leptin-resistant circuitry.\n\nKEY POINTS:\nLeptin signals the hypothalamus to suppress appetite (POMC activation, NPY/AgRP inhibition) and increase energy expenditure (sympathetic thermogenesis). It is a metabolic gatekeeper for reproduction, explaining hypothalamic amenorrhea in energy deficit. Common obesity features leptin resistance, and weight loss-induced leptin decline triggers compensatory hyperphagia promoting regain."
  },
  {
    "id": 436,
    "categoryId": 4,
    "question": "Oxytocin is synthesized in the Hypothalamus and released by the Posterior Pituitary. Its two main physical functions are:",
    "options": [
      "A) Milk synthesis and Uterine relaxation",
      "B) Milk ejection (Let-down) and Uterine contraction",
      "C) Water retention and Vasoconstriction",
      "D) Ovulation and Menstruation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Milk ejection / let-down reflex and uterine contraction).\n\nPATHOPHYSIOLOGY:\nOxytocin is a nine-amino-acid peptide synthesized by magnocellular neurons in the hypothalamic paraventricular and supraoptic nuclei, transported to the posterior pituitary for storage and release. Its two primary peripheral functions involve smooth muscle contraction mediated through the oxytocin receptor (OXTR), a Gq-coupled receptor that increases intracellular calcium.\n\nMILK EJECTION:\nThe let-down reflex is a neuroendocrine arc. Infant suckling stimulates nipple mechanoreceptors, transmitting afferent signals via intercostal nerves to the hypothalamus, triggering pulsatile oxytocin release. Oxytocin causes myoepithelial cells surrounding mammary alveoli to contract, squeezing milk through lactiferous ducts. This reflex can be conditioned (infant crying, nursing anticipation) and inhibited by stress/catecholamines. Critical distinction: prolactin (anterior pituitary) drives milk synthesis; oxytocin drives milk ejection. Both are necessary for successful lactation.\n\nUTERINE CONTRACTION:\nOxytocin receptor density increases ~200-fold during the third trimester under estrogen influence. The Ferguson reflex is a positive feedback loop: fetal descent and cervical dilation activate stretch receptors \u2192 afferent pelvic splanchnic nerve signals to hypothalamus \u2192 oxytocin release \u2192 stronger contractions \u2192 further cervical dilation. This escalates until delivery removes the stimulus. Postpartum, oxytocin drives uterine involution, compressing spiral arteries at the placental site for hemostasis.\n\nCLINICAL APPLICATION:\nSynthetic oxytocin (Pitocin) is used for labor induction/augmentation, active management of the third stage to reduce postpartum hemorrhage, and treatment of uterine atony (the most common PPH cause, ~80% of cases). Monitoring is essential: excessive dosing causes tachysystole compromising fetal oxygenation, and prolonged high-dose infusion risks water intoxication and hyponatremia from structural similarity to ADH allowing V2 receptor cross-reactivity at pharmacologic doses.\n\nKEY POINTS:\nOxytocin's primary functions are milk ejection (myoepithelial contraction via the let-down reflex) and uterine contraction (Ferguson reflex during labor, postpartum hemostasis). Prolactin makes milk; oxytocin ejects it. Pitocin is used for induction, augmentation, and PPH prevention, with monitoring for tachysystole and hyponatremia."
  },
  {
    "id": 437,
    "categoryId": 4,
    "question": "A lesion in the Ventromedial Nucleus of the Hypothalamus results in:",
    "options": [
      "A) Anorexia (Starvation)",
      "B) Hyperphagia (Uncontrollable eating) and Obesity",
      "C) Insomnia",
      "D) Loss of temperature regulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hyperphagia and Obesity).\n\nPATHOPHYSIOLOGY:\nThe hypothalamus regulates energy homeostasis through distinct nuclei. The ventromedial nucleus (VMH) functions as the satiety center, activated by energy surfeit signals (glucose, insulin, leptin), projecting to circuits that inhibit feeding and promote expenditure. Bilateral VMH destruction produces dramatic hyperphagia and severe obesity by removing the inhibitory brake on feeding. The lateral hypothalamic area (LHA) is the feeding/hunger center, containing orexin and MCH neurons activated by energy deficit signals (ghrelin, low glucose). Bilateral LHA lesions produce aphagia and weight loss. The arcuate nucleus at the hypothalamic base (adjacent to the fenestrated blood-brain barrier at the median eminence) serves as the primary sensory node, housing opposing NPY/AgRP (orexigenic) and POMC/CART (anorexigenic) populations that integrate peripheral signals.\n\nCLINICAL REASONING:\nHypothalamic obesity results from acquired VMH lesions disrupting satiety circuitry. Craniopharyngioma, a benign embryonal tumor from Rathke's pouch remnants, is the most common pediatric cause\u2014approximately 50-75% develop hypothalamic obesity from tumor infiltration or surgical damage (per JCEM). This obesity is refractory to behavioral interventions because it results from neuroanatomic disruption. Hypothalamic damage also produces reduced sympathetic tone (blunted energy expenditure), hyperinsulinemia (vagal hyperactivity driving beta-cell secretion), and concurrent pituitary deficiencies (GH deficiency, central hypothyroidism, adrenal insufficiency, diabetes insipidus).\n\nCLINICAL APPLICATION:\nSuspect hypothalamic pathology in patients with rapid unexplained weight gain (especially children/adolescents) accompanied by headache, visual field deficits (optic chiasm compression), polyuria/polydipsia, or growth failure. Brain MRI with contrast of the sellar/suprasellar region is the initial study. Other causes include surgical/radiation damage, infiltrative diseases (sarcoidosis, Langerhans cell histiocytosis), TBI, and Prader-Willi syndrome (loss of paternal genes at 15q11-q13 causing hyperphagia, hypogonadism, and GH deficiency). Management is challenging: GLP-1 agonists and bariatric surgery show variable benefit; pituitary hormone optimization and sleep-disordered breathing treatment are important adjuncts.\n\nKEY POINTS:\nVMH destruction produces hyperphagia and obesity by removing the satiety brake; LHA destruction causes aphagia. Craniopharyngioma is the most common cause of hypothalamic obesity in children. Rapid unexplained weight gain with headache or visual symptoms warrants neuroimaging and endocrine evaluation."
  },
  {
    "id": 438,
    "categoryId": 4,
    "question": "Secondary Hyperparathyroidism is most commonly seen in:",
    "options": [
      "A) Parathyroid Adenoma",
      "B) Chronic Kidney Disease (CKD)",
      "C) Vitamin D Toxicity",
      "D) Sarcoidosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Chronic Kidney Disease).\n\nPATHOPHYSIOLOGY:\nSecondary hyperparathyroidism in CKD results from progressive calcium, phosphorus, and vitamin D derangement. As nephrons are lost: (1) phosphate excretion declines (GFR <40-50 mL/min produces phosphate retention), and (2) renal 1-alpha-hydroxylase (CYP27B1) capacity decreases, reducing conversion of 25-hydroxyvitamin D to active calcitriol. Calcitriol deficiency impairs intestinal calcium absorption (normally via TRPV5/6 channels and calbindin). Elevated phosphorus further suppresses 1-alpha-hydroxylase and complexes ionized calcium. The parathyroid glands detect hypocalcemia via the calcium-sensing receptor (CaSR) and increase PTH secretion to stimulate osteoclastic bone resorption, renal calcium reabsorption, and 1-alpha-hydroxylase activity (progressively limited by declining renal mass).\n\nCLINICAL REASONING:\nFGF23 (osteocyte-secreted) is the earliest compensatory response in CKD, rising before PTH, phosphorus, or calcium become abnormal (per NEJM, KDIGO). FGF23 promotes renal phosphate excretion via FGFR1-Klotho but suppresses calcitriol production, contributing to the hyperparathyroidism cascade. Progressive CKD causes parathyroid hyperplasia and eventually autonomous secretion (tertiary hyperparathyroidism). Skeletal consequences (CKD-MBD) include osteitis fibrosa cystica (high-turnover from PTH excess), osteomalacia (impaired mineralization from calcitriol deficiency), and adynamic bone disease (oversuppressed turnover). Cardiovascular calcification from hyperphosphatemia is a leading cause of CV death in dialysis patients.\n\nTREATMENT:\nPer KDIGO 2017 guidelines: dietary phosphorus restriction (800-1000 mg/day) is first-line. Phosphate binders reduce intestinal absorption\u2014non-calcium-based (sevelamer, lanthanum) preferred over calcium-based to reduce vascular calcification. Active vitamin D analogs (calcitriol, paricalcitol) suppress PTH but risk hypercalcemia/hyperphosphatemia. Calcimimetics (cinacalcet, etelcalcetide) activate the CaSR, reducing PTH without raising calcium/phosphorus (EVOLVE trial, NEJM 2012). Parathyroidectomy is reserved for severe refractory tertiary hyperparathyroidism.\n\nKEY POINTS:\nSecondary hyperparathyroidism in CKD results from phosphate retention, reduced calcitriol, and hypocalcemia driving PTH excess. FGF23 is the earliest biomarker to rise. Per KDIGO: phosphate binders (sevelamer preferred), active vitamin D analogs, and calcimimetics suppress PTH without raising calcium."
  },
  {
    "id": 439,
    "categoryId": 4,
    "question": "Whipple's Triad is used to diagnose Insulinoma. It consists of:",
    "options": [
      "A) Hyperglycemia, Ketones, Acidosis",
      "B) Hypoglycemia symptoms, Low plasma glucose, Relief of symptoms with glucose",
      "C) Hypertension, Bradycardia, Sweating",
      "D) Polyuria, Polydipsia, Weight loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hypoglycemia symptoms, Low plasma glucose, Relief of symptoms with glucose).\n\nPATHOPHYSIOLOGY:\nWhipple's triad (Allen Whipple, 1938) establishes criteria for diagnosing hypoglycemia: (1) symptoms consistent with hypoglycemia (adrenergic: tremor, palpitations, diaphoresis, hunger; neuroglycopenic: confusion, visual changes, slurred speech, seizures, LOC), (2) documented low plasma glucose at time of symptoms (typically <55 mg/dL), and (3) symptom resolution upon glucose correction. This triad is essential because hypoglycemic symptoms are nonspecific, and establishing temporal concordance prevents misdiagnosis.\n\nCLINICAL REASONING:\nInsulinoma is the most common functional pancreatic NET (~1-4 per million/year), arising from beta cells that autonomously secrete insulin, producing fasting-predominant hyperinsulinemic hypoglycemia. Approximately 90% are solitary, benign, <2 cm, and curable by surgical enucleation; 5-10% are MEN 1-associated. The 72-hour supervised fast demonstrates Whipple's triad with endogenous hyperinsulinism: glucose <55 mg/dL, insulin \u22653 microIU/mL, C-peptide \u22650.6 ng/mL, proinsulin \u22655 pmol/L, and negative sulfonylurea/meglitinide screen. C-peptide is the critical differentiator: elevated with insulinoma (endogenous production) or sulfonylurea use; suppressed with exogenous insulin injection (which lacks C-peptide and suppresses endogenous secretion). Sulfonylurea drug screen distinguishes medication-induced from insulinoma.\n\nDIAGNOSIS AND TREATMENT:\nTumor localization uses pancreatic CT/MRI (~70-80% sensitivity) and endoscopic ultrasound (EUS, ~90-95% sensitivity with FNA). Selective arterial calcium stimulation with hepatic venous sampling localizes occult tumors. Surgical resection is curative in ~90%. Medical options for non-surgical candidates include diazoxide (inhibits insulin secretion via KATP channel opening), somatostatin analogs (octreotide), and everolimus (mTOR inhibitor, FDA-approved for pancreatic NETs).\n\nKEY POINTS:\nWhipple's triad (symptoms + low glucose + relief with correction) establishes hypoglycemia as the cause. C-peptide differentiates sources: elevated indicates endogenous (insulinoma or sulfonylurea), suppressed with high insulin indicates exogenous injection. Insulinomas are 90% solitary, 90% benign, 90% curable, with 5-10% MEN 1-associated."
  },
  {
    "id": 440,
    "categoryId": 4,
    "question": "Which medication is notorious for causing both Hypothyroidism and Hyperthyroidism due to its high Iodine content?",
    "options": [
      "A) Lisinopril",
      "B) Amiodarone",
      "C) Metformin",
      "D) Lithium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amiodarone).\n\nPATHOPHYSIOLOGY:\nAmiodarone causes thyroid dysfunction in ~15-20% of patients (per ATA) due to its remarkable iodine content: each 200 mg tablet contains ~75 mg organic iodine (37% molecular weight), releasing ~6-9 mg free iodine daily\u201420-40\u00d7 the recommended intake. Amiodarone also structurally resembles thyroid hormone and inhibits type 1/type 2 deiodinases, reducing T4-to-T3 conversion. This produces early changes in virtually all patients (elevated T4, reduced T3, transiently elevated TSH) that do not necessarily indicate disease and must be distinguished from true thyroid dysfunction.\n\nAMIODARONE-INDUCED HYPOTHYROIDISM:\nAIH occurs in ~5-15% of patients, more commonly in iodine-sufficient regions and with pre-existing autoimmunity. The massive iodine load inhibits hormone synthesis via the Wolff-Chaikoff effect. Normal glands escape through NIS downregulation, but glands with autoimmune thyroiditis fail to escape, producing sustained inhibition. Treatment: levothyroxine; amiodarone can generally continue.\n\nAMIODARONE-INDUCED THYROTOXICOSIS:\nAIT occurs in ~3-5% in iodine-sufficient regions (up to 10-12% in deficient regions). Two distinct types require different treatments:\n\nType 1 (Jod-Basedow): occurs with pre-existing thyroid pathology (Graves', nodular goiter). Iodine provides substrate for excess synthesis. Ultrasound shows increased Doppler vascularity. Treatment: thionamides (methimazole).\n\nType 2 (destructive thyroiditis): occurs in previously normal glands. Amiodarone cytotoxicity destroys follicular cells, releasing preformed hormone. Ultrasound shows absent Doppler vascularity. Treatment: glucocorticoids (prednisone 40-60 mg daily, tapered over 2-3 months).\n\nMixed forms are common, requiring combined therapy. Amiodarone's exceptionally long half-life (40-55 days) from lipophilic tissue distribution means dysfunction may persist months after discontinuation.\n\nKEY POINTS:\nAmiodarone causes thyroid dysfunction in 15-20% through massive iodine content and direct cytotoxicity. AIH results from failed Wolff-Chaikoff escape (treat with levothyroxine). AIT Type 1 is excess synthesis in pre-existing disease (thionamides); Type 2 is destructive thyroiditis in normal glands (glucocorticoids), distinguished by ultrasound Doppler."
  },
  {
    "id": 441,
    "categoryId": 4,
    "question": "The primary neurotransmitter of the Parasympathetic Nervous System (Rest and Digest) is:",
    "options": [
      "A) Norepinephrine",
      "B) Acetylcholine",
      "C) Glutamate",
      "D) Dopamine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acetylcholine).\n\nPATHOPHYSIOLOGY:\nAcetylcholine (ACh) is the primary neurotransmitter of the parasympathetic nervous system at both preganglionic and postganglionic synapses. This contrasts with the sympathetic system, which uses ACh at preganglionic synapses but norepinephrine at postganglionic junctions (except sympathetic cholinergic fibers to sweat glands and adrenal medulla). ACh acts through two receptor families: muscarinic receptors (G-protein-coupled, M1-M5) mediate postganglionic effects\u2014M2 decreases heart rate via Gi-mediated K+ channel opening, M3 causes bronchoconstriction, increases GI motility/secretion, promotes bladder contraction, and stimulates salivary/lacrimal/gastric acid secretion. Nicotinic receptors (ligand-gated ion channels) mediate transmission at all autonomic ganglia and the neuromuscular junction.\n\nCLINICAL REASONING:\nParasympathetic ACh effects are summarized by SLUDGE (Salivation, Lacrimation, Urination, Defecation, GI motility, Emesis)\u2014also the presentation of cholinergic excess (organophosphate poisoning). Anticholinergic medications produce opposite effects: tachycardia, mydriasis, dry mouth, urinary retention, constipation, decreased sweating, and CNS effects (confusion, agitation, hallucinations). Common offenders include antihistamines (diphenhydramine), TCAs, antipsychotics, overactive bladder drugs (oxybutynin), and antispasmodics. Elderly patients are especially susceptible due to reduced cholinergic tone, decreased drug clearance, and polypharmacy.\n\nCLINICAL APPLICATION:\nAnticholinergic burden is a recognized contributor to cognitive decline, falls, and hospitalization in elderly patients. The ACB scale and Beers Criteria (AGS) assess cumulative anticholinergic load; JAMA Internal Medicine linked higher exposure to increased dementia risk. Providers should assess anticholinergic burden during medication reconciliation, particularly for elderly patients with cognitive complaints, constipation, or falls. Important cholinergic drugs include cholinesterase inhibitors (donepezil, rivastigmine) for Alzheimer's, bethanechol for urinary retention, and pilocarpine for glaucoma/xerostomia. Organophosphate poisoning is treated with atropine (muscarinic antagonist) and pralidoxime (AChE reactivator, effective before irreversible enzyme aging).\n\nKEY POINTS:\nACh is the primary parasympathetic neurotransmitter at all postganglionic synapses, acting via muscarinic receptors (M2 bradycardia, M3 SLUDGE). Anticholinergic medications carry cumulative cognitive risk in elderly. Organophosphate crisis is treated with atropine and pralidoxime."
  },
  {
    "id": 442,
    "categoryId": 4,
    "question": "In Primary Adrenal Insufficiency (Addison's), the patient often has Hyperpigmentation. Why?",
    "options": [
      "A) Deposition of iron in the skin",
      "B) High ACTH levels co-secrete MSH (Melanocyte Stimulating Hormone)",
      "C) Jaundice",
      "D) Autoimmune destruction of melanocytes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (High ACTH levels co-secrete MSH / Melanocyte Stimulating Hormone).\n\nPATHOPHYSIOLOGY:\nHyperpigmentation in Addison's disease is explained by POMC biochemistry and HPA axis feedback. In primary adrenal insufficiency, adrenal cortex destruction (autoimmune adrenalitis ~80-90% in developed countries, followed by TB, histoplasmosis, hemorrhage, metastases) eliminates cortisol, removing negative feedback and causing ACTH to rise 10-100-fold. ACTH derives from POMC, cleaved by PC1 into ACTH, beta-lipotropin, and joining peptide. ACTH's first 13 amino acids contain the complete alpha-MSH sequence. At markedly elevated concentrations, ACTH activates MC1R on melanocytes via Gs-cAMP-CREB signaling, upregulating MITF and tyrosinase, increasing eumelanin production (per JCEM).\n\nCLINICAL PRESENTATION:\nPigmentation distribution is distinctive: sun-exposed skin, palmar creases (highly specific\u2014not from tanning), pressure points (knuckles, elbows, knees), friction areas (bra straps, waistband), areolae, buccal mucosa, and recent scars (pre-existing scars unchanged). This helps distinguish from hemochromatosis (bronze/slate-gray without mucosal involvement). Additional features include fatigue, weight loss, orthostatic hypotension, salt craving, hypoglycemia, and electrolyte abnormalities (hyponatremia, hyperkalemia, non-anion-gap metabolic acidosis from aldosterone deficiency).\n\nCLINICAL APPLICATION:\nCritical distinction: primary insufficiency has markedly elevated ACTH (causing hyperpigmentation), deficient aldosterone (hyperkalemia, sodium wasting), and low cortisol/DHEA-S. Secondary insufficiency has low/normal ACTH (no hyperpigmentation) and preserved aldosterone (RAAS-regulated, not ACTH-dependent). The cosyntropin stimulation test (250 mcg IV, cortisol at 30/60 min) is the standard diagnostic\u2014cortisol failing to exceed 18 mcg/dL indicates insufficiency. Primary requires both glucocorticoid replacement (hydrocortisone 15-25 mg daily in 2-3 divided doses, two-thirds AM) and mineralocorticoid replacement (fludrocortisone 0.05-0.2 mg daily). Secondary requires glucocorticoid only.\n\nKEY POINTS:\nHyperpigmentation in Addison's results from elevated ACTH (containing the MSH sequence) activating MC1R on melanocytes, distributed in palmar creases, buccal mucosa, and pressure points. Present in primary but absent in secondary insufficiency. Primary requires both glucocorticoid and mineralocorticoid replacement; secondary requires glucocorticoid only."
  },
  {
    "id": 443,
    "categoryId": 1,
    "question": "Somatostatin is the 'Universal Inhibitor'. It is secreted by the Hypothalamus and Pancreatic Delta cells to inhibit:",
    "options": [
      "A) Growth Hormone and Insulin/Glucagon",
      "B) Prolactin only",
      "C) Cortisol",
      "D) Aldosterone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Growth Hormone and Insulin/Glucagon).\n\nSOMATOSTATIN PHYSIOLOGY:\nSomatostatin (also called somatotropin release-inhibiting factor, SRIF) is a peptide hormone that acts as a universal inhibitory regulator throughout the body. It is produced by delta cells of the pancreatic islets, the hypothalamus (where it inhibits anterior pituitary growth hormone secretion), the gastrointestinal mucosa (D cells in the stomach and intestine), and neurons within the central nervous system. In the pancreatic islets, somatostatin is secreted in a paracrine fashion and inhibits both insulin secretion from beta cells and glucagon secretion from alpha cells, serving as a local brake on both glucose-lowering and glucose-raising hormones simultaneously.\n\nMECHANISM OF ACTION:\nSomatostatin binds to five G-protein-coupled receptor subtypes (SSTR1 through SSTR5) that inhibit adenylyl cyclase, reduce intracellular cAMP, activate potassium channels to hyperpolarize the cell membrane, and inhibit voltage-gated calcium channels, all of which suppress hormone secretion. Beyond the pancreas, somatostatin inhibits thyroid-stimulating hormone (TSH) release from the anterior pituitary, reduces gastric acid secretion, decreases splanchnic blood flow, and slows gastrointestinal motility and absorption.\n\nCLINICAL APPLICATIONS:\nThe synthetic somatostatin analogues octreotide and lanreotide exploit these inhibitory properties therapeutically. Octreotide is used to treat acromegaly (by suppressing growth hormone), carcinoid syndrome (by suppressing serotonin and other vasoactive peptides from neuroendocrine tumors), variceal bleeding (by reducing splanchnic blood flow and portal venous pressure), and refractory diarrhea. In acute variceal hemorrhage, octreotide is administered as an IV infusion alongside endoscopic band ligation as part of initial management.\n\nKEY POINTS:\nSomatostatin is the universal inhibitor produced by pancreatic delta cells, hypothalamus, and GI mucosa that suppresses growth hormone, insulin, and glucagon simultaneously. It acts via SSTR receptors to reduce cAMP and calcium-mediated secretion. Octreotide (synthetic analogue) is clinically used for acromegaly, carcinoid syndrome, and variceal bleeding."
  },
  {
    "id": 444,
    "categoryId": 1,
    "question": "In a 'Right Dominant' heart (85% of population), the Posterior Descending Artery (PDA) which supplies the AV Node arises from the:",
    "options": [
      "A) Left Circumflex Artery",
      "B) Right Coronary Artery (RCA)",
      "C) Left Anterior Descending (LAD)",
      "D) Coronary Sinus"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Right Coronary Artery).\n\nPATHOPHYSIOLOGY:\nCoronary dominance is determined by which artery gives rise to the posterior descending artery (PDA), which runs in the posterior interventricular groove and supplies the inferior wall of the heart and the posterior third of the interventricular septum. In approximately 85% of the population, the right coronary artery (RCA) gives rise to the PDA, defining a right-dominant circulation. In approximately 8% of individuals, the left circumflex artery gives rise to the PDA (left-dominant), and in 7% both arteries contribute (codominant).\n\nCLINICAL SIGNIFICANCE:\nThe RCA in a right-dominant heart supplies the sinoatrial (SA) node in approximately 60% of people and the atrioventricular (AV) node in approximately 90% via the AV nodal branch, which arises near the PDA origin at the crux of the heart. This is why inferior MIs (RCA territory) are frequently complicated by sinus bradycardia and AV conduction blocks (first-degree, second-degree Mobitz I/Wenckebach, or complete heart block). The left anterior descending (LAD) artery supplies the anterior wall, anterior septum, and apex, and is called the \"widow-maker\" because proximal LAD occlusion produces a large anterior MI with high mortality.\n\nKEY POINTS:\nIn 85% of the population (right-dominant circulation), the PDA arises from the RCA and supplies the inferior wall and AV node. Inferior MI from RCA occlusion commonly causes bradyarrhythmias and AV block because the RCA supplies the AV node in 90% of people. Left dominance (PDA from left circumflex) occurs in approximately 8% of individuals."
  },
  {
    "id": 445,
    "categoryId": 1,
    "question": "The earliest visible lesion of atherosclerosis, often seen even in children, is the:",
    "options": [
      "A) Fibrous Cap",
      "B) Fatty Streak",
      "C) Calcified Plaque",
      "D) Thrombus"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/atherosclerosis-progression.png", "alt": "Atherosclerosis: normal artery vs plaque, progression from formation to rupture and blood clot", "caption": "Atherosclerosis: normal artery compared with plaque; progression from formation to growth/rupture and blood clot (Cleveland Clinic ©2024)." }
    ],
    "explanation": "CORRECT: B (Fatty Streak).\n\nPATHOPHYSIOLOGY:\nThe fatty streak is the earliest visible lesion of atherosclerosis and can be found in the aorta of children as young as age 3 and in coronary arteries by adolescence. Fatty streaks are flat or slightly elevated yellow discolorations on the intimal surface of arteries, composed of lipid-laden macrophages (foam cells) and T lymphocytes that have accumulated beneath the endothelium. The process begins when circulating LDL particles infiltrate the arterial intima and become trapped in the extracellular matrix, where they undergo oxidative modification by reactive oxygen species.\n\nPROGRESSION OF ATHEROSCLEROSIS:\nOxidized LDL is recognized by scavenger receptors (SR-A, CD36) on macrophages, which internalize the lipid in an unregulated fashion (unlike the tightly regulated LDL receptor), transforming them into lipid-engorged foam cells. These foam cells, along with recruited T lymphocytes, constitute the fatty streak. Over years to decades, continued lipid accumulation, smooth muscle cell migration from the media, extracellular matrix deposition, and necrotic core formation transform the fatty streak into a mature atherosclerotic plaque with a fibrous cap. Not all fatty streaks progress to clinically significant plaques, and the factors determining which fatty streaks advance remain an active area of research.\n\nKEY POINTS:\nThe fatty streak is the earliest visible atherosclerotic lesion, composed of subendothelial foam cells (lipid-laden macrophages) and visible in children as young as age 3. It forms when LDL infiltrates the intima, undergoes oxidation, and is engulfed by macrophages via unregulated scavenger receptors. Over decades, fatty streaks can progress to mature plaques with fibrous caps and necrotic lipid cores."
  },
  {
    "id": 446,
    "categoryId": 1,
    "question": "Leriche Syndrome is caused by atherosclerotic occlusion of the distal aorta/iliac arteries. The classic triad of symptoms is:",
    "options": [
      "A) Calf pain, Edema, Varicose veins",
      "B) Buttock/Thigh Claudication, Erectile Dysfunction, Absent Femoral Pulses",
      "C) Arm pain, Syncope, Vertigo",
      "D) Abdominal pain, Bloody stool, Weight loss"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Buttock/Thigh Claudication, Erectile Dysfunction, Absent Femoral Pulses).\n\nPATHOPHYSIOLOGY:\nLeriche syndrome (aortoiliac occlusive disease) results from atherosclerotic occlusion of the distal abdominal aorta and/or bilateral common iliac arteries, obstructing blood flow to the lower extremities and pelvis. The classic triad, first described by French surgeon René Leriche in 1940, consists of bilateral buttock and thigh claudication (intermittent pain with walking due to ischemia of the gluteal and thigh muscles), erectile dysfunction (from inadequate blood flow through the internal iliac arteries to the penile vasculature), and absent or diminished femoral pulses bilaterally.\n\nCLINICAL PRESENTATION:\nPatients are typically middle-aged male smokers who present with exercise-limiting claudication involving the buttocks, hips, and thighs (more proximal than the calf claudication seen with femoral or popliteal disease). Erectile dysfunction may precede claudication symptoms by months to years and is often the earliest clinical manifestation because the internal iliac circulation is highly sensitive to proximal aortoiliac disease. Physical examination reveals absent or markedly diminished femoral pulses bilaterally and cool lower extremities.\n\nDIAGNOSIS AND TREATMENT:\nCT angiography or MR angiography confirms the diagnosis and defines the extent of disease. Treatment depends on severity: lifestyle modification and supervised exercise for mild symptoms, endovascular therapy (aortoiliac stenting) for moderate disease, and aortobifemoral bypass grafting (the gold standard for durable revascularization) for extensive or severe occlusive disease.\n\nKEY POINTS:\nLeriche syndrome is the classic triad of bilateral buttock/thigh claudication, erectile dysfunction, and absent femoral pulses from aortoiliac atherosclerotic occlusion. Erectile dysfunction may be the earliest symptom. Aortobifemoral bypass is the gold standard surgical treatment for extensive disease."
  },
  {
    "id": 447,
    "categoryId": 1,
    "question": "Most Acute Coronary Syndromes (Heart Attacks) are caused by:",
    "options": [
      "A) Slow, progressive narrowing of the artery to 100%",
      "B) Rupture of a 'Vulnerable Plaque' (Thin fibrous cap, large lipid core)",
      "C) Embolism from the lungs",
      "D) Vasospasm"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/heart-attack-myocardial-infarction.png", "alt": "Heart attack (myocardial infarction): plaque, blood clot, and dying heart muscle", "caption": "Heart attack: plaque rupture, thrombus, and lack of blood flow leading to myocardial infarction (Cleveland Clinic ©2025)." }
    ],
    "explanation": "CORRECT: B (Rupture of a Vulnerable Plaque).\n\nPATHOPHYSIOLOGY:\nThe majority of acute coronary syndromes (approximately 60 to 75%) result from rupture of a \"vulnerable\" (unstable) atherosclerotic plaque rather than from progressive luminal narrowing. The vulnerable plaque involves a thin fibrous cap (less than 65 micrometers), a large necrotic lipid core (occupying more than 40% of the plaque volume), abundant inflammatory macrophages that secrete matrix metalloproteinases (MMPs) degrading the structural collagen of the cap, and reduced smooth muscle cell density (fewer cells producing and maintaining the collagen matrix).\n\nMECHANISM OF RUPTURE:\nWhen the fibrous cap ruptures, the highly thrombogenic lipid core and tissue factor are exposed to circulating blood, triggering the coagulation cascade and platelet aggregation, forming an occlusive or sub-occlusive thrombus. Complete thrombotic occlusion produces STEMI, while partial occlusion or distal embolization produces NSTEMI or unstable angina. vulnerable plaques often cause only mild to moderate stenosis (less than 50% luminal narrowing) prior to rupture, which is why many patients experience MI as their first cardiovascular event without prior anginal symptoms, and why angiographic stenosis severity is a poor predictor of which lesions will cause future events.\n\nCLINICAL IMPLICATION:\nThis pathophysiology underlies the rationale for statin therapy and systemic risk reduction rather than relying solely on revascularization of stenotic lesions. Statins stabilize plaques by increasing fibrous cap thickness, reducing lipid core size, decreasing macrophage infiltration, and lowering MMP activity.\n\nKEY POINTS:\nMost acute coronary syndromes result from rupture of vulnerable plaques (thin fibrous cap, large lipid core, abundant macrophages), not from gradual stenotic progression. Vulnerable plaques often cause only mild stenosis before rupture, explaining why MI frequently occurs without prior symptoms. Statins stabilize plaques by thickening the fibrous cap and reducing inflammation."
  },
  {
    "id": 448,
    "categoryId": 1,
    "question": "The 'Circle of Willis' provides collateral blood flow to the brain. Which artery connects the Anterior circulation (Carotids) to the Posterior circulation (Vertebrobasilar)?",
    "questionImages": [
      { "src": "assets/circle-of-willis.png", "alt": "Circle of Willis anatomy, bottom view of brain", "caption": "Circle of Willis: arterial anastomotic ring at the base of the brain (Cleveland Clinic ©2024)." }
    ],
    "options": [
      "A) Anterior Communicating Artery (AComm)",
      "B) Posterior Communicating Artery (PComm)",
      "C) Middle Cerebral Artery (MCA)",
      "D) Basilar Artery"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Posterior Communicating Artery).\n\nANATOMY:\nThe Circle of Willis is an arterial anastomotic ring at the base of the brain that connects the anterior circulation (supplied by the internal carotid arteries) to the posterior circulation (supplied by the vertebral/basilar arteries), providing collateral blood flow that can compensate for occlusion of a major feeding vessel. The posterior communicating artery (PComm) is the critical link between these two systems, connecting the internal carotid artery (or its terminal branch, the middle cerebral artery) to the posterior cerebral artery (the terminal branch of the basilar artery) on each side.\n\nCOMPLETE CIRCLE COMPONENTS:\nThe complete Circle of Willis consists of the anterior communicating artery (AComm, connecting the two anterior cerebral arteries across the midline), both anterior cerebral arteries (A1 segments), both internal carotid artery terminations, both posterior communicating arteries (PComms, connecting anterior to posterior circulation), and both posterior cerebral arteries (P1 segments). The AComm connects right to left (anterior to anterior), while the PComm connects anterior to posterior.\n\nCLINICAL SIGNIFICANCE:\nA complete and functional Circle of Willis is present in only approximately 25 to 50% of the population, with the remainder having hypoplastic or absent segments (most commonly a hypoplastic PComm or A1 segment). Posterior communicating artery aneurysms are a common cause of cranial nerve III (oculomotor) palsy because the PComm runs adjacent to CN III, and an expanding aneurysm compresses the parasympathetic fibers on the outside of the nerve, producing a classic \"down and out\" pupil with mydriasis (dilated, fixed pupil).\n\nKEY POINTS:\nThe posterior communicating artery (PComm) connects the anterior circulation (carotid) to the posterior circulation (vertebrobasilar), providing critical collateral flow. The AComm connects right and left anterior circulations. PComm aneurysms classically cause CN III palsy with a dilated fixed pupil due to anatomic proximity."
  },
  {
    "id": 449,
    "categoryId": 1,
    "question": "An Aortic Dissection typically begins with a tear in which layer of the vessel wall?",
    "options": [
      "A) Tunica Externa (Adventitia)",
      "B) Tunica Media",
      "C) Tunica Intima",
      "D) Vasa Vasorum"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Tunica Intima).\n\nPATHOPHYSIOLOGY:\nAortic dissection begins with a tear in the tunica intima, the innermost layer of the arterial wall. This intimal tear allows high-pressure blood from the aortic lumen to enter the tunica media (the muscular/elastic middle layer), where it propagates along the plane of the medial layer, creating a false lumen that separates the intima from the adventitia. The dissection can propagate both anterograde (distally) and retrograde (proximally) from the initial tear site.\n\nPREDISPOSING FACTORS:\nWhile the tear begins in the intima, the underlying pathology is typically cystic medial degeneration (also called cystic medial necrosis), characterized by loss of smooth muscle cells, fragmentation of elastic fibers, and accumulation of mucoid material in the tunica media that weakens its structural integrity. Conditions associated with medial degeneration include chronic hypertension (the most common risk factor, present in 70% of cases), connective tissue disorders (Marfan syndrome with fibrillin-1 deficiency, Ehlers-Danlos type IV with type III collagen deficiency), bicuspid aortic valve, Turner syndrome, pregnancy (third trimester), cocaine and amphetamine use, and iatrogenic causes (cardiac surgery, catheterization).\n\nVESSEL WALL LAYERS:\nThe three layers of arterial walls from innermost to outermost are the tunica intima (endothelial cells and subendothelial connective tissue, separated from the media by the internal elastic lamina), the tunica media (smooth muscle cells, elastin, and collagen, which provides structural strength and elasticity), and the tunica adventitia (connective tissue with vasa vasorum, nervi vasorum, and lymphatics). The vasa vasorum are small blood vessels that supply the outer portion of the media and adventitia of large vessels.\n\nKEY POINTS:\nAortic dissection begins with a tear in the tunica intima that allows blood to enter and dissect along the tunica media. The underlying pathology is cystic medial degeneration (elastic fiber fragmentation and smooth muscle loss). Chronic hypertension is the most common predisposing factor (70% of cases), while connective tissue disorders (Marfan, Ehlers-Danlos IV) cause dissection in younger patients."
  },
  {
    "id": 450,
    "categoryId": 1,
    "question": "A patient complains of dizziness and arm pain when exercising his left arm. BP is 140/80 in the Right arm and 100/60 in the Left. Diagnosis?",
    "options": [
      "A) Aortic Stenosis",
      "B) Subclavian Steal Syndrome",
      "C) Thoracic Outlet Syndrome",
      "D) Raynaud's Phenomenon"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Subclavian Steal Syndrome).\n\nPATHOPHYSIOLOGY:\nSubclavian steal syndrome occurs when a hemodynamically significant stenosis or occlusion of the proximal subclavian artery (proximal to the vertebral artery origin) causes reversal of blood flow in the ipsilateral vertebral artery. Normally, blood flows anterograde through the vertebral artery toward the brain. When the proximal subclavian is severely stenosed, the distal subclavian pressure drops below vertebrobasilar pressure, and blood is \"stolen\" from the posterior cerebral circulation by flowing retrograde down the vertebral artery to supply the ipsilateral arm. During arm exercise, increased metabolic demand in the arm muscles further lowers distal subclavian pressure, exacerbating the vertebrobasilar steal and provoking symptoms.\n\nCLINICAL PRESENTATION:\nThe hallmark is a greater than 15 to 20 mmHg blood pressure differential between the arms (lower on the affected side) combined with vertebrobasilar insufficiency symptoms (dizziness, vertigo, visual disturbances, syncope) and ipsilateral arm claudication provoked by arm exercise. Here, the left arm BP (100/60) is significantly lower than the right (140/80), indicating left subclavian stenosis. Subclavian steal is more common on the left side because the left subclavian artery arises directly from the aortic arch (longer course, more susceptible to atherosclerosis) while the right subclavian branches from the brachiocephalic trunk.\n\nDIAGNOSIS AND TREATMENT:\nDuplex ultrasonography of the vertebral arteries demonstrating retrograde flow is the initial diagnostic study, with CTA or MRA confirming the subclavian stenosis. Symptomatic patients may require endovascular stenting or surgical bypass (carotid-subclavian bypass).\n\nKEY POINTS:\nSubclavian steal syndrome results from proximal subclavian stenosis causing retrograde vertebral artery flow that steals blood from the posterior cerebral circulation to supply the arm. The hallmark is arm BP differential greater than 15 to 20 mmHg with vertebrobasilar symptoms (dizziness, vertigo) provoked by arm exercise. It is more common on the left side due to the longer anatomic course of the left subclavian artery."
  },
  {
    "id": 451,
    "categoryId": 1,
    "question": "The primary cell type responsible for synthesizing the collagen 'Fibrous Cap' that stabilizes an atherosclerotic plaque is:",
    "options": [
      "A) Macrophage",
      "B) Vascular Smooth Muscle Cell",
      "C) Endothelial Cell",
      "D) T-Lymphocyte"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Smooth Muscle Cells).\n\nPLAQUE STABILITY:\nThe stability of an atherosclerotic plaque depends critically on the thickness and integrity of its fibrous cap. A thick, collagen-rich cap protects against plaque rupture, while a thin cap with a large underlying lipid-necrotic core is vulnerable to mechanical stress and inflammatory degradation. Vascular smooth muscle cells (VSMCs) are the primary cell type responsible for synthesizing the extracellular matrix components of the fibrous cap, including type I and type III collagen, elastin, and proteoglycans.\n\nPATHOPHYSIOLOGY:\nIn response to vascular injury and atherogenic stimuli, VSMCs undergo phenotypic switching from a contractile (quiescent) phenotype to a synthetic (proliferative) phenotype. Synthetic VSMCs migrate from the tunica media into the intima, where they proliferate and secrete collagen and other matrix proteins that form and maintain the fibrous cap. Transforming growth factor-beta (TGF-beta) and platelet-derived growth factor (PDGF) are key cytokines that stimulate VSMC migration, proliferation, and collagen production.\n\nPLAQUE VULNERABILITY:\nThe balance between collagen synthesis by VSMCs and collagen degradation by matrix metalloproteinases (MMPs) secreted by activated macrophages determines cap thickness and plaque stability. In vulnerable (unstable) plaques, inflammatory macrophages release MMP-1, MMP-2, MMP-9, and cathepsins that degrade collagen faster than VSMCs can replace it, leading to progressive cap thinning. Additionally, inflammatory cytokines (interferon-gamma from T-helper cells) directly inhibit VSMC collagen synthesis and promote VSMC apoptosis, further weakening the cap. When the thinned cap ruptures, the thrombogenic lipid core is exposed to flowing blood, triggering acute thrombus formation and acute coronary syndrome.\n\nKEY POINTS:\nSmooth muscle cells are the primary source of fibrous cap collagen through phenotypic switching from contractile to synthetic state. Plaque vulnerability results from imbalance between VSMC collagen synthesis and MMP-mediated degradation by inflammatory macrophages. Interferon-gamma from T cells inhibits VSMC collagen production and promotes apoptosis, further weakening the cap."
  },
  {
    "id": 452,
    "categoryId": 1,
    "question": "The Superior Mesenteric Artery (SMA) supplies the midgut. It passes OVER which structure, potentially compressing it (SMA Syndrome)?",
    "questionImages": [
      { "src": "assets/sma-syndrome.png", "alt": "SMA anatomy: SMA passing over duodenum and left renal vein", "caption": "SMA passing over the third part of the duodenum and left renal vein (SMA syndrome anatomy)." }
    ],
    "questionImageBelow": true,
    "options": [
      "A) The Stomach",
      "B) The 3rd portion of the Duodenum",
      "C) The Transverse Colon",
      "D) The Aorta"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The 3rd portion of the Duodenum).\n\nEMBRYOLOGIC BASIS:\nThe superior mesenteric artery (SMA) supplies structures derived from the embryonic midgut, which extends from the second part of the duodenum (distal to the ampulla of Vater) through the proximal two-thirds of the transverse colon. This territory includes the jejunum, ileum, cecum, appendix, ascending colon, and the proximal transverse colon. The SMA arises from the anterior surface of the abdominal aorta at approximately the L1 vertebral level, just below the celiac trunk, and passes anterior to (over) the third part of the duodenum and the uncinate process of the pancreas.\n\nSMA SYNDROME:\nThe anatomic relationship of the SMA passing over the duodenum is clinically significant because compression of the third part of the duodenum between the SMA anteriorly and the aorta posteriorly causes SMA syndrome (Wilkie syndrome), characterized by postprandial epigastric pain, nausea, bilious vomiting, and weight loss. This occurs when the aortomesenteric angle narrows below 22 to 25 degrees (normal 38 to 65 degrees) or the aortomesenteric distance decreases below 8 mm, most commonly following significant weight loss, spinal surgery with correction of lordosis, or prolonged immobilization.\n\nMESENTERIC ISCHEMIA:\nAcute SMA occlusion (from embolism or thrombosis) produces acute mesenteric ischemia, a surgical emergency with mortality exceeding 60 to 80% if not recognized and treated within 6 to 12 hours. The classic presentation is severe periumbilical abdominal pain that is disproportionate to physical examination findings (pain out of proportion to exam), often accompanied by bloody diarrhea as mucosal ischemia progresses to full-thickness bowel infarction.\n\nKEY POINTS:\nThe SMA supplies midgut-derived structures from the duodenum (distal to ampulla) through the proximal two-thirds of the transverse colon. It passes over the third part of the duodenum, and narrowing of the aortomesenteric angle causes SMA syndrome. Acute SMA occlusion produces mesenteric ischemia with pain out of proportion to exam findings, a surgical emergency with high mortality."
  },
  {
    "id": 453,
    "categoryId": 1,
    "question": "Chronic Venous Insufficiency causes 'Stasis Dermatitis' and ulcers. The underlying pathophysiology is:",
    "questionImages": [
      { "src": "assets/stasis-dermatitis.png", "alt": "Stasis dermatitis on lower leg", "caption": "Stasis dermatitis: erythema, scaling, and hyperpigmentation (DermNet)." }
    ],
    "options": [
      "A) Arterial blockage",
      "B) Incompetent valves leading to venous hypertension",
      "C) Bacterial infection",
      "D) Lymphatic blockage"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/venous-ulcer.png", "alt": "Venous ulcers on lower leg", "caption": "Venous ulcers in chronic venous insufficiency (DermNet)." }
    ],
    "explanation": "CORRECT: B (Incompetent Valves Leading to Venous Hypertension).\n\nPATHOPHYSIOLOGY:\nChronic venous insufficiency (CVI) results from incompetence of the venous valves in the lower extremity veins (superficial, deep, or perforating veins), which allows retrograde blood flow (reflux) during standing and walking. Normally, the one-way venous valves and the calf muscle pump work together to propel blood from the lower extremities back to the heart against gravity. When valves become incompetent (from prior deep vein thrombosis destroying valve leaflets, primary valve degeneration, or chronic venous dilation), blood refluxes distally, causing sustained venous hypertension in the lower leg.\n\nSTASIS DERMATITIS AND ULCER FORMATION:\nThe sustained venous hypertension transmits abnormally high pressures to the dermal microcirculation, causing capillary distension, increased permeability, extravasation of red blood cells and proteins into the perivascular tissues, and a chronic inflammatory response. Hemosiderin deposition from extravasated red cell breakdown produces the characteristic brown discoloration of the medial ankle (hemosiderin staining or brawny edema). Lipodermatosclerosis (fibrotic induration of the subcutaneous tissue producing an \"inverted champagne bottle\" leg shape) and venous stasis ulcers (typically located at the medial malleolus, shallow, irregular, with moderate exudate, and relatively painless compared to arterial ulcers) develop from the chronic inflammation and impaired tissue oxygenation.\n\nCLINICAL CLASSIFICATION:\nThe CEAP (Clinical-Etiology-Anatomy-Pathophysiology) classification stages CVI from C0 (no visible disease) through C6 (active ulceration). Management includes compression therapy (the cornerstone treatment, typically 30 to 40 mmHg graduated compression stockings), leg elevation, wound care for ulcers, and endovenous ablation or vein stripping for refractory cases.\n\nKEY POINTS:\nChronic venous insufficiency results from venous valve incompetence causing reflux and sustained venous hypertension in the lower leg. Hemosiderin deposition, lipodermatosclerosis, and medial malleolar ulcers develop from chronic microcirculatory inflammation. Compression therapy (30 to 40 mmHg) is the main treatment."
  },
  {
    "id": 454,
    "categoryId": 1,
    "question": "Abdominal Aortic Aneurysms (AAA) are defined as a dilation > 3.0 cm. At what size is surgical repair typically recommended (in men)?",
    "options": [
      "A) 3.5 cm",
      "B) 4.0 cm",
      "C) 5.5 cm",
      "D) 7.0 cm"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (5.5 cm diameter).\n\nAAA NATURAL HISTORY:\nAbdominal aortic aneurysms are defined as focal dilation of the infrarenal aorta to 3.0 cm or greater (normal diameter approximately 2.0 cm). The risk of rupture increases exponentially with aneurysm diameter, and the decision to pursue elective surgical repair balances rupture risk against operative morbidity and mortality. For men, the generally accepted threshold for elective repair is 5.5 cm, at which point the annual rupture risk (approximately 5 to 10%) exceeds the operative mortality risk (approximately 1 to 5% for open repair, 0.5 to 2% for endovascular repair). For women, repair is typically recommended at 5.0 cm because of a higher rupture rate at any given diameter compared to men.\n\nRUPTURE RISK BY DIAMETER:\nAneurysms smaller than 4.0 cm carry an annual rupture risk of less than 0.5%, while those between 4.0 and 4.9 cm rupture at approximately 0.5 to 1% per year, and those between 5.0 and 5.9 cm rupture at approximately 5 to 10% per year. Aneurysms 6.0 cm or larger carry an annual rupture risk of 10 to 20% or higher. Rapid expansion (greater than 0.5 cm in 6 months or greater than 1.0 cm per year) is also an indication for repair regardless of absolute diameter.\n\nSURVEILLANCE AND REPAIR:\nSmall aneurysms (3.0 to 5.4 cm) are managed with surveillance ultrasound at intervals determined by size: every 3 years for 3.0 to 3.9 cm, annually for 4.0 to 4.9 cm, and every 6 months for 5.0 to 5.4 cm. Endovascular aneurysm repair (EVAR) is preferred over open surgical repair when anatomy is suitable, offering lower perioperative mortality but requiring ongoing surveillance for endoleak. All patients should receive aggressive cardiovascular risk factor modification including smoking cessation, statin therapy, and blood pressure control.\n\nKEY POINTS:\nElective AAA repair is indicated at 5.5 cm in men and 5.0 cm in women, where annual rupture risk (5 to 10%) exceeds surgical mortality. Rapid expansion (greater than 0.5 cm in 6 months) also warrants repair. EVAR is preferred when anatomically suitable, and smaller aneurysms are managed with size-based surveillance intervals."
  },
  {
    "id": 455,
    "categoryId": 1,
    "question": "A patient has a carotid bruit. Ultrasound shows 80% stenosis of the Internal Carotid. He is asymptomatic. According to the CREST trial and guidelines, management is:",
    "options": [
      "A) Immediate Endarterectomy (CEA)",
      "B) Aggressive Medical Management (Statin/Antiplatelet/BP control) vs CEA",
      "C) Observation only",
      "D) Anticoagulation (Warfarin)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Medical management with antiplatelet therapy; surgery/stenting for symptomatic stenosis).\n\nASYMPTOMATIC CAROTID STENOSIS:\nThe management of asymptomatic carotid stenosis has evolved significantly as modern medical therapy has improved. Current evidence supports optimal medical management (antiplatelet therapy, high-intensity statin, blood pressure control, smoking cessation, and diabetes management) as the primary approach for most patients with asymptomatic carotid stenosis, even at high grades of narrowing. The annual stroke risk with modern best medical therapy for asymptomatic stenosis of 60 to 99% is now estimated at approximately 0.5 to 1% per year, which is substantially lower than the 2% annual rate observed in the landmark ACAS and ACST trials that originally supported prophylactic revascularization.\n\nSYMPTOMATIC STENOSIS:\nIn contrast, symptomatic carotid stenosis (defined as stenosis causing ipsilateral TIA or non-disabling stroke within the preceding 6 months) carries a much higher stroke recurrence risk and benefits from revascularization. The NASCET trial demonstrated that carotid endarterectomy (CEA) reduced the 2-year stroke risk from 26% to 9% in patients with symptomatic stenosis of 70 to 99%. The CREST trial showed similar outcomes between CEA and carotid artery stenting (CAS), though CEA had lower stroke rates and CAS had lower MI rates, with the combined primary endpoint being equivalent.\n\nCLINICAL DECISION-MAKING:\nFor selected asymptomatic patients with high-grade stenosis (70% or greater) and high-risk imaging features (echolucent plaque, silent infarcts on MRI, microemboli on transcranial Doppler), revascularization may still be considered if perioperative risk is low (less than 3% combined stroke and death rate). Patient life expectancy should exceed 3 to 5 years to derive benefit from prophylactic intervention.\n\nKEY POINTS:\nAsymptomatic carotid stenosis is primarily managed with optimized medical therapy (antiplatelet, statin, BP control), as modern medical management reduces annual stroke risk to approximately 0.5 to 1%. Symptomatic stenosis (TIA or stroke within 6 months) benefits from revascularization (CEA or CAS). Select asymptomatic patients with high-risk features may benefit from intervention if perioperative risk is low."
  },
  {
    "id": 456,
    "categoryId": 1,
    "question": "Which vein is commonly harvested for CABG (Bypass) surgery?",
    "options": [
      "A) Femoral Vein",
      "B) Great Saphenous Vein",
      "C) Cephalic Vein",
      "D) Jugular Vein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Great Saphenous Vein).\n\nANATOMY:\nThe great saphenous vein (GSV) is the longest vein in the body, originating at the dorsal venous arch of the foot, coursing anterior to the medial malleolus, ascending along the medial aspect of the leg and thigh, and draining into the femoral vein at the saphenofemoral junction in the groin (approximately 4 cm below and lateral to the pubic tubercle). It is the most commonly harvested venous conduit for coronary artery bypass grafting (CABG) because of its length (allowing multiple grafts from a single harvest), caliber (appropriate size match for coronary arteries), accessibility (superficial location along the medial leg), and expendability (the deep venous system provides adequate lower extremity drainage after harvest).\n\nSAPHENOUS VEIN VERSUS ARTERIAL GRAFTS:\nWhile the GSV is the most commonly used venous conduit, the left internal mammary artery (LIMA, also called the left internal thoracic artery or LITA) is the gold standard arterial graft due to its superior long-term patency. The LIMA-to-LAD graft has a 10-year patency rate exceeding 90%, compared to approximately 50 to 60% for saphenous vein grafts at 10 years. Vein grafts are susceptible to neointimal hyperplasia and accelerated atherosclerosis because veins are not accustomed to arterial pressures and undergo adaptive wall thickening and endothelial damage. The radial artery is increasingly used as a second arterial conduit.\n\nKEY POINTS:\nThe great saphenous vein is the most commonly harvested venous conduit for CABG due to its length, caliber, and expendability. However, the LIMA-to-LAD arterial graft has superior long-term patency (>90% at 10 years versus 50 to 60% for vein grafts). Vein graft failure results from neointimal hyperplasia and accelerated atherosclerosis from exposure to arterial pressure."
  },
  {
    "id": 457,
    "categoryId": 1,
    "question": "The Ankle-Brachial Index (ABI) is the ratio of ankle SBP to arm SBP. A value of 0.60 indicates:",
    "options": [
      "A) Normal",
      "B) Mild PAD",
      "C) Moderate PAD",
      "D) Critical Limb Ischemia"
    ],
    "correctAnswer": 2,
    "explanationImages": [
      { "src": "assets/pad-illustration.png", "alt": "Peripheral artery disease—narrow and blocked artery", "caption": "PAD: plaque narrowing and blocking arterial flow (Cleveland Clinic 2025)." }
    ],
    "explanation": "CORRECT: C (Moderate PAD).\n\nCLINICAL REASONING:\nThe ankle-brachial index (ABI) is the ratio of the highest systolic blood pressure at the ankle (measured at the dorsalis pedis and posterior tibial arteries) to the highest systolic blood pressure in the arms (brachial arteries), providing a simple, noninvasive measure of lower extremity arterial perfusion. Normal ABI is 1.0 to 1.4. The severity of peripheral arterial disease is classified by ABI as follows: borderline (0.91 to 0.99), mild PAD (0.70 to 0.90), moderate PAD (0.40 to 0.69), and severe PAD/critical limb ischemia (less than 0.40). An ABI of 0.60 therefore falls within the moderate PAD category.\n\nPATHOPHYSIOLOGY:\nPeripheral arterial disease results from atherosclerotic narrowing or occlusion of the arteries supplying the lower extremities, most commonly affecting the superficial femoral artery at the adductor hiatus (Hunter canal). Patients with moderate PAD typically experience intermittent claudication (reproducible calf, thigh, or buttock pain with walking that resolves with rest) at shorter walking distances. As disease progresses to severe PAD (ABI less than 0.40), ischemic rest pain and tissue loss (non-healing ulcers, gangrene) develop.\n\nIMPORTANT CAVEATS:\nABI greater than 1.4 is abnormally elevated and indicates non-compressible calcified arteries (commonly seen in diabetes and end-stage renal disease with medial arterial calcification), which renders the ABI unreliable. In these patients, toe-brachial index (TBI, normal greater than 0.7) is used instead because the digital arteries are less susceptible to calcification.\n\nKEY POINTS:\nAn ABI of 0.60 indicates moderate PAD (normal 1.0 to 1.4, mild 0.70 to 0.90, moderate 0.40 to 0.69, severe/CLI less than 0.40). The superficial femoral artery at the adductor hiatus is the most common site of PAD. ABI greater than 1.4 indicates non-compressible calcified arteries (diabetes, ESRD), requiring toe-brachial index instead."
  },
  {
    "id": 458,
    "categoryId": 1,
    "question": "Fibromuscular Dysplasia (FMD) is a non-atherosclerotic cause of Renal Artery Stenosis. It typically affects:",
    "options": [
      "A) Elderly men",
      "B) Young females",
      "C) Diabetics",
      "D) Smokers"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/fibromuscular-dysplasia-renal-artery.png", "alt": "Fibromuscular dysplasia of renal artery—string of beads, stenosis", "caption": "FMD of renal artery: string of beads, thickened walls, stenosis (Mayo Foundation)." }
    ],
    "explanation": "CORRECT: B (Young Females).\n\nPATHOPHYSIOLOGY:\nFibromuscular dysplasia (FMD) is a non-atherosclerotic, non-inflammatory vascular disease that causes abnormal cell growth in the arterial wall, most commonly affecting the renal arteries (60 to 75% of cases) and the extracranial carotid and vertebral arteries (25 to 30%). FMD predominantly affects women (female-to-male ratio of approximately 9:1) and typically presents between the ages of 15 and 50, in sharp contrast to atherosclerotic renal artery stenosis which affects older patients with traditional cardiovascular risk factors.\n\nANGIOGRAPHIC AND PATHOLOGIC CLASSIFICATION:\nThe most common subtype is medial fibroplasia (approximately 80 to 90% of FMD cases), which produces the classic \"string of beads\" appearance on angiography due to alternating areas of stenosis and post-stenotic dilation in the arterial wall. Less common subtypes include intimal fibroplasia and perimedial fibroplasia. FMD characteristically involves the mid and distal portions of the renal artery (in contrast to atherosclerotic disease, which involves the ostium and proximal renal artery).\n\nCLINICAL PRESENTATION AND MANAGEMENT:\nRenal artery FMD presents with secondary hypertension (often severe or refractory) in a young woman without traditional cardiovascular risk factors. Duplex ultrasonography is the initial screening study, with CTA or MRA for definitive imaging. Percutaneous transluminal angioplasty (PTA) without stenting is the treatment of choice for symptomatic renal FMD, with high technical success rates and durable results (unlike atherosclerotic renal artery stenosis, where angioplasty results are less favorable).\n\nKEY POINTS:\nFibromuscular dysplasia predominantly affects young women (9:1 female-to-male ratio) and involves the mid-to-distal renal artery (unlike atherosclerosis, which is ostial/proximal). The classic angiographic finding is a string of beads appearance from medial fibroplasia. Percutaneous angioplasty without stenting is the treatment of choice with excellent outcomes."
  },
  {
    "id": 459,
    "categoryId": 1,
    "question": "Elevated High-Sensitivity C-Reactive Protein (hs-CRP) predicts coronary events because:",
    "options": [
      "A) CRP causes clots directly",
      "B) CRP reflects systemic inflammation, which drives plaque instability",
      "C) CRP lowers LDL",
      "D) CRP is a type of cholesterol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (CRP Reflects Systemic Inflammation, Which Drives Plaque Instability).\n\nPATHOPHYSIOLOGY:\nHigh-sensitivity C-reactive protein (hs-CRP) is an acute-phase reactant produced primarily by the liver in response to interleukin-6 (IL-6) and other proinflammatory cytokines. Atherosclerosis is now understood to be fundamentally an inflammatory disease: inflammatory cells (macrophages, T lymphocytes) are present at every stage from fatty streak formation through plaque rupture, and the degree of systemic inflammation correlates with plaque vulnerability. Elevated hs-CRP serves as a biomarker for this systemic inflammatory burden, reflecting the activity of the inflammatory processes that destabilize atherosclerotic plaques by degrading the fibrous cap through matrix metalloproteinase secretion.\n\nCLINICAL APPLICATION:\nhs-CRP levels below 1.0 mg/L indicate low cardiovascular risk, 1.0 to 3.0 mg/L moderate risk, and above 3.0 mg/L high risk. The JUPITER trial demonstrated that rosuvastatin reduced major cardiovascular events by 44% in patients with elevated hs-CRP (greater than 2.0 mg/L) but normal LDL (less than 130 mg/dL), supporting the concept that inflammation independent of LDL level contributes to cardiovascular risk. hs-CRP is listed as a risk-enhancing factor in the 2018 ACC/AHA Guidelines that can help guide statin therapy decisions in borderline and intermediate-risk patients.\n\nKEY POINTS:\nElevated hs-CRP reflects systemic inflammation that drives atherosclerotic plaque instability through macrophage-mediated fibrous cap degradation. Levels are stratified as low risk (less than 1.0 mg/L), moderate (1.0 to 3.0), and high risk (greater than 3.0). The JUPITER trial demonstrated cardiovascular benefit of statin therapy in patients with elevated hs-CRP but normal LDL."
  },
  {
    "id": 460,
    "categoryId": 1,
    "question": "Raynaud's Phenomenon involves vasospasm of the digital arteries. The color change sequence is:",
    "questionImages": [
      { "src": "assets/raynaud-color-sequence.png", "alt": "Raynaud phenomenon color change sequence", "caption": "Color change sequence: pallor, cyanosis, and reperfusion (DermNet)." }
    ],
    "options": [
      "A) Red -> White -> Blue",
      "B) White (Ischemia) -> Blue (Hypoxia) -> Red (Reperfusion)",
      "C) Blue -> Red -> White",
      "D) White -> Red -> Blue"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/raynaud-pallor.png", "alt": "Raynaud phenomenon pallor phase", "caption": "Pallor phase: blanching of digits from vasospasm." }
    ],
    "explanation": "CORRECT: B (White, Blue, Red).\n\nPATHOPHYSIOLOGY:\nRaynaud phenomenon involves episodic vasospasm of the digital arteries and arterioles in response to cold exposure or emotional stress, producing a characteristic triphasic color change in the affected digits. The first phase is white (pallor), caused by intense vasospasm that completely occludes digital arterial flow, producing ischemia. The second phase is blue (cyanosis), as the residual deoxygenated blood in the capillary beds becomes stagnant and oxygen is extracted without replenishment. The third phase is red (rubor), occurring as the vasospasm resolves and reactive hyperemia causes vigorous reperfusion with oxygenated blood.\n\nPRIMARY VERSUS SECONDARY:\nPrimary Raynaud (Raynaud disease) occurs without any underlying condition, is more common (80 to 90% of cases), typically begins in women under age 30, and carries a benign prognosis without tissue damage. Secondary Raynaud (Raynaud phenomenon) is linked to an underlying connective tissue disease, most commonly systemic sclerosis (scleroderma, present in over 90% of scleroderma patients), systemic lupus erythematosus, mixed connective tissue disease, and dermatomyositis/polymyositis. Secondary Raynaud tends to be more severe and can cause digital ulceration, pitting scars, and critical digital ischemia with gangrene.\n\nMANAGEMENT:\nFirst-line treatment includes cold avoidance, hand warming, and smoking cessation. Pharmacologic therapy when needed starts with dihydropyridine calcium channel blockers (nifedipine, amlodipine) as first-line vasodilators. Severe refractory cases may require phosphodiesterase-5 inhibitors, prostacyclin analogues, or endothelin receptor antagonists (bosentan).\n\nKEY POINTS:\nThe Raynaud triphasic color sequence is white (vasospasm/ischemia), then blue (cyanosis/deoxygenation), then red (reactive hyperemia/reperfusion). Primary Raynaud is benign and common in young women, while secondary Raynaud is linked to connective tissue diseases (especially scleroderma) and can cause digital ulcers. Dihydropyridine CCBs (nifedipine) are first-line pharmacotherapy."
  },
  {
    "id": 461,
    "categoryId": 1,
    "question": "Coarctation of the Aorta (narrowing) typically occurs just distal to the Left Subclavian artery. Clinical signs include:",
    "options": [
      "A) Hypotension in legs, Hypertension in arms",
      "B) Hypertension in legs, Hypotension in arms",
      "C) Equal BP everywhere",
      "D) Cyanosis of the hands"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Hypotension in Legs, Hypertension in Arms).\n\nPATHOPHYSIOLOGY:\nCoarctation of the aorta is a congenital narrowing of the aorta, most commonly located just distal to the origin of the left subclavian artery at the site of the ductus arteriosus (juxtaductal coarctation). This anatomic narrowing creates a mechanical obstruction to blood flow: the upper body (head, neck, and arms, all supplied by branches arising proximal to the coarctation) receives normal or elevated blood flow, while the lower body (abdominal viscera and legs, supplied by the descending aorta distal to the coarctation) receives reduced blood flow and pressure. The result is hypertension in the upper extremities and hypotension in the lower extremities.\n\nCLINICAL PRESENTATION:\nThe hallmark physical examination finding is a significant blood pressure gradient between the upper and lower extremities (upper extremity systolic BP 20 mmHg or more higher than lower extremity BP) with diminished or delayed femoral pulses (radial-femoral pulse delay). Infants with severe coarctation may present with heart failure, shock, and ductal-dependent systemic circulation (requiring prostaglandin E1 to maintain ductal patency). Older children and adults may be asymptomatic or present with headache, epistaxis, leg claudication with exercise, or hypertension detected on routine examination. Associated anomalies include bicuspid aortic valve (present in 50 to 85% of cases), ventricular septal defect, and Turner syndrome (45,X).\n\nCOMPLICATIONS:\nLong-standing coarctation leads to collateral arterial circulation (intercostal arteries enlarge to bypass the obstruction, producing rib notching on chest radiograph), left ventricular hypertrophy, and increased risk of cerebral aneurysms (particularly Circle of Willis berry aneurysms) and aortic dissection.\n\nKEY POINTS:\nCoarctation of the aorta causes upper extremity hypertension with lower extremity hypotension and diminished femoral pulses (radial-femoral delay). It is located just distal to the left subclavian artery at the ductus arteriosus. Bicuspid aortic valve coexists in 50 to 85% of cases, and Turner syndrome is a key association."
  },
  {
    "id": 462,
    "categoryId": 1,
    "question": "Giant Cell Arteritis (Temporal Arteritis) affects large/medium vessels. A biopsy shows inflammation in the:",
    "options": [
      "A) Capillaries",
      "B) Internal Elastic Lamina",
      "C) Veins",
      "D) Lymphatics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Internal Elastic Lamina).\n\nPATHOPHYSIOLOGY:\nGiant cell arteritis (GCA, also called temporal arteritis) is a systemic granulomatous vasculitis of large and medium-sized arteries that predominantly affects branches of the external carotid artery (especially the temporal artery) and the aorta and its major branches in patients over 50 years of age. The pathologic hallmark is transmural granulomatous inflammation centered on the internal elastic lamina of the affected artery, with multinucleated giant cells, macrophages, and CD4+ T lymphocytes clustered at or near the internal elastic lamina, which is often fragmented and disrupted. The inflammatory process is driven by a T-cell-mediated immune response in which dendritic cells in the adventitia activate CD4+ T-helper cells, which then migrate to the media and produce interferon-gamma, stimulating macrophage differentiation into multinucleated giant cells.\n\nCLINICAL PRESENTATION:\nGCA classically presents with new-onset temporal headache, scalp tenderness, jaw claudication (pain with chewing, which is the most specific symptom), and constitutional symptoms (fever, malaise, weight loss). The most feared complication is anterior ischemic optic neuropathy (AION), causing sudden, irreversible monocular vision loss from occlusion of the posterior ciliary arteries, which occurs in approximately 15 to 20% of untreated patients. GCA is closely associated with polymyalgia rheumatica (PMR), with approximately 40 to 60% of GCA patients having concurrent PMR symptoms.\n\nDIAGNOSIS AND TREATMENT:\nESR is typically markedly elevated (often greater than 50 mm/hr, sometimes exceeding 100), and CRP is elevated. Temporal artery biopsy is the gold standard for diagnosis (though skip lesions can cause false-negative results, so a length of at least 1 to 2 cm should be obtained). High-dose corticosteroids (prednisone 40 to 60 mg/day, or IV methylprednisolone 1 g/day for 3 days if vision loss is present) must be started immediately upon clinical suspicion, before biopsy results are available, to prevent irreversible blindness.\n\nKEY POINTS:\nGCA shows granulomatous inflammation centered on the internal elastic lamina with multinucleated giant cells. Jaw claudication is the most specific symptom, and anterior ischemic optic neuropathy is the most feared complication. High-dose steroids must be started immediately upon clinical suspicion, before biopsy confirmation, to prevent irreversible vision loss."
  },
  {
    "id": 463,
    "categoryId": 1,
    "question": "Lymphedema differs from Venous Edema because Lymphedema:",
    "options": [
      "A) Pits easily",
      "B) Is usually bilateral",
      "C) Affects the dorsum of the foot (Stemmer's Sign) and is non-pitting",
      "D) Is improved with diuretics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Affects the Dorsum of the Foot / Stemmer Sign / Non-pitting).\n\nPATHOPHYSIOLOGY:\nLymphedema results from impaired lymphatic drainage that causes accumulation of protein-rich interstitial fluid in the subcutaneous tissues. Unlike venous edema (which is protein-poor transudative fluid that pits easily), lymphedema fluid has a high protein content (greater than 1.5 g/dL) that stimulates chronic fibroblast proliferation, collagen deposition, and adipose tissue hypertrophy, eventually producing firm, non-pitting edema. The Stemmer sign (inability to pinch and lift a fold of skin on the dorsum of the second toe) is a reliable clinical test for lymphedema because the dorsal foot skin is one of the first areas affected by lymphatic congestion and the earliest site to develop the fibrotic changes that prevent skin folding.\n\nCLINICAL DISTINCTION:\nVenous edema is typically bilateral, pitting, worst in the dependent position (improving with elevation), and associated with hemosiderin staining at the medial malleolus. Lymphedema characteristically involves the dorsum of the foot and toes (giving a \"boxy\" or squared-off appearance to the toes), is initially pitting but becomes non-pitting as fibrosis progresses, does not respond well to diuretics (because the issue is protein accumulation, not sodium/water retention), and does not improve as dramatically with elevation.\n\nCLASSIFICATION:\nPrimary lymphedema results from congenital abnormalities of lymphatic development (lymphatic hypoplasia, aplasia, or hyperplasia) and includes Milroy disease (congenital onset), lymphedema praecox (onset before age 35, most common form), and lymphedema tarda (onset after age 35). Secondary lymphedema is far more common worldwide and results from lymphatic obstruction or destruction by surgery (axillary lymph node dissection for breast cancer), radiation therapy, infection (filariasis is the most common cause globally), malignancy, or trauma.\n\nKEY POINTS:\nLymphedema is distinguished from venous edema by the positive Stemmer sign (inability to pinch dorsal toe skin), non-pitting quality (from fibrosis due to protein-rich fluid), dorsal foot involvement, and poor response to diuretics. Venous edema pits easily, responds to elevation, and involves the medial malleolus. Secondary lymphedema from surgery/radiation is the most common form in developed countries."
  },
  {
    "id": 464,
    "categoryId": 1,
    "question": "Critical Limb Ischemia (CLI) is defined by:",
    "questionImages": [
      { "src": "assets/cli-lower-limbs.png", "alt": "Lower limbs showing unilateral critical limb ischemia", "caption": "Unilateral CLI: affected limb with dusky discoloration and bandaged foot versus normal limb." }
    ],
    "options": [
      "A) Pain with walking 1 block",
      "B) Ischemic Rest Pain (pain at night/elevation) or Tissue Loss (Ulcers/Gangrene)",
      "C) An ABI of 0.8",
      "D) Swelling"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/cli-foot-gangrene.png", "alt": "Foot with critical limb ischemia and gangrene of the great toe", "caption": "CLI with dry gangrene of the hallux and ischemic changes." }
    ],
    "explanation": "CORRECT: B (Ischemic Rest Pain or Tissue Loss).\n\nPATHOPHYSIOLOGY:\nCritical limb ischemia (CLI, now also referred to as chronic limb-threatening ischemia or CLTI in the 2019 Global Vascular Guidelines) represents the most advanced stage of peripheral arterial disease and is defined by the presence of ischemic rest pain (pain occurring at rest, typically in the forefoot and toes, characteristically worse at night and when the leg is elevated, relieved by dependency) and/or tissue loss (non-healing ulcers, gangrene). CLI indicates that arterial blood flow is insufficient to meet basal metabolic demands of the tissues at rest, not merely during exercise as in intermittent claudication.\n\nHEMODYNAMIC CRITERIA:\nCLI is supported by objective hemodynamic measurements: ankle pressure less than 50 to 70 mmHg, toe pressure less than 30 to 50 mmHg, ABI typically less than 0.40, or transcutaneous oxygen pressure (TcPO2) less than 30 mmHg. The Rutherford classification stages PAD from category 0 (asymptomatic) through category 3 (severe claudication) to categories 4 (rest pain), 5 (minor tissue loss), and 6 (major tissue loss), with categories 4 through 6 constituting CLI.\n\nPROGNOSIS AND MANAGEMENT:\nCLI carries a grim prognosis without revascularization: approximately 25% of patients will undergo major amputation within one year. Urgent revascularization (endovascular or surgical bypass) is the primary treatment goal to achieve limb salvage. Risk factor modification (smoking cessation, statin therapy, antiplatelet therapy, diabetes and hypertension control) and wound care are essential adjuncts.\n\nKEY POINTS:\nCritical limb ischemia is defined by ischemic rest pain (worse at night, relieved by leg dependency) or tissue loss (non-healing ulcers, gangrene), indicating arterial flow insufficient for basal tissue metabolism. Hemodynamic criteria include ABI less than 0.40 and ankle pressure less than 50 to 70 mmHg. Without revascularization, approximately 25% of CLI patients require major amputation within one year."
  },
  {
    "id": 465,
    "categoryId": 5,
    "question": "A Varicocele ('Bag of Worms') is more common on the LEFT side because:",
    "options": [
      "A) The Left Testicle is larger",
      "B) The Left Spermatic Vein drains perpendicularly into the Renal Vein (High resistance)",
      "C) Gravity affects the left more",
      "D) The Left Spermatic Vein has no valves"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/varicocele-anatomy.png", "alt": "Varicocele vs normal: dilated pampiniform plexus veins above testicle", "caption": "Varicocele: dilated veins in spermatic cord vs normal anatomy (© Mayo Foundation for Medical Education and Research)." }
    ],
    "explanation": "CORRECT: B (The Left Spermatic Vein Drains Perpendicularly into the Renal Vein).\n\nANATOMY:\nA varicocele is an abnormal dilation of the pampiniform venous plexus within the spermatic cord, present in approximately 15% of adult males and in up to 40% of men evaluated for infertility. Varicoceles are significantly more common on the left side (approximately 80 to 90% of cases) due to a fundamental anatomic asymmetry in venous drainage. The left spermatic (testicular) vein drains into the left renal vein at a perpendicular (90-degree) angle, creating higher hydrostatic pressure and reduced efficiency of venous return compared to the right side. The right spermatic vein drains directly into the inferior vena cava at an oblique angle, which facilitates more efficient drainage.\n\nADDITIONAL CONTRIBUTING FACTORS:\nThe left renal vein crosses between the aorta and the superior mesenteric artery (a region susceptible to compression, known as the nutcracker phenomenon), which can further impede left spermatic venous outflow. The longer course of the left spermatic vein (due to the higher position of the left kidney) and incompetent or absent venous valves also contribute.\n\nCLINICAL SIGNIFICANCE:\nVaricoceles present as a \"bag of worms\" palpable in the scrotum that becomes more prominent with standing and Valsalva maneuver and decompresses in the supine position. A new right-sided varicocele or a varicocele that does not decompress in the supine position should raise concern for extrinsic compression of the IVC or right renal vein by a retroperitoneal mass (particularly renal cell carcinoma extending into the IVC). Varicoceles impair spermatogenesis through elevated intrascrotal temperature from venous stasis.\n\nKEY POINTS:\nLeft-sided varicoceles predominate (80 to 90%) because the left spermatic vein drains perpendicularly into the left renal vein (high resistance), while the right drains obliquely into the IVC (low resistance). A new isolated right-sided or non-decompressing varicocele should raise concern for retroperitoneal mass (renal cell carcinoma). Varicoceles impair fertility through elevated scrotal temperature."
  },
  {
    "id": 466,
    "categoryId": 1,
    "question": "The Portal Vein is formed by the confluence of which two veins?",
    "options": [
      "A) IVC and Renal Vein",
      "B) Splenic Vein and Superior Mesenteric Vein (SMV)",
      "C) Hepatic Vein and IVC",
      "D) Gastric Vein and Splenic Vein"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/portal-vein.png", "alt": "Portal vein and its branches—confluence of splenic and superior mesenteric veins", "caption": "Portal vein anatomy (Cleveland Clinic ©2023)." }
    ],
    "explanation": "CORRECT: B (Splenic Vein and Superior Mesenteric Vein).\n\nANATOMY:\nThe portal vein is formed by the confluence of the splenic vein and the superior mesenteric vein (SMV) behind the neck of the pancreas (at the level of L2). It ascends in the hepatoduodenal ligament (within the free edge of the lesser omentum) alongside the common bile duct (anterolateral) and the hepatic artery proper (anteromedial), then enters the liver at the porta hepatis where it divides into right and left portal branches.\n\nPORTAL CIRCULATION FUNCTION:\nThe portal venous system is a unique venous arrangement that drains blood from the gastrointestinal tract (stomach through rectum), spleen, pancreas, and gallbladder and delivers it to the liver for first-pass metabolism before it enters the systemic circulation via the hepatic veins and IVC. Approximately 75% of hepatic blood flow is delivered by the portal vein (nutrient-rich, partially deoxygenated), with the remaining 25% from the hepatic artery (oxygen-rich).\n\nCLINICAL SIGNIFICANCE:\nPortal hypertension (portal venous pressure gradient greater than 5 mmHg, clinically significant above 10 mmHg) develops most commonly from cirrhosis and leads to the formation of portosystemic collaterals at sites of portal-systemic anastomosis: esophageal varices (left gastric vein to esophageal veins), caput medusae (paraumbilical veins to epigastric veins), hemorrhoids (superior rectal to middle/inferior rectal veins), and splenorenal shunts.\n\nKEY POINTS:\nThe portal vein is formed by the confluence of the splenic vein and the superior mesenteric vein behind the neck of the pancreas. It delivers 75% of hepatic blood flow (nutrient-rich) for first-pass metabolism. Portal hypertension from cirrhosis causes portosystemic collaterals including esophageal varices, caput medusae, and hemorrhoids."
  },
  {
    "id": 467,
    "categoryId": 1,
    "question": "Nitric Oxide (NO) produced by endothelial cells causes vasodilation by increasing:",
    "options": [
      "A) cAMP",
      "B) cGMP in smooth muscle",
      "C) Calcium",
      "D) Angiotensin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (cGMP in Smooth Muscle).\n\nPATHOPHYSIOLOGY:\nNitric oxide (NO) is synthesized by endothelial nitric oxide synthase (eNOS) in vascular endothelial cells, which converts L-arginine to L-citrulline and NO using molecular oxygen, NADPH, and tetrahydrobiopterin (BH4) as cofactors. NO is a small, lipophilic gas that freely diffuses from the endothelium into the adjacent vascular smooth muscle cells, where it activates soluble guanylyl cyclase (sGC), an enzyme that converts GTP to cyclic guanosine monophosphate (cGMP). Elevated cGMP activates protein kinase G (PKG), which causes smooth muscle relaxation through multiple mechanisms: decreased intracellular calcium (by stimulating calcium efflux and inhibiting calcium influx), dephosphorylation of myosin light chain, and activation of potassium channels causing hyperpolarization.\n\nCLINICAL APPLICATIONS:\nNitroglycerin and other nitrate medications work by serving as exogenous NO donors, generating NO that activates the same sGC-cGMP pathway. Phosphodiesterase-5 (PDE-5) inhibitors (sildenafil, tadalafil) prevent the breakdown of cGMP by PDE-5, prolonging and amplifying the vasodilatory effect of NO, which is why combining nitrates with PDE-5 inhibitors causes dangerous hypotension. This pathway is also the basis for PDE-5 inhibitor use in erectile dysfunction (penile smooth muscle relaxation) and pulmonary arterial hypertension (pulmonary vascular smooth muscle relaxation).\n\nKEY POINTS:\nEndothelial NO activates soluble guanylyl cyclase in vascular smooth muscle, increasing cGMP which activates protein kinase G, causing vasodilation through calcium reduction and myosin dephosphorylation. Nitroglycerin works as an exogenous NO donor through this same pathway. PDE-5 inhibitors amplify NO signaling by preventing cGMP breakdown, explaining the dangerous synergy with nitrates."
  },
  {
    "id": 468,
    "categoryId": 1,
    "question": "Which artery is the primary blood supply to the femoral head (hip joint)?",
    "options": [
      "A) Obturator Artery",
      "B) Medial Circumflex Femoral Artery",
      "C) Femoral Artery proper",
      "D) Inferior Gluteal Artery"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Medial Circumflex Femoral Artery).\n\nANATOMY:\nThe medial circumflex femoral artery (MCFA) is the primary blood supply to the femoral head in adults, providing approximately 80% of the arterial flow through its lateral ascending (retinacular) branches that penetrate the hip joint capsule and course along the femoral neck beneath the synovial membrane. The MCFA typically arises from the deep femoral artery (profunda femoris) and courses posteriorly around the femoral neck.\n\nCLINICAL SIGNIFICANCE:\nThe vulnerability of this blood supply is the reason that femoral neck fractures carry a high risk of avascular necrosis (AVN, also called osteonecrosis) of the femoral head. Displaced femoral neck fractures can disrupt the retinacular branches of the MCFA, cutting off blood supply to the femoral head and leading to ischemic bone death. The incidence of AVN after displaced femoral neck fractures is approximately 15 to 30%, which is why displaced fractures in younger patients are treated with urgent open reduction and internal fixation (to preserve the native femoral head) rather than arthroplasty. In elderly patients with displaced femoral neck fractures, hemiarthroplasty or total hip arthroplasty is preferred because the high AVN risk makes femoral head preservation less favorable.\n\nADDITIONAL BLOOD SUPPLY:\nThe ligamentum teres artery (a branch of the obturator artery) provides a minor contribution to femoral head blood supply through the fovea capitis, but this source is insufficient to maintain femoral head viability if the MCFA supply is disrupted in adults. In children, the ligamentum teres artery contribution is more significant.\n\nKEY POINTS:\nThe medial circumflex femoral artery provides approximately 80% of the blood supply to the femoral head through retinacular branches along the femoral neck. Displaced femoral neck fractures disrupt this supply, causing avascular necrosis in 15 to 30% of cases. This vascular anatomy dictates surgical approach: urgent fixation in young patients versus arthroplasty in elderly patients."
  },
  {
    "id": 469,
    "categoryId": 1,
    "question": "USPSTF recommends one-time screening for AAA with Ultrasound in:",
    "options": [
      "A) All men > 65",
      "B) Men 65-75 who have ever smoked",
      "C) Women 65-75 who smoke",
      "D) Anyone with back pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Men 65 to 75 Who Have Ever Smoked).\n\nCLINICAL REASONING:\nThe United States Preventive Services Task Force (USPSTF) recommends one-time screening for abdominal aortic aneurysm (AAA) with abdominal ultrasonography in men aged 65 to 75 years who have ever smoked (defined as having smoked 100 or more cigarettes in their lifetime). This is a Grade B recommendation based on moderate net benefit. For men aged 65 to 75 who have never smoked, the USPSTF recommends selective screening based on individual clinical judgment (Grade C). The USPSTF found insufficient evidence to recommend for or against screening in women who have ever smoked and recommends against screening in women who have never smoked.\n\nEPIDEMIOLOGY:\nAAA (defined as aortic diameter 3.0 cm or greater) predominantly affects older men with a history of smoking. Smoking is the strongest modifiable risk factor, increasing AAA risk by 3 to 5-fold. Other risk factors include male sex, age over 65, family history of AAA, and other atherosclerotic disease (coronary, carotid, or peripheral). The male-to-female prevalence ratio is approximately 4 to 6:1.\n\nMANAGEMENT BASED ON SIZE:\nAAA smaller than 5.5 cm in men (or 5.0 cm in women) is managed with surveillance ultrasonography at intervals determined by aneurysm size, risk factor modification (smoking cessation is the most critical intervention to slow growth), and avoidance of strenuous lifting. Surgical repair (open or endovascular aneurysm repair, EVAR) is indicated when the aneurysm reaches 5.5 cm (men) or 5.0 cm (women), grows more than 0.5 cm in 6 months, or becomes symptomatic.\n\nKEY POINTS:\nThe USPSTF recommends one-time AAA screening with ultrasound in men aged 65 to 75 who have ever smoked (Grade B). Smoking is the strongest modifiable risk factor (3 to 5-fold increased risk). Elective repair is indicated at 5.5 cm in men or 5.0 cm in women, or with rapid growth greater than 0.5 cm in 6 months."
  },
  {
    "id": 470,
    "categoryId": 1,
    "question": "Thromboangiitis Obliterans (Buerger's Disease) is a non-atherosclerotic vasculitis strongly associated with:",
    "options": [
      "A) Alcohol",
      "B) Heavy Tobacco use",
      "C) Diabetes",
      "D) High Cholesterol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heavy Tobacco Use).\n\nPATHOPHYSIOLOGY:\nThromboangiitis obliterans (Buerger disease) is a non-atherosclerotic, segmental inflammatory vasculitis that affects small and medium-sized arteries and veins of the distal extremities, with an almost absolute association with tobacco use. The disease predominantly affects young male smokers (typically under age 45) and involves highly cellular, inflammatory thrombi in the arterial and venous lumen with relative preservation of the vessel wall architecture (in contrast to atherosclerosis, which involves intimal plaque formation, and other vasculitides, which involve transmural vessel wall destruction). The exact mechanism linking tobacco to the disease is not fully understood, but involves an immunologic response to tobacco antigens, endothelial dysfunction, and a prothrombotic state.\n\nCLINICAL PRESENTATION:\nPatients present with distal extremity ischemia affecting the hands and feet (unlike atherosclerotic PAD, which typically involves larger proximal vessels), including rest pain, digital ulcers, and gangrene of the fingers and toes. Superficial migratory thrombophlebitis (recurrent episodes of tender, erythematous, palpable subcutaneous cords) occurs in approximately 40% of patients and may precede arterial symptoms. The Raynaud phenomenon is also common. the diagnosis requires exclusion of other causes of distal ischemia (atherosclerosis, thrombophilia, autoimmune disease, embolic disease).\n\nMANAGEMENT:\nAbsolute and complete tobacco cessation (including all forms: cigarettes, cigars, smokeless tobacco, and even nicotine replacement in some patients) is the single most important intervention and is the only treatment proven to prevent disease progression and amputation. Patients who continue to smoke have amputation rates approaching 40 to 50%, while those who achieve complete cessation rarely require amputation.\n\nKEY POINTS:\nBuerger disease is a non-atherosclerotic inflammatory vasculitis with nearly absolute tobacco association, affecting distal small/medium arteries and veins in young male smokers under 45. It presents with digital ischemia, ulcers, and migratory superficial thrombophlebitis. Complete tobacco cessation is the only effective treatment, dramatically reducing the 40 to 50% amputation rate seen with continued smoking."
  },
  {
    "id": 471,
    "categoryId": 1,
    "question": "Oxidized LDL is particularly atherogenic because it:",
    "options": [
      "A) Is rapidly cleared by the liver",
      "B) Is taken up by Macrophages via Scavenger Receptors (unregulated)",
      "C) Repels platelets",
      "D) Dissolves plaques"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Taken Up by Macrophages via Unregulated Scavenger Receptors).\n\nPATHOPHYSIOLOGY:\nOxidized LDL (oxLDL) is a key driver of atherogenesis because it is internalized by macrophages through scavenger receptors (primarily SR-A1, CD36, and LOX-1) that, unlike the native LDL receptor, are not subject to negative feedback regulation by intracellular cholesterol levels. The native LDL receptor (LDL-R) on hepatocytes and other cells is tightly regulated: as intracellular cholesterol rises, SREBP-mediated transcription of the LDL receptor gene is suppressed, limiting further cholesterol uptake. In contrast, scavenger receptors on macrophages continue to internalize oxLDL regardless of how much cholesterol the cell has already accumulated, leading to massive intracellular lipid accumulation and transformation of the macrophage into a foam cell.\n\nPATHOGENIC EFFECTS:\nBeyond unregulated uptake, oxLDL has multiple additional proatherogenic effects. It is directly cytotoxic to endothelial cells, impairing endothelial function and promoting endothelial apoptosis. It is chemotactic for circulating monocytes (recruiting more inflammatory cells to the developing plaque) and inhibits macrophage emigration from the plaque. OxLDL stimulates smooth muscle cell proliferation and extracellular matrix production, and it promotes platelet adhesion and aggregation.\n\nCLINICAL RELEVANCE:\nThe atherogenic role of oxLDL explains why antioxidant therapies were hypothesized to reduce cardiovascular disease, though clinical trials of vitamin E and other antioxidant supplements failed to show benefit, suggesting that the oxidation process occurs within the vessel wall microenvironment and is not effectively addressed by systemic antioxidant supplementation. Statins reduce oxLDL indirectly by lowering total LDL (less substrate for oxidation) and through direct anti-inflammatory and antioxidant pleiotropic effects.\n\nKEY POINTS:\nOxidized LDL is highly atherogenic because macrophage scavenger receptors (SR-A, CD36) internalize it without negative feedback regulation, leading to uncontrolled cholesterol accumulation and foam cell formation. Native LDL receptors are tightly regulated and do not cause foam cell transformation. OxLDL is also directly cytotoxic to endothelium, chemotactic for monocytes, and prothrombotic."
  },
  {
    "id": 472,
    "categoryId": 1,
    "question": "Virchow's Triad describes the three factors predisposing to thrombosis:",
    "options": [
      "A) High BP, High Cholesterol, Smoking",
      "B) Stasis, Endothelial Injury, Hypercoagulability",
      "C) Pain, Pallor, Pulselessness",
      "D) Age, Obesity, Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Stasis, Endothelial Injury, Hypercoagulability).\n\nPATHOPHYSIOLOGY:\nVirchow's triad, first conceptualized by Rudolf Virchow in 1856, describes the three fundamental pathophysiologic factors that predispose to intravascular thrombosis. The first factor is venous stasis (abnormal blood flow), which occurs with immobility (prolonged bed rest, long-haul flights, paralysis), venous obstruction, or heart failure. Stasis allows activated clotting factors to accumulate locally rather than being diluted and cleared by flowing blood, and it prevents delivery of natural anticoagulants (antithrombin, protein C, protein S) to the site. The second factor is endothelial injury or dysfunction, which exposes subendothelial collagen and tissue factor, activating both the intrinsic and extrinsic coagulation cascades and promoting platelet adhesion. Endothelial injury occurs with surgery, trauma, indwelling catheters, and chronic inflammation. The third factor is hypercoagulability, which can be inherited (Factor V Leiden mutation, prothrombin G20210A mutation, protein C or S deficiency, antithrombin deficiency) or acquired (malignancy, pregnancy, oral contraceptives, antiphospholipid syndrome, nephrotic syndrome).\n\nCLINICAL APPLICATION:\nMost thrombotic events involve the interaction of two or more of these factors. For example, a postoperative patient (endothelial injury from surgery plus stasis from immobility) taking oral contraceptives (hypercoagulability) has a dramatically higher DVT risk than any single factor alone. Understanding Virchow's triad guides prophylaxis strategies: early ambulation and pneumatic compression address stasis, careful surgical technique minimizes endothelial injury, and pharmacologic thromboprophylaxis (heparin, enoxaparin) addresses hypercoagulability.\n\nKEY POINTS:\nVirchow's triad (venous stasis, endothelial injury, hypercoagulability) describes the three fundamental predispositions to thrombosis. Most thrombotic events involve interaction of two or more factors. This framework guides prophylaxis: ambulation addresses stasis, surgical technique minimizes endothelial injury, and pharmacologic anticoagulation addresses hypercoagulability."
  },
  {
    "id": 473,
    "categoryId": 1,
    "question": "The Popliteal Artery is the continuation of the Femoral Artery after it passes through the:",
    "options": [
      "A) Inguinal Ligament",
      "B) Adductor Hiatus (Hunter's Canal)",
      "C) Obturator Foramen",
      "D) Popliteal Fossa"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/leg-arteries-lower-limb.png", "alt": "Arterial blood supply of the lower limb and foot (anterior and posterior views)", "caption": "Lower limb arterial anatomy (Moore, Clinically Oriented Anatomy, 6th ed.)." }
    ],
    "explanation": "CORRECT: B (Adductor Hiatus / Hunter's Canal).\n\nANATOMY:\nThe femoral artery transitions to become the popliteal artery as it passes through the adductor hiatus (also called the hiatus of the adductor magnus), an opening in the tendinous insertion of the adductor magnus muscle at the distal medial thigh. The adductor canal (Hunter's canal, subsartorial canal) is the fascial tunnel in the middle third of the thigh through which the femoral artery, femoral vein, saphenous nerve, and nerve to the vastus medialis travel before reaching the adductor hiatus. The canal is bounded anterolaterally by the vastus medialis, posteriorly by the adductor longus and adductor magnus, and superficially (roof) by the sartorius muscle and the vastoaponeurotic membrane.\n\nCLINICAL SIGNIFICANCE:\nThe adductor hiatus is the most common site of atherosclerotic stenosis in peripheral arterial disease because the artery is fixed at this point and subjected to repetitive mechanical stress from thigh adduction and knee flexion. Superficial femoral artery (SFA) disease at the adductor canal is the classic location for claudication presenting as calf pain with walking. The popliteal artery, after emerging from the adductor hiatus, courses through the popliteal fossa behind the knee, where it is the deepest structure (closest to the femur) and is vulnerable to injury in posterior knee dislocations. Distally, the popliteal artery trifurcates into the anterior tibial, posterior tibial, and peroneal (fibular) arteries.\n\nKEY POINTS:\nThe femoral artery becomes the popliteal artery at the adductor hiatus (opening in the adductor magnus muscle), which is the most common site of atherosclerotic stenosis in PAD. The adductor canal (Hunter's canal) is the fascial tunnel proximal to the hiatus. The popliteal artery is vulnerable to injury in posterior knee dislocations and trifurcates into the anterior tibial, posterior tibial, and peroneal arteries."
  },
  {
    "id": 474,
    "categoryId": 7,
    "question": "Which of the four Rotator Cuff muscles is primarily responsible for internal rotation of the humerus?",
    "options": [
      "A) Supraspinatus",
      "B) Infraspinatus",
      "C) Teres Minor",
      "D) Subscapularis"
    ],
    "correctAnswer": 3,
    "explanationImages": [
      { "src": "assets/RC.webp", "alt": "Rotator cuff", "caption": "Rotator cuff image." }
    ],
    "explanation": "CORRECT: D (Subscapularis).\n\nPATHOPHYSIOLOGY:\nThe rotator cuff comprises four muscles providing dynamic glenohumeral stabilization by compressing the humeral head into the glenoid fossa. The subscapularis is the largest and strongest, originating from the anterior (costal) scapular surface and inserting on the lesser tuberosity\u2014the only anterior rotator cuff muscle. Its anterior line of pull makes it the primary internal rotator and a critical anterior stabilizer resisting anterior translation and external rotation forces. The three posterior muscles insert on the greater tuberosity: supraspinatus (from the supraspinous fossa) initiates the first 15\u00b0 of abduction; infraspinatus (from the infraspinous fossa) provides ~60% of external rotation strength; teres minor (from the lateral scapular border) provides ~40%.\n\nCLINICAL PRESENTATION:\nSubscapularis tears compromise anterior stability and internal rotation. Patients present with anterior shoulder pain, internal rotation weakness, and sometimes increased passive external rotation from loss of the anterior restraint. Provocative tests: the lift-off test (Gerber)\u2014dorsum of hand against lumbar spine, push away against resistance; inability indicates subscapularis insufficiency. The belly press test\u2014press palm against abdomen keeping elbow forward; elbow falling posterior indicates substitution for lost internal rotation. The bear hug test\u2014hand on opposite shoulder, resist examiner's external rotation force; high sensitivity for upper subscapularis tears.\n\nDIAGNOSIS AND MANAGEMENT:\nMRI with or without arthrography is the imaging modality of choice. Complete subscapularis tears are associated with medial subluxation of the long head of the biceps tendon, because the subscapularis and transverse humeral ligament form the medial wall of the bicipital groove. Isolated partial tears may be managed conservatively with physical therapy focused on strengthening remaining internal rotators and restoring scapular kinematics. Complete tears with biceps subluxation or significant functional impairment typically require surgical repair.\n\nKEY POINTS:\nThe subscapularis is the only anterior rotator cuff muscle, inserting on the lesser tuberosity, making it the primary internal rotator and anterior glenohumeral stabilizer. The lift-off, belly press, and bear hug tests assess integrity. Complete tears frequently associate with biceps tendon subluxation because the subscapularis forms the medial bicipital groove wall."
  },
  {
    "id": 475,
    "categoryId": 7,
    "question": "Wolff's Law describes the physiological principle that:",
    "options": [
      "A) Muscle fibers hypertrophy with stretch",
      "B) Bone remodels and strengthens in response to mechanical stress/load",
      "C) Cartilage regenerates if damaged",
      "D) Ligaments tighten with age"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bone remodels and strengthens in response to mechanical stress/load).\n\nPATHOPHYSIOLOGY:\nWolff's Law (1892) states that bone adapts its architecture in response to mechanical demands. Under increased loading, bone deposits new matrix along lines of principal stress, increasing cortical thickness and trabecular density. When loading is reduced, bone is resorbed and weakens. Osteocytes (90-95% of bone cells) are interconnected through a lacunar-canalicular network. Mechanical loading drives interstitial fluid through this network, generating shear stress that triggers osteocytes to reduce sclerostin secretion. Sclerostin normally inhibits Wnt signaling in osteoblasts; when sclerostin falls, Wnt signaling is disinhibited, increasing osteoblast proliferation and bone formation at sites of greatest strain. Piezoelectric potentials within the hydroxyapatite crystal lattice further stimulate osteoblast activity.\n\nCLINICAL SIGNIFICANCE:\nWeight-bearing impact exercise and resistance training generate high-magnitude strains that suppress sclerostin and stimulate osteoblasts, directly translating this principle into osteoporosis prevention and treatment. The converse explains why prolonged immobilization, bed rest, spinal cord injury, and microgravity cause rapid bone loss. Astronauts lose approximately 1 to 2% of bone mineral density per month in weight-bearing sites during spaceflight, and patients on prolonged bed rest experience similar disuse osteopenia. In rehabilitation, controlled mechanical loading through fracture sites stimulates callus formation and accelerates healing. Orthodontic tooth movement exploits this principle through sustained force causing resorption on the pressure side and formation on the tension side. Romosozumab, an anti-sclerostin monoclonal antibody approved for osteoporosis, pharmacologically mimics mechanical loading by blocking sclerostin and activating Wnt-mediated bone formation.\n\nKEY POINTS:\nWolff's Law states that bone remodels along lines of mechanical stress through osteocyte mechanotransduction, sclerostin suppression, and Wnt-mediated osteoblast signaling. Weight-bearing exercise builds bone while immobilization and microgravity cause rapid loss at 1 to 2% per month. Romosozumab mimics mechanical loading effects by blocking sclerostin."
  },
  {
    "id": 476,
    "categoryId": 7,
    "question": "The primary pathophysiologic defect in Osteoarthritis (OA) is:",
    "options": [
      "A) Autoimmune attack on the synovium",
      "B) Loss of Articular Cartilage and subchondral bone remodeling (Osteophytes)",
      "C) Deposition of Uric Acid crystals",
      "D) Infection of the joint space"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/hipoa.jpg", "alt": "Hip osteoarthritis", "caption": "Hip OA image." },
      { "src": "assets/kneeoa.jpg", "alt": "Knee osteoarthritis", "caption": "Knee OA image." }
    ],
    "explanation": "CORRECT: B (Loss of Articular Cartilage and subchondral bone remodeling with osteophyte formation).\n\nPATHOPHYSIOLOGY:\nOsteoarthritis (OA), the most common joint disease (over 300 million affected globally), involves progressive articular cartilage loss, subchondral bone remodeling, osteophyte formation, and synovial inflammation. Normal articular cartilage contains type II collagen (tensile strength) and aggrecan proteoglycans (water retention), creating a nearly frictionless surface. In OA, chondrocytes upregulate MMP-13 and aggrecanases (ADAMTS-4/5) while decreasing matrix production. IL-1 beta and TNF-alpha drive this catabolic shift, though inflammation is far less than in rheumatoid arthritis.\n\nCLINICAL PRESENTATION:\nAs cartilage thins, subchondral bone forms osteophytes at joint margins and develops subchondral cysts. Radiographic findings follow the mnemonic LOSS: Loss of joint space (asymmetric narrowing), Osteophytes, Subchondral sclerosis, Subchondral cysts. Patients present with use-related pain worsening with activity and improving with rest, morning stiffness lasting less than 30 minutes (versus greater than 60 minutes in RA), crepitus, and bony enlargement. Heberden nodes (DIP joints) and Bouchard nodes (PIP joints) are characteristic. Most commonly affected joints: knees, hips, hands (DIP, PIP, first CMC), and spine.\n\nTREATMENT:\nFirst-line non-pharmacologic interventions: exercise, weight loss (each kg lost reduces knee load by approximately 4 kg), physical therapy, and assistive devices. Pharmacologic first-line per ACR guidelines: topical NSAIDs (preferred for knee and hand OA) and oral NSAIDs at lowest effective dose. Intraarticular corticosteroids provide 4-8 weeks of flare relief. Duloxetine is recommended by ACR for inadequate first-line response, reflecting central sensitization in chronic OA pain. ACR conditionally recommends against intraarticular hyaluronic acid for knee OA. Total joint arthroplasty is reserved for refractory cases despite exhausted conservative measures.\n\nKEY POINTS:\nOA is progressive cartilage loss from chondrocyte catabolic-anabolic imbalance with secondary inflammation, unlike RA where autoimmune synovial inflammation is primary. Radiographic hallmarks follow the LOSS mnemonic. Morning stiffness less than 30 minutes distinguishes OA from RA (greater than 60 minutes)."
  },
  {
    "id": 477,
    "categoryId": 7,
    "question": "A 27-year-old recreational soccer player twists his planted knee while pivoting. He now has medial joint-line pain, intermittent locking/catching, and swelling that developed several hours later. Which diagnosis is most likely?",
    "options": [
      "A) Medial meniscus tear",
      "B) Anterior cruciate ligament (ACL) rupture",
      "C) Patellofemoral pain syndrome",
      "D) Pes anserine bursitis"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      { "src": "assets/NewsMeniscus.jpg", "alt": "Meniscus", "caption": "Meniscus image." }
    ],
    "explanation": "CORRECT: A (Medial meniscus tear).\n\nPATHOPHYSIOLOGY:\nThe menisci are fibrocartilaginous structures that improve load distribution, shock absorption, and knee stability. The medial meniscus is less mobile than the lateral meniscus because it is more firmly attached to the joint capsule and deep medial collateral ligament fibers, making it more vulnerable to injury during twisting or pivoting on a weight-bearing, partially flexed knee. This mechanism can create longitudinal, radial, flap, or bucket-handle tears, and displaced fragments can produce true mechanical symptoms.\n\nCLINICAL MANIFESTATIONS:\nClassic findings include medial joint-line pain and tenderness, pain with squatting or twisting, and mechanical symptoms such as catching, clicking, or locking. Effusion is often delayed (hours after injury) rather than immediate. In contrast, acute ACL rupture more often presents with a pop, rapid hemarthrosis, and a prominent sense of instability/giving way.\n\nDIAGNOSIS:\nDiagnosis is based on history plus focused knee examination. Joint-line tenderness, Thessaly testing, and McMurray maneuver increase suspicion when combined with a compatible mechanism and symptoms. Plain radiographs are used to exclude fracture and assess for coexisting osteoarthritis but do not directly diagnose meniscal tears. MRI is the preferred noninvasive test when diagnosis is uncertain, symptoms persist despite conservative treatment, or surgery is being considered.\n\nMANAGEMENT:\nInitial management for many stable tears is conservative: activity modification, short-term analgesics/NSAIDs as appropriate, and structured physical therapy emphasizing quadriceps and hip strengthening plus neuromuscular control. Urgent orthopedic referral is indicated for a locked knee or suspected displaced bucket-handle tear. When surgery is required, meniscal repair is preferred over meniscectomy when feasible, especially for peripheral vascular-zone tears, because preserving meniscal tissue lowers long-term osteoarthritis risk."
  },
  {
    "id": 478,
    "categoryId": 7,
    "question": "Spondylolisthesis refers to:",
    "options": [
      "A) A fracture of the Pars Interarticularis",
      "B) Anterior slippage of one vertebra over the one below it",
      "C) Narrowing of the spinal canal",
      "D) Herniation of a disc"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/spondylolisthesis.jpg", "alt": "Spondylolisthesis", "caption": "Spondylolisthesis image." }
    ],
    "explanation": "CORRECT: B (Anterior slippage of one vertebra over the one below it).\n\nPATHOPHYSIOLOGY:\nSpondylolisthesis is anterior displacement of one vertebral body relative to the vertebra below, most commonly L5 on S1, followed by L4 on L5. Isthmic spondylolisthesis results from a pars interarticularis defect (spondylolysis), the classic Scottie dog neck fracture on oblique radiographs, which permits anterior translation. Degenerative spondylolisthesis, the most common form in adults over 50, results from facet arthropathy and disc degeneration without a pars defect, predominantly at L4-L5. Isthmic spondylolisthesis predominates in young athletes performing repetitive hyperextension (gymnastics, football linemen, weightlifting). The Meyerding classification grades slippage: Grade I (less than 25%), Grade II (25-50%), Grade III (50-75%), Grade IV (75-100%), with Grade V representing spondyloptosis.\n\nCLINICAL PRESENTATION:\nMany low-grade cases are asymptomatic. When symptomatic, patients report low back pain worsening with extension and activity. Neurologic symptoms including radiculopathy, neurogenic claudication, and cauda equina syndrome may occur from canal or foraminal narrowing. Examination may reveal a palpable step-off at the affected level and hamstring tightness. Standing lateral radiographs are the initial imaging study for grading; MRI is obtained when neurologic symptoms are present to evaluate neural compression.\n\nTREATMENT:\nConservative management is first-line: activity modification, core stabilization and flexion-based physical therapy, and NSAIDs. Lumbar extension and high-impact activities should be avoided. Epidural steroid injections may temporarily relieve radicular symptoms. Surgical intervention (posterolateral fusion with or without decompression) is considered for progressive neurologic deficits, high-grade slips (Grade III or greater), or persistent symptoms refractory to at least 6 months of conservative therapy.\n\nKEY POINTS:\nSpondylolisthesis is forward vertebral slippage graded by the Meyerding classification. It must be distinguished from spondylolysis, the pars interarticularis fracture that often underlies isthmic spondylolisthesis. Degenerative spondylolisthesis at L4-L5 predominates in older adults, while isthmic spondylolisthesis at L5-S1 predominates in young athletes performing repetitive hyperextension."
  },
  {
    "id": 479,
    "categoryId": 7,
    "question": "Meralgia Paresthetica is a mononeuropathy caused by compression of which nerve?",
    "questionImages": [
      { "src": "assets/17959-meralgia-paresthetica.jpg", "alt": "Meralgia paresthetica", "caption": "Meralgia paresthetica image." }
    ],
    "options": [
      "A) Sciatic Nerve",
      "B) Lateral Femoral Cutaneous Nerve",
      "C) Femoral Nerve",
      "D) Obturator Nerve"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lateral Femoral Cutaneous Nerve).\n\nPATHOPHYSIOLOGY:\nMeralgia paresthetica is an entrapment mononeuropathy of the lateral femoral cutaneous nerve (LFCN), a pure sensory nerve arising from L2 and L3. The LFCN courses along the psoas, crosses the iliacus, and passes beneath or through the inguinal ligament near the anterior superior iliac spine (ASIS), where it is most vulnerable to compression. Risk factors include obesity, pregnancy, diabetes mellitus, tight clothing or belts, prolonged standing, and laparoscopic surgery with trocar placement near the ASIS.\n\nCLINICAL PRESENTATION:\nPatients present with numbness, tingling, burning, or dysesthesias over the anterolateral thigh, typically unilateral (bilateral in approximately 20%). The LFCN is purely sensory, so there is no motor weakness or reflex changes, distinguishing meralgia paresthetica from femoral neuropathy (quadriceps weakness, diminished patellar reflex) and L2-L3 radiculopathy (motor and sensory deficits with back pain). Symptoms worsen with prolonged standing, walking, or hip extension, and improve with sitting. Examination may reveal decreased sensation over the anterolateral thigh, and the pelvic compression test (symptom relief with downward pelvic pressure in lateral decubitus position) supports the diagnosis.\n\nTREATMENT:\nManagement begins with eliminating the compression source: weight loss, looser clothing, avoiding prolonged standing. These conservative measures alone resolve symptoms in most patients. NSAIDs and topical lidocaine patches provide symptomatic relief. For refractory cases, local anesthetic and corticosteroid injection at the inguinal ligament near the ASIS is both diagnostic and therapeutic. Gabapentin or pregabalin may address persistent neuropathic pain. Surgical decompression or neurectomy is reserved for cases unresponsive to prolonged conservative management.\n\nKEY POINTS:\nMeralgia paresthetica results from LFCN compression at the inguinal ligament, producing anterolateral thigh numbness and burning. The purely sensory nature of the LFCN means no motor weakness, distinguishing it from femoral neuropathy and lumbar radiculopathy. Obesity, pregnancy, tight clothing, and diabetes are common risk factors, and removal of the offending cause is often curative."
  },
  {
    "id": 480,
    "categoryId": 7,
    "question": "De Quervain's Tenosynovitis affects the tendons of the first dorsal compartment. The diagnostic maneuver is:",
    "questionImages": [
      { "src": "assets/dequarvain.png", "alt": "De Quervain tenosynovitis", "caption": "De Quervain image." }
    ],
    "options": [
      "A) Phalen's Test",
      "B) Finkelstein's Test",
      "C) Tinel's Sign",
      "D) Empty Can Test"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Finkelstein\'s Test).\n\nPATHOPHYSIOLOGY:\nDe Quervain\'s tenosynovitis is a stenosing tenosynovitis of the first dorsal compartment, containing the abductor pollicis longus (APL) and extensor pollicis brevis (EPB). Repetitive thumb abduction/extension or wrist radial-ulnar deviation causes tendon sheath thickening and inflammation within the fibro-osseous tunnel over the radial styloid. Most common in women aged 30-50, particularly new mothers who repetitively lift infants with thumbs abducted and wrists ulnar deviated (\"Baby Wrist\"). Risk factors include repetitive hand use, rheumatoid arthritis, pregnancy, and postpartum hormonal changes. An anatomic septum dividing the compartment into sub-compartments can predispose to the condition and treatment failure.\n\nCLINICAL PRESENTATION:\nPatients present with radial-sided wrist pain over the radial styloid, worsened by gripping, pinching, or thumb movements. Finkelstein\'s test is diagnostic: the patient tucks the thumb into the palm, makes a fist, and the examiner passively ulnar deviates the wrist. Sharp pain along the radial styloid confirms the diagnosis by stretching the inflamed APL and EPB tendons. This is distinct from Phalen\'s test (carpal tunnel), Tinel\'s sign (median nerve), and the empty can test (supraspinatus). Intersection syndrome causes more proximal dorsal forearm pain, 4-6 cm proximal to the wrist.\n\nTREATMENT:\nFirst-line: thumb spica splinting, activity modification, and NSAIDs. Corticosteroid injection into the first dorsal compartment sheath is highly effective (60-90% cure rate after single injection) when conservative measures fail. If a septum is present, both sub-compartments must be reached. Surgical release is reserved for cases refractory to at least two corticosteroid injections.\n\nKEY POINTS:\nFinkelstein\'s test diagnoses De Quervain\'s tenosynovitis: fist over tucked thumb followed by passive ulnar deviation. The condition involves APL and EPB tendons of the first dorsal compartment and is common in new mothers. Corticosteroid injection achieves 60-90% cure rates after a single injection."
  },
  {
    "id": 481,
    "categoryId": 7,
    "question": "Osteoclasts are responsible for bone resorption. They are activated by RANK-Ligand. Which medication mimics OPG (Osteoprotegerin) to block RANK-L and stop bone loss?",
    "options": [
      "A) Alendronate (Fosamax)",
      "B) Denosumab (Prolia)",
      "C) Teriparatide (Forteo)",
      "D) Raloxifene"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Denosumab).\n\nPATHOPHYSIOLOGY:\nBone homeostasis depends on balanced osteoblast-mediated formation and osteoclast-mediated resorption, regulated by the RANK-RANKL-OPG axis. RANKL, produced by osteoblasts and osteocytes, binds RANK on osteoclast precursors to stimulate osteoclast differentiation, activation, and survival. Osteoprotegerin (OPG) is a naturally occurring decoy receptor that competitively binds RANKL, preventing osteoclast formation. In osteoporosis, this balance shifts toward excessive resorption.\n\nCLINICAL REASONING:\nDenosumab (Prolia) is a fully human monoclonal antibody that mimics OPG by binding RANKL with high affinity, preventing it from engaging RANK and blocking osteoclast maturation. This distinguishes it from bisphosphonates (e.g., alendronate), which are incorporated into bone matrix and directly induce osteoclast apoptosis by inhibiting farnesyl pyrophosphate synthase in the mevalonate pathway. Teriparatide (Forteo) is an anabolic agent, a recombinant PTH analog stimulating osteoblast activity. Raloxifene is a SERM with estrogen agonist effects on bone but weaker antifracture efficacy limited to vertebral fractures.\n\nTREATMENT CONSIDERATIONS:\nDenosumab is administered subcutaneously every 6 months, advantageous for patients with GI intolerance, esophageal disorders, or renal impairment (not renally cleared). The FREEDOM trial demonstrated denosumab reduced vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% over 3 years. Critically, discontinuation causes rapid rebound bone resorption within 6 months with loss of gained density and increased vertebral fracture risk, including multiple vertebral fractures. Patients stopping denosumab must transition to a bisphosphonate to consolidate gains and prevent rebound loss.\n\nKEY POINTS:\nDenosumab mimics OPG by binding RANKL, preventing osteoclast maturation, which is mechanistically distinct from bisphosphonates that directly induce osteoclast apoptosis. Discontinuation causes rapid rebound resorption and increased vertebral fracture risk, mandating bisphosphonate transition. Denosumab is preferred in renal impairment because it is not renally cleared."
  },
  {
    "id": 482,
    "categoryId": 7,
    "question": "A 'Popeye Deformity' (bulge in the lower biceps) indicates rupture of:",
    "questionImages": [
      { "src": "assets/biceps-ten.jpg", "alt": "Biceps tendon", "caption": "Biceps tendon image." }
    ],
    "options": [
      "A) Distal Biceps Tendon",
      "B) Proximal Long Head of Biceps Tendon",
      "C) Proximal Short Head of Biceps Tendon",
      "D) Triceps Tendon"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/biceps-ten-tear-2.jpg", "alt": "Biceps tendon tear", "caption": "Biceps tendon tear image." }
    ],
    "explanation": "CORRECT: B (Proximal Long Head of Biceps Tendon).\n\nPATHOPHYSIOLOGY:\nThe biceps long head originates from the supraglenoid tubercle and superior glenoid labrum (the anchor for SLAP lesions), courses through the bicipital groove held by the transverse humeral ligament. The short head originates from the coracoid process. The long head is susceptible to degenerative tearing due to its intra-articular course, mechanical friction in the bicipital groove, and association with rotator cuff pathology. Chronic impingement, subscapularis tears (which destabilize the groove), and age-related degeneration are primary predisposing factors. Rupture typically occurs in patients over 50 with prior chronic shoulder pain from rotator cuff disease or biceps tendinopathy.\n\nCLINICAL PRESENTATION:\nRupture produces the characteristic Popeye deformity, a visible bulge in the distal anterior arm from the retracted, bunched muscle belly. Patients may report an acute pop, ecchymosis in the anterior arm, sudden relief of chronic anterior shoulder pain, and mild weakness with supination and elbow flexion. Functional deficit is relatively modest because the short head and brachialis compensate, preserving approximately 70 to 80% of supination and 80 to 90% of elbow flexion strength. This distinguishes it from distal biceps tendon rupture at the radial tuberosity, which causes significant supination strength loss and typically requires surgical repair.\n\nTREATMENT:\nNon-operative management is standard for older, lower-demand patients: brief rest, ice, NSAIDs, and progressive physical therapy. The cosmetic deformity is permanent but functionally well tolerated. Surgical tenodesis or tenotomy is considered for younger, active patients, manual laborers, those who cannot accept the cosmetic deformity, or patients with concurrent reparable rotator cuff tears.\n\nKEY POINTS:\nThe Popeye deformity results from proximal long head biceps tendon rupture, causing the muscle belly to retract distally. Functional loss is minimal as the short head and brachialis compensate, making non-operative management appropriate for most older adults. Distal biceps rupture causes significant supination weakness and typically requires surgical repair."
  },
  {
    "id": 483,
    "categoryId": 7,
    "question": "Trendelenburg Gait (hip drop) is caused by weakness of the:",
    "options": [
      "A) Gluteus Maximus",
      "B) Gluteus Medius (Abductor)",
      "C) Iliopsoas",
      "D) Hamstrings"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gluteus Medius).\n\nPATHOPHYSIOLOGY:\nThe gluteus medius is the primary hip abductor, stabilizing the pelvis during single-leg stance. It originates from the outer ilium and inserts on the greater trochanter. During walking, the stance-leg gluteus medius contracts to keep the pelvis level, preventing the contralateral side from dropping. The superior gluteal nerve (L4, L5, S1) innervates it; injury from hip surgery, improperly placed intramuscular injections, or L5 radiculopathy can cause weakness. Other causes include hip osteoarthritis, greater trochanteric bursitis, and muscular dystrophies.\n\nCLINICAL PRESENTATION:\nWhen the gluteus medius is weak, the pelvis drops on the contralateral side during single-leg stance, producing the Trendelenburg sign. Importantly, the sign is positive on the side of the standing leg, as it is the stance-leg abductor that is failing. For example, right gluteus medius weakness causes left pelvic drop when standing on the right leg. In walking, Trendelenburg gait results as the patient lurches the trunk toward the affected side to shift the center of gravity over the weight-bearing hip. Bilateral weakness produces a waddling gait, seen in muscular dystrophies. The test is performed by having the patient stand on one leg for 30 seconds while observing the pelvis from behind.\n\nTREATMENT:\nManagement targets the underlying cause. Physical therapy with hip abductor strengthening (side-lying abduction, clamshells, single-leg balance training) is the rehabilitation cornerstone. Superior gluteal nerve injury recovery may take 6-12 months. In hip osteoarthritis, total hip arthroplasty often improves abductor function, though care must avoid iatrogenic nerve injury. A contralateral-hand cane reduces demand on the weak abductor.\n\nKEY POINTS:\nThe gluteus medius is the primary hip abductor; weakness produces the Trendelenburg sign, positive on the standing-leg side. The superior gluteal nerve (L4, L5, S1) innervates it, and injury during hip surgery or injections causes Trendelenburg gait."
  },
  {
    "id": 484,
    "categoryId": 7,
    "question": "Polymyalgia Rheumatica (PMR) presents with stiffness and pain in the shoulders and hips. It is closely associated with:",
    "options": [
      "A) Giant Cell Arteritis (Temporal Arteritis)",
      "B) Lupus",
      "C) Rheumatoid Arthritis",
      "D) Gout"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Giant Cell Arteritis).\n\nPATHOPHYSIOLOGY:\nPolymyalgia rheumatica (PMR) is a systemic inflammatory condition affecting individuals over 50, peaking at ages 70-80, and 2 to 3 times more common in women. It involves immune-mediated inflammation of periarticular structures including subacromial and trochanteric bursae and joint capsules of the shoulder and hip girdles. Giant cell arteritis (GCA) is a granulomatous vasculitis of large and medium arteries, particularly the superficial temporal and ophthalmic arteries. PMR and GCA share immunogenetic associations (HLA-DR4), demographics, and IL-6/interferon-gamma inflammatory pathways, supporting them as a disease spectrum.\n\nCLINICAL PRESENTATION:\nPMR presents with bilateral symmetric aching and morning stiffness of the shoulder girdle, hip girdle, and neck, worst upon waking and improving with activity over 30 to 60 minutes. Constitutional symptoms include fatigue, low-grade fever, and weight loss. Labs characteristically show markedly elevated ESR (often greater than 40 to 50 mm/hr) and CRP with normocytic anemia. The critical association: approximately 15 to 30% of PMR patients have coexisting GCA, and up to 50% of GCA patients have PMR symptoms. GCA can cause permanent vision loss from anterior ischemic optic neuropathy. All PMR patients must be screened at every visit for GCA: new headache, scalp tenderness, jaw claudication, and visual changes.\n\nTREATMENT:\nPMR responds dramatically to low-dose prednisone (12.5 to 25 mg daily), with significant improvement within 24 to 72 hours. Failure to respond should prompt diagnostic reconsideration. Prednisone is tapered over 12 to 24 months guided by symptoms and inflammatory markers. GCA requires high-dose prednisone (40 to 60 mg daily) initiated immediately upon clinical suspicion, even before temporal artery biopsy, to prevent irreversible vision loss. Tocilizumab (IL-6 receptor antagonist) is approved as a steroid-sparing agent for both GCA and relapsing PMR per the GiACTA trial.\n\nKEY POINTS:\nPMR and GCA are closely linked, with 15 to 30% of PMR patients having coexisting GCA and 50% of GCA patients having PMR. All PMR patients must be screened for headache, jaw claudication, and visual symptoms. PMR responds to low-dose prednisone within 24 to 72 hours; GCA requires urgent high-dose prednisone."
  },
  {
    "id": 485,
    "categoryId": 7,
    "question": "A Colles' Fracture is a distal radius fracture with dorsal angulation ('Dinner Fork deformity'). It is most commonly caused by:",
    "questionImages": [
      { "src": "assets/21860-colles-fracture-fnl.jpg", "alt": "Colles fracture", "caption": "Colles fracture image." }
    ],
    "options": [
      "A) Direct blow",
      "B) Fall on Outstretched Hand (FOOSH)",
      "C) Twisting injury",
      "D) Overuse"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fall on Outstretched Hand).\n\nPATHOPHYSIOLOGY:\nA Colles fracture is a distal radius fracture with dorsal displacement and angulation, resulting from a fall on an outstretched hand (FOOSH) with the wrist in dorsiflexion. Axial loading through the hyperextended wrist creates tensile failure on the volar surface and compression dorsally, driving the distal fragment dorsally. This is the most common forearm fracture and the most common fracture in postmenopausal women, reflecting osteoporotic bone prevalence. Higher-energy mechanisms are required in younger patients. The Smith fracture is the reverse pattern with volar displacement from a fall on a flexed wrist.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes wrist pain, swelling, and the pathognomonic dinner fork deformity from dorsal displacement visible on lateral inspection. Neurovascular examination is essential, as acute carpal tunnel syndrome from median nerve compression occurs in 5 to 10% of distal radius fractures and requires urgent decompression. An associated ulnar styloid fracture is present in approximately 50 to 60% of cases. Standard PA and lateral wrist radiographs confirm diagnosis and assess displacement, angulation, articular involvement, and ulnar-sided injury.\n\nTREATMENT:\nStable, minimally displaced extra-articular fractures are managed with closed reduction, sugar-tong splinting, and conversion to short arm cast at 1 to 2 weeks. Immobilization is maintained 4 to 6 weeks with serial radiographs monitoring for loss of reduction. Unstable fractures (significant dorsal comminution, intra-articular extension, shortening greater than 5 mm, or loss of reduction) require surgical fixation, most commonly volar locking plate. All distal radius fractures in patients over 50 should prompt osteoporosis evaluation including DEXA screening, as this is a recognized fragility fracture that doubles subsequent hip fracture risk.\n\nKEY POINTS:\nA Colles fracture is a dorsally displaced distal radius fracture from FOOSH, producing the classic dinner fork deformity. Median nerve function must be assessed as acute carpal tunnel complicates 5 to 10% of cases. In patients over 50, it should be treated as a fragility fracture with osteoporosis evaluation and secondary prevention."
  },
  {
    "id": 486,
    "categoryId": 7,
    "question": "The 'Unhappy Triad' (O'Donoghue's Triad) of knee injury typically involves the ACL, MCL, and:",
    "options": [
      "A) LCL",
      "B) Medial Meniscus",
      "C) Lateral Meniscus",
      "D) Patellar Tendon"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/unhappytriad.jpg", "alt": "Unhappy triad", "caption": "Unhappy triad image." }
    ],
    "explanation": "CORRECT: B (Medial Meniscus).\n\nPATHOPHYSIOLOGY:\nThe unhappy triad (O\'Donoghue\'s triad) results from a valgus force to a flexed, externally rotated knee, classically from a lateral tackle in contact sports. The mechanism sequentially injures: the ACL (as the tibia translates anteriorly), the MCL (as valgus force exceeds its tensile strength), and the medial meniscus (firmly attached to the MCL\'s deep fibers and joint capsule via coronary ligaments, making it vulnerable when the MCL is disrupted). The ACL restrains anterior tibial translation, the MCL restrains valgus stress, and the medial meniscus serves as a secondary anterior stabilizer.\n\nCLINICAL PRESENTATION:\nPatients present after a lateral knee blow with immediate hemarthrosis (from ACL rupture), inability to bear weight, and knee \"giving way.\" Examination reveals a positive Lachman and anterior drawer test (ACL insufficiency), valgus laxity at 30 degrees flexion (MCL disruption), and joint line tenderness with positive McMurray test (meniscal injury). MRI confirms all three injuries with high sensitivity and specificity. While recent MRI studies show lateral meniscus tears are actually more common with acute ACL injuries due to greater lateral tibial subluxation, the classic board answer for the unhappy triad remains ACL, MCL, and medial meniscus.\n\nTREATMENT:\nACL reconstruction is recommended for active patients using hamstring or bone-patellar tendon-bone autograft. MCL injuries heal well conservatively (hinged knee brace, progressive rehabilitation) due to excellent blood supply; most grade I-II sprains are managed non-operatively. Medial meniscus tears in the peripheral red zone may be repaired, while avascular white zone tears require partial meniscectomy. Return to sport is typically 9-12 months after combined reconstruction.\n\nKEY POINTS:\nThe unhappy triad (O\'Donoghue\'s triad) classically involves ACL, MCL, and medial meniscus from a valgus/external rotation force. The MCL heals well conservatively due to robust blood supply, while ACL reconstruction is typically required in active patients."
  },
  {
    "id": 487,
    "categoryId": 7,
    "question": "Uric Acid crystals in Gout are identified on microscopy as:",
    "options": [
      "A) Positively birefringent, Rhomboid shape",
      "B) Negatively birefringent, Needle shape",
      "C) Non-birefringent, amorphous",
      "D) Spherical"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Negatively birefringent, Needle shape).\n\nPATHOPHYSIOLOGY:\nGout results from deposition of monosodium urate (MSU) crystals in joints when serum uric acid exceeds the saturation threshold of approximately 6.8 mg/dL. Hyperuricemia results from underexcretion (90% of cases, associated with CKD, diuretics, and genetic urate transporter variations) or overproduction (10%, associated with high purine intake, myeloproliferative disorders, and tumor lysis). MSU crystals activate the NLRP3 inflammasome in macrophages, triggering IL-1 beta release and intense neutrophilic inflammation. Definitive diagnosis requires joint aspiration showing negatively birefringent, needle-shaped crystals (yellow when parallel to the red compensator), contrasting with CPPD pseudogout crystals which are positively birefringent and rhomboid-shaped (blue when parallel).\n\nCLINICAL PRESENTATION:\nAcute gout presents with sudden severe pain, swelling, erythema, and warmth of a single joint, classically the first MTP joint (podagra) in approximately 50% of initial attacks. Attacks begin at night, peak within 12 to 24 hours, and the joint is so tender that even bedsheet weight is intolerable. Untreated flares self-resolve in 7 to 14 days. Risk factors: male sex, obesity, purine-rich diet, alcohol (particularly beer), thiazide and loop diuretics, CKD, and metabolic syndrome. Chronic tophaceous gout develops after years of inadequately treated hyperuricemia, with tophi in joints, bursae, and soft tissues.\n\nTREATMENT:\nAcute flares: NSAIDs at full doses, colchicine (low-dose regimen: 1.2 mg then 0.6 mg one hour later, equally effective and better tolerated than high-dose protocols), or corticosteroids (prednisone 30 to 40 mg daily for 5 to 7 days). Urate-lowering therapy (ULT) is indicated for recurrent flares (2 or more per year), tophi, CKD, or uric acid stones. Allopurinol (xanthine oxidase inhibitor) is first-line, started at 100 mg daily and titrated to target serum urate below 6 mg/dL. ULT should not begin during acute flares; start 2 to 4 weeks after resolution with prophylactic low-dose colchicine for 3 to 6 months to prevent mobilization flares.\n\nKEY POINTS:\nGout is diagnosed by negatively birefringent, needle-shaped MSU crystals versus positively birefringent, rhomboid CPPD crystals in pseudogout. Acute flares respond to NSAIDs, colchicine, or corticosteroids. Allopurinol targets serum urate below 6 mg/dL and should not be initiated during acute flares."
  },
  {
    "id": 488,
    "categoryId": 7,
    "question": "Spinal Stenosis typically presents with 'Neurogenic Claudication', which is defined as:",
    "options": [
      "A) Leg pain that worsens with walking and improves with sitting/flexion",
      "B) Leg pain that worsens with rest",
      "C) Leg pain that is constant",
      "D) Leg pain relieved by standing straight up"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      { "src": "assets/lss.jpg", "alt": "Lumbar spinal stenosis", "caption": "Lumbar spinal stenosis image." }
    ],
    "explanation": "CORRECT: A (Leg pain that worsens with walking and improves with sitting/flexion).\n\nPATHOPHYSIOLOGY:\nLumbar spinal stenosis is narrowing of the spinal canal compressing the cauda equina and nerve roots, most commonly from degenerative changes (disc bulging, facet hypertrophy, ligamentum flavum thickening, osteophytes) in patients over 60, typically at L4-L5. The hallmark is neurogenic claudication. Lumbar extension narrows the canal as the ligamentum flavum buckles inward and discs bulge posteriorly, compressing neural structures. Lumbar flexion opens the canal, relieving compression. This explains the classic shopping cart sign: patients lean forward for relief because flexion increases canal cross-sectional area by 10 to 15%.\n\nCLINICAL PRESENTATION:\nPatients describe bilateral or unilateral leg pain, heaviness, numbness, or weakness that develops with walking or standing and is relieved by sitting, squatting, or leaning forward. Symptoms worsen walking downhill (extension) and improve walking uphill (flexion). This distinguishes neurogenic from vascular claudication, where pain is produced by a fixed walking distance, relieved simply by standing still, and associated with diminished pulses and skin changes. In neurogenic claudication, peripheral pulses and ABI are normal. Neurologic examination may be normal at rest. MRI is the imaging study of choice. Per NEJM reviews, clinical severity does not always correlate with radiographic stenosis.\n\nTREATMENT:\nFirst-line: physical therapy emphasizing flexion-based exercises (Williams flexion exercises), core stabilization, and activity modification. Epidural steroid injections provide moderate short-term relief (2 to 6 weeks). NSAIDs and gabapentin or pregabalin may be adjuncts. Surgical decompression (laminectomy with or without fusion) is indicated for persistent symptoms despite 3 to 6 months of conservative therapy, progressive neurologic deficits, or significantly impaired quality of life. The SPORT trial (NEJM) demonstrated greater surgical improvement at 2 and 4 years compared to non-operative management.\n\nKEY POINTS:\nNeurogenic claudication involves leg pain worsening with walking and extension and improving with sitting or flexion (shopping cart sign), unlike vascular claudication relieved by standing still. Peripheral pulses are normal, and MRI confirms diagnosis. Flexion-based physical therapy is first-line; surgical decompression is reserved for failure of 3 to 6 months conservative management or progressive neurologic deficits."
  },
  {
    "id": 489,
    "categoryId": 7,
    "question": "Which nerve runs in the spiral groove of the humerus and is at risk during mid-shaft humerus fractures?",
    "questionImages": [
      { "src": "assets/humerus-fracture-midshaft.jpg", "alt": "Midshaft humerus fracture", "caption": "Midshaft humerus fracture image." }
    ],
    "options": [
      "A) Median Nerve",
      "B) Ulnar Nerve",
      "C) Radial Nerve",
      "D) Axillary Nerve"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Radial Nerve).\n\nPATHOPHYSIOLOGY:\nThe radial nerve (C5-T1), the largest branch of the posterior cord of the brachial plexus, courses through the spiral groove on the posterior mid-shaft humerus in direct contact with periosteum for approximately 7 centimeters. This makes it uniquely vulnerable to injury in humeral shaft fractures, with reported injury rates of 12 to 18%. The Holstein-Lewis fracture (distal-third spiral humeral fracture) carries the highest risk because the nerve is tethered at the lateral intermuscular septum. The radial nerve can also be injured iatrogenically during surgical fixation or by external compression (Saturday night palsy, honeymoon palsy).\n\nCLINICAL PRESENTATION:\nSpiral groove injury produces classic wrist drop: inability to extend the wrist and fingers at the MCP joints from paralysis of the forearm extensor compartment (extensor carpi radialis, extensor digitorum, extensor carpi ulnaris, extensor pollicis longus). The brachioradialis reflex is diminished. Sensory loss occurs over the dorsal first web space (superficial radial nerve territory). The triceps is typically spared because its branches arise proximal to the groove, distinguishing this from a higher posterior cord injury. Other key nerve-fracture associations: axillary nerve with proximal humerus fractures (deltoid weakness, lateral shoulder sensory loss) and ulnar nerve with medial epicondyle fractures (finger clawing, intrinsic muscle weakness).\n\nTREATMENT:\nMost radial nerve palsies from closed fractures are neuropraxias that recover spontaneously within 3 to 4 months. Initial management includes a wrist extension splint (cock-up splint) to prevent flexion contracture, range of motion exercises, and serial monitoring. EMG and nerve conduction studies are performed at 3 to 4 weeks (baseline) and repeated at 3 to 4 months to assess reinnervation. Surgical exploration is indicated for open fractures with palsy, palsy developing after reduction or fixation (iatrogenic entrapment), or failure of recovery by 3 to 4 months.\n\nKEY POINTS:\nThe radial nerve in the spiral groove is injured in 12 to 18% of humeral shaft fractures, producing classic wrist drop. The axillary nerve is at risk in proximal humerus fractures; the ulnar nerve in medial epicondyle fractures. Most closed-fracture radial nerve injuries are neuropraxias recovering within 3 to 4 months with wrist splinting."
  },
  {
    "id": 490,
    "categoryId": 7,
    "question": "The Sarcomere is the functional unit of muscle. Contraction occurs when:",
    "questionImages": [
      { "src": "assets/sarcomere.jpg", "alt": "Sarcomere", "caption": "Sarcomere image." }
    ],
    "options": [
      "A) Actin and Myosin filaments shorten",
      "B) Actin filaments slide over Myosin filaments (Sliding Filament Theory)",
      "C) Calcium binds to Myosin directly",
      "D) ATP is produced"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Actin filaments slide over Myosin filaments).\n\nPATHOPHYSIOLOGY:\nThe sarcomere is the basic contractile unit between two Z-lines, containing thin actin filaments (anchored to Z-lines) and thick myosin filaments (centered at the M-line). The sliding filament theory (Huxley, 1954) establishes that muscle contraction occurs by actin filaments sliding over myosin filaments toward the sarcomere center, increasing overlap without shortening of individual filaments.\n\nCLINICAL REASONING:\nAt rest, tropomyosin and troponin block myosin-binding sites on actin. When an action potential triggers calcium release from the sarcoplasmic reticulum via T-tubules, calcium binds troponin C, shifting tropomyosin to expose actin binding sites. The myosin head (pre-loaded with ADP and inorganic phosphate from ATP hydrolysis) binds actin, forming a cross-bridge. Phosphate release triggers the power stroke, pulling actin toward the M-line. ADP is released, new ATP binds causing myosin detachment, and ATP hydrolysis re-cocks the myosin head. This cycle repeats approximately 5 times per second per cross-bridge while calcium and ATP are available. Rigor mortis occurs after death because ATP depletion prevents myosin detachment, locking all cross-bridges.\n\nCLINICAL SIGNIFICANCE:\nMalignant hyperthermia, triggered by volatile anesthetics and succinylcholine, results from uncontrolled calcium release through defective ryanodine receptors, producing sustained contraction, rigidity, and extreme heat generation. Dantrolene specifically treats this by blocking sarcoplasmic reticulum calcium release. Myasthenia gravis involves autoantibodies against acetylcholine receptors, reducing the signal initiating muscle depolarization. Lambert-Eaton syndrome involves antibodies against presynaptic voltage-gated calcium channels, reducing acetylcholine release.\n\nKEY POINTS:\nMuscle contraction occurs by actin sliding over myosin (sliding filament theory), with filaments maintaining constant length. The cross-bridge cycle requires calcium binding to troponin to expose actin sites and ATP for myosin detachment. Rigor mortis results from ATP depletion; malignant hyperthermia from uncontrolled sarcoplasmic reticulum calcium release, treated with dantrolene."
  },
  {
    "id": 491,
    "categoryId": 7,
    "question": "Osgood-Schlatter Disease is an apophysitis caused by traction of the:",
    "questionImages": [
      { "src": "assets/osgood-schlatter.png", "alt": "Osgood Schlatter disease", "caption": "Osgood-Schlatter image." }
    ],
    "options": [
      "A) Quadriceps tendon on the patella",
      "B) Patellar tendon on the Tibial Tubercle",
      "C) Achilles tendon on the Calcaneus",
      "D) Hamstrings on the Ischium"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Patellar tendon on the Tibial Tubercle).\n\nPATHOPHYSIOLOGY:\nOsgood-Schlatter disease is a traction apophysitis of the tibial tubercle at the patellar tendon insertion on the secondary ossification center of the proximal tibia. During the adolescent growth spurt, long bones grow faster than musculotendinous units can lengthen, increasing tension at apophyseal insertions. The tibial tubercle apophysis is the weakest link in the extensor mechanism chain, and repetitive forceful quadriceps contraction during running, jumping, and kicking produces microavulsion injuries and inflammation. The condition affects adolescents aged 10 to 15 during peak growth velocity, is bilateral in up to 30%, and is associated with jumping sports (basketball, volleyball) and running sports (soccer, track). It is self-limited, resolving with skeletal maturity when the apophysis fuses, though a prominent tubercle may persist.\n\nCLINICAL PRESENTATION:\nPatients present with anterior knee pain localized to the tibial tubercle, worsening with running, jumping, squatting, kneeling, and stair climbing, and improving with rest. Examination reveals a tender, swollen, often prominent tibial tubercle. Pain is reproduced by resisted knee extension and direct palpation. The knee joint is stable with no effusion, no ligamentous laxity, and full range of motion, distinguishing this from intra-articular pathology. Diagnosis is clinical and does not require imaging in typical presentations. Sinding-Larsen-Johansson syndrome is a related traction apophysitis at the inferior patellar pole.\n\nTREATMENT:\nManagement is conservative: activity modification, relative rest from provocative activities, ice, and NSAIDs for flares, with reassurance of self-limited nature. Quadriceps and hamstring stretching reduces apophyseal tension, and eccentric quadriceps strengthening accelerates improvement. Protective padding allows continued sports participation. Complete activity cessation is generally unnecessary. Rarely, a persistent symptomatic ossicle may require surgical excision after skeletal maturity.\n\nKEY POINTS:\nOsgood-Schlatter disease is traction apophysitis of the tibial tubercle at the patellar tendon insertion during the adolescent growth spurt. Diagnosis is clinical: tibial tubercle tenderness, stable knee without effusion, pain with resisted extension. The condition is self-limited, resolving with skeletal maturity; treatment focuses on activity modification, stretching, and symptomatic relief."
  },
  {
    "id": 492,
    "categoryId": 7,
    "question": "The earliest and most sensitive sign of Compartment Syndrome is:",
    "options": [
      "A) Loss of pulse",
      "B) Pain out of proportion to injury (especially with passive stretch)",
      "C) Pallor",
      "D) Paralysis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pain out of proportion to injury, especially with passive stretch).\n\nPATHOPHYSIOLOGY:\nAcute compartment syndrome is a surgical emergency in which elevated pressure within a closed fascial compartment compromises tissue perfusion, leading to ischemia and irreversible necrosis if untreated. When intracompartmental pressure rises from hemorrhage or edema following fracture (tibial shaft fractures are the most common cause, approximately 36% of cases), crush injury, reperfusion, tight casts, or burns, it exceeds capillary perfusion pressure. Impaired venous outflow causes further edema in a vicious cycle. Tissue ischemia occurs at pressures (typically 30 mmHg or within 30 mmHg of diastolic pressure) far below arterial pressure, which is why peripheral pulses remain palpable until very late, as arterial flow is not occluded until pressures have already destroyed muscle and nerve.\n\nCLINICAL PRESENTATION:\nPain out of proportion to injury is the earliest and most sensitive finding. Pain is deep, unremitting, and worsened by passive stretch of the affected compartment muscles (e.g., passive plantarflexion in anterior leg compartment syndrome). The six P's (Pain, Pressure, Paresthesias, Paralysis, Pallor, Pulselessness) describe early-to-late progression. Paresthesias indicate nerve ischemia. Paralysis indicates muscle and nerve death (late). Pulselessness occurs only when pressure exceeds arterial pressure, by which time irreversible damage has occurred. In obtunded patients, continuous pressure monitoring is essential. Diagnosis is confirmed when pressure exceeds 30 mmHg absolute or delta pressure (diastolic minus compartment pressure) is less than 30 mmHg.\n\nTREATMENT:\nEmergent fasciotomy is definitive treatment. All constrictive dressings and casts must be removed immediately. In the leg, a two-incision four-compartment fasciotomy is standard. Wounds are left open for staged closure at 48 to 72 hours. Irreversible muscle necrosis begins within 4 to 6 hours of sustained ischemia; delay beyond 6 to 8 hours significantly increases amputation, permanent nerve injury, and Volkmann ischemic contracture risk. Rhabdomyolysis with myoglobinuria and acute kidney injury may complicate delayed cases.\n\nKEY POINTS:\nPain out of proportion to injury with passive stretch is the earliest sign; pulselessness is very late and indicates tissue death has already occurred. Emergent fasciotomy is required as irreversible necrosis begins within 4 to 6 hours. Tibial shaft fractures are the most common cause, and pulses remain present until late because tissue-destroying pressures are far below arterial pressure."
  },
  {
    "id": 493,
    "categoryId": 7,
    "question": "Ankylosing Spondylitis begins with inflammation at the:",
    "options": [
      "A) Cervical Spine",
      "B) Sacroiliac (SI) Joints",
      "C) Knee",
      "D) Costochondral joints"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/ankylosing-spondylitis.jpg", "alt": "Ankylosing spondylitis", "caption": "Ankylosing spondylitis image." }
    ],
    "explanation": "CORRECT: B (Sacroiliac Joints).\n\nPATHOPHYSIOLOGY:\nAnkylosing spondylitis (AS) is a chronic inflammatory spondyloarthritis involving entheseal inflammation with strong HLA-B27 association (approximately 90 to 95% of AS patients versus 6 to 8% of the general population). Disease begins at the sacroiliac joints in virtually all cases, making sacroiliitis the radiographic hallmark. The IL-23/IL-17 signaling axis drives chronic entheseal inflammation. Unlike RA where inflammation causes bone erosion, AS triggers paradoxical new bone formation producing syndesmophytes (bony bridges between vertebral bodies). Progressive syndesmophyte formation leads to spinal ankylosis, producing the classic bamboo spine. AS predominantly affects young men (onset ages 15 to 40, male-to-female ratio approximately 2 to 3:1).\n\nCLINICAL PRESENTATION:\nThe cardinal symptom is inflammatory back pain: insidious onset before age 40, duration greater than 3 months, morning stiffness greater than 30 minutes improving with exercise and not with rest, and alternating buttock pain, distinguishing it from mechanical back pain. Reduced spinal mobility is assessed by the modified Schober test (less than 5 cm lumbar expansion is abnormal). Reduced chest expansion (less than 2.5 cm) reflects costovertebral involvement. Extra-articular manifestations include anterior uveitis (most common, 25 to 40%), inflammatory bowel disease (up to 10% clinical, 60% subclinical), psoriasis, aortitis, and apical pulmonary fibrosis. ESR and CRP are elevated in 50 to 70%. Conventional radiographs may be normal early; MRI of the sacroiliac joints detects bone marrow edema before structural changes and is the recommended early imaging modality.\n\nTREATMENT:\nRegular exercise and physical therapy emphasizing posture, spinal extension, and range of motion are foundational. NSAIDs at full anti-inflammatory doses are first-line, with 70 to 80% reporting significant improvement. For inadequate response to two or more NSAIDs over 4 weeks, biologic therapy with TNF-alpha inhibitors or IL-17A inhibitors (secukinumab, ixekizumab) is recommended per ACR/SAA/SPARTAN 2019 guidelines. Conventional DMARDs are ineffective for axial disease.\n\nKEY POINTS:\nAS begins at the sacroiliac joints with strong HLA-B27 association; entheseal inflammation triggers new bone formation progressively fusing the spine. Inflammatory back pain is distinguished by onset before 40, morning stiffness improving with activity, and alternating buttock pain. MRI detects early sacroiliitis; first-line treatment is exercise plus full-dose NSAIDs, with TNF-alpha or IL-17A inhibitors for refractory disease."
  },
  {
    "id": 494,
    "categoryId": 7,
    "question": "The most common organism causing Osteomyelitis in healthy adults is:",
    "options": [
      "A) Salmonella",
      "B) Staphylococcus aureus",
      "C) Pseudomonas",
      "D) E. coli"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Staphylococcus aureus).\n\nPATHOPHYSIOLOGY:\nStaphylococcus aureus is the most common cause of osteomyelitis overall (approximately 50 to 70% of cases), owing to surface adhesins (MSCRAMMs) that bind bone matrix proteins including collagen, fibronectin, and bone sialoprotein. S. aureus forms biofilms, internalizes within osteocytes and osteoblasts, and induces osteoclast-mediated resorption, contributing to treatment difficulty and chronicity. Hematogenous osteomyelitis predominates in children (metaphyseal blood supply favors bacterial seeding, commonly distal femur and proximal tibia). In adults, hematogenous disease most commonly involves vertebral bodies, while contiguous-spread from diabetic foot ulcers or surgical wounds is the more prevalent adult form.\n\nCLINICAL PRESENTATION:\nAcute osteomyelitis presents with localized bone pain, tenderness, warmth, swelling, and fever. In children, refusal to bear weight may be the presenting sign. Chronic disease shows persistent drainage, sinus tracts, and low-grade pain. In diabetic foot osteomyelitis, the probe-to-bone test has approximately 89% positive predictive value. Labs show elevated ESR (often greater than 50 to 70 mm/hr) and CRP. Plain radiographs are normal in the first 10 to 14 days (30 to 50% bone loss needed for visible changes). MRI is most sensitive and specific (sensitivity 90 to 100%, specificity 80 to 90%). Bone biopsy with culture is the gold standard per IDSA guidelines, strongly recommended before starting antibiotics given MRSA prevalence.\n\nMICROBIOLOGY BY CONTEXT:\nS. aureus: most common overall. Pseudomonas: puncture wounds through sneakers. Salmonella: most common in sickle cell disease. Polymicrobial (gram-negatives and anaerobes): diabetic foot and decubitus ulcers. Coagulase-negative staphylococci: prosthetic joint infections. M. tuberculosis: vertebral osteomyelitis (Pott disease) in endemic regions.\n\nTREATMENT:\nParenteral antibiotics for 4 to 6 weeks (6 to 8 weeks for vertebral osteomyelitis) are standard, with empiric MRSA coverage narrowed by culture results. Surgical debridement is essential for chronic osteomyelitis with sequestrum, hardware infection, or antibiotic failure.\n\nKEY POINTS:\nS. aureus is the most common cause of osteomyelitis; Salmonella is classically associated with sickle cell disease and Pseudomonas with sneaker puncture wounds. MRI is the most sensitive imaging modality, and bone biopsy culture is the gold standard. Treatment is 4 to 6 weeks parenteral antibiotics with surgical debridement of necrotic bone."
  },
  {
    "id": 495,
    "categoryId": 7,
    "question": "Plantar Fasciitis is caused by microtears and degeneration of the fascia at its origin on the:",
    "questionImages": [
      { "src": "assets/plantar_1280.jpg", "alt": "Plantar fascia", "caption": "Plantar fascia image." }
    ],
    "options": [
      "A) Medial Calcaneal Tubercle",
      "B) Base of the 1st Metatarsal",
      "C) Talus",
      "D) Cuboid"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Medial Calcaneal Tubercle).\n\nPATHOPHYSIOLOGY:\nPlantar fasciitis is the most common cause of inferior heel pain (approximately 10% lifetime prevalence). The plantar fascia originates from the medial calcaneal tubercle and fans distally to the proximal phalanges, supporting the longitudinal arch via the windlass mechanism. The pathology is a degenerative enthesopathy (not truly inflammatory despite the \"-itis\" suffix); histology shows collagen degeneration and angiofibroblastic hyperplasia without inflammatory cells, hence the preferred term plantar fasciosis. Risk factors: obesity (BMI greater than 30, strongest modifiable risk factor), prolonged standing, running, pes planus or cavus, tight Achilles and gastrocnemius-soleus complex, and age 40 to 60. Calcaneal heel spurs, present in approximately 50% of cases, arise from the short flexor muscles (not the fascia) and are equally prevalent in asymptomatic individuals; they are not the pain source.\n\nCLINICAL PRESENTATION:\nThe hallmark is sharp, stabbing medial plantar heel pain with first morning steps (post-static dyskinesia) that improves after several minutes of walking but worsens with prolonged standing. Examination reveals maximal tenderness at the medial calcaneal tubercle, with pain reproduced by toe dorsiflexion (windlass mechanism). Diagnosis is clinical; imaging is unnecessary in typical cases. Imaging is reserved for atypical features (bilateral pain in young patients suggesting spondyloarthropathy, night pain suggesting tumor or stress fracture) or failure to respond after 6 weeks. Ultrasound showing fascia thickness greater than 4 mm supports the diagnosis.\n\nTREATMENT:\nConservative management succeeds in 80 to 90% of patients within 10 to 12 months. First-line: plantar fascia-specific stretching (dorsiflexing toes while palpating the fascia, 10 reps of 10-second holds three times daily, especially before first morning steps), supportive footwear with arch support, orthotics, and night splints maintaining 5 degrees of dorsiflexion. NSAIDs provide symptomatic relief. Corticosteroid injection offers 4 to 8 weeks of relief but carries 2 to 6% risk of fascial rupture and fat pad atrophy. Surgical partial fasciotomy is considered only after 6 to 12 months of failed conservative treatment.\n\nKEY POINTS:\nPlantar fasciitis is a degenerative enthesopathy at the medial calcaneal tubercle origin, presenting with classic post-static dyskinesia. Diagnosis is clinical; heel spurs are not the pain source. Conservative management including stretching, footwear, and orthotics succeeds in 80 to 90% within 10 to 12 months."
  },
  {
    "id": 496,
    "categoryId": 7,
    "question": "Anterior Shoulder Dislocation is the most common type. It puts the patient at risk for a 'Bankart Lesion', which is:",
    "options": [
      "A) A dent in the humeral head",
      "B) A tear of the anterior-inferior glenoid labrum",
      "C) A tear of the rotator cuff",
      "D) A fracture of the clavicle"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/bankart-lesion.jpg", "alt": "Bankart lesion", "caption": "Bankart lesion image." },
      { "src": "assets/hillsachs_1280.jpg", "alt": "Hill-Sachs lesion", "caption": "Hill-Sachs lesion image." }
    ],
    "explanation": "CORRECT: B (A tear of the anterior-inferior glenoid labrum).\n\nPATHOPHYSIOLOGY:\nAnterior shoulder dislocations account for approximately 95% of all shoulder dislocations, typically from forced abduction, external rotation, and extension. During dislocation, the humeral head shears off the anterior-inferior glenoid labrum, creating the Bankart lesion, the primary structural cause of recurrent anterior instability. The labrum deepens the glenoid fossa by approximately 50% and anchors the inferior glenohumeral ligament, the most important static anterior stabilizer. Bankart disruption reduces socket depth and creates a pathway for recurrent dislocation. A bony Bankart involves anterior glenoid rim fracture. The Hill-Sachs lesion is a posterolateral humeral head compression fracture from impact against the anterior glenoid rim, present in 40 to 90% of anterior dislocations.\n\nCLINICAL PRESENTATION:\nPatients present with severe pain, arm held in slight abduction and external rotation, and a squared-off shoulder contour. Pre-reduction neurovascular assessment is critical: the axillary nerve is injured in 5 to 14% of cases, producing lateral deltoid numbness (regimental badge area) and deltoid weakness. Pre- and post-reduction radiographs (AP and axillary views) are essential. MRI or MR arthrography evaluates Bankart and Hill-Sachs lesions and rotator cuff tears (occurring in 30 to 40% of first dislocations in patients over 40). Recurrence is strongly age-dependent: under 20 years, 70 to 90%; ages 20 to 40, 30 to 50%; over 40, less than 15% but with higher rotator cuff tear incidence.\n\nTREATMENT:\nImmediate closed reduction under sedation is initial management. Post-reduction: sling immobilization for 1 to 3 weeks followed by rotator cuff and periscapular strengthening. For young, active patients with Bankart lesion on MRI, evidence supports early arthroscopic Bankart repair to reduce the high recurrence rate. Surgical stabilization (arthroscopic Bankart repair or Latarjet procedure for significant glenoid bone loss) is indicated for recurrent instability. In older patients, rotator cuff repair takes priority.\n\nKEY POINTS:\nA Bankart lesion (anterior-inferior labral tear) is the primary cause of recurrent anterior instability; a Hill-Sachs lesion is a posterolateral humeral head compression fracture. The axillary nerve is injured in 5 to 14% of cases; test lateral deltoid sensation. Recurrence rates are age-dependent (70 to 90% under age 20), supporting early surgical repair in young active patients."
  },
  {
    "id": 497,
    "categoryId": 7,
    "question": "Lateral Epicondylitis ('Tennis Elbow') involves inflammation of the origin of which muscle group?",
    "questionImages": [
      { "src": "assets/jmm_lateral_epicondylitis_tennis_elbow.webp", "alt": "Lateral epicondylitis", "caption": "Lateral epicondylitis image." }
    ],
    "options": [
      "A) Wrist Flexors",
      "B) Wrist Extensors (specifically ECRB)",
      "C) Biceps",
      "D) Triceps"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Wrist Extensors, specifically Extensor Carpi Radialis Brevis).\n\nPATHOPHYSIOLOGY:\nLateral epicondylitis (tennis elbow) is a degenerative tendinopathy of the common extensor origin at the lateral epicondyle, primarily affecting the extensor carpi radialis brevis (ECRB). Only 5-10% of patients play tennis; repetitive occupational gripping and wrist extension are far more common causes. The pathology is angiofibroblastic dysplasia (fibroblast proliferation, vascular hyperplasia, disorganized collagen) rather than acute inflammation. The ECRB is preferentially affected because its undersurface abuts the capitellum, causing mechanical abrasion during forearm rotation. Typically affects adults aged 35-55 with equal gender distribution. Medial epicondylitis (golfer\'s elbow) affects the flexor-pronator origin and is 5-10 times less common.\n\nCLINICAL PRESENTATION:\nPatients present with lateral epicondylar pain radiating into the proximal extensor forearm, worsened by gripping and resisted wrist or middle finger extension. Provocative tests: Cozen\'s test (resisted wrist extension, forearm pronated, elbow extended), Mill\'s test (passive wrist flexion stretching the extensor origin), and the chair lift test (lifting a chair with forearm pronated). Diagnosis is clinical; imaging is not routinely needed but ultrasound or MRI can show tendon thickening and tears when required.\n\nTREATMENT:\nApproximately 80-90% of cases resolve within 12-18 months. First-line: activity modification, counterforce bracing (forearm strap 2-3 cm distal to the epicondyle), and eccentric wrist extensor strengthening, which has the strongest evidence base. NSAIDs provide short-term relief. Corticosteroid injection offers 4-6 weeks of benefit but worsens long-term outcomes with higher recurrence and is not recommended routinely. PRP shows promise for recalcitrant cases. Surgical ECRB debridement is reserved for cases refractory to 6-12 months of conservative management (85-90% success).\n\nKEY POINTS:\nLateral epicondylitis primarily involves the ECRB, diagnosed by pain with resisted wrist extension. Eccentric strengthening has the strongest evidence; corticosteroid injection worsens long-term outcomes. Approximately 80-90% resolve within 12-18 months; surgery is reserved for refractory cases."
  },
  {
    "id": 498,
    "categoryId": 7,
    "question": "A Baker's Cyst (Popliteal Cyst) is essentially:",
    "questionImages": [
      { "src": "assets/baker-cyst-8col-638859-001.webp", "alt": "Baker cyst", "caption": "Baker cyst image." }
    ],
    "options": [
      "A) A tumor",
      "B) Herniation of synovial fluid from the knee joint into the popliteal fossa",
      "C) An abscess",
      "D) A blood clot"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Herniation of synovial fluid from the knee joint into the popliteal fossa).\n\nPATHOPHYSIOLOGY:\nA Baker cyst (popliteal cyst) is distension of the gastrocnemius-semimembranosus bursa in the posteromedial popliteal fossa. This bursa communicates with the knee joint through a valvular posterior capsular opening in approximately 50% of adults. When intra-articular pathology causes excessive effusion, fluid is forced posteriorly by a one-way valve mechanism: knee flexion drives fluid into the bursa, while extension closes the opening. In adults, Baker cysts are almost always secondary to underlying knee pathology, most commonly osteoarthritis (approximately 50% of cases), followed by meniscal tears, rheumatoid arthritis, and gout. In children, they may be primary and typically resolve spontaneously. The cyst is a symptom of intra-articular pathology rather than a primary disorder.\n\nCLINICAL PRESENTATION:\nPatients present with posterior knee fullness and dull aching worsening with standing, walking, or full flexion. The cyst is best appreciated with the knee extended (Foucher sign: becomes soft with flexion). It is smooth, well-circumscribed, and transilluminates. The most important complication is rupture, causing acute dissection of synovial fluid into the calf with sudden pain, swelling, and erythema mimicking deep vein thrombosis, known as pseudothrombophlebitis syndrome. The crescent sign (medial malleolar ecchymosis) suggests rupture. Since Baker cysts can compress the popliteal vein and predispose to DVT, both conditions must be excluded.\n\nDIAGNOSIS AND TREATMENT:\nUltrasound is the initial imaging modality, confirming the cystic mass, excluding DVT with Doppler, and identifying rupture. MRI provides comprehensive evaluation of the cyst and underlying intra-articular pathology driving the effusion. Treatment must address underlying knee pathology; isolated cyst aspiration leads to rapid recurrence. Conservative management: activity modification, NSAIDs, physical therapy, and intra-articular corticosteroid injection into the knee joint (not the cyst). Arthroscopic treatment of underlying meniscal tears or cartilage lesions often resolves the cyst. Surgical excision is rarely necessary.\n\nKEY POINTS:\nA Baker cyst is bursal distension from a one-way valve mechanism driving joint fluid posteriorly, almost always indicating underlying knee pathology such as OA or meniscal tears. Rupture mimics DVT (pseudothrombophlebitis), and both can coexist. Treatment targets the underlying intra-articular pathology; isolated aspiration leads to recurrence."
  },
  {
    "id": 499,
    "categoryId": 7,
    "question": "Rickets (children) and Osteomalacia (adults) are caused by defective bone mineralization, usually due to:",
    "options": [
      "A) Vitamin D / Calcium deficiency",
      "B) Vitamin C deficiency",
      "C) Protein deficiency",
      "D) Estrogen deficiency"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Vitamin D / Calcium deficiency).\n\nPATHOPHYSIOLOGY:\nRickets (children with open growth plates) and osteomalacia (adults) represent defective mineralization of osteoid. Normal mineralization requires adequate calcium and phosphate to form hydroxyapatite crystals. Vitamin D promotes intestinal calcium and phosphate absorption, renal calcium reabsorption, and PTH regulation. When deficient, intestinal calcium absorption drops from approximately 30 to 35% to 10 to 15%, causing hypocalcemia that triggers secondary hyperparathyroidism. Elevated PTH mobilizes calcium from bone (maintaining serum calcium at skeletal expense), increases renal phosphate excretion (causing hypophosphatemia), and upregulates 1-alpha-hydroxylase. The resulting inadequate calcium-phosphate product causes osteoid accumulation without mineralization. Unlike osteoporosis (normal mineralization but reduced bone mass), osteomalacia involves poorly mineralized bone that deforms under stress.\n\nCLINICAL PRESENTATION:\nIn children, rickets causes skeletal deformities: frontal bossing, craniotabes, widened wrists and ankles, rachitic rosary (costochondral junction enlargement), genu varum or valgum, delayed fontanelle closure, growth retardation, and hypotonia. Severe hypocalcemia may cause seizures and cardiomyopathy. In adults, osteomalacia presents with diffuse bone pain (spine, pelvis, lower extremities), proximal muscle weakness with waddling gait, and insufficiency fractures. Looser zones (pseudofractures), radiolucent bands perpendicular to cortex, are pathognomonic. Labs: low 25-hydroxyvitamin D (best status indicator), low or low-normal calcium, low phosphate, elevated alkaline phosphatase, and elevated PTH. Risk factors: limited sun exposure, dark skin pigmentation, exclusive breastfeeding without supplementation, malabsorption (celiac, Crohn), CKD, and enzyme-inducing medications (phenytoin, carbamazepine, rifampin).\n\nTREATMENT:\nThe Endocrine Society recommends vitamin D 400 IU daily for all breastfed infants from birth. Adult deficiency: ergocalciferol 50,000 IU weekly for 8 to 12 weeks or equivalent cholecalciferol, then maintenance 1,000 to 2,000 IU daily targeting 25-hydroxyvitamin D above 30 ng/mL. Calcium supplementation (1,000 to 1,200 mg daily) supports remineralization. In renal osteodystrophy, active vitamin D metabolites (calcitriol) are required because the kidney cannot perform 1-alpha-hydroxylation.\n\nKEY POINTS:\nRickets and osteomalacia result from defective bone mineralization due to vitamin D deficiency, triggering secondary hyperparathyroidism that maintains serum calcium at skeletal expense. Labs characteristically show low 25-hydroxyvitamin D, elevated alkaline phosphatase, and elevated PTH. All breastfed infants should receive 400 IU vitamin D daily from birth per the Endocrine Society."
  },
  {
    "id": 500,
    "categoryId": 7,
    "question": "Females are at higher risk for ACL tears than males. Anatomical reasons include:",
    "options": [
      "A) Narrower Intercondylar Notch and wider Q-angle",
      "B) Stronger quadriceps",
      "C) Thicker ligaments",
      "D) Higher center of gravity"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Narrower Intercondylar Notch and wider Q-angle).\n\nPATHOPHYSIOLOGY:\nFemale athletes sustain ACL tears at 2 to 8 times the rate of males in the same cutting and pivoting sports, due to anatomic, hormonal, neuromuscular, and biomechanical factors. The primary anatomic risk factors are a narrower intercondylar notch (reducing ACL space and increasing impingement risk during pivoting near full extension) and a wider Q-angle (the angle from ASIS to patella center to tibial tubercle; females average 15 to 17 degrees versus males 10 to 14 degrees due to the wider pelvis), which increases the valgus moment at the knee during landing and cutting.\n\nCLINICAL REASONING:\nHormonal influences include estrogen receptors on the ACL, with injury rates clustering in the pre-ovulatory phase when estrogen rises and ligament laxity increases. Neuromuscular factors are the most modifiable risk factors. Female athletes land with greater knee valgus (dynamic valgus), less knee flexion, greater quadriceps dominance relative to hamstring activation, and reduced trunk and hip control. Hamstrings are the primary dynamic ACL protectors, resisting anterior tibial translation. Women demonstrate lower hamstring-to-quadriceps strength ratios, allowing unopposed anterior tibial shear when the quadriceps fires forcefully near full extension. The female ACL is also approximately 20% smaller in cross-sectional area when controlled for body size.\n\nTREATMENT AND PREVENTION:\nNeuromuscular training programs reduce female ACL injury rates by 50 to 70%. Programs such as FIFA 11+, PEP, and Sportsmetrics incorporate plyometric training emphasizing soft landings with knee flexion and avoidance of dynamic valgus, hamstring and gluteus medius strengthening, core stability, balance and proprioceptive exercises, and sport-specific agility drills. Programs are most effective when initiated before or during early adolescence and performed 2 to 3 times weekly throughout the season. The AAP and American Orthopaedic Society for Sports Medicine recommend neuromuscular training as standard in youth female athletic programs.\n\nKEY POINTS:\nFemale ACL tear rates are 2 to 8 times higher than males due to narrower intercondylar notch, wider Q-angle, hormonal effects on ligament laxity, and neuromuscular patterns including quadriceps dominance. Neuromuscular training emphasizing proper landing mechanics and hamstring strengthening reduces injury rates by 50 to 70% and should be standard in youth female athletics."
  },
  {
    "id": 501,
    "categoryId": 7,
    "question": "True Sciatica (Radiculopathy) is most commonly caused by:",
    "options": [
      "A) Piriformis Syndrome",
      "B) Herniated Disc compressing the nerve root",
      "C) SI Joint dysfunction",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/lumbarradiculopathy.webp", "alt": "Lumbar radiculopathy", "caption": "Lumbar radiculopathy image." }
    ],
    "explanation": "CORRECT: B (Herniated Disc compressing the nerve root).\n\nPATHOPHYSIOLOGY:\nLumbar radiculopathy (true sciatica) most commonly results from herniated nucleus pulposus compressing a nerve root. The annulus fibrosus develops degenerative tears allowing the nucleus to herniate posterolaterally (the posterior longitudinal ligament is thinnest laterally), compressing the traversing nerve root. L4-L5 and L5-S1 account for approximately 95% of lumbar herniations, affecting L5 and S1 roots respectively. Both mechanical compression and chemical irritation (phospholipase A2, TNF-alpha, interleukins) contribute, explaining why imaging severity does not always correlate with symptoms and why many improve as inflammation subsides. Disc material undergoes macrophage-mediated resorption, with significant size reduction in 60 to 80% of patients over 6 to 12 months.\n\nCLINICAL PRESENTATION:\nRadiculopathy produces sharp, shooting pain radiating from the buttock below the knee in a dermatomal pattern. L5 radiculopathy: dorsal foot pain, weak great toe and ankle dorsiflexion (foot drop), dorsal foot sensory loss. S1 radiculopathy: lateral foot and sole pain, weak plantarflexion, diminished ankle jerk, lateral foot sensory loss. L4 radiculopathy: medial leg pain, quadriceps weakness, diminished patellar reflex. The straight leg raise is positive at 30 to 70 degrees; crossed straight leg raise is less sensitive but highly specific. Piriformis syndrome (sciatic nerve compression in the deep gluteal space) is a far less common mimic diagnosed by pain with resisted hip external rotation. Imaging is reserved for red flags (progressive deficit, cauda equina syndrome, suspected malignancy or infection) or failure to improve after 6 weeks.\n\nTREATMENT:\nApproximately 80 to 90% improve within 6 to 12 weeks conservatively. First-line: patient education, activity as tolerated (prolonged bed rest is harmful), NSAIDs, and short-course oral corticosteroids for severe symptoms. Physical therapy with core stabilization and McKenzie method is recommended. Epidural steroid injections provide moderate short-term relief. Gabapentin or pregabalin may address neuropathic pain. Surgical discectomy is indicated for cauda equina syndrome (emergency), progressive motor deficit, or persistent radiculopathy despite 6 to 12 weeks of conservative therapy. The SPORT trial (JAMA) showed both groups improved, with surgery providing faster initial relief.\n\nKEY POINTS:\nTrue sciatica is most commonly caused by disc herniation at L4-L5 or L5-S1, producing dermatomal leg pain below the knee with corresponding motor, sensory, and reflex deficits. Approximately 80 to 90% improve within 6 to 12 weeks conservatively; imaging is reserved for red flags or failure to improve after 6 weeks. Piriformis syndrome is a far less common mimic."
  },
  {
    "id": 502,
    "categoryId": 7,
    "question": "Stenosing Tenosynovitis (Trigger Finger) involves a mismatch between the flexor tendon and the:",
    "questionImages": [
      { "src": "assets/trigger finger.webp", "alt": "Trigger finger", "caption": "Trigger finger image." }
    ],
    "options": [
      "A) A1 Pulley",
      "B) Carpal Tunnel",
      "C) Extensor Hood",
      "D) Collateral Ligament"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (A1 Pulley).\n\nPATHOPHYSIOLOGY:\nStenosing tenosynovitis (trigger finger) results from a size mismatch between the flexor tendon and the A1 pulley at the metacarpophalangeal (MCP) joint. The A1 pulley is the narrowest of the annular pulleys. Repetitive friction causes pulley thickening and fibrocartilaginous metaplasia, while the tendon develops a nodular thickening (Notta nodule). The swollen tendon passes through the narrowed pulley during flexion but catches on extension, producing clicking, locking, and painful snapping. Prevalence is 2-3%, peaking at ages 40-60, with women affected 2-6 times more than men. The ring finger and thumb are most commonly involved. Diabetes is the strongest risk factor (up to 10% of diabetic patients affected), often with multiple digits and poorer injection response. Other associations include rheumatoid arthritis, hypothyroidism, and repetitive gripping.\n\nCLINICAL PRESENTATION:\nPatients report painful catching or locking during finger motion, worse in the morning. Progression ranges from painless clicking to requiring passive manipulation to fixed flexion (Grade IV). Examination reveals a tender nodule over the A1 pulley at the volar MCP joint. Diagnosis is entirely clinical\u2014no imaging needed. Differential includes Dupuytren contracture (fixed flexion from palmar fascial cords without triggering), MCP osteoarthritis, and infectious or inflammatory tenosynovitis.\n\nTREATMENT:\nInitial management: activity modification, nighttime MCP extension splinting (effective in 50-70% of mild cases), and NSAIDs. Corticosteroid injection into the tendon sheath at the A1 pulley is first-line interventional treatment (57-93% success after single injection; lower in diabetics at 40-50%). Per AAOS guidelines, surgical open A1 pulley release is indicated after two failed injections, Grade IV locking, or patient preference, with >95% success. Percutaneous needle release is an alternative.\n\nKEY POINTS:\nTrigger finger results from tendon nodular thickening catching at a narrowed A1 pulley during extension. Diabetes is the strongest risk factor with multiple digits affected and poorer injection response. Corticosteroid injection is first-line (57-93% success), and surgical A1 pulley release is definitive for refractory cases."
  },
  {
    "id": 503,
    "categoryId": 7,
    "question": "Dupuytren's Contracture is a progressive fibrosis of the:",
    "options": [
      "A) Flexor Tendons",
      "B) Palmar Fascia",
      "C) Skin",
      "D) Median Nerve"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/dupuytrens.jpg", "alt": "Dupuytren contracture", "caption": "Dupuytren contracture image." }
    ],
    "explanation": "CORRECT: B (Palmar Fascia).\n\nPATHOPHYSIOLOGY:\nDupuytren disease is a fibroproliferative disorder of the palmar fascia (palmar aponeurosis) with progressive formation of nodules and cords that contract affected fingers into fixed flexion. Myofibroblasts proliferate, deposit excessive type III collagen, and generate contractile force via alpha-smooth muscle actin, progressively shortening the cords. The ring finger is most commonly affected (~65%), followed by the little finger. Crucially, the flexor tendons are entirely normal, distinguishing this from trigger finger. The condition has autosomal dominant inheritance with variable penetrance, predominantly affecting Northern European (Celtic/Scandinavian) descent (\"Viking disease\"). Men are affected 7-10 times more than women. Risk factors include diabetes (16-42% prevalence, often milder), alcohol use disorder, smoking, epilepsy, and vibratory tool exposure. Dupuytren diathesis indicates aggressive disease: early onset (<50), bilateral involvement, family history, and associated fibromatoses (Peyronie disease, Ledderhose disease, Garrod knuckle pads).\n\nCLINICAL PRESENTATION:\nDisease begins with a firm, painless nodule in the distal palmar crease, progressing to cords with flexion contracture primarily at the MCP joint, secondarily at the PIP joint. The Hueston tabletop test is positive when the patient cannot flatten the palm on a flat surface, generally indicating intervention is needed. Diagnosis is clinical. The key differential is trigger finger, which causes dynamic catching rather than fixed contracture.\n\nTREATMENT:\nIntervention is indicated when MCP contracture exceeds 30 degrees or any PIP contracture is present, as PIP contractures are harder to correct with higher recurrence. Collagenase clostridium histolyticum (Xiaflex) injection enzymatically degrades the cord; the CORD I trial (NEJM) showed reduction to 0-5 degrees in 64% of MCP and 28% of PIP joints. Needle aponeurotomy can be performed in-office. Open limited fasciectomy is the gold standard with lowest recurrence (~20-30% at 5 years for MCP). Dermofasciectomy is reserved for severe or recurrent disease. No medical therapy prevents progression.\n\nKEY POINTS:\nDupuytren disease involves the palmar fascia (not tendons), producing nodules and cords that contract the ring and little fingers into fixed flexion. Treatment is indicated when MCP contracture exceeds 30 degrees or any PIP contracture exists, with options including collagenase injection, needle aponeurotomy, and surgical fasciectomy."
  },
  {
    "id": 504,
    "categoryId": 14,
    "question": "Pancoast Tumors (Superior Sulcus Tumors) of the lung apex often present with shoulder pain and:",
    "options": [
      "A) Horner's Syndrome (Ptosis, Miosis, Anhidrosis)",
      "B) Bell's Palsy",
      "C) Foot Drop",
      "D) Hearing Loss"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Horner's Syndrome - Ptosis, Miosis, Anhidrosis).\n\nPATHOPHYSIOLOGY:\nPancoast tumors (superior sulcus tumors) are malignancies arising in the lung apex that invade adjacent structures in the thoracic inlet. The sympathetic chain, specifically the stellate ganglion (inferior cervical ganglion fused with the first thoracic ganglion), lies immediately adjacent to the lung apex and is vulnerable to direct tumor invasion. Disruption of the sympathetic chain produces ipsilateral Horner syndrome, the classic triad of ptosis (drooping of the upper eyelid from loss of sympathetic innervation to Muller's muscle), miosis (pupillary constriction from unopposed parasympathetic tone), and anhidrosis (loss of sweating on the ipsilateral face). The brachial plexus, particularly the C8 and T1 nerve roots, is also frequently invaded, causing severe neuropathic pain radiating down the medial arm and hand in an ulnar nerve distribution along with hand weakness and intrinsic muscle atrophy.\n\nCLINICAL PRESENTATION:\nPancoast tumors account for approximately 3 to 5% of all lung cancers, most commonly non-small cell histology. The presenting symptom is usually severe shoulder and arm pain that is frequently misdiagnosed as cervical radiculopathy, rotator cuff disease, or shoulder arthritis, delaying the correct diagnosis by months. The pain is characteristically relentless, worse at night, and radiates down the medial arm. Because apical lung tumors may not be visible on standard posteroanterior chest radiographs (obscured by overlying clavicle and first rib), CT or MRI of the chest and thoracic inlet is required for diagnosis.\n\nMANAGEMENT:\nTreatment typically involves trimodality therapy with concurrent chemoradiation followed by surgical resection, which has significantly improved survival compared to historical approaches. Preoperative MRI is essential for assessing invasion of the brachial plexus, subclavian vessels, and vertebral bodies, which determines surgical resectability.\n\nKEY POINTS:\nPancoast tumors cause Horner syndrome (ptosis, miosis, anhidrosis) by invading the stellate ganglion and cause severe medial arm pain by invading the C8-T1 nerve roots of the brachial plexus. Shoulder and arm pain from a Pancoast tumor is frequently misdiagnosed as musculoskeletal disease, delaying diagnosis. Apical lung tumors may be missed on standard chest radiographs and require CT or MRI of the thoracic inlet."
  },
  {
    "id": 505,
    "categoryId": 14,
    "question": "Iron Deficiency Anemia in a male or post-menopausal female is considered:",
    "options": [
      "A) Nutritional deficiency until proven otherwise",
      "B) Colorectal Cancer until proven otherwise",
      "C) Normal aging",
      "D) Caused by PPI use"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Colorectal Cancer until proven otherwise).\n\nPATHOPHYSIOLOGY:\nIron deficiency anemia in a male or postmenopausal female represents occult gastrointestinal blood loss until proven otherwise, because these populations lack the physiologic blood loss of menstruation that accounts for the majority of iron deficiency in premenopausal women. Chronic low-volume bleeding from gastrointestinal malignancies, particularly colorectal cancer, causes insidious iron store depletion over months to years. A right-sided colon cancer may bleed slowly without producing visible hematochezia, while the patient gradually develops iron deficiency and symptomatic anemia. This presentation is often the earliest clinical manifestation of an otherwise curable malignancy.\n\nDIAGNOSTIC APPROACH:\nIron deficiency anemia is identified by a microcytic anemia (MCV less than 80 fL) with low serum ferritin (less than 30 ng/mL, the most sensitive and specific single test), low serum iron, elevated total iron-binding capacity, and low transferrin saturation. Once confirmed in a male or postmenopausal female, both colonoscopy and esophagogastroduodenoscopy should be performed to evaluate for malignancy and other sources of occult bleeding including gastric ulcers, angiodysplasia, celiac disease, and Cameron erosions. A negative colonoscopy does not exclude upper GI sources, and both studies should be performed.\n\nTREATMENT:\nIron repletion is initiated concurrently with the diagnostic workup. Oral ferrous sulfate 325 mg (65 mg elemental iron) taken with vitamin C on an empty stomach is standard first-line therapy. Intravenous iron (ferric carboxymaltose, iron sucrose) is indicated for patients who cannot tolerate oral iron or have malabsorptive conditions. Reticulocyte count should rise within 5 to 7 days and hemoglobin should improve by 1 to 2 g/dL within 2 to 4 weeks, with iron stores requiring 3 to 6 months of continued supplementation.\n\nKEY POINTS:\nIron deficiency anemia in males and postmenopausal females is GI malignancy until proven otherwise and mandates both colonoscopy and upper endoscopy. Low ferritin (less than 30 ng/mL) is the most sensitive and specific single test for iron deficiency. The diagnostic workup is potentially life-saving, as colorectal cancer presenting with occult bleeding is often at an early, curable stage."
  },
  {
    "id": 506,
    "categoryId": 14,
    "question": "Inflammatory Breast Cancer is a particularly aggressive subtype that presents as:",
    "options": [
      "A) A painless, hard, mobile lump",
      "B) A painful cyst",
      "C) Diffuse erythema, edema ('Peau d'orange'), and warmth mimicking mastitis",
      "D) Nipple discharge only"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Skin erythema, edema, and peau d'orange without a discrete mass).\n\nPATHOPHYSIOLOGY:\nInflammatory breast cancer is an aggressive clinical subtype comprising 1 to 5% of all breast cancers. Tumor cells invade and obstruct the dermal lymphatic channels, blocking lymphatic drainage and producing the characteristic triad of skin erythema, breast edema, and peau d'orange (orange peel appearance from tethering of skin at points of dermal lymphatic obstruction by Cooper's ligaments). The inflammatory appearance results from lymphatic obstruction rather than infection, though the clinical resemblance to mastitis is striking. IBC is classified as at least T4d and therefore at minimum stage IIIB at diagnosis.\n\nCLINICAL PRESENTATION:\nIBC presents with rapid onset (less than 6 months) of breast erythema, warmth, edema, and skin thickening involving at least one-third of the breast. A discrete palpable mass is frequently absent, which distinguishes IBC from other locally advanced breast cancers and contributes to diagnostic delay. The critical clinical pearl is that breast erythema and edema failing to resolve after 7 to 10 days of antibiotics for presumed mastitis must raise immediate suspicion for IBC, prompting skin punch biopsy and imaging.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires skin punch biopsy demonstrating invasive carcinoma, with dermal lymphatic invasion supporting the diagnosis though not required. Treatment is multimodal: neoadjuvant chemotherapy first to reduce disease burden, followed by modified radical mastectomy, then postmastectomy radiation and appropriate adjuvant therapy. Breast-conserving surgery is contraindicated in IBC due to the diffuse nature of the disease.\n\nKEY POINTS:\nInflammatory breast cancer presents with rapid-onset breast erythema, edema, and peau d'orange caused by tumor emboli obstructing dermal lymphatics, not by infection. Failure of presumed mastitis to respond to antibiotics within 7 to 10 days mandates biopsy to exclude IBC. A discrete mass is often absent, IBC is at least stage IIIB at diagnosis, and breast-conserving surgery is contraindicated."
  },
  {
    "id": 507,
    "categoryId": 14,
    "question": "The classic triad of Renal Cell Carcinoma (RCC) is Hematuria, Flank Pain, and:",
    "options": [
      "A) Palpable Abdominal Mass",
      "B) Hypertension",
      "C) Jaundice",
      "D) Fever"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Palpable Abdominal Mass).\n\nCLINICAL PRESENTATION:\nThe classic triad of renal cell carcinoma consists of hematuria, flank pain, and a palpable abdominal or flank mass. However, this full triad is present in fewer than 10% of patients at diagnosis and when encountered indicates locally advanced or metastatic disease. The most common presentation of RCC in the modern era is an incidental renal mass discovered on cross-sectional imaging performed for unrelated indications, accounting for more than 50% of diagnoses. RCC arises from the renal tubular epithelium, most commonly as clear cell carcinoma (approximately 70 to 80% of cases).\n\nPARANEOPLASTIC MANIFESTATIONS:\nRCC is called the internist's tumor because of its protean paraneoplastic manifestations. These include erythrocytosis from ectopic erythropoietin production, hypercalcemia from PTHrP secretion, hypertension from renin secretion, and Stauffer syndrome (hepatic dysfunction with elevated alkaline phosphatase without liver metastases that resolves after nephrectomy). A left-sided varicocele that does not decompress in the supine position suggests left renal vein obstruction by tumor thrombus, as the left gonadal vein drains directly into the left renal vein.\n\nMANAGEMENT:\nLocalized disease is treated with partial nephrectomy (preferred for tumors 7cm or smaller to preserve renal function). RCC is characteristically resistant to conventional chemotherapy and radiation but is one of the most immunotherapy-responsive solid tumors, with checkpoint inhibitors (nivolumab plus ipilimumab) and VEGF-targeted therapies forming the backbone of advanced disease treatment.\n\nKEY POINTS:\nThe classic triad of hematuria, flank pain, and palpable mass is present in fewer than 10% of RCC cases and indicates advanced disease, while most cases are now discovered incidentally on imaging. RCC is notable for diverse paraneoplastic syndromes including erythrocytosis, hypercalcemia, and Stauffer syndrome. RCC is resistant to chemotherapy but highly responsive to immunotherapy and targeted therapies."
  },
  {
    "id": 508,
    "categoryId": 14,
    "question": "Acral Lentiginous Melanoma is the most common subtype in people with darker skin types (African/Asian descent). It typically appears on the:",
    "options": [
      "A) Face and Neck",
      "B) Trunk",
      "C) Palms, Soles, and under Nails (Subungual)",
      "D) Scalp"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Palms, soles, and nail beds).\n\nPATHOPHYSIOLOGY:\nAcral lentiginous melanoma is the most common melanoma subtype in people with darker skin tones, including those of African, Asian, and Hispanic descent, though it accounts for only 2 to 3% of all melanomas in Caucasian populations. Unlike the more common superficial spreading melanoma, ALM does not appear to be driven by ultraviolet radiation exposure, as it occurs exclusively on acral surfaces that receive minimal sun exposure. The pathogenesis involves distinct molecular pathways with frequent mutations in KIT and cyclin D1 rather than the BRAF mutations that characterize sun-exposed melanomas, which has therapeutic implications for targeted therapy in metastatic disease.\n\nCLINICAL PRESENTATION:\nALM presents as an irregularly pigmented macule or patch on the palm, sole, or nail bed, often with variation in color from tan to dark brown or black. Subungual melanoma causes melanonychia striata, a pigmented longitudinal streak in the nail plate that may widen over time. Hutchinson sign, the extension of pigment from the nail bed onto the surrounding nail fold, is a critical finding that strongly suggests malignancy and distinguishes subungual melanoma from benign causes such as ethnic nail pigmentation or subungual hematoma.\n\nDELAYED DIAGNOSIS:\nALM is frequently diagnosed at more advanced stages compared to other melanoma subtypes per data from Johns Hopkins. It occurs on locations not routinely inspected during self-examination, arises in populations often perceived as low risk for melanoma, and its appearance may not fit typical ABCDE criteria. This diagnostic delay results in thicker tumors at presentation and worse prognosis. A thorough skin examination in all patients regardless of skin tone should include inspection of the palms, soles, and nail beds.\n\nKEY POINTS:\nAcral lentiginous melanoma occurs on palms, soles, and nail beds and is the most common melanoma subtype in patients with darker skin tones. Hutchinson sign (pigment extending from the nail bed onto the nail fold) strongly suggests subungual melanoma. ALM is frequently diagnosed at advanced stages due to overlooked anatomic locations and perceived low risk in darker-skinned populations."
  },
  {
    "id": 509,
    "categoryId": 14,
    "question": "Painless Jaundice (yellow skin/eyes without abdominal pain) is the classic presentation of:",
    "options": [
      "A) Gallstones (Choledocholithiasis)",
      "B) Pancreatic Cancer (Head of Pancreas)",
      "C) Hepatitis A",
      "D) Alcoholic Cirrhosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pancreatic Cancer - Head of Pancreas).\n\nPATHOPHYSIOLOGY:\nPainless jaundice is the classic presentation of pancreatic head adenocarcinoma because of the intimate anatomic relationship between the head of the pancreas and the common bile duct. The distal common bile duct passes through or immediately behind the pancreatic head before entering the duodenum at the ampulla of Vater, and even a small mass can compress or obstruct the duct, preventing bile drainage. The resulting obstructive jaundice produces conjugated hyperbilirubinemia with the classic triad of jaundice, dark urine (conjugated bilirubin filtered by the kidneys), and pale acholic stools (absence of stercobilin). The absence of pain distinguishes malignant biliary obstruction from choledocholithiasis, which typically causes colicky right upper quadrant pain from acute ductal distension.\n\nCLINICAL PRESENTATION:\nCourvoisier's sign, a palpable non-tender distended gallbladder with jaundice, is a classic finding suggesting malignant obstruction, because gradual tumor growth allows the gallbladder to slowly dilate, unlike the chronically scarred gallbladder of gallstone disease. Additional features include unexplained weight loss, new-onset diabetes mellitus (present in up to 80% of pancreatic cancer patients and sometimes preceding cancer diagnosis by months), and anorexia. Painless jaundice in an adult over 50 is pancreatic or periampullary malignancy until proven otherwise.\n\nDIAGNOSIS AND MANAGEMENT:\nCT abdomen with pancreatic protocol is the initial imaging study, followed by endoscopic ultrasound with fine-needle aspiration for tissue diagnosis. CA 19-9 is the most commonly used serum marker but lacks sufficient sensitivity or specificity for screening. Surgical resection via pancreaticoduodenectomy (the Whipple procedure) is the only potentially curative treatment, feasible in only 15 to 20% of patients at diagnosis.\n\nKEY POINTS:\nPainless jaundice is the classic presentation of pancreatic head cancer from gradual bile duct compression, producing conjugated hyperbilirubinemia with dark urine and pale stools. Courvoisier's sign (palpable non-tender gallbladder with jaundice) suggests malignant rather than gallstone obstruction. Only 15 to 20% of pancreatic cancers are surgically resectable at diagnosis."
  },
  {
    "id": 510,
    "categoryId": 14,
    "question": "A 65-year-old presents with new onset back pain. X-ray shows 'Lytic Lesions' (punched out holes) in the spine. Labs show elevated Calcium and Creatinine. Diagnosis?",
    "options": [
      "A) Osteoporosis",
      "B) Multiple Myeloma",
      "C) Spinal Stenosis",
      "D) Prostate Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Multiple Myeloma).\n\nCLINICAL REASONING:\nThis presentation of new-onset back pain, lytic bone lesions, hypercalcemia, and renal insufficiency in an older adult is classic for multiple myeloma. The lytic lesions result from pathologic imbalance in bone remodeling: malignant plasma cells secrete osteoclast-activating cytokines (RANKL, interleukin-6) while producing osteoblast-inhibiting factors (DKK1, sclerostin), creating purely lytic lesions without surrounding sclerosis or reactive new bone.\n\nDIFFERENTIAL DIAGNOSIS:\nThe CRAB mnemonic captures the cardinal manifestations: Calcium elevation from bone resorption, Renal insufficiency from light chain cast nephropathy and hypercalcemia, Anemia from marrow infiltration, and Bone lesions (lytic). The differential for lytic bone lesions includes metastatic carcinoma (particularly lung, breast, kidney, and thyroid), but the combination with hypercalcemia and renal failure without an obvious primary tumor strongly favors myeloma. Metastatic prostate cancer characteristically produces osteoblastic (sclerotic) rather than lytic lesions, a critical distinguishing feature.\n\nDIAGNOSTIC WORKUP:\nEvaluation includes serum protein electrophoresis with immunofixation, serum free light chains with ratio, bone marrow biopsy with cytogenetics and FISH, beta-2 microglobulin, and appropriate imaging. An essential pearl. Low-dose whole-body CT, PET-CT, or whole-body MRI are the appropriate imaging modalities.\n\nKEY POINTS:\nMultiple myeloma produces purely lytic bone lesions from osteoclast activation with concurrent osteoblast suppression, and bone scan is often falsely negative because it detects osteoblastic rather than osteolytic activity. The CRAB criteria identify myeloma end-organ damage. Back pain in an older adult with unexplained hypercalcemia or renal insufficiency should prompt evaluation with serum protein electrophoresis and free light chains."
  },
  {
    "id": 511,
    "categoryId": 14,
    "question": "Prostate Cancer most commonly metastasizes to the:",
    "options": [
      "A) Brain",
      "B) Bone (Axial Skeleton)",
      "C) Liver",
      "D) Lungs"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bone - particularly spine and pelvis).\n\nPATHOPHYSIOLOGY:\nProstate cancer exhibits a striking predilection for bone metastasis, with approximately 90% of men who die from prostate cancer having bone involvement, most commonly in the axial skeleton (lumbar spine, pelvis, thoracic spine, ribs). The seed and soil hypothesis explains this tropism: prostate cancer cells express adhesion molecules and chemokine receptors (particularly CXCR4) that bind to complementary ligands in the bone marrow stroma (particularly CXCL12/SDF-1), facilitating homing and engraftment. Once established, prostate cancer cells stimulate osteoblast activity rather than osteoclast activity, producing the distinctive osteoblastic (sclerotic) metastases that appear as dense white lesions on imaging, in contrast to the lytic metastases of lung, renal, thyroid, and most breast cancers.\n\nCLINICAL MANIFESTATIONS:\nBone metastases cause intractable pain (often the presenting symptom of advanced disease), pathologic fractures, and spinal cord compression (an oncologic emergency requiring emergent MRI and treatment). Elevated serum alkaline phosphatase reflects osteoblastic activity and correlates with bone disease burden. PSA is typically markedly elevated and serves as a treatment response monitor.\n\nDIAGNOSIS AND MANAGEMENT:\nTechnetium-99m bone scan is highly sensitive for osteoblastic metastases and is the standard staging study, in contrast to myeloma where bone scan is unreliable. Treatment of metastatic castration-sensitive prostate cancer includes androgen deprivation therapy combined with androgen receptor pathway inhibitors (abiraterone, enzalutamide) plus or minus docetaxel per data from the STAMPEDE and LATITUDE trials. Bone-protective agents (zoledronic acid or denosumab) reduce skeletal events. Radium-223, a bone-targeting alpha-emitting radioisotope, provides both pain palliation and survival benefit.\n\nKEY POINTS:\nProstate cancer preferentially metastasizes to bone through molecular homing mechanisms, with approximately 90% of fatal cases having bone involvement. Metastases are characteristically osteoblastic, distinguishing them from lytic metastases of other cancers. Bone scan effectively detects prostate cancer bone metastases (unlike myeloma), and elevated alkaline phosphatase reflects osteoblastic activity."
  },
  {
    "id": 512,
    "categoryId": 14,
    "question": "Small Cell Lung Cancer (SCLC) is a neuroendocrine tumor notorious for causing which paraneoplastic syndrome?",
    "options": [
      "A) SIADH and Lambert-Eaton Myasthenic Syndrome",
      "B) Hypercalcemia",
      "C) Hypoglycemia",
      "D) Polycythemia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (SIADH and Lambert-Eaton Myasthenic Syndrome).\n\nPATHOPHYSIOLOGY:\nSmall cell lung cancer is a high-grade neuroendocrine carcinoma notorious for paraneoplastic syndromes. SCLC arises from pulmonary neuroendocrine cells (Kulchitsky cells) and retains the capacity for peptide hormone secretion. SIADH is the most common paraneoplastic syndrome, occurring in approximately 10 to 15% of SCLC patients. The tumor ectopically produces ADH (arginine vasopressin), causing impaired free water excretion, euvolemic hyponatremia, concentrated urine (osmolality greater than 100 mOsm/kg), and low serum osmolality. Lambert-Eaton myasthenic syndrome is an autoimmune condition in which the tumor provokes antibodies against presynaptic voltage-gated calcium channels (P/Q-type) at the neuromuscular junction, impairing acetylcholine release and causing proximal muscle weakness, hyporeflexia, and autonomic dysfunction.\n\nCLINICAL REASONING:\nSCLC is centrally located in the majority of cases, grows rapidly with a doubling time of approximately 30 days, and is considered systemic at diagnosis because of early widespread metastasis. Approximately 60 to 70% present with extensive-stage disease. The paraneoplastic pattern differs by histologic subtype: SCLC causes SIADH, ectopic ACTH (Cushing syndrome), and Lambert-Eaton syndrome, while squamous cell carcinoma of the lung causes hypercalcemia through PTHrP secretion. This histology-specific paraneoplastic distinction is a critical clinical concept.\n\nMANAGEMENT:\nSCLC is exquisitely sensitive to initial chemotherapy, with response rates of 60 to 80%, but relapse is nearly universal. Limited-stage disease is treated with concurrent cisplatin/etoposide plus thoracic radiation, with prophylactic cranial irradiation for responders. Extensive-stage disease is treated with platinum-etoposide plus a PD-L1 checkpoint inhibitor (atezolizumab or durvalumab).\n\nKEY POINTS:\nSCLC is linked to SIADH (hyponatremia from ectopic ADH), ectopic ACTH (Cushing syndrome), and Lambert-Eaton syndrome, while squamous cell lung cancer is linked to hypercalcemia from PTHrP. SCLC is considered systemic at diagnosis and responds dramatically to initial chemotherapy but relapses in the vast majority of cases. PD-L1 checkpoint inhibitors added to chemotherapy are now standard for extensive-stage disease."
  },
  {
    "id": 513,
    "categoryId": 14,
    "question": "The primary risk factor for Cervical Cancer (>99% of cases) is persistent infection with:",
    "options": [
      "A) Herpes Simplex Virus",
      "B) Human Papillomavirus (HPV) High-Risk strains (16, 18)",
      "C) Chlamydia",
      "D) Gonorrhea"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Human Papillomavirus, High-Risk strains 16 and 18).\n\nPATHOPHYSIOLOGY:\nHPV is the necessary cause of virtually all cervical cancers, with HPV DNA detectable in >99% of cervical squamous cell carcinomas. HPV types 16 and 18 are responsible for approximately 70% of cases. HPV infects the basal epithelial cells of the cervical transformation zone (the squamocolumnar junction) and integrates into the host genome. The oncogenic mechanism involves two viral proteins: E6, which binds and degrades the tumor suppressor p53 (disabling cell cycle arrest and apoptosis), and E7, which inactivates retinoblastoma protein (Rb), releasing E2F transcription factors and driving unregulated cell cycle progression. The simultaneous loss of both p53 and Rb creates the foundation for malignant transformation.\n\nCLINICAL SIGNIFICANCE:\nMost HPV infections are transient and cleared by the immune system within 1 to 2 years. Cervical cancer develops only when high-risk HPV persists for years, progressing through cervical intraepithelial neoplasia (CIN 1 through CIN 3) to invasive carcinoma. This prolonged pre-invasive phase enables effective screening. Current USPSTF guidelines recommend screening with cervical cytology (Pap smear), HPV co-testing, or primary HPV testing beginning at age 21 to 25, with intervals depending on strategy and patient age.\n\nPREVENTION:\nThe 9-valent HPV vaccine (Gardasil 9) targets HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, providing protection against strains responsible for approximately 90% of cervical cancers and the strains causing genital warts. The ACIP recommends routine vaccination at age 11 to 12 (can begin at age 9) with catch-up through age 26. Countries with high vaccine coverage such as Australia have demonstrated dramatic reductions in HPV prevalence and high-grade cervical abnormalities per data published in The Lancet.\n\nKEY POINTS:\nHPV is the necessary cause of cervical cancer, with types 16 and 18 responsible for approximately 70% of cases through the oncogenic actions of E6 (degrades p53) and E7 (inactivates Rb). The prolonged pre-invasive phase enables effective screening with Pap smear and HPV testing. The 9-valent HPV vaccine covers strains responsible for approximately 90% of cervical cancers and is recommended routinely at ages 11 to 12."
  },
  {
    "id": 514,
    "categoryId": 14,
    "question": "Hodgkin Lymphoma often presents with 'B-Symptoms'. These include:",
    "options": [
      "A) Headache, Vision changes, Dizziness",
      "B) Fever > 38C, Drenching Night Sweats, Weight Loss > 10%",
      "C) Rash, Itching, Swelling",
      "D) Cough, Dyspnea, Chest pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Fever greater than 38 degrees Celsius, drenching night sweats, weight loss greater than 10% in 6 months).\n\nPATHOPHYSIOLOGY:\nB-symptoms are a defined set of constitutional symptoms used in the Ann Arbor staging system for Hodgkin and non-Hodgkin lymphomas to indicate systemic disease activity. The three B-symptoms are unexplained fever greater than 38 degrees Celsius, drenching night sweats severe enough to require changing bedclothes, and unintentional weight loss exceeding 10% of body weight over the preceding 6 months. These symptoms are driven by cytokines released by malignant cells and the reactive inflammatory microenvironment, including interleukin-6, interleukin-1, and tumor necrosis factor-alpha. The designation B is appended to the stage (for example, stage IIB versus IIA) and carries prognostic significance, as patients with B-symptoms have a worse prognosis and may require more intensive treatment.\n\nCLINICAL PRESENTATION:\nHodgkin lymphoma most commonly presents with painless cervical or supraclavicular lymphadenopathy in a young adult. A distinctive clinical feature, though present in fewer than 10% of cases, is alcohol-induced lymph node pain, in which ingestion of alcohol provokes pain at the site of involved nodes within minutes. Pruritus, though not classified as a B-symptom, is another common associated finding. Mediastinal lymphadenopathy is present in approximately 60 to 70% of patients and may cause cough, chest pressure, or superior vena cava syndrome.\n\nSTAGING AND MANAGEMENT:\nPET-CT is the standard staging modality, as Hodgkin lymphoma is intensely FDG-avid. Treatment is tailored to stage and risk factors: early-stage favorable disease may require only abbreviated ABVD chemotherapy with or without involved-site radiation, while advanced-stage disease requires extended chemotherapy with interim PET-guided modifications.\n\nKEY POINTS:\nB-symptoms are specifically defined as unexplained fever greater than 38 degrees, drenching night sweats, and weight loss exceeding 10% in 6 months, and their presence worsens prognosis. Alcohol-induced lymph node pain, though uncommon, is a classic and highly specific finding in Hodgkin lymphoma. PET-CT is the standard staging modality due to the intense FDG-avidity of Hodgkin lymphoma."
  },
  {
    "id": 515,
    "categoryId": 14,
    "question": "Ovarian Cancer is often called the 'Silent Killer'. Early symptoms are vague but persistent, including:",
    "options": [
      "A) Heavy vaginal bleeding",
      "B) Bloating, early satiety, and pelvic pressure",
      "C) Breast tenderness",
      "D) Acute sharp pain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bloating, early satiety, and pelvic pressure).\n\nCLINICAL PRESENTATION:\nOvarian cancer is termed the silent killer because approximately 60 to 70% of cases are diagnosed at stage III or IV. The ovaries are located deep in the pelvis without a serosal barrier to contain tumor growth, allowing malignancy to spread freely throughout the peritoneal cavity via transperitoneal dissemination before producing symptoms that prompt evaluation. While historically described as asymptomatic in early stages, research has demonstrated that most women do experience symptoms, but they are vague, nonspecific, and easily attributed to benign conditions. The most frequently reported symptoms include persistent bloating or increased abdominal girth, pelvic or abdominal pain, difficulty eating or early satiety, and urinary frequency.\n\nRISK FACTORS:\nThe strongest risk factor is a germline BRCA1 mutation (lifetime ovarian cancer risk approximately 40 to 60%) or BRCA2 mutation (lifetime risk approximately 15 to 25%). Other risk factors include family history, nulliparity, endometriosis, and increasing age. Protective factors include oral contraceptive use (reducing risk by approximately 40 to 50% with 5 or more years of use through ovulation suppression per data published in The Lancet), multiparity, breastfeeding, and tubal ligation. Risk-reducing bilateral salpingo-oophorectomy is recommended for BRCA carriers typically by age 35 to 40 for BRCA1 carriers.\n\nSCREENING:\nThere is currently no effective general population screening test for ovarian cancer. Both the PLCO trial and the UK Collaborative Trial of Ovarian Cancer Screening failed to demonstrate mortality reduction with CA-125 and ultrasound screening. Epithelial ovarian cancer, which accounts for approximately 90% of cases, most commonly presents as high-grade serous carcinoma.\n\nKEY POINTS:\nOvarian cancer presents with nonspecific symptoms of persistent bloating, early satiety, pelvic pain, and urinary changes, contributing to late-stage diagnosis in the majority of cases. BRCA1 and BRCA2 mutations confer the highest risk, and risk-reducing salpingo-oophorectomy is recommended for carriers. No effective general population screening strategy exists, and oral contraceptive use reduces risk by 40 to 50% with prolonged use."
  },
  {
    "id": 516,
    "categoryId": 14,
    "question": "A palpable lymph node in the left supraclavicular fossa (Virchow's Node) suggests metastasis from:",
    "options": [
      "A) Thyroid Cancer",
      "B) Abdominal malignancy (Stomach/Pancreas)",
      "C) Breast Cancer",
      "D) Skin Cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Abdominal malignancy - Stomach or Pancreas).\n\nPATHOPHYSIOLOGY:\nVirchow's node is a palpable left supraclavicular lymph node representing metastatic spread from an abdominal or pelvic malignancy, most commonly gastric adenocarcinoma, pancreatic cancer, or ovarian cancer. The anatomic basis lies in the thoracic duct, the largest lymphatic vessel in the body, which collects lymphatic drainage from the entire abdomen, pelvis, lower extremities, and left thorax and empties into the venous system at the junction of the left subclavian and internal jugular veins. Tumor cells entering the abdominal lymphatic system travel through the thoracic duct and are deposited at its terminus in the left supraclavicular fossa, where they seed and enlarge the local lymph node. This finding is also known as Troisier's sign.\n\nCLINICAL SIGNIFICANCE:\nA palpable left supraclavicular lymph node in an adult is malignancy until proven otherwise and should prompt immediate investigation for an occult abdominal primary tumor. Right supraclavicular lymphadenopathy is more commonly associated with intrathoracic malignancies (lung and esophageal cancer) because the right lymphatic duct drains the right thorax and empties into the right subclavian vein. The malignancy rate in supraclavicular lymphadenopathy exceeds 50% in patients over age 40.\n\nDIAGNOSTIC APPROACH:\nEvaluation begins with fine-needle aspiration or core needle biopsy of the node, followed by CT of the chest, abdomen, and pelvis to identify the primary malignancy. Immunohistochemistry on the biopsy specimen helps determine tissue of origin when the primary site is not apparent. Upper endoscopy should be strongly considered given the classic association with gastric cancer.\n\nKEY POINTS:\nVirchow's node is a left supraclavicular lymph node representing metastasis from an abdominal malignancy, most classically gastric cancer, carried via the thoracic duct which drains the abdomen and empties into the left subclavian vein. A palpable supraclavicular node in an adult is malignancy until proven otherwise. Right supraclavicular nodes suggest intrathoracic malignancy, while left nodes suggest abdominal malignancy."
  },
  {
    "id": 517,
    "categoryId": 14,
    "question": "The most significant modifiable risk factor for Bladder Cancer (Transitional Cell Carcinoma) is:",
    "options": [
      "A) Alcohol",
      "B) Smoking",
      "C) High fat diet",
      "D) Caffeine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Smoking).\n\nPATHOPHYSIOLOGY:\nCigarette smoking is the most significant modifiable risk factor for urothelial carcinoma of the bladder, responsible for approximately 50% of cases. The mechanism involves absorption of aromatic amines and carcinogens from tobacco smoke through the pulmonary vasculature, followed by renal filtration and concentration in the urine, where these carcinogens are held in prolonged direct contact with the urothelial lining. Specific carcinogens include 4-aminobiphenyl, 2-naphthylamine, and acrolein, which induce DNA mutations in urothelial cells. The risk in current smokers is approximately 3 to 4-fold higher than in never-smokers, and remains elevated at approximately 2-fold in former smokers for at least 10 years after cessation.\n\nCLINICAL PRESENTATION:\nThe classic presenting symptom is painless gross hematuria, occurring in approximately 85% of patients. The hematuria is characteristically intermittent, and the absence of pain distinguishes it from urinary tract infection and nephrolithiasis. Some patients present with irritative voiding symptoms (frequency, urgency, dysuria) that may mimic infection, particularly with carcinoma in situ. Any adult over age 40 with unexplained hematuria requires cystoscopy and upper tract imaging.\n\nADDITIONAL RISK FACTORS:\nOccupational exposures to aromatic amines in the dye, rubber, leather, and textile industries carry significant risk. Cyclophosphamide (via its metabolite acrolein), pelvic radiation, and Schistosoma haematobium infection (endemic in the Nile Valley, associated with squamous cell carcinoma rather than urothelial) are additional recognized risk factors.\n\nKEY POINTS:\nSmoking accounts for approximately 50% of bladder cancers through renal filtration and urinary concentration of tobacco carcinogens in prolonged contact with the urothelium, conferring a 3 to 4-fold increased risk. Painless gross hematuria is the classic presentation, and any adult over 40 with unexplained hematuria requires cystoscopy. Smoking cessation remains beneficial though risk stays elevated for at least a decade."
  },
  {
    "id": 518,
    "categoryId": 14,
    "question": "The classic presentation of Endometrial Cancer is:",
    "options": [
      "A) Postmenopausal Bleeding",
      "B) Abdominal pain",
      "C) Weight loss",
      "D) Ascites"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Postmenopausal bleeding).\n\nPATHOPHYSIOLOGY:\nPostmenopausal bleeding, defined as any vaginal bleeding after 12 consecutive months of amenorrhea, is endometrial cancer until proven otherwise. The most common subtype (type I, endometrioid adenocarcinoma, approximately 80% of cases) results from chronic unopposed estrogen stimulation of the endometrium. Estrogen drives endometrial proliferation, and without cyclical progesterone to induce secretory transformation and shedding, the endometrium progresses through simple hyperplasia, complex hyperplasia, atypical hyperplasia, and ultimately invasive carcinoma. The major clinical advantage is that abnormal bleeding occurs in approximately 90% of cases, enabling early diagnosis.\n\nRISK FACTORS:\nRisk factors reflect conditions of prolonged unopposed estrogen: obesity (peripheral aromatization of androgens to estrogen, with risk approximately 7-fold for BMI greater than 40), chronic anovulation (as in PCOS), exogenous estrogen without progestin in women with an intact uterus, tamoxifen (an estrogen agonist on endometrium despite being a breast antagonist), early menarche, late menopause, and nulliparity. Lynch syndrome (hereditary nonpolyposis colorectal cancer syndrome) confers a 40 to 60% lifetime risk through defective DNA mismatch repair.\n\nDIAGNOSIS AND MANAGEMENT:\nInitial evaluation includes transvaginal ultrasound (endometrial thickness less than 4mm in postmenopausal women has a high negative predictive value) and endometrial biopsy, which is the definitive diagnostic test. Treatment is primarily surgical staging with total hysterectomy and bilateral salpingo-oophorectomy, with adjuvant therapy based on stage, grade, and histologic subtype. The majority of endometrial cancers are diagnosed at stage I and carry a 5-year survival exceeding 90%.\n\nKEY POINTS:\nPostmenopausal bleeding is endometrial cancer until proven otherwise, and the vast majority of cases present with bleeding, enabling early detection. Risk factors center on unopposed estrogen exposure including obesity, PCOS, and tamoxifen use. Lynch syndrome confers a 40 to 60% lifetime risk and should be considered in younger patients with endometrial cancer."
  },
  {
    "id": 519,
    "categoryId": 14,
    "question": "A brain tumor headache typically differs from a tension/migraine headache because it is:",
    "options": [
      "A) Worse in the morning (or wakes patient from sleep) and worsens with Valsalva/bending over",
      "B) Relieved by sleep",
      "C) Associated with visual aura",
      "D) Band-like"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Worse in the morning and with Valsalva maneuver).\n\nPATHOPHYSIOLOGY:\nHeadaches from intracranial mass lesions result from increased intracranial pressure (ICP) and have characteristic features differentiating them from primary headache disorders. ICP rises during sleep due to recumbent positioning (impaired venous drainage from the head) and CO2 retention from decreased respiratory drive, peaking in the early morning hours. This produces the classic pattern of headache that is worst upon waking. Valsalva maneuvers (coughing, straining, bending forward) transiently increase intrathoracic and intraabdominal pressure, which is transmitted to the intracranial compartment via the venous system, further elevating ICP and worsening pain.\n\nRED FLAG FEATURES:\nAdditional concerning features neurology guidelines include new headache in patients over age 50, progressive worsening over weeks to months, associated neurological deficits (focal weakness, sensory changes, visual disturbance, speech difficulty), new-onset seizures, personality or cognitive changes, and papilledema on fundoscopic examination. Headache that awakens the patient from sleep is particularly concerning because primary headache disorders (tension, migraine) typically improve with sleep rather than disrupt it.\n\nCONTRAST WITH PRIMARY HEADACHES:\nTension headaches are typically bilateral, band-like, and worse with stress but not positional. Migraines are often unilateral, pulsatile, with nausea and photophobia, and characteristically improve with sleep. Neither typically worsens with Valsalva or has morning predominance. The presence of positional or Valsalva-exacerbated headache in combination with any neurological symptoms warrants urgent brain imaging with contrast-enhanced MRI.\n\nKEY POINTS:\nBrain tumor headaches are classically worse in the morning from overnight ICP elevation and exacerbated by Valsalva maneuvers. These features distinguish them from tension headaches and migraines, which do not worsen with position or straining. New progressive headache with neurological deficits or papilledema requires urgent contrast-enhanced MRI."
  },
  {
    "id": 520,
    "categoryId": 14,
    "question": "Testicular Cancer usually presents as a painless mass in young men (15-35). Which tumor markers are essential for diagnosis/monitoring?",
    "options": [
      "A) PSA and CEA",
      "B) AFP, beta-HCG, and LDH",
      "C) CA-125",
      "D) Calcitonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (AFP, beta-HCG, and LDH).\n\nPATHOPHYSIOLOGY:\nTesticular cancer arises from germ cells and is classified into seminomas (approximately 40%) and non-seminomatous germ cell tumors (NSGCT: embryonal carcinoma, yolk sac tumor, choriocarcinoma, teratoma). It is the most common solid malignancy in young men aged 15 to 35. Risk factors include cryptorchidism (undescended testis, conferring a 4 to 8-fold increased risk), family history, and prior contralateral testicular cancer.\n\nTUMOR MARKERS:\nThree serum markers are essential for diagnosis, staging, and monitoring. Alpha-fetoprotein (AFP) is elevated in yolk sac tumors and embryonal carcinoma but is never elevated in pure seminoma, meaning an elevated AFP rules out pure seminoma regardless of histologic appearance. Beta-human chorionic gonadotropin (beta-HCG) is markedly elevated in choriocarcinoma and may be mildly elevated in seminoma. Lactate dehydrogenase (LDH) reflects overall tumor burden and is a prognostic marker. These markers must be drawn before orchiectomy for staging purposes and followed serially after treatment to detect recurrence.\n\nCLINICAL PRESENTATION AND MANAGEMENT:\nThe classic presentation is a painless testicular mass discovered incidentally or on self-examination. Any solid testicular mass in a young man is cancer until proven otherwise. Ultrasound reliably distinguishes solid (concerning) from cystic (usually benign) lesions. Radical inguinal orchiectomy, not trans-scrotal biopsy (which risks scrotal seeding and alters lymphatic drainage pathways), is both diagnostic and therapeutic. Seminomas are highly radiosensitive and chemosensitive, while advanced NSGCT is treated with BEP chemotherapy (bleomycin, etoposide, cisplatin). Cure rates exceed 95% even with metastatic disease.\n\nKEY POINTS:\nAFP, beta-HCG, and LDH are the essential testicular cancer markers, with AFP elevation specifically ruling out pure seminoma. All solid testicular masses require ultrasound and radical inguinal orchiectomy, never trans-scrotal biopsy. Testicular cancer has excellent cure rates exceeding 95% even when metastatic."
  },
  {
    "id": 521,
    "categoryId": 4,
    "question": "The most common type of Thyroid Cancer is:",
    "options": [
      "A) Follicular",
      "B) Papillary",
      "C) Medullary",
      "D) Anaplastic"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Papillary Thyroid Carcinoma).\n\nPATHOPHYSIOLOGY:\nPapillary thyroid carcinoma (PTC) is the most common thyroid malignancy (80-85% of all thyroid cancers). It arises from follicular epithelial cells, driven by MAPK pathway mutations: BRAF V600E (45-60% of PTC; associated with extrathyroidal extension, nodal metastasis, radioiodine refractoriness, and higher recurrence) and RET/PTC rearrangements (more common in radiation-associated and younger patients). These constitutively activate the RAS-RAF-MEK-ERK cascade. Childhood radiation exposure is the most established environmental risk factor with 5-30 year latency per NEJM and WHO data.\n\nCLINICAL PRESENTATION:\nPTC typically presents as a painless, firm thyroid nodule, often incidental on imaging. Female-to-male ratio is ~3:1, peaking in the 3rd-5th decades. Histologic hallmarks include nuclear grooves, intranuclear pseudoinclusions, and ground-glass \"Orphan Annie eye\" chromatin. PTC spreads via lymphatics, with 30-50% having cervical nodal metastases at presentation, yet 10-year survival exceeds 95%. Distant metastases (lung > bone) occur in only 2-5%. The ATA risk stratification system guides management based on tumor features and molecular markers.\n\nDIAGNOSIS AND TREATMENT:\nUltrasound features suggesting malignancy include hypoechogenicity, irregular margins, taller-than-wide shape, and microcalcifications (psammoma bodies, pathognomonic for PTC). The ATA sonographic pattern system guides FNA thresholds. FNA is reported via the Bethesda System for Reporting Thyroid Cytopathology. Molecular testing (Afirma, ThyroSeq v3) reclassifies indeterminate nodules (Bethesda III/IV). Per ATA guidelines, total thyroidectomy is recommended for tumors >4 cm, gross extrathyroidal extension, or nodal metastases; lobectomy suffices for unifocal 1-4 cm tumors without high-risk features. Radioactive iodine (I-131) ablation is given postoperatively for intermediate/high-risk patients. TSH suppression with levothyroxine and serum thyroglobulin monitoring guide long-term surveillance.\n\nKEY POINTS:\nPTC is the most common thyroid cancer (80-85%), driven by BRAF V600E in 45-60%, with excellent prognosis (>95% 10-year survival) despite frequent nodal involvement. FNA with Bethesda classification guides management. Treatment follows ATA risk stratification with thyroidectomy, selective radioactive iodine, TSH suppression, and thyroglobulin surveillance."
  },
  {
    "id": 522,
    "categoryId": 14,
    "question": "Osteosarcoma typically occurs in teenagers near the growth plates (knee) and has a classic X-ray appearance of:",
    "options": [
      "A) Onion Skinning",
      "B) Sunburst pattern and Codman's Triangle",
      "C) Soap Bubble",
      "D) Lytic hole"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Sunburst pattern and Codman triangle).\n\nPATHOPHYSIOLOGY:\nOsteosarcoma is the most common primary malignant bone tumor, producing osteoid (immature bone matrix) and arising classically in the metaphysis of long bones near the growth plates during periods of rapid skeletal growth. The distal femur and proximal tibia (around the knee) are the most common sites, accounting for approximately 50% of cases. Peak incidence occurs in adolescents during the growth spurt (ages 10 to 20), with a second smaller peak in older adults associated with Paget disease of bone and prior radiation exposure.\n\nIMAGING FEATURES:\nThe sunburst pattern on plain radiograph results from aggressive tumor growth that lifts the periosteum and stimulates rapid, disorganized reactive bone formation radiating outward from the cortex in a spiculated pattern. Codman triangle refers to the triangular area of periosteal new bone formation at the margin where the elevated periosteum meets the cortex, indicating that the tumor is growing faster than the periosteum can contain it. These aggressive periosteal reactions are characteristic but not entirely specific to osteosarcoma, as other aggressive bone lesions including Ewing sarcoma and osteomyelitis can produce similar findings. Ewing sarcoma more classically shows an onion-skinning (lamellated) periosteal reaction.\n\nDIAGNOSIS AND MANAGEMENT:\nDiagnosis requires biopsy, ideally performed by the orthopedic oncology team to ensure the biopsy tract is placed along the planned surgical approach. Standard treatment is neoadjuvant (pre-operative) multi-agent chemotherapy followed by surgical resection (limb-sparing surgery when feasible, which is possible in approximately 85 to 90% of cases), then adjuvant chemotherapy. The degree of tumor necrosis in the resected specimen following neoadjuvant chemotherapy is one of the most important prognostic factors.\n\nKEY POINTS:\nOsteosarcoma classically occurs in the metaphysis near the knee in adolescents and shows a sunburst periosteal reaction and Codman triangle on radiograph, reflecting aggressive tumor growth outpacing periosteal containment. Ewing sarcoma, by contrast, classically shows an onion-skinning pattern. Treatment involves neoadjuvant chemotherapy followed by limb-sparing surgical resection when feasible."
  },
  {
    "id": 523,
    "categoryId": 14,
    "question": "Carcinoid Syndrome (flushing/diarrhea) only occurs when a GI neuroendocrine tumor has metastasized to the:",
    "options": [
      "A) Lung",
      "B) Liver",
      "C) Bone",
      "D) Brain"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Liver).\n\nPATHOPHYSIOLOGY:\nCarcinoid syndrome occurs when serotonin and other vasoactive substances produced by a gastrointestinal neuroendocrine tumor reach the systemic circulation in sufficient quantities to cause symptoms. Under normal circumstances, serotonin released by a GI neuroendocrine tumor drains via the portal venous system to the liver, where hepatic monoamine oxidase efficiently metabolizes it before it can enter the systemic circulation. This hepatic first-pass metabolism explains why patients with localized GI neuroendocrine tumors, even those producing large amounts of serotonin, typically do not develop carcinoid syndrome. When the tumor metastasizes to the liver, serotonin is released directly from hepatic metastases into the hepatic veins and inferior vena cava, bypassing first-pass metabolism and entering the systemic circulation at biologically active concentrations.\n\nCLINICAL MANIFESTATIONS:\nThe classic symptoms of carcinoid syndrome are episodic flushing (sudden redness of the face and upper body), secretory diarrhea (from serotonin stimulation of intestinal motility and secretion), bronchospasm (wheezing), and right-sided valvular heart disease (carcinoid heart disease, characterized by endocardial fibrosis of the tricuspid and pulmonic valves from chronic serotonin exposure). Left-sided valves are spared because serotonin is metabolized during passage through the pulmonary vasculature. Diagnosis is confirmed by elevated 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid), the primary serotonin metabolite.\n\nEXCEPTION:\nBronchial carcinoid tumors and ovarian carcinoid tumors can cause carcinoid syndrome without liver metastases because their venous drainage does not pass through the portal system and hepatic first-pass metabolism.\n\nKEY POINTS:\nCarcinoid syndrome occurs only when a GI neuroendocrine tumor has metastasized to the liver, because hepatic first-pass metabolism normally degrades serotonin before it reaches the systemic circulation. Classic symptoms include flushing, diarrhea, bronchospasm, and right-sided valvular heart disease. Bronchial and ovarian carcinoids are exceptions that can cause syndrome without liver metastases because they bypass the portal circulation."
  },
  {
    "id": 524,
    "categoryId": 17,
    "question": "Persistent hoarseness (>2 weeks) in a smoker requires visualization of the vocal cords to rule out:",
    "options": [
      "A) Laryngeal Cancer (Squamous Cell)",
      "B) Vocal cord nodules",
      "C) GERD",
      "D) Hypothyroidism"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Laryngeal Cancer).\n\nPATHOPHYSIOLOGY:\nLaryngeal squamous cell carcinoma accounts for approximately 95% of laryngeal malignancies and is strongly associated with tobacco use and alcohol consumption, with a synergistic effect when combined. Carcinogens in tobacco smoke cause cumulative mucosal injury and DNA damage to the laryngeal epithelium, progressing through dysplasia to carcinoma in situ and invasive disease. Glottic (true vocal cord) tumors present earliest with hoarseness because even small lesions disrupt vocal cord vibration.\n\nCLINICAL PRESENTATION:\n- Persistent hoarseness or voice change lasting more than 2-3 weeks (earliest and most common symptom of glottic cancer)\n- Dysphagia, odynophagia, referred otalgia (supraglottic tumors)\n- Stridor or airway obstruction (advanced disease)\n- Neck mass (cervical lymphadenopathy from metastatic spread)\n- Hemoptysis, weight loss (late findings)\n\nDIAGNOSIS:\nAny patient with persistent hoarseness exceeding 2 weeks, especially with a smoking history, requires direct visualization of the larynx. Flexible fiberoptic laryngoscopy is the initial diagnostic procedure. Suspicious lesions require direct laryngoscopy with biopsy under general anesthesia for tissue diagnosis and staging. CT or MRI of the neck evaluates tumor extent and nodal disease.\n\nTREATMENT:\n- Early glottic cancer (T1-T2): Radiation therapy alone or endoscopic laser surgery, with cure rates exceeding 90%\n- Advanced disease: Combined chemoradiation or total laryngectomy\n- Voice preservation is a primary treatment goal for early-stage disease\n\nPRIMARY CARE PEARL:\nWhile benign causes of hoarseness (vocal polyps, laryngopharyngeal reflux, vocal cord nodules) are far more common, the 2-week rule in a smoker ensures early detection of laryngeal cancer when cure rates are highest. Do not empirically treat hoarseness in a smoker with acid suppression alone without laryngoscopy.\n\nKEY POINTS:\nPersistent hoarseness exceeding 2 weeks in a smoker requires laryngoscopy to rule out laryngeal cancer. Glottic tumors present early with hoarseness because vocal cord lesions impair vibration. Early detection allows voice-preserving treatment with cure rates above 90%.\n---"
  },
  {
    "id": 525,
    "categoryId": 14,
    "question": "Adenocarcinoma of the Esophagus is increasing in incidence and is primarily linked to:",
    "options": [
      "A) Alcohol and Smoking",
      "B) GERD, Barrett's Esophagus, and Obesity",
      "C) Hot tea consumption",
      "D) HPV"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (GERD, Barrett's Esophagus, and Obesity).\n\nPATHOPHYSIOLOGY:\nAdenocarcinoma of the esophagus has risen dramatically in incidence in Western countries over the past four decades and is now the predominant esophageal cancer type in the United States. The pathogenesis follows a well-characterized metaplasia-dysplasia-carcinoma sequence driven by chronic gastroesophageal reflux disease. Prolonged acid and bile exposure damages the normal squamous epithelium of the distal esophagus, which is replaced by intestinal-type columnar epithelium containing goblet cells, a condition known as Barrett's esophagus. Barrett's esophagus is the single most important risk factor for esophageal adenocarcinoma, conferring an annual transformation risk of approximately 0.5 to 1%, progressing through low-grade dysplasia and high-grade dysplasia before invasive cancer develops.\n\nRISK FACTORS:\nObesity (particularly visceral obesity) independently increases risk through multiple mechanisms including increased intra-abdominal pressure promoting reflux, pro-inflammatory adipokine secretion, and hyperinsulinemia. Other risk factors include chronic GERD symptoms (risk increases with duration and severity), male sex (8:1 male predominance), Caucasian race, tobacco use, and hiatal hernia.\n\nCONTRAST WITH SQUAMOUS CELL CARCINOMA:\nSquamous cell carcinoma of the esophagus arises in the upper and middle thirds, driven by tobacco and alcohol use, and remains the predominant type worldwide. Adenocarcinoma arises in the lower third (distal esophagus and gastroesophageal junction), driven by reflux and Barrett's metaplasia. This anatomic and etiologic distinction has direct implications for risk factor modification and surveillance strategy.\n\nKEY POINTS:\nEsophageal adenocarcinoma arises from the metaplasia-dysplasia-carcinoma sequence driven by chronic GERD, with Barrett's esophagus as the key precursor lesion. Obesity and chronic reflux are the primary modifiable risk factors. Squamous cell carcinoma of the upper esophagus is driven by tobacco and alcohol, while adenocarcinoma of the distal esophagus is driven by GERD and Barrett's."
  },
  {
    "id": 526,
    "categoryId": 14,
    "question": "Basal Cell Carcinoma (BCC) is the most common skin cancer. The classic lesion is:",
    "options": [
      "A) A scaly, rough patch (sandpaper)",
      "B) A pearly papule with telangiectasias and a rolled border",
      "C) A multicolored mole",
      "D) A purple nodule"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A pearly papule with telangiectasias and a rolled border).\n\nPATHOPHYSIOLOGY:\nBasal cell carcinoma is the most common skin cancer and the most common malignancy overall in humans, with approximately 3.6 million cases diagnosed annually in the United States. BCC arises from the basal layer of the epidermis and is strongly associated with cumulative ultraviolet radiation exposure, occurring most frequently on sun-exposed areas of the head and neck in fair-skinned individuals. The classic morphology is a pearly or translucent papule or nodule with surface telangiectasias (visible dilated blood vessels) and a rolled (raised) border, often with central ulceration in advanced lesions, historically described as a rodent ulcer.\n\nCLINICAL BEHAVIOR:\nBCC grows slowly through local tissue invasion and destruction but has an extremely low metastatic potential (less than 0.1% of cases), which distinguishes it from squamous cell carcinoma (SCC) of the skin. SCC presents as a scaly, keratotic, or ulcerated lesion and carries a moderate metastatic risk that increases with tumor size greater than 2cm, depth of invasion, perineural involvement, and immunosuppression. Melanoma, the most lethal skin cancer, is identified by the ABCDE criteria (Asymmetry, Border irregularity, Color variation, Diameter greater than 6mm, Evolution) and requires excisional biopsy with Breslow depth measurement for staging.\n\nTREATMENT:\nStandard treatment for BCC is surgical excision with histologically clear margins. Mohs micrographic surgery, which provides real-time margin assessment during surgery, is preferred for high-risk locations (face, especially nose, periorbital, and periauricular areas) where tissue conservation is critical and recurrence would be morbid. Superficial BCC can also be treated with topical imiquimod, photodynamic therapy, or electrodesiccation and curettage in select cases. Hedgehog pathway inhibitors (vismodegib, sonidegib) are available for locally advanced or metastatic BCC.\n\nKEY POINTS:\nBasal cell carcinoma presents as a pearly papule with telangiectasias and rolled borders, grows slowly by local invasion, and almost never metastasizes. Squamous cell carcinoma is scaly and ulcerated with moderate metastatic potential. Mohs micrographic surgery is preferred for high-risk facial locations where tissue conservation and clear margins are critical."
  },
  {
    "id": 527,
    "categoryId": 14,
    "question": "A child presents with bone pain, fever, fatigue, and bruising. Labs show blasts in the peripheral blood. The most common childhood cancer is:",
    "options": [
      "A) AML",
      "B) ALL (Acute Lymphoblastic Leukemia)",
      "C) CML",
      "D) CLL"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Acute Lymphoblastic Leukemia).\n\nPATHOPHYSIOLOGY:\nAcute lymphoblastic leukemia is the most common cancer and the most common leukemia in children, accounting for approximately 25% of all childhood cancers with a peak incidence between ages 2 and 5. ALL is a malignant clonal proliferation of lymphoid precursor cells (lymphoblasts) in the bone marrow that crowds out normal hematopoiesis, resulting in the simultaneous failure of all three major cell lines. The loss of red blood cell production causes anemia (fatigue, pallor), the loss of platelet production causes thrombocytopenia (bruising, petechiae, mucosal bleeding), and the loss of mature white blood cells causes neutropenia (recurrent or severe infections). Bone pain results from rapid expansion of the leukemic cell population within the marrow cavity, stretching the periosteum.\n\nCLINICAL PRESENTATION:\nChildren typically present with a combination of fatigue, pallor, fevers, bone or joint pain, bruising, and hepatosplenomegaly or lymphadenopathy from leukemic infiltration. The CBC characteristically shows anemia, thrombocytopenia, and a white blood cell count that may be elevated (with circulating blasts), normal, or low (aleukemic leukemia). The presence of lymphoblasts on peripheral blood smear is a critical finding that warrants emergent bone marrow evaluation with flow cytometry and cytogenetic analysis for definitive diagnosis and risk stratification.\n\nTREATMENT:\nModern multi-phase chemotherapy protocols have transformed childhood ALL from a uniformly fatal disease into one with overall cure rates exceeding 90% in standard-risk patients per data from the Children's Oncology Group and St. Jude Children's Research Hospital. Treatment consists of induction (to achieve remission), consolidation (to eliminate residual disease), CNS prophylaxis (intrathecal chemotherapy to prevent meningeal relapse), and maintenance therapy for a total duration of approximately 2 to 3 years. Risk stratification using age, WBC count, cytogenetics (the Philadelphia chromosome and MLL rearrangements confer high risk), and minimal residual disease assessment guides treatment intensity. Tumor lysis syndrome is a critical oncologic emergency consideration at treatment initiation.\n\nKEY POINTS:\nALL is the most common childhood cancer, presenting with bone marrow failure (anemia, thrombocytopenia, neutropenia) and bone pain from marrow expansion. Circulating blasts on peripheral smear warrant emergent bone marrow evaluation. Modern chemotherapy achieves cure rates exceeding 90% in standard-risk childhood ALL."
  },
  {
    "id": 528,
    "categoryId": 14,
    "question": "Sister Mary Joseph Nodule is a palpable nodule at the umbilicus. It represents metastasis from a:",
    "options": [
      "A) Pelvic or Abdominal malignancy (Ovarian/Gastric/Pancreatic)",
      "B) Lung cancer",
      "C) Breast cancer",
      "D) Melanoma"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Metastasis from an abdominopelvic malignancy).\n\nCLINICAL SIGNIFICANCE:\nA Sister Mary Joseph nodule is an umbilical metastasis representing advanced intra-abdominal or pelvic malignancy, named after Sister Mary Joseph Dempsey, a surgical assistant at St. Mary\u2019s Hospital (Mayo Clinic) who first recognized the association between umbilical nodules and intra-abdominal cancer. The most common primary sites are gastric, pancreatic, colorectal, and ovarian adenocarcinomas.\n\nPATHOPHYSIOLOGY:\nMetastatic spread to the umbilicus can occur through several anatomic routes: direct peritoneal seeding along the peritoneal surface to the umbilical region, lymphatic drainage pathways that converge near the umbilicus, hematogenous spread via the paraumbilical venous plexus, or extension along embryologic remnants including the urachus and obliterated umbilical arteries connecting the bladder and internal iliac vessels to the umbilical ring. The finding indicates widespread disease and is linked to a poor prognosis, with reported median survival of approximately 10 to 11 months per published case series.\n\nDIAGNOSTIC APPROACH:\nAn umbilical nodule in an adult should never be dismissed as a benign hernia or granuloma without histologic evaluation. Biopsy of the nodule (fine-needle aspiration or excisional biopsy) with immunohistochemistry to determine tissue of origin, followed by CT of the chest, abdomen, and pelvis for primary tumor identification and staging, is the standard workup. In women, CA-125 and pelvic imaging should be included given the frequency of ovarian cancer as the primary site.\n\nKEY POINTS:\nA Sister Mary Joseph nodule is an umbilical metastasis from an abdominopelvic malignancy, most commonly gastric, pancreatic, colorectal, or ovarian cancer. It represents advanced disease with poor prognosis. An umbilical nodule in an adult should never be assumed benign and requires biopsy and cross-sectional imaging to identify the primary malignancy."
  },
  {
    "id": 529,
    "categoryId": 14,
    "question": "Hepatocellular Carcinoma (HCC) screening involves Ultrasound and AFP every 6 months for high-risk patients. Who is high risk?",
    "options": [
      "A) Anyone with fatty liver",
      "B) Patients with Cirrhosis (any cause) or Chronic Hepatitis B",
      "C) Alcoholics without cirrhosis",
      "D) Diabetics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Patients with Cirrhosis or Chronic Hepatitis B).\n\nSCREENING RATIONALE:\nHepatocellular carcinoma surveillance with abdominal ultrasound and serum alpha-fetoprotein every 6 months is recommended by the AASLD and NCCN for patients at elevated risk, primarily those with cirrhosis from any cause and those with chronic hepatitis B infection. Cirrhosis is the single strongest risk factor, as approximately 80 to 90% of HCC cases arise in cirrhotic livers. The chronically injured, regenerating cirrhotic liver creates a pre-malignant field in which hepatocyte turnover, oxidative stress, and genomic instability accumulate, dramatically increasing the probability of malignant transformation.\n\nHEPATITIS B EXCEPTION:\nChronic hepatitis B is unique among HCC risk factors because it can cause HCC even without cirrhosis. HBV integrates its DNA directly into the hepatocyte genome, causing insertional mutagenesis that can activate oncogenes or inactivate tumor suppressor genes independent of the cirrhosis-mediated pathway. The AASLD recommends HCC surveillance for HBV carriers who are Asian males over age 40, Asian females over age 50, African or North American Black patients with HBV, patients with HBV and a family history of HCC, and any HBV patient with cirrhosis.\n\nSCREENING PERFORMANCE:\nAbdominal ultrasound has a sensitivity of approximately 60 to 80% for detecting early-stage HCC, which improves when combined with AFP measurement. Lesions detected on surveillance tend to be smaller and at an earlier stage, translating into increased eligibility for curative treatments including surgical resection, liver transplantation (within Milan criteria), and ablation. The 6-month interval is based on the average HCC tumor doubling time of approximately 4 to 6 months.\n\nKEY POINTS:\nHCC screening with ultrasound and AFP every 6 months is recommended for most patients with cirrhosis (any etiology) and chronic hepatitis B carriers, even without cirrhosis. HBV uniquely causes HCC through direct DNA integration and insertional mutagenesis independent of cirrhosis. Surveillance enables detection at earlier stages when curative treatment with resection, transplant, or ablation is feasible."
  },
  {
    "id": 530,
    "categoryId": 14,
    "question": "Leukoplakia is a white patch on the oral mucosa that cannot be scraped off. It is considered:",
    "options": [
      "A) Thrush (Candidiasis)",
      "B) Pre-malignant (risk of Squamous Cell Carcinoma)",
      "C) Lichen Planus",
      "D) Benign friction rub"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pre-malignant).\n\nDEFINITION:\nLeukoplakia means a white patch or plaque on the oral mucosa that cannot be scraped off and cannot be attributed to any other identifiable cause. It is a clinical descriptor, not a histologic diagnosis, and approximately 5 to 25% of leukoplakia lesions demonstrate dysplasia or carcinoma on biopsy. The whiteness results from epithelial hyperkeratosis (thickening of the keratin layer), making it adherent to the underlying mucosa, in contrast to oral thrush (candidiasis) which produces white plaques that can be scraped off, revealing an erythematous or bleeding base.\n\nRISK FACTORS:\nTobacco use (both smoking and smokeless tobacco) is the strongest risk factor for oral leukoplakia. Alcohol use acts synergistically with tobacco to increase risk. Chronic mechanical irritation from ill-fitting dentures, betel nut chewing (prevalent in South and Southeast Asia), and HPV infection (particularly types 16 and 18) are additional contributors. The lateral tongue and floor of mouth are the highest-risk locations for malignant transformation, while leukoplakia of the buccal mucosa carries a lower transformation risk.\n\nMANAGEMENT:\nAll leukoplakia lesions require biopsy to assess for dysplasia. Mild dysplasia may be observed with close follow-up after eliminating risk factors (smoking cessation, alcohol reduction). Moderate to severe dysplasia or carcinoma in situ requires excision or ablation. Erythroplakia, a red velvety patch on the oral mucosa, carries a substantially higher malignant potential than leukoplakia, with up to 50% harboring invasive squamous cell carcinoma at biopsy.\n\nKEY POINTS:\nLeukoplakia is a white oral mucosal patch that cannot be scraped off (unlike candidiasis) and is pre-malignant, with 5 to 25% showing dysplasia or carcinoma on biopsy. The lateral tongue and floor of mouth carry the highest transformation risk. All leukoplakia requires biopsy, and erythroplakia (red patches) carries even higher malignant potential with up to 50% harboring invasive cancer."
  },
  {
    "id": 531,
    "categoryId": 14,
    "question": "Hypercalcemia of Malignancy is most commonly caused by the tumor secreting:",
    "options": [
      "A) PTH (Parathyroid Hormone)",
      "B) PTHrP (PTH-related Protein)",
      "C) Vitamin D",
      "D) Calcitonin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (PTHrP - PTH-related Protein).\n\nPATHOPHYSIOLOGY:\nHypercalcemia of malignancy is the most common paraneoplastic endocrine syndrome and the most common cause of hypercalcemia in hospitalized patients. The predominant mechanism, accounting for approximately 80% of cases, is tumor secretion of parathyroid hormone-related protein (PTHrP), which shares structural homology with the first 13 amino acids of native PTH and binds the same PTH/PTHrP receptor on bone and kidney. This produces effects that mimic hyperparathyroidism: increased osteoclastic bone resorption (releasing calcium) and increased renal calcium reabsorption. However, unlike primary hyperparathyroidism, PTHrP does not stimulate renal 1-alpha-hydroxylase, so 1,25-dihydroxyvitamin D levels are typically low.\n\nLABORATORY DISTINCTION:\nThe characteristic laboratory pattern is elevated serum calcium, low (suppressed) intact PTH (because the parathyroid calcium-sensing receptor detects hypercalcemia and suppresses native PTH), and elevated PTHrP. This pattern distinguishes humoral hypercalcemia of malignancy from primary hyperparathyroidism, in which PTH is inappropriately elevated or normal. Squamous cell carcinomas (particularly lung), renal cell carcinoma, and breast cancer are the most common malignancies causing PTHrP-mediated hypercalcemia. Other mechanisms include direct osteolytic metastases (breast, myeloma) and tumor production of 1,25-dihydroxyvitamin D (lymphomas, granulomatous diseases).\n\nMANAGEMENT:\nAcute management of severe hypercalcemia includes aggressive intravenous normal saline hydration (200 to 300 mL/hour initially), intravenous bisphosphonate (zoledronic acid 4 mg), and calcitonin for rapid but transient effect. Denosumab is an alternative for bisphosphonate-refractory cases. Definitive treatment requires addressing the underlying malignancy.\n\nKEY POINTS:\nHypercalcemia of malignancy is most commonly caused by tumor-secreted PTHrP, which mimics PTH action on bone and kidney. The diagnostic lab pattern is high calcium, low PTH, and elevated PTHrP, distinguishing it from primary hyperparathyroidism. Squamous cell lung cancer, renal cell carcinoma, and breast cancer are the most common culprits."
  },
  {
    "id": 532,
    "categoryId": 14,
    "question": "Anthracyclines (e.g., Doxorubicin/Adriamycin) are notorious for causing dose-dependent toxicity to the:",
    "options": [
      "A) Kidneys",
      "B) Heart (Cardiomyopathy)",
      "C) Lungs",
      "D) Nerves"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Heart - Cardiomyopathy).\n\nPATHOPHYSIOLOGY:\nAnthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin) are among the most effective and widely used chemotherapy agents across numerous malignancies including breast cancer, lymphomas, sarcomas, and acute leukemias, but they carry a well-characterized risk of dose-dependent cardiotoxicity. The primary mechanism involves generation of reactive oxygen species through iron-dependent redox cycling of the anthracycline quinone moiety, causing oxidative damage to cardiomyocyte mitochondrial DNA, lipid membranes, and contractile proteins. Unlike most other cell types, cardiomyocytes have limited regenerative capacity and low levels of endogenous antioxidant defenses (particularly catalase), making them uniquely vulnerable to cumulative oxidative injury. An additional mechanism involves inhibition of topoisomerase 2-beta in cardiomyocytes, leading to DNA double-strand breaks and apoptosis.\n\nCLINICAL MANIFESTATIONS:\nAnthracycline cardiotoxicity manifests as a dose-dependent dilated cardiomyopathy that may present acutely during treatment, within the first year, or as late-onset cardiomyopathy years to decades after treatment. The risk increases significantly above a cumulative doxorubicin dose of 400 mg/m2, with heart failure incidence of approximately 5% at 400 mg/m2 and 26% at 550 mg/m2 per data published in the New England Journal of Medicine. The damage is cumulative and irreversible.\n\nMONITORING AND PREVENTION:\nEchocardiography or MUGA scan to assess left ventricular ejection fraction is required before initiating anthracycline therapy, at regular intervals during treatment, and during long-term survivorship follow-up. Dexrazoxane, an iron chelator, is the only FDA-approved cardioprotectant that reduces anthracycline cardiotoxicity and is considered when cumulative doses exceed 300 mg/m2.\n\nKEY POINTS:\nAnthracyclines cause dose-dependent irreversible cardiomyopathy through free radical damage to cardiomyocytes, with risk increasing significantly above cumulative doxorubicin doses of 400 mg/m2. Echocardiography monitoring before, during, and after treatment is mandatory. Other high-yield chemotherapy toxicities include bleomycin (pulmonary fibrosis), cisplatin (nephrotoxicity and ototoxicity), and vincristine (peripheral neuropathy)."
  },
  {
    "id": 533,
    "categoryId": 14,
    "question": "Squamous Cell Carcinoma of the Anus is strongly associated with:",
    "options": [
      "A) Hemorrhoids",
      "B) HPV Infection",
      "C) Inflammatory Bowel Disease",
      "D) Alcohol"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HPV Infection).\n\nPATHOPHYSIOLOGY:\nSquamous cell carcinoma of the anus is an HPV-driven malignancy with a pathogenesis analogous to cervical cancer. HPV types 16 and 18 are the causative strains in the vast majority of cases, with their oncoproteins E6 and E7 inactivating the tumor suppressors p53 and retinoblastoma protein respectively, driving malignant transformation of the squamocolumnar junction (the anal transition zone). Risk factors include receptive anal intercourse, multiple sexual partners, immunosuppression (particularly HIV infection, which increases anal cancer risk 30 to 80-fold), and cigarette smoking.\n\nCLINICAL PRESENTATION:\nAnal cancer most commonly presents with rectal bleeding, anal pain, a palpable mass, or pruritus, though it may be asymptomatic and detected on routine digital rectal examination. It is important to distinguish anal canal cancer (squamous cell carcinoma, HPV-driven) from rectal cancer (adenocarcinoma, not HPV-related), as the biology, treatment, and prognosis differ significantly.\n\nTREATMENT:\nThe standard of care for anal squamous cell carcinoma is the Nigro protocol, concurrent chemoradiation with 5-fluorouracil and mitomycin C. This organ-preserving approach achieves cure rates of approximately 80 to 90% for locoregional disease while preserving sphincter function and avoiding the need for abdominoperineal resection (permanent colostomy) in the majority of patients. Surgery is reserved for residual or recurrent disease after chemoradiation.\n\nPREVENTION:\nHPV vaccination with the 9-valent vaccine (Gardasil 9) protects against the HPV types responsible for anal cancer and is recommended for all individuals. Anal cancer screening with anal cytology (anal Pap smear) and high-resolution anoscopy is recommended for high-risk populations including HIV-positive individuals, men who have sex with men, and immunosuppressed patients per guidelines from Johns Hopkins and the HIV Medicine Association.\n\nKEY POINTS:\nAnal squamous cell carcinoma is driven by HPV types 16 and 18, analogous to cervical cancer, with HIV conferring a 30 to 80-fold increased risk. The Nigro protocol (concurrent chemoradiation) achieves high cure rates while preserving sphincter function. HPV vaccination protects against anal cancer, and screening with anal cytology is recommended for high-risk populations."
  },
  {
    "id": 534,
    "categoryId": 12,
    "question": "A parent is concerned that their 18-month-old is not talking enough. What is the expected speech milestone for this age?",
    "options": [
      "A) Cooing and babbling",
      "B) 6-20 words",
      "C) 2-word sentences",
      "D) 100% intelligible speech"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (6 to 20 words).\n\nCLINICAL REASONING:\nSpeech and language development follows a predictable trajectory with recognized milestones that serve as screening benchmarks at well-child visits. By 12 months, a child should have at least 1 to 3 recognizable words beyond \"mama\" and \"dada\" used with intent, along with communicative gesturing (pointing, waving). By 18 months, the expected vocabulary is approximately 10 to 25 words (with some variation across references citing 6 to 20 words), and the child should be able to follow simple one-step commands and point to familiar objects when named. By 24 months, the vocabulary expands to 50 or more words with emergence of two-word phrases (\"want milk,\" \"more juice\"), and speech should be approximately 50% intelligible to strangers. By 36 months, children produce three-word sentences and are approximately 75% intelligible.\n\nDEVELOPMENTAL SURVEILLANCE:\nMotor milestones provide additional context: social smile at 2 months, rolling at 4 to 6 months, sitting unsupported at 6 months, crawling at 9 months, pulling to stand at 9 to 12 months, and independent walking at 12 to 15 months. Gross motor, fine motor, language, and social-emotional domains should be assessed at every well-child visit. while individual variation exists, failure to reach specific milestones within defined windows warrants formal developmental evaluation rather than reassurance to \"wait and see\".\n\nRED FLAGS:\nAbsolute red flags warranting immediate referral include no babbling by 12 months, no single words by 16 months, no two-word spontaneous (not echolalic) phrases by 24 months, and any regression or loss of previously acquired language or social skills at any age. Hearing evaluation should be performed early in any child with speech delay, as hearing loss is a common and treatable cause.\n\nKEY POINTS:\nAt 18 months, the expected vocabulary is approximately 10 to 25 words, with the ability to follow simple commands and point to named objects. The milestone progression follows a predictable pattern: 1 to 3 words at 12 months, 10 to 25 words at 18 months, 50 or more words with two-word phrases at 24 months. Any loss of previously acquired skills at any age is an absolute red flag requiring immediate evaluation."
  },
  {
    "id": 535,
    "categoryId": 12,
    "question": "A 3-year-old presents with a fever of 103F for 4 days. The fever breaks, and suddenly a pink, macular rash appears on the trunk. Diagnosis?",
    "options": [
      "A) Measles",
      "B) Roseola (Exanthem Subitum)",
      "C) Scarlet Fever",
      "D) Varicella"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Roseola / Exanthem Subitum).\n\nPATHOPHYSIOLOGY:\nRoseola infantum (exanthem subitum, sixth disease) results from human herpesvirus 6 (HHV-6, primarily HHV-6B), which infects CD4+ T lymphocytes and monocytes during the primary viremic phase. It is one of the most common viral exanthems of early childhood, typically affecting infants aged 6 months to 2 years, with nearly all children seropositive by age 3. The virus is transmitted via salivary secretions from asymptomatic shedding by caregivers. After a 5 to 15-day incubation period, the child develops a high-grade fever (often 39.5 to 40.5 degrees Celsius) that persists for 3 to 5 days while the child appears surprisingly well (the characteristically \"well-appearing febrile child\").\n\nCLINICAL PRESENTATION:\nThe hallmark of roseola is the temporal pattern: high fever for 3 to 5 days, followed by abrupt defervescence, immediately followed by the appearance of a diffuse, blanching, pink macular or maculopapular rash that begins on the trunk and spreads centrifugally to the face and extremities. This \"fever then rash\" sequence is essentially pathognomonic and distinguishes roseola from other childhood exanthems. Measles, by contrast, shows rash appearing during ongoing fever with the rash starting on the face (behind the ears) and spreading caudally. Febrile seizures are the most significant complication, occurring in approximately 10 to 15% of primary HHV-6 infections during the febrile phase, and HHV-6 is the single most common viral trigger of febrile seizures in infancy.\n\nMANAGEMENT:\nTreatment is entirely supportive: antipyretics (acetaminophen, ibuprofen for children over 6 months) for fever management and comfort, and adequate hydration. The rash itself is not pruritic, requires no treatment, and resolves spontaneously within 1 to 2 days. No antiviral therapy is indicated for primary HHV-6 infection in immunocompetent children. The diagnosis is clinical, and laboratory testing is rarely needed.\n\nKEY POINTS:\nRoseola is diagnosed by its pathognomonic sequence of high fever for 3 to 5 days in a well-appearing child, followed by abrupt defervescence and immediate appearance of a truncal macular rash. HHV-6 is the most common viral cause of febrile seizures in infancy. The rash begins on the trunk and spreads outward (opposite of measles, which starts on the face and spreads downward)."
  },
  {
    "id": 536,
    "categoryId": 17,
    "question": "Croup (Laryngotracheobronchitis) is caused by Parainfluenza virus. The classic X-ray finding is:",
    "options": [
      "A) Thumbprint Sign",
      "B) Steeple Sign",
      "C) Sail Sign",
      "D) Air Bronchograms"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Steeple Sign).\n\nDIAGNOSIS:\nCroup (laryngotracheobronchitis), a viral infection causing inflammation and edema of the subglottic airway, most commonly caused by parainfluenza virus.\n\nCLINICAL REASONING:\nCroup typically affects children 6 months to 3 years and presents with the classic triad of barking \"seal-like\" cough, inspiratory stridor, and hoarseness, often preceded by URI symptoms. Symptoms characteristically worsen at night.\n\nSEVERITY ASSESSMENT (Westley Croup Score):\n- Mild: Occasional barking cough, no stridor at rest, no retractions\n- Moderate: Frequent cough, stridor at rest, mild retractions\n- Severe: Frequent cough, prominent stridor, severe retractions, decreased air entry, altered mental status\n\nTREATMENT:\n1. CORTICOSTEROIDS (all patients with croup):\n - Dexamethasone 0.6 mg/kg PO/IM (single dose) - drug of choice\n - Reduces airway edema, decreases return visits and hospitalization\n - Effective even for mild croup\n\n2. NEBULIZED EPINEPHRINE (moderate-severe):\n - Racemic epinephrine 0.5 mL of 2.25% solution OR L-epinephrine 0.5 mL/kg (max 5 mL) of 1:1000\n - Rapid onset (within minutes) but transient effect (2 hours)\n - Observe for 2-4 hours after administration for rebound\n\n3. Supportive care: Humidified air, hydration, avoid agitation\n\nCLINICAL PEARL:\nThe \"steeple sign\" on AP neck X-ray (subglottic narrowing) is classic but imaging is usually unnecessary if the diagnosis is clear clinically. Do NOT examine the throat with a tongue depressor - if epiglottitis is suspected (toxic appearance, drooling, tripod positioning), manage differently."
  },
  {
    "id": 537,
    "categoryId": 12,
    "question": "Meckel's Diverticulum is the most common congenital GI anomaly. The 'Rule of 2s' includes all EXCEPT:",
    "options": [
      "A) 2% of the population",
      "B) 2 feet from the ileocecal valve",
      "C) 2 inches long",
      "D) 2 years of chemotherapy required"
    ],
    "correctAnswer": 3,
    "explanation": "CORRECT: D (2 years of chemotherapy required is not part of the Rule of 2s).\n\nPATHOPHYSIOLOGY:\nMeckel diverticulum is a true diverticulum (containing all three layers of the bowel wall: mucosa, submucosa, and muscularis) located on the antimesenteric border of the ileum, representing the vestigial remnant of the omphalomesenteric (vitelline) duct that normally obliterates by the seventh week of gestation. It is the most common congenital anomaly of the gastrointestinal tract. The classic teaching mnemonic, the Rule of 2s, summarizes the key epidemiologic and anatomic features: occurs in approximately 2% of the population, is approximately 2 inches (5 cm) long, is located within 2 feet (60 cm) of the ileocecal valve, contains 2 types of ectopic tissue (gastric mucosa in approximately 50% and pancreatic tissue in approximately 5%), has a 2:1 male-to-female ratio for symptomatic presentation, and most commonly presents before age 2 years.\n\nCLINICAL PRESENTATION:\nThe majority of Meckel diverticula are asymptomatic and discovered incidentally. When symptomatic, the most common presentation in children under 2 years is painless rectal bleeding (bright red or maroon, often described as \"brick-colored\") caused by acid secretion from ectopic gastric mucosa within the diverticulum that ulcerates the adjacent normal ileal mucosa. In older children and adults, complications include intestinal obstruction (from volvulus, intussusception with the diverticulum as a lead point, or internal hernia), diverticulitis (mimicking appendicitis but with left lower quadrant or periumbilical pain), and rarely perforation.\n\nDIAGNOSIS AND TREATMENT:\nA Meckel scan (technetium-99m pertechnetate scintigraphy) is the diagnostic study of choice in children, with sensitivity of approximately 85 to 90%, because the radiotracer is taken up by ectopic gastric mucosa within the diverticulum. Pretreatment with a histamine H2-receptor antagonist (ranitidine or famotidine) enhances sensitivity by inhibiting secretion of the radiotracer by the gastric mucosa, allowing it to accumulate and improve visualization. Treatment of a symptomatic Meckel diverticulum is surgical excision (diverticulectomy or segmental ileal resection).\n\nKEY POINTS:\nThe Rule of 2s for Meckel diverticulum includes 2% prevalence, 2 feet from the ileocecal valve, 2 inches long, 2 types of ectopic tissue (gastric and pancreatic), 2:1 male-to-female ratio, and presentation before age 2. The most common pediatric presentation is painless rectal bleeding from ectopic gastric mucosa ulcerating adjacent ileum. The Meckel scan (technetium-99m pertechnetate) detects ectopic gastric tissue with approximately 85 to 90% sensitivity."
  },
  {
    "id": 538,
    "categoryId": 7,
    "question": "Legg-Calve-Perthes Disease is avascular necrosis of the femoral head. It typically affects:",
    "options": [
      "A) Obese adolescents (12-15 yrs)",
      "B) Boys age 4-8 with a painless limp",
      "C) Newborn females (breech)",
      "D) Athletes with knee pain"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/legg-calve-perthes-disease.jpg", "alt": "Legg Calve Perthes disease", "caption": "Legg-Calve-Perthes disease image." }
    ],
    "explanation": "CORRECT: B (Boys age 4 to 8 with a painless limp).\n\nPATHOPHYSIOLOGY:\nLegg-Calv\u00e9-Perthes disease (LCPD) is idiopathic avascular necrosis of the femoral head in children, from disruption of blood supply to the capital femoral epiphysis. Children aged 4-8 are vulnerable because the ligamentum teres artery provides most epiphyseal blood flow before lateral epiphyseal vessels fully mature. Proposed mechanisms include thrombophilia, repetitive microtrauma, and venous congestion. The femoral head undergoes predictable Waldenstr\u00f6m stages: necrosis with subchondral fracture, fragmentation with resorption, re-ossification, and remodeling. Boys are affected 4-5 times more than girls, with bilateral involvement in 10-15%. Risk factors include male sex, Caucasian ethnicity, low socioeconomic status, short stature, delayed skeletal age, and secondhand smoke.\n\nCLINICAL PRESENTATION:\nClassic presentation is insidious painless limp in a child aged 4-8, or mild activity-related hip/groin pain. Critical pearl: hip pathology commonly presents as knee pain via obturator nerve referred pain\u2014any limping child with knee pain must have the hip examined and imaged. Examination reveals restricted internal rotation and abduction (earliest and most sensitive findings). Trendelenburg sign may be positive. Radiographs may show widened medial joint space, a smaller/denser femoral epiphysis, and the crescent sign (subchondral fracture). MRI is most sensitive for early disease when radiographs are normal. Catterall and Herring lateral pillar classifications grade severity and guide prognosis.\n\nTREATMENT:\nThe goal is containment of the femoral head within the acetabulum as a biological mold during revascularization. Age at onset is the strongest prognostic factor\u2014children under 6 have excellent prognosis regardless of treatment. Younger children with mild-moderate involvement receive conservative management: activity restriction, NSAIDs, physical therapy maintaining abduction and internal rotation, and serial monitoring. Abduction bracing may maintain containment. Children over 8 or with severe involvement (Herring C) benefit from surgical containment via femoral varus osteotomy or Salter innominate osteotomy. Complications include coxa plana, leg length discrepancy, and premature hip osteoarthritis.\n\nKEY POINTS:\nLCPD is idiopathic AVN of the femoral head in boys aged 4-8, presenting with painless limp and restricted hip internal rotation/abduction. Any limping child with knee pain must have the hip examined (obturator nerve referred pain). Age at onset is the strongest prognostic factor, with treatment focused on femoral head containment."
  },
  {
    "id": 539,
    "categoryId": 6,
    "question": "Simple Febrile Seizures are common (6 months - 5 years). Which feature would classify a seizure as COMPLEX (requiring more workup)?",
    "options": [
      "A) Duration < 15 minutes",
      "B) Generalized tonic-clonic movement",
      "C) Focal features (one arm shaking) or Recurrence within 24 hours",
      "D) Post-ictal drowsiness"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Focal features or Recurrence within 24 hours).\n\nFEBRILE SEIZURE CLASSIFICATION:\nFebrile seizures occur in children aged 6 months to 5 years with fever (\u226538\u00b0C/100.4\u00b0F) without intracranial infection or other defined cause. A complex febrile seizure is defined by: focal onset (one limb or one side of the body), duration exceeding 15 minutes, or recurrence within the same 24-hour febrile illness.\n\nPATHOPHYSIOLOGY:\nThe developing brain has a lower seizure threshold due to immature inhibitory (GABAergic) circuits and enhanced excitatory (glutamatergic) neurotransmission. Fever further lowers this threshold through increased neuronal metabolic rate, IL-1 beta-mediated effects on hippocampal neurons, and temperature-dependent ion channel modulation. The rate of temperature rise may be more important than the absolute temperature in triggering seizures.\n\nCLINICAL EVALUATION:\nSimple febrile seizures are benign and do not require EEG, neuroimaging, or routine laboratory testing beyond identifying the fever source. Lumbar puncture should be considered in infants younger than 12 months (particularly if not fully immunized for H. influenzae type B or S. pneumoniae), children with meningeal signs, or those pretreated with antibiotics that may mask meningitis. Complex febrile seizures warrant more thorough evaluation including consideration of EEG and MRI.\n\nMANAGEMENT AND PROGNOSIS:\nMost febrile seizures stop within 2-3 minutes. Prolonged seizures (>5 minutes) are treated with benzodiazepines. Antipyretics provide comfort but do not prevent recurrence. Approximately 30% of children will have a recurrence; risk factors include age <18 months, lower fever at onset, shorter fever duration before seizure, and family history. Daily prophylactic anticonvulsants are not recommended given the benign nature and medication side effects. Simple febrile seizures do not increase epilepsy, developmental delay, or cognitive impairment risk.\n\nKEY POINTS:\nComplex febrile seizures are defined by focal features, duration >15 minutes, or recurrence within 24 hours, distinguishing them from benign simple febrile seizures. Simple febrile seizures require no EEG, imaging, or anticonvulsant prophylaxis. Approximately 30% of children will have recurrent febrile seizures, but the condition does not increase epilepsy risk."
  },
  {
    "id": 540,
    "categoryId": 12,
    "question": "Cephalohematoma differs from Caput Succedaneum because Cephalohematoma:",
    "options": [
      "A) Crosses suture lines",
      "B) Does NOT cross suture lines",
      "C) Is present immediately at birth",
      "D) Is edema of the scalp"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Does NOT cross suture lines).\n\nPATHOPHYSIOLOGY:\nCaput succedaneum and cephalohematoma are the two most common birth-related scalp injuries, and their critical distinction lies in the anatomic plane of fluid accumulation relative to the periosteum. Caput succedaneum is a collection of serosanguinous edema fluid in the subcutaneous tissue superficial to the periosteum and the skull. Because the subcutaneous tissue is continuous across the entire scalp with no barriers at suture lines, caput succedaneum freely crosses suture lines and may even extend across the midline. It is present at birth, results from the pressure of the dilating cervix on the presenting part during prolonged labor (particularly common with vacuum-assisted delivery), and resolves spontaneously within days.\n\nCephalohematoma, in contrast, is a subperiosteal hemorrhage (blood collection between the periosteum and the outer table of the skull). The periosteum is tightly adherent to the skull at the cranial suture lines, creating natural barriers that confine the hematoma to the surface of a single cranial bone. This periosteal confinement is what prevents a cephalohematoma from crossing suture lines, producing the characteristic well-demarcated, non-fluctuant swelling limited to one bone (most commonly the parietal bone). Cephalohematomas are not present at birth but develop over the first hours to days as slow subperiosteal bleeding accumulates. They resolve over weeks to months as the blood is gradually resorbed, and the breakdown of the trapped hemoglobin can cause or exacerbate neonatal hyperbilirubinemia (jaundice).\n\nCOMPLICATIONS:\nCephalohematomas occasionally calcify if they are large or persist for more than several weeks, producing a palpable bony ridge that typically remodels over months. Rarely, underlying linear skull fractures are associated (approximately 5 to 18% of cephalohematomas), and imaging should be considered for large or bilateral cephalohematomas. A subgaleal hemorrhage (bleeding in the potential space between the periosteum and the galeal aponeurosis) is a much more dangerous entity that crosses suture lines and can accumulate a life-threatening volume of blood; it is a neonatal emergency requiring urgent volume resuscitation.\n\nKEY POINTS:\nCephalohematoma is subperiosteal and does NOT cross suture lines because periosteum adheres tightly at sutures, while caput succedaneum is subcutaneous and freely crosses suture lines. Caput is present at birth and resolves in days; cephalohematoma develops over hours and resolves over weeks to months, potentially causing jaundice from hemoglobin breakdown. Subgaleal hemorrhage crosses suture lines and is a life-threatening neonatal emergency distinct from both."
  },
  {
    "id": 541,
    "categoryId": 1,
    "question": "Which congenital heart defect causes a fixed split S2?",
    "options": [
      "A) VSD",
      "B) Atrial Septal Defect (ASD)",
      "C) Tetralogy of Fallot",
      "D) PDA"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Atrial Septal Defect).\n\nPATHOPHYSIOLOGY:\nAn atrial septal defect (ASD) causes a fixed split S2 because the persistent left-to-right shunt at the atrial level continuously increases right ventricular volume, producing equal and constant right ventricular filling regardless of the respiratory cycle. Normally, the second heart sound (S2) is composed of aortic valve closure (A2) followed by pulmonic valve closure (P2). During inspiration, increased venous return to the right heart prolongs right ventricular ejection and delays P2, causing physiologic splitting that widens during inspiration and narrows during expiration. In ASD, the interatrial communication equalizes the filling of both atria throughout the respiratory cycle: during inspiration, when increased venous return would normally preferentially fill the right heart, the ASD allows redistribution so that both ventricles are affected equally, and during expiration, the shunt maintains continued excess right ventricular filling.\n\nTYPES OF ASD:\nThe most common type is the ostium secundum ASD (approximately 70% of cases), located in the central portion of the atrial septum at the fossa ovalis. Ostium primum ASD (approximately 20%) is located in the lower septum and is linked to endocardial cushion defects and mitral valve cleft, commonly seen in Down syndrome. Sinus venosus ASD (approximately 10%) is located near the junction of the superior vena cava and right atrium and is frequently associated with anomalous pulmonary venous return.\n\nCLINICAL FEATURES:\nASDs are often asymptomatic in childhood and may not be detected until adulthood. Physical examination reveals the fixed split S2, a systolic flow murmur at the left upper sternal border (from increased flow across the pulmonic valve, not across the ASD itself), and a mid-diastolic rumble at the left lower sternal border (from increased flow across the tricuspid valve). Long-standing unrepaired ASDs can lead to right heart volume overload, pulmonary hypertension, atrial arrhythmias (particularly atrial fibrillation/flutter), and eventually Eisenmenger syndrome (reversal of shunt direction from right-to-left when pulmonary vascular resistance exceeds systemic).\n\nKEY POINTS:\nASD produces a fixed split S2 because the interatrial communication equalizes ventricular filling regardless of respiration, maintaining constant delay in pulmonic valve closure. The systolic murmur is from increased pulmonic flow, not from flow across the defect itself. Long-standing ASD can cause pulmonary hypertension, atrial arrhythmias, and Eisenmenger syndrome."
  },
  {
    "id": 542,
    "categoryId": 12,
    "question": "Cryptorchidism (Undescended Testicle) increases the risk of:",
    "options": [
      "A) Renal failure",
      "B) Testicular Cancer and Infertility",
      "C) UTI",
      "D) Prostate cancer"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Testicular Cancer and Infertility).\n\nPATHOPHYSIOLOGY:\nCryptorchidism (undescended testis) is the most common congenital anomaly of the male genitourinary tract, affecting approximately 3 to 4% of full-term male newborns and up to 30% of preterm males. Normal testicular descent occurs in two phases: the transabdominal phase (guided by Mullerian inhibiting substance/anti-Mullerian hormone, occurring between weeks 8 and 15 of gestation) and the inguinoscrotal phase (guided by androgens and the genitofemoral nerve/CGRP, occurring between weeks 25 and 35). Failure of descent leaves the testis in the abdomen, inguinal canal, or prescrotal position, where the elevated temperature (1 to 2 degrees Celsius above scrotal temperature) impairs spermatogenesis and disrupts normal germ cell maturation, increasing both infertility risk and malignant transformation risk.\n\nCANCER RISK:\nUndescended testes carry a 4 to 8-fold increased risk of testicular cancer (primarily seminoma) compared to normally descended testes. The risk is highest for intra-abdominal testes and correlates with the duration of maldescent. the increased cancer risk applies to both the undescended testis and the contralateral normally descended testis, suggesting an underlying developmental field defect (testicular dysgenesis) rather than a purely positional effect. Orchiopexy (surgical fixation into the scrotum) does not eliminate the cancer risk but facilitates testicular self-examination and clinical palpation for early detection.\n\nFERTILITY:\nThe elevated intra-abdominal or inguinal temperature causes progressive germ cell depletion beginning as early as 6 months of age. Bilateral cryptorchidism results in infertility in the majority of untreated cases, and even unilateral cryptorchidism is linked to reduced sperm counts and decreased fertility. Early orchiopexy (performed by 6 to 12 months of age, or by 12 to 18 months).\n\nMANAGEMENT:\nSpontaneous descent occurs in approximately 70% of full-term cryptorchid infants by 6 months of age (adjusted for gestational age). If the testis remains undescended at 6 months, orchiopexy is recommended by 12 to 18 months. Impalpable testes require diagnostic laparoscopy to locate and either mobilize (for orchiopexy) or remove (if atrophic or intra-abdominal in an older patient).\n\nKEY POINTS:\nCryptorchidism increases testicular cancer risk 4 to 8-fold and causes infertility by impairing spermatogenesis through elevated temperature. Orchiopexy by 12 to 18 months optimizes fertility but does not eliminate cancer risk. The cancer risk affects both the undescended and the contralateral normally descended testis, suggesting an underlying developmental abnormality."
  },
  {
    "id": 543,
    "categoryId": 12,
    "question": "Fifth Disease (Erythema Infectiosum) presents with 'Slapped Cheeks'. The causative agent is:",
    "options": [
      "A) Coxsackie Virus",
      "B) Parvovirus B19",
      "C) Strep Pyogenes",
      "D) HHV-6"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Parvovirus B19).\n\nPATHOPHYSIOLOGY:\nParvovirus B19 is a small, non-enveloped single-stranded DNA virus with exclusive tropism for erythroid progenitor cells, which it enters via the P antigen (globoside) receptor on the cell surface. Once inside the erythroid precursor, the virus hijacks the cell's replication machinery, producing massive viral replication that lyses the cell. In immunocompetent children, this transient erythroid aplasia is clinically insignificant because normal red cell lifespan (120 days) provides a buffer. However, in patients with chronic hemolytic anemias (sickle cell disease, hereditary spherocytosis, thalassemia), where red cell survival is already shortened and the marrow must produce red cells at a markedly accelerated rate, even a brief cessation of erythropoiesis causes a precipitous drop in hemoglobin, known as transient aplastic crisis.\n\nCLINICAL PRESENTATION:\nIn otherwise healthy children, parvovirus B19 causes erythema infectiosum (fifth disease), which presents with a low-grade fever and mild upper respiratory prodrome followed by the characteristic \"slapped cheek\" appearance (bilateral, confluent erythema of both cheeks with circumoral pallor). One to four days after the facial erythema, a lacy, reticular (net-like) rash appears on the trunk and proximal extremities that may wax and wane with temperature changes, sunlight exposure, and bathing for several weeks. By the time the rash appears, the patient is no longer viremic and is no longer contagious. Adults, particularly women, may develop symmetric polyarthropathy affecting the small joints of the hands, wrists, and knees.\n\nSPECIAL POPULATIONS:\nIn pregnancy, maternal parvovirus B19 infection can cause fetal anemia, hydrops fetalis (from high-output cardiac failure due to severe fetal anemia), and fetal death, particularly when infection occurs during the second trimester. Pregnant women exposed to parvovirus should have serologic testing (IgM and IgG), if acutely infected, serial fetal ultrasound monitoring for hydrops. In immunocompromised patients (HIV, transplant recipients), chronic parvovirus infection causes persistent pure red cell aplasia requiring IVIG therapy.\n\nKEY POINTS:\nParvovirus B19 infects erythroid precursors via the P antigen receptor, causing fifth disease (slapped cheeks followed by lacy reticular rash) in healthy children and transient aplastic crisis in patients with chronic hemolytic anemias (sickle cell disease). Maternal infection during pregnancy can cause hydrops fetalis from severe fetal anemia. Patients are contagious during the prodromal viremic phase but not after the rash appears."
  },
  {
    "id": 544,
    "categoryId": 12,
    "question": "Hirschsprung Disease presents as failure to pass meconium in 48 hours. The pathophysiology is:",
    "options": [
      "A) Thickened pyloric sphincter",
      "B) Absence of ganglion cells (Auerbach/Meissner plexus) in the distal colon",
      "C) Pancreatic insufficiency",
      "D) Twisted bowel"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Absence of ganglion cells in the distal colon).\n\nPATHOPHYSIOLOGY:\nHirschsprung disease results from failure of neural crest cell migration during embryonic development, leading to an absence of ganglion cells (aganglionosis) in the myenteric (Auerbach) and submucosal (Meissner) plexuses of the distal bowel. Neural crest cells normally migrate craniocaudally through the developing gut between weeks 5 and 12 of gestation, and arrest of this migration at any point leaves the distal bowel aganglionic. The aganglionic segment cannot undergo the coordinated relaxation necessary for peristalsis, remaining in a state of tonic contraction that creates a functional obstruction. The rectosigmoid region is affected in approximately 80% of cases (short-segment disease), while the entire colon or even the small bowel can be involved in rare cases (long-segment and total colonic aganglionosis).\n\nCLINICAL PRESENTATION:\nThe hallmark presenting feature is failure to pass meconium within the first 48 hours of life, which occurs in approximately 90% of neonates with Hirschsprung disease (compared to 99% of normal neonates who pass meconium within 48 hours). Other neonatal presentations include abdominal distension, bilious vomiting, and feeding intolerance. A critically important distinction is that the dilated, distended bowel visible on imaging is the normal, ganglionated proximal colon that has expanded upstream of the obstruction, while the aganglionic distal segment appears narrow or normal-caliber. Enterocolitis (Hirschsprung-associated enterocolitis) is the most life-threatening complication, presenting with explosive diarrhea, fever, abdominal distension, and sepsis, and it can occur before or after surgical correction.\n\nDIAGNOSIS AND TREATMENT:\nRectal suction biopsy is the gold standard for diagnosis, demonstrating absence of ganglion cells and hypertrophied nerve trunks in the submucosa. Contrast enema may show a transition zone between the narrow aganglionic distal segment and the dilated normal proximal bowel, but biopsy is required for definitive diagnosis. Definitive treatment is surgical pull-through procedure (Soave, Duhamel, or Swenson), in which the aganglionic segment is resected and ganglionated bowel is anastomosed to the anus.\n\nKEY POINTS:\nHirschsprung disease results from arrested neural crest cell migration causing aganglionosis of the distal bowel, which remains tonically contracted and functionally obstructed. Failure to pass meconium within 48 hours is the classic presentation. The dilated bowel on imaging is the normal proximal colon, not the diseased segment. Rectal suction biopsy confirming absent ganglion cells is the diagnostic gold standard."
  },
  {
    "id": 545,
    "categoryId": 17,
    "question": "Acute Otitis Media (AOM) is diagnosed by:",
    "options": [
      "A) Red TM alone",
      "B) Bulging TM + Middle Ear Effusion + Inflammation",
      "C) Ear pain",
      "D) Fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bulging TM + Effusion + Signs of Acute Inflammation).\n\nPATHOPHYSIOLOGY:\nAcute otitis media (AOM) results from bacterial infection of the middle ear space, most commonly by Streptococcus pneumoniae, non-typeable Haemophilus influenzae, and Moraxella catarrhalis. Viral upper respiratory infections cause mucosal edema and Eustachian tube dysfunction, leading to negative middle ear pressure, effusion, and subsequent bacterial superinfection.\n\nDIAGNOSTIC CRITERIA (AAP 2013):\nAOM is diagnosed by the presence of:\n1. Moderate to severe bulging of the tympanic membrane (TM), OR\n2. Mild bulging of the TM with recent onset of ear pain (less than 48 hours) or intense TM erythema, OR\n3. New onset otorrhea not due to otitis externa\n- Pneumatic otoscopy demonstrating decreased TM mobility supports the diagnosis and is recommended by the AAP\n\nCRITICAL DISTINCTION:\n- A red TM alone does NOT diagnose AOM. Erythema can result from crying, fever, or manipulation during examination.\n- Middle ear effusion without signs of acute infection (no bulging, no erythema, no pain) is Otitis Media with Effusion (OME), which does NOT require antibiotic therapy. OME is managed with watchful waiting unless it persists beyond 3 months or causes hearing/speech concerns.\n\nTREATMENT:\n1. High-dose amoxicillin (80-90 mg/kg/day divided BID) is first-line\n2. Observation for 48-72 hours is appropriate for children over 2 years with mild, unilateral symptoms\n3. Pain management (ibuprofen, acetaminophen) is essential regardless of antibiotic decision\n4. Amoxicillin-clavulanate if treatment failure at 48-72 hours or recent amoxicillin use\n\nKEY POINTS:\nA bulging TM is the most reliable individual finding for diagnosing AOM. An erythematous TM alone is insufficient for diagnosis. OME (effusion without acute infection) does not require antibiotics. Pneumatic otoscopy is the recommended examination technique.\n---"
  },
  {
    "id": 546,
    "categoryId": 12,
    "question": "Constitutional Delay of Growth and Puberty ('Late Bloomer') is characterized by:",
    "options": [
      "A) Delayed Bone Age",
      "B) Advanced Bone Age",
      "C) High LH/FSH",
      "D) Short parents"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Delayed Bone Age).\n\nPATHOPHYSIOLOGY:\nConstitutional delay of growth and puberty is a normal variant of growth tempo rather than a pathologic condition. These children have physiologically slower skeletal maturation, meaning bone age (assessed by left hand/wrist radiograph using Greulich and Pyle or Tanner-Whitehouse atlases) is delayed 2-4 years relative to chronological age. The delayed bone age indicates growth plates remain open longer, preserving growth potential and allowing eventual normal adult height.\n\nCLINICAL PRESENTATION:\nChildren are consistently shorter than peers and enter puberty 2-4 years later than average. Crucially, growth velocity is normal for bone age (not chronological age), distinguishing constitutional delay from growth hormone deficiency and other pathologic causes where growth velocity is truly impaired. Family history of \"late blooming\" (late menarche in mother, continued growth into late teens in father) is present in 60-80% of cases.\n\nDIFFERENTIAL DIAGNOSIS:\nConstitutional delay is a diagnosis of exclusion. Key differentials include familial short stature (short parents, bone age equals chronological age, normal puberty timing, short adult height), growth hormone deficiency (declining growth velocity, delayed bone age, low IGF-1), hypothyroidism (growth failure, weight gain, fatigue, elevated TSH), Turner syndrome (short female, delayed puberty, web neck, 45,X karyotype), and chronic systemic illness (IBD, celiac disease, renal disease).\n\nMANAGEMENT:\nReassurance and watchful waiting are appropriate, as puberty eventually begins spontaneously with normal final adult height. For adolescents with significant psychosocial distress, short-term low-dose sex steroid therapy (testosterone for boys, estrogen for girls) can initiate pubertal development without compromising adult height.\n\nKEY POINTS:\nConstitutional delay is a normal variant with delayed bone age (2-4 years behind chronological age), late puberty, and eventual normal adult height. Growth velocity is normal for bone age, distinguishing it from pathologic growth failure. Familial short stature differs in that bone age equals chronological age and adult height is short."
  },
  {
    "id": 547,
    "categoryId": 2,
    "question": "Bronchiolitis in infants (< 2 years) is most commonly caused by RSV. The mainstay of treatment is:",
    "options": [
      "A) Albuterol",
      "B) Oral Steroids",
      "C) Supportive Care (Hydration/Oxygen/Suction)",
      "D) Antibiotics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Supportive Care - Hydration, Oxygen, and Nasal Suctioning).\n\nPATHOPHYSIOLOGY:\nBronchiolitis is an acute lower respiratory infection primarily affecting infants under 2 years, caused most commonly by RSV (50-80% of cases). The virus infects bronchiolar epithelium, causing necrosis, peribronchiolar inflammation, edema, and increased mucus production. The resulting debris and mucus obstruct small airways (~2 mm diameter in infants), producing air trapping, atelectasis, and ventilation-perfusion mismatch.\n\nCLINICAL REASONING:\nMultiple RCTs and systematic reviews, synthesized in the AAP Clinical Practice Guideline (2014, reaffirmed), demonstrate that no pharmacologic intervention changes outcomes. Bronchodilators (albuterol, epinephrine) are ineffective because obstruction results from inflammation and mucus plugging, not bronchospasm. Corticosteroids are ineffective because the inflammation is primarily neutrophilic rather than eosinophilic. Antibiotics are not indicated unless concurrent bacterial infection is documented.\n\nMANAGEMENT:\nTreatment is supportive: nasal suctioning to clear secretions, adequate hydration (oral if tolerated, nasogastric or IV if not), and supplemental oxygen to maintain saturation >90%. High-flow nasal cannula may benefit moderate-to-severe cases. Hospitalize for significant respiratory distress, sustained hypoxia, inadequate oral intake, or apnea, particularly in high-risk infants (premature, <12 weeks, congenital heart disease, chronic lung disease, immunodeficiency).\n\nPREVENTION:\nPalivizumab (anti-RSV F protein monoclonal antibody) is given monthly during RSV season for high-risk infants (prematurity <29 weeks, hemodynamically significant CHD, chronic lung disease of prematurity). Nirsevimab, a long-acting monoclonal antibody requiring only a single dose, was approved by the FDA and recommended by the CDC for all infants entering their first RSV season.\n\nKEY POINTS:\nBronchiolitis management is entirely supportive (suctioning, hydration, oxygen) per AAP guidelines, as bronchodilators, corticosteroids, and antibiotics do not improve outcomes. The obstruction is from inflammation and mucus, not bronchospasm. Palivizumab and nirsevimab provide RSV prophylaxis for high-risk and all infants, respectively."
  },
  {
    "id": 548,
    "categoryId": 17,
    "question": "Leukocoria (White Pupillary Reflex) in a newborn photograph requires immediate referral to rule out:",
    "options": [
      "A) Glaucoma",
      "B) Retinoblastoma",
      "C) Conjunctivitis",
      "D) Color blindness"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cancer - Retinoblastoma).\n\nPATHOPHYSIOLOGY:\nRetinoblastoma is the most common primary intraocular malignancy of childhood, arising from immature retinal cells (retinoblasts) due to biallelic inactivation of the RB1 tumor suppressor gene on chromosome 13q14. Heritable retinoblastoma (40% of cases) involves a germline RB1 mutation followed by a somatic second hit (Knudson two-hit hypothesis), typically presenting bilaterally and at younger ages (mean 12 months). Sporadic retinoblastoma (60%) involves two somatic mutations in a single retinal cell, presenting unilaterally and later (mean 24 months).\n\nCLINICAL PRESENTATION:\n- Leukocoria (white pupillary reflex): The most common presenting sign, caused by the white tumor mass behind the lens reflecting light instead of the normal red reflex\n- Strabismus (second most common sign): Tumor involvement of the macula causes visual loss and secondary misalignment\n- Less common: Red, painful eye (from secondary glaucoma or inflammation), proptosis (extraocular extension)\n\nDIAGNOSIS:\n- Red reflex testing at every well-child visit is the primary screening method (AAP Bright Futures)\n- Absent or white red reflex requires urgent ophthalmology referral within days\n- Retinal examination under anesthesia with indirect ophthalmoscopy is the gold standard\n- Orbital MRI (preferred over CT to avoid radiation in a child with possible germline RB1 mutation)\n- Biopsy is NOT performed (risk of extraocular tumor seeding)\n\nTREATMENT:\n- Small tumors: Focal therapies (laser photocoagulation, cryotherapy, thermotherapy)\n- Larger tumors: Intra-arterial or intravitreal chemotherapy, systemic chemoreduction\n- Advanced or refractory: Enucleation (eye removal)\n- Survival exceeds 95% in developed countries with early detection\n\nKEY POINTS:\nLeukocoria (absent red reflex) in a child is retinoblastoma until proven otherwise and requires urgent ophthalmology referral. Red reflex testing should be performed at every well-child visit. Heritable retinoblastoma carries risk of bilateral disease and secondary malignancies (osteosarcoma). Survival exceeds 95% with early treatment.\n---"
  },
  {
    "id": 549,
    "categoryId": 12,
    "question": "Kawasaki Disease involves fever > 5 days and 'CRASH' symptoms. The 'H' stands for:",
    "options": [
      "A) Headache",
      "B) Hands and Feet (Swelling/Peeling)",
      "C) Heart murmur",
      "D) Hypertension"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hands and Feet - Swelling and Peeling).\n\nDIAGNOSTIC CRITERIA:\nKawasaki disease is diagnosed clinically by fever \u22655 days plus \u22654 of 5 principal features (CRASH mnemonic): Conjunctivitis (bilateral, non-exudative, limbic-sparing), Rash (polymorphous, often with early perineal desquamation), Adenopathy (cervical, usually unilateral, \u22651.5 cm), Strawberry tongue and lip changes (red fissured lips, oropharyngeal erythema), and Hand/foot changes (acute: erythema and indurative edema of palms/soles; subacute: periungual desquamation beginning 2-3 weeks after fever onset).\n\nPATHOPHYSIOLOGY:\nKawasaki disease is an acute self-limited vasculitis of unknown etiology predominantly affecting children under 5, with peak incidence between 6 months and 2 years. It targets medium-sized muscular arteries, particularly the coronary arteries, where panarteritis can produce coronary artery aneurysms in 15-25% of untreated children. It is the leading cause of acquired heart disease in children in developed countries. Incomplete Kawasaki (fever with <4 criteria) should be considered in any child with prolonged unexplained fever, especially infants <6 months who have the highest coronary complication risk.\n\nTREATMENT:\nHigh-dose IVIG (2 g/kg single infusion) within the first 10 days plus high-dose aspirin (80-100 mg/kg/day divided QID) reduces coronary aneurysm incidence from ~25% to <5%. Aspirin is reduced to low-dose (3-5 mg/kg/day) after 48-72 hours afebrile and continued for 6-8 weeks minimum, or indefinitely if coronary abnormalities persist. Echocardiography is performed at diagnosis, 2 weeks, and 6-8 weeks. IVIG-refractory patients may require a second dose, corticosteroids, or infliximab.\n\nKEY POINTS:\nThe H in CRASH stands for Hands/feet changes (edema and erythema acutely; periungual desquamation subacutely). Kawasaki is the leading cause of acquired heart disease in children, with coronary aneurysms in 15-25% untreated. IVIG within 10 days reduces aneurysm risk to <5%. Always consider incomplete Kawasaki in prolonged unexplained pediatric fever."
  },
  {
    "id": 550,
    "categoryId": 12,
    "question": "Physiologic Jaundice of the Newborn appears:",
    "options": [
      "A) In the first 24 hours",
      "B) After 24 hours, peaking at day 3-5",
      "C) At 2 weeks of age",
      "D) Only in formula fed babies"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (After 24 hours, peaking at day 3 to 5).\n\nPATHOPHYSIOLOGY:\nPhysiologic jaundice of the newborn results from the normal postnatal transition in bilirubin metabolism. In utero, unconjugated bilirubin produced by the fetus crosses the placenta and is conjugated and excreted by the maternal liver. After birth, the neonate must independently process bilirubin, but several physiologic factors create a transient imbalance between bilirubin production and elimination: the newborn has a higher red blood cell mass with a shorter erythrocyte lifespan (approximately 90 days versus 120 days in adults), the immature hepatic UDP-glucuronosyltransferase (UGT1A1) enzyme has reduced conjugation capacity (reaching adult activity levels by approximately 14 weeks), and increased enterohepatic circulation of bilirubin occurs due to higher intestinal beta-glucuronidase activity and slower intestinal transit.\n\nCLINICAL REASONING:\nPhysiologic jaundice characteristically appears after 24 hours of life (typically on day 2 to 3), peaks between days 3 and 5 in term infants (or days 5 to 7 in preterm infants), and gradually resolves by 1 to 2 weeks. The critical clinical distinction is that jaundice appearing within the first 24 hours of life is always pathologic and requires urgent evaluation. The most common causes of pathologic early jaundice include hemolytic disease of the newborn (ABO incompatibility, Rh incompatibility), hereditary hemolytic anemias (G6PD deficiency, hereditary spherocytosis), and neonatal sepsis. The direct Coombs test (direct antiglobulin test) is the key laboratory study for distinguishing immune-mediated hemolysis (positive Coombs) from non-immune causes (negative Coombs).\n\nMANAGEMENT:\nBilirubin levels are monitored using the Bhutani nomogram (hour-specific total serum bilirubin plotted against the infant's age in hours) to identify neonates at risk for severe hyperbilirubinemia. Phototherapy is the primary treatment, using blue-green spectrum light (wavelength 460 to 490 nm) to convert unconjugated bilirubin into water-soluble photoisomers that can be excreted without hepatic conjugation. Exchange transfusion is reserved for bilirubin levels approaching or exceeding the threshold for acute bilirubin encephalopathy (kernicterus), which causes permanent neurologic damage including sensorineural hearing loss, choreoathetoid cerebral palsy, and upgaze palsy.\n\nKEY POINTS:\nPhysiologic jaundice appears after 24 hours and peaks at days 3 to 5, while jaundice within the first 24 hours is always pathologic (hemolysis, sepsis, ABO/Rh incompatibility) and requires urgent evaluation. The Bhutani nomogram guides management decisions based on hour-specific bilirubin levels. Kernicterus from severe unconjugated hyperbilirubinemia causes permanent neurologic damage including sensorineural hearing loss and choreoathetoid cerebral palsy."
  },
  {
    "id": 551,
    "categoryId": 12,
    "question": "To prevent SIDS (Sudden Infant Death Syndrome), the AAP recommends:",
    "options": [
      "A) Side sleeping",
      "B) Back to Sleep (Supine), firm mattress, no blankets/toys",
      "C) Co-sleeping in parents' bed",
      "D) Prone sleeping"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Back to Sleep, firm mattress, no blankets or toys).\n\nEPIDEMIOLOGY:\nSudden infant death syndrome is the leading cause of death in infants between 1 month and 1 year of age in the United States, with peak incidence between 2 and 4 months. The incidence of SIDS decreased by more than 50% following the 1994 Back to Sleep campaign (now called Safe to Sleep) that promoted supine sleeping, though rates have plateaued in recent years. The pathophysiologic model of SIDS involves a vulnerable infant (brainstem abnormalities affecting cardiorespiratory control and arousal, potentially involving serotonergic neuron dysfunction) during a critical developmental period, exposed to an exogenous stressor (prone positioning, soft bedding, overheating, smoke exposure).\n\nAAP SAFE SLEEP RECOMMENDATIONS:\nThe AAP 2022 updated policy statement on safe sleep recommends supine (back) positioning for every sleep period until 1 year of age. The infant should sleep on a firm, flat, non-inclined surface (such as a safety-approved crib mattress) with a tightly fitted sheet and nothing else in the sleep environment: no pillows, blankets, bumper pads, stuffed animals, wedges, or positioners. Room-sharing (infant sleeping in the parents' room in their own sleep surface) is recommended for at least the first 6 months and ideally the first year, as it reduces SIDS risk by approximately 50%. However, bed-sharing (infant sleeping in the same bed as adults) is explicitly recommended against due to the risk of suffocation, entrapment, and overlay.\n\nADDITIONAL PROTECTIVE FACTORS:\nBreastfeeding is linked to a reduced risk of SIDS (approximately 50% risk reduction with exclusive breastfeeding). Pacifier use at sleep onset has been associated with reduced SIDS risk, potentially by maintaining airway patency and promoting arousability. Avoidance of prenatal and postnatal tobacco smoke exposure is critical, as maternal smoking is one of the strongest modifiable risk factors for SIDS. Immunizations are protective, not causative, and up-to-date vaccination is linked to a 50% reduction in SIDS risk.\n\nKEY POINTS:\nThe AAP recommends supine positioning on a firm, flat surface with no loose bedding, room-sharing without bed-sharing, and avoidance of smoke exposure as the foundation of SIDS prevention. The Back to Sleep campaign reduced SIDS mortality by more than 50%. Breastfeeding, pacifier use, and up-to-date immunizations are additional protective factors."
  },
  {
    "id": 552,
    "categoryId": 12,
    "question": "Bilious (Green) vomiting in a neonate is a surgical emergency because it suggests:",
    "options": [
      "A) Pyloric Stenosis",
      "B) Malrotation with Volvulus",
      "C) Milk allergy",
      "D) GERD"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Malrotation with Volvulus).\n\nPATHOPHYSIOLOGY:\nIntestinal malrotation is a congenital anomaly from incomplete rotation and fixation of the midgut during embryonic development. Normally, the midgut undergoes 270-degree counterclockwise rotation around the superior mesenteric artery axis and returns to the abdomen by week 10, with cecal fixation to the right lower quadrant and the duodenojejunal junction (ligament of Treitz) to the left upper quadrant. In malrotation, the mesenteric base is abnormally narrow, creating a short pedicle around which the entire midgut can twist (volvulus), occluding the superior mesenteric artery and vein. The entire midgut can infarct within 6 hours of vascular occlusion.\n\nCLINICAL REASONING:\nBilious (green) vomiting in a neonate is a surgical emergency until proven otherwise. Bile enters at the ampulla of Vater (second portion of the duodenum), so bilious vomiting indicates obstruction distal to this point. Malrotation with midgut volvulus is the most dangerous and time-critical diagnosis. Approximately 75% present within the first month of life, 90% within the first year. The infant may initially appear well but can deteriorate rapidly to hemodynamic instability, abdominal distension, bloody stools indicating ischemia, and peritonitis.\n\nDIAGNOSIS AND TREATMENT:\nUpper GI contrast study is the gold standard, demonstrating abnormal position of the duodenojejunal junction (right of midline or below the duodenal bulb). The classic volvulus finding is a corkscrew or spiral appearance of the distal duodenum and jejunum. When clinical instability is present, surgical exploration should not be delayed for imaging. The Ladd procedure (detorsion, lysis of Ladd bands, mesenteric base widening, appendectomy, small bowel placed right and colon placed left) is definitive.\n\nKEY POINTS:\nBilious vomiting in a neonate is a surgical emergency suggesting malrotation with midgut volvulus, which can cause complete midgut infarction within 6 hours. Upper GI series is diagnostic and the Ladd procedure is definitive, but surgical exploration should not be delayed in an unstable infant."
  },
  {
    "id": 553,
    "categoryId": 12,
    "question": "Cow's milk should be avoided before age 1 year because it causes:",
    "options": [
      "A) Obesity",
      "B) Iron Deficiency Anemia (Microscopic GI bleeding)",
      "C) Calcium deficiency",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Iron Deficiency Anemia from microscopic GI bleeding).\n\nPATHOPHYSIOLOGY:\nCow's milk contributes to iron deficiency in infants through three distinct mechanisms. First, cow's milk has very low bioavailable iron content (approximately 0.5 mg/L with <10% absorption, compared to breast milk's approximately 0.3 mg/L with 50% absorption or iron-fortified formula's 12 mg/L). Second, the intact casein proteins in whole cow's milk cause microscopic intestinal hemorrhage in infants, resulting in occult gastrointestinal blood loss of approximately 1 to 2 mL per day (this protein-induced colitis resolves with gut maturation after 12 months of age). Third, cow's milk displaces iron-rich foods and formula from the infant's diet, reducing overall iron intake. The combination of low iron delivery, chronic blood loss, and dietary displacement makes whole cow's milk a significant cause of iron deficiency anemia in infancy.\n\nCLINICAL SIGNIFICANCE:\nIron deficiency in infancy is particularly concerning because of its neurodevelopmental consequences. Iron is essential for myelination, neurotransmitter synthesis (dopamine, serotonin), and hippocampal development during the rapid brain growth occurring in the first 2 years of life. Iron deficiency during this critical window has been associated with impaired cognitive development, behavioral problems, and decreased academic performance, with some studies suggesting that these effects may be only partially reversible even with subsequent iron repletion.\n\nAAP FEEDING RECOMMENDATIONS:\nThe AAP recommends exclusive breastfeeding (or iron-fortified formula) for the first 6 months, with introduction of iron-rich complementary foods (iron-fortified cereals, pureed meats) beginning at approximately 6 months. Whole cow's milk should not be introduced as the primary beverage until 12 months of age. After 12 months, whole milk consumption should be limited to 16 to 24 ounces per day to prevent displacement of iron-rich foods. The AAP recommends universal screening for iron deficiency anemia at 12 months of age.\n\nKEY POINTS:\nCow's milk before 12 months causes iron deficiency anemia through three mechanisms: low bioavailable iron, microscopic intestinal blood loss from casein-induced colitis, and displacement of iron-rich foods. Iron deficiency during infancy impairs myelination and neurotransmitter synthesis with potentially irreversible neurodevelopmental consequences. Whole cow's milk introduction should be delayed until 12 months and limited to 16 to 24 ounces daily."
  },
  {
    "id": 554,
    "categoryId": 12,
    "question": "A Still's Murmur (innocent) is characterized by:",
    "options": [
      "A) Diastolic rumbling",
      "B) Musical/Vibratory quality, systolic, LLSB, softer when standing",
      "C) Harsh, holosystolic, radiates to back",
      "D) Continuous machinery-like"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Musical or vibratory quality, systolic, left lower sternal border, softer when standing).\n\nPATHOPHYSIOLOGY:\nStill's murmur is the most common innocent (functional, benign) heart murmur of childhood, typically heard in children aged 2 to 7 years. It is produced by normal turbulent blood flow through the left ventricular outflow tract and across the aortic valve without any structural cardiac abnormality. The characteristic musical or vibratory quality (often described as sounding like a \"twanging string\" or \"humming\") distinguishes it from the harsher, blowing quality of pathologic murmurs. The murmur is heard best at the left lower sternal border or between the left lower sternal border and the apex, is low-pitched (grade I to III out of VI), systolic (occurring during ventricular ejection), and has no associated thrill, radiation, or diastolic component.\n\nCLINICAL REASONING:\nThe key diagnostic feature of innocent murmurs is their dynamic response to changes in preload. Still's murmur becomes softer or disappears with standing or Valsalva maneuver (both of which decrease venous return and preload to the heart, reducing flow across the outflow tract) and becomes louder with maneuvers that increase preload such as squatting, supine positioning, or during fever, exercise, and anemia. This dynamic behavior contrasts with pathologic murmurs: the murmur of hypertrophic obstructive cardiomyopathy (HOCM) paradoxically becomes louder with decreased preload (standing, Valsalva) because reduced ventricular volume worsens the dynamic outflow obstruction. Other features suggesting a pathologic murmur include diastolic timing, grade IV or higher intensity, harsh or blowing quality, radiation to the back or axilla, associated clicks or gallops, abnormal pulses, cyanosis, and failure to thrive.\n\nOTHER INNOCENT MURMURS:\nThe venous hum is a continuous, low-pitched murmur heard in the supraclavicular area (usually right-sided) caused by turbulent flow in the jugular veins. It disappears with compression of the ipsilateral internal jugular vein or when the patient lies supine. The peripheral pulmonary stenosis murmur is commonly heard in newborns and results from the relative disparity between the main and branch pulmonary arteries, typically resolving by 6 months of age.\n\nKEY POINTS:\nStill's murmur is identified by its musical or vibratory quality, systolic timing, location at the left lower sternal border, and characteristic softening with standing (decreased preload). Innocent murmurs become softer with decreased preload, while HOCM becomes louder, which is a critical distinguishing feature. Any diastolic murmur, grade IV or higher intensity, or murmur with associated abnormal findings warrants echocardiographic evaluation."
  },
  {
    "id": 555,
    "categoryId": 12,
    "question": "Hand-Foot-Mouth Disease is caused by Coxsackievirus. Is it contagious?",
    "options": [
      "A) No",
      "B) Yes, highly contagious via stool and saliva",
      "C) Only via blood",
      "D) Only to adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, highly contagious via stool and saliva).\n\nPATHOPHYSIOLOGY:\nHand, foot, and mouth disease results from enteroviruses, most commonly coxsackievirus A16 and enterovirus 71 (EV-A71), which belong to the Picornaviridae family. EV-A71 is linked to more severe disease, including neurologic complications such as brainstem encephalitis, aseptic meningitis, and acute flaccid paralysis. The virus is transmitted through multiple routes: fecal-oral (the primary route, as enteroviruses replicate in the gastrointestinal tract), direct contact with vesicle fluid, and respiratory droplets. Viral shedding in stool can persist for weeks after clinical recovery, maintaining contagion well beyond resolution of symptoms. The disease is most common in children under 5 years, with peak incidence in summer and early fall in temperate climates.\n\nCLINICAL PRESENTATION:\nThe illness begins with a low-grade fever, malaise, and sore throat, followed within 1 to 2 days by the characteristic enanthem (painful oral ulcers on the buccal mucosa, tongue, and hard palate) and exanthem (vesicular lesions on an erythematous base on the palms, soles, and dorsal surfaces of the hands and feet, and sometimes the buttocks and perineum). The oral ulcers are often the most distressing symptom, causing painful swallowing that can lead to dehydration in young children who refuse to drink. Onychomadesis (nail shedding) can occur 4 to 8 weeks after the illness and is self-limited.\n\nMANAGEMENT:\nTreatment is entirely supportive: adequate hydration (cold fluids and soft foods are better tolerated), oral analgesics (acetaminophen, ibuprofen), and topical oral anesthetics (viscous lidocaine mixed with diphenhydramine and antacid, known as \"magic mouthwash\") for pain relief. Dehydration from poor oral intake is the most common complication requiring medical attention. Children can generally return to daycare or school when afebrile and well enough to participate, though families should be counseled that fecal shedding continues and meticulous hand hygiene is essential for weeks after recovery.\n\nKEY POINTS:\nHand, foot, and mouth disease is highly contagious via fecal-oral, respiratory, and vesicle fluid contact, with fecal viral shedding persisting for weeks after clinical recovery. Coxsackievirus A16 is the most common cause, while enterovirus 71 carries risk of neurologic complications. Dehydration from painful oral ulcers limiting intake is the most common complication requiring medical attention."
  },
  {
    "id": 556,
    "categoryId": 12,
    "question": "Febrile UTI in a child < 2 years requires:",
    "options": [
      "A) Renal Ultrasound",
      "B) VCUG immediately",
      "C) CT Scan",
      "D) No imaging"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Renal Ultrasound).\n\nCLINICAL REASONING:\nA febrile urinary tract infection (temperature 38 degrees Celsius or greater) in a child under 2 years is presumed to represent pyelonephritis (upper tract infection) until proven otherwise. Pyelonephritis in this age group carries a significant risk of renal scarring, which can lead to hypertension, proteinuria, and impaired renal function over time, particularly with recurrent infections or with underlying urinary tract abnormalities. Identifying structural anomalies that predispose to recurrent infection is therefore essential for long-term renal preservation.\n\nIMAGING GUIDELINES:\nThe AAP Clinical Practice Guideline (revised 2011, reaffirmed) recommends renal and bladder ultrasound for all children aged 2 to 24 months after their first febrile UTI. Ultrasound evaluates for hydronephrosis, renal size asymmetry, duplicated collecting systems, ureterocele, and other structural abnormalities. It is noninvasive, radiation-free, and readily available. Voiding cystourethrogram (VCUG) is not performed routinely after a first febrile UTI but is indicated if the ultrasound reveals hydronephrosis, scarring, or other concerning findings, if the child has recurrent febrile UTIs, or if there are atypical clinical features (poor response to appropriate antibiotics within 48 hours, unusual organism, sepsis).\n\nVESICOURETERAL REFLUX:\nVCUG detects vesicoureteral reflux (retrograde flow of urine from the bladder into the ureters and renal pelvis), which is present in approximately 25 to 40% of children with UTI. VUR is graded I through V based on severity of reflux and ureteral and pelvic dilation. Low-grade VUR (grades I to III) resolves spontaneously in the majority of cases, while high-grade VUR (grades IV to V) may require surgical intervention (ureteral reimplantation or endoscopic injection). The role of continuous antibiotic prophylaxis for VUR is evolving, with the RIVUR trial demonstrating modest reduction in UTI recurrence but no significant impact on renal scarring.\n\nTREATMENT OF ACUTE INFECTION:\nFebrile UTI requires prompt antibiotic therapy for 7 to 14 days. Urine culture (obtained by catheterization or suprapubic aspiration in non-toilet-trained children, never by bag specimen for culture) guides therapy. E. coli accounts for 80 to 90% of pediatric UTIs.\n\nKEY POINTS:\nAll children aged 2 to 24 months require renal and bladder ultrasound after a first febrile UTI to evaluate for structural abnormalities predisposing to recurrent infection. VCUG is reserved for abnormal ultrasound, recurrent febrile UTI, or atypical features. VUR is found in 25 to 40% of children with UTI, and low grades typically resolve spontaneously."
  },
  {
    "id": 557,
    "categoryId": 12,
    "question": "Transient Synovitis (Toxic Synovitis) is the most common cause of hip pain in kids. It usually follows:",
    "options": [
      "A) Trauma",
      "B) A viral infection (URI)",
      "C) Bacterial sepsis",
      "D) Lyme disease"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (A viral infection / URI).\n\nPATHOPHYSIOLOGY:\nTransient (toxic) synovitis is a self-limited, noninfectious inflammatory hip joint process common in children aged 3-8 years. The strong temporal association with a preceding viral URI (typically 1-2 weeks prior) suggests post-infectious immune-mediated synovial inflammation. The resulting effusion causes pain and limits hip range of motion, particularly internal rotation and abduction.\n\nCLINICAL PRESENTATION:\nThe child presents with acute onset limp or refusal to walk, hip pain (which may be referred to the groin, thigh, or knee), and mildly limited range of motion. Crucially, the child appears well, is afebrile or has only low-grade temperature, and labs are normal or mildly elevated (WBC normal, ESR typically <20 mm/hr, CRP typically <2 mg/dL). A recent viral illness history is often elicited.\n\nCRITICAL DISTINCTION FROM SEPTIC ARTHRITIS:\nThe most important task is distinguishing transient synovitis from septic arthritis, an orthopedic emergency requiring urgent aspiration and drainage. The Kocher criteria are validated: fever >38.5\u00b0C, inability to bear weight, ESR >40 mm/hr, and WBC >12,000. Predicted probability of septic arthritis: ~3% with zero predictors, 40% with two, 93% with three, 99.6% with all four. Ultrasound-guided hip aspiration should be performed when \u22652 Kocher criteria are present.\n\nMANAGEMENT:\nTransient synovitis is managed with rest, NSAIDs, and observation. Symptoms resolve within 1-2 weeks. Follow up to ensure resolution\u2014persistent symptoms beyond 2 weeks should prompt evaluation for Legg-Calv\u00e9-Perthes disease.\n\nKEY POINTS:\nTransient synovitis typically follows a viral URI by 1-2 weeks, presenting as a well-appearing, afebrile child with a limp and normal inflammatory markers. Distinguish from septic arthritis using the Kocher criteria; \u22652 criteria warrant joint aspiration. Persistent symptoms beyond 2 weeks should prompt evaluation for Legg-Calv\u00e9-Perthes disease."
  },
  {
    "id": 558,
    "categoryId": 12,
    "question": "Children with Sickle Cell Disease are placed on prophylactic Penicillin until age 5 to prevent:",
    "options": [
      "A) S. aureus osteomyelitis",
      "B) Pneumococcal Sepsis",
      "C) Syphilis",
      "D) Malaria"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pneumococcal Sepsis).\n\nPATHOPHYSIOLOGY:\nThe spleen is the primary organ responsible for filtering encapsulated bacteria from the bloodstream through opsonin-dependent phagocytosis by splenic macrophages. In sickle cell disease, repeated episodes of vaso-occlusion within the splenic microvasculature cause progressive infarction and fibrosis, resulting in functional autosplenectomy (loss of splenic filtering function despite physical presence of the organ) by early childhood, typically by age 5 years in patients with HbSS disease. Without a functional spleen, patients are profoundly susceptible to overwhelming post-splenectomy infection (OPSI) from encapsulated organisms that depend on opsonization and splenic clearance for host defense. Streptococcus pneumoniae is the most common and most lethal organism in this setting, followed by Haemophilus influenzae type b and Neisseria meningitidis.\n\nCLINICAL EVIDENCE:\nThe landmark PROPS trial (Prophylaxis with Oral Penicillin in Children with Sickle Cell Anemia) published in the New England Journal of Medicine demonstrated that daily oral penicillin V prophylaxis (125 mg twice daily for children under 3 years, 250 mg twice daily for children 3 to 5 years) reduced the incidence of pneumococcal bacteremia by 84% in children with sickle cell disease under 5 years of age. This trial was so compelling that it was stopped early for ethical reasons, as withholding prophylaxis was no longer justifiable.\n\nCURRENT RECOMMENDATIONS:\nThe NHLBI recommend initiating penicillin V prophylaxis by 2 months of age and continuing at minimum until age 5 years. Discontinuation after age 5 may be considered in children with HbSS who have not had a previous serious pneumococcal infection or surgical splenectomy. In addition to penicillin prophylaxis, comprehensive pneumococcal vaccination (both PCV15 or PCV20 conjugate vaccine series and PPSV23 polysaccharide vaccine starting at age 2) is essential. Parents must be educated that any fever in a child with sickle cell disease is a medical emergency requiring immediate evaluation for sepsis.\n\nKEY POINTS:\nChildren with sickle cell disease undergo functional autosplenectomy by early childhood, making them profoundly susceptible to overwhelming pneumococcal sepsis. Prophylactic penicillin V from age 2 months to at least 5 years reduces pneumococcal bacteremia by 84%. Any fever in a child with sickle cell disease is a medical emergency requiring immediate evaluation."
  },
  {
    "id": 559,
    "categoryId": 12,
    "question": "Lead poisoning in children primarily causes damage to the:",
    "options": [
      "A) Liver",
      "B) Developing Brain (Neurocognitive)",
      "C) Lungs",
      "D) Skin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Developing Brain / Neurocognitive damage).\n\nPATHOPHYSIOLOGY:\nLead is a neurotoxin that has no known safe blood level in children. It exerts its toxic effects through multiple mechanisms: it substitutes for calcium in intracellular signaling pathways, disrupting synaptic transmission and long-term potentiation (critical for learning and memory); it inhibits N-methyl-D-aspartate (NMDA) glutamate receptors, impairing neurotransmitter release and neuronal migration; it disrupts the blood-brain barrier; and it causes oxidative stress through reactive oxygen species generation. Children are especially vulnerable because the developing brain undergoes rapid synaptogenesis, myelination, and dendritic arborization during the first years of life, and because children absorb a much higher fraction of ingested lead than adults (approximately 50% versus 10%) due to their immature gastrointestinal tract.\n\nCLINICAL MANIFESTATIONS:\nLead poisoning is often asymptomatic at low to moderate blood levels (less than 45 micrograms/dL), making screening essential. Neurocognitive effects include decreased IQ (an estimated 1 to 5 IQ point decrease for each 10 microgram/dL increase), learning disabilities, attention deficit and hyperactivity, behavioral problems, and poor academic performance. At higher levels, children may develop irritability, abdominal pain (lead colic), constipation, anorexia, and microcytic hypochromic anemia (lead inhibits delta-aminolevulinic acid dehydratase and ferrochelatase in the heme synthesis pathway, causing accumulation of protoporphyrin and ringed sideroblasts). Encephalopathy with seizures, cerebral edema, and coma occurs at very high levels (typically greater than 70 micrograms/dL) and can be fatal.\n\nSCREENING AND MANAGEMENT:\nThe CDC reference value for elevated blood lead level in children is 3.5 micrograms/dL (updated from the previous 5 micrograms/dL). The primary intervention at any level is identification and elimination of the lead source, which most commonly involves lead-based paint in pre-1978 housing (paint chips, contaminated dust and soil). Public health notification is required. Chelation therapy (succimer for oral chelation, calcium disodium EDTA with or without dimercaprol for parenteral chelation) is reserved for blood lead levels of 45 micrograms/dL or greater, or for symptomatic children.\n\nKEY POINTS:\nLead primarily damages the developing brain by disrupting synaptogenesis, neurotransmitter systems, and myelination, with no known safe blood level. Effects include decreased IQ, learning disabilities, and behavioral problems. The CDC reference value is 3.5 micrograms/dL, source elimination is the primary intervention, and chelation is reserved for levels of 45 or greater or symptomatic children."
  },
  {
    "id": 560,
    "categoryId": 4,
    "question": "The most common presentation of new-onset Type 1 Diabetes in children is:",
    "options": [
      "A) Incidental finding",
      "B) Polyuria, Polydipsia, Weight Loss",
      "C) Seizure",
      "D) Rash"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polyuria, Polydipsia, and Weight Loss progressing to DKA).\n\nPATHOPHYSIOLOGY:\nType 1 diabetes (T1DM) results from autoimmune destruction of pancreatic beta cells, producing absolute insulin deficiency. Autoreactive T lymphocytes infiltrate the islets (insulitis), progressing through ADA stages (Stage 1: autoantibodies with normoglycemia; Stage 2: dysglycemia; Stage 3: clinical diabetes). By Stage 3, approximately 80-90% of beta-cell mass is destroyed. Without insulin, blood glucose exceeds the renal threshold (~180 mg/dL), causing glycosuria and osmotic diuresis (polyuria), triggering compensatory polydipsia. The catabolic state drives unregulated lipolysis, proteolysis, and hepatic gluconeogenesis, producing weight loss despite adequate caloric intake.\n\nCLINICAL PRESENTATION:\nThe symptomatic period is typically brief (days to weeks). Parents report polyuria (including new-onset nocturnal enuresis in previously toilet-trained children\u2014an important early clue), polydipsia, weight loss, and fatigue. DKA occurs at initial presentation in 25-40% of children (per Diabetes Care), with rates highest in children under 5 (up to 50%) because symptoms are often misattributed to gastroenteritis or UTI. DKA develops when absolute insulin deficiency drives lipolysis, producing ketone bodies (beta-hydroxybutyrate, acetoacetate) and high-anion-gap metabolic acidosis (pH <7.3, bicarbonate <18). Manifestations include vomiting, abdominal pain, Kussmaul respirations, fruity breath, dehydration, and progressive obtundation. Cerebral edema is the most feared complication (~0.5-1% of pediatric DKA, 21-24% mortality per NEJM/Pediatrics data).\n\nDIAGNOSIS AND TREATMENT:\nDiagnosis requires ADA criteria hyperglycemia (random glucose \u2265200 with symptoms, fasting \u2265126, or HbA1c \u22656.5%) plus autoimmune markers (GAD65, IA-2, IAA, ZnT8 autoantibodies) and low C-peptide. DKA management per ISPAD guidelines: IV isotonic saline (gradual rehydration over 24-48 hours to minimize cerebral edema risk), continuous IV insulin (0.05-0.1 units/kg/hour, never bolus), potassium replacement (total body depleted despite normal/elevated serum levels from acidosis-driven shift), and frequent monitoring. Transition to subcutaneous insulin once DKA resolves (pH >7.3, bicarb >15, anion gap closed, tolerating PO). Long-term management: intensive insulin therapy (basal-bolus or pump), carbohydrate counting, and CGM recommended for all youth with T1DM.\n\nKEY POINTS:\nNew-onset T1DM presents with polyuria (nocturnal enuresis as early clue), polydipsia, and weight loss, with 25-40% presenting in DKA. DKA rates are highest under age 5 due to symptom misattribution. Cerebral edema is the most feared DKA complication (0.5-1% incidence, 21-24% mortality); fluid resuscitation should be gradual over 24-48 hours."
  },
  {
    "id": 561,
    "categoryId": 12,
    "question": "Pyloric Stenosis typically presents in first-born males at 3-6 weeks with:",
    "options": [
      "A) Bilious vomiting",
      "B) Non-bilious, projectile vomiting",
      "C) Diarrhea",
      "D) Fever"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Non-bilious, projectile vomiting).\n\nPATHOPHYSIOLOGY:\nInfantile hypertrophic pyloric stenosis results from progressive hypertrophy and hyperplasia of the circular smooth muscle of the pyloric sphincter, causing gastric outlet obstruction. The etiology is multifactorial, involving genetic susceptibility (concordance of approximately 25 to 40% in monozygotic twins, 4-fold increased risk in first-degree relatives), male sex (4 to 5:1 male-to-female ratio with firstborn males at highest risk), and environmental factors. Erythromycin exposure during the first 2 weeks of life significantly increases risk, likely through stimulation of motilin receptors on pyloric smooth muscle causing spasm and subsequent reactive hypertrophy.\n\nCLINICAL PRESENTATION:\nSymptoms characteristically begin at 3 to 6 weeks of age (rarely before 2 weeks or after 12 weeks) with progressive, forceful, projectile vomiting occurring immediately after feedings. The vomitus is always non-bilious (because the pyloric obstruction is proximal to the ampulla of Vater where bile enters the duodenum) and may become blood-tinged from associated gastritis or Mallory-Weiss tear. The infant remains hungry and feeds eagerly despite repeated vomiting (the \"hungry vomiter\"). On physical examination, visible gastric peristaltic waves may be seen traversing the abdomen from left to right, and a firm, mobile, olive-shaped mass (the hypertrophied pylorus) is palpable in the right upper quadrant or epigastrium in approximately 60 to 80% of cases.\n\nDIAGNOSIS AND TREATMENT:\nAbdominal ultrasound is the diagnostic study of choice, with pyloric muscle thickness greater than 3 mm and channel length greater than 15 mm considered diagnostic. The characteristic metabolic derangement is hypochloremic, hypokalemic metabolic alkalosresults from loss of gastric hydrochloric acid through persistent vomiting, with a paradoxical aciduria that develops when the kidneys preferentially reabsorb sodium with bicarbonate (to maintain volume) and excrete hydrogen ions and potassium. Treatment requires initial intravenous fluid resuscitation and correction of electrolyte and acid-base abnormalities before proceeding to the definitive surgical treatment: Ramstedt pyloromyotomy (longitudinal incision through the hypertrophied muscle to the submucosa without entering the mucosa), which is curative.\n\nKEY POINTS:\nPyloric stenosis presents at 3 to 6 weeks with projectile non-bilious vomiting in a hungry infant (firstborn male classically), with a palpable olive-shaped mass and visible peristaltic waves. Ultrasound showing pyloric muscle thickness greater than 3 mm is diagnostic. The metabolic derangement is hypochloremic, hypokalemic metabolic alkalosis with paradoxical aciduria, which must be corrected before pyloromyotomy."
  },
  {
    "id": 562,
    "categoryId": 12,
    "question": "Neonatal Acne (onset 2-3 weeks) requires:",
    "options": [
      "A) Topical Retinoids",
      "B) Reassurance (Resolves spontaneously)",
      "C) Oral Antibiotics",
      "D) Diet change"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reassurance - Resolves spontaneously).\n\nPATHOPHYSIOLOGY:\nNeonatal acne (neonatal cephalic pustulosis) develops in approximately 20% of newborns, typically appearing at 2 to 3 weeks of age. The pathogenesis involves stimulation of the neonatal sebaceous glands by maternal androgens (transferred transplacentally during the third trimester) and by the infant's own adrenal androgens during the postnatal hormonal surge (the \"mini-puberty\" of infancy). The resulting sebum production, combined with colonization of the pilosebaceous unit by Malassezia species (formerly Pityrosporum), produces the characteristic inflammatory papules and pustules on the cheeks, chin, forehead, and occasionally the scalp and upper chest.\n\nCLINICAL PRESENTATION:\nNeonatal acne presents as small erythematous papules and pustules on the face, typically without comedones (blackheads or whiteheads), which distinguishes it from true acne vulgaris. The lesions are self-limited and resolve spontaneously within 1 to 3 months as maternal hormone levels decline, requiring no treatment beyond gentle daily cleansing with water. Parents should be counseled to avoid applying lotions, oils, or over-the-counter acne products, which may irritate the newborn's delicate skin and prolong the condition.\n\nDIFFERENTIAL DIAGNOSIS:\nneonatal acne (onset at 2 to 3 weeks, self-limited) must be distinguished from infantile acne (onset at 3 to 6 months), which presents with true comedones in addition to papules and pustules and may require treatment with topical retinoids or other acne therapies because it can be more persistent and may cause scarring. Infantile acne should also prompt consideration of an underlying endocrine disorder (congenital adrenal hyperplasia, androgen-secreting tumor) if it is severe, persistent, or accompanied by other signs of androgen excess. Other conditions in the neonatal differential include erythema toxicum neonatorum (benign, evanescent erythematous macules and papules in the first 48 hours), milia (tiny white papules from keratin-filled epidermal cysts), and seborrheic dermatitis (greasy, yellowish scales on the scalp and face).\n\nKEY POINTS:\nNeonatal acne appears at 2 to 3 weeks due to maternal and neonatal androgens stimulating sebaceous glands and requires only reassurance, as it resolves spontaneously within 1 to 3 months. It is distinguished from infantile acne (onset at 3 to 6 months), which has comedones, may require treatment, and should prompt endocrine evaluation if severe. Neonatal acne lacks comedones and should not be treated with topical retinoids or acne medications."
  },
  {
    "id": 563,
    "categoryId": 12,
    "question": "Kernig's Sign involves:",
    "options": [
      "A) Flexing the neck causes hip flexion",
      "B) Pain when extending the knee with the hip flexed",
      "C) Pain with palpation of the tragus",
      "D) Rash that does not blanch"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pain when extending the knee with the hip flexed).\n\nPATHOPHYSIOLOGY:\nKernig and Brudzinski signs are physical examination maneuvers that detect meningeal irritation, most commonly caused by infection (bacterial or viral meningitis), subarachnoid hemorrhage, or carcinomatous meningitis. Inflammation of the meninges sensitizes the spinal nerve roots as they traverse the subarachnoid space, and maneuvers that stretch these inflamed nerve roots elicit pain and reflex protective muscle spasm. The sensitivity of these signs is limited (approximately 5% for Kernig and 5% for Brudzinski in adults per meta-analyses), meaning their absence does not exclude meningitis; however, when present, they are fairly specific and strongly suggest meningeal inflammation.\n\nKERNIG SIGN:\nKernig sign is performed with the patient supine by flexing the hip to 90 degrees and then attempting to passively extend the knee. The test is positive when extension of the knee beyond 135 degrees produces pain or resistance in the hamstrings and lower back. The mechanism is that knee extension with the hip flexed stretches the sciatic nerve and lumbosacral nerve roots (L4 through S3) that are surrounded by inflamed meninges, eliciting pain and involuntary resistance.\n\nBRUDZINSKI SIGN:\nBrudzinski sign is performed with the patient supine by passively flexing the neck toward the chest. The test is positive when neck flexion produces involuntary flexion of the hips and knees bilaterally. The mechanism is that cervical flexion stretches the inflamed spinal meninges, and the reflex hip and knee flexion is a protective response to reduce meningeal traction along the spinal cord.\n\nCLINICAL APPLICATION:\nIn neonates and young infants, classic meningeal signs including Kernig and Brudzinski signs are unreliable because the immature nervous system may not produce the expected reflex responses. In this population, a bulging fontanelle, irritability, poor feeding, temperature instability, and lethargy are more reliable indicators of meningeal irritation. In older children and adults, the classic meningitis triad of fever, neck stiffness, and altered mental status is present in approximately 44% of cases of bacterial meningitis.\n\nKEY POINTS:\nKernig sign is pain or resistance with knee extension while the hip is flexed to 90 degrees, caused by stretching inflamed lumbosacral nerve roots. Brudzinski sign is involuntary hip and knee flexion with passive neck flexion, reflecting spinal meningeal irritation. Both signs are specific but have low sensitivity for meningitis, and they are unreliable in neonates where bulging fontanelle and nonspecific signs predominate."
  },
  {
    "id": 564,
    "categoryId": 16,
    "question": "A 42-year-old woman with no family history of breast cancer asks about mammography screening. According to the 2024 USPSTF guidelines, what is the recommended screening approach for average-risk women?",
    "options": [
      "A) Mammogram every year starting at age 40",
      "B) Mammogram every 2 years from age 40-74",
      "C) Mammogram every 2 years starting at age 50",
      "D) Shared decision-making for women 40-49, then every 2 years from 50-74"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mammogram every 2 years from age 40 to 74).\n\nGUIDELINE UPDATE:\nThe USPSTF 2024 updated recommendation expanded breast cancer screening to begin at age 40 (previously 50 for average-risk women) with biennial (every 2 years) mammography continuing through age 74. This Grade B recommendation was driven by increasing breast cancer incidence in women under 50 and modeling studies demonstrating that starting screening at 40 prevents more breast cancer deaths across all racial and ethnic groups.\n\nEVIDENCE BASIS:\nRandomized controlled trials and meta-analyses demonstrate that mammographic screening reduces breast cancer mortality by approximately 15 to 20% in women aged 40 to 49 and 20 to 30% in women aged 50 to 69. The benefit derives from detecting cancers at earlier stages (smaller tumor size, lower likelihood of nodal involvement) when curative treatment is more effective. The 2024 USPSTF update particularly emphasized reducing screening disparities for Black women, who have a 40% higher breast cancer mortality rate than White women and are more likely to develop aggressive subtypes (triple-negative breast cancer) at younger ages.\n\nHARMS AND CONSIDERATIONS:\nScreening mammography has an approximately 10% false-positive rate per examination, leading to additional imaging and biopsies that cause anxiety and expense. Overdiagnosis (detecting cancers that would never have caused symptoms or death) is estimated at approximately 1 to 10% of screen-detected cancers. Dense breast tissue (categories C and D on BI-RADS) reduces mammographic sensitivity, and many states now require supplemental screening notification for women with dense breasts. The USPSTF noted insufficient evidence to assess the benefits and harms of supplemental screening with breast MRI or ultrasound in women with dense breasts.\n\nKEY POINTS:\nThe USPSTF 2024 recommendation is biennial mammography for all women aged 40 to 74 (expanded from previous age 50 start). Screening reduces breast cancer mortality by 15 to 30% depending on age group. The update was particularly motivated by reducing disparities in Black women, who have 40% higher breast cancer mortality and more frequent aggressive subtypes at younger ages."
  },
  {
    "id": 565,
    "categoryId": 16,
    "question": "A 32-year-old woman asks about cervical cancer screening. According to current guidelines, what is the PREFERRED screening method for women ages 30-65?",
    "options": [
      "A) Pap smear alone every 3 years",
      "B) HPV test alone every 5 years",
      "C) Co-testing (HPV + Pap) every 5 years",
      "D) HPV test alone every 3 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (HPV test alone every 5 years).\n\nGUIDELINE OPTIONS:\nCurrent cervical cancer screening guidelines (USPSTF 2018, ACS 2020) offer multiple evidence-based strategies for women aged 25 to 65: cervical cytology (Pap smear) alone every 3 years, primary HPV testing alone every 5 years (the ACS preferred strategy as of 2020), or co-testing (cytology plus HPV) every 5 years. The shift toward primary HPV testing reflects the understanding that virtually all cervical cancers are caused by persistent infection with high-risk HPV genotypes (types 16 and 18 account for approximately 70% of cervical cancers).\n\nRATIONALE FOR HPV-BASED SCREENING:\nHPV testing has higher sensitivity (approximately 95%) than cytology alone (approximately 55 to 80%) for detecting CIN3+ (high-grade cervical intraepithelial neoplasia and cancer), though it has somewhat lower specificity. Because HPV testing detects the causative agent rather than its cytologic consequences, it identifies precancerous lesions earlier in their natural history, and a negative HPV test provides greater reassurance (lower risk of CIN3+ over the next 5 years) than a negative cytology. This is why the screening interval for HPV testing is 5 years versus 3 years for cytology alone.\n\nSCREENING BOUNDARIES:\nScreening should begin at age 21 (with cytology) or age 25 (with HPV testing, with the most recent within 5 years). Women who have had a total hysterectomy with removal of the cervix for benign indications and have no history of CIN2+ do not require continued screening.\n\nKEY POINTS:\nPrimary HPV testing every 5 years is now the ACS preferred cervical cancer screening strategy for women 25 to 65, reflecting HPV's higher sensitivity for CIN3+ compared to cytology alone. Virtually all cervical cancers are caused by persistent high-risk HPV infection (types 16 and 18 account for 70%). Screening can stop after age 65 with adequate prior negative results."
  },
  {
    "id": 566,
    "categoryId": 16,
    "question": "A 55-year-old man with a 25 pack-year smoking history quit smoking 18 years ago. According to the 2023 ACS lung cancer screening guidelines, is he eligible for low-dose CT screening?",
    "options": [
      "A) No, he quit more than 15 years ago",
      "B) Yes, former smokers with â‰¥20 pack-years are eligible regardless of quit time",
      "C) Only if he resumes smoking",
      "D) Only with shared decision-making due to borderline eligibility"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Yes, former smokers with 20 or more pack-years are eligible regardless of quit time).\n\nMAJOR GUIDELINE CHANGE:\nThe American Cancer Society 2023 lung cancer screening guideline made a landmark change by removing the quit-within-15-years requirement that had been part of all previous lung cancer screening criteria. Under the updated ACS guideline, annual low-dose CT screening is recommended for individuals aged 50 to 80 with a 20 or more pack-year smoking history, regardless of how long ago they quit. This patient (25 pack-year history, quit 18 years ago) would have been ineligible under the USPSTF 2021 criteria (which retain the 15-year quit threshold) but is eligible under the ACS 2023 criteria.\n\nRATIONALE:\nThe removal of the quit-time restriction was based on evidence that former smokers retain significant lung cancer risk for decades after cessation. Studies from the National Lung Screening Trial and the PLCO cohort demonstrated that approximately 40% of lung cancer deaths in screening-eligible populations occurred in former smokers who had quit more than 15 years ago, meaning the quit-time threshold was systematically excluding a high-risk population from the mortality benefit of screening.\n\nCOMPARISON OF GUIDELINES:\nThe USPSTF 2021 criteria (age 50 to 80, 20 or more pack-years, current smoker or quit within 15 years) remain more restrictive and are the basis for insurance coverage mandates under the ACA. The ACS 2023 criteria are broader and may not yet be universally covered by insurance. Clinicians should be aware of both guidelines and advocate for screening in patients who meet ACS criteria even if they fall outside USPSTF criteria.\n\nKEY POINTS:\nThe ACS 2023 lung cancer screening guideline removed the quit-within-15-years requirement, making all former smokers with 20 or more pack-years eligible for annual LDCT regardless of quit duration. Approximately 40% of lung cancer deaths in screening-eligible populations occur in long-quit former smokers. The USPSTF 2021 criteria retain the 15-year quit threshold and are the basis for mandatory insurance coverage."
  },
  {
    "id": 567,
    "categoryId": 16,
    "question": "At what age should colorectal cancer screening begin in average-risk adults according to current ACS and USPSTF guidelines?",
    "options": [
      "A) 40 years",
      "B) 45 years",
      "C) 50 years",
      "D) 55 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (45 years).\n\nGUIDELINE UPDATE:\nBoth the American Cancer Society (2018) and the USPSTF (2021) lowered the recommended starting age for average-risk colorectal cancer screening from 50 to 45 years. This change was driven by a concerning 51% increase in colorectal cancer incidence in adults under 50 between 1994 and 2014, with the steepest rise in adults aged 40 to 49.\n\nSCREENING OPTIONS:\nMultiple modalities are acceptable for average-risk screening. Colonoscopy every 10 years is the most comprehensive option, allowing direct visualization, biopsy, and polypectomy in a single procedure. High-sensitivity stool-based tests include annual fecal immunochemical test (FIT, which detects human hemoglobin), FIT-DNA (Cologuard, every 3 years, combining FIT with methylated DNA markers), and annual guaiac-based fecal occult blood test (gFOBT). CT colonography (virtual colonoscopy) every 5 years and flexible sigmoidoscopy every 5 years (or every 10 years combined with annual FIT) are additional options. A positive stool-based test must be followed by diagnostic colonoscopy.\n\nRISK STRATIFICATION:\nThe age 45 starting point applies to average-risk individuals only. Higher-risk patients (first-degree relative with CRC before age 60, personal history of inflammatory bowel disease, hereditary syndromes such as Lynch or FAP) require earlier initiation and more frequent surveillance. African Americans have the highest CRC incidence and mortality of any racial group in the United States, and some guidelines have historically recommended screening beginning at age 45 for this population specifically.\n\nKEY POINTS:\nColorectal cancer screening for average-risk adults now begins at age 45 per both ACS guidelines, driven by rising CRC incidence in adults under 50. Multiple modalities are acceptable including colonoscopy every 10 years, annual FIT, and FIT-DNA every 3 years. Higher-risk patients require earlier initiation based on family history and risk factors."
  },
  {
    "id": 568,
    "categoryId": 16,
    "question": "According to the 2025 CDC immunization schedule, at what age should adults now routinely receive pneumococcal vaccination?",
    "options": [
      "A) 50 years",
      "B) 60 years",
      "C) 65 years",
      "D) 70 years"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Age 50).\n\nUPDATED PNEUMOCOCCAL VACCINATION:\nThe CDC's Advisory Committee on Immunization Practices (ACIP) updated adult pneumococcal vaccination recommendations. All adults should now receive pneumococcal vaccination starting at age 50 (previously 65 for healthy adults), using either PCV20 alone or PCV15 followed by PPSV23.\n\nRATIONALE FOR EARLIER VACCINATION:\nPneumococcal disease causes significant morbidity in adults 50-64, not just those â‰¥65. Earlier vaccination extends protection during a vulnerable decade and simplifies the schedule. Adults with risk factors (diabetes, heart disease, lung disease, smoking) have even higher pneumococcal disease risk.\n\nVACCINE OPTIONS:\nPCV20 (Prevnar 20) can be given as a single dose completing the series. Alternatively, PCV15 followed by PPSV23 at least one year later provides similar coverage. Adults previously vaccinated with PPSV23 alone should receive a PCV (either 15 or 20) at least one year later.\n\nHIGH-RISK POPULATIONS:\nImmunocompromised patients, asplenic patients, cochlear implant recipients, and CSF leak patients should be vaccinated earlier (any age) per specific schedules with both PCV and PPSV23.\n\nKEY POINTS:\nUniversal pneumococcal vaccination now starts at age 50, not 65. PCV20 alone or PCV15 + PPSV23 are acceptable regimens. High-risk individuals require vaccination at any age per specific recommendations."
  },
  {
    "id": 569,
    "categoryId": 16,
    "question": "A 58-year-old patient with COPD asks about the RSV vaccine. According to current guidelines, who should receive RSV vaccination?",
    "options": [
      "A) All adults 50 and older",
      "B) Adults 60+ routinely; ages 50-59 with increased risk for severe RSV disease",
      "C) Only adults 75 and older",
      "D) Only immunocompromised adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adults 60 and older routinely; ages 50 to 59 with increased risk for severe RSV disease).\n\nVACCINE BACKGROUND:\nRespiratory syncytial virus (RSV) vaccines (Arexvy by GSK and Abrysvo by Pfizer) were FDA-approved in 2023 for adults aged 60 and older, marking the first RSV vaccines available for the adult population. The CDC Advisory Committee on Immunization Practices (ACIP) updated recommendations to include routine RSV vaccination for adults aged 60 and older through shared clinical decision-making, and expanded eligibility in 2024 to include adults aged 50 to 59 with increased risk for severe RSV disease.\n\nHIGH-RISK CONDITIONS:\nConditions that increase the risk of severe RSV in adults include chronic lung disease (COPD, asthma), chronic heart disease (heart failure, coronary artery disease), moderate to severe immunocompromise, diabetes with end-organ complications, neurologic or neuromuscular conditions that impair airway clearance, chronic kidney or liver disease, and residence in nursing homes or long-term care facilities. This patient with COPD at age 58 would qualify under the expanded 50 to 59 high-risk criteria.\n\nCLINICAL SIGNIFICANCE:\nRSV causes approximately 60,000 to 160,000 hospitalizations and 6,000 to 10,000 deaths annually among adults aged 65 and older in the United States. Clinical trials demonstrated approximately 83% vaccine efficacy against RSV-associated lower respiratory tract disease in adults 60 and older. Both vaccines are administered as a single intramuscular dose, and current guidance is for a single lifetime dose (duration of protection and need for revaccination remain under study).\n\nKEY POINTS:\nRSV vaccination is recommended routinely for adults 60 and older and for adults 50 to 59 with conditions increasing severe RSV risk (COPD, heart failure, immunocompromise, diabetes). RSV causes 60,000 to 160,000 hospitalizations annually in older adults. Both approved vaccines (Arexvy, Abrysvo) are single-dose with approximately 83% efficacy against lower respiratory tract disease."
  },
  {
    "id": 570,
    "categoryId": 16,
    "question": "According to the 2025 CDC schedule, which adults should receive a SECOND dose of the 2024-2025 COVID-19 vaccine?",
    "options": [
      "A) All adults over 50",
      "B) Adults 65+ and those who are moderately/severely immunocompromised",
      "C) Only transplant recipients",
      "D) No one; one dose is sufficient for all adults"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Adults 65 and older and those who are moderately to severely immunocompromised).\n\nRATIONALE:\nThe immune response to COVID-19 vaccination wanes over time, and certain populations maintain lower and less durable antibody and T-cell responses. The 2024-2025 updated COVID-19 vaccine (targeting currently circulating variants) is recommended as a single dose for all individuals aged 6 months and older, with a second dose recommended for two specific populations: adults aged 65 and older and individuals who are moderately to severely immunocompromised.\n\nIMMUNOLOGIC BASIS:\nImmunosenescence (age-related decline in immune function) reduces the magnitude and durability of vaccine-induced immunity in older adults, with lower peak antibody titers and faster waning of neutralizing antibody levels. Moderately to severely immunocompromised individuals (active treatment with high-dose corticosteroids, cancer chemotherapy, solid organ transplant recipients on immunosuppressive therapy, advanced HIV with CD4 less than 200, and B-cell depleting therapy recipients) may fail to mount adequate primary responses to vaccination and benefit from additional antigen exposure.\n\nTIMING:\nThe additional dose should be administered at least 6 months after the initial 2024-2025 updated dose for adults 65 and older, and at least 2 months after for immunocompromised individuals (who may receive additional doses beyond two based on clinical judgment and immunologic status). Clinicians should not delay vaccination if the patient has not yet received the current season's formulation, as the updated vaccine provides the best available protection against circulating variants.\n\nKEY POINTS:\nAdults 65 and older and moderately to severely immunocompromised individuals should receive a second dose of the 2024-2025 updated COVID-19 vaccine due to immunosenescence and impaired vaccine responses respectively. The additional dose is given at least 6 months after the first for older adults and at least 2 months after for immunocompromised patients. Immunocompromised individuals may receive further doses based on clinical judgment."
  },
  {
    "id": 571,
    "categoryId": 4,
    "question": "According to the 2025 ADA Standards of Care, what is the recommended approach to glucose-lowering therapy in a patient with T2DM and established atherosclerotic cardiovascular disease (ASCVD)?",
    "options": [
      "A) Metformin monotherapy, add sulfonylurea if not at goal",
      "B) GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c",
      "C) Start insulin if A1c > 9%",
      "D) DPP-4 inhibitor as first-line after metformin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c).\n\nPATHOPHYSIOLOGY:\nThe ADA Standards of Care reflects a paradigm shift from glucocentric treatment to a comorbidity-driven, cardiorenal-metabolic approach\u2014selecting agents based on proven cardiovascular, heart failure, and CKD benefits independent of glycemic effects. This was catalyzed by landmark CVOTs: LEADER (NEJM 2016) showed liraglutide reduced MACE by 13% and CV death by 22%; SUSTAIN-6 showed semaglutide reduced MACE by 26%; REWIND showed dulaglutide reduced MACE by 12%. Among SGLT2 inhibitors, EMPA-REG OUTCOME showed empagliflozin reduced MACE by 14% and CV death by 38%; CANVAS showed canagliflozin reduced MACE by 14%. These benefits were independent of glycemic control.\n\nCLINICAL REASONING:\nThe ADA 2025 Standards recommends that for T2DM patients with established ASCVD (prior MI, stroke, PAD, revascularization, or >50% arterial stenosis), a GLP-1 RA or SGLT2 inhibitor with proven CV benefit should be included independent of A1c, glycemic target, or metformin use. For T2DM with heart failure, SGLT2 inhibitors carry a Class I recommendation based on DAPA-HF and EMPEROR-Reduced (HFrEF) and EMPEROR-Preserved and DELIVER (HFpEF) trials. For T2DM with CKD (eGFR 20-60 or UACR >200), SGLT2 inhibitors are recommended per CREDENCE and DAPA-CKD trials (30-39% kidney endpoint reductions).\n\nCLINICAL APPLICATION:\nAssess every T2DM patient for ASCVD, heart failure, and CKD at each visit, as comorbidities should drive medication selection. For ASCVD patients, initiate a GLP-1 RA (semaglutide, liraglutide, dulaglutide) or SGLT2 inhibitor (empagliflozin, dapagliflozin, canagliflozin) regardless of A1c. Metformin remains a reasonable adjunct. The 2025 guidelines also incorporate tirzepatide (dual GIP/GLP-1 agonist), which showed 15-20% weight loss in SURMOUNT trials and CV benefit in SURPASS-CVOT.\n\nKEY POINTS:\nThe ADA 2025 recommends GLP-1 RAs or SGLT2 inhibitors with proven CV benefit for T2DM with established ASCVD, independent of A1c. This comorbidity-driven approach prioritizes cardiorenal protection. SGLT2 inhibitors are specifically recommended for T2DM with heart failure and CKD based on landmark trials."
  },
  {
    "id": 572,
    "categoryId": 4,
    "question": "A patient has a fasting glucose of 118 mg/dL and HbA1c of 6.3%. According to ADA criteria, what is this patient's diagnosis?",
    "options": [
      "A) Normal",
      "B) Prediabetes",
      "C) Diabetes mellitus",
      "D) Impaired fasting glucose only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Prediabetes).\n\nPATHOPHYSIOLOGY:\nPrediabetes is an intermediate metabolic state with glucose levels above normal but below the diabetes threshold, reflecting progressive beta-cell dysfunction and worsening insulin resistance. Approximately 38% of US adults (98 million) have prediabetes; without intervention, 5-10% progress to T2DM annually, with up to 70% eventually developing diabetes. Each diagnostic test captures different dysglycemia aspects: fasting glucose reflects hepatic insulin resistance, the 2-hour OGTT reflects peripheral insulin resistance, and HbA1c reflects average glycemia over 2-3 months.\n\nCLINICAL REASONING:\nPer ADA criteria, prediabetes is defined by fasting glucose 100-125 mg/dL (impaired fasting glucose), 2-hour OGTT 140-199 mg/dL (impaired glucose tolerance), or HbA1c 5.7-6.4%. Diabetes is diagnosed at fasting glucose \u2265126, OGTT \u2265200, HbA1c \u22656.5%, or random glucose \u2265200 with symptoms. Abnormal results should be confirmed by repeat testing on a separate day. HbA1c caveats: falsely elevated with iron deficiency anemia or B12 deficiency; falsely reduced with hemolytic anemias or recent transfusion. Hemoglobin variants (HbS, HbC, HbE) may interfere with certain assays.\n\nCLINICAL APPLICATION:\nPrediabetes should trigger structured prevention. The Diabetes Prevention Program (DPP, NEJM 2001) demonstrated that lifestyle intervention (targeting 7% weight loss plus 150 minutes/week moderate exercise) reduced progression to diabetes by 58%, outperforming metformin (31% reduction), with benefits sustained at 10- and 15-year follow-up. The ADA recommends referral to a CDC-recognized Diabetes Prevention Program. Metformin may be considered for highest-risk patients: BMI \u226535, age <60, prior gestational diabetes, or rising A1c despite lifestyle changes. Screening is recommended for all adults \u226535 regardless of weight, and for any age with BMI \u226525 (\u226523 in Asian Americans) plus additional risk factors.\n\nKEY POINTS:\nPrediabetes is diagnosed by fasting glucose 100-125, OGTT 140-199, or HbA1c 5.7-6.4%, affecting 38% of US adults. The DPP demonstrated lifestyle intervention reduces progression to diabetes by 58%, outperforming metformin (31%). All patients with prediabetes should be referred to a CDC-recognized Diabetes Prevention Program."
  },
  {
    "id": 573,
    "categoryId": 1,
    "question": "According to the 2022 AHA/ACC/HFSA Heart Failure Guidelines (updated 2024), which medication class is now recommended for ALL patients with HFrEF regardless of diabetes status?",
    "options": [
      "A) DPP-4 inhibitors",
      "B) SGLT2 inhibitors",
      "C) GLP-1 receptor agonists",
      "D) Thiazolidinediones"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (SGLT2 Inhibitors).\n\nCLINICAL REASONING:\nThe 2022 AHA/ACC/HFSA Heart Failure Guidelines (with 2024 focused update) recommend SGLT2 inhibitors (dapagliflozin and empagliflozin) as one of the four pillars of guideline-directed medical therapy (GDMT) for most patients with heart failure with reduced ejection fraction (HFrEF, EF 40% or less), regardless of diabetes status. This represents a paradigm shift: SGLT2 inhibitors were originally developed as glucose-lowering agents for type 2 diabetes, but the cardiovascular outcome trials (DAPA-HF for dapagliflozin and EMPEROR-Reduced for empagliflozin) demonstrated significant reductions in the composite of cardiovascular death and heart failure hospitalization in HFrEF patients with and without diabetes.\n\nTHE FOUR PILLARS OF HFrEF GDMT:\nThe 2022 guidelines establish four foundational medication classes for HFrEF: an ARNI (sacubitril/valsartan, or ACEi/ARB if ARNI is not tolerated), an evidence-based beta-blocker (carvedilol, metoprolol succinate, or bisoprolol), a mineralocorticoid receptor antagonist (spironolactone or eplerenone), and an SGLT2 inhibitor (dapagliflozin or empagliflozin). The guidelines emphasize early initiation of all four classes (even before full dose uptitration of each) and rapid sequencing rather than the previous stepwise approach.\n\nEXPANDED INDICATIONS:\nSGLT2 inhibitors are now recommended across the entire ejection fraction spectrum of heart failure: HFrEF (EF 40% or less), HFmrEF (EF 41 to 49%), and HFpEF (EF 50% or greater) based on the DELIVER and EMPEROR-Preserved trials. The mechanism of benefit in heart failure involves natriuresis and osmotic diuresis (reducing congestion), improved myocardial energetics, reduced interstitial fibrosis, and decreased inflammation, all independent of glucose-lowering effects.\n\nKEY POINTS:\nSGLT2 inhibitors (dapagliflozin, empagliflozin) are now recommended for ALL HFrEF patients regardless of diabetes, as one of the four GDMT pillars alongside ARNI, evidence-based beta-blocker, and MRA. The benefit is independent of glucose lowering and extends across the entire HF ejection fraction spectrum. Guidelines now emphasize early initiation of all four drug classes simultaneously."
  },
  {
    "id": 574,
    "categoryId": 1,
    "question": "According to the 2017 ACC/AHA Hypertension Guidelines, what is the blood pressure threshold for initiating pharmacotherapy in a patient with 10-year ASCVD risk â‰¥10%?",
    "options": [
      "A) â‰¥120/80 mmHg",
      "B) â‰¥130/80 mmHg",
      "C) â‰¥140/90 mmHg",
      "D) â‰¥150/90 mmHg"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (130/80 mmHg or greater).\n\nGUIDELINE EVOLUTION:\nThe 2017 ACC/AHA Hypertension Clinical Practice Guidelines lowered the diagnostic threshold for hypertension from the previous JNC 7 standard of 140/90 mmHg to 130/80 mmHg, reclassifying approximately 31 million additional Americans as hypertensive. The revised classification defines normal BP as less than 120/80, elevated BP as systolic 120 to 129 with diastolic less than 80, Stage 1 hypertension as 130 to 139 systolic or 80 to 89 diastolic, and Stage 2 hypertension as 140 or greater systolic or 90 or greater diastolic.\n\nEVIDENCE BASIS:\nThe decision to lower the threshold was driven primarily by the SPRINT trial (Systolic Blood Pressure Intervention Trial), which demonstrated that targeting a systolic BP below 120 mmHg (intensive treatment) reduced major cardiovascular events by 25% and all-cause mortality by 27% compared to standard treatment targeting below 140 mmHg in high-risk patients without diabetes. Meta-analyses of over 60 clinical trials confirmed continuous cardiovascular risk reduction with lower BP targets, with no clear threshold below which benefit ceased.\n\nTREATMENT THRESHOLDS:\nThe guideline distinguishes between diagnosis and pharmacologic treatment initiation. For Stage 1 hypertension (130 to 139/80 to 89), lifestyle modification alone is recommended unless the patient has established ASCVD or a 10-year ASCVD risk of 10% or greater, in which case antihypertensive medication is also indicated. For Stage 2 hypertension (140/90 or greater), both lifestyle modification and pharmacotherapy are recommended for most patients regardless of ASCVD risk. First-line medication classes include thiazide diuretics, ACE inhibitors, ARBs, and calcium channel blockers.\n\nKEY POINTS:\nThe 2017 ACC/AHA guidelines define hypertension at 130/80 mmHg or greater, down from the previous 140/90 threshold, based on SPRINT trial evidence showing 25% cardiovascular event reduction with intensive targets. Stage 1 hypertension (130 to 139/80 to 89) requires pharmacotherapy only with established ASCVD or 10-year risk of 10% or greater. Stage 2 (140/90 or greater) warrants medication for most patients."
  },
  {
    "id": 575,
    "categoryId": 1,
    "question": "A patient has uncontrolled BP despite adherence to maximum doses of amlodipine, lisinopril, and chlorthalidone. According to current guidelines, what is the preferred fourth-line agent for resistant hypertension?",
    "options": [
      "A) Hydralazine",
      "B) Clonidine",
      "C) Spironolactone",
      "D) Doxazosin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Spironolactone).\n\nDEFINITION OF RESISTANT HYPERTENSION:\nResistant hypertension is blood pressure that remains above goal despite concurrent use of three antihypertensive medications from different classes at maximally tolerated doses, one of which must be a diuretic, or blood pressure controlled on four or more medications. Before diagnosing true resistant hypertension, clinicians must exclude pseudo-resistance: medication non-adherence (the most common cause), white coat hypertension (confirmed by ambulatory monitoring), improper BP measurement technique, and secondary causes of hypertension.\n\nPATHWAY-2 TRIAL:\nThe landmark PATHWAY-2 trial (Prevention and Treatment of Hypertension with Algorithm-based therapY-2) demonstrated that spironolactone was significantly more effective as fourth-line add-on therapy than bisoprolol, doxazosin, or placebo in patients with confirmed resistant hypertension. Spironolactone reduced systolic BP by an average of 8.7 mmHg more than placebo, compared to 4.5 mmHg for bisoprolol (beta-blocker) and 4.0 mmHg for doxazosin (alpha-blocker).\n\nPATHOPHYSIOLOGY:\nThe superiority of spironolactone reflects the role of aldosterone excess (termed aldosterone breakthrough) as a major driver of treatment-resistant hypertension. Even in patients already taking ACE inhibitors or ARBs, aldosterone levels may escape suppression over time through angiotensin-independent pathways (potassium-mediated secretion, ACTH stimulation, and autonomous adrenal production), contributing to sodium retention, volume expansion, and direct vascular stiffening. By directly blocking the mineralocorticoid receptor in both the kidney and vasculature, spironolactone addresses this pathophysiology. Eplerenone is an alternative with fewer anti-androgenic side effects (gynecomastia, breast tenderness) for patients who cannot tolerate spironolactone.\n\nKEY POINTS:\nSpironolactone is the most effective fourth-line agent for resistant hypertension, reducing systolic BP 8.7 mmHg more than placebo, outperforming both bisoprolol and doxazosin. Its superiority reflects aldosterone breakthrough as a key driver of resistant hypertension. Pseudo-resistance (non-adherence, white coat effect) must be excluded before diagnosing true resistant hypertension."
  },
  {
    "id": 576,
    "categoryId": 2,
    "question": "According to GOLD 2024 guidelines, a COPD patient on LAMA+LABA with frequent exacerbations has an eosinophil count of 400 cells/Î¼L. What is the next step?",
    "options": [
      "A) Add theophylline",
      "B) Add inhaled corticosteroid (ICS) to form triple therapy",
      "C) Start roflumilast",
      "D) Add azithromycin prophylaxis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Add inhaled corticosteroid to form triple therapy).\n\nCLINICAL REASONING:\nThe patient has COPD with frequent exacerbations despite LAMA plus LABA dual bronchodilator therapy, and a blood eosinophil count of 400 cells per microliter. The GOLD 2024 guidelines use blood eosinophil count as a biomarker to guide the decision to add ICS. With eosinophils of 400 (well above the 300 threshold), the recommended escalation is to add ICS to form LAMA/LABA/ICS triple therapy. The IMPACT trial (published in the New England Journal of Medicine) demonstrated that fluticasone furoate/umeclidinium/vilanterol triple therapy reduced moderate and severe exacerbations by 15% and all-cause mortality by 42% compared to LAMA/LABA alone in patients with elevated eosinophils. The ETHOS trial confirmed these findings with a budesonide-containing triple inhaler.\n\nEOSINOPHIL-GUIDED ICS THERAPY:\nThe rationale for eosinophil-guided therapy is that eosinophilic airway inflammation in COPD identifies a subset of patients whose exacerbations are driven by a steroid-responsive inflammatory phenotype, analogous to asthma. Eosinophils 300 or greater strongly support ICS addition with clear evidence of benefit. Eosinophils 100 to 300 provide moderate support, particularly with 2 or more exacerbations per year. Eosinophils less than 100 predict minimal ICS benefit with increased pneumonia risk, and ICS should be avoided or withdrawn in these patients.\n\nSTEPWISE ESCALATION:\nThe GOLD 2024 escalation pathway for persistent exacerbations follows a stepwise approach: LAMA monotherapy is escalated to LAMA/LABA, then to LAMA/LABA/ICS if eosinophils are 300 or greater. If exacerbations persist despite triple therapy, roflumilast (a phosphodiesterase-4 inhibitor, specifically for patients with FEV1 less than 50% predicted and chronic bronchitis phenotype) or chronic azithromycin (for former smokers, with QTc monitoring) is added. Theophylline has fallen out of favor due to its narrow therapeutic window and significant toxicity.\n\nKEY POINTS:\nBlood eosinophils 300 or greater in a COPD patient with persistent exacerbations on LAMA/LABA is the key indication for adding ICS to form triple therapy. The IMPACT and ETHOS trials demonstrated both exacerbation reduction and mortality benefit with triple therapy in eosinophilic COPD. Roflumilast and azithromycin are reserved for patients who continue to exacerbate despite optimized triple therapy."
  },
  {
    "id": 577,
    "categoryId": 2,
    "question": "According to GINA 2024 guidelines, what is the preferred reliever medication for adults with mild asthma (Track 1)?",
    "options": [
      "A) Short-acting beta-agonist (SABA) alone as needed",
      "B) As-needed low-dose ICS-formoterol",
      "C) Daily low-dose ICS plus SABA as needed",
      "D) Oral corticosteroids for exacerbations only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (As-needed low-dose ICS-formoterol).\n\nCLINICAL REASONING:\nThe Global Initiative for Asthma (GINA) 2024 guidelines represent a paradigm shift in asthma management by recommending against SABA-only treatment for any severity of asthma, including mild intermittent disease. This change reflects accumulating evidence that patients treated with SABA alone have increased risk of severe exacerbations and asthma-related death because SABA addresses only bronchospasm without treating the underlying eosinophilic airway inflammation that is present even in mild disease. The GINA 2024 preferred approach (Track 1) uses low-dose ICS-formoterol (budesonide-formoterol) as the sole reliever medication for Steps 1 and 2, ensuring that every rescue dose delivers both a rapid-onset bronchodilator (formoterol, which has an onset of action within 1 to 3 minutes comparable to albuterol) and an anti-inflammatory corticosteroid.\n\nTRACK 1 VS TRACK 2:\nTrack 1 (preferred) uses as-needed ICS-formoterol at Steps 1 and 2, progressing to ICS-formoterol as both maintenance and reliever therapy (MART) at Steps 3 through 5, with the same inhaler used for both scheduled and rescue dosing. Track 2 (alternative) retains SABA as the reliever but requires that an ICS be taken with every SABA dose, which presents significant adherence challenges. The SYGMA 1 and SYGMA 2 trials (published in the New England Journal of Medicine) demonstrated that as-needed budesonide-formoterol reduced severe exacerbations by 60 to 70% compared to SABA alone and was noninferior to daily ICS plus as-needed SABA for exacerbation prevention in mild asthma.\n\nSTEPWISE THERAPY:\nGINA 2024 Steps: Steps 1 to 2 use as-needed low-dose ICS-formoterol (Track 1) for symptom relief and anti-inflammatory coverage. Step 3 adds low-dose ICS-formoterol as daily maintenance plus as-needed reliever (MART). Step 4 escalates to medium-dose ICS-formoterol maintenance plus as-needed reliever. Step 5 involves high-dose ICS-formoterol, add-on LAMA (tiotropium), and consideration of biologic therapies guided by phenotype (anti-IgE omalizumab, anti-IL5 mepolizumab or benralizumab, anti-IL4/IL13 dupilumab, anti-TSLP tezepelumab).\n\nKEY POINTS:\nGINA 2024 recommends against SABA-only treatment for any asthma severity, favoring as-needed low-dose ICS-formoterol as the preferred reliever (Track 1) to ensure anti-inflammatory therapy with every rescue dose. The SYGMA trials demonstrated that PRN ICS-formoterol reduces severe exacerbations by 60 to 70% compared to SABA alone. The MART approach (maintenance and reliever therapy with a single ICS-formoterol inhaler) simplifies management at Steps 3 and above."
  },
  {
    "id": 578,
    "categoryId": 11,
    "question": "According to the 2024 ACP guidelines for major depressive disorder, what is recommended as first-line treatment for adults in the acute phase?",
    "options": [
      "A) Second-generation antidepressant monotherapy only",
      "B) CBT monotherapy only",
      "C) Either CBT or a second-generation antidepressant as monotherapy",
      "D) Combination therapy with antidepressant plus CBT for all patients"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Either CBT or a second-generation antidepressant as monotherapy).\n\nGUIDELINE BASIS:\nThe 2024 American College of Physicians (ACP) clinical practice guideline for acute-phase treatment of major depressive disorder (MDD) in adults recommends either cognitive behavioral therapy (CBT) or a second-generation antidepressant (SGA) as equivalent first-line monotherapy options. This recommendation reflects moderate-certainty evidence that CBT and SGAs produce comparable response and remission rates in acute MDD, with the choice depending on patient preference, access, cost, and side effect concerns.\n\nSECOND-GENERATION ANTIDEPRESSANTS:\nThe ACP guideline encompasses SSRIs (sertraline, escitalopram, fluoxetine, citalopram, paroxetine), SNRIs (venlafaxine, duloxetine, desvenlafaxine), bupropion, and mirtazapine as the second-generation antidepressant options. The guideline does not recommend one SGA over another as initial therapy because head-to-head trials show comparable efficacy, though side effect profiles differ and should guide selection (for example, bupropion for patients concerned about weight gain or sexual dysfunction, mirtazapine for patients with prominent insomnia and appetite loss).\n\nCOMBINATION THERAPY:\nThe ACP guideline does not recommend initial combination therapy (CBT plus antidepressant) for most patients, reserving this approach for patients who do not achieve adequate response with monotherapy. For patients with moderate to severe MDD who fail an initial adequate trial (6 to 8 weeks at therapeutic dose), augmentation strategies (adding an atypical antipsychotic such as aripiprazole, adding lithium, or combining CBT with pharmacotherapy) or switching medication class are recommended.\n\nTREATMENT DURATION:\nThe ACP recommends continuing antidepressant therapy for a minimum of 4 to 9 months after achieving remission to reduce relapse risk, with longer continuation (1 to 3 years or indefinitely) for patients with recurrent episodes, severe initial presentation, or residual symptoms.\n\nKEY POINTS:\nThe 2024 ACP guideline recommends CBT or a second-generation antidepressant as equivalent first-line monotherapy for acute MDD, with choice guided by patient preference and side effect profile. Combination therapy is reserved for monotherapy non-responders. Antidepressants should be continued 4 to 9 months after remission to prevent relapse."
  },
  {
    "id": 579,
    "categoryId": 11,
    "question": "The PHQ-9 is used for depression screening. A score of 15 indicates:",
    "options": [
      "A) Minimal depression",
      "B) Mild depression",
      "C) Moderately severe depression",
      "D) Severe depression"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Moderately severe depression).\n\nSCREENING TOOL:\nThe Patient Health Questionnaire-9 (PHQ-9) is a validated, self-administered depression screening and severity assessment instrument derived from the nine DSM-5 criteria for major depressive disorder. Each item is scored from 0 (not at all) to 3 (nearly every day) over the past 2 weeks, yielding a total score of 0 to 27. The USPSTF recommends screening all adults for depression in primary care using validated instruments such as the PHQ-9 (Grade B recommendation).\n\nSCORE INTERPRETATION:\nPHQ-9 severity thresholds are: 0 to 4 (minimal or no depression), 5 to 9 (mild depression), 10 to 14 (moderate depression), 15 to 19 (moderately severe depression), and 20 to 27 (severe depression). A score of 10 or greater has a sensitivity of 88% and specificity of 88% for major depressive disorder, making it an effective screening threshold. A score of 15, as in this case, indicates moderately severe depression warranting active treatment (pharmacotherapy, psychotherapy, or combination).\n\nCLINICAL APPLICATION:\nBeyond initial screening, the PHQ-9 is valuable for monitoring treatment response over time. A decrease of 5 or more points is considered a clinically meaningful response, and a score below 5 represents remission. The PHQ-9 should be administered at each visit during active treatment (every 2 to 4 weeks initially, then at follow-up intervals) to guide treatment adjustments. Question 9 specifically asks about suicidal ideation (\"thoughts that you would be better off dead or of hurting yourself\") and any positive response requires immediate safety assessment regardless of total score.\n\nKEY POINTS:\nPHQ-9 severity thresholds are: 0 to 4 minimal, 5 to 9 mild, 10 to 14 moderate, 15 to 19 moderately severe, 20 to 27 severe. A score of 10 or greater has 88% sensitivity and specificity for MDD. The PHQ-9 should be used for both screening and longitudinal treatment monitoring, with a 5-point decrease indicating clinically meaningful response and question 9 requiring immediate safety assessment if positive."
  },
  {
    "id": 580,
    "categoryId": 7,
    "question": "According to the 2024 USPSTF recommendation, which women should be screened for osteoporosis?",
    "options": [
      "A) All women over 50",
      "B) Women 65+ and postmenopausal women <65 at increased fracture risk",
      "C) Only women with prior fractures",
      "D) All postmenopausal women regardless of age"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Women 65+ and postmenopausal women under 65 at increased fracture risk).\n\nPATHOPHYSIOLOGY:\nOsteoporosis is characterized by low bone mass and microarchitectural deterioration, increasing fracture susceptibility. Peak bone mass is achieved by age 30, determined primarily by genetics (60-80%), nutrition, activity, and hormones. After peak, BMD declines 0.5-1% per year. At menopause, estrogen withdrawal accelerates loss to 2-5% per year for 5-7 years by removing estrogen\'s inhibitory effect on osteoclast activity, explaining why women develop osteoporosis earlier and more frequently. By age 80, women lose approximately 40% of peak bone mass versus 25% for men. Hip fractures carry 20-30% one-year mortality, and up to 50% of survivors never regain pre-fracture function.\n\nCLINICAL REASONING:\nThe 2024 USPSTF recommendation (Grade B) specifies screening all women 65+ and postmenopausal women under 65 at increased risk using central DXA of the hip and lumbar spine. Risk tools (FRAX, OST, ORAI) identify younger postmenopausal women warranting screening. The USPSTF issued an I statement for men due to insufficient evidence. Key risk factors: low body weight (<127 lbs), personal/parental fracture history, smoking, excessive alcohol (3+ drinks/day), glucocorticoid use (5+ mg prednisone for 3+ months), rheumatoid arthritis, and secondary causes (hyperparathyroidism, hyperthyroidism, celiac disease, CKD).\n\nDIAGNOSIS AND TREATMENT:\nT-scores classify: normal (at or above -1.0), osteopenia (-1.0 to -2.5), osteoporosis (-2.5 or below) at lumbar spine, femoral neck, or total hip. Fragility fractures also diagnose osteoporosis regardless of BMD. FRAX treatment thresholds: 3% or greater hip fracture or 20% or greater major osteoporotic fracture probability.\n\nNon-pharmacologic: calcium 1,000-1,200 mg/day, vitamin D 800-1,000 IU/day, weight-bearing exercise, fall prevention. First-line: oral bisphosphonates (alendronate 70 mg weekly or risedronate 35 mg weekly), reducing vertebral fractures 40-70% and hip fractures 40-50%. Denosumab for bisphosphonate-intolerant patients or renal impairment. Anabolic agents (teriparatide, romosozumab) for very high fracture risk. Bisphosphonate duration typically 3-5 years with reassessment per ACP guidelines.\n\nKEY POINTS:\nThe 2024 USPSTF recommends DXA screening for women 65+ and at-risk postmenopausal women under 65 (Grade B); evidence for men is insufficient. Osteoporosis is defined by T-score of -2.5 or below, or fragility fracture. Bisphosphonates reduce vertebral fractures 40-70% and hip fractures 40-50%, with 3-5 year duration followed by reassessment."
  },
  {
    "id": 581,
    "categoryId": 4,
    "question": "According to current guidelines, what is the first-line treatment for obesity (BMI â‰¥30)?",
    "options": [
      "A) GLP-1 receptor agonist medication",
      "B) Comprehensive lifestyle intervention (diet, physical activity, behavioral therapy)",
      "C) Bariatric surgery referral",
      "D) Low-carbohydrate diet alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Comprehensive lifestyle intervention: diet, physical activity, behavioral therapy).\n\nPATHOPHYSIOLOGY:\nObesity is a chronic, multifactorial disease driven by genetic susceptibility (BMI heritability ~40-70%), neurohormonal dysregulation (leptin, ghrelin, melanocortin pathways), environmental factors, and epigenetic modifications\u2014recognized as a disease by AMA and WHO. Visceral adipose tissue secretes proinflammatory adipokines (TNF-alpha, IL-6) and reduces adiponectin, creating chronic inflammation that drives insulin resistance, endothelial dysfunction, and atherogenesis. Ectopic lipid deposition in liver, muscle, and pancreas compounds metabolic dysfunction. Clinically meaningful weight loss of 5-10% significantly improves glycemia, blood pressure, triglycerides, sleep apnea, and osteoarthritis per ACC/AHA/TOS 2013 guidelines.\n\nCLINICAL REASONING:\nComprehensive lifestyle intervention is first-line per AHA/ACC/TOS and Endocrine Society guidelines for adults with BMI \u226530. The three essential components are: dietary modification (500-750 kcal/day deficit; multiple patterns show equivalent efficacy with adherence including Mediterranean, DASH, low-carb), physical activity (\u2265150 min/week moderate-intensity; 200-300 min/week for weight maintenance), and behavioral strategies (self-monitoring, stimulus control, goal setting, cognitive restructuring). High-intensity programs (\u226514 sessions in 6 months) produce 5-8% weight loss, as demonstrated in the DPP and Look AHEAD trials.\n\nTREATMENT ESCALATION:\nWhen lifestyle alone is insufficient after 3-6 months, pharmacotherapy is offered for BMI \u226530, or BMI \u226527 with comorbidities. Semaglutide 2.4 mg weekly (Wegovy) produced 14.9% weight loss in STEP 1 (NEJM 2021), and SELECT (NEJM 2023) showed 20% MACE reduction in patients with obesity and ASCVD. Tirzepatide (dual GIP/GLP-1 agonist, Zepbound) achieved up to 22.5% weight loss in SURMOUNT-1 (NEJM 2022). Bariatric surgery is indicated for BMI \u226540, BMI \u226535 with comorbidities, or BMI \u226530 with poorly controlled T2DM, producing 20-35% durable weight loss.\n\nKEY POINTS:\nComprehensive lifestyle intervention (diet, activity, behavioral therapy) is first-line, with high-intensity programs producing 5-8% weight loss. Add GLP-1 RAs after 3-6 months if insufficient; semaglutide and tirzepatide produce 15-22.5% loss. Weight management medications require long-term continuation due to neurohormonal counter-regulatory mechanisms."
  },
  {
    "id": 582,
    "categoryId": 17,
    "question": "According to AAP guidelines, vision screening using instrument-based screening should begin at what age?",
    "options": [
      "A) 6 months",
      "B) 12 months",
      "C) 3 years",
      "D) 5 years"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (12 months).\n\nSCREENING RATIONALE:\nEarly detection of amblyopia and its risk factors (refractive errors, strabismus, media opacities) during the critical period of visual development is essential. The visual system undergoes rapid maturation from birth through approximately age 7-8 years, and untreated amblyopia beyond this window becomes increasingly resistant to correction.\n\nVISION SCREENING BY AGE (AAP Bright Futures / AAPOS):\n\n1. NEWBORN TO 12 MONTHS:\n - Red reflex testing at every well-child visit (detects cataracts, retinoblastoma, large refractive errors)\n - External inspection of eyes and lids\n - Pupil examination (size, reactivity, symmetry)\n - Assess for fixation and following behavior\n - Instrument-based screening (photoscreening, autorefractors) can begin at 12 months\n\n2. AGES 1-3 YEARS:\n - Instrument-based screening (photoscreening or autorefraction) at every well-child visit\n - Assess for strabismus (corneal light reflex, cover-uncover test)\n - Continue red reflex testing\n\n3. AGES 3-5 YEARS:\n - Visual acuity testing when the child can cooperate (Lea symbols, HOTV charts)\n - Instrument-based screening as alternative if acuity testing is not feasible\n - Critical period for amblyopia detection and treatment\n\n4. SCHOOL AGE AND BEYOND:\n - Visual acuity screening at periodic well-child visits\n - Refer if screening fails\n\nRED FLAGS AT ANY AGE:\n- Leukocoria (white pupillary reflex) - urgent referral\n- Persistent strabismus beyond 4 months of age\n- Nystagmus\n- Ptosis obscuring the visual axis\n\nKEY POINTS:\nInstrument-based vision screening should begin at 12 months. Red reflex testing is performed at every well-child visit from birth. Amblyopia treatment is most effective when initiated during the critical period (before age 7). Photoscreening devices allow objective screening in preverbal children.\n---"
  },
  {
    "id": 583,
    "categoryId": 4,
    "question": "According to CDC Medical Eligibility Criteria (MEC), which contraceptive method is Category 4 (unacceptable health risk) for a 38-year-old woman who smokes 20 cigarettes/day?",
    "options": [
      "A) Copper IUD",
      "B) Progestin-only pill",
      "C) Combined oral contraceptive",
      "D) Depot medroxyprogesterone acetate"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Combined oral contraceptive).\n\nPATHOPHYSIOLOGY:\nThe contraindication to combined hormonal contraceptives (CHCs) in women \u226535 who smoke reflects the synergistic interaction between exogenous estrogen and smoking on arterial thrombotic risk. Ethinyl estradiol increases hepatic synthesis of procoagulant factors (II, VII, VIII, X, fibrinogen) while reducing antithrombin III, protein S, and tissue factor pathway inhibitor, shifting hemostasis toward a prothrombotic state. Smoking independently promotes arterial thrombosis through endothelial damage, platelet activation, elevated fibrinogen, increased blood viscosity, and coronary vasospasm. Combined, the effects are synergistic: women >35 who smoke and use CHCs have approximately 10-20-fold increased MI risk per WHO Collaborative Study and Lancet meta-analyses.\n\nCLINICAL REASONING:\nThe CDC US Medical Eligibility Criteria (US MEC) classifies CHCs as Category 4 (absolute contraindication) for women \u226535 smoking \u226515 cigarettes/day, and Category 3 (relative contraindication) for \u226535 smoking <15/day. Many clinicians treat any smoking at \u226535 as a CHC contraindication given difficulty quantifying consumption. Other Category 4 conditions include current/prior VTE, thrombogenic mutations (Factor V Leiden, prothrombin G20210A), ischemic heart disease or stroke, migraine with aura at any age, current breast cancer, and decompensated cirrhosis.\n\nCLINICAL APPLICATION:\nProgestin-only methods are safe for smokers regardless of age, as progestins do not significantly affect coagulation or arterial thrombotic risk. All Category 1 options include: progestin-only pills, DMPA, subdermal implant, levonorgestrel IUD, and copper IUD. LARCs (IUDs and implants) combine the highest typical-use effectiveness (>99%) with excellent safety. Counsel the patient that CHCs pose unacceptable cardiovascular risk, offer progestin-only or non-hormonal alternatives, and promote smoking cessation, which would remove the CHC contraindication and provide significant independent health benefits.\n\nKEY POINTS:\nCHCs are Category 4 (absolute contraindication) for women \u226535 who smoke, due to synergistic arterial thrombotic risk producing 10-20-fold increased MI risk per CDC US MEC. All progestin-only methods (POP, DMPA, implant, LNG-IUD) and copper IUD are Category 1 (safe) for smokers. Smoking cessation removes the CHC contraindication."
  },
  {
    "id": 584,
    "categoryId": 16,
    "question": "According to CDC guidelines, which sexually active populations should receive routine screening for chlamydia?",
    "options": [
      "A) All sexually active women under 25",
      "B) Only women with multiple partners",
      "C) Only pregnant women",
      "D) All sexually active adults annually"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (All sexually active women under 25).\n\nGUIDELINE BASIS:\nThe CDC, USPSTF, and American College of Obstetricians and Gynecologists (ACOG) recommend annual chlamydia screening for all sexually active women under age 25, regardless of symptoms or perceived risk factors. This is a Grade A USPSTF recommendation (high certainty of substantial net benefit). For women aged 25 and older, screening is recommended only with risk factors such as a new sexual partner, multiple partners, a partner with an STI, or inconsistent condom use.\n\nEPIDEMIOLOGY:\nChlamydia trachomatis is the most commonly reported bacterial STI in the United States, with approximately 1.8 million cases reported annually (and an estimated 2.9 million actual infections given significant underdiagnosis). The highest prevalence is in sexually active women aged 15 to 24, affecting approximately 1 in 20 in this age group. Approximately 70 to 80% of chlamydia infections in women are asymptomatic, meaning screening is the only way to detect most cases.\n\nCOMPLICATIONS OF UNTREATED INFECTION:\nUntreated chlamydia can ascend from the cervix to cause pelvic inflammatory disease (PID) in 10 to 15% of infected women, leading to tubal scarring, chronic pelvic pain, ectopic pregnancy, and tubal factor infertility. Chlamydia during pregnancy increases risk of preterm delivery and neonatal conjunctivitis and pneumonia. Screening and treatment with single-dose azithromycin (1g) or doxycycline (100mg twice daily for 7 days, now preferred by CDC 2021 guidelines for superior efficacy) prevents these complications.\n\nKEY POINTS:\nAnnual chlamydia screening is recommended for all sexually active women under 25 (USPSTF Grade A) because 70 to 80% of infections are asymptomatic and prevalence peaks in this age group. Untreated chlamydia causes PID in 10 to 15%, leading to infertility and ectopic pregnancy. Doxycycline 100mg BID for 7 days is now the CDC-preferred treatment over single-dose azithromycin."
  },
  {
    "id": 585,
    "categoryId": 16,
    "question": "According to the Beers Criteria, which medication class should generally be AVOIDED in older adults due to anticholinergic effects and fall risk?",
    "options": [
      "A) ACE inhibitors",
      "B) First-generation antihistamines (diphenhydramine)",
      "C) Calcium channel blockers",
      "D) Thiazide diuretics"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (First-generation antihistamines such as diphenhydramine).\n\nBEERS CRITERIA:\nThe American Geriatrics Society (AGS) Beers Criteria is the most widely referenced list of potentially inappropriate medications (PIMs) for older adults aged 65 and older. First-generation antihistamines (diphenhydramine, hydroxyzine, chlorpheniramine, promethazine) are among the most strongly recommended medications to avoid because of their potent anticholinergic properties.\n\nANTICHOLINERGIC BURDEN:\nFirst-generation antihistamines cross the blood-brain barrier readily and block central muscarinic acetylcholine receptors, producing cognitive impairment, confusion, delirium, sedation, falls, urinary retention, constipation, dry mouth, blurred vision, and tachycardia. Older adults are particularly vulnerable to these effects because of age-related reductions in hepatic metabolism (decreased CYP enzyme activity), renal clearance, and cholinergic neurotransmitter reserves (baseline acetylcholine levels decline with aging). Cumulative anticholinergic exposure has been associated with increased risk of dementia in large prospective studies.\n\nCOMMON CLINICAL PITFALLS:\nDiphenhydramine (Benadryl) is frequently used as an over-the-counter sleep aid (marketed as Unisom, ZzzQuil, and Tylenol PM) by older adults, making it one of the most commonly used Beers-listed medications. Clinicians should specifically ask about OTC sleep aids and allergy medications during medication reconciliation. Safer alternatives for insomnia include cognitive behavioral therapy for insomnia (CBT-I, first-line), melatonin, and if needed, low-dose trazodone or suvorexant. Safer alternatives for allergies include second-generation antihistamines (cetirizine, loratadine, fexofenadine) that have minimal blood-brain barrier penetration.\n\nKEY POINTS:\nThe Beers Criteria strongly recommend avoiding first-generation antihistamines (diphenhydramine, hydroxyzine) in older adults due to potent central anticholinergic effects causing confusion, falls, delirium, and cumulative dementia risk. Diphenhydramine is commonly hidden in OTC sleep aids (ZzzQuil, Tylenol PM). Safer alternatives include second-generation antihistamines for allergies and CBT-I for insomnia."
  },
  {
    "id": 586,
    "categoryId": 5,
    "question": "A patient with T2DM and CKD Stage 3 (eGFR 45) has persistent albuminuria (UACR 350 mg/g) despite maximum dose ACE inhibitor. According to KDIGO 2024 guidelines, which medication should be added?",
    "options": [
      "A) Add ARB to ACE inhibitor",
      "B) Add SGLT2 inhibitor",
      "C) Switch to calcium channel blocker",
      "D) Add aldosterone antagonist only"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Add SGLT2 inhibitor).\n\nGUIDELINE BASIS:\nThe KDIGO 2024 guidelines recommend SGLT2 inhibitors (dapagliflozin, empagliflozin) as first-line add-on therapy for patients with CKD and persistent albuminuria (UACR greater than 200 mg/g) despite maximum-dose RAAS blockade, regardless of diabetes status. This recommendation represents a paradigm shift in nephroprotection based on landmark trials.\n\nEVIDENCE:\nThe DAPA-CKD trial demonstrated that dapagliflozin reduced the composite endpoint of sustained GFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% compared to placebo in CKD patients (with or without diabetes), leading to early trial termination due to overwhelming benefit. The CREDENCE trial showed that canagliflozin reduced the risk of kidney failure by 30% in patients with type 2 diabetes and CKD. The EMPA-KIDNEY trial confirmed these findings with empagliflozin across a broader CKD population.\n\nMECHANISM:\nSGLT2 inhibitors reduce proximal tubular sodium and glucose reabsorption, increasing sodium delivery to the macula densa. This activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular pressure (the same protective hemodynamic effect as RAAS blockade, but through a complementary mechanism). Additional renoprotective mechanisms include reduced tubular workload and oxygen consumption, decreased inflammation, reduced fibrosis, and improved tubular energy metabolism through ketone utilization.\n\nFOUR PILLARS OF CKD CARE:\nThe KDIGO guidelines now describe the \"four pillars\" of evidence-based CKD management: RAAS blockade (ACE inhibitor or ARB, maximally tolerated dose), SGLT2 inhibitor (added for persistent albuminuria), finerenone (a nonsteroidal mineralocorticoid receptor antagonist for diabetic kidney disease with persistent albuminuria on RAAS blockade plus SGLT2i), and GLP-1 receptor agonist (for diabetic CKD patients needing additional glycemic and cardiovascular benefit).\n\nKEY POINTS:\nSGLT2 inhibitors (dapagliflozin, empagliflozin) are KDIGO-recommended as first add-on therapy for CKD with persistent albuminuria on maximum RAAS blockade, reducing kidney failure by 30 to 39% via tubuloglomerular feedback-mediated afferent arteriolar constriction. The four pillars of CKD care are RAAS blockade, SGLT2 inhibitor, finerenone, and GLP-1 agonist."
  },
  {
    "id": 587,
    "categoryId": 3,
    "question": "A 55-year-old man with chronic GERD asks about long-term PPI use. According to current evidence, which is a documented risk of prolonged PPI therapy?",
    "options": [
      "A) Increased risk of C. difficile infection",
      "B) Hepatotoxicity",
      "C) QT prolongation",
      "D) Pancreatitis"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Increased risk of C. difficile infection).\n\nPATHOPHYSIOLOGY:\nProton pump inhibitors raise intragastric pH from its normal range of 1-2 to above 4, effectively neutralizing the gastric acid barrier that normally serves as a first-line defense against ingested pathogens. Clostridioides difficile spores are acid-resistant, but the vegetative (active, toxin-producing) form is susceptible to gastric acid. By raising gastric pH, PPIs allow greater survival and passage of both vegetative C. difficile organisms and other enteric pathogens into the lower gastrointestinal tract. Multiple meta-analyses have demonstrated a 1.5 to 2.7-fold increased risk of C. difficile infection with PPI use.\n\nOTHER DOCUMENTED PPI RISKS:\nAdditional risks supported by moderate evidence include community-acquired pneumonia (due to bacterial overgrowth in the achlorhydric stomach with subsequent micro-aspiration), hypomagnesemia (which can be refractory to supplementation and cause cardiac arrhythmias), vitamin B12 deficiency (from impaired cleavage of protein-bound B12), calcium malabsorption with increased fracture risk (particularly hip fractures in postmenopausal women after more than one year of use), and increased risk of chronic kidney disease with long-term use. An association with dementia and gastric cancer has been suggested in observational studies but remains controversial and unconfirmed.\n\nCLINICAL IMPLICATIONS:\nThe FDA has issued safety communications regarding several of these risks. Current guidelines recommend prescribing PPIs at the lowest effective dose for the shortest duration necessary. Patients requiring long-term PPI therapy (Barrett's esophagus, severe erosive esophagitis, Zollinger-Ellison syndrome) should have their indication periodically reassessed, magnesium levels monitored, and bone density evaluated when additional osteoporosis risk factors are present. Step-down to H2 receptor antagonists should be attempted when appropriate.\n\nKEY POINTS:\nPPI use increases C. difficile infection risk 1.5 to 2.7-fold by raising gastric pH and eliminating the acid barrier to ingested pathogens. Other documented risks include pneumonia, hypomagnesemia, B12 deficiency, calcium malabsorption with fractures, and chronic kidney disease. PPIs should be prescribed at the lowest effective dose for the shortest duration. Long-term users require periodic reassessment and monitoring."
  },
  {
    "id": 588,
    "categoryId": 13,
    "question": "A patient with gout has a serum uric acid of 8.5 mg/dL and 3 flares in the past year. According to ACR guidelines, what is the target serum uric acid for urate-lowering therapy?",
    "options": [
      "A) < 8.0 mg/dL",
      "B) < 7.0 mg/dL",
      "C) < 6.0 mg/dL",
      "D) < 5.0 mg/dL"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (< 6.0 mg/dL).\n\nPATHOPHYSIOLOGY:\nGout results from deposition of monosodium urate crystals when serum uric acid exceeds its saturation point, approximately 6.8 mg/dL at physiologic temperature and pH. Crystal deposition triggers intense inflammation mediated by IL-1Î². The goal of urate-lowering therapy (ULT) is to reduce serum uric acid below its saturation point, allowing dissolution of existing crystal deposits and preventing new deposition and flares.\n\nTARGET URIC ACID LEVEL:\nCurrent guidelines recommend targeting serum uric acid below 6.0 mg/dL for most patients on urate-lowering therapy. This threshold provides a margin below the saturation point (6.8 mg/dL), accounting for variations in temperature, pH, and measurement. For patients with tophi or severe disease, a more aggressive target of <5.0 mg/dL may be appropriate to accelerate tophus resolution. The target should be maintained indefinitely, as discontinuing ULT leads to uric acid rebound and recurrent flares.\n\nACHIEVING TARGET:\nAllopurinol is first-line ULT. Start low (100mg daily, 50mg in CKD) and titrate by 100mg increments every 2-4 weeks until target uric acid is achieved. Many patients require 300-800mg daily; do not stop titrating at arbitrary dose limits if target is not met. Febuxostat is an alternative for allopurinol-intolerant patients. Probenecid (uricosuric) is an option for patients who are uric acid underexcreters with normal renal function.\n\nKEY POINTS:\nTarget serum uric acid is <6.0 mg/dL (or <5.0 mg/dL if tophi present). This target is below the saturation point of 6.8 mg/dL, promoting crystal dissolution. Titrate allopurinol to achieve target, not to a fixed dose."
  },
  {
    "id": 589,
    "categoryId": 8,
    "question": "A 35-year-old returning from Southeast Asia presents with 2 weeks of fever, dry cough, and night sweats. Chest X-ray shows upper lobe infiltrates with cavitation. PPD is 18mm. What is the most appropriate initial step?",
    "options": [
      "A) Start 4-drug RIPE therapy immediately",
      "B) Obtain 3 sputum samples for AFB smear and culture",
      "C) Start Isoniazid monotherapy",
      "D) Obtain CT chest with contrast"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Obtain 3 sputum samples for AFB smear and culture).\n\nPATHOPHYSIOLOGY:\nMycobacterium tuberculosis is an aerobic, acid-fast bacillus transmitted via airborne droplet nuclei. Following inhalation, the organism is phagocytosed by alveolar macrophages but resists intracellular killing due to its mycolic acid-rich cell wall. In immunocompetent hosts, T-cell-mediated granuloma formation typically contains the infection (latent TB). Active pulmonary TB develops when host immunity is overwhelmed, particularly in the upper lobes where higher oxygen tension favors mycobacterial growth. Cavitary disease, as seen in this patient, indicates high mycobacterial burden and increased infectivity.\n\nCLINICAL PRESENTATION:\nThis patientâ€™s presentation is classic for pulmonary tuberculosis: prolonged fever, night sweats, dry cough, travel to a TB-endemic region (Southeast Asia), upper lobe infiltrates with cavitation on chest X-ray, and a strongly positive PPD (â‰¥10mm is positive for individuals from endemic areas). The differential diagnosis for cavitary lung lesions includes lung abscess, malignancy, and endemic fungal infections, but the clinical picture strongly favors TB.\n\nDIAGNOSIS:\nObtaining microbiologic confirmation before starting treatment is critical. Three sputum samples collected on separate occasions maximize diagnostic sensitivity (single-sample sensitivity for AFB smear is only 50-60%). AFB smear results, available within 24 hours, guide infection control decisions. Culture enables drug susceptibility testing, which is essential given rising global rates of multidrug-resistant TB. Nucleic acid amplification testing (e.g., GeneXpert MTB/RIF) provides rapid confirmation and simultaneous rifampin resistance detection.\n\nTREATMENT:\nEmpiric 4-drug RIPE therapy (Rifampin, Isoniazid, Pyrazinamide, Ethambutol) should be initiated after sputum collection when clinical suspicion is high. The intensive phase lasts 2 months, followed by a continuation phase of isoniazid and rifampin for 4 months. Patients must be placed in airborne isolation (negative pressure room with N95 respirators for healthcare workers) until three consecutive negative AFB smears or clinical improvement on therapy.\n\nKEY POINTS:\nAlways obtain 3 sputum samples for AFB smear and culture before initiating TB treatment. Culture enables drug susceptibility testing, which is essential for directing therapy. Empiric RIPE therapy starts after sputum collection in high-suspicion cases. Airborne isolation is mandatory until infectivity is excluded.\n---"
  },
  {
    "id": 590,
    "categoryId": 8,
    "question": "A healthy 28-year-old woman presents with 1 day of dysuria and urinary frequency. She is afebrile with no flank pain. Urinalysis shows pyuria and bacteriuria. Per IDSA guidelines, what is the preferred empiric treatment?",
    "options": [
      "A) Ciprofloxacin 500mg BID x 3 days",
      "B) Nitrofurantoin 100mg BID x 5 days",
      "C) Amoxicillin-clavulanate 875mg BID x 7 days",
      "D) TMP-SMX DS BID x 3 days"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Nitrofurantoin 100mg BID x 5 days).\n\nPATHOPHYSIOLOGY:\nUncomplicated cystitis is a lower urinary tract infection occurring in non-pregnant, premenopausal women without urologic abnormalities. Escherichia coli accounts for approximately 75-95% of cases, with Staphylococcus saprophyticus, Klebsiella, and Proteus comprising most of the remainder. Uropathogens from the fecal flora colonize the periurethral area and ascend via the urethra. The short female urethra and proximity to the anus explain the much higher incidence in women compared to men.\n\nCLINICAL PRESENTATION:\nDysuria, urinary frequency, and urgency in a young, healthy, afebrile woman without vaginal symptoms have a positive predictive value exceeding 90% for cystitis. Urine culture is not required for diagnosis of uncomplicated cystitis but should be obtained when the presentation is atypical, when pyelonephritis is suspected (fever, flank pain, CVA tenderness), or in cases of recurrent infection.\n\nTREATMENT:\nThe IDSA 2010 guidelines recommend the following first-line agents for uncomplicated cystitis: nitrofurantoin monohydrate/macrocrystals 100mg BID for 5 days, trimethoprim-sulfamethoxazole (TMP-SMX) 160/800mg BID for 3 days (if local E. coli resistance is below 20%), or fosfomycin 3g as a single dose. Fluoroquinolones should be avoided for uncomplicated cystitis due to FDA black box warnings for serious adverse effects (tendinopathy, aortic dissection, neuropathy) and the need to preserve this antibiotic class for more serious infections. Nitrofurantoin achieves therapeutic concentrations only in urine, making it effective for cystitis but inappropriate for pyelonephritis or systemic infections.\n\nKEY POINTS:\nNitrofurantoin and TMP-SMX are first-line for uncomplicated cystitis. Fluoroquinolones should be reserved for complicated UTIs due to FDA safety concerns. Nitrofurantoin is effective only in the lower urinary tract and cannot treat pyelonephritis.\n---"
  },
  {
    "id": 591,
    "categoryId": 8,
    "question": "A 45-year-old male with HIV (CD4 count 85) presents with headache, fever, and confusion over 2 weeks. CSF shows elevated opening pressure, lymphocytic pleocytosis, low glucose, and positive India ink stain. What is the treatment of choice?",
    "options": [
      "A) Fluconazole 400mg daily",
      "B) Amphotericin B + Flucytosine induction, then Fluconazole",
      "C) Voriconazole",
      "D) Caspofungin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amphotericin B + Flucytosine induction, then Fluconazole).\n\nPATHOPHYSIOLOGY:\nCryptococcus neoformans is an encapsulated yeast found in soil contaminated with bird (especially pigeon) droppings. Inhalation leads to pulmonary infection, which in immunocompetent hosts is usually contained. In patients with advanced HIV (CD4 <100), the organism disseminates hematogenously to the central nervous system, where its polysaccharide capsule inhibits phagocytosis and allows uncontrolled replication. Cryptococcal meningitis is a common cause of meningitis in AIDS patients.\n\nCLINICAL PRESENTATION:\nUnlike bacterial meningitis, cryptococcal meningitis has an indolent, subacute presentation developing over days to weeks. Headache is the predominant symptom, often severe. Fever, altered mental status, and neck stiffness may be present but are less pronounced than in bacterial meningitis. Elevated intracranial pressure is common and is the major cause of early mortality; papilledema or cranial nerve palsies suggest dangerously elevated ICP.\n\nDIAGNOSIS:\nLumbar puncture typically shows elevated opening pressure (often >25 cm H2O), lymphocytic pleocytosis, elevated protein, and low glucose. India ink preparation reveals encapsulated yeast in 70-90% of HIV-associated cases. Cryptococcal antigen in CSF and serum is highly sensitive and specific and should be obtained when clinical suspicion exists.\n\nTREATMENT:\nInduction therapy for 2 weeks consists of amphotericin B deoxycholate plus flucytosine; this combination is superior to amphotericin alone. Consolidation therapy with fluconazole 400-800mg daily follows for 8 weeks. Maintenance therapy with fluconazole 200mg daily continues until immune reconstitution (CD4 >100 for â‰¥1 year with undetectable viral load). Serial lumbar punctures are critical to manage elevated ICP.\n\nKEY POINTS:\nCryptococcal meningitis presents subacutely with headache in AIDS patients with CD4 <100. India ink and cryptococcal antigen confirm diagnosis. Induction requires amphotericin B plus flucytosine, not fluconazole alone. Elevated ICP management with serial LPs is critical for survival."
  },
  {
    "id": 592,
    "categoryId": 17,
    "question": "A 60-year-old diabetic presents with severe ear pain, granulation tissue in the ear canal, and CN VII palsy. CT shows skull base erosion. What is the most likely pathogen?",
    "options": [
      "A) Staphylococcus aureus",
      "B) Pseudomonas aeruginosa",
      "C) Aspergillus",
      "D) Mucor"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pseudomonas aeruginosa).\n\nPATHOPHYSIOLOGY:\nMalignant (necrotizing) otitis externa is an aggressive, invasive infection that extends from the external auditory canal into the temporal bone and skull base. Pseudomonas aeruginosa is the causative organism in over 95% of cases. The infection begins as severe otitis externa, then spreads through the fissures of Santorini and the osseocartilaginous junction at the floor of the ear canal into the periosteum and bone. Progressive osteomyelitis of the temporal bone can extend to involve the skull base, petrous apex, and contralateral side.\n\nRISK FACTORS:\n- Diabetes mellitus (most common predisposing condition, present in 90% of cases)\n- Immunocompromised states (HIV/AIDS, chemotherapy, transplant recipients)\n- Elderly patients\n- Microangiopathy and impaired immune function in diabetics create a favorable environment for Pseudomonas invasion\n\nCLINICAL PRESENTATION:\n- Severe, deep ear pain disproportionate to examination findings, often worse at night\n- Purulent otorrhea refractory to topical antibiotic therapy\n- Granulation tissue at the osseocartilaginous junction of the ear canal (classic finding)\n- Cranial nerve palsies: CN VII (facial nerve) is affected first and most commonly; CN IX, X, XI, XII involvement indicates progressive skull base disease\n- CT temporal bone shows bony erosion; technetium-99m bone scan or gallium-67 scan assesses disease extent\n\nTREATMENT:\n1. Prolonged IV anti-pseudomonal antibiotics for 6-8 weeks minimum:\n - Ciprofloxacin (oral, if susceptible) or IV anti-pseudomonal beta-lactam (piperacillin-tazobactam, cefepime)\n - Culture-directed therapy is essential\n2. Strict glycemic control\n3. Surgical debridement for refractory cases or abscess formation\n4. Serial inflammatory markers (ESR, CRP) and imaging to monitor treatment response\n\nKEY POINTS:\nMalignant otitis externa results from Pseudomonas aeruginosa in diabetic or immunocompromised patients. Granulation tissue in the ear canal and disproportionate pain are hallmarks. Facial nerve palsy (CN VII) is the most common cranial nerve complication. Treatment requires prolonged anti-pseudomonal therapy for a minimum of 6 weeks.\n---"
  },
  {
    "id": 593,
    "categoryId": 8,
    "question": "A healthcare worker has a needlestick injury from an HIV-positive patient. She presents within 2 hours. According to CDC guidelines, when should post-exposure prophylaxis (PEP) be initiated?",
    "options": [
      "A) Within 72 hours, ideally within 2 hours",
      "B) Within 7 days",
      "C) Only if source has detectable viral load",
      "D) Only after baseline HIV testing confirms negative status"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Within 72 hours, ideally within 2 hours).\n\nPATHOPHYSIOLOGY:\nFollowing a percutaneous needlestick injury from an HIV-positive source, the virus must establish local infection in dendritic cells and CD4+ T lymphocytes before disseminating to regional lymph nodes and eventually establishing systemic infection with integration into the host genome. This brief window between inoculation and systemic dissemination represents the opportunity for post-exposure prophylaxis (PEP) to prevent infection. The average risk of HIV transmission from a percutaneous needlestick with HIV-infected blood is approximately 0.3% (1 in 300), though this varies with the source patientâ€™s viral load, depth of injury, device type, and presence of visible blood.\n\nCLINICAL REASONING:\nCDC guidelines recommend initiating PEP as soon as possible, ideally within 2 hours of exposure. The 72-hour window represents the outer limit of potential efficacy; beyond this timeframe, viral integration has likely occurred and PEP is not recommended. Animal studies demonstrate that efficacy declines dramatically with each hour of delay. Emergency departments should maintain PEP starter packs for immediate initiation without waiting for source patient confirmatory testing or specialist consultation.\n\nTREATMENT:\nThe preferred PEP regimen is a 3-drug combination of tenofovir disoproxil fumarate/emtricitabine (Truvada) plus either raltegravir or dolutegravir, continued for 28 days. Baseline HIV testing of the exposed worker documents seronegative status but must not delay PEP initiation. Follow-up HIV testing is performed at 6 weeks, 12 weeks, and 6 months post-exposure. Higher-risk exposures (deep injury, visible blood on device, hollow-bore needle, source with high viral load) warrant PEP without hesitation.\n\nKEY POINTS:\nPEP must be initiated within 72 hours, ideally within 2 hours of HIV exposure. Do not delay PEP for baseline testing or specialist consultation. The standard regimen is a 28-day, 3-drug antiretroviral combination. Percutaneous HIV transmission risk is approximately 0.3%.\n---"
  },
  {
    "id": 594,
    "categoryId": 8,
    "question": "A 55-year-old man from the Ohio River Valley presents with fever, cough, and hilar lymphadenopathy. He recently cleaned an old barn. Urine antigen test is positive. What is the diagnosis?",
    "options": [
      "A) Blastomycosis",
      "B) Histoplasmosis",
      "C) Coccidioidomycosis",
      "D) Tuberculosis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Histoplasmosis).\n\nPATHOPHYSIOLOGY:\nHistoplasma capsulatum is a dimorphic fungus endemic to the Ohio and Mississippi River Valleys. It thrives in soil enriched by bird or bat droppings, and inhalation of microconidia during activities that disturb contaminated soil (demolition of old buildings, exploring caves, cleaning chicken coops) leads to pulmonary infection. At body temperature, the organism converts to its pathogenic yeast form and is phagocytosed by alveolar macrophages, within which it survives, replicates, and disseminates via the reticuloendothelial system.\n\nCLINICAL PRESENTATION:\nApproximately 90% of infections are asymptomatic or produce a mild, self-limited flu-like illness. Acute pulmonary histoplasmosis presents with fever, cough, chest pain, and malaise 1-3 weeks after exposure. Chest imaging characteristically demonstrates hilar and mediastinal lymphadenopathy, sometimes with pulmonary infiltrates â€” captured by the mnemonic \"histo hits the hilum.\" Chronic cavitary histoplasmosis mimics pulmonary tuberculosis in patients with underlying emphysema. Progressive disseminated histoplasmosis occurs in immunocompromised patients (especially advanced HIV) and presents with fever, weight loss, hepatosplenomegaly, and pancytopenia.\n\nDIAGNOSIS:\nUrine and serum Histoplasma antigen testing offers high sensitivity for acute and disseminated disease and is the preferred rapid diagnostic test. Serology (complement fixation, immunodiffusion) supports diagnosis but may be negative early or in immunocompromised patients. Fungal culture and histopathology revealing small intracellular yeast (2-4 Î¼m) within macrophages are definitive.\n\nTREATMENT:\nMild acute pulmonary disease typically resolves spontaneously within 4 weeks and requires only observation. Moderate-to-severe pulmonary disease warrants itraconazole for 6-12 weeks. Severe pulmonary or disseminated disease requires induction with amphotericin B followed by consolidation with itraconazole for at least 12 months.\n\nKEY POINTS:\nHistoplasmosis is endemic to the Ohio and Mississippi River Valleys, transmitted via bird or bat droppings. \"Histo hits the hilum\" describes the characteristic hilar lymphadenopathy. Most cases are self-limited; severe or disseminated disease requires amphotericin B followed by itraconazole.\n---"
  },
  {
    "id": 595,
    "categoryId": 8,
    "question": "A 70-year-old nursing home resident with recent antibiotic use presents with watery diarrhea (10 episodes/day), abdominal pain, and WBC 22,000. Stool PCR is positive for C. difficile. Creatinine is 1.8 (baseline 1.0). What is the recommended treatment?",
    "options": [
      "A) Oral Metronidazole 500mg TID x 10 days",
      "B) Oral Vancomycin 125mg QID x 10 days",
      "C) Oral Fidaxomicin 200mg BID x 10 days",
      "D) IV Vancomycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral Vancomycin 125mg QID x 10 days).\n\nPATHOPHYSIOLOGY:\nClostridioides difficile is a spore-forming, gram-positive anaerobic bacillus that colonizes the colon when the normal gut microbiome is disrupted, most commonly by antibiotic exposure. The highest-risk antibiotics are clindamycin, fluoroquinolones, and broad-spectrum cephalosporins. C. difficile produces toxin A (enterotoxin) and toxin B (cytotoxin), which bind to colonocyte receptors, disrupt tight junctions, trigger intense neutrophilic inflammation, and cause the formation of pseudomembranes composed of fibrin, mucus, and inflammatory debris.\n\nCLINICAL PRESENTATION:\nPatients typically present with watery, nonbloody diarrhea (often >10 episodes per day), crampy abdominal pain, fever, and leukocytosis. Risk factors include recent antibiotic use, age over 65, hospitalization or nursing home residence, and proton pump inhibitor use. Severity is classified by the IDSA/SHEA 2021 guidelines: non-severe (WBC â‰¤15,000 and creatinine <1.5x baseline), severe (WBC >15,000 or creatinine â‰¥1.5x baseline), and fulminant (hypotension, shock, ileus, or megacolon).\n\nTREATMENT:\nFor non-severe initial episodes, fidaxomicin is now preferred over vancomycin due to lower recurrence rates, though oral vancomycin remains acceptable. For severe disease, as in this patient (WBC >15,000), oral vancomycin 125mg four times daily for 10 days remains an accepted regimen, though the 2021 IDSA/SHEA update now prefers fidaxomicin for all initial CDI episodes regardless of severity due to lower recurrence rates. For fulminant disease, oral vancomycin is combined with IV metronidazole, and rectal vancomycin enemas should be considered if ileus is present. IV vancomycin does not reach the colonic lumen and is ineffective for C. difficile infection. Metronidazole is no longer recommended as first-line monotherapy due to inferior efficacy.\n\nKEY POINTS:\nSevere C. difficile (WBC >15,000 or creatinine â‰¥1.5x baseline) requires oral vancomycin. IV vancomycin does not reach the colon and is ineffective. Fidaxomicin is now preferred for non-severe initial episodes. Metronidazole is no longer first-line monotherapy.\n---"
  },
  {
    "id": 596,
    "categoryId": 8,
    "question": "A 25-year-old sexually active woman presents with mucopurulent cervical discharge. NAAT is positive for Chlamydia trachomatis. Per CDC 2021 guidelines, what is the recommended treatment?",
    "options": [
      "A) Azithromycin 1g PO x 1 dose",
      "B) Doxycycline 100mg PO BID x 7 days",
      "C) Ceftriaxone 500mg IM x 1",
      "D) Levofloxacin 500mg PO daily x 7 days"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Doxycycline 100mg BID x 7 days).\n\nPATHOPHYSIOLOGY:\nChlamydia trachomatis (serovars D-K) is an obligate intracellular bacterium and the most common bacterial sexually transmitted infection in the United States. The organism infects columnar epithelial cells of the cervix, urethra, rectum, and pharynx, undergoing a unique developmental cycle alternating between the infectious elementary body and the replicative reticulate body. The host inflammatory response causes mucosal damage, which, if untreated, can lead to ascending infection and scarring.\n\nCLINICAL PRESENTATION:\nUp to 70% of women and 50% of men with chlamydial infection are asymptomatic. When symptomatic, women typically present with mucopurulent cervical discharge, postcoital bleeding, or dysuria. Untreated infection can ascend to cause pelvic inflammatory disease (PID), which may result in tubal scarring, ectopic pregnancy, and infertility. In men, urethritis and epididymitis are the primary complications. Reactive arthritis (formerly Reiter syndrome) is an uncommon but important sequela.\n\nTREATMENT:\nThe CDC 2021 STI Treatment Guidelines now recommend doxycycline 100mg twice daily for 7 days as the preferred treatment for uncomplicated chlamydia, based on superior efficacy data, particularly for rectal infections where azithromycin cure rates are significantly lower. Azithromycin 1g as a single dose remains an alternative when adherence is a concern. In pregnancy, azithromycin is the treatment of choice because doxycycline is contraindicated. Test of cure is not routinely needed except in pregnancy; retesting at 3 months is recommended due to high reinfection rates. All sexual partners from the preceding 60 days should be treated.\n\nKEY POINTS:\nDoxycycline 100mg BID for 7 days is now preferred over azithromycin for uncomplicated chlamydia. Azithromycin remains the preferred agent in pregnancy. Retest at 3 months for reinfection. Treat all recent sexual partners.\n---"
  },
  {
    "id": 597,
    "categoryId": 8,
    "question": "A 50-year-old hunter in the Northeast US presents with fever, headache, and a targetoid rash on his thigh. He removed an attached tick 1 week ago. What is the treatment for early Lyme disease?",
    "options": [
      "A) Doxycycline 100mg BID x 10-14 days",
      "B) Amoxicillin 500mg TID x 14-21 days",
      "C) Ceftriaxone 2g IV daily x 14 days",
      "D) Azithromycin 500mg daily x 5 days"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Doxycycline 100mg BID x 10-14 days).\n\nPATHOPHYSIOLOGY:\nLyme disease results from the spirochete Borrelia burgdorferi, transmitted through the bite of infected Ixodes (blacklegged or deer) ticks. The tick must be attached for at least 36-48 hours to transmit the organism, as the spirochete requires time to migrate from the tick midgut to salivary glands. Endemic areas include the Northeast (Maine to Virginia), Upper Midwest (Minnesota, Wisconsin), and Pacific coast. After inoculation into the skin, the spirochete disseminates through the bloodstream and lymphatics to joints, the heart, and the nervous system.\n\nCLINICAL PRESENTATION:\nErythema migrans (EM) is the key sign of early localized Lyme disease, appearing 3-30 days after the tick bite. The classic \"bullâ€™s-eye\" or target lesion with central clearing is present in only about 20% of cases; more commonly, EM appears as a uniformly erythematous, expanding patch that must reach at least 5 cm. Systemic symptoms including fatigue, myalgias, arthralgias, headache, and fever often accompany the rash. Disseminated Lyme (Stage 2) can cause multiple EM lesions, facial nerve palsy, meningitis, or cardiac conduction abnormalities (Lyme carditis with AV block). Late Lyme (Stage 3) typically manifests as migratory oligoarticular arthritis, especially of the knee.\n\nDIAGNOSIS AND TREATMENT:\nEarly localized Lyme disease with EM is a clinical diagnosis; serologic testing is often negative in the first weeks and should not delay treatment. Doxycycline 100mg BID for 10-14 days is first-line and also covers potential co-infections (Anaplasma, Ehrlichia) from the same tick bite. Alternatives for children under 8 or pregnant women include amoxicillin or cefuroxime for 14-21 days. Azithromycin is not recommended due to inferior efficacy.\n\nKEY POINTS:\nErythema migrans is a clinical diagnosis; do not delay treatment for serologic confirmation. Doxycycline 100mg BID for 10-14 days is first-line. Classic bullâ€™s-eye appearance occurs in only 20% of cases. Azithromycin is not recommended for Lyme disease.\n---"
  },
  {
    "id": 598,
    "categoryId": 8,
    "question": "A 40-year-old male with well-controlled HIV (CD4 500, undetectable viral load) asks about vaccinations. Which live vaccine may be given if CD4 is â‰¥200?",
    "options": [
      "A) Live attenuated influenza (nasal spray)",
      "B) BCG",
      "C) MMR",
      "D) Oral polio"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (MMR may be given if CD4 â‰¥200).\n\nPATHOPHYSIOLOGY:\nHIV infection progressively depletes CD4+ T lymphocytes, impairing cell-mediated immunity and increasing susceptibility to opportunistic infections and vaccine-preventable diseases. The CD4 count serves as a practical marker of immune competence: patients with CD4 counts below 200 cells/Î¼L have severely impaired cellular immunity and cannot safely control replicating organisms in live attenuated vaccines, while those with higher counts can mount adequate immune responses to contain attenuated vaccine viruses.\n\nCLINICAL REASONING:\nVaccination decisions in HIV-infected individuals must balance the need for infection prevention against the risk of vaccine-associated disease from live attenuated vaccines. Inactivated vaccines are safe at any CD4 count and should be given routinely: influenza (inactivated only), pneumococcal (PCV20 or PCV15 followed by PPSV23), hepatitis A and B, Tdap/Td, recombinant zoster (Shingrix), HPV, and COVID-19 vaccines. Vaccine response rates are lower in patients with suppressed CD4 counts, so vaccination is optimally administered after immune reconstitution on antiretroviral therapy when feasible.\n\nLIVE VACCINES IN HIV:\nMMR and varicella vaccines may be administered to HIV patients with CD4 counts â‰¥200 cells/Î¼L who lack evidence of immunity, as these patients can mount sufficient cellular immune responses to control the attenuated viruses. This is clinically important because measles and varicella cause severe, potentially fatal disease in immunocompromised hosts. If CD4 count is below 200, live vaccines must be deferred until immune reconstitution. Live attenuated influenza vaccine (LAIV), BCG, oral polio vaccine, and live oral typhoid vaccine are contraindicated regardless of CD4 count.\n\nKEY POINTS:\nMMR and varicella vaccines may be given to HIV patients with CD4 â‰¥200 but are contraindicated if CD4 <200. All inactivated vaccines are safe regardless of CD4 count. LAIV, BCG, oral polio, and live typhoid are always contraindicated in HIV-infected patients.\n---"
  },
  {
    "id": 599,
    "categoryId": 10,
    "question": "A 35-year-old woman presents with symmetric, silvery, scaly plaques on her elbows and knees with nail pitting. What is the first-line treatment for limited plaque psoriasis (<5% BSA)?",
    "questionImages": [
      {
        "src": "assets/plaque-psoriasis-question.png",
        "alt": "Plaque psoriasis on the elbow with silvery scale",
        "caption": "Question image: classic plaque psoriasis on an extensor surface."
      }
    ],
    "options": [
      "A) Oral Methotrexate",
      "B) Topical corticosteroids + Vitamin D analogs",
      "C) Phototherapy (UVB)",
      "D) Biologics (TNF inhibitors)"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Topical corticosteroids + Vitamin D analogs).\n\nPATHOPHYSIOLOGY:\nPsoriasis is a chronic immune-mediated disease driven by Th1 and Th17 pathways. Environmental triggers (infection, stress, medications such as lithium or beta-blockers, trauma via Koebner phenomenon) activate dendritic cells to release IL-12 and IL-23, stimulating Th17 cells to produce TNF-alpha, IL-17, and IL-22. This creates a self-amplifying inflammatory loop that accelerates keratinocyte turnover from the normal 28 days to 3-4 days, producing characteristic thickened erythematous plaques with silvery scale. Dilated dermal capillaries produce the erythematous base; the Auspitz sign (pinpoint bleeding upon scale removal) results from disruption of these vessels.\n\nCLINICAL PRESENTATION:\nPlaque psoriasis (~80-90% of cases) presents with well-demarcated, symmetric erythematous plaques with silvery-white scale on extensor surfaces (elbows, knees), scalp, lower back, and gluteal cleft. Nail involvement (~50%) includes pitting (most common), onycholysis, oil-drop discoloration, and subungual hyperkeratosis. Nail disease strongly correlates with psoriatic arthritis development.\n\nTREATMENT APPROACH:\nPer AAD/National Psoriasis Foundation guidelines, for limited plaque psoriasis (<5% BSA), first-line therapy is topical corticosteroids combined with vitamin D analogs (calcipotriene). The combination is synergistic: corticosteroids suppress inflammation while calcipotriene inhibits keratinocyte proliferation via vitamin D receptor-mediated gene transcription. Fixed-combination calcipotriene-betamethasone formulations improve adherence. Topical calcineurin inhibitors are useful for facial/intertriginous areas where steroid atrophy is a concern. For moderate-to-severe disease (>5-10% BSA), phototherapy (narrowband UVB), conventional systemics (methotrexate, cyclosporine, acitretin, apremilast), or biologics are indicated.\n\nCOMORBIDITY SCREENING:\nPsoriatic arthritis develops in ~30% and should be screened at every visit (morning stiffness, joint pain, enthesitis). Moderate-to-severe psoriasis confers 50% increased cardiovascular risk; screen for metabolic syndrome, diabetes, and dyslipidemia. Depression affects up to 30% and should be assessed routinely.\n\nKEY POINTS:\nTopical corticosteroids plus vitamin D analogs are first-line for limited plaque psoriasis (<5% BSA) per AAD guidelines. Psoriasis results from Th17-driven immune dysregulation accelerating keratinocyte turnover from 28 days to 3-4 days. Nail pitting in ~50% correlates with psoriatic arthritis risk. Screen all patients for psoriatic arthritis, cardiovascular disease, and depression."
  },
  {
    "id": 600,
    "categoryId": 10,
    "question": "A mother brings her 8-year-old with an itchy, coin-shaped, weeping lesion on the leg with a well-defined border and tiny vesicles. KOH prep is negative. What is the diagnosis?",
    "options": [
      "A) Tinea corporis",
      "B) Nummular eczema",
      "C) Psoriasis",
      "D) Contact dermatitis"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/discoid-eczema-dermnet.png",
        "alt": "Discoid eczema lesions over time showing coin-shaped plaques",
        "caption": "Discoid eczema progression with coin-shaped eczematous plaques over several days."
      }
    ],
    "explanation": "CORRECT: B (Nummular eczema).\n\nPATHOPHYSIOLOGY:\nNummular eczema (discoid eczema) is a chronic inflammatory condition with coin-shaped (nummular) plaques resulting from epidermal barrier dysfunction and immune dysregulation. Impaired filaggrin and ceramide production in the stratum corneum increases transepidermal water loss and susceptibility to irritants, triggering a Th2-dominant immune response with IL-4, IL-13, and IL-31 (the \"itch cytokine\"). Xerosis is the most significant predisposing factor, explaining winter and low-humidity worsening. Associated factors include atopic dermatitis, contact allergen sensitization (especially nickel), venous stasis, and stress.\n\nCLINICAL PRESENTATION:\nLesions are well-demarcated, round-to-oval plaques (1-10 cm). Acute lesions are erythematous with weeping, crusting, and peripheral vesicles. Chronic lesions become lichenified, scaly, and hyperpigmented. Legs are most commonly affected in men; women more often have upper extremity and trunk involvement. Lesions are intensely pruritic with frequent secondary excoriation and staphylococcal superinfection.\n\nDIAGNOSIS AND DIFFERENTIAL:\nThe critical distinction is from tinea corporis: tinea shows annular plaques with active, raised scaly borders and central clearing, whereas nummular eczema involves the entire surface uniformly without central clearing. KOH preparation is the essential bedside test\u2014negative KOH rules out dermatophyte infection. Other differentials include psoriasis (silvery scale, extensor surfaces, nail changes), contact dermatitis (geometric distribution), and rarely nummular-type mycosis fungoides (consider biopsy in refractory cases).\n\nMANAGEMENT:\nFirst-line: aggressive emollient therapy (fragrance-free creams or ointments applied after bathing) plus medium-potency topical corticosteroids (triamcinolone 0.1% ointment BID for 2-4 weeks). High-potency steroids (clobetasol) for recalcitrant body lesions. Topical calcineurin inhibitors for steroid-sparing maintenance. Treat secondary infection with oral antibiotics (cephalexin or dicloxacillin). Narrowband UVB phototherapy for widespread disease.\n\nKEY POINTS:\nNummular eczema presents with coin-shaped, uniformly involved plaques without central clearing, distinguishing it from tinea corporis. Negative KOH is essential to exclude dermatophytes. Treatment centers on barrier repair with emollients and medium-potency topical corticosteroids. Secondary staphylococcal infection is common and should be treated when present."
  },
  {
    "id": 601,
    "categoryId": 10,
    "question": "A 22-year-old with moderate acne has failed topical benzoyl peroxide and adapalene after 12 weeks. She uses reliable contraception. What is the next step?",
    "options": [
      "A) Add oral antibiotic (doxycycline)",
      "B) Switch to tretinoin cream",
      "C) Start isotretinoin",
      "D) Add topical clindamycin alone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Add oral antibiotic).\n\nPATHOPHYSIOLOGY OF ACNE:\nAcne vulgaris results from four interrelated processes: follicular hyperkeratinization causing plugging, excess sebum production stimulated by androgens, colonization by Cutibacterium acnes (formerly Propionibacterium acnes), and inflammation. Mild comedonal acne involves primarily the first two processes, while moderate-to-severe inflammatory acne involves all four, requiring treatment strategies that target bacterial proliferation and inflammation.\n\nACNE TREATMENT LADDER:\nMild comedonal acne responds to topical retinoids, which normalize follicular keratinization. Mild inflammatory acne benefits from adding benzoyl peroxide (bactericidal) and/or topical antibiotics. Moderate inflammatory acne, as in this patient who has failed topical therapy, warrants escalation to oral antibiotics combined with topical retinoid and benzoyl peroxide. Severe nodulocystic acne or acne unresponsive to oral antibiotics requires isotretinoin referral.\n\nORAL ANTIBIOTIC PRINCIPLES:\nDoxycycline 50-100mg daily or minocycline are first-line oral antibiotics for acne due to their anti-inflammatory properties beyond antibacterial effects. Antibiotics should never be used as monotherapy because resistance develops rapidly; always combine with benzoyl peroxide (which prevents resistance) and topical retinoid. Limit oral antibiotic duration to 3-4 months, then transition to topical maintenance therapy.\n\nHORMONAL THERAPY:\nFor women with acne following a hormonal pattern (jawline distribution, premenstrual flares, signs of hyperandrogenism), combined oral contraceptives or spironolactone are effective adjuncts and allow earlier discontinuation of antibiotics.\n\nKEY POINTS:\nModerate acne failing topical therapy warrants oral antibiotics plus topical retinoid plus benzoyl peroxide. Never use oral antibiotics as monotherapy; always combine with benzoyl peroxide to prevent resistance. Limit antibiotic duration to 3-4 months. Consider hormonal therapy in women with appropriate acne pattern."
  },
  {
    "id": 602,
    "categoryId": 10,
    "question": "A 65-year-old presents with a pearly, dome-shaped papule with telangiectasias and central depression on his nose. What is the most likely diagnosis?",
    "questionImages": [
      {
        "src": "assets/derm-0702.png",
        "alt": "Pearly dome-shaped facial papule suggestive of basal cell carcinoma",
        "caption": "Question image: pearly papule with rolled border on the face."
      }
    ],
    "options": [
      "A) Squamous cell carcinoma",
      "B) Basal cell carcinoma",
      "C) Melanoma",
      "D) Sebaceous hyperplasia"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/derm-0715.png",
        "alt": "Basal cell carcinoma with central ulceration and pearly border",
        "caption": "Explanation image: classic nodular basal cell carcinoma with central ulceration."
      }
    ],
    "explanation": "CORRECT: B (Basal cell carcinoma).\n\nPATHOPHYSIOLOGY:\nBasal cell carcinoma (BCC) is the most common human malignancy (~80% of non-melanoma skin cancers, ~3.6 million US cases annually). BCC arises from aberrant Hedgehog pathway activation in basal keratinocytes. The PTCH1 tumor suppressor normally inhibits the Smoothened (SMO) signal transducer; UV-induced PTCH1 mutations (~70% of sporadic BCCs) or SMO activating mutations lead to constitutive pathway activation and uncontrolled proliferation. Risk factors include cumulative UV exposure, fair skin (Fitzpatrick I-II), sunburn history, immunosuppression (10-fold increased risk in transplant recipients), and prior radiation. Gorlin syndrome (germline PTCH1 mutations) causes multiple BCCs at young age.\n\nCLINICAL PRESENTATION:\nNodular BCC (60-80%) presents as a pearly or translucent papule with arborizing telangiectasias, rolled borders, and possible central ulceration (\"rodent ulcer\"). Head and neck account for ~85%, with the nose being most common. Other subtypes: superficial BCC (scaly patch on trunk, mimics eczema), morpheaform/infiltrative BCC (scar-like, ill-defined, more aggressive), and pigmented BCC (can mimic melanoma). Dermoscopy reveals arborizing vessels, blue-gray ovoid nests, and leaf-like structures.\n\nMANAGEMENT:\nFor low-risk BCCs (nodular/superficial, small, trunk/extremities), standard excision with 4 mm margins achieves >95% cure. ED&C is appropriate for small superficial BCCs on low-risk sites. For high-risk BCCs (face\u2014especially nose, periorbital, periauricular\u2014morpheaform, or recurrent), Mohs micrographic surgery is the gold standard (99% cure rate with maximum tissue conservation). Topical imiquimod 5% and 5-fluorouracil are options for select superficial BCCs. Advanced or metastatic BCC (<0.5% of cases) is treated with Hedgehog pathway inhibitors (vismodegib, sonidegib).\n\nKEY POINTS:\nBCC is the most common skin cancer, driven by Hedgehog pathway dysregulation from UV-induced PTCH1 mutations. Classic presentation is a pearly papule with telangiectasias and rolled borders on the nose or central face. BCC is locally destructive but almost never metastasizes. Mohs surgery is gold standard for high-risk facial BCCs; Hedgehog inhibitors target advanced disease."
  },
  {
    "id": 603,
    "categoryId": 10,
    "question": "A patient starting a TNF inhibitor (adalimumab) for psoriasis has a positive PPD with negative chest X-ray. What must be done before starting the biologic?",
    "options": [
      "A) No treatment needed",
      "B) Treat latent TB for 1-2 months before starting biologic",
      "C) Start both simultaneously",
      "D) TNF inhibitors are contraindicated"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Treat latent TB for 1-2 months before starting biologic).\n\nPATHOPHYSIOLOGY:\nTNF-alpha is essential for maintaining granulomas that contain latent Mycobacterium tuberculosis. In LTBI, the immune system confines dormant bacilli within organized granulomas of macrophages, epithelioid cells, and giant cells. TNF-alpha promotes granuloma formation, maintenance, and intracellular mycobacterial killing. TNF inhibitors (adalimumab, infliximab, etanercept, certolizumab, golimumab) can disintegrate these granulomas, releasing dormant bacilli. Per JAMA and NEJM data, TNF inhibitors increase TB reactivation risk 2-30-fold, with monoclonal antibodies (infliximab, adalimumab) carrying higher risk than etanercept due to greater granuloma disruption.\n\nSCREENING REQUIREMENTS:\nAll patients must be screened before initiating any TNF inhibitor regardless of indication. Screening includes TB risk factor assessment (endemic country residence, healthcare work, incarceration, homeless shelter exposure, close TB contact), TST or IGRA (QuantiFERON-Gold Plus or T-SPOT.TB), and baseline chest radiograph. IGRA is preferred in BCG-vaccinated patients to avoid false positives. A positive screening test with negative chest radiograph defines LTBI.\n\nMANAGEMENT OF LTBI BEFORE BIOLOGIC INITIATION:\nPer CDC and ATS guidelines, initiate LTBI treatment at least 1-2 months before starting the TNF inhibitor to reduce mycobacterial burden, completing the full course concurrently. Preferred regimens: 3 months weekly isoniazid plus rifapentine (3HP, highest completion rates), 4 months daily rifampin, or 9 months daily isoniazid. Monitor hepatotoxicity with baseline and periodic LFTs, particularly with isoniazid-containing regimens.\n\nADDITIONAL PRE-BIOLOGIC SCREENING:\nScreen for hepatitis B (HBsAg, anti-HBc, anti-HBs) as TNF inhibitors can cause fatal HBV reactivation. Also obtain hepatitis C screening, CBC, CMP, and age-appropriate cancer screening. Administer live vaccines (varicella, MMR, live zoster) at least 2-4 weeks before therapy.\n\nKEY POINTS:\nTNF-alpha maintains granulomas containing latent TB; TNF inhibitors increase reactivation risk 2-30-fold. Screen all patients with IGRA or TST plus chest radiograph before biologic initiation. Begin LTBI treatment 1-2 months before the TNF inhibitor. Also screen for hepatitis B and ensure live vaccines are given before therapy."
  },
  {
    "id": 604,
    "categoryId": 10,
    "question": "A 30-year-old presents with flat-topped, polygonal, violaceous papules on wrists and ankles with fine white lines (Wickham striae). White lacy patches are on the buccal mucosa. What should be screened for?",
    "questionImages": [
      {
        "src": "assets/lichen-planus-oral-dermnet.png",
        "alt": "Reticulate oral lichen planus on buccal mucosa",
        "caption": "Reticulate white lacy lesions of oral lichen planus on the buccal mucosa."
      },
      {
        "src": "assets/lichen-planus-wrist-dermnet.png",
        "alt": "Flat-topped polygonal papules of lichen planus on volar wrist",
        "caption": "Flat-topped, shiny, polygonal papules of cutaneous lichen planus on the wrist."
      }
    ],
    "options": [
      "A) HIV",
      "B) Hepatitis C",
      "C) Syphilis",
      "D) Diabetes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Hepatitis C).\n\nPATHOPHYSIOLOGY:\nLichen planus is a chronic T-cell-mediated dermatosis in which cytotoxic CD8+ T lymphocytes target basal keratinocytes, causing apoptosis at the dermal-epidermal junction. Histopathology shows a band-like lichenoid lymphocytic infiltrate, saw-tooth acanthosis, and Civatte bodies (apoptotic keratinocytes). Wickham striae (pathognomonic fine white reticular lines) result from hypergranulosis. The condition is strongly associated with hepatitis C (HCV), with meta-analyses showing 2-5-fold increased HCV prevalence among lichen planus patients. The proposed mechanism involves HCV replication in epithelial cells altering keratinocyte antigenicity and triggering autoimmune T-cell response. This association is most robust in Mediterranean, Japanese, and Southeast Asian populations.\n\nCLINICAL PRESENTATION:\nThe classic 6 Ps: Purple, Polygonal, Planar (flat-topped), Pruritic Papules and Plaques on wrists, ankles, lower back, and shins. Oral involvement (50-70%) presents as white reticular patches on buccal mucosa and may be the sole manifestation. Oral erosive lichen planus carries 1-2% malignant transformation risk to SCC, requiring long-term surveillance. Nail involvement (~10%) includes ridging, thinning, and pterygium. Lichen planopilaris causes scarring alopecia. The Koebner phenomenon is well-documented.\n\nDIAGNOSIS AND SCREENING:\nDiagnosis is often clinical; biopsy confirms atypical cases showing lichenoid interface dermatitis. Direct immunofluorescence shows shaggy fibrinogen deposits at the basement membrane, distinguishing from lupus. All patients should be screened for HCV, as treatment can improve the skin disease. Medication history is essential\u2014lichenoid drug eruptions can be caused by ACE inhibitors, thiazides, NSAIDs, hydroxychloroquine, beta-blockers, and sulfonylureas, and resolve with discontinuation.\n\nMANAGEMENT:\nFirst-line: high-potency topical corticosteroids (clobetasol 0.05%). Oral disease is managed with topical steroid gels, tacrolimus, or intralesional triamcinolone. Widespread disease may require systemic acitretin, methotrexate, or mycophenolate. Cutaneous lichen planus is usually self-limited (1-2 years) though post-inflammatory hyperpigmentation persists. Oral disease follows a more chronic course.\n\nKEY POINTS:\nLichen planus presents with the 6 Ps and pathognomonic Wickham striae. Screen all patients for hepatitis C (2-5-fold increased association). Oral erosive disease carries 1-2% malignant transformation risk. Drug-induced lichenoid eruptions (ACE inhibitors, thiazides, NSAIDs) are key mimickers resolving with discontinuation."
  },
  {
    "id": 605,
    "categoryId": 10,
    "question": "A 45-year-old presents with facial flushing, central erythema, telangiectasias, and papules/pustules. No comedones are present. What is the first-line treatment?",
    "questionImages": [
      {
        "src": "assets/rosacea-question-face.png",
        "alt": "Centrofacial erythema and telangiectasias typical of rosacea",
        "caption": "Question image: persistent central facial erythema with visible telangiectasias."
      }
    ],
    "options": [
      "A) Topical metronidazole or ivermectin",
      "B) Topical benzoyl peroxide",
      "C) Oral isotretinoin",
      "D) Topical hydrocortisone"
    ],
    "correctAnswer": 0,
    "explanationImages": [
      {
        "src": "assets/rosacea-face.png",
        "alt": "Centrofacial erythema and papules consistent with rosacea",
        "caption": "Typical papulopustular rosacea pattern with persistent central facial erythema."
      }
    ],
    "explanation": "CORRECT: A (Topical metronidazole or ivermectin).\n\nPATHOPHYSIOLOGY:\nRosacea is a chronic inflammatory disorder of the central face driven by neurovascular dysregulation, innate immune activation, and microbial factors. Elevated kallikrein 5 (KLK5) cleaves cathelicidin (LL-37) into pro-inflammatory fragments promoting leukocyte chemotaxis, angiogenesis, and matrix degradation\u2014explaining both papulopustules and telangiectasias. TRPV channel activation on sensory neurons produces flushing in response to triggers (heat, alcohol, spicy foods, UV, stress). Demodex folliculorum mites proliferate to 10-20 times normal density in rosacea patients, and along with associated Bacillus oleronius trigger TLR-2-mediated inflammation, providing rationale for ivermectin and metronidazole efficacy.\n\nCLINICAL SUBTYPES:\nErythematotelangiectatic (subtype 1): persistent centrofacial erythema with telangiectasias and episodic flushing. Papulopustular (subtype 2): inflammatory papules and pustules on erythematous base. The critical distinction from acne is the absence of comedones, as rosacea does not involve follicular keratinization. Phymatous (subtype 3): sebaceous gland hypertrophy causing rhinophyma. Ocular (subtype 4): affects up to 50%, presenting with blepharitis, conjunctival injection, and meibomian gland dysfunction, and may precede cutaneous manifestations.\n\nMANAGEMENT:\nFor papulopustular rosacea, the AAD recommends topical therapy first-line: metronidazole 0.75-1%, ivermectin 1% cream (shown superior to metronidazole in the ATTRACT trial), and azelaic acid 15% gel. For moderate-to-severe disease, sub-antimicrobial doxycycline (40 mg modified-release daily) provides anti-inflammatory benefit without promoting resistance. Brimonidine gel and oxymetazoline cream target persistent erythema via vasoconstriction. Laser and IPL treat refractory telangiectasias. Rhinophyma requires surgical debulking. Topical corticosteroids are strictly contraindicated\u2014they initially mask symptoms but cause steroid rosacea with rebound flaring.\n\nKEY POINTS:\nRosacea is distinguished from acne by the absence of comedones and presence of centrofacial erythema. Topical metronidazole, ivermectin, or azelaic acid are first-line per AAD guidelines. Demodex overpopulation contributes to pathogenesis, explaining ivermectin's efficacy. Topical corticosteroids are contraindicated. Screen for ocular involvement, affecting up to 50% of patients."
  },
  {
    "id": 606,
    "categoryId": 10,
    "question": "A 60-year-old presents with a painful, grouped vesicular rash in a dermatomal distribution on the left chest, within 48 hours of onset. What is the treatment?",
    "questionImages": [
      {
        "src": "assets/herpes-zoster-dermnet.png",
        "alt": "Herpes zoster vesicular eruption in a thoracic dermatomal pattern",
        "caption": "Grouped vesicles in a unilateral dermatomal distribution consistent with shingles."
      }
    ],
    "options": [
      "A) Supportive care only",
      "B) Valacyclovir 1g TID x 7 days",
      "C) Acyclovir topical cream",
      "D) Corticosteroids alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Oral Valacyclovir 1g TID for 7 days).\n\nPATHOPHYSIOLOGY:\nHerpes zoster results from reactivation of varicella-zoster virus (VZV) latent in dorsal root or cranial nerve ganglia since primary varicella infection, often decades earlier. When cell-mediated immunity declines (aging, immunosuppression, stress), VZV reactivates, replicates, and travels anterogradely down the sensory nerve to the corresponding dermatome. Viral-induced neuronal inflammation and necrosis underlie both acute neuritis and postherpetic neuralgia (PHN, pain persisting >90 days after rash onset).\n\nCLINICAL PRESENTATION:\nA 1-5 day prodrome of burning, tingling, or stabbing dermatomal pain precedes the rash and can mimic cardiac, pulmonary, or abdominal disease. The eruption progresses from erythematous macules to grouped vesicles on an erythematous base, characteristically respecting the midline within a single dermatome. Thoracic dermatomes are most commonly affected. New vesicles form for 3-5 days, then crust and heal over 2-4 weeks. Herpes zoster ophthalmicus (V1) requires urgent ophthalmology evaluation. Hutchinson sign (nasal tip vesicles) predicts ocular complications. Ramsay Hunt syndrome (geniculate ganglion reactivation) produces facial palsy, ear vesicles, and hearing loss.\n\nTREATMENT:\nAntiviral therapy within 72 hours of rash onset (or while new lesions form) is the mainstay. Valacyclovir 1000 mg TID for 7 days is preferred over acyclovir due to superior bioavailability (54% vs 15-20%), allowing simpler dosing with higher sustained levels. Famciclovir 500 mg TID for 7 days is equivalent. Antivirals accelerate healing, reduce acute pain, and decrease PHN incidence and severity. PHN affects 10-18% overall and up to 50% of those over 60. Gabapentin or pregabalin during the acute phase may reduce PHN transition. Immunocompromised patients with disseminated zoster require IV acyclovir.\n\nPREVENTION:\nShingrix (recombinant adjuvanted vaccine) is recommended for all immunocompetent adults \u226550 and immunocompromised adults \u226519, providing >90% efficacy maintained through at least 7 years. The two-dose series has replaced the discontinued live Zostavax.\n\nKEY POINTS:\nHerpes zoster is VZV reactivation producing a unilateral dermatomal vesicular eruption. Valacyclovir within 72 hours is preferred for superior bioavailability. PHN risk increases with age, affecting up to 50% over age 60. Shingrix provides >90% protection for all adults \u226550."
  },
  {
    "id": 607,
    "categoryId": 10,
    "question": "A patient on hydrochlorothiazide develops an erythematous, blistering rash on sun-exposed areas. What is the diagnosis?",
    "options": [
      "A) Drug-induced lupus",
      "B) Phototoxic drug reaction",
      "C) Allergic contact dermatitis",
      "D) Stevens-Johnson syndrome"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/drug-induced-photosensitivity-dermnet.png",
        "alt": "Drug-induced photosensitivity with phototoxic eruption on sun-exposed skin",
        "caption": "Phototoxic drug eruption with characteristic sun-exposed distribution and sparing patterns."
      }
    ],
    "explanation": "CORRECT: B (Phototoxic drug reaction).\n\nPATHOPHYSIOLOGY:\nDrug-induced photosensitivity includes phototoxicity (~90% of cases) and photoallergy. In phototoxic reactions, the drug absorbs UVA radiation (320-400 nm) and generates reactive oxygen species damaging cellular membranes, DNA, and proteins. This is dose-dependent, non-immunologic, occurs on first exposure without sensitization, and resembles exaggerated sunburn. Photoallergic reactions involve type IV hypersensitivity: UV converts the drug into a hapten triggering T-cell-mediated immune response, requiring prior sensitization, presenting as eczematous dermatitis that may spread beyond sun-exposed areas.\n\nCLINICAL PRESENTATION:\nPhototoxic reactions present as exaggerated sunburn (erythema, edema, vesiculation, blistering) strictly confined to sun-exposed areas. Sharp demarcation at clothing lines is a critical diagnostic clue. Onset is acute, within minutes to hours of sun exposure on the offending medication. Photoallergic reactions present as pruritic eczematous dermatitis extending beyond photoexposed sites with 24-72 hour delayed onset.\n\nCOMMON PHOTOSENSITIZING MEDICATIONS:\nHydrochlorothiazide is the most commonly implicated, causing photosensitivity in up to 10% of users and linked to increased non-melanoma skin cancer risk with prolonged use (JAAD). Tetracyclines (doxycycline most phototoxic, up to 20%), fluoroquinolones (especially lomefloxacin, sparfloxacin), NSAIDs (piroxicam, naproxen), amiodarone (blue-gray discoloration from lipofuscin deposition), voriconazole (accelerated photocarcinogenesis), and sulfonamides are other major classes.\n\nMANAGEMENT:\nPrimary intervention is discontinuing the offending drug. If not feasible, strict photoprotection is essential: broad-spectrum sunscreen SPF 30+ reapplied every 2 hours, protective clothing, wide-brimmed hats, and avoiding peak UV hours (10 AM-4 PM). UVA protection is critical since most phototoxic reactions are UVA-mediated. Acute management includes cool compresses, topical corticosteroids, and emollients.\n\nKEY POINTS:\nPhototoxic reactions are dose-dependent, non-immunologic exaggerated sunburn responses confined to sun-exposed areas occurring on first exposure. Hydrochlorothiazide, doxycycline, and fluoroquinolones are most commonly implicated. Sharp demarcation at clothing lines distinguishes photosensitivity from other drug eruptions. UVA-blocking sunscreen is essential."
  },
  {
    "id": 608,
    "categoryId": 10,
    "question": "A 25-year-old presents with oval, salmon-colored patches following skin lines on the trunk, preceded by a single larger 'herald patch' 2 weeks ago. What is the management?",
    "questionImages": [
      {
        "src": "assets/pityriasis-rosea-trunk-dermnet.png",
        "alt": "Truncal pityriasis rosea with multiple oval salmon lesions",
        "caption": "Classic truncal distribution of pityriasis rosea lesions."
      }
    ],
    "options": [
      "A) Oral antifungals",
      "B) Reassurance - self-limited",
      "C) Oral corticosteroids",
      "D) Skin biopsy"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      {
        "src": "assets/pityriasis-rosea-dermnet.png",
        "alt": "Annular collaretted lesions in pityriasis rosea on the arms",
        "caption": "Classic pityriasis rosea with collarette scaling in oval lesions."
      }
    ],
    "explanation": "CORRECT: B (Reassurance - self-limited).\n\nPATHOPHYSIOLOGY:\nPityriasis rosea is an acute, self-limited papulosquamous eruption suspected to be triggered by reactivation of HHV-6 and/or HHV-7. Evidence includes viral DNA in lesions, seasonal clustering (spring/fall), mini-epidemics, rarity of recurrence (suggesting lasting immunity), and prodromal symptoms. It predominantly affects ages 10-35.\n\nCLINICAL PRESENTATION:\nThe eruption begins with a \"herald patch\"\u2014a 2-5 cm oval, salmon-pink plaque with a collarette of trailing scale\u2014on the trunk in ~70% of cases (often misdiagnosed as tinea corporis). After 1-2 weeks, numerous smaller (0.5-1.5 cm) oval patches develop over the trunk and proximal extremities, following skin cleavage lines (Langer lines) in the classic \"Christmas tree\" pattern on the back. Each lesion shows collarette scaling. The face, distal extremities, palms, and soles are typically spared. Pruritus ranges from absent to moderate.\n\nDIAGNOSIS AND CRITICAL DIFFERENTIAL:\nPityriasis rosea is a clinical diagnosis. The critical differential is secondary syphilis, which can produce identical oval scaly papules but typically involves palms and soles, with condylomata lata, mucous patches, and lymphadenopathy. RPR/VDRL should be obtained in any sexually active patient with this presentation. Other differentials: guttate psoriasis (droplet-shaped, thicker silvery scale, post-streptococcal), nummular eczema, tinea corporis (KOH positive), and drug eruptions (beta-blockers, ACE inhibitors, metronidazole).\n\nMANAGEMENT:\nThe eruption resolves spontaneously in 6-8 weeks (occasionally 12 weeks). Reassurance is primary management. For pruritus: emollients, topical corticosteroids, and oral antihistamines. Narrowband UVB phototherapy can accelerate resolution in widespread disease. Post-inflammatory dyspigmentation is common in darker skin tones, resolving over weeks to months.\n\nKEY POINTS:\nPityriasis rosea is self-limited (6-8 weeks), with the herald patch preceding the Christmas tree pattern by 1-2 weeks. Secondary syphilis is the most important diagnosis to exclude\u2014obtain RPR/VDRL in sexually active patients. Treatment is supportive with reassurance and topical steroids for pruritus."
  },
  {
    "id": 609,
    "categoryId": 5,
    "question": "A 65-year-old male with BPH has moderate LUTS (AUA-SI 18) with a 45g prostate. What is the most appropriate initial pharmacotherapy?",
    "options": [
      "A) Finasteride alone",
      "B) Tamsulosin alone",
      "C) Combination tamsulosin + finasteride",
      "D) Oxybutynin"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Combination tamsulosin plus finasteride).\n\nCLINICAL REASONING:\nThe patient has moderate LUTS (AUA Symptom Index 18, where 8 to 19 is moderate) with a prostate volume of 45 grams (greater than 30 to 40 grams, the threshold where 5-alpha reductase inhibitors provide benefit). For men with both moderate to severe symptoms and an enlarged prostate, combination therapy with an alpha-blocker plus a 5-alpha reductase inhibitor is superior to either agent alone.\n\nEVIDENCE:\nThe landmark CombAT (Combination of Avodart and Tamsulosin) trial demonstrated that combination therapy (dutasteride plus tamsulosin) was significantly superior to either monotherapy for reducing LUTS progression, acute urinary retention, and BPH-related surgery over 4 years. The MTOPS (Medical Therapy of Prostatic Symptoms) trial similarly showed that combination finasteride plus doxazosin reduced the risk of clinical progression by 66% compared to placebo (versus 39% for doxazosin alone and 34% for finasteride alone).\n\nPHARMACOLOGY:\nAlpha-1 adrenergic blockers (tamsulosin, alfuzosin, silodosin) relax prostatic and bladder neck smooth muscle by blocking alpha-1A receptors, providing rapid symptom relief within days to weeks. They do not reduce prostate size and do not prevent disease progression. 5-alpha reductase inhibitors (finasteride, dutasteride) block conversion of testosterone to dihydrotestosterone (DHT, the primary androgen driving prostate growth), reducing prostate volume by 20 to 30% over 6 to 12 months and decreasing the risk of acute urinary retention and need for surgery. Key side effects of 5-alpha reductase inhibitors include decreased libido, erectile dysfunction, decreased ejaculate volume, and reduced PSA by approximately 50% (requiring doubling of measured PSA for cancer screening interpretation).\n\nKEY POINTS:\nCombination alpha-blocker plus 5-alpha reductase inhibitor is superior to either alone for moderate to severe LUTS with an enlarged prostate (greater than 30 to 40g), reducing clinical progression by 66%. Alpha-blockers provide rapid symptom relief while 5-alpha reductase inhibitors reduce prostate volume by 20 to 30% over months. The 5-ARI halves PSA, requiring adjustment when screening for cancer."
  },
  {
    "id": 610,
    "categoryId": 5,
    "question": "A 45-year-old presents with sudden colicky left flank pain radiating to groin. CT shows a 4mm ureteral stone. He is afebrile with normal creatinine. What is the management?",
    "options": [
      "A) Emergent ureteroscopy",
      "B) Conservative management with medical expulsive therapy",
      "C) Extracorporeal shock wave lithotripsy",
      "D) Percutaneous nephrostomy"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/kidney-stones-anatomy.png", "alt": "Kidney stones: anatomy with calyceal, renal pelvic, and upper ureteral stone locations", "caption": "Kidney stones: anatomy and locations including calyceal, renal pelvic, and upper ureteral stones (© Pausner 2018)." }
    ],
    "explanation": "CORRECT: B (Conservative management with medical expulsive therapy).\n\nCLINICAL REASONING:\nThe patient presents with a classic renal colic episode (sudden colicky flank pain radiating to the groin) from a 4 mm ureteral stone, is afebrile, and has no signs of obstruction or infection. Stones 5 mm or smaller have a spontaneous passage rate of approximately 68 to 98% (with distal ureteral stones passing most reliably), making conservative management the appropriate first-line approach.\n\nMEDICAL EXPULSIVE THERAPY:\nAlpha-blockers (tamsulosin 0.4 mg daily) relax ureteral smooth muscle (particularly at the distal ureteroveiscal junction, the narrowest point and most common site of stone impaction) and facilitate stone passage. A meta-analysis demonstrated that tamsulosin increases spontaneous passage rates and reduces time to passage, particularly for stones 5 to 10 mm. Pain management with NSAIDs (ketorolac, ibuprofen) is preferred over opioids because NSAIDs reduce ureteral smooth muscle spasm and prostaglandin-mediated renal pelvic pressure in addition to providing analgesia.\n\nINDICATIONS FOR URGENT INTERVENTION:\nConservative management is contraindicated when any of the following are present: concurrent urinary tract infection with obstruction (obstructive pyelonephritis/pyonephrosis, a urologic emergency requiring emergent decompression via ureteral stent or percutaneous nephrostomy), solitary kidney with obstruction, bilateral obstruction, uncontrollable pain or vomiting, AKI, or stones greater than 10 mm (which rarely pass spontaneously).\n\nSTONE SIZE AND PASSAGE RATES:\nStones less than 5 mm pass spontaneously in approximately 68 to 98% of cases, 5 to 10 mm stones pass in approximately 47% of cases, and stones greater than 10 mm rarely pass and typically require intervention (extracorporeal shock wave lithotripsy or ureteroscopy with laser lithotripsy).\n\nKEY POINTS:\nUreteral stones 5 mm or smaller have a 68 to 98% spontaneous passage rate and are managed conservatively with tamsulosin (medical expulsive therapy) and NSAIDs (preferred over opioids). Urgent intervention is required for obstruction with infection, solitary kidney obstruction, bilateral obstruction, or stones greater than 10 mm. An afebrile patient with a small stone and no complications can be safely managed as an outpatient."
  },
  {
    "id": 611,
    "categoryId": 5,
    "question": "A 70-year-old woman with recurrent UTIs (4 in past year) is frustrated. She is postmenopausal. What is the most appropriate prophylactic strategy?",
    "options": [
      "A) Daily antibiotic prophylaxis only",
      "B) Cranberry supplements alone",
      "C) Vaginal estrogen + consider antibiotic prophylaxis",
      "D) Referral for cystoscopy first"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Vaginal estrogen plus consider antibiotic prophylaxis).\n\nCLINICAL REASONING:\nRecurrent urinary tract infections (defined as 2 or more UTIs in 6 months or 3 or more in 12 months) in postmenopausal women are primarily driven by genitourinary syndrome of menopause (GSM), formerly called vulvovaginal atrophy, caused by estrogen deficiency. Declining estrogen levels cause thinning of the vaginal and urethral epithelium, loss of the protective vaginal Lactobacillus flora (which normally maintain an acidic vaginal pH of 3.5 to 4.5), increase in vaginal pH (allowing colonization by uropathogenic E. coli), and reduced urethral mucosal coaptation.\n\nVAGINAL ESTROGEN:\nTopical vaginal estrogen (cream, ring, or tablet) restores vaginal epithelial thickness, repopulates Lactobacillus flora, lowers vaginal pH, and reduces vaginal colonization with uropathogens. Multiple randomized trials and a Cochrane review demonstrate that vaginal estrogen reduces UTI recurrence by approximately 50%. Vaginal estrogen has minimal systemic absorption and is considered safe even in many women with a history of breast cancer (with oncologist consultation).\n\nANTIBIOTIC PROPHYLAXIS:\nWhen vaginal estrogen alone is insufficient, low-dose continuous antibiotic prophylaxis (nitrofurantoin 50 to 100 mg nightly, TMP-SMX half-strength nightly, or post-coital prophylaxis with a single dose if UTIs are associated with sexual activity) reduces recurrence by 80 to 95%. Prophylaxis is typically continued for 6 to 12 months and then reassessed. Cranberry products have modest evidence (approximately 25% reduction in UTI risk in some studies) and may be offered as adjunctive prevention.\n\nKEY POINTS:\nRecurrent UTIs in postmenopausal women are primarily driven by estrogen deficiency causing loss of vaginal Lactobacillus, elevated pH, and uropathogen colonization. Vaginal estrogen reduces UTI recurrence by approximately 50% by restoring vaginal flora and has minimal systemic absorption. Low-dose antibiotic prophylaxis (80 to 95% reduction) is added when estrogen alone is insufficient."
  },
  {
    "id": 612,
    "categoryId": 5,
    "question": "A 55-year-old male has PSA 4.8 ng/mL (was 2.5 two years ago). DRE is normal. What is the most appropriate next step?",
    "options": [
      "A) Immediate prostate biopsy",
      "B) Repeat PSA and calculate velocity",
      "C) Reassurance - PSA <10 is normal",
      "D) Start finasteride"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Repeat PSA and calculate velocity).\n\nCLINICAL REASONING:\nThe patient has a PSA of 4.8 ng/mL (mildly elevated above the traditional 4.0 cutoff) that has risen from 2.5 two years prior, with a normal digital rectal exam. Before proceeding to prostate biopsy, the appropriate next step is to confirm the PSA elevation with a repeat measurement and calculate the PSA velocity (rate of change over time), because PSA can be transiently elevated by benign conditions.\n\nPSA VELOCITY:\nPSA velocity is calculated as the change in PSA divided by the time interval between measurements. A PSA velocity greater than 0.75 ng/mL per year is linked to an increased risk of prostate cancer and should prompt further evaluation (free PSA percentage, prostate MRI, or biopsy). This patient's velocity is approximately 1.15 ng/mL per year (4.8 minus 2.5 divided by 2 years), which exceeds the concerning threshold and warrants additional workup.\n\nTRANSIENT PSA ELEVATION:\nBenign causes of PSA elevation include BPH, prostatitis (acute bacterial prostatitis can raise PSA dramatically), recent ejaculation (within 48 hours), vigorous exercise (particularly cycling), urethral instrumentation, and UTI. A single elevated PSA should be confirmed before invasive procedures.\n\nNEXT STEPS AFTER CONFIRMATION:\nIf repeat PSA confirms elevation with a concerning velocity, further risk stratification may include free PSA percentage (<10% suggests cancer), Prostate Health Index (PHI), 4Kscore, or multiparametric MRI (mpMRI) of the prostate with PI-RADS scoring. MRI-targeted biopsy (fusion biopsy) has higher detection rates for clinically significant cancer compared to systematic transrectal ultrasound-guided biopsy.\n\nKEY POINTS:\nA rising PSA should be confirmed with repeat measurement and PSA velocity calculation before biopsy, as transient benign elevations are common. PSA velocity greater than 0.75 ng/mL per year is concerning for cancer. Multiparametric prostate MRI with PI-RADS scoring and MRI-targeted biopsy are increasingly used before or instead of systematic biopsy."
  },
  {
    "id": 613,
    "categoryId": 5,
    "question": "A 60-year-old woman reports urine loss when coughing or sneezing. She denies urgency. Exam reveals urethral hypermobility. What is the first-line treatment?",
    "options": [
      "A) Oxybutynin",
      "B) Pelvic floor muscle training",
      "C) Midurethral sling surgery",
      "D) Mirabegron"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Pelvic floor muscle training).\n\nCLINICAL REASONING:\nThe patient presents with stress urinary incontinence (SUI), defined as involuntary urine loss with increased abdominal pressure (coughing, sneezing, laughing, lifting, exercise) without urgency, caused by urethral hypermobility and/or intrinsic sphincter deficiency. Pelvic floor muscle training (PFMT, also called Kegel exercises) is the established first-line treatment for stress incontinence in women.\n\nEVIDENCE:\nA Cochrane systematic review of 31 trials confirmed that PFMT significantly improves or cures SUI compared to no treatment or sham exercises, with cure rates of 50 to 75% for mild to moderate stress incontinence. The exercises strengthen the pubococcygeus and levator ani muscles that support the urethra and bladder neck, restoring the urethral support mechanism that prevents urine leakage during abdominal pressure increases.\n\nPROGRAM DETAILS:\nAn effective PFMT program involves contracting the pelvic floor muscles (as if stopping the urine stream, though practice during urination is discouraged) for 8 to 12 seconds, 8 to 12 repetitions, 3 times daily, for a minimum of 3 months before assessing benefit. Supervised PFMT with a physiotherapist or biofeedback is more effective than self-directed exercises alone. Vaginal weighted cones and electrical stimulation devices are adjunctive options.\n\nSECOND-LINE OPTIONS:\nWhen PFMT is insufficient, duloxetine (an SNRI that increases urethral sphincter tone, approved for SUI in Europe but not FDA-approved for this indication in the US) may be considered. Pessary devices provide mechanical urethral support. Surgical options for refractory SUI include midurethral sling procedures (the gold standard surgical intervention, with 80 to 90% success rates), Burch colposuspension, and urethral bulking agents.\n\nKEY POINTS:\nPelvic floor muscle training (Kegel exercises) is first-line for stress urinary incontinence, with 50 to 75% cure rates for mild to moderate SUI. An effective program requires 8 to 12 second contractions, 8 to 12 reps, 3 times daily for at least 3 months. Supervised PFMT with biofeedback is superior to self-directed exercises; midurethral sling is the gold standard surgical option."
  },
  {
    "id": 614,
    "categoryId": 5,
    "question": "A 35-year-old male presents with gradual, painless scrotal swelling over several months. On exam the scrotum is diffusely enlarged, soft, and smooth; the mass transilluminates brightly. The testis cannot be palpated separately from the swelling. What is the diagnosis?",
    "options": [
      "A) Varicocele",
      "B) Hydrocele",
      "C) Testicular torsion",
      "D) Epididymal cyst (spermatocele)"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/hydrocele-anatomy.png", "alt": "Hydrocele anatomy: normal closed tract vs open processus vaginalis with fluid around testis", "caption": "Hydrocele: fluid in tunica vaginalis; open processus vaginalis allows abdominal fluid to collect (Cleveland Clinic ©2023)." }
    ],
    "bulletExplanation": "- CORRECT: B (Hydrocele).\n- Painless, gradual scrotal swelling that is soft, smooth, and transilluminates brightly, with the testis not palpable separately, is classic for hydrocele (fluid in the tunica vaginalis).\n- Diagnosis is clinical; ultrasound confirms and excludes solid masses. Small asymptomatic hydroceles may be observed; symptomatic or large ones are treated with hydrocelectomy.",
    "explanation": "CORRECT: B (Hydrocele).\n\nPATHOPHYSIOLOGY:\nA hydrocele is a fluid collection within the tunica vaginalis, the potential space surrounding the testis. In adults, most hydroceles are idiopathic (primary), resulting from an imbalance between fluid production and reabsorption by the tunica vaginalis mesothelium. Secondary hydroceles may follow epididymitis, orchitis, trauma, or testicular tumor. In children, communicating hydroceles occur when the processus vaginalis fails to obliterate after testicular descent, allowing peritoneal fluid to enter the scrotum. The fluid is typically clear and straw-colored. Large or long-standing hydroceles can cause discomfort due to weight and tension.\n\nCLINICAL MANIFESTATIONS:\nPatients present with painless, gradual scrotal swelling that may be unilateral or bilateral. The swelling is soft, smooth, and fluctuant; the testis is often difficult to palpate because it is surrounded by fluid. Transillumination—shining a light through the scrotum in a darkened room—is positive: the fluid-filled sac glows brightly, distinguishing it from solid masses. Pain is absent unless the hydrocele is very large or complicated by infection. In communicating hydroceles (children), size may vary with position or time of day.\n\nDIAGNOSIS:\nDiagnosis is usually clinical based on history and physical examination. Key findings are painless scrotal swelling, positive transillumination, and inability to palpate the testis separately (fluid surrounds it). Scrotal ultrasound confirms the diagnosis when needed: it shows an anechoic fluid collection surrounding the testis with no solid components. Ultrasound also helps exclude testicular malignancy or epididymal pathology in adults. In children, ultrasound may demonstrate a patent processus vaginalis in communicating hydroceles.\n\nMANAGEMENT:\nIn infants and young children, communicating hydroceles often resolve spontaneously as the processus vaginalis closes; observation until age 1 to 2 years is typical. In adults, small asymptomatic hydroceles may be observed. Symptomatic or large hydroceles are treated surgically: hydrocelectomy (evacuation of fluid and plication or excision of the tunica vaginalis) via a scrotal approach. Communicating hydroceles in children require high ligation of the patent processus vaginalis. Aspiration alone is not recommended due to high recurrence and infection risk."
  },
  {
    "id": 615,
    "categoryId": 15,
    "question": "A 55-year-old male presents with crushing substernal chest pain for 30 minutes. ECG shows ST elevation in V1-V4. The nearest PCI center is 90 minutes away. Your hospital can give fibrinolytics. What is the best strategy?",
    "options": [
      "A) Give fibrinolytics immediately",
      "B) Transfer for primary PCI regardless",
      "C) Give fibrinolytics if PCI cannot be done within 120 minutes",
      "D) Wait for troponin results"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Give fibrinolytics if PCI cannot be done within 120 minutes).\n\nPATHOPHYSIOLOGY:\nST-elevation myocardial infarction results from complete thrombotic occlusion of an epicardial coronary artery, almost always triggered by rupture or erosion of a vulnerable atherosclerotic plaque with superimposed thrombus formation. The duration of complete coronary occlusion directly determines the extent of irreversible myocardial necrosis, which progresses as a wavefront from the subendocardium outward to the epicardium over approximately 3 to 6 hours. This time-dependent relationship underlies the critical principle that \"time is muscle\" and drives the urgency of reperfusion therapy.\n\nCLINICAL REASONING:\nPrimary percutaneous coronary intervention (PCI) is the preferred reperfusion strategy for STEMI because it achieves higher rates of complete arterial recanalization, lower rates of reinfarction, and lower mortality compared to fibrinolysis. However, PCI must be performed within 120 minutes of first medical contact (FMC-to-balloon time) to maintain its superiority over fibrinolysis. When PCI cannot be achieved within this 120-minute window, as in this scenario where the nearest PCI center is 90 minutes away (with additional time required for transport logistics, catheterization lab activation, and the procedure itself), fibrinolytic therapy should be administered with a door-to-needle time goal of 30 minutes or less. Fibrinolytics are most effective within the first 3 hours of symptom onset. After receiving fibrinolytics, patients should still be transferred to a PCI-capable center for routine coronary angiography within 3 to 24 hours (the pharmacoinvasive strategy).\n\nCONTRAINDICATIONS TO FIBRINOLYSIS:\nAbsolute contraindications include active internal bleeding (excluding menses), history of hemorrhagic stroke at any time, ischemic stroke within 3 months, intracranial neoplasm or arteriovenous malformation, suspected aortic dissection, significant head or facial trauma within 3 months, and active bleeding or bleeding diathesis. Patients with contraindications should be transferred for primary PCI regardless of expected delay.\n\nKEY POINTS:\nPrimary PCI is preferred for STEMI but must be achievable within 120 minutes of first medical contact; when it cannot, fibrinolysis should be given within 30 minutes (door-to-needle). After fibrinolysis, transfer for coronary angiography within 3 to 24 hours (pharmacoinvasive strategy) is standard. Fibrinolytics are most effective within the first 3 hours of symptom onset."
  },
  {
    "id": 616,
    "categoryId": 15,
    "question": "A 45-year-old woman presents with sudden severe headache ('worst of my life') and neck stiffness. CT head is negative. What is the next step?",
    "options": [
      "A) Reassurance and discharge",
      "B) Lumbar puncture",
      "C) MRI brain",
      "D) CT angiogram immediately"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Lumbar puncture).\n\nPATHOPHYSIOLOGY:\nSubarachnoid hemorrhage, most commonly caused by rupture of a saccular (berry) aneurysm at the circle of Willis, is a neurological emergency carrying an overall mortality of approximately 25 to 50%. Ruptured aneurysms account for approximately 85% of nontraumatic SAH, with the remainder caused by perimesencephalic hemorrhage, arteriovenous malformations, and other vascular anomalies. The most common locations for saccular aneurysms are the anterior communicating artery (the single most common site), the posterior communicating artery, and the middle cerebral artery bifurcation. Risk factors include hypertension, smoking, excessive alcohol use, family history of SAH, and connective tissue disorders (autosomal dominant polycystic kidney disease, Ehlers-Danlos type IV).\n\nCLINICAL REASONING:\nThe hallmark presentation is a sudden-onset, severe headache described as the \"worst headache of my life\" (thunderclap headache), often accompanied by neck stiffness (meningismus from blood irritating the meninges), nausea, vomiting, photophobia, and altered consciousness. Non-contrast CT of the head is the initial diagnostic test and is approximately 98% sensitive within 6 hours of symptom onset, but sensitivity declines to approximately 93% at 12 hours and approximately 50% at 1 week as blood is gradually resorbed. When CT is negative but clinical suspicion remains high, lumbar puncture is mandatory. LP findings diagnostic of SAH include elevated red blood cells that do not clear across sequential tubes (distinguishing SAH from a traumatic tap) and xanthochromia (yellow discoloration of the supernatant CSF from bilirubin produced by in vivo hemoglobin degradation, which takes approximately 6 to 12 hours to develop).\n\nMANAGEMENT:\nOnce SAH is confirmed, CT angiography identifies the culprit aneurysm, and definitive treatment (either endovascular coiling or surgical clipping) should be performed as early as possible (ideally within 24 hours) to prevent devastating rebleeding. Nimodipine (60 mg orally every 4 hours for 21 days) is administered to reduce the risk of delayed cerebral ischemia from vasospasm, the most feared complication occurring between days 4 and 14.\n\nKEY POINTS:\nA negative CT does not rule out SAH, and lumbar puncture is mandatory when clinical suspicion is high, looking for non-clearing RBCs and xanthochromia. CT sensitivity for SAH declines significantly after 6 hours. Nimodipine reduces delayed cerebral ischemia from vasospasm, the most serious complication, occurring between days 4 and 14."
  },
  {
    "id": 617,
    "categoryId": 15,
    "question": "A patient in pulseless ventricular tachycardia persists after 2 shocks, CPR, and epinephrine. What is the next medication per ACLS?",
    "options": [
      "A) Lidocaine",
      "B) Amiodarone 300mg IV",
      "C) Magnesium 2g IV",
      "D) Procainamide"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Amiodarone 300mg IV).\n\nPATHOPHYSIOLOGY:\nPulseless ventricular tachycardia and ventricular fibrillation are shockable cardiac arrest rhythms in which organized or chaotic ventricular electrical activity fails to generate effective cardiac output. The myocardium in VF or pulseless VT is electrically active but mechanically ineffective, and defibrillation (delivery of an electrical countershock) is the only definitive treatment to restore an organized perfusing rhythm. The probability of successful defibrillation decreases by approximately 7 to 10% for each minute of delay.\n\nACLS ALGORITHM:\nThe Advanced Cardiovascular Life Support algorithm for shockable rhythms follows a structured sequence. High-quality CPR is initiated immediately and continued with minimal interruptions (goal chest compression fraction greater than 80%). The sequence proceeds as follows: first shock is delivered, followed by 2 minutes of CPR, then second shock, followed by 2 minutes of CPR with epinephrine 1 mg IV/IO (repeated every 3 to 5 minutes), then third shock, followed by 2 minutes of CPR with amiodarone 300 mg IV/IO bolus. If pulseless VT/VF persists, a subsequent dose of amiodarone 150 mg IV may be given. Amiodarone is a class III antiarrhythmic that blocks potassium, sodium, and calcium channels and has antiadrenergic properties, making it the most effective antiarrhythmic for shock-refractory VF/VT.\n\nIMPORTANT DISTINCTIONS:\nMagnesium sulfate (2 grams IV) is specifically indicated for torsades de pointes (polymorphic VT associated with QT prolongation) and should not be used routinely for VF/pVT. Lidocaine (1 to 1.5 mg/kg IV) is an acceptable alternative to amiodarone if amiodarone is unavailable. Throughout the arrest, reversible causes should be systematically addressed using the H's and T's framework: hypovolemia, hypoxia, hydrogen ion (acidosis), hypo/hyperkalemia, hypothermia, tension pneumothorax, tamponade, toxins, and thrombosis (coronary or pulmonary).\n\nKEY POINTS:\nThe ACLS shockable rhythm algorithm follows the sequence of shock, CPR, shock, CPR plus epinephrine, shock, CPR plus amiodarone 300 mg, with high-quality CPR and minimal interruptions as the foundation. Amiodarone is the first-line antiarrhythmic for shock-refractory VF/pVT, while magnesium is reserved specifically for torsades de pointes. Reversible causes should be systematically addressed using the H's and T's framework throughout the arrest."
  },
  {
    "id": 618,
    "categoryId": 15,
    "question": "A 30-year-old male after a house fire has singed nasal hairs, facial burns, and hoarse voice. O2 sat is 94%. What is the most critical immediate action?",
    "options": [
      "A) Apply silver sulfadiazine",
      "B) Obtain carboxyhemoglobin level",
      "C) Early endotracheal intubation",
      "D) IV fluid resuscitation"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Early endotracheal intubation).\n\nPATHOPHYSIOLOGY:\nInhalation injury is the leading cause of death in burn patients, responsible for approximately 60 to 80% of fire-related mortality. Thermal injury to the upper airway (above the glottis) from superheated air and steam causes progressive mucosal edema of the oropharynx, larynx, and supraglottic structures that can rapidly progress to complete airway obstruction over minutes to hours. The upper airway is extremely efficient at heat dissipation, so thermal injury rarely extends below the vocal cords except in the case of steam inhalation (which carries 4,000 times the heat capacity of dry air). Chemical injury to the lower airways and pulmonary parenchyma results from inhalation of toxic combustion products (aldehydes, hydrogen chloride, phosgene, sulfur dioxide) that cause tracheobronchitis, bronchospasm, and acute respiratory distress syndrome.\n\nCLINICAL REASONING:\nThe patient has multiple signs of inhalation injury: singed nasal hairs, facial burns, and hoarseness (indicating laryngeal edema). Additional red flags include carbonaceous sputum, stridor, drooling, oropharyngeal edema or erythema on direct visualization, and history of entrapment in an enclosed-space fire. The critical principle is that airway edema progresses rapidly and unpredictably, and a patient with a patent airway can develop complete obstruction within hours. The widely cited teaching: \"if you are thinking about intubating a burn patient, do it now.\" Delay until frank stridor or respiratory failure develops risks encountering a massively edematous airway that may be impossible to intubate, necessitating a surgical airway under catastrophic circumstances.\n\nADDITIONAL CONSIDERATIONS:\nPulse oximetry is unreliable with carbon monoxide poisoning because conventional pulse oximeters cannot distinguish carboxyhemoglobin from oxyhemoglobin, resulting in falsely normal or elevated SpO2 readings. A co-oximetry panel (carboxyhemoglobin and methemoglobin levels) should be obtained. High-flow 100% oxygen is administered to all fire victims (the half-life of carboxyhemoglobin decreases from approximately 5 hours on room air to approximately 60 to 90 minutes on 100% FiO2). Fluid resuscitation for burn patients follows the Parkland formula (4 mL/kg per percent total body surface area burned of lactated Ringer's over the first 24 hours), but airway management takes absolute priority.\n\nKEY POINTS:\nSinged nasal hairs, facial burns, and hoarseness are red flags for inhalation injury requiring early intubation before progressive airway edema makes it impossible. Pulse oximetry is unreliable in CO poisoning because it cannot distinguish carboxyhemoglobin from oxyhemoglobin. The clinical rule is to intubate early when inhalation injury is suspected rather than waiting for complete obstruction."
  },
  {
    "id": 619,
    "categoryId": 15,
    "question": "A 70-year-old on warfarin (INR 4.5) presents after a fall with headache and confusion. CT shows acute subdural hematoma with midline shift. What is the priority intervention?",
    "options": [
      "A) Neurosurgery only",
      "B) IV Vitamin K alone",
      "C) 4-factor PCC + IV Vitamin K",
      "D) FFP transfusion"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (4-factor PCC plus IV Vitamin K).\n\nPATHOPHYSIOLOGY:\nWarfarin inhibits vitamin K epoxide reductase (VKORC1), preventing the regeneration of reduced vitamin K required for hepatic gamma-carboxylation of clotting factors II, VII, IX, and X (and proteins C and S). The INR (international normalized ratio) reflects the degree of anticoagulation, with therapeutic ranges typically between 2.0 and 3.0 for most indications. An INR of 4.5 represents significant supratherapeutic anticoagulation with markedly elevated bleeding risk. In the setting of traumatic intracranial hemorrhage with midline shift, the anticoagulation must be reversed immediately, as expanding hematoma volume directly correlates with neurological deterioration and mortality.\n\nCLINICAL REASONING:\nThe patient has a life-threatening warfarin-associated intracranial hemorrhage requiring emergent reversal. Four-factor prothrombin complex concentrate (4F-PCC, brand name Kcentra) is the preferred reversal agent because it provides immediate, complete INR correction within minutes by directly supplying the deficient vitamin K-dependent clotting factors (II, VII, IX, X) in concentrated form. 4F-PCC is strongly preferred over fresh frozen plasma (FFP) for several reasons: it acts within 10 to 15 minutes versus 6 to 8 hours for FFP infusion, requires a small infusion volume (approximately 20 to 40 mL versus 800 to 1,600 mL for FFP, avoiding volume overload), does not require ABO blood type matching or thawing time, and achieves more reliable INR normalization. IV vitamin K (10 mg infused slowly over 10 to 20 minutes) must be administered concurrently because PCC provides only transient factor replacement (half-life of factor VII is approximately 6 hours), while vitamin K enables endogenous hepatic factor synthesis to sustain reversal over 12 to 24 hours, preventing INR rebound.\n\nMANAGEMENT:\nAfter anticoagulation reversal, emergent neurosurgical consultation is required for evaluation of surgical evacuation. INR should be rechecked within 30 minutes of PCC administration to confirm correction to less than 1.5. Blood pressure should be aggressively lowered (target systolic less than 140 mmHg).\n\nKEY POINTS:\n4-factor PCC is preferred over FFP for life-threatening warfarin reversal because it provides immediate, complete INR correction in a small volume without requiring blood typing or thawing. IV vitamin K must be given concurrently to sustain reversal and prevent INR rebound after PCC factor levels decline. The combination of PCC plus vitamin K is the standard of care for warfarin-associated intracranial hemorrhage."
  },
  {
    "id": 620,
    "categoryId": 17,
    "question": "An 8-year-old presents with drooling, dysphagia, and 'hot potato' voice after eating popcorn. He is sitting upright, leaning forward. No stridor at rest. O2 sat 96%. What is the best next step?",
    "options": [
      "A) Immediate cricothyrotomy",
      "B) Direct laryngoscopy in OR setting",
      "C) Bronchoscopy at bedside",
      "D) CT neck"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Direct laryngoscopy in OR).\n\nPATHOPHYSIOLOGY:\nForeign body aspiration in children is a common and potentially life-threatening event, with peak incidence between ages 1-3 years. Objects may lodge in the supraglottic, glottic, or bronchial airways. Partial obstruction allows air movement but may acutely progress to complete obstruction from edema, manipulation, or positional change.\n\nCLINICAL PRESENTATION:\n- History of acute choking episode while eating or playing with small objects\n- Drooling, dysphagia, and muffled or hot potato voice suggest a supraglottic or hypopharyngeal location\n- Stridor (inspiratory): Upper airway obstruction\n- Wheezing (expiratory): Lower airway/bronchial foreign body\n- A child sitting upright and leaning forward with no stridor at rest indicates partial obstruction with a patent airway\n\nCRITICAL MANAGEMENT:\n- If the child is stable (breathing, maintaining oxygen saturation, no stridor at rest): Do NOT perform blind finger sweeps, back blows, or bedside laryngoscopy. These maneuvers can convert a partial obstruction into a complete one.\n- Transport the child to the operating room for direct laryngoscopy and rigid bronchoscopy under general anesthesia with ENT/anesthesia\n- Allow the child to remain in the position of comfort; avoid agitation\n\nIF COMPLETE OBSTRUCTION (unable to speak, cough, or breathe):\n- Infants (less than 1 year): 5 back blows + 5 chest thrusts, repeat cycle\n- Children (over 1 year): Abdominal thrusts (Heimlich maneuver)\n- If unsuccessful: Attempt direct laryngoscopy and Magill forceps removal; prepare for surgical airway\n\nDIAGNOSTIC WORKUP:\nChest and neck radiographs (inspiratory and expiratory views) may show radiopaque foreign bodies, unilateral hyperinflation (air trapping from ball-valve obstruction), or atelectasis. Note that most aspirated objects in children (food items) are radiolucent.\n\nKEY POINTS:\nA stable child with suspected foreign body aspiration should go to the OR for controlled rigid bronchoscopy, not bedside intervention. Avoid agitating the child or performing maneuvers that could convert partial to complete obstruction. Abdominal thrusts or back blows are reserved for complete airway obstruction.\n---"
  },
  {
    "id": 621,
    "categoryId": 15,
    "question": "A 28-year-old presents after a seizure. Labs show sodium 118 mEq/L. He drank 6L of water during a marathon. What is the treatment?",
    "options": [
      "A) Fluid restriction alone",
      "B) Normal saline bolus",
      "C) Hypertonic saline (3%) bolus",
      "D) Demeclocycline"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Hypertonic saline 3% bolus).\n\nPATHOPHYSIOLOGY:\nHyponatremia (sodium <135 mEq/L) is the most common electrolyte abnormality. This patient has severe symptomatic hyponatremia (sodium 118 mEq/L with seizure) from acute water intoxication during a marathon. Excessive water dilutes extracellular sodium, creating an osmotic gradient driving water into brain cells and causing cerebral edema. In acute hyponatremia (<48 hours), the brain lacks time for osmotic adaptation (extrusion of intracellular solutes), so edema progresses rapidly from nausea to confusion, seizures, herniation, and death.\n\nCLINICAL REASONING:\nSevere symptomatic hyponatremia with seizures is a medical emergency requiring hypertonic saline (3% NaCl). Give a 100-150 mL bolus over 10-20 minutes, repeatable up to 2-3 times if symptoms persist. The goal is raising sodium by 4-6 mEq/L in the first 1-2 hours to reduce cerebral edema and stop seizures. Check sodium every 1-2 hours during correction.\n\nRISK OF OVERCORRECTION:\nChronic hyponatremia correction must be limited to avoid osmotic demyelination syndrome (ODS, formerly central pontine myelinolysis)\u2014a devastating complication from rapid osmotic shifts out of adapted brain cells, causing quadriplegia, pseudobulbar palsy, and locked-in syndrome. Maximum correction: 8 mEq/L in any 24-hour period for chronic hyponatremia. In acute hyponatremia (<48 hours, as in this marathon runner), ODS risk is lower because adaptation has not occurred, and more rapid correction is safer. Desmopressin (DDAVP) can relower sodium if overcorrection occurs.\n\nKEY POINTS:\nSevere symptomatic hyponatremia with seizures requires emergent 3% saline (100-150 mL bolus over 10-20 minutes), targeting 4-6 mEq/L rise in 1-2 hours. Chronic hyponatremia correction must not exceed 8 mEq/L/24 hours to avoid ODS. Acute hyponatremia (<48 hours) can be corrected more rapidly since osmotic adaptation has not occurred."
  },
  {
    "id": 622,
    "categoryId": 17,
    "question": "A 60-year-old diabetic presents with facial pain and a black necrotic eschar on the nasal turbinate. CT shows skull base erosion. He has DKA. What is the emergent treatment?",
    "options": [
      "A) IV antibiotics",
      "B) IV amphotericin B + emergent surgical debridement",
      "C) IV voriconazole",
      "D) Nasal packing"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (IV Amphotericin B + Emergent Surgical Debridement).\n\nDIAGNOSIS:\nRhinocerebral mucormycosis (zygomycosis), a rapidly progressive and life-threatening invasive fungal infection caused by fungi of the order Mucorales (Rhizopus, Mucor, Rhizomucor). This is a medical and surgical emergency with mortality rates of 50-80% even with treatment.\n\nCLINICAL PRESENTATION:\nThe classic presentation includes facial pain, nasal congestion progressing to black necrotic eschars on the nasal turbinates or palate, periorbital edema, and proptosis. The black eschar represents tissue infarction caused by fungal angioinvasion, where hyphae invade blood vessel walls, causing thrombosis and ischemic necrosis. CT imaging may show sinusitis with bony erosion, and the infection can rapidly extend into the orbit and brain.\n\nRISK FACTORS:\nDiabetic ketoacidosis is the most common predisposing condition because the acidotic, hyperglycemic environment with elevated free iron provides ideal growth conditions for Mucorales. Other risk factors include immunosuppression (transplant recipients, neutropenia), iron overload, and deferoxamine therapy.\n\nTREATMENT:\nTreatment requires BOTH aggressive antifungal therapy AND surgical debridement. IV liposomal amphotericin B is the drug of choice. Emergent surgical debridement of all necrotic tissue is essential because the fungal angioinvasion causes tissue infarction where antifungals cannot penetrate. Correction of the underlying DKA and metabolic derangements is critical. Posaconazole or isavuconazole can be used as step-down therapy.\n\nKEY POINTS:\nMucormycosis in a diabetic with DKA and black nasal eschar is a surgical emergency. Treatment requires both IV amphotericin B AND surgical debridement. Black eschar results from fungal angioinvasion causing vascular thrombosis and tissue necrosis."
  },
  {
    "id": 623,
    "categoryId": 15,
    "question": "A 25-year-old after MVC is tachycardic, hypotensive, with distended neck veins and muffled heart sounds. Breath sounds are equal. What is the diagnosis?",
    "options": [
      "A) Tension pneumothorax",
      "B) Cardiac tamponade",
      "C) Massive hemothorax",
      "D) Aortic transection"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Cardiac tamponade).\n\nPATHOPHYSIOLOGY:\nCardiac tamponade occurs when fluid accumulates in the pericardial space, compressing cardiac chambers and impairing diastolic filling. The pericardium is relatively noncompliant; acute accumulation of as little as 100-200 mL of blood can produce hemodynamic collapse. Rising intrapericardial pressure first compresses the right atrium and ventricle (lowest-pressure chambers), reducing venous return and cardiac output. As intrapericardial pressure approaches intracardiac diastolic pressures, equalization of diastolic pressures across all four chambers occurs\u2014the hemodynamic hallmark of tamponade.\n\nCLINICAL REASONING:\nThe patient presents with Beck's triad: hypotension (decreased cardiac output), jugular venous distension (impaired venous return), and muffled heart sounds (insulating blood layer). Beck's triad is present in approximately one-third of acute traumatic tamponade cases and is essentially pathognomonic. The critical distinction from tension pneumothorax: tamponade has equal bilateral breath sounds, while tension pneumothorax has absent breath sounds on the affected side with tracheal deviation. Pulsus paradoxus (systolic BP drop >10 mmHg during inspiration) is another classic finding, reflecting exaggerated interventricular septal shift in a fixed pericardial space.\n\nMANAGEMENT:\nPericardiocentesis (subxiphoid approach, often ultrasound-guided) is the emergency temporizing procedure. Removing even 15-20 mL can dramatically improve hemodynamics. Definitive treatment requires surgical exploration (emergency thoracotomy or sternotomy) to repair the cardiac injury. FAST ultrasound rapidly identifies pericardial fluid at the bedside.\n\nKEY POINTS:\nBeck's triad (hypotension, JVD, muffled heart sounds) with equal bilateral breath sounds identifies cardiac tamponade, distinguishing it from tension pneumothorax. Acute traumatic tamponade can result from as little as 100-200 mL of blood. Pericardiocentesis is the emergency temporizing procedure, with definitive surgical repair required."
  },
  {
    "id": 624,
    "categoryId": 11,
    "question": "A 35-year-old woman presents with depressed mood, anhedonia, and insomnia for 3 weeks after her mother's death. She denies suicidal ideation and is functioning at work. What is the most likely diagnosis?",
    "options": [
      "A) Major Depressive Disorder",
      "B) Normal grief reaction",
      "C) Adjustment Disorder",
      "D) Persistent Depressive Disorder"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Normal grief reaction).\n\nDIAGNOSTIC REASONING:\nThis patient presents with depressed mood, anhedonia, and insomnia lasting 3 weeks following the death of her mother, which is. The DSM-5 removed the previous \"bereavement exclusion\" that had prevented diagnosing MDD within 2 months of a loss, but clinicians must still exercise careful judgment in distinguishing normal grief from a major depressive episode.\n\nGRIEF VERSUS MAJOR DEPRESSION:\nNormal grief involves waves of sadness and longing that are often triggered by reminders of the deceased, with the ability to experience moments of positive emotion and humor interspersed between grief episodes. The bereaved person typically maintains a sense of self-worth, can envision a future (even if diminished), and the dysphoria is focused on the loss. Major depressive disorder, by contrast, features persistent, pervasive depressed mood unrelated to specific triggers, marked feelings of worthlessness or excessive guilt (beyond guilt about the deceased), inability to experience any pleasure, psychomotor retardation, and particularly suicidal ideation with a plan. This patient denies suicidal ideation and remains functional, supporting the grief diagnosis.\n\nPROLONGED GRIEF DISORDER:\nThe DSM-5-TR introduced prolonged grief disorder (PGD) as a new diagnosis for grief that persists beyond 12 months (6 months in ICD-11) and involves intense yearning, preoccupation with the deceased, identity disruption, marked difficulty accepting the death, emotional numbness, and significant functional impairment. At only 3 weeks, this patient's timeline is far too early for PGD or for diagnosing MDD in the context of bereavement.\n\nCLINICAL APPROACH:\nSupportive counseling, validation of the grief process, and close follow-up are appropriate. Red flags that should prompt reevaluation for MDD include suicidal ideation, psychotic features, severe functional decline, marked feelings of worthlessness, or persistent symptoms beyond 2 to 3 months without improvement.\n\nKEY POINTS:\nNormal grief features waves of sadness with preserved self-worth and intermittent positive emotions, while MDD features persistent pervasive dysphoria with worthlessness and suicidal ideation. At 3 weeks post-loss with maintained function and no suicidal ideation, this presentation is normal bereavement. Prolonged grief disorder requires symptoms persisting beyond 12 months."
  },
  {
    "id": 625,
    "categoryId": 11,
    "question": "A 45-year-old with depression has failed two adequate SSRI trials. His PHQ-9 is 18. What is the recommended next step?",
    "options": [
      "A) Try a third SSRI",
      "B) Augment with atypical antipsychotic or switch class",
      "C) Electroconvulsive therapy",
      "D) Psychotherapy alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Augment with atypical antipsychotic or switch class).\n\nCLINICAL REASONING:\nTreatment-resistant depression (TRD) is commonly defined as failure to achieve adequate response after two trials of antidepressants from different classes at adequate doses for adequate duration (typically 6 to 8 weeks each). This patient has failed two adequate SSRI trials with a PHQ-9 of 18 (moderately severe), warranting a change in strategy rather than a third SSRI trial.\n\nAUGMENTATION STRATEGIES:\nThe STAR*D trial (Sequenced Treatment Alternatives to Relieve Depression), the largest study of treatment-resistant depression, demonstrated that response rates diminish with each successive antidepressant trial: approximately 37% remitted with first-line citalopram, while only 13% remitted by the fourth treatment step. Evidence-based augmentation options include adding an atypical antipsychotic (aripiprazole has the strongest evidence, followed by quetiapine and brexpiprazole; aripiprazole augmentation produces remission in approximately 25 to 30% of SSRI non-responders), adding lithium (well-established augmentation with evidence from multiple RCTs), or adding thyroid hormone (T3, liothyronine 25 to 50 mcg/day).\n\nSWITCHING STRATEGIES:\nSwitching to a different antidepressant class (SNRI such as venlafaxine or duloxetine, bupropion, or mirtazapine) is an alternative to augmentation. Switching within the same class (trying a third SSRI) has diminishing returns and is generally not recommended after two adequate SSRI failures. Newer options for TRD include esketamine (Spravato) nasal spray (FDA-approved for TRD in conjunction with an oral antidepressant) and transcranial magnetic stimulation (TMS, FDA-cleared for MDD non-responsive to medication).\n\nWHEN TO CONSIDER ECT:\nElectroconvulsive therapy (ECT) remains the most effective treatment for severe, refractory depression (remission rates of 50 to 70%) and is indicated for TRD with psychotic features, severe suicidality, catatonia, or medication intolerance. It is not typically the next step after only two SSRI failures.\n\nKEY POINTS:\nAfter two adequate SSRI failures, augmentation (aripiprazole, lithium, T3) or switching class (to SNRI, bupropion, or mirtazapine) is recommended rather than trying a third SSRI. The STAR*D trial showed diminishing remission rates with each successive treatment step. Esketamine nasal spray and TMS are newer FDA-approved options for treatment-resistant depression."
  },
  {
    "id": 626,
    "categoryId": 11,
    "question": "A 22-year-old presents with 2 weeks of elevated mood, decreased sleep (3 hours/night), rapid speech, and impulsive spending. What is the diagnosis?",
    "options": [
      "A) Bipolar I Disorder, Manic Episode",
      "B) Bipolar II Disorder",
      "C) Cyclothymic Disorder",
      "D) ADHD"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Bipolar I Disorder, Manic Episode).\n\nDIAGNOSTIC CRITERIA:\nBipolar I disorder is defined by the occurrence of at least one manic episode lasting 7 or more days (or any duration if hospitalization is required). A manic episode requires a distinct period of abnormally and persistently elevated, expansive, or irritable mood with increased energy or activity, plus at least three of the following (four if mood is irritable only): decreased need for sleep (feeling rested after 3 hours, as in this patient), pressured speech, racing thoughts or flight of ideas, distractibility, increased goal-directed activity or psychomotor agitation, and excessive involvement in pleasurable activities with high potential for painful consequences (impulsive spending, sexual indiscretions, reckless investments).\n\nDIFFERENTIAL DIAGNOSIS:\nBipolar II disorder requires at least one hypomanic episode (lasting 4 or more days with less severe symptoms that do not cause marked functional impairment or require hospitalization) plus at least one major depressive episode. This patient's 2 weeks of severe symptoms with impulsive spending (functional impairment) exceeds hypomania criteria. Cyclothymic disorder involves chronic (2 or more years) fluctuating hypomanic and depressive symptoms that never meet full criteria for either a manic or major depressive episode. ADHD can feature distractibility, impulsivity, and restlessness but has a chronic, non-episodic course with onset before age 12.\n\nTREATMENT:\nAcute mania requires mood stabilization with lithium (the gold standard with the strongest evidence for both acute mania and long-term prophylaxis), valproic acid (rapid loading is effective for acute mania), or a second-generation antipsychotic (olanzapine, quetiapine, aripiprazole, risperidone). Antidepressant monotherapy is contraindicated in bipolar disorder due to the risk of inducing mania or rapid cycling.\n\nKEY POINTS:\nBipolar I requires at least one manic episode (7 or more days of elevated mood with decreased sleep need, pressured speech, grandiosity, and impulsive risk-taking). This is distinguished from Bipolar II (hypomania without marked impairment), cyclothymia (chronic subthreshold cycling), and ADHD (chronic non-episodic course). Lithium is the gold standard for acute mania and long-term prophylaxis."
  },
  {
    "id": 627,
    "categoryId": 11,
    "question": "A 70-year-old presents with progressive forgetfulness over 2 years, now getting lost in familiar places. MMSE is 20/30. Short-term memory loss is prominent. What is the most likely diagnosis?",
    "options": [
      "A) Delirium",
      "B) Alzheimer's disease",
      "C) Vascular dementia",
      "D) Normal aging"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Alzheimer's disease).\n\nCLINICAL REASONING:\nThis 70-year-old presents with the hallmark pattern of Alzheimer's disease: insidious onset of progressive memory impairment over 2 years, predominantly affecting short-term (episodic) memory, with gradual decline in spatial navigation (getting lost in familiar places) and an MMSE score of 20/30 (mild cognitive impairment to early dementia range). Alzheimer's disease accounts for 60 to 80% of all dementia cases and is a common cause of dementia in older adults.\n\nPATHOPHYSIOLOGY:\nAlzheimer's disease involves extracellular amyloid-beta plaques (from abnormal cleavage of amyloid precursor protein by beta and gamma secretases) and intracellular neurofibrillary tangles (composed of hyperphosphorylated tau protein) that initially accumulate in the entorhinal cortex and hippocampus (explaining the early prominence of short-term memory loss) before spreading to the temporal, parietal, and eventually frontal cortices. Synaptic loss and neuronal death produce progressive cortical atrophy visible on brain imaging.\n\nDIFFERENTIAL DIAGNOSIS:\nDelirium presents acutely (hours to days, not years), features fluctuating attention and consciousness, and is usually triggered by an identifiable medical cause (infection, medication, metabolic derangement). Vascular dementia characteristically presents with stepwise decline (sudden worsening coinciding with cerebrovascular events), focal neurologic deficits, and prominent executive dysfunction rather than isolated memory loss. Normal aging involves mild forgetfulness (misplacing keys, difficulty recalling names) but does not impair daily function or cause disorientation in familiar environments.\n\nMANAGEMENT:\nCholinesterase inhibitors (donepezil, rivastigmine, galantamine) are first-line pharmacotherapy for mild to moderate Alzheimer's disease, providing modest symptomatic improvement by increasing acetylcholine availability in the synaptic cleft. Memantine (an NMDA receptor antagonist) is added for moderate to severe disease. Newer anti-amyloid monoclonal antibodies (lecanemab, donanemab) have received FDA approval based on evidence of slowing cognitive decline in early Alzheimer's disease.\n\nKEY POINTS:\nAlzheimer's disease presents with insidious progressive short-term memory loss (hippocampal involvement) and is the most common dementia (60 to 80% of cases). It is distinguished from delirium (acute, fluctuating) and vascular dementia (stepwise, executive dysfunction). Cholinesterase inhibitors are first-line, with newer anti-amyloid antibodies (lecanemab) showing disease-modifying potential."
  },
  {
    "id": 628,
    "categoryId": 11,
    "question": "A 16-year-old has difficulty concentrating, is easily distracted, fidgets constantly, and interrupts others. Symptoms present since age 7 in multiple settings. What is the first-line pharmacotherapy?",
    "options": [
      "A) Atomoxetine",
      "B) Methylphenidate or amphetamine",
      "C) Bupropion",
      "D) Clonidine"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Methylphenidate or amphetamine).\n\nDIAGNOSTIC CONFIRMATION:\nThis patient meets DSM-5 criteria for ADHD: multiple symptoms of inattention (difficulty concentrating, easily distracted) and hyperactivity-impulsivity (fidgeting, interrupting others) present since age 7 (before age 12 criterion satisfied), occurring in multiple settings (school, home), and causing functional impairment. The combined presentation (both inattentive and hyperactive-impulsive symptoms) is the most common subtype.\n\nFIRST-LINE PHARMACOTHERAPY:\nStimulant medications (methylphenidate and amphetamine formulations) are first-line pharmacotherapy for ADHD in children, adolescents, and adults, American Academy of Child and Adolescent Psychiatry (AACAP). Stimulants have the largest effect sizes of any ADHD medication (effect size approximately 0.8 to 1.0, considered large) and produce improvement in approximately 70 to 80% of patients. Methylphenidate (Ritalin, Concerta, Focalin) blocks the dopamine transporter (DAT) and norepinephrine transporter (NET) in the prefrontal cortex and striatum, increasing catecholamine availability in the synaptic cleft. Amphetamine formulations (Adderall, Vyvanse) both block reuptake and promote active release of dopamine and norepinephrine from presynaptic vesicles.\n\nNON-STIMULANT ALTERNATIVES:\nAtomoxetine (Strattera), a selective norepinephrine reuptake inhibitor, is first-line for patients who cannot tolerate stimulants, have comorbid anxiety, or have substance abuse concerns. Alpha-2 agonists (guanfacine extended-release, clonidine extended-release) are second-line options, particularly useful for hyperactivity and oppositional symptoms. Bupropion has off-label evidence for adult ADHD but is not FDA-approved for this indication.\n\nMONITORING:\nBefore initiating stimulants, clinicians should assess cardiovascular risk (personal and family history of sudden cardiac death, structural heart disease, arrhythmias), obtain baseline height, weight, blood pressure, and heart rate. Ongoing monitoring includes growth parameters (stimulants may suppress appetite and slow growth), cardiovascular vitals, and screening for side effects including insomnia, appetite suppression, and mood changes.\n\nKEY POINTS:\nStimulants (methylphenidate, amphetamine) are first-line ADHD treatment with the largest effect sizes (0.8 to 1.0) and 70 to 80% response rates. They work by increasing prefrontal dopamine and norepinephrine via transporter blockade. Atomoxetine is first-line for patients with contraindications to stimulants. Pre-treatment cardiovascular screening and ongoing growth monitoring are essential."
  },
  {
    "id": 629,
    "categoryId": 11,
    "question": "A 55-year-old with alcohol use disorder wants to maintain abstinence. He drinks a pint of vodka daily with history of withdrawal seizures. Which FDA-approved medication reduces craving?",
    "options": [
      "A) Gabapentin",
      "B) Naltrexone",
      "C) Benzodiazepines",
      "D) Baclofen"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Naltrexone).\n\nPHARMACOLOGY:\nNaltrexone is an opioid receptor antagonist (blocking mu, kappa, and delta opioid receptors) that is FDA-approved for maintaining abstinence in alcohol use disorder (AUD). Three medications are FDA-approved for AUD: naltrexone (oral 50 mg daily or extended-release intramuscular injection 380 mg monthly), acamprosate (which modulates glutamate/GABA balance), and disulfiram (which inhibits aldehyde dehydrogenase causing an aversive reaction to alcohol).\n\nMECHANISM:\nAlcohol stimulates endogenous opioid release in the ventral tegmental area and nucleus accumbens, producing the rewarding and reinforcing effects that drive continued drinking. Naltrexone blocks these opioid receptors, reducing the pleasurable effects of alcohol (reward extinction), decreasing craving, and reducing the number of heavy drinking days. The COMBINE trial demonstrated that naltrexone (combined with medical management) significantly reduced heavy drinking days and improved drinking outcomes.\n\nCLINICAL CONSIDERATIONS:\nNaltrexone should not be initiated until the patient has completed acute detoxification and is no longer physically dependent on alcohol, as it does not treat or prevent withdrawal. This patient's history of withdrawal seizures mandates medically supervised detoxification with benzodiazepines (using the CIWA-Ar protocol) before starting naltrexone. Naltrexone is contraindicated in patients currently taking opioids (it will precipitate acute opioid withdrawal) and in acute hepatitis or liver failure (though mild to moderate liver disease is not a contraindication). Hepatic function should be monitored periodically.\n\nACAPROSATE VERSUS NALTREXONE:\nAcamprosate (which restores glutamate/GABA homeostasis disrupted by chronic alcohol exposure) is preferred in patients who have achieved complete abstinence, while naltrexone is more effective in patients whose goal is reducing heavy drinking. Acamprosate is renally eliminated and safe in liver disease but contraindicated in severe renal impairment.\n\nKEY POINTS:\nNaltrexone is an opioid antagonist that reduces alcohol reward and craving by blocking endogenous opioid release in the mesolimbic reward pathway. It must be initiated after detoxification (not during withdrawal) and is contraindicated with concurrent opioid use. The three FDA-approved AUD medications are naltrexone, acamprosate, and disulfiram."
  },
  {
    "id": 630,
    "categoryId": 11,
    "question": "A patient on fluoxetine 40mg for 6 months feels much better and wants to stop. What is the appropriate guidance?",
    "options": [
      "A) Stop immediately",
      "B) Taper over 2-4 weeks",
      "C) Continue 4-9 months from remission before tapering",
      "D) Switch medications first"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Continue 4 to 9 months from remission before tapering).\n\nGUIDELINE BASIS:\nThe APA, ACP, and NICE guidelines recommend continuing antidepressant therapy for a minimum of 4 to 9 months after achieving full symptomatic remission before considering tapering and discontinuation. This continuation phase is critical because the risk of relapse (return of the same depressive episode) is highest in the first 6 to 12 months after remission, and premature discontinuation is the single most common cause of depressive relapse.\n\nEVIDENCE:\nMultiple randomized controlled trials demonstrate that continuation-phase antidepressant therapy reduces relapse risk by approximately 50 to 70% compared to placebo substitution after remission. A meta-analysis in The Lancet Psychiatry confirmed that continuing antidepressants for 6 to 12 months after remission significantly reduces the likelihood of depressive recurrence across all antidepressant classes.\n\nTAPERING APPROACH:\nWhen discontinuation is appropriate, all SSRIs (except fluoxetine, which has a long half-life providing a built-in self-taper) should be gradually reduced over 4 to 8 weeks to minimize discontinuation syndrome (dizziness, nausea, brain zaps, irritability, insomnia). Fluoxetine at 40 mg can often be stopped without a prolonged taper due to its active metabolite norfluoxetine (half-life 4 to 16 days).\n\nMAINTENANCE THERAPY:\nPatients with risk factors for recurrence (three or more prior episodes, severe initial episode, residual symptoms, family history of recurrent depression, comorbid anxiety, early age of onset) should be considered for long-term maintenance therapy of 1 to 3 years or indefinitely. This patient at 6 months post-remission on a first episode should continue for at least 4 to 9 months from the point of remission before tapering.\n\nKEY POINTS:\nAntidepressants should be continued 4 to 9 months after achieving remission to prevent relapse, which is highest in the first 6 to 12 months. Premature discontinuation is a common cause of depressive relapse. Patients with three or more prior episodes, severe presentations, or residual symptoms should consider indefinite maintenance therapy."
  },
  {
    "id": 631,
    "categoryId": 11,
    "question": "A 30-year-old reports binge eating followed by self-induced vomiting 3-4 times per week for 6 months. She is normal weight. What is the first-line treatment?",
    "options": [
      "A) Fluoxetine 60mg daily",
      "B) Topiramate",
      "C) Cognitive Behavioral Therapy",
      "D) Hospitalization"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Cognitive Behavioral Therapy).\n\nDIAGNOSTIC CONTEXT:\nThis patient meets DSM-5 criteria for bulimia nervosa: recurrent episodes of binge eating (consuming an objectively large amount of food with a sense of loss of control) followed by compensatory behaviors (self-induced vomiting) occurring at least once per week for 3 months, with self-evaluation unduly influenced by body weight and shape, and not occurring exclusively during anorexia nervosa. Normal weight distinguishes bulimia from anorexia nervosa binge-purge subtype (which occurs at significantly low body weight).\n\nFIRST-LINE TREATMENT:\nCognitive Behavioral Therapy specifically adapted for eating disorders (CBT-E, or enhanced CBT) is the established first-line treatment for bulimia nervosa in adults, supported by the strongest evidence base of any intervention. CBT-E addresses the cognitive distortions maintaining the binge-purge cycle: overvaluation of weight and shape, dietary restraint and restriction (which triggers binge episodes), and compensatory behaviors. The treatment typically involves 20 sessions over 20 weeks and produces abstinence from binge-purge episodes in approximately 40 to 50% of patients, with an additional 30% achieving significant reduction.\n\nPHARMACOLOGIC OPTIONS:\nFluoxetine (Prozac) at 60 mg daily is the only FDA-approved medication for bulimia nervosa and is recommended as either an adjunct to CBT or as second-line monotherapy when CBT is unavailable or insufficient. The effective dose for bulimia (60 mg) is higher than the typical antidepressant dose (20 mg), and the anti-bulimic effect is independent of antidepressant action. Topiramate has off-label evidence for reducing binge frequency but is not first-line due to cognitive side effects.\n\nMEDICAL COMPLICATIONS:\nClinicians should monitor for complications of purging including hypokalemia (from vomiting-induced chloride and potassium losses), metabolic alkalosis, dental enamel erosion, parotid gland enlargement (sialadenosis), esophageal tears (Mallory-Weiss syndrome), and Russell's sign (calluses on dorsal knuckles from self-induced vomiting).\n\nKEY POINTS:\nCBT-E is first-line treatment for bulimia nervosa, achieving binge-purge abstinence in 40 to 50% of patients by addressing overvaluation of weight/shape and the restriction-binge-purge cycle. Fluoxetine 60 mg daily is the only FDA-approved medication and is second-line or adjunctive. Monitor for hypokalemia, metabolic alkalosis, dental erosion, and esophageal injury from purging."
  },
  {
    "id": 632,
    "categoryId": 11,
    "question": "A 25-year-old veteran reports intrusive memories, nightmares, hypervigilance, and avoidance 8 months after combat. What is the first-line treatment?",
    "options": [
      "A) Benzodiazepines",
      "B) Prazosin only",
      "C) Trauma-focused psychotherapy",
      "D) Antipsychotics"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Trauma-focused psychotherapy).\n\nDIAGNOSTIC CONTEXT:\nThis patient meets DSM-5 criteria for post-traumatic stress disorder (PTSD): exposure to a traumatic event (combat), followed by symptoms lasting more than 1 month across four symptom clusters: intrusion (intrusive memories, nightmares), avoidance (avoidance of trauma-related stimuli), negative alterations in cognition and mood, and hyperarousal (hypervigilance). At 8 months, this is well beyond the 1-month threshold that distinguishes PTSD from acute stress disorder (which resolves within 1 month).\n\nFIRST-LINE TREATMENT:\nTrauma-focused psychotherapies are recommended as first-line treatment for PTSD by the APA, VA/DoD Clinical Practice Guidelines, and international guidelines, with stronger evidence than pharmacotherapy. The three evidence-based trauma-focused therapies are Prolonged Exposure (PE, which involves repeated, systematic confrontation with trauma memories and avoided situations to facilitate emotional processing and extinction of fear responses), Cognitive Processing Therapy (CPT, which identifies and modifies maladaptive trauma-related beliefs called \"stuck points\"), and Eye Movement Desensitization and Reprocessing (EMDR, which uses bilateral stimulation during trauma recall to facilitate adaptive processing).\n\nPHARMACOTHERAPY:\nWhen pharmacotherapy is needed (as monotherapy if trauma-focused therapy is unavailable, or as augmentation), SSRIs (sertraline and paroxetine are the only FDA-approved medications for PTSD) and venlafaxine (SNRI) are first-line. Prazosin (an alpha-1 adrenergic antagonist) has evidence for reducing PTSD-related nightmares by blocking noradrenergic hyperactivation during sleep, though recent VA trials have shown mixed results. Benzodiazepines are not recommended for PTSD (they impair fear extinction, the mechanism underlying exposure therapy, and may worsen long-term outcomes).\n\nKEY POINTS:\nTrauma-focused psychotherapies (Prolonged Exposure, Cognitive Processing Therapy, EMDR) are first-line for PTSD, with stronger evidence than medications. Sertraline and paroxetine are the only FDA-approved PTSD pharmacotherapies. Benzodiazepines are specifically not recommended because they impair fear extinction and may worsen outcomes."
  },
  {
    "id": 633,
    "categoryId": 2,
    "question": "A 60-year-old with COPD (FEV1 45%) has had 3 exacerbations this year on tiotropium alone. Eosinophil count is 350 cells/ÂµL. According to GOLD 2024, what should be added?",
    "options": [
      "A) LABA only",
      "B) Inhaled corticosteroid",
      "C) Roflumilast",
      "D) Chronic azithromycin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Inhaled corticosteroid).\n\nCLINICAL REASONING:\nThe patient has COPD (FEV1 45% predicted, indicating severe airflow limitation), with a blood eosinophil count of 350 cells per microliter. Per the GOLD 2024 guidelines, the first escalation step from LAMA monotherapy for a frequent exacerbator is to add a LABA to form LAMA/LABA combination therapy. However, with eosinophils of 350 (exceeding the 300 threshold), the guidelines support proceeding directly to LAMA/LABA/ICS triple therapy, or at minimum adding ICS to the current LAMA, with subsequent LABA addition to complete the triple combination.\n\nRATIONALE FOR ICS IN EOSINOPHILIC COPD:\nElevated blood eosinophils identify a COPD phenotype with steroid-responsive airway inflammation. The FLAME trial demonstrated that LAMA/LABA was superior to ICS/LABA for exacerbation prevention in the general COPD population, but subgroup analyses consistently showed that patients with eosinophils 300 or greater derived significant additional benefit from ICS addition. ICS use in COPD carries a recognized risk of pneumonia (demonstrated in the TORCH and INSPIRE trials), which is why eosinophil-guided prescribing is essential: reserving ICS for patients most likely to benefit (eosinophils 300 or greater) while avoiding it in those unlikely to benefit (eosinophils less than 100), where pneumonia risk outweighs any anti-inflammatory advantage.\n\nALTERNATIVES NOT YET INDICATED:\nRoflumilast is a PDE4 inhibitor reserved for patients on triple therapy who continue to exacerbate, specifically those with chronic bronchitis phenotype and FEV1 less than 50%. While this patient's FEV1 of 45% would eventually qualify for roflumilast, it is not the next step before optimizing inhaler therapy. Chronic azithromycin is similarly a post-triple-therapy option for former smokers, requiring QTc monitoring and hearing assessment.\n\nKEY POINTS:\nIn a COPD patient on LAMA alone with frequent exacerbations and eosinophils 300 or greater, adding ICS (with LABA to form triple therapy) is the appropriate escalation. ICS use in COPD is guided by blood eosinophils to balance anti-inflammatory benefit against pneumonia risk. Roflumilast and azithromycin are reserved for persistent exacerbators despite optimized triple therapy."
  },
  {
    "id": 634,
    "categoryId": 2,
    "question": "A 50-year-old smoker with 35 pack-years quit 5 years ago. Per USPSTF 2021, is he eligible for lung cancer screening?",
    "options": [
      "A) No - must be current smoker",
      "B) No - quit too long ago",
      "C) Yes - meets criteria for annual low-dose CT",
      "D) No - only CXR is recommended"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Yes - meets criteria for annual low-dose CT).\n\nSCREENING RATIONALE:\nLung cancer is the leading cause of cancer death in the United States, and the majority of cases are diagnosed at advanced stages when curative treatment is no longer possible. The National Lung Screening Trial (NLST, published in the New England Journal of Medicine) demonstrated a 20% reduction in lung cancer mortality with annual low-dose CT compared to chest radiography in high-risk individuals. The subsequent NELSON trial confirmed these findings with a 24% mortality reduction in men.\n\nUSPSTF 2021 CRITERIA:\nThe USPSTF updated its lung cancer screening recommendation in 2021 to expand eligibility. Annual low-dose CT screening is recommended for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or have quit within the past 15 years. The 2021 update lowered the age threshold from 55 to 50 and the pack-year requirement from 30 to 20, substantially expanding the eligible population and addressing disparities in screening access among racial and ethnic minorities.\n\nAPPLICATION TO THIS PATIENT:\nThis patient meets all three criteria: age 50 (meets the 50 to 80 age range), 35 pack-year history (exceeds the 20 pack-year minimum), and quit 5 years ago (within the 15-year quit window). He is eligible for annual low-dose CT screening. Screening should be discontinued once the patient has not smoked for 15 years, develops a health condition that substantially limits life expectancy, or is unable or unwilling to undergo curative lung surgery.\n\nSHARED DECISION-MAKING:\nThe USPSTF recommends that screening be preceded by a shared decision-making discussion addressing the benefits (mortality reduction), harms (false-positive results leading to invasive procedures, incidental findings requiring follow-up, radiation exposure, overdiagnosis), and the importance of continued smoking cessation. Screening should be performed at centers with expertise in low-dose CT protocols and established processes for nodule management following the Lung-RADS classification system.\n\nKEY POINTS:\nUSPSTF 2021 recommends annual low-dose CT for adults aged 50 to 80 with 20 or more pack-year history who currently smoke or quit within 15 years. The NLST demonstrated a 20% lung cancer mortality reduction with LDCT screening. Screening is not a substitute for smoking cessation, and shared decision-making regarding benefits and harms is required."
  },
  {
    "id": 635,
    "categoryId": 2,
    "question": "A 35-year-old woman with asthma uses albuterol daily and wakes coughing 3 nights per week. She is on no controller. According to GINA 2024, what is the preferred treatment?",
    "options": [
      "A) Continue SABA alone",
      "B) Add daily low-dose ICS",
      "C) Start ICS-formoterol as maintenance and reliever (MART)",
      "D) Add daily LABA without ICS"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (ICS-formoterol as maintenance and reliever therapy, MART).\n\nCLINICAL REASONING:\nThe patient uses albuterol daily and wakes coughing 3 nights per week, indicating uncontrolled asthma with daily symptoms and frequent nocturnal awakenings on no controller therapy. Applying the Rules of Two, her symptom frequency (daily albuterol use) and nocturnal awakenings (3 per week, far exceeding 2 per month) place her at minimum in the moderate persistent category. However, the GINA 2024 approach focuses on treatment response rather than pre-treatment severity classification, and this patient clearly requires Step 3 therapy.\n\nTREATMENT APPROACH:\nGINA 2024 Step 3 preferred treatment (Track 1) is low-dose ICS-formoterol used as both maintenance and reliever therapy, known as the MART (Maintenance And Reliever Therapy) approach. The patient takes a scheduled dose of ICS-formoterol (typically budesonide-formoterol 200/6 mcg one inhalation twice daily) and uses the same inhaler for rescue symptoms as needed. This single-inhaler approach ensures anti-inflammatory corticosteroid delivery with every reliever dose, eliminates the need for a separate rescue inhaler, and simplifies the regimen to improve adherence.\n\nEVIDENCE BASE:\nThe MART approach has been validated in multiple large randomized controlled trials. The SMART (Single Maintenance and Reliever Therapy) program demonstrated that budesonide-formoterol as both maintenance and reliever reduced severe exacerbations by 45% compared to the same maintenance dose plus SABA rescue. The mechanism is that patients who are deteriorating automatically receive increased anti-inflammatory doses as their rescue use increases, providing an inherent self-adjusting feature.\n\nWHY NOT OTHER OPTIONS:\nContinuing SABA alone (A) is never recommended. Adding daily low-dose ICS (B) without a LABA would be Step 2 therapy, insufficient for this patient's symptom burden. Adding a daily LABA without ICS (D) is contraindicated in asthma due to the SMART trial evidence of increased asthma-related deaths with LABA monotherapy.\n\nKEY POINTS:\nThe MART approach (ICS-formoterol as both maintenance and reliever with a single inhaler) is the preferred GINA 2024 Step 3 therapy, ensuring anti-inflammatory delivery with every rescue dose. This self-adjusting strategy reduces severe exacerbations by 45% compared to fixed-dose maintenance plus SABA rescue. LABA monotherapy without ICS is contraindicated in asthma due to increased asthma-related death risk."
  },
  {
    "id": 636,
    "categoryId": 2,
    "question": "A 70-year-old with community-acquired pneumonia is admitted. CURB-65 score is 2. He has no recent hospitalization. What is the recommended empiric antibiotic regimen?",
    "options": [
      "A) Amoxicillin alone",
      "B) Respiratory fluoroquinolone OR beta-lactam + macrolide",
      "C) Vancomycin + piperacillin-tazobactam",
      "D) Azithromycin alone"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Respiratory fluoroquinolone alone OR beta-lactam plus macrolide).\n\nCLINICAL REASONING:\nThis 70-year-old patient has community-acquired pneumonia requiring hospital admission based on a CURB-65 score of 2. The CURB-65 score assigns one point each for Confusion, Uremia (BUN greater than 20 mg/dL), Respiratory rate 30 or greater, Blood pressure less than 90 systolic or 60 diastolic, and age 65 or older. A score of 0 to 1 supports outpatient management, a score of 2 warrants short hospitalization or closely supervised outpatient care, and a score of 3 to 5 requires hospitalization with ICU consideration for scores of 4 to 5.\n\nINPATIENT NON-ICU REGIMEN:\nFor non-ICU inpatients, the ATS/IDSA 2019 guidelines recommend two equivalent empiric regimens: a respiratory fluoroquinolone alone (levofloxacin 750 mg daily or moxifloxacin 400 mg daily), or a beta-lactam (ceftriaxone 1 to 2 grams IV daily, or ampicillin-sulbactam 1.5 to 3 grams IV every 6 hours) plus a macrolide (azithromycin 500 mg IV/PO daily). Both regimens provide coverage against the most common CAP pathogens: Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and atypical organisms (Mycoplasma, Chlamydophila, Legionella). The macrolide or fluoroquinolone component is essential for atypical coverage, as clinical presentation alone cannot reliably distinguish typical from atypical pneumonia.\n\nTREATMENT DURATION AND RESPONSE:\nA treatment duration of 5 days is adequate for the majority of patients who achieve clinical stability, defined as afebrile for 48 hours or more, improving respiratory status, ability to take oral medications, and hemodynamic stability without vasopressor support. Procalcitonin-guided therapy, with antibiotic discontinuation when levels fall below 0.25 ng/mL, has been shown to reduce antibiotic exposure without increasing adverse outcomes. Patients who fail to improve within 72 hours should be evaluated for complications (empyema, lung abscess), resistant organisms, or alternative diagnoses.\n\nKEY POINTS:\nInpatient non-ICU CAP empiric therapy is a respiratory fluoroquinolone alone or a beta-lactam plus macrolide. CURB-65 score of 2 warrants hospitalization for CAP management. Five days of antibiotics is sufficient for most patients achieving clinical stability within 48 to 72 hours."
  },
  {
    "id": 637,
    "categoryId": 17,
    "question": "A 45-year-old obese male (BMI 38) reports excessive daytime sleepiness, morning headaches, and witnessed apneas. What is the diagnostic test of choice?",
    "options": [
      "A) Overnight pulse oximetry",
      "B) Polysomnography",
      "C) Multiple Sleep Latency Test",
      "D) Serum ferritin"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Polysomnography).\n\nPATHOPHYSIOLOGY:\nObstructive sleep apnea (OSA) results from repetitive partial or complete collapse of the upper airway during sleep, caused by reduced pharyngeal muscle tone with anatomic narrowing. Each obstructive event causes hypoxemia, hypercapnia, increased respiratory effort, and cortical arousal (sleep fragmentation). The repetitive cycles of hypoxemia-reoxygenation generate oxidative stress and systemic inflammation that drive the cardiovascular, metabolic, and neurocognitive consequences of untreated OSA.\n\nCLINICAL PRESENTATION:\n- Excessive daytime sleepiness (cardinal symptom, assess with Epworth Sleepiness Scale)\n- Witnessed apneas (bed partner reports breathing pauses)\n- Loud, habitual snoring\n- Morning headaches (from nocturnal hypercapnia and cerebral vasodilation)\n- Nocturia, unrefreshing sleep, impaired concentration, mood disturbance\n\nRISK FACTORS:\nObesity (BMI greater than 30, strongest modifiable risk factor), male sex, age over 50, neck circumference greater than 17 inches (men) or 16 inches (women), craniofacial abnormalities (retrognathia, macroglossia), family history.\n\nDIAGNOSIS:\n1. In-laboratory polysomnography (PSG) is the gold standard diagnostic test, measuring airflow, respiratory effort, oxygen saturation, EEG, EOG, EMG, and body position\n2. Home sleep apnea testing (HSAT) is acceptable for patients with high pretest probability of moderate-to-severe OSA without significant comorbidities (per AASM 2017 guidelines)\n3. Severity classification by Apnea-Hypopnea Index (AHI): Mild (5-14), Moderate (15-29), Severe (30 or greater)\n\nTREATMENT:\n1. CPAP (continuous positive airway pressure): First-line for moderate-to-severe OSA\n2. Weight loss: 10% weight reduction can decrease AHI by approximately 26%\n3. Positional therapy (for positional OSA)\n4. Oral appliances (mandibular advancement devices): Alternative for mild-moderate OSA or CPAP intolerance\n5. Surgery (uvulopalatopharyngoplasty, hypoglossal nerve stimulation) for selected patients\n\nKEY POINTS:\nPolysomnography is the gold standard for OSA diagnosis. HSAT is appropriate for high-probability patients without major comorbidities. CPAP is first-line treatment for moderate-to-severe OSA. Untreated OSA significantly increases risk of hypertension, atrial fibrillation, stroke, and motor vehicle accidents.\n---"
  },
  {
    "id": 638,
    "categoryId": 2,
    "question": "A 55-year-old presents with progressive dyspnea and dry cough over 1 year. Exam reveals fine 'velcro' crackles at bases and clubbing. HRCT shows peripheral, basilar reticular opacities with honeycombing. What is the diagnosis?",
    "options": [
      "A) COPD",
      "B) Idiopathic pulmonary fibrosis",
      "C) Sarcoidosis",
      "D) Hypersensitivity pneumonitis"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Idiopathic Pulmonary Fibrosis).\n\nPATHOPHYSIOLOGY:\nIPF is a chronic, progressive, fatal fibrotic interstitial lung disease of unknown etiology affecting adults over 50. Repetitive subclinical alveolar epithelial injury (from smoking, microaspiration, viral infections, or genetic factors including TERT/TERC and surfactant protein mutations) triggers aberrant wound healing. The injured epithelium signals fibroblast proliferation and myofibroblast differentiation, depositing excessive collagen. Progressive fibrosis destroys alveolar architecture, thickens the alveolar-capillary membrane, reduces compliance, and impairs gas exchange.\n\nCLINICAL REASONING:\nClassic IPF phenotype: insidious progressive exertional dyspnea and nonproductive cough, fine bibasilar velcro-like inspiratory crackles (fibrotic alveoli snapping open), digital clubbing (~50%), and HRCT showing a usual interstitial pneumonia (UIP) pattern\u2014peripheral, basilar-predominant reticular opacities, honeycombing, traction bronchiectasis, and minimal ground-glass opacity. When definite UIP is present in appropriate clinical context, surgical lung biopsy is not required.\n\nPULMONARY FUNCTION TESTING:\nIPF produces a restrictive pattern (reduced FVC, preserved/elevated FEV1/FVC ratio), reduced total lung capacity, and disproportionately reduced DLCO reflecting impaired gas transfer. Serial FVC and DLCO monitor disease progression.\n\nTREATMENT:\nPirfenidone and nintedanib slow FVC decline by ~50% and are standard of care. Neither reverses established fibrosis; side effects include photosensitivity/GI upset (pirfenidone) and diarrhea/hepatotoxicity (nintedanib). Lung transplantation is the only survival-improving intervention and should be considered early. Median survival is 3-5 years. Corticosteroids and immunosuppressants are ineffective and potentially harmful, unlike in sarcoidosis or hypersensitivity pneumonitis.\n\nKEY POINTS:\nIPF presents with progressive dyspnea, velcro crackles, clubbing, and UIP pattern on HRCT. Pirfenidone and nintedanib slow decline but do not reverse fibrosis. Lung transplantation is the only survival-improving intervention. Corticosteroids are ineffective and potentially harmful in IPF."
  },
  {
    "id": 639,
    "categoryId": 13,
    "question": "A 35-year-old woman presents with fatigue, joint pain, and malar rash sparing nasolabial folds. Labs show positive ANA, anti-dsDNA, low C3/C4. Urinalysis shows proteinuria and RBC casts. What is the next priority step?",
    "options": [
      "A) Start hydroxychloroquine alone",
      "B) Renal biopsy",
      "C) Start NSAID",
      "D) Repeat ANA in 3 months"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Renal biopsy).\n\nDIAGNOSIS:\nThis patient presents with classic systemic lupus erythematosus (SLE) based on the malar rash sparing nasolabial folds, positive ANA, elevated anti-dsDNA, and hypocomplementemia (low C3 and C4 indicating complement consumption from immune complex deposition). The critical finding is the urinalysis showing proteinuria and RBC casts, which indicate active glomerulonephritis. RBC casts are pathognomonic for glomerular inflammation, in the context of SLE with serologic activity, strongly suggest lupus nephritis.\n\nWHY RENAL BIOPSY IS THE PRIORITY:\nRenal biopsy is essential because lupus nephritis is classified into six histologic classes (ISN/RPS classification) that carry vastly different prognoses and treatment requirements. Class I (minimal mesangial) and Class II (mesangial proliferative) have favorable prognosis and may require only supportive care. Class III (focal proliferative) and Class IV (diffuse proliferative) are the most common and most severe forms, requiring aggressive immunosuppressive induction therapy. Class V (membranous) causes nephrotic syndrome. Class VI (advanced sclerosing) represents irreversible damage. Because the clinical presentation alone cannot reliably distinguish between classes, biopsy findings directly determine whether the patient needs aggressive immunosuppression (mycophenolate mofetil or cyclophosphamide) or conservative management.\n\nTREATMENT FRAMEWORK:\nHydroxychloroquine is recommended for all SLE patients regardless of disease activity, as it reduces flares, organ damage accrual, and mortality. For Class III and IV lupus nephritis, induction therapy consists of high-dose corticosteroids plus either mycophenolate mofetil (preferred per 2024 EULAR/ERA guidelines for most patients) or intravenous cyclophosphamide (Euro-Lupus or NIH protocol). Belimumab (anti-BLyS) and voclosporin (calcineurin inhibitor) are now approved as add-on therapies that improve renal response rates. Maintenance therapy with mycophenolate mofetil continues for at least three to five years. ACE inhibitors or ARBs are used for proteinuria reduction and renoprotection.\n\nKEY POINTS:\nRBC casts on urinalysis in an SLE patient indicate glomerulonephritis and mandate renal biopsy to determine ISN/RPS class. Biopsy classification directly guides treatment intensity, as Class III and IV require aggressive immunosuppression while milder classes may not. Hydroxychloroquine is recommended for all SLE patients. Mycophenolate mofetil is the preferred induction agent for most proliferative lupus nephritis."
  },
  {
    "id": 640,
    "categoryId": 13,
    "question": "A 60-year-old man presents with sudden onset severe pain, swelling, and erythema of the first MTP joint. He recently started hydrochlorothiazide. Joint aspiration shows negatively birefringent crystals. What is the first-line treatment for acute gout?",
    "options": [
      "A) Allopurinol",
      "B) Colchicine, NSAIDs, or corticosteroids",
      "C) Probenecid",
      "D) Febuxostat"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Colchicine, NSAIDs, or corticosteroids).\n\nDIAGNOSIS:\nThis presentation is classic for acute gouty arthritis: sudden-onset severe pain, swelling, and erythema of the first metatarsophalangeal joint (podagra) in a patient with a new risk factor for hyperuricemia (hydrochlorothiazide). Joint aspiration confirming negatively birefringent, needle-shaped monosodium urate crystals under compensated polarized light microscopy is the gold standard for definitive diagnosis and distinguishes gout from pseudogout (calcium pyrophosphate crystals, which are positively birefringent and rhomboid-shaped).\n\nACUTE FLARE MANAGEMENT:\nThe 2020 American College of Rheumatology guidelines recommend three equally effective first-line options for acute gout flares. NSAIDs at full anti-inflammatory doses (naproxen 500 mg twice daily or indomethacin 50 mg three times daily) provide rapid relief and are appropriate for patients without contraindications (renal disease, peptic ulcer, cardiovascular risk). Colchicine is most effective when initiated within 12 to 36 hours of flare onset, using the low-dose regimen (1.2 mg followed by 0.6 mg one hour later), which the AGREE trial demonstrated is as effective as high-dose colchicine with significantly fewer gastrointestinal side effects. Systemic corticosteroids (prednisone 30 to 40 mg daily for 5 to 7 days) are excellent alternatives when NSAIDs and colchicine are contraindicated, such as in patients with chronic kidney disease. Intra-articular corticosteroid injection is highly effective for monoarticular flares.\n\nIMPORTANT DISTINCTION FROM URATE-LOWERING THERAPY:\nAllopurinol, febuxostat, and probenecid are urate-lowering therapies (ULTs) used for chronic gout management, not acute flare treatment. Per the 2020 ACR Guidelines, ULT can be started during an acute flare (conditionally recommended). Earlier concerns about worsening flares from rapid urate shifts have not been supported by clinical trials. ULT may be initiated during or after flare resolution, with concurrent anti-inflammatory prophylaxis (low-dose colchicine 0.6 mg daily or twice daily) for three to six months to prevent mobilization flares.\n\nKEY POINTS:\nAcute gout flares are treated with NSAIDs, colchicine, or corticosteroids, all with similar efficacy. Low-dose colchicine (1.2 mg then 0.6 mg) is as effective as high-dose with fewer side effects when started within 36 hours. Urate-lowering agents (allopurinol, febuxostat, probenecid) are for chronic management and should not be initiated during an acute flare. Negatively birefringent needle-shaped crystals on polarized microscopy confirm gout."
  },
  {
    "id": 641,
    "categoryId": 13,
    "question": "A 45-year-old woman with 6 months of symmetric joint pain and swelling in her hands (MCPs, PIPs) has positive RF and anti-CCP. X-rays show periarticular osteopenia. What is the first-line DMARD?",
    "options": [
      "A) Methotrexate",
      "B) Hydroxychloroquine",
      "C) Sulfasalazine",
      "D) Prednisone alone"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Methotrexate).\n\nDIAGNOSIS:\nThis patient presents with classic rheumatoid arthritis (RA): symmetric inflammatory polyarthritis involving the small joints of the hands (MCPs and PIPs, with characteristic sparing of the DIPs), positive rheumatoid factor (RF), positive anti-citrullinated peptide antibodies (anti-CCP, which is more specific than RF at greater than 95 percent specificity), and radiographic evidence of periarticular osteopenia (an early radiographic finding reflecting juxta-articular bone resorption from synovial inflammation). Morning stiffness lasting greater than one hour is a hallmark feature that distinguishes inflammatory arthritis from osteoarthritis.\n\nMETHOTREXATE AS FIRST-LINE DMARD:\nThe 2021 American College of Rheumatology guidelines strongly recommend methotrexate as the first-line disease-modifying antirheumatic drug (DMARD) for RA, regardless of disease activity level. Methotrexate is an antimetabolite that inhibits dihydrofolate reductase, but its anti-inflammatory mechanism in RA is primarily through promotion of adenosine release, which suppresses inflammatory cytokine production. It should be started as early as possible after diagnosis (ideally within three months of symptom onset) because the \"window of opportunity\" for preventing irreversible joint erosions is narrow. Typical starting dose is 7.5 to 15 mg orally once weekly, titrated up to 25 mg weekly as tolerated. Folic acid 1 mg daily (or folinic acid) is co-prescribed to reduce side effects (oral ulcers, nausea, hepatotoxicity, cytopenias). Monitoring includes baseline and periodic CBC, hepatic transaminases, creatinine, and hepatitis B and C screening.\n\nTREAT-TO-TARGET ESCALATION:\nThe treat-to-target approach reassesses disease activity every three months using validated composite measures (DAS28, CDAI, or SDAI), with the goal of achieving remission or low disease activity. If methotrexate monotherapy is insufficient at three to six months, options include adding a conventional synthetic DMARD (hydroxychloroquine, sulfasalazine, or leflunomide, often in \"triple therapy\"), adding a biologic DMARD (TNF inhibitors, IL-6 inhibitors such as tocilizumab, T-cell co-stimulation modulators such as abatacept, or B-cell depleting therapy with rituximab), or adding a targeted synthetic DMARD (JAK inhibitors such as tofacitinib or baricitinib).\n\nKEY POINTS:\nMethotrexate is the first-line DMARD for RA and should be started early to prevent irreversible joint damage. Anti-CCP antibodies are highly specific for RA and predict erosive disease. The treat-to-target strategy reassesses disease activity every three months, escalating to biologic or targeted synthetic DMARDs if methotrexate alone is insufficient. Folic acid supplementation is essential to reduce methotrexate side effects."
  },
  {
    "id": 642,
    "categoryId": 3,
    "question": "The gut microbiome plays a critical role in human health. Which of the following is a well-established function of the gut microbiome?",
    "options": [
      "A) Direct absorption of glucose into the bloodstream",
      "B) Production of short-chain fatty acids (SCFAs) that regulate immune function and gut barrier integrity",
      "C) Synthesis of all essential amino acids",
      "D) Complete digestion of dietary protein"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Production of short-chain fatty acids that regulate immune function and gut barrier integrity).\n\nPATHOPHYSIOLOGY:\nThe human gut microbiome comprises approximately 38 trillion microorganisms representing over 1,000 species, with the highest density in the colon. Commensal bacteria perform critical metabolic functions that the human genome cannot, most notably the anaerobic fermentation of dietary fiber and resistant starch into short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. These metabolites serve as a major communication pathway between the microbiome and host physiology.\n\nFUNCTIONS OF SHORT-CHAIN FATTY ACIDS:\nButyrate is the preferred energy source for colonocytes, providing approximately 60-70% of their metabolic fuel and maintaining the epithelial barrier through enhanced tight junction protein expression. Butyrate also exerts potent anti-inflammatory effects by inhibiting NF-kB signaling and histone deacetylase activity in immune cells, promoting the differentiation of regulatory T cells (Tregs) that suppress aberrant immune activation. Propionate is primarily metabolized by the liver and modulates gluconeogenesis and lipid metabolism. Acetate enters systemic circulation and influences appetite regulation through hypothalamic signaling and peripheral tissue energy metabolism.\n\nCLINICAL SIGNIFICANCE:\nReduced SCFA production (from low-fiber diets or dysbiosis) is linked to increased intestinal permeability (\"leaky gut\"), chronic low-grade inflammation, and elevated risk of inflammatory bowel disease, colorectal cancer, metabolic syndrome, and allergic disease. Dietary fiber intake of 25-35 grams per day, particularly from diverse plant sources, supports robust SCFA production. Emerging therapeutic approaches include targeted prebiotic supplementation and next-generation probiotics specifically selected for SCFA-producing capacity.\n\nKEY POINTS:\nShort-chain fatty acids (butyrate, propionate, acetate) are produced by bacterial fermentation of dietary fiber and are the primary mediator of microbiome-host interaction. Butyrate provides 60-70% of colonocyte energy and maintains gut barrier integrity through tight junction enhancement. SCFAs promote anti-inflammatory regulatory T cell differentiation. Adequate dietary fiber intake (25-35 g/day) supports healthy SCFA production."
  },
  {
    "id": 643,
    "categoryId": 6,
    "question": "The 'Gut-Brain Axis' describes bidirectional communication between the GI tract and the central nervous system. Through which primary pathway does the gut microbiome influence brain function?",
    "options": [
      "A) Direct bacterial migration to the CNS",
      "B) The vagus nerve, microbial metabolites, and immune signaling",
      "C) Absorption of neurotransmitters from dietary sources only",
      "D) Cerebrospinal fluid circulation"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The vagus nerve, microbial metabolites, and immune signaling).\n\nTHE GUT-BRAIN AXIS:\nThe gut-brain axis describes the bidirectional communication network between the gastrointestinal tract and the central nervous system, mediated primarily through the vagus nerve (providing direct neural connections), microbial metabolites that cross the blood-brain barrier, and immune signaling pathways. This communication system allows the gut microbiome to influence brain function, mood, cognition, and behavior, and explains the frequent co-occurrence of gastrointestinal and neuropsychiatric disorders.\n\nPATHOPHYSIOLOGY:\nThe vagus nerve serves as the primary neural highway between the gut and brain, with approximately 80% of its fibers being afferent (gut-to-brain). Gut microbiota stimulate vagal afferents through the production of short-chain fatty acids (SCFAs such as butyrate, propionate, and acetate), which modulate vagal signaling and also cross the blood-brain barrier to influence microglial function and neuroinflammation. Gut bacteria also produce neurotransmitter precursors and neurotransmitters directly: enterochromaffin cells produce approximately 90% of the body's serotonin, and certain bacteria synthesize GABA, dopamine precursors, and norepinephrine. The immune pathway involves cytokines (IL-6, TNF-alpha, IL-1 beta) produced in the gut that enter systemic circulation and modulate neuroinflammation and blood-brain barrier permeability.\n\nCLINICAL ASSOCIATIONS:\nDepression and anxiety are consistently associated with altered gut microbiome composition (reduced Lactobacillus and Bifidobacterium species). Irritable bowel syndrome (IBS) has a 50 to 90% comorbidity rate with anxiety and depression, illustrating the clinical relevance of the gut-brain connection. Stress alters gut permeability (\"leaky gut\"), microbiome composition, and motility through the hypothalamic-pituitary-adrenal axis, creating a bidirectional cycle.\n\nPRIMARY CARE IMPLICATIONS:\nWhen treating patients with functional GI disorders such as IBS, addressing co-morbid anxiety and depression is essential for optimal outcomes. This explains why antidepressants (particularly tricyclics and SSRIs) are effective treatments for IBS independent of their mood effects. Emerging research on probiotics (\"psychobiotics\") targeting specific bacterial strains shows promise for mood disorders, though evidence remains preliminary. A holistic approach recognizing the gut-brain connection improves management of both GI and neuropsychiatric complaints.\n\nKEY POINTS:\nThe gut-brain axis communicates through the vagus nerve, microbial metabolites (SCFAs), and immune signaling (cytokines), not through direct bacterial migration. Approximately 90% of the body's serotonin is produced in the gut, linking GI health to mood and cognition. Antidepressants are effective for IBS because the gut-brain axis makes GI and neuropsychiatric conditions bidirectionally connected."
  },
  {
    "id": 644,
    "categoryId": 8,
    "question": "Antibiotic use disrupts the gut microbiome. Which clinical consequence of antibiotic-induced dysbiosis has the strongest evidence base?",
    "options": [
      "A) Immediate weight gain",
      "B) Clostridioides difficile infection",
      "C) Development of Type 1 diabetes",
      "D) Acute kidney injury"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Clostridioides difficile infection).\n\nPATHOPHYSIOLOGY:\nThe healthy gut microbiome comprises trillions of commensal organisms that maintain colonization resistance â€” the ability to prevent pathogenic organisms from establishing infection through competition for nutrients, production of antimicrobial peptides, and maintenance of mucosal barrier integrity. Antibiotic exposure, particularly with broad-spectrum agents, reduces microbial diversity and eliminates protective commensal bacteria, creating an ecological niche for pathogenic organisms. Clostridioides difficile spores survive antibiotic exposure, germinate without competing flora, and proliferate to produce disease-causing toxins.\n\nCLINICAL MANIFESTATIONS:\nC. difficile infection (CDI) is the most clinically significant and well-documented consequence of antibiotic-induced dysbiosis. Risk increases with exposure to broad-spectrum antibiotics â€” particularly clindamycin, fluoroquinolones, and cephalosporins â€” and is cumulative with duration of antibiotic exposure and number of agents used. Elderly and hospitalized patients are at highest risk. CDI severity ranges from mild watery diarrhea to fulminant pseudomembranous colitis with toxic megacolon, septic shock, and death.\n\nMICROBIOME RECOVERY AND RESTORATION:\nGut microbiome diversity can take weeks to months to recover after antibiotic exposure, and some species may be permanently lost. Repeated antibiotic courses cause cumulative damage to microbial diversity. Fecal microbiota transplantation (FMT) has emerged as a highly effective therapy (>90% cure rate) for recurrent CDI by restoring a healthy microbial community and re-establishing colonization resistance, and it is now standard of care for patients with multiple CDI recurrences.\n\nKEY POINTS:\nC. difficile infection is the most important clinical consequence of antibiotic-induced gut dysbiosis. Antibiotic stewardship â€” prescribing only when necessary, using the narrowest effective spectrum, and limiting duration â€” is the primary strategy for microbiome preservation. Fecal microbiota transplantation is highly effective for recurrent CDI.\n---"
  },
  {
    "id": 645,
    "categoryId": 16,
    "question": "A patient asks about taking probiotics for general health. Based on current evidence, which statement about probiotics is MOST accurate?",
    "options": [
      "A) All probiotic supplements are equally effective for all conditions",
      "B) Probiotics have proven benefit for specific conditions like antibiotic-associated diarrhea, but evidence for general health is limited",
      "C) Probiotics permanently colonize the gut and replace native bacteria",
      "D) Probiotics are harmful and should be universally avoided"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Probiotics have proven benefit for specific conditions like antibiotic-associated diarrhea, but evidence for general health is limited).\n\nEVIDENCE-BASED INDICATIONS:\nProbiotic efficacy is strain-specific and condition-specific, meaning that benefits demonstrated for one bacterial strain in one condition cannot be extrapolated to other strains or conditions. The strongest evidence supports specific probiotic strains for specific clinical indications: Saccharomyces boulardii and Lactobacillus rhamnosus GG for prevention and treatment of antibiotic-associated diarrhea (number needed to treat approximately 8 to 13), VSL#3 for maintenance of remission in ulcerative colitis and pouchitis, and certain Bifidobacterium and Lactobacillus strains for reducing the duration of acute infectious diarrhea by approximately 1 day in children.\n\nLIMITATIONS FOR GENERAL HEALTH:\nDespite widespread marketing, evidence for probiotics improving general health, preventing colds, boosting immunity, or improving mood in healthy individuals is limited and inconsistent. Commercial probiotic supplements vary enormously in quality, viability (many products contain fewer live organisms than labeled), and strain composition. The FDA regulates probiotics as dietary supplements, not drugs, meaning manufacturers are not required to demonstrate efficacy before marketing. Furthermore, probiotic colonization is often transient (organisms disappear from stool within days to weeks of discontinuation), questioning the durability of any effects.\n\nCLINICAL GUIDANCE:\nClinicians should recommend specific, well-studied strains for specific indications rather than endorsing general probiotic use. For supporting overall gut microbial diversity, dietary interventions (high-fiber diets, fermented foods) have stronger evidence than probiotic supplements. The Stanford Sonnenburg Lab study demonstrated that a fermented food-rich diet (yogurt, kefir, kimchi, kombucha) increased gut microbiome diversity and reduced inflammatory markers more consistently than a high-fiber diet alone.\n\nKEY POINTS:\nProbiotic efficacy is strain-specific and condition-specific, with strongest evidence for antibiotic-associated diarrhea (S. boulardii, L. rhamnosus GG) and specific GI conditions. Evidence for general health benefits in healthy individuals is limited. Dietary fermented foods and high-fiber diets are more consistently supported for improving overall gut microbial diversity than supplements."
  },
  {
    "id": 646,
    "categoryId": 16,
    "question": "Which dietary pattern is most strongly associated with a diverse and healthy gut microbiome?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Diet high in processed foods and artificial sweeteners",
      "C) Plant-rich diet high in dietary fiber and fermented foods",
      "D) Liquid-only cleanse diets"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Plant-rich diet high in dietary fiber and fermented foods).\n\nEVIDENCE:\nA plant-rich diet high in dietary fiber and fermented foods is most strongly associated with a diverse and healthy gut microbiome. The human gut harbors approximately 38 trillion microorganisms (roughly equal to the number of human cells), and the composition of this microbial community is profoundly shaped by habitual dietary patterns.\n\nFIBER AND THE MICROBIOME:\nDietary fiber is the primary fuel source for beneficial colonic bacteria because humans lack the enzymes to digest complex polysaccharides, making them available exclusively for microbial fermentation. Fiber-fermenting bacteria (Faecalibacterium, Roseburia, Bifidobacterium, Prevotella) produce short-chain fatty acids (butyrate, propionate, acetate) that nourish colonocytes, strengthen the epithelial barrier, reduce intestinal permeability, and modulate systemic inflammation and immune function. Low-fiber diets starve these beneficial species, reducing microbial diversity and allowing expansion of mucin-degrading bacteria that erode the protective mucus layer.\n\nFERMENTED FOODS:\nThe Stanford Sonnenburg Lab randomized controlled trial demonstrated that a diet rich in fermented foods (yogurt, kefir, kimchi, sauerkraut, kombucha, miso) for 10 weeks significantly increased gut microbiome diversity and reduced 19 inflammatory markers (including IL-6 and CRP). Fermented foods introduce live microorganisms and their metabolites into the gut, providing both probiotic organisms and prebiotic substrates that support microbial community richness.\n\nCLINICAL APPLICATION:\nClinicians should recommend a diverse plant-rich diet (targeting 30 or more different plant foods per week) combined with regular fermented food consumption as the most evidence-based dietary strategy for gut microbiome health. This approach is more effective and cost-efficient than probiotic supplementation for promoting microbial diversity in healthy individuals.\n\nKEY POINTS:\nDietary fiber is the primary fuel for beneficial gut bacteria, and fiber fermentation produces short-chain fatty acids that nourish colonocytes and reduce systemic inflammation. The Stanford trial showed fermented foods increase microbiome diversity and reduce 19 inflammatory markers. A diverse plant-rich diet (30 or more plant foods per week) plus fermented foods is the most evidence-based strategy for gut health."
  },
  {
    "id": 647,
    "categoryId": 1,
    "question": "According to the American Heart Association, which dietary pattern has the strongest evidence for reducing cardiovascular disease risk?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Plant-based diet emphasizing fruits, vegetables, whole grains, legumes, and nuts",
      "C) Low-fat diet with unrestricted processed foods",
      "D) Carnivore diet"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-based diet emphasizing fruits, vegetables, whole grains, legumes, and nuts).\n\nAHA 2021 DIETARY GUIDANCE:\nThe American Heart Association's 2021 scientific statement on dietary guidance for improving cardiovascular health prioritizes a plant-predominant eating pattern built around fruits, vegetables, whole grains, legumes, nuts, and seeds as the foundation for cardiovascular risk reduction. This guidance represents a shift from focusing on individual nutrients to emphasizing overall dietary patterns, recognizing that whole-food plant-rich diets consistently reduce cardiovascular events across diverse populations.\n\nEVIDENCE BASE:\nMultiple large prospective cohort studies and randomized trials support the cardiovascular benefits of plant-rich dietary patterns. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra-virgin olive oil or mixed nuts reduced major cardiovascular events by approximately 30% compared to a low-fat control diet. Plant-based diets reduce cardiovascular risk through several mechanisms: lowering LDL cholesterol and blood pressure, improving insulin sensitivity and glycemic control, reducing systemic inflammation (measured by hs-CRP), and promoting a favorable gut microbiome that reduces TMAO production.\n\nPRACTICAL FRAMEWORK:\nThe AHA identifies ten key dietary features for cardiovascular health: adjusting caloric intake to maintain healthy weight, eating plenty of fruits and vegetables, choosing whole grains over refined grains, including healthy protein sources (primarily legumes, nuts, fish, and lean poultry), using liquid non-tropical plant oils (olive, canola), choosing minimally processed over ultra-processed foods, minimizing added sugars, reducing sodium, limiting alcohol, and applying these principles regardless of where food is prepared. The statement does not require strict vegetarianism but emphasizes that plant foods should constitute the majority of dietary intake.\n\nKEY POINTS:\nThe AHA 2021 dietary guidance prioritizes plant-predominant eating patterns emphasizing fruits, vegetables, whole grains, legumes, and nuts for cardiovascular risk reduction. The PREDIMED trial showed a 30% reduction in major cardiovascular events with Mediterranean diet. The AHA framework focuses on overall dietary patterns rather than individual nutrients and does not require strict vegetarianism."
  },
  {
    "id": 648,
    "categoryId": 4,
    "question": "A patient with newly diagnosed Type 2 Diabetes asks about dietary approaches. According to the American Diabetes Association, which statement about plant-based diets is accurate?",
    "options": [
      "A) Plant-based diets are contraindicated in diabetes due to carbohydrate content",
      "B) Plant-based diets can improve glycemic control and are a recommended dietary pattern for diabetes management",
      "C) Only animal-based ketogenic diets are recommended for diabetes",
      "D) Dietary interventions have no effect on diabetes outcomes"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-based diets can improve glycemic control and are a recommended dietary pattern for diabetes management).\n\nPATHOPHYSIOLOGY:\nPlant-based diets benefit type 2 diabetes through multiple mechanisms. Soluble fiber (legumes, oats, fruits) forms a viscous gel delaying gastric emptying and attenuating postprandial glycemic excursions. Fiber promotes satiety via GLP-1 and PYY secretion, facilitating caloric reduction. Whole plant foods' lower caloric density naturally reduces intake. Reduced saturated fat decreases intramyocellular and intrahepatic lipid accumulation\u2014key drivers of insulin resistance through diacylglycerol-mediated PKC activation impairing insulin receptor substrate signaling. Plant polyphenols reduce oxidative stress and inflammation (lowering CRP, TNF-alpha, IL-6) and modulate gut microbiome toward increased short-chain fatty acid production, enhancing insulin sensitivity (Diabetes Care, NEJM).\n\nCLINICAL EVIDENCE:\nThe ADA Standards of Care lists plant-based diets among recommended patterns for diabetes, alongside Mediterranean, DASH, and low-carbohydrate approaches. Barnard et al. (Diabetes Care, 2009) showed a low-fat vegan diet achieved greater HbA1c and LDL reduction versus conventional ADA diet. The Adventist Health Study-2 found vegans had 62% lower odds of developing T2DM. The PREDIMED trial (NEJM, 2013) showed Mediterranean diet reduced diabetes incidence by 40%. A meta-analysis in BMJ Open Diabetes Research and Care confirmed plant-based diets improved HbA1c, fasting glucose, and body weight.\n\nCLINICAL APPLICATION:\nEmphasize whole, minimally processed plant foods (legumes, whole grains, vegetables, fruits, nuts, seeds) over processed alternatives. Legumes are particularly valuable for high fiber, low glycemic index, and proven glycemic benefits (AJCN). Patients on insulin or sulfonylureas need proactive medication reduction to prevent hypoglycemia, as insulin sensitivity may improve within days. With strict vegan diets, monitor vitamin B12 (supplement universally), vitamin D, iron, omega-3s, calcium, and zinc.\n\nKEY POINTS:\nThe ADA recommends plant-based diets for diabetes management, supported by evidence of improved HbA1c, weight, and cardiovascular risk through fiber-mediated glycemic modulation, reduced ectopic lipid improving insulin sensitivity, and anti-inflammatory effects. Patients on insulin or sulfonylureas require proactive dose reduction. Emphasize whole plant foods over processed alternatives."
  },
  {
    "id": 649,
    "categoryId": 14,
    "question": "The American Institute for Cancer Research (AICR) recommends which dietary pattern for cancer prevention?",
    "options": [
      "A) Diet focused primarily on animal protein",
      "B) Diet where plant foods (vegetables, fruits, whole grains, legumes) fill at least 2/3 of the plate",
      "C) High-fat, low-fiber diet",
      "D) Diet with no restrictions on processed meats"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant foods filling at least 2/3 of the plate).\n\nRECOMMENDATION:\nThe American Institute for Cancer Research (AICR) and the World Cancer Research Fund recommend a dietary pattern in which plant foods (vegetables, fruits, whole grains, and legumes) fill at least two-thirds of the plate, with animal foods comprising one-third or less. This recommendation is based on systematic review of global cancer prevention research and aligns with dietary guidance from the American Cancer Society, which emphasizes a plant-rich dietary pattern for cancer risk reduction.\n\nPROTECTIVE MECHANISMS OF PLANT FOODS:\nDietary fiber reduces colorectal cancer risk through multiple mechanisms including increased stool bulk and reduced colonic transit time (decreasing carcinogen contact with the mucosa), promotion of beneficial gut microbiome fermentation producing short-chain fatty acids (particularly butyrate, which has anti-proliferative and pro-apoptotic effects on colonocytes), and improved insulin sensitivity. Antioxidants and phytochemicals including sulforaphane (from cruciferous vegetables such as broccoli and cauliflower) and lycopene (from tomatoes) have demonstrated anti-cancer properties in laboratory and epidemiologic studies. Plant-based diets are also associated with lower circulating levels of insulin-like growth factor-1 (IGF-1), reduced systemic inflammation, and lower body weight, all of which independently reduce cancer risk.\n\nHARMFUL DIETARY FACTORS:\nProcessed meat is classified as a Group 1 carcinogen and red meat as Group 2A by the WHO/IARC. Each 50-gram daily serving of processed meat increases colorectal cancer risk by approximately 18%. Alcohol increases risk of cancers of the breast, colon, liver, esophagus, oral cavity, and pharynx in a dose-dependent manner with no safe threshold for cancer prevention. Ultra-processed foods with high sugar content promote obesity and hyperinsulinemia, both independent cancer risk factors.\n\nKEY POINTS:\nThe AICR recommends plant foods filling at least two-thirds of the plate for cancer prevention, based on evidence that fiber, antioxidants, and phytochemicals reduce cancer risk through multiple mechanisms. Processed meat is a Group 1 carcinogen and red meat is Group 2A, with each 50-gram daily serving of processed meat increasing colorectal cancer risk by 18%. Counseling patients to make plants the majority of their diet is one of the most impactful and achievable cancer prevention strategies."
  },
  {
    "id": 650,
    "categoryId": 1,
    "question": "A patient with hypertension asks about the DASH diet. Which description is accurate?",
    "options": [
      "A) High sodium, high animal protein diet",
      "B) Plant-rich diet emphasizing fruits, vegetables, whole grains, and low-fat dairy while limiting sodium and saturated fat",
      "C) Liquid-only fasting protocol",
      "D) High-fat ketogenic approach"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Plant-rich diet emphasizing fruits, vegetables, whole grains, low-fat dairy, limiting sodium and saturated fat).\n\nDASH DIET OVERVIEW:\nThe DASH (Dietary Approaches to Stop Hypertension) diet is a well-validated eating pattern specifically designed and proven to lower blood pressure through dietary modification. The original DASH trial demonstrated that this dietary pattern reduces systolic blood pressure by approximately 5.5 mmHg and diastolic by 3.0 mmHg in hypertensive individuals compared to a typical American diet, with the DASH-Sodium trial showing additional reductions of 6 to 11 mmHg systolic when combined with sodium restriction to 1,500 mg per day.\n\nCORE COMPONENTS:\nThe DASH diet emphasizes high intake of fruits (4 to 5 servings daily), vegetables (4 to 5 servings), whole grains (6 to 8 servings), and low-fat dairy products (2 to 3 servings), which together provide abundant potassium, calcium, magnesium, and fiber. It includes lean proteins (fish, poultry, legumes, nuts) while limiting red meat, saturated fat, added sugars, and sodium. The combined mineral and micronutrient profile of the DASH diet is thought to be more effective than any single supplement because the nutrients work synergistically to promote natriuresis, vasodilation, and reduced sympathetic tone.\n\nBLOOD PRESSURE MECHANISMS:\nPotassium (target approximately 4,700 mg/day) promotes sodium excretion and directly relaxes vascular smooth muscle. Calcium and magnesium support endothelial function and modulate vascular tone. Dietary fiber and nitrates from green leafy vegetables enhance nitric oxide bioavailability, promoting vasodilation. Sodium restriction to 2,300 mg/day (ideal 1,500 mg/day) reduces intravascular volume and blunts the pressure response to angiotensin II. The 2017 ACC/AHA Hypertension Guidelines recommend the DASH diet as a first-line lifestyle intervention capable of achieving blood pressure reductions comparable to a single antihypertensive medication.\n\nKEY POINTS:\nThe DASH diet reduces systolic BP by approximately 5.5 mmHg, with additional 6 to 11 mmHg reduction when combined with sodium restriction to 1,500 mg/day. Its effectiveness comes from synergistic actions of potassium, calcium, magnesium, fiber, and nitrates rather than any single nutrient. The 2017 ACC/AHA guidelines recommend DASH as a first-line lifestyle intervention with BP-lowering effects comparable to monotherapy."
  },
  {
    "id": 651,
    "categoryId": 16,
    "question": "Which mechanism best explains why whole-food plant-based diets are effective for weight management without calorie counting?",
    "options": [
      "A) Plant foods have higher caloric density than animal foods",
      "B) Low caloric density and high fiber content promote satiety with fewer calories",
      "C) Plant foods suppress all hunger hormones permanently",
      "D) Plant-based diets work by causing malabsorption"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Low caloric density and high fiber content promote satiety with fewer calories).\n\nMECHANISM:\nWhole-food plant-based diets consistently produce weight loss in clinical trials even with ad libitum (unrestricted) eating, primarily because plant foods have low caloric density (calories per gram) and high fiber and water content that activate satiety mechanisms before caloric excess occurs. Non-starchy vegetables average 0.1 to 0.5 calories per gram, fruits average 0.3 to 0.7 cal/g, legumes average 1.0 to 1.5 cal/g, and whole grains average 1.0 to 1.5 cal/g, compared to cheese at 3 to 4 cal/g and oils at 9 cal/g.\n\nSATIETY PHYSIOLOGY:\nSatiety is regulated by a hierarchy of signals. Gastric stretch receptors (vagal mechanoreceptors) respond to food volume, not calories, sending fullness signals to the brainstem nucleus tractus solitarius. Intestinal nutrient sensors trigger release of satiety hormones including GLP-1, PYY, and CCK when nutrients reach the small intestine. Dietary fiber slows gastric emptying (prolonging gastric distension), increases chewing time, and is fermented to short-chain fatty acids that stimulate GLP-1 and PYY release from colonic L-cells. High-water-content foods (vegetables, fruits, soups) physically dilute caloric density while maintaining volume.\n\nCLINICAL EVIDENCE:\nThe BROAD study (randomized trial in New Zealand) showed that participants on a whole-food plant-based diet without calorie counting lost an average of 12 kg at 12 months. A meta-analysis of 12 randomized trials found that plant-based diets produced greater weight loss than control diets even without prescribed energy restriction. The volumetric approach (Rolls and colleagues, Penn State) demonstrates that reducing the caloric density of the diet by 25% produces spontaneous caloric reduction without perceived hunger.\n\nKEY POINTS:\nWhole-food plant-based diets produce weight loss without calorie counting because low caloric density and high fiber content activate gastric stretch receptors and gut satiety hormones (GLP-1, PYY) before caloric excess occurs. Vegetables average 0.1 to 0.5 cal/g versus oils at 9 cal/g. Clinical trials consistently show 10 to 12 kg weight loss at 12 months with ad libitum plant-based eating."
  },
  {
    "id": 652,
    "categoryId": 16,
    "question": "Oxidative stress, caused by an imbalance between free radicals and antioxidants, is implicated in the pathogenesis of which conditions?",
    "options": [
      "A) Atherosclerosis, diabetes complications, and neurodegenerative diseases",
      "B) Osteoarthritis only",
      "C) Allergic rhinitis",
      "D) Benign prostatic hyperplasia"
    ],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Atherosclerosis, diabetes complications, and neurodegenerative diseases).\n\nPATHOPHYSIOLOGY:\nOxidative stress occurs when the production of reactive oxygen species (ROS, including superoxide anion, hydrogen peroxide, and hydroxyl radical) exceeds the capacity of endogenous antioxidant defense systems (superoxide dismutase, catalase, glutathione peroxidase, and the thioredoxin system). This imbalance causes oxidative damage to lipids (lipid peroxidation), proteins (carbonyl formation and cross-linking), and DNA (8-hydroxydeoxyguanosine formation and strand breaks), contributing to cellular dysfunction and disease pathogenesis.\n\nDISEASE MECHANISMS:\nIn atherosclerosis, oxidized LDL is the key pathogenic trigger: ROS modify LDL particles in the arterial intima, making them recognizable by scavenger receptors on macrophages, which internalize oxidized LDL in an unregulated fashion to form foam cells, the key sign of early atherosclerotic plaques. In diabetes, hyperglycemia-driven mitochondrial ROS production activates four pathways of tissue damage: the polyol pathway, advanced glycation end-product (AGE) formation, protein kinase C activation, and the hexosamine pathway, collectively producing diabetic retinopathy, nephropathy, neuropathy, and accelerated atherosclerosis. In neurodegenerative diseases, the brain's high oxygen consumption (20% of total body oxygen), abundant polyunsaturated fatty acids (susceptible to peroxidation), and relatively low antioxidant capacity make it particularly vulnerable to oxidative damage.\n\nENDOGENOUS DEFENSE:\nThe Nrf2-Keap1 pathway is the master regulator of cellular antioxidant defense, controlling expression of over 200 cytoprotective genes including glutathione synthesis enzymes, heme oxygenase-1, and NAD(P)H quinone oxidoreductase. Dietary phytochemicals from colorful fruits and vegetables activate this pathway, potentially explaining the consistent association between plant-rich diets and reduced chronic disease risk.\n\nKEY POINTS:\nOxidative stress drives atherosclerosis (via LDL oxidation and foam cell formation), diabetic complications (via hyperglycemia-induced mitochondrial ROS), and neurodegeneration (due to the brain's high oxygen demand and low antioxidant reserves). The Nrf2 pathway is the master regulator of endogenous antioxidant defense. Dietary phytochemicals from plant foods activate Nrf2, linking plant-rich diets to chronic disease prevention."
  },
  {
    "id": 653,
    "categoryId": 16,
    "question": "Which dietary pattern has the strongest evidence for reducing oxidative stress and its associated chronic disease burden?",
    "options": [
      "A) High-protein, low-carbohydrate diet",
      "B) Mediterranean diet rich in polyphenols and antioxidants",
      "C) Low-fat diet with minimal nuts and oils",
      "D) Carnivore diet"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Mediterranean diet rich in polyphenols and antioxidants).\n\nEVIDENCE:\nThe Mediterranean dietary pattern has the strongest and most consistent evidence for reducing oxidative stress and its associated chronic disease burden. The PREDIMED trial demonstrated that a Mediterranean diet supplemented with extra virgin olive oil or nuts reduced major cardiovascular events by approximately 30% and oxidative stress biomarkers (oxidized LDL, malondialdehyde, 8-isoprostanes) compared to a low-fat control diet.\n\nANTIOXIDANT MECHANISMS:\nThe Mediterranean diet provides a diverse array of bioactive polyphenolic compounds from multiple food sources. Extra virgin olive oil contains hydroxytyrosol and oleocanthal (with anti-inflammatory potency comparable to low-dose ibuprofen). Red wine and berries provide resveratrol and anthocyanins. Vegetables provide carotenoids (lycopene, beta-carotene, lutein). Nuts provide vitamin E (alpha-tocopherol) and selenium. Herbs and spices (turmeric, rosemary, oregano) contribute curcumin, carnosic acid, and rosmarinic acid. These compounds act through multiple mechanisms: direct free radical scavenging, metal ion chelation (preventing Fenton reactions), activation of the Nrf2 antioxidant pathway, inhibition of NF-kB inflammatory signaling, and enhancement of endogenous antioxidant enzyme expression.\n\nWHY WHOLE FOODS EXCEED SUPPLEMENTS:\nThe synergistic interaction among the thousands of phytochemicals in whole foods produces antioxidant protection that isolated supplements cannot replicate. Whole foods deliver antioxidants in their natural matrix with complementary cofactors, fiber, and other bioactives that modulate absorption, bioavailability, and tissue distribution. This explains the paradox that antioxidant-rich dietary patterns consistently reduce disease while isolated antioxidant supplements have failed in randomized trials.\n\nKEY POINTS:\nThe Mediterranean diet has the strongest evidence for reducing oxidative stress through diverse polyphenols from olive oil (hydroxytyrosol), berries (anthocyanins), vegetables (carotenoids), and nuts (vitamin E). These compounds activate the Nrf2 pathway, scavenge free radicals, and inhibit NF-kB inflammation. Whole food antioxidant synergy exceeds what isolated supplements can achieve."
  },
  {
    "id": 654,
    "categoryId": 16,
    "question": "Why have large randomized controlled trials of antioxidant supplements (vitamin E, beta-carotene) generally failed to show cardiovascular benefit despite strong observational data?",
    "options": [
      "A) The doses used were too low",
      "B) Isolated supplements cannot replicate the complex synergy of whole food antioxidants and may disrupt redox signaling",
      "C) The trials were too short",
      "D) Participants were too healthy at baseline"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Isolated supplements cannot replicate the complex synergy of whole food antioxidants and may disrupt redox signaling).\n\nPARADOX:\nLarge randomized controlled trials of antioxidant supplements have consistently failed to show cardiovascular, cancer, or mortality benefit, and some have demonstrated harm, despite strong epidemiologic associations between antioxidant-rich diets and reduced chronic disease. The ATBC trial (Alpha-Tocopherol Beta-Carotene Cancer Prevention Study) showed that beta-carotene supplementation increased lung cancer risk by 18% in Finnish male smokers. The CARET trial (Beta-Carotene and Retinol Efficacy Trial) confirmed a 28% increase in lung cancer with beta-carotene in smokers and asbestos workers. The HOPE and HOPE-TOO trials showed no cardiovascular benefit from vitamin E, and the SELECT trial showed increased prostate cancer risk with vitamin E.\n\nREDOX SIGNALING DISRUPTION:\nThe failure of supplements reflects a fundamental misunderstanding of redox biology. Reactive oxygen species are not purely harmful: at physiologic concentrations, they serve as essential signaling molecules that regulate vascular tone (via hydrogen peroxide-mediated vasodilation), immune function (via the oxidative burst in neutrophils and macrophages), cellular adaptation to exercise (via ROS-mediated mitochondrial biogenesis), and apoptosis of damaged or precancerous cells. High-dose isolated antioxidants can suppress these beneficial ROS signaling pathways, potentially impairing immune surveillance, exercise adaptation, and tumor cell clearance.\n\nWHOLE FOOD SYNERGY:\nWhole foods contain thousands of phytochemicals that interact synergistically in ways that a single isolated compound cannot replicate. These compounds are delivered in a natural food matrix with fiber, healthy fats, and other nutrients that modulate absorption, bioavailability, and biological activity. Whole food antioxidants tend to modulate (rather than abolish) ROS signaling, activating endogenous defense pathways (Nrf2) rather than creating supraphysiologic antioxidant levels that disrupt redox homeostasis.\n\nKEY POINTS:\nAntioxidant supplement trials (ATBC, CARET, SELECT) showed no benefit and potential harm because high-dose isolated antioxidants disrupt beneficial ROS signaling needed for immune function, exercise adaptation, and tumor surveillance. Whole food antioxidants work synergistically and modulate (rather than abolish) redox signaling. Clinicians should recommend antioxidant-rich dietary patterns rather than supplements."
  },
  {
    "id": 655,
    "categoryId": 11,
    "question": "A patient with poorly controlled type 2 diabetes says, 'I know I should exercise more, but I just can't seem to make it happen.' Using motivational interviewing, what is the most appropriate response?",
    "options": [
      "A) 'You really need to exercise or your diabetes will get worse.'",
      "B) 'What would it look like if you were able to fit exercise into your routine?'",
      "C) 'Let me give you a handout about the benefits of exercise.'",
      "D) 'I'm referring you to a diabetes educator.'"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B ('What would it look like if you were able to fit exercise into your routine?').\n\nCLINICAL REASONING:\nThis question tests the application of motivational interviewing (MI) technique in a patient expressing ambivalence about behavior change. The patient's statement ('I know I should exercise more, but I just can't seem to make it happen') contains both change talk ('I know I should') and sustain talk ('I can't seem to make it happen'), indicating ambivalence, which is the central target of MI.\n\nMI TECHNIQUE APPLIED:\nOption B ('What would it look like if you were able to fit exercise into your routine?') is an open-ended, evocative question that invites the patient to envision a positive future with the behavior change already in place. This technique, sometimes called a \"miracle question\" or \"looking forward\" technique, elicits the patient's own motivations and solutions rather than imposing the clinician's agenda. It strategically amplifies change talk (the patient's own arguments for change) while avoiding the righting reflex (the clinician's instinct to correct, lecture, or prescribe).\n\nWHY OTHER OPTIONS ARE INCORRECT:\nOption A ('You really need to exercise or your diabetes will get worse') is a confrontational, directive statement that triggers the righting reflex and typically increases patient resistance (the \"expert trap\" that MI specifically avoids). Option C ('Let me give you a handout about the benefits of exercise') assumes the patient lacks information (an information deficit model) when the patient already knows they should exercise. Option D ('I'm referring you to a diabetes educator') bypasses the patient's autonomy and does not address the underlying ambivalence.\n\nSPIRIT OF MI:\nEffective MI operates from four principles: partnership (collaborative, not authoritarian), acceptance (respecting autonomy), compassion (prioritizing patient welfare), and evocation (drawing out the patient's own motivation rather than installing it).\n\nKEY POINTS:\nOpen-ended evocative questions ('What would it look like if...') elicit the patient's own change talk and solutions, which is the core mechanism of motivational interviewing. Directive statements and information-giving increase resistance when the patient is ambivalent. MI avoids the righting reflex and instead amplifies the patient's own arguments for change."
  },
  {
    "id": 656,
    "categoryId": 11,
    "question": "During a motivational interviewing session, a patient expresses ambivalence: 'Part of me wants to quit smoking, but I really enjoy it and it helps me cope with stress.' What is the clinician's primary goal in responding?",
    "options": [
      "A) Convince the patient that smoking is harmful",
      "B) Explore and amplify the patient's own 'change talk' while respecting their autonomy",
      "C) Set a firm quit date",
      "D) Prescribe nicotine replacement therapy immediately"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Explore and amplify the patient's own change talk while respecting their autonomy).\n\nCLINICAL REASONING:\nThe patient's statement contains clear ambivalence: 'Part of me wants to quit smoking' (change talk) versus 'I really enjoy it and it helps me relax' (sustain talk). In motivational interviewing, ambivalence is not an obstacle but the expected psychological state that precedes behavior change, and the clinician's role is to help tip the decisional balance toward change by selectively exploring and amplifying change talk.\n\nCHANGE TALK AND SUSTAIN TALK:\nChange talk consists of patient statements that favor behavior change and falls into two categories. Preparatory change talk includes desire ('I want to quit'), ability ('I could quit'), reasons ('Quitting would improve my health'), and need ('I need to quit for my kids'). Mobilizing change talk includes commitment ('I will quit'), activation ('I'm ready to quit'), and taking steps ('I called the quitline'). The clinician's task is to use reflective listening to selectively highlight and elaborate on change talk while acknowledging (but not amplifying) sustain talk.\n\nTECHNIQUES:\nWhen a patient expresses ambivalence, the MI-consistent approach involves reflecting back the change talk component ('It sounds like part of you really does want to quit'), asking elaboration questions ('Tell me more about that part of you that wants to quit'), and using a decisional balance exercise where the patient articulates both sides. The clinician respects the patient's autonomy (\"It's completely your decision\") because paradoxically, affirming freedom of choice reduces resistance and increases openness to change.\n\nWHY OTHER OPTIONS ARE INCORRECT:\nConvincing the patient that smoking is harmful (Option A) uses the expert/confrontational approach that triggers reactance. Setting a firm quit date (Option C) and prescribing NRT immediately (Option D) skip the exploration of ambivalence and impose solutions before the patient has resolved their own motivational conflict.\n\nKEY POINTS:\nIn MI, the clinician explores and amplifies change talk (patient's own arguments for change) while acknowledging but not reinforcing sustain talk. Ambivalence is the expected state before behavior change, not an obstacle. Affirming patient autonomy paradoxically reduces resistance and increases openness to change."
  },
  {
    "id": 657,
    "categoryId": 16,
    "question": "A 52-year-old executive with hypertension and anxiety asks how deep breathing exercises could benefit his health. Which physiological mechanism best explains the cardiovascular benefits of slow, diaphragmatic breathing?",
    "options": [
      "A) Increased sympathetic tone",
      "B) Activation of the parasympathetic nervous system via vagal stimulation, reducing heart rate and blood pressure",
      "C) Increased cortisol release",
      "D) Peripheral vasoconstriction"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Activation of the parasympathetic nervous system via vagal stimulation, reducing heart rate and blood pressure).\n\nPATHOPHYSIOLOGY OF THE RELAXATION RESPONSE:\nSlow, diaphragmatic breathing activates the parasympathetic nervous system through several interconnected mechanisms. When breathing rate decreases to approximately 6 breaths per minute, respiratory sinus arrhythmia is maximized, creating rhythmic fluctuations in heart rate that enhance vagal tone. The diaphragm's descent during deep inhalation stimulates stretch receptors in the lungs that signal via the vagus nerve to the nucleus tractus solitarius in the brainstem, triggering parasympathetic outflow. This \"relaxation response,\" first characterized by Herbert Benson at Harvard Medical School, produces measurable physiological changes: heart rate decreases, blood pressure drops, peripheral vascular resistance falls, and stress hormone secretion diminishes.\n\nCARDIOVASCULAR AND METABOLIC EFFECTS:\nThe shift from sympathetic to parasympathetic dominance has broad systemic effects beyond immediate hemodynamic changes. Reduced catecholamine levels decrease myocardial oxygen demand and arrhythmia risk. Lower cortisol secretion improves insulin sensitivity and reduces visceral fat accumulation over time. Heart rate variability (HRV), a marker of cardiac autonomic function and cardiovascular health, increases with regular relaxation practice. Studies demonstrate that patients with hypertension who practice slow breathing techniques can achieve modest but clinically meaningful reductions in systolic blood pressure of 4-6 mmHg, comparable to the effect of reducing dietary sodium.\n\nCLINICAL APPLICATIONS:\nFor primary care providers, breathing techniques represent a zero-cost, zero-side-effect adjunct to pharmacotherapy for hypertension and anxiety disorders. Practical instruction takes only minutes: have patients breathe in for 4 seconds, hold for 2 seconds, and exhale for 6 seconds, aiming for approximately 5-6 breath cycles per minute. Regular practice of 10-15 minutes daily produces cumulative benefits. These techniques are particularly valuable for patients who prefer non-pharmacological approaches or need additional blood pressure reduction beyond medication.\n\nKEY POINTS:\nSlow diaphragmatic breathing activates parasympathetic pathways via vagal stimulation, lowering heart rate and blood pressure. The relaxation response reduces cortisol and catecholamines, improving metabolic and cardiovascular parameters. Breathing techniques at 5-6 breaths per minute can reduce systolic blood pressure by 4-6 mmHg with regular practice."
  },
  {
    "id": 658,
    "categoryId": 16,
    "question": "Regular aerobic exercise produces cardiovascular benefits through which primary physiological adaptation?",
    "options": [
      "A) Increased resting sympathetic tone",
      "B) Decreased stroke volume",
      "C) Improved endothelial function with increased nitric oxide bioavailability and reduced arterial stiffness",
      "D) Increased peripheral vascular resistance"
    ],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Improved endothelial function with increased nitric oxide bioavailability and reduced arterial stiffness).\n\nPATHOPHYSIOLOGY:\nThe cardiovascular benefits of regular aerobic exercise are primarily mediated through improved endothelial function, which represents the restoration of the endothelium's ability to produce and respond to nitric oxide (NO). During exercise, increased blood flow generates laminar shear stress on the vascular endothelium, which activates endothelial nitric oxide synthase (eNOS) through phosphorylation at serine 1177 via the PI3K/Akt pathway. The resulting increase in NO production causes vasodilation, inhibits platelet aggregation, reduces leukocyte adhesion, and suppresses smooth muscle cell proliferation, all of which are atheroprotective.\n\nCHRONIC ADAPTATIONS:\nWith regular aerobic training, eNOS expression is chronically upregulated, increasing baseline NO bioavailability even at rest. Exercise simultaneously reduces oxidative stress (by upregulating superoxide dismutase, catalase, and glutathione peroxidase through the Nrf2 pathway), which prevents the superoxide-mediated destruction of NO that characterizes endothelial dysfunction in sedentary and metabolically unhealthy individuals. Additionally, regular exercise reduces arterial stiffness (measured by pulse wave velocity, the gold standard biomarker of vascular aging) by improving elastin-to-collagen ratios in the arterial wall and reducing advanced glycation end-product (AGE) cross-linking.\n\nCLINICAL IMPACT:\nThese vascular adaptations translate to measurable clinical benefits: resting blood pressure reduction of 5 to 8 mmHg systolic, improved flow-mediated dilation (the clinical measure of endothelial function), reduced resting heart rate, improved lipid profile (increased HDL, reduced triglycerides), and decreased systemic inflammation (reduced CRP, IL-6). The 2018 Physical Activity Guidelines state that each 1-MET increase in cardiorespiratory fitness is linked to approximately 12 to 15% reduction in cardiovascular and all-cause mortality.\n\nKEY POINTS:\nExercise improves cardiovascular health primarily through shear stress-mediated eNOS activation, increasing nitric oxide production that promotes vasodilation, platelet inhibition, and anti-inflammation. Chronic training upregulates eNOS expression, reduces oxidative stress via Nrf2-mediated antioxidant enzymes, and decreases arterial stiffness. Each 1-MET increase in fitness reduces cardiovascular mortality by 12 to 15%."
  },
  {
    "id": 659,
    "categoryId": 11,
    "question": "Exercise is recommended as an adjunctive treatment for major depressive disorder. Which neurobiological mechanism most directly explains its antidepressant effect?",
    "options": [
      "A) Decreased cerebral blood flow",
      "B) Increased BDNF expression promoting hippocampal neurogenesis and synaptic plasticity",
      "C) Suppression of serotonin synthesis",
      "D) Increased inflammatory cytokine production"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Increased BDNF expression promoting hippocampal neurogenesis and synaptic plasticity).\n\nPATHOPHYSIOLOGY:\nBrain-derived neurotrophic factor (BDNF) is the neurobiological mechanism most directly explaining the antidepressant effects of exercise. BDNF is a member of the neurotrophin family that binds to TrkB (tropomyosin receptor kinase B) receptors, activating intracellular signaling cascades (MAPK/ERK, PI3K/Akt, PLCgamma) that promote neuronal survival, dendritic branching, synaptogenesis, and neurogenesis in the hippocampal dentate gyrus.\n\nNEUROTROPHIC HYPOTHESIS OF DEPRESSION:\nThe neurotrophic hypothesis posits that depression is linked to reduced BDNF levels, hippocampal neuroplasticity impairment, and hippocampal volume loss, while recovery involves restoration of BDNF signaling and neuroplastic capacity. Post-mortem studies consistently show reduced BDNF expression in the hippocampus and prefrontal cortex of depressed individuals, and serum BDNF levels are lower in patients with MDD compared to healthy controls. Successful antidepressant treatment (both pharmacologic and exercise-based) is linked to normalization of BDNF levels.\n\nEXERCISE-BDNF PATHWAY:\nAerobic exercise increases BDNF through multiple pathways. Contracting skeletal muscle produces irisin (via cleavage of the membrane protein FNDC5), which crosses the blood-brain barrier and directly stimulates hippocampal BDNF gene expression through the PGC-1-alpha/FNDC5 pathway. Exercise-generated lactate also crosses the blood-brain barrier and activates BDNF transcription via the SIRT1 deacetylase pathway. Randomized trials demonstrate that 12 weeks of aerobic exercise increases hippocampal volume by approximately 2% in older adults (equivalent to reversing 1 to 2 years of age-related atrophy), an effect mediated by BDNF-driven neurogenesis.\n\nCLINICAL EVIDENCE:\nMeta-analyses confirm that exercise produces moderate-to-large antidepressant effect sizes (Hedges g approximately 0.5 to 0.7), comparable to pharmacotherapy for mild to moderate MDD. The 2024 ACP guidelines include exercise as a recommended treatment option for MDD. The effective dose is typically 150 minutes per week of moderate-intensity aerobic activity.\n\nKEY POINTS:\nExercise exerts antidepressant effects primarily through increased BDNF expression (via the irisin/PGC-1-alpha pathway from muscle contraction), promoting hippocampal neurogenesis and restoring the neuroplasticity deficit central to the neurotrophic hypothesis of depression. Twelve weeks of aerobic exercise increases hippocampal volume by approximately 2%. Exercise produces antidepressant effect sizes comparable to pharmacotherapy for mild to moderate MDD."
  },
  {
    "id": 660,
    "categoryId": 4,
    "question": "A 54-year-old patient is newly diagnosed with Type 2 diabetes (A1c 7.2%). Intensive lifestyle intervention addresses the underlying pathophysiology of Type 2 DM by:",
    "options": [
      "A) Increasing insulin secretion from beta cells",
      "B) Reducing insulin resistance through decreased visceral adiposity and improved mitochondrial function",
      "C) Blocking hepatic glucose production only",
      "D) Slowing carbohydrate absorption in the gut"
    ],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Reducing insulin resistance through decreased visceral adiposity and improved mitochondrial function).\n\nPATHOPHYSIOLOGY:\nType 2 diabetes is fundamentally a disease of insulin resistance and progressive beta-cell dysfunction. Insulin resistance precedes hyperglycemia by years. Visceral adipose tissue drives resistance through multiple mechanisms (Diabetes Care): excessive free fatty acid release stimulates hepatic gluconeogenesis and causes intramyocellular/intrahepatic lipid accumulation, generating diacylglycerols and ceramides that activate PKC isoforms blocking insulin receptor substrate signaling. Visceral fat secretes proinflammatory cytokines (TNF-alpha, IL-6) activating JNK/IKK-beta pathways that further impair signaling, while adiponectin secretion decreases, removing its protective effects.\n\nCLINICAL EVIDENCE:\nThe DPP (NEJM, 2001; 3,234 participants) demonstrated lifestyle intervention (7% weight loss, 150 min/week activity) reduced T2DM incidence by 58% versus placebo, outperforming metformin (31%). Greatest benefit in patients over 60 (71% reduction); sustained at 15-year follow-up. The DiRECT trial (Lancet, 2018) achieved diabetes remission (HbA1c <6.5% off medications) in 46% at 1 year, with 86% remission among those losing 15 kg or more. The Look AHEAD trial confirmed sustained improvements in HbA1c, weight, fitness, and reduced medication requirements.\n\nCLINICAL APPLICATION:\nExercise improves insulin sensitivity independently of weight loss. Muscle contraction activates AMPK, stimulating GLUT4 translocation via an insulin-independent pathway, lowering glucose even in resistant states. Regular exercise induces mitochondrial biogenesis through PGC-1-alpha, enhancing fatty acid oxidation and reducing toxic lipid intermediates. Resistance training expands muscle mass\u2014the primary site of glucose disposal. The ADA recommends 150+ minutes/week moderate aerobic activity plus 2-3 resistance sessions. For newly diagnosed T2DM with A1c 7.2%, 5-10% weight loss meaningfully improves insulin sensitivity, and remission is achievable with preserved beta-cell function.\n\nKEY POINTS:\nLifestyle intervention is the only truly disease-modifying T2DM treatment. The DPP showed 58% prevention; DiRECT achieved 46% remission at 1 year. Exercise improves glucose uptake via the insulin-independent AMPK-GLUT4 pathway and enhances mitochondrial function."
  },
  {
    "id": 661,
    "question": "A 28-year-old G1P0 at 32 weeks' gestation presents with blood pressure 158/102 mmHg, 3+ proteinuria on urine dipstick, and a headache. Labs show platelets 90,000 and AST 180. What is the diagnosis and most critical next step?",
    "options": ["A) Gestational hypertension; observe and recheck BP in 1 week", "B) Preeclampsia with severe features; administer magnesium sulfate and plan delivery", "C) HELLP syndrome only; transfuse platelets and continue pregnancy", "D) Chronic hypertension; increase home antihypertensive dose"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Preeclampsia with severe features; administer magnesium sulfate and plan delivery).\n\nPATHOPHYSIOLOGY:\nPreeclampsia results from failed extravillous trophoblast remodeling of uterine spiral arteries. Persistent vasoconstriction produces placental ischemia, triggering release of anti-angiogenic factors (sFlt-1, soluble endoglin) that antagonize VEGF and PlGF, causing widespread maternal endothelial dysfunction manifesting as hypertension, proteinuria (glomerular endotheliosis), and end-organ damage.\n\nDIAGNOSTIC CRITERIA:\nPreeclampsia: new-onset hypertension (BP >=140/90) after 20 weeks with proteinuria (>=300 mg/24h or protein/creatinine >=0.3) or end-organ dysfunction. Severe features include: BP >=160/110, thrombocytopenia (<100,000), elevated transaminases (>2x normal), creatinine >1.1, pulmonary edema, or cerebral/visual disturbances. This patient meets criteria based on blood pressure (158/102), thrombocytopenia (90,000), and elevated AST (180). The combination of hemolysis, elevated liver enzymes, and low platelets constitutes HELLP syndrome, a severe preeclampsia variant.\n\nMANAGEMENT:\nMagnesium sulfate for seizure prophylaxis: 4-6g IV loading dose, then 1-2 g/hour infusion. Antihypertensives (IV labetalol, IV hydralazine, or oral nifedipine) for acute severe hypertension to reduce stroke risk. Delivery is the definitive treatment. At 32 weeks with severe features, deliver after stabilization and antenatal corticosteroids (betamethasone) for fetal lung maturity if time permits.\n\nKEY POINTS:\nPreeclampsia with severe features (BP >=160/110, platelets <100,000, elevated transaminases) requires magnesium sulfate for seizure prophylaxis and delivery planning. HELLP syndrome is a severe variant. The root cause is failed spiral artery remodeling causing placental ischemia and release of anti-angiogenic factors producing systemic endothelial dysfunction.",
    "categoryId": 18
  },
  {
    "id": 662,
    "question": "A 32-year-old woman presents with heavy, painful periods, dyspareunia, and difficulty conceiving. Pelvic ultrasound shows a 4cm 'chocolate cyst' on the left ovary. What is the underlying diagnosis?",
    "options": ["A) Dermoid cyst (mature teratoma)", "B) Endometriosis with endometrioma", "C) Hemorrhagic corpus luteum cyst", "D) Polycystic ovarian syndrome"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Endometriosis with endometrioma).\n\nPATHOPHYSIOLOGY:\nEndometriosis is a chronic estrogen-dependent inflammatory condition with endometrial-like tissue growing outside the uterine cavity, most commonly on ovaries, tubes, uterosacral ligaments, and peritoneum. Ectopic tissue responds to cyclical hormonal stimulation, undergoing proliferation and menstrual breakdown. Unlike intrauterine blood, ectopic hemorrhage has no egress, causing inflammation, fibrosis, and adhesions. Repeated ovarian hemorrhage forms endometriomas (\"chocolate cysts\")\u2014containing thick, dark brown fluid of hemolyzed blood and hemosiderin.\n\nCLINICAL MANIFESTATIONS:\nThe classic triad: dysmenorrhea (progressive menstrual pain), dyspareunia (deep pain with intercourse from uterosacral/cul-de-sac involvement), and infertility (30-50% of affected women, via tubal adhesions, toxic peritoneal environment, and impaired endometrial receptivity). Additional symptoms include chronic pelvic pain and dyschezia during menstruation.\n\nDIAGNOSIS:\nLaparoscopy with histologic confirmation remains the gold standard. Endometriomas appear on transvaginal ultrasound as homogeneous hypoechoic cysts with low-level internal echoes (\"ground glass\" appearance) without internal Doppler vascularity. MRI aids in evaluating deep infiltrating endometriosis. CA-125 may be mildly elevated but lacks sensitivity and specificity.\n\nTREATMENT:\nMedical therapy suppresses estrogen-driven growth: continuous combined OCPs, progestins (norethindrone, medroxyprogesterone, levonorgestrel IUD), GnRH agonists (leuprolide with add-back therapy), or GnRH antagonists (elagolix, first oral GnRH antagonist FDA-approved for endometriosis). Surgical excision/ablation and endometrioma cystectomy are indicated for refractory symptoms, large endometriomas (>4 cm), and infertility.\n\nKEY POINTS:\nEndometriomas (\"chocolate cysts\") contain old hemolyzed blood from cyclic hemorrhage of ectopic endometrial tissue. The classic triad is dysmenorrhea, dyspareunia, and infertility (30-50%). Laparoscopy is the diagnostic gold standard. Treatment ranges from hormonal suppression to surgical excision.",
    "categoryId": 18
  },
  {
    "id": 663,
    "question": "A 52-year-old postmenopausal woman presents with hot flashes, vaginal dryness, and sleep disturbance that significantly impair her quality of life. She has no personal history of breast cancer, VTE, or cardiovascular disease. She is within 10 years of menopause onset. What is the most appropriate treatment?",
    "options": ["A) Black cohosh and soy isoflavones", "B) Systemic hormone replacement therapy (estrogen + progesterone)", "C) SSRI antidepressant only", "D) Testosterone replacement therapy"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Systemic hormone replacement therapy).\n\nEVIDENCE:\nSystemic menopausal hormone therapy (MHT) with estrogen plus progestogen is the most effective treatment for vasomotor symptoms (hot flashes, night sweats), reducing frequency and severity by 75-80%. NAMS 2022 and the Endocrine Society support MHT as first-line for moderate-to-severe vasomotor symptoms in women within 10 years of menopause onset or under age 60 without contraindications.\n\nTIMING HYPOTHESIS:\nThe \"timing hypothesis\" is supported by WHI reanalysis and the Danish Osteoporosis Prevention Study. Estrogen initiated within 10 years of menopause reduces coronary heart disease risk and all-cause mortality with favorable cardiovascular effects. Initiation >10 years post-menopause shifts risk unfavorably, increasing coronary events, stroke, and VTE. This patient at 52, within 10 years of menopause, falls within the favorable window.\n\nPROGESTOGEN REQUIREMENT:\nWomen with an intact uterus must receive progestogen to prevent estrogen-induced endometrial hyperplasia and cancer (unopposed estrogen increases risk 2-10 fold). Micronized progesterone is preferred over medroxyprogesterone acetate for its more favorable breast safety profile and preserved cardiovascular benefits. Post-hysterectomy women can receive estrogen alone.\n\nCONTRAINDICATIONS:\nAbsolute contraindications: personal history of breast cancer, active/prior VTE or PE, active liver disease, unexplained vaginal bleeding, known thrombophilia, and history of stroke or MI. Non-hormonal alternatives include paroxetine (only FDA-approved non-hormonal option for hot flashes), gabapentin, fezolinetant (neurokinin-3 receptor antagonist, FDA-approved 2023), and cognitive behavioral therapy.\n\nKEY POINTS:\nMHT is the most effective vasomotor symptom treatment (75-80% reduction), appropriate for symptomatic women within 10 years of menopause without contraindications. Progestogen is required with an intact uterus. The timing hypothesis is critical for favorable cardiovascular outcomes.",
    "categoryId": 18
  },
  {
    "id": 664,
    "question": "A 26-year-old woman presents with foul-smelling, thin, grayish-white vaginal discharge. Vaginal pH is 5.0. KOH 'whiff test' produces a strong fishy odor. Wet mount shows epithelial cells studded with bacteria. What is the diagnosis?",
    "options": ["A) Vulvovaginal candidiasis", "B) Bacterial vaginosis", "C) Trichomonas vaginalis", "D) Chlamydia cervicitis"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Bacterial vaginosis).\n\nPATHOPHYSIOLOGY:\nBacterial vaginosis (BV) is the most common cause of vaginal discharge in reproductive-age women, affecting approximately 29% of US women. BV represents a dysbiosis rather than a true infection: protective Lactobacillus species, which maintain vaginal pH at 3.5-4.5 through lactic acid and hydrogen peroxide production, are displaced by polymicrobial anaerobic overgrowth including Gardnerella vaginalis, Atopobium vaginae, Prevotella, Mobiluncus, and Mycoplasma hominis. This shift raises vaginal pH above 4.5 and produces volatile amines (putrescine, cadaverine, trimethylamine) responsible for the characteristic fishy odor.\n\nCLINICAL REASONING:\nThis patient meets all four Amsel criteria (3 of 4 required for diagnosis): thin, homogeneous, grayish-white discharge; vaginal pH greater than 4.5 (5.0 in this case); positive KOH whiff test; and clue cells on wet mount, which are epithelial cells with borders obscured by adherent coccobacilli. The Nugent scoring system using Gram stain is the research gold standard but is less practical in clinical settings. Key differential diagnoses include vulvovaginal candidiasis (thick cottage-cheese discharge, normal pH less than 4.5, pseudohyphae on KOH prep), trichomoniasis (frothy yellow-green discharge, motile flagellated protozoa, strawberry cervix), and chlamydial cervicitis (mucopurulent endocervical discharge without vaginal flora disruption).\n\nPer CDC STI Treatment Guidelines, first-line treatment is oral metronidazole 500 mg BID for 7 days or intravaginal metronidazole gel 0.75% for 5 days. Alternatives include oral or intravaginal clindamycin. Patients must avoid alcohol during metronidazole use and for 48 hours afterward due to a disulfiram-like reaction. Recurrence is common, affecting approximately 50% of patients within 12 months. BV in pregnancy increases the risk of preterm delivery and should be treated.\n\nKEY POINTS:\nBV is diagnosed using Amsel criteria, with clue cells being the single most specific finding. It represents Lactobacillus depletion and anaerobic overgrowth, not a traditional sexually transmitted infection. First-line treatment is metronidazole per CDC STI guidelines, with high recurrence rates necessitating patient counseling.",
    "categoryId": 18
  },
  {
    "id": 665,
    "question": "A 30-year-old nulligravid woman desires long-acting reversible contraception (LARC). She has a history of heavy menstrual bleeding. Which method provides BOTH highly effective contraception AND treatment of her menorrhagia?",
    "options": ["A) Copper IUD (Paragard)", "B) Levonorgestrel IUD (Mirena)", "C) Etonogestrel subdermal implant (Nexplanon)", "D) Depot medroxyprogesterone acetate (Depo-Provera)"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Levonorgestrel IUD/Mirena).\n\nPHARMACOLOGY:\nThe levonorgestrel-releasing intrauterine device (LNG-IUD, Mirena 52 mg) provides highly effective contraception (failure rate 0.2%, comparable to tubal ligation) while simultaneously delivering local progestogen to the endometrium that produces profound endometrial suppression (decidualization, stromal pseudodecidualization, and glandular atrophy), reducing menstrual blood loss by 80 to 97% within 6 months. Approximately 20% of users become amenorrheic by one year, increasing to 50% by 5 years. This dual benefit makes the LNG-IUD uniquely suited for women who desire both contraception and treatment of heavy menstrual bleeding.\n\nMECHANISM OF CONTRACEPTION:\nThe LNG-IUD prevents pregnancy through multiple mechanisms: thickening of cervical mucus (preventing sperm penetration), endometrial suppression (creating a hostile environment for implantation), partial suppression of ovulation in some cycles (though most users continue to ovulate), and a local foreign-body inflammatory reaction that is spermicidal. The continuous local progestogen delivery achieves high endometrial tissue concentrations with minimal systemic absorption, resulting in fewer systemic side effects compared to oral or injectable progestins.\n\nWHY NOT THE ALTERNATIVES:\nThe copper IUD (Paragard) is an excellent non-hormonal LARC option but actually increases menstrual bleeding by 20 to 50% and worsens dysmenorrhea, making it contraindicated in this patient with menorrhagia. The etonogestrel implant (Nexplanon) provides highly effective contraception (failure rate 0.05%, the most effective reversible method) but produces unpredictable bleeding patterns (irregular spotting, prolonged bleeding) in approximately 30% of users and is not reliably effective for treating heavy menstrual bleeding. Depot medroxyprogesterone (Depo-Provera) reduces menstrual bleeding and often induces amenorrhea, but it is linked to weight gain (average 5 kg over 2 years), delayed return to fertility (average 10 months after last injection), and bone density loss with prolonged use, making it less ideal for long-term use.\n\nADDITIONAL BENEFITS:\nThe LNG-IUD has FDA approval for treatment of heavy menstrual bleeding and is endorsed by ACOG as first-line medical therapy for menorrhagia. It also provides endometrial protection for women on estrogen therapy and reduces the risk of endometrial cancer and endometrial hyperplasia. It is effective for 8 years for contraception.\n\nKEY POINTS:\nThe levonorgestrel IUD (Mirena) is the only LARC that provides both highly effective contraception and treatment of heavy menstrual bleeding, reducing blood loss by 80 to 97% through local endometrial suppression. The copper IUD worsens menstrual bleeding and is contraindicated in menorrhagia. The LNG-IUD is ACOG-endorsed as first-line medical therapy for heavy periods.",
    "categoryId": 18
  },
  {
    "id": 666,
    "question": "A 25-year-old woman presents to the emergency department with sudden-onset severe right lower quadrant pain, nausea, and a positive pregnancy test (beta-hCG 1,800 mIU/mL). Transvaginal ultrasound shows no intrauterine pregnancy and free fluid in the cul-de-sac. What is the most likely diagnosis?",
    "options": ["A) Threatened abortion", "B) Ectopic pregnancy", "C) Ovarian torsion", "D) Ruptured ovarian cyst"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Ectopic pregnancy).\n\nPATHOPHYSIOLOGY:\nAn ectopic pregnancy occurs when a fertilized ovum implants outside the uterine cavity, most commonly in the fallopian tube (approximately 95% of cases, with the ampulla being the most frequent site followed by the isthmus and fimbriae). The fallopian tube lacks the thick, distensible myometrium and specialized decidual response of the uterus, so the growing trophoblast invades through the thin tubal wall, eventually causing tubal rupture, hemorrhage, and potentially life-threatening hemoperitoneum. Risk factors include prior ectopic pregnancy (10-fold increased risk), prior tubal surgery or pelvic inflammatory disease (tubal scarring and damage to ciliary function), endometriosis, IUD use (an IUD prevents intrauterine pregnancy more effectively than ectopic, so if pregnancy occurs with an IUD in place, the probability it is ectopic is increased), smoking (impairs tubal motility and ciliary function), and assisted reproductive technology.\n\nDIAGNOSTIC REASONING:\nThe discriminatory zone is the beta-hCG level above which a normal intrauterine pregnancy should be visible on transvaginal ultrasound, typically 1,500 to 2,000 mIU/mL. This patient's beta-hCG of 1,800 is above the discriminatory zone, yet no intrauterine pregnancy is visible, which is highly suspicious for ectopic pregnancy. Free fluid in the cul-de-sac (the most dependent peritoneal space) suggests hemoperitoneum from tubal rupture or leaking ectopic. In a hemodynamically stable patient, the combination of positive pregnancy test, beta-hCG above the discriminatory zone, absent intrauterine pregnancy on transvaginal ultrasound, and adnexal pathology or free fluid has a positive predictive value exceeding 95% for ectopic pregnancy.\n\nMANAGEMENT:\nHemodynamically unstable patients require emergent surgical intervention (laparoscopic salpingectomy or salpingostomy). For hemodynamically stable patients with an unruptured ectopic pregnancy, medical management with methotrexate (a folate antagonist that inhibits rapidly dividing trophoblastic tissue) is appropriate when beta-hCG is less than 5,000, the ectopic mass is less than 3.5 cm, no fetal cardiac activity is detected, and the patient can comply with follow-up. Expectant management may be considered for very low and declining beta-hCG levels.\n\nKEY POINTS:\nAn ectopic pregnancy should be suspected when beta-hCG is above the discriminatory zone (1,500 to 2,000) with no intrauterine pregnancy on transvaginal ultrasound. Free cul-de-sac fluid suggests tubal rupture and hemoperitoneum. The ampulla is the most common site (95% are tubal), and methotrexate is the standard medical treatment for stable, unruptured ectopic pregnancies meeting criteria.",
    "categoryId": 18
  },
  {
    "id": 667,
    "question": "A 35-year-old woman with regular cycles is trying to conceive. She asks when in her cycle she is most fertile. What is the most accurate counseling?",
    "options": ["A) The day of ovulation only", "B) The 6-day window ending on the day of ovulation (fertile window)", "C) Days 1-7 of the menstrual cycle", "D) The 3 days immediately after ovulation"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (The 6-day window ending on the day of ovulation).\n\nREPRODUCTIVE PHYSIOLOGY:\nThe fertile window encompasses 5 days before ovulation and the day of ovulation itself. Sperm survive in the female reproductive tract up to 5 days when cervical mucus is favorable (thin, watery, estrogen-influenced ferning-pattern mucus), maintaining fertilization capacity in cervical crypts and fallopian tubes. The oocyte is viable for only 12-24 hours after ovulation. Highest conception probability occurs when sperm are already present at ovulation.\n\nPEAK FERTILITY:\nConception probability is highest during the 2 days preceding ovulation (~25-30% per cycle), declines sharply on ovulation day, and approaches zero beyond 24 hours post-ovulation. In a 28-day cycle, ovulation occurs around day 14, making the window approximately days 9-14. However, ovulation timing varies significantly, making calendar methods alone unreliable.\n\nFERTILITY AWARENESS METHODS:\nUrinary LH surge kits detect the LH surge preceding ovulation by 24-36 hours, providing advance warning. Basal body temperature rises 0.2-0.5 degrees C post-ovulation from progesterone but only confirms ovulation retrospectively. Cervical mucus monitoring (Billings method) identifies the transition to copious, clear, stretchy mucus (spinnbarkeit) signaling the estrogen peak.\n\nCLINICAL COUNSELING:\nFor couples trying to conceive, intercourse every 1-2 days during the fertile window optimizes conception. Daily intercourse does not significantly improve rates over every-other-day. ACOG recommends infertility evaluation after 12 months of unprotected intercourse (6 months if age 35 or older).\n\nKEY POINTS:\nThe fertile window is the 6-day period ending on ovulation day, reflecting sperm survival (up to 5 days) and oocyte viability (12-24 hours). Peak fertility is the 2 days preceding ovulation. LH surge kits predict ovulation 24-36 hours in advance; basal body temperature only confirms retrospectively.",
    "categoryId": 18
  },
  {
    "id": 668,
    "question": "A 45-year-old woman undergoes cervical cancer screening. Her HPV test is positive for HPV 16, but cytology is negative (NILM). What is the appropriate management per ASCCP guidelines?",
    "options": ["A) Immediate colposcopy", "B) Repeat co-testing in 1 year", "C) No further follow-up needed", "D) Proceed directly to LEEP excision"],
    "correctAnswer": 0,
    "explanation": "CORRECT: A (Immediate colposcopy).\n\nASCCP GUIDELINE:\nThe 2019 ASCCP Risk-Based Management Consensus Guidelines recommend immediate colposcopy for any patient HPV 16 or 18 positive, even with negative cytology (NILM). HPV 16/18 carry substantially higher oncogenic risk, with ~4% probability of underlying CIN 3+ for HPV 16 with NILM\u2014exceeding the ASCCP colposcopy referral threshold of 4% immediate CIN 3+ risk.\n\nWHY HPV 16 IS DIFFERENT:\nHPV 16 causes ~50-60% of cervical cancers with a uniquely aggressive profile. It persists more frequently (30-40% beyond 12 months versus 10-15% for other high-risk types) and more efficiently drives progression through E6 and E7 oncoproteins degrading p53 and Rb respectively. HPV 16 E6 has particularly high p53 binding affinity. Even with normal cytology, meaningful probability of occult high-grade lesions exists given Pap sensitivity of only 50-80% for CIN 2+.\n\nCOMPARISON WITH OTHER HIGH-RISK HPV TYPES:\nNon-16/non-18 high-risk HPV (types 31, 33, 45, 52, 58) with NILM carries only 0.5-1% CIN 3+ risk, below the colposcopy threshold. These patients undergo repeat co-testing in 1 year; if HPV persists, colposcopy is indicated. If both negative at 1 year, repeat in 3 years (not routine 5-year intervals) due to elevated baseline risk.\n\nCOLPOSCOPY PROCEDURE:\nAcetic acid (3-5%) applied to the cervix under magnification identifies acetowhite epithelium and abnormal vascular patterns. Biopsies target abnormal areas; endocervical curettage is performed if the transformation zone is not fully visualized. If negative (CIN 1 or less), follow-up HPV testing in 1 year is required because HPV 16 positivity confers ongoing risk.\n\nKEY POINTS:\nHPV 16/18 positive with NILM cytology requires immediate colposcopy per 2019 ASCCP guidelines. HPV 16 causes 50-60% of cervical cancers, persists more frequently, and has higher E6/p53 binding affinity. Non-16/18 high-risk HPV with NILM requires repeat co-testing in 1 year.",
    "categoryId": 18
  },
  {
    "id": 669,
    "question": "A 38-year-old woman with a BMI of 34 presents with irregular, heavy periods occurring every 2-3 months and hirsutism. She is not trying to conceive. Endometrial biopsy shows simple hyperplasia without atypia. What is the most important pharmacologic intervention?",
    "options": ["A) Metformin alone", "B) Progestogen therapy (oral or intrauterine) to protect the endometrium", "C) Clomiphene citrate for ovulation induction", "D) Spironolactone for hirsutism"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Progestogen therapy to protect the endometrium).\n\nPATHOPHYSIOLOGY:\nThis patient has features: oligomenorrhea, hyperandrogenism (hirsutism), and obesity. In PCOS, chronic anovulation results in continuous estrogen production (from peripheral aromatization of androgens in adipose tissue and from the persistent follicles that produce estradiol without progressing to ovulation) without the cyclical progesterone secretion that normally follows ovulation from the corpus luteum. This creates a state of unopposed estrogen stimulation of the endometrium, which drives endometrial proliferation without the progesterone-mediated secretory transformation and organized shedding. Over time, unopposed estrogen produces endometrial hyperplasia, which can progress from simple hyperplasia without atypia (1% progression to endometrial cancer) to complex hyperplasia with atypia (29% progression to endometrial cancer).\n\nENDOMETRIAL PROTECTION:\nProgestogen therapy is the most critical intervention because it directly counteracts unopposed estrogen by inducing secretory transformation and organized shedding of the endometrium, reversing hyperplasia and preventing progression to endometrial cancer. Options include cyclic oral progestogen (medroxyprogesterone acetate 10 mg daily for 10 to 14 days each month to induce a withdrawal bleed), continuous progestogen (norethindrone acetate), the levonorgestrel IUD (Mirena, which provides continuous local progestogen delivery directly to the endometrium and is highly effective for hyperplasia regression), or combined oral contraceptives (which provide both progestogen for endometrial protection and suppress ovarian androgen production).\n\nCOMPREHENSIVE PCOS MANAGEMENT:\nWhile endometrial protection is the most urgent concern given the biopsy finding, comprehensive PCOS management also addresses hyperandrogenism (spironolactone, an anti-androgen, for hirsutism; combined OCPs to suppress ovarian androgens), metabolic syndrome (weight loss of 5 to 10% can restore ovulatory cycles, improve insulin sensitivity, and reduce androgens), and insulin resistance (metformin as adjunctive therapy). However, none of these address the immediate cancer risk from endometrial hyperplasia as directly as progestogen therapy.\n\nMONITORING:\nFollow-up endometrial biopsy should be performed after 3 to 6 months of progestogen therapy to confirm hyperplasia regression. If hyperplasia with atypia were present, the LNG-IUD or hysterectomy would be recommended given the 29% cancer progression rate.\n\nKEY POINTS:\nUnopposed estrogen from chronic anovulation in PCOS causes endometrial hyperplasia, with progression to cancer in 1% (simple without atypia) to 29% (complex with atypia). Progestogen therapy (oral cyclic, LNG-IUD, or combined OCPs) is the most critical intervention to induce endometrial shedding and reverse hyperplasia. The LNG-IUD is the most effective option for endometrial protection in PCOS.",
    "categoryId": 18
  },
  {
    "id": 670,
    "question": "A 28-year-old G2P1 at 28 weeks' gestation has a 1-hour glucose challenge test result of 155 mg/dL (threshold 140 mg/dL). She proceeds to the 3-hour oral glucose tolerance test and has 2 abnormal values. What is the diagnosis, and what is the most significant fetal risk if poorly controlled?",
    "options": ["A) Type 2 diabetes; neural tube defects", "B) Gestational diabetes; fetal macrosomia", "C) Impaired glucose tolerance; preterm birth", "D) Normal pregnancy; no fetal risk"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Gestational diabetes; fetal macrosomia).\n\nDIAGNOSTIC CRITERIA:\nGestational diabetes mellitus (GDM) means glucose intolerance first recognized during pregnancy and is diagnosed by the two-step approach recommended by ACOG. Step one is the 1-hour 50-gram glucose challenge test (GCT) at 24 to 28 weeks' gestation; a result of 140 mg/dL or greater (some centers use 130 or 135) is considered positive and requires the confirmatory 3-hour 100-gram oral glucose tolerance test (OGTT). Step two applies the Carpenter-Coustan criteria for the 3-hour OGTT: fasting 95 or greater, 1-hour 180 or greater, 2-hour 155 or greater, 3-hour 140 or greater. Two or more abnormal values confirm GDM. This patient meets criteria.\n\nPATHOPHYSIOLOGY:\nPregnancy is inherently a state of progressive insulin resistance driven by placental hormones (human placental lactogen, cortisol, progesterone, growth hormone variant, TNF-alpha) that antagonize maternal insulin signaling to ensure adequate glucose delivery to the fetus. In women with insufficient pancreatic beta-cell compensatory capacity (those with underlying insulin resistance from obesity, PCOS, family history, or prior GDM), blood glucose levels rise above normal, producing GDM. GDM affects approximately 6 to 9% of pregnancies.\n\nFETAL MACROSOMIA:\nThe most significant fetal risk of poorly controlled GDM is macrosomia (birth weight greater than 4,000 to 4,500 grams). Maternal hyperglycemia crosses the placenta (glucose crosses freely by facilitated diffusion), but maternal insulin does not. The fetal pancreas responds to chronically elevated glucose by producing excess insulin (fetal hyperinsulinemia), which acts as a potent growth factor driving excessive fetal adipose deposition, organomegaly (particularly hepatomegaly and cardiomegaly), and accelerated growth. This is the Pedersen hypothesis. Macrosomia increases the risk of shoulder dystocia (and its complications: brachial plexus injury/Erb palsy, clavicle fracture), birth trauma, operative delivery, and neonatal hypoglycemia (the hyperinsulinemic neonate rapidly becomes hypoglycemic after the placental glucose supply is removed at delivery).\n\nMANAGEMENT:\nDietary modification and glucose monitoring (fasting less than 95 mg/dL, 1-hour postprandial less than 140 or 2-hour less than 120) are first-line. Insulin is the preferred pharmacologic agent when dietary measures fail. Metformin and glyburide are alternatives but cross the placenta.\n\nKEY POINTS:\nGDM is diagnosed by the two-step process (1-hour GCT followed by 3-hour OGTT with 2 or more abnormal Carpenter-Coustan values) at 24 to 28 weeks. Fetal macrosomia is the most significant risk, driven by the Pedersen hypothesis (maternal hyperglycemia causes fetal hyperinsulinemia and excessive growth). Macrosomia increases shoulder dystocia, birth trauma, and neonatal hypoglycemia risk.",
    "categoryId": 18
  },
  {
    "id": 671,
    "question": "A 55-year-old postmenopausal woman presents with postmenopausal bleeding. She is obese (BMI 38) and has type 2 diabetes. Endometrial thickness on transvaginal ultrasound is 8mm. What is the most appropriate next step?",
    "options": ["A) Reassurance and follow-up ultrasound in 6 months", "B) Endometrial biopsy", "C) Start oral contraceptive pills", "D) Hysterectomy"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Endometrial biopsy).\n\nCLINICAL REASONING:\nPostmenopausal bleeding (PMB) means any vaginal bleeding occurring 12 months or more after the final menstrual period and must be evaluated to exclude endometrial cancer. Approximately 10% of women with PMB will be found to have endometrial carcinoma, making tissue sampling mandatory in virtually all cases. This patient has multiple additional risk factors for endometrial cancer: obesity (BMI 38, associated with excess peripheral aromatization of androgens to estrogen in adipose tissue, producing chronic unopposed estrogen stimulation), type 2 diabetes (associated with hyperinsulinemia, which promotes endometrial proliferation through insulin and IGF-1 receptor activation), and an endometrial thickness of 8 mm (exceeding the 4 mm threshold below which endometrial cancer is very unlikely in postmenopausal women).\n\nENDOMETRIAL THICKNESS THRESHOLD:\nIn postmenopausal women with bleeding, a transvaginal ultrasound showing an endometrial thickness of 4 mm or less has a >99% negative predictive value for excluding endometrial cancer, and biopsy can be deferred in this group. An endometrial thickness greater than 4 mm (as in this patient with 8 mm) requires tissue sampling. However, ultrasound thickness alone cannot distinguish benign causes (endometrial polyp, atrophic endometritis, hyperplasia) from malignancy, which is why histologic evaluation is necessary.\n\nBIOPSY METHODS:\nOffice endometrial biopsy (using a Pipelle device or similar suction curette) is the initial tissue sampling method of choice due to its low cost, convenience, minimal discomfort, and high sensitivity (90 to 98%) for detecting endometrial cancer. If the office biopsy is technically inadequate, non-diagnostic, or discordant with clinical suspicion, hysteroscopy with directed biopsy and/or dilation and curettage (D&C) is performed for definitive evaluation.\n\nENDOMETRIAL CANCER RISK FACTORS:\nThe primary risk factor framework for Type I endometrial cancer (endometrioid adenocarcinoma, accounting for 80% of cases) centers on chronic unopposed estrogen exposure: obesity, anovulation (PCOS), nulliparity, early menarche, late menopause, tamoxifen use (estrogenic effect on the endometrium despite anti-estrogenic effect on breast), and estrogen-only HRT without progestogen. Protective factors include combined oral contraceptives (each 5 years of use reduces endometrial cancer risk by approximately 25%), LNG-IUD, multiparity, and physical activity.\n\nKEY POINTS:\nAll postmenopausal bleeding requires evaluation to exclude endometrial cancer (present in approximately 10% of cases). Endometrial thickness greater than 4 mm on ultrasound warrants tissue sampling; 4 mm or less has >99% NPV for cancer. Office Pipelle biopsy is the first-line tissue sampling method with 90 to 98% sensitivity for endometrial cancer.",
    "categoryId": 18
  },
  {
    "id": 672,
    "question": "A 22-year-old woman presents for preconception counseling. She has epilepsy treated with valproic acid. What is the most critical medication-related counseling?",
    "options": ["A) Valproic acid is safe in pregnancy at low doses", "B) Valproic acid is the most teratogenic commonly used antiepileptic and should be switched before conception", "C) All antiepileptic drugs carry equal teratogenic risk", "D) She should stop all antiepileptics before conceiving"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Valproic acid is the most teratogenic commonly used AED and should be switched before conception).\n\nTERATOGENICITY:\nValproic acid (Depakote) carries a major congenital malformation rate of 9-11% (versus 2-3% baseline), making preconception medication change essential. Effects are dose-dependent, most pronounced during first-trimester organogenesis.\n\nSPECIFIC MALFORMATIONS:\nNeural tube defects (NTDs) are most characteristic, occurring in 1-2% of exposed pregnancies (10-20x baseline). Spina bifida is most common, from valproate's inhibition of folate metabolism and HDAC disruption during neural tube closure (by day 28, often before pregnancy recognition). Additional malformations: craniofacial anomalies, cardiac defects (ASD, VSD), skeletal abnormalities, and hypospadias. In-utero exposure reduces mean IQ by 8-11 points and increases autism risk 3-5 fold\u2014neurodevelopmental effects persisting without structural defects.\n\nSAFER ALTERNATIVES:\nLamotrigine and levetiracetam are preferred in pregnancy, with malformation rates near baseline (2-3%). Lamotrigine requires dose adjustment as estrogen-induced UGT upregulation reduces levels by 50-65% in the second/third trimesters. Carbamazepine carries intermediate risk (~3-5%). Transition off valproate must be completed before conception with seizure control confirmed.\n\nFOLIC ACID SUPPLEMENTATION:\nAll women of childbearing potential on AEDs should take high-dose folic acid (4 mg daily versus standard 0.4 mg), starting 1-3 months before conception through the first trimester. High-dose folate provides partial but incomplete NTD protection.\n\nKEY POINTS:\nValproic acid is the most teratogenic common AED (9-11% malformation rate), causing NTDs (1-2%), cardiac defects, and neurodevelopmental harm (8-11 point IQ reduction, increased autism risk). Lamotrigine and levetiracetam are preferred in pregnancy. Switch before conception; start high-dose folic acid (4 mg daily) at least 1-3 months pre-conception.",
    "categoryId": 18
  },
  {
    "id": 673,
    "question": "A 34-year-old woman 3 days postpartum presents with low mood, tearfulness, irritability, and difficulty sleeping. She is bonding with her infant and denies suicidal ideation. What is the most likely diagnosis?",
    "options": ["A) Postpartum depression", "B) Postpartum psychosis", "C) Postpartum 'baby blues'", "D) Adjustment disorder"],
    "correctAnswer": 2,
    "explanation": "CORRECT: C (Postpartum baby blues).\n\nDIAGNOSTIC REASONING:\nPostpartum blues (commonly called \"baby blues\") is a transient, self-limited mood disturbance affecting 50 to 80% of new mothers, typically beginning within 2 to 3 days of delivery, peaking around days 3 to 5, and resolving spontaneously within 2 weeks. The cardinal features are emotional lability (tearfulness, mood swings, irritability), mild anxiety, difficulty sleeping (beyond what is expected from newborn care demands), and feeling overwhelmed. the mother maintains the ability to bond with and care for her infant, and there are no psychotic symptoms or suicidal ideation. This patient at 3 days postpartum with the described symptoms and intact bonding and function fits this presentation.\n\nPATHOPHYSIOLOGY:\nThe dramatic hormonal changes following delivery are believed to trigger the baby blues. Estrogen and progesterone levels, which rise 100 to 1,000-fold during pregnancy, plummet within 48 hours of placental delivery. This rapid withdrawal affects serotonergic, GABAergic, and HPA-axis function. Additionally, prolactin surges, oxytocin fluctuations, thyroid function changes, sleep deprivation, and the psychosocial stress of new parenthood all contribute.\n\nDIFFERENTIAL DIAGNOSIS:\nPostpartum depression (PPD) is more severe, lasts longer (onset within 4 weeks, though often recognized later), and includes persistent depressed mood, anhedonia, significant functional impairment, difficulty bonding with the infant, excessive guilt or worthlessness, appetite and sleep changes beyond what is expected, and potentially suicidal ideation. PPD affects 10 to 15% of postpartum women and requires treatment (psychotherapy, SSRIs, or brexanolone/zuranolone for severe cases). Postpartum psychosis is a psychiatric emergency (0.1 to 0.2% of deliveries) presenting within 2 to 4 weeks with confusion, disorientation, hallucinations, delusions (often involving the infant), severe mood instability, and carries risk of infanticide and maternal suicide, requiring immediate hospitalization.\n\nMANAGEMENT:\nBaby blues requires only reassurance, emotional support, adequate rest, and help with infant care. No pharmacologic treatment is needed. However, if symptoms persist beyond 2 weeks, worsen, or include suicidal ideation or impaired bonding, the diagnosis should be reconsidered as PPD and formal screening (Edinburgh Postnatal Depression Scale) should be performed.\n\nKEY POINTS:\nPostpartum blues affects 50 to 80% of new mothers, begins within days of delivery, and resolves within 2 weeks without treatment. Key distinguishing features from postpartum depression are preserved bonding, maintained function, and self-limited course. If symptoms persist beyond 2 weeks or include impaired bonding, suicidal ideation, or functional decline, screen for postpartum depression with the Edinburgh scale.",
    "categoryId": 18
  },
  {
    "id": 674,
    "question": "A 29-year-old woman is diagnosed with breast cancer. Genetic testing reveals a BRCA1 mutation. Which of the following is the most accurate statement about her cancer risk?",
    "options": ["A) BRCA1 increases breast cancer risk only, not ovarian cancer risk", "B) BRCA1 confers a 60-70% lifetime risk of breast cancer and 40-45% risk of ovarian cancer", "C) BRCA1 mutations are autosomal recessive and require two mutant alleles", "D) Surveillance alone is sufficient; risk-reducing surgery is not recommended"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (BRCA1 confers 60-70% lifetime breast cancer risk and 40-45% ovarian cancer risk).\n\nGENETICS:\nBRCA1 (chromosome 17q21) and BRCA2 (chromosome 13q12.3) are tumor suppressor genes that encode proteins essential for homologous recombination DNA repair, a high-fidelity mechanism for repairing double-strand DNA breaks. BRCA mutations follow an autosomal dominant inheritance pattern with variable penetrance, meaning a single mutant allele (heterozygous state) is sufficient to confer significantly elevated cancer risk. When the remaining wild-type allele is lost or inactivated (loss of heterozygosity, the \"second hit\"), the cell loses its capacity for accurate DNA repair, accumulating mutations that drive carcinogenesis.\n\nCANCER RISKS:\nBRCA1 mutation carriers have a 60 to 70% cumulative lifetime risk of developing breast cancer (compared to 12% in the general population) and a 40 to 45% risk of ovarian cancer (compared to 1.3% in the general population). BRCA1-associated breast cancers are more frequently triple-negative (estrogen receptor-negative, progesterone receptor-negative, HER2-negative), high-grade, and basal-like subtype. BRCA2 carriers have a 45 to 55% lifetime breast cancer risk and a 15 to 20% ovarian cancer risk, with tumors more likely to be estrogen receptor-positive. Both mutations also increase risk of fallopian tube cancer, peritoneal cancer, pancreatic cancer, and male breast cancer (particularly BRCA2).\n\nRISK-REDUCING STRATEGIES:\nRisk-reducing bilateral mastectomy decreases breast cancer risk by approximately 90 to 95% and is offered after shared decision-making. Risk-reducing bilateral salpingo-oophorectomy (RRSO) is recommended by age 35 to 40 for BRCA1 carriers (or after completion of childbearing) and reduces ovarian cancer risk by approximately 80% and breast cancer risk by approximately 50% (through estrogen deprivation). For carriers who decline prophylactic surgery, enhanced surveillance includes annual breast MRI with contrast (starting at age 25 to 30) alternating with annual mammography at 6-month intervals, and consideration of chemoprevention with tamoxifen or oseloxifene.\n\nSCREENING RECOMMENDATIONS:\nThe USPSTF recommends that primary care clinicians assess women with a personal or family history of breast/ovarian/tubal/peritoneal cancer using validated tools (such as the USPSTF family history screening tool) and refer appropriate patients for genetic counseling and potential BRCA testing.\n\nKEY POINTS:\nBRCA1 confers 60 to 70% lifetime breast cancer risk and 40 to 45% ovarian cancer risk through autosomal dominant inheritance of impaired homologous recombination DNA repair. BRCA1 tumors are more often triple-negative. Risk-reducing salpingo-oophorectomy by age 35 to 40 reduces ovarian cancer risk by approximately 80% and breast cancer risk by approximately 50%.",
    "categoryId": 18
  },
  {
    "id": 675,
    "question": "A 19-year-old female college student presents requesting emergency contraception. She had unprotected intercourse 4 days ago. Which option is most effective at this time point?",
    "options": ["A) Levonorgestrel (Plan B) oral pill", "B) Copper IUD (Paragard) insertion", "C) Combined oral contraceptive pills (Yuzpe regimen)", "D) No effective option exists beyond 72 hours"],
    "correctAnswer": 1,
    "explanation": "CORRECT: B (Copper IUD insertion).\n\nPHARMACOLOGY:\nThe copper IUD (Paragard) is the most effective emergency contraception, reducing pregnancy risk by >99% when inserted within 5 days (120 hours) of unprotected intercourse. At 4 days post-intercourse, it is the only method maintaining near-maximal efficacy. Copper ions create a toxic intrauterine environment that is directly spermicidal, disrupts the acrosome reaction, and alters the endometrium to prevent implantation.\n\nCOMPARISON WITH ORAL OPTIONS:\nLevonorgestrel (Plan B, 1.5 mg) works primarily by delaying ovulation and has significantly diminished efficacy beyond 72 hours, dropping from ~85% within 24 hours to ~58% at 49-72 hours, with minimal efficacy thereafter. Effectiveness is also reduced in women >70 kg. Ulipristal acetate (ella, 30 mg), a selective progesterone receptor modulator, is effective up to 120 hours with more consistent efficacy than levonorgestrel but still less effective than the copper IUD (~98% versus >99%). The Yuzpe regimen is least effective (~75%) and limited to 72 hours.\n\nADDITIONAL BENEFITS:\nThe copper IUD provides ongoing highly effective contraception for up to 10-12 years, addressing both immediate and future needs in a single intervention. The LNG-IUD (Mirena) has emerging evidence for emergency contraception within 5 days, though not yet universally included in guidelines.\n\nKEY POINTS:\nThe copper IUD is the most effective emergency contraception (>99%), fully effective up to 5 days (120 hours). Levonorgestrel has reduced efficacy beyond 72 hours and in women over 70 kg. The copper IUD also provides ongoing contraception for 10-12 years, addressing both emergency and long-term needs.",
    "categoryId": 18
  },{"id":676,"categoryId":18,"question":"A 28-year-old G1P0 at 10 weeks gestation presents for her first prenatal visit. She has no medical history and takes no medications other than a prenatal vitamin. Which screening test is recommended at this visit to assess for chromosomal abnormalities?","options":["A) Quad screen","B) First-trimester combined screening (nuchal translucency + serum markers)","C) Amniocentesis","D) No screening needed until 20 weeks"],"correctAnswer":1,"explanation":"CORRECT: B (First-trimester combined screening).\n\nSCREENING APPROACH:\nFirst-trimester combined screening (performed between 11 and 14 weeks gestation) consists of nuchal translucency measurement on ultrasound plus maternal serum markers (free beta-hCG and pregnancy-associated plasma protein-A, PAPP-A) and provides a detection rate of approximately 82 to 87% for trisomy 21 (Down syndrome) with a 5% false-positive rate. This is the standard first-trimester screening offered to all pregnant patients regardless of age, as ACOG recommends that all pregnant individuals be offered aneuploidy screening or diagnostic testing.\n\nNUCHAL TRANSLUCENCY:\nThe nuchal translucency (NT) is a sonographic measurement of the fluid-filled space at the back of the fetal neck, measured between 11 weeks 0 days and 13 weeks 6 days (crown-rump length 45 to 84 mm). An NT measurement greater than 3.0 mm (or above the 99th percentile for gestational age) is linked to increased risk of trisomy 21, trisomy 18, trisomy 13, Turner syndrome, and congenital heart defects. Even when the karyotype is normal, an elevated NT warrants a detailed fetal echocardiogram at 18 to 22 weeks due to the 3 to 4-fold increased risk of structural cardiac anomalies.\n\nSERUM MARKERS:\nIn trisomy 21, free beta-hCG is elevated (approximately 2 MoM) and PAPP-A is decreased (approximately 0.4 MoM). In trisomy 18, both markers are decreased. These serum values are combined with NT measurement and maternal age to generate a risk score. If the risk exceeds a threshold (typically 1 in 270 to 1 in 300), diagnostic testing (chorionic villus sampling at 10 to 13 weeks or amniocentesis at 15 to 20 weeks) is offered.\n\nCELL-FREE DNA:\nCell-free DNA (cfDNA) screening, also called noninvasive prenatal testing (NIPT), analyzes fetal DNA fragments circulating in maternal blood and has the highest sensitivity (>99% for trisomy 21) and lowest false-positive rate (less than 0.1%) of any screening modality. ACOG now states that cfDNA screening may be offered to all pregnant individuals regardless of risk category. However, cfDNA remains a screening test and positive results require confirmatory diagnostic testing (amniocentesis or CVS).\n\nKEY POINTS:\nFirst-trimester combined screening (nuchal translucency plus free beta-hCG plus PAPP-A) at 11 to 14 weeks detects 82 to 87% of trisomy 21 cases. Cell-free DNA (NIPT) has >99% sensitivity but is a screening test requiring diagnostic confirmation. All pregnant patients should be offered aneuploidy screening regardless of age."},{"id":680,"categoryId":18,"question":"A 45-year-old woman presents with heavy menstrual bleeding (menorrhagia), pelvic pressure, and urinary frequency. Pelvic ultrasound reveals a 10 cm intramural uterine mass. Endometrial biopsy is benign. What is the most likely diagnosis?","options":["A) Endometrial cancer","B) Uterine leiomyoma (fibroid)","C) Ovarian cyst","D) Cervical polyp"],"correctAnswer":1,"explanation":"CORRECT: B (Uterine leiomyoma).\n\nPATHOPHYSIOLOGY:\nUterine leiomyomas (fibroids) are benign monoclonal neoplasms from uterine smooth muscle\u2014the most common pelvic tumors in women (~70% cumulative incidence in White women, >80% in Black women by age 50). They are estrogen/progesterone-dependent, growing during reproductive years and regressing post-menopause. Genetic drivers include MED12 mutations (~70%) and HMGA2 rearrangements. Risk factors: African American race (3-fold prevalence), early menarche, nulliparity, obesity, and family history.\n\nCLASSIFICATION AND SYMPTOMS:\nFIGO classification: submucosal (project into uterine cavity, most likely to cause heavy bleeding from increased endometrial surface area), intramural (within myometrium, most common, causing bulk symptoms and menorrhagia when large), and subserosal (project outward, primarily pressure symptoms). This patient's 10 cm intramural mass causes menorrhagia and bulk symptoms (pelvic pressure, urinary frequency).\n\nDIAGNOSIS:\nPelvic ultrasound is first-line, showing well-circumscribed hypoechoic masses with characteristic shadowing. MRI provides superior characterization and surgical planning. Saline infusion sonography or hysteroscopy best evaluates submucosal fibroids. Endometrial biopsy excludes pathology in women with abnormal bleeding, particularly over age 45.\n\nMANAGEMENT:\nMedical: hormonal contraceptives, GnRH agonists (leuprolide, temporary 35-65% shrinkage, limited to 6 months), GnRH antagonists with add-back (elagolix, FDA-approved for fibroid bleeding), tranexamic acid, and levonorgestrel IUD. Surgical: myomectomy (fertility-preserving), uterine artery embolization (85-90% symptom improvement), and hysterectomy (definitive for completed childbearing).\n\nKEY POINTS:\nFibroids are the most common pelvic tumors, estrogen/progesterone-dependent, with >80% cumulative incidence in Black women. Submucosal fibroids cause the most bleeding; intramural/subserosal cause bulk symptoms. Management ranges from medical therapy to myomectomy to hysterectomy."},{"id":681,"categoryId":18,"question":"A 19-year-old presents requesting contraception. She has migraines with visual aura. Which contraceptive method is absolutely contraindicated?","options":["A) Copper IUD","B) Combined oral contraceptive pill (estrogen + progestin)","C) Progestin-only pill","D) Etonogestrel implant (Nexplanon)"],"correctAnswer":1,"explanation":"CORRECT: B (Combined oral contraceptive pill).\n\nCONTRAINDICATION:\nCombined hormonal contraceptives (CHCs) containing estrogen (combined oral contraceptive pills, the patch, and the vaginal ring) are classified as Category 4 (absolute contraindication, unacceptable health risk) in women who have migraine with aura by the CDC Medical Eligibility Criteria (MEC) for Contraceptive Use and WHO guidelines. This restriction applies regardless of age and regardless of aura frequency.\n\nSTROKE RISK MECHANISM:\nMigraine with aura independently increases ischemic stroke risk by approximately 2-fold compared to women without migraine. Combined hormonal contraceptives independently increase ischemic stroke risk by approximately 1.5 to 2-fold through estrogen-mediated prothrombotic effects (increased hepatic synthesis of clotting factors II, VII, VIII, X, and fibrinogen, increased von Willebrand factor, and decreased antithrombin III and protein S). The combination of migraine with aura plus CHC use is synergistic rather than additive, increasing ischemic stroke risk by approximately 6 to 8-fold. Although the absolute risk remains relatively low in young women (approximately 8 per 100,000 per year), this is considered an unacceptable risk given the availability of safe alternatives.\n\nAURA VERSUS NO AURA:\nThe distinction between migraine with aura and migraine without aura is clinically critical for contraceptive counseling. Migraine with aura involves transient focal neurologic symptoms (visual scintillations, fortification spectra, hemianopia, unilateral paresthesias, or speech disturbance) lasting 5 to 60 minutes, which are thought to reflect cortical spreading depression and associated cerebrovascular changes that predispose to thrombosis. Migraine without aura carries a lower stroke risk, and CHCs are classified as Category 2 (advantages generally outweigh risks) in women under 35 with migraine without aura but Category 3 (risks generally outweigh advantages) in women 35 and older with migraine without aura.\n\nSAFE ALTERNATIVES:\nAll progestin-only methods are safe (Category 1 or 2) in women with migraine with aura: progestin-only pills (norethindrone, drospirenone), etonogestrel implant (Nexplanon), depot medroxyprogesterone acetate (DMPA), and hormonal IUDs (levonorgestrel). Copper IUDs are also Category 1 (no restriction). The etonogestrel implant and levonorgestrel IUD are the most effective reversible contraceptives (failure rate <1% per year, comparable to sterilization).\n\nKEY POINTS:\nCombined hormonal contraceptives are absolutely contraindicated (CDC MEC Category 4) in migraine with aura due to a synergistic 6 to 8-fold increase in ischemic stroke risk. The distinction between migraine with and without aura is essential for contraceptive counseling. All progestin-only methods and copper IUDs are safe alternatives, with implants and hormonal IUDs offering the highest efficacy."},{"id":683,"categoryId":18,"question":"A 26-year-old woman presents with mucopurulent cervical discharge. NAAT is positive for Chlamydia trachomatis. She has no drug allergies. What is the recommended treatment?","options":["A) Azithromycin 1g single dose only","B) Doxycycline 100mg BID for 7 days","C) Ciprofloxacin 500mg single dose","D) Metronidazole 500mg BID for 7 days"],"correctAnswer":1,"explanation":"CORRECT: B (Doxycycline 100mg BID for 7 days).\n\nGUIDELINE UPDATE:\nThe 2021 CDC STI Treatment Guidelines changed first-line chlamydia treatment from azithromycin 1g single dose to doxycycline 100 mg BID for 7 days, based on superior microbiologic cure rates, particularly for rectal infections (which may be asymptomatic in women via autoinoculation from the cervix).\n\nEVIDENCE FOR THE CHANGE:\nAzithromycin has a failure rate of 5-8% for urogenital and 15-22% for rectal chlamydia, versus <3% for doxycycline at both sites. Doxycycline provides sustained intracellular levels over 7 days (covering multiple 48-72 hour chlamydial replication cycles), while azithromycin's single-dose kinetics may not maintain adequate concentrations through enough cycles.\n\nCO-TREATMENT:\nWith chlamydia-gonorrhea co-infection rates of 10-30%, empiric gonorrhea treatment (ceftriaxone 500 mg IM, or 1g if >=150 kg) should be given if not excluded. All partners from the preceding 60 days must be treated (expedited partner therapy recommended). Test-of-cure is not routine but indicated in pregnancy. Repeat reinfection testing at 3 months is recommended.\n\nPREGNANCY CONSIDERATION:\nDoxycycline is contraindicated in pregnancy (fetal tooth discoloration, impaired bone growth). Azithromycin 1g remains recommended; amoxicillin 500mg TID for 7 days is an alternative. Test-of-cure at 4 weeks is required in pregnancy.\n\nCOMPLICATIONS OF UNTREATED CHLAMYDIA:\nUntreated cervicitis ascends to cause PID in 10-15%, leading to chronic pelvic pain, tubal infertility, and ectopic pregnancy. Chlamydia is the leading infectious cause of preventable infertility worldwide.\n\nKEY POINTS:\nDoxycycline 100mg BID for 7 days replaced azithromycin per 2021 CDC guidelines due to superior cure rates, especially for rectal infections (azithromycin fails 15-22%). Azithromycin remains first-line in pregnancy. Untreated chlamydia causes PID in 10-15%."},{"id":684,"categoryId":18,"question":"The USPSTF recommends initiating cervical cancer screening with Pap smear at what age?","options":["A) 18 years","B) 21 years","C) 25 years","D) 30 years"],"correctAnswer":1,"explanation":"CORRECT: B (21 years).\n\nPATHOPHYSIOLOGY:\nCervical cancer results from persistent infection with high-risk human papillomavirus (HPV), with types 16 and 18 responsible for approximately 70% of cases. HPV E6 and E7 oncoproteins inactivate tumor suppressors p53 and retinoblastoma protein (Rb), respectively, driving unchecked cell cycle progression. The progression from initial HPV infection through cervical intraepithelial neoplasia (CIN) to invasive carcinoma typically spans 10-20 years, providing a prolonged window for effective screening.\n\nCLINICAL REASONING:\nThe USPSTF (2018 recommendation, Grade A) recommends initiating cervical cancer screening at age 21 regardless of sexual debut or HPV vaccination status. Screening before age 21 is not recommended because cervical cancer is exceedingly rare in this age group (fewer than 1-2 cases per million), approximately 90% of adolescent HPV infections clear spontaneously within 1-2 years through robust cell-mediated immunity, and early screening leads to unnecessary colposcopies and excisional procedures that risk cervical insufficiency and preterm delivery in future pregnancies.\n\nScreening intervals per USPSTF: ages 21-29, cytology alone every 3 years (HPV co-testing is not recommended in this group due to high transient HPV positivity generating false positives); ages 30-65, three equivalent options including cytology every 3 years, primary high-risk HPV testing every 5 years, or co-testing every 5 years. Screening discontinues after age 65 with adequate prior negative results (three consecutive negative Pap tests or two negative HPV tests within 10 years, most recent within 5 years) and no history of CIN2 or higher.\n\nThe 9-valent HPV vaccine (Gardasil 9) covers types 6, 11, 16, 18, 31, 33, 45, 52, and 58, protecting against approximately 90% of cervical cancers per ACIP and CDC recommendations. Vaccination does not alter screening guidelines.\n\nKEY POINTS:\nCervical screening begins at age 21 per USPSTF regardless of sexual history or vaccination status. Screening intervals differ by age group. Screening stops after 65 with adequate prior negatives and no CIN2+ history."},{"id":685,"categoryId":18,"question":"A 35-year-old woman presents with galactorrhea, oligomenorrhea, and infertility. Laboratory testing reveals prolactin level of 180 ng/mL (normal <25). What is the most appropriate first-line treatment?","options":["A) Transsphenoidal surgery","B) Cabergoline (dopamine agonist)","C) Combined oral contraceptive pill","D) Observation"],"correctAnswer":1,"explanation":"CORRECT: B (Cabergoline).\n\nPATHOPHYSIOLOGY:\nProlactinomas are the most common functioning pituitary adenomas, accounting for approximately 40% of all pituitary tumors. Prolactin is unique among anterior pituitary hormones in that its secretion is tonically inhibited by dopamine from the tuberoinfundibular pathway acting on D2 receptors on lactotroph cells. Prolactinomas arise from clonal expansion of lactotroph cells that secrete prolactin autonomously. Hyperprolactinemia inhibits pulsatile GnRH secretion from the hypothalamus, which in turn suppresses LH and FSH release, causing hypogonadism manifesting as oligomenorrhea or amenorrhea, anovulatory infertility, and galactorrhea in women.\n\nPROLACTIN LEVEL AND TUMOR SIZE:\nA prolactin level of 180 ng/mL strongly suggests a macroprolactinoma (greater than 10 mm), as prolactin levels generally correlate with tumor size: microprolactinomas (less than 10 mm) typically produce levels of 25 to 200 ng/mL, while macroprolactinomas produce levels of 200 to over 10,000 ng/mL. The stalk effect must be distinguished: non-functioning pituitary adenomas that compress the pituitary stalk can mildly elevate prolactin (usually less than 100 to 150 ng/mL) by disrupting dopamine delivery from the hypothalamus. An MRI of the sella turcica is the imaging study of choice.\n\nMEDICAL THERAPY:\nDopamine agonists are the first-line treatment for prolactinomas of all sizes, even macroprolactinomas, which is unique among pituitary tumors (all other types are primarily surgical). Cabergoline is preferred over bromocriptine because it has higher efficacy (normalizes prolactin in approximately 85 to 90% of patients), better tolerability (less nausea, fewer side effects), and more convenient dosing (twice weekly versus daily). Dopamine agonists both suppress prolactin secretion and cause tumor shrinkage (typically 50 to 80% volume reduction within weeks to months) by inducing apoptosis and perivascular fibrosis in lactotroph cells.\n\nMONITORING AND SURGICAL INDICATIONS:\nProlactin levels and MRI should be monitored after initiation of therapy. Surgery (transsphenoidal adenomectomy) is reserved for patients who are intolerant of or resistant to dopamine agonists, have tumor apoplexy, have CSF rhinorrhea, or have visual field compromise that does not improve with medical therapy. Radiation therapy is a third-line option for refractory cases.\n\nKEY POINTS:\nProlactinomas are the only pituitary adenomas treated primarily with medical therapy rather than surgery. Cabergoline (dopamine D2 agonist) is first-line, normalizing prolactin in 85 to 90% and shrinking tumors by 50 to 80%. Prolactin levels correlate with tumor size (levels greater than 200 suggest macroprolactinoma). Hyperprolactinemia causes hypogonadism by suppressing GnRH pulsatility."},{"id":688,"categoryId":18,"question":"A 22-year-old woman with a history of irregular periods, hirsutism, and acne has a BMI of 32. Labs show elevated free testosterone, normal DHEA-S, and a 2:1 LH-to-FSH ratio. Pelvic ultrasound shows bilateral ovaries with 14 follicles each. What is the most likely diagnosis?","options":["A) Congenital adrenal hyperplasia","B) Polycystic ovary syndrome (PCOS)","C) Cushing syndrome","D) Hypothyroidism"],"correctAnswer":1,"explanation":"CORRECT: B (Polycystic ovary syndrome).\n\nDIAGNOSTIC CRITERIA:\nPCOS is diagnosed using Rotterdam criteria requiring two of three: oligo-ovulation/anovulation (irregular cycles, oligomenorrhea, amenorrhea), clinical or biochemical hyperandrogenism (hirsutism, acne, alopecia, elevated free testosterone), and polycystic ovarian morphology on ultrasound (>=12 follicles 2-9 mm per ovary or volume >10 mL). PCOS is a diagnosis of exclusion\u2014rule out thyroid disease (TSH), hyperprolactinemia, non-classic CAH (17-hydroxyprogesterone), and Cushing syndrome.\n\nPATHOPHYSIOLOGY:\nPCOS affects 6-12% of reproductive-age women. Central features are hyperandrogenism and insulin resistance in a self-reinforcing cycle. Insulin resistance (50-70%, independent of BMI) causes hyperinsulinemia that stimulates ovarian theca cell androgen production and suppresses hepatic SHBG, increasing free testosterone. Excess androgens disrupt follicular development, causing follicular arrest (polycystic appearance). Elevated LH-to-FSH ratio (often >=2:1) reflects increased GnRH pulse frequency.\n\nMETABOLIC CONSEQUENCES:\n30-40% have impaired glucose tolerance; 10% develop T2DM by age 40. Increased risk of metabolic syndrome, dyslipidemia, NAFLD, OSA, and cardiovascular disease. Screen with 2-hour OGTT (preferred over fasting glucose, which misses 30-40% of glucose intolerance) at diagnosis and every 1-3 years.\n\nMANAGEMENT:\nLifestyle modification is first-line (5-10% weight loss restores ovulation in 30-50%). Combined OCPs for menstrual regulation and hyperandrogenism (estrogen increases SHBG). Spironolactone for hirsutism/acne. Metformin improves insulin sensitivity. For infertility, letrozole replaced clomiphene as first-line ovulation induction per the PPCOS II trial.\n\nKEY POINTS:\nPCOS: Rotterdam criteria (two of three: anovulation, hyperandrogenism, polycystic morphology) after excluding other causes. Insulin resistance driving ovarian androgen excess is the central mechanism. Screen with 2-hour OGTT. Letrozole has replaced clomiphene for PCOS-related infertility."},{"id":689,"categoryId":18,"question":"A 38-year-old G3P2 at 32 weeks gestation presents with painless bright red vaginal bleeding. She has had two prior cesarean deliveries. Vitals are stable. What is the most likely diagnosis and what exam must be avoided?","options":["A) Placental abruption; avoid amniotomy","B) Placenta previa; avoid digital cervical exam","C) Vasa previa; avoid external cephalic version","D) Cervical polyp; avoid speculum exam"],"correctAnswer":1,"explanation":"CORRECT: B (Placenta previa; avoid digital cervical exam).\n\nDIAGNOSIS:\nPainless bright red vaginal bleeding in the third trimester is the classic presentation of placenta previa, where the placenta partially or completely covers the internal cervical os. Bleeding is painless because it results from disruption of placental vessels as the lower uterine segment thins, without contractions or abruption. This differs from placental abruption: painful, dark bleeding with a rigid, tender uterus.\n\nRISK FACTORS:\nThis patient has two major risk factors: prior cesarean deliveries and multiparity. Each cesarean increases previa risk via uterine scarring. With two prior cesareans, concern exists for placenta accreta spectrum (PAS), where the placenta invades the myometrium through the scar. PAS risk with previa rises per cesarean: ~3% with one, 11% with two, 40% with three, >=60% with four or more. Other risk factors: advanced maternal age, prior uterine surgery, smoking, and IVF.\n\nCRITICAL RESTRICTION:\nDigital cervical exam is absolutely contraindicated\u2014the examining finger can disrupt the placenta overlying the os, precipitating catastrophic hemorrhage. Transvaginal ultrasound is the safe, definitive diagnostic modality (>95% accuracy). Despite misconception, transvaginal ultrasound is safe because the probe does not enter the cervical canal.\n\nMANAGEMENT:\nAsymptomatic previa is managed expectantly with repeat imaging at 32-36 weeks (placental migration may occur). Planned cesarean at 36-37 weeks for uncomplicated previa. Symptomatic bleeding management depends on gestational age and stability: stable patients may be admitted with monitoring and blood availability; unstable patients require emergent cesarean regardless of gestational age.\n\nKEY POINTS:\nPainless bright red third-trimester bleeding suggests placenta previa; digital cervical exam is absolutely contraindicated. Transvaginal ultrasound is safe and diagnostic. Prior cesareans are the strongest risk factor and raise concern for placenta accreta spectrum, with risk escalating per additional cesarean."},
  {
    "id": 690,
    "categoryId": 1,
    "question": "A 58-year-old man with a history of ischemic cardiomyopathy presents with 3 days of worsening shortness of breath, orthopnea, and leg swelling. He sleeps on 3 pillows and has gained 4 kg. Exam shows jugular venous distension, bibasilar crackles, and 2+ pitting edema to the knees. What is the most likely diagnosis?",
    "options": [
      "A) COPD exacerbation",
      "B) Acute decompensated heart failure (systolic)",
      "C) Pulmonary embolism",
      "D) Bacterial pneumonia"
    ],
    "correctAnswer": 1,
    "explanationImages": [
      { "src": "assets/heart-diastolic-systolic.png", "alt": "Diastolic vs systolic heart failure", "caption": "Systolic HF: stretched, thin chambers that cannot pump." },
      { "src": "assets/pitting-edema.png", "alt": "Pitting edema in heart failure", "caption": "Pitting edema in decompensated heart failure." }
    ],
    "explanation": "CORRECT: B (Acute decompensated heart failure, systolic).\n\nPATHOPHYSIOLOGY:\nSystolic heart failure (HFrEF) is characterized by impaired left ventricular contractility and reduced ejection fraction (typically EF 40% or less). The ventricle dilates and remodels: chambers become stretched and thin, losing the ability to generate adequate stroke volume\u2014the heart cannot pump effectively. Myocardial injury (ischemia, infarction, pressure or volume overload) triggers neurohormonal activation (sympathetic nervous system, renin-angiotensin-aldosterone system), which initially compensates but eventually worsens remodeling and fluid retention, leading to congestion and acute decompensation.\n\nCLINICAL MANIFESTATIONS:\nClassic findings include dyspnea (often worse supine, improved with sitting\u2014orthopnea), paroxysmal nocturnal dyspnea, and fatigue. Physical exam may show jugular venous distension, displaced apical impulse, S3 gallop, bibasilar crackles, and peripheral pitting edema. Weight gain from fluid retention is common. In acute decompensation, congestion dominates: pulmonary edema from elevated filling pressures and systemic venous hypertension causing dependent edema, hepatomegaly, and ascites. Pitting edema is a hallmark of volume overload and reflects elevated capillary hydrostatic pressure from backward failure.\n\nDIAGNOSIS:\nDiagnosis rests on history, exam, natriuretic peptides (BNP or NT-proBNP elevated in HF), chest X-ray (cardiomegaly, pulmonary venous congestion, interstitial or alveolar edema), and echocardiography. Echocardiography confirms reduced LVEF (systolic dysfunction), assesses chamber size and wall motion, and excludes significant valvular disease. In acute decompensation, BNP/NT-proBNP help distinguish cardiac from pulmonary causes of dyspnea; levels may be lower in obesity and higher in renal dysfunction. ECG and troponin help identify acute ischemia as a precipitant.\n\nMANAGEMENT:\nAcute management focuses on diuresis (IV loop diuretics), supplemental oxygen or noninvasive ventilation for hypoxemia, and treatment of precipitants (ischemia, arrhythmia, nonadherence, infection). Guideline-directed medical therapy for chronic HFrEF includes ACE inhibitor or ARNI, evidence-based beta-blocker, MRA, and SGLT2 inhibitor; these reduce mortality and hospitalization. Avoid NSAIDs and negative inotropes in acute decompensation. Daily weights and sodium restriction help prevent recurrence. Revascularization or device therapy (ICD, CRT) is considered per guidelines based on EF and symptoms.\n\nKEY POINTS:\nAcute decompensated systolic HF presents with orthopnea, crackles, JVD, and pitting edema from congestion. Echocardiography confirms reduced EF; BNP supports the diagnosis. Acute treatment is diuresis and treat precipitants; chronic management uses GDMT (ACEi/ARNI, beta-blocker, MRA, SGLT2i) to reduce mortality and hospitalizations.",
    "bulletExplanation": "- CORRECT: B (Acute decompensated heart failure, systolic).\n- Systolic HF (HFrEF): dilated, thin ventricles with reduced EF; heart cannot pump; neurohormonal activation drives fluid retention and congestion.\n- Classic presentation: orthopnea, PND, crackles, JVD, pitting edema, weight gain; BNP and echo confirm; acute care is diuresis and treat precipitants; chronic GDMT (ACEi/ARNI, beta-blocker, MRA, SGLT2i) reduces mortality."
  }
];
const GERIATRICS_CATEGORY_ID = 19;
const AGE_60_PLUS_PATTERN = /\b(?:6\d|[7-9]\d|[1-9]\d{2})-year-old\b/i;
const OSTEOPOROSIS_KEYWORD_PATTERN = /\b(?:osteoporosis|osteopenia|dexa|t-score|alendronate|fosamax|bisphosphonate)\b/i;
const OLDER_ADULT_KEYWORD_PATTERN = /\b(?:elderly|older adults?|geriatric|beers criteria|dementia)\b/i;
const isGeriatricsQuestion = (questionText = "") => {
  const text = String(questionText);
  return AGE_60_PLUS_PATTERN.test(text) || OSTEOPOROSIS_KEYWORD_PATTERN.test(text) || OLDER_ADULT_KEYWORD_PATTERN.test(text);
};
for (const question of QUESTIONS) {
  if (isGeriatricsQuestion(question.question)) {
    question.categoryId = GERIATRICS_CATEGORY_ID;
  }
}
const QUESTION_MAP = Object.fromEntries(QUESTIONS.map(q => [q.id, q]));
const AudioContext = window.AudioContext || window.webkitAudioContext;
let audioCtx = null;
const getAudioContext = () => {
  if (!audioCtx) {
    audioCtx = new AudioContext();
  }
  return audioCtx;
};
const playSound = async (type) => {
  try {
    const ctx = getAudioContext();
    if (ctx && ctx.state === "suspended") {
      try {
        await ctx.resume();
      } catch (e) {
      }
    }
    const oscillator = ctx.createOscillator();
    const gainNode = ctx.createGain();
    oscillator.connect(gainNode);
    gainNode.connect(ctx.destination);
    oscillator.onended = () => { gainNode.disconnect(); oscillator.disconnect(); };
    switch (type) {
      case "correct":
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);
        oscillator.frequency.setValueAtTime(659.25, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.4);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.4);
        break;
      case "incorrect":
        oscillator.frequency.setValueAtTime(200, ctx.currentTime);
        oscillator.frequency.setValueAtTime(150, ctx.currentTime + 0.15);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "countdown":
        oscillator.frequency.setValueAtTime(440, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.2, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.15);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.15);
        break;
      case "start":
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(1046.5, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.3, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.5);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.5);
        break;
      case "warning":
        oscillator.type = "square";
        oscillator.frequency.setValueAtTime(880, ctx.currentTime);
        oscillator.frequency.setValueAtTime(440, ctx.currentTime + 0.1);
        oscillator.frequency.setValueAtTime(880, ctx.currentTime + 0.2);
        gainNode.gain.setValueAtTime(0.15, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "timeup":
        // Uplifting ascending major arpeggio (C-E-G-C)
        oscillator.type = "triangle";
        oscillator.frequency.setValueAtTime(523.25, ctx.currentTime);       // C5
        oscillator.frequency.setValueAtTime(659.25, ctx.currentTime + 0.15); // E5
        oscillator.frequency.setValueAtTime(783.99, ctx.currentTime + 0.30); // G5
        oscillator.frequency.setValueAtTime(1046.50, ctx.currentTime + 0.45);// C6
        gainNode.gain.setValueAtTime(0.25, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.28, ctx.currentTime + 0.45);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.9);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.9);
        // Add a bright shimmer on top
        const shimmer = ctx.createOscillator();
        const shimmerGain = ctx.createGain();
        shimmer.type = "sine";
        shimmer.frequency.setValueAtTime(1046.50, ctx.currentTime + 0.45);
        shimmer.frequency.setValueAtTime(1318.51, ctx.currentTime + 0.6);
        shimmerGain.gain.setValueAtTime(0, ctx.currentTime);
        shimmerGain.gain.setValueAtTime(0.15, ctx.currentTime + 0.45);
        shimmerGain.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 1.0);
        shimmer.connect(shimmerGain).connect(ctx.destination);
        shimmer.start(ctx.currentTime + 0.45);
        shimmer.stop(ctx.currentTime + 1.0);
        break;
      case "click":
        oscillator.frequency.setValueAtTime(600, ctx.currentTime);
        gainNode.gain.setValueAtTime(0.1, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.05);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.05);
        break;
      case "heartbeat": {
        const t = ctx.currentTime;
        oscillator.type = "sine";
        oscillator.frequency.setValueAtTime(80, t);
        gainNode.gain.setValueAtTime(1e-4, t);
        gainNode.gain.exponentialRampToValueAtTime(0.45, t + 8e-3);
        gainNode.gain.exponentialRampToValueAtTime(1e-4, t + 0.14);
        oscillator.start(t);
        oscillator.stop(t + 0.16);
        const click1 = ctx.createOscillator();
        const clickGain1 = ctx.createGain();
        click1.connect(clickGain1);
        clickGain1.connect(ctx.destination);
        click1.onended = () => { clickGain1.disconnect(); click1.disconnect(); };
        click1.type = "triangle";
        click1.frequency.setValueAtTime(150, t);
        clickGain1.gain.setValueAtTime(1e-4, t);
        clickGain1.gain.exponentialRampToValueAtTime(0.12, t + 5e-3);
        clickGain1.gain.exponentialRampToValueAtTime(1e-4, t + 0.06);
        click1.start(t);
        click1.stop(t + 0.08);
        const osc2 = ctx.createOscillator();
        const gain2 = ctx.createGain();
        osc2.connect(gain2);
        gain2.connect(ctx.destination);
        osc2.onended = () => { gain2.disconnect(); osc2.disconnect(); };
        osc2.type = "sine";
        osc2.frequency.setValueAtTime(90, t + 0.19);
        gain2.gain.setValueAtTime(1e-4, t + 0.19);
        gain2.gain.exponentialRampToValueAtTime(0.32, t + 0.198);
        gain2.gain.exponentialRampToValueAtTime(1e-4, t + 0.32);
        osc2.start(t + 0.19);
        osc2.stop(t + 0.34);
        const click2 = ctx.createOscillator();
        const clickGain2 = ctx.createGain();
        click2.connect(clickGain2);
        clickGain2.connect(ctx.destination);
        click2.onended = () => { clickGain2.disconnect(); click2.disconnect(); };
        click2.type = "triangle";
        click2.frequency.setValueAtTime(150, t + 0.19);
        clickGain2.gain.setValueAtTime(1e-4, t + 0.19);
        clickGain2.gain.exponentialRampToValueAtTime(0.08, t + 0.195);
        clickGain2.gain.exponentialRampToValueAtTime(1e-4, t + 0.25);
        click2.start(t + 0.19);
        click2.stop(t + 0.27);
        break;
      }
      case "streak":
        oscillator.type = "sine";
        oscillator.frequency.setValueAtTime(880, ctx.currentTime);
        oscillator.frequency.setValueAtTime(1108.73, ctx.currentTime + 0.05);
        oscillator.frequency.setValueAtTime(1318.51, ctx.currentTime + 0.1);
        gainNode.gain.setValueAtTime(0.2, ctx.currentTime);
        gainNode.gain.exponentialRampToValueAtTime(0.01, ctx.currentTime + 0.3);
        oscillator.start(ctx.currentTime);
        oscillator.stop(ctx.currentTime + 0.3);
        break;
      case "onfire": {
        const t = ctx.currentTime;
        // Layer 1: Power chord root (C5-G5-C6 rapid arpeggio)
        oscillator.type = "sawtooth";
        oscillator.frequency.setValueAtTime(523.25, t);
        oscillator.frequency.setValueAtTime(783.99, t + 0.06);
        oscillator.frequency.setValueAtTime(1046.50, t + 0.12);
        oscillator.frequency.setValueAtTime(1318.51, t + 0.18);
        gainNode.gain.setValueAtTime(0.18, t);
        gainNode.gain.setValueAtTime(0.22, t + 0.12);
        gainNode.gain.exponentialRampToValueAtTime(0.01, t + 0.55);
        oscillator.start(t);
        oscillator.stop(t + 0.55);
        // Layer 2: Bright octave shimmer
        const fire2 = ctx.createOscillator();
        const fireGain2 = ctx.createGain();
        fire2.connect(fireGain2).connect(ctx.destination);
        fire2.onended = () => { fireGain2.disconnect(); fire2.disconnect(); };
        fire2.type = "sine";
        fire2.frequency.setValueAtTime(1046.50, t + 0.05);
        fire2.frequency.setValueAtTime(1567.98, t + 0.15);
        fire2.frequency.setValueAtTime(2093.00, t + 0.25);
        fireGain2.gain.setValueAtTime(0.0001, t);
        fireGain2.gain.exponentialRampToValueAtTime(0.15, t + 0.1);
        fireGain2.gain.exponentialRampToValueAtTime(0.01, t + 0.6);
        fire2.start(t + 0.05);
        fire2.stop(t + 0.6);
        // Layer 3: Sub-bass punch for impact
        const fire3 = ctx.createOscillator();
        const fireGain3 = ctx.createGain();
        fire3.connect(fireGain3).connect(ctx.destination);
        fire3.onended = () => { fireGain3.disconnect(); fire3.disconnect(); };
        fire3.type = "sine";
        fire3.frequency.setValueAtTime(130.81, t);
        fire3.frequency.exponentialRampToValueAtTime(65.41, t + 0.15);
        fireGain3.gain.setValueAtTime(0.3, t);
        fireGain3.gain.exponentialRampToValueAtTime(0.01, t + 0.2);
        fire3.start(t);
        fire3.stop(t + 0.2);
        break;
      }
      default:
        break;
    }
  } catch (e) {
    console.log("Audio not available");
  }
};
function PCPLearningApp() {
  const FIREBASE_CHAT_DB_URL = "https://primary-care-learning-program-default-rtdb.firebaseio.com";
  const CHAT_MESSAGES_KEY = "pcp-chat-local";
  const CHAT_NAME_KEY = "pcp-chat-name";
  const CHAT_OWNER_SESSION_KEY = "pcp-chat-owner-session";
  const CHAT_OWNER_DELETE_CODE = "Puyt8_88";
  const CHAT_ICON = "assets/Gemini_Generated_Image_afw5k2afw5k2afw5.png";
  const CHAT_DELETE_DIRECTIVE_PREFIX = "__OWNER_DELETE__";
  const DEFAULT_PROGRESS = {
    answeredQuestions: {},
    incorrectQuestions: [],
    categoryProgress: {},
    totalCorrect: 0,
    totalAttempted: 0,
    gameHighScore: 0,
    bookmarkedQuestions: [],
    spacedReview: {}
  };
  const REVIEW_INTERVALS_MS = [24 * 60 * 60 * 1e3, 3 * 24 * 60 * 60 * 1e3, 7 * 24 * 60 * 60 * 1e3];
  const EXPLANATION_MODE_KEY = "pcp-explanation-mode";
  const [isMobile, setIsMobile] = useState(window.innerWidth < 768);
  const [currentView, setCurrentView] = useState("home");
  const [selectedCategory, setSelectedCategory] = useState(null);
  const [quizQuestions, setQuizQuestions] = useState([]);
  const [currentQuestionIndex, setCurrentQuestionIndex] = useState(0);
  const [selectedAnswer, setSelectedAnswer] = useState(null);
  const [showExplanation, setShowExplanation] = useState(false);
  const [quizResults, setQuizResults] = useState([]);
  const [gameMode, setGameMode] = useState(false);
  const [gameCountdown, setGameCountdown] = useState(null);
  const [gameTimeLeft, setGameTimeLeft] = useState(180);
  const [gameScore, setGameScore] = useState(0);
  const [gameAnswers, setGameAnswers] = useState([]);
  const [streak, setStreak] = useState(0);
  const [maxStreak, setMaxStreak] = useState(0);
  const [showGameIntro, setShowGameIntro] = useState(false);
  const [gameEnded, setGameEnded] = useState(false);
  const [warningShown, setWarningShown] = useState({ oneMin: false, tenSec: false });
  const [progress, setProgress] = useState(DEFAULT_PROGRESS);
  const [searchQuery, setSearchQuery] = useState("");
  const [searchResults, setSearchResults] = useState([]);
  const [explanationMode, setExplanationMode] = useState(() => {
    try {
      const stored = window.localStorage.getItem(EXPLANATION_MODE_KEY);
      return stored === "bullet" ? "bullet": "expanded";
    } catch (e) {
      return "expanded";
    }
  });
  const [soundEnabled, setSoundEnabled] = useState(true);
  const [chatMessages, setChatMessages] = useState([]);
  const [chatInput, setChatInput] = useState("");
  const [chatName, setChatName] = useState("");
  const [chatSyncMode, setChatSyncMode] = useState("local");
  const [chatOwnerMode, setChatOwnerMode] = useState(false);
  const [isSpeaking, setIsSpeaking] = useState(false);
  const [handsFreeMode, setHandsFreeMode] = useState(false);
  const [handsFreePhase, setHandsFreePhase] = useState("idle");
  const [isListening, setIsListening] = useState(false);
  const speechUtterRef = useRef(null);
  const handsFreeRef = useRef({ active: false, phase: "idle" });
  const recognitionRef = useRef(null);
  const micPermissionPrimedRef = useRef(false);
  const ttsKeepAliveRef = useRef(null);
  const wakeLockRef = useRef(null);
  const handleAnswerRef = useRef(null);
  const nextQuestionRef = useRef(null);
  const getShuffledOptionsRef = useRef(null);
  const gameTimerRef = useRef(null);
  const gameScoreRef = useRef(0);
  const progressRef = useRef(null);
  const highScoreAtGameStartRef = useRef(0);
  const saveTimeoutRef = useRef(null);
  const searchTimeoutRef = useRef(null);
  const chatPollRef = useRef(null);
  const chatOwnerTapCountRef = useRef(0);
  const chatOwnerTapResetRef = useRef(null);

  useEffect(() => {
    return () => {
      if (saveTimeoutRef.current) clearTimeout(saveTimeoutRef.current);
      if (searchTimeoutRef.current) clearTimeout(searchTimeoutRef.current);
      if (chatPollRef.current) clearInterval(chatPollRef.current);
      if (chatOwnerTapResetRef.current) clearTimeout(chatOwnerTapResetRef.current);
    };
  }, []);

useEffect(() => {
    gameScoreRef.current = gameScore;
  }, [gameScore]);
  useEffect(() => {
    progressRef.current = progress;
  }, [progress]);
  useEffect(() => {
    try {
      window.localStorage.setItem(EXPLANATION_MODE_KEY, explanationMode);
    } catch (e) {
    }
  }, [explanationMode]);
  useEffect(() => {
    const handleResize = () => {
      setIsMobile(window.innerWidth < 768);
    };
    window.addEventListener("resize", handleResize);
    return () => window.removeEventListener("resize", handleResize);
  }, []);
  useEffect(() => {
    const loadProgress = async () => {
      try {
        const saved = await window.storage.get("pcp-progress");
        if (saved && saved.value) {
          const parsed = JSON.parse(saved.value);
          setProgress({...DEFAULT_PROGRESS,...parsed,
            answeredQuestions: parsed?.answeredQuestions || {},
            incorrectQuestions: Array.isArray(parsed?.incorrectQuestions) ? parsed.incorrectQuestions: [],
            categoryProgress: parsed?.categoryProgress || {},
            bookmarkedQuestions: Array.isArray(parsed?.bookmarkedQuestions) ? parsed.bookmarkedQuestions: [],
            spacedReview: parsed?.spacedReview || {}
          });
        }
      } catch (e) {
        console.log("No saved progress found");
      }
    };
    loadProgress();
  }, []);
  const saveProgress = (newProgress) => {
    try {
      if (saveTimeoutRef.current) clearTimeout(saveTimeoutRef.current);
      saveTimeoutRef.current = setTimeout(() => {
        window.storage.set("pcp-progress", JSON.stringify(newProgress)).catch(() => {
          console.log("Could not save progress");
        });
      }, 250);
    } catch (e) {
      console.log("Could not save progress");
    }
  };
  const resetCategoryProgress = (categoryId) => {
    const categoryName = getCategoryById(categoryId)?.name || "this category";
    if (!window.confirm("Reset all progress for " + categoryName + "?\n\nThis will clear all answered questions, scores, bookmarks, and spaced review schedules for this category. This cannot be undone.")) return;
    setProgress((prev) => {
      const catQuestionIds = new Set(QUESTIONS.filter((q) => q.categoryId === categoryId).map((q) => q.id));
      const newAnswered = {};
      let removedCorrect = 0;
      let removedTotal = 0;
      Object.entries(prev.answeredQuestions || {}).forEach(([qId, isCorrect]) => {
        if (catQuestionIds.has(parseInt(qId))) {
          removedTotal++;
          if (isCorrect) removedCorrect++;
        } else {
          newAnswered[qId] = isCorrect;
        }
      });
      const newIncorrect = (prev.incorrectQuestions || []).filter((id) => !catQuestionIds.has(id));
      const newSpacedReview = {};
      Object.entries(prev.spacedReview || {}).forEach(([qId, val]) => {
        if (!catQuestionIds.has(parseInt(qId))) newSpacedReview[qId] = val;
      });
      const newBookmarks = (prev.bookmarkedQuestions || []).filter((id) => !catQuestionIds.has(id));
      const newCategoryProgress = {...prev.categoryProgress || {} };
      delete newCategoryProgress[categoryId];
      const updated = {...prev,
        answeredQuestions: newAnswered,
        incorrectQuestions: newIncorrect,
        spacedReview: newSpacedReview,
        bookmarkedQuestions: newBookmarks,
        categoryProgress: newCategoryProgress,
        totalAttempted: Math.max(0, (prev.totalAttempted || 0) - removedTotal),
        totalCorrect: Math.max(0, (prev.totalCorrect || 0) - removedCorrect)
      };
      saveProgress(updated);
      return updated;
    });
  };
  const resetAllProgress = () => {
    if (!window.confirm("Reset ALL progress for the entire learning program?\n\nThis will clear every answered question, score, bookmark, spaced review schedule, and game high score across all categories. This cannot be undone.")) return;
    const fresh = {...DEFAULT_PROGRESS };
    setProgress(fresh);
    saveProgress(fresh);
  };
  const play = (type) => {
    if (soundEnabled) playSound(type);
  };

  const cachedVoiceRef = useRef(null);
  const voicesLoadedRef = useRef(false);

  useEffect(() => {
    if (!window.speechSynthesis) return;
    const load = () => { voicesLoadedRef.current = true; };
    window.speechSynthesis.addEventListener("voiceschanged", load);
    if (window.speechSynthesis.getVoices().length) load();
    return () => window.speechSynthesis.removeEventListener("voiceschanged", load);
  }, []);

  const pickMaleVoice = () => {
    if (cachedVoiceRef.current) return cachedVoiceRef.current;
    const synth = window.speechSynthesis;
    const voices = synth.getVoices();
    if (!voices.length) return null;

    const femaleNames = /female|woman|fiona|kate|serena|moira|tessa|samantha|victoria|zoe|susan|karen|allison|ava|nicky|siri.*female/i;
    const ranked = [
      (v) => /Google UK English Male/i.test(v.name),
      (v) => /Google US English/i.test(v.name) && /male/i.test(v.name),
      (v) => /Microsoft Guy Online/i.test(v.name),
      (v) => /Microsoft David Online/i.test(v.name),
      (v) => /Microsoft Mark Online/i.test(v.name),
      (v) => /Microsoft David/i.test(v.name),
      (v) => /Microsoft Mark/i.test(v.name),
      (v) => /Microsoft Guy/i.test(v.name),
      (v) => /Daniel/i.test(v.name) && v.lang.startsWith("en") && /premium|enhanced/i.test(v.name),
      (v) => /Aaron/i.test(v.name) && v.lang.startsWith("en") && /premium|enhanced/i.test(v.name),
      (v) => /Daniel/i.test(v.name) && v.lang.startsWith("en"),
      (v) => /Aaron/i.test(v.name) && v.lang.startsWith("en-US"),
      (v) => /James/i.test(v.name) && v.lang.startsWith("en"),
      (v) => /\bmale\b/i.test(v.name) && v.lang.startsWith("en"),
      (v) => /David|Guy|Mark|Tom|Fred|Alex|Rishi|Oliver|Thomas|Gordon|Lee/i.test(v.name) && v.lang.startsWith("en"),
      (v) => v.lang.startsWith("en-GB") && !femaleNames.test(v.name),
      (v) => v.lang.startsWith("en-US") && !femaleNames.test(v.name),
      (v) => v.lang.startsWith("en") && !femaleNames.test(v.name),
    ];
    for (const test of ranked) {
      const match = voices.find(test);
      if (match) { cachedVoiceRef.current = match; return match; }
    }
    const fallback = voices.find((v) => v.lang.startsWith("en")) || voices[0];
    cachedVoiceRef.current = fallback;
    return fallback;
  };

  const stopSpeaking = useCallback(() => {
    if (ttsKeepAliveRef.current) { clearInterval(ttsKeepAliveRef.current); ttsKeepAliveRef.current = null; }
    window.speechSynthesis.cancel();
    speechUtterRef.current = null;
    setIsSpeaking(false);
  }, []);

  const normalizeMedicalSpeechText = useCallback((text) => {
    if (!text) return "";
    const replacements = [
      [/\bACC\/AHA\b/gi, "A C C A H A"],
      [/\bAHA\/ACC\b/gi, "A H A A C C"],
      [/\bASCVD\b/gi, "atherosclerotic cardiovascular disease"],
      [/\bAAP\b/gi, "A A P"],
      [/\bACG\b/gi, "A C G"],
      [/\bADA\b/gi, "A D A"],
      [/\bUSPSTF\b/gi, "U S P S T F"],
      [/\bCDC\b/gi, "C D C"],
      [/\bIDSA\b/gi, "I D S A"],
      [/\bKDIGO\b/gi, "K D I G O"],
      [/\bAOM\b/gi, "acute otitis media"],
      [/\bOM\b/gi, "otitis media"],
      [/\bAOE\b/gi, "acute otitis externa"],
      [/\bTM\b/g, "tympanic membrane"],
      [/\bmIU\/L\b/g, "milli international units per liter"],
      [/\bURI\b/gi, "upper respiratory infection"],
      [/\bLRTI\b/gi, "lower respiratory tract infection"],
      [/\bPNA\b/gi, "pneumonia"],
      [/\bCAP\b/gi, "community acquired pneumonia"],
      [/\bHAP\b/gi, "hospital acquired pneumonia"],
      [/\bCOPD\b/gi, "C O P D"],
      [/\bOSA\b/gi, "obstructive sleep apnea"],
      [/\bCHF\b/gi, "congestive heart failure"],
      [/\bHFPEF\b/gi, "heart failure with preserved ejection fraction"],
      [/\bHFREF\b/gi, "heart failure with reduced ejection fraction"],
      [/\bCAD\b/gi, "coronary artery disease"],
      [/\bACS\b/gi, "acute coronary syndrome"],
      [/\bMI\b/gi, "myocardial infarction"],
      [/\bNSTEMI\b/gi, "N S T E M I"],
      [/\bSTEMI\b/gi, "S T E M I"],
      [/\bAFIB\b/gi, "atrial fibrillation"],
      [/\bVT\b/gi, "ventricular tachycardia"],
      [/\bVF\b/gi, "ventricular fibrillation"],
      [/\bHTN\b/gi, "hypertension"],
      [/\bHLD\b/gi, "hyperlipidemia"],
      [/\bDVT\b/gi, "deep vein thrombosis"],
      [/\bVTE\b/gi, "venous thromboembolism"],
      [/\bPE\b/gi, "pulmonary embolism"],
      [/\bTIA\b/gi, "transient ischemic attack"],
      [/\bCVA\b/gi, "cerebrovascular accident"],
      [/\bICH\b/gi, "intracerebral hemorrhage"],
      [/\bSAH\b/gi, "subarachnoid hemorrhage"],
      [/\bAAA\b/gi, "abdominal aortic aneurysm"],
      [/\bPAD\b/gi, "peripheral artery disease"],
      [/\bPVD\b/gi, "peripheral vascular disease"],
      [/\bCKD\b/gi, "chronic kidney disease"],
      [/\bAKI\b/gi, "acute kidney injury"],
      [/\bESRD\b/gi, "end stage renal disease"],
      [/\bEGFR\b/gi, "E G F R"],
      [/\bBUN\b/gi, "B U N"],
      [/\bCREATININE\b/gi, "creatinine"],
      [/\bDKA\b/gi, "diabetic ketoacidosis"],
      [/\bHHS\b/gi, "hyperosmolar hyperglycemic state"],
      [/\bA1C\b/gi, "A 1 C"],
      [/\bHBA1C\b/gi, "hemoglobin A 1 C"],
      [/\bT1DM\b/gi, "type 1 diabetes mellitus"],
      [/\bT2DM\b/gi, "type 2 diabetes mellitus"],
      [/\bDMT2\b/gi, "diabetes mellitus type 2"],
      [/\bTSH\b/gi, "T S H"],
      [/\bT4\b/g, "T 4"],
      [/\bT3\b/g, "T 3"],
      [/\bPTH\b/gi, "P T H"],
      [/\bGERD\b/gi, "gastroesophageal reflux disease"],
      [/\bIBS\b/gi, "irritable bowel syndrome"],
      [/\bIBD\b/gi, "inflammatory bowel disease"],
      [/\bUC\b/gi, "ulcerative colitis"],
      [/\bPUD\b/gi, "peptic ulcer disease"],
      [/\bGI\b/gi, "G I"],
      [/\bGU\b/gi, "genitourinary"],
      [/\bUTI\b/gi, "urinary tract infection"],
      [/\bPID\b/gi, "pelvic inflammatory disease"],
      [/\bPCOS\b/gi, "polycystic ovary syndrome"],
      [/\bBPH\b/gi, "benign prostatic hyperplasia"],
      [/\bLUTS\b/gi, "lower urinary tract symptoms"],
      [/\bED\b/gi, "erectile dysfunction"],
      [/\bRA\b/gi, "rheumatoid arthritis"],
      [/\bOA\b/gi, "osteoarthritis"],
      [/\bACL\b/gi, "anterior cruciate ligament"],
      [/\bPCL\b/gi, "posterior cruciate ligament"],
      [/\bMCL\b/gi, "medial collateral ligament"],
      [/\bLCL\b/gi, "lateral collateral ligament"],
      [/\bIT\s+BAND\b/gi, "iliotibial band"],
      [/\bSLE\b/gi, "systemic lupus erythematosus"],
      [/\bPMR\b/gi, "polymyalgia rheumatica"],
      [/\bGCA\b/gi, "giant cell arteritis"],
      [/\bNMS\b/gi, "neuroleptic malignant syndrome"],
      [/\bMDD\b/gi, "major depressive disorder"],
      [/\bGAD\b/gi, "generalized anxiety disorder"],
      [/\bPTSD\b/gi, "post traumatic stress disorder"],
      [/\bADHD\b/gi, "attention deficit hyperactivity disorder"],
      [/\bSSRI\b/gi, "S S R I"],
      [/\bSNRI\b/gi, "S N R I"],
      [/\bMAOI\b/gi, "M A O I"],
      [/\bTCA\b/gi, "T C A"],
      [/\bNSAID\b/gi, "N S A I D"],
      [/\bPPI\b/gi, "P P I"],
      [/\bH2\b/g, "H 2"],
      [/\bACEI\b/gi, "A C E inhibitor"],
      [/\bACE-I\b/gi, "A C E inhibitor"],
      [/\bARB\b/gi, "A R B"],
      [/\bCCB\b/gi, "C C B"],
      [/\bBB\b/gi, "beta blocker"],
      [/\bDOAC\b/gi, "D O A C"],
      [/\bNOAC\b/gi, "N O A C"],
      [/\bSGLT2\b/gi, "S G L T 2"],
      [/\bGLP-?1\b/gi, "G L P 1"],
      [/\bCBC\b/gi, "C B C"],
      [/\bCMP\b/gi, "C M P"],
      [/\bBMP\b/gi, "B M P"],
      [/\bLFTS?\b/gi, "liver function tests"],
      [/\bAST\b/gi, "A S T"],
      [/\bALT\b/gi, "A L T"],
      [/\bALP\b/gi, "A L P"],
      [/\bINR\b/gi, "I N R"],
      [/\bPTT\b/gi, "P T T"],
      [/\bPT\b/gi, "P T"],
      [/\bCRP\b/gi, "C R P"],
      [/\bESR\b/gi, "E S R"],
      [/\bLDL\b/gi, "L D L"],
      [/\bHDL\b/gi, "H D L"],
      [/\bTG\b/gi, "triglycerides"],
      [/\bPSA\b/gi, "P S A"],
      [/\bECG\b/gi, "E C G"],
      [/\bEKG\b/gi, "E K G"],
      [/\bCXR\b/gi, "chest X ray"],
      [/\bCT\b/gi, "C T"],
      [/\bMRI\b/gi, "M R I"],
      [/\bUS\b/g, "ultrasound"],
      [/\bMRSA\b/gi, "M R S A"],
      [/\bMSSA\b/gi, "M S S A"],
      [/\bRSV\b/gi, "R S V"],
      [/\bHIV\b/gi, "H I V"],
      [/\bHPV\b/gi, "H P V"],
      [/\bHSV\b/gi, "H S V"],
      [/\bHBV\b/gi, "H B V"],
      [/\bHCV\b/gi, "H C V"],
      [/\bSTI\b/gi, "sexually transmitted infection"],
      [/\bSTD\b/gi, "sexually transmitted disease"],
      [/\bTB\b/gi, "tuberculosis"],
      [/\bH\.\s*PYLORI\b/gi, "Helicobacter pylori"],
      [/\bMALT\b/gi, "M A L T"],
      [/\bC\.\s*DIFF\b/gi, "C diff"],
      [/\bLDH\b/gi, "L D H"],
      [/\bBNP\b/gi, "B N P"],
      [/\bNT-?PROBNP\b/gi, "N T pro B N P"],
      [/\bABG\b/gi, "A B G"],
      [/\bVBG\b/gi, "V B G"],
      [/\bSpO2\b/g, "oxygen saturation"],
      [/\bFEV1\b/gi, "F E V 1"],
      [/\bFVC\b/gi, "F V C"],
      [/\bAPAP\b/gi, "acetaminophen"],
      [/\bSBP\b/gi, "systolic blood pressure"],
      [/\bDBP\b/gi, "diastolic blood pressure"],
      [/\bBP\b/g, "blood pressure"],
      [/\bHR\b/g, "heart rate"],
      [/\bRR\b/g, "respiratory rate"],
      [/\bBMI\b/gi, "B M I"],
      [/\bICU\b/gi, "I C U"],
      [/\bSOB\b/gi, "shortness of breath"],
      [/\bDOE\b/gi, "dyspnea on exertion"],
      [/\bJVD\b/gi, "jugular venous distension"],
      [/\bROM\b/gi, "range of motion"],
      [/\bADL\b/gi, "activities of daily living"],
      [/\bPRN\b/gi, "as needed"],
      [/\bBID\b/gi, "twice daily"],
      [/\bTID\b/gi, "three times daily"],
      [/\bQID\b/gi, "four times daily"],
      [/\bQHS\b/gi, "at bedtime"],
      [/\bQD\b/gi, "once daily"],
      [/\bPO\b/g, "by mouth"],
      [/\bIV\b/g, "I V"],
      [/\bIM\b/g, "intramuscular"],
      [/\bSC\b/g, "subcutaneous"],
      [/\bSQ\b/g, "subcutaneous"],
      [/\bWBC\b/gi, "white blood cell count"],
      [/\bRBC\b/gi, "red blood cell count"],
      [/\bHGB\b/gi, "hemoglobin"],
      [/\bHCT\b/gi, "hematocrit"],
      [/\bMCV\b/gi, "M C V"],
      [/\bPLT\b/gi, "platelet count"],
      [/\bANA\b/gi, "A N A"],
      [/\bRF\b/g, "rheumatoid factor"],
      [/\bPCR\b/gi, "P C R"],
      [/\bAED\b/gi, "A E D"],
      [/\bACE\b/gi, "A C E"],
      [/\bGFR\b/gi, "glomerular filtration rate"],
      [/\bEF\b/g, "ejection fraction"],
      [/\bLVEF\b/gi, "left ventricular ejection fraction"],
      [/\bPMH\b/gi, "past medical history"],
      [/\bHPI\b/gi, "history of present illness"],
      [/\bROS\b/gi, "review of systems"],
      [/\bNPO\b/gi, "nothing by mouth"],
      [/\bOTC\b/gi, "over the counter"],
      [/\bRUQ\b/gi, "right upper quadrant"],
      [/\bLUQ\b/gi, "left upper quadrant"],
      [/\bRLQ\b/gi, "right lower quadrant"],
      [/\bLLQ\b/gi, "left lower quadrant"],
      [/\bENT\b/gi, "ear nose and throat"],
      [/\bDMARD\b/gi, "D M A R D"],
      [/\bTNF\b/gi, "T N F"],
      [/\bPFT\b/gi, "pulmonary function test"],
      [/\bDTAP\b/gi, "D T A P"],
      [/\bMMR\b/gi, "M M R"],
      [/\bIPV\b/gi, "I P V"],
      [/\bHEP\s*[AB]\b/gi, (m) => m.replace(/HEP\s*/i, "hepatitis ")],
      [/\bPPD\b/gi, "P P D"],
      [/\bIGRA\b/gi, "I G R A"],
      [/\bFOBT\b/gi, "fecal occult blood test"],
      [/\bFIT\b/gi, "fecal immunochemical test"],
      [/\bDEXA\b/gi, "D E X A"],
      [/\bLDL-C\b/gi, "L D L cholesterol"],
      [/\bTLC\b/gi, "therapeutic lifestyle changes"],
      [/\bCPAP\b/gi, "C P A P"],
      [/\bBILEVEL\b/gi, "bilevel"],
      [/\bBIPAP\b/gi, "bi-pap"],
      [/\bABI\b/gi, "ankle brachial index"]
    ];
    let normalized = String(text);
    for (const [pattern, replacement] of replacements) {
      normalized = normalized.replace(pattern, replacement);
    }
    // Final polish for clinical narration: normalize units, ranges, and symbols.
    normalized = normalized.replace(/(\d+)x\/(week|month|day|year|night)/gi, (m, num, period) => { const words = {"1":"one","2":"two","3":"three","4":"four","5":"five","6":"six","7":"seven","8":"eight","9":"nine","10":"ten","12":"twelve"}; return (words[num] || num) + " times per " + period; }).replace(/(\d+)\s*-\s*(\d+)\s*%/g, "$1 to $2 percent").replace(/(\d+)\s*-\s*(\d+)\s*(year|week|day|month)s?\b/gi, "$1 to $2 $3").replace(/(\d+)\s*-\s*(\d+)/g, "$1 to $2").replace(/(\d+)\s*\/\s*(\d+)\s*mmHg\b/gi, "$1 over $2 millimeters of mercury").replace(/\bmmHg\b/gi, "millimeters of mercury").replace(/(\d{2,3})\s*\/\s*(\d{2,3})/g, "$1 over $2").replace(/\bmg\/kg\/day\b/gi, "milligrams per kilogram per day").replace(/\bmcg\/kg\/min\b/gi, "micrograms per kilogram per minute").replace(/\bmg\/dL\b/gi, "milligrams per deciliter").replace(/\bng\/mL\b/gi, "nanograms per milliliter").replace(/\bIU\/L\b/gi, "international units per liter").replace(/\bmEq\/L\b/gi, "milliequivalents per liter").replace(/\bmmol\/L\b/gi, "millimoles per liter").replace(/\bbeats\/min\b/gi, "beats per minute").replace(/\bbpm\b/g, "beats per minute").replace(/\bkg\/m2\b/gi, "kilograms per square meter").replace(/\bcmH2O\b/gi, "centimeters of water").replace(/\bÂ°\s*F\b/g, "degrees Fahrenheit").replace(/\bÂ°\s*C\b/g, "degrees Celsius").replace(/\b\d+\s*%\b/g, (m) => m.replace("%", " percent"));
    normalized = normalized.replace(/\b([A-Z]{3,5}\d?)\b/g, (match, token) => {
      if (/^\d+$/.test(token)) return match;
      if (/[AEIOU]/.test(token)) return token.toLowerCase();
      return token.split("").join(" ");
    });
    return normalized;
  }, []);

  const buildSpeechText = useCallback((text) => {
    let plain = String(text || "").replace(/\n+/g, ". ").replace(/\s{2,}/g, " ").replace(/---/g, "").trim();
    plain = plain.replace(/[â€¢â—â–ªâ–ºâ€“â€”]/g, ".").replace(/CORRECT:\s*([A-D])\)\s*/gi, "Correct answer, $1. ").replace(/KEY\s+LEARNING\s+POINTS?:?/gi, "Key learning points.").replace(/\.\s*\./g, ".").replace(/,\s*,/g, ",");
    return normalizeMedicalSpeechText(plain);
  }, [normalizeMedicalSpeechText]);

  const ensureMicPermission = useCallback(async () => {
    if (micPermissionPrimedRef.current) return true;
    const hasMediaDevices = !!(navigator.mediaDevices && navigator.mediaDevices.getUserMedia);
    if (!hasMediaDevices) {
      micPermissionPrimedRef.current = true;
      return true;
    }
    try {
      if (navigator.permissions && navigator.permissions.query) {
        const status = await navigator.permissions.query({ name: "microphone" });
        if (status && status.state === "granted") {
          micPermissionPrimedRef.current = true;
          return true;
        }
      }
    } catch (e) {
    }
    try {
      const stream = await navigator.mediaDevices.getUserMedia({ audio: true });
      stream.getTracks().forEach((track) => track.stop());
      micPermissionPrimedRef.current = true;
      return true;
    } catch (e) {
      return false;
    }
  }, []);

  const readAloud = useCallback((text) => {
    if (!text || !window.speechSynthesis) return;
    if (isSpeaking) { stopSpeaking(); return; }

    window.speechSynthesis.cancel();
    const utter = new SpeechSynthesisUtterance(buildSpeechText(text));
    const voice = pickMaleVoice();
    if (voice) utter.voice = voice;
    utter.rate = 1.0;
    utter.pitch = 1.0;
    utter.volume = 1;
    const cleanupKeepAlive = () => {
      if (ttsKeepAliveRef.current) { clearInterval(ttsKeepAliveRef.current); ttsKeepAliveRef.current = null; }
    };
    utter.onend = () => { cleanupKeepAlive(); speechUtterRef.current = null; setIsSpeaking(false); };
    utter.onerror = () => { cleanupKeepAlive(); speechUtterRef.current = null; setIsSpeaking(false); };

    speechUtterRef.current = utter;
    setIsSpeaking(true);
    if (ttsKeepAliveRef.current) clearInterval(ttsKeepAliveRef.current);
    ttsKeepAliveRef.current = setInterval(() => {
      if (window.speechSynthesis.speaking && !window.speechSynthesis.paused) {
        window.speechSynthesis.pause();
        window.speechSynthesis.resume();
      }
    }, 10000);
    window.speechSynthesis.speak(utter);
  }, [isSpeaking, stopSpeaking, buildSpeechText]);

  useEffect(() => {
    return () => {
      window.speechSynthesis.cancel();
      if (ttsKeepAliveRef.current) { clearInterval(ttsKeepAliveRef.current); ttsKeepAliveRef.current = null; }
      if (wakeLockRef.current) { try { wakeLockRef.current.release(); } catch(e) {} wakeLockRef.current = null; }
    };
  }, []);

  useEffect(() => {
    if (!showExplanation && isSpeaking && !handsFreeRef.current.active) stopSpeaking();
  }, [showExplanation, isSpeaking, stopSpeaking]);

  const speakAndWait = useCallback((text) => {
    return new Promise((resolve) => {
      if (!text || !window.speechSynthesis) { resolve(); return; }
      window.speechSynthesis.cancel();
      const builtText = buildSpeechText(text);
      const utter = new SpeechSynthesisUtterance(builtText);
      const voice = pickMaleVoice();
      if (voice) utter.voice = voice;
      utter.rate = 1.0;
      utter.pitch = 1.0;
      utter.volume = 1;
      let resolved = false;
      let keepAlive = null;
      let safetyTimer = null;
      const done = () => {
        if (resolved) return;
        resolved = true;
        if (keepAlive) { clearInterval(keepAlive); keepAlive = null; }
        if (safetyTimer) { clearTimeout(safetyTimer); safetyTimer = null; }
        resolve();
      };
      utter.onend = done;
      utter.onerror = done;
      keepAlive = setInterval(() => {
        if (window.speechSynthesis.speaking && !window.speechSynthesis.paused) {
          window.speechSynthesis.pause();
          window.speechSynthesis.resume();
        } else if (!window.speechSynthesis.speaking && !resolved) {
          done();
        }
      }, 10000);
      const safetyMs = Math.max(30000, builtText.length * 120);
      safetyTimer = setTimeout(() => {
        if (!resolved) { window.speechSynthesis.cancel(); done(); }
      }, safetyMs);
      window.speechSynthesis.speak(utter);
    });
  }, [buildSpeechText]);

  const initRecognition = useCallback(() => {
    const SpeechRec = window.SpeechRecognition || window.webkitSpeechRecognition;
    if (!SpeechRec) return null;
    if (recognitionRef.current) return recognitionRef.current;
    const rec = new SpeechRec();
    rec.lang = "en-US";
    rec.interimResults = false;
    rec.maxAlternatives = 5;
    rec.continuous = false;
    recognitionRef.current = rec;
    return rec;
  }, []);

  const listenForAnswer = useCallback(() => {
    return new Promise((resolve) => {
      if (recognitionRef.current) {
        try { recognitionRef.current.abort(); } catch(e) {}
        recognitionRef.current.onresult = null;
        recognitionRef.current.onend = null;
        recognitionRef.current.onerror = null;
        recognitionRef.current.onspeechend = null;
      }
      const SpeechRec = window.SpeechRecognition || window.webkitSpeechRecognition;
      if (!SpeechRec) { resolve(null); return; }
      const rec = new SpeechRec();
      rec.lang = "en-US";
      rec.interimResults = false;
      rec.maxAlternatives = 5;
      rec.continuous = false;
      recognitionRef.current = rec;

      setIsListening(true);
      setHandsFreePhase("listening");
      handsFreeRef.current.phase = "listening";

      let answered = false;
      const finish = (idx) => {
        if (answered) return;
        answered = true;
        setIsListening(false);
        rec.onresult = null;
        rec.onend = null;
        rec.onerror = null;
        try { rec.stop(); } catch(e) {}
        resolve(idx);
      };

      rec.onresult = (e) => {
        for (let i = 0; i < e.results.length; i++) {
          for (let j = 0; j < e.results[i].length; j++) {
            const t = e.results[i][j].transcript.trim().toUpperCase();
            if (/\bA\b|ALPHA|OPTION A|ANSWER A|FIRST/.test(t)) { finish(0); return; }
            if (/\bB\b|BRAVO|OPTION B|ANSWER B|SECOND/.test(t)) { finish(1); return; }
            if (/\bC\b|CHARLIE|OPTION C|ANSWER C|THIRD/.test(t)) { finish(2); return; }
            if (/\bD\b|DELTA|OPTION D|ANSWER D|FOURTH/.test(t)) { finish(3); return; }
          }
        }
      };
      rec.onend = () => {
        if (!answered && handsFreeRef.current.active) {
          setTimeout(() => {
            if (!answered && handsFreeRef.current.active) {
              try { rec.start(); } catch(e) { finish(null); }
            }
          }, 150);
        } else if (!answered) {
          finish(null);
        }
      };
      rec.onerror = (e) => {
        if (e.error === "not-allowed" || e.error === "service-not-allowed") {
          setHandsFreeMode(false);
          setHandsFreePhase("idle");
          handsFreeRef.current.active = false;
          setIsListening(false);
          alert("Microphone access is required for Hands-Free Mode. Please allow access and try again.");
          finish(null);
          return;
        }
        if (e.error !== "aborted" && e.error !== "no-speech") {
          finish(null);
        }
      };
      try { rec.start(); } catch(e) { finish(null); }
    });
  }, []);

  const runHandsFreeQuestion = useCallback(async (question, questionIndex, totalQuestions) => {
    if (!handsFreeRef.current.active) return;
    const shuffled = getShuffledOptionsRef.current ? getShuffledOptionsRef.current(question): { options: question.options || [], correctIndex: question.correctAnswer || 0 };

    setHandsFreePhase("reading-question");
    handsFreeRef.current.phase = "reading-question";
    await speakAndWait(`Question ${questionIndex + 1} of ${totalQuestions}. ${question.question}`);
    if (!handsFreeRef.current.active) return;

    setHandsFreePhase("reading-options");
    handsFreeRef.current.phase = "reading-options";
    for (let i = 0; i < shuffled.options.length; i++) {
      if (!handsFreeRef.current.active) return;
      const letter = String.fromCharCode(65 + i);
      const optionText = shuffled.options[i].replace(/^[A-D]\)\s*/, "");
      await speakAndWait(`${letter}. ${optionText}`);
    }
    if (!handsFreeRef.current.active) return;

    await speakAndWait("What is your answer?");
    if (!handsFreeRef.current.active) return;

    await new Promise((r) => setTimeout(r, 350));
    if (!handsFreeRef.current.active) return;

    const answerIdx = await listenForAnswer();
    if (!handsFreeRef.current.active || answerIdx === null) return;

    if (handleAnswerRef.current) handleAnswerRef.current(answerIdx);
    const isCorrect = answerIdx === shuffled.correctIndex;

    setHandsFreePhase("reading-result");
    handsFreeRef.current.phase = "reading-result";
    if (isCorrect) {
      await speakAndWait("Correct!");
    } else {
      const correctLetter = String.fromCharCode(65 + shuffled.correctIndex);
      const correctText = shuffled.options[shuffled.correctIndex].replace(/^[A-D]\)\s*/, "");
      await speakAndWait(`Incorrect. The correct answer is ${correctLetter}, ${correctText}.`);
    }
    if (!handsFreeRef.current.active) return;

    setHandsFreePhase("reading-explanation");
    handsFreeRef.current.phase = "reading-explanation";
    const cLetter = String.fromCharCode(65 + shuffled.correctIndex);
    const correctedExplanation = getExplanationText(question, cLetter);
    await speakAndWait(correctedExplanation);
    if (!handsFreeRef.current.active) return;

    setHandsFreePhase("advancing");
    handsFreeRef.current.phase = "advancing";
    await new Promise((r) => setTimeout(r, 800));
    if (!handsFreeRef.current.active) return;

    if (nextQuestionRef.current) nextQuestionRef.current();
  }, [speakAndWait, listenForAnswer, explanationMode]);

  const startHandsFree = useCallback(async () => {
    const rec = initRecognition();
    if (!rec) {
      alert("Your browser does not support speech recognition. Please use Chrome or Edge.");
      return;
    }
    const hasMicPermission = await ensureMicPermission();
    if (!hasMicPermission) {
      alert("Microphone access is required for Hands-Free Mode. Please allow access in your browser settings.");
      return;
    }
    try {
      if (navigator.wakeLock) {
        wakeLockRef.current = await navigator.wakeLock.request("screen");
      }
    } catch(e) {}
    setHandsFreeMode(true);
    handsFreeRef.current.active = true;
    handsFreeRef.current.phase = "idle";
    setHandsFreePhase("idle");
  }, [initRecognition, ensureMicPermission]);

  const stopHandsFree = useCallback(() => {
    handsFreeRef.current.active = false;
    handsFreeRef.current.phase = "idle";
    setHandsFreeMode(false);
    setHandsFreePhase("idle");
    setIsListening(false);
    if (ttsKeepAliveRef.current) { clearInterval(ttsKeepAliveRef.current); ttsKeepAliveRef.current = null; }
    window.speechSynthesis.cancel();
    if (recognitionRef.current) {
      try { recognitionRef.current.abort(); } catch(e) {}
      recognitionRef.current.onresult = null;
      recognitionRef.current.onend = null;
      recognitionRef.current.onerror = null;
      recognitionRef.current.onspeechend = null;
    }
    if (wakeLockRef.current) {
      try { wakeLockRef.current.release(); } catch(e) {}
      wakeLockRef.current = null;
    }
  }, []);

  const runHandsFreeRef = useRef(null);
  runHandsFreeRef.current = runHandsFreeQuestion;

  useEffect(() => {
    if (handsFreeMode && !showExplanation && handsFreeRef.current.phase === "idle") {
      const question = quizQuestions[currentQuestionIndex];
      if (question) {
        const timer = setTimeout(() => {
          if (runHandsFreeRef.current) runHandsFreeRef.current(question, currentQuestionIndex, quizQuestions.length);
        }, 400);
        return () => clearTimeout(timer);
      }
    }
  }, [handsFreeMode, currentQuestionIndex, showExplanation, quizQuestions]);

  useEffect(() => {
    if (currentView !== "quiz" && currentView !== "category-review") {
      if (handsFreeMode) stopHandsFree();
    }
  }, [currentView, handsFreeMode, stopHandsFree]);

  useEffect(() => {
    if (currentView === "category-questions" || currentView === "category-review") {
      window.scrollTo(0, 0);
    }
  }, [currentView]);

  const getChatName = async () => {
    try {
      const stored = await window.storage.get(CHAT_NAME_KEY);
      return stored && stored.value ? String(stored.value): "";
    } catch (e) {
      return "";
    }
  };
  const saveChatName = async (name) => {
    try {
      await window.storage.set(CHAT_NAME_KEY, String(name || "").trim());
    } catch (e) {
    }
  };
  const getOwnerSessionEnabled = async () => {
    try {
      const stored = await window.storage.get(CHAT_OWNER_SESSION_KEY);
      return !!(stored && String(stored.value || "") === "1");
    } catch (e) {
      return false;
    }
  };
  const setOwnerSessionEnabled = async (enabled) => {
    try {
      if (enabled) {
        await window.storage.set(CHAT_OWNER_SESSION_KEY, "1");
      } else {
        await window.storage.remove(CHAT_OWNER_SESSION_KEY);
      }
    } catch (e) {
    }
  };
  const unlockOwnerMode = async (enteredCode) => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) {
      return false;
    }
    if (String(enteredCode || "").trim() !== configuredCode) {
      alert("Access denied.");
      return false;
    }
    setChatOwnerMode(true);
    await setOwnerSessionEnabled(true);
    return true;
  };
  const lockOwnerMode = async () => {
    setChatOwnerMode(false);
    await setOwnerSessionEnabled(false);
  };
  const promptOwnerModeAccess = async () => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) return;
    if (chatOwnerMode) {
      await lockOwnerMode();
      return;
    }
    const entered = window.prompt("Enter access code");
    if (entered === null) return;
    await unlockOwnerMode(entered);
  };
  const handleChatTitleSecretTap = () => {
    chatOwnerTapCountRef.current += 1;
    if (chatOwnerTapResetRef.current) clearTimeout(chatOwnerTapResetRef.current);
    chatOwnerTapResetRef.current = setTimeout(() => {
      chatOwnerTapCountRef.current = 0;
      chatOwnerTapResetRef.current = null;
    }, 2600);
    if (chatOwnerTapCountRef.current >= 5) {
      chatOwnerTapCountRef.current = 0;
      if (chatOwnerTapResetRef.current) {
        clearTimeout(chatOwnerTapResetRef.current);
        chatOwnerTapResetRef.current = null;
      }
      promptOwnerModeAccess();
    }
  };
  const getMessageIdentity = (message) => {
    if (!message || typeof message !== "object") return "";
    return message.id || message.remoteId || `${message.ts || ""}-${message.name || ""}-${message.text || ""}`;
  };
  const parseDeleteDirective = (message) => {
    const raw = String(message?.text || "");
    if (!raw.startsWith(CHAT_DELETE_DIRECTIVE_PREFIX + "|")) return null;
    const parts = raw.split("|");
    return {
      id: parts[1] || "",
      remoteId: parts[2] || ""
    };
  };
  const buildDeleteDirectiveMessage = (targetMessage) => {
    const targetId = String(targetMessage?.id || "");
    const targetRemoteId = String(targetMessage?.remoteId || "");
    return {
      id: `owner-delete-${Date.now()}-${Math.random().toString(36).slice(2, 8)}`,
      name: "System",
      text: `${CHAT_DELETE_DIRECTIVE_PREFIX}|${targetId}|${targetRemoteId}`,
      ts: Date.now()
    };
  };
  const getLocalChatMessages = async () => {
    try {
      const stored = await window.storage.get(CHAT_MESSAGES_KEY);
      if (!stored || !stored.value) return [];
      const parsed = JSON.parse(stored.value);
      return Array.isArray(parsed) ? parsed: [];
    } catch (e) {
      return [];
    }
  };
  const setLocalChatMessages = async (messages) => {
    try {
      await window.storage.set(CHAT_MESSAGES_KEY, JSON.stringify(messages.slice(-300)));
    } catch (e) {
    }
  };
  const fetchRemoteMessages = async () => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base) return null;
    const url = `${base}/pcp-chat/messages.json?orderBy=%22$key%22&limitToLast=300`;
    const res = await fetch(url, { cache: "no-store" });
    if (!res.ok) throw new Error("chat fetch failed");
    const payload = await res.json();
    if (!payload || typeof payload !== "object") return [];
    const mapped = Object.entries(payload).map(([remoteId, value]) => {
      if (!value || typeof value !== "object") return null;
      return {...value,
        remoteId
      };
    }).filter(Boolean);
    const deletedIds = new Set();
    const deletedRemoteIds = new Set();
    mapped.forEach((msg) => {
      const directive = parseDeleteDirective(msg);
      if (!directive) return;
      if (directive.id) deletedIds.add(directive.id);
      if (directive.remoteId) deletedRemoteIds.add(directive.remoteId);
    });
    return mapped.filter((msg) => {
      if (parseDeleteDirective(msg)) return false;
      if (msg.id && deletedIds.has(msg.id)) return false;
      if (msg.remoteId && deletedRemoteIds.has(msg.remoteId)) return false;
      return true;
    }).sort((a, b) => (a.ts || 0) - (b.ts || 0));
  };
  const loadChatMessages = async () => {
    try {
      const remote = await fetchRemoteMessages();
      if (remote !== null) {
        setChatSyncMode("shared");
        setChatMessages(remote.slice(-300));
        return;
      }
    } catch (e) {
      setChatSyncMode("local");
    }
    const local = await getLocalChatMessages();
    setChatMessages(local.slice(-300));
  };
  const postChatMessage = async (message) => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base) return false;
    const url = `${base}/pcp-chat/messages.json`;
    const res = await fetch(url, {
      method: "POST",
      headers: { "Content-Type": "application/json" },
      body: JSON.stringify(message)
    });
    return !!res.ok;
  };
  const deleteRemoteChatMessage = async (remoteId) => {
    const base = String(FIREBASE_CHAT_DB_URL || "").trim().replace(/\/+$/, "");
    if (!base || !remoteId) return false;
    const url = `${base}/pcp-chat/messages/${encodeURIComponent(remoteId)}.json`;
    const res = await fetch(url, { method: "DELETE" });
    return !!res.ok;
  };
  const deleteChatMessage = async (message) => {
    if (!chatOwnerMode || !message) return;
    const confirmed = window.confirm("Delete this chat message?");
    if (!confirmed) return;
    play("click");
    if (chatSyncMode === "shared") {
      let removedRemote = false;
      if (message.remoteId) {
        removedRemote = await deleteRemoteChatMessage(message.remoteId);
      }
      if (removedRemote) {
        await loadChatMessages();
        return;
      }
      const directiveMessage = buildDeleteDirectiveMessage(message);
      const sentDirective = await postChatMessage(directiveMessage);
      if (sentDirective) {
        await loadChatMessages();
        return;
      }
      alert("Could not delete from shared cloud chat right now.");
      return;
    }
    const local = await getLocalChatMessages();
    const targetId = getMessageIdentity(message);
    const updated = local.filter((entry) => getMessageIdentity(entry) !== targetId).slice(-300);
    setChatMessages(updated);
    await setLocalChatMessages(updated);
  };
  const sendChatMessage = async () => {
    const text = chatInput.trim();
    if (!text) return;
    const name = chatName.trim() || "Clinician";
    const message = {
      id: `${Date.now()}-${Math.random().toString(36).slice(2, 8)}`,
      name,
      text,
      ts: Date.now()
    };
    setChatInput("");
    play("click");
    const sentRemote = await postChatMessage(message);
    if (sentRemote) {
      setChatSyncMode("shared");
      await loadChatMessages();
      return;
    }
    setChatSyncMode("local");
    const local = await getLocalChatMessages();
    const updated = [...local, message].slice(-300);
    setChatMessages(updated);
    await setLocalChatMessages(updated);
  };
  const copyChatSnapshot = async () => {
    const recent = chatMessages.slice(-20);
    const lines = recent.map((m) => {
      const stamp = new Date(m.ts || Date.now()).toLocaleString();
      return `${stamp} - ${m.name || "Clinician"}: ${m.text || ""}`;
    });
    const text = `Primary Care Provider Learning Program - Clinician Chat Snapshot\n${chatSyncMode === "shared" ? "Mode: Shared cloud chat": "Mode: Local device chat"}\n\n${lines.join("\n") || "No messages yet."}`;
    try {
      await navigator.clipboard.writeText(text);
      alert("Chat snapshot copied to clipboard.");
    } catch (e) {
      alert("Could not copy snapshot on this device.");
    }
  };
  useEffect(() => {
    const configuredCode = String(CHAT_OWNER_DELETE_CODE || "").trim();
    if (!configuredCode) {
      setChatOwnerMode(false);
      return;
    }
    getOwnerSessionEnabled().then((enabled) => {
      if (enabled) setChatOwnerMode(true);
    });
  }, []);
  useEffect(() => {
    getChatName().then((name) => {
      if (name) setChatName(name);
    });
  }, []);
  useEffect(() => {
    saveChatName(chatName);
  }, [chatName]);
  useEffect(() => {
    if (currentView !== "chat") return;
    let cancelled = false;
    const tick = async () => {
      if (cancelled) return;
      await loadChatMessages();
    };
    tick();
    chatPollRef.current = setInterval(tick, 4e3);
    return () => {
      cancelled = true;
      if (chatPollRef.current) {
        clearInterval(chatPollRef.current);
        chatPollRef.current = null;
      }
    };
  }, [currentView]);
  const recordAnswer = (questionId, categoryId, isCorrect) => {
    setProgress((prev) => {
      const updated = {...prev };
      const now = Date.now();
      updated.answeredQuestions = {...prev.answeredQuestions || {}, [questionId]: isCorrect };
      updated.totalAttempted = (prev.totalAttempted || 0) + 1;
      updated.totalCorrect = (prev.totalCorrect || 0) + (isCorrect ? 1: 0);
      let incorrect = Array.isArray(prev.incorrectQuestions) ? [...prev.incorrectQuestions]: [];
      if (isCorrect) {
        incorrect = incorrect.filter((id) => id !== questionId);
      } else if (!incorrect.includes(questionId)) {
        incorrect.push(questionId);
      }
      updated.incorrectQuestions = incorrect;
      const previousSchedule = prev.spacedReview && prev.spacedReview[questionId] ? prev.spacedReview[questionId]: null;
      const nextSpacedReview = {...prev.spacedReview || {} };
      if (!isCorrect) {
        nextSpacedReview[questionId] = {
          step: 0,
          lastResult: false,
          lastReviewedAt: now,
          nextReviewAt: now + REVIEW_INTERVALS_MS[0]
        };
      } else if (previousSchedule) {
        const nextStep = Math.min((previousSchedule.step || 0) + 1, REVIEW_INTERVALS_MS.length - 1);
        if ((previousSchedule.step || 0) >= REVIEW_INTERVALS_MS.length - 1) {
          delete nextSpacedReview[questionId];
        } else {
          nextSpacedReview[questionId] = {
            step: nextStep,
            lastResult: true,
            lastReviewedAt: now,
            nextReviewAt: now + REVIEW_INTERVALS_MS[nextStep]
          };
        }
      }
      updated.spacedReview = nextSpacedReview;
      const prevCat = prev.categoryProgress && prev.categoryProgress[categoryId] ? prev.categoryProgress[categoryId]: { correct: 0, total: 0 };
      updated.categoryProgress = {...prev.categoryProgress || {} };
      updated.categoryProgress[categoryId] = {
        total: (prevCat.total || 0) + 1,
        correct: (prevCat.correct || 0) + (isCorrect ? 1: 0)
      };
      saveProgress(updated);
      return updated;
    });
  };
  const effectiveMobile = isMobile;
  const shuffleArray = (array) => {
    const shuffled = [...array];
    for (let i = shuffled.length - 1; i > 0; i--) {
      const j = Math.floor(Math.random() * (i + 1));
      [shuffled[i], shuffled[j]] = [shuffled[j], shuffled[i]];
    }
    return shuffled;
  };
  const resetQuizState = (questions, view, startIndex = 0) => {
    setQuizQuestions(questions);
    setCurrentQuestionIndex(startIndex);
    setSelectedAnswer(null);
    setShowExplanation(false);
    setQuizResults([]);
    shuffledOptionsRef.current = {};
    setCurrentView(view);
  };
  const shuffledOptionsRef = useRef({});
  const getShuffledOptions = useCallback((question) => {
    if (!question) return { options: question?.options || [], correctIndex: 0, indexMap: [] };
    const cacheKey = question.id + "-" + currentQuestionIndex;
    if (shuffledOptionsRef.current[cacheKey]) return shuffledOptionsRef.current[cacheKey];
    const indices = question.options.map((_, i) => i);
    for (let i = indices.length - 1; i > 0; i--) {
      const j = Math.floor(Math.random() * (i + 1));
      [indices[i], indices[j]] = [indices[j], indices[i]];
    }
    const result = {
      options: indices.map((i) => question.options[i]),
      correctIndex: indices.indexOf(question.correctAnswer),
      indexMap: indices
      // indexMap[displayPos] = originalPos
    };
    const keys = Object.keys(shuffledOptionsRef.current);
    if (keys.length > 5) {
      delete shuffledOptionsRef.current[keys[0]];
    }
    shuffledOptionsRef.current[cacheKey] = result;
    return result;
  }, [currentQuestionIndex]);
  getShuffledOptionsRef.current = getShuffledOptions;
  const fixExplanationLetter = (text, correctLetter) => {
    if (!text || !correctLetter) return text;
    return text.replace(/^CORRECT:\s*[A-D]\b/, `CORRECT: ${correctLetter}`);
  };
  const countWords = (text) => String(text || "").trim().split(/\s+/).filter(Boolean).length;
  const toSentences = (text) => {
    const normalized = String(text || "").replace(/\s+/g, " ").trim();
    if (!normalized) return [];
    const matches = normalized.match(/[^.!?]+[.!?]?/g) || [];
    return matches.map((s) => s.trim()).filter(Boolean);
  };
  const capWords = (text, maxWords) => {
    const words = String(text || "").trim().split(/\s+/).filter(Boolean);
    if (words.length <= maxWords) return words.join(" ");
    return words.slice(0, Math.max(1, maxWords)).join(" ") + "...";
  };
  const extractSection = (text, sectionName) => {
    const re = new RegExp(`${sectionName}:\\s*([\\s\\S]*?)(?:\\n\\n[A-Z][A-Z\\s\\/\\-\\(\\)]{3,}:|\\n---|$)`, "i");
    const match = String(text || "").match(re);
    return match ? match[1].trim(): "";
  };
  const buildAutoBulletExplanation = (expandedText, correctLetter) => {
    const expanded = fixExplanationLetter(expandedText || "", correctLetter) || "";
    if (!expanded.trim()) return "";
    const lines = expanded.split("\n").map((l) => l.trim()).filter(Boolean);
    const correctLine = lines.find((l) => /^CORRECT:/i.test(l)) || "";
    const keyPoints = extractSection(expanded, "KEY POINTS");
    const clinicalReasoning = extractSection(expanded, "CLINICAL REASONING");
    const treatment = extractSection(expanded, "TREATMENT");
    const diagnosis = extractSection(expanded, "DIAGNOSIS");
    const presentation = extractSection(expanded, "CLINICAL PRESENTATION");
    const chosenBlocks = [keyPoints, clinicalReasoning, treatment, diagnosis, presentation].filter(Boolean);
    const candidateSentences = chosenBlocks.flatMap((b) => toSentences(b)).filter((s) => s.length > 0);
    const cleanedSentences = candidateSentences.map((s) => s.replace(/\s*\([^)]*NEJM[^)]*\)/gi, "").replace(/\s*\([^)]*Guideline[^)]*\)/gi, "").replace(/\s+/g, " ").trim()).filter(Boolean);
    const bullets = [];
    if (correctLine) bullets.push(correctLine);
    if (cleanedSentences[0]) bullets.push(capWords(cleanedSentences[0], 32));
    if (cleanedSentences[1]) bullets.push(capWords(cleanedSentences[1], 32));
    if (bullets.length < 3 && cleanedSentences[2]) bullets.push(capWords(cleanedSentences[2], 24));
    if (bullets.length === 1) {
      const fallback = toSentences(expanded).find((s) => !/^CORRECT:/i.test(s));
      if (fallback) bullets.push(capWords(fallback, 34));
    }
    let formatted = bullets.map((b) => `- ${b}`).join("\n");
    if (countWords(formatted) > 98) {
      const capped = [];
      let budget = 98;
      for (const b of bullets) {
        const currentWords = countWords(b);
        if (budget <= 0) break;
        if (currentWords <= budget) {
          capped.push(`- ${b}`);
          budget -= currentWords;
        } else {
          capped.push(`- ${capWords(b, budget)}`);
          budget = 0;
        }
      }
      formatted = capped.join("\n");
    }
    return formatted;
  };
  const getExplanationText = (question, correctLetter) => {
    const expanded = typeof question?.explanation === "string" ? question.explanation: "";
    const bullet = typeof question?.bulletExplanation === "string" ? question.bulletExplanation.trim(): "";
    if (explanationMode !== "bullet") {
      return fixExplanationLetter(expanded, correctLetter);
    }
    const chosenBullet = bullet ? fixExplanationLetter(bullet, correctLetter): buildAutoBulletExplanation(expanded, correctLetter);
    if (countWords(chosenBullet) > 98) {
      return capWords(chosenBullet, 98);
    }
    return chosenBullet || fixExplanationLetter(expanded, correctLetter);
  };
  const getCanonicalCorrectLetter = (question) => {
    const idx = Number.isInteger(question?.correctAnswer) ? question.correctAnswer: 0;
    return String.fromCharCode(65 + Math.min(3, Math.max(0, idx)));
  };
  const CURATED_BULLET_OVERRIDES = {
    21: "- CORRECT: B (Take with full glass of water, remain upright 30 minutes).\n- Oral alendronate must be taken fasting with plain water; food, milk, coffee, and other medications markedly reduce absorption.\n- Staying upright for at least 30 minutes reduces esophageal irritation/ulcer risk and improves safe delivery to the stomach.",
    22: "- CORRECT: B (SIADH).\n- Euvolemic hyponatremia with inappropriately concentrated urine and high urine sodium, plus normal thyroid/adrenal testing, is classic for SIADH.\n- First-line treatment is fluid restriction; in severe neurologic symptoms, use carefully monitored hypertonic saline and avoid overly rapid correction.",
    23: "- CORRECT: C (Bupropion is contraindicated).\n- Bupropion lowers seizure threshold and should be avoided in patients with a seizure disorder.\n- Prefer varenicline or nicotine replacement therapy for smoking cessation in this setting.",
    24: "- CORRECT: B (Nitrofurantoin).\n- For uncomplicated cystitis, when local TMP-SMX resistance exceeds 20%, nitrofurantoin is preferred empiric therapy.\n- Use only for lower UTI (not pyelonephritis) and avoid in significantly reduced renal function.",
    25: "- CORRECT: B (Female sex).\n- Female sex is a CHA2DS2-VASc component (1 point), but alone does not mandate anticoagulation.\n- Obesity, smoking, and hyperlipidemia are cardiovascular risks but are not score components.",
    26: "- CORRECT: A (No babbling by 12 months).\n- Absence of babbling by 12 months is an early social-communication red flag requiring prompt developmental evaluation.\n- Do not use watchful waiting when major language/social milestones are missed or when regression is reported.",
    27: "- CORRECT: C (Start high-dose prednisone immediately).\n- Suspected giant cell arteritis is vision-threatening; treat first and confirm with temporal artery biopsy/vascular imaging afterward.\n- Delaying glucocorticoids increases risk of irreversible ischemic optic neuropathy and permanent blindness.",
    28: "- CORRECT: B (Cauda equina syndrome).\n- Urinary retention plus saddle anesthesia in a back-pain patient is a spinal emergency.\n- Obtain emergent lumbar MRI and urgent surgical decompression (ideally within 24-48 hours) to reduce permanent bladder/bowel and motor deficits.",
    29: "- CORRECT: C (Intussusception).\n- Intermittent colicky pain, lethargy, and currant-jelly stool in an infant strongly indicates intussusception.\n- Confirm with ultrasound; air/contrast enema is usually diagnostic and therapeutic unless perforation/peritonitis mandates surgery.",
    30: "- CORRECT: C (Acute coronary syndrome).\n- Older adults, women, and patients with diabetes may present with atypical ACS symptoms (dyspnea, fatigue, nausea) without chest pain.\n- New anterior T-wave inversions in this context are ischemic until proven otherwise; treat and risk-stratify as ACS/NSTEMI.",
    31: "- CORRECT: B (Ruptured ectopic pregnancy).\n- Positive pregnancy test, hypotension/tachycardia, abdominal pain, and referred shoulder pain suggest hemoperitoneum from rupture.\n- This is a hemodynamic emergency requiring immediate resuscitation and urgent operative gynecologic management.",
    32: "- CORRECT: B (Valacyclovir suppression).\n- Recurrent herpes labialis at 6-8 episodes/year meets criteria for chronic suppressive antiviral therapy.\n- Daily valacyclovir reduces outbreak frequency; topical antivirals alone are usually less effective for frequent recurrences.",
    33: "- CORRECT: B (Thyroid storm).\n- Severe thyrotoxicosis with hyperthermia, marked tachycardia, agitation, and GI symptoms after stopping therapy is thyroid storm.\n- Treat urgently in sequence: beta-blocker, thionamide, iodine after thionamide, corticosteroid, and aggressive supportive ICU care.",
    34: "- CORRECT: B (Serotonin syndrome).\n- SSRI plus tramadol is a high-risk serotonergic combination; clonus/hyperreflexia strongly support serotonin toxicity.\n- Stop serotonergic drugs, provide supportive care and benzodiazepines, and escalate to cyproheptadine in moderate-severe cases.",
    35: "- CORRECT: B (Multiple myeloma).\n- CRAB findings (hypercalcemia, renal dysfunction, anemia, bone pain) with an M-spike strongly indicate plasma cell myeloma.\n- Confirm with marrow/light-chain studies and modern skeletal imaging; initiate myeloma-directed therapy promptly.",
    36: "- CORRECT: B (Acute angle-closure glaucoma).\n- Sudden severe eye pain, halos, headache/nausea, fixed mid-dilated pupil, and a firm globe indicate acute angle closure.\n- This is an ocular emergency: urgently lower IOP and arrange definitive laser peripheral iridotomy.",
    37: "- CORRECT: B (Bilateral hip X-rays with frog-leg view).\n- In obese adolescents, knee pain with external rotation gait can be referred pain from SCFE.\n- Immediate non-weight-bearing and urgent orthopedic management are required once suspected; do not delay with knee-only workup.",
    38: "- CORRECT: B (CT pulmonary angiography).\n- With non-low pretest probability and positive D-dimer, definitive chest imaging is indicated; CTPA is standard first-line when not contraindicated.\n- V/Q scanning is generally reserved for contrast contraindications or select pregnancy scenarios.",
    39: "- CORRECT: B (Acute mesenteric ischemia).\n- Severe abdominal pain out of proportion to exam in atrial fibrillation is classic for embolic mesenteric ischemia.\n- Elevated lactate supports ischemia; obtain emergent CT angiography and urgent vascular/surgical intervention.",
    40: "- CORRECT: B (Neisseria meningitidis).\n- Fever, meningismus, headache, and petechial rash in a college-aged patient is meningococcal disease until proven otherwise.\n- Start empiric IV antibiotics and droplet precautions immediately; give chemoprophylaxis to close contacts.",
    41: "- CORRECT: B (IV thrombolysis).\n- Acute focal neurologic deficit within treatment window plus CT negative for hemorrhage supports immediate reperfusion therapy eligibility assessment.\n- Give alteplase/tenecteplase when criteria are met; do not delay for MRI, and avoid aspirin for 24 hours after thrombolysis.",
    42: "- CORRECT: B (Stevens-Johnson syndrome spectrum).\n- Recent allopurinol exposure with fever, mucosal involvement, epidermal sloughing, and positive Nikolsky sign indicates severe drug reaction on the SJS/TEN continuum.\n- Stop the culprit drug immediately and initiate burn-unit/ICU-level supportive care with urgent ophthalmology involvement.",
    43: "- CORRECT: B (Testicular torsion).\n- Sudden unilateral pain, high-riding transverse testis, and absent cremasteric reflex are classic for torsion.\n- This is time-critical: urgent urologic detorsion/orchiopexy is needed; do not delay definitive care for prolonged diagnostics.",
    44: "- CORRECT: B (Needle decompression).\n- Hypotension, tracheal deviation, unilateral absent breath sounds, and acute distress indicate tension pneumothorax with obstructive shock.\n- Decompress immediately, then place definitive chest tube; do not wait for chest X-ray.",
    45: "- CORRECT: C (Do NOT use a tongue depressor).\n- Suspected epiglottitis with drooling/tripod positioning is a high-risk airway emergency in which agitation can precipitate complete obstruction.\n- Keep child calm, avoid throat instrumentation, and coordinate controlled airway management with anesthesia/ENT.",
    46: "- CORRECT: B (Rumack-Matthew nomogram).\n- In acute single acetaminophen ingestion, a 4-hour serum level plotted on the nomogram determines need for NAC.\n- Start NAC promptly when indicated (or empirically if timing is uncertain with concern for toxicity), as benefit is greatest early.",
    47: "- CORRECT: B (Magnesium sulfate).\n- Severe preeclampsia with neurologic symptoms requires magnesium sulfate for eclampsia seizure prophylaxis.\n- Control severe blood pressure separately (e.g., labetalol/hydralazine) and plan delivery after maternal stabilization given gestational age and severity.",
    48: "- CORRECT: C (Rabies immune globulin + vaccine).\n- Bat exposure during sleep is treated as potential rabies exposure even without visible bite marks.\n- For previously unvaccinated patients, give wound care plus RIG and vaccine series promptly before symptom onset.",
    49: "- CORRECT: B (Septic arthritis).\n- Acutely hot swollen joint with fever and synovial WBC 80,000 with neutrophilic predominance is highly concerning for septic arthritis.\n- Perform urgent drainage and start empiric IV antibiotics after cultures; cartilage damage can occur rapidly.",
    50: "- CORRECT: B (IV isotonic fluids first).\n- In DKA, volume depletion is immediately life-threatening and must be corrected before insulin-driven shifts.\n- Start normal saline, assess potassium early, then initiate insulin once potassium is safe; resolution is guided by anion gap closure.",
    51: "- CORRECT: A (Retinal detachment).\n- Flashes, new floaters, and painless \"curtain\" visual loss are classic warning features.\n- Urgent ophthalmology evaluation is required, especially if macula is still on, to preserve central vision.",
    52: "- CORRECT: B (Botulinum toxin blocks ACh release).\n- Infant botulism presents with constipation, poor feeding, and hypotonia; honey is a classic exposure source in infants under 12 months.\n- Mechanism is presynaptic SNARE cleavage with impaired acetylcholine release; treat supportively plus BabyBIG.",
    53: "- CORRECT: B (CT angiogram of the aorta).\n- Sudden tearing chest/back pain with marked inter-arm blood pressure difference is classic for acute aortic dissection.\n- Obtain urgent CTA and begin anti-impulse therapy with IV beta-blockade while arranging definitive type-specific management.",
    54: "- CORRECT: B (Lyme disease).\n- Facial nerve palsy plus knee symptoms after exposure in an endemic region strongly supports disseminated Lyme.\n- Confirm/treat per stage and presentation; doxycycline is first-line in appropriate patients, with IV therapy for selected severe involvement.",
    55: "- CORRECT: B (Hydrochlorothiazide).\n- Thiazides reduce lithium clearance and can precipitate toxicity (tremor, ataxia, GI symptoms, confusion) within days to weeks.\n- Avoid or adjust lithium carefully and monitor levels/renal status closely whenever interacting antihypertensives are introduced.",
    56: "- CORRECT: B (GBS, E. coli, Listeria).\n- In neonates, these are the key meningitis pathogens and drive empiric coverage choices.\n- Start age-appropriate broad therapy promptly (typically ampicillin plus gentamicin or cefotaxime) after full sepsis evaluation.",
    57: "- CORRECT: B (INR increases; reduce warfarin and monitor closely).\n- TMP-SMX significantly potentiates warfarin via CYP2C9 inhibition and reduced vitamin K-producing flora.\n- Use a safer alternative when possible or preemptively lower warfarin dose and recheck INR within a few days.",
    58: "- CORRECT: B (Fluoroquinolones, e.g., ciprofloxacin).\n- This class is associated with tendon injury/rupture and increased aortic aneurysm-dissection risk, especially in older or high-risk patients.\n- Reserve for scenarios lacking safer options and counsel patients to report tendon or vascular symptoms immediately.",
    59: "- CORRECT: B (Metformin contraindicated at this renal function).\n- With eGFR around 25, metformin is contraindicated because accumulation increases lactic acidosis risk.\n- Use renal-appropriate alternatives and reassess glycemic regimen based on CKD stage and cardiorenal comorbidity profile.",
    60: "- CORRECT: B (20 mg maximum daily citalopram dose in age >60).\n- Older adults have higher QT-prolongation risk from citalopram, with dose-dependent torsades risk.\n- Limit dose, review interacting QT-prolonging agents/electrolytes, and consider lower-risk SSRI alternatives when needed.",
    61: "- CORRECT: B (Hypokalemia).\n- Low potassium increases digoxin binding at Na/K-ATPase, amplifying toxicity even when digoxin levels are not markedly elevated.\n- In toxicity, correct potassium and assess rhythm urgently; reserve digoxin immune Fab for severe arrhythmias, hyperkalemia, or hemodynamic instability.",
    62: "- CORRECT: C (Meperidine/Demerol).\n- Its renally cleared metabolite normeperidine is neurotoxic and can accumulate, causing tremor, delirium, and seizures in CKD.\n- Avoid meperidine in renal impairment and in older adults; prefer safer opioids such as fentanyl with careful dose titration.",
    63: "- CORRECT: A (Lithium).\n- First-trimester lithium exposure is associated with Ebstein anomaly risk, though absolute risk is lower than historically reported.\n- Preconception counseling should balance relapse risk versus teratogenic risk and favor shared planning with psychiatry and maternal-fetal medicine.",
    64: "- CORRECT: B (Metronidazole).\n- For intra-abdominal infections, metronidazole provides reliable anaerobic coverage including Bacteroides fragilis.\n- Pair with gram-negative coverage when needed; clindamycin is less preferred below the diaphragm due to resistance patterns.",
    65: "- CORRECT: B (LAMA, e.g., tiotropium).\n- Antimuscarinic effects can worsen urinary retention (especially with BPH) and may precipitate angle-closure glaucoma if aerosol contacts the eyes.\n- Counsel on proper inhaler technique and monitor high-risk patients for urinary and ocular symptoms.",
    66: "- CORRECT: B (ACE inhibitor; switch to ARB).\n- ACE inhibition increases bradykinin, causing a persistent dry cough that is a class effect and often dose-independent.\n- ARBs maintain RAAS benefit with much lower cough risk; evaluate for angioedema history before selecting alternatives.",
    67: "- CORRECT: B (History of CAD/stroke).\n- Triptans are vasoconstrictive via 5-HT1B activity and can provoke ischemia in coronary or cerebrovascular disease.\n- Use non-vasoconstrictive options (e.g., gepants, ditans, optimized preventive therapy) in patients with vascular contraindications.",
    68: "- CORRECT: B (Two contraception methods plus monthly pregnancy testing).\n- Isotretinoin is highly teratogenic, so iPLEDGE requires strict pregnancy prevention and documented monthly testing.\n- Verify adherence before each refill and reinforce no blood donation during therapy and for 1 month after.",
    69: "- CORRECT: B (Vitamin B12, magnesium, and calcium).\n- Chronic PPI use can impair micronutrient absorption through sustained acid suppression, especially with long duration or high dose.\n- Reassess indication regularly, use the lowest effective dose, and monitor deficiencies in high-risk patients.",
    70: "- CORRECT: B (Empty stomach, 30-60 min before food; separate calcium/iron by 4 hours).\n- Levothyroxine absorption is highly timing-dependent and reduced by food, coffee, calcium, iron, and some acid suppressants.\n- Keep administration consistent and interpret TSH only after steady-state intervals (about 6 weeks).",
    71: "- CORRECT: B (Nitrates).\n- PDE5 inhibitors plus nitrates can cause profound refractory hypotension through excessive cGMP-mediated vasodilation.\n- Avoid coadministration entirely and observe nitrate-free intervals after PDE5 use (longer with tadalafil).",
    72: "- CORRECT: B (Lorazepam).\n- Lorazepam undergoes phase II glucuronidation with less reliance on oxidative hepatic metabolism, making it safer in liver dysfunction.\n- The LOT group (lorazepam, oxazepam, temazepam) is preferred when benzodiazepines are necessary in hepatic impairment.",
    73: "- CORRECT: B (Vitamin B6/pyridoxine).\n- Isoniazid functionally depletes pyridoxine and can cause dose-related peripheral neuropathy.\n- Give prophylactic pyridoxine in higher-risk patients (e.g., diabetes, alcoholism, pregnancy, HIV, CKD) and monitor for neuropathic symptoms.",
    74: "- CORRECT: C (Prior ACE inhibitor use requires 36-hour washout).\n- Starting sacubitril/valsartan too soon after an ACE inhibitor increases bradykinin-mediated angioedema risk.\n- Ensure full washout, then initiate ARNI with blood pressure, renal function, and potassium monitoring.",
    75: "- CORRECT: B (Phenytoin).\n- Classic adverse effects include gingival hyperplasia and hirsutism, along with ataxia, osteopenia, and CYP-mediated interactions.\n- Emphasize dental hygiene and periodic medication review; consider newer agents if toxicity burden outweighs benefit.",
    76: "- CORRECT: B (Omeprazole).\n- Omeprazole inhibits CYP2C19, reducing clopidogrel activation and potentially weakening antiplatelet effect.\n- Prefer pantoprazole (or H2 blockade when appropriate) when gastric protection is needed with clopidogrel.",
    77: "- CORRECT: B (Fournier gangrene).\n- SGLT2 inhibitors increase glycosuria, which commonly causes genital mycotic infections and rarely can precede necrotizing perineal infection.\n- Urgently evaluate genital pain, swelling, fever, or crepitus and stop SGLT2 therapy if severe infection is suspected.",
    78: "- CORRECT: B (Urate shifts can trigger/worsen flares).\n- Initiating urate-lowering therapy alters crystal equilibrium and can provoke acute inflammation despite long-term benefit.\n- Per ACR, ULT may start during a flare if anti-inflammatory prophylaxis is co-prescribed and treat-to-target follow-up is arranged.",
    79: "- CORRECT: B (Increased asthma-related death risk with LABA monotherapy).\n- LABAs bronchodilate but do not treat airway inflammation, which can mask worsening disease and raise severe-exacerbation risk.\n- In asthma, LABAs should be used only with an inhaled corticosteroid (preferably fixed ICS-LABA combination).",
    80: "- CORRECT: B (Teeth staining and enamel hypoplasia).\n- Tetracyclines chelate calcium in developing teeth and bone, causing permanent discoloration during periods of enamel mineralization.\n- Doxycycline may still be indicated for life-threatening infections (e.g., RMSF), where mortality risk outweighs dental risk.",
    81: "- CORRECT: A (Weight gain and sexual dysfunction are less common with bupropion).\n- As an NDRI, bupropion avoids serotonergic adverse effects that often drive SSRI nonadherence.\n- Still screen for contraindications such as seizure disorder or eating disorders before prescribing.",
    82: "- CORRECT: B (ACE inhibitors/ARBs).\n- Combining RAAS blockade with spironolactone synergistically increases hyperkalemia risk, especially in CKD or older adults.\n- Monitor potassium and creatinine soon after initiation or dose changes; counsel on high-potassium diet/supplements.",
    83: "- CORRECT: B (ACE inhibitors/ARBs are contraindicated in pregnancy).\n- Fetal RAAS blockade can cause renal dysgenesis, oligohydramnios, pulmonary hypoplasia, and neonatal renal failure.\n- Use pregnancy-compatible options (e.g., labetalol, nifedipine, methyldopa) and switch promptly when pregnancy is planned or confirmed.",
    84: "- CORRECT: B (Sulfonylureas).\n- They trigger glucose-independent insulin release, making hypoglycemia and falls a major concern in older adults.\n- Prefer lower-risk agents when possible; if used, avoid glyburide and set individualized glycemic targets.",
    85: "- CORRECT: B (Anticholinergic toxicity).\n- Delirium, mydriasis, dry skin/mucosa, urinary retention, ileus, and hyperthermia form the classic antimuscarinic toxidrome.\n- Distinguish from sympathomimetic toxicity by decreased sweating and bowel sounds; treat supportively and consider physostigmine in select severe cases.",
    86: "- CORRECT: B (Intensive lifestyle intervention).\n- In DPP, about 7% weight loss plus at least 150 min/week activity reduced progression to type 2 diabetes more than metformin over 3 years.\n- Lifestyle change remains first-line for prediabetes, with metformin added for higher-risk subgroups.",
    87: "- CORRECT: B (Mediterranean diet plus extra-virgin olive oil or nuts).\n- PREDIMED showed meaningful reduction in major cardiovascular events among high-risk adults versus low-fat control advice.\n- Emphasize overall dietary pattern quality rather than single nutrient substitution.",
    88: "- CORRECT: B (GLUT4 translocation from muscle contraction).\n- Exercise activates insulin-independent pathways (e.g., AMPK), increasing skeletal muscle glucose uptake acutely.\n- This supports counseling that activity improves glycemia even in insulin-resistant states.",
    89: "- CORRECT: B (Reduced insulin sensitivity plus higher ghrelin).\n- Experimental sleep restriction worsens glucose handling and appetite hormone balance, promoting overeating and metabolic risk.\n- Sleep optimization is a core cardiometabolic intervention, not just a wellness add-on.",
    90: "- CORRECT: C (LDL >130 is NOT an ATP III metabolic syndrome criterion).\n- Diagnostic components are central adiposity, high triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose.\n- LDL can be a treatment target, but it does not define metabolic syndrome diagnosis.",
    91: "- CORRECT: B (Cognitive Behavioral Therapy).\n- CBT has first-line efficacy for mild to moderate GAD and often provides durable benefit after treatment completion.\n- Shared decision-making should include CBT access, patient preference, and severity when choosing therapy versus medication.",
    92: "- CORRECT: C (Weight loss of 7-10%).\n- Sustained weight reduction has the strongest evidence for improving steatosis and can improve steatohepatitis and fibrosis risk in MASLD.\n- Pharmacologic options may be adjunctive in selected patients but do not replace lifestyle-based treatment.",
    93: "- CORRECT: B (TRE benefits are mostly from lower calorie intake and weight loss).\n- In many trials, time-restricted eating performs similarly to standard calorie restriction when energy deficit is comparable.\n- Set expectations around adherence and total intake, not fasting window alone.",
    94: "- CORRECT: C (Structured aerobic exercise can be as effective as sertraline at 4 months).\n- Trials such as SMILE support exercise as a therapeutic option for mild-to-moderate depression.\n- For safety and adherence, prescribe specific frequency/intensity and track follow-up outcomes.",
    95: "- CORRECT: C (Omega-3 polyunsaturated fats: EPA/DHA).\n- Omega-3 intake is associated with anti-inflammatory signaling and improved cardiometabolic profiles compared with trans and high saturated fat patterns.\n- Favor whole-food sources (fatty fish, nuts/seeds) within an overall Mediterranean-style pattern.",
    96: "- CORRECT: B (Waist circumference is a proxy for visceral adiposity).\n- Visceral fat is more strongly linked to insulin resistance, dyslipidemia, and cardiovascular risk than BMI alone.\n- Use waist metrics alongside BMI to better stratify cardiometabolic risk in routine practice.",
    97: "- CORRECT: B (Sarcopenia prevention).\n- Resistance training counters age-related muscle and strength loss, reducing frailty, falls, and loss of independence.\n- Combine progressive resistance exercise with adequate protein intake for best functional outcomes in older adults.",
    98: "- CORRECT: B (Depersonalization/cynicism).\n- The Maslach model defines burnout with emotional exhaustion, depersonalization, and reduced personal accomplishment.\n- Identifying depersonalization early is clinically important because it can degrade therapeutic alliance and care quality.",
    99: "- CORRECT: B (Recommended about 25-30 g/day; average intake about 15 g/day).\n- The U.S. population fiber gap contributes to cardiometabolic and GI risk burden.\n- Increase fiber gradually with hydration to improve tolerance and reduce bloating during dietary transitions.",
    100: "- CORRECT: C (Amlodipine/CCB).\n- In Black adults without CKD or diabetes, CCBs and thiazides generally produce better BP and stroke outcomes than ACE inhibitor monotherapy.\n- Select initial therapy by comorbidity and population evidence, then titrate to guideline BP targets.",
    101: "- CORRECT: B (Insulin resistance/hyperinsulinemia).\n- Hyperinsulinemia drives ovarian androgen excess and lowers SHBG, increasing free testosterone and anovulation.\n- Treat the metabolic driver with weight reduction, activity, and insulin-sensitizing strategy while addressing fertility and endometrial risk.",
    102: "- CORRECT: C (Plant-slant pattern with legumes as staples).\n- Longevity cohorts consistently share mostly whole-food plant intake, frequent beans, and low ultra-processed food burden.\n- Blue Zones outcomes reflect combined diet, movement, social structure, and purpose rather than a single \"superfood\" effect.",
    103: "- CORRECT: B (Prefrontal cortex).\n- Mindfulness programs are associated with preserved cortical thickness and improved top-down emotional regulation with aging.\n- Use as adjunctive therapy for stress, anxiety, and relapse prevention; benefits depend on sustained practice, not brief exposure alone.",
    104: "- CORRECT: B (Fructose bypasses PFK-1 regulation in the liver).\n- This favors de novo lipogenesis, hepatic fat accumulation, and uric acid generation when intake is high, especially in liquid form.\n- Counsel to reduce sugar-sweetened beverages first, where metabolic benefit is often largest.",
    105: "- CORRECT: B (Potassium).\n- DASH lowers blood pressure partly through higher potassium intake plus lower sodium and improved dietary pattern quality.\n- Check kidney function and medications before aggressive potassium counseling in CKD or RAAS-blocked patients.",
    106: "- CORRECT: B (Fasting insulin or HOMA-IR).\n- Compensatory hyperinsulinemia often appears before fasting glucose/A1c abnormalities in insulin-resistant states.\n- Interpret with clinical context and trend over time; no single cutoff replaces risk-factor and phenotype assessment.",
    107: "- CORRECT: B (Aerobic exercise).\n- Aerobic training robustly upregulates BDNF and supports neuroplasticity, mood, and cognitive resilience.\n- Prescribe exercise as medicine with specific dose (frequency, intensity, duration) to improve adherence and outcomes.",
    108: "- CORRECT: B (HR/BP fall quickly; MI risk drops substantially within a year).\n- Cardiovascular recovery starts within minutes to hours after cessation and compounds over months to years.\n- Pair counseling with pharmacotherapy (NRT/varenicline/bupropion) to maximize quit success.",
    109: "- CORRECT: A (Hypertension and metabolic syndrome).\n- Hyperuricemia tracks with endothelial dysfunction, insulin resistance, and cardiometabolic risk beyond gout burden alone.\n- Address root drivers (weight, fructose/alcohol excess, CKD, medications) while treating symptomatic gout appropriately.",
    110: "- CORRECT: B (Quality of relationships).\n- Long-term cohort data show strong social connection predicts healthier aging and better survival independent of wealth or status.\n- Incorporate social isolation screening into primary care risk assessment and care planning.",
    111: "- CORRECT: C (UPFs bypass satiety, promote overconsumption, disrupt metabolic health).\n- Hyperpalatability, low fiber structure, and rapid energy delivery can increase intake despite matched calories/macros in short-term trials.\n- Focus counseling on minimally processed pattern shifts rather than perfection.",
    112: "- CORRECT: B (Breast, colon, and endometrial cancers).\n- Chronic hyperinsulinemia/IGF signaling and adiposity-related inflammation increase proliferation risk in these tissues.\n- Weight management, activity, and metabolic control are meaningful cancer-risk reduction strategies.",
    113: "- CORRECT: A (Open-ended questions, Affirmations, Reflections, Summaries).\n- OARS skills elicit patient change talk and reduce resistance versus directive counseling.\n- Use reflective listening and summaries to reinforce autonomy and improve behavior-change adherence.",
    114: "- CORRECT: B (Acute pancreatitis; stop GLP-1 RA and send to ER).\n- Persistent severe epigastric pain radiating to the back with vomiting is red-flag pancreatitis, not routine titration nausea.\n- Discontinue the agent immediately and avoid rechallenge after confirmed drug-induced pancreatitis.",
    115: "- CORRECT: B (CGM Time in Range reveals variability/hypoglycemia missed by A1c).\n- A1c reflects average glycemia, but misses dangerous swings, nocturnal lows, and postprandial spikes.\n- Use TIR, time-below-range, and AGP patterns to personalize medication and lifestyle adjustments.",
    116: "- CORRECT: B (Primary hyperaldosteronism/Conn syndrome).\n- Resistant hypertension plus hypokalemia is classic for autonomous aldosterone excess with renin suppression.\n- Screen with aldosterone-renin ratio, then pursue confirmatory testing and subtype-directed therapy.",
    117: "- CORRECT: B (Cervical radiculopathy).\n- Positive Spurling with arm-radiating pain indicates foraminal nerve-root irritation rather than isolated shoulder pathology.\n- Localize by dermatomal deficits/reflex changes and treat conservatively first unless progressive neurologic deficits emerge.",
    118: "- CORRECT: B (Screen for prior decreased need for sleep/racing thoughts).\n- Bipolar depression can present as MDD; SSRI monotherapy may precipitate mania or rapid cycling if bipolar disorder is missed.\n- Obtain a targeted bipolar history (or MDQ) before starting antidepressants.",
    119: "- CORRECT: A (Start at least moderate-intensity statin).\n- Adults age 40-75 with diabetes are a statin-benefit group regardless of baseline 10-year ASCVD risk calculation.\n- Escalate to high-intensity when additional risk enhancers are present and LDL-lowering goals are not met.",
    120: "- CORRECT: B (Adaptive thermogenesis defends higher weight after loss).\n- Falling leptin/rising ghrelin and reduced energy expenditure create biologic pressure toward regain, not simply willpower failure.\n- Counsel obesity as a chronic disease requiring long-term behavioral, pharmacologic, and sometimes procedural support.",
    121: "- CORRECT: B (Lumbar radiculopathy/sciatica from disc herniation).\n- Pain radiating below the knee in a dermatomal pattern favors nerve-root pathology over simple lumbar strain.\n- Screen red flags (progressive weakness, saddle anesthesia, bladder dysfunction) and treat conservatively first if absent.",
    122: "- CORRECT: B (No; ADHD symptoms must begin before age 12).\n- Adult-onset inattentiveness usually reflects mimics such as anxiety, depression, sleep disorder, substance use, or thyroid disease.\n- Confirm developmental history and functional impairment before prescribing stimulants.",
    123: "- CORRECT: B (Estrogen-only therapy after hysterectomy).\n- Progestogen is needed only for endometrial protection in patients with an intact uterus.\n- Use lowest effective dose, consider transdermal route in higher VTE/cardiometabolic risk, and reassess benefit-risk regularly.",
    124: "- CORRECT: B (A mole that looks different from the patient's other nevi).\n- The Ugly Duckling sign improves melanoma detection by identifying a lesion that breaks the person's baseline nevus pattern.\n- Low biopsy threshold is appropriate for outlier lesions, even if classic ABCDE features are incomplete.",
    125: "- CORRECT: B (SGLT2 inhibitors and GLP-1 receptor agonists).\n- These classes provide kidney-protective benefit beyond glucose lowering in diabetic CKD populations.\n- They complement RAAS blockade and risk-factor control, with class-specific contraindication and monitoring considerations.",
    126: "- CORRECT: C (Adjust oral therapy and recheck in 48-72 hours).\n- Severe asymptomatic hypertension without acute end-organ injury is hypertensive urgency, not emergency.\n- Avoid rapid BP drops and avoid immediate-release nifedipine; focus on gradual outpatient optimization and close follow-up.",
    127: "- CORRECT: B (Lachman test).\n- Lachman at 20 to 30 degrees is the most sensitive bedside exam for ACL disruption, especially acutely.\n- Confirm with MRI when needed and evaluate associated meniscal/chondral injury before return-to-play planning.",
    128: "- CORRECT: B (Calculate FIB-4 index).\n- In suspected MASLD, fibrosis risk stratification determines prognosis and referral urgency more than transaminase elevation alone.\n- FIB-4 helps triage who can remain in primary care versus who needs elastography/hepatology evaluation.",
    129: "- CORRECT: B (Avoid in uncontrolled hypertension or arrhythmia history).\n- Phentermine is sympathomimetic and can worsen tachycardia, blood pressure control, and arrhythmic risk.\n- Perform cardiovascular screening and use only within approved short-term indications and monitoring framework.",
    130: "- CORRECT: D (CBT-I).\n- ACP and sleep guidelines support CBT-I as first-line chronic insomnia treatment due to durable efficacy and lower harm than sedative-hypnotics.\n- Medications are adjunctive or second-line when behavioral treatment access/response is limited.",
    131: "- CORRECT: B (First-step morning pain/post-static dyskinesia).\n- Plantar fasciitis classically hurts most after rest, then improves with initial movement before recurring with prolonged loading.\n- Prioritize fascia and Achilles stretching, footwear support, and activity modification before procedures.",
    132: "- CORRECT: B (DPP-4 effects are glucose-dependent).\n- Incretin-based enhancement of insulin secretion attenuates as glucose normalizes, minimizing monotherapy hypoglycemia risk.\n- This contrasts with sulfonylureas, which stimulate insulin release independent of ambient glucose.",
    133: "- CORRECT: A (Gout, diabetes, and hypercalcemia).\n- Thiazides can increase urate, worsen glycemic control, and raise calcium through renal tubular effects.\n- Use lower doses and monitor metabolic adverse effects in patients with relevant comorbidity risk.",
    134: "- CORRECT: B (PCOS).\n- Oligomenorrhea plus clinical hyperandrogenism in this phenotype strongly supports PCOS after excluding thyroid, prolactin, CAH, and Cushing etiologies.\n- Address cycle control, endometrial protection, fertility goals, and cardiometabolic risk in parallel.",
    135: "- CORRECT: B (18- and 24-month visits).\n- AAP recommends universal ASD screening with M-CHAT-R/F at both time points, alongside ongoing developmental surveillance.\n- Any parental concern or regression warrants prompt referral regardless of screening result.",
    136: "- CORRECT: B (Yes, this is clinical osteoporosis).\n- A fragility vertebral fracture establishes osteoporosis requiring treatment even when DXA is only osteopenic.\n- Prior vertebral fracture markedly raises near-term fracture risk and justifies pharmacologic therapy now.",
    137: "- CORRECT: B (Serotonin discontinuation syndrome).\n- Abrupt paroxetine cessation can cause FINISH symptoms, especially dizziness, nausea, and characteristic \"brain zaps\" within days.\n- Restart and taper more gradually when severe; prefer planned step-down strategies for short half-life SSRIs.",
    138: "- CORRECT: B (Delirium).\n- Acute onset, fluctuating attention, and visual hallucinations over days strongly indicate delirium rather than chronic neurodegeneration.\n- Treat as a medical emergency: identify precipitant (infection, drugs, metabolic causes) and correct quickly.",
    139: "- CORRECT: B (Age 50).\n- USPSTF criteria are age 50-80, at least 20 pack-years, and current smoking or quit within 15 years for annual LDCT.\n- Shared decision-making is essential given false positives and downstream procedural risk.",
    140: "- CORRECT: B (Contraindicated).\n- GLP-1 receptor agonists are contraindicated with personal/family history of medullary thyroid carcinoma or MEN2.\n- This warning does not apply to papillary/follicular thyroid cancers; verify thyroid cancer type before decisions.",
    141: "- CORRECT: B (ABPM or validated home BP logs).\n- White-coat hypertension is confirmed by elevated office readings with normal out-of-office averages.\n- Confirm before long-term pharmacotherapy and continue periodic monitoring for progression to sustained hypertension.",
    142: "- CORRECT: B (Rat-bite punched-out erosions with overhanging edges).\n- Chronic tophaceous gout causes juxta-articular erosions while joint space is often relatively preserved until late disease.\n- Imaging pattern helps distinguish gout from RA and OA in chronic inflammatory arthropathy workups.",
    143: "- CORRECT: B (Urgent ophthalmology referral).\n- Hutchinson sign implies nasociliary involvement and substantially higher risk of ocular herpes zoster complications.\n- Start antivirals promptly and arrange same-day eye evaluation to prevent vision-threatening sequelae.",
    144: "- CORRECT: B (SIBO).\n- Day-progressive bloating/distension with IBS-like symptoms and poor response to basic dietary therapy should prompt SIBO consideration.\n- Confirm with appropriate breath testing when indicated and treat plus address recurrence drivers (motility, medications, anatomy).",
    145: "- CORRECT: B (Chronic GERD plus at least 2 risk factors).\n- Barrett screening is risk-targeted, not universal for all reflux patients.\n- Risk stratification should include sex, age, race, obesity pattern, smoking history, and family history.",
    146: "- CORRECT: C (Observation/supportive care without routine antibiotics).\n- In immunocompetent CT-confirmed uncomplicated diverticulitis, selective non-antibiotic management is guideline-concordant.\n- Reserve antibiotics for complicated disease, systemic illness, immunosuppression, or unreliable follow-up.",
    147: "- CORRECT: B (Random colon biopsies).\n- Microscopic colitis often has normal-appearing mucosa endoscopically and is diagnosable only on histology.\n- In older adults with chronic watery diarrhea, biopsy is essential even when colonoscopy appears visually normal.",
    148: "- CORRECT: B (Dicyclomine).\n- Antispasmodic therapy can reduce meal-triggered IBS cramping by dampening cholinergic smooth-muscle spasm.\n- Use cautiously in patients sensitive to anticholinergic burden, especially older adults.",
    149: "- CORRECT: C (Gluten challenge before serology/biopsy).\n- Celiac testing requires active gluten exposure; prolonged gluten avoidance can create false-negative results.\n- HLA-DQ2/DQ8 is useful to exclude disease when negative, but cannot confirm diagnosis when positive.",
    150: "- CORRECT: B (Dysphagia).\n- Dysphagia is an alarm feature requiring prompt EGD rather than empiric-only dyspepsia management.\n- Early endoscopic evaluation helps exclude stricture, eosinophilic disease, and upper GI malignancy.",
    151: "- CORRECT: C (Serum IgG is inappropriate for test-of-cure).\n- Antibody titers can remain positive long after eradication and do not indicate active infection.\n- Use stool antigen or urea breath test after correct timing and medication washout.",
    152: "- CORRECT: A (Low-dose tricyclic antidepressants).\n- In functional dyspepsia with normal EGD and negative H. pylori, visceral pain modulation with low-dose TCA is evidence-supported.\n- Start low, titrate gradually, and monitor anticholinergic and sedation effects.",
    153: "- CORRECT: B (Oral fidaxomicin or oral vancomycin).\n- Current guidance no longer favors metronidazole as first-line for initial non-severe CDI.\n- Severity stratification and recurrence prevention planning should be built into initial treatment selection.",
    154: "- CORRECT: B (Rebound acid hypersecretion).\n- Abrupt PPI cessation can trigger transient symptom rebound from compensatory gastrin/parietal-cell adaptations.\n- Tapering or bridge strategies improve discontinuation success and reduce unnecessary chronic PPI dependence.",
    155: "- CORRECT: B (Anorectal manometry).\n- Refractory constipation with straining despite soft stool suggests a defecatory disorder such as pelvic floor dyssynergia.\n- Confirm physiology before escalating laxatives; biofeedback is often highly effective once diagnosed.",
    156: "- CORRECT: B (Restrict fermentable oligo-, di-, mono-saccharides and polyols).\n- FODMAP reduction lowers osmotic load and bacterial gas production, improving IBS bloating in selected patients.\n- Use the full elimination-reintroduction-personalization sequence to avoid unnecessary long-term restriction.",
    157: "- CORRECT: B (Isolated mild unconjugated hyperbilirubinemia).\n- Gilbert syndrome is benign and often triggered by fasting, stress, or intercurrent illness with otherwise normal liver chemistries.\n- Recognizing the pattern prevents repeated unnecessary hepatic workups.",
    158: "- CORRECT: B (Diverticulosis).\n- In older adults, painless brisk hematochezia is classically diverticular bleeding until proven otherwise.\n- Stabilize first, then localize/treat source with colonoscopy or CTA based on hemodynamic context.",
    159: "- CORRECT: B (Vitamin B12 deficiency).\n- SIBO can consume cobalamin and produce the characteristic low-B12 pattern, sometimes with relatively preserved/elevated folate.\n- Check and replete B12 while treating underlying overgrowth to prevent neurologic sequelae.",
    160: "- CORRECT: B (Steatorrhea).\n- Exocrine pancreatic insufficiency from chronic pancreatitis causes greasy, floating, foul-smelling stools and fat-soluble vitamin deficiency risk.\n- Confirm with fecal elastase when appropriate and start pancreatic enzyme replacement with meals.",
    161: "- CORRECT: B (Start at age 40 or 10 years before affected first-degree relative diagnosis).\n- A first-degree relative with CRC before age 60 places the patient in a higher-risk screening pathway.\n- Colonoscopy is preferred and typically repeated at shorter intervals (often every 5 years).",
    162: "- CORRECT: B (Atopic disease association).\n- EoE commonly coexists with asthma, eczema, allergic rhinitis, and food allergy due to shared type-2 immune biology.\n- Dysphagia/food impaction should prompt biopsy-based diagnosis even if endoscopic findings are subtle.",
    163: "- CORRECT: B (Cannabinoid hyperemesis syndrome).\n- Chronic cannabis exposure can paradoxically cause cyclic vomiting with characteristic temporary relief from hot showers.\n- Definitive treatment is cannabis cessation; recurrent ED visits are common until this diagnosis is recognized.",
    164: "- CORRECT: B (Head-of-bed elevation and left-side sleeping).\n- Nocturnal reflux improves when gravity and anatomy reduce esophageal acid exposure during sleep.\n- Use bed blocks or a wedge (not stacked pillows) and avoid late meals for additive benefit.",
    165: "- CORRECT: B (Linaclotide).\n- Linaclotide is a GC-C agonist that increases cGMP, drives intestinal chloride/fluid secretion, and improves IBS-C symptoms.\n- It also helps visceral pain; diarrhea is the main dose-limiting adverse effect.",
    166: "- CORRECT: B (Biliary colic pattern).\n- Episodic steady RUQ/epigastric pain after fatty meals lasting about 1 to 4 hours is classic for transient cystic-duct obstruction.\n- Persistent pain beyond 4 to 6 hours, fever, or leukocytosis raises concern for acute cholecystitis.",
    167: "- CORRECT: B (LES displacement reduces diaphragmatic anti-reflux support).\n- Sliding hiatal hernia weakens the LES-crural diaphragm barrier and increases reflux burden.\n- Manage GERD first medically; consider surgery for refractory symptoms or large/complicated hernia.",
    168: "- CORRECT: B (Hold clopidogrel 5 to 7 days pre-procedure if safe).\n- Expected polypectomy elevates bleeding risk on P2Y12 inhibition, so temporary interruption is often needed.\n- Coordinate with cardiology in stented/high-thrombotic-risk patients; aspirin is usually continued.",
    169: "- CORRECT: A (After viral gastroenteritis).\n- Postinfectious villous-tip injury transiently reduces lactase activity, causing secondary lactose intolerance.\n- Symptoms usually resolve as mucosa heals; temporary lactose reduction is often sufficient.",
    170: "- CORRECT: D (COPD is not a classic extra-intestinal IBD manifestation).\n- Common IBD EIMs include uveitis, erythema nodosum, peripheral/axial arthritis, and PSC.\n- Some EIMs parallel gut activity, while others (e.g., axial disease, PSC) may run independently.",
    171: "- CORRECT: B (Functional dyspepsia).\n- Persistent dyspepsia after H. pylori treatment with normal EGD strongly supports a gut-brain interaction disorder.\n- Management is subtype-directed (acid suppression/prokinetic/neuromodulator/behavioral strategies).",
    172: "- CORRECT: C (Functional bloating/gas).\n- Distension that resolves overnight points to functional/fermentation physiology rather than fixed structural pathology.\n- This temporal pattern helps avoid unnecessary structural imaging when exam/labs are reassuring.",
    173: "- CORRECT: A (AST > ALT, often near 2:1).\n- Alcohol-associated injury is classically AST-predominant due to mitochondrial injury and relative ALT suppression.\n- Marked transaminases >1000 are atypical and should prompt alternative etiologies.",
    174: "- CORRECT: B (Lipoprotein[a]).\n- Lp(a) is largely genetically determined and is recommended once in life for inherited ASCVD risk refinement, especially with premature family history.\n- Elevated Lp(a) is a risk-enhancer even when LDL appears only modestly elevated.",
    175: "- CORRECT: C (Monitor and repeat TSH in 3 to 6 months).\n- Asymptomatic older adults with subclinical hypothyroidism and TSH below 10 are usually observed rather than immediately treated.\n- Reassess trajectory/symptoms and avoid overtreatment harms (AF, fracture risk).",
    176: "- CORRECT: B (Up-titrate allopurinol to urate target below 6 mg/dL).\n- Treat-to-target gout management requires active dose titration; 100 mg daily is usually a starting dose, not endpoint therapy.\n- Continue prophylaxis/monitoring during titration to reduce flare risk.",
    177: "- CORRECT: B (Consider a bisphosphonate drug holiday).\n- After 5 years oral bisphosphonate with stable BMD and no fractures, low-to-moderate risk patients may pause therapy with surveillance.\n- This differs from denosumab, which should not be stopped without transition planning.",
    178: "- CORRECT: C (Start ACE inhibitor with diet counseling and close lab follow-up).\n- Mild baseline hyperkalemia does not automatically preclude RAAS blockade when proteinuric CKD benefit is substantial.\n- Recheck potassium/creatinine within about 1 week and adjust with mitigation strategies if needed.",
    179: "- CORRECT: C (Grade D: do not initiate aspirin for primary prevention at age 60+).\n- In this age group, bleeding risk generally outweighs primary-prevention cardiovascular benefit.\n- Aspirin remains indicated for secondary prevention unless contraindicated.",
    180: "- CORRECT: C (Coagulopathy is a COEIN cause).\n- PALM are structural causes; COEIN are non-structural etiologies of abnormal uterine bleeding.\n- Consider inherited bleeding disorders (e.g., von Willebrand disease) when heavy bleeding patterns suggest coagulopathy.",
    181: "- CORRECT: C (No routine follow-up).\n- Fleischner 2017 recommends no surveillance for incidental solid nodules under 6 mm in low-risk patients due to very low malignancy probability.\n- Risk-stratify by smoking/cancer history and nodule features before ordering serial CTs.",
    182: "- CORRECT: C (Class 7 low-potency hydrocortisone).\n- Face, groin, and intertriginous skin absorb steroid more readily and are high-risk for atrophy and steroid adverse effects.\n- Use the lowest potency for the shortest duration and consider calcineurin inhibitors for chronic sensitive-site disease.",
    183: "- CORRECT: C (Respiratory fluoroquinolone or beta-lactam plus macrolide/doxycycline).\n- COPD plus recent macrolide exposure raises resistance risk, so azithromycin monotherapy is inadequate.\n- Follow ATS/IDSA comorbidity pathways and reassess severity/site-of-care with CURB-65 context.",
    184: "- CORRECT: B (Taper by about 25% every 1 to 2 weeks).\n- Long-term zolpidem should be deprescribed gradually to avoid rebound insomnia and withdrawal-related destabilization.\n- Pair taper with CBT-I and fall-risk mitigation, especially in older adults on Beers-list sedative-hypnotics.",
    185: "- CORRECT: C (SGLT2 inhibitors).\n- EMPEROR-Preserved and DELIVER established outcome benefit in HFpEF where prior classes had inconsistent hard-endpoint benefit.\n- Use regardless of diabetes status unless contraindicated, as part of modern guideline-based HF care.",
    186: "- CORRECT: B (Methylmalonic acid).\n- MMA is the most specific metabolic marker for tissue-level B12 deficiency when serum B12 is borderline.\n- Elevated homocysteine is supportive but less specific because it also rises in folate deficiency.",
    187: "- CORRECT: B (Range of motion).\n- Preserved joint ROM suggests olecranon bursitis (extra-articular), while septic arthritis causes severe pain with passive ROM.\n- If septic arthritis is suspected, perform urgent joint aspiration and start appropriate IV therapy promptly.",
    188: "- CORRECT: B (Yes, still vaccinate with Shingrix).\n- Prior shingles does not provide reliable lifelong protection against recurrence.\n- Adults 50+ should receive the 2-dose recombinant zoster series once acute illness has resolved.",
    189: "- CORRECT: B (Free PSA percentage).\n- In the PSA gray zone (about 4 to 10 ng/mL), lower free-to-total PSA ratios increase cancer likelihood and improve specificity over total PSA alone.\n- Use alongside shared decision-making, exam findings, and risk-stratification tools.",
    190: "- CORRECT: B (Propranolol or primidone).\n- These are first-line agents for essential tremor and reduce action tremor amplitude in many patients.\n- Select based on comorbidities and contraindications; escalate to procedural options for refractory functional impairment.",
    191: "- CORRECT: B (Telogen effluvium).\n- Diffuse shedding 2 to 4 months after childbirth with club hairs on pull test is classic postpartum telogen effluvium.\n- Reassure on self-limited course while screening for reversible contributors (thyroid, iron deficiency).",
    192: "- CORRECT: B (Vertigo, tinnitus, sensorineural hearing loss).\n- Episodic vertigo lasting 20 minutes to hours plus fluctuating auditory symptoms supports Meniere disease.\n- First-line management includes sodium restriction and symptom-directed vestibular/antiemetic therapy.",
    193: "- CORRECT: B (Retinal nerve fiber layer micro-infarctions).\n- Cotton-wool spots indicate ischemic retinal injury in diabetic retinopathy and signal more advanced microvascular disease.\n- Tight glycemic/BP control and ophthalmology follow-up reduce progression risk.",
    194: "- CORRECT: A (Ezetimibe).\n- For true statin intolerance, ezetimibe is first-line non-statin LDL-lowering therapy with established cardiovascular outcomes support.\n- Add PCSK9 inhibitor or bempedoic acid when additional LDL reduction is required by risk level.",
    195: "- CORRECT: B (Familial hypocalciuric hypercalcemia).\n- Mild hypercalcemia with non-suppressed PTH, very low urine calcium, and family history strongly favors FHH over primary hyperparathyroidism.\n- Confirm with calcium-clearance ratio/genetics when needed and avoid non-beneficial parathyroidectomy.",
    196: "- CORRECT: B (SCFE).\n- Frog-leg lateral hip views are crucial because early slips can be missed on AP films.\n- Suspected SCFE requires immediate non-weight-bearing and urgent orthopedic fixation to reduce AVN risk.",
    197: "- CORRECT: D (Associated nausea is NOT a core Rome IV criterion).\n- IBS diagnosis requires recurrent abdominal pain with relation to defecation and/or stool frequency/form changes.\n- Positive symptom-based diagnosis helps avoid unnecessary exclusionary testing when alarm features are absent.",
    198: "- CORRECT: D (All of the above).\n- Janeway lesions, Osler nodes, and Roth spots are classic peripheral findings of infective endocarditis, though not always present.\n- Diagnosis still hinges on blood cultures plus echocardiographic evidence within modified Duke framework.",
    199: "- CORRECT: B (Long-term oxygen therapy).\n- In severe resting hypoxemia (SpO2 88% or less), oxygen used at least 15 hours/day improves survival in COPD.\n- This benefit does not extend to moderate desaturation alone, so proper indication criteria matter.",
    200: "- CORRECT: B (Graduated stepwise return-to-play).\n- Concussion recovery requires symptom-free progression through staged exertion, minimum about 24 hours per stage.\n- Any recurrence mandates step-back to prior stage; normal CT does not clear immediate return to contact.",
    201: "- CORRECT: C (CT urogram plus cystoscopy).\n- In higher-risk microscopic hematuria (older smoker), both upper and lower tract evaluation are needed to exclude urothelial malignancy.\n- Do not assume benign etiology without risk-stratified urologic workup.",
    202: "- CORRECT: C (Continue iron 3 to 6 months after hemoglobin normalizes).\n- Hemoglobin correction precedes iron-store repletion; stopping early risks relapse.\n- Follow ferritin/transferrin markers and keep searching for the underlying blood-loss source.",
    203: "- CORRECT: B (St. John's Wort).\n- It is serotonergic and can precipitate serotonin toxicity when combined with SSRIs/SNRIs/triptans/tramadol.\n- It also induces CYP pathways and can reduce efficacy of many critical medications.",
    204: "- CORRECT: B (NSAIDs constrict afferent arteriole; ACE inhibitors dilate efferent arteriole).\n- This dual hemodynamic effect lowers intraglomerular pressure and can precipitate AKI, especially with volume depletion/diuretics.\n- Avoid the \"triple whammy\" and monitor renal function after medication changes.",
    205: "- CORRECT: B (L5 root).\n- Foot drop and inability to heel-walk localize strongly to L5 radiculopathy.\n- Evaluate urgently if progressive weakness or cauda equina red flags accompany lumbar radicular pain.",
    206: "- CORRECT: B (Haldane effect plus worsened V/Q mismatch).\n- Oxygen-induced hypercapnia in severe COPD is mostly from gas-exchange physiology, not just hypoxic-drive suppression.\n- Titrate oxygen to target saturation about 88 to 92% with close reassessment.",
    207: "- CORRECT: B (Volume overload/systolic heart failure).\n- In adults, an S3 gallop is a specific bedside clue to elevated filling pressures and dilated ventricle physiology.\n- Correlate with congestion findings and objective HF evaluation rather than auscultation alone.",
    208: "- CORRECT: B (Supraspinatus).\n- Supraspinatus initiates the first 15 degrees of abduction and stabilizes the humeral head for deltoid function.\n- Weak/painful initiation should prompt cuff-focused exam and imaging when clinically indicated.",
    209: "- CORRECT: B (Peripheral insulin resistance occurs first).\n- Compensatory hyperinsulinemia can maintain normoglycemia for years before overt diabetes appears.\n- Early detection of metabolic risk allows prevention before major beta-cell decline.",
    210: "- CORRECT: B (Parietal cells).\n- Parietal cells produce both intrinsic factor and gastric acid; IF is required for terminal ileal B12 absorption.\n- Autoimmune loss of this function causes pernicious anemia and chronic B12 deficiency risk.",
    211: "- CORRECT: B (Heme synthesis defect in iron deficiency).\n- Iron deficiency impairs iron incorporation into protoporphyrin, causing microcytic hypochromic anemia.\n- Differentiate from globin defects (thalassemia) and chronic inflammatory iron sequestration states.",
    212: "- CORRECT: B (Median nerve).\n- Thumb-index-middle sensory symptoms with pinky sparing are classic for carpal tunnel localization.\n- Nocturnal splinting is first-line; escalate for persistent weakness/thenar changes or severe electrodiagnostic disease.",
    213: "- CORRECT: B (Lymphocytic infiltration and fibrosis).\n- Hashimoto thyroiditis is primarily T-cell mediated autoimmune destruction, with anti-TPO as a key marker.\n- Monitor thyroid trajectory over time, since progression to overt hypothyroidism is common.",
    214: "- CORRECT: B (Reduced FEV1/FVC ratio).\n- Obstructive disease is defined by disproportionate expiratory flow limitation on spirometry.\n- Distinguish from restrictive patterns by confirming lung volumes when FVC is low with preserved ratio.",
    215: "- CORRECT: B (Increased stroke volume).\n- Frank-Starling physiology links higher preload to stronger contraction and greater stroke volume within physiologic range.\n- In advanced HF, this curve flattens, so preload loading yields congestion with limited output gain.",
    216: "- CORRECT: B (One-third distance from right ASIS to umbilicus).\n- McBurney point tenderness localizes appendiceal peritoneal irritation in classic appendicitis presentations.\n- Clinical scoring plus appropriate imaging should guide timely surgical referral.",
    217: "- CORRECT: C (Arterial stiffness/loss of compliance).\n- Age-related aortic stiffening raises systolic pressure and widens pulse pressure, producing isolated systolic hypertension.\n- Treatment should focus on reducing CV risk while avoiding excessive diastolic pressure drop.",
    218: "- CORRECT: A (Bone, kidney, gut).\n- PTH raises serum calcium through bone resorption, renal calcium retention/phosphaturia, and calcitriol-mediated intestinal absorption.\n- This tri-organ physiology explains lab patterns in primary versus secondary hyperparathyroid states.",
    219: "- CORRECT: C (Transient LES relaxations).\n- GERD is chiefly a sphincter-control/exposure disorder rather than simple acid overproduction.\n- PPIs reduce acidity but not all reflux events; persistent cases may need barrier-focused strategies.",
    220: "- CORRECT: A (Type I immediate hypersensitivity).\n- Peanut anaphylaxis is IgE-mediated mast-cell degranulation with rapid multisystem involvement.\n- Immediate intramuscular epinephrine is first-line, with airway/circulation support and post-event action planning.",
    221: "- CORRECT: A (Increased hydrostatic pressure plus low oncotic pressure).\n- Cirrhosis causes portal hypertension that pushes fluid out of splanchnic vessels, while low albumin reduces plasma fluid retention.\n- PCP action: confirm portal-hypertensive ascites with SAAG (>=1.1) and start sodium restriction plus spironolactone/furosemide.",
    222: "- CORRECT: B (CN VII facial nerve).\n- Bell palsy is a peripheral (LMN) facial palsy involving the entire hemiface, including forehead weakness (unlike most cortical stroke patterns).\n- Start corticosteroids within 72 hours and protect the cornea with lubricants/taping if eye closure is incomplete.",
    223: "- CORRECT: B (Competition for urate excretion in the renal tubule).\n- Thiazides and ketosis from rapid weight loss reduce uric acid clearance, acutely increasing serum urate and provoking crystal flare.\n- In recurrent gout, avoid trigger drugs when possible and use gradual weight-loss counseling rather than crash dieting.",
    224: "- CORRECT: B (Low renal perfusion/hypotension/hypovolemia).\n- Juxtaglomerular renin release is triggered by reduced afferent stretch, low distal sodium delivery, and beta-1 sympathetic signaling.\n- Resulting angiotensin II and aldosterone increase vasoconstriction and sodium/water retention to restore effective arterial volume.",
    225: "- CORRECT: B (Inflammation and mucus production).\n- Late-phase asthma (hours later) is driven by eosinophilic/type-2 airway inflammation, edema, and mucus hypersecretion, not just smooth-muscle spasm.\n- This is why controller inhaled corticosteroids are essential even when rescue bronchodilators improve early symptoms.",
    226: "- CORRECT: B (Anterior translation of the tibia relative to the femur).\n- The ACL is the primary restraint to anterior tibial translation and contributes major rotational stability during pivoting/cutting.\n- Positive Lachman and pivot instability after a \"pop\"/hemarthrosis should prompt ACL-focused imaging and sports-ortho planning.",
    227: "- CORRECT: B (Amylin).\n- Amylin is co-secreted with insulin by pancreatic beta cells and helps blunt postprandial glucose via slower gastric emptying and reduced glucagon.\n- In type 2 diabetes, islet amyloid from amylin misfolding is common and contributes to progressive beta-cell dysfunction.",
    228: "- CORRECT: B (Upregulation of hepatic LDL receptors).\n- Statin inhibition of HMG-CoA reductase lowers hepatocyte cholesterol, which upregulates LDL receptor expression and clears circulating LDL.\n- Clinical implication: LDL reduction depends on receptor function, so receptor-deficient familial hypercholesterolemia responds less.",
    229: "- CORRECT: B (Nasopharynx).\n- The Eustachian tube connects middle ear to nasopharynx for pressure equalization, drainage, and protection from refluxed secretions.\n- Pediatric tube anatomy (shorter, more horizontal) increases otitis media risk, especially with adenoidal obstruction.",
    230: "- CORRECT: B (Filling failure from stiffness/impaired relaxation).\n- HFpEF has preserved EF but elevated filling pressures from reduced LV compliance and delayed relaxation, causing congestion and exertional dyspnea.\n- Treat comorbid drivers (HTN, obesity, AF, CKD) and consider SGLT2 inhibitors for outcome benefit.",
    231: "- CORRECT: B (Narrowing of the hypothalamic thermoneutral zone).\n- Estrogen withdrawal destabilizes thermoregulation (KNDy/neurokinin pathways), so tiny core-temperature shifts trigger flushing and diaphoresis.\n- Menopausal symptom management can include hormone therapy when appropriate or nonhormonal options if estrogen is unsuitable.",
    232: "- CORRECT: B (Inflammation).\n- The four acne pillars are hyperkeratinization, sebum excess, C. acnes proliferation, and inflammation that drives papules/pustules/nodules.\n- Therapeutically, retinoids plus benzoyl peroxide target core pathogenesis and help prevent antibiotic resistance.",
    233: "- CORRECT: C (L1-L2).\n- The adult spinal cord ends at the conus near L1-L2; below this, descending nerve roots form the cauda equina.\n- Clinical relevance: lumbar puncture is done at L3-L4 or L4-L5 to reduce cord-injury risk.",
    234: "- CORRECT: B (Inferior wall MI; avoid nitroglycerin).\n- ST elevation in II, III, aVF localizes inferior MI, often RCA territory, with possible right-ventricular involvement.\n- Nitrates can precipitate severe hypotension in RV infarct due to preload dependence; obtain right-sided leads when suspected.",
    235: "- CORRECT: C (Immediate ER referral for admission/workup).\n- A TIA with ABCD2 score 5 is high early-stroke risk and should not be managed as routine outpatient follow-up.\n- Urgent inpatient imaging/rhythm-vascular evaluation enables rapid secondary prevention (e.g., antiplatelets, carotid intervention when indicated).",
    236: "- CORRECT: B (0.3-0.5 mg of 1 mg/mL [1:1,000] IM).\n- Adult anaphylaxis treatment is immediate intramuscular epinephrine in the anterolateral thigh, repeatable every 5-15 minutes as needed.\n- Avoid IV push dosing meant for cardiac arrest unless in monitored refractory shock protocols.",
    237: "- CORRECT: B (Anterior uveitis/iritis).\n- Ciliary flush, small irregular pupil, and consensual photophobia strongly indicate anterior uveal inflammation rather than simple conjunctivitis.\n- This is vision-threatening: urgent ophthalmology care, topical steroids, and cycloplegic therapy are standard.",
    238: "- CORRECT: B (Acute limb ischemia).\n- Sudden painful pale cold pulseless limb with poor capillary refill is an arterial occlusion emergency (classic ischemic \"6 Ps\").\n- Give immediate systemic heparin and obtain urgent vascular revascularization assessment to prevent limb loss.",
    239: "- CORRECT: C (Immediate transfer to OR; no imaging delay).\n- Unstable hypotension with severe back pain and pulsatile abdominal mass is presumed ruptured AAA until proven otherwise.\n- In hemodynamic instability, definitive operative control takes priority over CT because delay markedly increases mortality.",
    240: "- CORRECT: B (Risk of cavernous sinus thrombosis).\n- Infections from the facial danger triangle can spread retrograde via valveless venous channels to the cavernous sinus.\n- Fever/headache with progressive facial-orbital symptoms after lesion manipulation warrants emergent evaluation and IV broad-spectrum therapy.",
    241: "- CORRECT: C (Lumbar puncture).\n- Thunderclap headache is subarachnoid hemorrhage until proven otherwise, and a negative CT does not fully exclude SAH (especially later presentations).\n- Next mandatory step is LP for xanthochromia/non-clearing RBCs, then aneurysm-directed management if confirmed.",
    242: "- CORRECT: B (Thumb spica splint plus repeat imaging).\n- FOOSH plus anatomic snuffbox tenderness is treated as scaphoid fracture despite negative initial X-ray because early films can miss nondisplaced injury.\n- Immobilize immediately to reduce nonunion/AVN risk and repeat X-ray (or obtain early MRI) in about 10-14 days.",
    243: "- CORRECT: B (Foreign body aspiration).\n- A witnessed choking episode with persistent respiratory symptoms can represent airway foreign body even with a normal chest X-ray.\n- High clinical suspicion warrants urgent bronchoscopy (usually rigid in children) for diagnosis and removal.",
    244: "- CORRECT: B (SBP <100 and RR >22, with altered mentation).\n- qSOFA components are altered mental status, systolic BP <=100 mmHg, and respiratory rate >=22/min.\n- Score >=2 in suspected infection signals high risk and should trigger urgent sepsis evaluation and treatment escalation.",
    245: "- CORRECT: B (Cyanide poisoning; hydroxocobalamin).\n- Smoke inhalation with severe lactic/anion-gap acidosis suggests cellular hypoxia from cyanide inhibition of mitochondrial oxidative phosphorylation.\n- Give hydroxocobalamin promptly (plus high-flow oxygen), and treat possible concurrent carbon monoxide exposure.",
    246: "- CORRECT: B (IV hydrocortisone, stress dose).\n- Addisonian crisis causes hypotension refractory to fluids/pressors because cortisol is required for vascular catecholamine responsiveness.\n- Treat immediately with IV hydrocortisone and isotonic fluids; do not delay for confirmatory labs.",
    247: "- CORRECT: C (Immediate IV antibiotics plus dexamethasone).\n- In suspected bacterial meningitis, treatment delay increases mortality, so empiric therapy comes before CT/LP when diagnostics are delayed.\n- Obtain blood cultures if possible first, but never postpone early antimicrobials for imaging logistics.",
    248: "- CORRECT: B (Compartment syndrome).\n- Pain out of proportion, pain with passive stretch, and a tense \"woody\" compartment after fracture are classic early findings.\n- This is limb-threatening: emergent fasciotomy is definitive, and waiting for pulse loss is a dangerous late mistake.",
    249: "- CORRECT: A (Hyperkalemia; calcium gluconate first).\n- Peaked T waves with QRS widening indicate electrically unstable hyperkalemia with risk of malignant arrhythmia.\n- First step is IV calcium to stabilize myocardium, then shift potassium intracellularly and remove total body potassium.",
    250: "- CORRECT: B (Peritonsillar abscess).\n- Hot-potato voice, trismus, unilateral peritonsillar swelling, and contralateral uvular deviation are classic PTA findings.\n- Priorities are airway assessment, drainage, and antibiotics covering streptococci plus oral anaerobes.",
    251: "- CORRECT: B (Elevate presenting part and emergency C-section).\n- Cord prolapse threatens acute fetal hypoxia from cord compression and requires immediate decompression while preparing definitive delivery.\n- Keep a hand elevating the presenting part, position mother to reduce compression, and proceed emergently to operative delivery.",
    252: "- CORRECT: B (Neuroleptic malignant syndrome).\n- Fever, severe rigidity, altered mental status, autonomic instability, and very high CK after dopamine-blocking drugs strongly indicate NMS.\n- Stop antipsychotic immediately, give aggressive supportive care/IV fluids, and use ICU-level monitoring with specific therapy as needed.",
    253: "- CORRECT: C (Risk of cavernosal fibrosis and permanent impotence).\n- Ischemic priapism is a compartment-like low-flow state; prolonged hypoxia damages corporal smooth muscle.\n- Erections >4 hours require urgent urologic treatment (aspiration plus intracavernosal phenylephrine).",
    254: "- CORRECT: B (Nursemaid elbow; reduction).\n- Toddlers with traction injury who hold the arm pronated/flexed without swelling or deformity most likely have radial head subluxation.\n- Perform bedside reduction (supination-flexion or hyperpronation); imaging is usually unnecessary in classic presentation.",
    255: "- CORRECT: A (Hypertension, bradycardia, irregular respirations).\n- Cushing triad is a late sign of critically elevated ICP and impending herniation, not an early benign finding.\n- Start ICP temporizing measures and obtain emergent neurosurgical management immediately.",
    256: "- CORRECT: B (Within 60 minutes).\n- Avulsed permanent tooth survival depends on periodontal ligament cell viability, which declines quickly with dry time.\n- Reimplant promptly or store in appropriate medium (best practical option: cold milk) and arrange urgent dental follow-up.",
    257: "- CORRECT: C (>50,000 WBC/mm3).\n- Synovial WBC >50,000 with neutrophil predominance strongly suggests septic arthritis, though crystals can coexist and do not exclude infection.\n- Treat as emergency: culture/Gram stain, start empiric antibiotics, and obtain urgent joint drainage.",
    258: "- CORRECT: B (Full-thickness esophageal rupture).\n- Boerhaave syndrome is transmural perforation after forceful emesis, unlike Mallory-Weiss which is mucosal tear only.\n- Rapid recognition and urgent surgical/critical care management are essential because delay markedly increases mortality.",
    259: "- CORRECT: B (HIT).\n- A platelet fall >50% with new thrombosis after heparin exposure is classic for immune-mediated heparin-induced thrombocytopenia.\n- Stop all heparin immediately and start a non-heparin anticoagulant while confirmatory testing is pursued.",
    260: "- CORRECT: B (Osborn/J wave).\n- Hypothermia classically produces J-point (Osborn) waves, often with bradycardia and interval prolongation as temperature falls.\n- Management focuses on core rewarming and careful arrhythmia-aware resuscitation in unstable severe hypothermia.",
    261: "- CORRECT: B (Hypothermia, bradycardia, altered mental status).\n- Myxedema coma is severe decompensated hypothyroidism with high mortality and global hypometabolism.\n- Give IV hydrocortisone before/with IV levothyroxine and provide ICU-level supportive care while treating triggers.",
    262: "- CORRECT: B (Place the bleeding lung down).\n- In massive hemoptysis, death risk is often asphyxiation from blood flooding the non-bleeding lung.\n- Lateral decubitus with bleeding side dependent is a temporizing airway-protection maneuver while definitive control is arranged.",
    263: "- CORRECT: A (Pain out of proportion and crepitus).\n- Necrotizing fasciitis should be suspected when severe deep pain and systemic toxicity exceed superficial skin findings.\n- Do not delay for extensive workup: start broad IV antibiotics and obtain emergent surgical debridement.",
    264: "- CORRECT: B (Non-starchy vegetables).\n- These have the lowest caloric density, so patients can eat high volume with fewer calories and better satiety.\n- This supports weight-loss counseling focused on food volume quality rather than strict portion deprivation alone.",
    265: "- CORRECT: C (SBP drops about 5-7 mmHg for up to 22 hours).\n- A single aerobic session can produce post-exercise hypotension, especially in people with hypertension.\n- Reinforce that each workout has an immediate BP benefit in addition to long-term training effects.",
    266: "- CORRECT: B (Fragments REM and causes rebound wakefulness later).\n- Alcohol may shorten sleep latency but degrades second-half sleep quality and increases awakenings.\n- Counsel patients that alcohol is a poor chronic sleep strategy and can worsen sleep apnea risk.",
    267: "- CORRECT: C (Whole fruit is linked to better glycemic outcomes/risk reduction).\n- Fiber-rich intact fruit slows sugar absorption versus juice or refined sugar sources.\n- In type 2 diabetes, emphasize whole-fruit patterns rather than blanket fruit restriction.",
    268: "- CORRECT: C (Preparation stage).\n- The patient intends to act soon and is already taking practical steps (researching cessation classes).\n- Best PCP move is to set a quit date, build a concrete plan, and offer evidence-based pharmacotherapy support.",
    269: "- CORRECT: C (Varied plant intake over a day provides all essential amino acids).\n- Protein combining at every single meal is unnecessary when overall intake and diversity are adequate.\n- Reassure patients and guide toward balanced legumes, grains, nuts/seeds, and soy foods.",
    270: "- CORRECT: B (Visceral fat deposition and hippocampal atrophy).\n- Chronic cortisol excess drives central adiposity, insulin resistance, and neurocognitive stress effects over time.\n- Stress/sleep/movement interventions are cardiometabolic and brain-health treatment, not optional add-ons.",
    271: "- CORRECT: C (Butyrate).\n- Colonocytes primarily use butyrate generated by microbiome fermentation of dietary fiber.\n- Low-fiber intake reduces butyrate production and may weaken barrier function and anti-inflammatory signaling.",
    272: "- CORRECT: B (Energy use while sitting quietly at rest).\n- One MET is the resting metabolic equivalent used to scale physical-activity intensity and fitness capacity.\n- This helps translate exercise prescriptions into practical moderate and vigorous activity targets.",
    273: "- CORRECT: B (Heme iron is less tightly regulated; overload risk is higher).\n- Non-heme iron absorption is more physiologically regulated by body iron status and hepcidin signaling.\n- Counseling can favor plant-forward iron sources in patients with oxidative/cardiometabolic risk concerns.",
    274: "- CORRECT: A (Sodium bicarbonate or more fruits/vegetables).\n- In CKD, chronic dietary acid load can worsen metabolic acidosis and accelerate nephron injury.\n- Goal-directed alkali therapy and base-producing dietary patterns help preserve kidney function trajectory.",
    275: "- CORRECT: B (Deep slow-wave sleep).\n- Glymphatic clearance of beta-amyloid and other waste is most active during restorative deep sleep.\n- Sleep protection is a core long-term brain-health intervention, not just a fatigue-management issue.",
    276: "- CORRECT: A (Specific, Measurable, Achievable, Relevant, Time-bound).\n- SMART framing converts vague goals into behavior plans that can be tracked and adjusted.\n- Use shared, time-limited targets in follow-up to improve adherence and clinical outcomes.",
    277: "- CORRECT: B (Leptin).\n- Leptin from adipose tissue signals satiety pathways in the hypothalamus and helps regulate energy balance.\n- In common obesity, leptin resistance often blunts this signal, which helps explain persistent hunger despite high stores.",
    278: "- CORRECT: C (High-impact/weight-bearing loading).\n- Osteogenic response depends on mechanical loading magnitude and rate; low-impact activities are less effective for BMD.\n- Pair impact/resistance training with fall-prevention work and fracture-risk-tailored modifications.",
    279: "- CORRECT: B (Broccoli sprouts/cruciferous vegetables).\n- Sulforaphane from glucoraphanin activates Nrf2-driven antioxidant and detox gene programs.\n- Practical counseling: preserve myrosinase activity (e.g., light cooking) to improve bioactive yield.",
    280: "- CORRECT: B (Obstructive sleep apnea).\n- STOP-BANG is a validated OSA risk screen; scores >=3 generally indicate elevated pretest probability.\n- High-risk patients need formal sleep evaluation because untreated OSA worsens cardiometabolic and arrhythmic risk.",
    281: "- CORRECT: C (Fasting/caloric restriction and exercise).\n- Autophagy is upregulated when nutrient signaling (mTOR) is reduced and energy-stress signaling (AMPK) is increased.\n- This supports counseling that movement and periodic energy deficit promote cellular repair pathways beyond weight change alone.",
    282: "- CORRECT: C (Insufficient evidence for cessation recommendation; use FDA-approved aids).\n- Major guidelines do not endorse e-cigarettes as first-line quit therapy due to uncertain long-term safety and variable nicotine exposure.\n- Prefer evidence-based cessation treatment: behavioral support plus NRT, varenicline, or bupropion.",
    283: "- CORRECT: B (Comparable to smoking about 15 cigarettes/day).\n- Social isolation is an independent mortality risk factor with significant cardiometabolic, neuropsychiatric, and inflammatory burden.\n- PCP action: screen for loneliness/isolation and include social-connection interventions in routine care plans.",
    284: "- CORRECT: B (Fructose).\n- High fructose loads are metabolized largely in the liver and preferentially drive de novo lipogenesis and triglyceride production.\n- Counseling priority is reducing sugar-sweetened beverages and ultra-processed added-sugar sources.",
    285: "- CORRECT: B (Potassium).\n- DASH lowers blood pressure partly through higher potassium intake, alongside lower sodium and improved whole-diet quality.\n- Reinforce potassium-rich foods when safe, with CKD/RAAS-medication context considered during counseling.",
    286: "- CORRECT: C (Sedentary behavior and processed meats).\n- Chronic oxidative/inflammatory exposures are associated with shorter telomeres and accelerated biologic aging signatures.\n- Lifestyle prescriptions that improve activity and dietary quality are reasonable long-horizon healthy-aging strategies.",
    287: "- CORRECT: B (Omega-3 fatty acids, EPA-predominant).\n- Adjunctive EPA has evidence for depressive symptom improvement, likely via anti-inflammatory and neurobiologic mechanisms.\n- Screen for severity/suicidality and use as adjunct, not replacement, for guideline-based depression care.",
    288: "- CORRECT: B (Lutein and zeaxanthin).\n- These carotenoids concentrate in the macula, filtering blue light and supporting antioxidant retinal protection.\n- In appropriate AMD patients, follow AREDS2-style evidence and avoid beta-carotene in smokers/former smokers.",
    289: "- CORRECT: B (A cardiovascular \"canary in the coal mine\").\n- New erectile dysfunction often reflects systemic endothelial dysfunction and can precede overt coronary disease.\n- Use ED as an opportunity for aggressive CV risk assessment and prevention optimization.",
    290: "- CORRECT: B (Folate/Vitamin B9).\n- Neural tube closure occurs very early, so preventive folate must be present before many pregnancies are recognized.\n- Recommend preconception supplementation for patients who could become pregnant, with higher doses in prior NTD history.",
    291: "- CORRECT: B (Group 1 carcinogenic to humans).\n- WHO/IARC classifies processed meat as carcinogenic, with strongest evidence for colorectal cancer risk.\n- Clinical counseling should focus on substitution patterns rather than perfection-based messaging.",
    292: "- CORRECT: A (Binding bile acids in the gut).\n- Soluble fiber increases bile acid excretion, driving hepatic cholesterol use and LDL receptor upregulation.\n- Practical options include oats, legumes, and psyllium as additive LDL-lowering nutrition therapy.",
    293: "- CORRECT: B (Melatonin).\n- Evening blue-light exposure suppresses melatonin signaling and can delay circadian sleep timing.\n- Sleep counseling should include screen/light hygiene, especially in delayed sleep phase or insomnia-prone patients.",
    294: "- CORRECT: B (MBSR, yoga, or tai chi).\n- ACP recommends non-pharmacologic first-line care for chronic low back pain before routine medication escalation.\n- Use multimodal plans (activity, mind-body, function goals) and reserve imaging for red-flag scenarios.",
    295: "- CORRECT: B (Peppermint oil).\n- Enteric-coated peppermint oil can reduce IBS pain/bloating via smooth-muscle calcium-channel effects and antispasmodic action.\n- Main caution is reflux symptoms; use enteric formulations and monitor tolerance.",
    296: "- CORRECT: B (Magnesium and riboflavin/B2).\n- These supplements have evidence-supported roles in migraine prevention and are useful for patients preferring non-drug adjuncts.\n- Combine with trigger management and standard prophylaxis decisions based on headache burden/disability.",
    297: "- CORRECT: B (Pregnancy-induced nausea).\n- Ginger has supportive evidence and guideline acceptance for nausea/vomiting of pregnancy at typical dosing ranges.\n- Use within obstetric care plans and escalate to pharmacologic regimens when symptoms are persistent or severe.",
    298: "- CORRECT: B (Bipolar disorder).\n- SAMe can enhance monoaminergic signaling and may precipitate mania/hypomania in susceptible patients.\n- Screen for bipolar history before recommending over-the-counter mood supplements.",
    299: "- CORRECT: B (Statin-associated muscle symptoms).\n- CoQ10 is often used for SAMS based on biologic plausibility, though trial results are mixed.\n- In symptomatic patients, combine shared decision-making with statin rechallenge/alternative dosing or non-statin options as needed.",
    300: "- CORRECT: B (Circadian rhythm disorders and sleep-onset issues).\n- Melatonin works best as a chronobiotic (timing signal), not as a broad sedative for all insomnia phenotypes.\n- Clinical effectiveness depends heavily on timing relative to desired sleep schedule.",
    301: "- CORRECT: B (Black pepper/piperine and fat).\n- Curcumin has poor oral bioavailability; piperine reduces rapid metabolism and fat improves absorption of this lipophilic compound.\n- If patients use turmeric supplements, counsel on interaction potential and realistic symptom expectations.",
    302: "- CORRECT: B (Kava kava).\n- Kava has anxiolytic evidence in some studies but carries clinically relevant hepatotoxicity risk.\n- For GAD, prioritize safer first-line care (CBT/SSRIs/SNRIs) and avoid unsupervised kava use.",
    303: "- CORRECT: B (Antibiotic-associated diarrhea and C. difficile recurrence).\n- Saccharomyces boulardii has strongest probiotic evidence in this setting and is resistant to antibacterial antibiotics.\n- Avoid in severely immunocompromised patients or central-line patients due to rare fungemia risk.",
    304: "- CORRECT: A (Tension headache and migraine).\n- Biofeedback has evidence for reducing headache frequency/severity through autonomic and muscle-tension regulation.\n- It is a useful non-drug adjunct, especially when medication side effects or overuse are concerns.",
    305: "- CORRECT: B (Vitamin K2).\n- K2 activates calcium-handling proteins (e.g., osteocalcin, matrix Gla protein) that support bone mineralization and limit ectopic calcification.\n- Check anticoagulant context: vitamin K supplements can interfere with warfarin management.",
    306: "- CORRECT: B (Magnesium).\n- Magnesium supports insulin signaling and is frequently low in diabetes due to renal losses and poor intake.\n- In selected patients, repletion can modestly improve metabolic control and symptom burden (e.g., cramps).",
    307: "- CORRECT: A (NVP support and late-term labor induction contexts).\n- Evidence is strongest for nausea/vomiting of pregnancy (especially P6-based approaches), with more limited data for induction effects.\n- Use only trained practitioners and integrate with standard obstetric guideline care.",
    308: "- CORRECT: B (Lovastatin).\n- Monacolin K in red yeast rice is chemically equivalent to lovastatin and carries similar myopathy/hepatotoxicity interaction risks.\n- Product potency/contamination is variable, so \"natural\" does not mean safer or standardized.",
    309: "- CORRECT: B (Rare liver toxicity reported; monitor).\n- Black cohosh efficacy for hot flashes is mixed, and rare but serious hepatotoxicity cases have been described.\n- If used, limit duration, monitor liver symptoms/labs, and prefer proven alternatives when needed.",
    310: "- CORRECT: B (Guided slow paced breathing under 10 breaths/min).\n- Device-guided breathing lowers sympathetic tone and can modestly reduce blood pressure.\n- It is an adjunctive strategy, not a replacement for guideline lifestyle/pharmacologic therapy.",
    311: "- CORRECT: B (Fibromyalgia symptom management).\n- Randomized trial evidence supports tai chi as similar or better than aerobic exercise for multidomain fibromyalgia outcomes.\n- Recommend as a sustainable low-impact option when conventional exercise is poorly tolerated.",
    312: "- CORRECT: B (No better than placebo for flow/nocturia).\n- Large trials and Cochrane data do not show meaningful BPH benefit from saw palmetto.\n- Counsel toward evidence-based LUTS therapies (alpha-blocker, 5-ARI, or combination when indicated).",
    313: "- CORRECT: B (Inhibits rhinovirus replication/attachment in nasal mucosa).\n- Zinc lozenges can shorten cold duration when started early (within about 24 hours).\n- Avoid intranasal zinc due to anosmia risk; use short-term oral lozenges only.",
    314: "- CORRECT: B (INR decreases; clot risk rises).\n- Vitamin K-rich green powders can antagonize warfarin and reduce anticoagulation effect.\n- Keep vitamin K intake consistent and recheck INR soon after supplement/diet changes.",
    315: "- CORRECT: B (Falsely low TSH with falsely high T4).\n- High-dose biotin interferes with biotin-streptavidin immunoassays, mimicking hyperthyroidism.\n- Hold biotin before testing and suspect assay interference when labs mismatch clinical picture.",
    316: "- CORRECT: B (IgG sensitivities/intolerances).\n- For delayed food-trigger symptoms, elimination-rechallenge is the practical diagnostic standard; commercial IgG panels are not reliable.\n- Distinguish this clearly from IgE allergy, which needs formal allergy-directed testing.",
    317: "- CORRECT: B (Drug-resistant epilepsy in children).\n- Ketogenic therapy is evidence-based for refractory pediatric epilepsy and specific metabolic epilepsies.\n- It requires specialist supervision due to nutritional and metabolic adverse-effect risks.",
    318: "- CORRECT: B (Moderate-to-severe pain subset benefit).\n- GAIT found limited overall effect, with possible signal in a subgroup with more severe knee OA pain.\n- If trialed, set stop rules and continue core OA care (exercise, weight, analgesic strategy).",
    319: "- CORRECT: A (CYP3A4 inducer).\n- St. John's Wort lowers levels of many critical medications via enzyme/transporter induction.\n- Always screen supplement use because interactions can cause contraceptive failure, thrombosis, rejection, or virologic failure.",
    320: "- CORRECT: B (Modulating HPA-axis and cortisol stress response).\n- Adaptogens are theorized to improve stress resilience through neuroendocrine regulation, but evidence quality is variable.\n- Use as adjunctive options only, alongside proven stress/sleep/exercise/psychotherapy strategies.",
    321: "- CORRECT: B (Small but statistically significant).\n- Omega-3s in ADHD show modest benefit, well below stimulant effect sizes, but signal is reproducible in pooled trials.\n- Best use is adjunctive care, especially with EPA-forward formulations and family preference for low-risk add-ons.",
    322: "- CORRECT: B (Avoid high-dose antioxidants during active radiation).\n- Radiation and some chemotherapy rely on oxidative damage; large antioxidant doses may blunt antitumor effect.\n- Coordinate all supplements with oncology, while maintaining normal whole-food nutrition unless otherwise directed.",
    323: "- CORRECT: B (A real physiologic response, ethically harnessed).\n- Placebo effects involve measurable neurobiology (expectation, endogenous analgesic pathways), not patient fabrication.\n- Clinicians should optimize therapeutic context (empathy, framing, alliance) without deception.",
    324: "- CORRECT: B (Hepcidin).\n- Hepcidin is the master iron regulator; when elevated, it suppresses ferroportin and blocks gut iron export/absorption.\n- This mechanism explains iron sequestration patterns in inflammation-related anemia.",
    325: "- CORRECT: B (Thalassemia trait).\n- In microcytosis, Mentzer index <13 favors thalassemia trait, while >13 more often supports iron deficiency.\n- Confirm with iron studies and hemoglobin electrophoresis before empiric long-term iron therapy.",
    326: "- CORRECT: C (Bone marrow production failure).\n- Very low reticulocytes in anemia indicate inadequate marrow response rather than peripheral destruction/loss.\n- Next steps should evaluate hypoproliferative causes (nutritional deficiency, marrow disease, CKD/inflammation).",
    327: "- CORRECT: B (Platelet adhesion plus Factor VIII carriage).\n- vWF bridges platelets to injured endothelium and stabilizes circulating Factor VIII.\n- Deficiency causes mucocutaneous bleeding and may prolong aPTT via secondary low Factor VIII activity.",
    328: "- CORRECT: A (Recent viral illness, typically 1-3 weeks prior).\n- Pediatric ITP often follows viral infection and presents as isolated thrombocytopenia in an otherwise well child.\n- If bleeding is mild, observation is usually appropriate because spontaneous recovery is common.",
    329: "- CORRECT: B (Chronic lymphocytic leukemia).\n- Marked lymphocytosis with smudge cells in an older adult is classic for CLL.\n- Confirm with flow cytometry and stage clinically; many asymptomatic patients start with watchful waiting.",
    330: "- CORRECT: D (Joint swelling is NOT in the TTP pentad).\n- TTP classically involves thrombocytopenia, MAHA, neurologic findings, renal injury, and fever.\n- Do not wait for full pentad: thrombocytopenia plus schistocyte hemolysis should trigger urgent plasma exchange pathway.",
    331: "- CORRECT: B (Increases fetal hemoglobin, HbF).\n- Hydroxyurea reduces sickling by increasing HbF and also lowers vaso-occlusive inflammatory burden.\n- It is core disease-modifying therapy in severe sickle cell disease with strong outcome benefit.",
    332: "- CORRECT: B (Unregulated intestinal iron absorption).\n- HFE-related hemochromatosis lowers effective hepcidin signaling, allowing excess ferroportin-mediated iron entry.\n- Screen with transferrin saturation/ferritin and treat confirmed overload with therapeutic phlebotomy.",
    333: "- CORRECT: A (Factor V resistant to Protein C inactivation).\n- Factor V Leiden causes APC resistance, prolonging procoagulant activity and increasing venous thrombosis risk.\n- Risk is magnified by estrogen exposure, immobility, surgery, and pregnancy.",
    334: "- CORRECT: A (Fava beans).\n- In G6PD deficiency, oxidant stressors can trigger acute hemolysis because RBC antioxidant defense is impaired.\n- Counsel lifelong trigger avoidance, including specific drugs and infection-related risk awareness.",
    335: "- CORRECT: B (Neurologic symptoms).\n- B12 and folate both cause megaloblastic anemia, but neurologic deficits point to B12 deficiency.\n- Never treat unexplained macrocytosis with folate alone until B12 deficiency is excluded.",
    336: "- CORRECT: B (Acute hemolytic transfusion reaction).\n- Fever, flank pain, and dark urine minutes after transfusion strongly suggest ABO-incompatible intravascular hemolysis.\n- Stop transfusion immediately, support hemodynamics/renal perfusion, and activate blood-bank emergency protocol.",
    337: "- CORRECT: A (Lytic bone lesions).\n- In myeloma CRAB criteria, the B refers to osteolytic bone disease from osteoclast activation and osteoblast suppression.\n- Evaluate fracture risk and start bone-protective management when indicated.",
    338: "- CORRECT: B (Observation if no severe bleeding).\n- Classic childhood ITP with isolated thrombocytopenia and mild skin findings is often managed conservatively.\n- Reserve IVIG/steroids for clinically significant bleeding or high-risk situations.",
    339: "- CORRECT: B (Encapsulated bacteria).\n- Asplenic patients are at lifelong risk of fulminant sepsis from S. pneumoniae, H. influenzae, and N. meningitidis.\n- Prevention requires vaccination strategy, urgent fever action plans, and appropriate prophylaxis counseling.",
    340: "- CORRECT: B (JAK2 mutation).\n- About 95% of polycythemia vera cases harbor JAK2 driver mutations causing EPO-independent erythrocytosis.\n- Management prioritizes thrombosis prevention (hematocrit control, aspirin, and cytoreduction when risk is high).",
    341: "- CORRECT: A (CML).\n- The Philadelphia chromosome t(9;22) creates BCR-ABL, a constitutively active tyrosine kinase that defines classic CML.\n- Confirm molecularly and monitor transcript response during TKI-based therapy.",
    342: "- CORRECT: A (Protein C deficiency).\n- Warfarin can transiently lower protein C faster than procoagulant factors, creating early hypercoagulable risk.\n- Prevent with heparin bridging and avoid high loading strategies when initiating vitamin K antagonists.",
    343: "- CORRECT: B (Hodgkin lymphoma).\n- Reed-Sternberg \"owl-eye\" cells are the diagnostic hallmark of Hodgkin lymphoma.\n- Typical spread is contiguous nodal progression, and modern therapy is highly curative in many patients.",
    344: "- CORRECT: B (Extrinsic pathway).\n- PT/INR primarily reflects Factor VII activity plus common-pathway factors.\n- This is why PT/INR is the key laboratory used for warfarin monitoring.",
    345: "- CORRECT: B (Lead poisoning).\n- Basophilic stippling reflects impaired RNA degradation in erythrocytes and is classically associated with lead toxicity.\n- Confirm with lead-focused labs/history and address environmental exposure source promptly.",
    346: "- CORRECT: B (Hypocellularity with fatty marrow).\n- Aplastic anemia is marrow failure with pancytopenia due to reduced hematopoietic stem-cell activity.\n- Biopsy showing markedly hypocellular marrow helps distinguish it from leukemic or infiltrative hypercellular processes.",
    347: "- CORRECT: A (D-dimer).\n- With low Wells pretest probability, a negative high-sensitivity D-dimer can safely exclude DVT without immediate ultrasound.\n- Positive results require confirmatory imaging because specificity is limited.",
    348: "- CORRECT: D (Temperature is not a 4Ts component).\n- HIT 4Ts are thrombocytopenia degree, timing, thrombosis, and other causes.\n- Low scores effectively rule out HIT; intermediate/high scores need immediate heparin cessation pathway and confirmatory testing.",
    349: "- CORRECT: A (HyperK, hyperphos, hyperuricemia, hypocalcemia).\n- Tumor lysis syndrome releases intracellular ions and nucleic acids, causing characteristic life-threatening metabolic derangements.\n- Start aggressive prophylaxis/management early in high-risk malignancy treatment settings.",
    350: "- CORRECT: B (RBC membrane proteins like spectrin/ankyrin).\n- Hereditary spherocytosis is a membrane-skeleton defect causing less deformable spherocytes and splenic hemolysis.\n- Typical clues include elevated MCHC, spherocytes, and hemolytic findings.",
    351: "- CORRECT: C (X-linked recessive).\n- Hemophilia A (Factor VIII deficiency) classically affects males, with female carriers usually asymptomatic.\n- Severity tracks with residual factor level and bleeding phenotype, especially hemarthroses.",
    352: "- CORRECT: B (Folate deficiency plus direct marrow toxicity).\n- Alcohol-related macrocytosis commonly reflects both nutritional deficiency and direct suppressive effects on erythropoiesis.\n- Workup should not stop at folate alone; assess broader marrow/liver and deficiency contributors.",
    353: "- CORRECT: B (Immediate IV broad-spectrum antibiotics).\n- Febrile neutropenia is an oncologic emergency; empiric anti-pseudomonal coverage should begin rapidly.\n- Do not delay treatment for prolonged diagnostics when ANC is critically low with fever.",
    354: "- CORRECT: C (Immediate, non-specific response).\n- Innate immunity responds within minutes-hours via pattern recognition, unlike slower antigen-specific adaptive memory responses.\n- This distinction guides early infection physiology and clinical biomarker expectations.",
    355: "- CORRECT: B (Immune-complex deposition).\n- SLE is a type III hypersensitivity process with antigen-antibody complexes activating complement in tissues.\n- Low complement and organ-specific inflammatory injury patterns fit this mechanism.",
    356: "- CORRECT: B (IgM).\n- IgM is the first isotype in primary acute response before class-switching to higher-affinity IgG/other classes.\n- Clinically, IgM often suggests recent infection when interpreted in context.",
    357: "- CORRECT: B (Pannus formation).\n- RA synovitis forms invasive pannus that erodes cartilage and bone, driving irreversible joint damage.\n- Early treat-to-target DMARD strategy is critical to prevent structural progression.",
    358: "- CORRECT: C (TSH receptor).\n- Graves disease features stimulatory antibodies to TSH receptors, producing autonomous thyroid hormone excess.\n- This receptor-level autoimmune activation explains hyperthyroidism and extra-thyroid manifestations.",
    359: "- CORRECT: B (Humoral immunity and allergy/parasite response).\n- Th2 signaling promotes B-cell antibody responses (especially IgE) and eosinophilic anti-helminth pathways.\n- Th1/Th2 balance helps frame atopy patterns and immune phenotype discussions.",
    360: "- CORRECT: B (CNS myelin/oligodendrocytes).\n- Multiple sclerosis is autoimmune demyelination of central nervous system pathways.\n- This differentiates MS from peripheral demyelinating disorders that involve Schwann-cell pathology.",
    361: "- CORRECT: C (Small-intestinal villi).\n- In celiac disease, tTG-modified gliadin drives immune-mediated villous injury with malabsorption.\n- Diagnosis requires gluten exposure during testing; treatment is strict lifelong gluten avoidance.",
    362: "- CORRECT: A (Dry eyes and dry mouth).\n- Sjogren syndrome targets exocrine glands, causing keratoconjunctivitis sicca and xerostomia.\n- Screen for associated autoimmune disease and monitor for systemic complications (including lymphoma risk).",
    363: "- CORRECT: B (They replicate and mimic natural infection).\n- Live attenuated vaccines stimulate broader and longer-lasting immune memory than inactivated products.\n- They are generally contraindicated in significant immunosuppression and pregnancy contexts.",
    364: "- CORRECT: B (Anti-GAD65).\n- Type 1 diabetes is autoimmune beta-cell destruction; anti-GAD is a common confirmatory autoantibody.\n- Autoantibody testing helps distinguish T1DM/LADA from type 2 in diagnostically uncertain adults.",
    365: "- CORRECT: B (Th17/IL-17 pathway).\n- Psoriasis is driven by IL-23/Th17 signaling with IL-17-mediated keratinocyte hyperproliferation.\n- This is the biologic rationale for IL-17/IL-23-targeted therapies.",
    366: "- CORRECT: B (Immune surveillance in white pulp).\n- Splenic white pulp activates B/T-cell responses to blood-borne antigens; red pulp filters aged/damaged cells.\n- Loss of splenic immune function increases vulnerability to encapsulated organisms.",
    367: "- CORRECT: B (ACh receptors at the neuromuscular junction).\n- Myasthenia gravis causes fatigable weakness from antibody-mediated postsynaptic transmission failure.\n- Ocular/bulbar symptoms are common early; monitor for respiratory crisis progression.",
    368: "- CORRECT: B (HLA-B27).\n- Ankylosing spondylitis has a strong HLA-B27 association and classically presents with inflammatory axial pain.\n- Evaluate for extra-articular disease (e.g., uveitis) and treat per axial spondyloarthritis pathways.",
    369: "- CORRECT: B (Membrane pore-mediated lysis).\n- The complement MAC (C5b-9) forms pores in target membranes, especially effective against Neisseria.\n- Complement defects can present with recurrent severe bacterial infections.",
    370: "- CORRECT: B (Collagen overproduction).\n- Systemic sclerosis combines vasculopathy with fibroblast-driven collagen deposition in skin and organs.\n- Early organ screening (lung, renal, cardiac, GI) is crucial for prognosis and management.",
    371: "- CORRECT: D (Type IV delayed hypersensitivity).\n- Poison ivy and TB skin test are T-cell mediated delayed reactions, typically peaking at 48-72 hours.\n- This mechanism is antibody-independent, unlike types I-III.",
    372: "- CORRECT: B (Parietal cells/intrinsic factor).\n- Pernicious anemia causes B12 malabsorption via autoimmune intrinsic-factor pathway failure.\n- Treat with B12 replacement and monitor neurologic recovery risk when diagnosis is delayed.",
    373: "- CORRECT: B (Heart valves, especially mitral).\n- Rheumatic fever reflects molecular mimicry after GAS infection with autoimmune cardiac injury.\n- Prompt strep treatment and secondary prophylaxis reduce recurrent valvular damage risk.",
    374: "- CORRECT: B (Lungs and kidneys).\n- Goodpasture (anti-GBM disease) causes pulmonary-renal syndrome from anti-type IV collagen antibodies.\n- This is a treatment emergency: plasmapheresis plus immunosuppression should not be delayed.",
    375: "- CORRECT: B (p-ANCA).\n- p-ANCA is more associated with ulcerative colitis, while ASCA more often tracks with Crohn disease.\n- Serologies are adjunctive only and do not replace endoscopic/histologic diagnosis.",
    376: "- CORRECT: B (Apoptosis via negative selection).\n- In thymic central tolerance, strongly self-reactive T cells are deleted to prevent autoimmunity.\n- Failure of this checkpoint raises autoimmune disease risk.",
    377: "- CORRECT: B (c-ANCA/anti-PR3).\n- Granulomatosis with polyangiitis is an ANCA-associated vasculitis with ENT, lung, and renal involvement.\n- Early immunosuppressive treatment is essential to reduce organ-threatening progression.",
    378: "- CORRECT: A (Th1 response).\n- Sarcoid granulomas are driven by Th1/macrophage activation with non-caseating pathology.\n- Check multisystem involvement and calcium metabolism abnormalities during evaluation.",
    379: "- CORRECT: B (Ascending weakness).\n- Guillain-Barre classically progresses from legs upward with areflexia and potential respiratory compromise.\n- Monitor pulmonary function serially and treat early with IVIG or plasma exchange.",
    380: "- CORRECT: B (Anaphylaxis risk with IgA-containing blood products).\n- Selective IgA deficiency is often asymptomatic but can cause severe transfusion reactions via anti-IgA antibodies.\n- Use washed/IgA-deficient products when transfusion is required and document this risk clearly.",
    381: "- CORRECT: B (Melanocytes).\n- Vitiligo is autoimmune melanocyte destruction causing sharply demarcated depigmented patches.\n- Screen for associated autoimmune comorbidity (especially thyroid disease) and offer skin-directed plus psychosocial support.",
    382: "- CORRECT: B (PTT).\n- APS is prothrombotic clinically but can prolong aPTT in vitro due to phospholipid-dependent assay interference.\n- Confirm persistent antiphospholipid antibodies and manage thrombosis/pregnancy risk with guideline-directed anticoagulation.",
    383: "- CORRECT: B (Helminths/multicellular parasites).\n- Eosinophils are specialized for anti-parasitic cytotoxicity and are also central effectors in allergic inflammation.\n- Persistent eosinophilia should prompt targeted workup for parasitic, atopic, drug, and systemic causes.",
    384: "- CORRECT: B (CN III oculomotor nerve).\n- Uncal herniation classically causes ipsilateral blown pupil from compressive CN III parasympathetic fiber injury.\n- This is a neurosurgical emergency requiring immediate ICP-lowering measures and urgent definitive intervention.",
    385: "- CORRECT: B (Arm/face > leg weakness, plus aphasia if dominant hemisphere).\n- MCA territory strokes preferentially affect lateral motor cortex, explaining face-arm predominance.\n- Dominant hemisphere involvement adds language deficits; non-dominant involvement often causes neglect.",
    386: "- CORRECT: B (Urinary incontinence, gait disturbance, dementia).\n- NPH classically presents as \"wet, wobbly, wacky,\" with gait change usually earliest and most treatment-responsive.\n- MRI plus large-volume tap response supports shunt candidacy assessment.",
    387: "- CORRECT: B (Biconvex lens, does not cross sutures).\n- Epidural hematoma is usually arterial (middle meningeal) and can deteriorate rapidly after a lucid interval.\n- Treat as neurosurgical emergency with urgent evacuation when clinically indicated.",
    388: "- CORRECT: C (Thenar atrophy).\n- Thenar wasting indicates advanced median motor denervation in carpal tunnel syndrome.\n- This severity finding supports urgent hand-surgery consideration to prevent irreversible weakness.",
    389: "- CORRECT: B (Amyloid plaques and tau tangles).\n- Alzheimer pathology is defined by extracellular amyloid-beta deposition and intracellular hyperphosphorylated tau tangles.\n- Clinical progression reflects neuroanatomic spread of these degenerative processes.",
    390: "- CORRECT: B (CN V2/V3 electric-shock pain).\n- Trigeminal neuralgia causes brief severe lancinating attacks, often triggered by light touch/chewing/talking.\n- First-line treatment is carbamazepine/oxcarbazepine, with imaging to exclude secondary structural causes.",
    391: "- CORRECT: C (Spasticity, hyperreflexia, Babinski).\n- These are classic UMN findings from loss of descending inhibitory control over spinal reflex circuits.\n- In contrast, LMN injury produces atrophy, fasciculations, and depressed reflexes.",
    392: "- CORRECT: B (Substantia nigra pars compacta).\n- Parkinson disease reflects degeneration of nigrostriatal dopaminergic neurons with basal ganglia circuit imbalance.\n- Core syndrome is bradykinesia plus tremor/rigidity/postural signs, with alpha-synuclein pathology.",
    393: "- CORRECT: B (Awareness is impaired).\n- Focal impaired-awareness seizures differ from focal aware seizures by altered consciousness and post-event amnesia.\n- Accurate classification guides driving counseling, safety planning, and medication strategy.",
    394: "- CORRECT: B (Trigeminovascular system).\n- Migraine pain arises from trigeminal activation with CGRP-mediated meningeal neuroinflammation and nociceptive transmission.\n- This is the mechanistic basis for triptans and CGRP-pathway therapies.",
    395: "- CORRECT: B (Ipsilateral motor/vibration loss with contralateral pain/temp loss).\n- Brown-Sequard pattern reflects differing spinal tract decussation anatomy.\n- Recognizing this localization pattern accelerates diagnosis of hemicord injury and cause.",
    396: "- CORRECT: B (HINTS exam).\n- In continuous acute vestibular syndrome, dangerous HINTS findings suggest central stroke over peripheral neuritis.\n- Any central-pattern HINTS component warrants urgent stroke-level imaging/evaluation.",
    397: "- CORRECT: B (Worsens with use and improves with rest).\n- Myasthenic weakness is fatigable due to reduced neuromuscular transmission safety margin.\n- Diurnal worsening and activity-provoked ptosis/diplopia are key bedside clues.",
    398: "- CORRECT: C (Both UMN and LMN).\n- ALS uniquely combines corticospinal and anterior horn cell degeneration in one progressive syndrome.\n- Mixed UMN/LMN exam with preserved sensation strongly supports this diagnosis.",
    399: "- CORRECT: B (Confusion, ataxia, ophthalmoplegia).\n- Wernicke encephalopathy is thiamine-deficiency neurotoxicity and requires immediate parenteral thiamine.\n- Give thiamine before glucose in at-risk patients to prevent neurologic worsening.",
    400: "- CORRECT: B (Thumb and index finger).\n- C6 radiculopathy classically radiates to lateral forearm/thumb-index with biceps/wrist-extension involvement.\n- Correlate dermatome, myotome, and reflex changes to improve cervical root localization.",
    401: "- CORRECT: B (Bacterial meningitis).\n- CSF with high protein, low glucose, and neutrophilic predominance is classic for pyogenic meningitis.\n- Treat immediately with empiric antibiotics (plus dexamethasone when indicated) without diagnostic delays.",
    402: "- CORRECT: B (Sympathetic chain lesion).\n- Horner syndrome (ptosis, miosis, anhidrosis) localizes to oculosympathetic pathway disruption.\n- New painful Horner syndrome requires urgent evaluation for carotid dissection and other dangerous causes.",
    403: "- CORRECT: B (Stepwise progression).\n- Vascular dementia often declines in discrete drops after ischemic injury, unlike smoother Alzheimer trajectories.\n- Management emphasizes aggressive cerebrovascular risk reduction to slow further decline.",
    404: "- CORRECT: B (NIF/FVC monitoring).\n- In Guillain-Barre, serial respiratory metrics detect impending ventilatory failure earlier than pulse oximetry alone.\n- Use objective thresholds to plan elective airway support before decompensation.",
    405: "- CORRECT: B (4th/5th digit numbness).\n- Cubital tunnel syndrome compresses the ulnar nerve at the elbow, producing ring-small finger paresthesia and intrinsic hand weakness.\n- Progressive weakness/atrophy warrants electrodiagnostic confirmation and surgical referral consideration.",
    406: "- CORRECT: B (Transient neurologic dysfunction without acute infarction).\n- Modern TIA is tissue-based, not time-based; transient symptoms with DWI infarct are reclassified as stroke.\n- Treat as high early-risk event with urgent secondary prevention workup and intervention.",
    407: "- CORRECT: B (Behavioral/personality change and aphasia early).\n- Frontotemporal dementia often presents with disinhibition, apathy, or language decline before major memory loss.\n- Younger onset pattern and frontal-temporal signs help distinguish from typical Alzheimer phenotype.",
    408: "- CORRECT: B (Small unmyelinated pain-temperature fibers).\n- Diabetic neuropathy often starts with small-fiber injury, causing burning pain and thermal sensory loss.\n- Early foot-risk counseling and glycemic optimization are essential even before severe numbness develops.",
    409: "- CORRECT: B (Direct sensory-to-motor spinal synapse).\n- Deep tendon reflexes are monosynaptic arcs that bypass cortical processing for speed.\n- Reflex pattern helps localize UMN versus LMN pathology at bedside.",
    410: "- CORRECT: B (Glutamate excitatory; GABA inhibitory).\n- CNS function depends on balanced excitatory and inhibitory signaling; imbalance contributes to seizures and neurotoxicity.\n- Many sedative/anticonvulsant drugs work by enhancing GABAergic tone.",
    411: "- CORRECT: C (Benzodiazepine first-line).\n- Status epilepticus is seizure >5 minutes or recurrent seizures without recovery and needs immediate benzodiazepine therapy.\n- Follow with second-line IV antiseizure agents rapidly if seizures persist.",
    412: "- CORRECT: B (Action/postural tremor, often alcohol-responsive).\n- Essential tremor appears with use/posture, while Parkinson tremor is typically resting and accompanied by bradykinesia/rigidity.\n- First-line essential tremor options include propranolol or primidone.",
    413: "- CORRECT: B (Peripheral roots below cord termination).\n- Cauda equina compression causes LMN findings because affected structures are peripheral nerve roots, not cord tissue.\n- Red-flag bladder/bowel or saddle symptoms require emergent decompression pathway.",
    414: "- CORRECT: B (Optic chiasm compression).\n- Pituitary macroadenoma classically compresses crossing nasal retinal fibers, causing bitemporal hemianopsia.\n- In prolactin-secreting tumors, dopamine agonists are usually first-line even with macro lesions.",
    415: "- CORRECT: B (Dopamine).\n- Prolactin is uniquely under tonic inhibitory hypothalamic dopamine control rather than dominant releasing-hormone stimulation.\n- D2 blockade or stalk disruption commonly causes hyperprolactinemia in clinical practice.",
    416: "- CORRECT: B (Posterior pituitary/hypothalamic axis injury).\n- Central DI reflects deficient ADH production/release from hypothalamic-neurohypophyseal pathways.\n- Differentiate from nephrogenic DI because treatment response (desmopressin) differs fundamentally.",
    417: "- CORRECT: B (Facial twitch with facial-nerve tapping).\n- Chvostek sign reflects hypocalcemic neuromuscular hyperexcitability; Trousseau is often more sensitive/specific.\n- Symptomatic hypocalcemia requires prompt correction and magnesium assessment.",
    418: "- CORRECT: C (Epinephrine about 80%, norepinephrine about 20%).\n- Adrenal medulla is a modified sympathetic ganglion releasing catecholamines into circulation under splanchnic cholinergic stimulation.\n- This physiology explains pheochromocytoma symptom patterns and testing strategy.",
    419: "- CORRECT: B (Headache, diaphoresis/palpitations, tachycardia).\n- Pheochromocytoma causes episodic catecholamine surges with paroxysmal sympathetic symptoms and hypertension.\n- Always alpha-block before beta-block to avoid unopposed alpha-mediated hypertensive crisis.",
    420: "- CORRECT: B (Early satiety, bloating, vomiting undigested food).\n- Diabetic autonomic/vagal neuropathy can cause gastroparesis with delayed gastric emptying and erratic glycemic excursions.\n- Management combines meal-structure changes, glucose optimization, and prokinetic/antiemetic strategies.",
    421: "- CORRECT: C (ACTH-secreting pituitary adenoma).\n- Cushing disease is a pituitary ACTH-driven subtype of hypercortisolism, distinct from adrenal, ectopic, or exogenous causes.\n- Diagnosis follows a sequence: confirm cortisol excess, determine ACTH dependence, then localize source.",
    422: "- CORRECT: B (Profound intellectual disability and growth failure).\n- Untreated congenital hypothyroidism disrupts early neurodevelopment and linear growth during critical windows.\n- Universal newborn screening plus treatment within the first weeks prevents irreversible outcomes.",
    423: "- CORRECT: B (Sheehan syndrome).\n- Severe postpartum hemorrhage can cause ischemic anterior pituitary necrosis with agalactia and amenorrhea.\n- Replace glucocorticoids before thyroid hormone to avoid precipitating adrenal crisis.",
    424: "- CORRECT: B (Cortisol inhibits CRH and ACTH).\n- The HPA axis is stabilized by dual negative feedback at hypothalamic and pituitary levels.\n- Chronic exogenous steroids suppress this axis, so tapering and stress-dose planning are essential.",
    425: "- CORRECT: B (Euvolemic hyponatremia with concentrated urine).\n- SIADH causes water retention with inappropriately high urine osmolality/sodium despite low serum osmolality.\n- Correct sodium cautiously to avoid osmotic demyelination and treat underlying cause.",
    426: "- CORRECT: B (Autonomic neuropathy with blunted glucagon/epinephrine response).\n- Recurrent hypoglycemia in long-standing diabetes can erase warning symptoms (HAAF physiology).\n- Use CGM alerts and hypoglycemia-avoidance strategies to restore awareness and reduce severe events.",
    427: "- CORRECT: B (Serotonin).\n- Carcinoid syndrome symptoms are largely driven by vasoactive mediator release, classically serotonin, from NETs with systemic escape.\n- Confirm biochemically (e.g., 5-HIAA) and treat symptom burden with somatostatin-pathway therapy.",
    428: "- CORRECT: B (Blocks T4-to-T3 conversion and sympathetic overdrive).\n- Propranolol rapidly improves hemodynamic instability in thyroid storm and reduces active hormone effect.\n- It is part of urgent multimodal, sequence-sensitive treatment (beta-blocker, thionamide, iodine, steroid).",
    429: "- CORRECT: A (Carpal tunnel syndrome).\n- Soft tissue overgrowth in acromegaly commonly compresses the median nerve, making CTS a frequent neurologic clue.\n- New CTS with progressive acral/facial enlargement should prompt IGF-1-directed endocrine workup.",
    430: "- CORRECT: B (Lethargy, depression, atrial fibrillation).\n- Elderly hyperthyroidism may be \"apathetic,\" lacking classic hyperadrenergic signs and presenting subtly.\n- Always include thyroid testing in unexplained weight loss, new AF, or atypical mood decline.",
    431: "- CORRECT: B (Sympathetic vasomotor fiber damage).\n- Diabetic autonomic neuropathy impairs baroreflex-mediated vasoconstriction, causing orthostatic hypotension.\n- Manage with volume/behavioral strategies first, then pressor agents if persistent and symptomatic.",
    432: "- CORRECT: D (Pheochromocytoma is not a MEN1 'P').\n- MEN1 classically involves parathyroid, pituitary, and pancreatic/duodenal NET disease.\n- Pheochromocytoma aligns with MEN2/RET syndromes, so syndrome differentiation matters for surveillance.",
    433: "- CORRECT: B (Suprachiasmatic nucleus).\n- Retinal light input entrains the SCN, which controls pineal melatonin timing through sympathetic output.\n- This pathway explains circadian misalignment and the impact of evening blue-light exposure.",
    434: "- CORRECT: B (Hypokalemia with metabolic alkalosis).\n- Primary hyperaldosteronism increases ENaC-driven sodium reabsorption, promoting renal potassium and hydrogen loss.\n- Screen resistant hypertension with ARR and pursue subtype-directed treatment.",
    435: "- CORRECT: B (Satiety signaling and increased energy expenditure).\n- Leptin from adipocytes informs hypothalamic energy-state sensing and suppresses appetite pathways.\n- Common obesity reflects leptin resistance, not leptin deficiency, which explains persistent hunger biology.",
    436: "- CORRECT: B (Milk ejection and uterine contraction).\n- Oxytocin triggers myoepithelial let-down and labor/postpartum uterine smooth-muscle contraction.\n- Distinguish from prolactin, which drives milk synthesis rather than ejection.",
    437: "- CORRECT: B (Hyperphagia and obesity).\n- Ventromedial hypothalamic lesions remove satiety signaling, producing severe overeating and weight gain.\n- Suspect hypothalamic pathology in rapid unexplained obesity with sellar/suprasellar symptoms.",
    438: "- CORRECT: B (CKD).\n- Secondary hyperparathyroidism in CKD is driven by phosphate retention, low calcitriol, and chronic hypocalcemic signaling.\n- Management centers on phosphate control, vitamin D pathway therapy, and calcimimetic strategies when indicated.",
    439: "- CORRECT: B (Symptoms + low glucose + relief with glucose).\n- Whipple triad confirms true hypoglycemia physiology before labeling insulinoma or other etiologies.\n- Biochemical context (insulin/C-peptide/proinsulin and sulfonylurea screen) separates endogenous vs exogenous causes.",
    440: "- CORRECT: B (Amiodarone).\n- High iodine load and direct thyroid effects can cause both hypo- and hyperthyroid states during therapy.\n- Baseline and periodic thyroid-function monitoring are mandatory with long-term use.",
    441: "- CORRECT: B (Acetylcholine).\n- The parasympathetic system uses acetylcholine at postganglionic synapses to drive rest-and-digest functions.\n- Anticholinergic medications can cause dry mouth, constipation, urinary retention, tachycardia, and confusion, especially in older adults.",
    442: "- CORRECT: B (High ACTH co-secretes MSH activity).\n- In primary adrenal insufficiency, low cortisol removes feedback inhibition, so ACTH rises markedly.\n- Elevated ACTH/POMC signaling stimulates melanocytes, causing hyperpigmentation (often in palmar creases and oral mucosa).",
    443: "- CORRECT: A (Growth hormone and insulin/glucagon).\n- Somatostatin is a broad inhibitory hormone that suppresses pituitary GH and pancreatic insulin and glucagon release.\n- Octreotide uses this physiology clinically (for example, acromegaly and selected neuroendocrine syndromes).",
    444: "- CORRECT: B (Right coronary artery).\n- In right-dominant circulation (most patients), the PDA arises from the RCA and often supplies the AV nodal region.\n- This is why inferior RCA ischemia can present with bradycardia or AV block.",
    445: "- CORRECT: B (Fatty streak).\n- Fatty streaks are the earliest visible atherosclerotic lesions, formed by lipid-laden foam cells in the intima.\n- They can appear early in life and may progress over time to fibrous-capped plaques.",
    446: "- CORRECT: B (Buttock/thigh claudication, erectile dysfunction, absent femoral pulses).\n- Leriche syndrome reflects aortoiliac occlusive disease causing reduced pelvic and lower-extremity perfusion.\n- Bilateral diminished femoral pulses with proximal claudication is the key bedside clue.",
    447: "- CORRECT: B (Rupture of a vulnerable plaque).\n- Most ACS events result from plaque rupture or erosion with superimposed thrombosis, not gradual fixed narrowing alone.\n- Ongoing risk reduction (statin, BP control, smoking cessation, antiplatelet strategy when indicated) targets this process.",
    448: "- CORRECT: B (Posterior communicating artery).\n- The PComm links carotid (anterior) circulation to vertebrobasilar/posterior circulation in the Circle of Willis.\n- This collateral pathway helps maintain cerebral perfusion when one arterial territory is compromised.",
    449: "- CORRECT: C (Tunica intima).\n- Aortic dissection starts with an intimal tear, then blood tracks into the media to create a false lumen.\n- Sudden tearing chest or back pain with pulse/BP asymmetry should trigger urgent dissection evaluation.",
    450: "- CORRECT: B (Subclavian steal syndrome).\n- Proximal subclavian stenosis can reverse ipsilateral vertebral flow, causing neurologic symptoms with arm exertion.\n- A significant inter-arm BP difference with exertional arm symptoms supports the diagnosis.",
    451: "- CORRECT: B (Vascular smooth muscle cell).\n- Smooth muscle cells synthesize collagen for the fibrous cap that stabilizes atherosclerotic plaque.\n- Inflammatory macrophage enzymes degrade cap collagen and increase rupture risk.",
    452: "- CORRECT: B (Third portion of the duodenum).\n- The SMA passes anterior to the third part of the duodenum; compression here causes SMA syndrome.\n- Consider this in post-weight-loss patients with postprandial pain, early satiety, and bilious vomiting.",
    453: "- CORRECT: B (Incompetent valves leading to venous hypertension).\n- CVI causes reflux and chronic venous hypertension, producing edema, stasis dermatitis, and hemosiderin skin changes.\n- Venous ulcers are usually shallow and near the medial malleolus; compression therapy is first-line.",
    454: "- CORRECT: C (5.5 cm in men).\n- Elective AAA repair is generally recommended at 5.5 cm in men (often 5.0 cm in women) or with rapid expansion.\n- Smaller aneurysms are managed with surveillance imaging plus aggressive cardiovascular risk reduction.",
    455: "- CORRECT: B (Aggressive medical management vs selected CEA).\n- Asymptomatic carotid stenosis is usually treated first with optimal medical therapy (statin, antiplatelet, BP and risk-factor control).\n- Revascularization is reserved for carefully selected high-grade cases when perioperative stroke/death risk is low.",
    456: "- CORRECT: B (Great saphenous vein).\n- The great saphenous vein is the most commonly harvested venous conduit for CABG.\n- Arterial grafts such as LIMA generally provide superior long-term patency, but GSV remains widely used.",
    457: "- CORRECT: C (Moderate PAD).\n- An ABI of 0.60 falls in the moderate peripheral arterial disease range (about 0.40-0.69).\n- Combine exercise therapy and risk-factor modification; escalate vascular evaluation if symptoms are limiting or limb threat appears.",
    458: "- CORRECT: B (Young females).\n- Fibromuscular dysplasia is a non-atherosclerotic cause of renal artery stenosis that classically affects younger women.\n- Mid-distal renal involvement with a string-of-beads pattern helps distinguish it from proximal atherosclerotic disease.",
    459: "- CORRECT: B (Inflammation marker of plaque instability).\n- Elevated hs-CRP reflects systemic inflammation linked to atherosclerotic plaque vulnerability and future coronary risk.\n- It is a risk-enhancing marker, not a cholesterol type and not a direct cause of clot formation.",
    460: "- CORRECT: B (White -> Blue -> Red).\n- Raynaud episodes progress from ischemic pallor to cyanosis, then reactive hyperemia with reperfusion.\n- Frequent severe attacks, tissue injury, or late-onset symptoms should prompt evaluation for secondary autoimmune causes.",
    461: "- CORRECT: A (Hypotension in legs, hypertension in arms).\n- Coarctation just distal to the left subclavian causes upper-extremity hypertension with reduced lower-extremity perfusion.\n- A key exam clue is radial-femoral delay and an arm-to-leg systolic gradient (often >=20 mmHg).",
    462: "- CORRECT: B (Internal elastic lamina).\n- Giant cell arteritis shows granulomatous inflammation centered on and disrupting the internal elastic lamina.\n- In suspected GCA, start high-dose steroids immediately to prevent irreversible vision loss; do not wait for biopsy.",
    463: "- CORRECT: C (Dorsum of foot involvement with non-pitting edema/positive Stemmer sign).\n- Lymphedema is protein-rich edema that becomes firm and non-pitting with fibrosis, unlike typical venous edema.\n- Poor diuretic response and inability to pinch dorsal toe skin support lymphedema.",
    464: "- CORRECT: B (Ischemic rest pain or tissue loss).\n- Critical limb-threatening ischemia is defined by rest pain, nonhealing ischemic ulcers, or gangrene, not exertional claudication alone.\n- This requires urgent vascular assessment and revascularization planning to reduce amputation risk.",
    465: "- CORRECT: B (Left spermatic vein drains perpendicularly into the left renal vein).\n- This drainage geometry raises venous pressure, making left-sided varicocele far more common.\n- New isolated right-sided or non-reducing varicocele should prompt evaluation for retroperitoneal/renal pathology.",
    466: "- CORRECT: B (Splenic vein + superior mesenteric vein).\n- The portal vein forms behind the pancreatic neck and carries nutrient-rich splanchnic blood to the liver for first-pass processing.\n- Portal hypertension can produce varices, caput medusae, and other portosystemic collateral signs.",
    467: "- CORRECT: B (Increased cGMP in vascular smooth muscle).\n- Endothelial nitric oxide activates soluble guanylyl cyclase, raising cGMP and causing smooth-muscle relaxation.\n- Nitrates and PDE-5 inhibitors act on this pathway; coadministration can cause severe hypotension.",
    468: "- CORRECT: B (Medial circumflex femoral artery).\n- In adults, retinacular branches from the medial circumflex femoral artery are the dominant blood supply to the femoral head.\n- Displaced femoral neck fractures can disrupt this flow and increase avascular necrosis risk.",
    469: "- CORRECT: B (Men 65-75 who have ever smoked).\n- USPSTF recommends one-time AAA ultrasound screening in men 65-75 with any smoking history (>=100 lifetime cigarettes).\n- Men in this age range who never smoked are selective-screening cases based on individual risk.",
    470: "- CORRECT: B (Heavy tobacco use).\n- Thromboangiitis obliterans is a non-atherosclerotic inflammatory occlusive disease strongly linked to tobacco exposure.\n- Complete tobacco cessation is the only intervention proven to halt progression and lower amputation risk.",
    471: "- CORRECT: B (Unregulated macrophage scavenger receptor uptake).\n- Oxidized LDL is taken up by macrophages via scavenger receptors without normal feedback limits, promoting foam-cell formation.\n- This drives plaque growth and instability, explaining why inflammation control and LDL lowering matter.",
    472: "- CORRECT: B (Stasis, endothelial injury, hypercoagulability).\n- Virchow's triad summarizes the three core mechanisms that increase thrombosis risk.\n- PCP prevention strategy maps directly to this model: mobilize patients, reduce vessel injury risks, and anticoagulate when indicated.",
    473: "- CORRECT: B (Adductor hiatus/Hunter canal).\n- The femoral artery becomes the popliteal artery after passing through the adductor hiatus.\n- This transition zone is a common location for PAD-related flow-limiting disease causing exertional calf claudication.",
    474: "- CORRECT: D (Subscapularis).\n- Subscapularis is the only anterior rotator cuff muscle and the primary internal rotator of the humerus.\n- Internal-rotation weakness and positive lift-off/belly-press testing support subscapularis pathology.",
    475: "- CORRECT: B (Bone remodels and strengthens with load).\n- Wolff's law states bone architecture adapts to mechanical stress via remodeling along stress lines.\n- Weight-bearing/resistance exercise improves bone health; disuse and immobilization accelerate bone loss.",
    476: "- CORRECT: B (Loss of articular cartilage with subchondral remodeling/osteophytes).\n- OA is primarily a degenerative joint process with cartilage breakdown plus subchondral bone change, not autoimmune synovitis.\n- Typical pattern is activity-related pain, brief morning stiffness, and radiographic joint-space loss with osteophytes.",
    477: "- CORRECT: A (Medial meniscus tear).\n- Pivoting on a planted knee with delayed effusion, joint-line pain, and locking/catching is classic for meniscal injury.\n- ACL rupture more often presents with immediate hemarthrosis, audible pop, and early instability.",
    478: "- CORRECT: B (Anterior slippage of one vertebra over the one below).\n- Spondylolisthesis is vertebral translation, often from isthmic pars defects or degenerative facet-disc disease.\n- Differentiate from spondylolysis, which is the pars fracture itself without required slippage.",
    479: "- CORRECT: B (Lateral femoral cutaneous nerve).\n- Meralgia paresthetica is entrapment of this pure sensory nerve, causing anterolateral thigh burning/numbness.\n- Lack of motor deficit helps distinguish it from femoral neuropathy or lumbar radiculopathy.",
    480: "- CORRECT: B (Finkelstein's test).\n- De Quervain tenosynovitis involves APL and EPB tendons in the first dorsal compartment at the radial styloid.\n- Positive Finkelstein reproduces radial wrist pain; first-line care is thumb-spica splinting, activity modification, and NSAIDs.",
    481: "- CORRECT: B (Denosumab).\n- Denosumab is an anti-RANKL monoclonal antibody that functionally mimics OPG and suppresses osteoclast activation.\n- If stopping denosumab, transition to another antiresorptive to reduce rebound vertebral fracture risk.",
    482: "- CORRECT: B (Proximal long head of biceps tendon).\n- Classic Popeye deformity reflects proximal long-head rupture with distal muscle belly retraction.\n- Many older adults are managed nonoperatively, while distal biceps rupture is more function-limiting and often surgical.",
    483: "- CORRECT: B (Gluteus medius).\n- Hip abductor weakness causes contralateral pelvic drop during single-leg stance (Trendelenburg sign).\n- Superior gluteal nerve injury, hip pathology, or L5-related weakness are common contributors.",
    484: "- CORRECT: A (Giant cell arteritis).\n- PMR and GCA are closely linked inflammatory disorders in older adults and may coexist.\n- New headache, scalp tenderness, jaw claudication, or visual symptoms in PMR should trigger urgent GCA evaluation and treatment.",
    485: "- CORRECT: B (Fall on outstretched hand).\n- Colles fracture is a distal radius fracture with dorsal angulation after FOOSH.\n- In older adults, this is a fragility-fracture pattern and should prompt osteoporosis risk assessment.",
    486: "- CORRECT: B (Medial meniscus).\n- The classic unhappy triad includes ACL, MCL, and medial meniscus injury after valgus-rotational trauma.\n- Combined ligament-meniscal injury warrants early stability-focused exam and orthopedic follow-up.",
    487: "- CORRECT: B (Negatively birefringent, needle-shaped crystals).\n- Monosodium urate crystals in gout are needle-like and negatively birefringent on polarized microscopy.\n- This finding distinguishes gout from CPPD, which has positively birefringent rhomboid crystals.",
    488: "- CORRECT: A (Leg pain worsens with walking and improves with sitting/flexion).\n- Neurogenic claudication from lumbar stenosis is posture dependent and classically relieved by flexion (shopping-cart sign).\n- This pattern helps distinguish it from vascular claudication, which improves simply with rest.",
    489: "- CORRECT: C (Radial nerve).\n- The radial nerve runs in the humeral spiral groove and is vulnerable in mid-shaft humerus fractures.\n- Wrist/finger extension weakness (wrist drop) supports radial neuropathy.",
    490: "- CORRECT: B (Actin slides over myosin).\n- Sarcomere shortening occurs by increased overlap of actin and myosin, not shortening of filament lengths.\n- Calcium binds troponin C to permit cross-bridge cycling; ATP is required for myosin head detachment/reset.",
    491: "- CORRECT: B (Patellar tendon on the tibial tubercle).\n- Osgood-Schlatter is traction apophysitis at the tibial tubercle in active adolescents.\n- Management is usually conservative with load modification, stretching, and symptom-guided return to sport.",
    492: "- CORRECT: B (Pain out of proportion, especially with passive stretch).\n- This is the earliest and most sensitive clinical sign of acute compartment syndrome.\n- Pulselessness and paralysis are late findings; urgent fasciotomy is limb-saving.",
    493: "- CORRECT: B (Sacroiliac joints).\n- Ankylosing spondylitis typically begins with sacroiliitis before advanced spinal ankylosis develops.\n- In younger patients with inflammatory back pain, SI-focused evaluation is key to early diagnosis.",
    494: "- CORRECT: B (Staphylococcus aureus).\n- S. aureus is the most common osteomyelitis pathogen in otherwise healthy adults.\n- Empiric therapy should cover staphylococci while culture and source details guide narrowing.",
    495: "- CORRECT: A (Medial calcaneal tubercle).\n- Plantar fasciitis is a degenerative enthesopathy at the plantar fascia origin on the medial calcaneal tubercle.\n- First-step morning heel pain is typical; initial care is stretching, load modification, and supportive footwear.",
    496: "- CORRECT: B (Tear of the anterior-inferior glenoid labrum).\n- A Bankart lesion is the labral injury linked to recurrent anterior shoulder instability.\n- Distinguish from Hill-Sachs lesion, which is a posterolateral humeral head impaction defect.",
    497: "- CORRECT: B (Wrist extensors, especially ECRB).\n- Lateral epicondylitis is most often an ECRB tendinopathy at the common extensor origin.\n- Pain with resisted wrist extension/grip supports diagnosis; activity modification and rehab are first-line.",
    498: "- CORRECT: B (Herniation of synovial fluid into the popliteal fossa).\n- A Baker cyst is usually secondary to intra-articular knee pathology with excess effusion.\n- Rupture can mimic DVT clinically, so unilateral calf swelling may require exclusion of thromboembolism.",
    499: "- CORRECT: A (Vitamin D / calcium deficiency).\n- Rickets and osteomalacia are mineralization defects, most commonly from inadequate vitamin D availability with downstream calcium-phosphate imbalance.\n- Differentiate from osteoporosis, which has reduced bone mass but normal mineralization.",
    500: "- CORRECT: A (Narrower intercondylar notch and wider Q-angle).\n- Female ACL injury risk is multifactorial; anatomic and neuromuscular factors both contribute.\n- Prevention programs emphasizing landing mechanics and hip-knee control can reduce noncontact ACL injury risk.",
    501: "- CORRECT: B (Herniated disc compressing the nerve root).\n- Lumbar disc herniation (most often L4-L5 or L5-S1) is the most common cause of true radiculopathy/sciatica.\n- Most cases improve within 6-12 weeks with conservative management; urgent surgical referral is reserved for progressive motor deficit or cauda equina signs.",
    502: "- CORRECT: A (A1 pulley).\n- Trigger finger results from a size mismatch between the flexor tendon and the narrowed A1 pulley at the MCP joint.\n- Diabetes is a strong risk factor; first-line treatment is corticosteroid injection into the tendon sheath, which has high success rates.",
    503: "- CORRECT: B (Palmar fascia).\n- Dupuytren disease is fibroproliferative thickening of the palmar fascia causing progressive flexion contracture, not a tendon disorder.\n- The ring and little fingers are most commonly affected; intervention is considered when the tabletop test is positive (hand cannot be placed flat).",
    504: "- CORRECT: A (Horner syndrome: ptosis, miosis, anhidrosis).\n- Pancoast tumors at the lung apex invade the stellate ganglion and lower brachial plexus.\n- Persistent shoulder/arm pain with ipsilateral Horner findings in a smoker should prompt chest imaging to evaluate for apical lung malignancy.",
    505: "- CORRECT: B (Colorectal cancer until proven otherwise).\n- In males and postmenopausal females, iron deficiency anemia mandates GI evaluation for occult blood loss, especially colorectal malignancy.\n- Bidirectional endoscopy (colonoscopy and EGD) is standard workup; do not attribute to diet alone without investigation.",
    506: "- CORRECT: C (Diffuse erythema, edema/peau d'orange, and warmth mimicking mastitis).\n- Inflammatory breast cancer presents without a discrete mass; dermal lymphatic invasion produces the inflammatory appearance.\n- Breast erythema unresponsive to antibiotics within 7-10 days requires urgent biopsy to exclude IBC.",
    507: "- CORRECT: A (Palpable abdominal mass).\n- The classic RCC triad is hematuria, flank pain, and palpable mass, though the full triad appears in fewer than 10% of cases.\n- Most RCC is now found incidentally on imaging; any unexplained hematuria warrants urologic evaluation.",
    508: "- CORRECT: C (Palms, soles, and under nails).\n- Acral lentiginous melanoma is the most common melanoma subtype in darker-skinned populations and occurs on non-sun-exposed acral surfaces.\n- Subungual melanonychia striata with Hutchinson sign (periungual pigment spread) requires biopsy to exclude melanoma.",
    509: "- CORRECT: B (Pancreatic head cancer).\n- Painless obstructive jaundice with a palpable nontender gallbladder (Courvoisier sign) is the hallmark of periampullary malignancy.\n- Contrast this with choledocholithiasis, which typically presents with colicky RUQ pain and tenderness.",
    510: "- CORRECT: B (Multiple myeloma).\n- Lytic bone lesions with hypercalcemia, renal insufficiency, and anemia (CRAB criteria) in an older adult is myeloma until proven otherwise.\n- Serum and urine protein electrophoresis with immunofixation and free light chains are key initial diagnostic studies.",
    511: "- CORRECT: B (Bone, particularly the axial skeleton).\n- Prostate cancer produces characteristically osteoblastic (sclerotic) bone metastases, unlike the lytic pattern of most other solid tumors.\n- New back or pelvic pain in a patient with known prostate cancer should prompt bone imaging evaluation.",
    512: "- CORRECT: A (SIADH and Lambert-Eaton myasthenic syndrome).\n- SCLC is a neuroendocrine tumor that ectopically produces ADH (causing euvolemic hyponatremia) and can trigger antibodies against presynaptic calcium channels (Lambert-Eaton).\n- SCLC is almost always smoking-related, centrally located, and treated primarily with chemoradiation rather than surgery.",
    513: "- CORRECT: B (HPV high-risk strains 16 and 18).\n- Persistent high-risk HPV infection is the necessary cause of virtually all cervical cancers, with E6/E7 oncoproteins inactivating p53 and Rb.\n- HPV vaccination and guideline-concordant cervical screening (cytology and/or HPV testing) are the cornerstones of prevention.",
    514: "- CORRECT: B (Fever >38C, drenching night sweats, >10% weight loss in 6 months).\n- B-symptoms are formally defined constitutional symptoms used in lymphoma staging and carry prognostic significance.\n- Painless cervical lymphadenopathy in a young adult with B-symptoms should prompt urgent evaluation for lymphoma.",
    515: "- CORRECT: B (Bloating, early satiety, pelvic pressure).\n- Ovarian cancer symptoms are often vague and attributed to benign conditions, contributing to late-stage diagnosis in most cases.\n- Persistent new-onset bloating, pelvic/abdominal pain, or early satiety lasting more than a few weeks in a woman warrants pelvic imaging.",
    516: "- CORRECT: B (Abdominal malignancy, especially gastric or pancreatic).\n- A palpable left supraclavicular (Virchow) node is the terminus of the thoracic duct and suggests intra-abdominal malignancy.\n- Any firm, nontender supraclavicular lymph node in an adult requires prompt biopsy and staging workup.",
    517: "- CORRECT: B (Smoking).\n- Cigarette smoking accounts for roughly half of all bladder cancer cases via urinary concentration of tobacco-derived aromatic amines.\n- Painless gross hematuria is the classic presenting symptom; even a single episode warrants cystoscopy and upper-tract imaging.",
    518: "- CORRECT: A (Postmenopausal bleeding).\n- Any vaginal bleeding after 12 months of amenorrhea is endometrial cancer until proven otherwise and requires endometrial sampling.\n- Chronic unopposed estrogen (obesity, PCOS, tamoxifen) is the primary risk driver for type I endometrial cancer.",
    519: "- CORRECT: A (Worse in the morning and with Valsalva/bending).\n- Headache from raised intracranial pressure worsens with recumbency and maneuvers that increase intrathoracic/venous pressure.\n- New progressive headache with focal deficits, seizure, or papilledema warrants urgent neuroimaging.",
    520: "- CORRECT: B (AFP, beta-HCG, and LDH).\n- These three markers are essential for testicular cancer diagnosis, staging, and post-treatment surveillance.\n- Elevated AFP excludes pure seminoma regardless of histology; beta-HCG elevation is seen in choriocarcinoma and sometimes seminoma.",
    521: "- CORRECT: B (Papillary thyroid carcinoma).\n- PTC accounts for 80-85% of thyroid cancers; it spreads via lymphatics but carries an excellent prognosis in most patients.\n- BRAF V600E mutation is the most common driver and is associated with higher recurrence and radioiodine resistance.",
    522: "- CORRECT: B (Sunburst pattern and Codman triangle).\n- Osteosarcoma is the most common primary malignant bone tumor and classically arises near the knee in adolescents.\n- Sunburst reflects aggressive periosteal bone formation; Codman triangle is the periosteal elevation at the tumor margin.",
    523: "- CORRECT: B (Liver).\n- Carcinoid syndrome only manifests when liver metastases release serotonin directly into the systemic circulation, bypassing hepatic first-pass metabolism.\n- Diagnose biochemically with 24-hour urine 5-HIAA; manage symptoms with somatostatin analogues (octreotide).",
    524: "- CORRECT: A (Laryngeal cancer/squamous cell carcinoma).\n- Persistent hoarseness over 2-3 weeks in a smoker requires direct laryngoscopy to visualize the vocal cords.\n- Glottic tumors cause early hoarseness because even small lesions disrupt cord vibration, enabling earlier detection.",
    525: "- CORRECT: B (GERD, Barrett esophagus, and obesity).\n- Esophageal adenocarcinoma follows a metaplasia-dysplasia-carcinoma sequence driven by chronic acid/bile reflux.\n- Barrett esophagus (intestinal metaplasia of distal esophageal mucosa) is the key premalignant condition and requires surveillance endoscopy.",
    526: "- CORRECT: B (Pearly papule with telangiectasias and a rolled border).\n- BCC is the most common human malignancy; it grows locally and very rarely metastasizes.\n- Sun-exposed head/neck skin in fair-skinned individuals is the classic location; biopsy any suspicious pearly or non-healing lesion.",
    527: "- CORRECT: B (ALL / acute lymphoblastic leukemia).\n- ALL is the most common childhood cancer, peaking at ages 2-5, and presents with marrow failure signs (anemia, thrombocytopenia, neutropenia) plus bone pain.\n- Peripheral smear blasts and bone marrow biopsy confirm diagnosis; prognosis in children is favorable with modern therapy.",
    528: "- CORRECT: A (Pelvic or abdominal malignancy).\n- A Sister Mary Joseph nodule is an umbilical metastasis indicating advanced intra-abdominal cancer (commonly gastric, ovarian, or pancreatic).\n- Any new firm umbilical nodule in an adult warrants biopsy and cross-sectional imaging.",
    529: "- CORRECT: B (Cirrhosis from any cause or chronic hepatitis B).\n- HCC surveillance with ultrasound and AFP every 6 months is recommended for patients with cirrhosis or chronic HBV.\n- Chronic HBV uniquely causes HCC even without cirrhosis because HBV DNA integrates into the hepatocyte genome.",
    530: "- CORRECT: B (Pre-malignant lesion with risk of squamous cell carcinoma).\n- Leukoplakia is a non-scrapable white oral patch that carries a 5-25% risk of dysplasia or carcinoma on biopsy.\n- Distinguish from thrush, which scrapes off; all persistent leukoplakia warrants biopsy, especially with tobacco/alcohol history.",
    531: "- CORRECT: B (PTHrP / parathyroid hormone-related protein).\n- PTHrP accounts for roughly 80% of malignancy-associated hypercalcemia by mimicking PTH at bone and kidney receptors.\n- Key lab distinction: PTH is suppressed while PTHrP is elevated, unlike primary hyperparathyroidism where PTH itself is high.",
    532: "- CORRECT: B (Heart / cardiomyopathy).\n- Anthracycline cardiotoxicity is cumulative and dose-dependent, driven by ROS-mediated cardiomyocyte injury and topoisomerase 2-beta inhibition.\n- Monitor with serial echocardiography or MUGA; dexrazoxane may be used as a cardioprotectant in selected patients.",
    533: "- CORRECT: B (HPV infection).\n- Anal squamous cell carcinoma is HPV-driven (types 16/18), analogous to cervical cancer pathogenesis.\n- HIV-positive individuals have a 30-80-fold increased risk; HPV vaccination reduces incidence of precursor lesions.",
    534: "- CORRECT: B (6-20 words).\n- By 18 months, a child should have approximately 10-25 words and follow simple one-step commands.\n- Failure to meet this milestone warrants hearing evaluation and developmental assessment at the well-child visit.",
    535: "- CORRECT: B (Roseola / exanthem subitum).\n- The hallmark sequence is 3-5 days of high fever in a well-appearing child, followed by abrupt defervescence and a blanching truncal rash.\n- Caused by HHV-6; the main risk during the febrile phase is febrile seizure, not the rash itself.",
    536: "- CORRECT: B (Steeple sign).\n- Subglottic narrowing on AP neck radiograph produces the steeple sign, supporting croup diagnosis.\n- All croup patients benefit from a single dose of dexamethasone; nebulized epinephrine is added for moderate-to-severe stridor at rest.",
    537: "- CORRECT: D (2 years of chemotherapy is NOT part of the Rule of 2s).\n- Meckel diverticulum follows the Rule of 2s: 2% prevalence, 2 feet from ileocecal valve, 2 inches long, 2 types of ectopic tissue, presents before age 2.\n- Painless rectal bleeding in a young child from ectopic gastric mucosa is the classic symptomatic presentation.",
    538: "- CORRECT: B (Boys age 4-8 with a painless limp).\n- Legg-Calve-Perthes is idiopathic AVN of the femoral head in young children, with a strong male predominance.\n- Insidious limp or groin/thigh/knee pain with limited hip abduction and internal rotation should prompt hip imaging.",
    539: "- CORRECT: C (Focal features or recurrence within 24 hours).\n- Complex febrile seizures are defined by focal onset, duration >15 minutes, or recurrence within the same febrile illness.\n- Simple febrile seizures are benign and do not require EEG, neuroimaging, or antiepileptic therapy.",
    540: "- CORRECT: B (Does NOT cross suture lines).\n- Cephalohematoma is a subperiosteal bleed confined by periosteal attachments at suture lines, unlike caput succedaneum which crosses sutures.\n- Cephalohematoma may take weeks to resolve and can be associated with underlying linear skull fracture.",
    541: "- CORRECT: B (Atrial septal defect).\n- ASD produces a fixed split S2 because the interatrial shunt equalizes ventricular filling across the respiratory cycle.\n- Unlike physiologic splitting, the A2-P2 interval does not vary with inspiration or expiration.",
    542: "- CORRECT: B (Testicular cancer and infertility).\n- Cryptorchidism raises testicular cancer risk 4-8-fold and impairs spermatogenesis due to elevated scrotal temperature.\n- Orchiopexy is recommended by 6-12 months of age to optimize fertility potential and facilitate future examination.",
    543: "- CORRECT: B (Parvovirus B19).\n- Parvovirus B19 causes erythema infectiosum with the hallmark slapped-cheek rash followed by a lacy reticular body rash.\n- In patients with chronic hemolytic anemias (e.g., sickle cell), parvovirus can trigger transient aplastic crisis due to its tropism for erythroid precursors.",
    544: "- CORRECT: B (Absence of ganglion cells in the distal colon).\n- Hirschsprung disease results from failed neural crest cell migration, leaving the distal bowel aganglionic and tonically contracted.\n- Failure to pass meconium within 48 hours is the classic neonatal presentation; diagnosis is confirmed by rectal suction biopsy.",
    545: "- CORRECT: B (Bulging TM with middle ear effusion and acute inflammation).\n- A red TM alone does not diagnose AOM; bulging, decreased mobility, and signs of acute infection are required.\n- Per AAP guidelines, observation without antibiotics may be appropriate for mild AOM in children over 2 years without severe symptoms.",
    546: "- CORRECT: A (Delayed bone age).\n- Constitutional delay is a normal growth variant where skeletal maturation lags behind chronological age, preserving growth potential.\n- A positive family history of late puberty and normal growth velocity for bone age help distinguish it from pathologic short stature.",
    547: "- CORRECT: C (Supportive care: hydration, oxygen, nasal suctioning).\n- No pharmacologic therapy (bronchodilators, steroids, or antibiotics) has been shown to change outcomes in bronchiolitis.\n- Palivizumab prophylaxis is indicated for high-risk infants (preterm, hemodynamically significant CHD, chronic lung disease) to prevent severe RSV disease.",
    548: "- CORRECT: B (Retinoblastoma).\n- Leukocoria (absent red reflex/white pupillary reflex) is the most common presenting sign of retinoblastoma and requires urgent ophthalmologic referral.\n- RB1 gene inactivation follows the Knudson two-hit model; heritable forms present earlier and often bilaterally.",
    549: "- CORRECT: B (Hands and feet: swelling and peeling).\n- In CRASH, H = hand/foot changes (acute edema progressing to periungual desquamation in the subacute phase).\n- The most critical complication is coronary artery aneurysm; timely IVIG plus aspirin within 10 days of fever onset reduces this risk from ~25% to <5%.",
    550: "- CORRECT: B (After 24 hours, peaking at day 3-5).\n- Physiologic jaundice reflects the normal transition to independent bilirubin metabolism with immature hepatic conjugation.\n- Jaundice appearing within the first 24 hours is always pathologic and requires urgent evaluation (hemolysis, sepsis, etc.).",
    551: "- CORRECT: B (Back to sleep on a firm surface, no loose bedding/toys).\n- Supine sleeping position is the single most important modifiable factor for SIDS prevention.\n- Room-sharing without bed-sharing is recommended; additional measures include pacifier use, avoiding overheating, and a smoke-free environment.",
    552: "- CORRECT: B (Malrotation with volvulus).\n- Bilious vomiting in a neonate is a surgical emergency because midgut volvulus can produce complete mesenteric vascular occlusion and bowel infarction within hours.\n- Obtain an emergent upper GI series; do not delay surgical consultation.",
    553: "- CORRECT: B (Iron deficiency anemia from microscopic GI bleeding).\n- Cow's milk before age 1 causes occult intestinal blood loss, has poor iron bioavailability, and displaces iron-rich foods.\n- Breast milk or iron-fortified formula is recommended for the first 12 months; whole cow's milk can be introduced at age 1.",
    554: "- CORRECT: B (Musical/vibratory, systolic, LLSB, softer with standing).\n- Still's murmur is the most common innocent murmur of childhood and has no associated structural heart disease.\n- Innocent murmurs decrease with standing (reduced preload) and increase with fever, anemia, or anxiety; any diastolic murmur is pathologic.",
    555: "- CORRECT: B (Yes, highly contagious via fecal-oral route and respiratory droplets).\n- Coxsackievirus A16 and enterovirus 71 are the primary causative agents; fecal shedding persists for weeks after clinical recovery.\n- Oral vesicles cause painful feeding; supportive care with adequate hydration is the mainstay of treatment.",
    556: "- CORRECT: A (Renal ultrasound).\n- AAP guidelines recommend renal/bladder ultrasound after a first febrile UTI in children 2-24 months to evaluate for structural anomalies.\n- VCUG is reserved for recurrent febrile UTI, abnormal ultrasound findings, or atypical clinical features suggesting vesicoureteral reflux.",
    557: "- CORRECT: B (A viral infection/URI).\n- Transient synovitis is the most common cause of acute hip pain in children aged 3-8 and typically follows a recent viral illness.\n- Distinguishing it from septic arthritis is critical: a well-appearing, afebrile child with normal or mildly elevated inflammatory markers favors transient synovitis.",
    558: "- CORRECT: B (Pneumococcal sepsis).\n- Functional asplenia from repeated splenic infarction in sickle cell disease leaves children highly vulnerable to encapsulated organisms, especially S. pneumoniae.\n- Prophylactic penicillin is started by 2 months of age and continued through at least age 5, along with pneumococcal vaccination.",
    559: "- CORRECT: B (Developing brain / neurocognitive damage).\n- Lead has no safe blood level in children; even low levels impair IQ, attention, and behavior during critical neurodevelopmental windows.\n- CDC reference value is 3.5 mcg/dL; sources include lead paint in pre-1978 housing, contaminated water, and imported goods.",
    560: "- CORRECT: B (Polyuria, polydipsia, and weight loss).\n- These classic osmotic symptoms result from hyperglycemia exceeding the renal glucose threshold, causing glycosuria and obligate water loss.\n- New nocturnal enuresis in a previously toilet-trained child is an important early clue; up to 30% of children present in DKA at diagnosis.",
    561: "- CORRECT: B (Non-bilious, projectile vomiting).\n- Pyloric stenosis causes gastric outlet obstruction proximal to the ampulla, so vomitus is always non-bilious.\n- Classic presentation is a 3-6-week-old firstborn male with progressive projectile vomiting and a palpable 'olive' in the epigastrium; ultrasound confirms the diagnosis.",
    562: "- CORRECT: B (Reassurance; resolves spontaneously).\n- Neonatal acne is a benign, self-limited condition driven by maternal/adrenal androgens and Malassezia colonization.\n- No treatment is needed; it typically clears within weeks to a few months without scarring.",
    563: "- CORRECT: B (Pain when extending the knee with the hip flexed at 90 degrees).\n- Kernig sign detects meningeal irritation by stretching inflamed spinal nerve roots.\n- Sensitivity is low (~5%), so a negative test does not rule out meningitis; clinical suspicion should drive LP decision-making.",
    564: "- CORRECT: B (Biennial mammography from age 40 to 74).\n- The 2024 USPSTF update lowered the screening start age to 40 for average-risk women, based on rising incidence in younger women.\n- This is a Grade B recommendation; screening every 2 years balances cancer detection against false-positive callbacks and overdiagnosis.",
    565: "- CORRECT: B (Primary HPV testing alone every 5 years).\n- HPV testing has higher sensitivity for CIN3+ than cytology alone and targets the causative agent directly.\n- Acceptable alternatives include Pap alone every 3 years or co-testing every 5 years; screening can stop after age 65 with adequate prior negative results.",
    566: "- CORRECT: B (Yes; ACS 2023 removed the quit-time restriction for >=20 pack-year smokers).\n- Under the ACS 2023 guideline, annual low-dose CT is recommended for ages 50-80 with >=20 pack-years regardless of when they quit.\n- Note that USPSTF 2021 criteria still retain a 15-year quit-time limit; know which guideline your practice follows.",
    567: "- CORRECT: B (Age 45).\n- Both ACS and USPSTF now recommend starting average-risk CRC screening at 45, driven by rising incidence in younger adults.\n- Colonoscopy every 10 years, annual FIT, or FIT-DNA every 3 years are all acceptable options; a positive stool-based test always requires follow-up colonoscopy.",
    568: "- CORRECT: A (Age 50).\n- ACIP updated recommendations now advise routine pneumococcal vaccination starting at age 50 (previously 65 for healthy adults).\n- PCV20 as a single dose is the simplest option; alternatively, PCV15 followed by PPSV23 at least 1 year later provides comparable coverage.",
    569: "- CORRECT: B (Adults 60+ routinely; ages 50-59 with increased risk).\n- RSV vaccination is recommended for adults 60 and older, with expanded eligibility for high-risk adults aged 50-59 (e.g., COPD, CHF, immunocompromise).\n- This patient with COPD at age 58 qualifies under the high-risk expansion.",
    570: "- CORRECT: B (Adults 65+ and moderately/severely immunocompromised).\n- A second dose of the updated COVID-19 vaccine targets populations with reduced or less durable immune responses.\n- Immunosenescence and iatrogenic immunosuppression both reduce vaccine-induced antibody durability, justifying the additional dose.",
    571: "- CORRECT: B (GLP-1 RA or SGLT2 inhibitor with proven CV benefit, independent of A1c).\n- ADA 2025 standards recommend cardiorenal-benefit-driven agent selection in T2DM with established ASCVD, regardless of baseline glycemic control.\n- This reflects a shift from glucocentric prescribing to comorbidity-directed pharmacotherapy.",
    572: "- CORRECT: B (Prediabetes).\n- Fasting glucose 100-125 mg/dL or A1c 5.7-6.4% meets ADA criteria for prediabetes.\n- Structured lifestyle intervention (weight loss of 7%, 150 min/week moderate activity) reduces progression to T2DM by ~58% per the DPP trial.",
    573: "- CORRECT: B (SGLT2 inhibitors).\n- SGLT2 inhibitors are now one of the four pillars of HFrEF GDMT (with ARNI/ACEi/ARB, beta-blocker, and MRA), recommended regardless of diabetes status.\n- DAPA-HF and EMPEROR-Reduced demonstrated reduced HF hospitalization and CV death in patients with and without diabetes.",
    574: "- CORRECT: B (>=130/80 mmHg).\n- The 2017 ACC/AHA guidelines lower the pharmacotherapy threshold to 130/80 for patients with >=10% 10-year ASCVD risk, diabetes, CKD, or known CVD.\n- For lower-risk patients (<10% ASCVD risk), the threshold for medication remains 140/90 after lifestyle optimization.",
    575: "- CORRECT: C (Spironolactone).\n- The PATHWAY-2 trial demonstrated spironolactone is the most effective fourth-line agent for resistant hypertension.\n- This works because unrecognized hyperaldosteronism is a frequent contributor to treatment resistance; monitor potassium and renal function.",
    576: "- CORRECT: B (Add ICS to form LAMA/LABA/ICS triple therapy).\n- GOLD 2024 guidelines use blood eosinophils as a biomarker; counts >=300 cells/mcL strongly favor ICS addition.\n- The IMPACT and ETHOS trials showed triple therapy reduces exacerbations and mortality in eosinophilic COPD.",
    577: "- CORRECT: B (As-needed low-dose ICS-formoterol).\n- GINA 2024 recommends against SABA-only treatment at any asthma severity because it does not address underlying inflammation.\n- ICS-formoterol as a single reliever ensures every rescue dose delivers both bronchodilation and anti-inflammatory treatment.",
    578: "- CORRECT: C (Either CBT or a second-generation antidepressant as monotherapy).\n- The 2024 ACP guideline considers CBT and SGAs equivalent first-line options for acute MDD, with choice guided by patient preference and access.\n- Combination therapy (CBT + medication) is reserved for severe, recurrent, or treatment-resistant cases.",
    579: "- CORRECT: C (Moderately severe depression).\n- PHQ-9 scores of 15-19 indicate moderately severe depression; a score >=10 has ~88% sensitivity and specificity for MDD.\n- Use the PHQ-9 both for screening and for tracking treatment response over time.",
    580: "- CORRECT: B (Women 65+ and postmenopausal women <65 at increased fracture risk).\n- USPSTF recommends DXA screening for all women 65 and older, and for younger postmenopausal women with risk factors (e.g., low body weight, smoking, family history, steroid use).\n- FRAX or similar tools help identify postmenopausal women under 65 who meet the screening threshold.",
    581: "- CORRECT: B (Comprehensive lifestyle intervention: diet, physical activity, behavioral therapy).\n- Lifestyle modification is first-line for all patients with obesity; even 5-10% weight loss significantly improves cardiometabolic outcomes.\n- Pharmacotherapy (e.g., GLP-1 RAs) and bariatric surgery are adjuncts when lifestyle alone is insufficient, not replacements for it.",
    582: "- CORRECT: B (12 months).\n- AAP/AAPOS guidelines recommend instrument-based vision screening (photoscreening or autorefraction) beginning at age 12 months.\n- Early detection of amblyopia risk factors during the critical visual development window is essential for effective treatment.",
    583: "- CORRECT: C (Combined oral contraceptive).\n- Combined hormonal contraceptives are CDC MEC Category 4 (absolute contraindication) in women >=35 who smoke due to synergistic arterial thrombosis risk.\n- Progestin-only methods and IUDs remain safe alternatives in this population.",
    584: "- CORRECT: A (All sexually active women under 25).\n- Annual chlamydia screening for all sexually active women under 25 is a USPSTF Grade A recommendation, regardless of symptoms.\n- Most chlamydial infections are asymptomatic; untreated infection can ascend to cause PID, ectopic pregnancy, and tubal infertility.",
    585: "- CORRECT: B (First-generation antihistamines like diphenhydramine).\n- Beers Criteria strongly recommend avoiding highly anticholinergic drugs in older adults due to fall risk, confusion, urinary retention, and cognitive impairment.\n- Use non-anticholinergic alternatives (e.g., second-generation antihistamines like cetirizine or loratadine) when an antihistamine is needed.",
    586: "- CORRECT: B (Add SGLT2 inhibitor).\n- KDIGO 2024 recommends SGLT2 inhibitors for CKD with persistent albuminuria despite maximal RAAS blockade, regardless of diabetes status.\n- Do NOT combine ACE inhibitor + ARB (dual RAAS blockade increases hyperkalemia and AKI risk without added benefit).",
    587: "- CORRECT: A (Increased risk of C. difficile infection).\n- PPI-induced hypochlorhydria reduces the gastric acid barrier, increasing susceptibility to C. difficile and other enteric pathogens.\n- Use the lowest effective PPI dose for the shortest duration; periodically reassess ongoing need at every visit.",
    588: "- CORRECT: C (Target serum uric acid <6.0 mg/dL).\n- The ACR target of <6.0 provides a margin below the urate saturation point (~6.8), promoting crystal dissolution and preventing flares.\n- Start allopurinol low (100 mg/day, lower in CKD) and titrate to target; provide anti-inflammatory prophylaxis during ULT initiation.",
    589: "- CORRECT: B (Obtain 3 sputum samples for AFB smear and culture).\n- Microbiologic confirmation with sputum AFB smears and cultures is essential before or concurrent with starting RIPE therapy.\n- Culture provides species identification and drug susceptibility testing, which guides therapy duration and regimen adjustments.",
    590: "- CORRECT: B (Nitrofurantoin 100 mg BID x 5 days).\n- Nitrofurantoin is a preferred first-line agent for uncomplicated cystitis per IDSA/AUA guidelines, along with TMP-SMX (if local resistance <20%).\n- Fluoroquinolones should be reserved for complicated UTI or pyelonephritis to limit resistance and adverse effects.",
    591: "- CORRECT: B (Amphotericin B + flucytosine induction, then fluconazole consolidation/maintenance).\n- Cryptococcal meningitis in advanced HIV requires aggressive induction therapy; fluconazole monotherapy alone has unacceptable mortality.\n- Elevated opening pressure is common and may require serial therapeutic LPs or a shunt for ICP management.",
    592: "- CORRECT: B (Pseudomonas aeruginosa).\n- Malignant otitis externa is a Pseudomonas-driven skull base osteomyelitis, classically in elderly diabetic or immunocompromised patients.\n- Cranial nerve palsies (especially CN VII) and granulation tissue in the ear canal are hallmark findings; treat with prolonged IV antipseudomonal antibiotics.",
    593: "- CORRECT: A (Within 72 hours, ideally within 2 hours).\n- HIV PEP should be initiated as soon as possible after exposure; efficacy diminishes significantly beyond 72 hours.\n- The standard regimen is a 3-drug ART combination (e.g., tenofovir/emtricitabine + dolutegravir) continued for 28 days.",
    594: "- CORRECT: B (Histoplasmosis).\n- Histoplasma capsulatum is endemic to the Ohio/Mississippi River Valleys; exposure to soil contaminated by bird or bat droppings is the classic risk.\n- Hilar lymphadenopathy with positive urine antigen and compatible exposure history clinches the diagnosis.",
    595: "- CORRECT: B (Oral vancomycin 125 mg QID x 10 days).\n- Oral vancomycin is first-line for initial non-fulminant C. difficile infection per IDSA/SHEA guidelines; fidaxomicin is an alternative with lower recurrence rates.\n- Metronidazole is no longer preferred as first-line for C. difficile in adults.",
    596: "- CORRECT: B (Doxycycline 100 mg BID x 7 days).\n- CDC 2021 guidelines shifted the preferred chlamydia treatment from single-dose azithromycin to doxycycline based on superior cure rates, especially for rectal infection.\n- Test of cure is not routine but is recommended in pregnancy; always treat sexual partners.",
    597: "- CORRECT: A (Doxycycline 100 mg BID x 10-14 days).\n- Doxycycline is the preferred first-line for early localized and early disseminated Lyme disease in non-pregnant adults and children >=8 years.\n- Erythema migrans is a clinical diagnosis; serologic testing is insensitive in early disease and should not delay treatment.",
    598: "- CORRECT: C (MMR vaccine, if CD4 >=200).\n- MMR is the notable exception among live vaccines in HIV: it may be given when CD4 is >=200 cells/mcL.\n- Live attenuated influenza, BCG, and oral polio remain contraindicated in HIV regardless of CD4 count.",
    599: "- CORRECT: B (Topical corticosteroids + vitamin D analogs).\n- For limited plaque psoriasis (<5% BSA), topical therapy is first-line; high-potency steroids for body plaques, lower potency for face/flexures.\n- Systemic therapy (methotrexate, biologics) is reserved for moderate-severe disease or psoriatic arthritis.",
    600: "- CORRECT: B (Nummular eczema).\n- Coin-shaped, well-demarcated eczematous plaques with vesicles and a negative KOH prep distinguish nummular eczema from tinea corporis.\n- Treatment is emollients plus mid-to-high-potency topical corticosteroids; identify and address triggers such as dry skin and irritants.",
    601: "- CORRECT: A (Add oral antibiotic — doxycycline).\n- Moderate acne unresponsive to 12 weeks of topical retinoid + benzoyl peroxide warrants escalation to oral antibiotics (doxycycline or minocycline) combined with topical agents.\n- Always pair oral antibiotics with benzoyl peroxide to prevent resistance, and limit course to 3–4 months before transitioning to topical maintenance.",
    602: "- CORRECT: B (Basal cell carcinoma).\n- A pearly, dome-shaped papule with telangiectasias, rolled borders, and central depression on the nose is classic for nodular BCC, the most common human malignancy.\n- Refer high-risk facial BCCs for Mohs micrographic surgery; counsel on sun protection and perform regular full-skin exams.",
    603: "- CORRECT: B (Treat latent TB for 1–2 months before starting biologic).\n- TNF-alpha maintains granulomas containing latent TB; TNF inhibitors increase reactivation risk 2–30-fold, mandating LTBI treatment before biologic initiation.\n- Preferred LTBI regimens include 3 months weekly INH + rifapentine (3HP); also screen for hepatitis B and ensure live vaccines are given before therapy.",
    604: "- CORRECT: B (Hepatitis C).\n- Lichen planus (flat-topped violaceous papules, Wickham striae, oral reticular patches) has a 2–5-fold association with HCV; screen all patients.\n- Also consider drug-induced lichenoid eruptions (ACE inhibitors, thiazides, NSAIDs) and monitor oral erosive lichen planus for 1–2% malignant transformation risk.",
    605: "- CORRECT: A (Topical metronidazole or ivermectin).\n- Rosacea is distinguished from acne by the absence of comedones; first-line topicals per AAD include metronidazole, ivermectin (superior per ATTRACT trial), and azelaic acid.\n- Topical corticosteroids are strictly contraindicated (cause steroid rosacea with rebound); screen for ocular involvement present in up to 50% of patients.",
    606: "- CORRECT: B (Valacyclovir 1 g TID × 7 days).\n- Valacyclovir within 72 hours of herpes zoster onset accelerates healing, reduces acute pain, and decreases postherpetic neuralgia incidence, with superior bioavailability over acyclovir.\n- Recommend Shingrix (>90% efficacy) for all immunocompetent adults ≥50; PHN risk rises sharply with age, affecting up to 50% of patients over 60.",
    607: "- CORRECT: B (Phototoxic drug reaction).\n- Hydrochlorothiazide is a common photosensitizer; phototoxic reactions are dose-dependent, non-immunologic, and present as exaggerated sunburn sharply confined to sun-exposed areas.\n- Discontinue the offending agent if feasible; prescribe UVA-blocking broad-spectrum sunscreen and counsel on photoprotective clothing and peak UV avoidance.",
    608: "- CORRECT: B (Reassurance — self-limited).\n- Pityriasis rosea is a self-limited eruption (6–8 weeks) with a herald patch followed by a Christmas-tree pattern of oval, salmon-colored patches along skin cleavage lines.\n- Obtain RPR/VDRL in sexually active patients to exclude secondary syphilis, which can mimic this presentation but typically involves palms and soles.",
    609: "- CORRECT: C (Combination tamsulosin + finasteride).\n- For moderate-to-severe LUTS with an enlarged prostate (>30–40 g), combination alpha-blocker + 5-alpha reductase inhibitor reduces clinical progression by 66% (MTOPS/CombAT trials).\n- Counsel that 5-ARIs halve PSA (double measured PSA for cancer screening) and may cause sexual side effects; alpha-blockers provide rapid symptom relief within days.",
    610: "- CORRECT: B (Conservative management with medical expulsive therapy).\n- Ureteral stones ≤5 mm have 68–98% spontaneous passage rates; tamsulosin relaxes distal ureteral smooth muscle and facilitates passage.\n- Use NSAIDs (not opioids) as preferred analgesics; urgent intervention is required for fever/infection with obstruction, solitary kidney obstruction, or stones >10 mm.",
    611: "- CORRECT: C (Vaginal estrogen + consider antibiotic prophylaxis).\n- Recurrent UTIs in postmenopausal women are driven by estrogen-deficiency loss of vaginal Lactobacillus, elevated pH, and uropathogen colonization; topical estrogen reduces recurrence ~50%.\n- Add low-dose antibiotic prophylaxis (nitrofurantoin or TMP-SMX nightly) when estrogen alone is insufficient; vaginal estrogen has minimal systemic absorption and is safe in most patients.",
    612: "- CORRECT: B (Repeat PSA and calculate velocity).\n- A single elevated PSA should be confirmed before biopsy, as transient elevations (BPH, prostatitis, recent ejaculation) are common; PSA velocity >0.75 ng/mL/year raises cancer suspicion.\n- If confirmed, risk-stratify with free PSA, PHI/4Kscore, or multiparametric prostate MRI with PI-RADS scoring before proceeding to biopsy.",
    613: "- CORRECT: B (Pelvic floor muscle training).\n- PFMT (Kegel exercises) is first-line for stress urinary incontinence, achieving 50–75% cure for mild-to-moderate SUI with a supervised 3-month program.\n- Supervised PFMT with biofeedback is superior to self-directed exercises; midurethral sling is the gold standard surgical option (80–90% success) for refractory cases.",
    614: "- CORRECT: B (Epididymal cyst/spermatocele).\n- A painless, transilluminating mass separate from and posterior to the testis with a normal testis is classic for an epididymal cyst or spermatocele.\n- Any solid, non-transilluminating intratesticular mass in a young male must be considered cancer until proven otherwise — obtain scrotal ultrasound for all scrotal masses.",
    615: "- CORRECT: C (Give fibrinolytics if PCI cannot be done within 120 minutes).\n- Primary PCI is preferred for STEMI but must be achievable within 120 minutes of first medical contact; when it cannot, administer fibrinolytics with a door-to-needle goal ≤30 minutes.\n- After fibrinolysis, transfer for coronary angiography within 3–24 hours (pharmacoinvasive strategy); fibrinolytics are most effective within 3 hours of symptom onset.",
    616: "- CORRECT: B (Lumbar puncture).\n- A negative CT does not rule out SAH (sensitivity declines after 6 hours); LP is mandatory when clinical suspicion is high, looking for non-clearing RBCs and xanthochromia.\n- If SAH is confirmed, obtain CT angiography to identify the culprit aneurysm and start nimodipine to prevent delayed cerebral ischemia from vasospasm (days 4–14).",
    617: "- CORRECT: B (Amiodarone 300 mg IV).\n- In the ACLS shockable-rhythm algorithm, amiodarone 300 mg IV is given after the third shock (following epinephrine) for shock-refractory VF/pulseless VT; a second dose of 150 mg may follow.\n- Magnesium is reserved specifically for torsades de pointes; systematically address reversible causes (H's and T's) throughout the arrest.",
    618: "- CORRECT: C (Early endotracheal intubation).\n- Singed nasal hairs, facial burns, and hoarseness indicate inhalation injury with progressive supraglottic edema that can rapidly cause complete airway obstruction — intubate early.\n- Pulse oximetry is unreliable in CO poisoning (cannot distinguish carboxyhemoglobin); obtain co-oximetry and administer 100% O2 to all fire victims.",
    619: "- CORRECT: C (4-factor PCC + IV Vitamin K).\n- 4-factor PCC reverses warfarin within minutes by directly supplying factors II, VII, IX, X in a small volume, preferred over FFP for life-threatening bleeding.\n- IV vitamin K must be given concurrently to sustain reversal and prevent INR rebound after PCC factor levels decline (factor VII half-life ~6 hours).",
    620: "- CORRECT: B (Direct laryngoscopy in OR setting).\n- A stable child with suspected foreign body aspiration (drooling, hot-potato voice, no stridor at rest) should go to the OR for controlled rigid bronchoscopy — avoid bedside maneuvers that risk converting partial to complete obstruction.\n- Emergent Heimlich maneuver or back blows are reserved for complete airway obstruction (unable to speak, cough, or breathe).",
    621: "- CORRECT: C (Hypertonic saline 3% bolus).\n- Severe symptomatic hyponatremia with seizures is a medical emergency; give 100–150 mL of 3% NaCl over 10–20 minutes, targeting a 4–6 mEq/L rise in 1–2 hours.\n- Limit chronic hyponatremia correction to ≤8 mEq/L per 24 hours to avoid osmotic demyelination syndrome; acute water intoxication (<48 hours) tolerates faster correction.",
    622: "- CORRECT: B (IV amphotericin B + emergent surgical debridement).\n- Black necrotic nasal eschar in a patient with DKA is rhinocerebral mucormycosis until proven otherwise — a surgical emergency with 50–80% mortality even with treatment.\n- Both IV liposomal amphotericin B and aggressive surgical debridement are required; antifungals alone cannot penetrate infarcted tissue caused by fungal angioinvasion.",
    623: "- CORRECT: B (Cardiac tamponade).\n- Beck's triad (hypotension, JVD, muffled heart sounds) with bilateral equal breath sounds is pathognomonic for cardiac tamponade, distinguishing it from tension pneumothorax (absent breath sounds on one side).\n- Perform bedside FAST ultrasound for rapid diagnosis; pericardiocentesis is the emergency temporizing procedure, with definitive surgical repair required.",
    624: "- CORRECT: B (Normal grief reaction).\n- At 3 weeks post-loss with waves of sadness, preserved functioning, and no suicidal ideation, this presentation is normal bereavement — not MDD.\n- Red flags prompting reassessment for MDD include suicidal ideation, psychotic features, severe functional decline, or persistent symptoms beyond 2–3 months without improvement.",
    625: "- CORRECT: B (Augment with atypical antipsychotic or switch class).\n- After two adequate SSRI failures, augment (aripiprazole, lithium, or T3) or switch class (SNRI, bupropion, mirtazapine) rather than trying a third SSRI.\n- Esketamine nasal spray and TMS are FDA-approved for treatment-resistant depression; ECT (50–70% remission) is reserved for severe refractory cases or psychotic features.",
    626: "- CORRECT: A (Bipolar I Disorder, Manic Episode).\n- Two weeks of elevated mood, decreased sleep need, pressured speech, and impulsive spending meet DSM-5 criteria for a manic episode (≥7 days), defining Bipolar I.\n- First-line acute mania treatment is lithium, valproate, or a second-generation antipsychotic; antidepressant monotherapy is contraindicated due to mania/rapid-cycling risk.",
    627: "- CORRECT: B (Alzheimer's disease).\n- Insidious progressive short-term memory loss with spatial disorientation over 2 years in a 70-year-old is the hallmark of Alzheimer's disease, the most common dementia (60–80% of cases).\n- Cholinesterase inhibitors (donepezil) are first-line for mild-to-moderate disease; anti-amyloid antibodies (lecanemab) now offer disease-modifying potential in early AD.",
    628: "- CORRECT: B (Methylphenidate or amphetamine).\n- Stimulant medications are first-line for ADHD per AACAP guidelines, with the largest effect sizes (0.8–1.0) and 70–80% response rates across all age groups.\n- Before starting stimulants, screen for cardiovascular risk; monitor height, weight, BP, and heart rate at follow-up. Atomoxetine is first-line when stimulants are contraindicated.",
    629: "- CORRECT: B (Naltrexone).\n- Naltrexone is an opioid antagonist that reduces alcohol craving and reward by blocking endogenous opioid release in the mesolimbic pathway; it is one of three FDA-approved AUD medications.\n- Initiate only after detoxification (not during withdrawal); contraindicated with concurrent opioid use. Acamprosate is an alternative preferred in patients with hepatic impairment.",
    630: "- CORRECT: C (Continue 4–9 months from remission before tapering).\n- APA/NICE guidelines recommend continuing antidepressants 4–9 months after full remission; premature discontinuation is the most common cause of depressive relapse.\n- Patients with ≥3 prior episodes, severe presentations, or residual symptoms should consider indefinite maintenance; fluoxetine's long half-life allows a less gradual taper.",
    631: "- CORRECT: C (Cognitive Behavioral Therapy).\n- CBT-E is first-line for bulimia nervosa, achieving 40–50% binge-purge abstinence by targeting overvaluation of weight/shape and the restriction-binge-purge cycle.\n- Fluoxetine 60 mg daily is the only FDA-approved medication for bulimia (second-line or adjunctive); monitor for hypokalemia, metabolic alkalosis, and dental erosion.",
    632: "- CORRECT: C (Trauma-focused psychotherapy).\n- Trauma-focused therapies (Prolonged Exposure, CPT, EMDR) are first-line for PTSD per VA/DoD and APA guidelines, with stronger evidence than pharmacotherapy.\n- Sertraline and paroxetine are the only FDA-approved PTSD medications; benzodiazepines are specifically not recommended because they impair fear extinction and may worsen outcomes.",
    633: "- CORRECT: B (Inhaled corticosteroid).\n- In COPD with frequent exacerbations and blood eosinophils ≥300 cells/mcL, GOLD 2024 supports adding ICS to LAMA (with LABA) to form triple therapy for this steroid-responsive phenotype.\n- ICS use in COPD is guided by eosinophil count to balance benefit against pneumonia risk; roflumilast and azithromycin are reserved for persistent exacerbators on optimized triple therapy.",
    634: "- CORRECT: C (Yes — meets criteria for annual low-dose CT).\n- USPSTF 2021 recommends LDCT screening for adults aged 50–80 with ≥20 pack-year history who currently smoke or quit within 15 years; this patient (age 50, 35 pack-years, quit 5 years ago) qualifies.\n- Shared decision-making is required before screening; LDCT reduced lung cancer mortality by 20% (NLST) and is not a substitute for smoking cessation counseling.",
    635: "- CORRECT: C (ICS-formoterol as maintenance and reliever therapy — MART).\n- GINA 2024 Step 3 preferred therapy is low-dose ICS-formoterol as both maintenance and reliever with a single inhaler, ensuring anti-inflammatory delivery with every rescue dose.\n- MART reduces severe exacerbations by 45% versus fixed-dose maintenance + SABA rescue; LABA monotherapy without ICS is contraindicated in asthma due to increased death risk.",
    636: "- CORRECT: B (Respiratory fluoroquinolone OR beta-lactam + macrolide).\n- Inpatient non-ICU CAP per ATS/IDSA 2019: levofloxacin/moxifloxacin monotherapy OR ceftriaxone + azithromycin; both cover typical and atypical pathogens.\n- Five days of antibiotics is sufficient for patients achieving clinical stability within 48–72 hours; CURB-65 score of 2 warrants hospital admission.",
    637: "- CORRECT: B (Polysomnography).\n- In-lab polysomnography is the gold standard for diagnosing obstructive sleep apnea, measuring AHI to classify severity (mild 5–14, moderate 15–29, severe ≥30).\n- CPAP is first-line for moderate-to-severe OSA; home sleep testing is acceptable for high-probability patients without significant comorbidities per AASM guidelines.",
    638: "- CORRECT: B (Idiopathic pulmonary fibrosis).\n- Progressive dyspnea, velcro crackles, clubbing, and HRCT showing peripheral basilar honeycombing (UIP pattern) are diagnostic for IPF; biopsy is unnecessary when HRCT is definitive.\n- Pirfenidone and nintedanib slow FVC decline but do not reverse fibrosis; lung transplantation is the only survival-improving intervention. Corticosteroids are ineffective and potentially harmful.",
    639: "- CORRECT: B (Renal biopsy).\n- RBC casts on urinalysis in SLE with active serology (anti-dsDNA, low complement) indicate glomerulonephritis; biopsy is mandatory to classify ISN/RPS class and guide treatment intensity.\n- Class III/IV lupus nephritis requires aggressive immunosuppression (mycophenolate or cyclophosphamide); hydroxychloroquine is recommended for all SLE patients regardless of disease activity.",
    640: "- CORRECT: B (Colchicine, NSAIDs, or corticosteroids).\n- Acute gout flares are treated with NSAIDs, low-dose colchicine (1.2 mg then 0.6 mg within 36 hours), or corticosteroids — all first-line per ACR 2020 guidelines.\n- Urate-lowering agents (allopurinol, febuxostat) are for chronic management; negatively birefringent needle-shaped crystals on polarized microscopy confirm gout over pseudogout.",
    641: "- CORRECT: A (Methotrexate).\n- Methotrexate is the first-line DMARD for RA per ACR 2021 guidelines; start within 3 months of symptom onset to prevent irreversible joint erosions during the window of opportunity.\n- Co-prescribe folic acid 1 mg daily to reduce side effects; if monotherapy insufficient at 3–6 months, escalate to biologic or JAK inhibitor per treat-to-target strategy.",
    642: "- CORRECT: B (Production of short-chain fatty acids regulating immune function and gut barrier integrity).\n- Commensal gut bacteria ferment dietary fiber into SCFAs (butyrate, propionate, acetate) that nourish colonocytes, strengthen tight junctions, and promote anti-inflammatory regulatory T-cell differentiation.\n- Recommend 25–35 g/day dietary fiber from diverse plant sources to support robust SCFA production and microbial diversity.",
    643: "- CORRECT: B (The vagus nerve, microbial metabolites, and immune signaling).\n- The gut-brain axis communicates bidirectionally via vagal afferents (~80% of vagal fibers), SCFAs crossing the blood-brain barrier, and systemic cytokines — not via direct bacterial migration.\n- This explains why antidepressants (TCAs, SSRIs) are effective for IBS and why GI and psychiatric conditions frequently co-occur.",
    644: "- CORRECT: B (Clostridioides difficile infection).\n- Antibiotics disrupt colonization resistance by eliminating protective commensal flora, creating an ecological niche for C. difficile spore germination and toxin production.\n- Practice antibiotic stewardship (narrowest spectrum, shortest duration); fecal microbiota transplant achieves >90% cure for recurrent CDI by restoring microbial diversity.",
    645: "- CORRECT: B (Probiotics have proven benefit for specific conditions like antibiotic-associated diarrhea, but evidence for general health is limited).\n- Probiotic efficacy is strain-specific: S. boulardii and L. rhamnosus GG for antibiotic-associated diarrhea (NNT ~8–13); VSL#3 for pouchitis remission maintenance.\n- For general gut health, recommend dietary fermented foods and high-fiber diets over supplements, as they more consistently improve microbial diversity.",
    646: "- CORRECT: C (Plant-rich diet high in dietary fiber and fermented foods).\n- Dietary fiber is the primary fuel for beneficial gut bacteria; fermented foods (yogurt, kefir, kimchi) increased microbiome diversity and reduced 19 inflammatory markers in the Stanford trial.\n- Recommend diverse plant intake (≥30 different plant foods per week) plus regular fermented foods as the most evidence-based strategy for gut microbial health.",
    647: "- CORRECT: B (Plant-based diet emphasizing fruits, vegetables, whole grains, legumes, and nuts).\n- AHA 2021 dietary guidance prioritizes plant-predominant eating patterns for CV risk reduction; PREDIMED showed ~30% reduction in major CV events with a Mediterranean diet.\n- Focus on overall dietary patterns rather than individual nutrients: minimize ultra-processed foods, added sugars, and sodium while maximizing whole plant foods.",
    648: "- CORRECT: B (Plant-based diets can improve glycemic control and are a recommended dietary pattern for diabetes management).\n- The ADA Standards of Care lists plant-based diets among recommended patterns for T2DM; benefits include improved HbA1c, reduced insulin resistance, and lower CV risk.\n- Patients on insulin or sulfonylureas need proactive dose reduction to prevent hypoglycemia; with strict vegan diets, supplement vitamin B12 universally.",
    649: "- CORRECT: B (Plant foods filling at least 2/3 of the plate).\n- The AICR recommends plant foods (vegetables, fruits, whole grains, legumes) constitute at least 2/3 of the plate for cancer prevention based on fiber, antioxidant, and phytochemical mechanisms.\n- Processed meat is a Group 1 carcinogen (18% increased CRC risk per 50 g/day); counsel patients to limit processed and red meat intake.",
    650: "- CORRECT: B (Plant-rich diet emphasizing fruits, vegetables, whole grains, and low-fat dairy while limiting sodium and saturated fat).\n- DASH reduces SBP by ~5.5 mmHg; combined with sodium restriction to 1,500 mg/day, reductions reach 6–11 mmHg — comparable to monotherapy per 2017 ACC/AHA guidelines.\n- Its synergistic potassium, calcium, magnesium, and fiber content is more effective than any single mineral supplement for blood pressure reduction.",
    651: "- CORRECT: B (Low caloric density and high fiber content promote satiety with fewer calories).\n- Whole plant foods activate gastric stretch receptors and gut satiety hormones (GLP-1, PYY) before caloric excess occurs because of their high volume-to-calorie ratio.\n- Clinical trials show 10–12 kg weight loss at 12 months with ad libitum plant-based eating; calorie counting is often unnecessary with whole-food, plant-rich diets.",
    652: "- CORRECT: A (Atherosclerosis, diabetes complications, and neurodegenerative diseases).\n- Oxidative stress drives atherosclerosis via LDL oxidation and foam cell formation, diabetic complications via hyperglycemia-induced mitochondrial ROS, and neurodegeneration due to the brain's high O2 demand.\n- Dietary phytochemicals from colorful fruits and vegetables activate the Nrf2 antioxidant defense pathway, linking plant-rich diets to chronic disease prevention.",
    653: "- CORRECT: B (Mediterranean diet rich in polyphenols and antioxidants).\n- PREDIMED demonstrated ~30% CV event reduction and decreased oxidative stress biomarkers with a Mediterranean diet supplemented with olive oil or nuts.\n- Whole food antioxidants work synergistically (olive oil hydroxytyrosol, berry anthocyanins, vegetable carotenoids, nut vitamin E) in ways isolated supplements cannot replicate.",
    654: "- CORRECT: B (Isolated supplements cannot replicate the complex synergy of whole food antioxidants and may disrupt redox signaling).\n- Large RCTs (ATBC, CARET, SELECT) showed no benefit and potential harm from antioxidant supplements because high-dose isolates disrupt beneficial ROS signaling for immune function and tumor surveillance.\n- Recommend antioxidant-rich dietary patterns rather than supplements; whole foods modulate (not abolish) redox balance via Nrf2 activation.",
    655: "- CORRECT: B ('What would it look like if you were able to fit exercise into your routine?').\n- This open-ended evocative question elicits the patient's own change talk and solutions — the core mechanism of motivational interviewing — rather than lecturing or prescribing.\n- Directive statements increase resistance in ambivalent patients; MI avoids the righting reflex and instead amplifies the patient's own arguments for change.",
    656: "- CORRECT: B (Explore and amplify the patient's own change talk while respecting their autonomy).\n- In MI, ambivalence is the expected state before change; the clinician selectively reflects and elaborates on change talk rather than arguing or prescribing solutions.\n- Affirming patient autonomy paradoxically reduces resistance; avoid the expert trap of confronting, lecturing, or immediately prescribing pharmacotherapy.",
    657: "- CORRECT: B (Activation of the parasympathetic nervous system via vagal stimulation, reducing heart rate and blood pressure).\n- Slow diaphragmatic breathing (~6 breaths/min) maximizes respiratory sinus arrhythmia and vagal tone, shifting autonomic balance from sympathetic to parasympathetic dominance.\n- Regular practice (10–15 min/day) can reduce SBP by 4–6 mmHg — a zero-cost, zero-side-effect adjunct to antihypertensive pharmacotherapy.",
    658: "- CORRECT: C (Improved endothelial function with increased nitric oxide bioavailability and reduced arterial stiffness).\n- Exercise-generated shear stress activates eNOS, increasing nitric oxide production that promotes vasodilation, inhibits platelet aggregation, and is atheroprotective.\n- Each 1-MET increase in cardiorespiratory fitness reduces cardiovascular and all-cause mortality by 12–15% (2018 Physical Activity Guidelines).",
    659: "- CORRECT: B (Increased BDNF expression promoting hippocampal neurogenesis and synaptic plasticity).\n- Exercise stimulates BDNF via the muscle-derived irisin/PGC-1-alpha pathway; 12 weeks of aerobic exercise increases hippocampal volume by ~2%, reversing 1–2 years of age-related atrophy.\n- Exercise produces antidepressant effect sizes comparable to pharmacotherapy for mild-to-moderate MDD; recommend 150 min/week moderate aerobic activity.",
    660: "- CORRECT: B (Reducing insulin resistance through decreased visceral adiposity and improved mitochondrial function).\n- The DPP showed lifestyle intervention (7% weight loss, 150 min/week activity) reduced T2DM incidence by 58%; DiRECT achieved 46% remission at 1 year with structured weight loss.\n- Exercise activates the insulin-independent AMPK-GLUT4 pathway, improving glucose uptake even in insulin-resistant states; 5–10% weight loss meaningfully improves sensitivity.",
    661: "- CORRECT: B (Preeclampsia with severe features; administer magnesium sulfate and plan delivery).\n- BP >=160/110, platelets <100K, and elevated AST define preeclampsia with severe features (HELLP variant); magnesium sulfate for seizure prophylaxis and delivery planning are priorities.\n- Root cause is failed spiral artery remodeling causing placental ischemia; at 32 weeks with severe features, deliver after stabilization and antenatal corticosteroids.",
    662: "- CORRECT: B (Endometriosis with endometrioma).\n- A chocolate cyst is an ovarian endometrioma containing hemolyzed blood from cyclic hemorrhage of ectopic endometrial tissue; the classic triad is dysmenorrhea, dyspareunia, and infertility (30–50%).\n- Medical treatment (continuous OCPs, progestins, GnRH agonists/antagonists) suppresses estrogen-driven growth; surgical excision is indicated for large endometriomas (>4 cm) or refractory symptoms.",
    663: "- CORRECT: B (Systemic hormone replacement therapy — estrogen + progesterone).\n- MHT is the most effective treatment for vasomotor symptoms (75–80% reduction), appropriate for symptomatic women within 10 years of menopause without contraindications per NAMS 2022.\n- Women with an intact uterus must receive progestogen to prevent endometrial hyperplasia; micronized progesterone is preferred for its more favorable breast safety profile.",
    664: "- CORRECT: B (Bacterial vaginosis).\n- BV is diagnosed by Amsel criteria: thin grayish discharge, pH >4.5, positive whiff test, and clue cells (most specific finding) — reflecting Lactobacillus depletion and anaerobic overgrowth.\n- First-line is metronidazole 500 mg BID x 7 days per CDC STI guidelines; recurrence is common (~50% at 12 months), necessitating patient counseling.",
    665: "- CORRECT: B (Levonorgestrel IUD — Mirena).\n- The LNG-IUD uniquely provides both highly effective contraception (0.2% failure) and treatment of heavy menstrual bleeding, reducing blood loss by 80–97% through local endometrial suppression.\n- The copper IUD worsens menstrual bleeding and is contraindicated in menorrhagia; the LNG-IUD is ACOG-endorsed as first-line medical therapy for heavy periods.",
    666: "- CORRECT: B (Ectopic pregnancy).\n- Beta-hCG above the discriminatory zone (1,500–2,000) with no intrauterine pregnancy on TVUS plus free cul-de-sac fluid is highly suspicious for ectopic pregnancy.\n- Stable unruptured ectopics meeting criteria (hCG <5,000, mass <3.5 cm, no fetal cardiac activity) may be treated with methotrexate; unstable patients require emergent surgical intervention.",
    667: "- CORRECT: B (The 6-day window ending on the day of ovulation).\n- The fertile window reflects sperm survival (up to 5 days) and oocyte viability (12–24 hours); peak conception probability is the 2 days before ovulation (~25–30% per cycle).\n- Counsel intercourse every 1–2 days during the fertile window; urinary LH kits predict ovulation 24–36 hours in advance and are more clinically useful than basal body temperature.",
    668: "- CORRECT: A (Immediate colposcopy).\n- HPV 16/18 positive with NILM cytology requires immediate colposcopy per 2019 ASCCP guidelines because HPV 16 carries ~4% risk of underlying CIN 3+, exceeding the referral threshold.\n- HPV 16 causes 50–60% of cervical cancers with high persistence and E6/p53 binding affinity; non-16/18 high-risk HPV with NILM requires only repeat co-testing in 1 year.",
    669: "- CORRECT: B (Progestogen therapy to protect the endometrium).\n- Chronic anovulation in PCOS produces unopposed estrogen causing endometrial hyperplasia; progestogen (cyclic oral, LNG-IUD, or combined OCPs) reverses hyperplasia and prevents cancer.\n- Simple hyperplasia without atypia has 1% cancer progression risk; follow-up biopsy at 3–6 months confirms regression. The LNG-IUD is the most effective endometrial protection option.",
    670: "- CORRECT: B (Gestational diabetes; fetal macrosomia).\n- GDM is confirmed by the two-step approach (1-hour GCT then 3-hour OGTT with >=2 abnormal Carpenter-Coustan values) at 24–28 weeks; affects 6–9% of pregnancies.\n- Fetal macrosomia is the key risk, driven by the Pedersen hypothesis (maternal hyperglycemia causes fetal hyperinsulinemia and excessive growth), increasing shoulder dystocia and neonatal hypoglycemia.",
    671: "- CORRECT: B (Endometrial biopsy).\n- All postmenopausal bleeding requires evaluation to exclude endometrial cancer (~10% of cases); endometrial thickness >4 mm on TVUS warrants tissue sampling.\n- Office Pipelle biopsy is first-line (90–98% sensitivity); this patient's obesity, diabetes, and 8 mm endometrium are major risk factors for endometrioid adenocarcinoma.",
    672: "- CORRECT: B (Valproic acid is the most teratogenic commonly used AED and should be switched before conception).\n- Valproic acid carries 9–11% major malformation rate (NTDs 1–2%, cardiac defects) and reduces mean IQ by 8–11 points; lamotrigine and levetiracetam are safer alternatives (~2–3%).\n- Start high-dose folic acid (4 mg daily) at least 1–3 months pre-conception; complete the transition off valproate with confirmed seizure control before pregnancy.",
    673: "- CORRECT: C (Postpartum baby blues).\n- Baby blues affect 50–80% of new mothers, begin within days of delivery, and resolve within 2 weeks; preserved bonding, maintained function, and no suicidal ideation distinguish it from PPD.\n- If symptoms persist beyond 2 weeks or include impaired bonding or functional decline, screen for postpartum depression with the Edinburgh Postnatal Depression Scale.",
    674: "- CORRECT: B (BRCA1 confers 60–70% lifetime breast cancer risk and 40–45% ovarian cancer risk).\n- BRCA1 mutations follow autosomal dominant inheritance with impaired homologous recombination DNA repair; BRCA1 tumors are more often triple-negative.\n- Risk-reducing salpingo-oophorectomy by age 35–40 reduces ovarian cancer risk by ~80% and breast cancer risk by ~50%; enhanced surveillance includes annual breast MRI starting at age 25–30.",
    675: "- CORRECT: B (Copper IUD insertion).\n- The copper IUD is the most effective emergency contraception (>99%), fully effective up to 5 days (120 hours) — the only option with near-maximal efficacy at 4 days post-intercourse.\n- Levonorgestrel (Plan B) has diminished efficacy beyond 72 hours and in women >70 kg; the copper IUD also provides ongoing contraception for 10–12 years.",
    676: "- CORRECT: B (First-trimester combined screening — nuchal translucency + serum markers).\n- First-trimester combined screening (11–14 weeks) detects 82–87% of trisomy 21 with 5% false-positive rate; cell-free DNA (NIPT) has >99% sensitivity but remains a screening test.\n- ACOG recommends offering aneuploidy screening to all pregnant patients regardless of age; NT >3.0 mm also warrants fetal echocardiography for cardiac anomalies.",
    680: "- CORRECT: B (Uterine leiomyoma — fibroid).\n- Fibroids are the most common pelvic tumors (estrogen/progesterone-dependent), with >80% cumulative incidence in Black women by age 50; submucosal fibroids cause the most bleeding.\n- Management ranges from hormonal therapy (OCPs, GnRH agents, LNG-IUD) to myomectomy (fertility-preserving) to hysterectomy; uterine artery embolization achieves 85–90% symptom improvement.",
    681: "- CORRECT: B (Combined oral contraceptive pill — estrogen + progestin).\n- Combined hormonal contraceptives are absolutely contraindicated (CDC MEC Category 4) in migraine with aura due to a synergistic 6–8-fold increase in ischemic stroke risk.\n- All progestin-only methods (POP, implant, DMPA, hormonal IUD) and copper IUDs are safe alternatives; the distinction between migraine with vs. without aura is critical for contraceptive counseling.",
    683: "- CORRECT: B (Doxycycline 100 mg BID for 7 days).\n- Per 2021 CDC STI guidelines, doxycycline replaced azithromycin as first-line for chlamydia due to superior cure rates, especially for rectal infections (azithromycin fails 15–22%).\n- Treat partners from the past 60 days; azithromycin 1 g remains first-line in pregnancy. Untreated chlamydia causes PID in 10–15%, the leading infectious cause of preventable infertility.",
    684: "- CORRECT: B (21 years).\n- USPSTF recommends initiating cervical screening at age 21 regardless of sexual debut or HPV vaccination; screening before 21 causes unnecessary procedures with negligible cancer yield.\n- Ages 21–29: cytology every 3 years. Ages 30–65: cytology q3yr, HPV q5yr, or co-testing q5yr. Discontinue after 65 with adequate prior negatives.",
    685: "- CORRECT: B (Cabergoline — dopamine agonist).\n- Prolactinomas are the only pituitary adenomas treated primarily with medical therapy; cabergoline normalizes prolactin in 85–90% and shrinks tumors by 50–80% via D2 receptor agonism.\n- Prolactin levels correlate with tumor size (>200 suggests macroprolactinoma); surgery is reserved for dopamine agonist resistance, intolerance, or visual compromise unresponsive to medical therapy.",
    688: "- CORRECT: B (Polycystic ovary syndrome).\n- PCOS is diagnosed via Rotterdam criteria (2 of 3: anovulation, hyperandrogenism, polycystic morphology) after excluding thyroid disease, CAH, hyperprolactinemia, and Cushing syndrome.\n- Screen with 2-hour OGTT (not fasting glucose, which misses 30–40%); 5–10% weight loss restores ovulation in 30–50%. Letrozole is now first-line for PCOS-related infertility per PPCOS II.",
    689: "- CORRECT: B (Placenta previa; avoid digital cervical exam).\n- Painless bright red third-trimester bleeding suggests placenta previa; digital cervical exam is absolutely contraindicated as it can precipitate catastrophic hemorrhage.\n- Prior cesareans are the strongest risk factor and raise concern for placenta accreta spectrum (risk escalates per additional cesarean); transvaginal ultrasound is safe and diagnostic."
  };
  const getBulletDraftText = (question) => {
    const override = CURATED_BULLET_OVERRIDES[question?.id];
    if (override) return override;
    const canonicalLetter = getCanonicalCorrectLetter(question);
    const authored = typeof question?.bulletExplanation === "string" ? question.bulletExplanation.trim(): "";
    return authored || buildAutoBulletExplanation(question?.explanation || "", canonicalLetter);
  };
  useEffect(() => {
    for (const q of QUESTIONS) {
      if (!q) continue;
      if (typeof q.bulletExplanation === "string" && q.bulletExplanation.trim()) continue;
      q.bulletExplanation = getBulletDraftText(q);
    }
  }, []);
  const bulletStats = useMemo(() => {
    let available = 0;
    let under100 = 0;
    for (const q of QUESTIONS) {
      const text = getBulletDraftText(q);
      if (text && text.trim()) available += 1;
      if (countWords(text) <= 100) under100 += 1;
    }
    return { available, under100, total: QUESTIONS.length };
  }, []);
  const normalizeImageEntries = (images, fallbackAlt) => {
    if (!images) return [];
    const raw = Array.isArray(images) ? images: [images];
    return raw.map((item, idx) => {
      if (typeof item === "string") {
        const src = item.trim();
        if (!src) return null;
        return { src, alt: `${fallbackAlt} ${idx + 1}`, caption: "" };
      }
      if (!item || typeof item !== "object") return null;
      const src = String(item.src || "").trim();
      if (!src) return null;
      return {
        src,
        alt: String(item.alt || `${fallbackAlt} ${idx + 1}`),
        caption: item.caption ? String(item.caption): ""
      };
    }).filter(Boolean);
  };
  const startQuiz = (count) => {
    play("click");
    resetQuizState(shuffleArray(QUESTIONS).slice(0, count), "quiz");
  };
  const startCategoryReview = (categoryId) => {
    play("click");
    setSelectedCategory(categoryId);
    setCurrentView("category-questions");
  };
  const startCategoryQuiz = (categoryId, startIndex = 0) => {
    play("click");
    const categoryQuestions = QUESTIONS.filter((q) => q.categoryId === categoryId);
    resetQuizState(categoryQuestions, "category-review", startIndex);
  };
  const handleAnswer = (answerIndex) => {
    if (selectedAnswer !== null && !gameMode) return;
    setSelectedAnswer(answerIndex);
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const shuffled = getShuffledOptions(currentQuestion);
    const isCorrect = answerIndex === shuffled.correctIndex;
    if (gameMode) {
      if (isCorrect) {
        play("correct");
        setGameScore((prev) => prev + 1);
        setStreak((prev) => {
          const newStreak = prev + 1;
          if (newStreak > maxStreak) setMaxStreak(newStreak);
          if (newStreak >= 10) {
            play("onfire");
          } else if (newStreak === 3 || newStreak === 5) {
            play("streak");
          }
          return newStreak;
        });
      } else {
        play("incorrect");
        setStreak(0);
      }
      setGameAnswers((prev) => [...prev, {
        question: currentQuestion,
        userAnswer: answerIndex,
        isCorrect,
        shuffledCorrectLetter: String.fromCharCode(65 + shuffled.correctIndex),
        userAnswerText: shuffled.options[answerIndex],
        correctAnswerText: shuffled.options[shuffled.correctIndex]
      }]);
      recordAnswer(currentQuestion.id, currentQuestion.categoryId, isCorrect);
      setTimeout(() => {
        if (currentQuestionIndex < quizQuestions.length - 1) {
          play("heartbeat");
          setCurrentQuestionIndex((prev) => prev + 1);
          setSelectedAnswer(null);
        } else {
          const unseen = QUESTIONS.filter((q) => !gameSeenIdsRef.current.has(q.id));
          let moreQuestions;
          if (unseen.length >= 20) {
            moreQuestions = shuffleArray(unseen).slice(0, 50);
          } else {
            moreQuestions = shuffleArray(QUESTIONS).slice(0, 50);
          }
          moreQuestions.forEach((q) => gameSeenIdsRef.current.add(q.id));
          setQuizQuestions((prev) => [...prev,...moreQuestions]);
          setCurrentQuestionIndex((prev) => prev + 1);
          setSelectedAnswer(null);
        }
      }, 700);
    } else {
      play(isCorrect ? "correct": "incorrect");
      setShowExplanation(true);
      recordAnswer(currentQuestion.id, currentQuestion.categoryId, isCorrect);
      setQuizResults((prev) => [...prev, { questionId: currentQuestion.id, isCorrect }]);
    }
  };
  const nextQuestion = () => {
    play("heartbeat");
    if (handsFreeRef.current.active) {
      handsFreeRef.current.phase = "idle";
      setHandsFreePhase("idle");
    }
    if (currentQuestionIndex < quizQuestions.length - 1) {
      setCurrentQuestionIndex((prev) => prev + 1);
      setSelectedAnswer(null);
      setShowExplanation(false);
    } else {
      if (handsFreeMode) stopHandsFree();
      setCurrentView("quiz-complete");
    }
  };
  handleAnswerRef.current = handleAnswer;
  nextQuestionRef.current = nextQuestion;
  const initiateGameMode = () => {
    play("click");
    setShowGameIntro(true);
  };
  const startGameCountdown = () => {
    play("click");
    setShowGameIntro(false);
    let count = 3;
    setGameCountdown(count);
    play("countdown");
    const countdownInterval = setInterval(() => {
      count -= 1;
      if (count <= 0) {
        clearInterval(countdownInterval);
        setGameCountdown(null);
        play("start");
        startGame();
        return;
      }
      setGameCountdown(count);
      play("countdown");
    }, 1e3);
  };
  const gameSeenIdsRef = useRef(/* @__PURE__ */ new Set());
  const startGame = () => {
    highScoreAtGameStartRef.current = progressRef.current?.gameHighScore ?? progress.gameHighScore ?? 0;
    gameSeenIdsRef.current = /* @__PURE__ */ new Set();
    setGameMode(true);
    setGameTimeLeft(180);
    setGameScore(0);
    setGameAnswers([]);
    setStreak(0);
    setMaxStreak(0);
    setGameEnded(false);
    setWarningShown({ oneMin: false, tenSec: false });
    shuffledOptionsRef.current = {};
    const initial = shuffleArray(QUESTIONS).slice(0, 100);
    initial.forEach((q) => gameSeenIdsRef.current.add(q.id));
    setQuizQuestions(initial);
    setCurrentQuestionIndex(0);
    setSelectedAnswer(null);
    setCurrentView("game");
    gameTimerRef.current = setInterval(() => {
      setGameTimeLeft((prev) => {
        if (prev <= 1) {
          clearInterval(gameTimerRef.current);
          play("timeup");
          endGame();
          return 0;
        }
        if (prev === 61) {
          play("warning");
          setWarningShown((p) => ({...p, oneMin: true }));
          setTimeout(() => setWarningShown((p) => ({...p, oneMin: false })), 2e3);
        }
        if (prev === 11) {
          play("warning");
          setWarningShown((p) => ({...p, tenSec: true }));
        }
        return prev - 1;
      });
    }, 1e3);
  };
  const endGame = () => {
    setGameEnded(true);
    setGameMode(false);
    const finalScore = gameScoreRef.current ?? 0;
    setProgress((prev) => {
      const prevHigh = prev.gameHighScore || 0;
      if (finalScore > prevHigh) {
        const updated = {...prev, gameHighScore: finalScore };
        saveProgress(updated);
        return updated;
      }
      return prev;
    });
  };
  const handleSearch = (query) => {
    setSearchQuery(query);

    if (searchTimeoutRef.current) clearTimeout(searchTimeoutRef.current);

    if (query.trim() === "") {
      setSearchResults([]);
      return;
    }

    searchTimeoutRef.current = setTimeout(() => {
      const q = query.toLowerCase();
      const results = QUESTIONS.filter(
        (item) =>
          item.question.toLowerCase().includes(q) ||
          item.options.some((opt) => opt.toLowerCase().includes(q)) ||
          item.explanation.toLowerCase().includes(q) || (item.bulletExplanation || "").toLowerCase().includes(q)
      );
      setSearchResults(results);
    }, 150);
  };
  const highlightText = (text, query) => {
    if (!query || query.trim() === "") return text;
    const parts = text.split(new RegExp(`(${query.replace(/[.*+?^${}()|[\]\\]/g, "\\$&")})`, "gi"));
    return parts.map(
      (part, i) => part.toLowerCase() === query.toLowerCase() ? React.createElement("mark", { key: i, style: { background: "#fef08a", padding: "1px 2px", borderRadius: "2px" } }, part): part
    );
  };
  const startIncorrectReview = () => {
    play("click");
    const incorrectQuestions = QUESTIONS.filter(
      (q) => progress.incorrectQuestions.includes(q.id)
    );
    if (incorrectQuestions.length === 0) return;
    resetQuizState(shuffleArray(incorrectQuestions), "quiz");
  };
  const spacedReviewSchedule = useMemo(() => {
    const schedule = progress.spacedReview || {};
    return Object.entries(schedule).map(([qId, item]) => {
      const id = parseInt(qId, 10);
      return { id, item };
    }).filter(({ id, item }) => !!QUESTION_MAP[id] && item && typeof item.nextReviewAt === "number").sort((a, b) => a.item.nextReviewAt - b.item.nextReviewAt);
  }, [progress.spacedReview]);
  const dueReviewQuestionIds = useMemo(() => {
    const now = Date.now();
    return spacedReviewSchedule.filter(({ item }) => item.nextReviewAt <= now).map(({ id }) => id);
  }, [spacedReviewSchedule]);
  const dueReviewQuestions = useMemo(
    () => dueReviewQuestionIds.map((id) => QUESTION_MAP[id]).filter(Boolean),
    [dueReviewQuestionIds]
  );
  const upcomingReviewQuestionIds = useMemo(() => {
    const now = Date.now();
    return spacedReviewSchedule.filter(({ item }) => item.nextReviewAt > now).map(({ id }) => id);
  }, [spacedReviewSchedule]);
  const upcomingReviewQuestions = useMemo(
    () => upcomingReviewQuestionIds.map((id) => QUESTION_MAP[id]).filter(Boolean),
    [upcomingReviewQuestionIds]
  );
  const nextUpcomingDueText = useMemo(() => {
    if (upcomingReviewQuestionIds.length === 0) return "No upcoming reviews";
    const nextItem = progress.spacedReview?.[upcomingReviewQuestionIds[0]];
    if (!nextItem || typeof nextItem.nextReviewAt !== "number") return "Upcoming reviews";
    const msUntil = nextItem.nextReviewAt - Date.now();
    if (msUntil <= 0) return "Due now";
    if (msUntil < 24 * 60 * 60 * 1e3) return "Next due: later today";
    if (msUntil < 48 * 60 * 60 * 1e3) return "Next due: tomorrow";
    const days = Math.ceil(msUntil / (24 * 60 * 60 * 1e3));
    return `Next due: ${days} days`;
  }, [progress.spacedReview, upcomingReviewQuestionIds]);
  const startDueReview = () => {
    play("click");
    if (dueReviewQuestions.length === 0) return;
    resetQuizState(shuffleArray(dueReviewQuestions), "quiz");
  };
  const startUpcomingReview = () => {
    play("click");
    if (upcomingReviewQuestions.length === 0) return;
    resetQuizState(shuffleArray(upcomingReviewQuestions), "quiz");
  };
  const toggleBookmark = (questionId) => {
    play("click");
    setProgress((prev) => {
      const bookmarks = Array.isArray(prev.bookmarkedQuestions) ? [...prev.bookmarkedQuestions]: [];
      const idx = bookmarks.indexOf(questionId);
      if (idx >= 0) {
        bookmarks.splice(idx, 1);
      } else {
        bookmarks.push(questionId);
      }
      const updated = {...prev, bookmarkedQuestions: bookmarks };
      saveProgress(updated);
      return updated;
    });
  };
  const isBookmarked = (questionId) => {
    return Array.isArray(progress.bookmarkedQuestions) && progress.bookmarkedQuestions.includes(questionId);
  };
  const startBookmarkReview = () => {
    play("click");
    const bookmarkedQs = QUESTIONS.filter(
      (q) => Array.isArray(progress.bookmarkedQuestions) && progress.bookmarkedQuestions.includes(q.id)
    );
    if (bookmarkedQs.length === 0) return;
    resetQuizState(shuffleArray(bookmarkedQs), "quiz");
  };
  const startQuizFromQuestion = (questionId) => {
    play("click");
    const question = QUESTION_MAP[questionId];
    if (!question) return;
    resetQuizState([question], "quiz");
  };
  const goHome = () => {
    play("click");
    if (gameTimerRef.current) {
      clearInterval(gameTimerRef.current);
    }
    setGameMode(false);
    setGameEnded(false);
    setShowGameIntro(false);
    setGameCountdown(null);
    setCurrentView("home");
    setSearchQuery("");
    setSearchResults([]);
  };
  const getCategoryById = (id) => CATEGORIES.find((c) => c.id === id);
  const renderCategoryIcon = (icon, size = 36) => {
    // Optical size compensation for a few Material-symbol / ligature icons that render smaller.
    // Apply only to non-badge contexts (badges use size ~14).
    if (size > 16) {
      const multipliers = {
        shield: 1.85,      // Preventive
        virus: 1.85,       // Infectious Disease
        neuro: 1.85,       // Neurology
        cardio: 1.5,       // Cardiovascular
        pancreas: 1.35,    // Endocrine (moderate boost)
        wizard: 1.3        // Geriatrics
      };
      const mult = multipliers[icon];
      if (mult) size = Math.round(size * mult);
    }
    switch (icon) {
      case "pancreas":
        return /* @__PURE__ */ React.createElement(PancreasIcon, { size });
      case "kidneys":
        return /* @__PURE__ */ React.createElement(KidneyBeansIcon, { size });
      case "telophase":
        return /* @__PURE__ */ React.createElement(TelophaseIcon, { size });
      case "lotion":
        return /* @__PURE__ */ React.createElement(LotionBottleIcon, { size });
      case "heent":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "virus":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "shield":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", borderRadius: "4px" } });
      case "cardio":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "neuro":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "hema":
        return /* @__PURE__ */ React.createElement("img", { src: "data:image/png;base64,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", style: { width: size, height: size, objectFit: "contain", display: "block" } })
      case "wizard":
        return /* @__PURE__ */ React.createElement(GeriatricsWizardIcon, { size });
      case "womens":
        return /* @__PURE__ */ React.createElement(FemaleIcon, { size });
      default:
        return /* @__PURE__ */ React.createElement("span", { style: { fontSize: Math.round(size * 0.9), lineHeight: 1, display: "inline-block" } }, icon);
    }
  };
  const renderBadgeCategoryIcon = (icon) => {
    const baseSize = 14;
    const scaleMap = {
      shield: 1.35,
      virus: 1.35,
      neuro: 1.35,
      cardio: 1.15,
      pancreas: 1.10,
      heent: 1.20,
      telophase: 1.10,
      lotion: 1.05,
      kidneys: 1.05,
      hema: 1.05,
      wizard: 1.2
    };
    const scale = scaleMap[icon] || 1;
    const inner = renderCategoryIcon(icon, baseSize);
    return /* @__PURE__ */ React.createElement(
      "span",
      {
        style: {
          display: "inline-flex",
          width: baseSize,
          height: baseSize,
          alignItems: "center",
          justifyContent: "center",
          flex: `0 0 ${baseSize}px`
        }
      },
      /* @__PURE__ */ React.createElement(
        "span",
        {
          style: {
            display: "inline-flex",
            alignItems: "center",
            justifyContent: "center",
            transform: scale !== 1 ? `scale(${scale})`: void 0,
            transformOrigin: "center",
            lineHeight: 1
          }
        },
        inner
      )
    );
  };

  const ExpandableText = ({ text }) => {
    if (!text) return null;
    const lines = text.split("\n").filter((l) => l.trim() !== "");
    const formatted = lines.map((line, i) => {
      const trimmed = line.trim();
      if (/^[A-Z][A-Z\s\/\-\(\)]{3,}:/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          fontWeight: 700,
          color: "#1e40af",
          marginTop: i > 0 ? "14px": "4px",
          marginBottom: "4px",
          fontSize: "13px",
          letterSpacing: "0.3px",
          borderBottom: "1px solid rgba(30, 64, 175, 0.15)",
          paddingBottom: "3px"
        } }, trimmed);
      }
      if (/^[-â€¢]\s/.test(trimmed) || /^\d+[\.\)]\s/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          paddingLeft: "16px",
          marginBottom: "3px",
          lineHeight: 1.5,
          position: "relative"
        } }, trimmed);
      }
      if (/^CORRECT:/.test(trimmed)) {
        return /* @__PURE__ */ React.createElement("div", { key: i, style: {
          fontWeight: 700,
          color: "#059669",
          fontSize: "14px",
          marginBottom: "8px",
          padding: "6px 10px",
          background: "rgba(5, 150, 105, 0.08)",
          borderRadius: "6px",
          borderLeft: "3px solid #059669"
        } }, trimmed);
      }
      let formatted_line = trimmed;
      return /* @__PURE__ */ React.createElement("div", { key: i, style: {
        marginBottom: "4px",
        lineHeight: 1.55
      } }, formatted_line);
    });
    return /* @__PURE__ */ React.createElement("div", { style: styles.explanationText }, formatted);
  };
  const formatTime = (seconds) => {
    const mins = Math.floor(seconds / 60);
    const secs = seconds % 60;
    return `${mins}:${secs.toString().padStart(2, "0")}`;
  };
  const getStreakStatus = () => {
    if (streak >= 10) return { text: "ON FIRE! \u{1F525}\u{1F525}\u{1F525}", color: "#FF4500" };
    if (streak >= 5) return { text: "HEATING UP! \u{1F525}\u{1F525}", color: "#FF6B35" };
    if (streak >= 3) return { text: "Heating Up! \u{1F525}", color: "#FFA500" };
    return { text: `Streak: ${streak}`, color: "#64748b" };
  };
  const totalQuestions = QUESTIONS.length;
  const answeredCount = Object.keys(progress.answeredQuestions).length;
  const categoryAnsweredCounts = useMemo(() => {
    const counts = {};
    CATEGORIES.forEach((cat) => {
      counts[cat.id] = { answered: 0, correct: 0 };
    });
    Object.entries(progress.answeredQuestions).forEach(([qId, isCorrect]) => {
      const question = QUESTION_MAP[parseInt(qId)];
      if (question) {
        counts[question.categoryId].answered += 1;
        if (isCorrect) counts[question.categoryId].correct += 1;
      }
    });
    return counts;
  }, [progress.answeredQuestions]);
  const correctRate = progress.totalAttempted > 0 ? Math.round(progress.totalCorrect / progress.totalAttempted * 100): 0;
  const styles = useMemo(() => ({
    app: {
      minHeight: "100vh",
      background: "linear-gradient(180deg, #f8fafc 0%, #eef2f7 55%, #e9edf4 100%)",
      fontFamily: "-apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Helvetica, Arial, sans-serif",
      color: "#1e293b",
      padding: effectiveMobile ? "12px": "24px",
      position: "relative",
      overflow: "hidden"
    },
    backgroundPattern: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      backgroundImage: `
        radial-gradient(circle at 20% 10%, rgba(71, 85, 105, 0.035) 0%, transparent 55%),
        radial-gradient(circle at 85% 75%, rgba(51, 65, 85, 0.03) 0%, transparent 55%)
      `,
      pointerEvents: "none",
      zIndex: 0
    },
    content: {
      position: "relative",
      zIndex: 1,
      maxWidth: effectiveMobile ? "100%": "1400px",
      margin: "0 auto"
    },
    header: {
      position: "sticky",
      top: effectiveMobile ? "8px": "16px",
      zIndex: 20,
      display: "flex",
      justifyContent: "space-between",
      alignItems: "center",
      marginBottom: effectiveMobile ? "16px": "24px",
      padding: effectiveMobile ? "10px 12px": "12px 16px",
      background: "rgba(255, 255, 255, 0.82)",
      backdropFilter: "blur(12px)",
      borderRadius: "16px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 8px 24px rgba(15, 23, 42, 0.07)",
      flexWrap: "wrap",
      gap: "12px"
    },
    logo: {
      display: "flex",
      alignItems: "center",
      gap: "12px",
      cursor: "pointer"
    },
    logoText: {
      fontSize: effectiveMobile ? "15px": "18px",
      fontWeight: "800",
      letterSpacing: "-0.02em",
      color: "#0f172a"
    },
    logoSubtext: {
      fontSize: effectiveMobile ? "12px": "13px",
      color: "#475569",
      marginTop: "2px"
    },
    logoMark: {
      width: effectiveMobile ? "34px": "38px",
      height: effectiveMobile ? "34px": "38px",
      borderRadius: "8px",
      objectFit: "contain",
      userSelect: "none"
    },
    controls: {
      display: "flex",
      gap: "8px",
      alignItems: "center"
    },
    explanationToggleWrap: {
      display: "inline-flex",
      background: "rgba(15, 23, 42, 0.08)",
      borderRadius: "20px",
      padding: "3px",
      gap: "2px",
      border: "1px solid rgba(15, 23, 42, 0.06)"
    },
    explanationToggleBtn: (active) => ({
      border: "none",
      borderRadius: "18px",
      padding: effectiveMobile ? "6px 10px" : "7px 14px",
      fontSize: effectiveMobile ? "11px" : "12px",
      fontWeight: 600,
      cursor: "pointer",
      background: active ? "linear-gradient(135deg, #334155, #1e293b)" : "transparent",
      color: active ? "#ffffff" : "#64748b",
      transition: "all 0.25s ease",
      display: "inline-flex",
      alignItems: "center",
      gap: "5px",
      boxShadow: active ? "0 2px 8px rgba(15, 23, 42, 0.25)" : "none",
      letterSpacing: "0.01em",
      lineHeight: 1,
      whiteSpace: "nowrap"
    }),
    soundBtn: {
      width: "40px",
      height: "40px",
      borderRadius: "50%",
      border: "none",
      background: soundEnabled ? "rgba(16, 185, 129, 0.15)": "rgba(239, 68, 68, 0.15)",
      color: soundEnabled ? "#059669": "#dc2626",
      cursor: "pointer",
      fontSize: "18px",
      transition: "all 0.2s"
    },
    chatIconBtn: {
      width: "48px",
      height: "48px",
      border: "none",
      background: "transparent",
      cursor: "pointer",
      display: "inline-flex",
      alignItems: "center",
      justifyContent: "center",
      padding: 0,
      overflow: "hidden",
      borderRadius: "12px",
      transition: "all 0.2s"
    },
    chatButtonIcon: {
      width: "64px",
      height: "64px",
      objectFit: "cover",
      objectPosition: "center",
      display: "block",
      borderRadius: 0
    },
    chatHeaderIconWrap: {
      width: "44px",
      height: "44px",
      display: "inline-flex",
      alignItems: "center",
      justifyContent: "center",
      overflow: "hidden",
      borderRadius: "12px",
      flexShrink: 0
    },
    chatHeaderIconImg: {
      width: "58px",
      height: "58px",
      objectFit: "cover",
      objectPosition: "center",
      display: "block",
      borderRadius: 0
    },
    card: {
      background: "rgba(255, 255, 255, 0.98)",
      backdropFilter: "blur(10px)",
      borderRadius: "16px",
      padding: effectiveMobile ? "16px": "24px",
      marginBottom: "16px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 10px 24px rgba(15, 23, 42, 0.07)"
    },
    statsGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "repeat(2, 1fr)": "repeat(4, 1fr)",
      gap: "16px",
      marginBottom: "24px"
    },
    statCard: {
      background: "linear-gradient(135deg, rgba(71, 85, 105, 0.1), rgba(51, 65, 85, 0.1))",
      borderRadius: "12px",
      padding: "16px",
      textAlign: "center",
      border: "1px solid rgba(71, 85, 105, 0.15)"
    },
    statValue: {
      fontSize: effectiveMobile ? "24px": "32px",
      fontWeight: "700",
      background: "linear-gradient(135deg, #475569, #334155)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent"
    },
    statLabel: {
      fontSize: "12px",
      color: "#64748b",
      marginTop: "4px",
      textTransform: "uppercase",
      letterSpacing: "1px"
    },
    actionGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "1fr": "repeat(2, 1fr)",
      gap: "16px",
      marginBottom: "24px"
    },
    actionCard: (color) => ({
      background: `linear-gradient(135deg, ${color}15, ${color}08)`,
      borderRadius: "16px",
      padding: "24px",
      cursor: "pointer",
      border: `2px solid ${color}30`,
      transition: "all 0.3s",
      textAlign: "center"
    }),
    actionIcon: {
      fontSize: "48px",
      marginBottom: "12px"
    },
    actionTitle: {
      fontSize: "20px",
      fontWeight: "600",
      marginBottom: "8px",
      color: "#1e293b"
    },
    actionDesc: {
      fontSize: "14px",
      color: "#64748b"
    },
    categoryGrid: {
      display: "grid",
      gridTemplateColumns: effectiveMobile ? "repeat(2, 1fr)": "repeat(4, 1fr)",
      gap: "12px"
    },
    categoryCard: (color) => ({
      background: "rgba(255, 255, 255, 0.92)",
      borderRadius: "12px",
      padding: effectiveMobile ? "10px": "12px",
      cursor: "pointer",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      borderTop: `3px solid ${color}cc`,
      boxShadow: "0 6px 16px rgba(15, 23, 42, 0.06)",
      transition: "transform 0.2s ease, box-shadow 0.2s ease",
      textAlign: "center",
      display: "flex",
      flexDirection: "column",
      alignItems: "center",
      justifyContent: "flex-start",
}),
    categoryIcon: {
      marginBottom: "8px",
      display: "flex",
      justifyContent: "center",
      alignItems: "center",
      height: effectiveMobile ? "52px": "64px",
      width: "100%"
    },
    categoryName: {
      fontSize: effectiveMobile ? "12px": "14px",
      fontWeight: "500",
      color: "#334155",
      minHeight: effectiveMobile ? "28px": "32px",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      lineHeight: "1.2"
    },
    searchContainer: {
      marginBottom: "24px"
    },
    searchInput: {
      width: "100%",
      padding: "14px 20px",
      borderRadius: "12px",
      border: "2px solid rgba(0,0,0,0.1)",
      background: "rgba(255, 255, 255, 0.98)",
      color: "#1e293b",
      fontSize: "16px",
      outline: "none",
      transition: "border-color 0.2s",
      boxSizing: "border-box"
    },
    questionCard: {
      background: "rgba(255, 255, 255, 0.98)",
      borderRadius: "20px",
      padding: effectiveMobile ? "16px": "24px",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      boxShadow: "0 10px 24px rgba(15, 23, 42, 0.07)"
    },
    questionHeader: {
      display: "flex",
      justifyContent: "space-between",
      alignItems: "center",
      marginBottom: "14px",
      flexWrap: "wrap",
      gap: "10px"
    },
    questionProgress: {
      fontSize: effectiveMobile ? "13px": "14px",
      color: "#64748b"
    },
    categoryBadge: (color) => ({
      background: `${color}20`,
      color,
      padding: "6px 12px",
      borderRadius: "20px",
      fontSize: "12px",
      fontWeight: "500",
      display: "inline-flex",
      alignItems: "center",
      gap: "6px",
      lineHeight: 1
    }),
    categoryBadgeLarge: (color) => ({
      background: `${color}14`,
      color,
      padding: effectiveMobile ? "12px 18px": "14px 24px",
      borderRadius: "16px",
      fontSize: effectiveMobile ? "15px": "16px",
      fontWeight: "700",
      display: "inline-flex",
      alignItems: "center",
      gap: effectiveMobile ? "12px": "14px",
      lineHeight: 1,
      border: `2px solid ${color}35`,
      letterSpacing: "0.02em",
      boxShadow: `0 2px 8px ${color}18`
    }),
    questionText: {
      fontSize: effectiveMobile ? "21px": "24px",
      lineHeight: "1.55",
      marginBottom: "16px",
      color: "#0f172a",
      fontWeight: "600"
    },
    questionTextCompact: {
      fontSize: effectiveMobile ? "19px": "21px",
      lineHeight: "1.52",
      marginBottom: "12px",
      color: "#0f172a",
      fontWeight: "600"
    },
    quizImageGroup: {
      display: "grid",
      gap: "10px",
      marginBottom: "14px"
    },
    quizImageCard: {
      margin: 0,
      background: "rgba(255, 255, 255, 0.9)",
      border: "1px solid rgba(15, 23, 42, 0.12)",
      borderRadius: "12px",
      overflow: "hidden"
    },
    quizImage: {
      display: "block",
      width: "auto",
      maxWidth: "100%",
      height: "auto",
      maxHeight: effectiveMobile ? "320px": "520px",
      objectFit: "contain",
      margin: "0 auto",
      background: "rgba(148, 163, 184, 0.15)"
    },
    quizImageCaption: {
      fontSize: "12px",
      lineHeight: "1.4",
      color: "#475569",
      padding: "8px 10px"
    },
    optionsContainer: {
      display: "flex",
      flexDirection: "column",
      gap: "9px"
    },
    optionBtn: (isSelected, isCorrect, showResult) => {
      let bg = "rgba(148, 163, 184, 0.14)";
      let border = "rgba(71, 85, 105, 0.35)";
      if (showResult) {
        if (isCorrect) {
          bg = "rgba(16, 185, 129, 0.15)";
          border = "#10b981";
        } else if (isSelected && !isCorrect) {
          bg = "rgba(239, 68, 68, 0.15)";
          border = "#ef4444";
        }
      } else if (isSelected) {
        bg = "rgba(71, 85, 105, 0.15)";
        border = "#475569";
      }
      return {
        padding: effectiveMobile ? "14px 14px": "14px 16px",
        minHeight: effectiveMobile ? "50px": "48px",
        borderRadius: "12px",
        border: `2px solid ${border}`,
        background: bg,
        color: "#334155",
        cursor: showResult ? "default": "pointer",
        fontSize: effectiveMobile ? "15px": "16px",
        lineHeight: "1.4",
        textAlign: "left",
        transition: "all 0.2s"
      };
    },
    explanationBox: {
      background: "rgba(71, 85, 105, 0.08)",
      borderRadius: "12px",
      padding: "20px",
      marginTop: "20px",
      borderLeft: "4px solid #475569"
    },
    explanationTitle: {
      fontSize: "16px",
      fontWeight: "600",
      color: "#334155",
      marginBottom: "12px"
    },
    explanationText: {
      fontSize: "14px",
      lineHeight: "1.45",
      color: "#475569"
    },
    nextBtn: {
      width: "100%",
      padding: effectiveMobile ? "16px": "15px",
      minHeight: effectiveMobile ? "52px": "48px",
      borderRadius: "12px",
      border: "none",
      background: "linear-gradient(135deg, #475569, #334155)",
      color: "white",
      fontSize: effectiveMobile ? "17px": "16px",
      fontWeight: "600",
      cursor: "pointer",
      marginTop: effectiveMobile ? "16px": "18px",
      transition: "transform 0.2s, box-shadow 0.2s",
      boxShadow: "0 4px 15px rgba(71, 85, 105, 0.25)"
    },
    backBtn: {
      padding: effectiveMobile ? "12px 16px": "10px 20px",
      minHeight: effectiveMobile ? "44px": "40px",
      borderRadius: "8px",
      border: "2px solid rgba(0,0,0,0.15)",
      background: "transparent",
      color: "#475569",
      cursor: "pointer",
      fontSize: effectiveMobile ? "15px": "14px",
      marginBottom: effectiveMobile ? "14px": "20px",
      display: "flex",
      alignItems: "center",
      gap: "8px"
    },
    gameTimer: {
      position: "fixed",
      top: effectiveMobile ? "70px": "20px",
      left: "50%",
      transform: "translateX(-50%)",
      background: gameTimeLeft <= 10 ? "linear-gradient(135deg, #ef4444, #dc2626)": gameTimeLeft <= 60 ? "linear-gradient(135deg, #f59e0b, #d97706)": "linear-gradient(135deg, #475569, #334155)",
      padding: "12px 32px",
      borderRadius: "40px",
      fontSize: "28px",
      fontWeight: "700",
      color: "white",
      boxShadow: "0 4px 20px rgba(0,0,0,0.2)",
      zIndex: 100,
      animation: gameTimeLeft <= 10 ? "pulse 0.5s infinite": "none"
    },
    streakCounter: {
      position: "fixed",
      top: effectiveMobile ? "70px": "20px",
      right: "20px",
      background: "rgba(255, 255, 255, 0.98)",
      padding: "10px 20px",
      borderRadius: "12px",
      fontSize: "16px",
      fontWeight: "600",
      color: getStreakStatus().color,
      boxShadow: "0 4px 15px rgba(0,0,0,0.1)",
      zIndex: 100,
      border: `2px solid ${getStreakStatus().color}30`,
      transition: "all 0.3s"
    },
    countdownOverlay: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      background: "rgba(255, 255, 255, 0.98)",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      zIndex: 1e3
    },
    countdownNumber: {
      fontSize: "150px",
      fontWeight: "900",
      background: "linear-gradient(135deg, #475569, #334155, #1e293b)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent",
      animation: "countdownPulse 1s ease-out"
    },
    gameIntroOverlay: {
      position: "fixed",
      top: 0,
      left: 0,
      right: 0,
      bottom: 0,
      background: "rgba(255, 255, 255, 0.98)",
      display: "flex",
      alignItems: "center",
      justifyContent: "center",
      zIndex: 1e3,
      padding: "20px"
    },
    gameIntroCard: {
      background: "linear-gradient(135deg, rgba(255, 255, 255, 0.98), rgba(248, 250, 252, 0.95))",
      borderRadius: "24px",
      padding: effectiveMobile ? "24px": "40px",
      maxWidth: "500px",
      textAlign: "center",
      border: "2px solid rgba(71, 85, 105, 0.2)",
      boxShadow: "0 20px 60px rgba(71, 85, 105, 0.15)"
    },
    gameIntroIcon: {
      fontSize: "64px",
      marginBottom: "20px"
    },
    gameIntroTitle: {
      fontSize: "32px",
      fontWeight: "800",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      WebkitBackgroundClip: "text",
      WebkitTextFillColor: "transparent",
      marginBottom: "20px"
    },
    gameIntroDesc: {
      fontSize: "16px",
      color: "#64748b",
      lineHeight: "1.8",
      marginBottom: "24px"
    },
    gameIntroFeature: {
      display: "flex",
      alignItems: "center",
      gap: "12px",
      padding: "12px",
      background: "rgba(0,0,0,0.03)",
      borderRadius: "8px",
      marginBottom: "12px",
      textAlign: "left",
      color: "#334155"
    },
    beginBtn: {
      width: "100%",
      padding: "18px",
      borderRadius: "12px",
      border: "none",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      color: "white",
      fontSize: "20px",
      fontWeight: "700",
      cursor: "pointer",
      marginTop: "20px",
      transition: "transform 0.2s",
      boxShadow: "0 4px 20px rgba(245, 158, 11, 0.3)"
    },
    warningBanner: {
      position: "fixed",
      top: effectiveMobile ? "120px": "80px",
      left: "50%",
      transform: "translateX(-50%)",
      background: "linear-gradient(135deg, #f59e0b, #ef4444)",
      padding: "10px 30px",
      borderRadius: "30px",
      fontSize: "18px",
      fontWeight: "700",
      color: "white",
      zIndex: 100,
      animation: "shake 0.5s ease-in-out",
      boxShadow: "0 4px 20px rgba(245, 158, 11, 0.4)"
    },
    resultsContainer: {
      maxHeight: "400px",
      overflowY: "auto",
      marginTop: "20px"
    },
    resultItem: (isCorrect) => ({
      background: isCorrect ? "rgba(16, 185, 129, 0.08)": "rgba(239, 68, 68, 0.08)",
      borderRadius: "12px",
      padding: "16px",
      marginBottom: "12px",
      borderLeft: `4px solid ${isCorrect ? "#10b981": "#ef4444"}`
    }),
    chatNotice: {
      background: "rgba(245, 158, 11, 0.12)",
      border: "1px solid rgba(245, 158, 11, 0.35)",
      color: "#92400e",
      borderRadius: "10px",
      padding: "10px 12px",
      marginBottom: "12px",
      fontSize: "13px",
      lineHeight: "1.4"
    },
    chatMessageList: {
      maxHeight: effectiveMobile ? "360px": "420px",
      overflowY: "auto",
      border: "1px solid rgba(15, 23, 42, 0.08)",
      borderRadius: "12px",
      background: "rgba(255,255,255,0.92)",
      padding: "10px"
    },
    chatMessageItem: {
      borderBottom: "1px solid rgba(148, 163, 184, 0.2)",
      padding: "8px 4px"
    },
    chatInput: {
      width: "100%",
      border: "1px solid rgba(71, 85, 105, 0.3)",
      borderRadius: "10px",
      padding: "10px 12px",
      fontSize: "14px",
      outline: "none",
      boxSizing: "border-box"
    },
    chatActions: {
      display: "flex",
      gap: "10px",
      marginTop: "12px",
      flexWrap: "wrap"
    },
    chatDeleteBtn: {
      padding: "4px 8px",
      borderRadius: "8px",
      border: "1px solid rgba(239, 68, 68, 0.35)",
      background: "rgba(239, 68, 68, 0.08)",
      color: "#b91c1c",
      cursor: "pointer",
      fontSize: "12px",
      fontWeight: "600"
    },
    secondaryBtn: {
      padding: "10px 14px",
      borderRadius: "10px",
      border: "1px solid rgba(71, 85, 105, 0.28)",
      background: "white",
      color: "#334155",
      cursor: "pointer",
      fontSize: "14px",
      fontWeight: "600"
    },
    progressBar: {
      width: "100%",
      height: "6px",
      background: "rgba(0,0,0,0.08)",
      borderRadius: "3px",
      overflow: "hidden",
      marginTop: "6px"
    },
    progressFill: (percent, color) => ({
      width: `${percent}%`,
      height: "100%",
      background: color || "linear-gradient(135deg, #475569, #334155)",
      borderRadius: "3px",
      transition: "width 0.5s ease"
    })
  }), [effectiveMobile]);
  const renderHome = () => /* @__PURE__ */ React.createElement(React.Fragment, null,
    /* @__PURE__ */ React.createElement("div", { style: styles.statsGrid },
      /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, answeredCount, "/", totalQuestions), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Questions Seen")),
      /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, correctRate, "%"), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Accuracy")),
      /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, progress.gameHighScore), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Game High Score"))
    ),
    /* @__PURE__ */ React.createElement("div", { style: styles.searchContainer }, /* @__PURE__ */ React.createElement(
      "input",
      {
        type: "text",
        placeholder: "Search questions, answers, or topics...",
        style: styles.searchInput,
        value: searchQuery,
        onChange: (e) => handleSearch(e.target.value)
      }
    )),
    searchResults.length > 0 && /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h3", { style: { marginBottom: "16px", color: "#475569" } }, "Search Results (", searchResults.length, searchResults.length > 20 ? " - showing first 20" : "", ")"), /* @__PURE__ */ React.createElement("div", { style: { maxHeight: "400px", overflowY: "auto" } }, searchResults.slice(0, 20).map((q, i) => {
      const cat = getCategoryById(q.categoryId);
      return /* @__PURE__ */ React.createElement(
        "div",
        {
          key: i,
          style: {
            padding: "12px",
            background: "rgba(0,0,0,0.03)",
            borderRadius: "8px",
            marginBottom: "8px",
            cursor: "pointer",
            border: "1px solid rgba(0,0,0,0.06)",
            transition: "all 0.15s ease"
          },
          onClick: () => startQuizFromQuestion(q.id),
          onMouseEnter: (e) => {
            e.currentTarget.style.background = "rgba(37, 99, 235, 0.06)";
            e.currentTarget.style.borderColor = "rgba(37, 99, 235, 0.2)";
          },
          onMouseLeave: (e) => {
            e.currentTarget.style.background = "rgba(0,0,0,0.03)";
            e.currentTarget.style.borderColor = "rgba(0,0,0,0.06)";
          }
        },
        /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", alignItems: "center" } }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(cat.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(cat.icon)), cat.name), /* @__PURE__ */ React.createElement("span", { style: { fontSize: "12px", color: "#94a3b8" } }, "Click to quiz ->")),
        /* @__PURE__ */ React.createElement("p", { style: { marginTop: "8px", fontSize: "14px", color: "#475569", lineHeight: 1.4 } }, highlightText(q.question.substring(0, 120) + (q.question.length > 120 ? "..." : ""), searchQuery))
      );
    }))),
    /* @__PURE__ */ React.createElement("div", { style: styles.actionGrid }, /* @__PURE__ */ React.createElement(
      "div",
      {
        style: styles.actionCard("#475569"),
        onClick: () => startQuiz(3),
        onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
        onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F4DD}"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "3 Random Questions"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "Quick Practice")
    ), /* @__PURE__ */ React.createElement(
      "div",
      {
        style: styles.actionCard("#334155"),
        onClick: () => startQuiz(10),
        onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
        onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F4DA}"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "10 Random Questions"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "Full Practice Session")
    ), /* @__PURE__ */ React.createElement(
      "div",
      {
        style: styles.actionCard("#f59e0b"),
        onClick: initiateGameMode,
        onMouseEnter: (e) => e.currentTarget.style.transform = "translateY(-4px)",
        onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F3AE}"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Game Mode"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, "3 Minutes - Beat Your Score!")
    ), /* @__PURE__ */ React.createElement(
      "div",
      {
        style: {
          ...styles.actionCard("#ef4444"),
          opacity: progress.incorrectQuestions.length === 0 ? 0.5 : 1,
          cursor: progress.incorrectQuestions.length === 0 ? "not-allowed" : "pointer"
        },
        onClick: progress.incorrectQuestions.length > 0 ? startIncorrectReview : null,
        onMouseEnter: (e) => {
          if (progress.incorrectQuestions.length > 0) e.currentTarget.style.transform = "translateY(-4px)";
        },
        onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F504}"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Review Incorrect"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, progress.incorrectQuestions.length, " Questions to Review")
    ), /* @__PURE__ */ React.createElement(
      "div",
      {
        style: {
          ...styles.actionCard("#eab308"),
          opacity: (progress.bookmarkedQuestions?.length || 0) === 0 ? 0.5 : 1,
          cursor: (progress.bookmarkedQuestions?.length || 0) === 0 ? "not-allowed" : "pointer",
          borderColor: "rgba(234, 179, 8, 0.3)",
          background: "linear-gradient(135deg, rgba(234, 179, 8, 0.04), rgba(245, 158, 11, 0.08))"
        },
        onClick: (progress.bookmarkedQuestions?.length || 0) > 0 ? startBookmarkReview : null,
        onMouseEnter: (e) => {
          if ((progress.bookmarkedQuestions?.length || 0) > 0) e.currentTarget.style.transform = "translateY(-4px)";
        },
        onMouseLeave: (e) => e.currentTarget.style.transform = "translateY(0)"
      },
      /* @__PURE__ */ React.createElement("div", { style: styles.actionIcon }, "\u{1F516}"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionTitle }, "Bookmarked"),
      /* @__PURE__ */ React.createElement("div", { style: styles.actionDesc }, progress.bookmarkedQuestions?.length || 0, " Saved Questions")
    )),
    /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h2", { style: { marginBottom: "20px", fontSize: "20px", color: "#1e293b" } }, "Study by Category"), /* @__PURE__ */ React.createElement("div", { style: styles.categoryGrid }, CATEGORIES.map((cat) => {
      const catProgress = progress.categoryProgress[cat.id];
      const catQuestions = QUESTIONS.filter((q) => q.categoryId === cat.id).length;
      const catAnswered = categoryAnsweredCounts[cat.id] || { answered: 0, correct: 0 };
      const answeredPercent = catQuestions > 0 ? Math.round(catAnswered.answered / catQuestions * 100) : 0;
      const correctPercent = catAnswered.answered > 0 ? Math.round(catAnswered.correct / catAnswered.answered * 100) : 0;
      return /* @__PURE__ */ React.createElement(
        "div",
        {
          key: cat.id,
          style: styles.categoryCard(cat.color),
          onClick: () => startCategoryReview(cat.id),
          onMouseEnter: (e) => e.currentTarget.style.transform = "scale(1.03)",
          onMouseLeave: (e) => e.currentTarget.style.transform = "scale(1)"
        },
        /* @__PURE__ */ React.createElement("div", { style: styles.categoryIcon }, renderCategoryIcon(cat.icon, effectiveMobile ? 28 : 36)),
        /* @__PURE__ */ React.createElement("div", { style: styles.categoryName }, cat.name),
        /* @__PURE__ */ React.createElement("div", { style: {
          fontSize: "11px",
          color: "#64748b",
          marginTop: "auto",
          paddingTop: "8px",
          width: "100%"
        } }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", alignItems: "center", marginBottom: "4px" } }, /* @__PURE__ */ React.createElement("span", null, catAnswered.answered, "/", catQuestions, " answered"), catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("span", { style: {
          color: correctPercent >= 80 ? "#16a34a" : correctPercent >= 60 ? "#d97706" : "#dc2626",
          fontWeight: "600"
        } }, correctPercent, "% \u2713")), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(answeredPercent, cat.color) })))
      );
    }))),
    answeredCount > 0 && /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginTop: "32px", paddingTop: "24px", borderTop: "1px solid rgba(0,0,0,0.06)" } }, /* @__PURE__ */ React.createElement("button", { style: { background: "none", border: "1px solid rgba(239, 68, 68, 0.3)", color: "#dc2626", padding: "10px 24px", borderRadius: "8px", cursor: "pointer", fontSize: "13px", fontWeight: "500", transition: "all 0.15s ease" }, onClick: resetAllProgress, onMouseEnter: (e) => { e.currentTarget.style.background = "rgba(239, 68, 68, 0.08)"; }, onMouseLeave: (e) => { e.currentTarget.style.background = "none"; } }, "\u{1F5D1}\uFE0F Reset All Progress"))
  );
  const renderCategoryQuestions = () => {
    if (!selectedCategory) return null;
    const category = getCategoryById(selectedCategory);
    const categoryQuestions = QUESTIONS.filter((q) => q.categoryId === selectedCategory);
    const catAnswered = categoryAnsweredCounts[selectedCategory] || { answered: 0, correct: 0 };
    const answeredPercent = categoryQuestions.length > 0 ? Math.round(catAnswered.answered / categoryQuestions.length * 100): 0;
    const correctPercent = catAnswered.answered > 0 ? Math.round(catAnswered.correct / catAnswered.answered * 100): 0;
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"), /* @__PURE__ */ React.createElement("div", { style: {...styles.card,
      background: `linear-gradient(135deg, ${category.color}18, ${category.color}08)`,
      border: `1px solid ${category.color}40`
    } }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", alignItems: "center", gap: "16px", marginBottom: "16px", flexWrap: "wrap" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "48px", display: "flex", alignItems: "center", justifyContent: "center", width: "96px", height: "96px", flexShrink: 0 } }, renderCategoryIcon(category.icon, 48)), /* @__PURE__ */ React.createElement("div", { style: { flex: 1, minWidth: "180px" } }, /* @__PURE__ */ React.createElement("h2", { style: { margin: 0, fontSize: effectiveMobile ? "22px": "26px", color: "#1e293b" } }, category.name), /* @__PURE__ */ React.createElement("div", { style: { fontSize: "14px", color: "#64748b", marginTop: "4px" } }, catAnswered.answered, " of ", categoryQuestions.length, " questions answered", catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("span", { style: {
      marginLeft: "12px",
      color: correctPercent >= 80 ? "#16a34a": correctPercent >= 60 ? "#d97706": "#dc2626",
      fontWeight: "600"
    } }, correctPercent, "% correct")), /* @__PURE__ */ React.createElement("div", { style: {...styles.progressBar, marginTop: "8px", height: "8px" } }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(answeredPercent, category.color) })))), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", gap: "10px", flexWrap: "wrap" } }, /* @__PURE__ */ React.createElement(
      "button",
      {
        style: {
          padding: "10px 20px",
          borderRadius: "10px",
          border: "none",
          background: `linear-gradient(135deg, ${category.color}, ${category.color}cc)`,
          color: "white",
          cursor: "pointer",
          fontSize: "14px",
          fontWeight: "600",
          transition: "all 0.2s",
          boxShadow: `0 4px 12px ${category.color}40`
        },
        onClick: () => startCategoryQuiz(selectedCategory, 0)
      },
      "\u25B6 Start from Beginning"
    ), catAnswered.answered > 0 && catAnswered.answered < categoryQuestions.length && (() => {
      const firstUnansweredIdx = categoryQuestions.findIndex((q) => !(q.id in progress.answeredQuestions));
      return firstUnansweredIdx > 0 ? /* @__PURE__ */ React.createElement(
        "button",
        {
          style: {
            padding: "10px 20px",
            borderRadius: "10px",
            border: `2px solid ${category.color}60`,
            background: "rgba(255,255,255,0.8)",
            color: category.color,
            cursor: "pointer",
            fontSize: "14px",
            fontWeight: "600",
            transition: "all 0.2s"
          },
          onClick: () => startCategoryQuiz(selectedCategory, firstUnansweredIdx)
        },
        "\u23ED Continue (Q",
        firstUnansweredIdx + 1,
        ")"
      ): null;
    })(), catAnswered.answered > 0 && /* @__PURE__ */ React.createElement("button", { style: { padding: "10px 20px", borderRadius: "10px", border: "1px solid rgba(239, 68, 68, 0.3)", background: "none", color: "#dc2626", cursor: "pointer", fontSize: "13px", fontWeight: "500", transition: "all 0.15s ease", marginLeft: "auto" }, onClick: (e) => { e.stopPropagation(); resetCategoryProgress(selectedCategory); }, onMouseEnter: (e) => { e.currentTarget.style.background = "rgba(239, 68, 68, 0.08)"; }, onMouseLeave: (e) => { e.currentTarget.style.background = "none"; } }, "\u{1F5D1}\uFE0F Reset Category"))), /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h3", { style: { margin: "0 0 16px 0", fontSize: "17px", color: "#1e293b" } }, "Questions (", categoryQuestions.length, ")"), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", flexDirection: "column", gap: "8px" } }, categoryQuestions.map((q, idx) => {
      const wasAnswered = q.id in progress.answeredQuestions;
      const wasCorrect = progress.answeredQuestions[q.id];
      return /* @__PURE__ */ React.createElement(
        "div",
        {
          key: q.id,
          style: {
            display: "flex",
            alignItems: "flex-start",
            gap: "12px",
            padding: effectiveMobile ? "12px": "14px 16px",
            borderRadius: "10px",
            border: `1px solid ${wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.25)": "rgba(220, 38, 38, 0.25)": "rgba(0,0,0,0.08)"}`,
            background: wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.04)": "rgba(220, 38, 38, 0.04)": "rgba(248, 250, 252, 0.6)",
            cursor: "pointer",
            transition: "all 0.2s"
          },
          onClick: () => startCategoryQuiz(selectedCategory, idx),
          onMouseEnter: (e) => {
            e.currentTarget.style.boxShadow = "0 4px 12px rgba(0,0,0,0.08)";
            e.currentTarget.style.transform = "translateY(-1px)";
          },
          onMouseLeave: (e) => {
            e.currentTarget.style.boxShadow = "none";
            e.currentTarget.style.transform = "translateY(0)";
          }
        },
        /* @__PURE__ */ React.createElement("div", { style: {
          width: "28px",
          height: "28px",
          borderRadius: "8px",
          display: "flex",
          alignItems: "center",
          justifyContent: "center",
          fontSize: "13px",
          fontWeight: "700",
          flexShrink: 0,
          marginTop: "1px",
          background: wasAnswered ? wasCorrect ? "rgba(22, 163, 74, 0.15)": "rgba(220, 38, 38, 0.15)": "rgba(0,0,0,0.06)",
          color: wasAnswered ? wasCorrect ? "#16a34a": "#dc2626": "#94a3b8"
        } }, wasAnswered ? wasCorrect ? "\u2713": "\u2717": idx + 1),
        /* @__PURE__ */ React.createElement("div", { style: {
          flex: 1,
          fontSize: effectiveMobile ? "13px": "14px",
          lineHeight: "1.5",
          color: "#334155"
        } }, q.question.length > 150 ? q.question.substring(0, 150) + "\u2026": q.question),
        isBookmarked(q.id) && /* @__PURE__ */ React.createElement("span", { style: { fontSize: "14px", flexShrink: 0, marginTop: "2px" } }, "\u{1F516}")
      );
    }))));
  };
  const renderQuiz = () => {
    if (quizQuestions.length === 0) return null;
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const category = getCategoryById(currentQuestion.categoryId);
    const questionImages = normalizeImageEntries(currentQuestion.questionImages || currentQuestion.questionImage, "Question image");
    const explanationImages = normalizeImageEntries(currentQuestion.explanationImages || currentQuestion.explanationImage, "Explanation image");
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: currentView === "category-review" ? () => {
      play("click");
      setCurrentView("category-questions");
    }: goHome }, "\u2190 ", currentView === "category-review" ? "Back to Questions": "Back to Home"), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", alignItems: "center", justifyContent: "flex-end", marginBottom: "8px", gap: "8px" } }, handsFreeMode && handsFreePhase === "listening" && /* @__PURE__ */ React.createElement("span", { style: {
      display: "inline-flex", alignItems: "center", gap: "6px",
      padding: "4px 12px", borderRadius: "16px", fontSize: "13px", fontWeight: 600,
      background: "rgba(239, 68, 68, 0.1)", color: "#dc2626",
      border: "1px solid rgba(239, 68, 68, 0.3)",
      animation: "pulse 1.5s ease-in-out infinite"
    } }, "\u{1F3A4} Listening..."),
    handsFreeMode && handsFreePhase !== "listening" && handsFreePhase !== "idle" && /* @__PURE__ */ React.createElement("span", { style: {
      display: "inline-flex", alignItems: "center", gap: "6px",
      padding: "4px 12px", borderRadius: "16px", fontSize: "13px", fontWeight: 500,
      background: "rgba(37, 99, 235, 0.08)", color: "#1d4ed8",
      border: "1px solid rgba(37, 99, 235, 0.2)"
    } }, "\u{1F50A} Speaking..."),
    /* @__PURE__ */ React.createElement("button", {
      onClick: handsFreeMode ? stopHandsFree: startHandsFree,
      style: {
        display: "inline-flex", alignItems: "center", gap: "6px",
        padding: "8px 14px", borderRadius: "10px", cursor: "pointer",
        fontSize: "13px", fontWeight: 600, border: "none",
        background: handsFreeMode ? "linear-gradient(135deg, #dc2626, #b91c1c)": "linear-gradient(135deg, #2563eb, #1d4ed8)",
        color: "white", transition: "all 0.2s",
        boxShadow: handsFreeMode ? "0 2px 8px rgba(220, 38, 38, 0.3)": "0 2px 8px rgba(37, 99, 235, 0.3)"
      }
    }, handsFreeMode ? "\u23F9 Stop Hands-Free": "\u{1F3A7} Hands-Free Mode")), /* @__PURE__ */ React.createElement("div", { style: styles.questionCard }, /* @__PURE__ */ React.createElement("div", { style: styles.questionHeader }, /* @__PURE__ */ React.createElement("span", { style: styles.questionProgress }, "Question ", currentQuestionIndex + 1, " of ", quizQuestions.length), /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadgeLarge(category.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", transform: "scale(2.0)", transformOrigin: "center" } }, renderBadgeCategoryIcon(category.icon)), category.name)), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(
      (currentQuestionIndex + 1) / quizQuestions.length * 100
    ) })), questionImages.length > 0 && !currentQuestion.questionImageBelow && /* @__PURE__ */ React.createElement("div", { style: styles.quizImageGroup }, questionImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-qimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: showExplanation ? styles.questionTextCompact: styles.questionText }, currentQuestion.question), questionImages.length > 0 && currentQuestion.questionImageBelow && /* @__PURE__ */ React.createElement("div", { style: styles.quizImageGroup }, questionImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-qimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), (() => {
      const shuffled = getShuffledOptions(currentQuestion);
      return /* @__PURE__ */ React.createElement("div", { style: styles.optionsContainer }, shuffled.options.map((option, idx) => /* @__PURE__ */ React.createElement(
        "button",
        {
          key: idx,
          style: styles.optionBtn(
            selectedAnswer === idx,
            idx === shuffled.correctIndex,
            showExplanation
          ),
          onClick: () => handleAnswer(idx),
          disabled: showExplanation
        },
        /* @__PURE__ */ React.createElement("span", { style: {
          fontWeight: "600",
          marginRight: "12px",
          color: "#64748b"
        } }, String.fromCharCode(65 + idx), "."),
        option.replace(/^[A-D]\)\s*/, "")
      )));
    })(), showExplanation && /* @__PURE__ */ React.createElement("div", { style: styles.explanationBox }, /* @__PURE__ */ React.createElement("div", { style: styles.explanationTitle }, selectedAnswer === getShuffledOptions(currentQuestion).correctIndex ? "\u2705 Correct!": "\u274C Incorrect"), explanationImages.length > 0 && /* @__PURE__ */ React.createElement("div", { style: styles.quizImageGroup }, explanationImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-eimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement(
      "button",
      {
        onClick: () => toggleBookmark(currentQuestion.id),
        style: {
          display: "inline-flex",
          alignItems: "center",
          gap: "6px",
          padding: "6px 12px",
          marginBottom: "12px",
          background: isBookmarked(currentQuestion.id) ? "rgba(234, 179, 8, 0.15)": "rgba(0,0,0,0.04)",
          border: isBookmarked(currentQuestion.id) ? "1px solid rgba(234, 179, 8, 0.4)": "1px solid rgba(0,0,0,0.08)",
          borderRadius: "8px",
          cursor: "pointer",
          fontSize: "13px",
          color: isBookmarked(currentQuestion.id) ? "#b45309": "#64748b",
          fontWeight: isBookmarked(currentQuestion.id) ? 600: 400
        }
      },
      isBookmarked(currentQuestion.id) ? "Bookmarked": "\u{1F3F7}\uFE0F Bookmark"
    ), window.speechSynthesis && /* @__PURE__ */ React.createElement(
      "button",
      {
        onClick: () => readAloud(getExplanationText(currentQuestion, String.fromCharCode(65 + getShuffledOptions(currentQuestion).correctIndex))),
        "aria-label": isSpeaking ? "Stop reading": "Read aloud",
        style: {
          display: "inline-flex",
          alignItems: "center",
          gap: "6px",
          padding: "6px 12px",
          marginBottom: "12px",
          marginLeft: "8px",
          background: isSpeaking ? "rgba(37, 99, 235, 0.12)": "rgba(0,0,0,0.04)",
          border: isSpeaking ? "1px solid rgba(37, 99, 235, 0.35)": "1px solid rgba(0,0,0,0.08)",
          borderRadius: "8px",
          cursor: "pointer",
          fontSize: "13px",
          color: isSpeaking ? "#1d4ed8": "#64748b",
          fontWeight: isSpeaking ? 600: 400,
          transition: "all 0.2s ease"
        }
      },
      isSpeaking ? "\u{1F50A} Stop": "\u{1F50A} Read Aloud"
    ), /* @__PURE__ */ React.createElement(ExpandableText, { text: getExplanationText(currentQuestion, String.fromCharCode(65 + getShuffledOptions(currentQuestion).correctIndex)) })), showExplanation && /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: nextQuestion }, currentQuestionIndex < quizQuestions.length - 1 ? "Next Question \u2192": "View Results")));
  };
  const renderGame = () => {
    if (quizQuestions.length === 0) return null;
    const currentQuestion = quizQuestions[currentQuestionIndex];
    const category = getCategoryById(currentQuestion.categoryId);
    const streakStatus = getStreakStatus();
    const gameQuestionImages = normalizeImageEntries(currentQuestion.questionImages || currentQuestion.questionImage, "Question image");
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("div", { style: styles.gameTimer }, "\u23F1\uFE0F ", formatTime(gameTimeLeft)), /* @__PURE__ */ React.createElement("div", { style: styles.streakCounter }, streakStatus.text), warningShown.oneMin && /* @__PURE__ */ React.createElement("div", { style: styles.warningBanner }, "\u26A0\uFE0F 1 MINUTE LEFT!"), warningShown.tenSec && !warningShown.oneMin && /* @__PURE__ */ React.createElement("div", { style: styles.warningBanner }, "\u26A0\uFE0F 10 SECONDS!"), /* @__PURE__ */ React.createElement("div", { style: { marginTop: effectiveMobile ? "80px": "60px" } }, /* @__PURE__ */ React.createElement("div", { style: {
      display: "flex",
      justifyContent: "space-between",
      marginBottom: "16px",
      padding: "0 8px"
    } }, /* @__PURE__ */ React.createElement("span", { style: { color: "#059669", fontWeight: "600" } }, "Score: ", gameScore), /* @__PURE__ */ React.createElement("span", { style: { color: "#64748b" } }, "Question #", gameAnswers.length + 1)), /* @__PURE__ */ React.createElement("div", { style: styles.questionCard }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadgeLarge(category.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", transform: "scale(2.0)", transformOrigin: "center" } }, renderBadgeCategoryIcon(category.icon)), category.name), gameQuestionImages.length > 0 && /* @__PURE__ */ React.createElement("div", { style: {...styles.quizImageGroup, marginTop: "12px" } }, gameQuestionImages.map((img, idx) => /* @__PURE__ */ React.createElement("figure", { key: `${currentQuestion.id}-gqimg-${idx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: {...styles.questionText, marginTop: "16px" } }, currentQuestion.question), (() => {
      const shuffled = getShuffledOptions(currentQuestion);
      return /* @__PURE__ */ React.createElement("div", { style: styles.optionsContainer }, shuffled.options.map((option, idx) => /* @__PURE__ */ React.createElement(
        "button",
        {
          key: idx,
          style: styles.optionBtn(selectedAnswer === idx, false, false),
          onClick: () => handleAnswer(idx)
        },
        /* @__PURE__ */ React.createElement("span", { style: {
          fontWeight: "600",
          marginRight: "12px",
          color: "#64748b"
        } }, String.fromCharCode(65 + idx), "."),
        option.replace(/^[A-D]\)\s*/, "")
      )));
    })())));
  };
  const renderGameResults = () => /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginBottom: "24px" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "64px", marginBottom: "16px" } }, "\u{1F3AE}"), /* @__PURE__ */ React.createElement("h1", { style: {
    fontSize: "36px",
    background: "linear-gradient(135deg, #f59e0b, #ef4444)",
    WebkitBackgroundClip: "text",
    WebkitTextFillColor: "transparent",
    marginBottom: "8px"
  } }, "Game Over!"), /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b" } }, "Time's Up!")), /* @__PURE__ */ React.createElement("div", { style: styles.statsGrid }, /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameScore), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Final Score")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameAnswers.length), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Questions Answered")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, gameAnswers.length > 0 ? Math.round(gameScore / gameAnswers.length * 100): 0, "%"), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Accuracy")), /* @__PURE__ */ React.createElement("div", { style: styles.statCard }, /* @__PURE__ */ React.createElement("div", { style: styles.statValue }, maxStreak), /* @__PURE__ */ React.createElement("div", { style: styles.statLabel }, "Best Streak"))), gameScore > (highScoreAtGameStartRef.current || 0) && /* @__PURE__ */ React.createElement("div", { style: {
    background: "linear-gradient(135deg, rgba(245, 158, 11, 0.15), rgba(239, 68, 68, 0.15))",
    borderRadius: "12px",
    padding: "16px",
    textAlign: "center",
    marginBottom: "20px",
    border: "2px solid rgba(245, 158, 11, 0.4)"
  } }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F3C6}"), /* @__PURE__ */ React.createElement("span", { style: {
    marginLeft: "12px",
    fontSize: "18px",
    fontWeight: "600",
    color: "#d97706"
  } }, "NEW HIGH SCORE!")), /* @__PURE__ */ React.createElement("h3", { style: { marginBottom: "16px", color: "#334155" } }, "Review Your Answers:"), /* @__PURE__ */ React.createElement("div", { style: styles.resultsContainer }, gameAnswers.map((answer, idx) => {
    const cat = getCategoryById(answer.question.categoryId);
    const revQImgs = normalizeImageEntries(answer.question.questionImages || answer.question.questionImage, "Question image");
    const revEImgs = normalizeImageEntries(answer.question.explanationImages || answer.question.explanationImage, "Explanation image");
    return /* @__PURE__ */ React.createElement("div", { key: idx, style: styles.resultItem(answer.isCorrect) }, /* @__PURE__ */ React.createElement("div", { style: {
      display: "flex",
      justifyContent: "space-between",
      marginBottom: "8px"
    } }, /* @__PURE__ */ React.createElement("span", { style: styles.categoryBadge(cat.color) }, /* @__PURE__ */ React.createElement("span", { style: { display: "inline-flex", alignItems: "center", marginRight: "4px" } }, renderBadgeCategoryIcon(cat.icon)), cat.name), /* @__PURE__ */ React.createElement("span", { style: {
      color: answer.isCorrect ? "#10b981": "#ef4444",
      fontWeight: "600"
    } }, answer.isCorrect ? "\u2705 Correct": "\u274C Incorrect")), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "14px", marginBottom: "8px", color: "#334155" } }, answer.question.question), revQImgs.length > 0 && /* @__PURE__ */ React.createElement("div", { style: {...styles.quizImageGroup, marginBottom: "10px" } }, revQImgs.map((img, imgIdx) => /* @__PURE__ */ React.createElement("figure", { key: `${answer.question.id}-grqimg-${imgIdx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#475569" } }, /* @__PURE__ */ React.createElement("strong", null, "Your answer:"), " ", (answer.userAnswerText || answer.question.options[answer.userAnswer]).replace(/^[A-D]\)\s*/, "")), !answer.isCorrect && /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#059669" } }, /* @__PURE__ */ React.createElement("strong", null, "Correct answer:"), " ", (answer.correctAnswerText || answer.question.options[answer.question.correctAnswer]).replace(/^[A-D]\)\s*/, "")), /* @__PURE__ */ React.createElement("details", { style: { marginTop: "8px" } }, /* @__PURE__ */ React.createElement("summary", { style: { fontSize: "12px", color: "#2563eb", cursor: "pointer", fontWeight: 500 } }, "Show Explanation"), /* @__PURE__ */ React.createElement("div", { style: { marginTop: "8px" } }, /* @__PURE__  */ React.createElement("button", { onClick: () => toggleBookmark(answer.question.id), style: { display: "inline-flex", alignItems: "center", gap: "6px", padding: "6px 10px", marginTop: "0px", marginBottom: "8px", background: isBookmarked(answer.question.id) ? "rgba(234, 179, 8, 0.15)": "rgba(0,0,0,0.04)", border: isBookmarked(answer.question.id) ? "1px solid rgba(234, 179, 8, 0.4)": "1px solid rgba(0,0,0,0.08)", borderRadius: "8px", cursor: "pointer", fontSize: "12px", color: isBookmarked(answer.question.id) ? "#b45309": "#64748b", fontWeight: isBookmarked(answer.question.id) ? 600: 400 } }, isBookmarked(answer.question.id) ? "Bookmarked": "\u{1F3F7}\uFE0F Bookmark"), window.speechSynthesis && /* @__PURE__ */ React.createElement("button", { onClick: () => readAloud(getExplanationText(answer.question, answer.shuffledCorrectLetter)), "aria-label": isSpeaking ? "Stop reading": "Read aloud", style: { display: "inline-flex", alignItems: "center", gap: "6px", padding: "6px 12px", marginBottom: "8px", marginLeft: "8px", background: isSpeaking ? "rgba(37, 99, 235, 0.12)": "rgba(0,0,0,0.04)", border: isSpeaking ? "1px solid rgba(37, 99, 235, 0.35)": "1px solid rgba(0,0,0,0.08)", borderRadius: "8px", cursor: "pointer", fontSize: "12px", color: isSpeaking ? "#1d4ed8": "#64748b", fontWeight: isSpeaking ? 600: 400, transition: "all 0.2s ease" } }, isSpeaking ? "\u{1F50A} Stop": "\u{1F50A} Read Aloud"), revEImgs.length > 0 && /* @__PURE__ */ React.createElement("div", { style: {...styles.quizImageGroup, marginTop: "10px", marginBottom: "10px" } }, revEImgs.map((img, imgIdx) => /* @__PURE__ */ React.createElement("figure", { key: `${answer.question.id}-greimg-${imgIdx}`, style: styles.quizImageCard }, /* @__PURE__ */ React.createElement("img", { src: img.src, alt: img.alt, style: styles.quizImage, loading: "lazy", decoding: "async" }), !!img.caption && /* @__PURE__ */ React.createElement("figcaption", { style: styles.quizImageCaption }, img.caption)))), /* @__PURE__ */ React.createElement(ExpandableText, { text: getExplanationText(answer.question, answer.shuffledCorrectLetter) }))));
  })), /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: goHome }, "Return Home"));
  const renderQuizComplete = () => {
    const correct = quizResults.filter((r) => r.isCorrect).length;
    const total = quizResults.length;
    const percent = Math.round(correct / total * 100);
    return /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("div", { style: { textAlign: "center", marginBottom: "24px" } }, /* @__PURE__ */ React.createElement("div", { style: { fontSize: "64px", marginBottom: "16px" } }, percent >= 80 ? "\u{1F389}": percent >= 60 ? "\u{1F44D}": "\u{1F4DA}"), /* @__PURE__ */ React.createElement("h1", { style: {
      fontSize: "36px",
      marginBottom: "8px",
      color: "#1e293b"
    } }, "Quiz Complete!"), /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b" } }, "You scored ", correct, " out of ", total, " (", percent, "%)")), /* @__PURE__ */ React.createElement("div", { style: styles.progressBar }, /* @__PURE__ */ React.createElement("div", { style: styles.progressFill(percent, percent >= 80 ? "#10b981": percent >= 60 ? "#f59e0b": "#ef4444") })), /* @__PURE__ */ React.createElement("div", { style: { marginTop: "20px", marginBottom: "20px" } }, percent >= 80 && /* @__PURE__ */ React.createElement("p", { style: { color: "#059669", textAlign: "center" } }, "Excellent work! You've mastered this material! \u{1F31F}"), percent >= 60 && percent < 80 && /* @__PURE__ */ React.createElement("p", { style: { color: "#d97706", textAlign: "center" } }, "Good job! Keep practicing to improve further! \u{1F4AA}"), percent < 60 && /* @__PURE__ */ React.createElement("p", { style: { color: "#dc2626", textAlign: "center" } }, "Keep studying! Review the incorrect questions to improve. \u{1F4D6}")), /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: selectedCategory ? () => {
      play("click");
      setCurrentView("category-questions");
    }: goHome }, selectedCategory ? "Back to Category": "Return Home"));
  };
  const renderChatLegacy = () => {
    const modeText = chatSyncMode === "shared" ? "Shared cloud chat active": "Local device chat only";
    return /* @__PURE__ */ React.createElement(React.Fragment, null, /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"), /* @__PURE__ */ React.createElement("div", { style: styles.card }, /* @__PURE__ */ React.createElement("h2", { style: { margin: "0 0 8px 0", color: "#1e293b" } }, "\u{1F5E3}\uFE0F Clinician Collaboration Chat"), /* @__PURE__ */ React.createElement("p", { style: { margin: "0 0 12px 0", color: "#64748b", fontSize: "14px" } }, modeText), /* @__PURE__ */ React.createElement("div", { style: styles.chatNotice }, "\u26A0\uFE0F Do not include patient identifiers or PHI. Keep messages educational and operational."), !String(FIREBASE_CHAT_DB_URL || "").trim() && /* @__PURE__ */ React.createElement("div", { style: {...styles.chatNotice, background: "rgba(59, 130, 246, 0.08)", borderColor: "rgba(59, 130, 246, 0.3)", color: "#1e3a8a" } }, "Cloud sync is not configured. Set FIREBASE_CHAT_DB_URL in this file to enable organization-wide shared chat."), /* @__PURE__ */ React.createElement("div", { style: { display: "grid", gridTemplateColumns: effectiveMobile ? "1fr": "220px 1fr", gap: "10px", marginBottom: "12px" } }, /* @__PURE__ */ React.createElement(
      "input",
      {
        style: styles.chatInput,
        value: chatName,
        maxLength: 40,
        placeholder: "Your display name",
        onChange: (e) => setChatName(e.target.value)
      }
    ), /* @__PURE__ */ React.createElement(
      "input",
      {
        style: styles.chatInput,
        value: chatInput,
        maxLength: 600,
        placeholder: "Type a message to colleagues...",
        onChange: (e) => setChatInput(e.target.value),
        onKeyDown: (e) => {
          if (e.key === "Enter" && !e.shiftKey) {
            e.preventDefault();
            sendChatMessage();
          }
        }
      }
    )), /* @__PURE__ */ React.createElement("div", { style: styles.chatActions }, /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: sendChatMessage }, "Send Message"), /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: loadChatMessages }, "Refresh"), /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: copyChatSnapshot }, "Copy Snapshot")), /* @__PURE__ */ React.createElement("div", { style: styles.chatMessageList }, chatMessages.length === 0 ? /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b", margin: "8px 4px" } }, "No messages yet. Start the conversation."): chatMessages.slice(-120).map((m) => /* @__PURE__ */ React.createElement("div", { key: m.id || `${m.ts}-${m.name}`, style: styles.chatMessageItem }, /* @__PURE__ */ React.createElement("div", { style: { display: "flex", justifyContent: "space-between", gap: "10px", marginBottom: "2px" } }, /* @__PURE__ */ React.createElement("strong", { style: { color: "#1e293b", fontSize: "13px" } }, m.name || "Clinician"), /* @__PURE__ */ React.createElement("span", { style: { color: "#94a3b8", fontSize: "12px", flexShrink: 0 } }, new Date(m.ts || Date.now()).toLocaleString())), /* @__PURE__ */ React.createElement("div", { style: { color: "#334155", fontSize: "14px", whiteSpace: "pre-wrap", wordBreak: "break-word" } }, m.text || ""))))));
  };
  const renderChat = () => {
    const modeText = chatSyncMode === "shared" ? "Shared cloud chat active": "Local device chat only";
    return /* @__PURE__ */ React.createElement(
      React.Fragment,
      null,
      /* @__PURE__ */ React.createElement("button", { style: styles.backBtn, onClick: goHome }, "\u2190 Back to Home"),
      /* @__PURE__ */ React.createElement(
        "div",
        { style: styles.card },
        /* @__PURE__ */ React.createElement("h2", { style: { margin: "0 0 8px 0", color: "#1e293b", display: "inline-flex", alignItems: "center", gap: "8px" }, onClick: handleChatTitleSecretTap }, /* @__PURE__ */ React.createElement("span", { style: styles.chatHeaderIconWrap }, /* @__PURE__ */ React.createElement("img", { src: CHAT_ICON, alt: "", "aria-hidden": "true", style: styles.chatHeaderIconImg })), "Clinician Collaboration Chat"),
        /* @__PURE__ */ React.createElement("p", { style: { margin: "0 0 12px 0", color: "#64748b", fontSize: "14px" } }, modeText),
        /* @__PURE__ */ React.createElement("div", { style: styles.chatNotice }, "\u26A0\uFE0F Do not include patient identifiers or PHI. Keep messages educational and operational."),
        !String(FIREBASE_CHAT_DB_URL || "").trim() && /* @__PURE__ */ React.createElement("div", { style: {...styles.chatNotice, background: "rgba(59, 130, 246, 0.08)", borderColor: "rgba(59, 130, 246, 0.3)", color: "#1e3a8a" } }, "Cloud sync is not configured. Set FIREBASE_CHAT_DB_URL in this file to enable organization-wide shared chat."),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: { display: "grid", gridTemplateColumns: effectiveMobile ? "1fr": "220px 1fr", gap: "10px", marginBottom: "12px" } },
          /* @__PURE__ */ React.createElement(
            "input",
            {
              style: styles.chatInput,
              value: chatName,
              maxLength: 40,
              placeholder: "Your display name",
              onChange: (e) => setChatName(e.target.value)
            }
          ),
          /* @__PURE__ */ React.createElement(
            "input",
            {
              style: styles.chatInput,
              value: chatInput,
              maxLength: 600,
              placeholder: "Type a message to colleagues...",
              onChange: (e) => setChatInput(e.target.value),
              onKeyDown: (e) => {
                if (e.key === "Enter" && !e.shiftKey) {
                  e.preventDefault();
                  sendChatMessage();
                }
              }
            }
          )
        ),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: styles.chatActions },
          /* @__PURE__ */ React.createElement("button", { style: styles.nextBtn, onClick: sendChatMessage }, "Send Message"),
          /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: loadChatMessages }, "Refresh"),
          /* @__PURE__ */ React.createElement("button", { style: styles.secondaryBtn, onClick: copyChatSnapshot }, "Copy Snapshot")
        ),
        /* @__PURE__ */ React.createElement(
          "div",
          { style: styles.chatMessageList },
          chatMessages.length === 0 ? /* @__PURE__ */ React.createElement("p", { style: { color: "#64748b", margin: "8px 4px" } }, "No messages yet. Start the conversation."): chatMessages.slice(-120).map((m) => {
            const messageKey = getMessageIdentity(m) || `${m.ts}-${m.name}`;
            const canDeleteMessage = chatOwnerMode && (chatSyncMode !== "shared" || !!m.remoteId);
            return /* @__PURE__ */ React.createElement(
              "div",
              { key: messageKey, style: styles.chatMessageItem },
              /* @__PURE__ */ React.createElement(
                "div",
                { style: { display: "flex", justifyContent: "space-between", gap: "10px", marginBottom: "2px" } },
                /* @__PURE__ */ React.createElement("strong", { style: { color: "#1e293b", fontSize: "13px" } }, m.name || "Clinician"),
                /* @__PURE__ */ React.createElement(
                  "div",
                  { style: { display: "flex", alignItems: "center", gap: "8px", flexShrink: 0 } },
                  /* @__PURE__ */ React.createElement("span", { style: { color: "#94a3b8", fontSize: "12px" } }, new Date(m.ts || Date.now()).toLocaleString()),
                  canDeleteMessage && /* @__PURE__ */ React.createElement("button", { style: styles.chatDeleteBtn, onClick: () => deleteChatMessage(m) }, "Delete")
                )
              ),
              /* @__PURE__ */ React.createElement("div", { style: { color: "#334155", fontSize: "14px", whiteSpace: "pre-wrap", wordBreak: "break-word" } }, m.text || "")
            );
          })
        )
      )
    );
  };
  return /* @__PURE__ */ React.createElement("div", { style: styles.app }, /* @__PURE__ */ React.createElement("div", { style: styles.backgroundPattern }), showGameIntro && /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroOverlay }, /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroCard }, /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroIcon }, "\u{1F3AE}"), /* @__PURE__ */ React.createElement("h1", { style: styles.gameIntroTitle }, "GAME MODE"), /* @__PURE__ */ React.createElement("p", { style: styles.gameIntroDesc }, "Test your knowledge under pressure! Answer as many questions as you can in 3 minutes."), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u23F1\uFE0F"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "3 Minutes"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "Race against the clock"))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F525}"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Streak Bonus"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, 'Build your streak - get "Heating Up!"'))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u26A0\uFE0F"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Time Warnings"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "1 minute and 10 second warnings"))), /* @__PURE__ */ React.createElement("div", { style: styles.gameIntroFeature }, /* @__PURE__ */ React.createElement("span", { style: { fontSize: "24px" } }, "\u{1F3C6}"), /* @__PURE__ */ React.createElement("div", null, /* @__PURE__ */ React.createElement("strong", null, "Beat Your High Score"), /* @__PURE__ */ React.createElement("p", { style: { fontSize: "12px", color: "#64748b", margin: 0 } }, "Current: ", progress.gameHighScore, " points"))), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.beginBtn,
      onClick: startGameCountdown,
      onMouseEnter: (e) => e.currentTarget.style.transform = "scale(1.02)",
      onMouseLeave: (e) => e.currentTarget.style.transform = "scale(1)"
    },
    "BEGIN"
  ), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: {...styles.backBtn,
        width: "100%",
        marginTop: "12px",
        marginBottom: 0,
        justifyContent: "center"
      },
      onClick: () => setShowGameIntro(false)
    },
    "Cancel"
  ))), gameCountdown !== null && /* @__PURE__ */ React.createElement("div", { style: styles.countdownOverlay }, /* @__PURE__ */ React.createElement("div", { style: styles.countdownNumber }, gameCountdown)), /* @__PURE__ */ React.createElement("div", { style: styles.content }, /* @__PURE__ */ React.createElement("header", { style: styles.header }, /* @__PURE__ */ React.createElement("div", { style: styles.logo, onClick: goHome, role: "button", tabIndex: 0, onKeyDown: (e) => {
    if (e.key === "Enter" || e.key === " ") goHome();
  } }, /* @__PURE__ */ React.createElement("img", { style: styles.logoMark, src: "data:image/png;base64,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", alt: "Caduceus" }), /* @__PURE__ */ React.createElement("div", { style: { display: "flex", flexDirection: "column", lineHeight: 1.1 } }, /* @__PURE__ */ React.createElement("span", { style: styles.logoText }, "Primary Care Provider Learning Program"), /* @__PURE__ */ React.createElement("span", { style: styles.logoSubtext }, "Clinical microlearning \u2022 quizzes \u2022 rapid review"))), /* @__PURE__ */ React.createElement("div", { style: styles.controls },
  /* @__PURE__ */ React.createElement("div", { style: styles.explanationToggleWrap },
    /* @__PURE__ */ React.createElement("button", { style: styles.explanationToggleBtn(explanationMode === "expanded"), onClick: () => { play("click"); setExplanationMode("expanded"); }, title: "Expanded Answer Mode" }, "\u{1F4D6}", !effectiveMobile && " Expanded"),
    /* @__PURE__ */ React.createElement("button", { style: styles.explanationToggleBtn(explanationMode === "bullet"), onClick: () => { play("click"); setExplanationMode("bullet"); }, title: "Bullet Point Mode" }, "\u{1F4CB}", !effectiveMobile && " Bullet")
  ),
  /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.soundBtn,
      onClick: () => setSoundEnabled(!soundEnabled)
    },
    soundEnabled ? "\u{1F50A}": "\u{1F507}"
  ), /* @__PURE__ */ React.createElement(
    "button",
    {
      style: styles.chatIconBtn,
      "aria-label": "Open Chat",
      title: "Open Chat",
      onClick: () => {
        play("click");
        setCurrentView("chat");
      }
    },
    /* @__PURE__ */ React.createElement("img", { src: CHAT_ICON, alt: "", "aria-hidden": "true", style: styles.chatButtonIcon })
  ))), currentView === "home" && renderHome(), currentView === "category-questions" && renderCategoryQuestions(), currentView === "quiz" && renderQuiz(), currentView === "category-review" && renderQuiz(), currentView === "game" && !gameEnded && renderGame(), currentView === "game" && gameEnded && renderGameResults(), currentView === "quiz-complete" && renderQuizComplete(), currentView === "chat" && renderChat()), /* @__PURE__ */ React.createElement("style", null, `
        @keyframes pulse {
          0%, 100% { transform: translateX(-50%) scale(1); }
          50% { transform: translateX(-50%) scale(1.05); }
        }
        
        @keyframes countdownPulse {
          0% { transform: scale(0.5); opacity: 0; }
          50% { transform: scale(1.2); }
          100% { transform: scale(1); opacity: 1; }
        }
        
        @keyframes shake {
          0%, 100% { transform: translateX(-50%); }
          10%, 30%, 50%, 70%, 90% { transform: translateX(calc(-50% - 5px)); }
          20%, 40%, 60%, 80% { transform: translateX(calc(-50% + 5px)); }
        }
        
        * {
          box-sizing: border-box;
        }
        
        body {
          margin: 0;
          padding: 0;
        }::-webkit-scrollbar {
          width: 8px;
        }::-webkit-scrollbar-track {
          background: rgba(0,0,0,0.05);
          border-radius: 4px;
        }::-webkit-scrollbar-thumb {
          background: rgba(0,0,0,0.15);
          border-radius: 4px;
        }::-webkit-scrollbar-thumb:hover {
          background: rgba(0,0,0,0.25);
        }
        
        input::placeholder {
          color: #94a3b8;
        }


  /* Accessibility + polish */
  button:focus-visible, [role="button"]:focus-visible, input:focus-visible {
    outline: 3px solid rgba(37, 99, 235, 0.55);
    outline-offset: 2px;
  }
  button:disabled {
    opacity: 0.55;
    cursor: not-allowed;
  }
  @media (prefers-reduced-motion: reduce) {
    * { transition: none !important; animation: none !important; scroll-behavior: auto !important; }
  }
`));
}
const root = ReactDOM.createRoot(document.getElementById("root"));
root.render(/* @__PURE__ */ React.createElement(PCPLearningApp, null));
  </script>
  <script>
    // Register service worker for offline support and cache-busting
    if ("serviceWorker" in navigator) {
      navigator.serviceWorker.register("sw.js").then(function(reg) {
        // Check for updates every time the page loads
        reg.update();
      }).catch(function() {
        // SW registration failed â€” app still works, just no offline support
      });
    }
  </script>
</body>
</html>

